<SEC-DOCUMENT>0000310158-22-000003.txt : 20220225
<SEC-HEADER>0000310158-22-000003.hdr.sgml : 20220225
<ACCEPTANCE-DATETIME>20220225164428
ACCESSION NUMBER:		0000310158-22-000003
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		142
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220225
DATE AS OF CHANGE:		20220225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merck & Co., Inc.
		CENTRAL INDEX KEY:			0000310158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221918501
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06571
		FILM NUMBER:		22681109

	BUSINESS ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033
		BUSINESS PHONE:		908-740-4000

	MAIL ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merck & Co. Inc.
		DATE OF NAME CHANGE:	20091103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SCHERING PLOUGH CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrk-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:c2671c01-457c-407e-affb-5c2ec2e9dc08,g:df117aec-e688-48b3-9aac-3f4fd6688d4e,d:1e1e934bfffd457891fb6e33dae50d64--><html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:mrk="http://www.merck.com/20211231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrk-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF80L2ZyYWc6NGE5ODExMmM1OGUxNDI4NTkwZTFlMWI3MjdiYzlhMjMvdGFibGU6ZGM0YWExNGIwMDZmNDljOGEwYTExZjQ5YjE2NDQzMzcvdGFibGVyYW5nZTpkYzRhYTE0YjAwNmY0OWM4YTBhMTFmNDliMTY0NDMzN180LTEtMS0xLTA_9f648663-3ae2-4d67-83bc-a4faca6ac860">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF80L2ZyYWc6NGE5ODExMmM1OGUxNDI4NTkwZTFlMWI3MjdiYzlhMjMvdGFibGU6ZGM0YWExNGIwMDZmNDljOGEwYTExZjQ5YjE2NDQzMzcvdGFibGVyYW5nZTpkYzRhYTE0YjAwNmY0OWM4YTBhMTFmNDliMTY0NDMzN181LTEtMS0xLTA_970fdfbc-3571-4f6f-9871-4ce8604434ad">2021</ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF80L2ZyYWc6NGE5ODExMmM1OGUxNDI4NTkwZTFlMWI3MjdiYzlhMjMvdGFibGU6ZGM0YWExNGIwMDZmNDljOGEwYTExZjQ5YjE2NDQzMzcvdGFibGVyYW5nZTpkYzRhYTE0YjAwNmY0OWM4YTBhMTFmNDliMTY0NDMzN182LTEtMS0xLTA_4f443312-89f1-487d-802a-dd56214e36c6">FY</ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF80L2ZyYWc6NGE5ODExMmM1OGUxNDI4NTkwZTFlMWI3MjdiYzlhMjMvdGFibGU6ZGM0YWExNGIwMDZmNDljOGEwYTExZjQ5YjE2NDQzMzcvdGFibGVyYW5nZTpkYzRhYTE0YjAwNmY0OWM4YTBhMTFmNDliMTY0NDMzN185LTEtMS0xLTA_c19bef8e-358a-4165-ad6a-b97672265e2f">0000310158</ix:nonNumeric><ix:nonNumeric contextRef="ic1a2739cca2046f0abc863ed20b48d0b_D20210101-20211231" name="mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzUz_b48cccc3-76a0-476d-bb80-193b05cdb46c">P3M</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i84ebf0636d2b4c2daa4201ebca56405d_D20210602-20210602" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTQyL2ZyYWc6OWMyYTgzYmIwZmRmNDg1MTlhMmVhMGUxMTJkZTUyN2UvdGV4dHJlZ2lvbjo5YzJhODNiYjBmZGY0ODUxOWEyZWEwZTExMmRlNTI3ZV8xMDk5NTExNjI3ODUz_9a2e852b-01a5-4ae0-8700-9bfbf262caa7">0.1</ix:nonFraction><ix:nonNumeric contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_16a2eb8c-e452-4c08-a1c1-253a7ae69d38">http://fasb.org/us-gaap/2021-01-31#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_51a0e69b-3d06-4866-8735-b4018eea9421">http://fasb.org/us-gaap/2021-01-31#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_a62e225e-815f-4743-87ec-8f20071b70d4">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_f733f0e1-fc32-4cc4-af08-cafbad4247b5">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_640b8294-5ffb-4269-b064-66281ca04383">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_7eda0372-d2d2-488c-a2da-c5fb07ed06fd">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODEvZnJhZzowMzY4NWYzNDU3OTg0ZmI2YjQ3MGIyZDY4NmUwNzY0Mi90YWJsZTo2NTZjZDY2ZDQxOGY0MTUzOTBiNTU4MWNjYmI4ZjhiNi90YWJsZXJhbmdlOjY1NmNkNjZkNDE4ZjQxNTM5MGI1NTgxY2NiYjhmOGI2XzEtMS0xLTEtMA_c216bd1c-8a80-4aa3-8a45-60b560e04012">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrk-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19fa39a0158d4ac3a19217bc596e4123_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46992b35b0554da8a6375df5c7dc327e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1852627ad8f34be7a1cca870e27e5bae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a98152d3a5b419398f05b5c58fb8024_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d3d9b0d798490eb3d016707f5c8fb3_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie0f012095b0b4d82a0ee2d4237014df1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib8b85b81b3df4143813c92eac8590ae3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i296a96e660db43169f0376b184f4d3fc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i241c8aa1377540ad88e44cceb968c204_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2112d614d9a45828458276b54ac3348_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd9336867cce49919c9a776ee62bc1b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b062550448c4f5b877548d6eda89d15_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib908a2ace6f544bd91b2adcb40f2f0af_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b25cba6160a4486b14740ddd2b481ef_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e94e814bd0149bd847f2783d90c9d48_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40203e52d1c440a6b89559fa168b081a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0171e54cbd894628b6188119563a887e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3acd7fea33f491a9299de32f18ce21a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e784cab819d451499c362b12111a27a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01dd7de0cf6f4ace976de5b22d6ba095_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5a5580f8dad412cb034d3e6ad78653f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a458b3d31d042a4bb104dc181064e79_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e651f0bdf0a4e5c85db0a3c85be51f1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5734fc741d6d4e0480d4a89bf0739099_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7071cda02b544795b02b9668d83532cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ce079367344ee799a79a4d8a61dcdf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia95480df7b48466b8fe2970840b6d96e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1468cd3ea95419fb66e7dd8d3547410_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd27579d0594b8c836cf9cb029ccdb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if91e41b657e142838655904b6ffc2b4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i747b6da151fd47548889dcf4acf9f07e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i629510fd09f5448784fc756b630535b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1f8e2c09b84254b99b8e105564e52b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44fbc319828d43888404b362300c8719_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22154b3c72564c4184ae4a06c41144ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49673c36f67e4d93b4ebbe225a478e72_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52711b1bf6764fd78c0ef6f9e7df950f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5889b314dc6846e99dfdc5dd5b0d4d4d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb199531c9a4be79a55f354540b66f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5771d34675734e438d53901618ffd853_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2a1e33e2f04030829641bc2c24a05c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e9a7df047274290ad191b1e08bfc7ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333ee6c0baa94ce7a67cc850a8d3a772_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c6f9da4227441da8480f88901779b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i020c181c0f60421080b1a0cdcce948b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mrk:segment</xbrli:measure></xbrli:unit><xbrli:context id="ic1a2739cca2046f0abc863ed20b48d0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbf378454e1d4b12a87f05c8d4852a45_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e19dcf50aa4fd1ae7e9d3a8ea60763_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ef868a5ade24c99b03f00ffa9481beb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3844e8babf814713b968b4e3c289a5c6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42166b8ad497486faa87ed01b29e3d22_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c24ba602a542c0b8c9b0ef7ed35ee3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad274281f336490a9ef2ec84cddc2518_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f1aaf80bf5248b6b6375fd958a9e703_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib66800d952274b52b8a0a168fe298ecc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b1ac66b90724fe18f56ea110536b64b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be0b42ed8034d95ba4e13ab6fbbf535_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b030dcad117451495b0cce71d1a6fc8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1098dc170e941f38477fba57b8cf5ae_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2498efe88024feb8dbf6cebe7b9e1c4_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id35e3e3e253f4a6eb98018307707afde_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16aa05ee3ee141d2ace6ce8e2e932362_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb5df78dae84a27b551e06a2a2ae854_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i162cf24607d24678bb2c7252e0441829_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11ebf3cfa71a410e931e1ac91fd56a8d_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5475fea5427a4a45a8d0f7c70cc2edc1_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3694ffb88a4c26905566a5aadc567e_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if35f0cdded8a441882d65448ee48c8ed_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ebf0636d2b4c2daa4201ebca56405d_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iab98fe0036ab490284530f0ef5a067b9_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c67fcd89a8b4082808554b5f0549fc8_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c62b473540e4792973e3e5eff8e852b_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700f5502bfe547d29c56588dcd1c2a57_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i078bab656180438fb5b9e6e2b822296a_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ad6313c93cd46b38072ff32e2d4d398_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if845b3b4c08c45efbf34f152a3076b6b_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66e156b81e874c37998b4260b293e32d_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691918582c3344e899b4df21192718a3_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e47ab987cd4d3abdc343a64acdfcdc_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i363a34970b28487fb538f79d80bd5c63_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dbe981b0dce44c7b9140f5b1e642a2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ab2e68dea743c09e757b18af5181e8_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OralAndInjectableFormulationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85efbd1b835b4a8e8e7140e9b606ea82_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OralFormulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ab7dec508142c597fc9e631c500889_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InjectableFormulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0caff53de00b40f0b2a4242ec4f7b853_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a13694e029b4e109b43b40ab0e2f486_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4df9ebe39004e61b4723b8728950ca9_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee08b09a26eb4dbf9c1fc7400dd403eb_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8782918165654defab8aad5b032f7b4e_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b7f6216f9b24aefaf5499aeeae375cb_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65036a0df1a24e1286b3b620969af227_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbd4e250c5234f40a49f0424a7b9ca39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2125d5f6f642d48b2728270ed20dcf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d5e8e876a74d78b9b4adb360ed3859_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4bb721c83cb4d6baf3edaee991beff8_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i154453efc9bf49d9b6c2e7bdb4a3667d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i887204908c64421d9da59e4d3c3099b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e331a60d4604a2b9a0563cb2271e112_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c941f925d9424e9b42b6b4bb3d68b8_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2bd91e11abc48aeac94ddad807d22c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i090c4ce27a88432b994b5cd38555a37b_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie34faa097b834cfa9a5bcfcaf8c87262_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f789b2accd9484992688f3f01dfdf11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48c7436c3f434009bc43ed8fb64f30db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37947affd59e45db9bf4247d22ef2445_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a44796f0e99454095c4177490b7a1fc_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id735e23c835a42d7a629be7b46a33b70_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia094e3f9230741fb85ffb13181d20935_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22dbddf74d0346e2bcda039fb5251dc8_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd702d7339fc4907beb6de920d2ebfcb_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94eccca165db4204b5fe7cd15369ff52_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i0772900bf1714a1286b8a8be67ef1352_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46379c7182e540b2828bf31f0181f842_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id62a4bb25fc844f59220aa4a94682bd9_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffce628751d64772b2c55aabb65ac5b4_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf228ffc1f9146219d66ae63268e5646_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SentinelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i253e7eb6731846cd8297aa6fff74e2a7_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c2134703ab44a17a75303f1e2bbc346_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd20b1fb1b1840cd97ca9a25e317e07f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72336269c0e4853bb62f08578a8703e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41279252c9624ed8a4c7a81861188d80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5bd531bb0694347bbaa1de33894a3f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d06568f20aa4404ac1d16b234d39d17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d3b73f821cd4774aad66eb73f3a5f66_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:IAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38be38fc4a954d74a422539b6c013245_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia80b8fd970c84658b490d1b62ee60672_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00f0fb0e68c34bcc9ac14ca5a1d30e3e_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863cd316ea5d4a879ae66467e3f51ad8_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d468ad359d4b3c907fa0ca583c3707_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02366c725d8e4b61a487fbc509afa833_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3aa932f580f42fba20f4fb291aa005d_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c7c2e213af64bed83c7c5be126fe2b5_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b43da370e844376a5ef3e3c317c068c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d46d7a5f1d84985a8798afe9a116fcd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:CommercialmilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i094e0d6dfc6e43d8a71ef15cc8afa929_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b1a5803b6e4bb1b34750d30eaca4d0_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b06079ce243471f80c224e28eca9bc0_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb86c75b69646909c1e731b110cd594_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353be6859e8a4c909dc868bb55fa96ef_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1fd1624d0a447a0a77222b18fdb866f_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38900b44f49245e2a2fe07fe9834a8cc_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3255f0f1f154600bc059456bba5499d_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14319073e5c3479eb00e19929756ed79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5702456494b740da8508f5b853110e3d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida96075caa59419780179c2f9b3c3546_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa55a231791b4a4c9b8b8459d1b149dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98306b224b47475488e911e85f203624_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a357f883cf8403d91477b70cff00a8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i642c3ff7f9414f5392688e1239f63e01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica0a3fd966314c5dac24c390abc72914_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8bd0a10b28b427cb9d90dfe3a600d6c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic810a621774c4c99983badd39ea9eba9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03aabfbe2af64606bfcdc9b7244adddb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46c263ae58e241119936ff1e15d0ea2a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id016daaee2884b7f93108c6df370f620_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76cfcf2bfbe4407ca26ac87fbf3ba4d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d4f6c2d4ef45beaae183fe55dbf354_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica857d506be742ee8d273ccfcb812e2a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93d60c48bbfb4999a5474c6c5295cf07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc366f05419417e83c83213cac8477c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib054f661c3f042f99541982143ad5e6f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8e6351182024603b7f62da8e5b885f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafe4a4c0ebe0439a803c537ea10a6d6a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b90e12bc9ba43f7abb9022574ae4b38_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7365ef92cc904089a49a56598ef8d5e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109c40ef87d24d13bd2b5cc4cf386752_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6154dfd2961f4f43916c01e33c8d1386_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56b97e6d098246129353599999e69659_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if375a5c48628477c973fbc4fd1d1b133_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie381877a89e94c45bc4b63e6dc00f506_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c672ce6ee24fd083c1fcaea23ee2bd_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3303c07747a54842b62042d5a21e6f09_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a431121ab94fd3aeaeff71b65fbed1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if502cf4525474a359d96f230ac724e3f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7239a77febd64e6582c7bd34411f3af6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i328e047b1fe9465cba44b2312c36a1f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie554c78a55284e71b4e43682b58e067e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8e076f12b4342f1b585a7f637e3c832_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd44ea5d24342129e8b6ebb5a4efdb2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia98a6294caf44811bdfc230489f05f54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1775b6c3bb3245dfa916e2e3ecfac7c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4981e17b20a547c8bc03157a8ea2bd94_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if383a9214fb545e98c021a08266ee37c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78dcd3d033904438964f0f1e38a578c6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb3a0fe626d42bd8f53d27a0a6cc6c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19ffe322d7c84b43864b069f78e9b3e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d6795e1450e497ea457f40aeb36be13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db97feaad864168aa38dfed369a69a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9860090665459d8fec0ff943a45f30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31bedff9aa684372b0af5c1ba6c41467_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if064fdd725ea4a7c982907c44a941df6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19adf582d06f45aca49da637284ec35a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cbdb424aa5944669afe3610141ee5d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56eee0d6468b4e67837ceae0dbff2f9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie04e36743dcd41d3b045117f4f3b8170_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e1a080606b4e4592e4f4733ceb6c81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if90b8c08c37a41ffa4f6848991b4a7da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1570e7027e0e496ab090442e8a8be4af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17edb9f092f7485f9426b08af9218bf2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00f8c65ee807407dab9ca51108c58857_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id18a472cdb414425a36e2fc4fc858400_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0a967edb06f4521aaaaa2ecf0a9b105_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia746274f620f40c1851d95a52bb1fec0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7e96dc6c32d41be85aaddf645d42386_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78cbe3c61444fe491dc47f1246975d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d7ebb400b14b728855eecc7c992f50_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c74b59b3824b859e175ea5af3e1de3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a2d934adf3844c9948a3c90a53001de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia59c375a867e43f387fc23f684540a1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic524b8d83ef44a209ae2f8d59984ad9f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie861385c736d4571ac97d10e57900db0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891ef023d6cf4c1594a15170a05474b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id72f5afaff1c4203b2ae637d11fe6fb6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e1fc699103401fbce35712191d910b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e3a1eb707a4bc0b1578b9e4e15f60b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideff38e8d1af4d7ca70fc010025279b6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia185bf2a1911407099126af09d6781da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342fe69beb814c41a97a7aef4c9ac973_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0452510b6e3c4fbd81f8cddba0a9d033_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0003ff4798514c25a8591c162be15992_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd82ed31d7346f58d217331940bd0d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i817d4a5d455b48e0835d76a3e57a68b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8063a63e130649cd85c2717196b54dde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e584cc2eff43599af7e4d668e4568c_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="course"><xbrli:measure>mrk:course</xbrli:measure></xbrli:unit><xbrli:context id="i5bf2c56c247444b38c99429fcfcc161e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b951c64d4e94488b0076bc63024ee64_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i756ba880ce0840268980b9aab4635b5a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dce085486ee43df951fdeb7914c2311_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedKingdomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc01fdd92ce142b8bd16ad6681f5c303_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedKingdomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="market"><xbrli:measure>mrk:market</xbrli:measure></xbrli:unit><xbrli:context id="if9796277d9ba47be91cb5b887f734e7e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedNationsChildrensFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>mrk:country</xbrli:measure></xbrli:unit><xbrli:context id="i32e28bb8b9aa4b7293ac191de6dddfe4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia356d15f44884231bebbcd7fcdd11f4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i097bcd95db4c4868880f6e0af7fcc0c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib15900e9713c45c48f0b905cb6dda370_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00fb66ab96ce42d89c8d0763fcc77ddb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b31b8b00cfe47f490681a6d81cd140b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i737ff51dc12248dfac6273aae238abff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1726f56cf343c482a8f9ccb64bd59a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13200a779dce464f80cba863cea9e407_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1fde0285ad7451a9e92d2f80b91240f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e67b3bb86584dab8782e051cf58baff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aaca85009704ba19f1513e1e6c78715_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31dc8ec6b8e445b7b1b2b75aa10c997f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida45dba4790a481d8b49ae4d99983799_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73cb7250e044a5f85e091f1f1ddae2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i946b15bf33724eab9cd37c967a566b18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ee296e8eeb43419e7163aaf951d1c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf3f8d9415a448c18444c1d1d8b1fe42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31323381bed94598b8252be522569bca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56683f71b6048a5b950676e5147ddf6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8e2c2edc5a34bdb938b2ab9082b4ef0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac2c9d18fc948e3b3936a9c1745217a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59278b50186c44eea02cd1646e7b396b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfe328f6c7a841e2b8499cc76eb20e1a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbbd36fe79ec4490af6d95ad286eece6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0f65c662794b7c9441b60c88d828a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a62cdc5b588461686edf03bf5ad6825_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4caa478726464d649c33751164cc0d70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebd95b3f5d7d4a40ada1f89d7f2b3807_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba6383149a1b416d85737bb951015359_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16cf5190146b4f96b1360695ccb6edd8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30f607f077f64c3daf4b01cf7298bfcd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50bddbb672804072ba20c9dda2af5613_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380e21df60bd41249e37f76c96e5b370_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0297bc36963248d48192cc37c891ebd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa96945711e74e16af5a510b6ad45e87_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i310042e57f8648c1910a64c356d6e4e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46fa1a240c9641f582948709782ebebb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e16f47e6744b63b974f8c45a0aebce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib320e53fbe8f4a71a079672c21ab5589_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i403dfea81e9b44b38f3a6469fc84c66b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie002d0c48a3741839131c30916e5272c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f343081e674fb6824fe0f6ea3f51b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67a74b90c27a4d51bc7a5b722f81b3b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19696965a5c496d8add86515a1be5ec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d842b6322f4be89cdc492a4a169002_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacdb4cd333404a72ab7e9c4a06cbe2c1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf1ad6c7e2d42f2b67fbb17e45f48ff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3f09c566f04978a062c5b475fcb376_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d31ca3c243847fca3ff1222d83159af_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111c43d6a309499f9624c33e82a4ffc9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ccf2924ac4f40168f4b02f65db200ee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf00dc1bbf9946288b16b5451fe51cd5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ce6215e57c2458a9afd417343c63d14_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd0c801111b849889a3cb1999277404a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16730c4a678e4c64b56d69ad77692225_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f15ce626aad44f58292eedaa374a985_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5f02c13fd4747fc989b60fd784585bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id069b94a80af42e4888ed8c2211e56e1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9199f48459144d88986872e9ce83bcc8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1a06d7e97b4f2da011319e92c97eb9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6560744cffdb44c6a15e0de8cb3125c5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa2324a7bd9442db621352f34648867_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb507ac1c0b432293ffd49cc271e612_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if561463c4bc4425caa176dc7d55ee265_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc98ae55b3748a19a4a059028c47b39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5bbf238dd6a44468ac376288e4e1add_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id389b623812d474ea6c5ac6b16c29504_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb664c71c0594335bb3a3f87041223a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b9087bb1864779b2109ddd342e45f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d11003c0d414a6e8d574694e9ec9dea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6e9ec1cceb94d9bae732843b25cdb75_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee26aaae9074659993d6d84e4de1ffb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02721ef0aaab4a4caee301f22e9386ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84bb7bc1ceda4f948a3090842627e654_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e1bd075f93491e9df5f7f32bd7ad1f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib65521c997c84ef8b37cc9b21ffd59d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie72e897aad094644a983458bfe8704d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeeff8ebe3be4a60ab7c727335780af7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9352e4c6900b48a3965ce12d07bf3a06_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie137bb0fd9d44320bee063d82bfcf668_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4e9d32d55204511bafd6a9816b6f024_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a496974bc6443bb93bb621dd56fc567_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df804136d5442df9b3d7abea422a604_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2bbb9db2c294c3ba3a6368380f2e03e_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>mrk:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="i8fe94b07a3fc4572a433b1102b900e44_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i310109d6898342d49bc826875e191ad6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de5cdef0a234eefaec97bc914e30cc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i591a75ce070d4aaf981adbe405971c39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752aeb3870ee4f6bbfd196995b6998d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6611393547d42b1bc24ebbbb98dc51d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ac86e44601419fa50cb8bfba8997cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd3c2b08bde54d01b9032cf85c1bae1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c86a1b952c48f7861dbe9b5aeab121_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36b163f3e8e43d6ae5f69d6957c282f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28e71a0f38b8445fad18e25a0d495afe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0bd1d54e2d34252a1c972fe50060600_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c7da2a453a443a3976d58aac76e2b44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09985e2ea91f4c08a1fb3fe016edfca0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70cfa0f51218476493154e53e8b1dbb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ab442d7528e4761a37ccabe79942355_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30aa462731e489cadd31a7b7aa3f2c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98d4a664ab5b4b76bf159dc924348812_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19fc35655fc94795bae5c9b1bf8ef198_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9731ca41dc5346328715b1b72d90d14a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bfc38d37e5a42ac8fc03da3a897894d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516472e36f9d496aa8c94bb0c311f117_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ccd34269c794e22960b8ccb14c99461_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e2b59714c6844d68d8390e2770ef044_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90d34918e9842f5b8088721b0df39e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b7d60396c746879acbf1477ac19434_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idee6fff4646d4707a2a06f61ed411ffe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20fbc9f911a54d23b75ffedfccc36c36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59169c0f6834a5a9361dc5a5dd9fb50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ea01dfaf7b4584b7cb6e99f32d5f16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i733145edccf544dba291d9978b2c7899_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1efd7da37e42404d934244b631380e00_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6696a02570e049eead17b64f1424b15f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib57b83c73b584975acd4aa8663d43dd8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1d3b1cd3244e0aad923e07c063a9cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i539bde58e63e4ef48c1df31dfc07d91a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02bd2346097c4b3b9fe8e30de60e2cf3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4641a8e98d45b995aa58ccc3163f5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c61111e751460c82200beada745607_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i713d31c07f5a4005843f4d9cf95d467d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a88bace3aac440ea9b4d06c6c356839_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief07c343564f4087b2e4707c3e91f20e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe1bc7905c64eee8380775080e0e9ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d6586ddd354fdab6d1c9bcba27020f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c020fbadbb34c96a252288c30f7d10c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6efd6ed9184294a5fe275ff87e45f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1883b0f48cea47939cd4e2cd6084fd78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32737545f1ac4e5788d077690a87566c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8165d1112e047829b04b7cf5d434fdc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b37f94f01344d068373b8eadf59831f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a5e799c31be4b2b97f3af704a0044b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7088d09c4094d16b9f7a4d53c7aa102_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief2d0cb66d6843a2b24234f1871d47d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7753d387d18e460ba9fe6aa0c2630a87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2278c012f1844a228077b20f27d2ee75_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb2266cfce24ebfb26a77e0821736a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c3ce1e7833a43afb07fd5c57894ed59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9eec4c9abea402cbed26716dfe0330c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fe99227a96e498abb64a74bdc78ffa9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d46b377a489415a9f6e4c66fe01bf48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06b300d5fc54b4b9783aa98a7eb7558_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bd24ccfb9ef45e5b7c7e11d85d3c5a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4831a0db655443696586e7bf7801c3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5cd4dd6f92f4fb4aeba7cc718e0b003_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b812ad7f9c4916b7d12f5ddf65dea2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if476e20ccbac40da9954263fe92cc4a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i380f7c1970374c70a7b006dd0d7d14d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48cd974a9dc24b368f72dbb106104fdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49bf71bb091429a952fad2e1c3ff77b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64f9cfb107d04007a2a989ea4edc5d95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0972f005da4b289e0431985712cca1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc26049b03349d5a347c39c0b1c2d52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75d16e884674d4b891ec0ff23d5093a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6d94719de4466686b830a0d3f35adc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67eac5db6f054e3180b3bf214875c398_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2922f1eb3341d59ffc36b1dec737f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6772ab94dd5b401f86bc3a27f2707c7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief19c5f56cee4d83ac0c396c293b6749_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65dd20d822a044fa906443ea329c9a4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6df1f9215da4dd8b4038a15c4d03869_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e2c14bb74904e8c96d89c5cd96c9212_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7f502712974d0099042d3487baaba4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5e50550f1a1441eb77bd65c2709b78d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10944a8fad9a45dbad295162e3f81b90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a924a8c7478492599a96afaa7e429bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id51fe3efcb094b65bcae5a4a5eb91051_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ddf9e42a484a8ab8fe46200c4b1460_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87fd36653fe4e028384eb4df59b37d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87476d0b8816403891dc417aaa9709e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaab118969b6042d18ed16e3ea6721990_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137f81c1d5584d34869c5b39909172a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96634206fbd44c669c42fbc69576e46c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedcde32f3e3347d6ad26d923ef7bf728_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i023622ad5898409ea6e74a7865b4ad94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b4c1c59dd545679bbdd8960724fdb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd18623cbffe4173b5c074fecac0d9ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f7d706f0cb44e4b3153791e14d9f6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374759bb016f41888888e78791dd4ab0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68fef76e57547f7bdc2cbb70b67de87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9444d5b1664f58a02728dfddbf063e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i040ff5ea36d3484ea651ef737fdff71a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if97446d23ecf43389079d10a5ca90ec7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f2ba44854df404fa52145c11e69cd99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id66a61dac3da49dcaba07eaff95d4ed3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a6ab54db1664800b50dfbdaff4462cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i833b3ba93d614377a2cfecac4c5866e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dbc4d9a77694d4e882a111f60ec428f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ec83c194e1744edba2a8a35ddd3a21f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45f95df00da14c09af18c27401b54ae3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i132e97951baa4113bcc1bae3044eb719_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb83adad926e453482286d737c575b36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d7907189bb4207bb49c42bee6f1dfd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fabc58b05ff44ed9522b607c9a248bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774c5a342b514fc886c9641360c25a17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b17ce920094858a99911bb86e14711_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if376a86c326f475d9363b305b989f5ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32c6fca8f8164d468cff272eeba8634f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47597a8ab7540518bde99ada02a6412_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba40621af6f34b0c95e94ed7710c5944_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70af15b795b3483b886c630cdd41133d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie64824a2ab1d473089f51fd77c18511b_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe9a0ab54434720b0cf1a566885c13a_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if11ef0dcf23f4836b169d65009b32b67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9281f223aedf4b3bb8e9b4c609a7ffcd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3aec1ab29624b00ae21ee1541745253_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603759dc019d4b2a92e63a7c43c81202_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1e538358a0404a97553c780f46ab33_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1acd2394418419a847e9c266f2fd96b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2263f3e53dbf46e49603498a02a8dd4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc491b98f87c48fb9a82e390d80b4690_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07617b881607408cb61cf2b2cf92be00_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052ad8a1361041b1a1e984ec500adab0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb26ec2f5da740a3bc8fbb26528a6eba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2606072a417c44aca18c5c159c178685_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a27173a90934ada9d520eceda174831_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed00c6f79924c5aac07fb1cde0defe2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i088cc2519a19414c8e3186d5e4e8a023_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dbb367e3e5946fdae5de683a45bd0da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d1b633d5da4aafad19b8e301c01923_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife16e0d66c324162af7d23d581f9e520_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic859cf2414014f41b9ff0a1bc9a8edca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i922da6ff675f4e36b395123bd41f860c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bf7db39f15a4eb598543794b5cb18d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0418b77d11494b49b8670d97efc20a6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9287dd64826c40ae9176320df60031ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4679263e59f543019e17c0b7fc2182cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62b877fdaf564761be440e19be29b2c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8899dd9c654bfbac46b393cd7d3264_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2377a28ca84de48887e30dfe2d5537_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i332ad40fc06246e8899471a208f82f55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25cf501ae0374a8db4041a26e5ccaba7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1235021626ea40d68c48483cac1e238e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i571d3003c339474b8a92cd20e397f126_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d884f9483546dcbadd8236be97f3a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib27e295e010541d7a58a958648701bed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie81297921b384692b3eb61bf4efc821e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d6a0c4542c41ffa80fc7096731b88f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1188336496264ef18e60cdee67b0cb7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e8562560c434644bad56e82266c221a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SotaterceptMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie71ea2fb304b4cf08e846d2e023c3048_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e62506b0ff84122affab840c3ae7e5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GefapixantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321bbe1dae804437a98c0bfa6c5e9802_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c730eccd1b44f8962e3a3b83bcdaf7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3df148b8481d43589980b5d43c439d34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf91833342104fa49cf3cfd60cca2c5c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IOmetPharmaLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f5157cdcdc4b5fb735395ee19116dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94c025ef9d554744b2deaf2bb4227962_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae9f90a84a045708d897dad62fa6f48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85becd9ff8a491c842d4ef0416f1bfa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17dae8a27f274a1f9b71d7a871389f36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb06f869aee84648b3f08b5c22658045_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A215NotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee399b5bb9e4f7382fa9bed6063f3e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A215NotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i666ad1c871a5437daefbf379c3ae7a1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A275NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f677306c544591b8bdc15d6568cad1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A275NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4603067c37764e92871db7d73bb6a41e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ab29f77d5a54d36880055884c3d208a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if25f9151edb34efe9659838c9851b5e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f198e2b6c8242329a2d6cce74447c22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb70a7318804000a0b25e0954dccccc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if272cc9ec9314c9b954ca02afdf19912_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i330c8b376f0845b981e104e9da711b0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A170NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1d4c4db752a47e1929b1bd9b0221ef3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A170NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e29e43c73b04d478539ff08737d0321_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A290NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifce508fabf274d7fa48a9d9ef29611c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A290NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if938e22e704043879505c140022bccd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c90a6837f441e4b263d84bf547260b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75a2923a86ee4187a9d8e30f1302bad4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6dc540edbe4a84988990cbdefe13d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i178e4bc051044e76b42ccbb46d917f9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i325a7820086449098f9f5e7c422cda0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333858d5ddd54903ba67c9eaba12bf2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95bb17180d994e87ab3f841a7c846700_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23e62f8001740b7b380115c4ba260c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d7bae96e8b46fe83ce2a84bc3c0cb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i449243770d5a4a3aadefa2f9bb07dd48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A190NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i186f6c50dad74e3a8ea966fe8407b0d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A190NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0adefdd4fd64c70843942c5ea526307_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3307530aa44190849bb1be7e10ad8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76684c6e7e7941fd886f959ebdf9684b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id60a350fed0a495da16890e319f026be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i311636cf40db4f85b916067268059c87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e284b03ac364d3e8d78fbfa391cb0be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7435768c60e4451a21d4ba610ecc268_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee70c6efaceb4bd8a3f32437df0c8a5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a4e8734f76f48d190b8676cdac0c206_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a04e2cfd3a641758e42b169902efdc5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i130360c441d842fda96aa1a87003755c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4181b1f1a852487da488d837c8158ebd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1267e41a13d4a82939639506b0b47e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if189170ce36b4eafb6f7201a9ca6ae4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ae7163839e44318d2e1239dac4e116_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc406a9bf2f434eafd58f22ac831620_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a64ddf383234fde89422eb58d5a04d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5f2f1899dbf46acb52be81d989d18b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0065ecadcbc4c46aedfe9502ae528f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674f0f6f35ce404ca1e28b4ade93aafa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic84be8ae9e69454eb62cd343daebc684_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0900466410461fadb2b25dacab282a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i443dc9e5f3c14c26b4627206e39cb2d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie314f63b9375416f8539d5d713836ce5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed29c8d391249e7b1ab655051fd96a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if16c9874988749a6b9d4de2a351876c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6381683a577b43b3a4f20e5ee2a42a23_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774de7dc3f4a439e9ef258e52ad97260_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6230e83c438e4a4b8ad400ee569ba5e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A63DebenturesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5cc9da918f54ffe9561a30e890c176e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A63DebenturesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf3fd779ab0345a4b5682f42d4df167e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9334d22b30c34db685a58c5c19efc4c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6615a4b358b4458cb9f301a9917387a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ff4d5f08ad4af5886628a1bbba25b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief565eb90eb64c95925824555f9e9d46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87c57d8615014148a065e980841d3dc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida73e3479c1f4e4687a0d8cc7ff79ca9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6dee25ec5f47f0b9d50258c662b2e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd0a9a37e0245ff9bf9f6ac947f019f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic816dee0d6f44f3e9271509aa2068b19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0836d3b184984272bd57f286fc63992e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>mrk:case</xbrli:measure></xbrli:unit><xbrli:context id="i4d2e8bc60a0148298d49f7245816f760_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4692914ed0347bb9847781d8d6fbef2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46200e06c7a04756a48759eed40c9e41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ee4600a50543649e2d1a72ee56c5dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>mrk:claim</xbrli:measure></xbrli:unit><xbrli:context id="i7ce296e507f349c6bd47b0823480f591_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>mrk:Plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i95ea257d9c4d4c4fbbd6847991aa1d0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica45cfeeb70a4e189cf234b69c9b1ed3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:PatentlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c06720f33624299898d274fe0bf9d14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8826f2e082a14b209b4b18a5290f7a91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9c3612f056401fb72e41a133ef96aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc6c432152d469a9be95a1902906f56_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide665a6ad8774e8695a7587e4b025cb3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00edd76d055e4b64afd262bffa0b265e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96029d87c50446529e49db206d363e3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7408e11850240218278c7eae714eb3a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba967fbd75634791abd5af201082537c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i178e704826a843dfa1384049fd999736_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20446a0c4abb418588d30ab024ada07f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfd71cacd403473c93f86070341b371c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i382c108bc8474154b35a6d4fdd79419a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b6db65c6024850a158f13f22048bf4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cfd3d09310f4317b6f6249083ad8378_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe10670a16e24ae9ace40787b5ce2a22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0aeb1e3ef794674a96fff2b9d26c8e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id17c6f956a4e491bb84b7d1e3a57f150_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7718651d7bc40ef9616b0d6567d4a64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27d33c6ed3449c6bf53ce5acffed5d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b9083971f54521ad14c9f68c6611c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76d34893501497c8338c478a45c7b0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2203d4639810407383286a40f8685df1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2f1c43c814b41b488e8134de602f0f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37e1626071144092beaba6babfdd27fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb4792b128164e4abdf42d752f6b3c2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f0f6b50d341424ab17a88ac1dabec97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5089b458f08249059c8517844cbfc375_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ca7b42ee03e4960a864194df69e164a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fbbeaa396c141b0a6b6351e2f4827c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae2b18472b24703bb9488d9d606bcb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib222fc4bb6d643ceb99b004ab5acd309_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i395bb955653e420e886491134570b658_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1c560946da41119cf3ed20ed9a3a21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf83da73f5164932a265dca954005724_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9243705e6b154b6aa3bd6af2236836e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63dd5c670a0c459fae41752f3906d605_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6774d1da76d4da2b5a0219216a610e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb9748ba281494181282cff265c56e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa42d6dd3f814707bc449ce9962c43dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8baeeb84552840538a8162507d1d3a8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a079dfc52a4a6497a425eeb1403e8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba0e181a34f4aaba795297286899f6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12d3fc8ceebe427fb6bd5603436c2c53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdb1065a32e34de0b0f43368d0777874_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i784c90e7bd294dc88132ba65ade89e56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ee628429c5b4b66bb61ce127cc28e2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49fb7d46a5334d3bac5d2d4116e11efc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62c401195a1c4761a19b5cdadde85849_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b501a9ec7d4dea8f9112a428ef72c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1c7c92675e40b1b1e2ca3fc8e0d851_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5141bbf8e94b49f7a0aa873c881c5fd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f48949b908e47e1864aa29acc116ec4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f58f3724274bc6b0bf3a72767dec82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae3975a126cb44be9d32abdad7ef4792_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02abcc69be99452c8ce2101132639629_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e3b50b3dba44aadb2c0ce56a935394e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd9e94b26ed5494abf5baee5b79b943f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63f253095b9d4d2cae95926ac75da379_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e82a23e98a7447f8a12f4ab996a88c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df7467a741d426880031a7209c24355_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i981b91cc3e4e423692ebf62688a6e073_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7e2e5a9fcaf49569cbade9e54075f58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1edc21c2cd0343e5b7e3413d27bf3fc2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878cc16768774bbaaf020a38a72e6aff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc8c49f9da2e48ee9aa0dad038b7bb6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6edfb93331994daaad9ccbd6a3ff2d16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5141467dce724a88a3c16a16dc6e57bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id687b7cf31b44549a0832f1284c3b22e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e01ea44f0044e7d91022ca6977facea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e7bb1d9889a46a389725e7f47bc44e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf4a94a0a6d04223852740fc12c45b3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d79d8008eed47b6bfe7d6f012412074_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff79da55ddf46a8a205167e0e830e71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife3fd5de6b3642078db592881517d635_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2dfeb6b2ea94e89a81b426dff17a96d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6be5d66271948aa8671b0ef9f628d22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c9bf0ebd284c25b3cb345c5806e946_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if550fbbab92e4a0393c402773c5a53c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b79ac72fb4241bc81c3ec6b5b6328b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab77361384864106be3cf07dc9d4c939_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780cd04510ba457c89c22dffb8ea2e1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22749de8cf749bdbeef2616d2d8d6ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie831c58af1194dadafaceb30180cdd0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336582d966b84b16b300a96248672867_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06dd0193192145d6a6d7021a9dd8f817_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21bbf4eeebfb45518c50300f370d3966_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2778b4fbd1b45ffb87524b7514583a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ec4cb354474da4bbd6842b97202f41_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9b0274b7734fcfbb1b0c73ee0c7da0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f74d89c62ca43fc8d49c4f183628eb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5a1db66bff04574a73feba1773e8409_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02446a35871f4693b8e5acc1f9a5b7de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0989ca72ed7543d093e13b1133771ff6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce6426bb9e749e9bcd7521d23f5c407_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib65644eadb2b4fa1a6c40d00289f4f35_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i962f8425aa3040a69e84e834f0b0f346_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b57daa317543c6a71e4c01cbe79b46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b98f27bd3184965a9bc7698e47ad89d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e86bd2f96d4a0c9cc3b9f4e0850708_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if74bfe6b3728464e8f867a4499a49cf9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ecf6e1df51340bbaba2f059fec3465a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796214cf8fae486795991741a4067066_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1637d8c529464e04832eabd1d29ad359_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa69b52074c40c6919a723ecff07d91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77f365cc16f54180a306da2bc7aee6a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffbd9fca0edc4beb8128fe8f2eaab268_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75257cca48cb459382be06af1340c22d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i400ddc9234554cba8b43aea81b2f3b12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe56286d4ea44f1aae537601d99ea7ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4cf65bb3ba540209a17504e51e8e63c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6941b80bcbf5486ca983dfe0369cd741_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97d1993aeff4c979b35dd2e4f863df4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fd3b14d2a9c494aa14fbdcb6fb11f9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9790f5a9551417380bff30595e606aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ded4752a21d440a80630cbd004ec39b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c179b8078b940dc99ef97ff0435620f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaa64b0d1dd44c1ca28cecbd821aa477_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ffbcf1eb5b41d7b00120fe3ee1352e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db319e5ae454d27afcda3fd19764a79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706ca6f052df467cb8f58b4806f630c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30f0da2cf5e1450d9c71192c487952c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44fe692f8a764fea898fec5aa9111d12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i379e05b6692f4dd48df63d0606e10804_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac502293aa264b42aa9d2b66841da851_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29262e1dfa004785a42f1051bb310323_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f9aca5533a45719f02ea5e54e22cbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ac8e7222dd4ad2875cdd76fbdbf312_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92ab01903744a8bb55dfac3169a2f28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce94dcb4f694c35afda081b8f7df941_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5cd6c26a754923b47fb82b1d835e26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie809e18ae31c4a759d00ca9258dfe590_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0670034fe75f4d2192a609e94de300e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05abcec58f8e487c81199b7f51eaef9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id147c2024aff4ce09865ffaf7bfc6e1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1a7f9d852f245d68f1669370ba8ea37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c3b3f7029dc4097b2e2fe7e1e985e18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fbca24807fc45728ae28f4fe314fa94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia92db765e927452a886deda18e0ec49e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c7e60832cf84f69b1d73b1f05f3a237_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc9294e66deb48e4a276489e2d5fbdd9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad21e08ece0443f09e98d2df051b2720_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d4508410614547944dd3263008dfa1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d27a90fefee49c6bd2314841eaac836_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14f445cef0a94f3d858a4e92b44e53dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib402ec846ebb4646b9e19d44aa463e42_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib23f4c405736447893c2ed0ba5129d03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c0e35ee479451baa6f3dffbdb78a83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6099682544f4ab6885c0649f5ab634e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9499680b2a3b46c692bbfca28d92fa99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icadc8586f8c14f1599940106a4a639f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137b41dccc2a451a8661523b56e79847_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e264e35d0845cb9d3d40717095240c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbdc9d92cae54e3388f07afc57b2e738_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b7acb7de364282992d39b44d6c732b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ddd68d8b0db49c6b4809aa72bf47d60_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19f7fa74b02f420fa18a1752a0f640d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6074254ef5dd404ab34a3d26ea726aa1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9f0c02f2b3e4264bec1d52a63e9ad74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eb2ef278f5044ea82584e0170c78683_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e92e9adedd8495e89c3a894377ecdd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74519ccd850f450985a56ff14ca4b7b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fbcea62d0ed4955ac41d050862b0e34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic56cac3dd6c044c78e322e9ef1a9d386_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f6500c95d2415997c537d9ec576b14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a23ebdda2d14f27ba9a6dff74a6bb93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie263eba552824ca8b7bc26dc2b1e3c03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i500f88f01cbb476cbf8d0869fa88f998_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife7b52747c1c4adbb18078f65218a7b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb20ddb11d8244308c74bbd88c09e832_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4b5c61354004941911815be12a06d46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575c68e47b1441f4b370a4373fcd38ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb56ee6d545047549d0817e0e372530e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33d81e4466bd41e4b377ed1df2ea8e56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e0f2f727aa4b97ac781a4fed704c4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7739919ef6a3464e8636dba4a13f4976_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia616155b2f954117981e48d2681acb1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ff224138dc04bb5bcb654572597d15c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299c4edd1f2c40aaaf1ba172f892df50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6be1fc79ba48d990cd4dda9a8296c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b4299473e14a998ff1749df6fabbad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieda8181c2b92463f832b2b807385e1fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica5c9a82e7a14132ae1bc5575aa82c6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45b430cbec34f7ab97e3b77aa48d4b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88665ad826e641d683cd947d6542e94a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e4eed3d574f4c3b90b6ec3fbf015cbc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9092910402714a39aa0adcd1cdc3fd8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0977763dab53428ea24d011484e19d42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e6aaee1f8734728ad3f49f6e109d45e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646ea08b951e47a28a3b3a458d5f19c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7376c87bfaef4564894e5aa0078bf290_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707265f378224c11812d0a38d0ca7c46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d671f19e027414790d54572de238e8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i976895874b4548edab0975dff614e53a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia948bae53d494c0fa79a34e4feab974b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0c88c3aebd6403fb5e73ba3df2752da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3101abbfd6104bf9961e4797c1fc7a59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f53799ef4a489f9b8523196b414ed1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd54b143c2f54e0b899d7f7221b49435_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50d4f261c68445c8ae56f66fe852bae3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81fb3f5ab0be4cb8be61559da9ba2513_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8688a36baca47b99958cbc03224ade5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib528900af6b84f9f883fce50d5d90e15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i597378302fc14c5688b47d18bf9609ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c35baef64594afe9308f4038d2cc019_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b32ee0e7ad4477d84343a59721b904a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10aa657ebd0f4ff8bde707e6da253978_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e1b8d26f324b76a4c50b0c70101c62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12fb9df356b24a28a7100d667bfecc3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30cd90083da946e2867764d0280e60ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c1df4974f5423196b196d52fcb54a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1056686abda14133bbb25a974481bf51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777644be6c2f496cb431e433227cf5e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaadae92a049a4d5c988b6a3155d0fea9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67cdc14fb7854ae6ab8daac50bf5b18a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4e4116135e74738941265923fae287e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba72f924d50f448995676c787615f080_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6335958a344a435583e593f08493ef84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc7e70eb2b30488facea1f9b7925c9d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61638e78d26452fbd7dcb3dc3b0b9a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29c3faf60ab14164abe7ec068a5e8acc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i392677707f7e41c59c65694477a60d86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d1b3b11ab744479c9bf01ef20dc759_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331730bf6efb44d682e209f3086f5deb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aed454000324ddfb59ec630f8ca840d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if44f8b9ae40243fdab6b2eeea80bdadb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53221686a07c4c2692910544bf9e5f7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f304228c0b47459eb2df8092a19197_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35aa130d32044270a7ca14c1c500e128_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd5948864f247fb8240d73efa22974a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id79d1d134fab4804b1f8916d27f270bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica51247083bc45349d5f1aa4494688cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67efbd0183464528a19f2f2370692b97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3d2bbb957c495e8f423ace831f825b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7032f825e9148319be784239d5dc247_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9375a5e955a43e4b015b97beb369e80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad73c6a4016949568ba9ffec4920197d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99736db639604a3b9e19d5223863228a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0989033959b24547b6d2f0250223be9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i062dd5eba1074bd9b7e1f64bbe49f973_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b4fa5b2309b4501b0b66a49e6b61e2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f5c0ebcbab4a01a984c3b118e581fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f1f45c17984c09b0569f1408b068a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d7b39df984e4cc8a43284b6c372e087_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if87e1269e4974cacb4df9177b0d52da2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0038c792d634a9ba8b15407c89e2895_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec324fd291e244f2a0f252da445766bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacb4e5f9e58140afb021278770b30523_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e89844fc4dc4df08d07363b5b09c838_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf01a553998e486db4187f11f6c70b9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i431015c47e6d427ab97b03d0f8688df5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e027fa8d0004e2f893102d1de5efaf0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbed2e49029849b3943ac5cbdb11cfcf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02f3afa788a448f7a63c0f0ccc99339e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ea805daaef473299b9ae21f484efbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35f7bd0fb86b414a9c2c97debb06568e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f9f4e4430546bd9a3b6f9954b477dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0543e0d9beb449b8a879873310de464a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08c5624edf264ef78c72a7cc903e4d53_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cf767adb1b441a08fdbf662ead15031_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae0b2dd3b32941cc92817703c2a4e429_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c9c0618cec84c088e773da09a42ef8f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb24ab962e0d4ce68a8f9e970430d6d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib51e5e37dd5440398f596d5a49edb8c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdeac8350d854b17860499847d42ea25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88cb35a2c8a0448c83339d1060a7a9cf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6c5629485f4afeb50f9607d49405b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib03dc9f34fcb49d685cc8f077e1f7d9b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd4a51131f4d4e358c9cecca8b9026d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6008424e527d4605b76b5c541489c471_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6924e6dd4542c39440e5e6128bd0b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48869176aa064f5b84788a6a483e5d0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b32614e3a94518839d5155b07abd5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4193bedff7b5470093b4777d0ca284e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86abfbda1f9146a4a6851f8c322ef63a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b1148bd1f04038a1852875553f8c89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f0a39a74efd4a798069f6dc88d2753f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e83024d7d194652beabf70b37e52087_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9efddc2c4eb4b51ac27ed6cd9f54f5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c24038538054e02b5a035f3e61a08dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a0ff66d0a1341e8afc7ed8586d8a024_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e6daeaa1d88470ca8bab0e45dcff6cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa6e26e2efe4d9ea09bc81d737de0e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id06d07a27e9045a094b87e5c189c3954_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a22f408073435e909cf7aa033ebc6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice177b53b8bf471bbf10d5357f0e823f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51e1329bd56243e18e983e2de609a849_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0a5086b5128478aa64899a4b8b33cf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b13ef32d5364a38917129aff9fec7b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica90cf7838a7461289b9ba848c17f909_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id626f58b4ed04285b83a1f5f564106f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85b5f8a81b5d42fbb063b001b277bd2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i121d0ae7b5584cf08889319e21df6f00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ab8af9defb944fcb4a112b4a4fd3754_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica3c0900036b4c57b95574ad6d4370aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia23692c19eb34a1f8e06494fa27cd511_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8677bf18cb544efa1b2a3272f0a47a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6b068cf6ab41fb9bfee3a5fd9d9251_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f2b2c632f44cd1a8f7e0b0d9bb1c56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if643fb5543124a6894df897dc47be455_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4df17beca4f4aae9917df8f72802d26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96b69b9758d9428fa6eee4787db14eb3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f07f5009ef24afdb2515077be35b2c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47b6f8be3a54363980225411f0cde09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd4eb7c2144745c5a54d9ff57aeffc3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03afe5c2d65644bf8233215d9ed8ce21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667292d025a9462f937f9e358ff4597b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e7a58a77c914de6a53aea5b50437da4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8888c94d17e84a6c8685bb3aa616ceab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabf411e7ed154695860581e937aea220_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib427fd64730a44df9cddac5399f38153_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c47a65b46544c38b3b012501b67980_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1da62d5a32854107a7b16eacacfd2bc5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7f6d0dd3ee4a929304b9754f6827b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a86ee5eed134b6c89a7d0fa2be8b6b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d73446659a4e33b8b0a661934a44b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf7ccf80013542b487ab201e6f185f08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a9e21c8c54c43daa17d22d749c695e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e32729f23f4e5dbbc51b849d911757_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b0f77300a243acb6a9ebbfcb1aaa2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b86fee24be648ad94520f4a1978a1cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c501dddf974f5abc029b567480dbee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i091b7006b6ea46b3b61e3eecc932c387_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b5b17f159a845539e0a01013b211052_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bdda57c7bdb4c5bb74a961da2c1d8aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica17e9ff742a40d783b5644277161e30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0ef3d891cbc4cd69295e9cecc6d5a62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e02936176ce456aaf00f889622803e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i483bd58d24394b3b80eb5b353b8efbdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i793918a7fdaf491fb0c1dbcd66331c49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc268366729489591fd438b0fe8fe17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd69e0aa38ac4ec7b4f7d1c9516ad2e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icebfe327fd3d4adab637ef455f461fcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b3c817820c64372aa410440be5205a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic83f94a689444e288ae0dbed266bd406_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b704682926148cc84a8db8efc5c796a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4628916abc4126927023ae15fd0a85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie15d37d6fcf94f1d962a65444ddad466_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia130b62a5f43450aa1a3339b37134132_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3df7f246cf14229afdd2685344a7de4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2807f56dcaab490eac85b298b86298c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib26b7b22b4244d81b6f3cc21118aec61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf9ac56392a463fac3b411b9205a0a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6a02cc27c7c4c2f8ba5429f74eab5dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee3239325c8c46efac7fc183d07c9374_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63554eec91f4d6ab395b9acc70717d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i287ca8ea377b4ed080264796be545504_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8db09a55de19497b9b70d729546fbb1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14d98b7a9bf04af8884803848570265d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e091f2feda475987d31a21e338c4f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf7c43c5492487a99e3564c60260e5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f74f7cbb854caba1a1c57ac918a3ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc35b4c7594d4187a5cb7cc2d7f4d264_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90407e0949ed436885a9125ae3ff3616_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i728b0c1d082a441b95dd386a599c8098_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc07cc2ffcc4a07b93ab604fa085182_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3750cadf46e42dfb107576386473746_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb00f009ed984b3e9d7ce65a1632e458_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6dd6a6d63e54e938c5a72c294269cc1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08fc130457454a08b3f267225ed6ed27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6467d1906b2f4d7e8bf6f78423b52659_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de3243e532c4de2852c89993a892b41_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e47c270d1243bab3c87f29d058155f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf563768fe14889b1e01fe62524d07f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a491066de6b4e4792fdd0a3377e0b54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb93f5076a643298235176fc92ef07c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e1bd81b4d648f3b5b45923274ecfc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e40afe1730c4117941b66edb4d40d3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1910fb48ae8b47d59024291ba45240d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149179b3d497412eaee0ad158abcd1d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1e84e538d73498da4853df1d5a84ecf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i495b7eb9aafb434b88ff4e62c501d012_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2370d975c61e4aaa91def0aa9732dfc1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfbfb9218ab84c998baded784956a8d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3eb3c9e8db1400ab82cf431989eeb20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0f174f676614246ac5cc662923bd7de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1deac4fc07e246e48d31f4bb339ce199_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied9cc57e45454c60a2afcf99a471a7a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea250ccc936041e7a2dfb8b6d72e949b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc0707765e4e4b9ea9465ed6da91604f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib36b1192c28e46a9bc24708ace77b04c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa625a65fc9249b88c46cf2eac079bb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec626e4bae224a9f838923e9721430eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf509bb5a7f240e8bfdf5c3c69c7f006_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad12fdc5a7d14e5ea50cf778b94402fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9213c4b474fe4561ae99450da35e89eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i755061a1bfda44be8dce382e25583fc2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e72546c73c4aa4ae96105aad140dd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DefinedBenefitPlanCashandOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb0d794972b549a0b3f947ab5849bf7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74135854883f44a0bb9ee84c11306656_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i818016db2b54406e88278d77b05a6d54_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42dbde811d0f43b89555c0b2477f1fac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58dc9cde42be4f269b8259f1f6a7f155_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf22a93cc2d4d0a814975c167a0a1fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9977d228ad648dea6127cc9cf399ac2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb2ff06220a49eb8adeb3181d31932d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:HealthcareServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3b1868b07e42d9beeb1de061d22b1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:IncomeTaxesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb2506788d4645da9386ce90a8f1d696_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7418d8deee94241a890cc5e06e3fb35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i412ceb3578cd4323882f96bffbb8f4c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee0d42255922420582e8788d38817637_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a9a13cd0a149fd8df342c997fb0ade_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i622d15e154f84cc28b01ef17d5fe85b8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mrk:ConsumercarebusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84dc814a0974bf0836891662899fabc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9efea9cf6b604686982b9cdfac42f3df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76e98608767a40d2a24b489eafd3e853_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9158afc2f18a4d47b2a3ce049a91f164_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b88606a448480e91ccbb985a641950_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i836d57ab500a430aa624c66b51480417_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67716ab8d95d41c1918c1fd2f92b31b0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53553e2c388c408a80697cd5600f2014_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a24da076c044d1fa1d2d467928316c3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2d1a929ea734ccb8df8f7b64219510e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3b8b15d7e64a8f9877988ce4a10017_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i125b2cdaed7c4239afe4d7fce006c0b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c54f5a5a29a410190d2348b3cb74190_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice3199f2dd06439293c869fd20ba1ae5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib83101efb98444978fff619393569f09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144b086740d64654bd9a30061c1a7812_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51564faf2000464284c4a9cae610de81_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16d9426fdca4a16a4bd46315c4d4084_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4063360a866a4d7484c9f7904b09eb53_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6168466248344c884d7d9bc139939b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i615fa016c2ed4e2383a651cb2aab2822_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id92ec4a36cf94e91ae66e6a887ecd413_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i192fe0af931a48ed803ea8f1c256afe9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf472479cca849d1b21d8c0dc0ed9d69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb6c7a465398473797dd31962d89b8c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9f5696787284d468844d796e307282b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i306e82501fa8410bb91080177d50d682_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib425c1e1a40c4df8944d884d3d307ad0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i924ea9183ae449d796b1a0a7b05f0e67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if225d2f0b77c4d51944e158ac6b67edc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a311768e0b74998947f7049aaba9c79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8de7afcf6cd04006ba705dd72d2915dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia855c9dc8c7e44ce9dc6bc2b51ed6d1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief0fabdbe30d4ec8b1cd71e2cd64c3ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c80f2ba2ae4750bb0b2f180be80c68_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1ce584193c48a6b0103a7644f7ef6f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54db7d5cebb4ef48b74f960b41c1c27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5639e6827db9445ca99ec3429d38514b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i585f62c2af3048dab19b2ccec8904d68_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i118a055047184fcfaf92090074d7ad4b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed4f4d9b9f84b11afd909432b51fa6b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7ee5ac9fe1248559264115ca0ce8e31_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ca7fbd199642df8e35c5b087f2f181_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412a988a09de489e882e0bf3f1cdad5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b7bca2629345b48bdf4ab1a9cc002a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b89ac54cd84d5f97104114e72eb401_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf7482af6de46c1b860e27aaab98d93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dcf9b8bc9de4148a0ee6c3a5a6f2815_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2464e70d7ef4f7bb40db6173462adaf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d5e11e3ccd6431c909fb49ed639bb98_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3890b29d4919406994442f1b5b0164b3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i126a4a0ccf3f40efaba2835b745502dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifec348f46f8349989fde334c3a0e6693_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie62a9ffa2b864eba96a15816fc03a298_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96bd5d4591c74fc59a16a07549d1b809_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedd13c82855e45e18ee1bcb4674461b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48dea599db224c139d74cfb868f7ca31_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if671aaa852bb4d1cafc2487adea83e34_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06e29a49f9e146509c3cb1014ab81958_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbecde3516774ea4a214f44d642a3ea4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30ab7314f4724a408939aecfacc08cdb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67504f9dc2414b458ecaaf3418bf800b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7410d9a99f3144d289bb5915b56f611f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30070b5abd3a408f95c70d3b9328afa1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c07bfb932384999b083744d5271f56b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d896fcb2b074166b1af7ecd1df7ecc5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4449be5f9f4d4dd7bb5f71f197d1195e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24b2aefb0cd4d1b92b0312679c47a00_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ad66ab734b47e3b0b68f6d3ecd75cf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092a9a3dd77c432aa3fd0dfe58c9fc24_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee03932a98f4e90a47a62b45b98473d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f84682c651e42369b0be205d5dc544b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d55e46f9c6a4d77998096a6a91e85c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69815c97a5284f8892611939d8f5ebb7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8887b54a6020401cafc8b73bf4852968_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8d5492cb544bc9894b3d738712a155_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8f17a778d3d46d6a0f56138bb37401e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8600b39d154c5299e9b719a4e65eff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6ea600d207424d9ebdc43381b8d663_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb046a0ba0c04045b30d5722effaafb2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5bfe0049f14a07b613d265fd540357_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350b1e0896d840898c101f9718c2c2f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdcd82740163451e95d5ef31c1a6f103_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59e38a3f1f14f8c99ea483759e328a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb83f4e70884ababc7ef0c9ff8f1f20_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3921cbd5aeac4547b3df48439ab8f6d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ce69f481d241f28a3dee75585ddbbc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbceb0e389804da8ae6d0759d4119f73_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e8ffa354eb405b9df85f225faa97a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6825addbac14de89b7448f21f1dbe0d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7528d7d63d24a0ebc48ba15ef1742c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3e69f638636462c981930e509c9d3c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a52444ed7149d9a832be8c913ccfb2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2262179634dd4d6eb718ea17322c0302_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i290541092ab24a35bbac3de5b7d6757f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb120af06d848bd9bd55575768c0454_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie68cf814d8754d468098e25c4faec59e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec491afd16ff4fe9ac6ba8cce69bdefc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3727a4b434224ffab2d1dd6ab2a31446_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie09b13d69e694ea999debfb5ba7aa578_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic347c94c641d49f6b9ce87d0eac2090f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d75f1dea9e4e668d532d7b2c10b2e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec4b2a3d76b4364b2d56779a19fa6ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43bc6db40c0145fa82725faf6c749c89_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if76ee5e9706c4379b1703add36dffafe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ddb209f66734519ba2f0f9440875f4c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i287f086f0a1348718abecee8bf3fbdbf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d92ef43e74548739e46fef213a2b691_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a4d1d25cbb48a890bf52a4c3b2ce24_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c9956b24fe747cead1ba231ba98dfdc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i621acda9e95e42d49d9d543db91d4937_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4146bb447d743da9ee890800435e8b8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e080a31cc484b33b1889bec0d989641_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f25ff9318914fa99b0b7fc3b0911f02_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc9f572a206f4619a83415208462c648_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14128500dc8496a9a941b07e7570826_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b4e19b01d14af2b9e7a5be87b0ba14_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i680941386a504ccaa708270ef21bba50_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3351be1b9677432389243aef036d0f4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7339a2912de4accacec0a80f0cbde96_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2c9827e87644e79a48ea79d80420a22_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ea00653e9e4cee964d9489c3bd0732_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d42dde9fe44012ad67da4ad05352c6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5022ef10f96e4b7aa61a055fd68efe83_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef9b40b31044eefab0cf6ddf301bf11_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6cc9260dfb142b3ae1b4e51b2636178_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2985d0dd5ea145ce8d2f0ef7df6b36cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c0ac23a8c384de6a68683e097588935_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica9555c3b16d4029b0bdd2a58b8ca117_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e00b0f2a574b709afc847e290d1f4d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc00e8952a6492f83da929648c7859c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb2f997ceca4c2db0eb415936f392d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i588ccd376cce4c459b89838c0dc320a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2ca26bde454c769f7a36998e53e53c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe6c4413e27f4dbdaed582d92345ee15_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe52f351a8d4153a56a10fd4e76f488_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82d4d56c6b614201adb1944e0e9e1c92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i044a677ce7ed4b15a2562a43b2b9abd8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbe73e300fe4433fa589eb9c59eef229_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b81951a30894213954768ae743f31a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd822d77da04087961e1a434edc2bdb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i919922d6658d4bf094bffc6057c2d318_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2a5bec58714422fbaf00a68687b7d72_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f251d58dc4741a5b4bc331916be0226_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i238867c42030496c888ff5fec0f238f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05c8e25b2f143a6a83cd529f6a9edb3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3caea6cd27384755bedf9d283e539fe4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49045b590b94189b3ba82d3341d8dc1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib08607411f484218996fb2684f207c26_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57867663740a4d66a1abfa217c854234_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17685f23777c4777b25d05b30847170a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if341417b19c14b84884a2711d11c29c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id336dc1a92684f6d959130b607011823_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49ea5e6124f4cb291979ada6f6e1d4a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i360f6b57fbae4cd3a936581cb768c93c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i790f602712d84379bed540b6f76fc57b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id141d171a5bb4e19948360b7c1265792_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a6fdd6f73f41219529c1d7d8607b4d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide35d7caf43044a8842880c9892d8610_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b2ade8ccf2247a083b1043ad7d0e5a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf3d0c3a557a4c4a845f4c3c31bf35fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0948681bcbfe41be84f9be49d7bee81b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id628e1c6911e4ad79edefc7fbd510f4c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ceda0300e794bddb9081944d2f35ec9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9682639f648451a9580e7c6106d6bea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfe45979c5843819de5fd1faa5f6164_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5014f16e8514b5fa48152d56fdf4acb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab537984b5264cc6ab6b179f58898f76_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i653304b28e3a4aba996ff5ad6455596d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc699a519cd4da6b9151325ddcc9476_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6522f24b64a418290e82b61d41d2138_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id497588ccac6414284ef2d78c4360759_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57de4669b2c404ba2df9d8c63350b95_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05c9b8eb51bf4bfdb4aa84f8464b6ad4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c5d62997704e51815fd6ff6a3f63f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e966b911fc84965a21f483f48ad5f9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670abf0ceee14b2bb45e1d0361ced108_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0875049533455190662cb3270eca92_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e34030eb894f44a8c12d5525d6bd13_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d3bc8edf0b84232bcf558d786724b9e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08867c31927d455abd0c72bb2f6dd29f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca75dc6c120487cab23cf75b4de21d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i573ac9203d854868906b1f2a5afd90e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d492c360fb47b893486098bafc98b4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75797ab2cf2f4e1ca746e1ac560446c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5527cbc51fe7422dbd7d4c2cf6cfcd9f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d4058d922d48bfa4f4476cc78aa40d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff774d7ca444bf697bf7b5e3ab1a652_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54e43721fb14ed08c10d118aa1018f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e35d6b25834f2f8c64c46be0b8e79b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1399a756a222419cb0f46fbcf7b54698_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id72757c16e414c11b68254cb75195b3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75b7a5a1281432abceddda5981a31d6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8971c73b69b24487819c96119033483f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe780ac69be4298a4650d36dd0c8e48_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9af6d5d2383c47e9b7f3aae3de39cd9c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36b66816cc44e4b89e9cca0a8e2fc39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2128d2249b5433c8c29182a6113f86a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6802fc4302e74a7fb1b161db797c4710_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i335b959ce3ae469ea04ba9f29a1064b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4eca5885fc0477bb9a10919f5131fce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ef4256ffaa4cf08d46414850e9f302_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fc97751676240338ec6973bc3f4329b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f098b0847574bfaa047e6960ba579da_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic789d859ce7147209a488fcef20e508a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad804308bbf473898a71229679ec50c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8fd691878ec45c88dccd5fc5b741c66_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d83bf3c10424ac1b31714923c7c7222_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd7b557051941028e48d4c7979df2d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1f22b920f0142a7a77c93888483253f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a08aa9a691f42a684ca26528ec547e8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89c5034ed9c54f56861f85fb06ac04b8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20da1a75201d44228058bec6bb25681c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc21603e76ba43718a1da2416c551b71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i860379b9e6694ee69337ca4a63a63ee9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ad805324a7466aaa2adf87437b786d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49c259f812e0493c9a80f73147db4d87_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie334b2fb8b4f428eae8891ba5428e8ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b03e2bf2dfd474289cfb9e6b903b9e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib19f798e233b445dad2d45692dd72895_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2747d6aa809047c68d271b385afc8f32_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i362f6d1d48a4452382e6007cfe8aba1e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e40e495bd0b4d74a40b380b6538afee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfcb3bbc22441859e766a0bf136e8f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7844fb1fab6b467795efe381ddc3d257_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i077c0c6c35484b8d80c194006e499277_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaad4da76bf1442ad9c12d29fa802065d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6abee35368bc428188fc163b9c321692_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia410bb854da34475906908a70e1b9ddd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d519f01b8384c2bbf73455aae73e495_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb7e2aa6c1ea4be2baa790c8abd97c73_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida5e0a42af0a415dbc7ac173403c6c0f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1120f19a2bf44abbb0c3dc54b2a33858_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe420bf94cdc4e508956f70224f4c347_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875bb4453f9346a9889252db74a91e92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id52da847ebfb42a892f32e61b9768325_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31403cbad4be41ff806afb334c3cc801_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e7beb95553472b82caa89c381f3e73_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id707418566a14de9abb8afa077ffcce7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbba2c093f84e089af32d87b1ea49e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4359fa8ee9ae4e1ca5acfc1ef3d4769a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i855aacd97879416694b822d5b5a4e61f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053d6ba1ed2841b3916017660c6df7d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib04c71c3f757454aa800a15a8010af43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c1036618754c889e448fee724b87f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if22268e596b0476aa1a363dc33a72e0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5fc3ab73c2d4c188100a9ccbc477ac4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eddcbbe421b4d6fb2d8b67f56b5b5f7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ade6018d32b4458a32138623c4dd828_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f4bd9b10014321983b0401d103bbd4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f952e92f0ca4e6483f30550b71d62ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a7a6ab9b3e4c83ba2682007c4d5f5a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i409834fa971041c59a9219af6cc8a8fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab2f301fabb64c4b9a1224b62e33cf45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e8d6fd87284f119ad6bbeb297f087b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f80c96aec434110897f030eab369d00_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05ecde19c334fc3869d0a13c50b3d91_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b51fa1e63844c0a772c0468f3aecc2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f4c85d94b444cc93caffa1905c6ad7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec26147c7b0f4628a255c9ed76696470_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c0463faf174f59a03cfbd4c245e30b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac282dd562d44386a140bff679bd6312_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8227972e5ae047dcb65cacbe11fda43e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief9e718c9899485dac81e79d2b65a8c1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902f509e24c5427593e3c70a397619cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c92b7d768b04f0496a1e4096d91ca45_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b64b45d21a43908135485c4336af56_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b007460a32c4c97a79e96fba3124285_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa79b78c2ca447ee97688bc48b4bb2a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7e4a72b7eb4ea4aa580f1844e390d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67bce372466c44158bf7d70262025e3c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53fdee9f2db04a4ab37654bf8ad3ce55_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcecb7d348a3418fb83648e67423787b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d3835e3db0c4b86b4b85421ffd621a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391af24746af409e98e68c04fd6b1a6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6f76e1d339d419f8e388024ded2d57c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd674a922374a05b288a846e7656f8f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice28c52b471c4e2990f1d5fda9a6605a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dd74afd8fe9493dbddd22f40067b822_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if84e446473224b92a8e962c9c6661bef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92e22bab44c4a8585d741cb84b22e0b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d4f819332f4489a002b37af48a6b7b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f07294b8d184726bdd9f9431afa7552_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic659ca2172564f53a729023707985665_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8410cf640294595a9c6c3993a24c454_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice06d069455f4c78a72b7a22c07b369f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9405751ff5f547cb86645a579c2708c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c516c5302941878e7cd4bc6ff5a4be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i980d80d9d41b4b498a1d29eae232be01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d40fffde89545dba8648608f3dae7f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fa1c27df5144fb9b2e20a19423662bc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14452d35763c4c49b6af96a9eedff2c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c19fc0232664dbb82ab1947769dbc56_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3c67e1533834abb9370666fb82dabbe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie42b1731f9424c6490b9e6d7083ba158_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700c5af718dc4cc7a9afb37161495201_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i244f5c86b05d45859ccbbae1bc5a1e4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07ef034ee544842829927be984fee2c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa0b2b1f7064efc9056cdd5245618a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9887835dab646e18759f89f0b92d691_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f650db9484346c99e5ce03c627df6a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2dd5fc45690468599bc819ec36baa72_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb0c9180eaed41789a00b00eaa6420dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee23680a9ed04180b885349d2534edf5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47cf1b70e6843698113f3bbfd683a3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i485ba6b68e3543b6a383a01f55dc222e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91f4520623a2490cb524e95878a17cbb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97c7636f13a047af99200a56c856358a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdb5826a89fe434cacb3a48a5d577261_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b6e713277c47e29642541d538d06f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c78a1f59ce94b479267d48bca0bdcf7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5553318c17394c7c86186b52781cbbf1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3887d92fb9d4538b9b8882d8131625e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1126352971dd46669a405313ec339037_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idefdfd681b4e4b51923fd6feb08020aa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd29895771bf4e55817628fdfec5709d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dbed4d7248d48c98107ad18eed29ce9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba4578f496546feae50404f7c94acf7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb727fa4e7aa4178a7b1e42c772bdcb7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fcd9e2f534e45aeaf0506c607d7115c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f39fabecb0945059db383224430a917_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d71201413c34bac8b783c4fe7712fce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id86c1551379c460aa0a9da151aab63c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5faa00c2fd48289d394fa06ad542e8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702054b971f24d8d84a6e2447ac82145_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80d78a41cef745c09b4167941714950f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83ef2bbdf9d4c628f48c7199364718a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65d141d77524275b769848de141bc4a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e4eed626644fac94b8f8c13407308e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0317b49ef7a406ab77915a805d48780_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadfd209928014784a6e2ed68f848e3da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f86df598e9d4df4b133bb5dfcb2e6c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b351db0a29943e88f99348848e492c8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f96c6b07354101b83e5657c2f98734_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77becba44594afaa9cd2ceb1fd401d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0089f10a0e6b4fc399437bdbe0f24541_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc8434b69594d2faec9792cab27130a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89793641482a462a8870d840e39282bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e29b586bba44708bb5e13fc1cccac7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52450a8e8d2546b5bd337d8497a5289c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69892ca182474febb07a4d42f2311e31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6db0658921f94c4da60d8ab9e661845b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i960c222e9b7d4a59927d7e6165657a27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff168ce1b424a539e923a9b1865cba9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c65b2ff6c94bb8bcc3df47b62d5705_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb7975455e654a058dcc8d1764cb18b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc2004b75c2c4673a8d52b5496f1f227_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic467a8caacc54f36b9cd0bbb7b623a98_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c87fa80f5a449daba8c6132b457304_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4457dd521ae041f5801d7bde8d26fffe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib520017c77134d6d8203bb67065a1066_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba482b7988f246148ad09c509cd17ccd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd9499f0549458ca5c8d1f40663fd48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ace3e3f4dc49a9b53a1d8959fe23aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1e1e934bfffd457891fb6e33dae50d64_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As filed with the Securities and Exchange Commission on February&#160;25, 2022 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.985%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">WASHINGTON, D. C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:120%">_________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjYw_adf26d85-adc3-45d1-969e-69efa6b15aa7">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(MARK ONE)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.550%"><tr><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6OTkxM2FkZGU1ZTFlNDg1NmI2ZTNmNzhhNmEyOTgxOWMvdGFibGVyYW5nZTo5OTEzYWRkZTVlMWU0ODU2YjZlM2Y3OGE2YTI5ODE5Y18wLTEtMS0xLTA_a10e8944-d8c6-4656-8d7b-83cb14e766bb">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Annual Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div></td></tr></table></div><div style="padding-left:144pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yMjY_8fa38186-a478-4092-9102-78dc60cb3417"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yMjY_5309e26d-3654-4fb6-b35f-2c0217d9c0fe">December 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.550%"><tr><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6NDdjNmJjMmNiZjMxNDhhMmJmNTAyYmY4OTE5M2VlNGMvdGFibGVyYW5nZTo0N2M2YmMyY2JmMzE0OGEyYmY1MDJiZjg5MTkzZWU0Y18wLTEtMS0xLTA_6298d2e7-3eb6-4762-99af-38fa113dabbb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="padding-left:144pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjY2_0dbff403-e753-4178-9616-88c269c6a203">1-6571</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:120%">_________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjYx_acda676d-8481-4151-a7de-e69ca0888822">Merck&#160;&amp; Co., Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.637%"><tr><td style="width:1.0%"></td><td style="width:20.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YzQyNjVjOTU1NzA1NGYxOGIyMzc5MWYwN2YzMGFhYmIvdGFibGVyYW5nZTpjNDI2NWM5NTU3MDU0ZjE4YjIzNzkxZjA3ZjMwYWFiYl8wLTAtMS0xLTA_f7e7c263-fdc0-4764-91f2-28722554deab">2000 Galloping Hill Road</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YzQyNjVjOTU1NzA1NGYxOGIyMzc5MWYwN2YzMGFhYmIvdGFibGVyYW5nZTpjNDI2NWM5NTU3MDU0ZjE4YjIzNzkxZjA3ZjMwYWFiYl8xLTAtMS0xLTA_f0a7d6c5-ff7a-459f-8ee3-00d89ac5b46e">Kenilworth</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YzQyNjVjOTU1NzA1NGYxOGIyMzc5MWYwN2YzMGFhYmIvdGFibGVyYW5nZTpjNDI2NWM5NTU3MDU0ZjE4YjIzNzkxZjA3ZjMwYWFiYl8xLTItMS0xLTA_250b7312-fba7-42a5-a28e-79835bd48ebd">New Jersey</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YzQyNjVjOTU1NzA1NGYxOGIyMzc5MWYwN2YzMGFhYmIvdGFibGVyYW5nZTpjNDI2NWM5NTU3MDU0ZjE4YjIzNzkxZjA3ZjMwYWFiYl8xLTMtMS0xLTA_1a6bfd4b-132a-40bf-8c3c-df44b2c05432">07033</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjU3_89d848c0-4647-40ac-8a6d-f44250c414bd">908</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjYy_a366f45e-2a59-4f8b-8e1c-745db56a3941">740-4000</ix:nonNumeric> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.405%"><tr><td style="width:1.0%"></td><td style="width:48.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YmU1NjBkZTVmNjVjNDQwY2JiNGFiYmIxY2YxZDM2ZTIvdGFibGVyYW5nZTpiZTU2MGRlNWY2NWM0NDBjYmI0YWJiYjFjZjFkMzZlMl8wLTAtMS0xLTA_db1f4447-fdbe-4502-a23e-c4764ef925ef">New Jersey</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YmU1NjBkZTVmNjVjNDQwY2JiNGFiYmIxY2YxZDM2ZTIvdGFibGVyYW5nZTpiZTU2MGRlNWY2NWM0NDBjYmI0YWJiYjFjZjFkMzZlMl8wLTEtMS0xLTA_97266e6d-e005-4ae8-96b2-9bf2923e0fba">22-1918501</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S Employer Identification No.)</span></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.405%"><tr><td style="width:1.0%"></td><td style="width:35.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities Registered pursuant to Section&#160;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of Each Exchange on which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF8yLTAtMS0xLTA_cd02ec22-7c68-41a4-9b9f-e845e92d7591">Common Stock ($0.50&#160;par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF8yLTEtMS0xLTA_ef9d20b2-3685-4eae-85ee-6939d1597270">MRK</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF8yLTItMS0xLTA_cc273aaa-9ea0-4b70-ac04-042ff3deaf19">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i19fa39a0158d4ac3a19217bc596e4123_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF80LTAtMS0xLTA_36320325-959f-4970-87cc-547305ba1f2e">0.500% Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i19fa39a0158d4ac3a19217bc596e4123_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF80LTEtMS0xLTA_e03d87a4-b51b-4273-9620-fca27719673e">MRK 24</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i19fa39a0158d4ac3a19217bc596e4123_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF80LTItMS0xLTA_d5183acc-7d94-4e94-b470-962b151cdfa1">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i46992b35b0554da8a6375df5c7dc327e_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF81LTAtMS0xLTA_c25fc072-213f-451d-8f5c-f2ec631a9fae">1.875% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i46992b35b0554da8a6375df5c7dc327e_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF81LTEtMS0xLTA_2cc03c42-c670-40a8-960f-326f79891c77">MRK/26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i46992b35b0554da8a6375df5c7dc327e_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF81LTItMS0xLTA_bd472cf8-e357-4a0b-a89b-e0373394f299">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1852627ad8f34be7a1cca870e27e5bae_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF82LTAtMS0xLTA_982e4f90-96e3-4c35-8929-99cd5826f63a">2.500% Notes due 2034</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1852627ad8f34be7a1cca870e27e5bae_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF82LTEtMS0xLTA_dc75a312-585b-47d4-877e-09235403e445">MRK/34</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1852627ad8f34be7a1cca870e27e5bae_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF82LTItMS0xLTA_ba8646be-36cf-4d8b-9739-3c88dfa6d62e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a98152d3a5b419398f05b5c58fb8024_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF83LTAtMS0xLTA_57b337d2-a07b-47d2-abe7-903d2fce72ea">1.375% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a98152d3a5b419398f05b5c58fb8024_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF83LTEtMS0xLTA_06d81c9c-72ec-408f-ad7e-c98212cac986">MRK 36A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a98152d3a5b419398f05b5c58fb8024_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF83LTItMS0xLTA_53ce0c18-6f40-44ce-bde2-dcbcc1c537df">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of shares of Common Stock ($0.50&#160;par value) outstanding as of January&#160;31, 2022: <ix:nonFraction unitRef="shares" contextRef="ib7d3d9b0d798490eb3d016707f5c8fb3_I20220131" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl80ODM_4279d827-7bb2-499b-b406-361439faa852">2,527,733,606</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Aggregate market value of Common Stock ($0.50&#160;par value) held by non-affiliates on June&#160;30, 2021 based on closing price on June&#160;30, 2021: $<ix:nonFraction unitRef="usd" contextRef="ie0f012095b0b4d82a0ee2d4237014df1_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl82MDM_ed227440-64e7-4b91-b410-755d5c630960">196,870,000,000</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.    &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjU4_243cd5d7-7b8e-47aa-9623-d63ab8bf19b7">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#9746;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjYz_f377839b-0375-4c14-98e8-740e48e1eed6">No</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#9746;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjY0_08f6215a-00f3-4597-900f-11c0a2abeba7">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#9746;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjU1_effe8213-acd8-46a8-b16b-91b9572a4663">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#9746;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#9744; </span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check One):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.898%"><tr><td style="width:1.0%"></td><td style="width:20.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MTU2OWM4MTExNmM2NGZhOWFlMjg0Y2ZkZjg1M2ZlMDcvdGFibGVyYW5nZToxNTY5YzgxMTE2YzY0ZmE5YWUyODRjZmRmODUzZmUwN18wLTAtMS0xLTA_fd89efa6-d675-4912-94a1-dd2cbc80e8d8">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MTU2OWM4MTExNmM2NGZhOWFlMjg0Y2ZkZjg1M2ZlMDcvdGFibGVyYW5nZToxNTY5YzgxMTE2YzY0ZmE5YWUyODRjZmRmODUzZmUwN18xLTMtMS0xLTA_774a323c-84ff-423c-98d1-6d34c8e3acd3">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MTU2OWM4MTExNmM2NGZhOWFlMjg0Y2ZkZjg1M2ZlMDcvdGFibGVyYW5nZToxNTY5YzgxMTE2YzY0ZmE5YWUyODRjZmRmODUzZmUwN18yLTMtMS0xLTA_dbcaaaee-66f2-4062-b9cb-d5b7cd7b9e4e">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744; </span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjU5_f5d1206f-bfc0-473f-8953-bfdf1913dda4">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> &#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8zODQ4MjkwNjk5OTEz_7f45d3b6-9328-48a4-9f60-b8ef2387eec0">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Documents Incorporated by Reference:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Part of Form 10-K</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6OTZhMDAxN2M1NmVlNDA4NGFjYzIyZmRlZjdlYWY3ODAvdGFibGVyYW5nZTo5NmEwMDE3YzU2ZWU0MDg0YWNjMjJmZGVmN2VhZjc4MF8yLTAtMS0xLTA_be14877a-67de-4246-916f-11cc3fe7eb00" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022, to be filed with the </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities and Exchange Commission within 120&#160;days after the close of the fiscal year covered by this report</span></div></ix:nonNumeric></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Part&#160;III</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_10">Part&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_52">27</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_55">Cautionary Factors that May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_55">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_58">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_58">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_61">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_61">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_64">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_64">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_67">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_67">43</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_70">Executive Officers of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_70">44</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_73">Part&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_76">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_76">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_79">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_121">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_121">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_124">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_124">79</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_127">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_127">79</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_142">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_142">83</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_202">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_202">140</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_2170">Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_2170">142</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_205">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_205">143</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_208">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_208">143</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_211">Management&#8217;s Report</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_211">143</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_214">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_214">144</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_2380">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_2380">144</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_214">Part&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_220">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_220">145</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_223">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_223">145</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_226">Security Ownership of Certain Beneficial Owners and Management and Related</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_226"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_226">Stockholder&#160;Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_226">146</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_229">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_229">146</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_232">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_232">146</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_235">Part&#160;IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_238">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_238">147</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#3030ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3030ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_250">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_250">151</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_253">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1e1e934bfffd457891fb6e33dae50d64_253">152</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_13"></div><div style="padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Business.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#8217;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment in the first quarter of 2020.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned, licensed to, promoted or distributed by Merck, its subsidiaries or affiliates, except as noted. All other trademarks or services marks are those of their respective owners.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_16"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spin-Off of Organon &amp; Co.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off (the Spin-Off) of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. </span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Company sales, including sales of the Company&#8217;s top pharmaceutical products, as well as sales of animal health products, were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,754</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,288</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Molnupiravir</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">893</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">807</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">769</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,568</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">382</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"> Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Other revenues are primarily comprised of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. Certain of the products within the Company&#8217;s franchises are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), the Company&#8217;s anti-PD-1 (programmed death receptor-1) therapy, as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin Lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors), including MSI-H/dMMR colorectal cancer (CRC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma, including non-muscle invasive bladder cancer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and non-squamous NSCLC, in combination with chemotherapy for HNSCC, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with platinum-and fluoropyrimidine-based chemotherapy for esophageal or GEJ carcinoma, in combination with chemotherapy, with or without bevacizumab, for cervical cancer, in combination with chemotherapy for triple-negative breast cancer (TNBC), in combination with axitinib for advanced renal cell carcinoma (RCC), and in combination with lenvatinib for endometrial carcinoma or RCC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for certain patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved as a monotherapy for the adjuvant treatment of certain patients with RCC. In addition, the Company recognizes alliance revenue related to sales of Lynparza (olaparib), an oral poly (ADP-ribose) polymerase&#160;(PARP) inhibitor, for certain types of advanced ovarian, breast, pancreatic, and prostate cancers; and Lenvima (lenvatinib) for certain types of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with RCC, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for certain patients with endometrial carcinoma or RCC.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccines</span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 (Human Papillomavirus 9-valent Vaccine, Recombinant), vaccines to help prevent certain diseases caused by certain types of human papillomavirus (HPV);</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M&#8722;M&#8722;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles, mumps and rubella; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaqta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (hepatitis A vaccine, inactivated) indicated for the prevention of disease caused by hepatitis A virus in persons 12 months of age and older.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection, a medication for the reversal of two types of neuromuscular blocking agents used during surgery; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(letermovir) for the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Primaxin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (imipenem and cilastatin) for injection, an antibiotic for the treatment of certain bacterial infections; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (posaconazole), an antifungal agent for the prevention of certain invasive fungal infections; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cancidas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (caspofungin acetate) for injection, an anti-fungal agent for the treatment of certain fungal infections; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invanz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ertapenem) for injection, an antibiotic for the treatment of certain bacterial infections; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunology</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (infliximab), a treatment for inflammatory diseases, both of which the Company markets in Europe, Russia and Turkey.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Belsomra </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(suvorexant), an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virology</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molnupiravir, an investigational oral antiviral COVID-19 medicine;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adempas (riociguat), a cardiovascular drug for the treatment of pulmonary arterial hypertension; Verquvo (vericiguat), a medicine to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in certain adults with symptomatic chronic heart failure and reduced ejection fraction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diabetes</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin/metformin HCl) for the treatment of type 2 diabetes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Animal Health</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceuticals, vaccines and health management solutions and services, as well as an extensive suite of digitally connected identification, traceability and monitoring products. Principal products in this segment include:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Livestock Products</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nuflor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Florfenicol) antibiotic range for use in cattle and swine; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bovilis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vista</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine lines for infectious diseases in cattle; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Banamine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Flunixin meglumine) bovine and swine anti-inflammatory; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estrumate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (cloprostenol sodium) for the treatment of fertility disorders in cattle; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Matrix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (altrenogest) fertility management for swine; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resflor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (florfenicol and flunixin meglumine)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a combination broad-spectrum antibiotic and non-steroidal anti-inflammatory </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug for bovine respiratory disease; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zuprevo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Tildipirosin) for bovine respiratory disease; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zilmax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (zilpaterol hydrochloride) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revalor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (trenbolone acetate and estradiol) to improve production efficiencies in beef cattle; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safe-Guard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fenbendazole) de-wormer for cattle; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M+Pac&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Mycoplasma Hyopneumoniae Bacterin) swine pneumonia vaccine; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Porcilis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Lawsonia intracellularis baterin) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Circumvent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Porcine Circovirus Vaccine, Type&#160;2, Killed Baculovirus Vector) vaccine lines for infectious diseases in swine; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nobilis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Innovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Live Marek&#8217;s Disease Vector)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine lines for poultry; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paracox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coccivac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> coccidiosis vaccines; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exzolt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a systemic treatment for poultry red mite infestations; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Slice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Emamectin benzoate) parasiticide for sea lice in salmon; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aquavac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Avirulent Live Culture)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Norvax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccines against bacterial and viral disease in fish; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compact PD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine for salmon; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aquaflor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Florfenicol) antibiotic for farm-raised fish; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allflex Livestock Intelligence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> solutions for animal identification, monitoring and traceability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companion Animal Products</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a line of oral and topical parasitic control products, including the original </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fluralaner) products for dogs and cats that last up to 12 weeks; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(fluralaner)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> One-Month</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a monthly product for dogs, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Plus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fluralaner/moxidectin), a two-month product for cats; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sentinel,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a line of oral parasitic products for dogs including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sentinel Spectrum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (milbemycin oxime, lufenuron, and praziquantel) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sentinel Flavor Tabs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (milbemycin oxime, lufenuron); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Optimmune </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(cyclosporine), an ophthalmic ointment;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Nobivac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine lines for flexible dog and cat vaccination; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otomax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Gentamicin sulfate, USP; Betamethasone valerate USP; and Clotrimazole USP ointment)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mometamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Gentamicin sulfate, USP, Mometasone Furoate Monohydrate and Clotrimazole, USP, Otic Suspension)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Posatex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Orbifloxacin, Mometasone Furoate Monohydrate and Posaconazole, Suspension) ear ointments for acute and chronic otitis; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caninsulin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vetsulin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (porcine insulin zinc suspension) diabetes mellitus treatment for dogs and cats; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Panacur</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fenbendazole)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safeguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fenbendazole) broad-spectrum anthelmintic (de-wormer) for use in many animals; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regumate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (altrenogest) fertility management for horses; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prestige</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine line for horses; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scalibor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Deltamethrin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/Exspot</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for protecting against bites from fleas, ticks, mosquitoes and sandflies; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sure Petcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products for companion animal identification and well-being, including the microchip and pet recovery system </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Again</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of sales of the Company&#8217;s products, see Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; below.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_22"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Product Approvals and Authorizations</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a summary of significant product approvals and authorizations received by the Company in 2021.</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approval</span></div></td></tr><tr style="height:38pt"><td colspan="3" rowspan="5" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">European Commission (EC) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as monotherapy for the first-line treatment of adult patients with MSI-H or dMMR CRC.</span></div></td></tr><tr style="height:48pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as monotherapy for the treatment of adult and pediatric patients aged 3 years and older with relapsed or refractory cHL who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.</span></div></td></tr><tr style="height:62pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. Food and Drug Administration (FDA) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of patients with locally advanced or metastatic esophageal or GEJ (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation.</span></div></td></tr><tr style="height:48pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma.</span></div></td></tr><tr style="height:47pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">China&#8217;s National Medical Products Administration (NMPA) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as a monotherapy for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR CRC that is KRAS, NRAS and BRAF all wild-type.</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.927%"></td><td style="width:0.1%"></td></tr><tr style="height:60pt"><td colspan="3" rowspan="13" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or HER2-negative GEJ adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score [CPS] &#8805;10).</span></div></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as monotherapy for the treatment of patients with locally advanced cSCC that is not curable by surgery or radiation.</span></div></td></tr><tr style="height:48pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021<br/></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> plus Lenvima for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.</span></div></td></tr><tr style="height:41pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the treatment of patients with high-risk, early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, then continued as single agent as adjuvant treatment after surgery.</span></div></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy.</span></div><div><span><br/></span></div></td></tr><tr style="height:51pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan Pharmaceuticals and Medical Devices Agency (PMDA) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the treatment of patients with PD-L1-positive, hormone receptor-negative and HER2-negative, inoperable or recurrent breast cancer.</span></div><div><span><br/></span></div></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PMDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the treatment of patients with unresectable, advanced or recurrent MSI-H CRC.</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> plus Lenvima for the first-line treatment of adult patients with advanced RCC.</span></div></td></tr><tr style="height:48pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NMPA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in combination with platinum- and fluoropyrimidine-based chemotherapy for first-line treatment of patients with locally advanced, unresectable or metastatic carcinoma of the esophageal or GEJ.</span></div></td></tr><tr style="height:48pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2021<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS &#8805;1) as determined by an FDA-approved test.</span></div></td></tr><tr style="height:50pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2021<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic TNBC in adults whose tumors express PD-L1 (CPS &#8805;1) and who have not received prior chemotherapy for metastatic disease.</span></div></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.</span></div><div><span><br/></span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">plus Lenvima as a first-line treatment for adult patients with advanced RCC.</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.927%"></td><td style="width:0.1%"></td></tr><tr style="height:50pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> plus Lenvima for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum&#8209;containing therapy in any setting and who are not candidates for curative surgery or radiation. </span></div></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PMDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in combination with chemotherapy (5-fluorouracil plus cisplatin) for the first-line treatment of patients with radically unresectable, advanced or recurrent esophageal carcinoma.</span></div></td></tr><tr style="height:74pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as a monotherapy for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection. The FDA also expanded the indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as adjuvant treatment for stage III melanoma following complete resection to include pediatric patients (12 years and older).</span></div></td></tr><tr style="height:53pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan&#8217;s Ministry of Health, Labor and Welfare (MHLW) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in combination with Lenvima for the treatment of patients with unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy. </span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NMPA approved Lynparza as monotherapy for the treatment of adult patients with germline or somatic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment that included a new hormonal agent (abiraterone, enzalutamide).</span></div></td></tr><tr style="height:72pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">molnupiravir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA granted Emergency Use Authorization (EUA) for molnupiravir to treat mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.</span></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MHLW granted molnupiravir Special Approval for Emergency for the treatment of infectious disease caused by SARS-CoV-2.</span></td></tr><tr style="height:48pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance<br/></span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for active immunization for the prevention of invasive disease caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Streptococcus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.</span></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for active immunization for the prevention of invasive disease and pneumonia caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Streptococcus pneumoniae</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in individuals 18 years of age and older.</span></div></td></tr><tr style="height:48pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Verquvo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved Verquvo to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic HF and ejection fraction less than 45%.</span></div></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approved Verquvo for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring IV therapy.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Welireg</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.</span></div></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Being jointly developed and commercialized in a worldwide collaboration with AstraZeneca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Being jointly developed and commercialized in a worldwide collaboration with Ridgeback Biopharmaceuticals LP. Molnupiravir has not been approved by the FDA but has been authorized for emergency use.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Being jointly developed and commercialized in a worldwide collaboration with Bayer AG. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_25"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition and the Health Care Environment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets in which the Company conducts its business and the pharmaceutical industry in general are highly competitive and highly regulated. The Company&#8217;s competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers, and animal health care companies. The Company&#8217;s operations may be adversely affected by generic and biosimilar competition as the Company&#8217;s products mature, as well as technological advances of competitors, industry consolidation, patents granted to competitors, competitive combination products, new products of competitors, the generic availability of competitors&#8217; branded products, and new information from clinical trials of marketed products or post-marketing surveillance. In addition, patent rights are increasingly being challenged by competitors, and the outcome can be highly uncertain. An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical competition involves a rigorous search for technological innovations and the ability to market these innovations effectively. With its long-standing emphasis on research and development, the Company is well-positioned to compete in the search for technological innovations. The Company is active in acquiring and marketing products through external alliances, such as licensing arrangements and collaborations and has been refining its sales and marketing efforts to address changing industry conditions. However, the introduction of new products and processes by competitors may result in price reductions and product displacements, even for products protected by patents. For example, the number of compounds available to treat a particular disease typically increases over time and can result in slowed sales growth or reduced sales for the Company&#8217;s products in that therapeutic category.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The highly competitive animal health business is affected by several factors including regulatory and legislative issues, scientific and technological advances, product innovation, the quality and price of the Company&#8217;s products as well as competitors&#8217; products, effective promotional efforts and the frequent introduction of generic products by competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Environment and Government Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access. Changes to the U.S. health care system as part of health care reform enacted in prior years, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s revenue performance in 2021 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect revenue performance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces increasing pricing pressure from managed care organizations, government agencies and programs that could negatively affect the Company&#8217;s sales and profit margins, including, through (i) practices of managed care organizations, federal and state exchanges, and institutional and governmental purchasers, and (ii) federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 and the Patient Protection and Affordable Care Act (ACA).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state governments for many years have pursued methods to reduce the cost of drugs and vaccines for which they pay. For example, federal and state laws require the Company to pay specified rebates for medicines reimbursed by Medicaid and to provide discounts for medicines purchased by certain state and federal entities such as the Department of Defense, Veterans Affairs, Public Health Service entities and hospitals serving a disproportionate share of low income or uninsured patients.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in the U.S., consolidation and integration among health care providers is a major factor in the competitive marketplace for pharmaceutical products. Health plans and pharmacy benefit managers (PBMs) have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance. Private third-party insurers, as well as governments, employ formularies to control costs by negotiating discounted prices in exchange for formulary inclusion. Failure to obtain timely or adequate pricing or formulary placement for Merck&#8217;s products or obtaining such placement at unfavorable pricing could adversely affect revenue. In addition to formulary tier co-pay differentials, private health insurance companies and self-insured employers have been increasing the cost-sharing required from beneficiaries, particularly for branded pharmaceuticals and biotechnology products. Private health insurance companies also are increasingly imposing utilization management tools, such as clinical protocols, requiring prior authorization for a branded product or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine. These same management tools are also used in treatment areas in which the payor has taken the position that multiple branded products are therapeutically comparable. As the U.S. payor market concentrates further, pharmaceutical companies may face greater pricing pressure from private third-party payors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide information about the Company&#8217;s pricing practices, the Company annually posts on its website its Pricing Transparency Report for the U.S. The report provides the Company&#8217;s average annual list price, net price increases, and average discounts across the Company&#8217;s U.S. portfolio dating back to 2010. In 2021, the Company&#8217;s gross U.S. sales were reduced by 43.5% as a result of rebates, discounts and returns.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legislative Changes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Congress actively considered multiple versions of drug pricing legislation that could significantly impact branded pharmaceutical manufacturers. This legislation would implement a government negotiation plan for certain products covered by Medicare Parts B and D, institute financial penalties for price increases above inflation, and redesign the Medicare Part D program to include a cap on patients&#8217; out of pocket costs and realign the liability for costs of the benefit among manufacturers, health plans, and the government. It is unclear when or if this legislation will be passed by Congress, and it remains very uncertain as to what other proposals, if any, may be included as part of future federal legislative proposals that would directly or indirectly affect the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2021, Congress passed the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Rescue Plan Act of 2021, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to Medicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the Average Manufacturer Price (AMP) in rebates to state Medicaid programs for Medicaid-covered drugs. As a result of this provision, beginning in 2024, it is possible that manufacturers may have to pay state Medicaid programs more in rebates than they received on sales of particular products. This change could present a risk to Merck in the future for drugs that have high Medicaid utilization and rebate exposure that is more than 100% of the AMP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also faces increasing pricing pressure in the states, which are looking to exert greater influence over the price of prescription drugs. A number of states have passed pharmaceutical price and cost transparency laws. These laws typically require manufacturers to report certain product price information or other financial data to the state. Some laws also require manufacturers to provide advance notification of price increases. The Company expects that states will continue their focus on pharmaceutical pricing and will increasingly shift to more aggressive price control tools such as Prescription Drug Affordability Boards that have the authority to conduct affordability reviews and establish upper payment limits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Changes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Centers for Medicare &amp; Medicaid Services (CMS) issued the Medicaid rebate final rule that implemented provisions of the ACA effective April 1, 2016. The rule provides comprehensive guidance on the calculation of AMP and Best Price, two metrics used to determine the rebates drug manufacturers are required to pay to state Medicaid programs. On December 21, 2020, CMS issued a final rule making significant changes to these requirements. Effective January 1, 2023, this final rule changes the way that manufacturers must calculate Best Price in relation to certain patient support programs, including coupons. PhRMA, a pharmaceutical industry trade group of which the Company is a member, filed a complaint challenging this rule as invalid asserting that it conflicts </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the plain language of the Medicaid drug rebate statute. Should this legal challenge fail, the impact of this and other provisions in this final rule could adversely impact the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Department of Health and Human Services Office of Inspector General issued a Final Rule that would, effective January 1, 2023, eliminate the Anti-Kickback Statute safe harbor for rebates paid to Medicare Part D plans or to PBMs on behalf of such plans. While the Company cannot anticipate the effects of this change to the way it currently contracts, this new framework could significantly alter the way it does business with Part D Plan Sponsors and PBMs on behalf of such plans. This rulemaking also established, effective January 1, 2021, a new safe harbor for point of sale discounts at the pharmacy counter and a new safe harbor for certain service arrangements between pharmaceutical manufacturers and PBMs. Congress has delayed implementation of this Final Rule until January 1, 2026 and pending federal legislation would repeal it entirely.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry also could be considered a potential source of savings via other legislative and administrative proposals that have been debated but not enacted. These types of revenue generating or cost saving proposals include additional direct price controls. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">European Union</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts toward health care cost containment remain intense in the European Union (EU). The Company faces competitive pricing pressure resulting from generic and biosimilar drugs. In addition, a majority of countries in the EU attempt to contain drug costs by engaging in reference pricing in which authorities examine pre-determined markets for published prices of drugs. Reference pricing may either compare a product&#8217;s prices in other markets (external reference pricing), or compare a product&#8217;s price with those of other products in a national class (internal reference pricing). The authorities then use the price data to set new local prices for brand-name drugs, including the Company&#8217;s drugs. Guidelines for examining reference pricing are usually set in local markets and can be changed pursuant to local regulations. Some EU Member States have established free-pricing systems, but regulate the pricing for drugs through profit control plans. Others seek to negotiate or set prices based on the cost-effectiveness of a product or an assessment of whether it offers a therapeutic benefit over other products in the relevant class. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In some EU Member States, cross-border imports from low-priced markets also exert competitive pressure that may reduce pricing within an EU Member State.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, EU Member States have the power to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement. In the EU, pricing and reimbursement plans vary widely from Member State to Member State. Some EU Member States provide that drug products may be marketed only after a reimbursement price has been agreed. Some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to already available therapies or so-called health technology assessments (HTA), in order to obtain reimbursement or pricing approval. The HTA of pharmaceutical products is becoming an increasingly common part of the pricing and reimbursement procedures in most EU Member States. The HTA process, which is governed by the national laws of these countries, involves the assessment of the cost-effectiveness, public health impact, therapeutic impact and/or the economic and social impact of use of a given pharmaceutical product in the national health care system of the individual country in which it is conducted. Ultimately, HTA measures the added value of a new health technology compared to existing ones. The outcome of HTAs regarding specific pharmaceutical products will often influence the pricing and reimbursement status granted to these pharmaceutical products by the regulatory authorities of individual EU Member States. A negative HTA of one of the Company&#8217;s products may mean that the product is not reimbursable or may force the Company to reduce its reimbursement price or offer discounts or rebates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A negative HTA by a leading and recognized HTA body could also undermine the Company&#8217;s ability to obtain reimbursement for the relevant product outside a jurisdiction. For example, EU Member States that have not yet developed HTA mechanisms may rely to some extent on the HTA performed in other countries with a developed HTA framework, to inform their pricing and reimbursement decisions. HTA procedures require additional data, reviews and administrative processes, all of which increase the complexity, timing and costs of obtaining product reimbursement and exert downward pressure on available reimbursement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain reimbursement or pricing approval in some EU Member States, the Company may be required to conduct studies that compare the cost-effectiveness of the Company&#8217;s product candidates to other therapies that are considered the local standard of care. There can be no assurance that any EU Member State will allow favorable pricing, reimbursement and market access conditions for any of the Company&#8217;s products, or that it will be feasible to conduct additional cost-effectiveness studies, if required.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brexit</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the United Kingdom (UK) held a referendum in which voters approved an exit from the EU, commonly referred to as &#8220;Brexit.&#8221; As a result of that referendum and subsequent negotiations, the UK left the EU on January 31, 2020. A transitional period applied from January 31, 2020 until December 31, 2020, and during this period the EU and UK operated as if the UK was an EU Member State, and the UK continued to participate in the EU Customs Union allowing for the freedom of movement for people and goods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It was announced on December 24, 2020, that the EU and the UK agreed to a Trade and Cooperation Agreement (TCA). The TCA sets out the new arrangements for trade of goods, including medicines and vaccines, which allows goods to continue to flow between the EU and the UK. The TCA was signed on December 30, 2020, was applied provisionally as of January 1, 2021, and entered into force on May 1, 2021. As a result of the TCA, the Company believes that its operations will not be materially adversely affected by Brexit. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Japan</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, the pharmaceutical industry is subject to government-mandated annual price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order re-pricings for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules. The next government-mandated price reduction will occur in April 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">China</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business in China has grown rapidly in the past few years, and the importance of China to the Company&#8217;s overall pharmaceutical and vaccines business has increased accordingly. Continued growth of the Company&#8217;s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company&#8217;s current in-line products, and the absence of trade impediments or adverse pricing controls. In recent years, the Chinese government has introduced and implemented a number of structural reforms to accelerate the shift to innovative products and reduce costs. Since 2017, there have been multiple new policies introduced by the government to improve access to new innovation, reduce the complexity of regulatory filings, and accelerate the review and approval process. This has led to a significant increase in the number of new products being approved each year. While the mechanism for drugs being added to the government&#8217;s National Reimbursement Drug List (NRDL) evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. In 2021, drugs were added to the NRDL with an average of more than 60% price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through volume based procurement (VBP). In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Emerging Markets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls and measures impacting intellectual property, including in exceptional cases, threats of compulsory licenses (especially for COVID-19 vaccines and drugs), that aim to put pressure on the price of innovative pharmaceuticals or result in constrained market access to innovative medicine. The Company anticipates that pricing pressures and market access challenges will continue in the future to varying degrees in the emerging markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond pricing and market access challenges, other conditions in emerging market countries can affect the Company&#8217;s efforts to continue to grow in these markets, including potential political instability, changes in trade sanctions and embargoes, significant currency fluctuation and controls, financial crises, limited or changing </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">availability of funding for health care, credit worthiness of health care partners, such as hospitals, due to COVID-19, and other developments that may adversely impact the business environment for the Company. Further, the Company may engage third-party agents to assist in operating in emerging market countries, which may affect its ability to realize continued growth and may also increase the Company&#8217;s risk exposure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addressing global cost containment pressures, the Company engages in public policy advocacy with policymakers and continues to work to demonstrate that its medicines provide value to patients and to those who pay for health care. The Company advocates with government policymakers to encourage a long-term approach to sustainable health care financing that ensures access to innovative medicines and does not disproportionately target pharmaceuticals as a source of budget savings. In markets with historically low rates of health care spending, the Company encourages those governments to increase their investments and adopt market reforms in order to improve their citizens&#8217; access to appropriate health care, including medicines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating conditions have become more challenging under the global pressures of competition, industry regulation and cost containment efforts. Although no one can predict the effect of these and other factors on the Company&#8217;s business, the Company continually takes measures to evaluate, adapt and improve the organization and its business practices to better meet customer needs and believes that it is well-positioned to respond to the evolving health care environment and market forces.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is also subject to regulation by regional, country, state and local agencies around the world focused on standards and processes for determining drug safety and effectiveness, as well as conditions for sale or reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of particular importance is the FDA in the U.S., which administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling, and marketing of prescription pharmaceuticals. In some cases, the FDA requirements and practices have increased the amount of time and resources necessary to develop new products and bring them to market in the U.S. At the same time, the FDA has committed to expediting the development and review of products bearing the &#8220;breakthrough therapy&#8221; designation, which has accelerated the regulatory review process for medicines with this designation. The FDA has also undertaken efforts to bring generic competition to market more efficiently and in a more timely manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU has adopted directives and other legislation concerning the classification, approval for marketing, labeling, advertising, manufacturing, wholesale distribution, integrity of the supply chain, pharmacovigilance and safety monitoring of medicinal products for human use. These provide mandatory standards throughout the EU, which may be supplemented or implemented with additional regulations by the EU Member States. In particular, EU regulators may approve products subject to a number of post-authorization conditions. Examples of typical post-authorization commitments include additional pharmacovigilance, the conduct of clinical trials, the establishment of patient registries, physician or patient education and controlled distribution and prescribing arrangements. Non-compliance with post-authorization conditions, pharmacovigilance and other obligations can lead to regulatory action, including the variation, suspension or withdrawal of the marketing authorizations, or other enforcement or regulatory actions, including the imposition of financial penalties. The Company&#8217;s policies and procedures are already consistent with the substance of these directives; consequently, it is believed that they will not have any material effect on the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it will continue to be able to conduct its operations, including launching new drugs, in this regulatory environment. (See &#8220;Research and Development&#8221; below for a discussion of the regulatory approval process.)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access to Medicines</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global health care company, Merck&#8217;s primary role is to discover and develop innovative medicines and vaccines. The Company also recognizes that, in collaboration with key stakeholders, it has a role to play in helping to ensure that its science advances health care, and its products are accessible and affordable. The Company is committed to ensuring a reliable, safe global supply of its quality medicines and vaccines, and to developing, testing and implementing innovative solutions that address barriers to access and affordability of its medicines and vaccines. The Company&#8217;s approach is designed to enable it to serve the greatest number of patients today, while </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meeting the needs of patients in the future. The Company&#8217;s efforts in this regard are wide-ranging and include a set of principles that the Company strives to embed into its operations and business strategies to guide the Company&#8217;s worldwide approach to expanding access to health care. In addition, through innovative social investments, including philanthropic programs and impact investing, Merck is also helping to strengthen health systems and build capacity, particularly in under-resourced communities. The Merck Patient Assistance Program provides medicines and adult vaccines for free to people in the U.S. who do not have prescription drug or health insurance coverage and who, without the Company&#8217;s assistance, cannot afford their Merck medicines and vaccines. Merck has funded &#8220;Merck for Mothers,&#8221; a long-term effort with global health partners to end preventable deaths from complications of pregnancy and childbirth. Merck has also provided funds to the Merck Foundation, an independent grantmaking organization, which has partnered with a variety of organizations dedicated to improving global health.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_28"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Privacy and Data Protection</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a significant number of privacy and data protection laws and regulations globally, many of which place restrictions on the Company&#8217;s ability to transfer, access and use personal data across its business. The legislative and regulatory landscape for privacy and data protection continues to evolve. There has been increased attention to privacy and data protection issues in both developed and emerging markets with the potential to affect directly the Company&#8217;s business, including the EU General Data Protection Regulation (GDPR), which went into effect in May 2018 and imposes penalties of up to 4% of global revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR and related implementing laws in individual EU Member States govern the collection and use of personal health data and other personal data in the EU. The GDPR increased responsibility and liability in relation to personal data that the Company processes. It also imposes a number of strict obligations and restrictions on the ability to process (which includes collection, analysis and transfer of) personal data, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification of data processing obligations to the national data protection authorities, and the security and confidentiality of the personal data. Further, the GDPR prohibits the transfer of personal data to countries outside of the EU that are not considered by the EC to provide an adequate level of data protection, including to the U.S., except if the data controller meets very specific requirements. Following the Schrems II decision of the Court of Justice of the EU on July 16, 2020, there is considerable uncertainty as to the permissibility of international data transfers under the GDPR. In light of the implications of this decision, the Company may face difficulties regarding the transfer of personal data from the EU to third countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines and other administrative penalties as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices is often updated or otherwise revised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is, moreover, a growing trend towards required public disclosure of clinical trial data in the EU which adds to the complexity of obligations relating to processing health data from clinical trials. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against the Company, harm to its reputation, and adversely impact its business and operating results. The uncertainty regarding the interplay between different regulatory frameworks further adds to the complexity that the Company faces with regard to data protection regulation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2021, China&#8217;s 13th National People&#8217;s Congress passed the Personal Information Protection Law (PIPL) that aims to standardize the handling of personal information in China which became effective on November 1, 2021. The PIPL currently applies to the processing of personal information of natural persons in China, the processing of personal information outside China where the purpose is to provide products and services in China, and to analyze the activities of individuals in China. While similar to the GDPR, the PIPL contains unique requirements not found in the GDPR.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has developed and implemented comprehensive plans to ensure compliance with the PIPL, with those relating to data localization and cross-border transfers yet to be completed pending forthcoming guidance from the Cyberspace Administration of China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional laws and regulations enacted in the U.S. (such as the California Consumer Privacy Act), Europe, Asia, and Latin America, have increased enforcement and litigation activity in the U.S. and other developed markets, as well as increased regulatory cooperation among privacy authorities globally. The Company has adopted a comprehensive global privacy program to manage these evolving requirements and risks and to facilitate the transfer of personal information across international borders.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_31"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, PBMs and other institutions. Human health vaccines are sold primarily to physicians, wholesalers, physician distributors and government entities. The Company&#8217;s professional representatives communicate the effectiveness, safety and value of the Company&#8217;s pharmaceutical and vaccine products to health care professionals in private practice, group practices, hospitals and managed care organizations. The Company sells its animal health products to veterinarians, distributors and animal producers.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_34"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents, Trademarks and Licenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent protection is considered, in the aggregate, to be of material importance to the Company&#8217;s marketing of its products in the U.S. and in most major foreign markets. Patents may cover products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">per se</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pharmaceutical formulations, processes for, or intermediates useful in, the manufacture of products, or the uses of products. Protection for individual products extends for varying periods in accordance with the legal life of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent and its scope of coverage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Food and Drug Administration Modernization Act includes a Pediatric Exclusivity Provision that may provide an additional six months of market exclusivity in the U.S. for indications of new or currently marketed drugs if certain agreed upon pediatric studies are completed by the applicant. Current U.S. patent law provides additional patent term for periods when the patented product was under regulatory review by the FDA. The EU also provides an additional six months of pediatric market exclusivity attached to a product&#8217;s Supplementary Protection Certificate (SPC). Japan provides the additional term for pediatric studies attached to market exclusivity unrelated to patent term.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent portfolios developed for products introduced by the Company normally provide market exclusivity. The Company has the following key patent protection in the U.S., the EU, Japan and China (including the potential for patent term extensions (PTE) and SPCs where indicated) for the following marketed products:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.736%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Product</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration (U.S.)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration (EU)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration (Japan)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">(China)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Janumet XR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Isentress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022-2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Bravecto</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 (patents), 2029 (SPCs)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gardasil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 (patents)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> 2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032-2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (patents), 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028-2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 (patents), 2028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adempas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (patents), 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segluromet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 (patents), 2034 (SPCs)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Steglatro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 (patents), 2034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Steglujan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(with pending PTE)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 (patents), 2034 (SPCs)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verquvo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2035 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(13)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Vaxneuvance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No Patent</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Delstrigo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031 (patents), 2033 (SPCs)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Pifeltro</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031 (patents), 2033 (SPCs)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Recarbrio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2035 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="margin-top:2pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note:&#160;&#160;&#160;&#160;Compound patent unless otherwise noted.&#160;Certain of the products listed may be the subject of patent litigation. See Item&#160;8. &#8220;Financial Statements and Supplementary Data,&#8221; Note 11. &#8220;Contingencies and Environmental Liabilities&#8221; below.</span></div><div style="margin-top:2pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">N/A:&#160;&#160;&#160;&#160;Currently no marketing approval.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.21pt">The EU date represents the expiration date for the following four countries: France, Germany, Italy, and Spain (Major EU Markets). If SPC applications have been filed but have not been granted in all Major EU Markets, both the patent expiry date and the SPC expiry date are listed.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.21pt">The PTE system in Japan allows for a patent to be extended more than once provided the later approval is directed to a different indication from that of the previous approval. This may result in multiple PTE approvals for a given patent, each with its own expiration date.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.21pt">Eligible for 6 months Pediatric Exclusivity.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.21pt">Expiry date reflects the approved product and includes granted PTE for the 600 mg tablet in Japan.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.21pt">The Company has no marketing rights in the U.S., Japan or China.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.21pt">The distribution agreement with Janssen Pharmaceuticals, Inc. expires on October 1, 2024.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.21pt">Part of a global strategic oncology collaboration with Eisai Co., Ltd.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.21pt">Part of a global strategic oncology collaboration with AstraZeneca.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.21pt">Being commercialized in a worldwide collaboration with Bayer AG.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.94pt">The Company has no marketing rights in the U.S.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.94pt">Being commercialized and promoted in a worldwide, except Japan, collaboration with Pfizer Inc.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.94pt">The Company has no marketing rights in Japan.</span></div><div style="margin-top:2pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.94pt">The Company has no marketing rights in the EU, Japan or China.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following key U.S. patent protection for drug candidates under review in the U.S. by the FDA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional patent term may be provided for these pipeline candidates based on Patent Term Restoration and Pediatric Exclusivity.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Under Review in the U.S. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Currently Anticipated</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration (in the U.S.)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MK-7264 (gefapixant)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has the following key U.S. patent protection for drug candidates in Phase 3 development:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Phase 3 Drug Candidate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Currently Anticipated</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Year of Expiration (in the U.S.)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MK-8591 (islatravir)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MK-7962 (sotatercept)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MK-8591A (doravirine + islatravir)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2032 (pending PTE for doravirine)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MK-1308A (quavonlimab + pembrolizumab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2035</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MK-7684A (vibostolimab + pembrolizumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2035</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MK-4280A (favezelimab + pembrolizumab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2035</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MK-1654 (clesrovimab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MK-4482 (molnupiravir)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2038</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.44pt">Received Emergency Use Authorization from the FDA for the treatment of high-risk adults with mild to moderate COVID-19. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise noted, the patents in the above charts are compound patents. Each patent may be subject to a future patent term restoration of up to five years and six month pediatric market exclusivity, either or both of which may be available. In addition, depending on the circumstances surrounding any final regulatory approval of the compound, there may be other listed patents or patent applications pending that could have relevance to the product as finally approved; the relevance of any such application would depend upon the claims that ultimately may be granted and the nature of the final regulatory approval of the product. Also, regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a compound&#8217;s patent estate. In the U.S., the data protection generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication and 12 years from first marketing approval of a biological product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the expiration of a compound patent normally results in a loss of market exclusivity for the covered pharmaceutical product, commercial benefits may continue to be derived from: (i)&#160;later-expiring patents on processes and intermediates related to the most economical method of manufacture of the active ingredient of such product; (ii)&#160;patents relating to the use of such product; (iii)&#160;patents relating to novel compositions and formulations; and (iv)&#160;in the U.S. and certain other countries, market exclusivity that may be available under relevant law. The effect of product patent expiration on pharmaceutical products also depends upon many other factors such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of the process for manufacture of the active ingredient of the product and the requirements of new drug provisions of the Federal Food, Drug and Cosmetic Act or similar laws and regulations in other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions to market exclusivity are sought in the U.S. and other countries through all relevant laws, including laws increasing patent life. Some of the benefits of increases in patent life have been partially offset by an increase in the number of incentives for and use of generic products. Additionally, improvements in intellectual property laws are sought in the U.S. and other countries through reform of patent and other relevant laws and implementation of international treaties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information with respect to the Company&#8217;s patents, see Item&#160;1A. &#8220;Risk Factors&#8221; and Item&#160;8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;11. &#8220;Contingencies and Environmental Liabilities&#8221; below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, all of the Company&#8217;s important products are sold under trademarks that are considered in the aggregate to be of material importance. Trademark protection continues in some countries as long as used; in other countries, as long as registered. Registration is for fixed terms and can be renewed indefinitely.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty income in 2021 on patent and know-how licenses and other rights amounted to $286 million. Merck also incurred royalty expenses amounting to $2.4 billion in 2021 under patent and know-how licenses it holds.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business is characterized by the introduction of new products or new uses for existing products through a strong research and development program. At December 31, 2021, approximately 17,500 people were employed in the Company&#8217;s research activities. The Company prioritizes its research and development efforts and focuses on candidates that it believes represent breakthrough science that will make a difference for patients and payers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a number of long-term exploratory and fundamental research programs in biology and chemistry as well as research programs directed toward product development. The Company&#8217;s research and development model is designed to increase productivity and improve the probability of success by prioritizing the Company&#8217;s research and development resources on candidates the Company believes are capable of providing unambiguous, promotable advantages to patients and payers and delivering the maximum value of its approved medicines and vaccines through new indications and new formulations. Merck is pursuing emerging product opportunities independent of therapeutic area or modality (small molecule, biologics and vaccines) and is building its biologics capabilities. The Company is committed to ensuring that externally sourced programs remain an important component of its pipeline strategy, with a focus on supplementing its internal research with a licensing and external alliance strategy focused on the entire spectrum of collaborations from early research to late-stage compounds, as well as access to new technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s clinical pipeline includes candidates in multiple disease areas, including cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, respiratory diseases, and vaccines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the development of human health products, industry practice and government regulations in the U.S. and most foreign countries provide for the determination of effectiveness and safety of new chemical compounds through pre-clinical tests and controlled clinical evaluation. Before a new drug or vaccine may be marketed in the U.S., recorded data on pre-clinical and clinical experience are included in the New Drug Application (NDA) for a drug or the Biologics License Application (BLA) for a vaccine or biologic submitted to the FDA for the required approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the Company&#8217;s scientists discover a new small molecule compound or biologic that they believe has promise to treat a medical condition, the Company commences pre-clinical testing with that compound. Pre-clinical testing includes laboratory testing and animal safety studies to gather data on chemistry, pharmacology, immunogenicity and toxicology. Pending acceptable pre-clinical data, the Company will initiate clinical testing in accordance with established regulatory requirements. The clinical testing begins with Phase 1 studies, which are designed to assess safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic activity of the compound in humans. If favorable, additional, larger Phase&#160;2 studies are initiated to determine the efficacy of the compound in the affected population, define appropriate dosing for the compound, as well as identify any adverse effects that could limit the compound&#8217;s usefulness. In some situations, the clinical program incorporates adaptive design methodology to use accumulating data to decide how to modify aspects of the ongoing clinical study as it continues, without undermining the validity and integrity of the trial. One type of adaptive clinical trial is an adaptive Phase 2a/2b trial design, a two-stage trial design consisting of a Phase 2a proof-of-concept stage and a Phase 2b dose-optimization finding stage. If data from the Phase&#160;2 trials are satisfactory, the Company commences large-scale Phase&#160;3 trials to confirm the compound&#8217;s efficacy and safety. Another type of adaptive clinical trial is an adaptive Phase 2/3 trial design, a study that includes an interim analysis and an adaptation that changes the trial from having features common in a Phase 2 study (e.g. multiple dose groups) to a design similar to a Phase 3 trial. An adaptive Phase 2/3 trial design reduces timelines by eliminating activities which would be required to start a separate study. Upon completion of Phase 3 trials, if satisfactory, the Company submits regulatory filings with the appropriate regulatory agencies around the world to have the product candidate approved for marketing. There can be no assurance that a compound that is the result of any particular program will obtain the regulatory approvals necessary for it to be marketed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine development follows the same general pathway as for drugs. Pre-clinical testing focuses on the vaccine&#8217;s safety and ability to elicit a protective immune response (immunogenicity). Pre-marketing vaccine clinical trials are typically done in three phases. Initial Phase 1 clinical studies are conducted in normal subjects to evaluate the safety, tolerability and immunogenicity of the vaccine candidate. Phase&#160;2 studies are dose-ranging studies. Finally, Phase&#160;3 trials provide the necessary data on effectiveness and safety. If successful, the Company submits regulatory filings with the appropriate regulatory agencies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA review process begins once a complete NDA or BLA is submitted, received and accepted for review by the agency. Within 60 days after receipt, the FDA determines if the application is sufficiently complete to permit a substantive review. The FDA also assesses, at that time, whether the application will be granted a priority review or standard review. Pursuant to the Prescription Drug User Fee Act V (PDUFA), the FDA review period target for NDAs or original BLAs is either six months, for priority review, or ten months, for a standard review, from the time the application is deemed sufficiently complete. Once the review timelines are determined, the FDA will generally act upon the application within those timelines, unless a major amendment has been submitted (either at the Company&#8217;s own initiative or the FDA&#8217;s request) to the pending application. If this occurs, the FDA may extend the review period to allow for review of the new information, but by no more than three months. Extensions to the review period are communicated to the Company. The FDA can act on an application either by issuing an approval letter or by issuing a Complete Response Letter (CRL) stating that the application will not be approved in its present form and describing all deficiencies that the FDA has identified. Should the Company wish to pursue an application after receiving a CRL, it can resubmit the application with information that addresses the questions or issues identified by the FDA in order to support approval. Resubmissions are subject to review period targets, which vary depending on the underlying submission type and the content of the resubmission.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has four program designations &#8212; Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review &#8212; to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening conditions. The Fast Track designation provides pharmaceutical manufacturers with opportunities for frequent interactions with FDA reviewers during the product&#8217;s development and the ability for the manufacturer to do a rolling submission of the NDA/BLA. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The Breakthrough Therapy designation provides manufacturers with all of the features of the Fast Track designation as well as intensive guidance on implementing an efficient development program for the product and a commitment by the FDA to involve senior managers and experienced staff in the review. The Accelerated Approval designation allows the FDA to approve a product based on an effect on a surrogate or intermediate endpoint that is reasonably likely to predict a product&#8217;s clinical benefit and generally requires the manufacturer to conduct required post-approval confirmatory trials to verify the clinical benefit. The Priority Review designation means that the FDA&#8217;s goal is to take action on the NDA/BLA within six months, compared to ten months under standard review. More than one of these special designations can be granted for a given application (i.e., a product designated as a Breakthrough Therapy may also be eligible for Priority Review).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the COVID-19 public health crisis, the U.S. Secretary of Health and Human Services has exercised statutory authority to determine that a public health emergency exists, and declared these circumstances justify the emergency use of drugs and biological products as authorized by the FDA. While in effect, this declaration enables the FDA to issue Emergency Use Authorizations (EUAs) permitting distribution and use of specific medical products absent NDA/BLA submission or approval, including products to treat or prevent diseases or conditions caused by the SARS-CoV-2 virus, subject to the terms of any such EUAs. The FDA must make certain findings to grant an EUA, including that it is reasonable to believe based on the totality of evidence that the drug or biologic may be effective, and that known or potential benefits when used under the terms of the EUA outweigh known or potential risks. Additionally, the FDA must find that there is no adequate, approved and available alternative to the emergency use. The FDA may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect the public health or safety.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary method the Company uses to obtain marketing authorization of pharmaceutical products in the EU is through the &#8220;centralized procedure.&#8221; This procedure is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and is also available for certain new chemical compounds and products. A company seeking to market an innovative pharmaceutical product through the centralized procedure </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">must file a complete set of safety data and efficacy data as part of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA). After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA. It is also possible for new chemical products to obtain marketing authorization in the EU through a &#8220;mutual recognition procedure&#8221; in which an application is made to a single member state and, if the member state approves the pharmaceutical product under a national procedure, the applicant may submit that approval to the mutual recognition procedure of some or all other EU Member States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S. and the EU, the Company submits marketing applications to national regulatory authorities. Examples of such are the Ministry of Health, Labour and Welfare in Japan, the National Medical Products Administration in China, Health Canada, Ag&#234;ncia Nacional de Vigil&#226;ncia Sanat&#225;ria in Brazil, Korea Food and Drug Administration in South Korea, and the Therapeutic Goods Administration in Australia. Each country has a separate and independent review process and timeline. In many markets, approval times can be longer as the regulatory authority requires approval in a major market, such as the U.S. or the EU, and issuance of a Certificate of Pharmaceutical Product from that market before initiating their local review process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Update</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the U.S. and internationally or in late-stage clinical development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-4482, molnupiravir, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics LP. The FDA granted Emergency Use Authorization (EUA) for molnupiravir in December 2021; as updated in February 2022, to authorize molnupiravir for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. Molnupiravir is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. Molnupiravir has also received conditional marketing authorization in the UK and Special Approval for Emergency in Japan. In November 2021, the EMA issued a positive scientific opinion for molnupiravir, which is intended to support national decision-making on the possible use of molnupiravir prior to marketing authorization. In October 2021, the EMA initiated a rolling review for molnupiravir for the treatment of COVID-19 in adults. Merck plans to work with the Committee for Medicinal Products for Human Use of the EMA to complete the rolling review process to facilitate initiating the formal review of the MAA. Applications to other regulatory bodies worldwide are underway. Molnupiravir is also being evaluated for post-exposure prophylaxis in the Phase 3 MOVe-AHEAD trial, which is evaluating the efficacy and safety of molnupiravir for the prevention of COVID-19 in adults who reside with a person with COVID-19. As previously announced, data from the MOVe-IN clinical trial indicated that molnupiravir is unlikely to demonstrate a clinical benefit in hospitalized patients, who generally had a longer duration of symptoms prior to study entry; therefore, the decision was made not to proceed to Phase 3.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA. The NDA for gefapixant is based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck&#8217;s NDA for gefapixant. In the CRL, the FDA requested additional information related to measurement of efficacy. The CRL was not related to the safety of gefapixant. Merck is reviewing the letter and considering next steps. Gefapixant is also under review in the EU, although the review period has been extended pending the receipt of additional information from the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">V114 is an investigational 15-valent pneumococcal conjugate vaccine under review in Japan for use in adults. V114 was approved in the U.S. in 2021 for use in adults where it is marketed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under priority review by the FDA for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age. The FDA grants priority review to medicines and vaccines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment or prevention of a serious condition. The FDA set a PDUFA date of April 1, 2022. The supplemental BLA is supported by results from Phase 2 and Phase 3 clinical studies in pediatric populations including infants, children, and adolescents. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-3475, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,650 clinical trials, including more than 1,250 trials that combine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with other cancer treatments. These studies encompass more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review in the EU for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection based on data from the Phase 3 KEYNOTE-716 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review in Japan for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy (surgical removal of a kidney) based on data from the Phase 3 KEYNOTE-564 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review by the FDA for the treatment of patients with advanced endometrial cancer that is MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. This submission is based on data from the KEYNOTE-158 trial. The FDA set a PDUFA date of March 28, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review in the EU for the treatment of unresectable or metastatic MSI-H or dMMR colorectal, endometrial, gastric, small intestine, biliary, or pancreatic cancer in adults who have received prior therapy. The proposed indication is based on the results from the KEYNOTE-164 and KEYNOTE-158 trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy is under review in the EU and Japan for the treatment of patients with high-risk, early-stage TNBC as neoadjuvant treatment, and then as a single agent as adjuvant treatment after surgery based on data from the KEYNOTE-522 trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review in Japan for treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy with or without bevacizumab is also under review in the EU and Japan for the first-line treatment of patients with persistent, recurrent or metastatic cervical cancer based on the KEYNOTE-826 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Merck, the European Organisation for Research and Treatment of Cancer and the European Thoracic Oncology Platform announced that the Phase 3 KEYNOTE-091 trial investigating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> met one of its dual primary endpoints of disease-free survival (DFS) for the adjuvant treatment of patients with stage IB-IIIA NSCLC following surgical resection regardless of PD-L1 expression. Based on an interim analysis review conducted by an independent Data Monitoring Committee, adjuvant treatment with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulted in a statistically significant and clinically meaningful improvement in DFS compared with placebo in the all-comer population of patients with stage IB-IIIA NSCLC. At the interim analysis, there was also an improvement in DFS for patients whose tumors express PD-L1 (tumor proportion score [TPS] &#8805;50%) treated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared to placebo; however, this dual primary endpoint did not meet statistical significance per the pre-specified statistical plan. The trial will continue to analyze DFS in patients whose tumors express high levels of PD-L1 (TPS &#8805;50%) and evaluate overall survival, a key secondary endpoint. Results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7339, Lynparza, is an oral PARP inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca PLC. In November 2021, the FDA accepted for priority review a supplemental NDA for Lynparza for the adjuvant treatment of patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutated, human epidermal growth factor receptor 2 (HER2)-negative high-risk, early-stage breast cancer who have already been treated with chemotherapy either before or after surgery based on the results from the Phase 3 OlympiA trial. The FDA set a PDUFA date during the first quarter of 2022. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This indication is also under review in the EU. Lynparza is also under review in the EU for the treatment of certain patients with metastatic castration-resistant prostate cancer based on the PROpel clinical trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7902, Lenvima, is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai). Merck and Eisai are studying the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program that includes 17 Phase 3 studies across 14 different tumor types (biliary cancer, CRC, endometrial carcinoma, esophageal cancer, gastric cancer, glioblastoma, HCC, HNSCC, melanoma, pancreatic cancer, prostate cancer, NSCLC, SCLC and RCC).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck and Eisai announced that the FDA issued a CRL regarding Merck&#8217;s and Eisai&#8217;s applications seeking accelerated approval for the first-line treatment of patients with unresectable HCC based on the KEYNOTE-524/Study 116 trial. Ahead of the PDUFA action dates of Merck&#8217;s and Eisai&#8217;s applications, another combination therapy was approved based on a randomized, controlled trial that demonstrated improvement in overall survival versus standard-of-care treatment. Consequently, the CRL stated that Merck&#8217;s and Eisai&#8217;s applications do not provide evidence that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Lenvima represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for KEYNOTE-524/Study 116 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the current approved indications for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or for Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and Eisai have stopped LEAP-007, the Phase 3 study evaluating the first-line treatment of Lenvima in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in participants with metastatic squamous or non-squamous NSCLC, whose tumors are PD-L1 positive with no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EGFR </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ALK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genomic tumor aberrations. The trial has been discontinued following the recommendation of the external Data Monitoring Committee (eDMC) which met, as scheduled, to assess safety and futility. The eDMC determined that the study had met the criteria for declaring futility and the benefit/risk profile of the combination did not support continuing the trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and Eisai have closed LEAP-011 for further enrollment. LEAP-011 is a Phase 3 study evaluating Lenvima in combination with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the first-line treatments of patients with platinum-ineligible urothelial carcinoma. Enrollment was closed following the recommendation of the eDMC, which met, as scheduled, to assess safety and futility. The eDMC determined that the benefit/risk profile of the combination did not support continuing the trial and improvements in outcomes in favor of the combination were unlikely to be as high as initially hypothesized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has several other programs in Phase 3 clinical development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-1308A is the coformulation of quavonlimab, Merck&#8217;s novel investigational anti-CTLA-4 antibody, with pembrolizumab being evaluated for the treatment of RCC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcutaneous MK-3475, pembrolizumab, is being evaluated for comparability with the intravenous formulation in NSCLC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-4280A is the coformulation of favezelimab, Merck&#8217;s novel investigational anti-LAG3 therapy, with pembrolizumab, being evaluated for the treatment of CRC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-6482, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (belzutifan), is a hypoxia-inducible factor-2&#945; (HIF-2&#945;) inhibitor being evaluated for a supplemental indication for the treatment of patients with RCC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7119, Tukysa, is a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers in development for the treatment of breast cancer. In September 2020, Seagen granted Merck an exclusive license and entered into a co-development agreement with Merck to accelerate the global reach of Tukysa. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7684A is the coformulation of vibostolimab, an anti-TIGIT therapy, with pembrolizumab being evaluated for the treatment of NSCLC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Merck announced that the FDA had placed clinical holds on the investigational new drug applications for the oral and implant formulations of islatravir (MK-8591) for HIV-1 pre-exposure prophylaxis </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(PrEP); the injectable formulation of islatravir for HIV-1 treatment and prophylaxis; and the oral doravirine/islatravir (MK-8591A) HIV-1 once-daily treatment regimen. The FDA&#8217;s clinical hold is based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. Merck previously announced it had stopped dosing in the Phase 2 IMAGINE-DR clinical trial of islatravir in combination with MK-8507 (MK-8591-013) and paused enrollment in the once-monthly Phase 3 PrEP studies, (MK-8591-022 and MK-8591-024). With the FDA&#8217;s clinical hold, no new studies may be initiated. Additionally, Merck and Gilead have made the decision to stop all dosing of participants in the Phase 2 clinical study evaluating an oral-weekly combination treatment regimen of islatravir and Gilead&#8217;s investigational lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. This decision follows the joint announcement on November 23, 2021 of a temporary hold on further enrollment and screening in the study, which commenced in October 2021. The two companies will assess whether a different dosing of islatravir in combination with lenacapavir may provide a once-weekly oral therapy option for people living with HIV. Merck and Gilead remain committed to their collaboration, which aims to develop long-acting new treatment options to address the unmet needs for people living with HIV.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7962, sotatercept, is a potentially first-in-class therapy for the treatment of pulmonary arterial hypertension (PAH). Sotatercept is in clinical trials as an add-on to current standard of care for the treatment of PAH. Sotatercept was obtained in connection with Merck&#8217;s acquisition of Acceleron Pharma Inc. in 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-1654, clesrovimab, is a respiratory syncytial virus (RSV) monoclonal antibody that is being evaluated for the prevention of RSV medically attended lower respiratory tract infection in infants and certain children over 2 years of age. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck announced the discontinuation of development of MK-7110 which was being evaluated for the treatment of hospitalized patients with COVID-19. Merck obtained MK-7110 in December 2020 through its acquisition of OncoImmune, a privately held clinical-stage biopharmaceutical company. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential EUA application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#8217;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the FDA approved updated labeling for Steglatro, Steglujan and Segluromet, medicines for adults with type 2 diabetes, to include the primary efficacy and safety results from the VERTIS CV trial, which assessed the effect of Steglatro compared with placebo on cardiovascular outcomes in adult patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The FDA issued a CRL concerning the Company&#8217;s application for a new indication, based on additional results from the VERTIS CV trial, to reduce the risk of hospitalization for heart failure. The Company has determined not to pursue the indication.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chart below reflects the Company&#8217;s research pipeline as of February&#160;22, 2022. Candidates shown in Phase&#160;3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase&#160;2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase&#160;1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 3 (Phase 3 entry date)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Under Review</span></td></tr><tr style="height:321pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-0482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-1026 (nemtabrutinib)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-1308 (quavonlimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(2)</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Hepatocellular </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Small-Cell-Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:107%">MK-2140 (zilovertamab vedotin)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-4280 (favezelimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%"> </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-4830</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-5890</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:115%">MK-6440 (ladiratuzumab vedotin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-1.92pt;vertical-align:baseline">(1)(3)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Gastric</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:115%">MK-6482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-style:italic;font-weight:400;line-height:115%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-1.92pt;vertical-align:baseline">(3)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Rare cancers</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Von Hippel-Lindau Disease-Associated Tumors (EU)</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(1)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Bladder</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Cervical</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Gastric</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(1)(3)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-7684 (vibostolimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(2)</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Melanoma </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Cervical</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Glioblastoma</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">V937</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">Solid Tumors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">Cardiovascular</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-2060</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">Chikungunya Virus Vaccine</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">V184</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-8591B (islatravir+MK-8507)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(4)</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-8591D (islatravir+lenacapavir)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.57pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-1.92pt;vertical-align:baseline">(1)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">Nonalcoholic Steatohepatitis (NASH)</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-3655</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-6024</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">Overgrowth Syndrome</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-7075 (miransertib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">V116</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-5475</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">Schizophrenia</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-8189</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:700;line-height:110%">Treatment Resistant Depression</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:110%">MK-1942</span></div></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-4482 (molnupiravir) (May 2021)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(1)(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%"> (U.S)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Renal Cell (April 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Biliary (September 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Gastric (May 2015) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Hepatocellular (May 2016) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Mesothelioma (May 2018)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Ovarian (December 2018)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Prostate (May 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Small-Cell Lung (May 2017)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-3475 (pembrolizumab subcutaneous) </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (August 2021)</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Colorectal (November 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-6482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:110%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Renal Cell (February 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Breast (October 2019)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Colorectal (August 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (June 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Small-Cell Lung (December 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (April 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Colorectal (April 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Esophageal (July 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Gastric (December 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Head and Neck (February 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Melanoma (March 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (March 2019)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-8591A (doravirine+islatravir) (February 2020)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">HIV-1 Prevention</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-8591 (islatravir) (February 2021)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-7962 (sotatercept) (January 2021)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Respiratory Syncytial Virus</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%">MK-1654 (clesrovimab) (November 2021)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">New Molecular Entities/Vaccines</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-4482 (molnupiravir)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%"> (EU)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Cough</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-7264 (gefapixant) (U.S.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%"> (EU)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">V114 (JPN)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Certain Supplemental Filings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;    Adjuvant Treatment of  Stage IIB or IIC Melanoma</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">(KEYNOTE-716) (EU)</span></div><div style="padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;    Adjuvent Renal Cell Cancer </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">(KEYNOTE-564) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;    MSI-H or dMMR Endometrial Cancer </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">(KEYNOTE-158) (U.S.)</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;padding-left:6.73pt">MSI-H or dMMR Six Tumor Basket</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">(KEYNOTE-158) (EU) </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;    High-Risk Early-Stage Triple-Negative Breast Cancer (KEYNOTE-522) (EU) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;    Tumor Mutational Burden-High (KEYNOTE-158) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;    Cervical Cancer (KEYNOTE-826) (EU) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:110%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">-Mutated HER2-Negative Adjuvant Breast Cancer (OlympiA) (U.S.) (EU)</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;padding-left:6.73pt">First-Line Metastatic Prostate Cancer</span></div><div style="padding-left:18pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">(PROpel) (EU)</span></div><div style="padding-left:18pt;text-indent:4.5pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;    First-Line Metastatic Hepatocellular Carcinoma</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-524) (U.S.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(7)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#8226;    Advanced Unresectable Renal Cell Carcinoma</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-581) (JPN)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.27pt;vertical-align:baseline">(8)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%">&#160;</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr style="height:305pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%">Footnotes:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Being developed in a collaboration.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">  Being developed in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">  Being developed as monotherapy and/or in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Keytruda.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">On FDA clinical hold.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Available in the U.S. under Emergency Use Authorization.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> In January 2022, the FDA issued a CRL. Merck is reviewing the CRL and considering next steps. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">  In July 2020, the FDA issued a CRL for Merck&#8217;s and Eisai&#8217;s applications. Merck and Eisai intend to submit additional data when available to the FDA. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> Approved on February 25, 2022.</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div><span><br/></span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had approximately 68,000 employees worldwide, with approximately 27,000 employed in the U.S., including Puerto Rico, and, additionally, approximately 14,000 third-party contractors globally.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Approximately 67,000 of the Company&#8217;s employees are full-time employees. Women and individuals from underrepresented ethnic groups comprise approximately 50% and 32% of its workforce (the Company defines workforce as its employees) in the U.S., respectively. Women comprise 46% of the members of the Board of Directors. Additionally, the Company&#8217;s executive team is made up of 33% women. Approximately 23% of the Company&#8217;s employees are represented by various collective bargaining groups. The Company&#8217;s voluntary turnover rate was approximately 8.8% and 6.0%, respectively, in 2021 and 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes that its employees are critical to meet the needs of its patients and customers and that its ability to excel depends on the integrity, skill, and diversity of its employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Third party contractors include the Company&#8217;s temporary workers, independent contractors, and freelancers who are viewed as full-time equivalent employees. They exclude outsourced service providers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a comprehensive approach to ensure recruiting, retention and leadership development goals are systematically executed throughout the Company and that it hires talented leaders to achieve improved gender parity and representation across all dimensions of diversity. The Company provides training to its managers and external recruiting organizations on strategies to mitigate unconscious bias in the candidate selection and hiring process. In addition, the Company utilizes a comprehensive communications strategy, employee branding and marketing outreach, social media and strategic alliance partnerships to reach a broad pool of talent in its critical business areas. In 2021, the Company hired approximately 8,700 employees across the globe through various channels including the Company&#8217;s external career site, direct passive candidate sourcing, diversity partnerships, employee referrals, universities and other external sources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Diversity and Inclusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diversity and inclusion are fundamental to the Company&#8217;s success and core to future innovation. The Company fosters a globally diverse and inclusive workforce for its employees by creating an environment of belonging, engagement, equity, and empowerment. The Company is proactive and intentional about diversity hiring and development programs to advance talent. The Company creates competitive advantages by leveraging diversity and inclusion to accelerate business performance. This includes fostering global supplier diversity, integrating diversity and inclusion into the Company&#8217;s commercialization strategies and leveraging employee insights to improve performance. In addition to these efforts, the Company has ten Employee Business Resource Groups that provide opportunities for employees to take an active part in contributing to the Company&#8217;s inclusive culture through their work in talent acquisition and development, business and customer insights and social and community outreach.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s diversity goals include increasing representation in senior management roles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by 2024 of (i) women globally to 40%, up from 31% in 2020, (ii) Black/African Americans in the U.S. to 10%, up from 3% in 2020, and (iii) Hispanics/Latinos in the U.S. to 10%, up from 5% in 2020. At December 31, 2021, representation in senior management roles at the Company for (i) women globally was 36%, (ii) Black/African Americans in the U.S. was 7%, and (iii) Hispanics/Latinos in the U.S. was 6%. In addition, by 2025, the Company seeks to maintain or exceed both its current inclusion index score and its current employee engagement index score.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Senior management role&#8221; is defined as an individual holding either a Vice President or Senior Vice President title.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Inclusion Index is the average favorability score for employees&#8217; responses to three items in the employee pulse survey (manager supports inclusion, sense of belonging, leaders value perspective). The Employee Engagement Index is the average favorability score for employees&#8217; responses to items in the employee survey.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Gender and Ethnicity Performance Data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women in the workforce</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">50%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women in the workforce in the U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women on the Board of Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">46%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women in executive roles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">33%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Women in management roles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">44%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups on the Board of Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups in executive roles (U.S.)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">42%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups in the workforce (U.S.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups in management roles (U.S.)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">26%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New hires that were female</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">53%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New hires that were members of underrepresented ethnic groups (U.S.)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">46%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">As of 12/31. As self-identified to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Prior period data has not been restated to adjust for the Organon Spin-Off.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;Executive role&#8221; is defined as an individual holding an Executive Vice President title.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;Management role&#8221; is defined as all managers with direct reports other than executives as defined in note 3.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Benefits</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a valuable total rewards package reflecting its commitment to attract, retain and motivate its talent, and support its employees and their families in every stage of life. The Company continuously monitors and adjusts its compensation and benefit programs to ensure they are competitive, contemporary, helpful and engaging, and that they support strategic imperatives such as diversity and inclusion, equity, flexibility, quality, security and affordability. For example, the Company added a personal health care concierge service to assist U.S. employees participating in the Company medical plan with their health care needs. Aligned with its business and in support of its cancer care strategy, the Company also improved cancer screening benefits, added resources and provided immediate access to a leading cancer center of excellence for U.S. employees. Globally, the Company implemented a minimum standard of 12 weeks of paid parental leave, which inclusively applies to all parents. In the U.S., the Company&#8217;s benefits rank in the top quartile of Fortune 100 companies under the Aon 2021 Benefits Index. The Company has been included in Seramount (previously the Working Mother) 100 Best Companies ranking for 35 consecutive years and was named a Seramount top ten Best Company for Dads in 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Wellbeing</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is committed to helping its employees and their families improve their own health and wellbeing. The Company&#8217;s culture of wellbeing is referred to as &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Live it</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, which includes programs to support preventive health, emotional and financial wellbeing, physical fitness and nutrition. It is designed to inspire all employees to pursue, enjoy, and share healthy lifestyles. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Live it</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S. in 2011 and today is available in every country in which the Company has employees. In addition, many of the Company&#8217;s larger sites offer onsite health clinics that provide an array of services to help its employees stay or get well, including vaccinations, cancer and biometric screenings, travel medicine and advice, diagnosis and treatment of non-occupational illnesses or injuries, health counseling and referrals. The Company&#8217;s overall employee wellbeing program was recognized for excellence in health and wellbeing by receiving the most recent highest-level awards from the Business Group on Health and the American Heart Association.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Response</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes that it has a unique responsibility to help in response to the COVID-19 pandemic and is committed to supporting and protecting its employees and their families, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of antiviral approaches and supporting its health care providers and the communities in which they serve. The Company continues to provide employees with easy and regular access to information, including details regarding the Company&#8217;s tracking process, guidance around hygiene measures and travel and best practices for working from home. Examples of pandemic support resources and programs available to the Company&#8217;s employees include pay continuation for workers who have been sick or exposed, volunteer policy adjustment to enable employees with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medical backgrounds to volunteer in SARS-CoV-2-related activities, resources to prioritize physical and mental wellness, adjustments to medical plans to cover 100% of a COVID-19-related diagnosis, testing and treatment, backup childcare and more.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engaging Employees</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company strives to foster employee engagement by promoting a safe, positive, diverse and inclusive work environment that provides numerous opportunities for two-way communication with employees. Some of the Company&#8217;s key programs and initiatives include promoting global employee engagement surveys, ongoing pulse checks to the organization for interim feedback on specific topics, fostering professional networking and collaboration, identifying and providing opportunities for volunteering and establishing positive, cooperative business relations with designated employee representatives. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Management and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company pursues its goal of becoming the world&#8217;s premier research-based biopharmaceutical company, there is a consistent focus on the importance of continuously developing its diverse and talented people. The Company&#8217;s current talent management system supports company-wide performance management, leadership development, talent reviews and succession planning. Annual performance reviews help further the professional development of the Company&#8217;s employees and ensure that the Company&#8217;s workforce is aligned with the Company&#8217;s objectives. The Company seeks to continuously build the skills and capabilities of its workforce to accelerate talent, improve performance and mitigate risk through relevant continuous learning experiences. This includes, but is not limited to, building leadership and management skills, as well as providing technical and functional training to all employees.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_43"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Sustainability</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company strives to be a strong environmental steward, and realizes that its strategy and efforts need to continuously improve for the Company to excel in an increasingly resource-constrained world. The Company&#8217;s environmental sustainability strategy has three areas of focus:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Driving efficiency in operations;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Designing new products to minimize environmental impact; and</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reducing any impacts in the Company&#8217;s upstream and downstream value chain.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recently adopted a set of new climate goals to address the rising expectations of its customers, investors, external stakeholders and employees regarding the environmental impact of its operations and supply chain. These goals include achieving carbon neutrality for greenhouse gas emissions across operations (Scopes 1 and 2) by 2025, reducing Scope 1 and 2 greenhouse gas emissions 46% by 2030 (from a 2019 baseline), reducing value chain (Scope 3) greenhouse gas emissions by 30% by 2030 (from a 2019 baseline), and sourcing 100% renewable energy for purchased electricity by 2025. The Company&#8217;s absolute greenhouse gas reduction targets have been verified by the Science Based Target initiative. Other environmental sustainability initiatives of the Company include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Global water use and stewardship.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s global water strategy aims to achieve sustainable water management within its operations and its supply chain, as well as address water-related risk. Access to clean water is critical for human health, and water is a key input to the Company&#8217;s manufacturing operations. The Company&#8217;s sites employ a variety of technologies and techniques, such as closed-loop cooling systems and reused reverse osmosis &#8220;reject water,&#8221; to reduce the Company&#8217;s water footprint and improve operational performance.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Waste management and diversion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company continuously strives to reduce the amount of operational waste it generates and to maximize the use of environmentally beneficial disposal methods such as recycling, composting and waste-to-energy.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Product stewardship and green and sustainable science.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s product stewardship program focuses on identifying and either preventing or minimizing potential safety and environmental hazards throughout a product&#8217;s life cycle. The Company is also committed to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">understanding, managing and reducing the environmental impacts of its products and the materials associated with discovering and producing them. The Company&#8217;s green and sustainable science program uses a &#8220;green-by-design&#8221; approach. By using more efficient and innovative processing methods and technologies, the Company is reducing the amount of energy, water and raw materials the Company uses to make the Company&#8217;s products, thereby reducing the amount of waste the Company generates and lowering the Company&#8217;s production costs.</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Animal conservation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is a leading worldwide supplier of individual identification, real-time data access and advanced analytics for the animal conservation community. This enables the Company to produce actionable insights that inform recovery actions on a global scale, for species ranging from wild fish to penguins. The Company also provides wild fish conservation monitoring equipment and real-time video monitoring technology to advance fish health and welfare. Together, these technologies help to promote biodiversity and support the global need for reliable and safe sources of protein.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management does not believe that expenditures related to these initiatives should have a material adverse effect on the Company&#8217;s financial condition, results of operations, liquidity or capital resources for any year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company completed its inaugural issuance of a $1.0 billion sustainability bond, which was part of an $8.0 billion underwritten bond offering. The Company intends to use the net proceeds from the sustainability bond offering to support projects and partnerships in the Company&#8217;s priority environmental, social and governance (ESG) areas and contribute to the advancement of the United Nations Sustainable Development Goals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck believes that climate change could present risks to its business. Some of the potential impacts of climate change to its business include increased operating costs due to additional regulatory requirements, physical risks to the Company&#8217;s facilities, water limitations and disruptions to its supply chain. These potential risks are integrated into the Company&#8217;s business planning including investment in reducing energy usage, water use and greenhouse gas emissions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Regulation and Remediation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites. Expenditures for remediation and environmental liabilities were $12 million in 2021 and are estimated to be $24 million in the aggregate for the years 2022 through 2026. These amounts do not consider potential recoveries from other parties. The Company has taken an active role in identifying and accruing for these costs and, in management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $40 million and $43 million at December&#160;31, 2021 and 2020, respectively. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $40 million in the aggregate. Management also does not believe that these expenditures should have a material adverse effect on the Company&#8217;s financial condition, results of operations, liquidity or capital resources for any year.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Area Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations outside the U.S. are conducted primarily through subsidiaries. Sales worldwide by subsidiaries outside the U.S. as a percentage of total Company sales were 54% in 2021 and were 53% in both 2020 and 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s worldwide business is subject to risks of currency fluctuations, governmental actions and other governmental proceedings abroad. The Company does not regard these risks as a deterrent to further expansion of its operations abroad. However, the Company closely reviews its methods of operations and adopts strategies responsive to changing economic and political conditions.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has operations in countries located in Latin America, the Middle East, Africa, Eastern Europe and Asia Pacific. Business in these developing areas, while sometimes less stable, offers important opportunities for growth over time.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Internet website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">merck.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will make available, free of charge at the &#8220;Investors&#8221; portion of its website, its Annual Report on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, and all amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). The address of that website is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company will provide without charge a copy of its Annual Report on Form 10-K, including financial statements and schedules, upon the written request of any shareholder to the Office of the Secretary, Merck &amp; Co., Inc., 2000&#160;Galloping Hill Road, K1-4157, Kenilworth, NJ 07033 U.S.A.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate governance guidelines and the charters of the Board of Directors&#8217; four standing committees are available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">merck.com/company-overview/leadership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and all such information is available in print to any shareholder who requests it from the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020/2021 Environmental, Social &amp; Governance (ESG) Progress Report, which provides enhanced ESG disclosures, is available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">merck.com/company-overview/responsibility/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Information in the Company&#8217;s ESG Progress Report is not incorporated by reference into this Form 10-K.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_52"></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.8pt">Risk Factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks that if realized could materially adversely affect its business, results of operations, cash flow, financial condition or prospects. The following is a summary of the principal risk factors facing the Company:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As the Company&#8217;s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Key products generate a significant amount of the Company&#8217;s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that lose patent protection.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company faces continued pricing pressure with respect to its products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by certain governments, could negatively affect the Company&#8217;s operating results.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company faces intense competition from lower cost generic products.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company faces intense competition from competitors&#8217; products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 2021 and 2020, COVID-19-related disruptions had an adverse impact on the Company&#8217;s business, operations and financial performance. The Company is unable to predict the full extent to which the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company&#8217;s business, results of operations, cash flows and prospects.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Environmental, social and governance (ESG) matters may impact the Company&#8217;s business and reputation.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to attract and retain highly qualified personnel could affect the Company&#8217;s ability to successfully develop and commercialize products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company may not be able to realize the expected benefits of its investments in emerging markets.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmaceutical products can develop unexpected safety or efficacy concerns.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company&#8217;s business.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company&#8217;s future results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developments following regulatory approval may adversely affect sales of the Company&#8217;s products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is subject to a variety of U.S. and international laws and regulations.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adverse outcomes in current or future legal matters could negatively affect Merck&#8217;s business.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability insurance for products may be limited, cost prohibitive or unavailable.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is increasingly dependent on sophisticated software applications and computing infrastructure. In 2017, the Company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations. The Company could be a target of future cyber-attacks.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Social media and mobile messaging platforms present risks and challenges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above list is not exhaustive, and the Company faces additional challenges and risks. Investors should carefully consider all of the information set forth in this Form 10-K, including the following risk factors, before deciding to invest in any of the Company&#8217;s securities.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks below are not the only ones the Company faces. Additional risks not currently known to the Company or that the Company presently deems immaterial may also impair its business operations. The Company&#8217;s business, financial condition, results of operations, cash flow or prospects could be materially adversely affected by any of these risks. This Form&#160;10-K also contains forward-looking statements that involve risks and uncertainties. The Company&#8217;s results could materially differ from those anticipated in these forward-looking statements as a result of certain factors, including the risks it faces described below and elsewhere. See &#8220;Cautionary Factors that May Affect Future Results&#8221; below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to the Company&#8217;s Business</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent protection is considered, in the aggregate, to be of material importance to the Company&#8217;s marketing of human health and animal health products in the U.S. and in most major foreign markets. Patents covering products that it has introduced normally provide market exclusivity, which is important for the successful marketing and sale of its products. The Company seeks patents covering each of its products in each of the markets where it intends to sell the products and where meaningful patent protection is available.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the Company succeeds in obtaining patents covering its products, third parties or government authorities may challenge or seek to invalidate or circumvent its patents and patent applications. It is important for the Company&#8217;s business to successfully assert and defend the patent rights that provide market exclusivity for its products. The Company is often involved in patent disputes relating to challenges to its patents or claims by third parties of infringement against the Company. The Company asserts and defends its patents both within and outside the U.S., including by filing claims of infringement against other parties. See Item&#160;8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;11. &#8220;Contingencies and Environmental Liabilities&#8221; below. In particular, manufacturers of generic pharmaceutical products from time to time file abbreviated NDAs with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned or licensed by the Company. The Company normally responds by asserting its patent with a lawsuit alleging patent infringement. Patent litigation and other challenges to the Company&#8217;s patents are costly and unpredictable and may deprive the Company of market exclusivity for a patented product or, in some cases, third-party patents may prevent the Company from marketing and selling a product in a particular geographic area.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies or in other circumstances, which could diminish or eliminate sales and profits from those regions and negatively affect the Company&#8217;s results of operations. Further, court decisions relating to other companies&#8217; patents, potential legislation in both the U.S. and certain foreign markets relating to patents, as well as regulatory initiatives may result in a more general weakening of intellectual property protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more important products lose patent protection in profitable markets, sales of those products are likely to decline significantly as a result of generic versions of those products becoming available. The Company&#8217;s results of operations may be adversely affected by the lost sales unless and until the Company has launched commercially successful products that replace the lost sales. In addition, if products that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively affect product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A chart listing the patent protection for certain of the Company&#8217;s marketed products, and U.S. patent protection for candidates in Phase 3 clinical development is set forth above in Item&#160;1. &#8220;Business &#8212; Patents, Trademarks and Licenses.&#8221;</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As the Company&#8217;s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company depends upon patents to provide it with exclusive marketing rights for its products for some period of time. Loss of patent protection for one of the Company&#8217;s products typically leads to a significant and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rapid loss of sales for that product as lower priced generic versions of that drug become available. In the case of products that contribute significantly to the Company&#8217;s sales, the loss of market exclusivity can have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will lose market exclusivity in the U.S. in January 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will lose market exclusivity in the EU in September 2022 and in China in July 2022. The Company anticipates sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in these markets will decline substantially after the loss of exclusivity.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key products generate a significant amount of the Company&#8217;s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to generate profits and operating cash flow depends largely upon the continued profitability of the Company&#8217;s key products, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda, Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9, Lynparza, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In particular, in 2021, the Company&#8217;s oncology portfolio, led by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represented a substantial portion of the Company&#8217;s revenue growth. As a result of the Company&#8217;s dependence on key products, any event that adversely affects any of these products or the markets for any of these products could have a significant adverse impact on results of operations and financial condition. These events could include loss of patent protection, increased costs associated with manufacturing, generic or over-the-counter availability of the Company&#8217;s product or a competitive product, the discovery of previously unknown side effects, results of post-approval trials, increased competition from the introduction of new, more effective treatments and discontinuation or removal from the market of the product for any reason. Such events could have a material adverse effect on the sales of any such products.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that lose patent protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to remain competitive, the Company, like other major pharmaceutical companies, must continue to launch new products. Expected declines in sales of products after the loss of market exclusivity mean that the Company&#8217;s future success is dependent on its pipeline of new products, including new products that it may develop through collaborations and joint ventures and products that it is able to obtain through license or acquisition. To accomplish this, the Company commits substantial effort, funds and other resources to research and development, both through its own dedicated resources and through various collaborations with third parties. There is a high rate of failure inherent in the research and development process for new drugs and vaccines. As a result, there is a high risk that funds invested by the Company in research programs will not generate financial returns. This risk profile is compounded by the fact that this research has a long investment cycle. To bring a pharmaceutical compound from the discovery phase to market may take a decade or more and failure can occur at any point in the process, including later in the process after significant funds have been invested.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the research and development process, see Item&#160;1. &#8220;Business &#8212; Research and Development&#8221; above. Each phase of testing is highly regulated and during each phase there is a substantial risk that the Company will encounter serious obstacles or will not achieve its goals. Therefore, the Company may abandon a product in which it has invested substantial amounts of time and resources. Some of the risks encountered in the research and development process include the following: pre-clinical testing of a new compound may yield disappointing results; competing products from other manufacturers may reach the market first; clinical trials of a new drug may not be successful; a new drug may not be effective or may have harmful side effects; a new drug may not be approved by the regulators for its intended use; it may not be possible to obtain a patent for a new drug; payers may refuse to cover or reimburse the new product; or sales of a new product may be disappointing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot state with certainty when or whether any of its products now under development will be approved or launched; whether it will be able to develop, license or otherwise acquire compounds, product candidates or products; or whether any products, once launched, will be commercially successful. The Company must maintain a continuous flow of successful new products and successful new indications for existing products sufficient both to cover its substantial research and development costs and to replace sales that are lost as profitable products lose market exclusivity or are displaced by competing products or therapies. Failure to do so in the short </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term or long term would have a material adverse effect on the Company&#8217;s business, results of operations, cash flow, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products that appear promising in development may fail to reach the market or fail to succeed for numerous reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">findings of ineffectiveness, superior safety or efficacy of competing products, or harmful side effects in clinical or pre-clinical testing;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to receive the necessary regulatory approvals, including delays in the approval of new products and new indications, or the anticipated labeling, and uncertainties about the time required to obtain regulatory approvals and the benefit/risk standards applied by regulatory agencies in determining whether to grant approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure in certain markets to obtain reimbursement commensurate with the level of innovation and clinical benefit presented by the product;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of economic feasibility due to manufacturing costs or other factors; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclusion from commercialization by the proprietary rights of others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, if certain pipeline programs are cancelled or if the Company believes that their commercial prospects have been reduced, the Company may recognize material non-cash impairment charges for those programs that were measured at fair value and capitalized in connection with acquisitions or certain collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to successfully develop and market new products in the short term or long term would have a material adverse effect on the Company&#8217;s business, results of operations, cash flow, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company faces continued pricing pressure with respect to its products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces continued pricing pressure globally and, particularly in mature markets, from managed care organizations, government agencies and programs that could negatively affect the Company&#8217;s sales and profit margins. In the U.S., these include (i)&#160;practices of managed care groups and institutional and governmental purchasers, (ii)&#160;U.S. federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug Improvement and Modernization Act of 2003 and the ACA, and (iii) state activities aimed at increasing price transparency, including new laws as noted above in Item 1. &#8220;Competition and the Health Care Environment.&#8221; Changes to the health care system enacted as part of health care reform in the U.S., as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, could result in further pricing pressures. In addition, in the U.S., larger customers have received higher rebates on drugs in certain highly competitive categories. The Company must also compete to be placed on formularies of managed care organizations. Exclusion of a product from a formulary can lead to reduced usage in the managed care organization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide information about the Company&#8217;s pricing practices, the Company annually posts on its website&#160;its Pricing Transparency Report for the U.S. The report provides the Company&#8217;s average annual list price and net price increases across the Company&#8217;s U.S. portfolio dating back to 2010. In 2021, the Company&#8217;s gross U.S. sales were reduced by 43.5% as a result of rebates, discounts and returns.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., numerous major markets, including the EU, Japan and China have pervasive government involvement in funding health care and, in that regard, fix the pricing and reimbursement of pharmaceutical and vaccine products. Consequently, in those markets, the Company is subject to government decision making and budgetary actions with respect to its products. In Japan, the pharmaceutical industry is subject to government-mandated annual price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order re-pricing for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects pricing pressures to continue in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by certain governments, could negatively affect the Company&#8217;s operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business may be adversely affected by local and global economic conditions, including with respect to inflation, interest rates, and costs of raw materials and packaging. Uncertainty in global economic and geopolitical conditions may result in a slowdown to the global economy that could affect the Company&#8217;s business by reducing the prices that drug wholesalers and retailers, hospitals, government agencies and managed health care providers may be able or willing to pay for the Company&#8217;s products or by reducing the demand for the Company&#8217;s products, which could in turn negatively impact the Company&#8217;s sales and result in a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above in &#8220;Competition and the Health Care Environment,&#8221; global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s revenue performance in 2021 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. The Company anticipates all of these actions, and additional actions in the future, will continue to negatively affect revenue performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If credit and economic conditions worsen, the resulting economic and currency impacts in the affected markets and globally could have a material adverse effect on the Company&#8217;s results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic has caused some disruption and volatility in the Company&#8217;s global supply chain network, and the Company may experience disruptions in availability and delays in shipments of raw materials and packaging, as well as related cost inflation. Any such disruptions, delays or costs may result in the Company&#8217;s inability to meet demand for the Company&#8217;s products.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company faces intense competition from lower cost generic products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the Company faces increasing competition from lower-cost generic products. The patent rights that protect its products are of varying strengths and durations. In addition, in some countries, patent protection is significantly weaker than in the U.S. or in the EU. In the U.S. and the EU, political pressure to reduce spending on prescription drugs has led to legislation and other measures that encourage the use of generic and biosimilar products. Although it is the Company&#8217;s policy to actively protect its patent rights, generic challenges to the Company&#8217;s products can arise at any time, and the Company&#8217;s patents may not prevent the emergence of generic competition for its products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss of patent protection for a product typically is followed promptly by generic substitutes, reducing the Company&#8217;s sales of that product. Availability of generic substitutes for the Company&#8217;s drugs may adversely affect its results of operations and cash flow. In addition, proposals emerge from time to time in the U.S. and other countries for legislation to further encourage the early and rapid approval of generic drugs. Any such proposal that is enacted into law could worsen this substantial negative effect on the Company&#8217;s sales and, potentially, its business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company faces intense competition from competitors&#8217; products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s products face intense competition from competitors&#8217; products. This competition may increase as new products enter the market. In such an event, the competitors&#8217; products may be safer or more effective, more convenient to use, have better insurance coverage or reimbursement levels or be more effectively marketed and sold than the Company&#8217;s products. Alternatively, in the case of generic competition, including the generic availability of competitors&#8217; branded products, they may be equally safe and effective products that are sold at a substantially lower price than the Company&#8217;s products. As a result, if the Company fails to maintain its competitive position, this could have a material adverse effect on its business, cash flow, results of operations, financial condition and prospects. In addition, if products that were measured at fair value and capitalized in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with acquisitions experience difficulties in the market that negatively impact product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In 2021 and 2020, COVID-19-related disruptions had an adverse impact on the Company&#8217;s business, operations and financial performance. The Company is unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business and financial results were negatively impacted by COVID-19-related disruptions in 2021 and 2020. The continued duration and severity of the COVID-19 pandemic is uncertain, rapidly changing and difficult to predict. The degree to which COVID-19-related disruptions impact the Company&#8217;s results in 2022 will depend on future developments, beyond the Company&#8217;s knowledge or control, including, but not limited to, the duration of the pandemic, its severity, the success of actions taken to contain or prevent the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the COVID-19 pandemic impacted the Company&#8217;s business in numerous ways. As expected, within the Company&#8217;s human health business, which is comprised largely of physician-administered products, revenue was negatively impacted by social distancing measures and fewer well visits, which negatively affected vaccine and oncology sales in particular. The estimated negative impact of COVID-19-related disruptions to Merck&#8217;s revenue for the full year 2021 was approximately $1.3 billion, attributable to the Pharmaceutical segment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck believes that global health systems and patients have largely adapted to the impacts of COVID-19, however, roughly 75% of Merck&#8217;s Pharmaceutical segment revenue is comprised of physician-administered products which could be adversely affected by the pandemic if its effects worsen. Despite the Company&#8217;s efforts to manage the impacts of the COVID-19 pandemic, their ultimate effect will also depend on factors beyond the Company&#8217;s knowledge or control, including the duration of the COVID-19 pandemic as well as governmental and third-party actions taken to contain or prevent the spread and treatment of the virus and mitigate its public health and economic effects. In addition, any future pandemic, epidemic or similar public health threat could present similar risks to the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent of the Company&#8217;s operations outside the U.S. is significant. Risks inherent in conducting a global business include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in medical reimbursement policies and programs and pricing restrictions in key markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple regulatory requirements that could restrict the Company&#8217;s ability to manufacture and sell its products in key markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade protection measures and import or export licensing requirements, including the imposition of trade sanctions or similar restrictions by the U.S. or other governments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign exchange fluctuations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminished protection of intellectual property in some countries; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible nationalization and expropriation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there may be changes to the Company&#8217;s business and political position if there is instability, disruption or destruction in a significant geographic region, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest; and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease. In particular, in February 2022, armed conflict escalated between Russia and Ukraine. It is not possible to predict the broader consequences of this conflict, which could include sanctions, embargoes, regional instability, geopolitical shifts and adverse effects on macroeconomic conditions, currency exchange rates and financial markets.</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company&#8217;s business, results of operations, cash flows and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that climate change has the potential to negatively affect its business and results of operations, cash flows and prospects. The Company is exposed to physical risks (such as extreme weather conditions or rising sea levels), risks in transitioning to a low-carbon economy (such as additional legal or regulatory requirements, changes in technology, market risk and reputational risk) and social and human effects (such as population dislocations and harm to health and well-being) associated with climate change. These risks can be either acute (short-term) or chronic (long-term).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adverse impacts of climate change include increased frequency and severity of natural disasters and extreme weather events such as hurricanes, tornados, wildfires (exacerbated by drought), flooding, and extreme heat. Extreme weather and sea-level rise pose physical risks to the Company&#8217;s facilities as well as those of its suppliers. Such risks include losses incurred as a result of physical damage to facilities, loss or spoilage of inventory, and business interruption caused by such natural disasters and extreme weather events. Other potential physical impacts due to climate change include reduced access to high-quality water in certain regions and the loss of biodiversity, which could impact future product development. These risks could disrupt the Company&#8217;s operations and its supply chain, which may result in increased costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New legal or regulatory requirements may be enacted to prevent, mitigate, or adapt to the implications of a changing climate and its effects on the environment. These regulations, which may differ across jurisdictions, could result in the Company being subject to new or expanded carbon pricing or taxes, increased compliance costs, restrictions on greenhouse gas emissions, investment in new technologies, increased carbon disclosure and transparency, upgrade of facilities to meet new building codes, and the redesign of utility systems, which could increase the Company&#8217;s operating costs, including the cost of electricity and energy used by the Company. The Company&#8217;s supply chain would likely be subject to these same transitional risks and would likely pass along any increased costs to the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, social and governance (ESG) matters may impact the Company&#8217;s business and reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental authorities, non-governmental organizations, customers, investors, external stakeholders and employees are increasingly sensitive to ESG concerns, such as diversity and inclusion, climate change, water use, recyclability or recoverability of packaging, and plastic waste. This focus on ESG concerns may lead to new requirements that could result in increased costs associated with developing, manufacturing and distributing the Company&#8217;s products. The Company&#8217;s ability to compete could also be affected by changing customer preferences and requirements, such as growing demand for more environmentally friendly products, packaging or supplier practices, or by failure to meet such customer expectations or demand. While the Company strives to improve its ESG performance, the Company risks negative stockholder reaction, including from proxy advisory services, as well as damage to its brand and reputation, if the Company does not act responsibly, or if the Company is perceived to not be acting responsibly in key ESG areas, including equitable access to medicines and vaccines, product quality and safety, diversity and inclusion, environmental stewardship, support for local communities, corporate governance and transparency, and addressing human capital factors in the Company&#8217;s operations. If the Company does not meet the ESG expectations of its investors, customers and other stakeholders, the Company could experience reduced demand for its products, loss of customers, and other negative impacts on the Company&#8217;s business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to attract and retain highly qualified personnel could affect the Company&#8217;s ability to successfully develop and commercialize products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s success is largely dependent on its continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical research and development, governmental regulation and commercialization. Competition for qualified personnel in the pharmaceutical industry, both in the U.S. and internationally, is intense. The Company cannot be sure that it will be able to attract and retain quality personnel or that the costs of doing so will not materially increase.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has, in the past, experienced difficulties in manufacturing certain of its products, including vaccines. For example, in 2020 the Company issued a product recall for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following the identification of product sterility issues. The Company may, in the future, experience other difficulties and delays in manufacturing its products, such as (i)&#160;failure of the Company or any of its vendors or suppliers to comply with Current Good Manufacturing Practices and other applicable regulations and quality assurance guidelines that could lead to manufacturing shutdowns, product shortages and delays in product manufacturing; (ii)&#160;delays related to the construction of new facilities or the expansion of existing facilities, including those intended to support future demand for the Company&#8217;s products; and (iii)&#160;other manufacturing or distribution problems including supply chain delays, shortages in raw materials, changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in types of products produced, or physical limitations that could impact continuous supply. In addition, the Company could experience difficulties or delays in manufacturing its products caused by natural disasters, such as hurricanes. Manufacturing difficulties can result in product shortages, leading to lost sales and reputational harm to the Company.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company may not be able to realize the expected benefits of its investments in emerging markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been taking steps to increase its sales in emerging markets. However, there is no guarantee that the Company&#8217;s efforts to expand sales in these markets will succeed. Some countries within emerging markets may be especially vulnerable to periods of global financial instability or may have very limited resources to spend on health care. In order for the Company to successfully implement its emerging markets strategy, it must attract and retain qualified personnel. The Company may also be required to increase its reliance on third-party agents within less developed markets, which may affect its ability to realize continued growth and may also increase the Company&#8217;s risk exposure. In addition, many of these countries have currencies that fluctuate substantially and, if such currencies devalue and the Company cannot offset the devaluations, the Company&#8217;s financial performance within such countries could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business in China has grown rapidly in the past few years, and the importance of China to the Company&#8217;s overall pharmaceutical and vaccines business outside the U.S. has increased accordingly. Continued growth of the Company&#8217;s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company&#8217;s currently marketed products, and the absence of trade impediments or adverse pricing controls. As noted above in &#8220;Competition and the Health Care Environment,&#8221; pricing pressure in China has increased as the Chinese government has been taking steps to reduce costs, including implementing health care reform that has led to the acceleration of generic substitution, where available. While the mechanism for drugs being added to the NRDL evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. In 2021, drugs were added to the NRDL with an average of more than 60% price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through the government&#8217;s VBP program. In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward. In addition, the Company anticipates that the reported inquiries made by various governmental authorities involving multinational pharmaceutical companies in China may continue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all these reasons, sales within emerging markets carry significant risks. However, at the same time macro-economic growth of selected emerging markets is expected to outpace Europe and even the U.S., leading to significant increased health care spending in those countries and access to innovative medicines for patients. A failure to maintain the Company&#8217;s presence in emerging markets could therefore have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in multiple jurisdictions and virtually all sales are denominated in currencies of the local jurisdiction. Additionally, the Company has entered and will enter into business development transactions, borrowings or other financial transactions that may give rise to currency and interest rate exposure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company cannot, with certainty, foresee and mitigate against such adverse fluctuations, fluctuations in currency exchange rates, interest rates and inflation could negatively affect the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate against the adverse impact of these market fluctuations, the Company will from time to time enter into hedging agreements. While hedging agreements, such as currency options and forwards and interest rate swaps, may limit some of the exposure to exchange rate and interest rate fluctuations, such attempts to mitigate these risks may be costly and not always successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s interest rate derivatives and investments are based on the London Interbank Offered Rate (LIBOR), and a portion of Merck&#8217;s indebtedness bears interest at variable interest rates, primarily based on LIBOR. LIBOR is the subject of recent national, international and other regulatory guidance and proposals for reform, which will cause LIBOR to cease to exist entirely in the future. While the Company has begun to implement alternative reference rates as alternatives to LIBOR, the Company cannot predict the consequences and timing of any additional or unexpected developments, which could include an increase in interest expense and will also require the amendment of contracts that reference LIBOR.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical products can develop unexpected safety or efficacy concerns.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unexpected safety or efficacy concerns can arise with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, or declining sales, as well as product liability, consumer fraud and/or other claims, including potential civil or criminal governmental actions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company depends on third parties, including suppliers, alliances with other pharmaceutical and biotechnology companies, and third-party service providers, for key aspects of its business including development, manufacture and commercialization of its products and support for its information technology (IT) systems. Failure of these third parties to meet their contractual, regulatory and other obligations to the Company or the development of factors that materially disrupt the relationships between the Company and these third parties could have a material adverse effect on the Company&#8217;s business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales of key animal health products could be adversely affected by a number of risk factors including certain risks that are specific to the animal health business. For example, the outbreak of disease carried by animals, such as African Swine Fever, could lead to their widespread death and precautionary destruction as well as the reduced consumption and demand for animals, which could adversely affect the Company&#8217;s results of operations. Also, the outbreak of any highly contagious diseases near the Company&#8217;s main production sites could require the Company to immediately halt the manufacture of its animal health products at such sites or force the Company to incur substantial expenses in procuring raw materials or products elsewhere. Other risks specific to animal health include epidemics and pandemics, government procurement and pricing practices, weather and global agribusiness economic events. In addition, sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represent a significant portion of the Company&#8217;s Animal Health segment sales. Any negative event with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could have a material adverse effect on the Company&#8217;s Animal Health sales. As the Animal Health segment of the Company&#8217;s business becomes more significant, the impact of any such events on future results of operations would also become more significant.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company&#8217;s future results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development, testing, manufacturing and commercialization of biologics and vaccines, particularly human and animal health vaccines, is a long, complex, expensive and uncertain process. There are unique risks and uncertainties related to biologics and vaccines, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There may be limited access to, and supply of, normal and diseased tissue samples, cell lines, pathogens, bacteria, viral strains and other biological materials. In addition, government regulations in multiple jurisdictions, such as the U.S. and the EU, could result in restricted access to, or transport or use of, such materials. If the Company loses access to sufficient sources of such materials, or if tighter restrictions are imposed on the use of such materials, the Company may not be able to conduct research activities as planned and may incur additional development costs.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The development, manufacturing and marketing of biologics and vaccines are subject to regulation by the FDA, the EMA and other regulatory bodies. These regulations are often more complex and extensive than the regulations applicable to other pharmaceutical products. For example, in the U.S., a BLA, including both pre-clinical and clinical trial data and extensive data regarding the manufacturing procedures, is required for human vaccine candidates, and FDA approval is generally required for the release of each manufactured commercial human vaccine lot.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing biologics and vaccines, especially in large quantities, is often complex and may require the use of innovative technologies to handle living micro-organisms. Each lot of an approved biologic and vaccine must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, the Company may be required to provide pre-clinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biologics and vaccines are frequently costly to manufacture because production ingredients are derived from living animal or plant material, and most biologics and vaccines cannot be made synthetically. In particular, keeping up with the demand for vaccines may be difficult due to the complexity of producing vaccines.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The use of biologically derived ingredients can lead to variability in the manufacturing process and could lead to allegations of harm, including infections or allergic reactions, which allegations would be reviewed through a standard investigation process that could lead to closure of product facilities due to possible contamination. Any of these events could result in substantial costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Government Regulation and Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above in &#8220;Competition and the Health Care Environment,&#8221; the Company believes that the health care industry will continue to be subject to increasing regulation as well as political and legal action, as future proposals to reform the health care system are considered by the Executive branch, Congress and state legislatures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Centers for Medicare &amp; Medicaid Services (CMS) issued the Medicaid rebate final rule that implemented provisions of the ACA effective April 1, 2016. The rule provides comprehensive guidance on the calculation of Average Manufacturer Price and Best Price; two metrics utilized to determine the rebates drug manufacturers are required to pay to state Medicaid programs. On December 21, 2020, the CMS issued a final rule making significant changes to these requirements. Effective January 1, 2023, this final rule also changes the way that manufacturers must calculate Best Price, in relation to certain patient support programs, including coupons. PhRMA, a pharmaceutical industry trade group, of which the Company is a member, filed a complaint challenging this rule as invalid asserting that it conflicts with the plain language of the Medicaid drug rebate statute. Should this legal </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenge fail, the impact of this and other provisions in this final rule could adversely impact the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Congress passed the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Rescue Plan Act of 2021, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to Medicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the Average Manufacturer Price (AMP) in rebates to state Medicaid programs for Medicaid-covered drugs. As a result of this provision, beginning in 2024, it is possible that manufacturers may have to pay state Medicaid programs more in rebates than they received on sales of particular products. This change could present a risk to Merck in the future for drugs that have high Medicaid utilization and rebate exposure that is more than 100% of the AMP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company cannot predict what additional future changes in the health care industry in general, or the pharmaceutical industry in particular, will occur; however, any changes could have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities, including research, pre-clinical testing, clinical trials and the manufacturing and marketing of its products, are subject to extensive regulation by numerous federal, state and local governmental authorities in the U.S., including the FDA, and by foreign regulatory authorities, including in the EU, Japan and China. In the U.S., the FDA administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling and marketing of prescription pharmaceuticals. In some cases, the FDA requirements have increased the amount of time and resources necessary to develop new products and bring them to market in the U.S. Regulation outside the U.S. also is primarily focused on drug safety and effectiveness and, in many cases, reduction in the cost of drugs. The FDA and foreign regulatory authorities, including in the EU, Japan and China, have substantial discretion to require additional testing, to delay or withhold registration and marketing approval and to otherwise preclude distribution and sale of a product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the Company is successful in developing new products, it will not be able to market any of those products unless and until it has obtained all required regulatory approvals in each jurisdiction where it proposes to market the new products. Once obtained, the Company must maintain approval as long as it plans to market its new products in each jurisdiction where approval is required. The Company&#8217;s failure to obtain approval, significant delays in the approval process, or its failure to maintain approval in any jurisdiction will prevent it from selling the products in that jurisdiction. The Company would not be able to realize revenues for those new products in any jurisdiction where it does not have approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Developments following regulatory approval may adversely affect sales of the Company&#8217;s products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after a product reaches the market, certain developments following regulatory approval may decrease demand for the Company&#8217;s products, including the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results in post-approval Phase 4 trials or other studies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the re-review of products that are already marketed;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recall or loss of marketing approval of products that are already marketed;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changing government standards or public expectations regarding safety, efficacy, quality or labeling changes;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scrutiny of advertising and promotion; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the withdrawal of indications granted pursuant to accelerated approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, clinical trials and post-marketing surveillance of certain marketed drugs of the Company and of competitors within the industry have raised concerns that have led to recalls, withdrawals or adverse labeling of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketed products. Clinical trials and post-marketing surveillance of certain marketed drugs also have raised concerns among some prescribers and patients relating to the safety or efficacy of pharmaceutical products in general that have negatively affected the sales of such products. In addition, increased scrutiny of the outcomes of clinical trials has led to increased volatility in market reaction. Further, these matters often attract litigation and, even where the basis for the litigation is groundless, considerable resources may be needed to respond.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, following in the wake of product withdrawals and other significant safety issues, health authorities such as the FDA, the EMA, Japan&#8217;s PMDA and China&#8217;s NMPA have increased their focus on safety when assessing the benefit/risk balance of drugs. Some health authorities appear to have become more cautious when making decisions about approvability of new products or indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of any of the Company&#8217;s products, it could significantly reduce demand for the product or require the Company to take actions that could negatively affect sales, including removing the product from the market, restricting its distribution or applying for labeling changes. Further, in the current environment in which all pharmaceutical companies operate, the Company is at risk for product liability and consumer protection claims and civil and criminal governmental actions related to its products, research and/or marketing activities. In addition, dissemination of promotional materials through evolving digital channels serves to increase visibility and scrutiny in the marketplace.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is subject to a variety of U.S. and international laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently subject to a number of government laws and regulations and, in the future, could become subject to new government laws and regulations. The costs of compliance with such laws and regulations, or the negative results of non-compliance, could adversely affect the business, cash flow, results of operations, financial condition and prospects of the Company; these laws and regulations include (i) additional health care reform initiatives in the U.S. or in other countries, including additional mandatory discounts or fees;  (ii) the U.S. Foreign Corrupt Practices Act or other anti-bribery and corruption laws; (iii) new laws, regulations and judicial or other governmental decisions affecting pricing, drug reimbursement, and access or marketing within or across jurisdictions; (iv) changes in intellectual property laws; (v) changes in accounting standards; (vi) new and increasing data privacy regulations and enforcement, particularly in the EU, the U.S., and China; (vii) legislative mandates or preferences for local manufacturing of pharmaceutical or vaccine products; (viii) emerging and new global regulatory requirements for reporting payments and other value transfers to health care professionals; (ix) environmental regulations; and (x) the potential impact of importation restrictions, embargoes, trade sanctions and legislative and/or other regulatory changes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to evolving and complex tax laws in the jurisdictions in which it operates. Significant judgment is required for determining the Company&#8217;s tax liabilities, and the Company&#8217;s tax returns are routinely examined by various tax authorities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2015 Organization for Economic Cooperation and Development (OECD) Base Erosion and Profit Shifting project, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its accrual for tax contingencies is adequate for all open years based on past experience, interpretations of tax law, and judgments about potential actions by tax authorities; however, due to the complexity of tax contingencies, the ultimate resolution of any tax matters may result in payments greater or less than amounts accrued. In addition, the Company may be negatively affected by changes in tax laws, or new tax laws, affecting, for example, tax rates, and/or revised tax law interpretations in domestic or foreign jurisdictions, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, among others, any potential changes to the existing U.S. tax law by the current U.S. Presidential administration and Congress, as well as any changes in tax law resulting from the implementation of the OECD&#8217;s two-pillar solution to reform the international tax landscape</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has taken the position, based on the opinions of tax counsel, that its distribution of Organon common stock in connection with the 2021 Spin-Off of Organon qualifies as a transaction that is tax-free for U.S. federal income tax purposes. If any facts, assumptions, representations, and undertakings from the Company and Organon regarding the past and future conduct of their respective businesses and other matters are </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorrect or not otherwise satisfied, the Spin-Off may not qualify for tax-free treatment, which could result in significant U.S. federal income tax liabilities for the Company and its shareholders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverse outcomes in current or future legal matters could negatively affect Merck&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current or future litigation, claims, proceedings and government investigations could preclude or delay the commercialization of Merck&#8217;s products or could adversely affect Merck&#8217;s business, results of operations, cash flow, prospects and financial condition. Such legal matters may include, but are not limited to: (i) intellectual property disputes; (ii) adverse decisions in litigation, including product safety and liability, consumer protection and commercial cases; (iii) anti-bribery regulations, such as the U.S. Foreign Corrupt Practices Act, including compliance with ongoing reporting obligations to the government resulting from any settlements; (iv) recalls or withdrawals of pharmaceutical products or forced closings of manufacturing plants; (v) product pricing and promotional matters; (vi) lawsuits, claims and administrative proceedings asserting, or investigations into, violations of securities, antitrust, Federal and state pricing, consumer protection, data privacy and other laws and regulations; (vii) environmental, health, safety and sustainability matters, including regulatory actions in response to climate change; and (viii) tax liabilities resulting from assessments from tax authorities. See Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note 11, &#8220;Contingencies and Environmental Liabilities&#8221; for more information on the Company&#8217;s legal matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Merck informed the U.S. Department of Health and Human Services, Health Resources and Services Administration (HHS) that Merck was implementing an update to its Section 340b program integrity initiative, pursuant to which Merck required all hospital covered entities to provide 340b claims data for all claims originating from contract pharmacies. For those entities that declined to submit such claims data, Merck&#8217;s new initiative provided that it would no longer voluntarily honor 340b discounts or chargebacks for contract pharmacy transactions, except for a single contract pharmacy of the hospital covered entity&#8217;s choice.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2021, HHS sent letters to numerous drug manufacturers stating that it had determined that those manufacturers&#8217; actions restricting contract pharmacy transactions were in violation of the 340b statute and further stating that if those manufacturers did not cease their restrictions, HHS might seek both repayment of overcharges as well as civil monetary penalties. Those manufacturers are now in litigation with the U.S. government seeking to confirm the legality of the restrictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck did not receive a similar letter from HHS. However, HHS could seek to implement administrative proceedings to recover overcharges and/or impose civil monetary penalties against Merck. If such proceedings were implemented against Merck a negative outcome could have a material adverse effect on Merck&#8217;s business, results of operations, cash flow, prospects and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product liability insurance for products may be limited, cost prohibitive or unavailable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of a number of factors, product liability insurance has become less available while the cost of such insurance has increased significantly. The Company is subject to a substantial number of product liability claims. See Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note 11. &#8220;Contingencies and Environmental Liabilities&#8221; below for more information on the Company&#8217;s current product liability litigation. With respect to product liability, the Company self-insures substantially all of its risk, as the availability of commercial insurance has become more restrictive. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities. The Company will continually assess the most efficient means to address its risk; however, there can be no guarantee that insurance coverage will be obtained or, if obtained, will be sufficient to fully cover product liabilities that may arise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Technology</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company is increasingly dependent on sophisticated software applications and computing infrastructure. In 2017, the Company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations. The Company could be a target of future cyber-attacks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is increasingly dependent on sophisticated software applications, complex information technology systems, computing infrastructure, and cloud service providers (collectively, IT systems) to conduct </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">critical operations. Certain of these systems are managed, hosted, provided or used by third parties to assist in conducting the Company&#8217;s business. Disruption, degradation, or manipulation of these IT systems through intentional or accidental means by the Company&#8217;s employees, third parties with authorized access or unauthorized third parties could adversely affect key business processes. Cyber-attacks against the Company&#8217;s IT systems or third-party providers&#8217; IT systems, such as cloud-based systems, could result in exposure of confidential information, the modification of critical data, and/or the failure of critical operations. Misuse of any of these IT systems could result in the disclosure of sensitive personal information or the theft of trade secrets, intellectual property, or other confidential business information. The Company continues to leverage new and innovative technologies across the enterprise to improve the efficacy and efficiency of its business processes, including data acquisition; the use of which can create new risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations, and resulting losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has implemented a variety of measures to further enhance and modernize its systems to guard against similar attacks in the future, and also is pursuing an enterprise-wide effort to enhance the Company's resiliency against future cyber-attacks, including incidents similar to the 2017 attack. The objective of these efforts is not only to protect against future cyber-attacks, but also to improve the speed of the Company&#8217;s recovery from such attacks and enable continued business operations to the greatest extent possible during any recovery period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks and network disruptions, including the 2017 cyber-attack, on the Company&#8217;s operations and financial condition has not been material to date, the Company continues to be a target of events of this nature and expects them to continue. The Company monitors its data, information technology and personnel usage of Company IT systems to reduce these risks and continues to do so on an ongoing basis for any current or potential threats. There can be no assurance that the Company&#8217;s efforts to protect its data and IT systems or the efforts of third-party providers to protect their IT systems will be successful in preventing disruptions to the Company&#8217;s operations, including its manufacturing, research and sales operations. Such disruptions have in the past and could in the future result in loss of revenue, or the loss of critical or sensitive information from the Company&#8217;s or the Company&#8217;s third-party providers&#8217; databases or IT systems and have in the past and could in the future also result in financial, legal, business or reputational harm to the Company and substantial remediation costs.</span></div><div style="margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Social media and mobile messaging platforms present risks and challenges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inappropriate and/or unauthorized use of certain social media and mobile messaging channels could cause brand damage or information leakage or could lead to legal implications, including from the improper collection and/or dissemination of personally identifiable information. In addition, negative or inaccurate posts or comments about the Company or its products on any social networking platforms could damage the Company&#8217;s reputation, brand image and goodwill. Further, the disclosure of non-public Company-sensitive information by the Company&#8217;s workforce or others through external media channels could lead to information loss. Although there are internal Company Social Media and Mobile Messaging Policies that guide employees on appropriate personal and professional use of these platforms for communication about the Company, the processes in place may not completely secure and protect information. Identifying new points of entry as new communication tools expand also presents new challenges.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_55"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Factors that May Affect Future Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Cautionary Statements Under the Private Securities Litigation Reform Act of 1995)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called &#8220;forward-looking statements,&#8221; all of which are based on management&#8217;s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company&#8217;s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and include </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company&#8217;s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. The Company does not assume the obligation to update any forward-looking statement. The Company cautions you not to place undue reliance on these forward-looking statements. Although it is not possible to predict or identify all such factors, they may include the following:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Competition from generic and/or biosimilar products as the Company&#8217;s products lose patent protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Increased &#8220;brand&#8221; competition in therapeutic areas important to the Company&#8217;s long-term business performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The difficulties and uncertainties inherent in new product development. The outcome of the lengthy and complex process of new product development is inherently uncertain. A drug candidate can fail at any stage of the process and one or more late-stage product candidates could fail to receive regulatory approval. New product candidates may appear promising in development but fail to reach the market because of efficacy or safety concerns, the inability to obtain necessary regulatory approvals, the difficulty or excessive cost to manufacture and/or the infringement of patents or intellectual property rights of others. Furthermore, the sales of new products may prove to be disappointing and fail to reach anticipated levels.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Pricing pressures, both in the U.S. and abroad, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The impact of the global COVID-19 pandemic and any future pandemic, epidemic, or similar public health threat, on the Company&#8217;s business, operations and financial performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Changes in government laws and regulations, including laws governing intellectual property, and the enforcement thereof affecting the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Efficacy or safety concerns with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental concerns and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cyber-attacks on the Company&#8217;s or third-party providers&#8217; information technology systems, which could disrupt the Company&#8217;s operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Lost market opportunity resulting from delays and uncertainties in the approval process of the FDA and foreign regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Increased focus on privacy issues in countries around the world, including the U.S., the EU, and China. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect directly the Company&#8217;s business, including recently enacted laws in a majority of states in the U.S. requiring security breach notification.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Changes in tax laws including changes related to the taxation of foreign earnings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Changes in accounting pronouncements promulgated by standard-setting or regulatory bodies, including the Financial Accounting Standards Board and the SEC, that are adverse to the Company.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Economic factors over which the Company has no control, including changes in inflation, interest rates and foreign currency exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This list should not be considered an exhaustive statement of all potential risks and uncertainties. See &#8220;Risk Factors&#8221; above.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_58"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.36pt">Unresolved Staff Comments.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_61"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Properties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters is currently located in Kenilworth, New Jersey. The Company has previously announced that it intends to consolidate its New Jersey campuses into a single corporate headquarters location in Rahway, New Jersey by the end of 2023. The Company also maintains operational or divisional headquarters in Kenilworth, New Jersey; Madison, New Jersey and Upper Gwynedd, Pennsylvania. Principal U.S. research facilities are located in Rahway and Kenilworth, New Jersey; West Point, Pennsylvania; Boston and Cambridge, Massachusetts; South San Francisco, California; and Elkhorn, Nebraska (Animal Health). Principal research facilities outside the U.S. are located in the United Kingdom, Switzerland and China. Merck&#8217;s manufacturing operations are currently headquartered in Whitehouse Station, New Jersey. The Company also has production facilities for human health products at seven locations in the U.S. and Puerto Rico. Outside the U.S., through subsidiaries, the Company owns or has an interest in manufacturing plants or other properties in Japan, Singapore, South Africa, and other countries in Western Europe, Central and South America, and Asia. A number of properties were transferred to Organon in the Spin-Off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures were $4.4 billion in 2021, $4.4 billion in 2020 and $3.4 billion in 2019. In the U.S., these amounted to $2.8 billion in 2021, $2.6 billion in 2020 and $1.9 billion in 2019. Abroad, such expenditures amounted to $1.6 billion in 2021, $1.8 billion in 2020, and $1.5 billion in 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries own their principal facilities and manufacturing plants under titles that they consider to be satisfactory. The Company believes that its properties are in good operating condition and that its machinery and equipment have been well maintained. The Company believes that its plants for the manufacture of products are suitable for their intended purposes and have capacities and projected capacities, including previously disclosed capital expansion projects, that will be adequate for current and projected needs for existing Company products. Some capacity of the plants is being converted, with any needed modification, to the requirements of newly introduced and future products.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_64"></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item is incorporated herein by reference to Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;11. &#8220;Contingencies and Environmental Liabilities&#8221;.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_67"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Mine Safety Disclosures.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:5pt;text-indent:45pt"><span><br/></span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_70"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers of the Registrant (ages as of February&#160;1, 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All officers listed below serve at the pleasure of the Board of Directors. None of these officers was elected pursuant to any arrangement or understanding between the officer and any other person(s).</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Offices and Business Experience</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Robert M. Davis</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Executive Officer and President (since July 2021); Executive Vice President, Global Services, and Chief Financial Officer (since April 2016)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Sanat Chattopadhyay</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Executive Vice President and President, Merck Manufacturing Division (since March 2016)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Richard R. DeLuca, Jr.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Executive Vice President and President, Merck Animal Health (since September 2011)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cristal Downing </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Executive Vice President and Chief Communications &amp; Public Affairs Officer (since August 2021); Vice President Medical Devices, Global Communications and Public Affairs Johnson &amp; Johnson (December 2020-August 2021); Vice President Financial Communication, Johnson &amp; Johnson (January 2018-December 2020); Prior to that, Senior Director Communications at Johnson &amp; Johnson</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kenneth C. Frazier</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Executive Chairman (since July 2021); Prior to that, Chairman, President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Julie L. Gerberding</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">65</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Executive Vice President and Chief Patient Officer, Population Health and Sustainability (since July 2016)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rita A. Karachun</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Vice President Finance - Global Controller (since March 2014)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Michael A. Klobuchar</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Executive Vice President, Chief Strategy Officer (since July 2021); Senior Vice President, CFO of Merck R&amp;D and Head of Global Portfolio and Alliance Management (January 2019-June 2021); Senior Vice President of Corporate Strategy and Planning and President of Emerging Businesses (December 2017-January 2019); Prior to that, Vice President, Global Business and Financial Planning</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lisa LeCointe-Cephas</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Senior Vice President, Chief Ethics and Compliance Officer (since April 2021); Executive Director, Head of Global Investigations (February 2018 &#8211; April 2021); Prior to that, Senior Counsel, Litigation and Government Investigations, Bristol-Myers Squibb Company</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Dean Li</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2021); Vice President, Translational Medicine (March 2017-November 2017); Prior to that, Chief Scientific Officer and Associate Vice President, University of Utah Health Sciences</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Caroline Litchfield</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Executive Vice President and Chief Financial Officer (since April 2021); Senior Vice President, Corporate Treasurer (January 2018-March 2021); Prior to that, Senior Vice President, Global Human Health </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Steven C. Mizell<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Executive Vice President, Chief Human Resources Officer (since December 2016)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">David M. Williams</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Executive Vice President, Chief Information and Digital Officer (Since August 2020); Acting Chief Information and Digital Officer (December 2019-August 2020); Vice President and Chief Information Officer, Merck Animal Health (May 2017-December 2019); Prior to that, Associate Vice President and Chief Information Officer, Merck Animal Health</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jennifer Zachary</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary (since January 2020); Executive Vice President and General Counsel (April 2018-January 2020); Prior to that, Partner, Covington &amp; Burling LLP</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2022, the Company announced that Ms. Arpa Garay will lead Human Health Global Marketing and Mr. Jannie Oosthuizen will lead U.S. Human Health. Both Ms. Garay and Mr. Oosthuizen will become Executive Officers of the Company, effective February 28, 2022. </span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Offices and Business Experience</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Arpa Garay</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President, Global Oncology and Digital (since January 2022); President, Global Pharmaceuticals, Commercial Analytics, Digital Marketing (March 2019-January 2022); Senior Vice President, U.S. Vaccines Business Unit (June 2017-March 2019); Prior to that, Managing Director MSD, Norway</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jannie Oosthuizen</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Vice President and President Merck U.S. Human Health (since January 2022); Senior Vice President and Head of Global Oncology Commercial (January 2021-December 2021); Senior Vice President and President of MSD K.K. (July 2016-December 2020)</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_76"></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal market for trading of the Company&#8217;s Common Stock is the New York Stock Exchange (NYSE) under the symbol MRK. </span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;31, 2022, there were approximately 99,932 shareholders of record of the Company&#8217;s Common Stock.</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuer purchases of equity securities for the three months ended December&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">($&#160;in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">of Shares</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average&#160;Price<br/>Paid Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Approximate&#160;Dollar&#160;Value&#160;of&#160;Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">That May Yet Be Purchased</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 &#8212; October 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,194</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$74.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,194</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 &#8212; November 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 &#8212; December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,194</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$74.92</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,194</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">All shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion in Merck shares for its treasury.</span></div><div><span><br/></span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph assumes a $100 investment on December&#160;31, 2016, and reinvestment of all dividends, in each of the Company&#8217;s Common Stock, the S&amp;P 500 Index, and a composite peer group of major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Johnson&#160;&amp; Johnson, Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Roche Holding AG, and Sanofi SA.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of Five-Year Cumulative Total Return</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc., Composite Peer Group and S&amp;P 500 Index</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of<br/>Period&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021/2016<br/>CAGR*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$159</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PEER GROUP**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr></table></div><div style="text-align:center"><img src="mrk-20211231_g1.jpg" alt="mrk-20211231_g1.jpg" style="height:280px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.641%"><tr><td style="width:1.0%"></td><td style="width:27.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.5</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.9</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.6</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.5</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PEER GROUP</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.0</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.4</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.6</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.6</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.8</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.5</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.1</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.3</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.3</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Compound Annual Growth Rate</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Peer group average was calculated on a market cap weighted basis as of December 31, 2016. </span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Performance Graph will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference. In addition, the Performance Graph will not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC or subject to Regulation 14A or 14C, other than as provided in Regulation S-K, or to the liabilities of section 18 of the Securities Exchange Act of 1934, except to the extent that the Company specifically requests that such information be treated as soliciting material or specifically incorporates it by reference into a filing under the Securities Act or the Exchange Act.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_82"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Description of Merck&#8217;s Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#8217;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spin-Off of Organon &amp; Co.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off (see Note 3 to the consolidated financial statements).</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_85"></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution from Continuing Operations Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Calculation not meaningful. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs and certain other items. For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS (see &#8220;Non-GAAP Income and Non-GAAP EPS&#8221; below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, Merck delivered on its strategic priorities by executing commercially to drive strong revenue and earnings growth in the year, completing key business development transactions, accelerating its broad pipeline, and achieving notable regulatory milestones. Also, on June 2, 2021, Merck completed the spin-off of Organon. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales were $48.7 billion in 2021, an increase of 17% compared with 2020, or 16% excluding the favorable effect of foreign exchange. The sales increase was driven primarily by growth in oncology, vaccines, hospital acute care and animal health. Additionally, revenue in 2021 reflects the benefit of sales of molnupiravir, an investigational oral antiviral COVID-19 treatment. As discussed below, COVID-19-related disruptions negatively affected sales in 2021, but to a lesser extent than in 2020, which benefited year-over-year sales growth. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck continues to execute scientifically compelling business development opportunities to augment its pipeline. In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company evaluating the transforming growth factor (TGF)-beta superfamily of proteins through the development of pulmonary and hematologic therapies. In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Additionally, Merck entered into a collaboration with Gilead Sciences, Inc. (Gilead) to jointly develop and commercialize long-acting treatments in HIV.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Merck received over 30 approvals and filed over 20 New Drug Applications (NDAs) and supplemental Biologics License Applications (BLAs) across the U.S., the EU, Japan and China. During 2021, the Company received numerous regulatory approvals within oncology. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received approval for additional indications in the U.S. and/or internationally as monotherapy in the therapeutic areas of breast, colorectal, cutaneous squamous cell, esophageal, melanoma and renal cell cancers, as well as in combination with chemotherapy in the therapeutic areas of breast, cervical, gastric or gastroesophageal junction cancers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was also approved in combination with Lenvima both for the treatment of certain adult patients with endometrial cancer and for the treatment of renal cell cancer. Lenvima is being developed in collaboration with Eisai Co., Ltd. (Eisai). Lynparza, which is being developed in collaboration with AstraZeneca PLC (AstraZeneca), received approval in China as monotherapy for the treatment of certain adult patients with metastatic castration resistant prostate cancer. Additionally, the U.S. Food and Drug Administration (FDA) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2&#945;) inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL) </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disease who require therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2021, as updated in February 2022, the FDA granted Emergency Use Authorization (EUA) for molnupiravir, an investigational oral antiviral COVID-19 treatment being developed in a collaboration with Ridgeback Biotherapuetics LP (Ridgeback). Molnupiravir also received conditional marketing authorization in the United Kingdom (UK) and Special Approval for Emergency in Japan. Also in 2021, the FDA and the European Commission (EC) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Pneumococcal 15-valent Conjugate Vaccine), a pneumococcal conjugate vaccine for use in adults. Additionally, Verquvo, a medicine to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults was approved in the U.S., the EU and Japan. Verquvo is being jointly developed with Bayer AG (Bayer). In January 2022, the Japan Ministry of Health, Labor and Welfare (MHLW) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lyfnua</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (gefapixant) for adults with refractory or unexplained chronic cough. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the recent regulatory approvals discussed above, the Company advanced its late-stage pipeline with several regulatory submissions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review in the U.S. and/or internationally for supplemental indications for the treatment of certain patients with triple negative breast, cervical, endometrial, melanoma, renal cell and tumor mutation burden-high (TMBH) cancers. Lynparza is under review for supplemental indications for the treatment of certain patients with breast and prostate cancers. Lenvima is under review in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a supplemental indication for the treatment of certain patients with hepatocellular carcinoma (HCC). MK-4482, molnupiravir, is under a rolling review by the European Medicines Agency (EMA); MK-7264, gefapixant, a selective, non-narcotic, orally-administered, investigational P2X3-receptor antagonist being developed for the treatment of refractory, chronic cough is under review in the U.S. and the EU; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(V114), a 15-valent pneumococcal conjugate vaccine, is under priority review by the FDA for the prevention of invasive pneumococcal disease in pediatric patients. V114 is also under review in Japan for use in adults. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Phase 3 oncology programs include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the therapeutic areas of biliary, cutaneous squamous cell, gastric, hepatocellular, mesothelioma, ovarian, prostate and small-cell lung cancers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Lynparza as monotherapy for colorectal cancer and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for non-small-cell lung and small-cell lung cancers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Lenvima in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for colorectal, esophageal, gastric, head and neck, melanoma and non-small-cell lung cancers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for RCC; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-1308A, the coformulation of quavonlimab, Merck&#8217;s novel investigational anti-CTLA-4 antibody, and pembrolizumab for RCC; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-3475, pembrolizumab subcutaneous for non-small-cell lung cancer (NSCLC); </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-7119, Tukysa (tucatinib), which is being developed in collaboration with Seagen Inc. (Seagen), for breast cancer;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-4280A, the coformulation of favezelimab, Merck&#8217;s novel investigational anti-LAG3 therapy, and pembrolizumab for colorectal cancer; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-7684A, the coformulation of vibostolimab, an anti-TIGIT therapy, and pembrolizumab for NSCLC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has candidates in Phase 3 clinical development in several other therapeutic areas including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-7962, sotatercept, for the treatment of pulmonary arterial hypertension (PAH), which was obtained in the Acceleron acquisition; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-1654, clesrovimab, for the prevention of respiratory syncytial virus; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-8591, islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) for the prevention of HIV-1 infection (which is on clinical hold);  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-8591A, islatravir in combination with doravirine for the treatment of HIV-1 infection (which is on clinical hold); and </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">MK-4482, molnupiravir, which is reflected in Phase 3 development in the U.S. as it remains investigational following EUA. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is allocating resources to support its commercial opportunities in the near term while investing heavily in research to support future innovations and long-term growth. Research and development expenses in 2021 reflect higher clinical development spending and increased investment in discovery research and early drug development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Merck&#8217;s Board of Directors approved an increase to the Company&#8217;s quarterly dividend, raising it to $0.69 per share from $0.65 per share on the Company&#8217;s outstanding common stock. During 2021, the Company returned $7.5 billion to shareholders through dividends and share repurchases.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company completed its inaugural issuance of a $1.0 billion sustainability bond, which was part of an $8.0 billion underwritten bond offering. The Company intends to use the net proceeds from the sustainability bond offering to support projects and partnerships in the Company&#8217;s priority environmental, social and governance (ESG) areas and contribute to the advancement of the United Nations Sustainable Development Goals.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the COVID-19 pandemic Merck has remained focused on protecting the safety of its employees, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of an antiviral therapy, supporting efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines (see below), and supporting health care providers and Merck&#8217;s communities. Although COVID-19-related disruptions negatively affected results in 2021 and 2020, Merck continues to experience strong global underlying demand across its business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Merck&#8217;s sales were unfavorably affected by COVID-19-related disruptions, which resulted in an estimated negative impact to Merck&#8217;s Pharmaceutical segment sales of approximately $1.3 billion. Roughly 75% of Merck&#8217;s Pharmaceutical segment revenue is comprised of physician-administered products, which, despite strong underlying demand, have been affected by social distancing measures and fewer well visits. Merck&#8217;s sales were favorably affected by the authorization of molnupiravir in several markets as discussed further below, which resulted in sales of $952 million in 2021. In 2020, the estimated negative impact of COVID-19-related disruptions to Merck&#8217;s sales was approximately $2.1 billion, of which approximately $2.0 billion was attributable to the Pharmaceutical segment and approximately $50 million was attributable to the Animal Health segment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck announced it was discontinuing the development of MK-7110 (formerly known as CD24Fc) for the treatment of hospitalized patients with COVID-19, which was obtained as part of Merck&#8217;s acquisition of OncoImmune (see Note 4 to the consolidated financial statements). This decision resulted in charges of $207&#160;million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2021. In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#8217;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305&#160;million in 2020, of which $260&#160;million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the remaining $45&#160;million of costs were reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Operating expenses reflect a minor positive effect in 2021 as investments in COVID-19-related research largely offset the favorable impact of lower spending in other areas due to the COVID-19 pandemic. Operating expenses were positively affected in 2020 by approximately $500 million primarily due to lower promotional and selling costs, as well as lower research and development expenses, net of investments in COVID-19-related antiviral and vaccine research programs. In addition, the COVID-19 pandemic has caused some disruption and volatility in the Company&#8217;s global supply chain network, and the Company may in the future experience disruptions in availability and delays in shipments of raw materials and packaging, as well as related cost inflation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the FDA granted EUA for molnupiravir based on positive results from the Phase 3 MOVe-OUT clinical trial. Additionally, in December 2021, Japan&#8217;s MHLW granted Special Approval for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergency for molnupiravir. In November 2021, the UK Medicines and Healthcare products Regulatory Agency granted conditional marketing authorization for molnupiravir. In addition, in October 2021, the EMA initiated a rolling review for molnupiravir. Merck plans to work with the Committee for Medicinal Products for Human Use of the EMA to complete the rolling review process to facilitate initiating the formal review of the Marketing Authorization Application. Merck is developing molnupiravir in collaboration with Ridgeback. The companies are actively working with other regulatory agencies worldwide to submit applications for emergency use or marketing authorization. Merck has entered into advance purchase and supply agreements for molnupiravir in more than 30 markets. See Note 5 to the consolidated financial statements for additional information related to the collaboration with Ridgeback.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Merck announced it had entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, is providing Merck with funding to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. Merck has also entered into agreements to support the manufacturing and supply of Johnson &amp; Johnson&#8217;s SARS-CoV-2/COVID-19 vaccine. Merck is using certain of its facilities in the U.S. to produce drug substance, formulate and fill vials of Johnson &amp; Johnson&#8217;s vaccine. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pricing</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform enacted in prior years, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s revenue performance in 2021 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect revenue performance.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales grew 17% in 2021 primarily due to higher sales in the oncology franchise largely driven by strong growth of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and increased alliance revenue from Lynparza and Lenvima, as well as higher sales in the vaccines franchise, primarily attributable to growth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Also contributing to revenue growth in 2021 were higher sales in the virology franchise attributable to molnupiravir, higher sales in the hospital acute care franchise, reflecting growth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as higher sales of animal health products. Additionally, sales in 2021 benefited from higher third-party manufacturing sales and the achievement of milestones for an out-licensed product that triggered contingent payments to Merck. As discussed above, COVID-19-related disruptions unfavorably affected sales in 2021, but to a lesser extent than in 2020, which benefited year-over-year sales growth. Sales growth in 2021 was partially offset by lower sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, the suspension of sales in 2020 of hospital acute care product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and lower sales of virology products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales in the U.S. grew 14% in 2021 primarily driven by higher sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, sales of molnupiravir, higher sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased alliance revenue from Lynparza and Lenvima, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as higher sales of animal health products. Lower sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset revenue growth in the U.S. in 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales increased 20% in 2021 primarily due to growth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, sales of molnupiravir, increased alliance revenue from Lynparza and Lenvima, as well as higher sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Prevymis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and animal health products. International sales growth in 2021 was partially offset by lower sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. International sales represented 54% and 53% of total sales in 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales increased 6% in 2020 primarily due to higher sales in the oncology franchise, as well as growth in certain hospital acute care products and animal health. Growth in these areas was largely offset by the negative effects of the COVID-19 pandemic as discussed above, competitive pressure in the virology franchise and pricing pressure in the diabetes franchise.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 to the consolidated financial statements for details on sales of the Company&#8217;s products. A discussion of performance for select products in the franchises follows.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:29.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue - Lenvima </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), HCC, NSCLC, melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, primary mediastinal large B-cell lymphoma, TMB-H cancer (solid tumors), and urothelial carcinoma including non-muscle invasive bladder cancer. Additionally, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved as monotherapy for the adjuvant treatment of certain patients with RCC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy, with or without bevacizumab for cervical cancer, in combination with chemotherapy for esophageal cancer, in combination with chemotherapy for gastric cancer, in combination with chemotherapy for HNSCC, in combination with chemotherapy for triple-negative-breast cancer (TNBC), in combination with axitinib for advanced RCC, and in combination with Lenvima for both endometrial carcinoma and RCC. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical development program includes studies across a broad range of cancer types.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> grew 20% in 2021 driven by higher demand as the Company continues to launch </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with multiple new indications globally, although the COVID-19 pandemic had a dampening effect on growing demand by negatively affecting the number of new patients starting treatment. Sales in the U.S. continue to build across the multiple approved indications, in particular for the treatment of advanced NSCLC as monotherapy, and in combination with chemotherapy for both nonsquamous and squamous metastatic NSCLC, along with continued uptake in the TNBC, RCC, HNSCC, MSI-H cancer, and esophageal cancer indications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales growth in international markets reflects continued uptake predominately for the NSCLC, HNSCC and RCC indications, particularly in Europe. Sales growth in 2021 was partially offset by lower pricing in Europe, China and Japan. Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> grew 30% in 2020 driven by higher demand globally, particularly in the U.S. and Europe, although the COVID-19 pandemic had an unfavorable effect on growing demand. Sales growth in 2020 was partially offset by lower pricing in Japan and Europe. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received numerous regulatory approvals in 2021 summarized below.</span></div><div style="padding-left:45pt;text-indent:45pt"><span><br/></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approval</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EC approval as a first-line treatment in adult patients with MSI-H or dMMR colorectal cancer based on the KEYNOTE-177 study.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EC approval of an expanded label as monotherapy for the treatment of adult and pediatric patients aged 3 years and older with relapsed or refractory cHL who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option based on the KEYNOTE-204 and KEYNOTE-087 trials. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approval in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of certain patients with locally advanced or metastatic esophageal or GEJ carcinoma that is not amenable to surgical resection or definitive chemoradiation based on the KEYNOTE-590 trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approval in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or GEJ adenocarcinoma based on the KEYNOTE-811 trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EC approval of the 400 mg every six weeks (Q6W) dosing regimen to indications where </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is administered in combination with other anticancer agents.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">June 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">China&#8217;s National Medical Products Administration (NMPA) approval as a first-line treatment of adult patients with MSI-H or dMMR colorectal cancer that is KRAS, NRAS and BRAF all wild-type based on the KEYNOTE-177 study.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">June 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EC approval in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or HER2-negative GEJ adenocarcinoma in adults whose tumors express PD-L1 based on the KEYNOTE-590 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approval as monotherapy for the treatment of patients with locally advanced cSCC that is not curable by surgery or radiation based on the KEYNOTE-629 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> plus Lenvima for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation based on the KEYNOTE-775/Study 309 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for treatment of patients with high-risk, early-stage TNBC in combination with chemotherapy as neoadjuvant treatment and then continued as single agent as adjuvant treatment after surgery based on the KEYNOTE-522 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> plus Lenvima for the first-line treatment of adult patients with advanced RCC based on the KEYNOTE-581 trial/Study 307 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA) approval for the treatment of patients with unresectable, advanced or recurrent MSI-H colorectal cancer based on the KEYNOTE-177 trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Japan&#8217;s PMDA approval for the treatment of patients with PD-L1-positive, hormone receptor-negative and HER2-negative, inoperable or recurrent breast cancer based on the KEYNOTE-355 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">China&#8217;s NMPA approval in combination with chemotherapy for the first-line treatment of patients with locally advanced, unresectable or metastatic carcinoma of the esophagus or GEJ based on the KEYNOTE-590 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">October 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approval in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer based on the KEYNOTE-826 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">October 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EC approval in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic TNBC in adults whose tumors express PD-L1 and who have not received prior chemotherapy for metastatic disease based on the KEYNOTE-355 trial.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approval for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions based on the KEYNOTE-564 trial.</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EC approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">plus Lenvima for the first-line treatment of adult patients with advanced RCC based on the CLEAR (Study 307)/KEYNOTE-581 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EC approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> plus Lenvima for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum&#8209;containing therapy in any setting and who are not candidates for curative surgery or radiation based on the KEYNOTE-775/Study 309 trial. </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan&#8217;s PMDA approval in combination with chemotherapy (5-fluorouracil plus cisplatin) for the first-line treatment of patients with radically unresectable, advanced or recurrent esophageal carcinoma in combination with chemotherapy based on the KEYNOTE-590 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FDA approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection based on the KEYNOTE-716 trial; FDA expanded the indication for the adjuvant treatment of stage III melanoma following complete resection to include pediatric patients (12 years and older).</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Japan&#8217;s MHLW approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in combination with Lenvima for the treatment of patients with unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy based on the KEYNOTE-775/Study 309 trial. </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Merck announced it was voluntarily withdrawing the U.S. indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with metastatic small-cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. The withdrawal of this indication was done in consultation with the FDA and does not affect other indications for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As announced in January 2020, KEYNOTE-604, the confirmatory Phase 3 trial for this indication, met one of its dual primary endpoints of progression-free survival but did not reach statistical significance for the other primary endpoint of overall survival.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Merck initiated the withdrawal of the U.S. accelerated approval indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with recurrent locally advanced or metastatic gastric or GEJ adenocarcinoma whose tumors express PD-L1, with disease progression on or after two or more prior lines of therapy. The decision was made in consultation with the FDA following the Oncologic Drugs Advisory Committee evaluation of this third-line gastric cancer indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy because it failed to meet its post-marketing requirement of demonstrating an overall survival benefit in a Phase 3 study. The withdrawal of this indication does not affect other indications for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the terms of the more significant of these agreements, Merck pays a royalty of 6.5% on worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through 2023 to one third party; this royalty will decline to 2.5% for 2024 through 2026 and will terminate thereafter. The Company pays an additional 2% royalty on worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to another third party, the termination date of which varies by country; this royalty will expire in the U.S. in 2024 and in major European markets in 2025. The royalties are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca (see Note 5 to the consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced ovarian, breast, pancreatic and prostate cancers. Alliance revenue related to Lynparza grew 36% in 2021 and 63% in 2020 due to continued uptake across the multiple approved indications in the U.S., Europe, Japan and China. In June 2021, Lynparza was granted conditional approval in China as monotherapy for the treatment of certain previously treated adult patients with germline or somatic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutated metastatic castration-resistant prostate cancer based on the results of the PROfound trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai (see Note 5 to the consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, HCC, in combination with everolimus for certain patients with RCC, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> both for the treatment of certain patients with endometrial carcinoma and for the treatment of certain patients with RCC. Alliance revenue related to Lenvima grew 21% in 2021 and 44% in 2020 primarily due to higher demand in the U.S. and China. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(aprepitant), for the prevention of certain chemotherapy-induced nausea and vomiting, declined 13% in 2021 reflecting lower volumes in Europe and China. Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased 63% in 2020 primarily due to lower demand and pricing in the U.S. due to generic competition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Injection following U.S. patent expiry in September 2019. Also contributing to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales decline in 2020 was lower demand in Europe and Japan as a result of generic competition for the oral formulation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following loss of market exclusivity in May 2019 and December 2019, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Koselugo (selumetinib) was granted conditional approval in the EU for the treatment of pediatric patients three years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas based on positive results from the National Cancer Institute Cancer Therapy Evaluation Program-sponsored SPRINT Stratum 1 trial. Koselugo was approved by the FDA in April 2020. Koselugo is part of the same collaboration with AstraZeneca referenced above that includes Lynparza. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral HIF-2&#945; inhibitor, for the treatment of adult patients with VHL disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. The approval was based on results from the open-label Study 004 trial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was obtained as part of Merck&#8217;s 2019 acquisition of Peloton Therapeutics, Inc. (Peloton). See Note 4 to the consolidated financial statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ProQuad</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">893</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 44% in 2021 driven primarily by strong global demand, particularly in China, as well as increased supply. Higher pricing in China and the U.S. also contributed to sales growth in 2021. Sales growth in 2021 was unfavorably affected by the replenishment in 2020 of doses borrowed from the U.S. Centers for Disease Control and Prevention (CDC) Pediatric Vaccine Stockpile, which favorably affected sales by $120 million in 2020. The timing of public sector purchases in the U.S. also partially offset sales growth in 2021. Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 grew 5% in 2020 primarily due to higher volumes in China and the replenishment in 2020 of doses borrowed from the CDC Pediatric Vaccine Stockpile in 2019. The replenishment resulted in the recognition of sales of $120 million in 2020, which, when combined with the reduction of sales of $120 million in 2019 due to the borrowing, resulted in a favorable impact to sales of $240 million in 2020 compared with 2019. Lower demand in the U.S. and Hong Kong, SAR, PRC attributable to the COVID-19 pandemic partially offset the increase in sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 in 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9. Under the terms of the more significant of these agreements, Merck pays a 7% royalty on worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 to one third party (royalty obligations under this agreement expire in December 2023) and an additional 7% royalty on sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 in the U.S. to another third party (these royalty obligations expire in December 2028). The royalties are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, grew 14% in 2021 due to higher sales in the U.S. reflecting higher demand driven by the ongoing COVID-19 pandemic recovery, as well as higher pricing. Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> declined 10% in 2020 driven primarily by lower demand in the U.S. resulting from fewer measles outbreaks in 2020 compared with 2019, coupled with the unfavorable impact of the COVID-19 pandemic, partially offset by higher pricing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II, a vaccine to help protect against measles, mumps and rubella, grew 3% in 2021 primarily due to higher sales in the U.S. reflecting the ongoing COVID-19 pandemic recovery inclusive of higher public sector mix of business. Lower demand in Europe partially offset </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M&#8209;M&#8209;R&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II sales growth in 2021. Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II declined 31% in 2020 driven primarily by lower demand in the U.S. resulting from fewer </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measles outbreaks in 2020 compared with 2019, coupled with the unfavorable impact of the COVID-19 pandemic. Lower demand in Brazil also contributed to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II sales decline in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a vaccine to help prevent chickenpox (varicella), grew 18% in 2021 primarily reflecting the ongoing COVID-19 pandemic recovery and higher pricing in the U.S. Higher government tenders in Brazil also contributed to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales growth in 2021. Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> declined 15% in 2020 driven primarily by lower demand in the U.S. resulting from the COVID-19 pandemic, partially offset by higher pricing. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales decline in 2020 was also attributable to lower government tenders in Brazil.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, a vaccine to help prevent pneumococcal disease, declined 18% in 2021 primarily due to lower sales in the U.S. attributable to lower demand reflecting prioritization of COVID-19 vaccination, partially offset by higher pricing. Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 grew 17% in 2020 primarily due to higher volumes in Europe and the U.S. attributable in part to heightened awareness of pneumococcal vaccination. Higher pricing in the U.S. also contributed to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 sales growth in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for active immunization for the prevention of invasive disease caused by 15 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Streptococcus pneumoniae</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> serotypes in adults 18 years of age and older. In December 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by the EC. These approvals were based on data from seven clinical studies assessing safety, tolerability, and immunogenicity in adults. In October 2021, the CDC&#8217;s Advisory Committee on Immunization Practices (ACIP) voted to recommend vaccination either with a sequential regimen of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> followed by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, or with a single dose of 20-valent pneumococcal conjugate vaccine both for adults 65 years and older and for adults ages 19 to 64 with certain underlying medical conditions. These recommendations subsequently were adopted by the director of the CDC and the U.S. Department of Health and Human Services and published in the CDC&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Morbidity and Mortality Weekly Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2021, Merck announced a settlement and license agreement with Pfizer Inc. (Pfizer), resolving all worldwide patent infringement litigation related to the use of Merck&#8217;s investigational and licensed pneumococcal conjugate vaccine (PCV) products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the terms of the agreement, Merck will make certain regulatory milestone payments to Pfizer, as well as royalty payments on the worldwide sales of its PCV products. The Company will pay royalties of 7.25% of net sales of all Merck PCV products through 2026; and 2.5% of net sales of all Merck PCV products from 2027 through 2035.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxelis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine), developed as part of a U.S.-based partnership between Merck and Sanofi Pasteur, is now available in the U.S. for active immunization of children six weeks through four years of age to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Haemophilus influenzae</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> type b. In February 2021, the CDC&#8217;s ACIP included </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxelis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a combination vaccine option in the CDC&#8217;s Recommended Child and Adolescent Immunization Schedule. Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxelis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. are made through the U.S.-based Merck/Sanofi Pasteur partnership, the results of which are reflected in equity income from affiliates included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Supply sales to the partnership are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxelis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved in the EU where it is marketed directly by Merck and Sanofi Pasteur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Calculation not meaningful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 28% in 2021 due to higher demand globally, particularly in the U.S. and Europe, attributable to the COVID-19 pandemic recovery, as well as increased usage of neuromuscular blockade reversal agents and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s growing share within the class. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was also approved by the FDA in June 2021 for pediatric patients aged 2 years and older undergoing surgery. Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> grew 6% in 2020 due to higher demand globally, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particularly in the U.S. However, fewer elective surgeries as a result of the COVID-19 pandemic unfavorably affected demand in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 32% in 2021 and increased 70% in 2020 due to continued uptake since launch in several markets, particularly in Europe and the U.S. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an antifungal agent for the prevention of certain invasive fungal infections, declined 21% in 2021 primarily due to generic competition in Europe, partially offset by higher demand in China. The patent that provided market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a number of major European markets expired in December 2019. As a result, the Company is experiencing lower demand for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in these markets due to generic competition and expects the decline to continue. Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> declined 50% in 2020 due to generic competition in the U.S. and in Europe. The patent that provided U.S.&#160;market exclusivity for certain forms of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> representing the majority of U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales expired in July 2019. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections, and subsequently issued a product recall, following the identification of product sterility issues. As a result, the Company recorded an intangible asset impairment charge in 2020 related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 9 to the consolidated financial statements). A phased resupply of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was initiated in the fourth quarter of 2021, which the Company expects to continue during 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunology</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a once-monthly subcutaneous treatment for certain inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined 2% in 2021 and were nearly flat in 2020. Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are being unfavorably affected by biosimilar competition for competing products. The Company expects this competition will continue to unfavorably affect sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a treatment for inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined 9% in 2021 and decreased 20% in 2020 driven by ongoing biosimilar competition in the Company&#8217;s marketing territories in Europe. The Company lost market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in major European markets in 2015 and no longer has market exclusivity in any of its marketing territories. The Company is experiencing pricing and volume declines in these markets as a result of biosimilar competition and expects the declines to continue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketing rights with respect to these products will revert to Janssen Pharmaceuticals, Inc. on October 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Virology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molnupiravir</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">769</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molnupiravir is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback (see Note 5 to the consolidated financial statements). The FDA granted an EUA for molnupiravir in December 2021; as updated in February 2022, to authorize molnupiravir for the treatment of mild to moderate COVID-19 in high-risk adults for whom alternative FDA-approved or authorized treatment options are not </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accessible or clinically appropriate. Also in December 2021, Japan&#8217;s MHLW granted Special Approval for Emergency for molnupiravir to treat infectious disease caused by SARS-CoV-2. In November 2021, the UK&#8217;s MHRA granted conditional marketing authorization for molnupiravir to treat mild to moderate COVID-19 in adults at risk of developing severe illness. Merck has entered into advance purchase and supply agreements for molnupiravir in more than 30 markets and Merck began shipping molnupiravir in the fourth quarter of 2021 to countries where it is approved or authorized. Sales of molnupiravir were $952 million in 2021 primarily consisting of sales in the U.S., the UK and Japan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 10% in 2021 and decreased 12% in 2020 primarily due to competitive pressure particularly in Europe and the U.S. The Company expects competitive pressure for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to continue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zepatier</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a treatment for adult patients with chronic hepatitis C virus genotype (GT) 1 or GT4 infection, declined 23% in 2021 primarily due to lower demand from competitive pressure in the U.S. and Europe. Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zepatier</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> declined 55% in 2020 driven by lower demand globally due to competition and declining patient volumes, coupled with the impact of the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adempas and Verquvo are part of a worldwide collaboration with Bayer to market and develop soluble guanylate cyclase (sGC) modulators (see Note 5 to the consolidated financial statements). Adempas is approved for the treatment of certain types of PAH. Verquvo was approved in the U.S. in January 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was also approved in Japan in June 2021 and in the EU in July 2021. These approvals were based on the results of the VICTORIA trial. Alliance revenue from the collaboration grew 22% in 2021 and rose 38% in 2020. Revenue from the collaboration also includes sales of Adempas and Verquvo in Merck&#8217;s marketing territories. Sales of Adempas in Merck&#8217;s marketing territories grew 14% in 2021 primarily reflecting higher demand in Europe.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diabetes</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,288</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, medicines that help lower blood sugar levels in adults with type 2 diabetes, were nearly flat in 2021 and declined 4% in 2020. Sales performance in both periods reflects continued pricing pressure and lower demand in the U.S., largely offset by higher demand in certain international markets, particularly in China. The Company expects U.S. pricing pressure to continue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will lose market exclusivity in the U.S. in January 2023, in the EU in September 2022, and in China in July 2022. The Company anticipates sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in these markets will decline substantially after the loss of exclusivity. Combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., Europe and China represented 33%, 24% and 9%, respectively, of total combined </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales in 2021.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_94"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Animal Health Segment</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livestock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of livestock products grew 12% in 2021 primarily due to higher demand for ruminant products, including animal health intelligence solutions for animal identification, monitoring and traceability, as well as higher demand for poultry and swine products. Sales of livestock products increased 6% in 2020 predominantly due to an additional five months of sales in 2020 related to the April 2019 acquisition of Antelliq, a leader in digital animal identification, traceability and monitoring solutions (see Note 4 to the consolidated financial statements). Sales of companion animal products grew 29% in 2021 and rose 10% in 2020 primarily due to higher demand for parasiticides, including the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of products, as well as higher demand for companion animal vaccines. </span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs, Expenses and Other</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,634</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">661</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,655&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Calculation not meaningful.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $13.6 billion in both 2021 and 2020 and was $12.0 billion in 2019. Cost of sales includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $1.6 billion in 2021, $1.8 billion in 2020 and $1.7 billion in 2019. Costs in 2021 and 2020 also include charges of $225 million and $260 million, respectively, related to the discontinuation of COVID-19 development programs (see Note 4 to the consolidated financial statements). Additionally, costs in 2020 and 2019 include intangible asset impairment charges of $1.6&#160;billion and $705 million related to marketed products and other intangibles (see Note 9 to the consolidated financial statements). The Company may recognize additional impairment charges in the future related to intangible assets that were measured at fair value and capitalized in connection with business combinations and such charges could be material. Costs in 2020 also include inventory write-offs of $120 million related to a recall for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 9 to the consolidated financial statements). Also included in cost of sales are expenses associated with restructuring activities, which amounted to $160 million in 2021, $175 million in 2020 and $251 million in 2019, primarily reflecting accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin was 72.0% in 2021 compared with 67.2% in 2020. The gross margin improvement in 2021 reflects lower impairments and amortization of intangible assets (noted above), as well as the favorable effects of product mix and lower inventory write-offs. Partially offsetting the gross margin improvement in 2021 were higher manufacturing costs, the impact of molnupiravir (which has a lower gross margin due to profit sharing with Ridgeback as discussed in Note 5 to the consolidated financial statements), and higher compensation and benefit costs. Gross margin was 67.2% in 2020 compared with 69.3% in 2019. The gross margin decline in 2020 reflects the unfavorable effects of higher impairments and amortization of intangible assets, pricing pressure, a charge related to the discontinuation of COVID-19 vaccine development programs, and higher inventory write-offs related to the recall of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(noted above), partially offset by the favorable effects of product mix and lower restructuring costs.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses were $9.6 billion in 2021, an increase of 8% compared with 2020. The increase was primarily due to higher administrative costs, including compensation and benefits, higher promotional expenses in support of the Company&#8217;s key growth pillars, and higher acquisition-related costs, including costs related to the acquisition of Acceleron. The COVID-19 pandemic drove lower spending in 2020 which contributed to the increase in SG&amp;A expenses in 2021. These increases were partially offset by the favorable effects of foreign exchange and a contribution in 2020 to the Merck Foundation. SG&amp;A expenses were $9.0 billion in 2020, a decline of 5% compared with 2019. The decline was driven primarily by lower administrative, selling and promotional costs, including lower travel and meeting expenses, due in part to the COVID-19 pandemic, and the favorable effect of foreign exchange, partially offset by a contribution to the Merck Foundation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses were $12.2 billion in 2021, a decline of 9% compared with 2020 primarily due to lower upfront payments related to acquisitions and collaborations. The decline was partially offset by higher clinical development spending and increased investment in discovery research and early drug development, net of the reimbursement of a portion of molnupiravir development costs through the partnership with Ridgeback. Higher compensation and benefit costs, higher in-process research and development (IPR&amp;D) impairment charges, as well as costs related to the acquisition of Acceleron also partially offset the decline in R&amp;D expenses in 2021. R&amp;D expenses were $13.4 billion in 2020, an increase of 38% compared with 2019. The increase was driven largely by higher upfront payments related to acquisitions and collaborations, higher clinical development spending and increased investment in discovery research and early drug development. Higher restructuring costs also contributed to the increase in R&amp;D expenses in 2020. The increase in R&amp;D expenses in 2020 was partially offset by lower IPR&amp;D impairment charges and lower costs resulting from the COVID-19 pandemic, net of spending on COVID-19-related vaccine and antiviral research programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company&#8217;s research and development division that focuses on human health-related activities, which were $7.1 billion in 2021, $6.5 billion in 2020 and $6.0 billion in 2019. Also included in R&amp;D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&amp;D activities, including depreciation, production and general and administrative, which in the aggregate were $3.0 billion in 2021, $2.6 billion in 2020 and $2.6 billion in 2019. Additionally, R&amp;D expenses in 2021 include a $1.7 billion charge for the acquisition of Pandion. R&amp;D expenses in 2020 include a $2.7 billion charge for the acquisition of VelosBio Inc., a $462 million charge for the acquisition of OncoImmune and charges of $826 million related to transactions with Seagen. R&amp;D expenses in 2019 include a $993 million charge for the acquisition of Peloton. See Note 4 to the consolidated financial statements for more information on these transactions. R&amp;D expenses also include IPR&amp;D impairment charges of $275 million, $90 million and $172 million in 2021, 2020 and 2019, respectively (see Note 9 to the consolidated financial statements). The Company may recognize additional impairment charges in the future related to the cancellation or delay of other pipeline programs that were measured at fair value and capitalized in connection with business combinations and such charges could be material. In addition, R&amp;D expenses in 2021 and 2020 include $28 million and $83 million, respectively, of costs associated with restructuring activities, primarily relating to accelerated depreciation. R&amp;D expenses also include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration recorded in connection with business combinations. The Company recorded $35 million of expenses in 2021 compared with a net reduction in expenses of $95 million and $39 million in 2020 and 2019, respectively, related to changes in these estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. The Company expects to record charges of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $400 million in 2022 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in annual net cost savings of approximately $900 million by the end of 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $661 million in 2021, $575 million in 2020 and $626 million in 2019. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional costs associated with the Company&#8217;s restructuring activities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs. The Company recorded aggregate pretax costs of $868 million in 2021, $880 million in 2020 and $915 million in 2019 related to restructuring program activities (see Note 6 to the consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, was $1.3 billion of income in 2021 compared with $890 million of income in 2020 primarily due to higher income from investments in equity securities, net, largely related to higher realized and unrealized gains on certain investments including the disposition in 2021 of the Company&#8217;s ownership interest in Preventice Solutions Inc. (Preventice) as a result of the acquisition of Preventice by Boston Scientific, partially offset by higher foreign exchange losses and pension settlement costs. Other (income) and expense, net, was $890 million of income in 2020 compared with $129 million of expense in 2019, primarily due to higher income from investments in equity securities, net, largely related to Moderna, Inc. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details on the components of Other (income) expense, net, see Note 15 to the consolidated financial statements.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment profits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-reportable segment profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations Before Taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&amp;A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&amp;A and R&amp;D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&amp;D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in &#8220;Other&#8221; in the above table. Also included in &#8220;Other&#8221; are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing sales. Beginning in 2021, the amortization of intangible assets previously included as part of the calculation of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment profits is now included in unallocated non-segment corporate expenses. Prior period Pharmaceutical and Animal Health segment profits have been recast to reflect this change on a comparable basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits grew 19% in 2021 primarily due to higher sales and the favorable effect of foreign exchange, partially offset by higher administrative and promotional costs. Pharmaceutical segment profits increased 11% in 2020 driven primarily by higher sales, as well as lower selling and promotional costs. Animal Health segment profits grew 17% in 2021 reflecting higher sales, partially offset by higher promotional, selling and administrative costs. Animal Health segment profits increased 4% in 2020 driven primarily by higher sales and lower promotional and selling costs, partially offset by higher R&amp;D costs and the unfavorable effect of foreign exchange.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes on Income</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates from continuing operations were 11.0% in 2021, 22.9% in 2020 and 21.8% in 2019. The full year effective income tax rate reflects a favorable mix of income and expense, as well as higher foreign tax credits from ordinary business operations that the Company was able to credit in 2021. The effective income tax rate from continuing operations in 2021 also reflects the beneficial impact of the settlement of a foreign tax matter, as well as a net tax benefit of $207&#160;million related to the settlement of certain federal income tax matters (see Note 16 to the consolidated financial statements). The effective income tax rate from continuing operations in 2021 also reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized. The effective income tax rate in 2020 reflects the unfavorable impact of a charge for the acquisition of VelosBio for which no tax benefit was recognized. The effective income tax rate in 2019 reflects the favorable impact of a $106&#160;million net tax benefit related to the settlement of certain federal income tax matters (see Note 16 to the consolidated financial statements) and the reversal of tax reserves established in connection with the 2014 divestiture of Merck&#8217;s Consumer Care (MCC) business due to the lapse in the statute of limitations. In addition, the effective income tax rate in 2019 reflects the unfavorable impact of a charge for the acquisition of Peloton for which no tax benefit was recognized and charges of $117 million related to the finalization of treasury regulations for the transition tax associated with the 2017 enactment of U.S. tax legislation known as the Tax Cuts and Jobs Act (TCJA) (see Note 16 to the consolidated financial statements). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income (Loss) Attributable to Noncontrolling Interests</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to noncontrolling interests was $13 million in 2021, $4 million in 2020 and $(84) million in 2019. The loss in 2019 was driven primarily by the portion of goodwill impairment charges related to certain businesses in the Healthcare Services segment that were attributable to noncontrolling interests.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Income and Non-GAAP EPS from Continuing Operations</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are alternative views of the Company&#8217;s performance that Merck is providing because management believes this information enhances investors&#8217; understanding of the Company&#8217;s results as it permits investors to understand how management assesses performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities and certain other items. These excluded items are significant components in understanding and assessing financial performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes non-GAAP&#160;EPS. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management&#8217;s annual compensation is derived in part using non-GAAP pretax income. Since non-GAAP income and non-GAAP&#160;EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP&#160;EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between GAAP financial measures and non-GAAP financial measures (from continuing operations) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:69.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from continuing operations before taxes as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from investments in equity securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of Pandion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charges for the discontinuation of COVID-19 development programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of VelosBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charges for the formation of collaborations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of Peloton</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP income from continuing operations before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,576&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes on income as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated tax benefit on excluded items </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net tax benefit from the settlement of certain federal income tax matters</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax benefit from the reversal of tax reserves related to the divestiture of MCC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net tax charge related to the finalization of treasury regulations related to the enactment of the TCJA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP taxes on income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,934</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,510&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income (loss) attributable to noncontrolling interests as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income from continuing operations attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS assuming dilution from continuing operations as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP EPS assuming dilution from continuing operations</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Amount in 2020 includes a $1.6 billion intangible asset impairment charge related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Amount in 2019 includes a $612 million intangible asset impairment charge related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. See Note 9 to the consolidated financial statements.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Includes $826 million related to transactions with Seagen. See Note 4 to the consolidated financial statements. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition and Divestiture-Related Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude costs related to restructuring actions (see Note&#160;6 to the consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs. </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income and Losses from Investments in Equity Securities</span></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Items</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS are charges for the acquisitions of Pandion, VelosBio, OncoImmune and Peloton, as well as charges related to collaborations, including transactions with Seagen (see Note 4 to the consolidated financial statements). Also excluded from non-GAAP income and non-GAAP EPS are charges related to the discontinuation of COVID-19 development programs (see Note 4 to the consolidated financial statements). Additionally, excluded from non-GAAP income and non-GAAP EPS are certain tax items, including net tax benefits related to the settlement of certain federal income tax matters, an adjustment to tax benefits recorded in conjunction with the 2015 acquisition of Cubist Pharmaceuticals, Inc., a tax benefit related to the reversal of tax reserves established in connection with the 2014 divestiture of MCC, and a net tax charge related to the finalization of U.S. treasury regulations related to the TCJA (see Note 16 to the consolidated financial statements). </span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Pipeline</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the U.S. and internationally, as well as in late-stage clinical development. A chart reflecting the Company&#8217;s current research pipeline as of February&#160;22, 2022 and related discussion is set forth in Item&#160;1. &#8220;Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and Development&#8221; above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, Research Collaborations and License Agreements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck continues to remain focused on pursuing opportunities that have the potential to drive both near- and long-term growth. Certain recent transactions are summarized below; additional details are included in Note 4 to the consolidated financial statements. Merck actively monitors the landscape for growth opportunities that meet the Company&#8217;s strategic criteria.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Merck and Gilead entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck&#8217;s investigational NRTTI, islatravir, and Gilead&#8217;s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck acquired Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for total consideration of $1.9 billion. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Merck acquired Acceleron, a publicly traded biopharmaceutical company, for total consideration of $11.5&#160;billion. Acceleron is evaluating the TGF-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron&#8217;s lead therapeutic candidate, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with PAH. Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. In addition to sotatercept, Acceleron&#8217;s portfolio includes Reblozyl (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is being evaluated in clinical trials for additional indications for hematology therapies. Reblozyl is being developed and commercialized through a global collaboration with Bristol Myers Squibb. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with business combinations, the Company has recorded the fair value of in-process research projects which, at the time of acquisition, had not yet reached technological feasibility. At December&#160;31, 2021, the balance of IPR&amp;D was $9.3 billion (see Note 9 to the consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates. The time periods to receive approvals from the FDA and other regulatory agencies are subject to uncertainty. Significant delays in the approval process, or the Company&#8217;s failure to obtain approval at all, would delay or prevent the Company from realizing revenues from these products. Additionally, if the IPR&amp;D programs require additional clinical trial data than previously anticipated, or if the programs fail or are abandoned during development, then the Company will not realize the future cash flows it has estimated and recorded as IPR&amp;D as of the acquisition date. If such circumstances were to occur, the Company&#8217;s future operating results could be adversely affected and the Company may recognize impairment charges, which could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020, and 2019 the Company recorded IPR&amp;D impairment charges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $275 million, $90 million and $172 million, respectively (see Note 9 to the consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional research and development will be required before any of the remaining programs reach technological feasibility. The costs to complete the research projects will depend on whether the projects are brought to their final stages of development and are ultimately submitted to the FDA or other regulatory agencies for approval. </span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_103"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures were $4.4 billion in 2021, $4.4 billion in 2020 and $3.4 billion in 2019. Expenditures in the U.S. were $2.8 billion in 2021, $2.6 billion in 2020 and $1.9 billion in 2019. The Company plans to invest approximately $20 billion in capital projects from 2021-2025 including expanding manufacturing capacity for oncology, vaccine and animal health products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $1.6 billion in 2021, $1.7 billion in 2020 and $1.6 billion in 2019, of which $1.1 billion in 2021, $1.2 billion in 2020 and $1.2 billion in 2019, related to locations in the U.S. Total depreciation expense in 2021, 2020 and 2019 included accelerated depreciation of $91 million, $268 million and $233 million, respectively, associated with restructuring activities (see Note&#160;6 to the consolidated financial statements).</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_106"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s strong financial profile enables it to fund research and development, focus on external alliances, support in-line products and maximize upcoming launches while providing significant cash returns to shareholders.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Selected Data</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt to total liabilities and equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities of continuing operations to total debt</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4:1</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2:1</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3:1</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in working capital in 2021 compared with 2020 is primarily related to decreased short-term debt. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities of continuing operations was $13.1 billion in 2021 compared with $7.6 billion in 2020 and $8.9 billion in 2019. The higher cash provided by operating activities of continuing operations in 2021 reflects stronger operating performance. Cash provided by operating activities of continuing operations includes upfront and milestone payments related to collaborations of $435 million in 2021, $2.9 billion in 2020 and $805 million in 2019. Cash provided by operating activities of continuing operations continues to be the Company&#8217;s source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance capital expenditures, treasury stock purchases and dividends paid to shareholders. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities of continuing operations was $16.4 billion in 2021 compared with $9.2 billion in 2020. The higher use of cash in investing activities of continuing operations was primarily due to higher cash used for acquisitions, including for the acquisition of Acceleron, and lower proceeds from sales of securities and other investments, partially offset by the 2020 purchase of Seagen common stock. Cash used in investing activities of continuing operations was $9.2 billion in 2020 compared with $2.5 billion in 2019. The increase was driven primarily by lower proceeds from the sales of securities and other investments, higher use of cash for acquisitions, higher capital expenditures and the purchase of Seagen common stock, partially offset by lower purchases of securities and other investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities of continuing operations was $3.1 billion in 2021 compared with a use of cash in financing activities of continuing operations of $2.8 billion in 2020. The change was primarily driven by the cash distribution received from Organon in connection with the spin-off (see Note 3 to the consolidated financial statements), higher proceeds from the issuance of debt (see below) and lower purchases of treasury stock, partially offset by a net decrease in short-term borrowings in 2021 compared with a net increase in short-term borrowings in 2020, higher payments on debt (see below) and higher dividends paid to shareholders. Cash used in financing activities of continuing operations was $2.8 billion in 2020 compared with $8.9 billion in 2019. The lower use of cash in financing activities of continuing operations was driven primarily by a net increase in short-term borrowings in 2020 compared with a net decrease in short-term borrowing in 2019, as well as lower purchases of treasury stock, partially offset by higher payments on debt (see below), lower proceeds from the issuance of debt (see below), higher dividends paid to shareholders and lower proceeds from the exercise of stock options.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company issued $8.0&#160;billion principal amount of senior unsecured notes consisting of $1.5&#160;billion of 1.70% notes due 2027, $1.0&#160;billion of 1.90% notes due 2028, $2.0&#160;billion of 2.15% notes due 2031, $2.0&#160;billion of 2.75% notes due 2051 and $1.5&#160;billion of 2.90% notes due 2061. Merck used the net proceeds from the offering of the 2027 notes, the 2031 notes, the 2051 notes and the 2061 notes for general corporate purposes, including the repayment of outstanding commercial paper borrowings (including commercial paper borrowings in connection with Merck&#8217;s acquisition of Acceleron), and other indebtedness. Merck allocated an amount equal to the net proceeds of the offering of the notes due in 2028 to finance or refinance, in whole or in part, projects and partnerships in the Company&#8217;s priority ESG areas.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company issued $4.5&#160;billion principal amount of senior unsecured notes consisting of $1.0&#160;billion of 0.75% notes due 2026, $1.25&#160;billion of 1.45% notes due 2030, $1.0&#160;billion of 2.35% notes due 2040 and $1.25&#160;billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including the repayment of outstanding commercial paper borrowings and other indebtedness.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company issued $5.0 billion principal amount of senior unsecured notes consisting of $750 million of 2.90% notes due 2024, $1.75 billion of 3.40% notes due 2029, $1.0 billion of 3.90% notes due 2039, and $1.5 billion of 4.00% notes due 2049. The Company used the net proceeds from the offering for general corporate purposes, including the repayment of outstanding commercial paper borrowings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company&#8217;s $1.25 billion, 2.35% notes matured in accordance with their terms and were repaid. In 2021, the Company&#8217;s $1.15 billion, 3.875% notes and the Company&#8217;s &#8364;1.0 billion, 1.125% notes matured in accordance with their terms and were repaid. In 2020, the Company&#8217;s $1.25 billion, 1.85% notes and $700 million floating-rate notes matured in accordance with their terms and were repaid.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects foreseeable liquidity and capital resource requirements to be met through existing cash and cash equivalents and anticipated cash flows from operations, as well as commercial paper borrowings and long-term borrowings if needed. Merck believes that its sources of financing will be adequate to meet its future requirements. The Company&#8217;s material cash requirements arising in the normal course of business primarily include:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Obligations and Interest Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; See Note 10 to the consolidated financial statements for further detail of the Company&#8217;s debt obligations and the timing of expected future principal and interest payments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Liabilities &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the enactment of the TCJA, the Company is required to pay a one-time transition tax, which the Company has elected to pay over a period of eight years through 2025 as permitted under the TCJA. Additionally, the Company has liabilities for unrecognized tax benefits, including interest and penalties. See Note 16 to the consolidated financial statements for further information pertaining to the transition tax and liabilities for unrecognized tax benefits. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 to consolidated financial statements for further details of the Company&#8217;s lease obligations and the timing of expected future lease payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Milestone Payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The Company has accrued liabilities for contingent sales-based milestone payments related to collaborations with AstraZeneca, Eisai, and Bayer where payment has been deemed probable, but remains subject to the achievement of the related sales milestone. See Note 5 to the consolidated financial statements for additional information related to these sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Purchase obligations are enforceable and legally binding obligations for purchases of goods and services including minimum inventory contracts, research and development and advertising. Purchase obligations also include future inventory purchases the Company has committed to in connection with certain divestitures. As of December 31, 2021, the Company had total purchase obligations of $5.3&#160;billion, of which $1.6&#160;billion is estimated to be payable in 2022.</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company filed a securities registration statement with the U.S. Securities and Exchange Commission (SEC) under the automatic shelf registration process available to &#8220;well-known seasoned issuers&#8221; which is effective for three years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it maintains a conservative financial profile. The Company places its cash and investments in instruments that meet high credit quality standards, as specified in its investment policy guidelines. These guidelines also limit the amount of credit exposure to any one issuer. The Company does not participate in any off-balance sheet arrangements involving unconsolidated subsidiaries that provide financing or potentially expose the Company to unrecorded financial obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Merck&#8217;s Board of Directors increased the quarterly dividend, declaring a quarterly dividend of $0.69 per share on the Company&#8217;s outstanding common stock that was paid in January 2022. In January 2022, the Board of Directors declared a quarterly dividend of $0.69 per share on the Company&#8217;s common stock for the second quarter of 2022 payable in April 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Merck&#8217;s Board of Directors authorized purchases of up to $10 billion of Merck&#8217;s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions, on or off an exchange, or in privately negotiated transactions. In May 2021, Merck restarted its share repurchase program, which the Company had temporarily suspended in March 2020. The Company spent $840 million to purchase 11 million shares of its common stock for its treasury during 2021 under this program. As of&#160;December&#160;31, 2021, the Company&#8217;s remaining share repurchase </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorization was $5.0 billion. The Company purchased $1.3 billion and $4.8 billion of its common stock during 2020 and 2019, respectively, under authorized share repurchase programs.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments Market Risk Disclosures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management, and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (Loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Merck principally sells foreign currency in its revenue hedging program, a uniform weakening of the U.S. dollar would yield the largest overall potential loss in the market value of these hedge instruments. The market value of Merck&#8217;s hedges would have declined by an estimated $648 million and $593 million at December&#160;31, 2021 and 2020, respectively, from a uniform 10% weakening of the U.S.&#160;dollar. The market value was determined using a foreign exchange option pricing model and holding all factors except exchange rates constant. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck&#8217;s major foreign currency exposures relative to the U.S.&#160;dollar. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hedging instrument. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sensitivity analysis to changes in the value of the U.S.&#160;dollar on foreign currency denominated derivatives, investments and monetary assets and liabilities indicated that if the U.S.&#160;dollar uniformly weakened by 10% against all currency exposures of the Company at December&#160;31, 2021 and 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would have declined by approximately $125 million and $99 million in 2021 and 2020, respectively. Because the Company was in a net short (payable) position relative to its major foreign currencies after consideration of forward contracts, a uniform weakening of the U.S. dollar will yield the largest overall potential net loss in earnings due to exchange. This measurement assumes that a change in one foreign currency relative to the U.S.&#160;dollar would not affect other foreign currencies relative to the U.S.&#160;dollar. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck&#8217;s major foreign currency exposures relative to the U.S.&#160;dollar. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company was a party to nine pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below. </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These interest rate swaps matured in February 2022.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. See Note 2 to the consolidated financial statements for a discussion of the pending discontinuation of LIBOR as part of reference rate reform. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment portfolio includes cash equivalents and short-term investments, the market values of which are not significantly affected by changes in interest rates. The market value of the Company&#8217;s medium- to long-term fixed-rate investments is modestly affected by changes in U.S.&#160;interest rates. Changes in medium- to long-term U.S.&#160;interest rates have a more significant impact on the market value of the Company&#8217;s fixed-rate borrowings, which generally have longer maturities. A sensitivity analysis to measure potential changes in the market value of Merck&#8217;s investments and debt from a change in interest rates indicated that a one percentage point increase in interest rates at December&#160;31, 2021 and 2020 would have positively affected the net aggregate market value of these instruments by $3.2 billion and $2.6 billion, respectively. A one percentage point decrease at December&#160;31, 2021 and 2020 would have negatively affected the net aggregate market value by $3.9 billion and $3.1 billion, respectively. The fair value of Merck&#8217;s debt was determined using pricing models reflecting one percentage point shifts in the appropriate yield curves. The fair values of Merck&#8217;s investments were determined using a combination of pricing and duration models.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_112"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements are prepared in conformity with GAAP and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates. Application of the following accounting policies result in accounting estimates having the potential for the most significant impact on the financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions and Dispositions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses, the Company makes certain judgments, which include assessment of the inputs, processes, and outputs associated with the acquired set of activities. If the Company determines that substantially all of the fair value of gross assets included in a transaction is concentrated in a single asset (or a group of similar assets), the assets would not represent a business. To be considered a business, the assets in a transaction need to include an input and a substantive process that together significantly contribute to the ability to create outputs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. The fair values of intangible assets are determined utilizing information available near the acquisition date based on expectations and assumptions that are deemed reasonable by management. Given the considerable judgment involved in determining fair values, the Company typically obtains assistance from third-party valuation specialists for significant items. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as asset lives, can materially affect the Company&#8217;s results of operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of identifiable intangible assets related to currently marketed products and product rights are primarily determined by using an income approach through which fair value is estimated based on each asset&#8217;s discounted projected net cash flows. The Company&#8217;s estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products where applicable; relevant industry and therapeutic area growth drivers and factors; current and expected trends in technology and product life cycles; the time and investment that will be required to develop products and technologies; the ability to obtain marketing and regulatory approvals; the ability to manufacture and commercialize the products; the extent and timing of potential new product introductions by the Company&#8217;s competitors; and the life of each asset&#8217;s underlying patent and any related patent term extension, if any. The net cash flows are then probability-adjusted where appropriate to consider the uncertainties associated with the underlying assumptions, as well as the risk profile of the net cash flows utilized in the valuation. The probability-adjusted future net cash flows of each product are then discounted to present value utilizing an appropriate discount rate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of identifiable intangible assets related to IPR&amp;D are also determined using an income approach, through which fair value is estimated based on each asset&#8217;s probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using an appropriate discount rate. Amounts allocated to acquired IPR&amp;D are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s business combinations involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Changes in any of the inputs may result in a significantly different fair value adjustment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines the transaction will not be accounted for as an acquisition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired IPR&amp;D with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership transfer to the customer and the Company is entitled to payment. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covers chargebacks and rebates. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its provision for aggregate customer discounts. There were no material adjustments to estimates associated with the aggregate customer discount provision in 2021, 2020 or 2019.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in the aggregate customer discount accrual related to U.S. sales is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,776</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,412</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,844</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for chargebacks are reflected as a direct reduction to accounts receivable and accruals for rebates as current liabilities. The accrued balances relative to these provisions included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $207 million and $2.6 billion, respectively, at December&#160;31, 2021 and were $208 million and $2.6 billion, respectively, at December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. The product returns provision for U.S. pharmaceutical sales as a percentage of U.S. net pharmaceutical sales was 0.9% in 2021, 0.5% in 2020 and 1.0% in 2019. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through its distribution programs with U.S.&#160;wholesalers, the Company encourages wholesalers to align purchases with underlying demand and maintain inventories below specified levels. The terms of the programs allow the wholesalers to earn fees upon providing visibility into their inventory levels, as well as by achieving certain performance parameters such as inventory management, customer service levels, reducing shortage claims and reducing product returns. Information provided through the wholesaler distribution programs includes items such as sales trends, inventory on-hand, on-order quantity and product returns.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wholesalers generally provide only the above-mentioned data to the Company, as there is no regulatory requirement to report lot level information to manufacturers, which is the level of information needed to determine the remaining shelf life and original sale date of inventory. Given current wholesaler inventory levels, which are generally less than a month, the Company believes that collection of order lot information across all wholesale customers would have limited use in estimating sales discounts and returns.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories Produced in Preparation for Product Launches</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventories produced in preparation for product launches sufficient to support estimated initial market demand. Typically, capitalization of such inventory does not begin until the related product candidates are in Phase&#160;3 clinical trials and are considered to have a high probability of regulatory approval. The Company monitors the status of each respective product within the regulatory approval process; however, the Company generally does not disclose specific timing for regulatory approval. If the Company is aware of any specific risks or contingencies other than the normal regulatory approval process or if there are any specific issues identified during the research process relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory would generally not be capitalized. Expiry dates of the inventory are affected by the stage of completion. The Company manages the levels of inventory at each stage to optimize the shelf life of the inventory in relation to anticipated market demand in order to avoid product expiry issues. For inventories that are capitalized, anticipated future sales and shelf lives support the realization of the inventory value as the inventory shelf life is sufficient to meet initial product launch requirements. Inventories produced in preparation for product launches capitalized at December&#160;31, 2021 and 2020 were $256 million and $279 million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Environmental Liabilities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property and commercial litigation, as well as certain additional matters including governmental and environmental matters (see Note&#160;11 to the consolidated financial statements). The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reserves as of December&#160;31, 2021 and 2020 of approximately $230 million and $235 million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. When a legitimate claim for contribution is asserted, a liability is initially accrued based upon the estimated transaction costs to manage the site. Accruals are adjusted as site investigations, feasibility studies and related cost assessments of remedial techniques are completed, and as the extent to which other potentially responsible parties who may be jointly and severally liable can be expected to contribute is determined.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites and takes an active role in identifying and accruing for these costs. In the past, Merck performed a worldwide survey to assess all sites for potential contamination resulting from past industrial activities. Where assessment indicated that physical investigation was warranted, such investigation was performed, providing a better evaluation of the need for remedial action. Where such need was identified, remedial action was then initiated. As definitive information became available during the course of investigations and/or remedial efforts at each site, estimates were refined and accruals were established or adjusted accordingly. These estimates and related accruals continue to be refined annually.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. Expenditures for remediation and environmental liabilities were $12 million in 2021 and are estimated to be $24 million in the aggregate for the years 2022 through 2026. In management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $40 million and $43 million at December&#160;31, 2021 and 2020, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $40 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#8217;s financial condition, results of operations or liquidity for any year.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, including grants of stock options, over the requisite service period based on the grant date fair value of the awards. The Company determines the fair value of certain share-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. Total pretax share-based compensation expense from continuing operations was $479 million in 2021, $441 million in 2020 and $388 million in 2019. At December&#160;31, 2021, there was $699 million of total pretax unrecognized compensation expense related to nonvested stock option, restricted stock unit and performance share unit awards which will be recognized over a weighted-average period of 1.9&#160;years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pensions and Other Postretirement Benefit Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost for pension plans totaled $748 million in 2021, $450 million in 2020 and $134 million in 2019. Net periodic benefit credit for other postretirement benefit plans was $83 million in 2021, $59 million in 2020 and $49 million in 2019. Pension and other postretirement benefit plan information for financial reporting purposes is calculated using actuarial assumptions including a discount rate for plan benefit obligations </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and an expected rate of return on plan assets. The changes in net periodic benefit cost year over year for pension plans are attributable to settlement charges incurred by certain plans, as well as changes in the discount rate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The discount rates for the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans ranged from 2.60% to 3.10% at December&#160;31, 2021, compared with a range of 2.10% to 2.80% at December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rate of return, the Company considers long-term compound annualized returns of historical market data, current market conditions and actual returns on the Company&#8217;s plan assets. Using this reference information, the Company develops forward-looking return expectations for each asset category and a weighted-average expected long-term rate of return for a target portfolio allocated across these investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2022, the expected rate of return for the Company&#8217;s U.S. pension and other postretirement benefit plans will be 6.70%, compared to a range of 6.50% to 6.70% in 2021. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans is allocated 30% to 45% in U.S.&#160;equities, 15% to 30% in international equities, 35% to 45% in fixed-income investments, and up to 5% in cash and other investments. The portfolio&#8217;s equity weighting is consistent with the long-term nature of the plans&#8217; benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 11%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial assumptions are based upon management&#8217;s best estimates and judgment. A reasonably possible change of plus (minus) 25&#160;basis points in the discount rate assumption, with other assumptions held constant, would have had an estimated $85 million favorable (unfavorable) impact on the Company&#8217;s net periodic benefit cost in 2021. A reasonably possible change of plus (minus) 25&#160;basis points in the expected rate of return assumption, with other assumptions held constant, would have had an estimated $58&#160;million favorable (unfavorable) impact on Merck&#8217;s net periodic benefit cost in 2021. Required funding obligations for 2022 relating to the Company&#8217;s pension and other postretirement benefit plans are not expected to be material. The preceding hypothetical changes in the discount rate and expected rate of return assumptions would not impact the Company&#8217;s funding requirements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss amounts, which primarily reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions, are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Expected returns for pension plans are based on a calculated market-related value of assets. Net loss amounts in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs have been recorded in connection with restructuring programs designed to streamline the Company&#8217;s cost structure. As a result, the Company has made estimates and judgments regarding its future plans, including future termination benefits and other exit costs to be incurred when the restructuring actions take place. When accruing termination costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. In connection with these actions, management also assesses the recoverability of long-lived assets employed in the business. In certain instances, asset lives have been shortened based on changes in the expected useful lives of the affected assets. Severance and other related costs are reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Asset-related charges are reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses depending upon the nature of the asset.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairments of Long-Lived Assets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses changes in economic, regulatory and legal conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company&#8217;s property, plant and equipment, goodwill and other intangible assets.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its long-lived assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows approach.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the factors considered in the assessment include general macroeconomic conditions, conditions specific to the industry and market, cost factors which could have a significant effect on earnings or cash flows, the overall financial performance of the reporting unit, and whether there have been sustained declines in the Company&#8217;s share price. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other acquired intangible assets (excluding IPR&amp;D) are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. When events or circumstances warrant a review, the Company will assess recoverability from future operations using pretax undiscounted cash flows derived from the lowest appropriate asset groupings. Impairments are recognized in operating results to the extent that the carrying value of the intangible asset exceeds its fair value, which is determined based on the net present value of estimated future cash flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. For impairment testing purposes, the Company may combine separately recorded IPR&amp;D intangible assets into one unit of account based on the relevant facts and circumstances. Generally, the Company will combine IPR&amp;D intangible assets for testing purposes if they operate as a single asset and are essentially inseparable. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The judgments made in evaluating impairment of long-lived intangibles can materially affect the Company&#8217;s results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate is based on pretax income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. An estimated effective tax rate for a year is applied to the Company&#8217;s quarterly operating results. In the event that there is a significant unusual or one-time item recognized, or expected to be recognized, in the Company&#8217;s quarterly operating results, the tax attributable to that item would be separately calculated and recorded at the same time as the unusual or one-time item. The Company considers the resolution of prior year tax matters to be such items. Significant judgment is required in determining the Company&#8217;s tax provision and in evaluating its tax positions. The recognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at the reporting date. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. If the more likely than not threshold is not met in the period for which a tax position is taken, the Company may subsequently recognize the benefit of that tax position if the tax matter is effectively settled, the statute of limitations expires, or if the more likely than not threshold is met in a subsequent period (see Note&#160;16 to the consolidated financial statements).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax regulations require items to be included in the tax return at different times than the items are reflected in the financial statements. Timing differences create deferred tax assets and liabilities. Deferred tax assets generally represent items that can be used as a tax deduction or credit in the tax return in future years for which the Company has already recorded the tax benefit in the financial statements. The Company establishes valuation allowances for its deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense recognized in the financial statements for which payment has been deferred or expense for which the Company has already taken a deduction on the tax return, but has not yet recognized as expense in the financial statements. </span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_115"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently issued accounting standards, see Note 2 to the consolidated financial statements.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_118"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Factors That May Affect Future Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called &#8220;forward-looking statements,&#8221; all of which are based on management&#8217;s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company&#8217;s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company&#8217;s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company&#8217;s filings with the Securities and Exchange Commission, especially on this Form&#160;10-K and Forms 10-Q and 8-K. In Item&#160;1A. &#8220;Risk Factors&#8221; of this annual report on Form&#160;10-K the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_121"></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.8pt">Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the discussion under &#8220;Financial Instruments Market Risk Disclosures&#8221; in Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Financial Statements and Supplementary Data.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_127"></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;padding-left:24.93pt">Financial Statements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consolidated balance sheet of Merck&#160;&amp; Co., Inc. and subsidiaries as of December&#160;31, 2021 and 2020, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December&#160;31, 2021, the notes to consolidated financial statements, and the report dated February&#160;25, 2022 of PricewaterhouseCoopers LLP, independent registered public accounting firm, are as follows:</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_130"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statement of Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEtMS0xLTEtMA_e9ba35a1-796a-4918-8a31-563f710742c7">48,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEtMy0xLTEtMA_5d4fe67b-5bc5-41e9-9c6a-cfdfc2a60b24">41,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEtNS0xLTEtMA_8321d7e8-dee6-4216-9684-6e006ea722b5">39,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzMtMS0xLTEtMA_17d43010-6c6a-4f90-af90-e56054600278">13,626</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzMtMy0xLTEtMA_0df2c995-12ec-48c1-bc74-5d167864d049">13,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzMtNS0xLTEtMA_f600dbdd-76bf-493d-9617-9b6fca060895">12,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzQtMS0xLTEtMA_71a42e63-a99d-4409-b948-35a9177e8a12">9,634</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzQtMy0xLTEtMA_889c1fd4-07aa-407d-9b50-d871855fc7e4">8,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzQtNS0xLTEtMA_a832c3c5-69da-4a85-9f2f-8e69c57806e3">9,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzUtMS0xLTEtMA_f496c194-20ee-4a69-8e5b-b9864cf00059">12,245</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzUtMy0xLTEtMA_d847a44a-aee5-47aa-b911-c2725a7727f2">13,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzUtNS0xLTEtMA_196c1a45-a1f2-4eab-88d9-3f7feb4226e6">9,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzYtMS0xLTEtMA_f35d5eae-2038-4f07-b966-5c61edc076a2">661</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzYtMy0xLTEtMA_06e293e5-e311-49dc-bf90-bcbf63c47c70">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzYtNS0xLTEtMA_753c1b48-89ad-4949-9cd4-e96f30f35406">626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzctMS0xLTEtMA_f86853c3-579f-4c7a-9a52-011609aea341">1,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzctMy0xLTEtMA_a99eca07-7b63-4e79-a856-07713a5afb32">890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzctNS0xLTEtMA_0bfea1ba-1532-4ff9-8b6c-d14343e9d14d">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzgtMS0xLTEtMA_a488a162-91de-490e-9ac9-58ed9d212031">34,825</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzgtMy0xLTEtMA_6985870e-b086-4ae3-ad43-23324d516db9">35,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzgtNS0xLTEtMA_208627e9-1756-4379-a7c9-98809e4b180b">31,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income from Continuing Operations Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzktMS0xLTEtMA_cc6bcfb1-a5a3-452c-9818-33adde30fac2">13,879</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzktMy0xLTEtMA_a5a2a19a-4e03-48c9-9e0b-28bd60ea1ce4">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzktNS0xLTEtMA_9efdec63-62df-46d5-9df0-de3e6ca1632d">7,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Taxes on Income from Continuing Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEwLTEtMS0xLTA_cfaac8ab-57e6-48ee-accd-58c70a1fe153">1,521</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEwLTMtMS0xLTA_868578af-081d-4c75-9043-a91a337e9602">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEwLTUtMS0xLTA_885b2339-18dc-41e0-8fba-42bcf46f4c05">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net Income from Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzExLTEtMS0xLTA_a48daa18-150b-4cc7-8a99-e5b31066f9c8">12,358</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzExLTMtMS0xLTA_89bf656b-704b-4c0f-a2af-b3f0c0d205d6">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzExLTUtMS0xLTA_8d7daa28-6724-4f16-ad93-d922d3069248">5,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Less: Net Income (Loss) Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEyLTEtMS0xLTA_e44cf497-5815-4e4d-8754-75f319134778">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEyLTMtMS0xLTA_a9ad8a8f-ee5b-4d9e-8eed-d4f8e29f2889">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEyLTUtMS0xLTA_7aa2f02f-28e4-4a80-89d5-1e07a5a60569">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEzLTEtMS0xLTA_1da5a490-6afc-44e5-b58b-8dd963f88930">12,345</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEzLTMtMS0xLTA_157a8de2-def9-447c-9e6d-d1ed0eb0da4f">4,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEzLTUtMS0xLTA_804b8665-0a8f-43e3-9d96-1d707242653a">5,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE0LTEtMS0xLTgy_4d19ddd7-a246-43c9-a0d9-8f332591202a">704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE0LTMtMS0xLTgy_83acf2cd-4baa-4f05-bb14-b4c2badb3b81">2,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE0LTUtMS0xLTgy_e74cfd78-0295-427e-aca6-0f46d4fa507d">4,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE1LTEtMS0xLTExNw_d6fb79df-7b47-43ed-8a07-d8539ccc2699">13,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE1LTMtMS0xLTExOQ_08540730-c04d-433c-a68d-f75ce6d4e98c">7,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE1LTUtMS0xLTEyMQ_37880ec2-7f82-4a95-b3fe-7681183e9730">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE3LTEtMS0xLTkz_444163db-27e7-4b03-bda9-1f48be58b3c7">4.88</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE3LTMtMS0xLTkz_ee7c4a06-b07e-4899-ab67-5d8d0bf01053">1.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE3LTUtMS0xLTkz_3d3924f1-8718-4489-8ced-4962479732ca">2.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE4LTEtMS0xLTkz_97f1064b-48f0-4074-bfa9-deeecd0a4270">0.28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE4LTMtMS0xLTkz_a5a39938-057a-4c52-a9f8-39cf73533dda">1.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE4LTUtMS0xLTkz_dfc2bc28-51e9-4707-8953-36e8ad8f08a9">1.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE5LTEtMS0xLTkz_61c5ac76-3545-4a4b-93e5-ff074d6f98fd">5.16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE5LTMtMS0xLTkz_823db72e-99e7-49e1-8add-cf82b94a33a7">2.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE5LTUtMS0xLTkz_c28ca42d-1c30-46d6-a827-f37dd36c9193">3.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIxLTEtMS0xLTkz_7e6f5f10-bb3e-48b8-b9ed-38f76547e401">4.86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIxLTMtMS0xLTkz_b638bd4b-37c9-4773-99dd-eaf625f27893">1.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIxLTUtMS0xLTkz_1c4b19b3-5418-49d6-b987-d1a1627d2d1a">2.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIyLTEtMS0xLTkz_ffd6ba73-f4ce-4e69-9c62-d2e248cad854">0.28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIyLTMtMS0xLTkz_8c6f1e3a-eb5d-4157-a897-092f3e25489a">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIyLTUtMS0xLTkz_f8ff745e-2021-44c3-a5c1-bfcd58467f4a">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIzLTEtMS0xLTkz_e0f2f41a-1738-4d46-80f0-9198dc142463">5.14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIzLTMtMS0xLTkz_cb05a712-703f-43f1-9fc9-5ea1dfd9269b">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIzLTUtMS0xLTkz_d646b9dd-4944-412a-8d37-edbf27d590ea">3.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statement of Comprehensive Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">($ in millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzEtMS0xLTEtMA_521f1f22-1cbc-40ec-892e-db367184cb0c">13,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzEtMy0xLTEtMA_382c7b0f-172f-41fc-810b-86da0797b552">7,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzEtNS0xLTEtMA_639334cb-fc98-4814-9805-df33921b88a1">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other Comprehensive Income (Loss) Net of Taxes:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on derivatives, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzMtMS0xLTEtMA_ad9fc7d8-44a5-439a-bdc7-c7b56c04e173">410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzMtMy0xLTEtMA_0d349181-0c49-47d7-a300-cbceda974528">297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzMtNS0xLTEtMA_14ea9195-63c2-40a6-b979-690be23ad27b">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on investments, net of reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzQtMS0xLTEtMA_6af2a394-7922-446c-a635-45035d6251f2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzQtMy0xLTEtMA_31aa3cbd-ba96-4fa6-a9de-21d4b57e7fe0">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzQtNS0xLTEtMA_94e995f1-b454-431a-97c4-ca8bdf920b3a">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Benefit plan net gain (loss) and prior service credit (cost), net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzUtMS0xLTEtMA_4df18903-d2f8-42ff-9e17-f5dc37607fd8">1,769</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzUtMy0xLTEtMA_8531386b-2cc3-4a5a-86f4-354843d3568b">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzUtNS0xLTEtMA_f057e166-aec8-428a-812d-f654ba72e260">705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative translation adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzYtMS0xLTEtMA_b1e1a232-e5e9-46ae-b24d-286587b221ee">423</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzYtMy0xLTEtMA_6e41a195-eaad-412e-bc49-518198bc031c">153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzYtNS0xLTEtMA_34470082-e5bb-4f14-b4ae-cd0d3851c218">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzctMS0xLTEtMA_d7cdd2a5-182f-4b9c-9e9f-5b3f305a885f">1,756</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzctMy0xLTEtMA_22a69c9d-b8a2-449e-8063-32e8d1537e19">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzctNS0xLTEtMA_31cc660f-fd8a-42c2-a52c-ee82533e48e5">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzgtMS0xLTEtMA_d86d73fd-90d9-4c86-ad86-c091a9c17d0f">14,805</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzgtMy0xLTEtMA_14fe7302-8ff2-4e9c-9f6e-0238d285cc84">6,626</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzgtNS0xLTEtMA_5b068ca7-e5b8-4b13-af7e-62ec0408f0b7">9,195</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Balance Sheet</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMtMS0xLTEtMA_ebebfa54-f656-4433-a39b-55585c424c67">8,096</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMtMy0xLTEtMA_89b7c4f8-55cf-4ec2-b3b7-b22bf6b5e1ab">8,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts receivable (net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjUxN2UyMzlmMGM3OTQwMmRhNmNkOTE3Zjk5OGY4NjlmXzY4_5a32a1d4-6f07-430d-a805-3f3ad58cd972">62</ix:nonFraction> in 2021 </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjUxN2UyMzlmMGM3OTQwMmRhNmNkOTE3Zjk5OGY4NjlmXzgz_0217a804-65e5-460b-93aa-82aa597fee90">67</ix:nonFraction> in 2020) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzUtMS0xLTEtMA_4431ac25-7ded-46f6-97b2-6fd2ea3f68e9">9,230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzUtMy0xLTEtMA_4e91e170-f7bb-4132-ab04-8d412e585805">6,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inventories (excludes inventories of $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjBkNDc5YjQ4ZTNiODRlYmRiNDJkMDg1Y2Q2MWY2YjhhXzQy_6e6ad75e-3cf2-4ff5-8bd3-d3b4264768e8">2,194</ix:nonFraction> in 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjBkNDc5YjQ4ZTNiODRlYmRiNDJkMDg1Y2Q2MWY2YjhhXzU3_24845acb-5bf3-4c9c-bcc0-8f34b7df91a5">2,070</ix:nonFraction> in 2020</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">classified in Other assets - see Note&#160;8)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzYtMS0xLTEtMA_5ac94e46-6cb6-4df4-960d-cc069639d365">5,953</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzYtMy0xLTEtMA_c545f58b-144d-412c-b950-fa267a3715b2">5,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzctMS0xLTEtMA_b9b8715b-3413-4466-90fd-6bc1a25a7b22">6,987</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzctMy0xLTEtMA_e2a5b587-cf77-42f8-92b3-af12639d741b">4,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzgtMS0xLTEtMjE5_80f0151e-33d3-4ff2-970d-70312b8712ff">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzgtMy0xLTEtMjE5_c9a6126d-a7f9-4647-8988-e4e4bdb24080">2,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzgtMS0xLTEtMA_c27f01b7-6e85-434a-b456-41e5b2236199">30,266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzgtMy0xLTEtMA_2efae1d0-0bad-4db3-8eaa-df40defc0707">27,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzktMS0xLTEtMA_a8dd747c-cc1c-4881-8f41-823b53198064">370</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzktMy0xLTEtMA_dc14356e-07ab-4908-9140-c4b47d1823c5">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property, Plant and Equipment (at cost)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzExLTEtMS0xLTA_57b239d5-9b4a-48c4-a7d3-231b7f35227d">326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzExLTMtMS0xLTA_3d9c77a0-84d2-41e8-b0a6-2d74559fd947">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzEyLTEtMS0xLTA_464bd42e-03e7-413d-a279-742a1f787f18">12,529</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzEyLTMtMS0xLTA_bea89b63-2a9c-4a40-ab40-b21edfc9bd68">11,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Machinery, equipment and office furnishings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzEzLTEtMS0xLTA_1af9bce8-a6ca-47de-bb90-9f751ce9f833">16,303</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzEzLTMtMS0xLTA_a4849aef-033d-4b82-83c8-057f7d89351b">15,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE0LTEtMS0xLTA_69cf5fdb-03c8-436b-ac31-eadfece8731b">8,313</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE0LTMtMS0xLTA_d8b6613d-61cb-4447-81f7-e6e07ab7db41">6,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE1LTEtMS0xLTA_bb4cec65-8a5d-49a1-8746-12fa5bbb724d">37,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE1LTMtMS0xLTA_cb0fce7f-61a2-4b72-95c2-b42f4446f6ca">35,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE2LTEtMS0xLTA_8126faf8-d41f-4c7f-83c7-3c538d4111b7">18,192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE2LTMtMS0xLTA_355f969a-cb99-45fc-9143-71740046122e">18,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE3LTEtMS0xLTA_7fdae8e1-042a-4b8a-9f19-640de42a5454">19,279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE3LTMtMS0xLTA_2e9a779e-8090-4520-9ab3-85f903b2bc47">17,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE4LTEtMS0xLTA_5e21be3a-52f2-425e-9763-4d06b28c6bfe">21,264</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE4LTMtMS0xLTA_c7f02453-1e92-451f-9501-ce92bcfe4ece">18,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other Intangibles, Net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE5LTEtMS0xLTA_860886f0-9209-4bb8-b91a-a6f97b7f01dd">22,933</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE5LTMtMS0xLTA_fe62178f-6f8d-46a5-87ad-fb32f463f2a2">14,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIwLTEtMS0xLTA_ab37fd1d-2053-42f1-8e3e-2e5fd3098c24">11,582</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIwLTMtMS0xLTA_3e06a069-609b-472f-b652-91cf226563f8">9,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncurrent Assets of Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIyLTEtMS0xLTIyNQ_ebb85da5-a215-49ab-8e69-1d96ce0d5c7a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIyLTMtMS0xLTIyNQ_448a0e3d-f56c-41a7-9e8d-5a5674ab8321">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIxLTEtMS0xLTA_546e4f98-373f-4a69-b235-67ed2fefc9c1">105,694</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIxLTMtMS0xLTA_16d46af4-916d-4e3c-86a7-ade069fbcdc0">91,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI0LTEtMS0xLTA_e1f5e3a6-c871-4af0-8c3a-3e1182e5c560">2,412</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI0LTMtMS0xLTA_757c0ca1-e915-40f8-93ed-316cb68d23d4">6,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI1LTEtMS0xLTA_23ab7f59-6683-40e8-9f99-1cacde0d34b8">4,609</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI1LTMtMS0xLTA_0a83687c-7b2c-4053-8ec1-3c00907c4093">4,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI2LTEtMS0xLTA_5af407b3-3a32-4d5c-bc26-42f268ac8f91">13,859</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI2LTMtMS0xLTA_ab8cfb62-ee8e-4bed-9cea-0633b4dbadc3">12,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI3LTEtMS0xLTA_7c8bddea-0901-4b6c-b2ae-72620784b191">1,224</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI3LTMtMS0xLTA_5d064474-804f-469d-9ba6-9e811165a3a2">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI4LTEtMS0xLTA_b35c3071-388f-46d8-9286-02ff0884ac06">1,768</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI4LTMtMS0xLTA_89b838d4-c65f-4269-b635-eb755ed00213">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMxLTEtMS0xLTIzMg_41cf10f7-a24b-4bc4-a442-2db3865930bf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMxLTMtMS0xLTIzMg_8e498149-9f14-4d84-9215-8f3145175619">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI5LTEtMS0xLTA_a80c1640-8639-4ae1-9b64-2ec48b150a09">23,872</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI5LTMtMS0xLTA_ac47419d-58ce-479b-9d74-0d5af8105d8b">27,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMwLTEtMS0xLTA_b152454c-5f69-4b97-8a39-25f44266826a">30,690</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMwLTMtMS0xLTA_59cbcdad-54c3-4e07-8910-2662c8220341">25,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMxLTEtMS0xLTA_843e9e4a-b6e8-427c-8a9c-c0b87110cee2">3,441</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMxLTMtMS0xLTA_1a576a8b-28b4-4eed-807b-0965441c899f">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMyLTEtMS0xLTA_9dc79f90-d553-45b3-b044-d9f4e1cf2213">9,434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMyLTMtMS0xLTA_2f654fdd-3509-49a5-b82c-06c655c5eefa">12,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncurrent Liabilities of Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM2LTEtMS0xLTIzNg_f42015ac-cb6b-4b65-aba1-abbacaf8ba9b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM2LTMtMS0xLTIzNg_23e8618f-ac23-4122-95b4-b662b71554db">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV8xOQ_2c8287c4-47f4-4c17-a172-f5c5291d4a10"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV8xOQ_aeaf67c6-fc4c-47fe-ae65-dcd620621416">0.50</ix:nonFraction></ix:nonFraction> par value</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Authorized - <ix:nonFraction unitRef="shares" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV80NQ_04e7169c-aae2-4a7c-b1da-a869de70a375"><ix:nonFraction unitRef="shares" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV80NQ_d9b49194-1b02-42fc-813b-4ad339937dee">6,500,000,000</ix:nonFraction></ix:nonFraction> shares</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issued - <ix:nonFraction unitRef="shares" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV82NA_03bfcdb2-b4f0-4c7c-8072-bc9deff64e9a"><ix:nonFraction unitRef="shares" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV82NA_5e519b5b-2694-442b-bb3a-3f4ed3f0d8ca">3,577,103,522</ix:nonFraction></ix:nonFraction> shares in 2021 and 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTEtMS0xLTA_6a5edc83-4a70-41b5-897c-63ecbb8c537c">1,788</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTMtMS0xLTA_14d698ba-2839-43a1-b161-3ba3e6c5587c">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM1LTEtMS0xLTA_895822f1-f017-4a20-a3a3-046e85e3c3da">44,238</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM1LTMtMS0xLTA_f0242c1d-175b-4a8d-8c15-3e24b6a50488">39,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM2LTEtMS0xLTA_c7a7d05f-2d74-427c-a2db-435c02a53049">53,696</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM2LTMtMS0xLTA_8e3d1cb5-1228-4e67-b2ae-9db1473e5f47">47,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM3LTEtMS0xLTA_bc25d9e4-812c-40c7-a95f-5f9e0740fa3c">4,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM3LTMtMS0xLTA_cd02bbf9-ce2b-43bc-976e-5bfe54e24326">6,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM4LTEtMS0xLTA_ed8c971f-9fb4-46a3-9362-00ea468501bd">95,293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM4LTMtMS0xLTA_08650af9-a791-4541-88ef-078d6f999f5d">82,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Less treasury stock, at cost:  <ix:nonFraction unitRef="shares" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjphM2QzZGZkMmQ3MzM0MDZiODI0OTU2YWVhYTAxMzlmNV8zNQ_6a423aa5-a9b3-48fd-b356-0c2badc9de7b">1,049,499,023</ix:nonFraction> shares in 2021 and <ix:nonFraction unitRef="shares" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjphM2QzZGZkMmQ3MzM0MDZiODI0OTU2YWVhYTAxMzlmNV81Nw_023f3329-6bf0-4fd8-9788-d35b79a2bed9">1,046,877,695</ix:nonFraction> shares in 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM5LTEtMS0xLTA_7fac78ab-b185-4fd5-b0bb-98acf29e9254">57,109</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM5LTMtMS0xLTA_817aa7ae-647a-45de-b9b5-a53bcb5c1660">56,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQwLTEtMS0xLTA_5898af42-c355-43c3-9742-7a36e1bb90d0">38,184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQwLTMtMS0xLTA_e06188b3-d7af-4138-954f-b4ebcf2ac4aa">25,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQxLTEtMS0xLTA_446eb612-5fa5-4b43-b11e-15eb206ad9d6">73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQxLTMtMS0xLTA_7aff6a1d-e29c-47c5-b118-3db2c3c62f0b">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQyLTEtMS0xLTA_d1cdc249-d400-445e-8123-8e998f476bbc">38,257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQyLTMtMS0xLTA_93722287-8f46-4a2d-8293-1d7423c256dc">25,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQzLTEtMS0xLTA_86578844-6e1a-4045-9c1e-8e605260bcae">105,694</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQzLTMtMS0xLTA_9af57dbe-3d28-497a-bd61-19b0fce22224">91,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of this consolidated financial statement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statement of Equity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:41.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance January&#160;1, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i296a96e660db43169f0376b184f4d3fc_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtMS0xLTEtMA_89e5df36-634a-40a3-974c-b4c0e603412e">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i241c8aa1377540ad88e44cceb968c204_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtMy0xLTEtMA_489fb923-2cd2-43fb-bbac-cb549fe757ce">38,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2112d614d9a45828458276b54ac3348_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtNS0xLTEtMA_2144a647-db54-469b-b7e9-bd7b56d3dee9">42,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd9336867cce49919c9a776ee62bc1b2_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtNy0xLTEtMA_d040d4fb-5fad-410b-aa29-c98a8b49dc6b">5,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b062550448c4f5b877548d6eda89d15_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtOS0xLTEtMA_af67db55-006c-4262-a3b6-60710d0fd0d1">50,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib908a2ace6f544bd91b2adcb40f2f0af_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtMTEtMS0xLTA_990d7078-8999-4b97-8a44-147ff436512e">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b25cba6160a4486b14740ddd2b481ef_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtMTMtMS0xLTA_fc71de36-fec6-4609-af53-e2f66716879a">26,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e94e814bd0149bd847f2783d90c9d48_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzItNS0xLTEtMA_02bd8560-91da-428f-8b3d-3c816a060f73">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzItMTMtMS0xLTA_7f1a3f6e-f5b6-49ef-9330-1f04526a16b7">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40203e52d1c440a6b89559fa168b081a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzQtNy0xLTEtMA_f7cbb7ab-30bf-4b4a-9312-272c6ec2decd">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzQtMTMtMS0xLTA_33235937-09cd-4d32-8d18-aa6253054af7">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYzE3NzQ4MGIxMDQ1ZTY4NDcwZjhhNWEyMDVhYWMyXzQ1_3cf5dfe6-8346-4db1-a6ae-f06901532e01">2.26</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e94e814bd0149bd847f2783d90c9d48_D20190101-20191231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzUtNS0xLTEtMA_3ed79eff-fb7a-491b-9ffc-c911348e760a">5,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzUtMTMtMS0xLTA_527d74bf-2987-49ef-81bd-a8a8952e4b93">5,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0171e54cbd894628b6188119563a887e_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzYtMy0xLTEtMA_1fcd5d67-4f55-4c64-936a-4a95f0a9a284">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzYtOS0xLTEtMA_878254da-5f5c-4935-9d46-989471c1bfbf">5,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzYtMTMtMS0xLTA_67ef27ac-59b9-4017-88c5-f87ba1c0a50c">4,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3acd7fea33f491a9299de32f18ce21a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzctMTEtMS0xLTA_5b8b8582-73c9-48ee-9ecc-01c97afe39d2">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzctMTMtMS0xLTA_4bf8399e-dbc8-4d6e-b28a-27010f637a38">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3acd7fea33f491a9299de32f18ce21a_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzgtMTEtMS0xLTA_78c3a021-0739-4eb3-a469-5dbcf16b6864">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzgtMTMtMS0xLTA_86222da5-7526-41ff-a7b0-0a1c0eeb29f6">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0171e54cbd894628b6188119563a887e_D20190101-20191231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzktMy0xLTEtMA_2832d499-92c8-42b2-8501-18aebf4cc644">148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzktOS0xLTEtMA_6c188337-5bb9-47c1-8b53-ad8789a43409">759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzktMTMtMS0xLTA_cdc49d7f-a8c5-4313-a9ff-68e3647982d6">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e784cab819d451499c362b12111a27a_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTEtMS0xLTA_35175175-0f36-4c33-b83f-22303572fbd1">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01dd7de0cf6f4ace976de5b22d6ba095_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTMtMS0xLTA_0ecd0bde-6e81-4767-8be2-6e1ad7d0786a">39,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a5580f8dad412cb034d3e6ad78653f_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTUtMS0xLTA_a83caba9-3c80-4755-9c56-48d7dfff9159">46,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a458b3d31d042a4bb104dc181064e79_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTctMS0xLTA_a5ffc2a2-781a-4f46-af83-a2a9b0b64f1d">6,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e651f0bdf0a4e5c85db0a3c85be51f1_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTktMS0xLTA_baa97b90-6f44-42d1-ba3a-31d698f1613b">55,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5734fc741d6d4e0480d4a89bf0739099_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTExLTEtMS0w_99fdedc4-8e13-458b-9806-e9bb98a1a72e">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTEzLTEtMS0w_9bdba587-e8ad-4394-8400-cda103285036">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ce079367344ee799a79a4d8a61dcdf_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzExLTUtMS0xLTA_d637576e-f41b-4527-bf51-0f040cbe1add">7,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzExLTEzLTEtMS0w_04cef684-4f37-4f94-993d-710a5c580e14">7,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia95480df7b48466b8fe2970840b6d96e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEyLTctMS0xLTA_55a746da-61a7-48b8-8c8c-2267417b87eb">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEyLTEzLTEtMS0w_c32dfbe0-903c-43e9-9e16-a70bc5a7d637">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZGEwZTM0OGZmYTU0YTY5YmUxZjZkYmM0ZDY5Y2Y2MV80NQ_b774ebbf-dbf2-49e1-8a5b-c848e09eba59">2.48</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ce079367344ee799a79a4d8a61dcdf_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEzLTUtMS0xLTA_d22a887a-8c74-45ad-964a-6e7f05e1cb1c">6,307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEzLTEzLTEtMS0w_9233d961-84f7-4cd3-a4bb-fcec38559a54">6,307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE0LTktMS0xLTA_a75989e0-1df4-4d84-9ca2-3e3d835697e3">1,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE0LTEzLTEtMS0w_d4ffe6c1-790c-4118-98e3-e3307f7a3f63">1,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1468cd3ea95419fb66e7dd8d3547410_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE1LTExLTEtMS0w_3c0c641a-4540-49c8-8882-55766c41280d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE1LTEzLTEtMS0w_8a553ef6-9758-4956-b91f-1ee85d8b722a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1468cd3ea95419fb66e7dd8d3547410_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE2LTExLTEtMS0w_a78bf35b-94ac-4507-855f-fa186159063f">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE2LTEzLTEtMS0w_e2827e7d-6194-40af-85bc-269f7b7a8534">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dd27579d0594b8c836cf9cb029ccdb8_D20200101-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE3LTMtMS0xLTA_fe73d54b-9321-43e6-97f9-95244131fe1e">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE3LTktMS0xLTA_738174e3-a4ac-4a94-97da-7a2e214d8d33">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE3LTEzLTEtMS0w_afebef70-fae5-469b-af13-06bf27711104">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91e41b657e142838655904b6ffc2b4c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTEtMS0xLTA_5fc42eed-084f-4115-baaf-c7391dc06a07">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747b6da151fd47548889dcf4acf9f07e_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTMtMS0xLTA_cab66bfa-5058-43cd-b210-5fbbfc434de0">39,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629510fd09f5448784fc756b630535b7_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTUtMS0xLTA_418ebc26-6054-4657-8d9e-c8925d03b543">47,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d1f8e2c09b84254b99b8e105564e52b_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTctMS0xLTA_8e6d93a5-6dde-47d6-8992-96cfab3f9258">6,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44fbc319828d43888404b362300c8719_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTktMS0xLTA_ae93175a-198d-47ca-a1d8-fa673f2f12c7">56,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22154b3c72564c4184ae4a06c41144ca_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTExLTEtMS0w_b057d3b7-4fd5-49b2-a36d-904d3f8154ec">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTEzLTEtMS0w_56f8b8c5-d835-4cd1-8d13-0fefb849bcc9">25,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49673c36f67e4d93b4ebbe225a478e72_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE5LTUtMS0xLTA_2b71ac16-c59f-45b6-9a0c-d5a3657f0cfd">13,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE5LTEzLTEtMS0w_fa974938-c923-4a95-b26e-099e0b3ace91">13,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52711b1bf6764fd78c0ef6f9e7df950f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIwLTctMS0xLTA_ae4094b5-00d9-40e2-87f8-63829b296783">1,756</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIwLTEzLTEtMS0w_65715aea-edd4-4fa7-b33f-a8cc03ed45a4">1,756</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjozYjkwNThlODM4YTY0ZTdkOWEzYWU5NjI2OGNkMTdlZl80NQ_61e68984-0e78-49f7-ac72-e92cb5fbc451">2.64</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49673c36f67e4d93b4ebbe225a478e72_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIxLTUtMS0xLTA_83ac3102-9fef-46a6-84a4-49aa843a6f57">6,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIxLTEzLTEtMS0w_d534b2e5-4f8b-4a2a-8d97-fa53c5233756">6,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTktMS0xLTA_ddb00d4f-3ca5-45a9-bc13-abf4f13599c6">840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTEzLTEtMS0w_6962bc0b-d25f-407b-bd3b-a63b42315d88">840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Spin-off of Organon &amp; Co.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5889b314dc6846e99dfdc5dd5b0d4d4d_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTMtMS0xLTM5Nzk_0114f0dc-e91d-4fd2-a0c6-d911662a294b">4,643</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52711b1bf6764fd78c0ef6f9e7df950f_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTctMS0xLTM5ODI_1ad466d9-f128-4e20-a4bc-b9b79970d07e">449</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fb199531c9a4be79a55f354540b66f2_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTExLTEtMS0zOTg4_4e112ff7-e5c9-4e44-916a-a4938b992bb3">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTEzLTEtMS0zOTg4_510092d7-0021-477c-a2ba-3af38692f1e6">5,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb199531c9a4be79a55f354540b66f2_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIzLTExLTEtMS0w_2b344edc-1a07-4a75-a0d3-225f13211a63">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIzLTEzLTEtMS0w_27063127-842a-4bb0-8403-315213acdae4">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fb199531c9a4be79a55f354540b66f2_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI0LTExLTEtMS0w_6c59251f-aa07-4873-859d-08652e6571b3">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI0LTEzLTEtMS0w_6d38de5f-e0d6-447a-b76a-06401c12f241">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5889b314dc6846e99dfdc5dd5b0d4d4d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI1LTMtMS0xLTA_bf736118-7cf2-49d7-916a-201e4a262881">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI1LTktMS0xLTA_699e879e-05cf-40e2-90e6-c217c1da0f1f">518</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI1LTEzLTEtMS0w_c3c07038-e321-4110-aa4d-9d4dd0923c69">525</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5771d34675734e438d53901618ffd853_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTEtMS0xLTA_2af6cbbe-f076-456c-b6c0-15b127c14d02">1,788</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2a1e33e2f04030829641bc2c24a05c_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTMtMS0xLTA_c880487d-dc9d-414d-b5bd-20f04a8c99c9">44,238</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9a7df047274290ad191b1e08bfc7ee_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTUtMS0xLTA_84c06c69-6b07-4b72-9dd2-8629c8d79365">53,696</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i333ee6c0baa94ce7a67cc850a8d3a772_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTctMS0xLTA_5f8b8515-7ca9-4ae5-91fb-6d9ff7f9967f">4,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10c6f9da4227441da8480f88901779b2_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTktMS0xLTA_d87c8e83-028e-4a68-8d44-350304968543">57,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020c181c0f60421080b1a0cdcce948b8_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTExLTEtMS0w_a91e2cb1-806f-40fd-a1d9-d44c78e99f0d">73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTEzLTEtMS0w_7cc276d9-f8db-4834-b501-e39ef1027b20">38,257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of this consolidated financial statement.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statement of Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">($ in millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:69.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzItMS0xLTEtMA_18521275-470d-49c9-863a-b2a27105df60">12,358</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzItMy0xLTEtMA_63699d28-e2d4-4de4-99d8-1f7cfd9ae34c">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzItNS0xLTEtMA_617814d0-b732-4e36-ac2d-5a57c6a98c0f">5,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQtMS0xLTEtMA_ac13e178-3522-4756-aa89-c461e0e3064b">1,636</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQtMy0xLTEtMA_d07a2ba3-8559-4b64-802e-b92d3650d16f">1,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQtNS0xLTEtMA_47a039d4-50ff-4e5c-a021-93fe8065fb19">1,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUtMS0xLTEtMA_862dfdab-ff7c-4ba5-9341-1717ea119954">1,578</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUtMy0xLTEtMA_ca28db63-b4c9-4840-aa00-50dd28fecbd6">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUtNS0xLTEtMA_b7b35b8f-befd-40ce-bcde-37f973833ffe">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzYtMS0xLTEtMA_d651607f-d1d7-478b-a5c8-f01111c5047c">302</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzYtMy0xLTEtMA_ff46211a-95a0-48fc-98d5-eb0f1a2c1a3c">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzYtNS0xLTEtMA_3931e30a-c319-4834-98a5-0955ddb17791">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Income from investments in equity securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMS0xLTEtMjcyMDI_cc0d0dcb-cf38-4eb6-9548-7cb0a41c2e65">1,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMy0xLTEtMjcyMDI_e31ec640-fcaf-4f2c-9567-9ca7490e9163">1,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctNS0xLTEtMjcyMDI_e3fb56bd-5552-4821-9af7-048e954dd174">170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Charge for the acquisition of Pandion Therapeutics, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMS0xLTEtMzQ5_d5a7ade7-f3ef-486e-bab1-72f0d3f9538a">1,556</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMy0xLTEtMzQ5_e96a60e6-e230-4b19-a0e0-aca9307958ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctNS0xLTEtMzQ5_83184db3-c661-487a-857d-c8fb8d7c7180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Charge for the acquisition of VelosBio Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMS0xLTEtMA_1b4f5c14-e0fc-47db-bbb6-2bd091062ebc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMy0xLTEtMA_61d6bd96-31bc-4e2a-b8ef-529e83cece25">2,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctNS0xLTEtMA_3ad4b2bf-4d93-4416-b4b3-35198a613d6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Charge for the acquisition of Peloton Therapeutics, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzgtMS0xLTEtMA_06cdbc4f-2f00-4938-a379-f80a3cdd9611">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzgtMy0xLTEtMA_2d468631-03e9-4a70-9095-37569c013059">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzgtNS0xLTEtMA_9f15e317-2a40-4774-ba1f-dbcd338a3faa">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEwLTEtMS0xLTA_73e3c463-9a1f-4c94-9088-6e4046ae020b">187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEwLTMtMS0xLTA_2279143b-ace1-4f21-9274-ff76b4a59fbe">566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEwLTUtMS0xLTA_e0190d70-84e7-4581-b40f-580bb9bcd6ff">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzExLTEtMS0xLTA_1a9d1a00-7129-4d20-ba1b-97fe5a22e804">479</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzExLTMtMS0xLTA_44ffe05e-d348-444e-b32e-f936e846931e">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzExLTUtMS0xLTA_4b1405ea-e0ac-4353-a220-0a199f679515">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEyLTEtMS0xLTA_f6451dc0-9b84-4442-be0b-a33263299558">805</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEyLTMtMS0xLTA_73d638c4-e278-41fc-a341-da5e4f22275e">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEyLTUtMS0xLTA_09e9735a-0881-43f6-a3e9-024a0cbd18a4">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE0LTEtMS0xLTA_cb162f52-95cf-40ab-85f3-ac768aa338c5">2,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE0LTMtMS0xLTA_305151f9-37cb-493c-b8e0-51ed3ea103da">1,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE0LTUtMS0xLTA_d463f052-b10e-44d3-b5c2-de8a8c00fdbe">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE1LTEtMS0xLTA_984d44b2-eeef-4433-a102-00a80be65649">674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE1LTMtMS0xLTA_e2c166e0-a306-4163-b266-e300a460cc24">895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE1LTUtMS0xLTA_1142218e-c6c4-4a05-968e-e41959bd51c2">473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE2LTEtMS0xLTA_c4f27af8-048b-4d2f-885c-a2c17582c384">405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE2LTMtMS0xLTA_6190d1ba-86e1-4771-a431-dbbe37ef812e">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE2LTUtMS0xLTA_632edd88-c489-4a6f-b7a2-8205628f453b">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE3LTEtMS0xLTA_c08e8c2c-ae6f-499b-98e1-b7fda5f9d72f">277</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE3LTMtMS0xLTA_4d3c53e0-f1cd-4604-9043-781056457057">1,152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE3LTUtMS0xLTA_ad8f6f0f-914c-48b9-923e-aaac0ebfaa4d">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE4LTEtMS0xLTA_52be77c6-44cf-4a90-8bc3-347f22f2ef3c">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE4LTMtMS0xLTA_e6ce017d-4067-4410-9b49-4d72118834f3">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE4LTUtMS0xLTA_5fef6116-7aef-4d82-85a7-12b5012b0c97">1,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE5LTEtMS0xLTA_1fef4eba-a691-4396-a0d8-60371060db99">484</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE5LTMtMS0xLTA_58b673d9-82c5-43cd-aa48-9c19cc718f9e">617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE5LTUtMS0xLTA_52adc9a2-8e06-4c21-b8ad-bb816910bdd6">733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIwLTEtMS0xLTA_11dbc501-3801-4a00-94cb-a62460a949eb">1,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIwLTMtMS0xLTA_51539ed5-6ed1-4e81-ab9b-e3f7daa0e6b6">2,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIwLTUtMS0xLTA_0fc8c323-9846-48e9-8845-609f61f154e9">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net Cash Provided by Operating Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIxLTEtMS0xLTA_e0a4fcca-7ccd-4159-8c36-fbcbc2226b5b">13,122</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIxLTMtMS0xLTA_d10b5db1-a276-43d4-8037-ca9793263b64">7,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIxLTUtMS0xLTA_0c9bad9d-5ae8-4a17-9fd9-d47e5755ab97">8,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIzLTEtMS0xLTA_2bba2918-5ae3-4e1f-9a7c-78fa40992f35">4,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIzLTMtMS0xLTA_ddaa5983-3525-442b-a173-867ebead8518">4,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIzLTUtMS0xLTA_f46cf3a0-3575-45ff-9e5e-c70dc6d32384">3,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Purchase of Seagen Inc. common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI0LTEtMS0xLTA_6d0ec6c0-af3c-490e-8e8a-03d9fd9a0d4b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI0LTMtMS0xLTA_9f9efb07-5333-4e5b-bc08-d2ee37e5f474">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI0LTUtMS0xLTA_72b0da84-864e-40f0-8d89-bbd0bb963994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Purchases of securities and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI1LTEtMS0xLTA_d17b03b1-3fe5-4a1e-b744-8852ac9f6770">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI1LTMtMS0xLTA_7cb51c6a-7f70-4104-a873-71ec0e11d879">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI1LTUtMS0xLTA_9f21bc94-fbfc-481c-aead-77ec9f90085b">3,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Proceeds from sales of securities and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI2LTEtMS0xLTA_88b61f0b-5508-4ab7-8250-c40bbd282912">1,026</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI2LTMtMS0xLTA_788c709a-00c9-494d-9ad9-b5dd08943202">2,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI2LTUtMS0xLTA_586f5360-dc58-40bc-b709-1f310d8be0d7">8,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Acquisition of Acceleron Pharma Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTEtMS0xLTMwODI1_d1dfe9ae-b6c2-4b14-b9b5-0eb11ed7ad30">11,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTMtMS0xLTMwODI1_97ed436c-2fda-4b3a-bc4f-1bd47fed0a1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTUtMS0xLTMwODI1_a2da1116-9eaa-4062-8d51-144089f68e8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Acquisition of Pandion Therapeutics, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTEtMS0xLTM2MQ_244777cd-d0aa-4064-a05e-faf76db990df">1,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTMtMS0xLTM2MQ_64e41939-af7a-413c-9190-55d3ee409b9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTUtMS0xLTM2MQ_2d7de3bf-f7f5-49b2-8f44-a49be6877c9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Acquisition of VelosBio Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTEtMS0xLTA_977cc2d8-b2d0-48a1-a04a-01d04418d39a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTMtMS0xLTA_4be79c44-c78d-4484-990b-3913a2539d74">2,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTUtMS0xLTA_0a4b6000-5a56-4117-96a0-a8d79d4f3060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Acquisition of ArQule, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTEtMS0xLTA_296a7926-7b42-43a7-9d43-d06a3a6065bb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTMtMS0xLTA_3557826c-9e99-42ed-9cee-7b9ec3828437">2,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTUtMS0xLTA_f4c2f99f-4306-400f-81ba-925388e26b3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Acquisition of Antelliq Corporation, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:PaymentsToAcquireBusinessSixNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI5LTEtMS0xLTA_7ad61afc-905f-4562-ac7a-edc38ab4f234">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:PaymentsToAcquireBusinessSixNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI5LTMtMS0xLTA_17a7fcaa-5919-4b6d-9563-29c81abec790">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:PaymentsToAcquireBusinessSixNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI5LTUtMS0xLTA_5bd84aad-d174-4453-8e00-8ff56410bd62">3,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Acquisition of Peloton Therapeutics, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:PaymentsToAcquireBusinessSevenNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMwLTEtMS0xLTA_21f016e6-c7bb-4ac0-bc00-1e0fca0937cf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:PaymentsToAcquireBusinessSevenNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMwLTMtMS0xLTA_ab828225-3844-4e74-95cb-03d8eb05cae4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:PaymentsToAcquireBusinessSevenNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMwLTUtMS0xLTA_7d20f158-3bd3-49a9-bb7c-5c39e3194524">1,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMxLTEtMS0xLTA_85012c7d-b156-435d-a153-f855fe512d14">179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMxLTMtMS0xLTA_d72a8b81-35c5-4e92-9f17-40e4f4cf1327">1,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMxLTUtMS0xLTA_a28109f9-0cc9-4e13-b816-fc859d441f15">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMyLTEtMS0xLTA_39f0a70f-32ca-47cf-82e0-6e5eb9a0638f">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMyLTMtMS0xLTA_1210635d-4493-4b01-9d43-301338f165e1">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMyLTUtMS0xLTA_bf0c0dac-e92c-4297-9da3-55116ec00b7d">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMzLTEtMS0xLTA_cf9a6e32-d997-43aa-96a0-64de0014c4f6">16,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMzLTMtMS0xLTA_1dda5f7f-4f1c-4e0c-b426-f4613c1c565c">9,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMzLTUtMS0xLTA_5946b379-d804-4a9d-925f-f604900db97a">2,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM1LTEtMS0xLTA_f075454f-315f-4d95-af14-0f50822e7702">3,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM1LTMtMS0xLTA_8f44f53a-866c-416c-886f-003ccc2de11c">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM1LTUtMS0xLTA_86cd2179-cd70-4a47-a663-01cb702ff597">3,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Payments on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM2LTEtMS0xLTA_c5187021-3f97-4ee7-a655-91ee0f44fe62">2,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM2LTMtMS0xLTA_0a08f0d1-6e05-4709-b604-f5a76e3ee381">1,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM2LTUtMS0xLTA_b994d496-9581-4cc8-a651-52b895835aea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Proceeds from issuance of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM3LTEtMS0xLTA_d7f84f0c-1722-4e42-880f-6084e65adf28">7,936</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM3LTMtMS0xLTA_6fff5615-7286-4dc6-abd5-6dfec8cf0d9b">4,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM3LTUtMS0xLTA_0495f626-b6c2-4300-8e0b-5dc1a671a0f2">4,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Distribution from Organon &amp; Co.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTEtMS0xLTI3MjM5_5e2843be-9fca-4142-b274-bca9061b0b68">9,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTMtMS0xLTI3MjM5_84441b2a-3955-4a25-92d2-dea8dbfcd687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTUtMS0xLTI3MjM5_2543d47f-b099-4b39-b8c3-b24ee475dbee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM4LTEtMS0xLTA_0aab910c-b95f-4e80-815a-fe72a7d6bd4c">840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM4LTMtMS0xLTA_067a3151-6d65-4fac-bc97-d54c97558867">1,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM4LTUtMS0xLTA_136c3624-19cd-45f0-8c6b-e86109b072b4">4,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Dividends paid to stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM5LTEtMS0xLTA_fb91928e-d6b7-4e01-b7ec-893c6845214b">6,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM5LTMtMS0xLTA_ab087481-ec6d-4077-9b00-277ee5878d0b">6,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM5LTUtMS0xLTA_39ab1d13-630f-47fe-9220-c76202b78666">5,695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTEtMS0xLTA_600c9a76-0ce7-46ab-a301-93860cffe7cd">202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTMtMS0xLTA_7dfdc3be-dca0-4858-bcd6-b8837979e8c0">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTUtMS0xLTA_984cd637-fc1c-433e-a42b-69a8bb3088aa">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQxLTEtMS0xLTA_3f7a0a78-6efa-4768-bf02-b3b9d972d7fe">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQxLTMtMS0xLTA_4cc87bd7-05e0-434d-9e85-205188b69166">436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQxLTUtMS0xLTA_0dd1e382-6946-4c70-81d1-6145eea6b66c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net Cash Provided by (Used in) Financing Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQyLTEtMS0xLTA_00d19f7e-003f-42bc-97a4-9d24cb514517">3,097</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQyLTMtMS0xLTA_23c54f83-a95d-4662-8b14-019ceac13178">2,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQyLTUtMS0xLTA_d0acc823-92c5-4c1c-abbe-9a3671a44376">8,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTEtMS0xLTI3Mzcy_920eaa2e-6850-43ce-8862-8042be8fcb67">987</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTMtMS0xLTI3Mzcy_b441fab9-7c9c-4469-9c35-23d905199335">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTUtMS0xLTI3Mzcy_c4579d23-2394-4b43-b490-c826cf49d4d5">4,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ3LTEtMS0xLTI3Mzcy_385ba00c-b2ae-4fe4-b234-4486f9e18fbd">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ3LTMtMS0xLTI3Mzcy_3012af77-cd80-4d10-a6ae-27c072bf9a05">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ3LTUtMS0xLTI3Mzcy_a2c1847e-af84-49c9-ac5f-205aaa81c254">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ4LTEtMS0xLTI3Mzcy_c6320ddc-7515-4426-8c54-09d5ab6bcd0a">504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ4LTMtMS0xLTI3Mzcy_56313de4-a9ef-4ba3-874c-6ad4c964e5da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ4LTUtMS0xLTI3Mzcy_73dd4689-932d-49fc-bb8c-32e52f0431d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net Cash Flows Provided by Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUwLTEtMS0xLTI3NDA5_e089510b-a880-4ffe-814e-b02a508b55b0">349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUwLTMtMS0xLTI3NDEy_3db7b2c3-0e0e-4e2c-812f-35746ccc140e">2,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUwLTUtMS0xLTI3NDE1_46aaa6e1-1643-40a4-9f9f-1d007f28d882">4,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQzLTEtMS0xLTA_f0d638dd-4f62-4166-9709-851519570aed">133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQzLTMtMS0xLTA_7b8b2446-e46c-48cb-ae5e-2bb058a26cfb">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQzLTUtMS0xLTA_0e0e4241-281b-462e-8c96-cd4b79d05d71">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ0LTEtMS0xLTA_80859024-76d9-4794-87c4-afc05eb9ad30">14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ0LTMtMS0xLTA_520c44bc-12e1-4ad9-8205-0ec97bac474f">1,769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ0LTUtMS0xLTA_51194b29-8883-45b2-8f20-d3f77b4e0532">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjozMmJjNTc4NjJjMGI0MTkxOGE4NWRkYzIzMDUyMjZlNl83OA_d18a870a-e489-48cd-a4dd-518633fcbc27">103</ix:nonFraction> of restricted cash at January 1, 2021 included in Other Assets - see Note 7)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ1LTEtMS0xLTA_3e222830-3ecf-4146-ba89-50d518dcc9d5">8,153</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ1LTMtMS0xLTA_e0903fe4-43d2-4550-9526-f36ba9c8fd11">9,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b25cba6160a4486b14740ddd2b481ef_I20181231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ1LTUtMS0xLTA_0eb5cb76-9a91-4784-bd40-45d93d44f3ae">7,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Less: Cash and cash equivalents related to discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzU0LTEtMS0xLTI3NTU1_9a3fb545-1fa0-46f4-a968-63da1233a067">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzU0LTMtMS0xLTI3NTU1_b8ad4163-81e2-482d-91d6-53e857848c70">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzU0LTUtMS0xLTI3NTU1_a2f58079-ecbb-4fe3-816e-56f8d1c7ef5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at End of Year (includes $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZDM1MWRjNGE4Y2Y0MWEyOThlZmU5NGIzZGFhOTUxZV83Mg_7b55fd53-9c23-48a9-ac32-4f00200ecc99">71</ix:nonFraction> of restricted cash at December 31, 2021 included in Other Assets - see Note 7)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTEtMS0xLTA_71942e21-bbb9-41be-bed5-4ca795183046">8,167</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTMtMS0xLTA_289ae0cb-57c0-48c1-ae43-cd09d279aaca">8,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTUtMS0xLTA_ef4b5a9c-63c7-4e93-8ac1-a8feb705f302">9,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of this consolidated financial statement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_145"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDUvZnJhZzpmNmJlNjA3MzFkODA0NmE1OTM4MDg4NTIwNDVmMDlkNy90ZXh0cmVnaW9uOmY2YmU2MDczMWQ4MDQ2YTU5MzgwODg1MjA0NWYwOWQ3XzM2Mjk_661fe58e-576e-4426-b093-abe03342aab0" continuedAt="i8423cb64a3434d7e893c351d77fbed7c" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="i8423cb64a3434d7e893c351d77fbed7c"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#8217;s operations are principally managed on a products basis and include <ix:nonFraction unitRef="segment" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDUvZnJhZzpmNmJlNjA3MzFkODA0NmE1OTM4MDg4NTIwNDVmMDlkNy90ZXh0cmVnaW9uOmY2YmU2MDczMWQ4MDQ2YTU5MzgwODg1MjA0NWYwOWQ3XzMyMQ_7275f4f7-3683-45e4-961b-f351e907f254">two</ix:nonFraction> operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin-Off of Organon &amp; Co. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off (see Note 3).</span></div></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_148"></div><div style="margin-bottom:6pt;margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjQw_b77b6bcd-7f01-4767-b266-e8702fc391b1" continuedAt="i5c475ecb931d49b49076a71b47851533" escape="true">Summary of Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i5c475ecb931d49b49076a71b47851533" continuedAt="i172e74d890084f8a924fa75852fc3f26"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTYy_ca27e6c2-a2c2-4404-97e7-15833e6537f4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#8217; interests are shown as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTQx_f715607d-57af-4be7-988a-1916d55da175" continuedAt="i130744245d69409f9f9c5e52474c6035" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i172e74d890084f8a924fa75852fc3f26" continuedAt="if72013c9af274e709f155c83ad65b8b2"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i130744245d69409f9f9c5e52474c6035">defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</ix:continuation></span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTA5_c32c77a4-cf79-43b4-ad1e-b55fe2e76a10" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NDY2_a32fa0e1-a15d-431b-a40d-d0f2a6013d3c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTMx_a16ee105-a551-452e-866a-31f98168c83e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTAy_ad01a300-1e70-4d65-aac9-893f02373be7" continuedAt="ib051a03f6de74c999e9a9fecff1254db" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#8217;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="if72013c9af274e709f155c83ad65b8b2" continuedAt="i245eab19873c47ff8d4bcf1f4cf39cd0"><div style="margin-top:6pt;text-align:justify"><ix:continuation id="ib051a03f6de74c999e9a9fecff1254db"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTg3_1a88ee29-bc03-40dd-84aa-b849222fb6b2" continuedAt="i84a83bd9eb8d45c29ecb0f7b0191e58e" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#8217;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzk2MTg_a2cfeae7-8173-46ff-929d-3e80b440fc76">12.3</ix:nonFraction> billion in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzk2Mjg_10ffe377-75f6-4253-840d-e5c582239270">11.4</ix:nonFraction> billion in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzk2NDE_31ca5b07-f4c0-4edb-a367-c348522face7">9.9</ix:nonFraction> billion in 2019. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:AccrualForChargebacks" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzExMzg3_9528a693-e419-4546-b46a-5255ba2fdd88">207</ix:nonFraction> </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i245eab19873c47ff8d4bcf1f4cf39cd0" continuedAt="ie3d8024c4f944cdf970f4c75a1ad3013"><ix:continuation id="i84a83bd9eb8d45c29ecb0f7b0191e58e"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="mrk:AccrualForRebates" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzExMzk0_af85f9cc-8da2-4b45-9c12-c0a74048f004">2.6</ix:nonFraction> billion, respectively, at December&#160;31, 2021 and were $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="mrk:AccrualForChargebacks" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzExNDI3_358c693a-954b-4acc-84b1-d31b6171145c">208</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-8" name="mrk:AccrualForRebates" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzExNDM0_54ca717f-9f96-4923-a17e-6ac8b4705965">2.6</ix:nonFraction> billion, respectively, at December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzUz_b48cccc3-76a0-476d-bb80-193b05cdb46c">three</span> to <ix:nonNumeric contextRef="idbf378454e1d4b12a87f05c8d4852a45_D20210101-20211231" name="mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzU5_f1105399-c44b-47b8-a665-2bb3affb85a8">six months</ix:nonNumeric> before and <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzcz_356a7fd8-93c8-420f-9280-d8946dbb7551">12</ix:nonNumeric> months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically <ix:nonNumeric contextRef="i48e19dcf50aa4fd1ae7e9d3a8ea60763_D20210101-20211231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyOTc5_335d8d3d-20c0-4c38-b71f-61c735df76ba">36</ix:nonNumeric> days from receipt of invoice and for U.S. animal health customers are typically <ix:nonNumeric contextRef="i3ef868a5ade24c99b03f00ffa9481beb_D20210101-20211231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzMDYy_439acd79-2f01-43eb-880c-a8b8bada9526">30</ix:nonNumeric> days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to <ix:nonNumeric contextRef="i3844e8babf814713b968b4e3c289a5c6_D20210101-20211231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzMTkz_cefb6577-e390-441e-b987-7dfa8f716f98">90</ix:nonNumeric> days. Outside of the U.S., payment terms are typically <ix:nonNumeric contextRef="i42166b8ad497486faa87ed01b29e3d22_D20210101-20211231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzMjYw_9f1b9660-e6e9-4113-9ed3-4fde1b4d0f01">30</ix:nonNumeric> days to <ix:nonNumeric contextRef="i74c24ba602a542c0b8c9b0ef7ed35ee3_D20210101-20211231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzMjcx_55135472-a634-4125-8f07-31762d3eea1d">90</ix:nonNumeric> days, although certain markets have longer payment terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for disaggregated revenue disclosures.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTU2_447bd28c-61a0-4a6d-9b12-889a8cb3571a" continuedAt="id25ee4bbce3340d9a3af5bb7208bd078" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from <ix:nonNumeric contextRef="iad274281f336490a9ef2ec84cddc2518_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNjE0_45386768-4340-4d43-9a48-0758ecffe08c">25</ix:nonNumeric> to <ix:nonNumeric contextRef="i5f1aaf80bf5248b6b6375fd958a9e703_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNjIw_550b6b84-3630-4fce-88cd-92f01abca183">45</ix:nonNumeric>&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and from <ix:nonNumeric contextRef="ib66800d952274b52b8a0a168fe298ecc_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNjUz_f5180bb5-206a-4eca-b93b-d73387bb74e4">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i0b1ac66b90724fe18f56ea110536b64b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNjU5_88984db1-0a67-4435-ac07-48dece48e515">15</ix:nonNumeric>&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id25ee4bbce3340d9a3af5bb7208bd078">.</ix:continuation> Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-8" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNzQy_5db35aa1-58d2-4767-9f2f-0eeb567527f5">1.6</ix:nonFraction> billion in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-8" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNzUy_ed7c909d-4690-4a14-828e-8c3dd3cbb3de">1.7</ix:nonFraction> billion in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-8" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNzY1_f33a1246-4eb3-4c6c-ba4a-d030f830eb17">1.6</ix:nonFraction> billion in 2019.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTAz_791fee9a-282c-4a4e-af85-956fc4bebe61" continuedAt="i6a3c4c1be2f046ff8e5344fea299e036" escape="true">Advertising and Promotion Costs &#8212;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6a3c4c1be2f046ff8e5344fea299e036"> Advertising and promotion costs are expensed as incurred.</ix:continuation> The Company recorded advertising and promotion expenses of $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzOTI2_2544828b-456e-42c3-974b-2ad6ad826677">2.0</ix:nonFraction> billion in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzOTM2_62df5e15-f01c-4911-bf22-644ef11fce5d">1.8</ix:nonFraction> billion in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzOTQ5_9b44e284-578b-40bb-be1e-0a47b5d6e57a">1.9</ix:nonFraction> billion in 2019.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:InternalUseSoftwarePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjA5_0ad92a21-4589-4f7a-b29e-ef6994b30cd5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from <ix:nonNumeric contextRef="i8be0b42ed8034d95ba4e13ab6fbbf535_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzE0NTQ3_2754b76f-0085-41b6-b62a-82528384df48">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i4b030dcad117451495b0cce71d1a6fc8_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzE0NTUz_80c3f5a9-e923-4259-84cc-8d13cf155fd8">10</ix:nonNumeric>&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NDkw_e9e4ccba-b707-4b0c-b7dc-9302346ada73" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjU2_7297affe-ec23-4bc8-aa8d-10d190e0ebf2" continuedAt="i5490b69fda624b688a395c8dc231fe0e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from <ix:nonNumeric contextRef="ic1a2739cca2046f0abc863ed20b48d0b_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzE1OTA1_8742aa42-a567-4db9-b08f-1d3a3522031e">2</ix:nonNumeric> to <ix:nonNumeric contextRef="idbf378454e1d4b12a87f05c8d4852a45_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzE1OTEx_a0a077b8-b81e-437b-8abe-b0dc4117ca5a">24</ix:nonNumeric>&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ie3d8024c4f944cdf970f4c75a1ad3013" continuedAt="i11b9353b5f9143608f13ff98f296e175"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5490b69fda624b688a395c8dc231fe0e">future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</ix:continuation></span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTM2_1ba5373c-fd07-4feb-a973-e8f20205c35b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="mrk:ContingentConsiderationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTU4_1edac947-ac1b-4dba-8353-a52503aa4b68" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjQ0_6b604580-e25c-404c-8b88-26d1570542c2" continuedAt="i21e310de44be4f79b21fc7cfc8dc4b1c" escape="true">Research and Development&#160;&#8212;&#160;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i21e310de44be4f79b21fc7cfc8dc4b1c">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTkz_4877d869-5133-48e1-80a5-3c4ca39ef2f4" continuedAt="i9f7705d9f1334a609d5387aeab5de4f9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i11b9353b5f9143608f13ff98f296e175" continuedAt="ice4d6ca475ea448abc7a377335db2b81"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:continuation id="i9f7705d9f1334a609d5387aeab5de4f9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></ix:continuation></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjIw_bbbadda6-196f-4fdb-9499-390b798ab326" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NDg4_ee265a1e-3bec-4020-9741-ac4f5b7547da" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjYw_d696f261-833d-4c5d-8220-2febebbb5ef2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTA3_36e622a6-0dcb-4570-a330-fbb3f8fd0924" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income from Continuing Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NDk5_c7582492-d9f7-4c7c-8047-f342b1573f1a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTc1_3f21053e-bf55-412a-8547-75c6baaee524" continuedAt="ic8c332cac9e04be7ab5c11ffb7e4b610" escape="true">Reclassifications&#160;&#8212;&#160;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8c332cac9e04be7ab5c11ffb7e4b610">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ice4d6ca475ea448abc7a377335db2b81" continuedAt="i4aed37ec74464728949920de6896a976"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjEy_3e780737-fec6-40dd-8323-b1ab6b91bedc" continuedAt="i471f8bc5c2284ae3965898175affb397" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued amended guidance on the accounting for convertible instruments and contracts in an entity&#8217;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The amended guidance is effective for interim and annual periods in 2022. The application of the amendments in the new guidance are to be applied either on a modified retrospective or a retrospective basis. There was no impact to the Company&#8217;s consolidated financial statements upon adoption on January 1, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards&#160;Not Yet Adopted &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements. The Company is progressing in its evaluation of LIBOR cessation exposures, including the review of debt-related contracts, leases, business development and licensing arrangements, royalty and other agreements. The Company has amended certain agreements and continues to review other agreements for potential impacts. With regard to debt-related exposures in particular, all existing interest rate swaps linked to LIBOR will mature in 2022. The Company is still evaluating the impact to its LIBOR-based debt. Based on its evaluation thus far, the Company does not anticipate a material impact to its consolidated financial statements as a result of reference rate reform. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have a material impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4aed37ec74464728949920de6896a976"><ix:continuation id="i471f8bc5c2284ae3965898175affb397">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to the company&#8217;s financial statements. The guidance is effective for annual periods beginning in 2022 and is to be applied on either a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_2102"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM3NjQ0_726e36a1-ec5f-476f-a44b-a32025ef5865" continuedAt="i57cac2db79234609b565b439a8fb373f" escape="true">Spin-Off of Organon &amp; Co.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i57cac2db79234609b565b439a8fb373f" continuedAt="i7f44b3dfab7548608c05c50444ebbf9c">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one-tenth of a share of Organon&#8217;s common stock for each share of Merck common stock held by such shareholder. The </ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i7f44b3dfab7548608c05c50444ebbf9c" continuedAt="i7d3f6d069c9842bb86079565d7783561"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $<ix:nonFraction unitRef="usd" contextRef="ib1098dc170e941f38477fba57b8cf5ae_I20210602" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NTEx_5b9972f3-1da7-4c4e-b282-a7c6870ec0fd">9.5</ix:nonFraction>&#160;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NTI1_c7aa325b-ec98-4212-8e15-b91dd1fddda5">9.0</ix:nonFraction>&#160;billion were distributed by Organon to Merck in connection with the spin-off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within <ix:nonNumeric contextRef="if2498efe88024feb8dbf6cebe7b9e1c4_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NTU4_613fd8f2-0d08-483f-baa0-a00cdf1e5766">25</ix:nonNumeric> months following the spin-off. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture and supply certain formulated pharmaceutical products for Organon, and (c) package and label certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from <ix:nonNumeric contextRef="id35e3e3e253f4a6eb98018307707afde_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NjA1_a7f8a2b7-0062-48c8-97bf-11db18177e20">four years</ix:nonNumeric> to <ix:nonNumeric contextRef="i16aa05ee3ee141d2ace6ce8e2e932362_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NjI0_878a62a1-be7f-4113-9fa7-3c49b2fe3641">ten years</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in the consolidated statement of income for the above MSAs include sales of $<ix:nonFraction unitRef="usd" contextRef="iaeb5df78dae84a27b551e06a2a2ae854_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF80Mzk4MDQ2NTMyMjc5_a110911a-b550-40f4-b75f-053f60f2f467">219</ix:nonFraction>&#160;million and related cost of sales of $<ix:nonFraction unitRef="usd" contextRef="iaeb5df78dae84a27b551e06a2a2ae854_D20210101-20211231" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF80Mzk4MDQ2NTMyMjkz_900758ce-2a02-44e1-b2b5-feb9572a87be">195</ix:nonFraction>&#160;million in 2021. Amounts included in the consolidated statement of income for the TSAs was immaterial in 2021. The amount due from Organon under the above agreements was $<ix:nonFraction unitRef="usd" contextRef="i162cf24607d24678bb2c7252e0441829_I20211231" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0Nzkz_a0c7792a-708e-4b4c-8dc2-f2e1f2fc977d">964</ix:nonFraction>&#160;million at December&#160;31, 2021 and is reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount due to Organon under these agreements was $<ix:nonFraction unitRef="usd" contextRef="i162cf24607d24678bb2c7252e0441829_I20211231" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0ODA3_85a5f271-0115-4447-b3a4-a6213d4e7fcb">400</ix:nonFraction>&#160;million at December&#160;31, 2021 and is included in A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ccrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the women&#8217;s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company&#8217;s consolidated statement of income as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through June 2, 2021, the date of the spin-off. Prior periods have been recast to reflect this presentation. As a result of the spin-off of Organon, Merck incurred separation costs of $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM3NTcx_7953811b-f545-42a8-8358-d945f301b28b">556</ix:nonFraction>&#160;million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM3NTg1_816e071d-1fd5-4aa8-84fd-ffa7d4aa1170">743</ix:nonFraction>&#160;million in 2020, which are also included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. As of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i7d3f6d069c9842bb86079565d7783561" continuedAt="iec752e54167b4d978dbe91384fbf77ca"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM3NjQz_24da022f-e7ce-4446-8376-7764605d662c" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xLTEtMS0xLTMzODk_73d1a0d4-5c8c-4a8f-b088-9d0968e8dbc5">2,512</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xLTMtMS0xLTMzOTM_960e501a-8382-4674-8386-1563384ff9e0">6,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xLTUtMS0xLTM3MzE3_00a5c606-571a-4f34-9c50-12b26f3b25d2">7,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8zLTEtMS0xLTMzODk_259122f4-6242-4c92-9ef9-cde1eb8262a5">789</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8zLTMtMS0xLTMzOTM_1c5e8360-7466-472c-9c11-83639a88aff1">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8zLTUtMS0xLTM3MzE3_c9415951-ebcd-44c6-9434-54c90f60abf7">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV80LTEtMS0xLTMzODk_1e3ae89a-6df1-4427-b956-fef2c8fba300">877</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV80LTMtMS0xLTMzOTM_2a2ee812-b06c-4b39-9f61-100f6ad033b1">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV80LTUtMS0xLTM3MzE3_b4f9e08c-fb9f-4abc-8754-0a53d010a86d">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV81LTEtMS0xLTMzODk_338217a2-d112-4358-800f-8f10478e714f">103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV81LTMtMS0xLTMzOTM_459aac6c-75c5-4492-90fc-7bd98e2eab53">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV81LTUtMS0xLTM3MzE3_777f72f4-c0b2-4cda-a9e2-51e43a2f6daa">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV82LTEtMS0xLTMzODk_df399f66-ad41-41ce-9a17-5da9e73032d5">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV82LTMtMS0xLTMzOTM_c04e042f-7416-4316-b7b0-e8b0a73b1e8f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV82LTUtMS0xLTM3MzE3_13bd04d9-aa0e-447c-9f18-a32589d643bc">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV83LTEtMS0xLTMzODk_6cb0c61f-22e8-4952-8c51-50b7d7175a64">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV83LTMtMS0xLTMzOTM_0b3e7d06-0646-4341-951d-b624756834e7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV83LTUtMS0xLTM3MzE3_1581a32a-8be3-44ff-a8cc-ab13fde1b295">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV84LTEtMS0xLTMzODk_d34d5d4d-3055-48d1-87c5-12bb4032e2aa">1,755</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV84LTMtMS0xLTMzOTM_0e334052-f920-4fd7-ac1b-c477a128287e">3,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV84LTUtMS0xLTM3MzE3_2820105e-4e34-49a2-98fe-d1975c59b95a">3,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV85LTEtMS0xLTMzODk_41a1b392-6a58-4b25-b69e-514527a21398">757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV85LTMtMS0xLTMzOTM_ce0624d4-c86d-473d-b0fc-e6b5a3b8d982">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV85LTUtMS0xLTM3MzE3_22b23ec6-7093-46c2-ae47-4658ad8abace">4,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMC0xLTEtMS0zMzg5_3d106c51-1a51-4543-b133-2fd4319e1fd2">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMC0zLTEtMS0zMzkz_41274616-8fb0-4a86-bd79-9fee40d17eb2">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMC01LTEtMS0zNzMxNw_c01ff7fa-e7f4-4531-92bf-fed5b4d73f20">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMS0xLTEtMS0zMzg5_a27dbf8b-286d-4abe-bb24-2b2756098054">707</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMS0zLTEtMS0zMzkz_358d3f6a-4826-4040-ba2f-44481284bc48">2,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMS01LTEtMS0zNzMxNw_acf65e3c-386f-4f84-91ab-199aab551a45">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMi0xLTEtMS0zMzg5_516dc4d8-1dee-4c0b-84f0-997b32965f73">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMi0zLTEtMS0zMzkz_475b5730-83b8-4753-b528-634197361ff7">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMi01LTEtMS0zNzMxNw_373897ec-27b9-4d0a-9fc6-764151f48b42">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMy0xLTEtMS0zMzg5_1de5e53c-765d-44b6-bf97-8f77191ea21d">704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMy0zLTEtMS0zMzkz_7b5b6dc1-6f95-417d-a47c-e8481554a89d">2,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMy01LTEtMS0zNzMxNw_6dc18e90-a5f1-42e5-bbae-4b6304d06218">4,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of assets and liabilities of discontinued operations are as follows:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xLTItMS0xLTMzNDY_fa35abd7-72a9-4142-ac43-404c957e4b5c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, less allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8yLTItMS0xLTMzNDY_7d93dda5-b5e7-4366-b9cf-e3f32f801c74">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8zLTItMS0xLTMzNDY_3e3e9f78-a21f-40d1-97c5-df1a0e60b5e3">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF80LTItMS0xLTMzNDY_ab89e891-ad96-499b-b850-a1cce5024cf7">867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF81LTItMS0xLTMzNDY_da9f616b-d0bc-4552-8957-652186f57466">2,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF83LTItMS0xLTMzNDY_c2f8a387-965a-40b1-80f4-64d7afd2ad14">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF84LTItMS0xLTMzNDY_9b85b5f4-387f-49a0-bb64-e7bd5971f40c">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF85LTItMS0xLTMzNDY_b496767e-24cf-47c7-ab2f-c29def86e31a">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xMC0yLTEtMS0zMzQ2_414eccb7-87a8-417d-86ce-0bc10cce59db">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent Assets of Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xMS0yLTEtMS0zMzQ2_dee8a8d7-966b-4a65-bf25-14ba1fdc6861">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xMy0yLTEtMS0zMzQ2_1de27d65-d1dd-4bb0-a569-6bced204ac7d">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xNC0yLTEtMS0zMzQ2_3b3a4cf8-acdb-422c-9bdc-a106c1b45282">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" sign="-" name="mrk:DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xNS0yLTEtMS0zMzQ2_06ff2f42-4365-44e5-9686-b178e6dcd0be">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xNi0yLTEtMS0zMzQ2_8b27f816-ebfa-4857-a183-9c28a2e3b764">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xOC0yLTEtMS0zMzQ2_abac63ae-66fc-4d60-9a2e-fcf48379be3b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xOS0yLTEtMS0zMzQ2_794ba03e-7e64-48d9-9813-042e0aeaff28">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent Liabilities of Discontinued Operations</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8yMC0yLTEtMS0zMzQ2_03268d7d-354b-477b-acc8-cbf983a40759">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the spin-off of Organon, Merck distributed net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602" decimals="-8" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NjM4_c09cd35e-abe8-4899-a97c-a80e523b208c">5.1</ix:nonFraction>&#160;billion as of June 2, 2021 consisting of debt of $<ix:nonFraction unitRef="usd" contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602" decimals="-8" name="mrk:DisposalGroupIncludingDiscontinuedOperationsDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NjUy_9e36f837-7f7d-41e5-9803-9010784fd7a9">9.4</ix:nonFraction>&#160;billion (described above), goodwill of $<ix:nonFraction unitRef="usd" contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NjY2_d67bd2ad-9093-45d6-8988-b07600e18e35">1.4</ix:nonFraction>&#160;billion, property, plant and equipment of $<ix:nonFraction unitRef="usd" contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4Njgw_4e369f5a-2e1b-4687-b0c8-4746810c7c03">981</ix:nonFraction>&#160;million, cash of $<ix:nonFraction unitRef="usd" contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4Njk0_3cc2cd12-c8d1-41ff-8862-10297dda2065">929</ix:nonFraction>&#160;million, inventory of $<ix:nonFraction unitRef="usd" contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NzA4_0e22eee4-723a-44d1-83c0-14f80ec47c98">815</ix:nonFraction>&#160;million, other intangibles, net, of $<ix:nonFraction unitRef="usd" contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NzIy_ece8563e-c392-4a5b-ac92-e2fe411c3ba0">519</ix:nonFraction>&#160;million and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NzM2_282d11b8-3bc6-43b4-b06d-c0cb6c5478b2">328</ix:nonFraction>&#160;million. The spin-off also resulted in a net decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $<ix:nonFraction unitRef="usd" contextRef="i11ebf3cfa71a410e931e1ac91fd56a8d_D20210602-20210602" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4ODQz_683511c4-38c6-4150-a794-8d35000bef3e">449</ix:nonFraction> million consisting of $<ix:nonFraction unitRef="usd" contextRef="i5475fea5427a4a45a8d0f7c70cc2edc1_D20210602-20210602" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4ODI3_940496b7-982b-4026-aeea-9e8912de17f1">421</ix:nonFraction> million for the derecognition of net losses on foreign currency translation adjustments and $<ix:nonFraction unitRef="usd" contextRef="iad3694ffb88a4c26905566a5aadc567e_D20210602-20210602" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4ODIy_8d3d391c-abd2-44e1-9e96-dd1559601762">28</ix:nonFraction> million associated with employee benefit plans. The distribution of the net liabilities and reduction to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulted in a net $<ix:nonFraction unitRef="usd" contextRef="if35f0cdded8a441882d65448ee48c8ed_D20210602-20210602" decimals="-8" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4ODU5_732d9b5e-4539-44f3-9bcb-d218f8aac1f8">4.6</ix:nonFraction> billion increase to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iec752e54167b4d978dbe91384fbf77ca">Expenses for curtailments, settlements and termination benefits provided to certain employees were incurred in connection with the spin-off (see Note 14). Additionally, all outstanding Merck stock options, restricted stock units (RSUs) and performance share units (PSUs) (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees (see Note 13).</ix:continuation></span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_151"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4NDgyOTA3NTYzMTc_7b84aa6c-0341-42d9-9268-1d57a363e1c5" continuedAt="i2cc5588808a941249b79631c4990a034" escape="true">Acquisitions, Research Collaborations and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i2cc5588808a941249b79631c4990a034" continuedAt="icf190549024c4e998de594bc746b796f"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="iab98fe0036ab490284530f0ef5a067b9_D20211101-20211130" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk2NTU_1fae82f0-f066-49ab-88ff-3fdaa5af8dda">11.5</ix:nonFraction>&#160;billion. Acceleron is evaluating the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron&#8217;s lead therapeutic candidate, sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. Under a previous agreement assumed by Merck, Bristol Myers Squibb (BMS) was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay <ix:nonFraction unitRef="number" contextRef="i6c67fcd89a8b4082808554b5f0549fc8_D20211101-20211130" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1Nzc0MjU_0f4aa386-da2f-4450-862a-4f5039ddf76c">22</ix:nonFraction>% royalties on future sales of sotatercept in the PH field to BMS. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to sotatercept, Acceleron&#8217;s portfolio includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated in Phase 2 and Phase 3 trials for additional indications for hematology therapies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is being developed and commercialized through a global collaboration with BMS. In connection with this ongoing collaboration, Merck receives a <ix:nonFraction unitRef="number" contextRef="i5c62b473540e4792973e3e5eff8e852b_D20211101-20211130" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2OTQ4MTU_908f8982-1911-4b8a-97ea-bd3d972ba605">20</ix:nonFraction>% sales royalty from BMS which could increase to a maximum of <ix:nonFraction unitRef="number" contextRef="i700f5502bfe547d29c56588dcd1c2a57_D20211101-20211130" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NzUxMTM_50e2148b-ec86-4f6e-8ec3-69211d595e7d">24</ix:nonFraction>% based on sales levels. This royalty will be reduced by <ix:nonFraction unitRef="number" contextRef="i6c67fcd89a8b4082808554b5f0549fc8_D20211101-20211130" decimals="2" name="mrk:RoyaltyRateDeductionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1Nzc2MDQ_0d791c6f-a2f4-4697-9c25-05738202c37a">50</ix:nonFraction>% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Merck is eligible to receive future contingent milestone payments including up to $<ix:nonFraction unitRef="usd" contextRef="i078bab656180438fb5b9e6e2b822296a_D20211101-20211130" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE2NDkyNjc1MjgyMTI_867ecd4c-1de0-4684-8230-823e4836c056">20</ix:nonFraction>&#160;million in regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i2ad6313c93cd46b38072ff32e2d4d398_D20211101-20211130" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE2NDkyNjc1MjgyNTE_d449a8f4-9cb2-40d6-a0b0-2964b328fa40">80</ix:nonFraction>&#160;million in sales-based milestones. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as a business combination. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="if845b3b4c08c45efbf34f152a3076b6b_I20211130" decimals="-6" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2OTAwNzI_a7624876-6940-46b2-862b-4314cc869474">280</ix:nonFraction>&#160;million of costs directly related to the acquisition of Acceleron, consisting primarily of share-based compensation payments to settle non-vested equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs in 2021. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="icf190549024c4e998de594bc746b796f" continuedAt="ie6bd99a78b8a44288e1d487eed3a2162"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4NDgyOTA3NDUxNjY_97fb74f6-b214-47e9-8ca7-4b2cbb374751" continuedAt="id9f768215a5f44bfb3b0d6b7c6b6f99e" escape="true"><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Acceleron is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e156b81e874c37998b4260b293e32d_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzEtMS0xLTEtMzU5MzA_35cd0f11-8545-4401-bcbd-b597ee484170">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e156b81e874c37998b4260b293e32d_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzItMS0xLTEtMzU5NzU_9b180cd2-237d-4bd5-a9db-d42de0e57e46">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D - sotatercept </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e156b81e874c37998b4260b293e32d_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzQtMS0xLTEtMzU5MzM_a0bceda1-151d-4a4d-9c22-5e72bdaffc54">6,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and product rights - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reblozyl </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonNumeric contextRef="iab98fe0036ab490284530f0ef5a067b9_D20211101-20211130" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzYtMC0xLTEtMzYzMTQvdGV4dHJlZ2lvbjo4NzQwM2Q2MmM5ZDE0MThmYmJlMTk0NzNhZTMxNzJhM18xMDk5NTExNjI3ODg4_7114d30d-e34f-4c90-b346-957768fe7242">12</ix:nonNumeric> year useful life)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e156b81e874c37998b4260b293e32d_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzYtMS0xLTEtMzU5Mzg_b7dfccd1-5745-4035-a915-3e0acd9d700c">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66e156b81e874c37998b4260b293e32d_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzctMS0xLTEtMzU5NDA_0e380877-e9d5-4c6c-8d09-2c30c6956ba8">1,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e156b81e874c37998b4260b293e32d_I20211119" decimals="-6" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzgtMS0xLTEtMzU5NDc_bf235d40-260c-4ea1-a8c3-cdb40ebd382e">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e156b81e874c37998b4260b293e32d_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzgtMi0xLTEtNDI3NTU_8f89e0e3-2d1c-4de1-b895-a552b6e3d19a">9,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e156b81e874c37998b4260b293e32d_I20211119" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzEwLTEtMS0xLTM1OTQ5_ef8a229c-13ec-4ac1-9850-2102ee1849e3">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e156b81e874c37998b4260b293e32d_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzExLTEtMS0xLTM1OTUx_c7f157b2-9af7-4025-ac5e-d38bd8c5b608">11,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="i691918582c3344e899b4df21192718a3_I20211119" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE2NDkyNjc1MDQ2NDU_a44dd9a3-9efc-45b6-a838-9d3df2746e7d">7.5</ix:nonFraction>% for sotatercept and <ix:nonFraction unitRef="number" contextRef="i691918582c3344e899b4df21192718a3_I20211119" decimals="3" name="mrk:IntangibleAssetProductsAndProductRightsMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NzQ0MTI_64c859fe-4580-4aad-bc35-da5924978d9a">6.0</ix:nonFraction>% for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Total consideration paid of $<ix:nonFraction unitRef="usd" contextRef="ib5e47ab987cd4d3abdc343a64acdfcdc_D20210401-20210430" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3MjU_446d0d6b-9300-46d0-9fa9-80fd3f81cdff">1.9</ix:nonFraction> billion included $<ix:nonFraction unitRef="usd" contextRef="ib5e47ab987cd4d3abdc343a64acdfcdc_D20210401-20210430" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3MTE_93d44bea-5493-4099-a4a5-be68a9c8ed44">147</ix:nonFraction>&#160;million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $<ix:nonFraction unitRef="usd" contextRef="i363a34970b28487fb538f79d80bd5c63_I20210430" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3NDI_dd4e64f8-b5cc-4594-8c71-3aa8848978a3">156</ix:nonFraction> million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i3dbe981b0dce44c7b9140f5b1e642a2d_D20210101-20211231" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3NTk_20027b2f-3727-49c6-a4f8-b50ae837ae80">1.7</ix:nonFraction> billion in 2021 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead&#8217;s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Merck and Gilead will share operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. Global development and commercialization costs will be shared <ix:nonFraction unitRef="number" contextRef="i62ab2e68dea743c09e757b18af5181e8_D20210301-20210331" decimals="2" name="mrk:ProfitShareCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3NjM_ec29d711-f0b7-4b08-998c-4ba044d249e7">60</ix:nonFraction>% Gilead and <ix:nonFraction unitRef="number" contextRef="i62ab2e68dea743c09e757b18af5181e8_D20210301-20210331" decimals="2" name="mrk:ProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3Njg_cf2c8328-417e-44ed-a517-4ea601c0cfba">40</ix:nonFraction>% Merck across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation revenue tiers. Upon passing $<ix:nonFraction unitRef="usd" contextRef="i85efbd1b835b4a8e8e7140e9b606ea82_D20210301-20210331" decimals="-8" name="mrk:SalesThreshold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NTMyMjU_bcd1754f-db26-46fa-868f-304f40d0df63">2.0</ix:nonFraction>&#160;billion a year in net product sales for the oral combination, the revenue split will adjust to <ix:nonFraction unitRef="number" contextRef="i85efbd1b835b4a8e8e7140e9b606ea82_D20210301-20210331" decimals="2" name="mrk:ProfitShareCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3NzQ_f23836a0-5731-4f78-a31a-4752eee73735">65</ix:nonFraction>% Gilead and <ix:nonFraction unitRef="number" contextRef="i85efbd1b835b4a8e8e7140e9b606ea82_D20210301-20210331" decimals="2" name="mrk:ProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3Nzk_0708065e-c0b4-4292-980e-6b185bb8934c">35</ix:nonFraction>% Merck for any revenues above the threshold. Upon passing $<ix:nonFraction unitRef="usd" contextRef="if1ab7dec508142c597fc9e631c500889_D20210301-20210331" decimals="-8" name="mrk:SalesThreshold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3ODQ_a2a59343-7d1b-45aa-be0c-91345ecc84ae">3.5</ix:nonFraction>&#160;billion a year in net product sales for the injectable combination, the revenue split will adjust to <ix:nonFraction unitRef="number" contextRef="if1ab7dec508142c597fc9e631c500889_D20210301-20210331" decimals="2" name="mrk:ProfitShareCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3OTg_1f5961e9-0a28-4a3f-bc4a-eb7b1efa1439">65</ix:nonFraction>% Gilead and <ix:nonFraction unitRef="number" contextRef="if1ab7dec508142c597fc9e631c500889_D20210301-20210331" decimals="2" name="mrk:ProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NTMyNDI_2891b8a3-2c18-43a9-acdf-f1002e220f18">35</ix:nonFraction>% Merck for any revenues above the threshold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the U.S. Food and Drug Administration (FDA) placed full or partial clinical holds on investigational new drug applications for certain oral, implant and injectable formulations of islatravir based on </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ie6bd99a78b8a44288e1d487eed3a2162" continuedAt="i50b4c89622a342cb8ce13d7ba9921963"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. As a result of these holds, Merck and Gilead made the decision to stop all dosing of participants in a Phase 2 clinical study evaluating islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. The two companies are assessing whether a different dosing of islatravir in combination with lenacapavir may provide a once-weekly oral therapy option for people living with HIV. Merck and Gilead remain committed to their collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva&#8217;s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0caff53de00b40f0b2a4242ec4f7b853_D20210101-20210131" decimals="-6" name="mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4MDQ_4c272e74-7b19-4d06-96b2-e460ffeb7c6e">30</ix:nonFraction>&#160;million, which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0caff53de00b40f0b2a4242ec4f7b853_D20210101-20210131" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4MTc_9bd3c246-014d-4594-aa1b-a3a1590dda64">15</ix:nonFraction>&#160;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $<ix:nonFraction unitRef="usd" contextRef="i6a13694e029b4e109b43b40ab0e2f486_D20210101-20210131" decimals="-5" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4MzA_a28b222d-2e2f-4e74-b426-855ab84462b0">217.5</ix:nonFraction>&#160;million in developmental milestones, $<ix:nonFraction unitRef="usd" contextRef="ie4df9ebe39004e61b4723b8728950ca9_D20210101-20210131" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4NDY_02a8ae10-ccbb-4226-b989-113b6206540e">570</ix:nonFraction>&#160;million in regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="iee08b09a26eb4dbf9c1fc7400dd403eb_D20210101-20210131" decimals="-7" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4NjA_a468362e-fa00-46ef-a90e-eb760a154c2a">1.05</ix:nonFraction>&#160;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i8782918165654defab8aad5b032f7b4e_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2NzYwMTA_0639f13a-89a4-4c72-b50e-4d36dc54f160"><ix:nonFraction unitRef="number" contextRef="i8782918165654defab8aad5b032f7b4e_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2NzYwMTA_28f7b126-a603-4d33-8a34-a9217a2d4348">7</ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8b7f6216f9b24aefaf5499aeeae375cb_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4NzY_b073c687-b6f8-48e6-a883-4b795f9e8a0f">14</ix:nonFraction>% on future sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i65036a0df1a24e1286b3b620969af227_D20201201-20201231" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2ODAwOTY_fad8f390-96d5-4096-8d22-e9a12246aad8">423</ix:nonFraction>&#160;million. OncoImmune&#8217;s lead therapeutic candidate (MK-7110) was being evaluated for the treatment of patients hospitalized with COVID-19. The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $<ix:nonFraction unitRef="usd" contextRef="i65036a0df1a24e1286b3b620969af227_D20201201-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE4MjU_dbd4f272-24ba-4051-a2d1-0d9a45eb8830">50</ix:nonFraction>&#160;million for a <ix:nonFraction unitRef="number" contextRef="ifbd4e250c5234f40a49f0424a7b9ca39_I20201231" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE4MzQ_5d9da416-40b5-4efa-bad9-bb05f9cffebb">20</ix:nonFraction>% ownership interest in the new entity, which was valued at $<ix:nonFraction unitRef="usd" contextRef="ifbd4e250c5234f40a49f0424a7b9ca39_I20201231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE4OTU_a8307574-8f94-4970-bb53-120cfffb6dfd">33</ix:nonFraction>&#160;million resulting in a $<ix:nonFraction unitRef="usd" contextRef="i65036a0df1a24e1286b3b620969af227_D20201201-20201231" decimals="-6" name="mrk:PremiumOnSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE5MTM_a9dee810-531f-4fc8-bfdd-6c1db567c8cd">17</ix:nonFraction>&#160;million premium. Merck also recognized other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="ifbd4e250c5234f40a49f0424a7b9ca39_I20201231" decimals="-6" sign="-" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2NzgwNTM_892a6c21-5988-426c-86a8-d263069a06b7">22</ix:nonFraction>&#160;million. The Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i1a2125d5f6f642d48b2728270ed20dcf_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2NzgxNTQ_1cb4a073-83f1-470d-bd46-d83a980bceaf">462</ix:nonFraction>&#160;million in 2020 related to this transaction. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential Emergency Use Authorization (EUA) application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#8217;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $<ix:nonFraction unitRef="usd" contextRef="i87d5e8e876a74d78b9b4adb360ed3859_D20210101-20211231" decimals="-6" name="mrk:ChargesRelatedToProgramDiscontinuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2Nzk5MDI_7d70c210-c386-469c-b276-375ec7b2d6c7">207</ix:nonFraction>&#160;million in 2021, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $<ix:nonFraction unitRef="usd" contextRef="id4bb721c83cb4d6baf3edaee991beff8_D20201201-20201231" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzIyMDI_dcd4f0d1-b0a3-4013-adde-f83f427eab04">2.8</ix:nonFraction> billion. VelosBio&#8217;s lead investigational candidate is zilovertamab vedotin (MK-2140), an antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $<ix:nonFraction unitRef="usd" contextRef="i154453efc9bf49d9b6c2e7bdb4a3667d_I20201231" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzI1ODY_cc2b0751-269d-4571-af29-68168aa9c4a8">180</ix:nonFraction>&#160;million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i887204908c64421d9da59e4d3c3099b6_D20200101-20201231" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzI2NDc_69116e4c-86f6-4323-a361-9bf7d3f022f5">2.7</ix:nonFraction> billion in 2020 related to the transaction. During 2021, the Company recorded adjustments to these amounts which resulted in a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i1e331a60d4604a2b9a0563cb2271e112_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDkyNzQ_e6630ba5-cf5f-4b04-8524-2697f643836e">43</ix:nonFraction>&#160;million, an increase to total consideration paid of $<ix:nonFraction unitRef="usd" contextRef="ic5c941f925d9424e9b42b6b4bb3d68b8_D20211201-20211231" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQ5NDc4MDI0MTAyNjc_136bb662-a778-4c7f-b47d-5aa5c5b9ec01">47</ix:nonFraction>&#160;million, and an increase to net assets recorded of $<ix:nonFraction unitRef="usd" contextRef="if2bd91e11abc48aeac94ddad807d22c4_I20211231" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDkzOTA_43c7add9-816a-41bb-9a1a-6a9eda6e1920">90</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen) announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i50b4c89622a342cb8ce13d7ba9921963" continuedAt="icbf900419cb24098a58710421520c300"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i090c4ce27a88432b994b5cd38555a37b_D20200901-20200930" decimals="-6" name="mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM0Mzg_091c51fb-7496-438f-8936-2f355ba53ec7">600</ix:nonFraction>&#160;million and a $<ix:nonFraction unitRef="usd" contextRef="i090c4ce27a88432b994b5cd38555a37b_D20200901-20200930" decimals="-8" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM0NDc_c9f8dc0c-161a-4f96-b52d-661bbce6e8df">1.0</ix:nonFraction>&#160;billion equity investment in <ix:nonFraction unitRef="shares" contextRef="ie34faa097b834cfa9a5bcfcaf8c87262_I20200930" decimals="-6" name="us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM0NzE_b61fd713-3d58-43a3-aafd-f1b65c03325c">5</ix:nonFraction>&#160;million shares of Seagen common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie34faa097b834cfa9a5bcfcaf8c87262_I20200930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM1MTg_c55a70e7-a4c7-4c4b-aa6b-5f69c2b476bd">200</ix:nonFraction> per share. Merck recorded $<ix:nonFraction unitRef="usd" contextRef="i6f789b2accd9484992688f3f01dfdf11_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM1NDc_5d22b64c-3d71-4d7a-b1df-e8dd9137fa10">616</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020 related to this transaction reflecting the upfront payment as well as a $<ix:nonFraction unitRef="usd" contextRef="i48c7436c3f434009bc43ed8fb64f30db_D20200101-20201231" decimals="-6" name="mrk:PremiumOnSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM2Njc_1b96dd8d-1e41-4aef-97e5-6565f9e7d95a">16</ix:nonFraction>&#160;million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i090c4ce27a88432b994b5cd38555a37b_D20200901-20200930" decimals="-8" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4NTI_4485c0cf-7786-462c-96e3-963c85012f4a">2.6</ix:nonFraction>&#160;billion, including $<ix:nonFraction unitRef="usd" contextRef="i37947affd59e45db9bf4247d22ef2445_D20200901-20200930" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4NjY_df0bf359-3ad1-4c1e-8d60-f50a425187d2">850</ix:nonFraction>&#160;million in development milestones and $<ix:nonFraction unitRef="usd" contextRef="i0a44796f0e99454095c4177490b7a1fc_D20200901-20200930" decimals="-7" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4OTk_0764fecf-849c-4123-853f-905f50f15682">1.75</ix:nonFraction>&#160;billion in sales-based milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $<ix:nonFraction unitRef="usd" contextRef="id735e23c835a42d7a629be7b46a33b70_D20200901-20200930" decimals="-6" name="mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQ4ODU_bbc513d0-5bbd-473b-adb0-835b150f27b3">210</ix:nonFraction>&#160;million, which were recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ia094e3f9230741fb85ffb13181d20935_D20200901-20200930" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUwNDg_e6c52387-dd26-4813-9600-7d70d47887fd">65</ix:nonFraction>&#160;million and will receive tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i22dbddf74d0346e2bcda039fb5251dc8_D20200901-20200930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUwOTg_0ea61b9b-c3c8-4bbb-aa14-41f578d54baf">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibd702d7339fc4907beb6de920d2ebfcb_D20200901-20200930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUxMDQ_c467a0d4-9eaa-4187-888c-6fa593d38cfc">33</ix:nonFraction>% based on annual sales levels of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#8364;<ix:nonFraction unitRef="eur" contextRef="i94eccca165db4204b5fe7cd15369ff52_D20200901-20200930" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUzMjg_5989a3ac-fa47-4d8f-9530-b9d9fce14354">256</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i94eccca165db4204b5fe7cd15369ff52_D20200901-20200930" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUzMzI_0c4f31af-601e-4024-8fde-46f83c3cc7b9">302</ix:nonFraction>&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $<ix:nonFraction unitRef="usd" contextRef="i0772900bf1714a1286b8a8be67ef1352_I20200930" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU0NTA_b9ae82da-180a-41a9-9f71-177d9fe6a98b">289</ix:nonFraction>&#160;million and other net assets of $<ix:nonFraction unitRef="usd" contextRef="i0772900bf1714a1286b8a8be67ef1352_I20200930" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU0Nzc_6b1f62a7-7fa2-42b9-bc73-ada2841e0a88">13</ix:nonFraction>&#160;million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $<ix:nonFraction unitRef="usd" contextRef="i46379c7182e540b2828bf31f0181f842_D20200701-20200731" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU2Nzk_f5e031e0-e94e-43d1-b35b-656f71e323f0">410</ix:nonFraction>&#160;million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $<ix:nonFraction unitRef="usd" contextRef="id62a4bb25fc844f59220aa4a94682bd9_D20200701-20200731" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU4NTc_263aa086-1421-475d-8925-2b60a2e5ae92">401</ix:nonFraction>&#160;million related to currently marketed products and inventory of $<ix:nonFraction unitRef="usd" contextRef="iffce628751d64772b2c55aabb65ac5b4_I20200731" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU5MTY_3e25215e-e6e6-4615-a5d4-5c52012a5dcd">9</ix:nonFraction>&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of <ix:nonNumeric contextRef="iaf228ffc1f9146219d66ae63268e5646_D20200701-20200731" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzYyNzA_411018cd-dd6e-4689-8b9f-bda637866195">15</ix:nonNumeric> years. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. See Note 5 for additional information related to this collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $<ix:nonFraction unitRef="usd" contextRef="i253e7eb6731846cd8297aa6fff74e2a7_D20200601-20200630" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc0NzU_908a6276-42f5-400b-9bf3-76db568873b3">366</ix:nonFraction> million. The acquisition originally provided for Merck to make additional contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc1NzM_4a95b9b6-a8e7-477b-b74a-10562912e4b1">740</ix:nonFraction>&#160;million. The transaction was accounted for as a business combination. The Company determined the fair value of the contingent consideration was $<ix:nonFraction unitRef="usd" contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc3MTg_f4c595fe-b00d-4d38-b180-7187bc0a30de">85</ix:nonFraction>&#160;million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc5NTA_e1011dfa-a3e6-484d-8f21-7b0abc22b14e">113</ix:nonFraction>&#160;million, cash of $<ix:nonFraction unitRef="usd" contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc5NjI_6aa34bbe-177b-43ca-a65c-56a7efb33740">59</ix:nonFraction>&#160;million, deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc5ODk_da9c97f5-8a8f-4d08-9cb7-0f44d5719249">72</ix:nonFraction>&#160;million and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630" decimals="-6" sign="-" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzgwMjE_c06a3268-a35b-400e-8a06-d4f659004ae2">32</ix:nonFraction>&#160;million. The excess of the consideration transferred over the fair value of net assets acquired of $<ix:nonFraction unitRef="usd" contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzgxMTU_86e6fdad-f391-4631-a3b5-e5def0a1b441">239</ix:nonFraction>&#160;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;D impairment charge of $<ix:nonFraction unitRef="usd" contextRef="idd20b1fb1b1840cd97ca9a25e317e07f_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg1ODM_2dc5f94d-d3c5-465d-a67f-688fc8132e82">90</ix:nonFraction>&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. The Company also recorded a reduction in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses resulting from a decrease in the related liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="idd20b1fb1b1840cd97ca9a25e317e07f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg3ODY_4f5b1a24-a327-435a-876f-d5e245572449">45</ix:nonFraction>&#160;million since future contingent milestone payments have been reduced to $<ix:nonFraction unitRef="usd" contextRef="ia72336269c0e4853bb62f08578a8703e_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg4NTM_3d4ad195-6db9-4a92-bf75-af284fae84f4">450</ix:nonFraction>&#160;million in the aggregate, including up to $<ix:nonFraction unitRef="usd" contextRef="i41279252c9624ed8a4c7a81861188d80_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg4OTA_d516c855-4e89-437a-a7e5-c78d37fdfb2f">60</ix:nonFraction>&#160;million for development milestones, up to $<ix:nonFraction unitRef="usd" contextRef="if5bd531bb0694347bbaa1de33894a3f9_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg5Mjc_fe53d1e3-86e6-41fa-b79e-f2938087fc5e">196</ix:nonFraction>&#160;million for regulatory approval milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i7d06568f20aa4404ac1d16b234d39d17_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg5NzY_5a847f4e-c854-4f04-bf09-bbce304f3028">194</ix:nonFraction>&#160;million for commercial milestones.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="icbf900419cb24098a58710421520c300" continuedAt="i4a4b8a667eb7466392eeea91b097e667"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $<ix:nonFraction unitRef="usd" contextRef="i8d3b73f821cd4774aad66eb73f3a5f66_D20200501-20200531" decimals="-5" name="mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzkzODc_a75c2114-f632-4b96-a722-8c20a4a02b9b">6.5</ix:nonFraction>&#160;million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#8217;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231" decimals="-6" name="mrk:ChargesRelatedToProgramDiscontinuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwMzY4_427180ee-839a-44e5-9c21-c696f3d605ba">305</ix:nonFraction>&#160;million in 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231" decimals="-6" name="us-gaap:ProductionRelatedImpairmentsOrCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwMzg5_e19f75d1-d64d-463e-be7a-934925918d38">260</ix:nonFraction>&#160;million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The remaining $<ix:nonFraction unitRef="usd" contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwNTU4_ececa6d0-ea66-490b-8703-2630f2a1b3fd">45</ix:nonFraction>&#160;million of costs were reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $<ix:nonFraction unitRef="usd" contextRef="ia80b8fd970c84658b490d1b62ee60672_D20200101-20200131" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzExMDUw_cb85e4d6-47cc-4188-acbf-723346fdeadb">2.7</ix:nonFraction> billion included $<ix:nonFraction unitRef="usd" contextRef="i00f0fb0e68c34bcc9ac14ca5a1d30e3e_I20200131" decimals="-6" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzExMDYy_0fb6e3ed-e07e-42eb-870c-98fb83695e79">138</ix:nonFraction>&#160;million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i00f0fb0e68c34bcc9ac14ca5a1d30e3e_I20200131" decimals="-6" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzExMjQz_4dd8f6c3-85b6-497b-9b7e-aa6d524b6a96">95</ix:nonFraction>&#160;million of costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020. ArQule&#8217;s lead investigational candidate, nemtabrutinib (MK-1026), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as a business combination.</span></div><ix:continuation id="id9f768215a5f44bfb3b0d6b7c6b6f99e" continuedAt="ic47d46df33f94ee5a42d83ff37ea677b"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzEtMS0xLTEtMA_9faa2c26-5462-4a12-8d4b-612df1e62e31">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D - nemtabrutinib </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzItMS0xLTEtMA_8acf2faf-45dc-4f5c-95a2-6131d2aca421">2,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzMtMS0xLTEtMA_a971c178-2d25-4f07-850c-e22f0a251d6a">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzQtMS0xLTEtMA_ff20b942-3c2b-437a-81eb-0ffcd4225e3c">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116" decimals="-6" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzUtMS0xLTEtMA_5c706159-f41f-4d45-affa-1a605c7505bc">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzYtMS0xLTEtMA_f5e68e10-4545-4d40-973d-fbc1b2cf406d">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzctMS0xLTEtMA_8f2b40f4-a5d7-4fd3-be94-354a687a963a">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzgtMS0xLTEtMA_92a680ae-296f-4a5e-bd18-14e88feceab5">2,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="i02d468ad359d4b3c907fa0ca583c3707_I20200116" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEyMTE4_67a9db57-79e0-4445-a01a-f558581f9643">12.5</ix:nonFraction>%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Merck recorded a $<ix:nonFraction unitRef="usd" contextRef="i02366c725d8e4b61a487fbc509afa833_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE3MTQwMzA_e967f4a0-730e-4589-8f80-5b7fe4e9fdfd">275</ix:nonFraction> million intangible asset impairment charge related to nemtabrutinib (see Note 9).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2&#945; (HIF-2&#945;) for the treatment of patients with cancer and other non-oncology diseases. Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if3aa932f580f42fba20f4fb291aa005d_D20190701-20190731" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEyODA5_ba9cbd6f-7953-446c-89bb-cf0b78bdc61e">1.2</ix:nonFraction> billion. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $<ix:nonFraction unitRef="usd" contextRef="i2c7c2e213af64bed83c7c5be126fe2b5_I20190731" decimals="-6" name="mrk:AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzMDk3_49ecb352-881d-4382-b2a1-e1230c65b2c7">157</ix:nonFraction> million, deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i2c7c2e213af64bed83c7c5be126fe2b5_I20190731" decimals="-6" name="mrk:AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzMTI5_211a3b4a-ac63-4ac6-9ebc-8d84ec2a5890">52</ix:nonFraction> million, and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i2c7c2e213af64bed83c7c5be126fe2b5_I20190731" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzMTYy_fbfb33a0-a445-40d1-99fd-ff327b226780">4</ix:nonFraction> million at the acquisition </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i4a4b8a667eb7466392eeea91b097e667" continuedAt="i2140d82a55a64a848e87e963dbb1b39b"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i0b43da370e844376a5ef3e3c317c068c_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzMjM4_d7e2dcb5-7625-41a5-9d8d-f93f96fa8708">993</ix:nonFraction> million in 2019 related to the transaction. Former Peloton shareholders received a $<ix:nonFraction unitRef="usd" contextRef="i4d46d7a5f1d84985a8798afe9a116fcd_D20210101-20211231" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2ODMzMDA_2eddb61e-75e6-4fdf-8f2c-f748de88f8ee">50</ix:nonFraction> million milestone payment from Merck in 2021 upon first commercial sale of Peloton&#8217;s lead candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (belzutifan), which was approved as monotherapy in the U.S. in August 2021. Former Peloton shareholders are also eligible to receive $<ix:nonFraction unitRef="usd" contextRef="i094e0d6dfc6e43d8a71ef15cc8afa929_D20190701-20190731" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2ODM1Mzg_bd6ceed9-3c8e-4626-b4f6-bf5a229162c1">50</ix:nonFraction> million upon U.S. regulatory approval as a combination therapy, as well as up to $<ix:nonFraction unitRef="usd" contextRef="i73b1a5803b6e4bb1b34750d30eaca4d0_D20190701-20190731" decimals="-7" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2ODM2MTU_886aa262-9c2d-4aa4-add7-b6428dd7ba26">1.05</ix:nonFraction> billion of sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $<ix:nonFraction unitRef="usd" contextRef="i2b06079ce243471f80c224e28eca9bc0_D20190401-20190401" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzNTg0_26a8348a-b23c-4034-b2ff-104039d6dbcb">2.3</ix:nonFraction> billion to acquire all outstanding shares of Antelliq and spent $<ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzNjQz_83e81ee9-06aa-4bad-bf51-ee80657e1212">1.3</ix:nonFraction> billion to repay Antelliq&#8217;s debt. The transaction was accounted for as a business combination. </span></div><ix:continuation id="ic47d46df33f94ee5a42d83ff37ea677b"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:1pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzEtMS0xLTEtMA_79ae8c64-2700-4473-82c4-a0872de71355">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzItMS0xLTEtMA_4d7834ae-8884-4445-84bc-e216b212ebaa">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzMtMS0xLTEtMA_0a9fe23b-eb0a-4f5f-a153-048e2f62645e">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzQtMS0xLTEtMA_f01f87c3-3162-4567-b353-81523d5f77b1">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from <ix:nonNumeric contextRef="i6bb86c75b69646909c1e731b110cd594_D20190401-20190401" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1YWQwZjUyZDZiMzQ4N2I5YjY1NGRjNDRhN2VjMWRlXzYy_3db0565a-709e-468a-903a-bf9a9163f4a5">18</ix:nonNumeric>-<ix:nonNumeric contextRef="i353be6859e8a4c909dc868bb55fa96ef_D20190401-20190401" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1YWQwZjUyZDZiMzQ4N2I5YjY1NGRjNDRhN2VjMWRlXzY1_737a0945-f46e-4f9e-ab20-0e007908920f">24</ix:nonNumeric> years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzUtMS0xLTEtMA_ea04608e-a05f-472f-8c2c-ff384596f446">2,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzYtMS0xLTEtMA_de178ab4-b428-4970-a6c8-960691a1ed39">589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" sign="-" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzctMS0xLTEtMA_ae171dc3-7081-4007-96a5-07f8c8692f95">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzgtMS0xLTEtMA_a9034f1a-ffdc-4c04-a4c3-63a3e606517b">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzktMS0xLTEtMA_cffbb12b-f07e-4390-8f31-8a776260ae2b">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzEwLTEtMS0xLTA_ab3765b6-5c9d-4003-8c95-a413d8a87a11">3,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="ib1fd1624d0a447a0a77222b18fdb866f_I20190401" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE0MDY5_a9e03221-129b-4190-8971-a409dba1631e">11.5</ix:nonFraction>%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div></ix:continuation><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401" decimals="-6" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE0NTIw_eef5e1c5-534a-4654-a3c3-de8cc746c596">47</ix:nonFraction> million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2019.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:continuation id="i2140d82a55a64a848e87e963dbb1b39b" continuedAt="i401b01e8019c45ab93689654c55c6216"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i401b01e8019c45ab93689654c55c6216"> approaches to enable the body&#8217;s immune system to fight disease, for $<ix:nonFraction unitRef="usd" contextRef="i38900b44f49245e2a2fe07fe9834a8cc_D20190401-20190430" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE0ODk0_c2bec6c1-2450-4d03-9b95-4eeab8c3c302">301</ix:nonFraction> million in cash. The transaction was accounted for as a business combination. Merck recognized intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ib3255f0f1f154600bc059456bba5499d_I20190430" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE1MDEx_9edf74fa-844d-4691-8f7d-0727a43c2b62">156</ix:nonFraction> million, cash of $<ix:nonFraction unitRef="usd" contextRef="ib3255f0f1f154600bc059456bba5499d_I20190430" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE1MDIz_a8902768-b7ed-4b2c-987a-041cc6069e88">83</ix:nonFraction> million and other net assets of $<ix:nonFraction unitRef="usd" contextRef="ib3255f0f1f154600bc059456bba5499d_I20190430" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE1MDUw_c79ccad5-b2c3-4fb2-87b1-4abee0b4d752">42</ix:nonFraction> million. The excess of the consideration transferred over the fair value of net assets acquired of $<ix:nonFraction unitRef="usd" contextRef="ib3255f0f1f154600bc059456bba5499d_I20190430" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE1MTQ0_57b02eca-626e-4e60-850c-e4259c62bef1">20</ix:nonFraction> million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed.</ix:continuation> </span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_154"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwNjI3_2ab11239-647b-4105-8063-ffea2291893e" continuedAt="iaab5ac00bb07454a811e8be8105295d5" escape="true">Collaborative Arrangements</ix:nonNumeric></span></div><ix:continuation id="iaab5ac00bb07454a811e8be8105295d5" continuedAt="i8bb523ccac9248529fdeb899a17cec52"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below.</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i8bb523ccac9248529fdeb899a17cec52" continuedAt="i3e83d6e13470475aac528a2969a006b6"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing AstraZeneca&#8217;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. Merck made sales-based milestone payments to AstraZeneca aggregating $<ix:nonFraction unitRef="usd" contextRef="i14319073e5c3479eb00e19929756ed79_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM1ODg_cafb3c19-21e7-4b39-be86-a755c52be526">550</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5702456494b740da8508f5b853110e3d_D20190101-20191231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM1OTU_691a7d17-61da-4cbe-9fc8-677266e4a321">200</ix:nonFraction> million in 2020 and 2019, respectively. As of December&#160;31, 2021, sales-based milestone payments accrued but not yet paid totaled $<ix:nonFraction unitRef="usd" contextRef="ida96075caa59419780179c2f9b3c3546_I20211231" decimals="-6" name="mrk:MilestonePaymentsAccruedSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwOTk1MTE2NTUxMDI_0d5ab1fb-eb52-4138-9f74-ddb89211e833">400</ix:nonFraction>&#160;million. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ida96075caa59419780179c2f9b3c3546_I20211231" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM3MTE_cf5c2c25-5770-4f40-8adf-2064d81127d1">2.7</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019, Lynparza received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ifa55a231791b4a4c9b8b8459d1b149dd_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM5MTU_ebddb720-5357-4dec-b0a8-62767eb2cd83">160</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i98306b224b47475488e911e85f203624_D20190101-20191231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM5MTk_a132c184-4230-469f-92ca-d3f17e664f35">60</ix:nonFraction> million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ida96075caa59419780179c2f9b3c3546_I20211231" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsRegulatory" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQwMzg_389223d5-fb52-4ece-a420-382e368c55ef">1.4</ix:nonFraction> billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="i4a357f883cf8403d91477b70cff00a8b_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQxOTc_92ef5404-3f58-432d-98e6-27b253527225">1.1</ix:nonFraction> billion at December&#160;31, 2021 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwNjIx_7b430b7a-d6e9-405c-bb3b-ee111287d345" continuedAt="i722f6b4527e2411697f782a2a1b01244" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i642c3ff7f9414f5392688e1239f63e01_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEtMS0xLTEtMA_b51580d6-04f4-467d-ac12-23752259f15c">989</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0a3fd966314c5dac24c390abc72914_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEtMy0xLTEtMA_1e15561b-27e2-4f05-966e-f253f46f6d51">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8bd0a10b28b427cb9d90dfe3a600d6c_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEtNS0xLTEtMA_2e9c0b39-eff3-4cf6-a864-f844576aeaaf">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic810a621774c4c99983badd39ea9eba9_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzItMS0xLTEtMA_5da69606-67f5-4480-abfe-0442a57d69d8">29</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03aabfbe2af64606bfcdc9b7244adddb_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzItMy0xLTEtMA_3faf38a2-5613-4bf6-902b-57401d8e8051">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c263ae58e241119936ff1e15d0ea2a_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzItNS0xLTEtMA_14f6f093-2756-4f92-a280-3b481bdfbd76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id016daaee2884b7f93108c6df370f620_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzMtMS0xLTEtMA_5231b1ae-2b26-422c-814e-968d47afdb9a">1,018</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cfcf2bfbe4407ca26ac87fbf3ba4d9_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzMtMy0xLTEtMA_239752a8-b2a7-4e8d-9867-b4b7961b49cb">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d4f6c2d4ef45beaae183fe55dbf354_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzMtNS0xLTEtMA_97175544-cd56-4e9a-965c-640e1b51ecc3">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica857d506be742ee8d273ccfcb812e2a_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzUtMS0xLTEtMA_0cfe65cd-3177-4fe1-a7c2-59c8d253bf97">167</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d60c48bbfb4999a5474c6c5295cf07_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzUtMy0xLTEtMA_a10bcb46-dc41-4649-8ad1-c68abbdc861c">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc366f05419417e83c83213cac8477c_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzUtNS0xLTEtMA_9dfd1ed7-d188-4071-8de4-8d16a73d1f16">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib054f661c3f042f99541982143ad5e6f_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzYtMS0xLTEtMA_afcf76d8-26b9-47db-8096-6e331c960f99">178</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e6351182024603b7f62da8e5b885f4_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzYtMy0xLTEtMA_fbf8c18e-36aa-4106-b982-0ad0e47a015d">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe4a4c0ebe0439a803c537ea10a6d6a_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzYtNS0xLTEtMA_2a555955-c77c-4ed7-b0d2-a3768362338f">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b90e12bc9ba43f7abb9022574ae4b38_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzctMS0xLTEtMA_a51ff3bc-92bb-49f5-8129-5cd5bfb5496d">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7365ef92cc904089a49a56598ef8d5e2_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzctMy0xLTEtMA_e1a28f95-3d26-497d-b7f4-9e467a7181a1">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109c40ef87d24d13bd2b5cc4cf386752_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzctNS0xLTEtMA_528a08de-e755-4bf5-b3dc-f151a5d9253f">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6154dfd2961f4f43916c01e33c8d1386_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEwLTEtMS0xLTA_601689e0-0f9c-4503-9b01-d9afafe46d92">271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b97e6d098246129353599999e69659_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEwLTMtMS0xLTA_2c8aebe6-ec14-40d7-9bf9-a73dca8c25c9">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ccounts payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if375a5c48628477c973fbc4fd1d1b133_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzExLTEtMS0xLTA_b146a083-cd31-4320-8d89-6570eb25f81b">415</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie381877a89e94c45bc4b63e6dc00f506_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzExLTMtMS0xLTA_003318d0-d27c-4848-938d-b419eec28943">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued milestone payments.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i3e83d6e13470475aac528a2969a006b6" continuedAt="i87fc41ee01544766a57585e0bd3f5aa8"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $<ix:nonFraction unitRef="usd" contextRef="ie3c672ce6ee24fd083c1fcaea23ee2bd_D20210301-20210331" decimals="-6" name="mrk:LicenseOptionPaymentRelatedToCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzYxNTI_9def2650-7822-45de-9028-c5cde7bb103c">125</ix:nonFraction> million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. Merck made sales-based milestone payments to Eisai aggregating $<ix:nonFraction unitRef="usd" contextRef="i3303c07747a54842b62042d5a21e6f09_D20210101-20211231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwOTk1MTE2NTcxOTE_84872507-238a-442d-922b-9001672b9473">200</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i56a431121ab94fd3aeaeff71b65fbed1_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzY4OTc_95ac13e2-2974-438d-aa42-d0c8f16a8fce">500</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if502cf4525474a359d96f230ac724e3f_D20190101-20191231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzY5MDQ_f122a8f0-1cf2-4a81-a04d-6a905ef4eb04">50</ix:nonFraction> million&#160;in 2021, 2020 and 2019, respectively. As of December&#160;31, 2021, sales-based milestone payments accrued but not yet paid totaled $<ix:nonFraction unitRef="usd" contextRef="i7239a77febd64e6582c7bd34411f3af6_I20211231" decimals="-6" name="mrk:MilestonePaymentsAccruedSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwOTk1MTE2NTcyMzk_4864eddd-325f-4509-926f-9511df5dda18">600</ix:nonFraction>&#160;million. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i7239a77febd64e6582c7bd34411f3af6_I20211231" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzcwMDg_e6c63a04-bf40-43ad-854f-9d0ff0e5e5f6">2.6</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i328e047b1fe9465cba44b2312c36a1f0_D20210101-20211231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwOTk1MTE2NTczMzc_1aa7798d-5391-4a29-95b9-6c47ec10a802">75</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie554c78a55284e71b4e43682b58e067e_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzcyMDU_7f7a757e-f938-44a4-a420-fae05a79eb79">10</ix:nonFraction>&#160;million, respectively, from Merck to Eisai. As of December&#160;31, 2021, a regulatory approval milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i7239a77febd64e6582c7bd34411f3af6_I20211231" decimals="-6" name="mrk:MilestonePaymentsAccruedRegulatory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQzOTgwNDY1NTczNzI_0e4c5e86-1f57-4998-a7b1-7488df7183dc">25</ix:nonFraction>&#160;million was accrued but not yet paid. Potential future regulatory milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i7239a77febd64e6582c7bd34411f3af6_I20211231" decimals="-6" name="mrk:PotentialFutureMilestonePaymentsRegulatory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzczMDE_7ec18d96-f094-467b-a28b-d48166487ae4">25</ix:nonFraction> million remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="ia8e076f12b4342f1b585a7f637e3c832_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzc0NTk_ef74dc73-b249-4f88-b2d1-a4679dbc982d">1.0</ix:nonFraction> billion at December&#160;31, 2021 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><ix:continuation id="i722f6b4527e2411697f782a2a1b01244" continuedAt="i7fff4d56fa9647ddbbadeb32873e6f73"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd44ea5d24342129e8b6ebb5a4efdb2_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEtMS0xLTEtMA_46496585-3fc2-4f46-b0e0-660e8839ac7c">704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98a6294caf44811bdfc230489f05f54_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEtMy0xLTEtMA_a5433ae7-fc1b-4e27-a029-959032a078c8">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1775b6c3bb3245dfa916e2e3ecfac7c9_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEtNS0xLTEtMA_7baa1032-d5e0-49b4-be85-e1679e04efda">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4981e17b20a547c8bc03157a8ea2bd94_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzMtMS0xLTEtMA_0fdf18d8-91d8-4376-8828-c36d2e7a48ae">195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if383a9214fb545e98c021a08266ee37c_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzMtMy0xLTEtMA_99cc20e5-18ee-4ed9-9f18-673c7f87c3a9">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78dcd3d033904438964f0f1e38a578c6_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzMtNS0xLTEtMA_2b162a1d-3a42-484a-9b52-e5810f101dd0">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb3a0fe626d42bd8f53d27a0a6cc6c3_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzQtMS0xLTEtMA_123dc721-8cbd-4821-b790-83f798065bdb">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ffe322d7c84b43864b069f78e9b3e7_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzQtMy0xLTEtMA_66e62494-f2f7-4f98-a3f3-4de2a4b50f0c">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6795e1450e497ea457f40aeb36be13_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzQtNS0xLTEtMA_17ef0ade-3678-4e84-aca5-65bc1a80f4dd">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db97feaad864168aa38dfed369a69a9_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzUtMS0xLTEtMA_d65de57c-af7e-448f-9721-5c4de03fa83c">173</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9860090665459d8fec0ff943a45f30_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzUtMy0xLTEtMA_2a3b13d6-1b54-44b5-83e6-de3cd081b1e7">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bedff9aa684372b0af5c1ba6c41467_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzUtNS0xLTEtMA_1b2de13c-c5dd-40a9-9174-6524cbf2a3fd">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if064fdd725ea4a7c982907c44a941df6_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzgtMS0xLTEtMA_b8495c7a-7496-4144-9610-5d141f74feb3">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19adf582d06f45aca49da637284ec35a_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzgtMy0xLTEtMA_2c0361e4-a5d0-4180-92a7-5fc9ed09a9c5">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbdb424aa5944669afe3610141ee5d0_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzktMS0xLTEtMA_d6576095-e1cb-4395-9bbc-f2df5fe3e5d0">625</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56eee0d6468b4e67837ceae0dbff2f9c_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzktMy0xLTEtMA_bfd5ce2a-b77c-493a-ad11-fb7aab5c8494">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04e36743dcd41d3b045117f4f3b8170_I20211231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEwLTEtMS0xLTA_7991742b-034a-4c79-b4ec-f68549d026ea">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e1a080606b4e4592e4f4733ceb6c81_I20201231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEwLTMtMS0xLTA_3827b100-ade1-4dd2-8964-d1d0bad98bb5">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#8217;s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales of Adempas and Verquvo in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $<ix:nonFraction unitRef="usd" contextRef="if90b8c08c37a41ffa4f6848991b4a7da_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzk2NTI_531d32db-16e4-4f9d-9404-eae438b8571d">375</ix:nonFraction>&#160;million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $<ix:nonFraction unitRef="usd" contextRef="i1570e7027e0e496ab090442e8a8be4af_I20211231" decimals="-6" name="mrk:MilestonePaymentsAccruedSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzk4Nzc_d6a3673a-4dc3-4d6b-a4a8-dbaae33eda5e">400</ix:nonFraction> million sales-based milestone </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i87fc41ee01544766a57585e0bd3f5aa8" continuedAt="ia6d50d89295f4c2f8dd48df09de88831"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment that was outstanding under this agreement. Accordingly, Merck recorded a liability of $<ix:nonFraction unitRef="usd" contextRef="i1570e7027e0e496ab090442e8a8be4af_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzk5NTc_69d889ce-4a82-4b64-bb6e-2529eea6e89f">400</ix:nonFraction>&#160;million and a corresponding increase to the intangible assets related to this collaboration. Merck also recognized $<ix:nonFraction unitRef="usd" contextRef="i17edb9f092f7485f9426b08af9218bf2_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQzOTgwNDY1MjUzMjI_987d928e-c904-4e32-8838-0af513ea538d">153</ix:nonFraction>&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in 2021. In January 2022, Merck made this final milestone payment to Bayer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $<ix:nonFraction unitRef="usd" contextRef="i00f8c65ee807407dab9ca51108c58857_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwMjQz_1a16843a-0cc1-451b-ab25-981e28ce233a">806</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id18a472cdb414425a36e2fc4fc858400_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQzOTgwNDY1NTg3OTc_c812a141-b965-44ae-a9b4-4451e758a5ab">68</ix:nonFraction> million, respectively, at December&#160;31, 2021 and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.</span></div><ix:continuation id="i7fff4d56fa9647ddbbadeb32873e6f73" continuedAt="i3b0d206afb64418f9632ef37b9c696f6"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a967edb06f4521aaaaa2ecf0a9b105_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEtMS0xLTEtMA_126282e8-bf1f-42f0-b52c-a6e4deb1342b">342</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia746274f620f40c1851d95a52bb1fec0_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEtMy0xLTEtMA_40faa826-424b-4301-ad59-2ba8f7c68539">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e96dc6c32d41be85aaddf645d42386_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEtNS0xLTEtMA_31d95906-c04e-472a-8e43-a2aa81983f1c">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78cbe3c61444fe491dc47f1246975d8_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzItMS0xLTEtMA_5a9e931e-e2d3-4abf-85ef-74474201b530">252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d7ebb400b14b728855eecc7c992f50_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzItMy0xLTEtMA_99a01f3b-6404-4b56-a860-4cfd9ddb203e">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c74b59b3824b859e175ea5af3e1de3_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzItNS0xLTEtMA_8a85bce1-e637-4de8-bd5d-fb6b973cb859">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a2d934adf3844c9948a3c90a53001de_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtMS0xLTEtMzUyMw_db2690e8-d410-4211-95c5-ff0ee7e7ceb0">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia59c375a867e43f387fc23f684540a1c_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtMy0xLTEtMzUyMw_115bfe4f-808f-4a98-93de-9ead65ad84dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic524b8d83ef44a209ae2f8d59984ad9f_D20190101-20191231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtNS0xLTEtMzUyMw_82a57025-f354-441a-8a31-91f9be390452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a967edb06f4521aaaaa2ecf0a9b105_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtMS0xLTEtMA_d07ee806-4dc3-4799-bd84-af5b01737b84">601</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia746274f620f40c1851d95a52bb1fec0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtMy0xLTEtMA_bc03429b-5f4e-40ff-a633-dfa9aeb32c77">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e96dc6c32d41be85aaddf645d42386_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtNS0xLTEtMA_8645d51e-f2f9-4e72-a722-9df287f87a89">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie861385c736d4571ac97d10e57900db0_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzUtMS0xLTEtMA_9f6e6e93-072f-4435-b774-7c99d8b19351">424</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891ef023d6cf4c1594a15170a05474b4_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzUtMy0xLTEtMA_43fcdab5-3685-4900-828f-04bdf6f87d49">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72f5afaff1c4203b2ae637d11fe6fb6_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzUtNS0xLTEtMA_00973f30-5de6-4313-b029-5826d64a566c">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e1fc699103401fbce35712191d910b_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzYtMS0xLTEtMA_148ef678-9200-419b-88d2-9a7ae527d3e7">126</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e3a1eb707a4bc0b1578b9e4e15f60b_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzYtMy0xLTEtMA_ca65fc84-2f26-49b3-b910-ac624f492684">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideff38e8d1af4d7ca70fc010025279b6_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzYtNS0xLTEtMA_3ef71f4d-b02d-48aa-a787-3e548d6328ad">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia185bf2a1911407099126af09d6781da_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzctMS0xLTEtMA_0c539bb6-09f4-4017-89eb-968d0bfa1a80">53</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342fe69beb814c41a97a7aef4c9ac973_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzctMy0xLTEtMA_08445fac-db15-4fe0-9e39-4ac204a2d3dc">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0452510b6e3c4fbd81f8cddba0a9d033_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzctNS0xLTEtMA_17a99ff2-0502-460b-947a-6865ed02be92">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0003ff4798514c25a8591c162be15992_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEwLTEtMS0xLTA_9240c5d0-6a9b-4411-96a4-c3283f5af165">114</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd82ed31d7346f58d217331940bd0d2_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEwLTMtMS0xLTA_3ec1c469-9b86-43d4-ac68-31183dddea85">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817d4a5d455b48e0835d76a3e57a68b0_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzExLTEtMS0xLTA_20b91db1-2193-46a8-9159-eec2e674a3f6">472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8063a63e130649cd85c2717196b54dde_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzExLTMtMS0xLTA_c0957017-18de-4587-9471-ef2af8199d6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Includes amortization of intangible assets. Amount in 2021 includes $<ix:nonFraction unitRef="usd" contextRef="ie861385c736d4571ac97d10e57900db0_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQzOTgwNDY1MjU1ODQ_dbf474cf-4fb8-4146-9803-5f10fd303497">153</ix:nonFraction> million of cumulative amortization catch-up expense as noted above. In addition, cost of sales in all periods now includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued milestone payment.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck and Ridgeback, a closely held biotechnology company, entered into a collaboration agreement to develop molnupiravir (MK-4482), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit share calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#8217;s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the FDA granted EUA for molnupiravir. Under a previously announced procurement agreement with the U.S. government, Merck agreed to supply <ix:nonFraction unitRef="course" contextRef="i50e584cc2eff43599af7e4d668e4568c_D20211201-20211231" decimals="-5" name="mrk:SupplyCommitmentQuantityCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg2Njc_997ff1e0-b02e-4a9d-a922-fa57e5994de0">3.1</ix:nonFraction>&#160;million courses of molnupiravir to the U.S. government upon EUA or approval from the FDA, of which approximately <ix:nonFraction unitRef="course" contextRef="i5bf2c56c247444b38c99429fcfcc161e_D20210101-20211231" decimals="-3" name="mrk:SupplyCommitmentQuantityDelivered" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg2ODA_0b68eb4c-8155-466d-90d6-eaed2a5b9232">888,000</ix:nonFraction> courses were delivered in 2021. This procurement of molnupiravir is being supported in whole or in part with federal funds. Additionally, in December 2021, Japan&#8217;s Ministry of Health, Labor and Welfare granted Special Approval for Emergency in Japan for molnupiravir. Under a supply agreement, the Japanese government will purchase <ix:nonFraction unitRef="course" contextRef="i5b951c64d4e94488b0076bc63024ee64_D20211201-20211231" decimals="-5" name="mrk:SupplyCommitmentQuantityCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg2ODk_37b3ccb0-3ace-44b3-87c2-0e6bc86633fe">1.6</ix:nonFraction>&#160;million courses of molnupiravir, of which approximately <ix:nonFraction unitRef="course" contextRef="i756ba880ce0840268980b9aab4635b5a_D20210101-20211231" decimals="-5" name="mrk:SupplyCommitmentQuantityDelivered" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3MDI_adbede86-463c-4a72-b229-db41a668265a">200,000</ix:nonFraction> courses were delivered in 2021. Also, in November 2021, the Medicines and Healthcare products Regulatory Agency in the United Kingdom (UK) granted conditional marketing authorization for molnupiravir. The UK government has committed to purchase a total of <ix:nonFraction unitRef="course" contextRef="i3dce085486ee43df951fdeb7914c2311_D20211101-20211130" decimals="-4" name="mrk:SupplyCommitmentQuantityCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3MTE_9eac7fb0-58ef-4528-ac2a-fbf94038beaa">2.23</ix:nonFraction>&#160;million courses of molnupiravir, of which approximately <ix:nonFraction unitRef="course" contextRef="ibc01fdd92ce142b8bd16ad6681f5c303_D20210101-20211231" decimals="-3" name="mrk:SupplyCommitmentQuantityDelivered" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3MjU_8aefb98a-ddf3-4177-af0a-adae4e2677c0">152,000</ix:nonFraction> courses were delivered in 2021. Merck has entered into advance purchase and supply agreements for molnupiravir in more than <ix:nonFraction unitRef="market" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-1" name="mrk:SupplyCommitmentMinimumNumberOfMarkets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3MzQ_3a754709-95f3-45bf-b7a6-08f1bc2ad8a0">30</ix:nonFraction> markets. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ia6d50d89295f4c2f8dd48df09de88831"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and Ridgeback are committed to providing timely access to molnupiravir globally through a comprehensive supply and access approach, which includes investing at risk to produce millions of courses of therapy; tiered pricing based on the ability of governments to finance health care; entering into supply agreements with governments as noted above; allocating up to <ix:nonFraction unitRef="course" contextRef="if9796277d9ba47be91cb5b887f734e7e_D20210101-20211231" decimals="-6" name="mrk:SupplyCommitmentQuantityCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3Mzk_9d92f7ce-ed80-43c3-bd8d-4c8c4e2da8b7">3</ix:nonFraction>&#160;million courses of therapy to the United Nations Children&#8217;s Fund (UNICEF) for use in adults; and granting voluntary licenses to generic manufacturers and to the Medicines Patent Pool (MPP) to make generic molnupiravir available in more than <ix:nonFraction unitRef="country" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-2" name="mrk:NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3NTA_a4440c30-805f-4b8f-8fd5-ad68f0f641d0">100</ix:nonFraction> low- and middle-income countries following local regulatory authorizations or approvals. Merck, Ridgeback and Emory University will not receive royalties for sales of molnupiravir under the MPP agreement (molnupiravir was invented at Emory University and licensed to Ridgeback) for as long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization. </span></div><ix:continuation id="i3b0d206afb64418f9632ef37b9c696f6"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molnupiravir sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e28bb8b9aa4b7293ac191de6dddfe4_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzEtMS0xLTEtMzQ3NzI_db95e199-2263-4384-a9bb-292a147746f0">952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia356d15f44884231bebbcd7fcdd11f4e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzEtMy0xLTEtMzk4ODk_f662943d-face-4024-a9d5-0ce0b97a30bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097bcd95db4c4868880f6e0af7fcc0c0_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzUtMS0xLTEtMzQ3NzI_9a76a85b-2a63-43b1-9d13-9c95afb62b32">494</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15900e9713c45c48f0b905cb6dda370_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzMtMy0xLTEtMzk5MTI_65ab3bc4-9128-4861-b918-0280548e435e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fb66ab96ce42d89c8d0763fcc77ddb_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzYtMS0xLTEtMzQ3NzI_df8dd18d-6045-432f-a336-500c5b845c1e">33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b31b8b00cfe47f490681a6d81cd140b_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzQtMy0xLTEtMzk5MTI_2c5f56c3-411a-4151-b595-b66a083447ab">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i737ff51dc12248dfac6273aae238abff_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzctMS0xLTEtMzQ3NzI_7e7824a5-02e8-424b-ba26-e443351eb9ea">60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1726f56cf343c482a8f9ccb64bd59a_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzUtMy0xLTEtMzk5MTI_a975a27e-9a7e-4e19-b140-2b312f3b50ef">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13200a779dce464f80cba863cea9e407_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzExLTEtMS0xLTM0Nzcy_b8bf238e-aec2-4226-afc7-c6fb6eba5214">283</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1fde0285ad7451a9e92d2f80b91240f_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzgtMy0xLTEtMzk5Mjg_09c428a7-3bde-49d0-bd33-76e0269a7026">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount in 2020 includes upfront payment.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued royalty and milestone payments.</span></div></ix:continuation></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_157"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzM2MTM_6423e94c-2ec5-4188-a231-f78f1264c53b" continuedAt="i594e6dd2f9d54228b88e1988f8081df9" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="i594e6dd2f9d54228b88e1988f8081df9" continuedAt="ibe9886d3b7d24bf9992ce5f0e219b092"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzkzNg_a4baa16f-9d6d-4e4a-8712-dfd9d6fcbec5">3.5</ix:nonFraction> billion. The Company estimates that approximately <ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4Xzk4MQ_ff9edca5-ed74-4085-8ddb-101d9999cf61">70</ix:nonFraction>% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately <ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzExMzc_55c09a3a-858a-4a81-b391-327a16f6b7c1">30</ix:nonFraction>% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzE1MTM_d481f1c6-f422-41f7-8b44-b8952368a39a">868</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzE1MjM_bbd0422c-19b8-4e4a-9199-f3c5fa024d00">880</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzE1MzY_4dd5f5aa-c62c-4802-aa4b-75d32f3d8e4e">915</ix:nonFraction> million in 2019 related to restructuring program activities. Since inception of the Restructuring Program through December&#160;31, 2021, Merck has recorded total pretax accumulated costs of approximately $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzE3MTQ_e0fdec6e-213f-48fc-b7e8-61616a4dcea2">2.7</ix:nonFraction> billion. The Company expects to record charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i2e67b3bb86584dab8782e051cf58baff_I20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzEwOTk1MTE2MzI0NTQ_a421f0e4-8b2e-4764-a3b2-305ca469ca72">400</ix:nonFraction> million in 2022 related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ibe9886d3b7d24bf9992ce5f0e219b092" continuedAt="i842cf200b2504ca8a768206c26d98cea"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzM2MTU_9551b5c9-1147-4b32-b77c-17530abfa0f5" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aaca85009704ba19f1513e1e6c78715_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzItMS0xLTEtMA_38f3d1b0-86e2-4b6e-b7e3-9e1b8042a223">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31dc8ec6b8e445b7b1b2b75aa10c997f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzItMy0xLTEtMA_acc0d44c-b106-4712-af6f-c4ed3f7bcb50">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida45dba4790a481d8b49ae4d99983799_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzItNS0xLTEtMA_054b9fab-f3f1-4ec9-81a9-2a55d86d32d5">108</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73cb7250e044a5f85e091f1f1ddae2d_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzItNy0xLTEtMA_e352d8d9-09f7-4d80-bbfa-2b32b85225f6">160</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946b15bf33724eab9cd37c967a566b18_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzMtMS0xLTEtMA_cc814c09-d476-47a5-87f5-01008d15d826">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee296e8eeb43419e7163aaf951d1c2_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzMtMy0xLTEtMA_c616a465-cc27-4d87-bfe2-208ab6866ad1">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf3f8d9415a448c18444c1d1d8b1fe42_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzMtNS0xLTEtMA_1bd3234c-4356-4e8e-81ae-f746858f03cb">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31323381bed94598b8252be522569bca_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzMtNy0xLTEtMA_d5ec6457-b85d-4fd4-8bb8-2699ea18af82">19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id56683f71b6048a5b950676e5147ddf6_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzQtMS0xLTEtMA_6716b54b-9fcc-45f3-b6b0-65fc43588129">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e2c2edc5a34bdb938b2ab9082b4ef0_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzQtMy0xLTEtMA_dd276064-6801-4911-97d8-b8a2fd7b36c5">27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac2c9d18fc948e3b3936a9c1745217a_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzQtNS0xLTEtMA_485d1994-74a4-4bc4-b11d-c47ebecbb27f">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59278b50186c44eea02cd1646e7b396b_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzQtNy0xLTEtMA_1e2d82bb-cd90-423b-a3fc-edd696f9ffff">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe328f6c7a841e2b8499cc76eb20e1a_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzUtMS0xLTEtMA_e09d7612-7466-440a-b7b7-a9faf74f82b1">451</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbbd36fe79ec4490af6d95ad286eece6_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzUtMy0xLTEtMA_27c8be14-3a9c-460e-985d-cff06a37a742">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice0f65c662794b7c9441b60c88d828a8_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzUtNS0xLTEtMA_4a6912dd-3a7a-4d0c-9fc6-161d1d22221e">210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a62cdc5b588461686edf03bf5ad6825_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzUtNy0xLTEtMA_00176531-e01c-4396-9933-7af561c8e2d3">661</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4caa478726464d649c33751164cc0d70_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzYtMS0xLTEtMA_533b4a05-4047-4684-b037-e3041a14f23e">451</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzYtMy0xLTEtMA_4ecb69f7-6f8d-4621-abc7-50f11b495ed4">91</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzYtNS0xLTEtMA_1e91cbf4-8e5f-4df3-9c06-4dd160007de8">326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzYtNy0xLTEtMA_08e11146-6463-408f-bf70-fe55735892a2">868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd95b3f5d7d4a40ada1f89d7f2b3807_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzgtMS0xLTEtMA_f8a2d2e3-c824-4b49-821a-5bf72f43259f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba6383149a1b416d85737bb951015359_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzgtMy0xLTEtMA_bfe63798-9d5a-45df-a494-5d31dc3e9c0e">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cf5190146b4f96b1360695ccb6edd8_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzgtNS0xLTEtMA_455a707c-3519-4f49-b869-e860cb7eed36">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30f607f077f64c3daf4b01cf7298bfcd_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzgtNy0xLTEtMA_b70e4b79-c968-4f54-9737-abde5eb2e474">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50bddbb672804072ba20c9dda2af5613_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzktMS0xLTEtMA_37b59fde-b3ca-4d06-b5cd-0522496bb722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380e21df60bd41249e37f76c96e5b370_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzktMy0xLTEtMA_04eae235-e91f-40ed-b743-ae20517cf52a">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0297bc36963248d48192cc37c891ebd4_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzktNS0xLTEtMA_c871cacb-7753-4673-9d8f-f15bac770a58">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa96945711e74e16af5a510b6ad45e87_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzktNy0xLTEtMA_2a3090ca-5592-49c2-8f8d-8066d0cbd0e3">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310042e57f8648c1910a64c356d6e4e6_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEwLTEtMS0xLTA_bf0d6abd-76c0-4cfb-a34e-ddc59c06ca3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46fa1a240c9641f582948709782ebebb_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEwLTMtMS0xLTA_14af2165-a968-41ef-9b01-36931c856397">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e16f47e6744b63b974f8c45a0aebce_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEwLTUtMS0xLTA_2d50afb3-ba4d-4254-9e3d-7423543e84d4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c7436c3f434009bc43ed8fb64f30db_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEwLTctMS0xLTA_86afdce2-088a-4c15-bce8-1197fdf5abc8">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib320e53fbe8f4a71a079672c21ab5589_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzExLTEtMS0xLTA_7169d962-34c1-4329-a339-af9e9f03eeef">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403dfea81e9b44b38f3a6469fc84c66b_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzExLTMtMS0xLTA_4de9c858-1462-4962-8e69-258e3b05d8db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie002d0c48a3741839131c30916e5272c_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzExLTUtMS0xLTA_10b1296b-3e15-4123-9f03-8a086a456ba2">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f343081e674fb6824fe0f6ea3f51b3_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzExLTctMS0xLTA_5ba13bca-83d2-4fa5-a433-294330778bec">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEyLTEtMS0xLTA_8366fcb5-991a-4169-8a19-34c53b1f419a">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEyLTMtMS0xLTA_840e12bc-40b6-4d5a-a969-ed1119e56178">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEyLTUtMS0xLTA_9a562958-a908-4e9c-9678-faaf95627a8c">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEyLTctMS0xLTA_f5b1c8b5-7a85-4fe7-9895-46a83ce839b4">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a74b90c27a4d51bc7a5b722f81b3b2_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE0LTEtMS0xLTA_fc5d2746-f352-490c-85e1-a7f3fa6438e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id19696965a5c496d8add86515a1be5ec_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE0LTMtMS0xLTA_70e886c1-9517-4dfa-b3a2-167e09e52151">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d842b6322f4be89cdc492a4a169002_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE0LTUtMS0xLTA_45ff26ed-4f25-4e18-9ecf-c95790f4cc25">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacdb4cd333404a72ab7e9c4a06cbe2c1_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE0LTctMS0xLTA_822a0435-ee8c-4ecf-ab28-052b2d0529fc">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf1ad6c7e2d42f2b67fbb17e45f48ff_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE1LTEtMS0xLTA_74eef182-cb1d-4b41-a931-d249c9e9221b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb3f09c566f04978a062c5b475fcb376_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE1LTMtMS0xLTA_67ce0f83-25c9-43ea-b5ae-c964d8554f95">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d31ca3c243847fca3ff1222d83159af_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE1LTUtMS0xLTA_ab937252-33b4-4bad-914a-629e3b736ce3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111c43d6a309499f9624c33e82a4ffc9_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE1LTctMS0xLTA_e65e11f6-a7dc-4298-ae28-49dd5372094e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ccf2924ac4f40168f4b02f65db200ee_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE2LTEtMS0xLTA_4f88d3ef-6078-47da-9540-8a31df88c926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf00dc1bbf9946288b16b5451fe51cd5_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE2LTMtMS0xLTA_85181c25-54c9-49d4-a24c-f5d603a7b339">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce6215e57c2458a9afd417343c63d14_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE2LTUtMS0xLTA_ec32e9ad-9c84-4879-95be-33639accdb0a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0c801111b849889a3cb1999277404a_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE2LTctMS0xLTA_775b69cd-bc5e-4833-91eb-b59fc621cbca">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16730c4a678e4c64b56d69ad77692225_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE3LTEtMS0xLTA_64c81241-288e-4ab1-9acb-deda1247f731">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f15ce626aad44f58292eedaa374a985_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE3LTMtMS0xLTA_af97b001-d779-4fb8-a29b-c7a24c6e49ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5f02c13fd4747fc989b60fd784585bb_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE3LTUtMS0xLTA_7f02e7c9-6504-4ee7-9ecc-d2879da5892f">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069b94a80af42e4888ed8c2211e56e1_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE3LTctMS0xLTA_f0a2f193-4ce7-4ddc-ae48-b45e5fd91616">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9199f48459144d88986872e9ce83bcc8_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE4LTEtMS0xLTA_8d8fc983-e8bd-45a1-8a5c-cbb39f1cd269">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1a06d7e97b4f2da011319e92c97eb9_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE4LTMtMS0xLTA_6ac4b385-e693-4ec9-92b5-e700f2386331">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6560744cffdb44c6a15e0de8cb3125c5_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE4LTUtMS0xLTA_178b3ac4-c9b6-4286-a499-864675bfb006">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE4LTctMS0xLTA_98a3d94c-ab01-4596-9420-1a7ad72730da">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2021, 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;14) and share-based compensation. </span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzM2MjM_ffe30eea-fcf6-4678-858d-961ad6614744" continuedAt="i15daabc194ac4c26919ceb5b3e760559" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:45.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa2324a7bd9442db621352f34648867_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzEtMS0xLTEtMA_b664fb15-3114-4d5b-ab83-4fd071481c66">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb507ac1c0b432293ffd49cc271e612_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzEtMy0xLTEtMA_152796ee-2282-423b-a6d6-15eeca2734b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if561463c4bc4425caa176dc7d55ee265_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzEtNS0xLTEtMA_5480ef5d-0dc8-446b-9ef2-e15923bd196c">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzEtNy0xLTEtMA_5cf43290-c3c8-45a0-80f4-085571309891">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzItMS0xLTEtMA_7cc6aaae-005a-4105-b22f-68b98a49a1ce">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzItMy0xLTEtMA_2e9ad7cb-17a6-48d5-b67c-bc81ce0ba3bc">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzItNS0xLTEtMA_8cbc0132-494b-42aa-a851-83813f55dddc">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzItNy0xLTEtMA_41dd39a5-69be-4e54-871b-6fe3e47b45ed">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzMtMS0xLTEtMA_fc68d80b-1a2a-4d9d-85e8-fd855f59671c">508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzMtMy0xLTEtMA_88a5e51e-65e7-4e1e-98f1-9157d0be4e2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzMtNS0xLTEtMA_8b6e6090-7925-4d29-acc2-e22f2dd5cf96">271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzMtNy0xLTEtMA_726585aa-d0a2-47b6-9765-56cc3942ed9f">779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzQtMS0xLTEtMA_8591f54e-03a1-4a99-a618-b7ba2f735ffb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzQtMy0xLTEtMA_4b555799-c7bd-4a20-ae20-7954fe8a99d4">268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzQtNS0xLTEtMA_e8cb63e9-8105-49d9-b7e4-89458b99571b">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzQtNy0xLTEtMA_d936144e-0ac8-4a57-9608-83c9125923ab">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc98ae55b3748a19a4a059028c47b39_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzUtMS0xLTEtMA_0d42a94f-7621-4b2c-8015-138c8f3048c1">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bbf238dd6a44468ac376288e4e1add_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzUtMy0xLTEtMA_92a71058-31a1-4101-b399-559621b505be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id389b623812d474ea6c5ac6b16c29504_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzUtNS0xLTEtMA_f893bf46-13fe-4f04-9a6d-3f24bfbd3bd7">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzUtNy0xLTEtMA_e8bd5ca1-c52f-4aa5-a8db-e6eb8ec5ba17">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4caa478726464d649c33751164cc0d70_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzYtMS0xLTEtMA_29ddf8c2-edb4-4b48-9337-6ea12589cfc6">451</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzYtMy0xLTEtMA_038b55fa-1c7e-415b-90f1-1b38d1e9d0a1">91</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzYtNS0xLTEtMA_c194e780-4234-415a-a998-11f7aff73216">326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzYtNy0xLTEtMA_038b8a8b-6510-4865-b32a-3c1c675d2416">868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4caa478726464d649c33751164cc0d70_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzctMS0xLTEtMA_9edaa43e-b0b5-4ada-8a75-3d63e69c73de">422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzctMy0xLTEtMA_933c3d4d-170d-465a-a5fa-4a3a530b584b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzctNS0xLTEtMA_e0e5de5f-6a21-420b-965e-2ad441c8630e">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzctNy0xLTEtMA_ea94b252-9038-46ba-a9aa-cfc0fcafbd37">608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4caa478726464d649c33751164cc0d70_D20210101-20211231" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzgtMS0xLTEtMA_289245df-8bdb-4d62-afd1-4a308210cce7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzgtMy0xLTEtMA_b586fd59-e618-41ad-908d-a49e7abc7375">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzgtNS0xLTEtMA_8b871717-21e0-4175-90dd-622b1c447a84">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzgtNy0xLTEtMA_a46b9b8e-2aff-498f-8ff7-f0fb1b612120">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December&#160;31, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb664c71c0594335bb3a3f87041223a1_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzktMS0xLTEtMA_e50d78ce-8bbb-4941-ac01-4cd9a99c4c5f">596</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b9087bb1864779b2109ddd342e45f4_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzktMy0xLTEtMA_a44b0e9b-dd9f-44cc-80d0-8b1dca4f65e9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d11003c0d414a6e8d574694e9ec9dea_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzktNS0xLTEtMA_3ff7b0f5-7ce5-4c6d-9336-44401fdece32">41</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzktNy0xLTEtMA_754d404a-343f-488c-8afa-6d0895e64057">637</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i842cf200b2504ca8a768206c26d98cea" continuedAt="i50d512a5db6f4c2497a2e68328e1872a"><ix:continuation id="i15daabc194ac4c26919ceb5b3e760559" continuedAt="i81a1c0f2970a4bf29985252f7a9268a0">(1)&#160;&#160;&#160;&#160;</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i50d512a5db6f4c2497a2e68328e1872a"><ix:continuation id="i81a1c0f2970a4bf29985252f7a9268a0">The remaining cash outlays are expected to be substantially completed by the end of 2023.</ix:continuation></ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjU1_742d56c7-41d9-469d-98b2-eeb40d7e093f" continuedAt="i628769ee7e534f3c857a711aff72fcc5" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i628769ee7e534f3c857a711aff72fcc5" continuedAt="i0c614d1abef940e2b7e1f0d62db0885a"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than <ix:nonNumeric contextRef="if6e9ec1cceb94d9bae732843b25cdb75_D20210101-20211231" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE0ODU_6156b8ed-c157-4b97-a28a-ec2fb5952f17">two years</ix:nonNumeric> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than <ix:nonNumeric contextRef="i1ee26aaae9074659993d6d84e4de1ffb_D20210101-20211231" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzQ5MTc_9dccba6b-9226-4df2-8e97-c29e6166d953">one year</ix:nonNumeric>.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i0c614d1abef940e2b7e1f0d62db0885a" continuedAt="i2101f0e0e1ac492da44f5a59c9a54f8d"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjI0_b9c7970e-dc2c-4e47-839f-fe45d6abae9c" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:35.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtMS0xLTEtMA_f5d41a5d-587d-4c75-aaef-a4feae77aecd">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02721ef0aaab4a4caee301f22e9386ad_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtMy0xLTEtMA_8c8e78bb-8647-4ad6-80f2-9bd30a2013e2">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84bb7bc1ceda4f948a3090842627e654_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtNS0xLTEtMA_4dad5742-bfee-4cf0-b8e9-8aa3c2409f91">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3e1bd075f93491e9df5f7f32bd7ad1f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtNy0xLTEtMA_44f6931a-d44c-411c-a065-20eeb4717d70">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib65521c997c84ef8b37cc9b21ffd59d6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtOS0xLTEtMA_6f2651dd-6f01-4ce0-b92f-591d89772a02">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie72e897aad094644a983458bfe8704d2_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtMTEtMS0xLTA_ea42e8fa-a16d-4a38-9e88-a3633fad40cf">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibeeff8ebe3be4a60ab7c727335780af7_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtMS0xLTEtMA_58b6fa85-8f6f-4dd9-ac9e-d03adbabb235">296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9352e4c6900b48a3965ce12d07bf3a06_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtMy0xLTEtMA_c0dd7a45-6ee9-454c-9f09-0dd16b7542a4">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie137bb0fd9d44320bee063d82bfcf668_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtNS0xLTEtMA_08615bf4-e93b-4929-a12c-6b245cbd96cb">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e9d32d55204511bafd6a9816b6f024_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtNy0xLTEtMA_9fe0b64a-0bd1-46ff-8458-3efe5e0e9ed8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a496974bc6443bb93bb621dd56fc567_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtOS0xLTEtMA_df682006-d29f-4c2d-823d-6a0d7c964e2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df804136d5442df9b3d7abea422a604_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtMTEtMS0xLTA_1c74e6f4-3cea-4e10-8fbc-e1f026585c23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021,&#160;<ix:nonFraction unitRef="interest_rate_swap" contextRef="ia2bbb9db2c294c3ba3a6368380f2e03e_I20210131" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzY5ODU_726114e9-392e-4ce2-8cd4-da0d217314a8">five</ix:nonFraction> interest rate swaps with a total notional amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="ia2bbb9db2c294c3ba3a6368380f2e03e_I20210131" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzcwMzM_a174e0db-f5a9-4ba3-a430-6b21059d2dc8">1.15</ix:nonFraction>&#160;billion&#160;matured. These swaps effectively converted the Company&#8217;s&#160;$<ix:nonFraction unitRef="usd" contextRef="i8fe94b07a3fc4572a433b1102b900e44_I20210131" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzcwOTg_219af197-c1d9-42af-99c7-ea5dd8994f10">1.15</ix:nonFraction>&#160;billion,&#160;<ix:nonFraction unitRef="number" contextRef="i8fe94b07a3fc4572a433b1102b900e44_I20210131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzcxMDI_9bb1bdb9-3248-4159-9591-51ccd59c2238">3.875</ix:nonFraction>%&#160;fixed-rate notes due 2021 to variable rate debt. <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjIx_cc5a9e60-1c9b-464d-8c7a-426bcd63c292" continuedAt="i81f94425fc5442d6a418157b0fc9a12c" escape="true">At December&#160;31, 2021, the Company was a party to <ix:nonFraction unitRef="interest_rate_swap" contextRef="i310109d6898342d49bc826875e191ad6_I20211231" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzcxODg_c53d1f80-c2b2-40ec-8550-d2d5555f40dc">nine</ix:nonFraction> pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: </ix:nonNumeric></span></div><ix:continuation id="i81f94425fc5442d6a418157b0fc9a12c"><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9de5cdef0a234eefaec97bc914e30cc3_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjM0MGI4YzBmYjdmODQyMWViN2Y3OTEyZWRkMTM2N2I2XzQ_f67ee628-b64d-474f-adc8-49b6db118324">2.40</ix:nonFraction>% notes due 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de5cdef0a234eefaec97bc914e30cc3_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzMtMS0xLTEtMA_cf8c2519-2cdd-4131-8e8a-be18cdfdf8b6">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="interest_rate_swap" contextRef="i9de5cdef0a234eefaec97bc914e30cc3_I20211231" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzMtMy0xLTEtMA_3bf678c7-0945-40d0-9ebe-e8ef1cd9852e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de5cdef0a234eefaec97bc914e30cc3_I20211231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzMtNS0xLTEtMA_7d909550-3bdf-4775-b465-10e6de57c6bc">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i591a75ce070d4aaf981adbe405971c39_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJjYzExOWI0NGNhMTQ1YjBiNjU4MjE1NjE0Mzg0MWU2XzQ_0a55091e-00db-43e1-bba0-5feede995d9f">2.35</ix:nonFraction>% notes due 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591a75ce070d4aaf981adbe405971c39_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzQtMS0xLTEtMA_09e44543-cf20-4652-900b-aa31fe82f71a">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="interest_rate_swap" contextRef="i591a75ce070d4aaf981adbe405971c39_I20211231" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzQtMy0xLTEtMA_935e82c7-86ad-43a1-9f9e-af6937cb897e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591a75ce070d4aaf981adbe405971c39_I20211231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzQtNS0xLTEtMA_83d8dec2-44ee-4b96-a2b7-c71ce1fab4ec">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These interest rate swaps matured in February 2022.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. See Note 2 for a discussion of the pending discontinuation of LIBOR as part of reference rate reform. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i2101f0e0e1ac492da44f5a59c9a54f8d" continuedAt="i11fff2ed16c64ae4acffff3a25c4c733"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjQ4_0e660cdc-0981-478f-b76b-d9946980d845" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:43.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752aeb3870ee4f6bbfd196995b6998d0_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzMtMS0xLTEtMA_8451d6d0-7371-4e53-bf7f-666a8930685c">2,263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6611393547d42b1bc24ebbbb98dc51d_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzMtMy0xLTEtMA_0e4f7c29-4c47-4a97-9397-64d1e2865554">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752aeb3870ee4f6bbfd196995b6998d0_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzMtNS0xLTEtMA_650d4393-9033-4273-9189-8c40abf0bbdb">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6611393547d42b1bc24ebbbb98dc51d_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzMtNy0xLTEtMA_1758b38f-d181-4a0f-83ae-70828d300f2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ac86e44601419fa50cb8bfba8997cc_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzQtMS0xLTEtMA_244d2f19-2798-4001-9f13-8172db82d9b6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3c2b08bde54d01b9032cf85c1bae1b_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzQtMy0xLTEtMA_9dce19ec-da54-4374-bed1-7f5e101c2dfd">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ac86e44601419fa50cb8bfba8997cc_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzQtNS0xLTEtMA_e60c8cbe-9636-4b3f-b838-f64eaf467821">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3c2b08bde54d01b9032cf85c1bae1b_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzQtNy0xLTEtMA_cdbc9e9f-96d1-4e62-b155-8ca5b2c3337e">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5Mjg3_291c576a-83bb-4cb8-8348-90441e7f5739" escape="true"><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c86a1b952c48f7861dbe9b5aeab121_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzQtMy0xLTEtMA_da7c6964-16e3-4c24-af1d-5b3292012ff5">14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c86a1b952c48f7861dbe9b5aeab121_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzQtNy0xLTEtMA_a2ac2c2b-6344-4bba-9375-a7ed54d55f26">2,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36b163f3e8e43d6ae5f69d6957c282f_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzQtOS0xLTEtMA_157f634b-3e70-4e28-bae9-03e206b37681">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36b163f3e8e43d6ae5f69d6957c282f_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzQtMTMtMS0xLTA_00e387dc-0c4c-428f-83ea-ddf2cb0b1d13">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e71a0f38b8445fad18e25a0d495afe_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzUtMy0xLTEtMA_8d2c2ba2-f261-45b0-810e-3e05bfe3dc55">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e71a0f38b8445fad18e25a0d495afe_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzUtNy0xLTEtMA_f8390a0a-6d67-4421-9941-3130f5262684">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0bd1d54e2d34252a1c972fe50060600_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzUtOS0xLTEtMA_7e466cb9-a07b-438c-8957-80f2116741ba">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0bd1d54e2d34252a1c972fe50060600_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzUtMTMtMS0xLTA_5ba6007d-c379-41e7-b963-d146dffe7d84">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c7da2a453a443a3976d58aac76e2b44_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzctMy0xLTEtMA_e4c3e696-9660-4468-8836-a72238281d6f">271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c7da2a453a443a3976d58aac76e2b44_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzctNy0xLTEtMA_47133da6-0e2e-4657-ba9b-cf8534687adc">6,778</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09985e2ea91f4c08a1fb3fe016edfca0_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzctOS0xLTEtMA_12a637d8-439e-4fdd-963e-136d8a85e867">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09985e2ea91f4c08a1fb3fe016edfca0_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzctMTMtMS0xLTA_8b3f3b5d-3356-4cc6-9be4-a5223ee6e1a0">3,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cfa0f51218476493154e53e8b1dbb5_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzgtMy0xLTEtMA_e126b43e-3122-4043-b484-52d6e6f88357">43</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cfa0f51218476493154e53e8b1dbb5_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzgtNy0xLTEtMA_f17454fc-c553-4225-8b1f-97400f357913">1,551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab442d7528e4761a37ccabe79942355_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzgtOS0xLTEtMA_f7b57715-d6a4-4dee-8ea8-f296df6c6008">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab442d7528e4761a37ccabe79942355_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzgtMTMtMS0xLTA_a97b8568-b7c4-4a5f-904d-3a3ad0ca689c">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30aa462731e489cadd31a7b7aa3f2c2_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzktNS0xLTEtMA_84e8c669-d0cf-46ee-9f95-f5eeed15b240">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30aa462731e489cadd31a7b7aa3f2c2_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzktNy0xLTEtMA_fe864114-af7c-4a35-9594-f3398bc3c079">1,623</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d4a664ab5b4b76bf159dc924348812_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzktMTEtMS0xLTA_a18a33f5-7d49-405b-864d-db9ce7bcb66f">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d4a664ab5b4b76bf159dc924348812_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzktMTMtMS0xLTA_96e70d4f-f80b-40b6-9112-094436a92469">5,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc35655fc94795bae5c9b1bf8ef198_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEwLTUtMS0xLTA_174f689a-9bf4-4090-aff3-773a2d7f876d">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fc35655fc94795bae5c9b1bf8ef198_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEwLTctMS0xLTA_6758db49-1770-4dee-8c03-ec620065fe2f">43</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9731ca41dc5346328715b1b72d90d14a_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEwLTExLTEtMS0w_57984d03-3158-4240-af24-2a32986135e8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9731ca41dc5346328715b1b72d90d14a_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEwLTEzLTEtMS0w_bc3d8bd4-99af-4bd9-bbba-edbd5cf37ef6">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bfc38d37e5a42ac8fc03da3a897894d_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTMtMS0xLTA_974dcd0e-baf8-4594-8be7-ff71885de6f2">328</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bfc38d37e5a42ac8fc03da3a897894d_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTUtMS0xLTA_8c6d3927-17a9-4b61-a8e6-cfc7ec40695f">25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bfc38d37e5a42ac8fc03da3a897894d_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTctMS0xLTA_cfb0690a-fb23-4fa2-ba82-4fc695684433">12,245</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516472e36f9d496aa8c94bb0c311f117_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTktMS0xLTA_c2ecfc60-7eb8-4624-b2d5-bbb3372700d2">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516472e36f9d496aa8c94bb0c311f117_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTExLTEtMS0w_420cedcd-db3b-4429-ad3a-b73ad5cf23b7">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516472e36f9d496aa8c94bb0c311f117_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTEzLTEtMS0w_792551aa-70d4-406d-a673-073784880308">13,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccd34269c794e22960b8ccb14c99461_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEzLTMtMS0xLTA_5442c90e-33d4-4e1b-bd5d-d688e2ddb519">221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccd34269c794e22960b8ccb14c99461_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEzLTctMS0xLTA_b5de9704-d409-461a-b893-c8aa9996afda">10,073</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e2b59714c6844d68d8390e2770ef044_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEzLTktMS0xLTA_626da3d0-0dc2-4a77-95b4-0e6f7c82dbc3">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e2b59714c6844d68d8390e2770ef044_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEzLTEzLTEtMS0w_44356b0b-962d-4591-90e9-fec6953b4e35">7,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90d34918e9842f5b8088721b0df39e4_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE0LTUtMS0xLTA_6e05dd7c-a8c3-4874-aadc-d5cb479e78c2">96</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90d34918e9842f5b8088721b0df39e4_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE0LTctMS0xLTA_ee50e669-14c2-4812-a5a3-2bf96ee3d637">10,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5b7d60396c746879acbf1477ac19434_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE0LTExLTEtMS0w_c1e42dc6-864d-4a6b-92a1-b2c6737e44ce">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5b7d60396c746879acbf1477ac19434_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE0LTEzLTEtMS0w_f8c829f5-6571-4030-9d73-b68d01891fe7">11,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee6fff4646d4707a2a06f61ed411ffe_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTMtMS0xLTA_19dcfa72-be26-485e-a504-5ccf013b4762">221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee6fff4646d4707a2a06f61ed411ffe_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTUtMS0xLTA_3f8da9c8-8e24-4416-89be-6974e49211e1">96</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee6fff4646d4707a2a06f61ed411ffe_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTctMS0xLTA_b18f19db-4e20-43f1-84ad-458a4a682e21">20,713</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20fbc9f911a54d23b75ffedfccc36c36_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTktMS0xLTA_dbb0064e-d15e-4868-91ff-e8477a83b286">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20fbc9f911a54d23b75ffedfccc36c36_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTExLTEtMS0w_4b9d157a-e1b2-4401-b5a4-b700c83df089">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20fbc9f911a54d23b75ffedfccc36c36_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTEzLTEtMS0w_01618452-a571-45ce-b2a8-6bd502e564fb">19,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTMtMS0xLTA_6f0248b2-4a66-4969-8ea1-1fbd342f8c30">549</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTUtMS0xLTA_af7d8371-09d2-4d7d-b914-9f6f66f1c3c3">121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTctMS0xLTA_11c2df32-09b1-4d51-a794-71d44dacbcec">32,958</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTktMS0xLTA_0e676790-14f0-4f25-b969-28dc56047aa9">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTExLTEtMS0w_5d706834-ff3e-4207-af03-7e2924dfd465">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTEzLTEtMS0w_c29ea7e4-dfac-470a-9721-8d659f631a53">32,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="mrk:OffsettingAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjE0_3769cf90-2014-44be-b761-fcd6a40054bc" continuedAt="i07040dfb5a914cc89c6e117adcee4978" escape="true">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><ix:continuation id="i07040dfb5a914cc89c6e117adcee4978"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:59.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzItMS0xLTEtMA_3f5b7322-8819-4967-8d73-96864daedbc6">549</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzItMy0xLTEtMA_95271355-c601-4738-b1ba-2211cb1d9969">121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzItNS0xLTEtMA_5528fb0e-d4d8-48f3-b025-08c50b18c7e2">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzItNy0xLTEtMA_ea698cf3-8af6-4cdc-8539-ecd84484d5c1">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzMtMS0xLTEtMA_181a6533-45a5-437f-b2e5-a02249e924c6">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzMtMy0xLTEtMA_33224fc9-2fc2-40c3-b228-2edae0cea09c">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzMtNS0xLTEtMA_2359984b-00b0-4e51-8c07-be7e0001fb45">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzMtNy0xLTEtMA_994990f2-7b33-436d-b4a1-9ae1a18aa540">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collateral posted/received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzQtMS0xLTEtMA_b485f4d6-42c6-4f0c-9067-4c301788613d">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzQtMy0xLTEtMA_43a852a7-7e94-4826-9a35-82f51d338348">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzQtNS0xLTEtMA_f2a1f580-3ad8-4dc8-a101-92a7196a9d6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzQtNy0xLTEtMA_58198cd9-7b98-4ddb-9c89-307d52f8ca54">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzUtMS0xLTEtMA_950d2b30-cf00-4ee0-800a-a02a130ed1e4">275</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzUtMy0xLTEtMA_c7ef1d0b-4fe2-445f-89ff-832b3de8d4b4">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzUtNS0xLTEtMA_1e83e8b3-15f9-4677-8a92-11383103cb22">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzUtNy0xLTEtMA_f33228be-0293-4a0a-bcb5-aca4a5b0809e">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i11fff2ed16c64ae4acffff3a25c4c733" continuedAt="i113cba5d0a0642208da27c9c63be7a83"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjQy_847cb678-db82-4bb5-9e10-f7c709c90cac" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMS0xLTEtMA_e9ba35a1-796a-4918-8a31-563f710742c7">48,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMy0xLTEtMA_5d4fe67b-5bc5-41e9-9c6a-cfdfc2a60b24">41,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItNS0xLTEtMA_8321d7e8-dee6-4216-9684-6e006ea722b5">39,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItNy0xLTEtMA_f86853c3-579f-4c7a-9a52-011609aea341">1,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItOS0xLTEtMA_a99eca07-7b63-4e79-a856-07713a5afb32">890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMTEtMS0xLTA_0bfea1ba-1532-4ff9-8b6c-d14343e9d14d">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMTMtMS0xLTA_91d06469-023f-4ab7-808c-1c5a8ba9946d">1,756</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMTUtMS0xLTA_2f3e958e-1094-43a0-8543-bbbb764e562e">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMTctMS0xLTA_e0d435cf-2c56-4f5f-bbe7-5d972fc3f489">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib59169c0f6834a5a9361dc5a5dd9fb50_D20210101-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzUtNy0xLTEtMA_72fbcbba-8c18-4d0c-9b51-21b1e2720a80">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ea01dfaf7b4584b7cb6e99f32d5f16_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzUtOS0xLTEtMA_35d523a1-83f4-4092-b85c-e491acaedd07">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733145edccf544dba291d9978b2c7899_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzUtMTEtMS0xLTA_83ce2b9a-8346-4bbd-910b-0476783a6c0e">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59169c0f6834a5a9361dc5a5dd9fb50_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzYtNy0xLTEtMA_3ecc9d4c-7c86-4285-9924-d5b32a8440c4">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12ea01dfaf7b4584b7cb6e99f32d5f16_D20200101-20201231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzYtOS0xLTEtMA_4a19ec6f-6fbf-40ae-b61a-bc6372587953">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733145edccf544dba291d9978b2c7899_D20190101-20191231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzYtMTEtMS0xLTA_d25514ea-b23a-4648-a206-0e7a49582565">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzktMTMtMS0xLTA_68b6ed04-9639-499c-9865-19485a345e78">333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02721ef0aaab4a4caee301f22e9386ad_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzktMTUtMS0xLTA_cd48f40a-a98c-46a8-962a-32ec092b8bb3">383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84bb7bc1ceda4f948a3090842627e654_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzktMTctMS0xLTA_45fa81ea-9bef-46cb-a359-be5c51c27ba4">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1efd7da37e42404d934244b631380e00_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTEtMS0xLTA_a2447880-7b33-46ca-8098-623b3cf9258f">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6696a02570e049eead17b64f1424b15f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTMtMS0xLTA_2424d00a-9e35-4032-b039-4b3210e5f195">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57b83c73b584975acd4aa8663d43dd8_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTUtMS0xLTA_c088cb72-a2d3-4164-a7e2-6d3121e7d169">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTEzLTEtMS0w_583f1f68-b336-4e9f-a6b9-2ce275cf2e7a">194</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02721ef0aaab4a4caee301f22e9386ad_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTE1LTEtMS0w_ff396b28-f565-4991-9363-639c10333376">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84bb7bc1ceda4f948a3090842627e654_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTE3LTEtMS0w_c3ae838f-11ec-472c-b4a9-0ab3f9f09e1c">255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib59169c0f6834a5a9361dc5a5dd9fb50_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEyLTctMS0xLTA_b66f5d90-8b5d-471f-bcb3-8acfc9ccb1f3">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12ea01dfaf7b4584b7cb6e99f32d5f16_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEyLTktMS0xLTA_202042e5-4530-44ac-a5e5-6a2d95aaf5cb">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i733145edccf544dba291d9978b2c7899_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEyLTExLTEtMS0w_526f0968-5f6a-40ac-85c1-61fdbfe188b3">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1d3b1cd3244e0aad923e07c063a9cc_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEzLTEzLTEtMS0w_ddd9d787-6933-4d50-8918-506f55d8cdaa">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539bde58e63e4ef48c1df31dfc07d91a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEzLTE1LTEtMS0w_a06d29fd-7542-4fe6-b45f-f6fe764bea92">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02bd2346097c4b3b9fe8e30de60e2cf3_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEzLTE3LTEtMS0w_fed4aa30-20b5-4cef-a0f4-89e9cd9d5125">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjY5_022d539a-f117-4763-b39a-5a54f6ca4318" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:41.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e1bd075f93491e9df5f7f32bd7ad1f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzMtMy0xLTEtMA_9d7ae229-2bf0-47a6-be99-802e810797b5">313</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib65521c997c84ef8b37cc9b21ffd59d6_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzMtNS0xLTEtMA_cf2da042-fbd9-4430-afa4-f3ae39c504e8">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72e897aad094644a983458bfe8704d2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzMtNy0xLTEtMA_2eaaca5f-1a14-4bbb-8a41-a2ae9070c663">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4641a8e98d45b995aa58ccc3163f5d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzQtMy0xLTEtMA_9236409c-5676-487c-9ec8-c53414fabc8f">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c61111e751460c82200beada745607_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzQtNS0xLTEtMA_eaa9d696-a647-433e-ae77-7e9d58b9d5bf">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i713d31c07f5a4005843f4d9cf95d467d_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzQtNy0xLTEtMA_e472f7c9-ff25-4234-9ca5-a727055fcf10">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a88bace3aac440ea9b4d06c6c356839_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzUtMy0xLTEtMA_4c36caf3-21f1-495f-bda1-f2cbd793f7d5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief07c343564f4087b2e4707c3e91f20e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzUtNS0xLTEtMA_89953910-2401-49fe-826c-d19f84e68a86">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe1bc7905c64eee8380775080e0e9ce_D20190101-20191231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzUtNy0xLTEtMA_508665f9-5ea2-4fd7-8841-af4147a79b28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d6586ddd354fdab6d1c9bcba27020f_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzYtMy0xLTEtMA_44e9b5e6-90e8-441a-bed3-7f7b87924c49">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c020fbadbb34c96a252288c30f7d10c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzYtNS0xLTEtMA_0b8e5335-3d98-477a-85be-8941960b59a4">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6efd6ed9184294a5fe275ff87e45f2_D20190101-20191231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzYtNy0xLTEtMA_52fcd90a-fbde-4c39-ad69-0c7ac785bbd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company estimates $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzk2NzA_78e24d41-f1e1-42c3-841a-ac6efa6c01e4">170</ix:nonFraction> million of pretax net unrealized gains on derivatives maturing within the next 12&#160;months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i113cba5d0a0642208da27c9c63be7a83" continuedAt="i804b918facfa4c319ee1031022a43920"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5Mjc3_3b0244a5-66de-4d20-81f1-8a129cdff389" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December&#160;31 is as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:27.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1883b0f48cea47939cd4e2cd6084fd78_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMS0xLTEtMA_3a294c60-4c94-4fcd-85b6-b1e8395cad26">80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1883b0f48cea47939cd4e2cd6084fd78_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMy0xLTEtMA_fe565491-20e8-4157-881c-0112b5b54db3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1883b0f48cea47939cd4e2cd6084fd78_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtNS0xLTEtMA_a8e2c8cf-0e4a-49ba-b7ca-b66559689f22">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1883b0f48cea47939cd4e2cd6084fd78_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtNy0xLTEtMA_1c351bb5-41ce-4c87-877b-e5611522d380">80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32737545f1ac4e5788d077690a87566c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtOS0xLTEtMA_b6d758d8-1239-44d7-83cb-d27e78035ef5">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32737545f1ac4e5788d077690a87566c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMTEtMS0xLTA_1d6417a3-a350-43a7-a997-c4b9a33a0440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32737545f1ac4e5788d077690a87566c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMTMtMS0xLTA_6a570fef-f239-48a7-ba35-30e44e5cd96a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32737545f1ac4e5788d077690a87566c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMTUtMS0xLTA_0691cd98-4567-4430-a16b-56f9c4190b69">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMS0xLTEtMA_23ce1236-7083-4915-82bb-0210015be1a8">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMy0xLTEtMA_45aae2bc-5fb2-4d38-b224-4528ed610090">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtNS0xLTEtMA_1c92a30c-95f9-42c2-a4e2-d58229f7d616">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtNy0xLTEtMA_c470d4ff-a1de-4068-99bd-fe53a43a523d">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtOS0xLTEtMA_bbe50853-a766-4aad-9164-10a534bb5d8a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMTEtMS0xLTA_df6862e8-d8ec-4503-94a7-86d287ea6706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMTMtMS0xLTA_8d3c814c-6936-4385-9c51-09aa3a3bb04b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMTUtMS0xLTA_c9ba656f-e74d-47d6-988c-aad19afd969c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8165d1112e047829b04b7cf5d434fdc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMS0xLTEtMA_cb6066c9-3b8c-421f-b5f1-1c3d129cd90c">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8165d1112e047829b04b7cf5d434fdc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMy0xLTEtMA_561166d7-c5d2-4427-bc97-e2eacdd9b637">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8165d1112e047829b04b7cf5d434fdc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtNS0xLTEtMA_7364ad4f-ef4d-46f8-80ac-4dfbdabcab51">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8165d1112e047829b04b7cf5d434fdc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtNy0xLTEtMA_51d6951d-70ef-4a00-acef-3cf36d0c89df">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b37f94f01344d068373b8eadf59831f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtOS0xLTEtMA_a9c806b5-04ff-43da-a244-96be63953590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b37f94f01344d068373b8eadf59831f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMTEtMS0xLTA_e8b031df-9be4-42e5-a00b-fa3325e25ce7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b37f94f01344d068373b8eadf59831f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMTMtMS0xLTA_593a4657-221d-4106-8d7a-ea7430527c41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b37f94f01344d068373b8eadf59831f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMTUtMS0xLTA_59dbaa56-f282-43e3-907f-2ce5002b4324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMS0xLTEtMA_a232a1a5-b747-4f02-a12e-acffcb49cb70">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMy0xLTEtMA_a3cf6b9f-5932-4426-9b4a-5ebdc1fd4f65">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtNS0xLTEtMA_cc6a3fdd-8f22-4688-b322-36e80c08ed6b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtNy0xLTEtMA_c86892ef-0197-4069-8f63-9044e1801225">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtOS0xLTEtMA_ffc9214c-d8cc-494b-9383-2676c59a15a5">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMTEtMS0xLTA_20ace1e4-68b7-4271-ba5e-eb44b2bbae32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMTMtMS0xLTA_86d92783-1b0a-41f2-b2a7-2cb2ee83f1ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMTUtMS0xLTA_e7b1d932-0241-4c56-85eb-73f8ad724cba">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzktNy0xLTEtMA_00198171-6c50-47c1-b287-56a1eb0ba312">1,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzktMTUtMS0xLTA_46298776-07a1-46dc-b4da-7eeb817df849">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzEwLTctMS0xLTA_e44f6621-5e4b-45f8-a5bd-7eed6a5da91a">1,733</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzEwLTE1LTEtMS0w_be035657-1e5a-4a20-839a-b9be77851ff5">1,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2021 were $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwMjg4_c1601801-e4d9-437f-bd95-d12b62230b87">232</ix:nonFraction> million during 2021. Unrealized net gains recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwNDA4_3589bda4-db2a-4b36-b53e-01708a366ce0">163</ix:nonFraction> million during 2020.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, the Company also had $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwNDU3_b9db6412-f9b4-4a64-bd9f-004fc6608360">596</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwNDY0_f85487e9-46d1-4abf-a6d4-c3abd511bfc9">586</ix:nonFraction> million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During 2021, the Company recorded unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwNjMy_16a47a63-662d-48ea-bcbe-11958cb92735">110</ix:nonFraction> million and unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwOTk1MTE2NDkxMzU_b6b36c01-f6eb-4be9-8cbd-7edc4f5702aa">1</ix:nonFraction> million related to certain of these equity investments still held at December&#160;31, 2021. During 2020, the Company recorded unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwOTk1MTE2NDkxNTY_95a0b586-71a7-4a52-baf7-a4d53a6cb54d">62</ix:nonFraction> million and unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwOTI0_8d83aa02-a595-4b56-90dd-ad8e8a19f821">3</ix:nonFraction> million related to certain of these investments still held at December&#160;31, 2020. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December&#160;31, 2021 were $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzExMjQx_3bf8904b-fb19-4f1d-8f73-9bf76161aace">234</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzExMjQ4_40a486dc-d41e-4b0b-a896-cd9d56c76d5a">7</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, the Company also had $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjczNjU_c9223316-cee1-4d5d-9af4-fbc58004c918">1.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjczNzk_085ec0b1-2b3a-4804-978a-b9c5388637fb">800</ix:nonFraction>&#160;million, respectively, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. (Gains) losses recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating to these investment funds were $(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjczOTM_316f0acb-33b5-4c1e-b2bb-3c03506349ae">1.4</ix:nonFraction>)&#160;billion, $(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0Njc0MDc_b353a358-c127-4f3f-8374-842fea1b99ee">583</ix:nonFraction>)&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0Njc0MjE_7a25735b-711a-4520-9dc2-1d8e81e97de1">113</ix:nonFraction>&#160;million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i804b918facfa4c319ee1031022a43920" continuedAt="ib2f010e69c794c489778d81f5b4d5340"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjI5_bcbd594f-4cb7-408a-a775-0746d132f0ca" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:18.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5e799c31be4b2b97f3af704a0044b9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMS0xLTEtMA_c5f0683b-3194-40d6-a3e7-ca780d4d72e9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7088d09c4094d16b9f7a4d53c7aa102_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMy0xLTEtMA_afc17bb4-0520-47a1-a566-379ce6df4ad1">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2d0cb66d6843a2b24234f1871d47d9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtNS0xLTEtMA_abbe834b-9baf-409b-acfe-577c905dc98b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7753d387d18e460ba9fe6aa0c2630a87_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtNy0xLTEtMA_1a355c67-7827-4b75-94f7-bea1f6e7fe1d">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2278c012f1844a228077b20f27d2ee75_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtOS0xLTEtMA_38d95664-8069-4767-bdab-469bcf814dfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb2266cfce24ebfb26a77e0821736a3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMTEtMS0xLTA_eee724b4-5910-4106-aa52-3db3ee6b7319">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3ce1e7833a43afb07fd5c57894ed59_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMTMtMS0xLTA_bbffade5-6ccc-47f6-b612-3d76dd07055d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9eec4c9abea402cbed26716dfe0330c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMTUtMS0xLTA_394e7751-f44e-4614-bce6-a85afa1e28ae">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe99227a96e498abb64a74bdc78ffa9_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTEtMS0xLTA_da35f57e-15e4-465c-b197-a90c4590cfb7">368</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d46b377a489415a9f6e4c66fe01bf48_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTMtMS0xLTA_2235b091-4372-444b-9554-5ed80efe153e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06b300d5fc54b4b9783aa98a7eb7558_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTUtMS0xLTA_c1422ced-893a-47ca-88eb-ac0641583624">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd24ccfb9ef45e5b7c7e11d85d3c5a7_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTctMS0xLTA_bd68c5bb-b9b5-41af-b7f3-9395eccf7f84">368</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4831a0db655443696586e7bf7801c3a_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTktMS0xLTA_cd5fe5f4-d24e-48a5-8d18-f4ed689632dd">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5cd4dd6f92f4fb4aeba7cc718e0b003_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTExLTEtMS0w_7dcbc4be-786f-4e1b-9040-802ef6697876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b812ad7f9c4916b7d12f5ddf65dea2_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTEzLTEtMS0w_f23b4443-d1b1-4eb6-bc2b-841423dc4214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if476e20ccbac40da9954263fe92cc4a2_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTE1LTEtMS0w_0d1e4768-3f8e-4d75-924a-ec1b3fdf9f6b">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTEtMS0xLTA_f4e651cd-d5ca-47bd-91f7-5da370e6d826">368</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTMtMS0xLTA_a1cb33f3-5b15-4b6e-81da-5e5f7505b15f">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTUtMS0xLTA_fa3bfbbc-aa76-4bec-bbd4-b924dfa4daa3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTctMS0xLTA_3b81c51d-bdba-4d13-a474-e7048281d58e">370</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTktMS0xLTA_f18913b2-f2c1-48e1-bdb3-6bae102c2cb4">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0972f005da4b289e0431985712cca1_I20201231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTExLTEtMS0w_cb4ccd9f-d623-404a-b83d-cf50eea4d91d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTEzLTEtMS0w_c41971f5-90a1-495a-bc4f-0815b8cc5389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTE1LTEtMS0w_be7a0cba-dde7-4763-b486-18b78b2cfe9f">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75d16e884674d4b891ec0ff23d5093a_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTEtMS0xLTA_28b411b6-4a40-4bdb-af8d-b3c62be3f85d">80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6d94719de4466686b830a0d3f35adc_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTMtMS0xLTA_956d25ae-d150-46f2-830a-933265da057c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67eac5db6f054e3180b3bf214875c398_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTUtMS0xLTA_878df8d6-d574-48b8-a937-e83c76b5795d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2922f1eb3341d59ffc36b1dec737f1_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTctMS0xLTA_c16db914-b6a5-4f79-a172-5267bf1fa8ff">80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6772ab94dd5b401f86bc3a27f2707c7f_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTktMS0xLTA_3deec615-1b4c-4a44-a900-244d6a2d9eab">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief19c5f56cee4d83ac0c396c293b6749_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTExLTEtMS0w_5ffa7021-a1a3-4588-a9dc-575e303e3781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65dd20d822a044fa906443ea329c9a4d_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTEzLTEtMS0w_d3ed0176-9f56-4d65-9f53-bea8f7957972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6df1f9215da4dd8b4038a15c4d03869_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTE1LTEtMS0w_46417332-bbd8-46f4-8f1b-42aca3717bc7">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2c14bb74904e8c96d89c5cd96c9212_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTEtMS0xLTM4Njky_84538a72-f430-4fa8-a075-b78d51d4a540">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7f502712974d0099042d3487baaba4_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTMtMS0xLTM4NzAx_a36514c0-6fb0-4703-acec-1e0c0873bc26">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e50550f1a1441eb77bd65c2709b78d_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTUtMS0xLTM4NzAx_29c6c0bc-c6c4-4ea2-9282-bed0acab8d3b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10944a8fad9a45dbad295162e3f81b90_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTctMS0xLTM4NzEy_f28a5abc-4396-4dee-adb2-aa4dcc80d050">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a924a8c7478492599a96afaa7e429bb_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTktMS0xLTM4NzA4_3059343d-de43-48d2-9111-5ff43541a641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51fe3efcb094b65bcae5a4a5eb91051_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTExLTEtMS0zODcwOA_a40e391b-6bef-4f4b-ac18-e20ec554ada7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ddf9e42a484a8ab8fe46200c4b1460_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTEzLTEtMS0zODcwOA_b5fdbfab-f9d9-4993-ba2e-ce3477a5b84b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87fd36653fe4e028384eb4df59b37d6_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTE1LTEtMS0zODcxMg_8e689044-bf16-4b81-973c-261de3be77d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe99227a96e498abb64a74bdc78ffa9_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTEtMS0xLTA_e025b02a-39ad-44f5-8626-b3102718edc2">1,279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d46b377a489415a9f6e4c66fe01bf48_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTMtMS0xLTA_35d7b1af-318d-4028-ab70-97e790f9ecc3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06b300d5fc54b4b9783aa98a7eb7558_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTUtMS0xLTA_dcccd37a-360a-457e-83aa-fce6cec08696">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd24ccfb9ef45e5b7c7e11d85d3c5a7_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTctMS0xLTA_c6324188-a72a-460e-90bb-86cc25f2bccc">1,279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4831a0db655443696586e7bf7801c3a_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTktMS0xLTA_51b0861d-8e13-476e-b6e0-80ba726ee3d0">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5cd4dd6f92f4fb4aeba7cc718e0b003_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTExLTEtMS0w_2363732d-4106-4497-a026-3a996668a112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b812ad7f9c4916b7d12f5ddf65dea2_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTEzLTEtMS0w_56ca71e2-20a5-4815-b5eb-c034135bf4bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if476e20ccbac40da9954263fe92cc4a2_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTE1LTEtMS0w_b94e5702-b670-4511-a136-899f7a4d873e">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTEtMS0xLTA_1844f958-958e-4b19-a2e4-c4430c3199b7">1,363</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTMtMS0xLTA_808fafdb-1f3d-407b-aa4b-0a292451fbad">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTUtMS0xLTA_ac557872-f728-4608-ab36-bc53472238a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTctMS0xLTA_fdbe25a5-556b-47d8-86f5-9b08e9e8d0a3">1,363</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTktMS0xLTA_8d1a2ef1-8abd-4525-b056-d41584c25143">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0972f005da4b289e0431985712cca1_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTExLTEtMS0w_e207744d-b14e-4f55-9878-54d5389b941f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTEzLTEtMS0w_3debc0d5-2f26-4411-b384-040c3a77cabb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTE1LTEtMS0w_5a46d699-6827-4515-8eb8-e3f0802903b6">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87476d0b8816403891dc417aaa9709e2_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTEtMS0xLTA_908ae9d4-b8f0-4440-acce-7f5901bf69ba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab118969b6042d18ed16e3ea6721990_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTMtMS0xLTA_f2e90347-c054-45a9-a8dd-64e66a83a3fa">351</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137f81c1d5584d34869c5b39909172a4_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTUtMS0xLTA_1ce7e848-be48-4e92-986e-ae287ea1b825">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96634206fbd44c669c42fbc69576e46c_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTctMS0xLTA_e0ae27b2-4daa-40d4-86fc-9a1c83cead4c">351</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcde32f3e3347d6ad26d923ef7bf728_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTktMS0xLTA_b27bbe7e-c8b3-4429-baf9-f8368a3286a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023622ad5898409ea6e74a7865b4ad94_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTExLTEtMS0w_26bb37c5-b03a-49ba-87f4-dd6746263815">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b4c1c59dd545679bbdd8960724fdb8_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTEzLTEtMS0w_71d57a49-6dc9-4284-af87-8c705775a3b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd18623cbffe4173b5c074fecac0d9ff_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTE1LTEtMS0w_26b5b871-5e61-441a-99ac-c3cf7c067635">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f7d706f0cb44e4b3153791e14d9f6b_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTEtMS0xLTUwMDQ1_b1ee4890-efa6-434c-99b6-295732d92ea8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374759bb016f41888888e78791dd4ab0_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTMtMS0xLTUwMDQ1_3a829142-8d9e-4915-9522-18d9dd947c90">184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68fef76e57547f7bdc2cbb70b67de87_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTUtMS0xLTUwMDQ1_e157a018-c41a-41be-a6ae-bf3badc53604">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9444d5b1664f58a02728dfddbf063e_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTctMS0xLTUwMDQ1_efc30a49-85a1-4a28-aba7-29430afc4760">184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040ff5ea36d3484ea651ef737fdff71a_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTktMS0xLTUwMDQ1_574498d9-69ad-4079-82f9-920176baf565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if97446d23ecf43389079d10a5ca90ec7_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTExLTEtMS01MDA0NQ_afa0c9ff-c707-4496-bd20-cc027467a1f5">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2ba44854df404fa52145c11e69cd99_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTEzLTEtMS01MDA0NQ_6506e091-0f91-47b0-aa4e-44bbd13b4422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66a61dac3da49dcaba07eaff95d4ed3_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTE1LTEtMS01MDA0NQ_4c4e3272-c9fb-43d7-afa0-25e793a7e71c">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a6ab54db1664800b50dfbdaff4462cf_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTEtMS0xLTA_ee7b80cc-11fb-4421-8783-913de2b4ac29">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833b3ba93d614377a2cfecac4c5866e9_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTMtMS0xLTA_09b0f4b8-e9f3-48ef-93f5-4f94b557eb02">14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dbc4d9a77694d4e882a111f60ec428f_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTUtMS0xLTA_e459fcef-109c-44d0-ae7d-9a0b04d389fb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ec83c194e1744edba2a8a35ddd3a21f_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTctMS0xLTA_564b2c3d-ef3b-40cc-82cd-99b6c5f0d5fa">14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f95df00da14c09af18c27401b54ae3_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTktMS0xLTA_483d9e05-d9b2-4de6-810f-5219f9d1e370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132e97951baa4113bcc1bae3044eb719_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTExLTEtMS0w_151b9a32-7774-4c91-b753-f6d178c99959">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb83adad926e453482286d737c575b36_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTEzLTEtMS0w_5217b5e9-fd2e-4400-afbc-c1274e08b2dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d7907189bb4207bb49c42bee6f1dfd_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTE1LTEtMS0w_a8b5177a-f361-4a59-845a-35baf39ddf89">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTEtMS0xLTA_8fe2598f-2b32-43a8-b09c-85d7a48ca6ac">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTMtMS0xLTA_44076a15-c71a-4fdf-86cb-31a8401e04d6">549</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTUtMS0xLTA_b6c98a36-68f6-4734-a901-35ee7d5ad302">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTctMS0xLTA_3ce3bc38-90ca-42af-9733-77c2867fafad">549</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTktMS0xLTA_a7d43569-63d3-4d82-9280-8e680dc7a413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0972f005da4b289e0431985712cca1_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTExLTEtMS0w_4717fea5-8470-44db-aecb-dadf6bde377e">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTEzLTEtMS0w_fbef2681-423b-45c7-bbd8-a4f241ed62c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTE1LTEtMS0w_763dcf9b-625f-4c38-a4ee-f924b81f17dd">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTEtMS0xLTA_42c08107-978f-4815-ba72-acbae1f433ec">1,731</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTMtMS0xLTA_9aa7fe45-bdba-4e9f-a302-4357aab5834d">551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTUtMS0xLTA_78e690a0-5ea0-4df7-817c-2044fcdabee9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTctMS0xLTA_9ef20c9f-45bc-4039-a92e-4f4cd7481d59">2,282</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTktMS0xLTA_93f01b94-5d46-4ff1-8dfa-151083789598">1,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0972f005da4b289e0431985712cca1_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTExLTEtMS0w_e9cc52d1-fda3-4e19-b6e5-48ba30696072">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTEzLTEtMS0w_ec67f072-7593-4a5a-bb05-53dada3d5954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTE1LTEtMS0w_14c84454-51fb-4b94-ae7e-53636cd63b13">2,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTEtMS0xLTA_cf9359ad-0563-454c-9bf5-151b70c92248">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTMtMS0xLTA_e46d301f-061e-4bb4-bba8-192fed5f8db9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTUtMS0xLTA_f3f5c16c-d9dc-498b-8345-5b372189f3a3">777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTctMS0xLTA_17c4164d-472a-4d1b-a802-5e68a3617440">777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTktMS0xLTA_b29a199e-19a2-40b0-998f-07fc2a561a8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0972f005da4b289e0431985712cca1_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTExLTEtMS0w_310a82ac-3bad-402a-8895-4ba589131065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTEzLTEtMS0w_ee3a9cc6-573b-4ec0-b91e-73938b929a69">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTE1LTEtMS0w_6f67912e-0c40-4b05-8d86-dd71cea1d0fe">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87476d0b8816403891dc417aaa9709e2_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTEtMS0xLTA_0c10c765-fc8b-47ed-889d-5a552dda807c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab118969b6042d18ed16e3ea6721990_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTMtMS0xLTA_707cac5e-4b7f-404d-be57-8ea76b75a278">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137f81c1d5584d34869c5b39909172a4_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTUtMS0xLTA_24a6b2f2-2f97-4745-8674-53462e341bdb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96634206fbd44c669c42fbc69576e46c_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTctMS0xLTA_460f4272-da18-4691-81fb-40b3d5eed747">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcde32f3e3347d6ad26d923ef7bf728_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTktMS0xLTA_bdd3606d-245a-4f78-a2c8-8c9a7978edf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023622ad5898409ea6e74a7865b4ad94_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTExLTEtMS0w_b879d195-8285-4a84-a3e9-dbb49c7f2d38">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b4c1c59dd545679bbdd8960724fdb8_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTEzLTEtMS0w_28f362fb-0c57-42e8-80cd-6382a339afe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd18623cbffe4173b5c074fecac0d9ff_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTE1LTEtMS0w_7fa1ca56-34c8-4162-ae0a-d2e05fc6ad9c">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f7d706f0cb44e4b3153791e14d9f6b_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTEtMS0xLTA_a09a2883-7a87-4079-b975-078f90489c81">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374759bb016f41888888e78791dd4ab0_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTMtMS0xLTA_f9589d8f-8f20-422e-9cd7-f242720829f2">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68fef76e57547f7bdc2cbb70b67de87_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTUtMS0xLTA_6084e9db-90f1-48d3-bc53-4042504ec717">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9444d5b1664f58a02728dfddbf063e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTctMS0xLTA_d17b352a-a31b-4212-917c-f9f1aaa01167">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040ff5ea36d3484ea651ef737fdff71a_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTktMS0xLTA_53c0144c-61a3-4391-867b-d0f608b8614e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if97446d23ecf43389079d10a5ca90ec7_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTExLTEtMS0w_350e5120-8820-4af0-9511-bb136ce3f0bf">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2ba44854df404fa52145c11e69cd99_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTEzLTEtMS0w_68dae751-061a-42a0-91f1-cd178a719e37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66a61dac3da49dcaba07eaff95d4ed3_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTE1LTEtMS0w_225d575f-ac71-4d57-ba56-882e34c908ff">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTEtMS0xLTA_bd029d7f-416d-483e-8070-c76b5cd14f50">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTMtMS0xLTA_09338bfb-02c3-4a3c-a095-717d0dedcb42">121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTUtMS0xLTA_cbb8ec59-72f9-4119-a672-786755d37a12">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTctMS0xLTA_aa26241b-bbc6-4cf0-86d3-20cde2f7c44b">121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTktMS0xLTA_ce7eb526-4689-4716-bbbe-51a23249eb95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0972f005da4b289e0431985712cca1_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTExLTEtMS0w_b84752ac-d571-4b63-8b73-fe19ebfcedaf">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTEzLTEtMS0w_511eb2f1-5980-47b1-a7b7-6ae048c11ea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTE1LTEtMS0w_987697f7-ef86-4802-8131-bb022686895a">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTEtMS0xLTA_06ed4381-0098-4618-b30d-059f646a7eee">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTMtMS0xLTA_8eabe1fb-627f-4cfa-8be1-80db84e44679">121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTUtMS0xLTA_8b207591-5a8e-4eb4-b9e0-7e15422f095a">777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTctMS0xLTA_0274097c-6654-4716-9637-f12cb13a170e">898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTktMS0xLTA_fff62128-173e-46ea-b26c-324e0a8c5c99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0972f005da4b289e0431985712cca1_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTExLTEtMS0w_4e0522bd-10ae-4c37-bb76-a519725f5e50">525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTEzLTEtMS0w_7b661ce7-758a-4978-a487-9eaf2e14bc3e">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTE1LTEtMS0w_8bdf0277-2dd2-44ef-8b2a-61851b31dd4d">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i6fabc58b05ff44ed9522b607c9a248bc_I20201231" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzNDIz_3182fc8b-66e5-46a8-9fc7-15e60d525eb5"><ix:nonFraction unitRef="usd" contextRef="i774c5a342b514fc886c9641360c25a17_I20211231" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzNDIz_5b396db0-8092-4527-ba09-90cc5012f547">6.8</ix:nonFraction></ix:nonFraction> billion (which would be considered Level 2 in the fair value hierarchy). </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ib2f010e69c794c489778d81f5b4d5340" continuedAt="ib0e979d0a5fc4d95baec1645364ca359"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjEx_bbd377a3-e881-428d-afa2-a9588dd2e833" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzEtMS0xLTEtMA_bfc255ab-aae5-4618-8870-1c22bce8b5ef">841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzEtMy0xLTEtMA_46f75c70-01dd-494f-9fb7-32a8ae4614b1">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzItMS0xLTEtMA_2ab323e4-d270-4341-b956-a8d8f5bd2c9e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzItMy0xLTEtMA_6d80a68b-1d64-46d6-8767-d2c0f7804424">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzMtMS0xLTEtMA_d5594988-50bd-4de1-9876-dd5ca4bda562">57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzMtMy0xLTEtMA_3b063d17-a524-44b3-bf25-4bc41de202f3">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzQtMS0xLTEtMA_f3bcaaf1-f6e5-4c61-a9a3-493689646195">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzQtMy0xLTEtMA_1b10895c-e6c0-459d-80a9-9005715d6167">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzUtMS0xLTEtMzg0NTQ_434610f5-987f-4428-a793-878620d3cd39">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzUtMy0xLTEtMzg0NTQ_6b47162d-f0e9-49df-b752-1df4bac1db9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)(3)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzUtMS0xLTEtMA_df996d54-9903-40b3-ad74-caf603cd703f">777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzUtMy0xLTEtMA_c602407d-0bde-48d4-885d-c81b2a6b5887">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Balance at December&#160;31, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzODcx_03a1a45d-b930-4e34-ab50-a9e865f68b76">151</ix:nonFraction> million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At December&#160;31, 2021 and 2020, $<ix:nonFraction unitRef="usd" contextRef="i70b17ce920094858a99911bb86e14711_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzOTgz_746fb80b-3d91-4e4f-94a3-4fe8e3485c62">620</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if376a86c326f475d9363b305b989f5ac_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzOTkw_315b6320-cb8c-4dac-be23-a197d8d2d48e">711</ix:nonFraction> million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of <ix:nonFraction unitRef="number" contextRef="i70b17ce920094858a99911bb86e14711_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE0MTk5_7fd7e507-8504-4b0d-9f35-bfdd4aad4917">11.5</ix:nonFraction>% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of <ix:nonFraction unitRef="number" contextRef="i32c6fca8f8164d468cff272eeba8634f_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE0NDYx_3d51cf08-a809-4619-9d50-9c827e502b16">8</ix:nonFraction>% to present value the cash flows.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 4). The payments of contingent consideration in both years relate to the Sanofi Pasteur MSD liabilities described above. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at December&#160;31, 2021, was $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE1NDY0_6cfddb1c-4cbf-4a0e-96fe-2efe3aad69ff">35.7</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE1NTAx_9fe193ea-561b-4606-be93-68d5788d2e3c">33.1</ix:nonFraction> billion and at December&#160;31, 2020, was $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE1NTE5_27a83acd-5a43-433f-a486-73b4deb8d9cb">36.0</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE1NTU2_57fad1bc-c6da-4c7e-a228-942b05d23b62">31.8</ix:nonFraction> billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately <ix:nonFraction unitRef="number" contextRef="if47597a8ab7540518bde99ada02a6412_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzM4NDgyOTA3MjE5OTg_fb9cccfd-9980-40d1-93df-3d54fc6528d6">20</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="iba40621af6f34b0c95e94ed7710c5944_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzM4NDgyOTA3MjIwMDM_5e24cf80-f6b7-42ed-97f7-a16a7d069878">15</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i70af15b795b3483b886c630cdd41133d_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzM4NDgyOTA3MjIwMDg_630fd87f-7370-40a6-95d7-a57d2df6bb97">10</ix:nonFraction>%, respectively, of total accounts receivable at December&#160;31, 2021. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $<ix:nonFraction unitRef="usd" contextRef="ie64824a2ab1d473089f51fd77c18511b_D20211001-20211231" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE3NDQz_f618a00a-9056-4fb5-930e-d6b2fd07a065">2.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i4fe9a0ab54434720b0cf1a566885c13a_D20201001-20201231" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE3NDUw_a37ddbca-60ca-4116-82ae-debdfb3cae82">2.1</ix:nonFraction> billion of accounts receivable as of December&#160;31, 2021 and 2020, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2021 and 2020, the Company had collected $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE3OTg4_b080deb5-9699-46c7-b97c-41876c03878e">62</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE3OTk1_b343a710-e006-42c3-8665-aa34eeff8dff">102</ix:nonFraction>&#160;million, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="ib0e979d0a5fc4d95baec1645364ca359" continuedAt="i462f8033d0dd40ae98e23cbed486dc53"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in January 2022 and 2021, respectively. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><ix:continuation id="i462f8033d0dd40ae98e23cbed486dc53" continuedAt="i8500324f128144e4b261dd31eb551577"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjE2MDc_87f811eb-7d75-43cb-878c-6fe25063bf43">164</ix:nonFraction> million at December&#160;31, 2021. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8500324f128144e4b261dd31eb551577">. Cash collateral advanced by the Company to counterparties was $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjE0Mzg_b6f900ff-79ad-40ce-bfec-8397b4e91ba0">36</ix:nonFraction> million at December&#160;31, 2020.</ix:continuation> </span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_163"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzU0Mg_a9e90795-a5c9-47f6-9b4c-24c336ba00f2" continuedAt="i920518ffa2b245f9be6a0d58491f8b3d" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i920518ffa2b245f9be6a0d58491f8b3d"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzU0NQ_0f221c21-5492-4277-a766-5faa090a86d1" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzEtMS0xLTEtMA_38b54029-9be3-4f3f-bac6-4e05e2a616af">1,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzEtMy0xLTEtMA_83b25cc6-9a94-4d7a-9307-903b55536152">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzItMS0xLTEtMA_5647ec3d-5a77-4c55-be2f-20b0ef6518df">6,220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzItMy0xLTEtMA_d5638c43-2abf-4844-a65d-45fa50a33dd6">5,949</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzMtMS0xLTEtMA_26051a24-ed99-4bec-8376-63a86b17143d">196</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzMtMy0xLTEtMA_d7530144-3711-4a1e-a682-c4663cee2959">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzQtMS0xLTEtMA_3024d344-5491-47c3-9873-ce86b77686ba">8,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzQtMy0xLTEtMA_2db94539-6598-41fc-8a6d-0e10222241bc">7,705</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzUtMS0xLTEtMA_a3cd3bbf-8af8-47c1-b8ec-5c059fc82b2a">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzUtMy0xLTEtMA_fbbc0db6-af74-4429-9d9d-d20c70cf82b2">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzYtMS0xLTEtMA_5bc94dab-42f2-4276-a724-8867147575aa">8,147</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzYtMy0xLTEtMA_7e4efb17-f9ba-4874-858d-90b019fcbb2a">7,624</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzgtMS0xLTEtMA_d2cd7aa5-38b2-424a-9d8e-8646d46c4c00">5,953</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzgtMy0xLTEtMA_89ff8182-848f-40af-b0ae-4cf86e27d145">5,554</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzktMS0xLTEtMA_6a53971d-ad4d-47a4-8228-00e7a99d472e">2,194</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzktMy0xLTEtMA_8fd49b83-e033-4b5e-a8b0-d7ae035b8b4a">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised approximately $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:LIFOInventoryAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzEzMQ_58f6f3cc-00a0-4023-a0dd-db03d90038f1">3.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-8" name="us-gaap:LIFOInventoryAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzEzOA_1145578e-b633-4581-87a3-a5ae452cc4a4">2.8</ix:nonFraction> billion at December&#160;31, 2021 and 2020, respectively. Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At December&#160;31, 2021 and 2020, these amounts included $<ix:nonFraction unitRef="usd" contextRef="if11ef0dcf23f4836b169d65009b32b67_I20211231" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzMyMQ_191c0c37-6841-4d22-85f0-870d27e854cf">1.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i9281f223aedf4b3bb8e9b4c609a7ffcd_I20201231" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzMyOA_fd78f08e-8875-449f-8ec2-546adf82a48b">1.8</ix:nonFraction> billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $<ix:nonFraction unitRef="usd" contextRef="if3aec1ab29624b00ae21ee1541745253_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzQzOA_93d50847-afd7-4ac7-b466-49d59d0e3960">256</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i603759dc019d4b2a92e63a7c43c81202_I20201231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzQ0NQ_f8e9bdb1-8f86-49c8-a064-9d2c98387ce7">279</ix:nonFraction> million at December&#160;31, 2021 and 2020, respectively, of inventories produced in preparation for product launches.</span></div></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_166"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMTY_c0f30196-5f1c-46d7-9f31-17f8d9912fed" continuedAt="i68f2652e83034175b7613a72b9946a19" escape="true">Goodwill and Other Intangibles</ix:nonNumeric></span></div><ix:continuation id="i68f2652e83034175b7613a72b9946a19" continuedAt="ib4ef7ecab81b45f99c581bf351645cdf"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMTM_60086d61-b14c-43c4-b5d5-e39eae78f6f4" continuedAt="i0fb915df8e2248a4ac6bfbac9b06b104" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1e538358a0404a97553c780f46ab33_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzEtMS0xLTEtMA_c5ee31e3-7e93-40d3-8d07-5b50df6ee39d">14,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1acd2394418419a847e9c266f2fd96b_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzEtMy0xLTEtMA_d4b8fdbd-7b46-4611-89c6-8346f97d4f4a">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2263f3e53dbf46e49603498a02a8dd4b_I20191231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzEtNS0xLTEtMA_a194ee36-823a-43e4-adac-0b8ddabf340e">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzEtNy0xLTEtMA_dba67900-1ac0-48dd-8514-7e4a9f05445e">18,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc491b98f87c48fb9a82e390d80b4690_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzItMS0xLTEtMA_d4ccf3a8-3dd0-4985-bf77-3fd18118b588">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07617b881607408cb61cf2b2cf92be00_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzItMy0xLTEtMA_01e5a8f5-f9f9-481e-8517-e4d9e00879d3">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052ad8a1361041b1a1e984ec500adab0_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzItNS0xLTEtMA_92b39a45-b262-4116-9f5e-1575b634a1be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzItNy0xLTEtMA_b43591bd-6536-4afc-9332-0c3482fc7090">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc491b98f87c48fb9a82e390d80b4690_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzMtMS0xLTEtMA_f22e0926-7f17-4c33-ab35-7254a7cf6662">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07617b881607408cb61cf2b2cf92be00_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzMtMy0xLTEtMA_adb132ff-66b4-4ef1-aae6-fa9384b123cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i052ad8a1361041b1a1e984ec500adab0_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzMtNS0xLTEtMA_3b8e7f11-8140-4422-8b03-f26c4b96fc1d">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzMtNy0xLTEtMA_7fdc242b-f611-458d-8e60-892caca5bebb">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc491b98f87c48fb9a82e390d80b4690_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzQtMS0xLTEtMA_7299a87c-43c9-4c87-b437-b5bf28dbeec1">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07617b881607408cb61cf2b2cf92be00_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzQtMy0xLTEtMA_2f187da2-8465-45d4-90f5-900237da9d3a">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052ad8a1361041b1a1e984ec500adab0_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzQtNS0xLTEtMA_34c7f5d3-bc5d-47c0-aa2f-327ba82c2649">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzQtNy0xLTEtMA_db5e2ad7-cd4f-4323-8b9d-52effb060984">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb26ec2f5da740a3bc8fbb26528a6eba_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzUtMS0xLTEtMA_79b44d5e-a8c8-4a3b-b362-ef72226447a9">15,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2606072a417c44aca18c5c159c178685_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzUtMy0xLTEtMA_bef1d02a-fd49-4cd9-bc2b-0da915ddab05">3,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a27173a90934ada9d520eceda174831_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzUtNS0xLTEtMA_ca26e1b0-5f1a-454b-82cf-1fa15a1cb470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzUtNy0xLTEtMA_8fcf037b-9dc7-42bf-808d-843092a7a14f">18,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed00c6f79924c5aac07fb1cde0defe2_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzYtMS0xLTEtMA_952badba-4c82-4114-9e60-5565249155d6">2,431</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088cc2519a19414c8e3186d5e4e8a023_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzYtMy0xLTEtMA_bcc29e44-416a-4cb6-90aa-3a2c9abe02a5">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dbb367e3e5946fdae5de683a45bd0da_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzYtNS0xLTEtMA_8fba0e9f-a1fa-4bec-af72-35b6636af077">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzYtNy0xLTEtMA_202f6542-8f56-497a-8bae-7d39da54063e">2,436</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaed00c6f79924c5aac07fb1cde0defe2_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzgtMS0xLTEtMA_adff89ca-ebeb-4461-b864-5d30f9ae50b5">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i088cc2519a19414c8e3186d5e4e8a023_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzgtMy0xLTEtMA_cd4fbc98-5c3c-49ee-ba6f-490c1878411f">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dbb367e3e5946fdae5de683a45bd0da_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzgtNS0xLTEtMA_845e85e0-4f8f-47be-9727-11bf53482bb0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzgtNy0xLTEtMA_af208d8f-2dd5-4ce9-8c5f-2993ab79c6a4">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47d1b633d5da4aafad19b8e301c01923_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzktMS0xLTEtMA_c255f47b-8167-4f2b-be1c-2ae47075004f">17,997</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife16e0d66c324162af7d23d581f9e520_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzktMy0xLTEtMA_180a1256-a4a9-4724-9b52-9364c9038c54">3,267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic859cf2414014f41b9ff0a1bc9a8edca_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzktNS0xLTEtMA_bc1c06b5-e415-4c36-8a09-75450b148c72">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzktNy0xLTEtMA_bf5752d4-28b4-4f63-b0f8-c980a75185ec">21,264</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i0fb915df8e2248a4ac6bfbac9b06b104" continuedAt="i5dd470836d304cce8f60cc1184c6e476">(2)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i5dd470836d304cce8f60cc1184c6e476"> Accumulated goodwill impairment losses were $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzI2Mg_06835680-266f-4ee6-be19-a32460c0cb0f"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzI2Mg_8db071cf-1b1c-462f-bf06-459ed5c6b85a">531</ix:nonFraction></ix:nonFraction> million at both December&#160;31, 2021 and 2020.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The additions to goodwill in the Pharmaceutical segment in 2021 were primarily related to the acquisition of Acceleron. The additions to goodwill in the Pharmaceutical segment in 2020 were primarily related to the acquisitions of ArQule and Themis. See Note 4 for more information on these acquisitions. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ib4ef7ecab81b45f99c581bf351645cdf" continuedAt="i64b8ae0063684cf6a6a788d55a1b56d0"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMzc_1990fc21-fe29-4576-9be0-93fe19f96794" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other acquired intangibles at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:25.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922da6ff675f4e36b395123bd41f860c_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItMS0xLTEtMA_8912fe7c-78fb-417d-853f-67a528a2fa4a">23,671</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922da6ff675f4e36b395123bd41f860c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItMy0xLTEtMA_393cd957-1378-4d88-893d-d0c07a434955">15,776</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922da6ff675f4e36b395123bd41f860c_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItNS0xLTEtMA_eb87a0ba-a6fe-4935-b7f4-2959ba33b309">7,895</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf7db39f15a4eb598543794b5cb18d4_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItNy0xLTEtMA_12ebbcd6-a4e6-450a-b628-d0192a6604b8">20,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf7db39f15a4eb598543794b5cb18d4_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItOS0xLTEtMA_3efc9251-4274-40f8-a333-28c2e4ec5f0a">16,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf7db39f15a4eb598543794b5cb18d4_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItMTEtMS0xLTA_6c281c07-4aea-4d4f-a6b1-3fbe5f7a2774">4,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0418b77d11494b49b8670d97efc20a6f_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzQtMS0xLTEtMA_d6fd4153-5cd2-4c5a-b54e-8a6836bb2634">9,281</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0418b77d11494b49b8670d97efc20a6f_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzQtNS0xLTEtMA_d0bb64c2-f872-4707-aad5-426dea7c39cc">9,281</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9287dd64826c40ae9176320df60031ab_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzQtNy0xLTEtMA_b137af48-55a5-40b8-ae9b-e85be27fa971">3,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9287dd64826c40ae9176320df60031ab_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzQtMTEtMS0xLTA_1d23980a-4f22-4044-aad0-50e5a9be36b2">3,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4679263e59f543019e17c0b7fc2182cb_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtMS0xLTEtMA_134a7715-aa8c-458d-a8d3-2dcb91f20297">2,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4679263e59f543019e17c0b7fc2182cb_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtMy0xLTEtMA_cab3d6ab-d947-4505-a5a3-55145cae97ea">493</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4679263e59f543019e17c0b7fc2182cb_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtNS0xLTEtMA_1c521e14-3883-4f03-b14f-14820eb36842">2,389</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b877fdaf564761be440e19be29b2c5_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtNy0xLTEtMA_d0743b46-f423-4a9c-a5dd-30866c70e27c">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b877fdaf564761be440e19be29b2c5_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtOS0xLTEtMA_ec49d73f-772a-415c-b1ad-7b30e16bdc13">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b877fdaf564761be440e19be29b2c5_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtMTEtMS0xLTA_82c7e3af-2bb6-4e85-9073-531c24ec2b91">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8899dd9c654bfbac46b393cd7d3264_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtMS0xLTEtMA_4e585a3f-ddef-4c4b-aa5d-12c55cb1d07a">6,604</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8899dd9c654bfbac46b393cd7d3264_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtMy0xLTEtMA_1feb0e05-9bca-4c1b-95aa-0f6b1699cba9">3,236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8899dd9c654bfbac46b393cd7d3264_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtNS0xLTEtMA_5441f6a2-332b-44a5-831e-e5e8195a71fa">3,368</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2377a28ca84de48887e30dfe2d5537_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtNy0xLTEtMA_87d5b399-8e2a-4109-b9cf-9501fff1b19d">6,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2377a28ca84de48887e30dfe2d5537_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtOS0xLTEtMA_5a5f5024-4931-44f2-9cd6-d5cc9fc73d38">2,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2377a28ca84de48887e30dfe2d5537_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtMTEtMS0xLTA_2d9ddc20-40ea-4963-bdfc-fcb84163fa4c">3,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctMS0xLTEtMA_b2e4085e-cd43-411b-858c-6776ddc9ea6e">42,438</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctMy0xLTEtMA_08c97df1-5b2e-4277-b9dd-98209e78ca17">19,505</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctNS0xLTEtMA_b2f3018c-bd09-40f3-8405-4d9ad7d0abae">22,933</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctNy0xLTEtMA_e2ab50cb-4703-4917-bf0c-07906c2254cc">33,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctOS0xLTEtMA_4e104ef2-ffc2-4b85-a1b0-9132de8d16fe">19,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctMTEtMS0xLTA_6d1883d4-5f4d-4aeb-9a06-81a847fe3886">14,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, IPR&amp;D, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. Some of the more significant acquired intangibles, on a net basis, related to human health marketed products (included in products and product rights above) at December&#160;31, 2021 include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i332ad40fc06246e8899471a208f82f55_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDM3NjA_9b51b6ac-baeb-4faf-b498-5d062fbe79f2">3.8</ix:nonFraction> billion; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i25cf501ae0374a8db4041a26e5ccaba7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEyNzY_1b68586e-c17c-45fa-89fa-f7cbae39e2a6">478</ix:nonFraction> million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, $<ix:nonFraction unitRef="usd" contextRef="i1235021626ea40d68c48483cac1e238e_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE2NDkyNjc0NjExMzM_2efb215d-8293-4c46-84bd-908a774cd0a5">191</ix:nonFraction> million; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i571d3003c339474b8a92cd20e397f126_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE2NDkyNjc0NTc3MzU_408c7d49-cd1b-4225-b5f5-e8b07fcb133a">145</ix:nonFraction> million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Dificid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i24d884f9483546dcbadd8236be97f3a2_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEzMzg_3fb6eff2-e549-4371-bbb9-5dc1bc181d54">145</ix:nonFraction> million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="ib27e295e010541d7a58a958648701bed_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEzNjU_34277fde-00c1-4187-81cd-ba3f49c1a258">138</ix:nonFraction> million; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="ie81297921b384692b3eb61bf4efc821e_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEzODI_bb602d3c-7e33-455f-9e28-4582118280d7">101</ix:nonFraction> million. Additionally, the Company had $<ix:nonFraction unitRef="usd" contextRef="i34d6a0c4542c41ffa80fc7096731b88f_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE0MTY_9df5d22f-4f24-4c43-8933-d0cb3461f6f4">5.0</ix:nonFraction> billion of net acquired intangibles related to animal health marketed products at December&#160;31, 2021, of which $<ix:nonFraction unitRef="usd" contextRef="i1188336496264ef18e60cdee67b0cb7e_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE1MDY_fdbdb381-9d00-4949-9486-ce076635e784">2.3</ix:nonFraction>&#160;billion relate primarily to trade names obtained through the 2019 acquisition of Antelliq (see Note 4). At December&#160;31, 2021, IPR&amp;D primarily relates to MK-7962 (sotatercept), $<ix:nonFraction unitRef="usd" contextRef="i7e8562560c434644bad56e82266c221a_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDgyMjM_7d366802-c94d-4aa4-9078-a43ad2d7f115">6.4</ix:nonFraction> billion, obtained through the acquisition of Acceleron in 2021 (see Note 4); MK-1026 (nemtabrutinib), $<ix:nonFraction unitRef="usd" contextRef="ie71ea2fb304b4cf08e846d2e023c3048_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDgyMzQ_23dfaff0-2071-423e-9f92-4806c1b59590">2.0</ix:nonFraction> billion, obtained through the acquisition of ArQule in 2020 (see below and Note 4); and MK-7264 (gefapixant) $<ix:nonFraction unitRef="usd" contextRef="i5e62506b0ff84122affab840c3ae7e5f_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDgyNDA_00ede734-a2bb-4e74-a1fe-60ef02fbd42e">832</ix:nonFraction> million, obtained through the acquisition of Afferent Pharmaceuticals in 2016. Some of the more significant net intangible assets included in licenses and other above at December&#160;31, 2021 include Lynparza, $<ix:nonFraction unitRef="usd" contextRef="i4a357f883cf8403d91477b70cff00a8b_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDk1MDE_92ef5404-3f58-432d-98e6-27b253527225">1.1</ix:nonFraction> billion, related to a collaboration with AstraZeneca; Lenvima, $<ix:nonFraction unitRef="usd" contextRef="ia8e076f12b4342f1b585a7f637e3c832_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDk1MTg_ef74dc73-b249-4f88-b2d1-a4679dbc982d">1.0</ix:nonFraction> billion, related to a collaboration with Eisai; Adempas, $<ix:nonFraction unitRef="usd" contextRef="i00f8c65ee807407dab9ca51108c58857_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2MzYzMzk_1a16843a-0cc1-451b-ab25-981e28ce233a">806</ix:nonFraction> million related to a collaboration with Bayer; and Verquvo, $<ix:nonFraction unitRef="usd" contextRef="id18a472cdb414425a36e2fc4fc858400_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2MzYzNDQ_c812a141-b965-44ae-a9b4-4451e758a5ab">68</ix:nonFraction> million, also related to a collaboration with Bayer. See Note 5 for additional information related to the intangible assets associated with these collaborations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i321bbe1dae804437a98c0bfa6c5e9802_D20200101-20201231" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzIyMjk_a5d564f7-92cc-4d76-b563-4aad0c5bf6f0">1.6</ix:nonFraction>&#160;billion within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset for impairment. The Company revised its cash flow forecasts for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $<ix:nonFraction unitRef="usd" contextRef="i321bbe1dae804437a98c0bfa6c5e9802_D20200101-20201231" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzMyNzg_ebbfd8cf-c0d5-4b83-b502-2774905e90bc">120</ix:nonFraction>&#160;million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2020 related to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recall. A phased resupply of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was initiated in the fourth quarter of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company recorded impairment charges related to marketed products and other intangibles of $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzM1Mjc_1b01f01d-5bf4-494f-af04-ab5401c325ef">705</ix:nonFraction> million. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="i60c730eccd1b44f8962e3a3b83bcdaf7_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzM1NDc_e18f97fa-8d05-46bf-a0b5-7137440304d1">612</ix:nonFraction> million related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible Gram-positive organisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i64b8ae0063684cf6a6a788d55a1b56d0"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i02366c725d8e4b61a487fbc509afa833_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE2NDkyNjc0NTA0MTY_e967f4a0-730e-4589-8f80-5b7fe4e9fdfd">275</ix:nonFraction> million IPR&amp;D impairment charge within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies, obtained in connection with the acquisition of ArQule (see Note 4). As part of Merck&#8217;s annual impairment assessment of IPR&amp;D intangible assets, the Company estimated the current fair value of nemtabrutinib utilizing projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect the current competitive landscape for nemtabrutinib, including increased expected development costs for additional clinical trial data needed to develop nemtabrutinib, as well as a delay in the anticipated launch date for nemtabrutinib, which collectively reduced the projected future cash flows and estimated fair value. Additionally, the discount rate utilized to determine the current fair value of the asset was reduced to <ix:nonFraction unitRef="number" contextRef="i3df148b8481d43589980b5d43c439d34_I20211231" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzM4NDgyOTA3MTMxNzM_532b38ce-fc8a-4d78-b5df-7c2b4097d69a">8.5</ix:nonFraction>% to reflect the current risk profile of the asset. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;D impairment charge noted above. The remaining IPR&amp;D intangible asset related to nemtabrutinib is $<ix:nonFraction unitRef="usd" contextRef="ie71ea2fb304b4cf08e846d2e023c3048_I20211231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDg0MDU_23dfaff0-2071-423e-9f92-4806c1b59590">2.0</ix:nonFraction> billion. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2MzYwMzM_d1cd5afe-20ab-4e79-8ae7-55a91441c076">90</ix:nonFraction> million IPR&amp;D impairment charge related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck&#8217;s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzU0NTY_741f1e7d-f570-4d3e-8db2-31e2376b0ec6">45</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2MzYwMjY_34422a2c-0a2f-47a1-bd4e-609d84b960a9">172</ix:nonFraction> million of IPR&amp;D impairment charges. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="idf91833342104fa49cf3cfd60cca2c5c_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzU1NTE_032e7ccb-f879-429c-aed9-a2b3f1fc7007">155</ix:nonFraction> million relates to the write-off of the intangible asset balance for programs obtained in connection with the acquisition of IOmet Pharma Ltd following a review of clinical trial results conducted by Merck, along with external clinical trial results for similar compounds. The discontinuation of this clinical development program also resulted in a reversal of the related liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="idf91833342104fa49cf3cfd60cca2c5c_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzU5NjE_e8a49afe-1a87-4b5f-8602-a11ceed47634">11</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense primarily recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzY5NDg_6488d598-0b14-42f6-a076-f1457547e517">1.6</ix:nonFraction> billion in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzY5NTg_0d4035a0-e74a-4e07-a140-66f0792d3489">1.8</ix:nonFraction> billion in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzY5NzE_29548b7d-da20-4d7f-bc3d-3fa9f610bf4e">1.7</ix:nonFraction> billion in 2019. The estimated aggregate amortization expense for each of the next five years is as follows: 2022, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcwNzc_585ece78-7071-4edf-b596-895bd28c30a2">1.7</ix:nonFraction> billion; 2023, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcwODU_bf0ac298-2ad6-4e29-953c-eaebcc8a9a0d">1.6</ix:nonFraction> billion; 2024, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcwOTM_6b8fc779-9bdd-4090-98c4-beb23b0a42d4">1.6</ix:nonFraction> billion; 2025, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMDE_3ce12c56-1cbe-4345-ab04-a5bc2bea3854">1.4</ix:nonFraction> billion; 2026, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMDk_69b08474-3fea-4479-9d48-4c917c371874">1.4</ix:nonFraction> billion.</span></div></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_169"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3NzY_cfecc3ce-7210-49f4-8b23-0da3d4364c6f" continuedAt="i84e9e0cd9feb4bedab731f8b9832448a" escape="true">Loans Payable, Long-Term Debt and Leases</ix:nonNumeric></span></div><ix:continuation id="i84e9e0cd9feb4bedab731f8b9832448a" continuedAt="ifb99e8e3198d455081253be45d27798f"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans Payable</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans payable at December&#160;31, 2021 included $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzk1_414b7de8-ddb0-463b-9db8-e86df84beb36">2.3</ix:nonFraction> billion of notes due in 2022 and $<ix:nonFraction unitRef="usd" contextRef="ia4f5157cdcdc4b5fb735395ee19116dc_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzE0Nw_a93bfb35-c5ca-4922-889a-f2861d27b466">149</ix:nonFraction> million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December&#160;31, 2020 included $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-8" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzI1OQ_117c796d-a8bf-448a-95f9-0ef5915535bd">2.3</ix:nonFraction> billion of notes due in 2021, $<ix:nonFraction unitRef="usd" contextRef="i94c025ef9d554744b2deaf2bb4227962_I20201231" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzI4NA_9bf966e1-85af-40d2-b303-d25cbeaf547d">4.0</ix:nonFraction> billion of commercial paper borrowings and $<ix:nonFraction unitRef="usd" contextRef="ifae9f90a84a045708d897dad62fa6f48_I20201231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzMxMQ_162954b6-cc01-4bda-a399-2c9245f1b0ae">73</ix:nonFraction> million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was <ix:nonFraction unitRef="number" contextRef="ia85becd9ff8a491c842d4ef0416f1bfa_I20211231" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQ2NA_7cad4344-03cb-4654-bc97-6666a1642a33">0.08</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i94c025ef9d554744b2deaf2bb4227962_I20201231" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQ3MQ_192c783d-86aa-4ebc-89cf-d8f17522a825">0.79</ix:nonFraction>% for the years ended December&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ifb99e8e3198d455081253be45d27798f" continuedAt="ie0be01c0ec194944bbf68d2d96da94b4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3ODA_d788e0df-1ad5-4f56-b0f5-d3cd448ebe4e" escape="true"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17dae8a27f274a1f9b71d7a871389f36_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEtMC0xLTEtMC90ZXh0cmVnaW9uOjY1MTI2MGE1NDVmNjQxMDhiNmNiYzIxYjU3ZGZjMzgyXzQ_e33987e9-f96b-40d8-9229-9022f57a6152">2.75</ix:nonFraction>% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17dae8a27f274a1f9b71d7a871389f36_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEtMS0xLTEtMA_55d695d3-9c85-4340-8072-845c77ad12ee">2,495</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb06f869aee84648b3f08b5c22658045_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEtMy0xLTEtMA_dde19294-eead-46b6-a24d-b2c831c34344">2,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMC0xLTEtMzE1OTQvdGV4dHJlZ2lvbjpjZGY4NmE3OTQ4OTM0MmNhOGU5MzQ2MmNlMWZiYzgzN18xMDk5NTExNjI3ODA3_05df83c8-5c6d-4657-a211-7d960590a212">2.15</ix:nonFraction>% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMS0xLTEtMzE1NjY_31808f78-1e47-44bd-aaaf-9614fba4a1e2">1,986</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee399b5bb9e4f7382fa9bed6063f3e7_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMy0xLTEtMzE1NzM_abf58752-f4c7-41fd-8479-e2ed0507d9f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i666ad1c871a5437daefbf379c3ae7a1e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMC0xLTEtMzE3MjcvdGV4dHJlZ2lvbjo0ZTE1NTk2Y2Y1OTI0ZTA0YmFjMTRmMzFiMDdhYTQ4Y18xMDk5NTExNjI3ODA1_e3a83f01-ec50-458c-a7da-dd64dccf473e">2.75</ix:nonFraction>% notes due 2051</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666ad1c871a5437daefbf379c3ae7a1e_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMS0xLTEtMzE1ODA_a79cc7bc-d389-4309-8fbf-ebc876bbfb83">1,979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f677306c544591b8bdc15d6568cad1_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMy0xLTEtMzE1ODc_4460fc86-f19b-4a10-b6ce-01a392e91f6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4603067c37764e92871db7d73bb6a41e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMC0xLTEtMC90ZXh0cmVnaW9uOmY1ZGI0YjJkYjY2ZjRiMDRhMTY5ZTZlNzZjNGYyYmFlXzQ_a919b2ae-d051-4efb-b10d-519a59a7a652">3.70</ix:nonFraction>% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4603067c37764e92871db7d73bb6a41e_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMS0xLTEtMA_5f2ee038-d7fa-4597-bae8-f6a326e0dae6">1,977</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab29f77d5a54d36880055884c3d208a_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMy0xLTEtMA_649ac7bc-74b8-4444-93a1-47768c836066">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if25f9151edb34efe9659838c9851b5e0_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmQyNmUwNWQzNTJkOTQ5ZThiOGZjN2YyN2JkMTIxZDYzXzQ_f3fd7cf6-6992-4e4e-9bfb-19880942f39b">2.80</ix:nonFraction>% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25f9151edb34efe9659838c9851b5e0_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMS0xLTEtMA_2582fbc4-c6d5-4fed-b177-fabb42824fc5">1,749</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f198e2b6c8242329a2d6cce74447c22_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMy0xLTEtMA_edcc19ac-dfdf-4325-b944-61d4d8542993">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6eb70a7318804000a0b25e0954dccccc_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMjAxMmNkMjRhMDRlMTRiMGIzNzNlNTQ1ZmE2OWEwXzQ_a6d5ad17-f5b5-4f65-8068-04c684deaf42">3.40</ix:nonFraction>% notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb70a7318804000a0b25e0954dccccc_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzQtMS0xLTEtMA_45429096-e66c-41ee-9629-09bca3c46af5">1,736</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if272cc9ec9314c9b954ca02afdf19912_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzQtMy0xLTEtMA_bbd522d3-74d1-4ca9-a109-2306f8a10b29">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i330c8b376f0845b981e104e9da711b0e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMC0xLTEtMzE3NDUvdGV4dHJlZ2lvbjoxYmU4MjMwZWM1NWM0Y2U2OWIwYjZjMzcxZTQ2YmQ4M180Mzk4MDQ2NTExMTMz_b1bbf6ad-8310-4c7d-8a9c-5447e89d97f1">1.70</ix:nonFraction>% notes due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i330c8b376f0845b981e104e9da711b0e_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMS0xLTEtMzE2MTY_440b037f-558a-41ae-898d-bb2686d32d5e">1,493</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d4c4db752a47e1929b1bd9b0221ef3_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMy0xLTEtMzE2MjM_429a2a40-71f2-42f5-aa86-0ec00ea173ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e29e43c73b04d478539ff08737d0321_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMC0xLTEtMzE3ODcvdGV4dHJlZ2lvbjpjMzhjYjczNzljOTg0YzFmODYyNmJiOGEwY2FlYTRkNF80Mzk4MDQ2NTExMTM0_9a05b8c7-65ad-4a15-b2cc-da3eaea19ce0">2.90</ix:nonFraction>% notes due 2061</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e29e43c73b04d478539ff08737d0321_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMS0xLTEtMzE2MzA_97f26a95-940a-47ca-a587-e093ffeddceb">1,484</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce508fabf274d7fa48a9d9ef29611c3_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMy0xLTEtMzE2Mzc_1c3de1da-41e2-4ce2-9022-9ee3b3aee594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if938e22e704043879505c140022bccd0_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjJjZmY0ZjVmZGY1NTRjZWQ4MjBiMTBhZWM5NGU3MWUzXzQ_3dc0287c-dd65-4190-8745-5d78c4aebcb1">4.00</ix:nonFraction>% notes due 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if938e22e704043879505c140022bccd0_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzUtMS0xLTEtMA_60b4fb97-2f0d-412e-8a07-c89ef52eea21">1,470</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c90a6837f441e4b263d84bf547260b_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzUtMy0xLTEtMA_b86c4f99-7248-418b-9111-f69dd32c2af0">1,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75a2923a86ee4187a9d8e30f1302bad4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMC0xLTEtMC90ZXh0cmVnaW9uOjI0NTNiODgyMGI4MzQ0NDliOTAxZGI5MmFlOGNhYzg5XzQ_b301991e-e562-4b76-b539-2a5735a49936">4.15</ix:nonFraction>% notes due 2043</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a2923a86ee4187a9d8e30f1302bad4_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMS0xLTEtMA_0969d52d-5862-406c-bafa-9a0a0cfd881f">1,239</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6dc540edbe4a84988990cbdefe13d5_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMy0xLTEtMA_bd7b932a-efe5-4b81-a043-230eeed13453">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i178e4bc051044e76b42ccbb46d917f9e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMC0xLTEtMC90ZXh0cmVnaW9uOmY2N2I2YzRkMGFmMjRjOTE4NDJlMTFjZTY2OTNiYjY1XzQ_d0200852-2718-4761-a601-3ef0a84d261f">1.45</ix:nonFraction>% notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e4bc051044e76b42ccbb46d917f9e_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMS0xLTEtMA_24686d07-e3c5-46a2-958b-32ee3ff3d462">1,235</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325a7820086449098f9f5e7c422cda0d_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMy0xLTEtMA_d285e8ad-c9d4-4b42-8951-991a0996adbf">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i333858d5ddd54903ba67c9eaba12bf2a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTAtMS0xLTM5MzgyL3RleHRyZWdpb246MjQ2M2U1YmViYzdhNDAxYTllN2MzNzBiMWZiNGM3YmNfNA_84f83448-5ba6-4aad-9bf7-24d4a40bc043">2.45</ix:nonFraction>% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333858d5ddd54903ba67c9eaba12bf2a_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTEtMS0xLTM5Mzgy_84b7cc0c-018d-428b-a367-4e7ee6870152">1,212</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95bb17180d994e87ab3f841a7c846700_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTMtMS0xLTM5Mzgy_9d2410cb-6312-4dc2-9cd1-beb01f198ccf">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic23e62f8001740b7b380115c4ba260c4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzktMC0xLTEtMC90ZXh0cmVnaW9uOjZjYWMwZmE4NTVlMzQwODJiNzkzZGE3MjAyNzVjYWZiXzQ_09e4eb0e-1fbe-45d5-881d-1ff0475696ec">1.875</ix:nonFraction>% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic23e62f8001740b7b380115c4ba260c4_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzktMS0xLTEtMA_6d987a05-2f50-4d6d-bc18-5f1f973ab9e5">1,123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d7bae96e8b46fe83ce2a84bc3c0cb6_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzktMy0xLTEtMA_cb22b193-26b3-4f70-8564-ea6c8c644fdb">1,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i449243770d5a4a3aadefa2f9bb07dd48_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMmY0OWI4YTA5NWY0ZTkwYWU4NTNkYWM3NDA1NTMzYV80Mzk4MDQ2NTExMTMz_e62b03d1-f029-4a36-b3db-1438f4229a75">1.90</ix:nonFraction>% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449243770d5a4a3aadefa2f9bb07dd48_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEwLTEtMS0xLTA_15ae47c5-0f71-4ffc-8559-ea3168af194c">994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186f6c50dad74e3a8ea966fe8407b0d2_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEwLTMtMS0xLTA_e9932375-029e-406f-9752-69450c4987f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0adefdd4fd64c70843942c5ea526307_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjozMzJkMTlhOTc3NjQ0NTRjOGE1NDlhODdiZDA1MGE0MF80_39c34e61-b358-4168-8a42-91a7300291c9">0.75</ix:nonFraction>% notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0adefdd4fd64c70843942c5ea526307_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTEtMS0xLTA_80f53093-b8db-4495-b6d3-8208fb849449">993</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3307530aa44190849bb1be7e10ad8d_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTMtMS0xLTA_50354229-7eb2-44bf-a4b7-2ae8498d1bb0">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76684c6e7e7941fd886f959ebdf9684b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjpkODAxMzc3NTRhMTM0NGYyYTU1NzMyZjRkZWQ5M2QxMl80_583dbc08-5e28-44ae-b4aa-d4165fbfaf31">3.90</ix:nonFraction>% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76684c6e7e7941fd886f959ebdf9684b_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEzLTEtMS0xLTA_e5c92a2e-e2fc-40bd-b8e3-80ff3f21e99c">984</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60a350fed0a495da16890e319f026be_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEzLTMtMS0xLTA_8da399b3-4429-4352-a105-6e11476dacfa">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i311636cf40db4f85b916067268059c87_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmYzI5ZjliMzBlY2Y0MjI0YTEwZjA3NGRmZDA5YmM4YV80_a5c80b6d-c04f-431c-b80f-3f90271b8da6">2.35</ix:nonFraction>% notes due 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311636cf40db4f85b916067268059c87_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE0LTEtMS0xLTA_41a8fa77-e806-409e-bed6-ebfd2ec32f12">983</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e284b03ac364d3e8d78fbfa391cb0be_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE0LTMtMS0xLTA_4d786c9d-3947-451e-9d08-1c524e2eddbb">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib7435768c60e4451a21d4ba610ecc268_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE1LTAtMS0xLTAvdGV4dHJlZ2lvbjozMTNhMTI4YTZmMWQ0YWM1YTVhMDA5YTQyM2ZjNmJmMl80_f83dd2d0-ba3c-4b76-86f6-abc3f67be875">2.90</ix:nonFraction>% notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7435768c60e4451a21d4ba610ecc268_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE1LTEtMS0xLTA_fb44c434-393a-4bb1-bf5d-9d57f912153e">748</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee70c6efaceb4bd8a3f32437df0c8a5b_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE1LTMtMS0xLTA_012867bb-ceda-4575-ae4c-c73008217a2b">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a4e8734f76f48d190b8676cdac0c206_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZGEwN2Y3ZWViNWQ0NzdlOTk4MDVjYmYyNjFhYTEwOF80_028cd4f8-e389-47f2-865e-e8ba42070d0b">6.50</ix:nonFraction>% notes due 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4e8734f76f48d190b8676cdac0c206_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE2LTEtMS0xLTA_c00ab300-5e03-4187-a481-5d3dd7c48403">715</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a04e2cfd3a641758e42b169902efdc5_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE2LTMtMS0xLTA_d09bdbe7-fa5e-4c15-a3fb-a62c4b9868c3">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i130360c441d842fda96aa1a87003755c_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjo4N2VlMGQwOTEzMzg0NmQ3YTA5MzIxYmU5YTIwNGEyM180_df779c8d-238f-46c6-b565-050200b07380">0.50</ix:nonFraction>% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i130360c441d842fda96aa1a87003755c_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE3LTEtMS0xLTA_706a1de4-6d2b-446a-a028-6b368d537d3f">563</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4181b1f1a852487da488d837c8158ebd_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE3LTMtMS0xLTA_dbc33078-b491-4080-8617-7a46b0055e93">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1267e41a13d4a82939639506b0b47e0_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjpiOWIxNTA5OTRkYzI0YWNkYmQxNDM1MDFiNTk1YWNhMF80_3dc6aa76-05b8-409f-8289-53ac6d068ab4">1.375</ix:nonFraction>% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1267e41a13d4a82939639506b0b47e0_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE4LTEtMS0xLTA_01e84d5c-038c-48d0-92c9-ca61e0f6e74f">559</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if189170ce36b4eafb6f7201a9ca6ae4b_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE4LTMtMS0xLTA_0fbc8fbb-49d8-4482-92b0-9cd4b2cc0336">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84ae7163839e44318d2e1239dac4e116_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE5LTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmJhYjE2Njc4NDY0NDcyYjFhNWUwZDhmZDdlZDIxMF80_8ec48738-e702-482a-bdc0-d2454013af0f">2.50</ix:nonFraction>% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ae7163839e44318d2e1239dac4e116_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE5LTEtMS0xLTA_62164bc7-739a-4418-8682-800e056fa435">558</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc406a9bf2f434eafd58f22ac831620_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE5LTMtMS0xLTA_fc0c5192-2b9b-42bb-bdf5-1190f8528503">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a64ddf383234fde89422eb58d5a04d0_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjo0Nzk0YjVkYzA0OTA0ZWM3ODliMTA1ZWNjYmIyMmI5Y180_110b2900-c0d9-4045-9c33-eda29601f02c">3.60</ix:nonFraction>% notes due 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a64ddf383234fde89422eb58d5a04d0_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIwLTEtMS0xLTA_791ed217-5ca7-4bf9-a279-d295c2454e6d">491</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f2f1899dbf46acb52be81d989d18b8_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIwLTMtMS0xLTA_e7347554-14db-467f-8d23-f93b5b0eb8ff">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0065ecadcbc4c46aedfe9502ae528f5_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjplY2M5MWY2YWVmZjQ0MmE0Yjg4ZmQ2N2JlZThmMzUwNF80_c7a474f5-fca2-401b-ad03-9be87628767b">6.55</ix:nonFraction>% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0065ecadcbc4c46aedfe9502ae528f5_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIxLTEtMS0xLTA_987cbd9d-1148-46ce-9198-27c610038b69">409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674f0f6f35ce404ca1e28b4ade93aafa_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIxLTMtMS0xLTA_45c82ad5-8801-4a2b-bf1a-5d79df2b8017">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic84be8ae9e69454eb62cd343daebc684_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNTM3Y2NmYzJmNzk0MTVjYjRlMDY4Mjk4N2YyOGZkY180_129ec326-6063-4cbe-b25f-c9fc53217564">5.75</ix:nonFraction>% notes due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84be8ae9e69454eb62cd343daebc684_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIyLTEtMS0xLTA_4a73615f-496b-4b1f-be4a-eee955908298">338</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0900466410461fadb2b25dacab282a_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIyLTMtMS0xLTA_fb046c93-d4fd-4665-b579-f357c8f80846">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i443dc9e5f3c14c26b4627206e39cb2d8_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTNkMzg0ZWMzODI0MmZlOTVjNjVkODUwNmQ1ZmY1MF80_9a75814e-dfe6-41fc-b36b-e8198da009e9">5.95</ix:nonFraction>% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i443dc9e5f3c14c26b4627206e39cb2d8_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIzLTEtMS0xLTA_41f631b6-84e4-4d42-9066-1f0239bd392c">306</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie314f63b9375416f8539d5d713836ce5_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIzLTMtMS0xLTA_be94e42c-596b-4c57-9c94-fb0db7e25431">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ed29c8d391249e7b1ab655051fd96a3_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpkOGIxYTI5YzE5ZWQ0ZDU0YjA5ZWM0NTczODQ1YzRjMF80_0647b257-4fc1-4e63-a4f6-de69d6cc6a9a">5.85</ix:nonFraction>% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed29c8d391249e7b1ab655051fd96a3_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI0LTEtMS0xLTA_d311fc83-03c7-4ea4-9e7a-e654929a3035">271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if16c9874988749a6b9d4de2a351876c9_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI0LTMtMS0xLTA_0faee997-4a5b-4d99-998e-2594072cb8c5">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6381683a577b43b3a4f20e5ee2a42a23_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjo0YTAxZTAxNWQ3Y2I0MjZhYjQyY2ZlMTc3NWM2NjliOF80_9c4b009a-bc26-4a2d-bb12-dd22732668ee">6.40</ix:nonFraction>% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6381683a577b43b3a4f20e5ee2a42a23_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI1LTEtMS0xLTA_9206db4d-96ed-4873-a390-cadb7bab618f">250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774de7dc3f4a439e9ef258e52ad97260_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI1LTMtMS0xLTA_386e4d5e-ad3b-41b3-9737-bea1ed6329e8">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6230e83c438e4a4b8ad400ee569ba5e6_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjpjYTFiY2VhNGY0ZmE0YWU1OTNiMjQzODBmMzM1ZjlmMl80_6c4d5c80-7d1d-4d37-b72a-85cda36c3dae">6.30</ix:nonFraction>% debentures due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6230e83c438e4a4b8ad400ee569ba5e6_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI2LTEtMS0xLTA_9008c909-2d37-48fb-967c-6925a969ccff">135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cc9da918f54ffe9561a30e890c176e_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI2LTMtMS0xLTA_fc02752c-ef4f-44be-9602-0baa83b61741">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf3fd779ab0345a4b5682f42d4df167e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI3LTAtMS0xLTkyMi90ZXh0cmVnaW9uOmEyNWY3NDBiY2NkZTQ4YjdiZjk1MjQ5MjcxNDJiNjY4XzQ_04ccd0e8-a89e-4e7a-87f1-f34fcf5ddca9">2.35</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3fd779ab0345a4b5682f42d4df167e_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI3LTEtMS0xLTkyMg_b967eb40-f39e-4127-9d30-614c045eacfe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9334d22b30c34db685a58c5c19efc4c5_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI3LTMtMS0xLTkyMg_0952de51-cc2f-402a-88c9-ccb6fbf83dc5">1,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6615a4b358b4458cb9f301a9917387a1_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI4LTAtMS0xLTkyOS90ZXh0cmVnaW9uOmQ2MTZhODc0ZjhmZDRjODU4YjMzZjQ4MzhmYzY3YzJjXzQ_613ef628-428f-4ee7-8909-b344c237dbe5">2.40</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6615a4b358b4458cb9f301a9917387a1_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI4LTEtMS0xLTkyOQ_d3a856ca-06d2-40f6-82ef-d64c7891d981">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ff4d5f08ad4af5886628a1bbba25b7_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI4LTMtMS0xLTkyOQ_136c7cb1-33b2-4cbe-b2f9-b83bcad1d66c">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief565eb90eb64c95925824555f9e9d46_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMxLTEtMS0xLTA_a86bb319-6bfa-4381-b24a-5df7e7d8dd70">215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c57d8615014148a065e980841d3dc9_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMxLTMtMS0xLTA_2fed0ca7-df09-4083-81ac-db866a74dc38">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMyLTEtMS0xLTA_5f388d2f-7a83-414f-bb64-48c7bf477566">30,690</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMyLTMtMS0xLTA_c70cf9b1-6834-4d97-9d37-67bc23167bd4">25,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of <ix:nonFraction unitRef="number" contextRef="ida73e3479c1f4e4687a0d8cc7ff79ca9_I20211231" decimals="4" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzc0Ng_fa6d16e1-bd64-44ab-90f1-c95b165c11f2">zero</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="i5a6dee25ec5f47f0b9d50258c662b2e5_I20201231" decimals="4" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzc1Mw_8b205f00-9468-4b82-9aad-61c93dc5c6c8">0.45</ix:nonFraction>% for 2021 and 2020, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of the <ix:nonFraction unitRef="number" contextRef="i6230e83c438e4a4b8ad400ee569ba5e6_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzgxMg_1c03360e-9b2e-4e04-9a26-909742275b45">6.30</ix:nonFraction>% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck&#8217;s option at any time, at varying redemption prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjAzNTE_6cbca659-b553-426f-8634-4209ac8a45ef">8.0</ix:nonFraction>&#160;billion principal amount of senior unsecured notes consisting of $<ix:nonFraction unitRef="usd" contextRef="i330c8b376f0845b981e104e9da711b0e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjAzNjU_a9439923-c25f-4ddb-883a-78f60aeca0a0">1.5</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i330c8b376f0845b981e104e9da711b0e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjAzNzk_38f112c4-eaac-4d83-88bc-f7550c62deea">1.70</ix:nonFraction>% notes due 2027, $<ix:nonFraction unitRef="usd" contextRef="i449243770d5a4a3aadefa2f9bb07dd48_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjAzODY_1d55c1d9-b185-4b9f-a936-264d83093f5f">1.0</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i449243770d5a4a3aadefa2f9bb07dd48_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0MDA_da4c7114-63a7-4d99-ac87-6a441a4e1b7f">1.90</ix:nonFraction>% notes due 2028, $<ix:nonFraction unitRef="usd" contextRef="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0MDc_a38dd06d-c78c-481e-a109-739ca29bcbf4">2.0</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0MjE_55224837-2e9e-4d26-85e3-2e1587bb80ea">2.15</ix:nonFraction>% notes due 2031, $<ix:nonFraction unitRef="usd" contextRef="i666ad1c871a5437daefbf379c3ae7a1e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0Mjg_5444e73b-1f7b-46a7-8902-9ce7ddaa1f3b">2.0</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i666ad1c871a5437daefbf379c3ae7a1e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0NDI_5fb5c56e-3703-4526-add5-76505ff4da1c">2.75</ix:nonFraction>% notes due 2051 and $<ix:nonFraction unitRef="usd" contextRef="i7e29e43c73b04d478539ff08737d0321_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0NDk_fd5d656b-8dc0-45ac-89c9-05dfca51b49e">1.5</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i7e29e43c73b04d478539ff08737d0321_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0NjM_7a07c507-6228-4a75-95f3-7f7a0c50fcab">2.90</ix:nonFraction>% notes due 2061. Merck used the net proceeds from the offering of the 2027 notes, the 2031 notes, the 2051 notes and the 2061 notes for general corporate purposes, including the repayment of outstanding commercial paper borrowings (including commercial paper borrowings in connection with Merck&#8217;s acquisition of Acceleron), and other indebtedness. Merck allocated an amount equal to the net proceeds of the offering of the notes due in 2028 to finance or refinance, in whole or in part, projects and partnerships in the Company&#8217;s priority environmental, social and governance (ESG) areas. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ie0be01c0ec194944bbf68d2d96da94b4" continuedAt="ie533a280edb045f3ba8a1acfe67eaf39"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s borrowings require that Merck comply with covenants and, at December&#160;31, 2021, the Company was in compliance with these covenants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate maturities of long-term debt for each of the next five years are as follows: 2022, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwMjQ_16fc9362-d7cc-40be-b6d3-7656628c6556">2.3</ix:nonFraction> billion; 2023, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwMzI_8e107027-fa3b-48f4-ba61-6d8a40f8e18d">1.7</ix:nonFraction> billion; 2024, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwNDA_868b213c-e228-48bc-b5a8-16b09d7c6ab9">1.3</ix:nonFraction> billion; 2025, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwNDg_b77f1bd9-9f99-4968-b936-d5eedcfb9ee0">2.5</ix:nonFraction> billion; 2026, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwNTY_4d48b8f0-2d80-4ae4-8ba4-04ebadfa5669">2.3</ix:nonFraction> billion. Interest payments related to these debt obligations are as follows: 2022, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk4NTg_59ab90f0-8b42-40ba-a0a4-1ea9805769b0">910</ix:nonFraction> million; 2023, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk4ODk_ca1bd0d9-ca90-4ed8-aee6-362ea319e6ae">875</ix:nonFraction> million; 2024, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk5MDI_2dc96cd8-408b-4730-b66d-511afe9bc887">838</ix:nonFraction> million; 2025, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk5MTU_f9a4e3bb-820e-4ae2-bc91-baa0dd778420">771</ix:nonFraction> million; 2026, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk5Mjg_f5923ebb-1d3c-4e0f-8c96-e5252ea6b350">743</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwNzk_f5b2a188-f8dd-4fa2-8d8f-cc9cc1588ea3">6.0</ix:nonFraction> billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of <ix:nonNumeric contextRef="i7bd0a9a37e0245ff9bf9f6ac947f019f_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzMwODM_50db9953-b9c8-41b4-8abc-718d82f2089d">seven years</ix:nonNumeric>, which include options to extend the leases for up to <ix:nonNumeric contextRef="i7bd0a9a37e0245ff9bf9f6ac947f019f_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzMxNDA_1c30babb-efbe-4ff0-aae9-5246be5adfd2">four years</ix:nonNumeric> where applicable. Vehicle leases are generally in effect for <ix:nonNumeric contextRef="ic816dee0d6f44f3e9271509aa2068b19_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzMyMDQ_1b7ffc84-12e4-4afb-baf2-9b42171291d1">four years</ix:nonNumeric>. The Company does not record short-term leases (leases with an initial term of 12 months or less) on the balance sheet; however, Merck currently has no short-term leases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company&#8217;s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company&#8217;s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost was $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzUzNTY_3838219b-84cb-401d-832b-82c752a53136">343</ix:nonFraction>&#160;million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzUzNDg_8e6b5575-4937-4a61-871f-8c0c465a2469">340</ix:nonFraction>&#160;million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzUzNDE_17725f60-6bf9-40b9-b476-ec0acc74f867">333</ix:nonFraction>&#160;million in 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU1MTI_4a069ca9-72bc-4f4a-9509-d6f3086e8770">340</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU0OTA_d95736a8-4360-4865-9918-e431584a7e97">334</ix:nonFraction>&#160;million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU0OTQ_c0da4395-a8c6-4b89-a465-002e0ba640a7">275</ix:nonFraction>&#160;million in 2019. Operating lease assets obtained in exchange for lease obligations were $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU1MzM_556e314d-29f8-49f1-a19f-c36fab3bd582">117</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU1Mjc_c6c102e3-4697-40dc-b1c4-2250fc77fac3">473</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU1MjA_65945ce4-3756-41d6-87ae-a0076365a1f4">125</ix:nonFraction> million in 2019. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ie533a280edb045f3ba8a1acfe67eaf39"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="mrk:AssetsandLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3NzE_cb1212e7-a788-4c66-b125-96b1f83337ed" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_16a2eb8c-e452-4c08-a1c1-253a7ae69d38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_51a0e69b-3d06-4866-8735-b4018eea9421"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMS0xLTEtMA_c765b9bd-b6cd-4d9f-89e9-b82097bf32c0">1,586</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMy0xLTEtMA_aab52b14-7cb2-4bf3-9df8-66bd397ccd6a">1,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_a62e225e-815f-4743-87ec-8f20071b70d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_f733f0e1-fc32-4cc4-af08-cafbad4247b5">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMS0xLTEtMA_95f841c5-cbb1-42e0-af15-6a386eeb06b4">304</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMy0xLTEtMA_fa77bd76-3daf-49e4-9ced-f993214a868c">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_640b8294-5ffb-4269-b064-66281ca04383"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_7eda0372-d2d2-488c-a2da-c5fb07ed06fd">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMS0xLTEtMA_9e2f8ee0-7b23-466b-904f-9f20640cebef">1,225</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMy0xLTEtMA_86759fc6-9123-40fc-a720-b9fffbf33e75">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzYtMS0xLTEtMA_ebf21154-b9f4-47c7-9eef-172291e1e1a1">1,529</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzYtMy0xLTEtMA_ffbd0f73-bea1-4ff4-8daa-d24a73dd7dac">1,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzctMS0xLTEtMA_47f601a5-211f-4edc-820a-067dd63a59e4">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzctMy0xLTEtMA_aadbc99d-c9aa-4f7a-8c60-d4a4be7540dc">8.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzgtMS0xLTEtMA_94ecfaf5-856a-472d-bd29-fddf880e692f">2.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzgtMy0xLTEtMA_dc1e9ae3-46ca-4974-8ad7-5da9884a2d32">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Includes prepaid leases that have no related lease liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3Nzg_dba7c05c-2536-41f8-997a-5fd68e2c4330" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzAtMS0xLTEtMA_d9706393-5775-4c6a-a250-84eae16add1a">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzEtMS0xLTEtMA_2ee9cae9-e321-44d3-bf64-9e88876fa491">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzItMS0xLTEtMA_4fb10e63-9516-4fb7-8d96-dfce9c0de5a3">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzMtMS0xLTEtMA_0862f214-c2cd-40cb-beba-2860578ac065">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzQtMS0xLTEtMA_659b4b9b-2216-406c-ac85-7a88afe7d6cd">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzUtMS0xLTEtMA_5a183668-8787-4471-bc5a-5f9f7900357e">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzYtMS0xLTEtMA_e6098350-5a32-4522-b9c8-94aec7523ea9">1,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzctMS0xLTEtMA_2d6af179-9a77-4b91-86ba-3b815118fa39">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzgtMS0xLTEtMA_2999e7e2-2efd-4496-86ad-47a52881b4d9">1,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3NjM_4ac1142e-d6e9-4395-903a-554084d8d287">86</ix:nonFraction> million.</span></div></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_172"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzMxNDQ5_c626aacc-191b-4f12-8778-85e711648bba" continuedAt="i76152de138c14f328d01977ad09eefde" escape="true">Contingencies and Environmental Liabilities </ix:nonNumeric></span></div><ix:continuation id="i76152de138c14f328d01977ad09eefde" continuedAt="i1bd8b3c249db4238bb72ff4868605dc4"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i1bd8b3c249db4238bb72ff4868605dc4" continuedAt="i122cef788abf44ac8d33fc85d00c9f8b"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fosamax</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (Fosamax Litigation). As of December&#160;31, 2021, approximately <ix:nonFraction unitRef="case" contextRef="i0836d3b184984272bd57f286fc63992e_I20211231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzI0NzA_33b64fd3-ce45-446c-88e5-b1829359fa6f">3,470</ix:nonFraction> cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately <ix:nonFraction unitRef="case" contextRef="i4d2e8bc60a0148298d49f7245816f760_D20140301-20140331" decimals="0" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzM2NzA_d0ec63d5-1927-46ae-a760-67415c46d27f">650</ix:nonFraction> cases on preemption grounds. Plaintiffs in approximately <ix:nonFraction unitRef="case" contextRef="i4d2e8bc60a0148298d49f7245816f760_D20140301-20140331" decimals="0" name="mrk:LossContingencyClaimsonAppealNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzM3MzA_f7a4f6b2-78b2-4229-a677-f5892ee08877">515</ix:nonFraction> of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#8217;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#8217;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#8217; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December&#160;31, 2021, Merck is aware of approximately <ix:nonFraction unitRef="case" contextRef="if4692914ed0347bb9847781d8d6fbef2_I20211231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzU4MTY_e5135806-3deb-42eb-a4b2-f7c225eeca22">675</ix:nonFraction> product users alleging that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the development of pancreatic cancer and other injuries. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). On March 9, 2021, the MDL Court issued an omnibus order granting defendants&#8217; summary judgment motions based on preemption and failure to establish general causation, as well as granting defendants&#8217; motions to exclude plaintiffs&#8217; expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and on October 5, 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants&#8217; summary judgment motions and also granting defendants&#8217; motions to exclude plaintiffs&#8217; expert witnesses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, <ix:nonFraction unitRef="case" contextRef="i46200e06c7a04756a48759eed40c9e41_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzcwNzA_d70c0d00-20cf-4315-a894-e324f16c55c3">six</ix:nonFraction> product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck&#8217;s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(relating to the Fosamax matter discussed above). Merck filed the opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that preemption presents a legal question to be resolved by the court. In May 2020, the Illinois Appellate Court issued a mandate to the state trial court, which, as of December 31, 2021, had not scheduled a case management conference or otherwise taken action.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately <ix:nonFraction unitRef="claim" contextRef="i89ee4600a50543649e2d1a72ee56c5dc_I20211231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzgzOTg_4160af14-d069-4dd2-a8ef-538c45e3ca29">50</ix:nonFraction> additional claims. The Company intends to continue defending against any remaining lawsuits.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i122cef788abf44ac8d33fc85d00c9f8b" continuedAt="i4b6b6711630443738ae6e4eaf6dee78d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney&#8217;s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government&#8217;s information request by seeking information relating to Merck&#8217;s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company&#8217;s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General&#8217;s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck&#8217;s development of an insulin glargine product, and its subsequent termination, as well as Merck&#8217;s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government&#8217;s investigation and intends to produce information and/or documents as necessary in response to the CID.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Company&#8217;s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S.&#160;These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings.&#160;Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants&#8217; motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants&#8217; motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants&#8217; motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. In December 2019, the district court granted the Merck Defendants&#8217; motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i4b6b6711630443738ae6e4eaf6dee78d" continuedAt="i6b07f577bcad4793948fce76c911b56b"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of 35 direct purchasers. In August 2020, the Fourth Circuit vacated the district court&#8217;s class certification order and remanded for further proceedings consistent with the court&#8217;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. Briefing on these objections is ongoing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court has heard argument on certain of the motions. The court may hold additional hearings on the other motions. Trial in this matter has been adjourned. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in August 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. In August 2021, the district court granted certification of a class of indirect purchasers. In September 2021, the Merck Defendants petitioned to appeal the class certification decision to the Fourth Circuit. The Fourth Circuit denied that petition on September 30, 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, United Healthcare Services, Inc. filed a lawsuit in the U.S. District Court for the District of Minnesota against the Merck Defendants and others (the UHC Action). The UHC Action makes similar allegations as those made in the Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class action, as well as allegations about Vytorin. In September 2020, the U.S. Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict Zetia litigation already in progress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Humana Inc. filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against Merck and others, alleging defendants violated state antitrust laws in multiple states. Also, in December 2020, Centene Corporation and others filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana. Both lawsuits allege similar anticompetitive acts to those alleged in the Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class action. In July 2021, the California Court ruled on defendants&#8217; Motion to Quash for lack of personal jurisdiction, granting the motion as to the out-of-state claims against defendants, and ordering limited jurisdictional discovery with regard to the California claims.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on July 16, 2021, Humana and Centene filed actions against the Merck Defendants in New Jersey in the Bergen County Superior Court, re-asserting the claims that were dismissed in their California action. In September 2021, the parties reached an agreement that Humana and Centene would file their claims in New Jersey federal court, seek a transfer of those claims to the multidistrict Zetia litigation already in progress, and subsequently dismiss the actions previously filed in California and New Jersey state courts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Kaiser Foundation Health Plan, Inc. similarly filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana and Centene. The Kaiser lawsuit alleges similar anticompetitive acts to those alleged in the Zetia class action. The Kaiser action was removed to the U.S. District Court for the Northern District of California on July 16, 2021. In September 2021, the U.S. Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict Zetia litigation already in progress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 2021, all of the insurer plaintiffs (Kaiser, Humana, and Centene) are part of the multidistrict Zetia litigation, and are proceeding with discovery in that action. On February 9, 2022, United Healthcare, Kaiser, and Humana each filed an amended complaint.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rotavirus Vaccines Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, MSD is a defendant in putative class action lawsuits filed in 2018 on behalf of direct purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, alleging violations of federal antitrust laws. The cases were consolidated in the Eastern District of Pennsylvania. In January 2019, the court denied MSD&#8217;s motions to compel arbitration and to dismiss the consolidated complaint. In February 2019, MSD appealed the court&#8217;s order on arbitration to the Third Circuit. In October 2019, the Third Circuit vacated the district court&#8217;s order and remanded for limited discovery on the issue of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i6b07f577bcad4793948fce76c911b56b" continuedAt="i31d95c96c0f247bcb43ea620e308645f"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arbitrability. On July 6, 2020, MSD filed a renewed motion to compel arbitration, and plaintiffs filed a cross motion for summary judgment as to arbitrability. On November 20, 2020, the district court denied MSD&#8217;s motion and granted plaintiffs&#8217; motion. On December 4, 2020, MSD filed a notice of appeal to the Third Circuit. MSD&#8217;s appeal is fully briefed, and the Third Circuit heard argument on September 24, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal on February 7, 2022 and took the matter under advisement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by <ix:nonFraction unitRef="plaintiff" contextRef="i7ce296e507f349c6bd47b0823480f591_D20210101-20211231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzE3ODUx_b7674a90-03dc-481d-a755-0ee9080a22ec">two</ix:nonFraction> former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The <ix:nonFraction unitRef="plaintiff" contextRef="i7ce296e507f349c6bd47b0823480f591_D20210101-20211231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzE4MzAz_b7674a90-03dc-481d-a755-0ee9080a22ec">two</ix:nonFraction> former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, <ix:nonFraction unitRef="case" contextRef="i95ea257d9c4d4c4fbbd6847991aa1d0a_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzE4NDM0_adbec6fa-af7e-4b18-9056-14e54e9a082c">two</ix:nonFraction> putative class action lawsuits on behalf of direct purchasers of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M&#8209;M&#8209;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;II vaccine, which charge that the Company misrepresented the efficacy of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck&#8217;s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits have proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck KGaA Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name &#8220;Merck&#8221; in the U.S. KGaA has filed suit against the Company in France, the UK, Germany, Switzerland, Mexico, India, Australia, Singapore, Hong Kong, SAR, PRC, and China alleging, among other things, unfair competition, trademark infringement and/or corporate name infringement. In the UK, Australia, Singapore, Hong Kong, SAR, PRC, and India, KGaA also alleges breach of the parties&#8217; coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in numerous jurisdictions outside of the U.S.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i31d95c96c0f247bcb43ea620e308645f" continuedAt="i0c4ec8d77e014ff680dd46fb3131b905"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with four generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against one generic company, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As previously disclosed, the FDA has granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. The Company currently anticipates that sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. will decline significantly after this date. However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin (2027 salt/polymorph patent), which, if determined to be valid, would preclude generic manufacturers from making sitagliptin phosphate salt and polymorphic forms until 2027 with the expiration of that patent, plus pediatric exclusivity. In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity, ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#8217;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, with closing arguments scheduled for April 13, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company has settled with <ix:nonFraction unitRef="case" contextRef="ica45cfeeb70a4e189cf234b69c9b1ed3_D20210101-20211231" decimals="0" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzI0ODY5_a630b960-d4db-4602-9955-0b191485ebca">21</ix:nonFraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i0c4ec8d77e014ff680dd46fb3131b905" continuedAt="i060bd90efed346b4a30156cec21589e2"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan has appealed the USPTO&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#8217;s application seeking approval of its sitagliptin tablets. The U.S. District Court for the District of Delaware has set a three-day bench trial in this matter beginning on October 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Germany, generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the generic companies are successful, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could lose market exclusivity in Germany at the same time as the expiry of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pediatric market exclusivity in September 2022. A hearing was held in June 2021 and the court decided that the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is invalid, which decision the Company has appealed. Challenges to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPC have also occurred in the following European countries: Austria, Czech Republic, Finland, France, Hungary, Italy, Portugal, Romania, Slovakia, and Sweden.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2021 and 2020 of approximately $<ix:nonFraction unitRef="usd" contextRef="i2c06720f33624299898d274fe0bf9d14_I20211231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzI4MTU2_8b0477b2-8eb5-4a5a-8a30-2be83fa9b770">230</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8826f2e082a14b209b4b18a5290f7a91_I20201231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzI4MTYz_c2293764-1a19-4564-8372-5d217e5735a0">235</ix:nonFraction> million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company&#8217;s potential liability varies greatly from site to site. For some sites the potential liability is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i060bd90efed346b4a30156cec21589e2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:AccrualForEnvironmentalLossContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzMwNzAy_fce77768-a0c6-428e-8e47-b0bc87ff0831">40</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:AccrualForEnvironmentalLossContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzEwOTk1MTE2NTk1NDg_7f0ed01b-a3e4-404f-9819-84c0e3dc6794">43</ix:nonFraction> million at December&#160;31, 2021 and 2020, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="mrk:TermForPayingOffEnvironmentalLiabilities" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzMwOTQ3_f0e0d89d-6aad-4a22-a14b-1af7dbd949a5">15</ix:nonNumeric>&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzMxMjM1_ee2db8f7-5245-45f6-a587-a4aa00639c87">40</ix:nonFraction> million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#8217;s financial condition, results of operations or liquidity for any year.</span></div></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_175"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90ZXh0cmVnaW9uOjc2YzUwOTgxNzRlOTRmN2JiODJiOTAxOTIzNGEzMzExXzExMzk_ec15ec6a-c390-4035-b597-04f61fa2cc07" continuedAt="i26cd725f50c343e193617e471035e6e3" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="i26cd725f50c343e193617e471035e6e3"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merck certificate of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90ZXh0cmVnaW9uOjc2YzUwOTgxNzRlOTRmN2JiODJiOTAxOTIzNGEzMzExXzcw_22b70d7f-1e83-4426-8b72-6f33ed88dcc8">6,500,000,000</ix:nonFraction>&#160;shares of common stock and <ix:nonFraction unitRef="shares" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90ZXh0cmVnaW9uOjc2YzUwOTgxNzRlOTRmN2JiODJiOTAxOTIzNGEzMzExXzEwMA_0178042a-0cf1-41a8-a55a-86545ed4e220">20,000,000</ix:nonFraction>&#160;shares of preferred stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Stock</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90ZXh0cmVnaW9uOjc2YzUwOTgxNzRlOTRmN2JiODJiOTAxOTIzNGEzMzExXzExMzY_1a4f5e89-e518-41d1-86f2-255e25cffb93" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if91e41b657e142838655904b6ffc2b4c_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItMS0xLTEtMA_fd0b25d9-d2b6-496e-82e2-3a588855f8f5">3,577</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44fbc319828d43888404b362300c8719_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItMy0xLTEtMA_50bfcb7c-24bf-489f-bb3a-ba1141cc2447">1,047</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e784cab819d451499c362b12111a27a_I20191231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItNS0xLTEtMA_9e775635-a2df-4133-a03c-6f1f9062da8c">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e651f0bdf0a4e5c85db0a3c85be51f1_I20191231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItNy0xLTEtMA_78d2d664-1fed-43cd-a838-04328af2539b">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i296a96e660db43169f0376b184f4d3fc_I20181231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItOS0xLTEtMA_e745e541-2d31-4cbc-9bdb-a9f46b3f665a">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b062550448c4f5b877548d6eda89d15_I20181231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItMTEtMS0xLTA_a9b9182e-033f-4554-9a8f-311e76e82cb5">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b9c3612f056401fb72e41a133ef96aa_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtMS0xLTEtMA_eec53348-1b1b-41cd-a418-cbb92f37d3fe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtMy0xLTEtMA_8622b436-06f4-4468-bff8-2e3f8e94e9b8">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbc6c432152d469a9be95a1902906f56_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtNS0xLTEtMA_eb34d683-1430-4cad-87ca-759c403209b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtNy0xLTEtMA_a144dcf9-44d7-4895-9276-5a5f24f2d2b6">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide665a6ad8774e8695a7587e4b025cb3_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtOS0xLTEtMA_cf9817a9-1b26-4114-882a-e90a7cd70874">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtMTEtMS0xLTA_4907cf00-9cb4-49f2-8bde-01f4d0a283d1">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b9c3612f056401fb72e41a133ef96aa_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtMS0xLTEtMA_bfbe7f4a-5406-4298-9e58-fbbef7c49a91">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtMy0xLTEtMA_2fdf1a20-3ec8-4230-925b-c49e8afb35d3">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbc6c432152d469a9be95a1902906f56_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtNS0xLTEtMA_8682a503-26aa-4e9c-933d-1c81f758411f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtNy0xLTEtMA_9325f6cc-34ba-4597-a880-7548c7fca6c0">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide665a6ad8774e8695a7587e4b025cb3_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtOS0xLTEtMA_84f5559f-e8ef-4bfe-b9c1-a660a8492bc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtMTEtMS0xLTA_0d3b3ab8-bfdc-4259-afa5-3319b3998991">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5771d34675734e438d53901618ffd853_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtMS0xLTEtMA_c48067ee-8b4a-4442-ba03-6e2a738d1b8b">3,577</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10c6f9da4227441da8480f88901779b2_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtMy0xLTEtMA_218b85d0-42bd-464f-822e-1e75001f5176">1,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if91e41b657e142838655904b6ffc2b4c_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtNS0xLTEtMA_c224dc18-5f62-4041-97ab-2eae57099679">3,577</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44fbc319828d43888404b362300c8719_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtNy0xLTEtMA_422f1d72-6f65-4b04-967c-a29a594f0d90">1,047</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e784cab819d451499c362b12111a27a_I20191231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtOS0xLTEtMA_f12c97b6-272b-4c1e-8cf8-75328270cb40">3,577</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e651f0bdf0a4e5c85db0a3c85be51f1_I20191231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtMTEtMS0xLTA_52e59c76-f48e-48df-b60d-3afaa488cac2">1,038</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div></ix:nonNumeric></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_178"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMjc_86cd8095-b860-40fc-b6d6-acc038f9ba7e" continuedAt="i678a542fb5e54f30935ee373356e9d71" escape="true">Share-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="i678a542fb5e54f30935ee373356e9d71" continuedAt="i66558726e954417bac6c108ffd73798d"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company&#8217;s shareholders.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQ1Mg_e5bbb2d5-f932-46a5-a7ad-0c338d58d5e5">93</ix:nonFraction> million shares collectively were authorized for future grants under the Company&#8217;s share-based compensation plans. These awards are settled with treasury shares.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwNTc_c5c0fb5d-3b7a-4beb-bcd7-503b33b694b6">three-year</ix:nonNumeric> period, with a contractual term of <ix:nonNumeric contextRef="ic1a2739cca2046f0abc863ed20b48d0b_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzgyNA_930d60de-1516-4666-b91e-db7d50c0990a">7</ix:nonNumeric>-<ix:nonNumeric contextRef="idbf378454e1d4b12a87f05c8d4852a45_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzgyNw_d87e8837-bbab-44dc-bb76-c7d590a0ba31">10</ix:nonNumeric>&#160;years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company&#8217;s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company&#8217;s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company&#8217;s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMTQ_8b2862bb-8117-47ae-a526-b746ab2ed6d1">three years</ix:nonNumeric>. RSU awards generally vest one-third each year over a <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwNTQ_f6892708-9217-4f4c-813f-faccd11f9a84">three-year</ix:nonNumeric> period.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i66558726e954417bac6c108ffd73798d" continuedAt="i5088519aef7f4941aa30ad50c7429539"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total pretax share-based compensation cost recorded in 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzEwOTk1MTE2MzcwNzA_6d6df354-34ea-4dca-aeda-ed9d68d838cd">498</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzEwOTk1MTE2MzcwODU_6cf64489-c06a-4a9b-9140-d5c4ec559fc6">475</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzEwOTk1MTE2MzcwOTk_fca5b699-fc80-4af0-9cd3-721b3f4234b2">417</ix:nonFraction>&#160;million, respectively, including $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIwNzY_d18856a6-26be-419a-94f2-89e9686f73ba">479</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIwODA_142d7a18-2e5b-47d3-94e5-c853ce8c6c4b">441</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIwODc_7c98212c-8ef6-491e-a073-9284e5ccabc6">388</ix:nonFraction> million, respectively, related to continuing operations. Income tax benefits for share-based compensation expense recognized in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIxNDE_780954fc-17f7-4124-9167-485db8f5a963">69</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIxNDU_24f9b0bf-3dc2-47a4-8b1e-84f48fc8f9d7">65</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIxNTI_ecec5f12-137b-40dc-967f-de13e1dbf3dd">57</ix:nonFraction> million, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company&#8217;s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price of options granted in 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMyNjA_3ca203e5-f321-432a-a079-fda9685e190d">75.99</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMyNjQ_e81e5a89-c1bc-4572-9b7a-57c0b0ce6dfb">77.67</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMyNzE_dca48bc7-649f-40ef-92e1-bff8254f57c0">80.05</ix:nonFraction> per option, respectively. <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwNTE_d9254a80-76b8-4ba9-9c6d-05afd1258251" continuedAt="ideee991bce974d9286affb7d46f1d6cb" escape="true">The weighted average fair value of options granted in 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMzNzI_7db41141-c3bc-4d80-9970-911b87c8f1d2">9.80</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMzNzY_82e6d2f8-9684-4c16-9cd7-db1224f9fc73">9.93</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMzODM_bc772e49-7a72-4a18-8284-ec25d2e04aef">10.63</ix:nonFraction> per option, respectively, and were determined using the following assumptions:</ix:nonNumeric></span></div><div style="margin-bottom:1pt"><ix:continuation id="ideee991bce974d9286affb7d46f1d6cb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzEtMS0xLTEtMA_099dadb2-c8fc-4267-8f18-fa0144a6baf9">3.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzEtMy0xLTEtMA_0ac51050-de86-42d6-96f7-4193697039e2">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzEtNS0xLTEtMA_799fd7b2-6478-4be4-b832-bc6e7f07f0f6">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzItMS0xLTEtMA_6cff7007-6826-4576-94c5-9dadcb644ab6">1.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzItMy0xLTEtMA_c2146642-fa9f-473b-b291-cbe8bb847d22">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzItNS0xLTEtMA_f80712c3-6b61-4fc9-a831-e9014c45f5e2">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzMtMS0xLTEtMA_335026e8-e632-4b47-a4ad-e17a1565ec61">20.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzMtMy0xLTEtMA_702f731a-bd67-4c56-87db-41c98e66785b">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzMtNS0xLTEtMA_0f743638-5bfe-41e2-a2d9-97a357f5a255">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzQtMS0xLTEtMA_341336e9-cbdd-47aa-947f-1543084c425a">5.9</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzQtMy0xLTEtMA_bf2c00e6-7be9-4f2f-9ac2-b4ad1270ce53">5.8</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzQtNS0xLTEtMA_660dbaa0-e5c9-42d3-9bce-8624dee0302d">5.9</ix:nonNumeric></span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMjM_6fbc57aa-8af7-4c92-a0ed-81d80f72cc5d" escape="true"><div style="margin-bottom:3pt;margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding January&#160;1, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzEtMS0xLTEtMA_4e9485ab-e7a3-4e33-8022-7084c36effbf">19,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzEtMy0xLTEtMA_7143702b-bc04-4eef-a5e6-2df459f93f63">63.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzItMS0xLTEtMA_8de57e51-8d55-4574-b3eb-a2ced64ff4ee">4,781</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzItMy0xLTEtMA_27ca6611-815b-4378-80e3-63f93039900e">75.99</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzMtMS0xLTEtMA_55f82d57-1679-456f-9f06-216b6d52b815">3,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzMtMy0xLTEtMA_6259bece-efb3-4d96-a579-f7f0d4deacd1">54.14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzQtMS0xLTEtMA_af95357c-1da9-4f84-9109-c0862ed6a6f9">626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzQtMy0xLTEtMA_54cd72db-4438-4eea-954b-4462f8b322e4">73.97</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards transferred to Organon in the spin-off</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-3" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMS0xLTEtNDMxMjk_a50c9393-4985-45c8-ab64-5c903220311f">1,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMy0xLTEtNDMxMjk_89e85dd0-eecc-4d6f-8821-050e2c6b11c8">72.15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustment to Merck awards related to the spin-off of Organon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-3" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMS0xLTEtMzY1MQ_b557037f-8e41-4661-9dcb-7bef1e2c1a19">646</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMy0xLTEtMzY1MQ_85ccb66e-3404-4cf6-8b7b-6dffb070ddbe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMS0xLTEtMA_8135c20c-0dcf-4208-86f5-7bbd9258c1ec">18,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMy0xLTEtMA_9edaa11b-1a53-4a72-acc7-0d57b21dc9b8">65.27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtNS0xLTEtMA_fb12c0e4-f844-4e27-868c-55fbc401bbb6">6.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtNy0xLTEtMA_553fc3a0-6c69-4993-b40c-96a6acf2fd41">213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzgtMS0xLTEtNDc3ODE_13d327d8-46e0-4532-a2dc-9273a4d2be2a">17,829</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzgtMy0xLTEtNDc3ODE_d98fe5e0-bddd-4359-9f70-7495bccb8890">64.90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzgtNS0xLTEtNDc3ODE_3b58149f-8365-4af1-b7ca-5b76dccdbd91">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzgtNy0xLTEtNDc3ODE_bb81f8d2-3e6d-44de-b54a-ea3b06e6aa5a">212</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzYtMS0xLTEtMA_e920c8ad-d933-44e5-9fab-1e0e18c9af05">12,136</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzYtMy0xLTEtMA_055475ef-3920-4cf7-beb9-5280e025ded4">60.41</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzYtNS0xLTEtMA_c6d2ca18-0ffe-44e9-b997-ff3604c25cf3">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzYtNy0xLTEtMA_42239e75-3892-48ae-bbf8-0726036b77ed">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Activity prior to the Organon spin-off has not been restated.</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  In connection with the spin-off of Organon, all outstanding Merck stock options (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMzY_bf291260-5d41-4f69-a5d1-31f834baa119" escape="true"><div style="margin-bottom:3pt;margin-top:7pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzEtMS0xLTEtMA_db802309-b0ba-4ce9-b1e3-62ae37268288">106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzEtMy0xLTEtMA_0612eaf3-2550-49e0-b562-630493e8cd4d">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzEtNS0xLTEtMA_f72b4fdb-b7bd-4768-a753-aa632a8c4bc2">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzItMS0xLTEtMA_a9e80790-dcda-49b8-99cc-88edafe2e3ec">27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzItMy0xLTEtMA_e0babddc-3db7-4695-805f-8f8c89edf20a">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzItNS0xLTEtMA_d1ea3a42-63e8-4e98-8cc5-984c16f849cf">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzMtMS0xLTEtMA_3d54e30a-cd1b-4dcd-bcca-42a1ff3e7500">202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzMtMy0xLTEtMA_d6050a38-32c8-4b06-8eb7-a94fc6a04490">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzMtNS0xLTEtMA_974bfc49-7f47-4891-abda-a72560fd7384">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i5088519aef7f4941aa30ad50c7429539"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMzQ_3c888da8-8d8a-4b29-a8ca-41c443535eb6" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested January 1, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00edd76d055e4b64afd262bffa0b265e_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzItMi0xLTEtMA_c672ad8e-9d7f-452a-a527-33e4b89f77b1">11,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00edd76d055e4b64afd262bffa0b265e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzItNC0xLTEtMA_54529939-eeaf-4823-bb26-9682a4c7a320">74.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96029d87c50446529e49db206d363e3e_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzItNi0xLTEtMA_97782cf6-b806-4a90-aff9-6ed595384f02">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96029d87c50446529e49db206d363e3e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzItOC0xLTEtMA_bf28f809-fab2-4bd9-8b86-ed07e9456a85">75.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzMtMi0xLTEtMA_51c3b8fa-a2d8-4f3c-8f6b-13fee497bf5e">7,897</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzMtNC0xLTEtMA_b743928f-b96a-4d28-bc15-65f120c99d97">76.16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzMtNi0xLTEtMA_ac7caa9c-54b7-4030-ab0e-06fbcd7d59d5">1,487</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzMtOC0xLTEtMA_d0873383-af0b-45fa-94a4-2723ff45107e">69.33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzQtMi0xLTEtMA_14c2245b-5360-4a86-873e-a62aea41b064">6,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzQtNC0xLTEtMA_1afc2cab-34b5-42c3-8f12-2e1a20925e4f">70.25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzQtNi0xLTEtMA_c5d8fd4b-e387-454f-9992-b8a3443c75a7">1,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzQtOC0xLTEtMA_cb9002b6-5451-41e5-ac27-7342250e5da2">57.14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzUtMi0xLTEtMA_99a5eb3d-70dd-4132-a3f8-ce9f78a69ad8">1,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzUtNC0xLTEtMA_ece58ba0-08dc-4e7f-855f-60fdc31b2e57">76.62</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzUtNi0xLTEtMA_454174d5-80a5-4674-8955-6f2d0b3d05d6">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzUtOC0xLTEtMA_42d605b5-4161-4353-a828-c95435040421">79.33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards transferred to Organon in the spin-off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="-3" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtMi0xLTEtNDMxMDU_1e8cc3f9-ee85-4794-94aa-3770b27cda4d">1,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNC0xLTEtNDMxMDU_0dd914e3-3c44-4a48-b985-eb85347e1803">76.99</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="-3" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNi0xLTEtNDMxMDU_7dadb4b2-88d6-4794-91cf-3bbf9a5d23ef">248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtOC0xLTEtNDMxMDU_41b0f013-acbe-4385-b533-8fd7dfe180cd">77.39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustment to Merck awards related to the spin-off of Organon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="-3" sign="-" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtMi0xLTEtMzY2NA_7325fab4-226a-4b6c-a0e8-55a3f31314da">368</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNC0xLTEtMzY2NA_8fdf9d36-b16a-4737-abf2-608d961e12d4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="-3" sign="-" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNi0xLTEtMzY2NA_a8161099-320e-446b-bce0-25cf3370030b">60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtOC0xLTEtMzY2NA_bce31136-dd31-4178-8874-3c0975bda50f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtMi0xLTEtMA_edfb313b-e0fb-4cdd-83e5-7bf445e16dc5">11,790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNC0xLTEtMA_f6cf284d-ef4b-4902-aedf-ffbec3630a56">74.88</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNi0xLTEtMA_4319a3a6-ff27-4f9e-aef7-a2dda02588eb">1,966</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtOC0xLTEtMA_cdbd9793-8b7e-4139-9fa9-c00746862610">77.13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected to vest December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231" decimals="-3" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzktMi0xLTEtNDc4MjE_dddddcdb-1e2f-4c2d-8ac6-14c67b8eca91">10,499</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzktNC0xLTEtNDc4MjE_410f5831-2a5e-48ee-975d-a951bad9c8fe">74.93</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231" decimals="-3" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzktNi0xLTEtNDc4MjE_c093619d-6d51-44b4-9469-b9bd1c0559e8">1,832</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzktOC0xLTEtNDc4MjE_9e8595f8-7170-4514-adcd-928a954e8a9c">77.40</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Activity prior to the Organon spin-off has not been restated.</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  In connection with the spin-off of Organon, all outstanding Merck RSUs and PSUs (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzM3NTk_ff828096-f036-48a9-9461-bce3dcd2a6ee">699</ix:nonFraction> million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzM5MjY_d5cb85e8-9879-4a71-a819-87f4bc58e139">1.9</ix:nonNumeric> years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_184"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxMTA_8772921f-bf30-411a-84e0-662cc0f3a734" continuedAt="i7d059c1b69dd46b9be66b175f0399232" escape="true">Pension and Other Postretirement Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i7d059c1b69dd46b9be66b175f0399232" continuedAt="i04de05b7e06d4d80b8fbed107785e7ac"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S.&#160;retirees and their dependents, through its other postretirement benefit plans. The Company uses December&#160;31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic Benefit Cost</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxNDM_a17c2ad7-515b-4212-b070-e4acceac5d6b" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:27.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other&#160;Postretirement&#160;Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMS0xLTEtMA_38bfc288-3cc7-4aa5-8f65-458abe49fa4a">403</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMy0xLTEtMA_dae2ca25-99dd-4603-ae60-46ef162602e7">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtNS0xLTEtMA_ba416c0f-ff26-4b79-8f36-7ad2bde111aa">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtNy0xLTEtMA_d2cf5e51-1f2c-440f-bf71-8c442806ac18">328</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtOS0xLTEtMA_c0ac3d5f-5ec7-4832-b5f2-419ca6f0b05c">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMTEtMS0xLTA_1aec4223-ea61-4a6c-9e21-06e841087789">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMTMtMS0xLTA_a9f8535c-9a6d-47f9-aacd-f64d1c5c9dab">48</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMTUtMS0xLTA_256e388b-59ca-42a8-a86b-fcec2a3eccf2">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMTctMS0xLTA_66ddb272-e4dc-426a-8890-817fc9ee2032">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMS0xLTEtMA_81f75b0c-d12a-4bf0-a136-2c574a786a2d">404</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMy0xLTEtMA_dd28af45-24f4-4b2c-9d8e-14561f3edfdd">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtNS0xLTEtMA_c0a0cb17-4f6d-40d1-a427-d7f71e58c409">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtNy0xLTEtMA_544a2380-d604-482d-af09-d052bc549fbf">123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtOS0xLTEtMA_484c938b-6b43-4b3a-b469-0849f57ae818">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMTEtMS0xLTA_d215d2f5-e0b6-4b7e-9032-02e0c97c1b5b">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMTMtMS0xLTA_4a5025c9-c2e3-4830-ba28-251233f7199f">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMTUtMS0xLTA_14500fa9-be87-42af-9a68-97d3bba3dfb1">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMTctMS0xLTA_59112e65-4d69-47a8-b507-af2b068d85d1">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMS0xLTEtMA_52687bd7-d851-4a7d-ad66-511bd3a63cee">755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMy0xLTEtMA_d3b565c2-aeb1-4bba-9bab-747535d41723">774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtNS0xLTEtMA_304f6e64-bbd0-4807-8b71-af5ed5b0cfd0">817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtNy0xLTEtMA_5a6d9862-5465-474a-90ef-57fa492d197f">416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtOS0xLTEtMA_90c60965-b082-4f8c-9ead-63c41e12e988">414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMTEtMS0xLTA_e0d56780-760a-403f-8312-f0d808449e40">425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMTMtMS0xLTA_3334b745-1930-4036-b355-2c0d741e796a">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMTUtMS0xLTA_03cfa5e1-5268-45ef-9ee1-e24923c5e0ba">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMTctMS0xLTA_6a4c1538-0a2a-40cb-a020-a53f297186f9">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMS0xLTEtMA_87752797-5cad-4cd3-af40-bbb4f68aebbf">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMy0xLTEtMA_36c3feeb-230c-4ec9-abeb-81b6dc689587">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtNS0xLTEtMA_f9092907-5569-49b2-8ef2-0a3ab157282e">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtNy0xLTEtMA_ff9fe4ad-e660-49cc-a7bb-4d35cab0d408">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtOS0xLTEtMA_523c2dd7-408b-43ec-b321-0f7819266ea2">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMTEtMS0xLTA_034dbd9f-fed4-4f6b-948a-3bbdfc45eed9">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMTMtMS0xLTA_d7f806c0-793a-4792-8179-709863934238">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMTUtMS0xLTA_a2d8a7bf-f012-46c7-8ad8-53c9fe596bba">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMTctMS0xLTA_33b779b4-8339-4384-ad14-561f8b869822">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMS0xLTEtMA_3012bfd3-2cd3-4186-90bc-c19cb0ab909c">298</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMy0xLTEtMA_424b9fa5-6be5-4e69-940c-d0e973f13dc2">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctNS0xLTEtMA_613d205e-c607-48e7-b655-c8d7a7839336">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctNy0xLTEtMA_831addd9-2f72-4d28-a68d-2685b780f555">142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctOS0xLTEtMA_f4b92e6c-d3c9-48d6-8c2d-a9def6e00a36">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMTEtMS0xLTA_6b59eb0a-3d39-4c12-a3a1-c285e92b3c07">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMTMtMS0xLTA_32b1ed41-836b-4b63-9682-3f317b5c7ba4">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMTUtMS0xLTA_5ceb65c7-db6b-498e-aef1-ea212ae66961">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMTctMS0xLTA_ab28a77e-2601-4d8f-91f7-45b76b5662fc">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMS0xLTEtMA_c0377e9f-7fd2-4b5c-a3f9-2828e36600a0">56</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMy0xLTEtMA_47eda253-874e-4b8b-ac83-100e8043ede3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtNS0xLTEtMA_361af269-34ef-4302-9138-7a8defac2073">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtNy0xLTEtMA_33c95fab-d774-457b-b73e-2d7b39481d18">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtOS0xLTEtMA_de12d239-6d21-4c36-9ab9-96caa3d3fa24">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMTEtMS0xLTA_85c53a2f-5c32-4a15-9116-f5825f2e3698">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMTMtMS0xLTA_7155d639-664e-46b6-8481-a6bbd101d68f">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMTUtMS0xLTA_5d6544b9-ad2a-4bbd-a385-f6c550589b15">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMTctMS0xLTA_231c2575-e3b9-4a70-bc2a-b4d4f6809bb5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMS0xLTEtMA_58559f48-89b9-4a0d-bf1f-c228d8389881">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMy0xLTEtMA_0001a123-66ae-4cfd-af85-44a0ef567d28">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktNS0xLTEtMA_c7766a01-4e2f-46c2-a25f-b8bccf5eae65">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktNy0xLTEtMA_c0b2af23-06ad-4f70-a922-c49d339e8974">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktOS0xLTEtMA_6f64336f-5f7d-4c02-8207-e9962c2fad07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMTEtMS0xLTA_b4d198a0-9f7f-4b6e-b740-ffe953f9ba33">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMTMtMS0xLTA_3eae051a-05be-4907-b081-658f1381110a">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMTUtMS0xLTA_01d65a10-8dfd-47f0-b1cd-24fe464ea589">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMTctMS0xLTA_e57bddc6-8564-422b-a49e-9f5665632bc7">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTEtMS0xLTA_1bc28b5e-e79d-46d7-9a71-3074d7628b98">216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTMtMS0xLTA_1a7e5c3c-cdca-4616-a699-bff56f865fd6">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTUtMS0xLTA_2d93dd7e-1bc6-4456-9ac0-bf706511d6a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTctMS0xLTA_31b6da1e-c550-4d84-aa7d-946242a97a7d">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTktMS0xLTA_838ce371-0fd0-4060-a505-9549ba1550df">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTExLTEtMS0w_f0dedbf8-6851-436a-87c5-35a7be972d6a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTEzLTEtMS0w_0a3eeebf-eed0-4ee2-a598-9cdb9968e67f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTE1LTEtMS0w_6ece5481-28c6-4e74-b361-5ed44adcbd8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTE3LTEtMS0w_ad87dbdd-a890-4fc0-979b-94ba087f01a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTEtMS0xLTA_a1741e2e-4ddc-434d-aa8f-c4c76abed172">600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTMtMS0xLTA_091e7767-b9d4-42ee-a7b8-6937e0b9f6b7">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTUtMS0xLTA_4ea9238b-280d-45c7-8fdd-72d45dc363b7">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTctMS0xLTA_1536c838-d155-439d-a9b2-666fc0c0be94">148</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTktMS0xLTA_ca78a50e-70ad-4742-95e1-8fc10380d66f">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTExLTEtMS0w_0fda5c76-c9f3-408e-a2c2-0a1c479b48d7">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTEzLTEtMS0w_67ddb2cb-b978-45b9-96fb-8aa446880a80">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTE1LTEtMS0w_22520852-8ccb-48ed-bcb1-feb4c32f3adc">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTE3LTEtMS0w_e81285e2-6f27-49ae-b5a6-b99a0743d1bc">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit) for pension and other postretirement benefit plans in 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;6), termination charges were recorded in 2021, 2020 and 2019 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i04de05b7e06d4d80b8fbed107785e7ac" continuedAt="ia1f846bac01e4412a53677e22834a131"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain pension plans. An increase in lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if related to the spin-off of Organon (each as noted above).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obligations and Funded Status</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwNzM_848ae41f-86a8-4730-a5e6-3a864271ec02" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:43.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.453%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtMS0xLTEtMA_7b0fb724-6b72-4e03-aa9d-30e71d339a9e">12,672</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e704826a843dfa1384049fd999736_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtMy0xLTEtMA_a333ee48-a2e5-40bb-ae31-441b4061206b">11,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtNS0xLTEtMA_8a63fe50-044d-4f54-8bdc-7cd85699addb">12,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtNy0xLTEtMA_ea04257b-ff8e-4367-a8d0-c025d355b586">10,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtOS0xLTEtMA_7f03c2d4-806d-4814-aadf-f0dc0c7bc3ed">1,221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd71cacd403473c93f86070341b371c_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtMTEtMS0xLTA_ac8e5c39-3b29-4a29-9918-b8bcf459a7de">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtMS0xLTEtMA_38dbeed3-684b-4ef4-87cd-c0ce58ea6662">1,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtMy0xLTEtMA_804f63a1-631f-4b21-ab11-ea96e8ca047f">1,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtNS0xLTEtMA_67145e75-8e5e-4f0c-9f40-4bb6d7e0ad41">891</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtNy0xLTEtMA_5c3bd1e7-8ea5-4d17-85cf-60f15683f630">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtOS0xLTEtMA_0975dfc8-47b6-4c56-a2a6-64ad3fcc4987">118</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtMTEtMS0xLTA_c79f0f81-d7ae-413b-a2fe-672e503bee09">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtMS0xLTEtMA_cb275f6c-771a-45f7-a815-014ad49bb215">305</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtMy0xLTEtMA_46f0aa25-b278-4c2b-8a02-c450ae3cfc54">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtNS0xLTEtMA_0e994128-e9b1-4dec-9c0c-f6dd66a8df14">189</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtNy0xLTEtMA_7ef087a4-1ba7-46a8-8c65-5f6a4c298602">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtOS0xLTEtMA_90ef3fa0-6e27-41ba-8ca4-26172da9ce85">33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtMTEtMS0xLTA_8f9bfcba-20c9-4b57-a1db-22a0c2994a81">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtMS0xLTEtMA_1d742b4c-33aa-4616-8277-9df48d894a3e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtMy0xLTEtMA_3bc70cb4-3129-43e5-8fa7-dde159a69edd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtNS0xLTEtMA_6e245e7d-f1bf-4e1c-840b-a976fd5572f7">671</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtNy0xLTEtMA_cdf5f0a6-7d05-414e-9010-1cf0d25d8ddf">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtOS0xLTEtMA_d6ec066c-f8ad-4e5a-93f4-b9a9446b49c4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtMTEtMS0xLTA_f2bb5bca-74da-4346-a66e-aa5bbf469166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctMS0xLTEtMA_63147b88-5e1a-42c2-b8d5-c660620f6b71">219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctMy0xLTEtMA_a8c04d85-ed14-4631-b62b-ae52dd2d1342">751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctNS0xLTEtMA_b595ac0d-c1f0-488b-9e2e-17cd3655a605">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctNy0xLTEtMA_ab0b4e95-e29a-4a37-9409-13deb7397fed">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctOS0xLTEtMA_831afa8e-3458-4bd4-8eab-6eab4800bf67">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctMTEtMS0xLTA_4249ad79-bf00-4e6e-b33c-3e6e71f9751c">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtMS0xLTEtMA_05b186dc-a743-4355-9938-d637cd35833e">941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtMy0xLTEtMA_3649f8b9-df81-4423-8d07-9315acb6eefc">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtNS0xLTEtMA_b1520d04-1279-4f34-864c-af6685c6cf18">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtNy0xLTEtMA_b19f2b13-9b6f-4e0b-a283-4810922b10a8">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtOS0xLTEtMA_0d565137-1c6f-4160-81ae-5389f4565ce0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtMTEtMS0xLTA_7678ef80-261a-4f58-9896-1e8b6d4f9227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMS0xLTEtNDEyNA_874445bf-0386-4920-85fd-f8c9291ab447">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMy0xLTEtNDEyNA_ff11d3cc-8279-49b9-a708-770e52ccd33a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktNS0xLTEtNDEyNA_433b562b-e205-4968-a2cf-06ba8b2fb57c">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktNy0xLTEtNDEyNA_6492b905-8307-41c7-b1f6-7b2ba3b639fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktOS0xLTEtNDEyNA_8438b7be-181d-40d9-ae2a-834e02ff0ddb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMTEtMS0xLTQxMjQ_9b94d4dc-281c-43f7-89ef-a5295db1a6ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMS0xLTEtMA_ecd12859-ee4f-482d-bd52-e318af26f6a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMy0xLTEtMA_3399fe89-d475-4b88-9408-29b011e55b74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktNS0xLTEtMA_aeccd92e-6064-405e-a23f-45fd10ac3a7b">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktNy0xLTEtMA_81052285-d0d7-4ba5-858c-09bccdfa2a29">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktOS0xLTEtMA_ba01d4af-08b6-4fe6-a2bf-dbe895fac9c5">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMTEtMS0xLTA_eafd0d10-e9d6-49a6-94fa-ca794eaf87d0">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTEtMS0xLTA_3760292d-f44e-4af3-93bd-ecb8b0f82bc1">13,067</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTMtMS0xLTA_8133020d-2ad6-47cf-9518-e32f013490ce">12,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTUtMS0xLTA_6d34026d-1d09-4ac9-b855-9506304c1bc6">12,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTctMS0xLTA_3d3aa934-3561-4463-a378-05d08ad25548">12,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTktMS0xLTA_dd1d7076-5305-4866-85fc-963bbbad9965">1,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTExLTEtMS0w_c807a184-f6fd-4ceb-8f29-c9724956c34e">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation January&#160;1</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTEtMS0xLTA_17193b87-e2b6-4e0b-ba7c-2ba42c6a5426">14,613</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178e704826a843dfa1384049fd999736_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTMtMS0xLTA_b06581ed-89ca-4f6f-b91f-ebf2cb886c9d">13,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTUtMS0xLTA_287d33c7-5475-4743-9e0f-e43ef172f56a">12,458</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTctMS0xLTA_a77a79ac-00c8-4685-8517-c46941004a29">10,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTktMS0xLTA_3e9f18bb-6d5a-4110-a049-6185f3a92c47">1,607</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd71cacd403473c93f86070341b371c_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTExLTEtMS0w_fb093bf3-ebc4-47ef-9b29-4ee522552d22">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTEtMS0xLTA_12969d70-aa0d-4801-aa9e-ab2200623d31">403</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTMtMS0xLTA_22a22104-0e8c-4825-bdf1-5964916dac09">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTUtMS0xLTA_8651ceb3-f5e2-4ec7-9536-c2dd7ebe361e">328</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTctMS0xLTA_bd3dce93-02ba-4a23-a2f1-85aed858dd06">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTktMS0xLTA_fa9f33f0-1eb4-48c8-99b2-e4cba462b82c">48</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTExLTEtMS0w_8603426f-9fda-47ad-b584-4297c43db11c">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTEtMS0xLTA_071533db-1ed6-401f-9783-8f7e9874ad2d">404</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTMtMS0xLTA_6e3fdf68-8b91-4729-aab3-166e187cd8d1">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTUtMS0xLTA_dbbccfe4-a070-405d-9fb7-427f1bda0a0c">123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTctMS0xLTA_aa1bb324-e88f-4f55-90ec-139033de7fd6">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTktMS0xLTA_e9c46d2c-68ac-42a3-b865-122040a71040">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTExLTEtMS0w_fac6b6e4-bb1b-47d7-99d8-a53c079033a6">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTEtMS0xLTA_47f89771-8a4e-4535-913a-4622de356253">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTMtMS0xLTA_9cfc4f11-aa22-4b13-9bfe-c5a6205a39dc">1,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTUtMS0xLTA_8e952d29-9c3b-4ddc-9345-b25b5d4b311c">240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTctMS0xLTA_40f87bae-4f4a-4529-9f45-30e9ffb763e9">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTktMS0xLTA_7d10c6a5-615b-498b-8251-d019e9f025a8">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTExLTEtMS0w_3f21940f-1bfc-4627-9ae6-ef701e1349ed">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTEtMS0xLTA_8029123c-05a8-4fb4-af07-315018c002bb">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTMtMS0xLTA_2b5c2a87-367a-4eb3-aeef-2910d7d7b7c5">751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTUtMS0xLTA_6699caa7-b489-42a3-91a4-fef4f4cf50e3">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTctMS0xLTA_5949d360-6eb2-4f3a-8cd1-bbb6cb4a880f">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTktMS0xLTA_5c35ac51-4945-41ba-80c7-49ab9dca933c">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTExLTEtMS0w_e5d986ad-9db9-411e-afa2-7e689b349db8">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTEtMS0xLTA_e6d9200a-8333-4b01-963d-782b83d4fcab">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTMtMS0xLTA_d72c749c-28e0-4bdf-829d-85bae81c987b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTUtMS0xLTA_123f3c84-7dc3-4b53-9a15-83a00bc31784">678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTctMS0xLTA_298b7284-ebd1-4142-9aa0-6c955599e10f">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTktMS0xLTA_baa36d0f-5177-48d3-8651-613ef80bf0e5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTExLTEtMS0w_2b0f637e-c3eb-4d4b-9e6f-b9db8b8fd411">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTEtMS0xLTA_631420e5-1640-4077-9b9b-a000e314fc11">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTMtMS0xLTA_8e1bab53-6718-4980-b22f-355c13f6f848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTUtMS0xLTA_a5bedb1d-214c-4f29-b0f8-d107a9a80644">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTctMS0xLTA_45fd259a-a6b8-4836-b379-adcb88c94539">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTktMS0xLTA_0ad9ff21-013c-465a-a01d-583166deaf82">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTExLTEtMS0w_d56dbe96-f1f3-4a2d-94a5-59a0d1628941">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTEtMS0xLTA_b236bf3d-6d4a-492b-9d4f-d1d5d556c264">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTMtMS0xLTA_1a97a5fc-f46b-46fb-80c1-09b342143126">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTUtMS0xLTA_0e6ff932-ece4-4fd6-9190-18bbd6b5bb59">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTctMS0xLTA_5dad6faf-2005-4e2c-ac59-ae50ca60d169">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTktMS0xLTA_55035dd7-a076-4dcb-a6c3-2fc197af3501">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTExLTEtMS0w_6ab5c96b-6dfc-4313-be10-b8a360caebb0">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTEtMS0xLTA_55279712-32ac-4245-9503-d55797b95aaf">56</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTMtMS0xLTA_35ba9a47-6824-4e5f-9dbc-170be03af516">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTUtMS0xLTA_69589fc1-fe69-4f78-981f-d48644839eba">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTctMS0xLTA_6ce0cef4-8151-4c3e-bd79-9a4ddb19c642">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTktMS0xLTA_299660ac-9dfa-47aa-a48b-70a5fe0ed66f">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTExLTEtMS0w_b27f96bc-42a6-4880-91a0-37a159e48f3e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTEtMS0xLTA_52610c1a-176a-4259-b255-3fa902318918">941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTMtMS0xLTA_c01d71da-e1ed-46c5-96ed-e133efe91ac1">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTUtMS0xLTA_e644d1c4-f6ff-4f69-80c4-4690d9a3b18f">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTctMS0xLTA_f6823642-dfdc-4b19-84d9-9d61188df9d1">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTktMS0xLTA_d8c1110c-0b19-4267-ac46-69bd4af15965">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTExLTEtMS0w_415f0287-1541-4641-9cc1-a42d6ee42bc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTEtMS0xLTQxMzA_93a5c12d-f5b1-4587-858a-c6aa3799b837">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTMtMS0xLTQxMzA_61e39b48-5606-448b-be02-ca517427d414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTUtMS0xLTQxMzA_efe27c0b-d66e-46df-bae7-4730820748f5">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTctMS0xLTQxMzA_f3f42981-58a2-40e6-8e12-f745b2be83aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTktMS0xLTQxMzA_b898b239-1399-405a-8a51-dd801a6396b9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTExLTEtMS00MTMw_f834f934-aa13-431b-908a-a792a2634e48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTEtMS0xLTA_2d511862-a589-4a51-8084-8db2378831ed">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTMtMS0xLTA_8ee20fc8-11fe-4016-b38d-5e8b6e84dc6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTUtMS0xLTA_cc215c82-dd26-4124-8ad6-a716cac61544">19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTctMS0xLTA_f834cb27-735b-426e-b206-eecb6e741334">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTktMS0xLTA_4a2c7a63-5df9-45bc-9d87-9161920374f1">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTExLTEtMS0w_8ac04772-eeb4-4a3c-b426-008be15e582a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTEtMS0xLTA_b1aa2934-4cd0-4be0-b5a8-7000a3992254">13,999</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTMtMS0xLTA_fc6bafc9-f191-439b-9075-9b7edf16504e">14,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTUtMS0xLTA_a8ad0823-a63d-4738-a66b-c636acd5ae57">11,575</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTctMS0xLTA_abb5c9a7-f289-4c25-b4d7-36e5523d92ec">12,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTktMS0xLTA_7d9c2b46-c011-4c57-89d6-37ff403bb577">1,541</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTExLTEtMS0w_f2fccce0-65d1-44eb-8213-2aa1b82c6453">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funded status December&#160;31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTEtMS0xLTA_c156ef90-27c1-4e5e-ab2a-e5e3e933dd9a">932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTMtMS0xLTA_e4c8f2ef-21fc-4190-9a75-604e6a93533a">1,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTUtMS0xLTA_efad6cae-8abf-47ba-b0b4-6a100838762b">620</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTctMS0xLTA_7f4172e0-cfb0-4f76-adeb-81611c0243f7">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTktMS0xLTA_ccb1a83b-1be9-4483-84ac-8abb0b2e6ec3">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTExLTEtMS0w_b965bbdf-c31f-474f-a557-52dcf4d22a41">386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTEtMS0xLTA_7cca40ed-3dbe-4cd5-a5ac-11477cb8ad3a">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTMtMS0xLTA_f0314b0f-18de-46bb-b312-501fad763bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTUtMS0xLTA_9b849444-7174-4b42-80aa-56cf5066801f">1,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTctMS0xLTA_f5d10ebd-d6a6-4c20-8366-32e5abbb36b9">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTktMS0xLTA_ca58b0ed-07e1-488f-bbbe-232867616763">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTExLTEtMS0w_b265937f-6ced-4cdf-854d-53ce8298ec96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTEtMS0xLTA_30bb5940-9229-428f-a733-329bf74d534d">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTMtMS0xLTA_680e3930-afa2-4c28-bd40-3eb78cee91f9">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTUtMS0xLTA_e09cc928-1076-4627-ad9d-3096932f0fa5">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTctMS0xLTA_56b92ea4-63cf-492b-885d-14021f1b30ba">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTktMS0xLTA_ab105b89-b615-46bd-b31f-461e2339ef97">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTExLTEtMS0w_a4714e6e-5771-413e-b29a-a4b03346bd80">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTEtMS0xLTA_397977be-947e-47dc-9397-dc4225316f7d">877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTMtMS0xLTA_90274a2d-3897-4d4c-9f12-25bc2f8fb1a5">1,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTUtMS0xLTA_f588a35d-d91a-496c-a07f-bb6924b6cb3f">753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTctMS0xLTA_315d2700-6010-46b2-8838-5d08ceb9a6b6">1,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTktMS0xLTA_291cbd56-001a-41d7-8d79-a741c997440c">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTExLTEtMS0w_984f8cd3-a212-4057-bc3a-03db5376e1ba">377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Actuarial (gains) losses primarily reflect changes in discount rates.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, the accumulated benefit obligation was $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzIwMjU_be68cf8f-518a-43a3-b7f1-af6c52938c5d">24.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzIwMzI_23049880-9e28-45e8-89cc-fd103d52dc4a">26.3</ix:nonFraction> billion, respectively, for all pension plans, of which $<ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzIwODI_6bc0f503-f7b7-4538-ae05-ae3085f30b0f">13.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzIwODk_7758bc7b-f28b-41c8-a99e-5a6eef78e61e">14.4</ix:nonFraction> billion, respectively, related to U.S. pension plans.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ia1f846bac01e4412a53677e22834a131" continuedAt="if320ab1e4f0c4967810dc0be357ae0a2"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxNDU_ed1c2ac7-1f71-4bc1-8dbe-c34166f3b8ef" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:63.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzMtMS0xLTEtMA_14ba045f-0251-40ef-8536-591bc6c3a19d">13,013</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzMtMy0xLTEtMA_6c3c80d2-f2cd-40c7-b055-20dcee64b0ac">14,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzMtNS0xLTEtMA_7e566071-5dad-4315-a5cd-6eee8f1bbb5a">2,507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzMtNy0xLTEtMA_9302d597-abcb-41e3-bf64-176e631ee4bb">8,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzQtMS0xLTEtMA_b451bb27-7ab2-44ea-905c-a7599e973ead">12,072</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzQtMy0xLTEtMA_266c9ab2-fe12-4892-b0ab-85b6154fa2aa">12,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzQtNS0xLTEtMA_cde94849-4405-4022-b61c-f1f14999fc10">1,731</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzQtNy0xLTEtMA_79cb3180-4e37-4118-bb28-3299283d6ad9">7,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzYtMS0xLTEtMA_362a133b-ab87-4fa7-a707-1b7850846d1d">12,916</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzYtMy0xLTEtMA_f7dda8dc-a7cf-424a-a237-ff653b7b28dd">13,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzYtNS0xLTEtMA_6ad68e06-10b1-4e0e-b99d-7415402976b5">2,462</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzYtNy0xLTEtMA_b0e8e1cc-3bad-4bb8-919f-381ab2b4f245">4,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzctMS0xLTEtMA_a76b3022-ff47-4fc5-94a7-669a058f2001">12,072</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzctMy0xLTEtMA_18bd30df-a7a5-4213-932c-7ffa42712ac6">11,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzctNS0xLTEtMA_5e2b319d-3005-48b6-bb8f-a9e9284a8888">1,723</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzctNy0xLTEtMA_c77d43fa-ccab-4e96-9110-65b38d3c1681">2,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plan Assets</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December&#160;31, 2021 and 2020, $<ix:nonFraction unitRef="usd" contextRef="ibe10670a16e24ae9ace40787b5ce2a22_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzMyODg_48e8fdc6-ae11-4059-8a50-7c086503fce1">943</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id0aeb1e3ef794674a96fff2b9d26c8e9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzMyOTU_b5a7ea2a-0c82-4abb-946d-3293ac481308">942</ix:nonFraction> million, respectively, or approximately <ix:nonFraction unitRef="number" contextRef="id17c6f956a4e491bb84b7d1e3a57f150_I20201231" decimals="2" name="mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzMzMzA_4cc829c8-40cb-4157-85d5-f01f7bc48a96"><ix:nonFraction unitRef="number" contextRef="ia7718651d7bc40ef9616b0d6567d4a64_I20211231" decimals="2" name="mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzMzMzA_722c9b37-eb55-41ae-9ed0-378e3995e5b6">4</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s pension investments were categorized as Level&#160;3 assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div style="text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="if320ab1e4f0c4967810dc0be357ae0a2" continuedAt="i33a3bad450d545c48780950c1296bf7a"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwODI_51eefd68-3745-465f-97a8-bcc9834327c9" continuedAt="ie606c465cbc542e0852493512f0bef9d" escape="true"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s pension plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:18.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie27d33c6ed3449c6bf53ce5acffed5d3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMS0xLTEtMA_47df0cba-e721-4e18-974c-d9832aa62807">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b9083971f54521ad14c9f68c6611c8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMy0xLTEtMA_4e1c00a3-88ba-44a0-89da-d183e0efeaf8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76d34893501497c8338c478a45c7b0b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtNS0xLTEtMA_ea245755-c4ae-4905-8db2-60e6671f3b7a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2203d4639810407383286a40f8685df1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtNy0xLTEtMA_c477938b-198a-4e5e-91b7-08d3e386c824">289</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f1c43c814b41b488e8134de602f0f3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtOS0xLTEtMA_66688750-015c-453b-98c6-233eb2744997">292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37e1626071144092beaba6babfdd27fd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTEtMS0xLTA_a6ef4454-1185-4de8-a7f2-5948524569b4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4792b128164e4abdf42d752f6b3c2f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTMtMS0xLTA_87a67da1-8d73-4ad9-bfb7-3b576b602d10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0f6b50d341424ab17a88ac1dabec97_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTUtMS0xLTA_ff87ed36-76b7-4411-b0e6-8304f5d05f73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5089b458f08249059c8517844cbfc375_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTctMS0xLTA_64f3ca37-b065-4efe-a934-385d784fcd7d">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ca7b42ee03e4960a864194df69e164a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTktMS0xLTA_270b0e7c-ed05-4076-a36e-0bca1ee2e2f0">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbbeaa396c141b0a6b6351e2f4827c8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMS0xLTEtMA_11c72f37-f8c2-4425-b6a6-e5854f58b32c">236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae2b18472b24703bb9488d9d606bcb1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMy0xLTEtMA_30251a5e-76ff-4f3c-bac1-150241f34027">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib222fc4bb6d643ceb99b004ab5acd309_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtNS0xLTEtMA_a2fb3dbd-8de9-4319-9ef6-01d719f163a7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i395bb955653e420e886491134570b658_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtNy0xLTEtMA_4a8d5e45-d35d-4bd8-be71-876a7215268c">3,799</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1c560946da41119cf3ed20ed9a3a21_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtOS0xLTEtMA_4753d3ea-7cc4-4170-9835-8bd58b4980ca">4,035</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf83da73f5164932a265dca954005724_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTEtMS0xLTA_650ea152-183b-493b-8364-d1c2b7e8c347">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9243705e6b154b6aa3bd6af2236836e7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTMtMS0xLTA_dd162692-41d2-441d-9531-b5ee3f6133e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63dd5c670a0c459fae41752f3906d605_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTUtMS0xLTA_5c6c7a9f-c72d-4b02-8362-e3f4fd6b5ee8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6774d1da76d4da2b5a0219216a610e8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTctMS0xLTA_c74ede5f-98c6-402d-938e-3fb27ba08183">3,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb9748ba281494181282cff265c56e7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTktMS0xLTA_57ab3eb5-2203-4c12-ad3d-ea67a42d7a8a">4,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa42d6dd3f814707bc449ce9962c43dc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMS0xLTEtMA_ec3e108e-6ff4-4b37-b948-3ede6b8f6aa6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8baeeb84552840538a8162507d1d3a8f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMy0xLTEtMA_643f29b3-20b0-4293-b0b8-06bded404569">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a079dfc52a4a6497a425eeb1403e8b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctNS0xLTEtMA_70d8ec71-3cdd-4790-b02b-425d686b3b89">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba0e181a34f4aaba795297286899f6d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctNy0xLTEtMA_27aa388e-d769-416a-b861-c4412980b457">919</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12d3fc8ceebe427fb6bd5603436c2c53_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctOS0xLTEtMA_47cd0822-1abd-4d7d-8572-2029502712c7">919</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb1065a32e34de0b0f43368d0777874_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTEtMS0xLTA_5f696db0-37d2-474d-86d2-c00dc31e036e">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784c90e7bd294dc88132ba65ade89e56_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTMtMS0xLTA_422539f2-2a0d-4a6b-baf6-37ca7b770602">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee628429c5b4b66bb61ce127cc28e2e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTUtMS0xLTA_61edf370-f680-4ca7-8eb4-350ca2fc508e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fb7d46a5334d3bac5d2d4116e11efc_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTctMS0xLTA_5988da9d-f9a9-4568-ba45-18a70aebcff6">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c401195a1c4761a19b5cdadde85849_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTktMS0xLTA_67677383-4d93-491d-bcb7-e8ede29f8ab6">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b501a9ec7d4dea8f9112a428ef72c2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMS0xLTEtMA_659dcc76-60eb-431c-a2f0-08a980ba3139">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1c7c92675e40b1b1e2ca3fc8e0d851_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMy0xLTEtMA_166e5370-7a78-43df-831a-c3fc9bc827ba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5141bbf8e94b49f7a0aa873c881c5fd5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtNS0xLTEtMA_5af3a5bf-f90e-4fdc-abf3-e4bced7fdb9c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f48949b908e47e1864aa29acc116ec4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtNy0xLTEtMA_d67f2e2d-6534-42b4-89d5-a7b8e953dc42">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f58f3724274bc6b0bf3a72767dec82_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtOS0xLTEtMA_6749bba8-e68c-4c3a-bc33-a7f664646fc4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3975a126cb44be9d32abdad7ef4792_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTEtMS0xLTA_00692a78-e144-4432-aec6-104f60499faa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02abcc69be99452c8ce2101132639629_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTMtMS0xLTA_ac9aa665-8fcc-46a4-96f0-7c0dde3c4766">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3b50b3dba44aadb2c0ce56a935394e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTUtMS0xLTA_3aa3fba1-2657-4b1b-9cee-bd7a9ff0ff0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9e94b26ed5494abf5baee5b79b943f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTctMS0xLTA_42d3fedc-9d4a-4594-b48f-0e4c4fe8166d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f253095b9d4d2cae95926ac75da379_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTktMS0xLTA_7282e92f-265e-44f4-b713-edb71e85f90d">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e82a23e98a7447f8a12f4ab996a88c1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTEtMS0xLTA_199a0b4f-0df2-42a8-a5c6-7d05c581f461">2,915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df7467a741d426880031a7209c24355_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTMtMS0xLTA_625457a1-bbaf-4dc1-bd95-3680948c2605">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981b91cc3e4e423692ebf62688a6e073_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTUtMS0xLTA_b45efa99-a8a5-49e5-a7f9-f3b36d7c1f09">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e2e5a9fcaf49569cbade9e54075f58_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTctMS0xLTA_43d0187a-a3bc-453c-9cba-3caabf98d855">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1edc21c2cd0343e5b7e3413d27bf3fc2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTktMS0xLTA_604029a9-9882-4283-be6a-a75a07de3bf0">2,915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878cc16768774bbaaf020a38a72e6aff_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTExLTEtMS0w_15d4dbdc-ec04-4712-940f-693da57ec59f">2,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc8c49f9da2e48ee9aa0dad038b7bb6d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTEzLTEtMS0w_f5dce15c-7281-4ee5-8d0a-886040f25a71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edfb93331994daaad9ccbd6a3ff2d16_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTE1LTEtMS0w_108cd19f-8b19-43f0-bd18-fad127c22eb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5141467dce724a88a3c16a16dc6e57bc_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTE3LTEtMS0w_ee9075ec-25af-481c-b6a1-d87e7ec0fb55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id687b7cf31b44549a0832f1284c3b22e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTE5LTEtMS0w_1b6f78ea-d24c-48a2-afef-986b5e57600f">2,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e01ea44f0044e7d91022ca6977facea_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTEtMS0xLTA_015342e8-1ab8-4732-b3bd-f6e66b8dfe51">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7bb1d9889a46a389725e7f47bc44e4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTMtMS0xLTA_6505288b-2b1c-496c-b07e-55d6cda61354">2,870</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4a94a0a6d04223852740fc12c45b3e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTUtMS0xLTA_b693cb46-a546-4a76-847c-089b481a75c6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d79d8008eed47b6bfe7d6f012412074_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTctMS0xLTA_c5bfbde0-450d-4a00-8927-846e48b21b6d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff79da55ddf46a8a205167e0e830e71_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTktMS0xLTA_bb64e647-c057-4234-8dcf-2a07f3431c2b">2,870</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife3fd5de6b3642078db592881517d635_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTExLTEtMS0w_a23f00d2-e959-475a-9418-63517696a8f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2dfeb6b2ea94e89a81b426dff17a96d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTEzLTEtMS0w_a2a5553c-aebf-473a-b97c-b698cee2c1b9">2,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6be5d66271948aa8671b0ef9f628d22_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTE1LTEtMS0w_2fe9e966-0f61-4ce5-8130-999519af5bb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c9bf0ebd284c25b3cb345c5806e946_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTE3LTEtMS0w_364a398c-075e-4012-b91a-595b8cb07e30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if550fbbab92e4a0393c402773c5a53c5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTE5LTEtMS0w_0a94f0c9-7f12-4191-87f9-62e6733868ad">2,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b79ac72fb4241bc81c3ec6b5b6328b0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTEtMS0xLTA_ecc22743-a3e0-4fde-b3d9-1d678b623e82">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab77361384864106be3cf07dc9d4c939_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTMtMS0xLTA_e3e810ee-a6c1-4428-b7d2-90761cf7ec2d">2,005</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780cd04510ba457c89c22dffb8ea2e1a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTUtMS0xLTA_1e0cccb9-99d3-49d8-9d03-2846d3832734">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22749de8cf749bdbeef2616d2d8d6ab_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTctMS0xLTA_ca5952ca-3312-4ddb-bbaf-3404223f6611">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie831c58af1194dadafaceb30180cdd0d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTktMS0xLTA_ac285761-03c1-42a5-a8bb-e27a3e6cd69d">2,005</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336582d966b84b16b300a96248672867_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTExLTEtMS0w_5a3b0a80-a3b8-4f6b-8ced-26d9bcbae420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dd0193192145d6a6d7021a9dd8f817_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTEzLTEtMS0w_e2e2b0ca-9af4-43fd-b424-ea5e52aeeab1">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21bbf4eeebfb45518c50300f370d3966_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTE1LTEtMS0w_d6ce2378-f9f3-4149-b524-7f415aaf5c91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2778b4fbd1b45ffb87524b7514583a6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTE3LTEtMS0w_589ccbe3-2d70-4246-95c8-d82879fc8e1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ec4cb354474da4bbd6842b97202f41_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTE5LTEtMS0w_2a7e7cf5-ed28-4d58-9c87-746168d91d42">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9b0274b7734fcfbb1b0c73ee0c7da0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTEtMS0xLTA_6f42ce9d-af35-47e3-8a84-a66eaeb2ec91">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f74d89c62ca43fc8d49c4f183628eb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTMtMS0xLTA_c28b8424-27c2-4ffd-a84a-c93aea734703">23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a1db66bff04574a73feba1773e8409_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTUtMS0xLTA_3a85ee2f-1b23-4902-9844-0b11da442f22">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02446a35871f4693b8e5acc1f9a5b7de_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTctMS0xLTA_49cdb48b-b1d2-438a-b383-d1d067f935eb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0989ca72ed7543d093e13b1133771ff6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTktMS0xLTA_ec440f10-39e8-4763-a741-c4be9abc4f7c">23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce6426bb9e749e9bcd7521d23f5c407_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTExLTEtMS0w_f7c7f27b-e652-4545-808f-26b84c96570e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib65644eadb2b4fa1a6c40d00289f4f35_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTEzLTEtMS0w_219e0a87-bdc0-49dc-a971-3b245a5fa41e">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962f8425aa3040a69e84e834f0b0f346_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTE1LTEtMS0w_769e52af-c7ae-494f-829e-ccdcdbc40bfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b57daa317543c6a71e4c01cbe79b46_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTE3LTEtMS0w_2e756834-ba83-4760-9ead-19a72d76020a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b98f27bd3184965a9bc7698e47ad89d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTE5LTEtMS0w_6f99ca0a-ba35-4e48-a793-2fbd3d743bf1">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e86bd2f96d4a0c9cc3b9f4e0850708_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTEtMS0xLTA_1e762626-485b-428c-87e9-8571eff0f893">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74bfe6b3728464e8f867a4499a49cf9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTMtMS0xLTA_fdbb245d-d474-4d9d-a1bb-2652e017f93f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecf6e1df51340bbaba2f059fec3465a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTUtMS0xLTA_c13c2688-7fb3-4538-9120-a3932745b34e">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796214cf8fae486795991741a4067066_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTctMS0xLTA_4739e620-41ca-4633-b4af-e7eeb847869b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1637d8c529464e04832eabd1d29ad359_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTktMS0xLTA_8770030e-7f3c-4516-9a50-943580236e9a">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa69b52074c40c6919a723ecff07d91_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTExLTEtMS0w_82c3e2bd-4ec9-4e50-bcb2-513738e9b464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77f365cc16f54180a306da2bc7aee6a4_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTEzLTEtMS0w_9d8d8818-0ace-46b0-9597-8d73f5f77695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffbd9fca0edc4beb8128fe8f2eaab268_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTE1LTEtMS0w_3659aa20-4666-435e-9552-dae973e872e5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75257cca48cb459382be06af1340c22d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTE3LTEtMS0w_1aee205d-d092-42f3-a8db-e129c8a2ac4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400ddc9234554cba8b43aea81b2f3b12_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTE5LTEtMS0w_521f4476-b9a7-4160-94d0-01dac77ddbf1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe56286d4ea44f1aae537601d99ea7ac_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTEtMS0xLTA_279fa912-42a8-4157-9421-02006e366bd6">3,156</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4cf65bb3ba540209a17504e51e8e63c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTMtMS0xLTA_5771ef33-2f77-43c5-974e-f6f63e6ce42d">4,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6941b80bcbf5486ca983dfe0369cd741_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTUtMS0xLTA_ff6d34cd-a6d3-4cd1-9986-34603a759901">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97d1993aeff4c979b35dd2e4f863df4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTctMS0xLTA_1277f309-6633-4dc3-84af-cf3f3b73a196">5,007</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTktMS0xLTA_8b5fa451-be13-4b56-8926-e09f1cf141db">13,067</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd3b14d2a9c494aa14fbdcb6fb11f9e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTExLTEtMS0w_1a342f11-d902-4c51-af02-f703d45ed59a">3,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9790f5a9551417380bff30595e606aa_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTEzLTEtMS0w_ff0d5f41-b948-40a0-bd82-fe4d1cf4dc51">4,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ded4752a21d440a80630cbd004ec39b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTE1LTEtMS0w_a215a09d-ef9a-49c3-8be3-37d2dd71c02d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c179b8078b940dc99ef97ff0435620f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTE3LTEtMS0w_c052bac5-1414-47e2-af8e-9642d6d257e6">5,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTE5LTEtMS0w_02c839ec-aa47-4f67-ae42-10fabc4b38c9">12,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa64b0d1dd44c1ca28cecbd821aa477_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTEtMS0xLTA_88bee902-ec4d-4e22-b9b1-370f087e926c">82</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ffbcf1eb5b41d7b00120fe3ee1352e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTMtMS0xLTA_19542870-c87e-445c-b5a1-a2fc1a28970f">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db319e5ae454d27afcda3fd19764a79_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTUtMS0xLTA_169a4bb7-8dba-408c-b4d3-3e2ce3067022">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706ca6f052df467cb8f58b4806f630c5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTctMS0xLTA_8175d9b0-ca7b-4cce-9446-d55ee94d380a">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30f0da2cf5e1450d9c71192c487952c0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTktMS0xLTA_31b7ad6f-06ce-42c4-afd4-61aa02baf2e6">110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44fe692f8a764fea898fec5aa9111d12_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTExLTEtMS0w_2b1ce910-0169-4860-9328-7e6b52c45727">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379e05b6692f4dd48df63d0606e10804_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTEzLTEtMS0w_560d3803-f70c-4572-9423-d2a2227db4b6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac502293aa264b42aa9d2b66841da851_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTE1LTEtMS0w_aff0bd57-d1c9-457b-84db-982115fa8d67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29262e1dfa004785a42f1051bb310323_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTE3LTEtMS0w_34504de3-b90f-4710-b7f6-d0a67be28062">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f9aca5533a45719f02ea5e54e22cbd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTE5LTEtMS0w_bbe55d7f-3daf-4ba3-a545-52a57cf3fce7">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ac8e7222dd4ad2875cdd76fbdbf312_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTEtMS0xLTA_39014c0f-c03c-485c-b4f6-e53f5b4206ff">531</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92ab01903744a8bb55dfac3169a2f28_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTMtMS0xLTA_ac6dc6db-8f2c-4a4d-8bde-21f724f21273">4,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce94dcb4f694c35afda081b8f7df941_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTUtMS0xLTA_ce59906e-c348-4025-b541-4a0a49a62bc8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5cd6c26a754923b47fb82b1d835e26_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTctMS0xLTA_decea34e-3de4-428d-bb9f-ac7aeb25c5a6">121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie809e18ae31c4a759d00ca9258dfe590_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTktMS0xLTA_6c3a7811-30d8-4832-adae-b04898614f93">4,944</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0670034fe75f4d2192a609e94de300e2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTExLTEtMS0w_387dabae-011b-4777-a3eb-d1bee7200415">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05abcec58f8e487c81199b7f51eaef9d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTEzLTEtMS0w_21dc399e-9015-4546-ab8b-68d4670c00f4">4,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id147c2024aff4ce09865ffaf7bfc6e1a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTE1LTEtMS0w_e9d9a4d4-b0ba-4a8f-b75c-a8d28e24e6ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a7f9d852f245d68f1669370ba8ea37_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTE3LTEtMS0w_b20f3f3b-0386-46f3-ab92-3b5aa7579e85">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3b3f7029dc4097b2e2fe7e1e985e18_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTE5LTEtMS0w_fa246f48-cee5-4a6f-805e-2c3679e5f9e3">4,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fbca24807fc45728ae28f4fe314fa94_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTEtMS0xLTA_6969da00-ebba-4be5-9714-694dfafbfcf3">240</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92db765e927452a886deda18e0ec49e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTMtMS0xLTA_98e0a1ee-e7f8-4bbd-87a5-fa89dc345abd">4,025</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7e60832cf84f69b1d73b1f05f3a237_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTUtMS0xLTA_03fb1b1e-26e1-4bda-b8c2-d79d2a70cd69">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9294e66deb48e4a276489e2d5fbdd9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTctMS0xLTA_f517298a-306b-4563-a71b-c50f61a0e809">171</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad21e08ece0443f09e98d2df051b2720_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTktMS0xLTA_d5ca843c-74cd-4047-830d-65632a375120">4,436</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d4508410614547944dd3263008dfa1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTExLTEtMS0w_ec9c1cb3-d703-4679-b982-7bdda1a3f7dc">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d27a90fefee49c6bd2314841eaac836_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTEzLTEtMS0w_e50b4f06-8834-4dcb-a07a-6bdfc5834a98">2,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f445cef0a94f3d858a4e92b44e53dd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTE1LTEtMS0w_ada34a5a-05dd-4126-a634-1615936fee1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib402ec846ebb4646b9e19d44aa463e42_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTE3LTEtMS0w_d2b65b65-ebf3-4d09-97be-956a204e57ee">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23f4c405736447893c2ed0ba5129d03_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTE5LTEtMS0w_bb5bd317-3b93-47e0-a148-ad906f637398">4,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c0e35ee479451baa6f3dffbdb78a83_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTEtMS0xLTA_cfae29c5-f87c-449f-b5ea-50ef479c29d8">137</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6099682544f4ab6885c0649f5ab634e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTMtMS0xLTA_0e6c9cbf-07c9-483f-a86e-a7f99287babb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9499680b2a3b46c692bbfca28d92fa99_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTUtMS0xLTA_fb30736d-7a61-4574-a8a7-97d646b46912">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icadc8586f8c14f1599940106a4a639f0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTctMS0xLTA_1c1346a5-fbe0-4ebd-acda-1b5712f20cfd">72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137b41dccc2a451a8661523b56e79847_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTktMS0xLTA_c0adce39-2ef5-4f41-a1ca-e52f5dba91a8">209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e264e35d0845cb9d3d40717095240c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTExLTEtMS0w_ca52e016-77e0-4024-a0c0-eafbebb5b174">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbdc9d92cae54e3388f07afc57b2e738_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTEzLTEtMS0w_6ef91729-10e8-4965-9d2a-894ff001b4ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27b7acb7de364282992d39b44d6c732b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTE1LTEtMS0w_f4033353-6876-45ce-a0eb-a9e1024c2367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ddd68d8b0db49c6b4809aa72bf47d60_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTE3LTEtMS0w_4ac1cd45-02fc-4f09-8f7c-af302a10bd50">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f7fa74b02f420fa18a1752a0f640d9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTE5LTEtMS0w_08b2e81a-dab0-4287-b45d-c1d5b32d2f7a">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074254ef5dd404ab34a3d26ea726aa1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTEtMS0xLTA_e3bc38a8-9ec7-46ca-9a60-7733086483cf">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9f0c02f2b3e4264bec1d52a63e9ad74_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTMtMS0xLTA_fcd9a978-e71d-4bc0-9088-8640a9a7ed55">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb2ef278f5044ea82584e0170c78683_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTUtMS0xLTA_b9bd47d1-83e1-46e6-9eed-62d0b8df24b6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e92e9adedd8495e89c3a894377ecdd3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTctMS0xLTA_fdbe674f-c94c-4c5e-8e39-e27485119b61">171</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74519ccd850f450985a56ff14ca4b7b7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTktMS0xLTA_32c58799-d457-47df-b748-a0028d922455">188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fbcea62d0ed4955ac41d050862b0e34_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTExLTEtMS0w_12e353eb-e767-4f97-aa0f-178f35ba58c6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56cac3dd6c044c78e322e9ef1a9d386_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTEzLTEtMS0w_064d2711-d2d9-46cd-946f-1cb2ead6d323">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f6500c95d2415997c537d9ec576b14_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTE1LTEtMS0w_0ba7a0e4-8cd0-4b62-97cc-70d7fff7797b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a23ebdda2d14f27ba9a6dff74a6bb93_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTE3LTEtMS0w_84adc4c8-a62b-4832-aeda-c9eb4e98ca91">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie263eba552824ca8b7bc26dc2b1e3c03_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTE5LTEtMS0w_1a0e9928-5d6d-4387-997f-ae4bffd942fe">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i500f88f01cbb476cbf8d0869fa88f998_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTEtMS0xLTA_85a1c09d-4e45-406c-8c47-1db7b47ec9e4">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7b52747c1c4adbb18078f65218a7b0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTMtMS0xLTA_ec7aa0a8-88df-4646-b9b1-9fcab8e96d44">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb20ddb11d8244308c74bbd88c09e832_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTUtMS0xLTA_71c4fec0-9f67-4316-a255-50655f3d1a1a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b5c61354004941911815be12a06d46_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTctMS0xLTA_6c570393-d712-4611-83c4-378e6712ea12">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i575c68e47b1441f4b370a4373fcd38ff_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTktMS0xLTA_5cceb729-c4ab-423e-ac7e-eb73a05121da">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb56ee6d545047549d0817e0e372530e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTExLTEtMS0w_3b827485-adf7-4e4f-911d-c91c24c53e21">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33d81e4466bd41e4b377ed1df2ea8e56_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTEzLTEtMS0w_f155995e-32ba-4e2b-a62a-73da1cbc5b5d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e0f2f727aa4b97ac781a4fed704c4d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTE1LTEtMS0w_319d3fd1-3401-42f0-b8d2-a23d95809486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7739919ef6a3464e8636dba4a13f4976_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTE3LTEtMS0w_63d54453-8b08-462e-ba47-24284996b60c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia616155b2f954117981e48d2681acb1b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTE5LTEtMS0w_5d03e4de-9c68-4343-85c2-85cf0a058943">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff224138dc04bb5bcb654572597d15c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTEtMS0xLTA_a5347fa3-b9da-4b3b-ab4e-5b3a5c974191">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299c4edd1f2c40aaaf1ba172f892df50_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTMtMS0xLTA_eb22d1ab-fa9d-41f0-98c7-5622d3734503">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6be1fc79ba48d990cd4dda9a8296c6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTUtMS0xLTA_fcfd830d-223a-4587-8f4f-2799e9b67fe3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b4299473e14a998ff1749df6fabbad_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTctMS0xLTA_7c61edf9-4af5-4970-bf33-fef6acd4f54d">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda8181c2b92463f832b2b807385e1fc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTktMS0xLTA_b1832787-add7-4a2f-ace0-a905d1f49906">17</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5c9a82e7a14132ae1bc5575aa82c6c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTExLTEtMS0w_0db7eef8-19fc-4b4c-aeca-cf76645282d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45b430cbec34f7ab97e3b77aa48d4b0_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTEzLTEtMS0w_bf76e35c-6653-4075-98c6-562e4c59fd22">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88665ad826e641d683cd947d6542e94a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTE1LTEtMS0w_a0c40815-1d99-459d-a928-cea760b4c308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4eed3d574f4c3b90b6ec3fbf015cbc_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTE3LTEtMS0w_876e4f8f-96b5-46e4-b776-ad500cfef0e0">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9092910402714a39aa0adcd1cdc3fd8b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTE5LTEtMS0w_e5087dbf-dec9-4c0d-b21a-d61e64ffd363">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0977763dab53428ea24d011484e19d42_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTEtMS0xLTA_23dc9e1a-071e-4766-835b-84003153c07a">369</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e6aaee1f8734728ad3f49f6e109d45e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTMtMS0xLTA_776e6c36-61d3-47f6-9e60-ee42de7fcc73">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646ea08b951e47a28a3b3a458d5f19c0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTUtMS0xLTA_c391df4f-4924-468c-9038-27d82aba0fc7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7376c87bfaef4564894e5aa0078bf290_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTctMS0xLTA_4a152857-74c1-4799-a697-a9d9b72fc6b4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707265f378224c11812d0a38d0ca7c46_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTktMS0xLTA_afda75f7-3145-4371-b93e-5729390320e3">369</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d671f19e027414790d54572de238e8e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTExLTEtMS0w_4bc36e17-4a41-4ef7-8f88-024cc246b72c">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i976895874b4548edab0975dff614e53a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTEzLTEtMS0w_ae9505f5-c525-4a01-a613-b16ae20c3e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia948bae53d494c0fa79a34e4feab974b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTE1LTEtMS0w_8f0004a7-a00d-43cb-9cf3-f9cedb4e8251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c88c3aebd6403fb5e73ba3df2752da_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTE3LTEtMS0w_4fc2fb4a-81e7-42b5-a44a-726e8d748d3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3101abbfd6104bf9961e4797c1fc7a59_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTE5LTEtMS0w_8231f6eb-27c0-41ea-b62e-d9d9e58974c4">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f53799ef4a489f9b8523196b414ed1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTEtMS0xLTA_0a8ef9ea-367c-4dfe-b387-8594c4245d24">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd54b143c2f54e0b899d7f7221b49435_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTMtMS0xLTA_8253fd34-0e6e-4249-9c5f-8af34618ea9a">591</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d4f261c68445c8ae56f66fe852bae3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTUtMS0xLTA_6b84ec80-1a7c-4e87-88e3-23d0c92376b8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fb3f5ab0be4cb8be61559da9ba2513_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTctMS0xLTA_2d37e23f-8b45-4c76-9b95-a128af7fc2da">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8688a36baca47b99958cbc03224ade5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTktMS0xLTA_11bce96e-e191-4916-8873-3ce616c3dbcb">597</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib528900af6b84f9f883fce50d5d90e15_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTExLTEtMS0w_084726f3-e568-4d6c-b212-946437c97c8c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597378302fc14c5688b47d18bf9609ee_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTEzLTEtMS0w_b22308fb-a967-4d87-8200-511b2cc88a36">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c35baef64594afe9308f4038d2cc019_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTE1LTEtMS0w_2421f360-d567-4878-a860-db0427f0933e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b32ee0e7ad4477d84343a59721b904a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTE3LTEtMS0w_7e35ee9a-c637-43db-ae42-a01c77ca98ec">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10aa657ebd0f4ff8bde707e6da253978_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTE5LTEtMS0w_db027d99-7a3d-4d8a-b13d-fee52a9c1ee2">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e1b8d26f324b76a4c50b0c70101c62_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTEtMS0xLTA_b50706fc-5d46-46ac-b70c-8fb0a44221e2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12fb9df356b24a28a7100d667bfecc3d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTMtMS0xLTA_f6d9ef6d-cb98-42d2-88de-d151257ca6a5">223</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cd90083da946e2867764d0280e60ff_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTUtMS0xLTA_212b9846-8440-48d8-804e-e1c10299b9ca">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c1df4974f5423196b196d52fcb54a7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTctMS0xLTA_3759d910-a5b3-481d-b924-f4876311fbca">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1056686abda14133bbb25a974481bf51_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTktMS0xLTA_bae4f5b9-03e1-41bf-a8a4-48bea74b4997">225</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777644be6c2f496cb431e433227cf5e2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTExLTEtMS0w_4866a400-e92c-40ad-b49a-79d48d9d508f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaadae92a049a4d5c988b6a3155d0fea9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTEzLTEtMS0w_2bed42c3-7a86-4571-bf4c-14f931726f6b">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cdc14fb7854ae6ab8daac50bf5b18a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTE1LTEtMS0w_ce8d3eef-e0d1-4b2b-84d2-5b9293fecc22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4e4116135e74738941265923fae287e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTE3LTEtMS0w_98162b2a-cba1-452d-bf15-8c8d02d86038">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba72f924d50f448995676c787615f080_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTE5LTEtMS0w_e38ba651-69f2-4e81-9efa-c4a1d249bd4a">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6335958a344a435583e593f08493ef84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTEtMS0xLTA_f3919839-281f-460e-b9c2-88a0e38525dc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7e70eb2b30488facea1f9b7925c9d2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTMtMS0xLTA_0612662e-5c91-431d-962e-a33a8160584a">90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61638e78d26452fbd7dcb3dc3b0b9a9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTUtMS0xLTA_c31da82e-cce0-43d2-a8a1-856913df6f6a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c3faf60ab14164abe7ec068a5e8acc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTctMS0xLTA_5114a190-f1b5-42c5-a4a7-191d9c1d0e76">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392677707f7e41c59c65694477a60d86_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTktMS0xLTA_d73358c4-9ce9-466f-8ec6-bd4eeb48f8e9">90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d1b3b11ab744479c9bf01ef20dc759_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTExLTEtMS0w_ab1adfcb-d121-42a6-bbff-3a3824adbb77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331730bf6efb44d682e209f3086f5deb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTEzLTEtMS0w_641bf74f-d3f0-4958-8759-c1749b1feff8">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aed454000324ddfb59ec630f8ca840d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTE1LTEtMS0w_cc5af041-b665-4124-8a4c-09ffdccc4945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if44f8b9ae40243fdab6b2eeea80bdadb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTE3LTEtMS0w_ec7f1df4-05ab-45c5-a13b-ffe0f7d58b62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53221686a07c4c2692910544bf9e5f7e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTE5LTEtMS0w_ff2a565b-8cfe-480b-9d5b-4d23263cc5b8">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7f304228c0b47459eb2df8092a19197_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTEtMS0xLTA_81360f2c-d597-41f4-bd36-5696fa29ee86">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35aa130d32044270a7ca14c1c500e128_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTMtMS0xLTA_8cb0b9dc-eabf-4db6-b75f-ad63d9e322df">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd5948864f247fb8240d73efa22974a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTUtMS0xLTA_1d17df35-3010-4b59-98aa-c5c2c2944a5c">937</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79d1d134fab4804b1f8916d27f270bb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTctMS0xLTA_4e05bb8c-5456-49b7-8916-1e157ff9af9d">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica51247083bc45349d5f1aa4494688cb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTktMS0xLTA_4c904536-f11b-4f2f-b1b1-34005f06b61b">982</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67efbd0183464528a19f2f2370692b97_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTExLTEtMS0w_c1c50ee3-6c8d-44ad-b124-6f7c3b10b3db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3d2bbb957c495e8f423ace831f825b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTEzLTEtMS0w_6a40f7fc-9ea7-44b6-bab9-9f1115d76ee4">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7032f825e9148319be784239d5dc247_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTE1LTEtMS0w_bbcd26c7-c068-44ba-8a4f-3e58c6c45e31">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9375a5e955a43e4b015b97beb369e80_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTE3LTEtMS0w_6d9df258-b456-429e-bc29-7fa208a48e70">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad73c6a4016949568ba9ffec4920197d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTE5LTEtMS0w_0b5e06c3-cd47-45a1-bf68-4a3cb20c773c">978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99736db639604a3b9e19d5223863228a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTEtMS0xLTA_8bc843c7-efd9-4ed0-b681-835b1ee827f1">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0989033959b24547b6d2f0250223be9b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTMtMS0xLTA_14eefa02-e543-49a8-9964-8bb767f1c47b">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i062dd5eba1074bd9b7e1f64bbe49f973_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTUtMS0xLTA_62bbfe21-6a01-4972-aedc-19238f811225">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b4fa5b2309b4501b0b66a49e6b61e2f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTctMS0xLTA_5cb002f9-0b32-40e9-aee0-cb463aeda75d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f5c0ebcbab4a01a984c3b118e581fc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTktMS0xLTA_0546df86-6abe-4e37-bbc1-ecf1de7d9ac4">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8f1f45c17984c09b0569f1408b068a4_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTExLTEtMS0w_515f3e5d-38c7-4f89-a6fa-a3da09d68d12">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7b39df984e4cc8a43284b6c372e087_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTEzLTEtMS0w_ccc5547e-9387-4477-b88b-999d01d2142b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87e1269e4974cacb4df9177b0d52da2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTE1LTEtMS0w_a4884b37-7f3c-4b69-9c55-e50f840b7a96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0038c792d634a9ba8b15407c89e2895_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTE3LTEtMS0w_d0239321-4006-4511-adf9-3aafafe18810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec324fd291e244f2a0f252da445766bc_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTE5LTEtMS0w_52905454-be4b-4bf8-bfcd-34f74219eaf0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacb4e5f9e58140afb021278770b30523_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTEtMS0xLTA_f07d7a53-ee40-46fe-942f-211713a6cd49">1,387</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e89844fc4dc4df08d07363b5b09c838_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTMtMS0xLTA_8322c2bc-e4dd-42aa-86b7-6e0cf7579b5d">9,293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf01a553998e486db4187f11f6c70b9a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTUtMS0xLTA_2d102eb1-ab9b-467f-ad15-41d64a89efaa">937</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i431015c47e6d427ab97b03d0f8688df5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTctMS0xLTA_85aaeb0a-bdf5-4ca7-947d-62b27e5bb6ef">578</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTktMS0xLTA_25f9b845-0dbe-4c8a-a95e-0a8808464a6b">12,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e027fa8d0004e2f893102d1de5efaf0_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTExLTEtMS0w_3b618927-d15f-4c3c-8021-2dde15814861">2,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbed2e49029849b3943ac5cbdb11cfcf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTEzLTEtMS0w_19088271-615b-4608-8a84-3a8331312bf8">7,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f3afa788a448f7a63c0f0ccc99339e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTE1LTEtMS0w_ca8954a2-3cb9-48ba-a006-778e9a245e19">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ea805daaef473299b9ae21f484efbe_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTE3LTEtMS0w_f6726600-4840-4e6b-9c66-40c7957a33d6">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTE5LTEtMS0w_fa800acc-68eb-4b5e-b553-0867f44e7f93">12,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The plans&#8217; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i33a3bad450d545c48780950c1296bf7a" continuedAt="i1cacf1f875e6468f89575bf7cdc4067e"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwODM_cf73b261-8fcc-4b00-b9e6-9ad1165dfeba" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#8217;s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:25.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.629%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f7bd0fb86b414a9c2c97debb06568e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMS0xLTEtMA_c31b0d10-1870-487a-bc0d-c5955a65728d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f9f4e4430546bd9a3b6f9954b477dc_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMy0xLTEtMA_3fe54daf-bfe7-4fa8-a559-2f3fd1ea4c4c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffbd9fca0edc4beb8128fe8f2eaab268_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtNS0xLTEtMA_9abd40e8-c4e3-4a53-ba17-7a57ed853215">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ded4752a21d440a80630cbd004ec39b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtNy0xLTEtMA_58539ed7-a611-43d7-817d-e4001d49242d">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0543e0d9beb449b8a879873310de464a_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtOS0xLTEtMA_babaeca2-b5c8-4208-8186-4654bcb85e80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c5624edf264ef78c72a7cc903e4d53_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMTEtMS0xLTA_9d6b19e1-fbe8-419c-aac8-882d197a9c08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf767adb1b441a08fdbf662ead15031_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMTMtMS0xLTA_1a534f0d-0bf7-4903-bbbb-4283687e46b3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae0b2dd3b32941cc92817703c2a4e429_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMTUtMS0xLTA_b9b75974-e2f5-4d53-b15c-490a95c89b57">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c9c0618cec84c088e773da09a42ef8f_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMS0xLTEtMA_0ab35b39-63d7-4526-9960-1c571f593d6f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb24ab962e0d4ce68a8f9e970430d6d4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMy0xLTEtMA_a5579f18-b81d-4c94-b95d-8c92a20988b4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib51e5e37dd5440398f596d5a49edb8c7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtNS0xLTEtMA_9c4c0936-5aa3-45a4-a26b-294393c502c9">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdeac8350d854b17860499847d42ea25_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtNy0xLTEtMA_ae4b64be-1fd8-4bee-aed9-b7211c907e54">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb35a2c8a0448c83339d1060a7a9cf_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtOS0xLTEtMA_df363943-ef8f-41fa-a9be-0e0993aa5acf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6c5629485f4afeb50f9607d49405b7_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMTEtMS0xLTA_1f919702-4d37-462e-a7b4-0865e7f1890b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib03dc9f34fcb49d685cc8f077e1f7d9b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMTMtMS0xLTA_38b100e5-c6ba-46a8-8034-eae494e28a11">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd4a51131f4d4e358c9cecca8b9026d2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMTUtMS0xLTA_43de9337-8d8b-4c86-94d8-55a639babc0f">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c9c0618cec84c088e773da09a42ef8f_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMS0xLTEtMA_925ef3fe-380f-4c86-b90d-996a088d5caf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb24ab962e0d4ce68a8f9e970430d6d4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMy0xLTEtMA_dbdd5c33-d566-4ad4-bf37-aceed97f8e39">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib51e5e37dd5440398f596d5a49edb8c7_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtNS0xLTEtMA_8e9fd7ab-156c-41fa-bb50-e7875df6537d">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdeac8350d854b17860499847d42ea25_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtNy0xLTEtMA_a6a60560-65ea-442f-a585-c21ed3966d2a">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb35a2c8a0448c83339d1060a7a9cf_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtOS0xLTEtMA_ec6ba653-39eb-4764-821c-ed2e54c019e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6c5629485f4afeb50f9607d49405b7_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMTEtMS0xLTA_08654202-baaf-4261-ad85-4782548922a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03dc9f34fcb49d685cc8f077e1f7d9b_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMTMtMS0xLTA_50c9c086-7725-41bd-809b-6d12cf66fe23">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd4a51131f4d4e358c9cecca8b9026d2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMTUtMS0xLTA_0f7ae651-5751-4aa6-8fcc-c585d4a46cca">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c9c0618cec84c088e773da09a42ef8f_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMS0xLTEtMA_514866d9-ab12-4ff1-aea9-7a2c92caa701">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb24ab962e0d4ce68a8f9e970430d6d4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMy0xLTEtMA_38297886-c24b-4207-8d7d-6d0561c2c9c1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib51e5e37dd5440398f596d5a49edb8c7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctNS0xLTEtMA_6752afab-7c7b-4555-8b28-10ce0d4a4206">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdeac8350d854b17860499847d42ea25_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctNy0xLTEtMA_0f82dac1-1d3f-4db9-8ffd-2633c35f3dfc">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88cb35a2c8a0448c83339d1060a7a9cf_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctOS0xLTEtMA_c0ec2dd7-c08f-4f0c-98eb-343337863877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6c5629485f4afeb50f9607d49405b7_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMTEtMS0xLTA_de786924-40aa-41bd-8806-0cde9d6fe99a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib03dc9f34fcb49d685cc8f077e1f7d9b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMTMtMS0xLTA_db95d43d-c618-4d44-bc39-a15ac17584d3">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd4a51131f4d4e358c9cecca8b9026d2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMTUtMS0xLTA_5043b3d0-1c9e-4959-a3eb-97daba1b6b30">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6008424e527d4605b76b5c541489c471_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMS0xLTEtMA_9d7465b3-052c-4a89-a4a3-7504911bd4f8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6924e6dd4542c39440e5e6128bd0b7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMy0xLTEtMA_66e751f4-4d0d-4ce3-8fb6-083b63cc6901">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecf6e1df51340bbaba2f059fec3465a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtNS0xLTEtMA_43b575fb-5080-4673-9385-1845a7f4591b">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6941b80bcbf5486ca983dfe0369cd741_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtNy0xLTEtMA_ad4a9074-cfa8-4546-97fa-ebb1a137a4fe">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f7bd0fb86b414a9c2c97debb06568e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtOS0xLTEtMA_e4510f97-7756-4d33-b416-e0557414052a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f9f4e4430546bd9a3b6f9954b477dc_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMTEtMS0xLTA_3f61a66a-6821-4c25-ab7d-8ab8f7ffefdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffbd9fca0edc4beb8128fe8f2eaab268_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMTMtMS0xLTA_159e787c-77ec-4056-8e51-2debe78ca8dd">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ded4752a21d440a80630cbd004ec39b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMTUtMS0xLTA_20c824f2-9b90-4370-a8c5-865c4c08106a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7032f825e9148319be784239d5dc247_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTEtMS0xLTA_8a4238cb-cb8b-46e4-afea-8d6e1ec600d7">935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88665ad826e641d683cd947d6542e94a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTMtMS0xLTA_289bdec2-d3a5-43f0-a0aa-6d072c4ec813">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87e1269e4974cacb4df9177b0d52da2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTUtMS0xLTA_d973ded1-8f54-4f89-8d19-00ab1e37220e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f3afa788a448f7a63c0f0ccc99339e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTctMS0xLTA_f1a8313d-179d-41a6-aeb4-0eaa5df938a3">935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48869176aa064f5b84788a6a483e5d0d_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTktMS0xLTA_aaa20415-f1f6-4552-8c90-d341dfbb3199">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b32614e3a94518839d5155b07abd5b_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTExLTEtMS0w_c28c27bd-ca8b-4d04-bbd3-d104f96012ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4193bedff7b5470093b4777d0ca284e3_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTEzLTEtMS0w_c7441ec7-41c2-449d-8625-509cc0be2c94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86abfbda1f9146a4a6851f8c322ef63a_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTE1LTEtMS0w_f040f283-93d9-4335-8ac2-692683669fe2">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b1148bd1f04038a1852875553f8c89_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTEtMS0xLTA_37d521ba-e12c-4655-a3b1-c69f01836cd2">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0a39a74efd4a798069f6dc88d2753f_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTMtMS0xLTA_681197eb-00f0-4ee6-b47b-77f1b5819ec2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e83024d7d194652beabf70b37e52087_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTUtMS0xLTA_78e36bd4-a3d1-4c25-acaf-fec6d0306276">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9efddc2c4eb4b51ac27ed6cd9f54f5d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTctMS0xLTA_8bc170b7-8844-44f8-ab56-8014fca86986">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c24038538054e02b5a035f3e61a08dd_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTktMS0xLTA_90124fcd-47a7-407b-8911-7e67f07d39c1">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0ff66d0a1341e8afc7ed8586d8a024_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTExLTEtMS0w_8cb68556-c90a-42d3-b5d5-7c3d1883fa28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7e6daeaa1d88470ca8bab0e45dcff6cc_D20200101-20201231" xsi:nil="true" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTEzLTEtMS0w_1f7fe28d-c380-4523-8f67-b914a8ea1b51"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa6e26e2efe4d9ea09bc81d737de0e6_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTE1LTEtMS0w_642edbd5-c534-4e1b-b695-72e0315df619">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b1148bd1f04038a1852875553f8c89_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTEtMS0xLTA_bf8c6a9a-f8fb-4aa4-92ea-d41d5829e140">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0a39a74efd4a798069f6dc88d2753f_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTMtMS0xLTA_b6ede1f1-9817-46eb-8b8b-53f1c8dd460a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e83024d7d194652beabf70b37e52087_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTUtMS0xLTA_7e4fee79-f28c-4fec-a337-ff6231bad611">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9efddc2c4eb4b51ac27ed6cd9f54f5d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTctMS0xLTA_d7101f8a-3dfc-4d84-9bd4-a5a07ce76dfb">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c24038538054e02b5a035f3e61a08dd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTktMS0xLTA_db51c916-5405-49cb-a59d-694e0103819c">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0ff66d0a1341e8afc7ed8586d8a024_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTExLTEtMS0w_7bb549a9-0993-4b61-a1fa-88fabe542586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6daeaa1d88470ca8bab0e45dcff6cc_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTEzLTEtMS0w_85b6b758-2bb0-4e7f-9aa4-1220235c66a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaa6e26e2efe4d9ea09bc81d737de0e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTE1LTEtMS0w_4ed01e88-8c28-4a6d-8f99-ab1f2e5a5d3e">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers in (out) of Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b1148bd1f04038a1852875553f8c89_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTEtMS0xLTA_b197d623-a38e-42e3-91cb-af1605e21fa0">78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0a39a74efd4a798069f6dc88d2753f_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTMtMS0xLTA_7dc2cb31-3744-4111-b1f1-ebe322c35b5a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e83024d7d194652beabf70b37e52087_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTUtMS0xLTA_4bc5894d-821c-45da-80c6-c5485aac8b46">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9efddc2c4eb4b51ac27ed6cd9f54f5d_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTctMS0xLTA_784eeb49-f674-4348-b29f-7a512f7d2dea">78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c24038538054e02b5a035f3e61a08dd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTktMS0xLTA_431b6690-deda-422d-bd6f-d51bee47671a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0ff66d0a1341e8afc7ed8586d8a024_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTExLTEtMS0w_842b580c-ba6b-4fbc-a38d-d6a4fb1a5465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6daeaa1d88470ca8bab0e45dcff6cc_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTEzLTEtMS0w_eb823942-4fda-465b-9152-d1b586d55b4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaa6e26e2efe4d9ea09bc81d737de0e6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTE1LTEtMS0w_5a91e160-3bff-4c9e-bf97-8a203770f981">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd5948864f247fb8240d73efa22974a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTEtMS0xLTA_c6e9e1c0-2052-47d7-b655-e188a56f2a68">937</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6be1fc79ba48d990cd4dda9a8296c6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTMtMS0xLTA_d2cdf3b6-78f1-4770-af4c-3b6f3bd6cdc6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i062dd5eba1074bd9b7e1f64bbe49f973_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTUtMS0xLTA_fef4d9a9-64e8-4943-bfa8-a39301f7b8f7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf01a553998e486db4187f11f6c70b9a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTctMS0xLTA_bd30199b-e873-4e6a-82d5-7cb04c289345">937</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7032f825e9148319be784239d5dc247_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTktMS0xLTA_b30f9a39-3aad-4609-be25-89ea28de8725">935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88665ad826e641d683cd947d6542e94a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTExLTEtMS0w_d1de8b12-ac8b-41e0-8285-2c9430e3d517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87e1269e4974cacb4df9177b0d52da2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTEzLTEtMS0w_c2cde8c4-8100-4328-9c6e-3fac18cb7efc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f3afa788a448f7a63c0f0ccc99339e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTE1LTEtMS0w_6e2e2a1b-07d1-4201-af38-4954f856cea2">935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="ie606c465cbc542e0852493512f0bef9d"><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:18.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id06d07a27e9045a094b87e5c189c3954_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMS0xLTEtMA_4cce8af1-f85d-431f-8090-ec5abeacfbd2">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a22f408073435e909cf7aa033ebc6f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMy0xLTEtMA_bd32ca86-e286-4b44-a712-d9fa06e1fb5c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice177b53b8bf471bbf10d5357f0e823f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtNS0xLTEtMA_cb8e4c79-bb83-4167-b566-78acb655682d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e1329bd56243e18e983e2de609a849_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtNy0xLTEtMA_eaae17fb-10ac-44ff-a602-99b5212b0d18">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a5086b5128478aa64899a4b8b33cf8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtOS0xLTEtMA_13bb0cad-4144-4933-a5aa-e40acc6e7f29">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b13ef32d5364a38917129aff9fec7b1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTEtMS0xLTA_299feaca-3827-4d4f-8902-ef119a2fc926">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica90cf7838a7461289b9ba848c17f909_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTMtMS0xLTA_6313ffde-2add-487a-822a-afd3d6cb78ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id626f58b4ed04285b83a1f5f564106f0_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTUtMS0xLTA_606e4c4e-2f72-46f5-910c-7498796938e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b5f8a81b5d42fbb063b001b277bd2a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTctMS0xLTA_93c3e4d6-481e-4a5c-b35e-7a804f7d9f34">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i121d0ae7b5584cf08889319e21df6f00_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTktMS0xLTA_96f1e1c5-3cf5-465f-9137-cbc830c155dc">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab8af9defb944fcb4a112b4a4fd3754_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMS0xLTEtMA_cd9fe6a1-b2f1-47dc-a1e0-26270c026bb1">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica3c0900036b4c57b95574ad6d4370aa_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMy0xLTEtMA_eb528a93-6158-4469-a046-e9d0664549e9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia23692c19eb34a1f8e06494fa27cd511_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtNS0xLTEtMA_c622caf4-0699-4af0-bcce-56629a1d10d2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8677bf18cb544efa1b2a3272f0a47a4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtNy0xLTEtMA_2711dc4a-34ab-44c0-af6a-4839ed81b320">378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6b068cf6ab41fb9bfee3a5fd9d9251_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtOS0xLTEtMA_9048ab47-3fe1-4a70-9aa2-d6d0af5b50d0">402</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f2b2c632f44cd1a8f7e0b0d9bb1c56_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTEtMS0xLTA_f17595bc-f72f-4f28-93d6-d994a80cd494">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if643fb5543124a6894df897dc47be455_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTMtMS0xLTA_d9c9b8a4-c366-491a-bde7-7a0518acccf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4df17beca4f4aae9917df8f72802d26_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTUtMS0xLTA_34496b19-5219-436f-b08b-b4045f122fe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b69b9758d9428fa6eee4787db14eb3_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTctMS0xLTA_54dd43b0-bc8a-4b4e-87fd-5874782d30f1">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f07f5009ef24afdb2515077be35b2c3_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTktMS0xLTA_da529ca8-34aa-4cc5-9ce4-e38856ca870a">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if47b6f8be3a54363980225411f0cde09_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMS0xLTEtMA_d32aa748-bb49-4c6f-9aef-39674441b726">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4eb7c2144745c5a54d9ff57aeffc3a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMy0xLTEtMA_e1cd5d37-1a2f-43ee-aa55-8b49146f4e79">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03afe5c2d65644bf8233215d9ed8ce21_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtNS0xLTEtMA_18fbfede-5684-4d5b-a358-a3f5d8219396">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667292d025a9462f937f9e358ff4597b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtNy0xLTEtMA_b70b9703-5b75-4b22-9aab-bdb69e23aa6d">92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7a58a77c914de6a53aea5b50437da4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtOS0xLTEtMA_e86f474f-0143-4da1-a510-f717bf49d913">92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8888c94d17e84a6c8685bb3aa616ceab_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTEtMS0xLTA_5b83aeb1-d809-42c0-a520-b413c0e16832">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf411e7ed154695860581e937aea220_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTMtMS0xLTA_3a28b67b-c50c-442b-af0f-14c9a2942c9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib427fd64730a44df9cddac5399f38153_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTUtMS0xLTA_0313733b-6c90-4be0-ab8a-e1d10ace2ffd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c47a65b46544c38b3b012501b67980_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTctMS0xLTA_5daef46d-89a8-48fc-8577-98859751be2d">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da62d5a32854107a7b16eacacfd2bc5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTktMS0xLTA_2f7407c3-e868-467a-b628-2fb5aa60fc38">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7f6d0dd3ee4a929304b9754f6827b9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMS0xLTEtMA_0d89e192-6a9d-4c0e-872e-393881b60317">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a86ee5eed134b6c89a7d0fa2be8b6b8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMy0xLTEtMA_3d6498e5-3801-4600-8843-c1cc1332e448">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d73446659a4e33b8b0a661934a44b2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctNS0xLTEtMA_4fcea71d-8db1-4290-b235-3e9f2c7fb1fd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icf7ccf80013542b487ab201e6f185f08_I20211231" xsi:nil="true" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctNy0xLTEtMA_2b118e86-0081-436c-8187-3698a9e5ead3"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9e21c8c54c43daa17d22d749c695e3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctOS0xLTEtMA_25375caa-1b39-4f15-82f0-2686d89d15db">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e32729f23f4e5dbbc51b849d911757_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTEtMS0xLTA_e28f2e37-ac76-4c29-9989-836952658f76">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b0f77300a243acb6a9ebbfcb1aaa2a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTMtMS0xLTA_fda277b4-3421-4465-9590-c351425f4810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b86fee24be648ad94520f4a1978a1cb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTUtMS0xLTA_3e7fa6df-e1bc-4cad-85eb-a7dc141cb8a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c501dddf974f5abc029b567480dbee_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTctMS0xLTA_6d34b84d-6891-4323-a0bb-f3b5fb53aaae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091b7006b6ea46b3b61e3eecc932c387_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTktMS0xLTA_887c8a3e-2f77-4360-9e86-29eb7e303556">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5b17f159a845539e0a01013b211052_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMS0xLTEtMA_cf8e3877-31b0-4901-85a2-13828969fc8b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bdda57c7bdb4c5bb74a961da2c1d8aa_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMy0xLTEtMA_f0a1314b-9b29-467a-87b1-4643bd9a9df2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica17e9ff742a40d783b5644277161e30_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtNS0xLTEtMA_89c85ef6-422e-42a5-810f-9e5ede7bcb36">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ef3d891cbc4cd69295e9cecc6d5a62_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtNy0xLTEtMA_f22810bd-373a-47c9-9be4-dd7d63960e16">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e02936176ce456aaf00f889622803e2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtOS0xLTEtMA_2632dd74-344f-425b-bc73-7a7bc4e03fc7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483bd58d24394b3b80eb5b353b8efbdb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTEtMS0xLTA_e6fa0ad8-5d30-41f7-b23c-0c16cb2e086f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793918a7fdaf491fb0c1dbcd66331c49_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTMtMS0xLTA_eebe644f-4ad0-40d7-b079-69ff95a5600c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc268366729489591fd438b0fe8fe17_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTUtMS0xLTA_18b00590-f55f-4efe-a980-70607b22aa85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd69e0aa38ac4ec7b4f7d1c9516ad2e4_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTctMS0xLTA_72b8c481-3a32-4802-940e-dbc3296705a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icebfe327fd3d4adab637ef455f461fcc_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTktMS0xLTA_8bdb73b2-7be6-4f00-ba9c-e05cc95f1a02">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3c817820c64372aa410440be5205a4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTEtMS0xLTA_1aa2b022-5b19-42bd-a036-c1f5bfecc7f3">290</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83f94a689444e288ae0dbed266bd406_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTMtMS0xLTA_ee7ff612-3506-4b14-b4ee-592da0bccca8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b704682926148cc84a8db8efc5c796a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTUtMS0xLTA_fcc0404c-1fde-4a9c-b41d-074e7e1a4414">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4628916abc4126927023ae15fd0a85_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTctMS0xLTA_7a2c226e-08a1-4eb9-ad4c-1455ac8c18fe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15d37d6fcf94f1d962a65444ddad466_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTktMS0xLTA_60525f58-63a2-4963-8055-ea6b1965b2e6">290</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia130b62a5f43450aa1a3339b37134132_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTExLTEtMS0w_b410fc7b-b199-435e-a43d-d3b3f185d26c">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df7f246cf14229afdd2685344a7de4_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTEzLTEtMS0w_bb4e2593-b7af-4586-b789-39296a7ed0d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2807f56dcaab490eac85b298b86298c8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTE1LTEtMS0w_afb0db8b-c22c-493d-a743-a8a1e729af14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26b7b22b4244d81b6f3cc21118aec61_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTE3LTEtMS0w_b7799811-fc51-43d3-a7ab-c4f8e8cbce5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf9ac56392a463fac3b411b9205a0a4_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTE5LTEtMS0w_3afa97de-e735-45be-88fe-d2ccb9624539">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6a02cc27c7c4c2f8ba5429f74eab5dc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTEtMS0xLTA_458cbc8c-6e60-435a-a572-b14df56613a5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee3239325c8c46efac7fc183d07c9374_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTMtMS0xLTA_79dafb73-b726-495f-99df-8e288b750009">275</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63554eec91f4d6ab395b9acc70717d3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTUtMS0xLTA_492302d7-62d3-437a-9717-a5e11c0fa6d9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i287ca8ea377b4ed080264796be545504_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTctMS0xLTA_88a8b4a6-81f3-43d6-836c-e3fb502b3fe3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db09a55de19497b9b70d729546fbb1c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTktMS0xLTA_cab0aa69-c31f-45f0-8470-3f8c0fc59d16">275</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d98b7a9bf04af8884803848570265d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTExLTEtMS0w_47961ad9-8025-4c94-b5f3-edf37142ab20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e091f2feda475987d31a21e338c4f2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTEzLTEtMS0w_9050e4aa-1f5e-4f33-a37a-1982ef42d574">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf7c43c5492487a99e3564c60260e5d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTE1LTEtMS0w_89962c00-dfce-4cf5-b263-b00789375822">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f74f7cbb854caba1a1c57ac918a3ad_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTE3LTEtMS0w_8ee0c6af-994c-473a-9320-da78297c0376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc35b4c7594d4187a5cb7cc2d7f4d264_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTE5LTEtMS0w_69aa3f62-2bda-4f63-94f1-ca86ea270274">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90407e0949ed436885a9125ae3ff3616_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTEtMS0xLTA_d4006f9a-5d6d-4dd7-8f91-8cf2386dd1a8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728b0c1d082a441b95dd386a599c8098_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTMtMS0xLTA_be74bfb5-2b54-42dc-b847-be4adb474ec0">191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc07cc2ffcc4a07b93ab604fa085182_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTUtMS0xLTA_df6d4166-0445-4c66-bd5e-bd0afa03b4e3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3750cadf46e42dfb107576386473746_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTctMS0xLTA_0fd901f4-cc41-475e-bc52-971c831c380d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb00f009ed984b3e9d7ce65a1632e458_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTktMS0xLTA_7d4a7c7e-0ffe-4109-8b52-ebc25c3b414f">191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6dd6a6d63e54e938c5a72c294269cc1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTExLTEtMS0w_97e16909-5e6b-4d1e-b190-8efe65c40616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08fc130457454a08b3f267225ed6ed27_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTEzLTEtMS0w_25f7bbad-aad4-46f2-bf56-cb6b13891ec8">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6467d1906b2f4d7e8bf6f78423b52659_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTE1LTEtMS0w_08654296-b761-4d8f-998a-6a3592a7187d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de3243e532c4de2852c89993a892b41_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTE3LTEtMS0w_27c24dfb-97dd-445c-bd7d-5a0c5bd48a0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e47c270d1243bab3c87f29d058155f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTE5LTEtMS0w_9c2ef73f-6971-43b5-97e7-35d8d8e810e8">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf563768fe14889b1e01fe62524d07f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTEtMS0xLTA_21a87c74-13af-445e-861a-e9579b4543e7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a491066de6b4e4792fdd0a3377e0b54_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTMtMS0xLTA_faa843ac-fbf4-4378-b41e-fac4431d95a7">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb93f5076a643298235176fc92ef07c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTUtMS0xLTA_6466148f-c305-47b6-84e5-498698b070f3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e1bd81b4d648f3b5b45923274ecfc0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTctMS0xLTA_7273bdbf-d188-47bf-a503-ebd361d3091a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e40afe1730c4117941b66edb4d40d3e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTktMS0xLTA_a5d68df2-8fa8-4006-b59a-743d25023a88">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1910fb48ae8b47d59024291ba45240d0_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTExLTEtMS0w_54125a9d-9b53-46cc-be05-eaeef423b8e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149179b3d497412eaee0ad158abcd1d5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTEzLTEtMS0w_14235f25-d24e-414f-b2f5-44cb6d40ef09">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e84e538d73498da4853df1d5a84ecf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTE1LTEtMS0w_b453f056-6279-4e7b-a4ee-185a9b4f7c6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495b7eb9aafb434b88ff4e62c501d012_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTE3LTEtMS0w_2f036a2e-d36e-4ce2-9cca-8ee784532538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2370d975c61e4aaa91def0aa9732dfc1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTE5LTEtMS0w_7980d468-2783-45a7-9b1d-1979959425cb">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbfb9218ab84c998baded784956a8d2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTEtMS0xLTA_e93322af-c2ed-4edd-aa2a-deb9779c8275">326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eb3c9e8db1400ab82cf431989eeb20_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTMtMS0xLTA_7cd7f83d-74f3-405c-b7fa-7483034f162a">468</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f174f676614246ac5cc662923bd7de_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTUtMS0xLTA_91076104-e972-4504-a9e6-9c26dc958926">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1deac4fc07e246e48d31f4bb339ce199_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTctMS0xLTA_8cdff4b5-10d4-4db2-b339-07ed5c847c8f">498</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTktMS0xLTA_497cb109-15a0-4a82-a4b6-efa18b327ef4">1,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9cc57e45454c60a2afcf99a471a7a6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTExLTEtMS0w_910692de-7d9f-413a-8458-2c96852fc831">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea250ccc936041e7a2dfb8b6d72e949b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTEzLTEtMS0w_8bf12d06-773c-4185-a838-ee381202d4b8">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc0707765e4e4b9ea9465ed6da91604f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTE1LTEtMS0w_f7c68944-f118-4a09-87ee-a991fca3b9ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib36b1192c28e46a9bc24708ace77b04c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTE3LTEtMS0w_d40d7040-9989-428e-aece-ac5843cb5e34">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTE5LTEtMS0w_dcbe4e70-1913-4691-80c2-a98efa025c19">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S.&#160;pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans is allocated <ix:nonFraction unitRef="number" contextRef="ifa625a65fc9249b88c46cf2eac079bb8_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzUzODg_f1bc9e8f-5f69-42af-925b-ce4325d5205e">30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iec626e4bae224a9f838923e9721430eb_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzUzOTQ_8204c630-a1a8-4d7b-884d-60657dc5b772">45</ix:nonFraction>% in U.S.&#160;equities, <ix:nonFraction unitRef="number" contextRef="ibf509bb5a7f240e8bfdf5c3c69c7f006_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0MTU_b204ad0b-c198-4350-b2e1-135b0804d960">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iad12fdc5a7d14e5ea50cf778b94402fd_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0MjE_044c1473-f4d7-41cb-a33b-708d294c0446">30</ix:nonFraction>% in international equities, <ix:nonFraction unitRef="number" contextRef="i9213c4b474fe4561ae99450da35e89eb_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0NTE_49643d79-ad35-4d44-bd8c-3f2c98e1fd70">35</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i755061a1bfda44be8dce382e25583fc2_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0NTc_c653d5ce-9091-4dee-950c-09a3b80d860e">45</ix:nonFraction>% in fixed-income investments, and up to <ix:nonFraction unitRef="number" contextRef="i95e72546c73c4aa4ae96105aad140dd7_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0OTk_6d5e0357-7730-490a-90c1-cf61a73b6cf0">5</ix:nonFraction>% in cash and other investments. The portfolio&#8217;s equity weighting is consistent with the long-term nature of the plans&#8217; benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates <ix:nonFraction unitRef="number" contextRef="idb0d794972b549a0b3f947ab5849bf7e_I20211231" decimals="2" name="mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU3MzU_3f0bc700-4dbc-4eb7-bc28-6f643200dee9">11</ix:nonFraction>%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i1cacf1f875e6468f89575bf7cdc4067e" continuedAt="i267138a77ade4ca399ceb1fb36d4cdfb"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Contributions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions during 2022 are expected to be approximately $<ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzYyOTU_66cda4a0-bd94-43bc-afab-9155e19de814">280</ix:nonFraction> million for U.S. pension plans, approximately $<ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzYzMzY_f5ccfd6c-2f1a-4884-b56e-74bcd76b6116">150</ix:nonFraction> million for international pension plans and approximately $<ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzYzODk_a2e4af71-483b-4d94-82fe-21b9495e274c">50</ix:nonFraction> million for other postretirement benefit plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Benefit Payments</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwNjQ_48072714-78b3-4c15-bf65-52cbc60f7867" escape="true"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzEtMS0xLTEtMA_8e653741-02f8-4b92-bcbe-4f2b123c4a00">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzEtMy0xLTEtMA_4929bebd-716b-42f4-981b-2c3212cc39a5">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzEtNS0xLTEtMA_9a3b2ea7-832e-4b97-87f4-e49f3bd98238">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzItMS0xLTEtMA_0d702a72-289c-449b-8d77-2781c0f926bc">745</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzItMy0xLTEtMA_ca510bf5-0c62-4bdf-929e-66e636b67f5f">275</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzItNS0xLTEtMA_17367d02-42ca-41fe-9d79-1ca39de0b080">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzMtMS0xLTEtMA_65d80ed8-c7d3-42ba-b125-8956d4868101">731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzMtMy0xLTEtMA_c6d09875-2412-4191-8a13-03ae9d23c1fd">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzMtNS0xLTEtMA_da9f1998-72fb-4ca8-98b4-467f55534dae">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzQtMS0xLTEtMA_fc56812f-06b2-4dbd-a7cc-6bbfe6602e38">748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzQtMy0xLTEtMA_f183101e-28c2-4288-8867-18b3c7195244">280</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzQtNS0xLTEtMA_004df056-3754-42c8-9d34-ef5691366c11">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzUtMS0xLTEtMA_c80e5c51-ef37-4f3c-a84b-b5e3e7ceae9a">770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzUtMy0xLTEtMA_5dfe3e78-3c9c-459b-a633-051735d9b08d">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzUtNS0xLTEtMA_8cd6e6ec-3315-4af8-9ab0-37d1ec7ec703">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027&#160;&#8212;&#160;2031</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzYtMS0xLTEtMA_02aa8f76-8ede-4176-b270-8b5c3d59ec96">4,230</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzYtMy0xLTEtMA_c7dc0592-760a-4151-a981-59a552dba551">1,715</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzYtNS0xLTEtMA_1f359259-7c21-4312-9639-8f7338c72f86">469</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amounts Recognized in Other Comprehensive Income</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwNjU_50aae49d-3fb2-4753-800c-92f729308d22" continuedAt="ie72e795ee4e647b4af71ebf7ec14681a" escape="true">The following amounts were reflected as components of </ix:nonNumeric></span><ix:continuation id="ie72e795ee4e647b4af71ebf7ec14681a" continuedAt="i6bebce926b594dfc83ad2f26e0ee93ad"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></ix:continuation></div><div style="margin-bottom:1pt"><ix:continuation id="i6bebce926b594dfc83ad2f26e0ee93ad"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:28.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gain (loss) arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMS0xLTEtMA_fcf550af-14da-4901-b75c-d6c8f242e6ab">1,048</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMy0xLTEtMA_7c43dfc3-f455-4609-b144-698854893944">448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtNS0xLTEtMA_76c865be-8a30-477d-a163-c2a33be9ed36">816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtNy0xLTEtMA_4d5c17b4-b3e0-46ea-a696-8b806e364d08">815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtOS0xLTEtMA_072133d0-5e3e-425d-9649-7578230e0560">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMTEtMS0xLTA_b267cffd-3239-4f28-b352-80e92ef5638b">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMTMtMS0xLTA_ceda3fa3-c109-489f-9d82-44d0fb3d729c">144</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMTUtMS0xLTA_043c4ccb-d01b-4038-b3af-18bdf799b118">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMTctMS0xLTA_dec6da0d-2ad4-4680-9c39-ab7d2fa04bf3">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMS0xLTEtMA_24fe3018-4b24-4a9c-87a3-8fe58eec9ab7">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMy0xLTEtMA_9c2d0a7d-501c-41d6-a59d-87ad191ee54a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtNS0xLTEtMA_ed10b125-20db-498a-9df7-1a532c1f01a6">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtNy0xLTEtMA_72ab7df2-99c6-4ed5-8c41-ecae5410c848">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtOS0xLTEtMA_969d9453-957b-4974-a3bc-0d98a9c1b34b">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMTEtMS0xLTA_9ffa5d9d-d156-4149-bc8f-197e15c1881c">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMTMtMS0xLTA_a52c0e38-74ce-40ee-b367-2d1b5cabc216">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMTUtMS0xLTA_235922c0-7e83-4c18-b9d5-c9a6cc0215fc">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMTctMS0xLTA_510c0479-1c3a-4531-b4c7-0ae59142a856">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMS0xLTEtMA_300a542c-dd17-4cde-9f75-f57d86f40318">1,045</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMy0xLTEtMA_27a9149e-1351-4d24-944d-4e3478af733d">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtNS0xLTEtMA_ce1cde50-6522-412a-bfd2-f5c3155acc98">820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtNy0xLTEtMA_4ae00600-0ea9-4eab-b435-ed00e8809f20">786</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtOS0xLTEtMA_5b75b8fe-962a-4606-a2ee-48225f2116eb">345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMTEtMS0xLTA_e86dedc6-1805-408f-96c4-435af8b1cadf">228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMTMtMS0xLTA_4bd13f70-1fc2-4062-9212-f08f4f3a9594">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMTUtMS0xLTA_83fbd908-4505-4c4e-b358-74b235e510a1">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMTctMS0xLTA_0eddb297-392c-437e-91f2-dc70eed1ec5c">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMS0xLTEtMA_72512422-0c96-4293-979a-528a4bc25d6b">298</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMy0xLTEtMA_75cfb44c-9081-4eaa-a259-41fb32690f06">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtNS0xLTEtMA_2665e8b0-1d0a-4a03-86e0-536ca94f23a1">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtNy0xLTEtMA_80a27209-6aaa-4535-ba4e-021cdb0de0da">142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtOS0xLTEtMA_ec1aa848-750d-4b77-8030-11966059747b">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMTEtMS0xLTA_f99c04c7-b71a-491f-bec8-51aefbd8c5ae">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMTMtMS0xLTA_b78fd730-f142-487d-b940-68172d72590a">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMTUtMS0xLTA_730c0c83-a89a-42ce-a851-52ef3b20edb1">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMTctMS0xLTA_603aecf0-b68a-4498-a1a4-7624ce46baaf">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMS0xLTEtMA_d5306579-5bfe-4550-a9fd-18ecedb366b9">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMy0xLTEtMA_3a1586dd-d73b-40d2-bd86-d855985dd13e">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctNS0xLTEtMA_8cdc72d7-6b3f-44ee-a9db-0d5914b448e9">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctNy0xLTEtMA_f266a82f-d716-4d4d-b899-fd044627b31b">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctOS0xLTEtMA_95e979a9-868c-4a74-9b6a-12e71aaa70cc">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMTEtMS0xLTA_60b56030-bd0e-43e4-8f13-39381a31af82">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMTMtMS0xLTA_8fd4221e-18b5-462c-8194-cc915116c200">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMTUtMS0xLTA_6742c041-3e8a-4042-9cf3-edd76aaeb472">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMTctMS0xLTA_0ceaed96-20fc-4136-8acf-d2cce7fd1e8e">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMS0xLTEtMA_9fa809e7-cd63-47a5-905f-9b6575d1c87d">260</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMy0xLTEtMA_e89f4b07-e556-4512-b000-43eeabe7ee16">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtNS0xLTEtMA_91b56272-200b-471c-aef1-63b840191798">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtNy0xLTEtMA_e01220e0-f138-442c-b2fa-d80584e23418">126</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtOS0xLTEtMA_cd0bc8d4-8c34-4b9b-b68b-b569201cb028">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMTEtMS0xLTA_d812c036-a51e-4600-9896-7fafc1b20940">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMTMtMS0xLTA_e8a7cdff-8a7a-4cb6-a2fd-276ab38a4561">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMTUtMS0xLTA_78d2bbdc-5e49-4e95-82a7-8f998b47231d">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMTctMS0xLTA_65bc9f02-9c48-4b0e-825b-bf4148485ecb">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i267138a77ade4ca399ceb1fb36d4cdfb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Actuarial Assumptions</span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxMTI_ea568f24-8fc7-45b4-9a22-7b2d5642231e" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:33.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;Pension&#160;and&#160;Other<br/>Postretirement&#160;Benefit&#160;Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtMS0xLTEtMA_3c612590-25ed-45a6-ab71-7649f60085ea">2.70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtMy0xLTEtMA_61e598c8-1e1d-4e76-b003-d7d5f7838260">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtNS0xLTEtMA_0df4f768-92b5-4175-948e-2342f418a7b8">4.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtNy0xLTEtMA_1e6a5f42-4bbd-4ec9-b77b-f876d0566d41">1.10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtOS0xLTEtMA_1edec8cd-341a-463a-a294-7f56bbcc296d">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtMTEtMS0xLTA_749c90e4-404b-4762-961e-0d62bfddc33a">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtMS0xLTEtMA_a7d1ce19-c984-4c7b-83d1-9df990f11a7a">6.70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtMy0xLTEtMA_0a26da8d-997a-4fb7-b81e-39b36faf0c90">7.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtNS0xLTEtMA_d178bd72-086b-4a93-847e-04146c6cc60c">8.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtNy0xLTEtMA_a7b1cca1-207e-4414-bed4-e6bee9299a29">3.80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtOS0xLTEtMA_77be7618-d10d-474b-8f79-19bbfb1b545a">4.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtMTEtMS0xLTA_f826eb98-ef3a-444d-9287-b7d7a2c22881">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtMS0xLTEtMA_89979e61-e9c7-4649-a8aa-4f6b29f21050">4.60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtMy0xLTEtMA_d87233bb-27e8-4167-9185-4d83e78b98f8">4.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtNS0xLTEtMA_e62d46cb-aa1a-4a04-a0ca-8f4b5d717173">4.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtNy0xLTEtMA_782d5412-0a8c-4d21-b70c-592942d89b0e">2.80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtOS0xLTEtMA_e231b6e4-6e6a-4bb6-9319-71f662f5b945">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtMTEtMS0xLTA_b55d14d5-9b65-46bf-9d76-971834ad4d1d">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtMS0xLTEtMA_986775dc-e1df-472c-af24-cd3902889756">4.70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtMy0xLTEtMA_0cd7bddc-2016-4db4-b8c7-55c8ea4573bb">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtNS0xLTEtMA_34ebc2ac-d91d-41ef-a5f7-9d3d6816bb7f">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtNy0xLTEtMA_86af32b0-0bd5-4991-b2e8-c81d7f1f3a08">3.00</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtOS0xLTEtMA_df2f1aac-d471-4233-9c56-32a2eb573120">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtMTEtMS0xLTA_91e0c4d0-9fe8-40d8-a942-7810a1a78378">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb0d794972b549a0b3f947ab5849bf7e_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtMS0xLTEtMA_31f15799-5e64-4d06-92f4-fcee9853f17e">3.00</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74135854883f44a0bb9ee84c11306656_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtMy0xLTEtMA_e9ff18cb-5a0e-4833-a826-a738d637757b">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i818016db2b54406e88278d77b05a6d54_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtNS0xLTEtMA_5a78f3c9-90e8-449a-a4c3-2f6737a87a62">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtNy0xLTEtMA_60f3d9ae-8e9b-4e48-a44c-a8d8eeec05a0">1.50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtOS0xLTEtMA_4c416f3a-ea92-4488-9b00-a3b076b5f751">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtMTEtMS0xLTA_714beec0-37fd-4a2f-af79-28ec3085f25d">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb0d794972b549a0b3f947ab5849bf7e_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktMS0xLTEtMA_49a4b230-f4ce-446c-9b84-cc0611fcde4c">4.60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74135854883f44a0bb9ee84c11306656_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktMy0xLTEtMA_40f603b5-d053-4185-9214-ee1f952b04da">4.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i818016db2b54406e88278d77b05a6d54_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktNS0xLTEtMA_f653d379-3bdf-4185-985a-7044d090b729">4.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktNy0xLTEtMA_041419da-b071-4635-aa03-fbc101a6cd7d">2.90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktOS0xLTEtMA_4058bfff-c76e-41dd-bf56-2f5836d4cb4d">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktMTEtMS0xLTA_0bf63e25-60eb-4f52-8464-8940f50f508a">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb0d794972b549a0b3f947ab5849bf7e_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTEtMS0xLTA_82abe72a-b434-4ddd-9612-121a411608bc">5.00</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74135854883f44a0bb9ee84c11306656_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTMtMS0xLTA_b70422dd-8411-41fc-8ccc-5dcb1d49b8a1">4.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i818016db2b54406e88278d77b05a6d54_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTUtMS0xLTA_d80fc752-37e6-4409-918a-54e82d38b8b9">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTctMS0xLTA_a8f2bc0f-ad0c-452b-92a3-7df0c420b50f">3.00</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTktMS0xLTA_e5f4db83-e562-438c-b075-2e54c4131160">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTExLTEtMS0w_e5b0c45c-2525-4849-ac06-eb8fdf20bbdf">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan&#8217;s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2022, the expected rate of return for the Company&#8217;s U.S. pension and other postretirement benefit plans will be <ix:nonFraction unitRef="number" contextRef="i42dbde811d0f43b89555c0b2477f1fac_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4Xzg1NjA_80a20631-048f-4eeb-9681-3c882213f0b5">6.70</ix:nonFraction>%, as compared to a range of <ix:nonFraction unitRef="number" contextRef="i58dc9cde42be4f269b8259f1f6a7f155_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4Xzg1OTY_de8473e5-0bc8-4b41-9024-a0325c5a591d">6.50</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ifaf22a93cc2d4d0a814975c167a0a1fe_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4Xzg2MDI_b3ae4b6f-3e7f-4544-a888-45953586dcc0">6.70</ix:nonFraction>% in 2021. </span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxNDE_98312fba-56d4-49fa-b3da-bdb919e759a6" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4OGJhNTY2MDRlMWY0N2U5YWY5Zjk3OTEyNjMxYmU4YS90YWJsZXJhbmdlOjg4YmE1NjYwNGUxZjQ3ZTlhZjlmOTc5MTI2MzFiZThhXzEtMS0xLTEtMA_b2246b7d-e51b-4033-9d78-9ec0f20808f0">6.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4OGJhNTY2MDRlMWY0N2U5YWY5Zjk3OTEyNjMxYmU4YS90YWJsZXJhbmdlOjg4YmE1NjYwNGUxZjQ3ZTlhZjlmOTc5MTI2MzFiZThhXzEtMy0xLTEtMA_c8c6a9ca-2781-498b-8b84-90418a03789d">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4OGJhNTY2MDRlMWY0N2U5YWY5Zjk3OTEyNjMxYmU4YS90YWJsZXJhbmdlOjg4YmE1NjYwNGUxZjQ3ZTlhZjlmOTc5MTI2MzFiZThhXzItMS0xLTEtMA_a2c333f6-b580-4117-b904-b95f050bb18c">4.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4OGJhNTY2MDRlMWY0N2U5YWY5Zjk3OTEyNjMxYmU4YS90YWJsZXJhbmdlOjg4YmE1NjYwNGUxZjQ3ZTlhZjlmOTc5MTI2MzFiZThhXzItMy0xLTEtMA_71788c2f-c859-477a-ace7-d02dff2947f9">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Savings Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwMjU_8e55b87e-787d-4c04-bc87-04e5ca029a00">158</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwMjk_3d7a8f16-45a6-43ba-945e-cf2df9df73bc">158</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwMzY_44ba681d-57b5-4496-a270-c05af2a237ce">143</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_187"></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzE0MjY_0186a6ee-2ae2-4728-996e-0c57db38c56c" continuedAt="ibb240d3b4d2445c59e20b7362297ca5c" escape="true">Other (Income) Expense, Net</ix:nonNumeric></span></div><ix:continuation id="ibb240d3b4d2445c59e20b7362297ca5c"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzE0MTc_3209cfa6-6124-44dd-8bf8-de9680f20a26" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzEtMS0xLTEtMA_6a36f0dc-2e28-4fcc-9113-96d1bbe4b7e0">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzEtMy0xLTEtMA_d21ae584-44c5-4084-884b-de95cbe5d569">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzEtNS0xLTEtMA_2ab3bd0f-f4d5-4f8e-8fd4-2f6eee197687">274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzItMS0xLTEtMA_8f7c2f1a-b204-4e73-8460-6ff3d6001161">806</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzItMy0xLTEtMA_9b734659-4d9c-4bc2-bf3f-320d59e3f698">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzItNS0xLTEtMA_c4fcd1d7-ec0e-45bd-82ce-8af53c1ab35a">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzMtMS0xLTEtMA_c62ac268-b230-4db3-9ecc-2696ad2c1a24">297</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzMtMy0xLTEtMA_cb9ab8b5-92e6-4c62-82ab-8d64f34e4d11">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzMtNS0xLTEtMA_30179f26-404c-428e-998b-b6f595ff499f">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzQtMS0xLTEtMA_2d9066c2-9a8d-44f1-8ab1-f0b739e8b158">1,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzQtMy0xLTEtMA_955609ea-6089-4b81-8192-b644c085f230">1,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzQtNS0xLTEtMA_a49b8ad9-b942-4160-95df-2840406c2f97">170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzUtMS0xLTEtMA_ea051a09-869c-4e12-bccf-4604ff87a672">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzUtMy0xLTEtMA_b50dd7c0-47e5-4973-a07d-8450f6634e83">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzUtNS0xLTEtMA_7b6ce491-d69d-494d-8857-f591b47837f1">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzYtMS0xLTEtMA_de9d06ee-5003-4677-8323-da7cf6704b02">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzYtMy0xLTEtMA_e6a0c884-9a53-4a5b-8037-fff54b0fde29">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzYtNS0xLTEtMA_de61dba5-c27c-4ef2-b2e4-8c880c06b465">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzctMS0xLTEtMA_f52e060d-1093-4808-9ff2-521c9254e0a2">1,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzctMy0xLTEtMA_7416a50c-00fe-445a-822b-b1bdeb5b0188">890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzctNS0xLTEtMA_16f4fa32-195d-46a6-93b7-d3326a30bd64">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates losses of approximately $<ix:nonFraction unitRef="usd" contextRef="if9977d228ad648dea6127cc9cf399ac2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzEwOTk1MTE2MzA0ODQ_cb788af3-d98f-4759-ad32-f9bc7f14ea72">500</ix:nonFraction>&#160;million will be recorded in the first quarter of 2022 from ownership interests in investment funds.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net (as presented in the table above) in 2019 includes $<ix:nonFraction unitRef="usd" contextRef="i3cb2ff06220a49eb8adeb3181d31932d_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzUyNg_1e505b75-4f13-46a0-a441-27a0edd4b08f">162</ix:nonFraction> million of goodwill impairment charges related to certain businesses in the Healthcare Services segment, which were fully divested by the first quarter of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid was $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzEzODM_9c3b4405-612d-4b07-a601-a06fb8de60ee">779</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzEzOTM_a1beeeef-0df0-4cb4-bd27-adb808a8f224">822</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzE0MDY_988f8267-e047-47d4-bac9-9fc94f41a040">841</ix:nonFraction> million in 2019.</span></div></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_190"></div><div style="margin-top:14pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUwOTc_cd1fb2df-14a2-44a4-be1a-acf5b15e9142" continuedAt="i4cd7be1875d74129aa25d45a7cd28fff" escape="true">Taxes on Income</ix:nonNumeric></span></div><ix:continuation id="i4cd7be1875d74129aa25d45a7cd28fff" continuedAt="if0fe916dbff6438583ac98d69a61fdc5"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxMDQ_f4934914-00a5-49fb-b9fb-00cb03650824" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:35.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItMS0xLTEtMA_7cf99248-2363-4108-a81c-2cf11ca3f81f">2,915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItMy0xLTEtMA_a1e5d601-42a2-420b-9932-5727e1e2db64">21.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItNS0xLTEtMA_dea2e9cb-c13a-4c5e-9476-5dc311a3ea65">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItNy0xLTEtMA_136981a5-148a-4bcf-8201-073bee8c5e2b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItOS0xLTEtMA_106cd3ee-befd-4e38-88d5-4ed78a803515">1,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItMTEtMS0xLTA_23fe2671-7686-4260-a75b-4270ab36de7a">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtMS0xLTEtMA_db182184-6c90-4167-b1f8-5f040f9ba3a5">1,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtMy0xLTEtMA_d45f1854-722c-4ce5-a3d6-04b0c66c0ef0">10.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtNS0xLTEtMA_c6bf6545-9270-4f4c-8649-ea22a7d94816">965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtNy0xLTEtMA_c1746737-8141-42f8-8e62-6f0b14f412be">16.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtOS0xLTEtMA_5d8f53aa-91a6-41d8-b577-f5170eec0091">461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtMTEtMS0xLTA_1b89ed96-8509-441d-82ee-b491b955614f">6.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtMS0xLTEtMA_e6b40bbb-3500-4ef7-b4be-2a8d6e6e8d92">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" sign="-" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtMy0xLTEtMA_6f9765db-ddb6-4a51-a4f7-6ab2ea81bcae">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtNS0xLTEtMA_bbb402e4-880b-4303-9f7a-737e5c155323">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtNy0xLTEtMA_62e17814-7ca2-493e-8cd8-8d170d0baec2">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtOS0xLTEtMA_1d269307-3806-4b31-8e4c-3fbf83e4487e">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtMTEtMS0xLTA_6110a3b6-b45f-48fb-b9df-b6508b6917ee">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMS0xLTEtNDkyNjE_e66bb819-9201-4e3c-b617-1f4006d52cab">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMy0xLTEtNDkyNjE_dcb82e1c-2bdc-4be5-90ab-59af8dd9f16e">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtNS0xLTEtNDkyNjE_9333e974-1843-455d-a29f-83e16ea789ce">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtNy0xLTEtNDkyNjE_c03414a3-5761-4cb9-b8de-e4c63d707751">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtOS0xLTEtNDkyNjE_409f0613-de33-4d0e-bd86-189d409efdcf">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMTEtMS0xLTQ5MjYx_1fc1b0a3-8e20-4931-a3e2-351f62a9272f">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMS0xLTEtMA_b56c01c5-05ac-49b5-bb8d-3cd4f67321af">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMy0xLTEtMA_fb99ae27-3acc-446e-9b20-2e6a025d0d41">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtNS0xLTEtMA_e40f2e50-8a15-4c0d-a569-f7a372c34d81">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtNy0xLTEtMA_bf07db90-ff2e-4416-9641-2c06f6ac1d78">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtOS0xLTEtMA_374c873a-f5f7-4315-beb4-d44d84bcb23d">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMTEtMS0xLTA_ed6c0c55-db03-4ffd-9968-f8fb53da3e18">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMS0xLTEtNDkyNzM_6dcb171d-1818-4979-854a-206a07b4dddf">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" sign="-" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMy0xLTEtNDkyNzM_e3ba1c40-7540-4b72-8a97-a711df55efab">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtNS0xLTEtNDkyNzM_006bc606-0147-4f59-bd77-2d16fbf1d0e0">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtNy0xLTEtNDkyNzM_d3f1b4ad-9a65-4af5-837b-d0b92f375f55">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtOS0xLTEtNDkyNzM_84c3090c-6838-4ae4-92af-e219cc090e8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMTEtMS0xLTQ5Mjcz_381388ac-560c-4ce2-9240-e4d5138cd84d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Pandion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMS0xLTEtMTY2OQ_d9a58920-482c-468f-b2b8-e49a5730b22e">356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMy0xLTEtMTY2OQ_95eafa10-4f78-400e-a9fd-1e2374cdce4a">2.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtNS0xLTEtMTY2OQ_46da2efb-d693-4ca4-9186-80c999ddd9db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtNy0xLTEtMTY2OQ_a26e5f94-4613-40dd-9cb9-1aa65c449305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtOS0xLTEtMTY2OQ_ed6bfd1a-8100-48b9-9706-98875786ac75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMTEtMS0xLTE2Njk_2fda4481-c1c1-4cab-ae34-434976016f20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTEtMS0xLTQ5Mjg1_6961600e-8606-4659-a971-41e6527352a4">102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTMtMS0xLTQ5Mjg1_680944d1-0084-4a5a-b2d7-52db7c72465b">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTUtMS0xLTQ5Mjg1_130de4ca-0c5a-4ee0-af0e-733b39536efb">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTctMS0xLTQ5Mjg1_65c9fec3-9f96-4405-8c0d-5a9c85d1239b">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTktMS0xLTQ5Mjg1_1709c10c-741f-4715-8a1f-e2039a043ee0">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTExLTEtMS00OTI4NQ_2f13f3d1-aebc-481a-ac08-bb2a3d3724b3">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktMS0xLTEtMA_9016c46e-1bff-4614-ad42-44487d18ac7e">61</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktMy0xLTEtMA_e68610f0-7bc7-4fe2-b537-25b429a06434">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktNS0xLTEtMA_dac40042-7137-4e6e-a12a-a689d61e07bb">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktNy0xLTEtMA_f4b92ce7-cae7-4a11-a274-e9d73e06a7cc">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktOS0xLTEtMA_e0a3bf1f-60db-46a2-ac3d-689b9dd45e62">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktMTEtMS0xLTA_5f1d85e4-1722-4782-b7c9-b44a47895c11">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs, including amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTEtMS0xLTQ5MzEw_a332ee3f-ef4c-4101-b619-6b76831d0459">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTMtMS0xLTQ5MzEw_fbae032b-499d-4324-9a73-78e8be361c63">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTUtMS0xLTQ5MzEw_4dfac976-848d-47f2-a787-0b0e3b645d7d">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTctMS0xLTQ5MzEw_59d03240-33df-4391-b04f-12fdf19d29c5">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTktMS0xLTQ5MzEw_b99d0123-4c55-430f-af1c-2d1759cb41aa">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTExLTEtMS00OTMxMA_5b759042-a199-4948-8834-d29d3d0d130c">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTEtMS0xLTA_653e95a7-bff9-41fa-9a7a-9627427e777b">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTMtMS0xLTA_38f6b054-b700-4751-b37f-febb44446798">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTUtMS0xLTA_33679186-f08a-4023-adf7-8279988770ee">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTctMS0xLTA_ea0cd153-80fb-434c-a8be-3923701c6ce5">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTktMS0xLTA_c200221b-22ff-4029-8053-0f62201718c6">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTExLTEtMS0w_b6c26d2d-bed0-456a-9002-8581fe546989">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTEtMS0xLTQ5Mjk4_d1d6bb8c-fe64-4a1c-9693-777453ed0edf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTMtMS0xLTQ5Mjk4_637d6d27-86c1-4aad-b2bb-2811c5b0a278">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTUtMS0xLTQ5Mjk4_95e144c1-b4d0-4ba0-ab39-51e1d89c4c73">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTctMS0xLTQ5Mjk4_c1747532-1e0f-427e-bf25-d77db471be9d">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTktMS0xLTQ5Mjk4_b6fc7425-702a-4474-b818-5ac409e3e5ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTExLTEtMS00OTI5OA_e1abb610-3c48-4265-a699-741eb32c39d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Peloton</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTEtMS0xLTA_7af0b16f-659e-4742-9951-e91cb4b6b83b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTMtMS0xLTA_3f262efa-629e-4f00-bef5-7e16c5ca5cd0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTUtMS0xLTA_15b27ccb-b797-4328-b3ca-84c4f087e617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTctMS0xLTA_8112e593-9f15-4b8b-8a27-47805867cd93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTktMS0xLTA_9d2e8bdf-db9d-4a00-828d-925ccfbd0592">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTExLTEtMS0w_e70c4052-b378-46ad-8fdc-151f52f1a1a9">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTEtMS0xLTA_1484a5a5-7044-4163-9f06-ea5962ff8998">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTMtMS0xLTA_8fd6db13-a259-4554-941d-762368ade830">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTUtMS0xLTA_afd587bd-0faa-43bd-94c2-6826f3c12016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTctMS0xLTA_88febb05-6a3e-4c84-993e-17714781b5e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTktMS0xLTA_268197f7-ce74-4968-bb05-9fa82be42533">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTExLTEtMS0w_72aed657-54fe-4d7a-934d-bb5d059e004a">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTEtMS0xLTA_05358249-9bea-4967-8d04-4ccf714fc3a7">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTMtMS0xLTA_0b6b7080-8ab8-4ae5-8ab5-bf285e23353f">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTUtMS0xLTA_13405e45-b55d-4bac-aae9-3d8e7f240c45">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTctMS0xLTA_78d8a911-fca4-4a7c-b6fb-41c31a4d2c3b">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTktMS0xLTA_fb315186-c2da-4cc4-8946-3054d5b92a14">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTExLTEtMS0w_e6386dbb-440b-4841-993c-8a909d2ed164">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTEtMS0xLTA_07635374-7af8-4772-91cb-b14d5bec7001">1,521</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTMtMS0xLTA_5eeddc65-38af-4f52-b040-a6f412c00c86">11.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTUtMS0xLTA_994421e3-9ae9-4316-9c03-7aa0a63dc90d">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTctMS0xLTA_e0a125a8-1e71-402b-a25c-5eda61ecb67a">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTktMS0xLTA_a99298e1-8d38-46eb-9da5-6366cefb747c">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTExLTEtMS0w_bd0d3c16-5d0d-4890-9981-54467d42d224">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (TCJA) was enacted in December 2017 and the Company reflected the impact of the TCJA in its 2017 financial statements. However, since application of certain provisions of the TCJA </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="if0fe916dbff6438583ac98d69a61fdc5" continuedAt="icce35dbb3bc24337b126418a5a1c5a3e"><div style="margin-top:3pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remained subject to further interpretation, in certain instances the Company made reasonable estimates of the effects of the TCJA, which were since finalized and resulted in additional income tax expense in 2018 and 2019. The Company&#8217;s remaining transition tax liability under the TCJA, which has been reduced by payments and the utilization of foreign tax credits, was $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzY5Nw_28e028af-0a69-4517-a4e0-ffefd8ce0975">2.6</ix:nonFraction> billion at December&#160;31, 2021, of which $<ix:nonFraction unitRef="usd" contextRef="i4d3b1868b07e42d9beeb1de061d22b1f_I20211231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzcxNg_c4ee8365-a545-45f9-8b48-2dc38430257e">390</ix:nonFraction> million is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the remainder of $<ix:nonFraction unitRef="usd" contextRef="idb2506788d4645da9386ce90a8f1d696_I20211231" decimals="-8" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzc3Ng_80abff14-1c2b-4115-bed4-526d8fc317e0">2.2</ix:nonFraction> billion is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the U.S., particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2022), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. Beginning in 2021, the Company has an additional tax incentive in the form of a tax holiday in Switzerland for a newly active legal entity which is effective through 2030. </span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxMDc_663ca790-2e9b-4b61-ac3d-b1fb7b250409" escape="true"><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzEtMS0xLTEtMA_52c2324f-f604-472c-9e37-a878f09ee391">1,854</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzEtMy0xLTEtMA_4ed720da-27d9-47ac-9e29-f46ef3f9cad4">3,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzEtNS0xLTEtMA_2f7c4cb0-2346-4755-bf19-367c180b8cba">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzItMS0xLTEtMA_58402377-a96a-4f83-a67d-f02166e8e698">12,025</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzItMy0xLTEtMA_cea4b89d-f7a8-445b-bbea-795698dd1a4a">9,677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzItNS0xLTEtMA_db985a99-91cd-420e-ad37-3f55b898d61e">7,237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzMtMS0xLTEtMA_5175eb97-c23c-4287-90e4-199b33490ed7">13,879</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzMtMy0xLTEtMA_610645cc-1c14-4963-9e78-438471e13908">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzMtNS0xLTEtMA_5282d04b-1146-4299-aca5-dcc6573e0d6b">7,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxNDc_3de82cb6-585b-47a0-961f-0c5c8963d43b" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on income from continuing operations consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzItMS0xLTEtMA_1b051f2d-d271-4316-bd98-c3c4031d23b8">74</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzItMy0xLTEtMA_1d01cd02-19dd-46e6-b725-374e4778574a">893</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzItNS0xLTEtMA_0bf7f371-65d1-42de-9ddf-63372bea7df3">642</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzMtMS0xLTEtMA_0c1a5f72-22da-4b4c-b03f-60956f2dc2ba">1,273</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzMtMy0xLTEtMA_1dc2ba80-0aba-44e7-bca1-7c9de505ed16">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzMtNS0xLTEtMA_a1de0f03-2c29-49ae-bae6-ae3d755ddf56">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzQtMS0xLTEtMA_4ae85d5b-2583-455c-b59f-d2b4167c3134">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzQtMy0xLTEtMA_fcb3d9c0-57ad-4356-9bbf-0918bb3e86e6">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzQtNS0xLTEtMA_8bd9ca5a-0c69-4ac6-985c-17ac93538992">40</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzUtMS0xLTEtMA_f52a1df3-6d36-4aed-bdb3-de993a392cea">1,334</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzUtMy0xLTEtMA_10c4fe34-0358-4477-b3e0-7111d801dd3f">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzUtNS0xLTEtMA_1a699664-a424-4f61-b4fa-4b8707682955">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzctMS0xLTEtMA_cee73f1c-3a94-48d3-9fc0-a5316c976b93">240</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzctMy0xLTEtMA_27fcf8fa-9951-47ce-ac7b-d42a6f34748c">605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzctNS0xLTEtMA_280015ca-aaaf-4cdc-b018-661f33427d0d">328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzgtMS0xLTEtMA_b6310a05-93a3-4ed7-8a5f-3a27dab5e060">77</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzgtMy0xLTEtMA_20d65dac-5091-4bea-b5b7-ed5487b27775">64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzgtNS0xLTEtMA_c73df0e2-1c7b-44be-ad19-add4315ad3b3">228</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzktMS0xLTEtMA_0a0585e4-598c-4a3f-888e-4f46fbcb2c29">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzktMy0xLTEtMA_a83dabae-21de-4e44-aba8-9c8a3692dd67">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzktNS0xLTEtMA_c07df3e9-3036-4e4b-945e-9d4103db8b01">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzEwLTEtMS0xLTA_d0d4f814-b15d-4a32-8655-55cda0b5a2cf">187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzEwLTMtMS0xLTA_0e6aa497-0a17-46f2-b8cb-8a0e011e6cd4">566</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzEwLTUtMS0xLTA_344e6833-50c0-402f-b0a5-17c8ee5b1bde">560</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzExLTEtMS0xLTA_faa7d47b-3f0a-4a09-80bb-3346473c843e">1,521</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzExLTMtMS0xLTA_6b135077-9a0c-48ca-8d21-be4907e9e745">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzExLTUtMS0xLTA_c6367602-fd6c-443e-bdb0-162f69118f4f">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="icce35dbb3bc24337b126418a5a1c5a3e" continuedAt="ic4e660219c4d41f19a6d47f9b4eba242"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxMzE_ba5847b4-3b8c-4036-8ac7-85ab30bdf231" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzItMS0xLTEtMA_a647f506-0332-43b5-a0f3-41d57a092233">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzItMy0xLTEtMA_1aa0e1ef-5c2c-4f5e-b86b-5fa338c6e011">2,933</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzItNS0xLTEtMA_c00b095f-ba9e-44a3-8501-7677479490cb">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzItNy0xLTEtMA_a906a278-48cb-47ab-bb14-2d8839c6a769">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzMtMS0xLTEtMA_214e484b-d31f-4142-8b1d-c4baee6654f1">119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzMtMy0xLTEtMA_e21469a9-90a2-4854-8a72-6c20272504da">370</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzMtNS0xLTEtMA_16c73da1-98e5-4e6d-9803-58e8aa87e8ac">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzMtNy0xLTEtMA_9bea1d16-e0f2-44e6-9b27-a8ebd83260d9">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzQtMS0xLTEtMA_22193a81-3e3a-447c-a7f1-81c23edea0bb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzQtMy0xLTEtMA_2e8c3037-4d65-488a-b18a-a1f533254b44">589</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzQtNS0xLTEtMA_73ce7d3b-f556-4b67-80de-961616128366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzQtNy0xLTEtMA_0747aabd-039c-486e-84e6-b9d8c8f9c769">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzUtMS0xLTEtMA_08f9760c-42c1-40d7-9d00-9b8c45af24c0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:DeferredTaxLiabilitiesEquityMethodInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzUtMy0xLTEtMA_6247c2fc-f7de-4744-b620-2df33753cdfb">335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzUtNS0xLTEtMA_b395ba29-ba0d-49f4-a594-9f1a7523d725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="mrk:DeferredTaxLiabilitiesEquityMethodInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzUtNy0xLTEtMA_2731bc52-308c-4bd3-8493-46076a4a51d2">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzYtMS0xLTEtMA_91af133c-df5c-4a01-8dc9-06fada664f05">487</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzYtMy0xLTEtMA_958cf0a0-4e21-4ded-ba6a-119b13abfe53">338</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzYtNS0xLTEtMA_43b01109-c264-4d96-843f-753f3bda5433">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzYtNy0xLTEtMA_1689fb8f-7a0e-4d9a-87c4-17c27553492e">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzctMS0xLTEtMA_19108cfa-b5de-4ba8-8b81-c4dedb4aa6b5">301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzctNS0xLTEtMA_b101b9e4-98e0-4f3e-8423-3ac9961a024b">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:DeferredTaxAssetsUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzgtMS0xLTEtMA_bcd2bd4f-961a-423f-9383-295c662dea82">75</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="mrk:DeferredTaxAssetsUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzgtNS0xLTEtMA_3989c752-2b08-468f-9fac-c01b83e02d8d">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzktMS0xLTEtMA_5edb47a1-a6e8-4c3e-a47d-b815eab46eb1">867</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzktNS0xLTEtMA_56880cfd-f51b-4805-8e2b-c334e22f8f51">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEwLTEtMS0xLTA_31a126a3-f101-4c8f-b1b8-b6888f4be73b">434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEwLTMtMS0xLTA_e63e2475-c9f0-46f9-9411-a4028a326872">180</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEwLTUtMS0xLTA_404c0930-b3bf-4f8e-a7f2-2208e70f862c">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEwLTctMS0xLTA_4b4735f6-82e6-4ba6-b0fb-d91d55035873">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzExLTEtMS0xLTA_bc2ccfa5-b7b3-485a-ad37-20bc66251714">2,283</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzExLTMtMS0xLTA_8e86f4ad-2ea2-47bd-a353-89fa833b1f65">4,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzExLTUtMS0xLTA_3e3ae5a1-a4f1-4258-b9a1-2e9d1d30fee1">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzExLTctMS0xLTA_9b737c8d-2958-4863-aecd-655f6586d662">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEyLTEtMS0xLTA_128e820c-ce5b-48f7-953c-eb6afe4d47ab">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEyLTUtMS0xLTA_9eecf7c0-24dd-4c97-a2b4-bf17ebbc3700">404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEzLTEtMS0xLTA_2f9fb38e-02ad-45a5-b699-917d3dcaee6f">1,996</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEzLTMtMS0xLTA_521af7eb-7d19-42c7-8531-fbc4383e3d6b">4,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEzLTUtMS0xLTA_b219dd43-a071-43d3-a65b-79e54e338c18">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEzLTctMS0xLTA_45a2ca69-08b0-44b7-842f-88b44c8b40fa">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE0LTMtMS0xLTA_b5bf8743-9c5f-4c5d-84f6-c811729f5e52">2,749</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE0LTctMS0xLTA_62c63990-7f2b-4598-9712-b0b39313fdb6">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7418d8deee94241a890cc5e06e3fb35_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE2LTEtMS0xLTA_6caf8411-55df-4c85-acae-766ab3e8ee2c">692</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412ceb3578cd4323882f96bffbb8f4c0_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE2LTUtMS0xLTA_5ced279d-4c95-445f-bd99-f4c4cfc55d95">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE3LTMtMS0xLTA_19d464b8-a68c-4c21-aeb5-a367ef612cf1">3,441</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE3LTctMS0xLTA_088e2894-e3aa-4af6-a20e-1a49f87e3ccc">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzIxMjM_5684a7d1-d5b0-410c-b2b6-8bcb7ffd6577">181</ix:nonFraction> million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="iee0d42255922420582e8788d38817637_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzIyMjI_0b8c9171-b212-451c-b2e1-4cc2a1271ccf">164</ix:nonFraction> million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzIzNTA_3c090196-51c6-4f70-b671-dc97271d78d4">686</ix:nonFraction> million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards. Valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="id6a9a13cd0a149fd8df342c997fb0ade_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQzOTgwNDY1MjUwNDQ_02d26574-b748-4372-a1a4-5136913f3c66">123</ix:nonFraction>&#160;million have been established on these U.S. tax credit carryforwards and NOL carryforwards. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid in 2021, 2020 and 2019 (including amounts attributable to discontinued operations) were $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI1NTM_f66cc417-45fc-4519-ba71-260f76ff7fdc">2.4</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI1NTc_656bd658-26dd-465d-b998-d7762b3b71ba">2.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI1NjQ_fef4642d-6b8b-4963-b5a0-87dcbaea9c32">4.5</ix:nonFraction> billion, respectively. Tax benefits relating to stock option exercises were $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI2MzU_dc1fe04e-7fb5-415a-bfaa-b9e0a1ad539c">21</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI2NDU_7bff5d9b-3a39-4554-9096-43343bc4bd5e">12</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI2NTg_2406a41f-90f7-4225-968e-9454fff63b28">65</ix:nonFraction> million in 2019. </span></div><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxMTc_1927e46e-3972-402a-9290-b28ac8b6948d" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzEtMS0xLTEtMA_2d5543f8-da22-4048-bcb4-e70b6992fd27">1,537</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzEtMy0xLTEtMA_644c64a9-6fef-4daf-956e-ff27f3ac7191">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b25cba6160a4486b14740ddd2b481ef_I20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzEtNS0xLTEtMA_f10e7044-ef34-4199-a1f8-cd73435eb89e">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzItMS0xLTEtMA_1af0b8c6-bcb8-4f9a-b0f0-d5fbf7e4313c">306</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzItMy0xLTEtMA_ce174669-620b-4787-ad73-eee68de2d560">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzItNS0xLTEtMA_c55203bb-aa30-455a-8996-e2f5e703149f">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzMtMS0xLTEtMA_e3b302bc-00ad-44d0-b204-b7838ac4978d">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzMtMy0xLTEtMA_20300c47-62b3-48db-aae2-27cb2d06c6bb">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzMtNS0xLTEtMA_88f5b517-a5ef-408b-8df8-92bc304b42ee">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzQtMS0xLTEtMA_de98c83e-24c6-4ce3-bd95-65dd724c11f3">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzQtMy0xLTEtMA_befada82-180a-471e-9f00-0b08a91b3d29">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzQtNS0xLTEtMA_88745945-43fc-4391-a352-32d024b1a0fb">454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzUtMS0xLTEtMA_514f4c95-3492-4d10-9251-d84d069bfd98">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzUtMy0xLTEtMA_9ace67b6-3896-4891-9f03-82983135ff0c">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzUtNS0xLTEtMA_3a38aef6-bf27-45ad-93dd-4924c9647230">356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzYtMS0xLTEtMA_52bff443-c097-4e86-93eb-2aa86fed6aa8">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzYtMy0xLTEtMA_a0dde91e-cd66-4543-ac2d-7e23209c2160">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzYtNS0xLTEtMA_e4f25c27-d971-42c3-a6a7-ed6f6646c300">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctMS0xLTEtMTYzNw_dfbdfaaa-1a08-45c4-a807-1f2d1a2d81a9">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctMy0xLTEtMTYzNw_9b760063-c7e7-4810-aadb-356bb338f9c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctNS0xLTEtMTYzNw_3038acb8-c1b0-4be8-8c6b-4399b19df6c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctMS0xLTEtMA_207f5f4b-67cd-4a20-8ac4-8f18f69261de">1,529</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctMy0xLTEtMA_4de47856-1774-4720-9adc-7517cb0e0bf2">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctNS0xLTEtMA_b90be423-cc1b-4def-b608-a422335f09e6">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Amounts in 2021 and 2019 reflect settlements with the IRS discussed below. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  Amount in 2019 includes $<ix:nonFraction unitRef="usd" contextRef="i622d15e154f84cc28b01ef17d5fe85b8_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI4NzE_305ce2f1-f729-4aa2-b104-0e28bf84e926">78</ix:nonFraction> million related to the divestiture of Merck&#8217;s Consumer Care business in 2014.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to recognize the unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzMwMTA_6cb22867-bdfe-4bfe-9915-de6ca6c439b7">1.5</ix:nonFraction> billion at December&#160;31, 2021, the income tax provision would reflect a favorable net impact of $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzMwODU_695cabf8-5883-4797-a023-d1caabd10d10">1.5</ix:nonFraction> billion.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December&#160;31, 2021 could decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzMzMzY_0b2a1b6c-c818-4f7d-8154-4e4d4c082693">11</ix:nonFraction> million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company&#8217;s </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="ic4e660219c4d41f19a6d47f9b4eba242"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties associated with uncertain tax positions amounted to a (benefit) expense of $(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzM5MjM_f03710cc-8a9a-493a-b255-675aad0afd9e">37</ix:nonFraction>) million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzM5MzM_dbb64edc-b82c-4924-9e4f-cd940fc05995">16</ix:nonFraction> million in 2020 and $(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzM5NDY_948d91d7-1e9f-47b5-9e47-92b1b28475fc">53</ix:nonFraction>) million in 2019. These amounts reflect the beneficial impacts of various tax settlements, including the settlements discussed below. Liabilities for accrued interest and penalties were $<ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQxMjM_247743f6-861d-4664-8dc0-99998a438488">192</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQxMzA_5e5c1114-519b-47ed-b6f2-09683c6908f5">205</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $<ix:nonFraction unitRef="usd" contextRef="ib84dc814a0974bf0836891662899fabc_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2Mzc0MjE_0f73e45a-b55b-4fae-8a39-01fd27db0dd9">190</ix:nonFraction>&#160;million (of which $<ix:nonFraction unitRef="usd" contextRef="i9efea9cf6b604686982b9cdfac42f3df_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcwOTQ_6f9de2f1-4374-4bca-ae2f-7a16d9051d75">172</ix:nonFraction>&#160;million related to continuing operations and $<ix:nonFraction unitRef="usd" contextRef="i76e98608767a40d2a24b489eafd3e853_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxMDg_7a4467f1-8a13-422f-8ff8-358edaf105fe">18</ix:nonFraction>&#160;million related to discontinued operations). The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="ib84dc814a0974bf0836891662899fabc_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2Mzc0NDM_8a1c34d5-4353-429e-9fd7-6b12f4b2cbc4">236</ix:nonFraction>&#160;million net tax benefit in 2021 (of which $<ix:nonFraction unitRef="usd" contextRef="i9efea9cf6b604686982b9cdfac42f3df_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxMzU_402b2749-285a-4bf9-b481-9a3b4e4aa8bf">207</ix:nonFraction>&#160;million related to continuing operations and $<ix:nonFraction unitRef="usd" contextRef="i76e98608767a40d2a24b489eafd3e853_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxNDk_84aff1a6-f7a1-490f-92eb-aa69539f1ac6">29</ix:nonFraction>&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the IRS concluded its examinations of Merck&#8217;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $<ix:nonFraction unitRef="usd" contextRef="i9158afc2f18a4d47b2a3ce049a91f164_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQzNDg_6ebe03b2-8a52-4d5c-a5c9-2fbec2437670">107</ix:nonFraction> million (of which $<ix:nonFraction unitRef="usd" contextRef="i85b88606a448480e91ccbb985a641950_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxNzY_1e782943-3443-44e9-aba1-52a3a5ae6d56">142</ix:nonFraction>&#160;million related to discontinued operations with an offsetting credit of $<ix:nonFraction unitRef="usd" contextRef="i836d57ab500a430aa624c66b51480417_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2NDAxNjE_f42f4952-4eb7-4019-9049-f278c638dae9">35</ix:nonFraction>&#160;million related to continuing operations). The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i9158afc2f18a4d47b2a3ce049a91f164_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQ1MzU_b6eeef64-ecc7-40f1-9774-11bad80b59aa">364</ix:nonFraction> million net tax benefit in 2019 (of which $<ix:nonFraction unitRef="usd" contextRef="i836d57ab500a430aa624c66b51480417_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxODk_63b1c048-427e-41ca-9d3c-3641facb83f7">106</ix:nonFraction>&#160;million related to continuing operations and $<ix:nonFraction unitRef="usd" contextRef="i85b88606a448480e91ccbb985a641950_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcyMDM_d0d4f1da-ec42-4fa7-a488-f688f33e3ea2">258</ix:nonFraction>&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS is currently conducting examinations of the Company&#8217;s tax returns for the years 2017 and 2018. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company&#8217;s income tax returns are open for examination for the period 2003 through 2021.</span></div></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_193"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzQxMg_1b4f4639-b681-4402-a892-b5957ef4e9c2" continuedAt="i3651dcda9345435bbcfb371c0a9c366f" escape="true">Earnings per Share</ix:nonNumeric></span></div><ix:continuation id="i3651dcda9345435bbcfb371c0a9c366f" continuedAt="i7d70d01579df407991261a28e3d1d426"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzQxMA_b4d494b6-184a-4817-9dff-ca037ea76457" escape="true"><div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMS0xLTEtMjYxNw_bc76a1c0-708e-4cc0-9b1d-69938feddf50">12,345</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMy0xLTEtMjYxNw_4fb43007-43f2-467d-9dee-dddc2362836c">4,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtNS0xLTEtMjYxNw_96d51feb-1bdb-4388-a7a1-7e06d32ea4bc">5,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItMS0xLTEtMjYxNw_13d726d8-5f13-4dee-b91c-d73a00cdda15">704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItMy0xLTEtMjYxNw_6b187f57-ff85-4766-ba5c-1019ebb5ecf7">2,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItNS0xLTEtMjYxNw_071bc1b1-1b5d-42c7-9c0f-42466110c482">4,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMS0xLTEtMA_71002ff4-7b68-45fd-be28-ca3b6c916890"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMS0xLTEtMA_abd68b94-daa2-49e7-898c-886b5ef8dcc0">13,049</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMy0xLTEtMA_809c44a2-7ea3-4885-8947-30bdc5405eb3"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMy0xLTEtMA_d2211447-67d8-450f-b05d-c81467147f44">7,067</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtNS0xLTEtMA_361c2733-ddb9-4f70-b923-cdba8a3ac951"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtNS0xLTEtMA_a8e5780d-c56d-48ed-a73f-3faf0cb266e9">9,843</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItMS0xLTEtMA_1fb0fd7c-3437-4a7f-9c13-04ef5f334d84">2,530</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItMy0xLTEtMA_f7a53062-9d6b-4597-b4d9-34e96132c1c4">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItNS0xLTEtMA_70da1ad6-5cf5-4bf5-a8c6-bff4dbd4ca86">2,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzMtMS0xLTEtMA_275273fd-f976-49ca-8456-e839edfcd92e">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzMtMy0xLTEtMA_73ab96fd-9494-4d95-a611-a59595e71d2f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzMtNS0xLTEtMA_45f2dded-25f2-4421-ac8b-c226e9cf5801">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzQtMS0xLTEtMA_0c1b21e7-7622-47c1-9e45-d733c5300b77">2,538</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzQtMy0xLTEtMA_d5568e4e-3fa0-4b5b-bfbf-017f01894eaf">2,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzQtNS0xLTEtMA_d675bb72-ff86-4ca7-8d52-8b632e111e88">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzgtMS0xLTEtMjY2OQ_f4c8db26-408b-4c06-b3ab-aafcc8ac1ff1">4.88</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzgtMy0xLTEtMjY2OQ_9196e04c-874d-494d-b17f-369595bb3fdf">1.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzgtNS0xLTEtMjY2OQ_22f572fe-5b91-4bd4-8433-cc26345d8f39">2.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzktMS0xLTEtMjY2OQ_a84d6cc8-524d-437f-adad-ad4496372541">0.28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzktMy0xLTEtMjY2OQ_8238c10c-911d-4647-b22b-272545b5165e">1.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzktNS0xLTEtMjY2OQ_d4322ec3-cebb-45a4-89d3-bb6e843f9bb2">1.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzUtMS0xLTEtMA_bffea7c9-ca5d-4482-b02d-63af78b5d808">5.16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzUtMy0xLTEtMA_8368a061-8edc-4015-8125-1b2812c068b9">2.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzUtNS0xLTEtMA_5944e4db-065d-4fc1-9caf-9d82cdd71277">3.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEyLTEtMS0xLTI2ODA_f27c45d5-52c0-4d3d-a404-af66459e6c46">4.86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEyLTMtMS0xLTI2ODA_4461c86c-dca2-49b1-8da5-4c10e826cd52">1.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEyLTUtMS0xLTI2ODA_4d964f51-ef75-4d92-a115-d9306ba0bbff">2.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEzLTEtMS0xLTI2ODA_33fd902d-0b7f-4f71-bc89-27ecd2b3050d">0.28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEzLTMtMS0xLTI2ODA_3b99722e-fd66-4dbe-99f0-09b154114720">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEzLTUtMS0xLTI2ODA_711a9753-2743-4f62-8d22-f3428854befa">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzYtMS0xLTEtMA_e18faf45-64f4-44ff-9097-a070227e7d71">5.14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzYtMy0xLTEtMA_7a0f6a1f-7961-4aa7-878f-6c3320c47b2b">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzYtNS0xLTEtMA_096a1e54-829f-4bcb-883b-99bb4b90f4b9">3.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7d70d01579df407991261a28e3d1d426">In 2021, 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzE4OQ_cae79c11-d9ac-419f-bdba-284d08de7554">9</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzE5Mw_fc9fbf45-623a-49dd-8bc3-0cbcd9f6b594">5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzIwMA_835f7517-c434-42ea-8316-163dec4878bf">2</ix:nonFraction> million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</ix:continuation></span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_196"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzg4Nw_08e78c9b-3385-431a-8991-969620edc339" continuedAt="i92335db8775a4299b31e95f840738878" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="i92335db8775a4299b31e95f840738878"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzg4Mw_f0237706-6413-444f-97d9-f9680f39f53b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:37.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.903%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1, 2019, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67716ab8d95d41c1918c1fd2f92b31b0_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtMS0xLTEtMA_78f8df45-6bf7-4b5c-ad06-4d332756f6cc">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53553e2c388c408a80697cd5600f2014_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtMy0xLTEtMA_3e2235a6-417c-463c-ad64-70fd2dd11e60">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a24da076c044d1fa1d2d467928316c3_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtNS0xLTEtMA_2b93ea78-f594-4fa5-bd4c-1a9b7750b22d">3,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2d1a929ea734ccb8df8f7b64219510e_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtNy0xLTEtMA_5394e905-e029-4a74-b5bc-26567195f784">2,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd9336867cce49919c9a776ee62bc1b2_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtOS0xLTEtMA_bc043dc3-150a-4f40-ac4c-e8401413fae9">5,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItMS0xLTEtMA_72cf5024-760a-484d-9567-ca69e017c223">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItMy0xLTEtMA_c5f2eecb-a494-4459-a002-67a0df8e5e76">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItNS0xLTEtMA_a60d98eb-1ebc-4ea2-a774-21611d636e9b">948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItNy0xLTEtMA_3d9324b4-6fae-45d3-87ae-dc1bfc44b21d">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItOS0xLTEtMA_edf9b032-ffc7-4286-a37a-797b1da0af19">610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtMS0xLTEtMA_000f91df-355f-4fc8-bf55-b05e31454f11">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtMy0xLTEtMA_e853b3e4-8a2a-4f80-99b7-e9387c7160c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtNS0xLTEtMA_bb6708c3-2f3f-430f-8eac-4801e1c2b7c6">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtNy0xLTEtMA_e871b54d-8998-485c-838a-8c9f4d50bebb">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtOS0xLTEtMA_a8d48722-aebc-4c3f-a3d4-c6ea56aafb6d">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtMS0xLTEtMA_cf1822bf-9051-4629-a7f0-f428153588c9">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtMy0xLTEtMA_0635beec-22de-41ed-852b-2aa208d26237">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtNS0xLTEtMA_da5ddfb3-026c-4708-9d4e-d3009bdb5fc2">756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtNy0xLTEtMA_5a479b89-1320-4faf-9189-7e630b7a8bfb">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtOS0xLTEtMA_18dcfb75-393f-4d98-b2e7-808a92cd8bad">449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtMS0xLTEtMA_6c5002bc-50d1-4872-bbbb-ad1a769d01f1">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtMy0xLTEtMA_a2fe5085-f6a5-4694-85f5-2e278806e5c0">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtNS0xLTEtMA_7800263b-33fc-4685-bf21-905b2f99dc38">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtNy0xLTEtMA_21affa4c-203b-4b4f-b8c2-5796999961ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtOS0xLTEtMA_63b5f7e6-3a76-46d3-b815-1e1839da4a84">239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtMS0xLTEtMA_f1578265-1e5f-4580-8faa-f1bebba37bf2">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtMy0xLTEtMA_b09f705f-6ae0-47a5-8902-06b141fc77c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtNS0xLTEtMA_285ef4fc-4c82-43d6-9bd5-18dcef39be0f">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtNy0xLTEtMA_81453916-fff5-4471-9683-05bce24f88b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtOS0xLTEtMA_2c04ceff-9e2d-4a58-88d7-c3bd7d2da359">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctMS0xLTEtMA_e442fc1d-6532-4d7d-a0d9-7ba359fa51fb">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctMy0xLTEtMA_e12569ee-c68a-457f-9a73-e14ec6b291eb">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctNS0xLTEtMA_96a7679a-e4f0-4ebf-a7b0-aa641ec1ba54">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctNy0xLTEtMA_3210f7fb-bd2c-48be-aa39-4b8d1d6f6cc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctOS0xLTEtMA_bb54e9ec-d263-4e8d-9549-2f8352628c86">199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtMS0xLTEtMA_c4d807d2-5947-44e6-a788-fe86c267e7fa">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtMy0xLTEtMA_a8242371-fefd-4538-84a7-667e3f234df9">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtNS0xLTEtMA_678fc666-0e2d-4f6b-9b2b-03012154f659">705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtNy0xLTEtMA_ba51b495-7578-4fff-a534-9901326474a2">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtOS0xLTEtMA_b964b7a4-1c49-4fbb-a07d-7ddfb07a3c29">648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e3b8b15d7e64a8f9877988ce4a10017_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTEtMS0xLTA_c3104c33-d764-467d-a18d-7822129f29dc">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i125b2cdaed7c4239afe4d7fce006c0b6_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTMtMS0xLTA_657e7102-d90a-4c0d-a6a0-5e9dd4fe2df1">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c54f5a5a29a410190d2348b3cb74190_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTUtMS0xLTA_fcb78633-2dd7-435f-a82e-7fc143a965ff">4,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice3199f2dd06439293c869fd20ba1ae5_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTctMS0xLTA_974d9670-3dee-496b-9fea-3d5ad892b1cd">1,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a458b3d31d042a4bb104dc181064e79_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTktMS0xLTA_6f2e51b4-52a2-4195-ad71-84d606a01685">6,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTEtMS0xLTA_3643a781-96b9-4a46-a982-f42fb9012d19">383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTMtMS0xLTA_1c22251f-804f-47db-8bc9-389a96fa84bf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTUtMS0xLTA_db35597c-9bc4-4aba-bb33-b15ad48e9375">599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTctMS0xLTA_23e86e10-171d-40d6-af8f-cd7477bc7a22">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTktMS0xLTA_c62f67bb-79c0-43de-8ed5-c8e597238cf0">915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTEtMS0xLTA_154539e0-47db-406a-bc45-09052720bb6f">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTMtMS0xLTA_e12785a9-84d5-4e26-b098-f8148ac7aa0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTUtMS0xLTA_86e8be02-cbb4-42f1-90ae-5b214b4727a5">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTctMS0xLTA_b6289a5a-4829-4fc3-96b8-460adb7b6196">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTktMS0xLTA_28aab6c3-0b30-4d4b-a3a4-ee6cd033bc75">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTEtMS0xLTA_29faf566-eb0b-4ca2-8ce9-a9e5fc6c4b6b">299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTMtMS0xLTA_92d3f5f7-d610-4288-897d-2ed5f43a9158">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTUtMS0xLTA_f9aa1777-9136-416f-80b6-809ee0aa465a">488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTctMS0xLTA_ea772fc7-baa5-4061-9a74-102f1cbcf423">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTktMS0xLTA_f560f966-d0d5-4ef2-8f24-e314a7d123ee">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTEtMS0xLTA_fd1636f6-720a-4898-b81b-b0eb7a4624da">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTMtMS0xLTA_a9710a99-70a5-4b98-857f-622e0e8cdabd">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTUtMS0xLTA_e89e1d0c-f94d-4764-9f67-160b264bcca2">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTctMS0xLTA_f18a7278-d0c1-4bfe-8eb2-3553e9b57d5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTktMS0xLTA_b5cfdbca-9c57-4774-903a-0925c399b001">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTEtMS0xLTA_563cb772-14a6-4009-9a19-a4f30750125a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTMtMS0xLTA_24edc921-6f51-47c6-98fc-d568f3d139b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTUtMS0xLTA_3dba9e0d-52a6-4149-aa72-af41222f09d6">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTctMS0xLTA_6aead144-35b2-4228-8e17-3a6dc895a728">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTktMS0xLTA_7423628d-7ad5-46b4-930f-6ffc182bd13a">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTEtMS0xLTA_2f1fd112-d46f-4829-ab09-c7cd5add1fea">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTMtMS0xLTA_44fa7876-ca6a-452c-a180-b869b74730a2">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTUtMS0xLTA_f33cea2e-c1c8-4559-b24b-4b4eac1474c3">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTctMS0xLTA_94c7dcc8-07be-4eef-948b-5c03767aa2ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTktMS0xLTA_cc1622bd-79a4-4eb9-908b-57d6a71dae85">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTEtMS0xLTA_1427a760-8854-4865-a5f6-c64ac06e4458">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTMtMS0xLTA_c386931d-93fb-4173-85d5-ba7c3d489f0d">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTUtMS0xLTA_e7afe2fc-1474-4e62-8c8c-5727cda5a3ce">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTctMS0xLTA_0c091807-5ee4-40f8-a85f-a26aeee5f1b7">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTktMS0xLTA_66c16e03-dc53-40c6-8599-9851a09acf27">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id16d9426fdca4a16a4bd46315c4d4084_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTEtMS0xLTA_869c15c1-f68d-4ea3-96ff-0db7e43d40bd">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4063360a866a4d7484c9f7904b09eb53_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTMtMS0xLTA_dd05d0b3-25a9-4731-a7f6-ca2db73ea229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6168466248344c884d7d9bc139939b7_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTUtMS0xLTA_20fda646-b0f6-496c-ae4b-8a95be8f1202">4,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i615fa016c2ed4e2383a651cb2aab2822_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTctMS0xLTA_9c21e43e-06d0-4f2e-b43d-560f19f1096c">1,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d1f8e2c09b84254b99b8e105564e52b_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTktMS0xLTA_654baa7a-9d6c-4aa5-816f-180c594fd015">6,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTEtMS0xLTA_56126825-6d76-4adb-9996-49c1cf9b4a69">333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTMtMS0xLTA_deb5f48a-77bb-4123-a6eb-506b3bc94fa0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTUtMS0xLTA_9db1b2cd-5bcf-451f-b8a1-849883d9e18d">1,922</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTctMS0xLTA_d807e7a8-f51e-4006-b32c-0512074da53b">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTktMS0xLTA_feb80543-c985-4032-9203-5db8ea3cebf4">1,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTEtMS0xLTA_044e26b4-03f9-4d12-9ee8-cb94af3941ca">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTMtMS0xLTA_dda6de81-3a39-4ddf-afcd-f161856214f9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTUtMS0xLTA_83cfc017-daff-466e-a7c5-5e183f3df7db">374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTctMS0xLTA_3729d69e-4980-4e91-9728-ff1fc1aafaaa">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTktMS0xLTA_6527a93f-2047-49bf-a4f2-54a626fb8147">568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTEtMS0xLTA_54e2e12f-6b5c-4efe-a65f-195d061f525e">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTMtMS0xLTA_705cdf35-da43-4697-9624-0ca8229f7490">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTUtMS0xLTA_e46f1050-c5ed-4b24-8746-426ba8c5f370">1,548</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTctMS0xLTA_c10aab31-f8ab-4ead-8b3a-1067072d0a49">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTktMS0xLTA_8575c02c-1f22-4346-afbc-4740e215880c">1,383</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTEtMS0xLTA_3cce5baf-e290-4ed5-9f39-7e82251271ff">192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTMtMS0xLTA_870432c4-6fee-4d9c-bc53-459d07d9321a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTUtMS0xLTA_ff02d74b-458b-490d-8b91-e43532e2841d">281</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTctMS0xLTA_9bd1fac1-64e9-47df-91fe-8a1a9c2418e3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTktMS0xLTA_07454ec0-0b71-437e-8b1e-5345b6501022">473</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTEtMS0xLTA_dec82d33-a460-48a7-9cd2-49c7e0a61720">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTMtMS0xLTA_4d83fa8a-9a5e-4ee6-b82c-3e4e7fd6a720">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTUtMS0xLTA_f3864d89-0b08-44ef-bed9-75b3923ef592">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTctMS0xLTA_5dc209bd-5174-46f2-b96a-a680aa593543">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTktMS0xLTA_772a7db9-772c-4ca0-9689-2acf2bea59de">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTEtMS0xLTA_978cc457-84ef-45b3-a181-7d7db4e231b0">152</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTMtMS0xLTA_54d6b99a-830f-4312-a81b-f17cfb22fff6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTUtMS0xLTA_4e37128b-0e60-40a3-ab86-ca2e83c56486">221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTctMS0xLTA_b0112a67-821d-4ef2-b954-c625baef60b9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTktMS0xLTA_cf203b4a-7f50-4db7-badd-3f15e54eaa03">373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTEtMS0xLTA_199cf0a4-da60-46f1-b23a-e37aafb72e43">410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTMtMS0xLTA_2547ed7c-2d15-4e12-95f3-af190b97850d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTUtMS0xLTA_7b9fd023-09cf-4ad6-9839-ea9b16b727c4">1,769</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTctMS0xLTA_13ea3c1d-1945-47fd-9308-29ce3a1a8275">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTktMS0xLTA_a588a368-a852-4f67-907c-5694225f0601">1,756</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Spin-off of Organon (see Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTEtMS0xLTIzNjc_ceb4c190-225b-484c-a17d-77cddbebaf91">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTMtMS0xLTIzNjc_8b825570-96b8-47ad-9f50-ffb37a8976e9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTUtMS0xLTIzNjc_9c2bc582-6fb5-4398-bf3c-6fc02a7710c2">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTctMS0xLTIzNjc_eb12cea5-07af-45c1-bdaa-c9700f24feb8">421</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52711b1bf6764fd78c0ef6f9e7df950f_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTktMS0xLTI0MTM_abc4959d-2ccb-4ec0-bbbe-a1a0aabfcf79">449</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92ec4a36cf94e91ae66e6a887ecd413_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTEtMS0xLTA_112db5e6-85aa-4786-8570-2e0321c4a334">144</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192fe0af931a48ed803ea8f1c256afe9_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTMtMS0xLTA_8effd6fc-387b-4fc6-bde4-f624af069335">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf472479cca849d1b21d8c0dc0ed9d69_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTUtMS0xLTA_052602ca-04fc-4e5f-b900-72bbc8387cef">2,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb6c7a465398473797dd31962d89b8c9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTctMS0xLTA_512c3d43-76e8-4cfc-85cf-d46622e8fc27">1,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i333ee6c0baa94ce7a67cc850a8d3a772_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTktMS0xLTA_3af9b8b4-42ec-4643-aedd-5370b8607724">4,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 14).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $<ix:nonFraction unitRef="usd" contextRef="id9f5696787284d468844d796e307282b_I20211231" decimals="-8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzUxNQ_6f8c008f-9025-483a-8111-31de57de552b">3.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i306e82501fa8410bb91080177d50d682_I20201231" decimals="-8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzUyMg_02d88d9b-c021-4dbc-b5b5-2b288176794d">5.4</ix:nonFraction> billion at December 31, 2021 and 2020, respectively, and other postretirement benefit plan net gain of $<ix:nonFraction unitRef="usd" contextRef="ib425c1e1a40c4df8944d884d3d307ad0_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzYxNg_3a35ecd1-13ab-47ee-af11-7c6b8b5909de">473</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i924ea9183ae449d796b1a0a7b05f0e67_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzYyMw_35188569-0527-42c6-9955-00abe0f283df">391</ix:nonFraction> million at December 31, 2021 and 2020, respectively, as well as pension plan prior service credit of $<ix:nonFraction unitRef="usd" contextRef="if225d2f0b77c4d51944e158ac6b67edc_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzcxNQ_d1fde680-352e-467f-adbf-22548a0464cf">190</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a311768e0b74998947f7049aaba9c79_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzcyMg_7262ae94-f656-4cfb-910b-4b1256fcf855">255</ix:nonFraction> million at December 31, 2021 and 2020, respectively, and other postretirement benefit plan prior service credit of $<ix:nonFraction unitRef="usd" contextRef="i8de7afcf6cd04006ba705dd72d2915dd_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzgyOA_5738e142-8e94-4798-9af9-862c852ea20f">181</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia855c9dc8c7e44ce9dc6bc2b51ed6d1c_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzgzNQ_f9fb6998-bc9d-4f45-8ca2-d08b7eedd8cb">244</ix:nonFraction> million at December 31, 2021 and 2020, respectively.</span></div></ix:nonNumeric></ix:continuation><div id="i1e1e934bfffd457891fb6e33dae50d64_199"></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NjI_f3800733-aa45-4e42-bcfd-4d4879b18796" continuedAt="i2c472229b70649bcbb7a98528858682e" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="i2c472229b70649bcbb7a98528858682e" continuedAt="i619ab650ec5d4442a1df00212bc62c11"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a products basis and include <ix:nonFraction unitRef="segment" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzExMg_7275f4f7-3683-45e4-961b-f351e907f254">two</ix:nonFraction> operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S.&#160;government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2021, the amortization of intangible assets previously included as part of the calculation of segment profits is now included in unallocated non-segment corporate expenses. Prior period Pharmaceutical and Animal Health segment profits have been recast to reflect this change on a comparable basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i619ab650ec5d4442a1df00212bc62c11" continuedAt="i1a0adc1727df449ca36882d0166543cf"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NDY_f8f7e7db-ff52-4df2-922b-5feab041fbd6" continuedAt="i3e8d28cc3f6c4ce98f516e9b7a39b904" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:30.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0fabdbe30d4ec8b1cd71e2cd64c3ea_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMS0xLTEtMA_2023e1e5-c3f3-4f3a-9549-eb987d8c2f66">9,765</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c80f2ba2ae4750bb0b2f180be80c68_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMy0xLTEtMA_49cbb339-6d2b-405a-85bb-9268f5043dac">7,421</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a1ce584193c48a6b0103a7644f7ef6f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtNS0xLTEtMA_8b6c5fd1-8653-48c3-a5e9-5de96838cc65">17,186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54db7d5cebb4ef48b74f960b41c1c27_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtNy0xLTEtMA_4e2ddb3f-8b24-445d-be80-087b3b52d4b5">8,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5639e6827db9445ca99ec3429d38514b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtOS0xLTEtMA_a203dcca-9b25-4826-87b7-144849ad7409">6,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585f62c2af3048dab19b2ccec8904d68_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMTEtMS0xLTA_bb61f92d-d098-4379-ad0b-01d702eb0b8c">14,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118a055047184fcfaf92090074d7ad4b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMTMtMS0xLTA_bbbaeaed-20da-48b0-95b0-c62da0636e08">6,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed4f4d9b9f84b11afd909432b51fa6b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMTUtMS0xLTA_c8757595-a51c-4167-ab88-f90c1ebc70a1">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ee5ac9fe1248559264115ca0ce8e31_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMTctMS0xLTA_9a527e6d-5dfa-466a-86a4-2e4bfe3bd359">11,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ca7fbd199642df8e35c5b087f2f181_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMS0xLTEtMA_feaa0080-34fd-4f86-b389-1b858a4d4fb3">515</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412a988a09de489e882e0bf3f1cdad5d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMy0xLTEtMA_0eeaa648-38c0-42a6-971d-d10916fff983">473</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b7bca2629345b48bdf4ab1a9cc002a_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtNS0xLTEtMA_75f4feb1-23ea-481f-ba4b-2a1eea5599ae">989</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b89ac54cd84d5f97104114e72eb401_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtNy0xLTEtMA_3653dc79-35c0-4a26-8138-1001f02b6be8">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf7482af6de46c1b860e27aaab98d93_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtOS0xLTEtMA_d3a220be-b10a-4d80-ab1d-f3af87ba5444">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dcf9b8bc9de4148a0ee6c3a5a6f2815_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMTEtMS0xLTA_a9a1b3cb-7568-4060-b924-371d77ce7595">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2464e70d7ef4f7bb40db6173462adaf_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMTMtMS0xLTA_8aecd1ae-ec8f-4917-968b-743f837277c2">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5e11e3ccd6431c909fb49ed639bb98_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMTUtMS0xLTA_5b0ddba3-22a9-4041-b34e-17d4bb5e1164">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3890b29d4919406994442f1b5b0164b3_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMTctMS0xLTA_62ff1306-018f-439d-8195-4d7f2c7dc758">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126a4a0ccf3f40efaba2835b745502dc_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMS0xLTEtMA_035f1ac8-d5a8-4675-88de-4b90cac26f19">417</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec348f46f8349989fde334c3a0e6693_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMy0xLTEtMA_4d22b1ab-fb14-4909-ba8e-a120fee622a1">287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62a9ffa2b864eba96a15816fc03a298_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtNS0xLTEtMA_604f3cb7-6a6b-48e3-a1ca-0554763b8394">704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96bd5d4591c74fc59a16a07549d1b809_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtNy0xLTEtMA_02c158e5-0e09-4809-a83e-5feacef2ff1e">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd13c82855e45e18ee1bcb4674461b2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtOS0xLTEtMA_11c9c59c-a7ca-4719-aaa6-834945a8b0a6">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48dea599db224c139d74cfb868f7ca31_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMTEtMS0xLTA_f777ea12-f713-4c35-85ca-dcba2aeac99a">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if671aaa852bb4d1cafc2487adea83e34_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMTMtMS0xLTA_b0f52d91-ae87-4b63-a71c-22b0741d0df5">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e29a49f9e146509c3cb1014ab81958_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMTUtMS0xLTA_0faf800e-689a-4dd1-96d8-b23106f7b4cc">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbecde3516774ea4a214f44d642a3ea4_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMTctMS0xLTA_4e0187fa-baca-43f3-b193-29bfb52717e1">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ab7314f4724a408939aecfacc08cdb_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMS0xLTEtMA_a0c02f82-0988-41da-b15a-4fb9400af231">1,881</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67504f9dc2414b458ecaaf3418bf800b_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMy0xLTEtMA_6a617470-6f6e-4142-a89a-3aa1850716f6">3,792</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7410d9a99f3144d289bb5915b56f611f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktNS0xLTEtMA_4a4fed8d-78d0-4930-8f7a-64304d35cc1c">5,673</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30070b5abd3a408f95c70d3b9328afa1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktNy0xLTEtMA_c529768f-a6af-40d9-a068-e96cfad68825">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c07bfb932384999b083744d5271f56b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktOS0xLTEtMA_71c5f6a8-9400-43c8-b799-9095c808dad0">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d896fcb2b074166b1af7ecd1df7ecc5_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMTEtMS0xLTA_7ffd458e-ca35-4d00-8bba-d124edf1bb5b">3,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4449be5f9f4d4dd7bb5f71f197d1195e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMTMtMS0xLTA_92fd14c3-2f26-4274-910a-88bc17f0f0a4">1,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24b2aefb0cd4d1b92b0312679c47a00_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMTUtMS0xLTA_8f2e292b-c18c-4230-9cd0-e32f705f8d0c">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ad66ab734b47e3b0b68f6d3ecd75cf_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMTctMS0xLTA_66dc82b9-f77b-4b4f-9a41-e9db0dc23d97">3,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092a9a3dd77c432aa3fd0dfe58c9fc24_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTEtMS0xLTA_cec6b7a4-4422-4bf1-8102-bc41f9c08168">1,629</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee03932a98f4e90a47a62b45b98473d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTMtMS0xLTA_f4d11897-3ef7-4909-b307-6bca7846fe31">506</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f84682c651e42369b0be205d5dc544b_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTUtMS0xLTA_64ac0ef2-af1a-4d9d-9132-90a492023298">2,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d55e46f9c6a4d77998096a6a91e85c0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTctMS0xLTA_5307674d-139e-4d11-b8a3-8bb843ea0c5a">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69815c97a5284f8892611939d8f5ebb7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTktMS0xLTA_70b152b7-9839-4772-894a-3161fcd5b3da">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8887b54a6020401cafc8b73bf4852968_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTExLTEtMS0w_fdd886ad-8186-41d8-82f5-e783fa3dc039">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d5492cb544bc9894b3d738712a155_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTEzLTEtMS0w_71955305-116f-4c64-99f0-ae07eec6b7ec">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8f17a778d3d46d6a0f56138bb37401e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTE1LTEtMS0w_f253c968-8ef7-4b34-b862-a7e40b18b226">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8600b39d154c5299e9b719a4e65eff_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTE3LTEtMS0w_8fa5ea7c-baa1-49f7-bf67-d2d2b39eebfd">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6ea600d207424d9ebdc43381b8d663_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTEtMS0xLTA_1feaea23-2a14-464a-9a49-33713223adbf">547</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb046a0ba0c04045b30d5722effaafb2_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTMtMS0xLTA_faabc7fa-6621-4352-a32c-5a3e06ba32f1">346</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5bfe0049f14a07b613d265fd540357_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTUtMS0xLTA_ab0e57e4-4886-4331-9e02-2afcf97b3460">893</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350b1e0896d840898c101f9718c2c2f2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTctMS0xLTA_4ecd1211-8bb7-4488-9a9d-954be8e5bcf4">727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdcd82740163451e95d5ef31c1a6f103_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTktMS0xLTA_e65fdb24-ad6d-43c1-8222-281e1c9cb87b">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59e38a3f1f14f8c99ea483759e328a1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTExLTEtMS0w_4cf408e0-621b-4715-b108-d4094bc967fe">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafb83f4e70884ababc7ef0c9ff8f1f20_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTEzLTEtMS0w_3f600018-984f-4963-b976-acb614cd75ef">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3921cbd5aeac4547b3df48439ab8f6d2_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTE1LTEtMS0w_2a9ae10d-2b14-4d70-861a-173fd8f00bad">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ce69f481d241f28a3dee75585ddbbc_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTE3LTEtMS0w_ffe37423-1874-4589-8075-875f113b1eca">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbceb0e389804da8ae6d0759d4119f73_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTEtMS0xLTA_1be814dc-c6d8-4aa3-99c6-fd4a9b629565">473</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e8ffa354eb405b9df85f225faa97a4_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTMtMS0xLTA_421821e7-48b7-41f1-b03f-58b4d596c635">334</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6825addbac14de89b7448f21f1dbe0d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTUtMS0xLTA_40ff43f1-b338-4bc1-9b0d-27d841db38e4">807</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7528d7d63d24a0ebc48ba15ef1742c2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTctMS0xLTA_3b6fe149-744e-4daf-b997-a89ab64f5fc7">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e69f638636462c981930e509c9d3c3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTktMS0xLTA_1c98dc41-1290-4821-a462-8f0dd7c14eb7">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17a52444ed7149d9a832be8c913ccfb2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTExLTEtMS0w_c9f212ec-82cb-49ce-b351-66e5211a726c">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2262179634dd4d6eb718ea17322c0302_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTEzLTEtMS0w_a828c0a4-9fb7-401b-9aa4-f2daada67f52">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290541092ab24a35bbac3de5b7d6757f_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTE1LTEtMS0w_7c34079b-846c-4992-af0e-96c229106364">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb120af06d848bd9bd55575768c0454_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTE3LTEtMS0w_66a956b7-19d4-4e82-a344-c340553e487c">791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68cf814d8754d468098e25c4faec59e_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTEtMS0xLTA_e20be0b0-873f-4491-bb72-7bf32988a163">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec491afd16ff4fe9ac6ba8cce69bdefc_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTMtMS0xLTA_afc0b605-19ca-4f13-ab42-bb0cb3d16dde">79</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3727a4b434224ffab2d1dd6ab2a31446_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTUtMS0xLTA_9a2efce4-4110-465b-aedd-1fec628a9e82">179</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09b13d69e694ea999debfb5ba7aa578_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTctMS0xLTA_f92c10ea-bddd-43d5-9ab2-c31d59fb4d55">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic347c94c641d49f6b9ce87d0eac2090f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTktMS0xLTA_45d3d6f3-7bc3-4c3a-81fc-1935bccfc4b4">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d75f1dea9e4e668d532d7b2c10b2e9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTExLTEtMS0w_3970e9ec-c0ad-4b9a-b88e-ad202c1f3167">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec4b2a3d76b4364b2d56779a19fa6ca_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTEzLTEtMS0w_7500b37f-54d8-49b1-8d62-ff73d693543e">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43bc6db40c0145fa82725faf6c749c89_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTE1LTEtMS0w_fa184d36-7e64-4ecd-ae9f-038bef31b124">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if76ee5e9706c4379b1703add36dffafe_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTE3LTEtMS0w_c0686b37-3e37-4449-9045-7bd2f764c30e">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddb209f66734519ba2f0f9440875f4c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTEtMS0xLTA_3e051995-2b2d-4c83-a4a4-62524b69dee8">762</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i287f086f0a1348718abecee8bf3fbdbf_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTMtMS0xLTA_c468dbab-8735-489b-8cf4-141cdf8cdf1d">770</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d92ef43e74548739e46fef213a2b691_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTUtMS0xLTA_1d00473f-4efe-4c04-ac7a-f756e6d347f7">1,532</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a4d1d25cbb48a890bf52a4c3b2ce24_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTctMS0xLTA_fd2a1a1e-aeb2-43e8-8427-40208fb7fa82">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c9956b24fe747cead1ba231ba98dfdc_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTktMS0xLTA_59eb50e1-c1ed-4f0f-a37d-2581357381fa">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i621acda9e95e42d49d9d543db91d4937_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTExLTEtMS0w_758fcbf0-33e1-477f-a03e-21bad4230b24">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4146bb447d743da9ee890800435e8b8_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTEzLTEtMS0w_f0667ab5-f47b-4971-8717-77690caa5e33">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e080a31cc484b33b1889bec0d989641_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTE1LTEtMS0w_a8cf54b9-8f12-4bf2-8607-63557407376f">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f25ff9318914fa99b0b7fc3b0911f02_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTE3LTEtMS0w_a501c29f-eaa7-4b52-b7a2-d688b7d01794">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9f572a206f4619a83415208462c648_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTEtMS0xLTI4NjM5_b7b3d68d-0f0c-4f56-aace-846ce289577b">153</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14128500dc8496a9a941b07e7570826_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTMtMS0xLTI4NjM5_25d5792c-0717-4ab4-8a31-bd5c7879b9f2">218</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b4e19b01d14af2b9e7a5be87b0ba14_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTUtMS0xLTI4NjM5_05b40543-a66c-4985-a260-e4751e1492b0">370</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i680941386a504ccaa708270ef21bba50_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTctMS0xLTI4NjM5_9fcc539e-5274-4856-8088-846d3f0e74d8">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3351be1b9677432389243aef036d0f4e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTktMS0xLTI4NjM5_1fd003cc-8212-4a56-ad84-0274542452b7">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7339a2912de4accacec0a80f0cbde96_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTExLTEtMS0yODYzOQ_aac62bf5-2d23-406b-b5d7-eb4f82651c2b">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c9827e87644e79a48ea79d80420a22_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTEzLTEtMS0yODYzOQ_233ca8b6-3d8a-4c4c-9eb2-276571c51c23">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ea00653e9e4cee964d9489c3bd0732_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTE1LTEtMS0yODYzOQ_a1f7b768-2f50-4514-9156-73d1c831b335">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d42dde9fe44012ad67da4ad05352c6_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTE3LTEtMS0yODYzOQ_72ef2105-1801-46d1-b215-727935f97b06">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5022ef10f96e4b7aa61a055fd68efe83_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTEtMS0xLTM2OTE4_cd7fd218-9fdf-44e2-9337-ed9bb952a3e3">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef9b40b31044eefab0cf6ddf301bf11_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTMtMS0xLTM2OTE4_a03a92cc-1c6b-4ebb-9972-65570a826a71">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cc9260dfb142b3ae1b4e51b2636178_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTUtMS0xLTM2OTE4_6d0f47c3-9deb-4040-b3f6-e1e85b742e45">259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2985d0dd5ea145ce8d2f0ef7df6b36cc_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTctMS0xLTM2OTE4_91a35130-2db2-4251-aaf1-eeed300c4dd5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0ac23a8c384de6a68683e097588935_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTktMS0xLTM2OTE4_0411bfa8-5d51-44b1-98be-ae69b56eb842">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9555c3b16d4029b0bdd2a58b8ca117_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTExLTEtMS0zNjkxOA_b9f47a10-e85c-4aed-888c-cfdbab0c670f">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0e00b0f2a574b709afc847e290d1f4d_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTEzLTEtMS0zNjkxOA_a12d3bd5-da5f-4f8c-91e6-c1d136504906">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc00e8952a6492f83da929648c7859c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTE1LTEtMS0zNjkxOA_da44efaa-a0c2-4563-a70f-cca371705217">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bb2f997ceca4c2db0eb415936f392d9_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTE3LTEtMS0zNjkxOA_af7d48d4-3eed-4f78-9858-6300d972b8f5">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588ccd376cce4c459b89838c0dc320a9_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTEtMS0xLTA_36efd89b-2fd3-4fea-b175-7d4b1d6d1016">60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2ca26bde454c769f7a36998e53e53c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTMtMS0xLTA_c213e0d0-d24d-49a6-833e-b6d01134fb73">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6c4413e27f4dbdaed582d92345ee15_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTUtMS0xLTA_356b89ad-ff35-4bae-9f14-fdf5725d0890">259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe52f351a8d4153a56a10fd4e76f488_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTctMS0xLTA_18724378-16c5-4d8b-9fd9-40fbb5ebfbb7">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82d4d56c6b614201adb1944e0e9e1c92_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTktMS0xLTA_5ba280ab-2c64-441c-a68a-044f1a16c831">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044a677ce7ed4b15a2562a43b2b9abd8_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTExLTEtMS0w_d869e81e-d116-4a7d-bf15-c610543134d8">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe73e300fe4433fa589eb9c59eef229_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTEzLTEtMS0w_523b1494-524e-4eae-b48d-602f35b3f4d4">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b81951a30894213954768ae743f31a0_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTE1LTEtMS0w_7adae931-8233-4537-9c15-6ab726321d16">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd822d77da04087961e1a434edc2bdb_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTE3LTEtMS0w_e4fd14f6-d5a7-41b6-87b0-8e6310a6c96a">662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919922d6658d4bf094bffc6057c2d318_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTEtMS0xLTA_c8404977-b8d0-4a3e-9c16-a5dba4182608">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a5bec58714422fbaf00a68687b7d72_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTMtMS0xLTA_9dd8f5b8-9cc0-40fc-9de3-c58279a5cfb0">208</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f251d58dc4741a5b4bc331916be0226_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTUtMS0xLTA_842d43eb-b815-40f9-9558-98671ee562b8">212</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i238867c42030496c888ff5fec0f238f4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTctMS0xLTA_e80a6bd8-09a3-4e15-8e78-d5f06930663e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c8e25b2f143a6a83cd529f6a9edb3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTktMS0xLTA_48d41027-b900-4508-bcf7-485647aba8be">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3caea6cd27384755bedf9d283e539fe4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTExLTEtMS0w_db2e91de-600b-4085-8012-06ddd16e4dd7">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49045b590b94189b3ba82d3341d8dc1_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTEzLTEtMS0w_23e88e86-be26-40cf-8772-861714d72d89">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib08607411f484218996fb2684f207c26_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTE1LTEtMS0w_751f6ee0-7fd6-40bd-8c95-a1bbfa00dd37">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57867663740a4d66a1abfa217c854234_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTE3LTEtMS0w_3907f276-0f5b-4898-9ee8-dde55d056385">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17685f23777c4777b25d05b30847170a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTEtMS0xLTA_d4dd9f29-ef4e-4a2e-b7ee-303939f63471">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if341417b19c14b84884a2711d11c29c4_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTMtMS0xLTA_4ec77fd9-4ce2-4816-bf31-8cb39021513d">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id336dc1a92684f6d959130b607011823_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTUtMS0xLTA_21008e36-d9d8-4c6a-9071-cc8d5560b819">202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic49ea5e6124f4cb291979ada6f6e1d4a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTctMS0xLTA_93f82a2b-f442-4f06-b418-9a818e4398dd">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i360f6b57fbae4cd3a936581cb768c93c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTktMS0xLTA_174a38d9-8f65-4f6a-804a-2de34f99f1ec">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790f602712d84379bed540b6f76fc57b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTExLTEtMS0w_106b1cb2-f683-4d14-a853-21aed6a22283">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id141d171a5bb4e19948360b7c1265792_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTEzLTEtMS0w_bba1f401-c458-4062-9a65-1da702f52c8d">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a6fdd6f73f41219529c1d7d8607b4d_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTE1LTEtMS0w_e1ee34c9-2575-477b-acec-6ad664dee833">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide35d7caf43044a8842880c9892d8610_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTE3LTEtMS0w_a6541dc7-7e0c-4ae3-96e4-6247c15bf865">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2ade8ccf2247a083b1043ad7d0e5a0_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTEtMS0xLTA_da83b48b-c4e7-4429-bcb5-72cfa9670387">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf3d0c3a557a4c4a845f4c3c31bf35fe_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTMtMS0xLTA_55a96727-b483-44b0-a86a-b088f4fb05d4">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0948681bcbfe41be84f9be49d7bee81b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTUtMS0xLTA_677c43f0-4d64-4676-b48f-ef52533db629">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id628e1c6911e4ad79edefc7fbd510f4c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTctMS0xLTA_97660f35-243c-4a68-83da-c789f4d1523a">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ceda0300e794bddb9081944d2f35ec9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTktMS0xLTA_3927a446-4d96-486a-b9d5-0456324a091d">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9682639f648451a9580e7c6106d6bea_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTExLTEtMS0w_daaf493b-bdae-4bf8-b249-f249073f2339">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfe45979c5843819de5fd1faa5f6164_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTEzLTEtMS0w_5d07d413-9379-4b5d-b0dd-e090ce2c00d6">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5014f16e8514b5fa48152d56fdf4acb_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTE1LTEtMS0w_d2708fb4-6401-49e6-b179-2b44f3569f8a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab537984b5264cc6ab6b179f58898f76_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTE3LTEtMS0w_0e4a21e9-2beb-4cd2-8d63-8873a1628f90">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653304b28e3a4aba996ff5ad6455596d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTEtMS0xLTA_f869c707-028c-41a1-a413-fec28a85f536">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc699a519cd4da6b9151325ddcc9476_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTMtMS0xLTA_7650f744-8d6b-4d63-b229-45e308e5c8cc">825</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6522f24b64a418290e82b61d41d2138_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTUtMS0xLTA_3f6a89ed-b600-4cbd-9638-1aea42c048c7">825</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id497588ccac6414284ef2d78c4360759_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTctMS0xLTA_98498d80-ac0c-4295-a33e-9688d5518eea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57de4669b2c404ba2df9d8c63350b95_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTktMS0xLTA_d8050b5a-c1ef-436b-b633-577665347ae5">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c9b8eb51bf4bfdb4aa84f8464b6ad4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTExLTEtMS0w_1c4726cf-e675-4844-aee2-3a24734c2d11">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c5d62997704e51815fd6ff6a3f63f8_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTEzLTEtMS0w_1e19afb3-a48b-4206-9d7d-b3a4e162812e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e966b911fc84965a21f483f48ad5f9b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTE1LTEtMS0w_710c5d29-aaa4-465a-a97b-c1649d425c56">830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670abf0ceee14b2bb45e1d0361ced108_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTE3LTEtMS0w_09e80501-c5f8-4e63-8def-13b402c46963">830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0875049533455190662cb3270eca92_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTEtMS0xLTA_1abb06c9-468c-4628-9f9e-30bc5dfaec3d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e34030eb894f44a8c12d5525d6bd13_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTMtMS0xLTA_d1d7e404-ea46-4c7a-b87b-784466e27090">299</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d3bc8edf0b84232bcf558d786724b9e_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTUtMS0xLTA_3dfbcb91-ac8f-43d7-856d-f8301f9887eb">299</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08867c31927d455abd0c72bb2f6dd29f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTctMS0xLTA_01cc1659-bad0-4d9c-8971-1b24d4f4bd28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca75dc6c120487cab23cf75b4de21d6_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTktMS0xLTA_77732773-73c8-461c-a700-44d67ee16184">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573ac9203d854868906b1f2a5afd90e2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTExLTEtMS0w_87df5e7f-0690-4af7-9931-ee55958aca35">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d492c360fb47b893486098bafc98b4_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTEzLTEtMS0w_2d92e002-8031-473e-a67c-963bf017901a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75797ab2cf2f4e1ca746e1ac560446c3_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTE1LTEtMS0w_de11efd3-14f9-41bd-92dc-e7635ad36e40">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5527cbc51fe7422dbd7d4c2cf6cfcd9f_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTE3LTEtMS0w_61d4c0f1-5aa1-4c06-a07d-a1ff3cd33ad8">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d4058d922d48bfa4f4476cc78aa40d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTEtMS0xLTA_5a42430d-581a-4f69-9640-092f983d5d50">78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff774d7ca444bf697bf7b5e3ab1a652_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTMtMS0xLTA_249c6b1e-f600-400b-bc52-beb7f1761e96">241</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54e43721fb14ed08c10d118aa1018f9_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTUtMS0xLTA_bfd6a5a4-1d12-4bfa-9b67-11f7d5de3f71">318</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e35d6b25834f2f8c64c46be0b8e79b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTctMS0xLTA_c32ce3ac-0a8d-4d38-8fee-50688918a549">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1399a756a222419cb0f46fbcf7b54698_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTktMS0xLTA_2ce76526-94a4-4082-9b06-9178b5edd297">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72757c16e414c11b68254cb75195b3e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTExLTEtMS0w_b1514489-82c3-40eb-9116-cdda9c655e02">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75b7a5a1281432abceddda5981a31d6_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTEzLTEtMS0w_0543222d-e801-4326-bc3e-ebf7a90267e1">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8971c73b69b24487819c96119033483f_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTE1LTEtMS0w_b52b2e7b-4d95-4c7b-9601-bf9a74b348a0">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe780ac69be4298a4650d36dd0c8e48_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTE3LTEtMS0w_10abc3fa-8ee4-44d7-afe9-e32c4f8f2d2c">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Molnupiravir</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af6d5d2383c47e9b7f3aae3de39cd9c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTEtMS0xLTM2MjE1_c8590424-28b0-45d0-8bc7-5d764b296595">632</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b66816cc44e4b89e9cca0a8e2fc39_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTMtMS0xLTM2MjE1_6b8698c9-b3ad-4a5c-868a-07b46c4aef96">320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2128d2249b5433c8c29182a6113f86a_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTUtMS0xLTM2MjE1_48863648-a766-4905-8c7d-73b41be32397">952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6802fc4302e74a7fb1b161db797c4710_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTctMS0xLTM2MjE1_a499956f-6acb-40cb-84f9-f6636ecba804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b959ce3ae469ea04ba9f29a1064b4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTktMS0xLTM2MjE1_6ee7d1e9-f74e-4b8f-a680-2e170bf94780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4eca5885fc0477bb9a10919f5131fce_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTExLTEtMS0zNjIxNQ_31e2ae06-7e4f-4b64-8c3a-ac90d1e83400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ef4256ffaa4cf08d46414850e9f302_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTEzLTEtMS0zNjIxNQ_301a2dcc-1a6b-4ab2-93fb-59a47914bb9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fc97751676240338ec6973bc3f4329b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTE1LTEtMS0zNjIxNQ_e3ab4da3-e3fe-41c1-ac92-93e16d938c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f098b0847574bfaa047e6960ba579da_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTE3LTEtMS0zNjIxNQ_3eda8864-aa96-46c7-9231-3a9dbc7951c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic789d859ce7147209a488fcef20e508a_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTEtMS0xLTA_4f4c3d7d-45a8-4c54-bfda-c281e7b8dd02">294</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icad804308bbf473898a71229679ec50c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTMtMS0xLTA_0370d051-2b41-4b47-b751-0546dc36598f">474</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8fd691878ec45c88dccd5fc5b741c66_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTUtMS0xLTA_c9dc3e04-9d92-483a-9250-193eb7f5f1d1">769</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d83bf3c10424ac1b31714923c7c7222_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTctMS0xLTA_1fbb1221-5a25-4562-8b14-644bc64ef2e8">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd7b557051941028e48d4c7979df2d5_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTktMS0xLTA_32c2e8d4-78fd-4882-b722-ccc19bc89631">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f22b920f0142a7a77c93888483253f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTExLTEtMS0w_f81b9191-0df5-41b3-b1d4-ae3af2778633">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a08aa9a691f42a684ca26528ec547e8_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTEzLTEtMS0w_ed479747-bc0a-4b61-b51e-88bf3c0a4f7b">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c5034ed9c54f56861f85fb06ac04b8_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTE1LTEtMS0w_8ee0c9da-0acf-4904-9fac-75ce1bb6424d">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20da1a75201d44228058bec6bb25681c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTE3LTEtMS0w_84a3eb09-b8d9-45a2-af25-aca61583ba13">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc21603e76ba43718a1da2416c551b71_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTEtMS0xLTA_7f2b0a8d-f390-450d-ab83-43ea63b396cd">312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860379b9e6694ee69337ca4a63a63ee9_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTMtMS0xLTA_f5b4f9c9-4a78-4fd7-b293-92f92f1658c6">30</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ad805324a7466aaa2adf87437b786d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTUtMS0xLTA_4946176f-3a2a-4142-8a86-d8dc5bf25111">342</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c259f812e0493c9a80f73147db4d87_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTctMS0xLTA_4b748adc-c39f-460e-8d3c-abee7363e2c3">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie334b2fb8b4f428eae8891ba5428e8ff_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTktMS0xLTA_f31a0189-9447-42e0-b6b2-5852299b53b7">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b03e2bf2dfd474289cfb9e6b903b9e5_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTExLTEtMS0w_8bd6f825-dad5-4ae4-aff8-1248081beb16">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19f798e233b445dad2d45692dd72895_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTEzLTEtMS0w_e244e3a6-f8b3-4f67-8db6-d8bb7bd2cb0e">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2747d6aa809047c68d271b385afc8f32_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTE1LTEtMS0w_34c48e74-cfe2-4081-83ce-e5f0a3722a6d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i362f6d1d48a4452382e6007cfe8aba1e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTE3LTEtMS0w_3ac4d93c-b0ef-49d5-8758-8761dd87a2a3">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e40e495bd0b4d74a40b380b6538afee_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTEtMS0xLTA_a7734f53-aab9-436c-8381-a4e73be12cdd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfcb3bbc22441859e766a0bf136e8f8_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTMtMS0xLTA_427500e7-450f-44be-9327-7fec54f7180a">252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7844fb1fab6b467795efe381ddc3d257_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTUtMS0xLTA_20e2bbff-d9ce-4522-8e68-db946c025570">252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077c0c6c35484b8d80c194006e499277_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTctMS0xLTA_38e8e4dc-5a19-4fb8-bd4e-1a01f76021b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaad4da76bf1442ad9c12d29fa802065d_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTktMS0xLTA_64b028d5-ec32-4fe2-a819-bc8abdcfd860">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abee35368bc428188fc163b9c321692_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTExLTEtMS0w_0543aa8a-2e0e-462d-abce-1fc0f3866c71">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410bb854da34475906908a70e1b9ddd_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTEzLTEtMS0w_246effe1-b9c7-48ad-9a16-1fdf154c757b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d519f01b8384c2bbf73455aae73e495_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTE1LTEtMS0w_55967405-fb22-4a2b-bb33-89621a6366d0">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7e2aa6c1ea4be2baa790c8abd97c73_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTE3LTEtMS0w_648704fd-3e2b-474f-a326-40359e15e5b3">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5e0a42af0a415dbc7ac173403c6c0f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTEtMS0xLTA_5c603c35-c696-463d-be54-a7e0642f89c1">1,404</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1120f19a2bf44abbb0c3dc54b2a33858_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTMtMS0xLTA_0cfcad49-8b08-464b-9b99-0ea2ae80aa2d">1,920</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe420bf94cdc4e508956f70224f4c347_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTUtMS0xLTA_08e59176-344b-4995-8523-5b2d99017463">3,324</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875bb4453f9346a9889252db74a91e92_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTctMS0xLTA_82ed5d8d-40cf-4878-a967-4cc314d43a5d">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52da847ebfb42a892f32e61b9768325_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTktMS0xLTA_ed54bc9c-202d-4869-a34d-2611f1e5f316">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31403cbad4be41ff806afb334c3cc801_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTExLTEtMS0w_90abb185-321d-480e-bad6-e35ffd9ec875">3,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e7beb95553472b82caa89c381f3e73_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTEzLTEtMS0w_5cdd7740-ee97-4d57-8341-3dad25623c67">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id707418566a14de9abb8afa077ffcce7_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTE1LTEtMS0w_80240667-3aff-4e7a-a313-5d4d398277c0">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbba2c093f84e089af32d87b1ea49e7_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTE3LTEtMS0w_dc3a7770-8fa9-4886-91a6-74f2f871c240">3,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4359fa8ee9ae4e1ca5acfc1ef3d4769a_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTEtMS0xLTA_84ad6b44-3f16-4f9d-b7b7-141eb0fa1e97">367</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855aacd97879416694b822d5b5a4e61f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTMtMS0xLTA_b29f0d22-0717-487e-976b-25315a0e006f">1,597</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i053d6ba1ed2841b3916017660c6df7d7_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTUtMS0xLTA_4df7b66e-cad0-4cf2-9e04-7d9dd42c20cb">1,964</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04c71c3f757454aa800a15a8010af43_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTctMS0xLTA_e3fbbe05-99a5-49b1-a9d0-71bef0cf3196">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c1036618754c889e448fee724b87f2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTktMS0xLTA_d05aade9-0e02-4397-a6f6-2939df241b82">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if22268e596b0476aa1a363dc33a72e0c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTExLTEtMS0w_b450d0db-8908-4987-81f6-26fca3ef40de">1,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5fc3ab73c2d4c188100a9ccbc477ac4_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTEzLTEtMS0w_19ff3ae1-73c4-4104-8513-9c59108ca0d7">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddcbbe421b4d6fb2d8b67f56b5b5f7_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTE1LTEtMS0w_78ce2360-36f8-483c-80a2-76b987612cdb">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ade6018d32b4458a32138623c4dd828_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTE3LTEtMS0w_c04b1dfb-5472-4055-bca1-a8df8c1d7cb8">2,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f4bd9b10014321983b0401d103bbd4_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTEtMS0xLTA_a21332f2-0f68-4b2b-83a8-a7257daa51bd">1,007</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f952e92f0ca4e6483f30550b71d62ae_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTMtMS0xLTA_b404b05d-115a-4f41-ae48-e9343e475c94">1,302</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a7a6ab9b3e4c83ba2682007c4d5f5a_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTUtMS0xLTA_cae38ea0-422e-4368-bc91-63ef07641d0b">2,310</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i409834fa971041c59a9219af6cc8a8fe_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTctMS0xLTA_e9f3e259-1218-418f-97ec-b5a9c76f2940">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab2f301fabb64c4b9a1224b62e33cf45_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTktMS0xLTA_88ec3d07-6369-43a2-8d38-3a2483efefce">1,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e8d6fd87284f119ad6bbeb297f087b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTExLTEtMS0w_c0cbc172-4ef1-497a-b769-7b3ffea1a169">2,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f80c96aec434110897f030eab369d00_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTEzLTEtMS0w_d1b23f06-67d1-4508-b1fd-4991f6fb722b">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05ecde19c334fc3869d0a13c50b3d91_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTE1LTEtMS0w_4d0e7f40-9dff-4bd6-a454-89d5ce71f89c">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b51fa1e63844c0a772c0468f3aecc2_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTE3LTEtMS0w_67f0c80e-4055-4ef4-8587-b17e338515de">2,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f4c85d94b444cc93caffa1905c6ad7_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTEtMS0xLTA_97e26595-60d8-4510-a866-3a5129b088c5">20,401</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec26147c7b0f4628a255c9ed76696470_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTMtMS0xLTA_43691ea2-28f8-45be-ae69-d94dfe3ab84e">22,353</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTUtMS0xLTA_16aaae66-ee3e-4ff9-b0e2-a6c47df6b25b">42,754</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c0463faf174f59a03cfbd4c245e30b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTctMS0xLTA_52a3564f-7c10-488a-89a9-07f573b24eb2">18,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac282dd562d44386a140bff679bd6312_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTktMS0xLTA_3017802e-1d81-4eb4-aa5e-5e3e6d8c18f8">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTExLTEtMS0w_e0c2a829-77ec-4b9a-b3c6-e93b2952430f">36,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8227972e5ae047dcb65cacbe11fda43e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTEzLTEtMS0w_00b52398-1bd1-4005-9b67-62862fbac441">16,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9e718c9899485dac81e79d2b65a8c1_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTE1LTEtMS0w_a32f9311-2247-49d6-8d04-222099fa1750">17,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTE3LTEtMS0w_88a58884-164b-43b0-889a-f58283c986ef">34,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i902f509e24c5427593e3c70a397619cb_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTEtMS0xLTA_916150d1-ec32-413c-a3e9-c30bc514387b">667</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c92b7d768b04f0496a1e4096d91ca45_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTMtMS0xLTA_9710d9e3-a326-4667-8773-b4b8f68367ab">2,628</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b64b45d21a43908135485c4336af56_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTUtMS0xLTA_f14a2d3a-5686-446f-a880-0192c7cc3b38">3,295</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b007460a32c4c97a79e96fba3124285_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTctMS0xLTA_40160fbe-80ac-4fac-a025-6e07f3b5fdb5">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa79b78c2ca447ee97688bc48b4bb2a4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTktMS0xLTA_dd0f474d-5617-411b-adbb-cada1a71462d">2,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7e4a72b7eb4ea4aa580f1844e390d4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTExLTEtMS0w_5766fda6-ba66-44c4-8a79-9773f78e56db">2,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bce372466c44158bf7d70262025e3c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTEzLTEtMS0w_0dd7cd1d-b6eb-4ad9-9373-dff0d912209a">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53fdee9f2db04a4ab37654bf8ad3ce55_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTE1LTEtMS0w_ab3793f3-0e23-4a28-90f1-e9f6d0cfb6ba">2,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcecb7d348a3418fb83648e67423787b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTE3LTEtMS0w_024b3a90-af1f-4764-9dea-827af7f6c7e7">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d3835e3db0c4b86b4b85421ffd621a8_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTEtMS0xLTA_bba315c5-9213-4ce8-8971-cacb4eb9f9a6">1,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i391af24746af409e98e68c04fd6b1a6a_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTMtMS0xLTA_7fcd887e-3ec9-4645-8e4d-9aa7eff85238">1,182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f76e1d339d419f8e388024ded2d57c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTUtMS0xLTA_d7b78680-60dd-4cdf-ba42-8b87b228f688">2,273</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd674a922374a05b288a846e7656f8f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTctMS0xLTA_23a51879-7d46-4a9e-9191-1ad12b25e90f">872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice28c52b471c4e2990f1d5fda9a6605a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTktMS0xLTA_3856a97d-9b57-4108-a732-d74b7060a2ef">892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd74afd8fe9493dbddd22f40067b822_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTExLTEtMS0w_67c5677c-790e-4087-b39d-3a6602284fbb">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84e446473224b92a8e962c9c6661bef_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTEzLTEtMS0w_a30cfe52-2f14-418c-aaf1-ce265216044c">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92e22bab44c4a8585d741cb84b22e0b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTE1LTEtMS0w_ed94018c-7bea-46e7-bf5c-2106bceca153">885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d4f819332f4489a002b37af48a6b7b_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTE3LTEtMS0w_dff38ac3-1cfc-4752-ae29-c66b631600b0">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f07294b8d184726bdd9f9431afa7552_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTEtMS0xLTA_93b8eff1-a4fe-4587-9f7b-4d7483f9a50b">1,758</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic659ca2172564f53a729023707985665_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTMtMS0xLTA_f7971ad4-9480-4caa-a620-2952eae9e8df">3,810</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTUtMS0xLTA_56e5620f-0f87-4817-84d8-82ddd3fb17b4">5,568</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8410cf640294595a9c6c3993a24c454_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTctMS0xLTA_0ba44a65-c248-4b78-b951-df328e3e53a0">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice06d069455f4c78a72b7a22c07b369f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTktMS0xLTA_d6ebf943-b750-4fa0-8dc0-26a5a05c3174">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTExLTEtMS0w_ab415cbc-0a4e-4cad-ad29-8d8cf7917a75">4,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9405751ff5f547cb86645a579c2708c9_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTEzLTEtMS0w_428f0eae-0965-4117-8718-b3c36c2349ad">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c516c5302941878e7cd4bc6ff5a4be_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTE1LTEtMS0w_3da442e2-8ab5-478e-ba65-1fa351ed09fe">3,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTE3LTEtMS0w_fb11b955-6998-4ad8-bf93-89ba46e82389">4,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980d80d9d41b4b498a1d29eae232be01_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTEtMS0xLTA_49b0ac78-49c8-45a3-8010-441fb2eed11a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d40fffde89545dba8648608f3dae7f5_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTMtMS0xLTA_55ebd349-eed1-4925-b11b-644d82e02889">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTUtMS0xLTA_26153f6a-32b0-488c-b39a-9b6a7ad89ab2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fa1c27df5144fb9b2e20a19423662bc_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTctMS0xLTA_9ceea117-f487-4c6c-8e60-2db11116d061">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14452d35763c4c49b6af96a9eedff2c6_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTktMS0xLTA_d1a55ff5-5b01-48fb-940d-6e61dc365dcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTExLTEtMS0w_80e1f954-a0aa-43cc-9f66-cb5871c62770">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c19fc0232664dbb82ab1947769dbc56_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTEzLTEtMS0w_764d453e-7f09-46f1-ba68-41b9ccd42005">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3c67e1533834abb9370666fb82dabbe_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTE1LTEtMS0w_0d5384e7-27bb-4aa8-97a3-643801f76b42">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTE3LTEtMS0w_8629e0a4-137d-4e3a-b1f9-119aab87fdd3">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42b1731f9424c6490b9e6d7083ba158_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTEtMS0xLTA_60ce99d4-c9a4-43dd-8032-15ac4bd112bb">22,159</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700c5af718dc4cc7a9afb37161495201_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTMtMS0xLTA_99b3340d-eb33-49fa-8f19-06219215f81a">26,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTUtMS0xLTA_67d43e31-bdaf-41ff-b7ad-b844ac1dad93">48,322</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i244f5c86b05d45859ccbbae1bc5a1e4f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTctMS0xLTA_42d4de7f-cbf4-494f-a05b-148a6a6e252c">19,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07ef034ee544842829927be984fee2c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTktMS0xLTA_a850567f-dd3b-4eb7-98c8-52f584e6916a">21,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTExLTEtMS0w_ad893593-1895-45f3-b41e-7f618a477ea3">41,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa0b2b1f7064efc9056cdd5245618a1_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTEzLTEtMS0w_ef2bc4e5-fbf0-48d9-8832-9808ac169865">18,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9887835dab646e18759f89f0b92d691_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTE1LTEtMS0w_da4edfd8-a8b4-4180-b940-d5feaf49ee8b">20,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTE3LTEtMS0w_e3942785-1bd6-4cd0-a89d-5617c1d0aadd">38,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f650db9484346c99e5ce03c627df6a8_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTEtMS0xLTA_5914affe-8332-468e-a451-dd499c358b37">266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2dd5fc45690468599bc819ec36baa72_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTMtMS0xLTA_eab65b72-1bd0-4863-8761-fea64cde3e7d">116</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb0c9180eaed41789a00b00eaa6420dd_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTUtMS0xLTA_48f664cc-893d-4aaf-bb8f-8f9712efc582">382</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee23680a9ed04180b885349d2534edf5_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTctMS0xLTA_e66a08ef-810e-4b3a-bfbb-a4fa013180e6">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47cf1b70e6843698113f3bbfd683a3f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTktMS0xLTA_269832a6-fa35-4293-8662-8557e87c2b81">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485ba6b68e3543b6a383a01f55dc222e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTExLTEtMS0w_b7a9574e-8c86-462a-a468-7307b367a849">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f4520623a2490cb524e95878a17cbb_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTEzLTEtMS0w_cedea8e6-d512-42fa-bb38-f2cc5e6d6091">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97c7636f13a047af99200a56c856358a_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTE1LTEtMS0w_bb373037-8b92-4f35-b8c3-6caddbe7c1c8">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb5826a89fe434cacb3a48a5d577261_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTE3LTEtMS0w_d0852f16-6c47-4a2b-b443-918e59856f1d">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b6e713277c47e29642541d538d06f1_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTEtMS0xLTA_fbee6936-b05e-4853-a4c1-f1ed3c8d156c">22,425</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c78a1f59ce94b479267d48bca0bdcf7_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTMtMS0xLTA_c6a6a0fc-9562-4648-a86a-aa85db7a3520">26,279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTUtMS0xLTA_7170a2b8-94e2-42ff-9ffa-29ca58540dc1">48,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5553318c17394c7c86186b52781cbbf1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTctMS0xLTA_6376409d-d91c-4058-af6e-dfc75a0ecf11">19,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3887d92fb9d4538b9b8882d8131625e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTktMS0xLTA_2f8c275c-fb2c-4c21-a278-70d3db2f2961">21,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTExLTEtMS0w_42b6d99b-d9cc-47d8-bfa5-42484a9e91b6">41,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1126352971dd46669a405313ec339037_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTEzLTEtMS0w_d77110bf-4f0b-4695-abc4-b0241557c49c">18,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idefdfd681b4e4b51923fd6feb08020aa_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTE1LTEtMS0w_5f1ad70a-71b4-43b8-987b-13426385a775">20,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTE3LTEtMS0w_8f51c7ad-a456-4ee2-957c-49b6152d2216">39,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. </span></div></ix:nonNumeric><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><ix:continuation id="i3e8d28cc3f6c4ce98f516e9b7a39b904"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales (including sales to Organon). Other for 2021 also includes $<ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzM4NDgyOTA3MDY1MDM_aa700d37-430f-41df-9569-d3f760233eeb">185</ix:nonFraction>&#160;million related to the achievement of milestones for an out-licensed product that triggered contingent payments to Merck.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i1a0adc1727df449ca36882d0166543cf" continuedAt="i4f243d77dd954b60b5e1f35010142c1b"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0ODI_4ab054ff-a9ee-4280-9f37-3b4608b86318" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b6e713277c47e29642541d538d06f1_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzEtMS0xLTEtMA_8c6f3621-7afe-4ada-98bd-931e88a0bc97">22,425</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5553318c17394c7c86186b52781cbbf1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzEtMy0xLTEtMA_932fd403-f1cd-4ef9-9853-f25038bc1ad5">19,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1126352971dd46669a405313ec339037_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzEtNS0xLTEtMA_acacc8be-c925-4c9c-b244-01621db18e3a">18,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd29895771bf4e55817628fdfec5709d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzItMS0xLTEtMA_922f79f7-85b3-479a-869f-7b73910cffb1">13,341</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dbed4d7248d48c98107ad18eed29ce9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzItMy0xLTEtMA_b0bc1c81-29d9-41fb-9702-c1c92de43449">11,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba4578f496546feae50404f7c94acf7_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzItNS0xLTEtMA_2caf855c-4c7d-44ce-9f2e-4242e5534422">10,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb727fa4e7aa4178a7b1e42c772bdcb7_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzMtMS0xLTEtMA_e51c0122-a0e5-48b9-adbf-c608dfbd2703">4,378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcd9e2f534e45aeaf0506c607d7115c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzMtMy0xLTEtMA_5de745a4-b0a2-4e97-aa55-ffc3473f2333">2,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f39fabecb0945059db383224430a917_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzMtNS0xLTEtMA_98d71152-535f-429c-a8e5-bfb582c71bee">2,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d71201413c34bac8b783c4fe7712fce_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzQtMS0xLTEtMA_4e5b0b98-cac1-4885-b2a9-84f8192e8bd8">2,726</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id86c1551379c460aa0a9da151aab63c0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzQtMy0xLTEtMA_a8ce5a4d-a545-4e29-9cbe-e3b07ff1110f">2,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5faa00c2fd48289d394fa06ad542e8_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzQtNS0xLTEtMA_c0ec445b-600a-4641-b487-e2152e0bb67e">2,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702054b971f24d8d84a6e2447ac82145_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzUtMS0xLTEtMA_3a712697-517e-4c7c-9a11-6560d53d8d87">2,407</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d78a41cef745c09b4167941714950f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzUtMy0xLTEtMA_65966d84-b81d-4b75-99fa-313aeffb2bd5">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83ef2bbdf9d4c628f48c7199364718a_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzUtNS0xLTEtMA_17c32b14-8861-4afa-bcfd-0eeabe54fd66">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65d141d77524275b769848de141bc4a_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzYtMS0xLTEtMA_29644a51-ece0-4a70-ab04-dfe4dab8bbae">2,206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e4eed626644fac94b8f8c13407308e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzYtMy0xLTEtMA_53254457-120f-4148-bbbc-90b5d2a51b71">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0317b49ef7a406ab77915a805d48780_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzYtNS0xLTEtMA_aa9a3e30-b260-4c66-b4e5-4d590b6f68b1">2,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadfd209928014784a6e2ed68f848e3da_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzctMS0xLTEtMA_05ab2a54-ce73-4f4b-9c47-09bfe4a46630">1,221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f86df598e9d4df4b133bb5dfcb2e6c3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzctMy0xLTEtMA_02963f38-2ed9-4440-b54b-486802d8dd3b">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b351db0a29943e88f99348848e492c8_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzctNS0xLTEtMA_093dca04-5497-4989-a1a8-6f2a090116c8">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzgtMS0xLTEtMA_92635d90-ca26-49aa-a273-5c610a06a311">48,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzgtMy0xLTEtMA_04e9daf3-3da6-4ec3-a934-9add3abb4f62">41,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzgtNS0xLTEtMA_76cfee26-1ddd-48ea-9ee5-71886a8b3f0e">39,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NTc_ffb6ccde-d4b0-4642-be1d-4208f5a69c82" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzItMS0xLTEtMA_5330200a-5706-48f2-9279-12867e443cc4">30,977</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzItMy0xLTEtMA_9e9367f3-2032-4fce-8017-7a93b7423d84">26,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzItNS0xLTEtMA_efa142d5-60c0-4713-92ee-8fef7e56d58a">23,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzMtMS0xLTEtMA_00d63fc9-3ad7-4a69-b296-84d8265b1835">1,950</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzMtMy0xLTEtMA_c5b50ae2-e36d-44a2-b37f-8f52fae43245">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzMtNS0xLTEtMA_7f5b096c-b4cb-46b2-bc2f-c376f8b2ee32">1,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzQtMS0xLTEtMA_8ed51149-8c30-4c0a-ad2f-7a87920e1d98">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzQtMy0xLTEtMA_83daf04e-c234-4b24-a488-d5cc73ec5593">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzQtNS0xLTEtMA_202ac495-2d04-41c2-87bd-f5ca1e4ae6b6">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzUtMS0xLTEtMA_0c64681c-37e6-4855-9657-957643dd8287">32,927</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzUtMy0xLTEtMA_367bc1e2-914c-4538-a69b-32e553385327">27,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzUtNS0xLTEtMA_e6d54afd-151e-44a2-b9cf-eb34b0e80146">25,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb0c9180eaed41789a00b00eaa6420dd_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzYtMS0xLTEtMA_e0dc359c-1136-456e-bec6-daf7388c96f2">156</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485ba6b68e3543b6a383a01f55dc222e_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzYtMy0xLTEtMA_ffe2a33c-3ca1-4337-81a0-812247dea3c7">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb5826a89fe434cacb3a48a5d577261_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzYtNS0xLTEtMA_f723da4e-4ab5-43e7-87f7-5d6d84172c3d">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzgtMS0xLTEtMA_a9398c08-0937-4f85-81e3-fa8cd0dcc21e">36</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzgtMy0xLTEtMA_f429e4ae-dfc9-4302-b0fe-a5c05723bbec">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzgtNS0xLTEtMA_ea7cdd20-5f30-4231-9caa-71d3d191bf4a">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzktMS0xLTEtMA_d8027688-d555-463c-b016-98233e6103a6">806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzktMy0xLTEtMA_8ed187cc-fd7a-4f25-bf61-27e02f2297c7">831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzktNS0xLTEtMA_3db3c6c1-bf3f-4229-add6-5791936130e9">893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTEtMS0xLTM4NzE_6dead26b-058b-4734-ba82-8389189822b2">1,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTMtMS0xLTM4NzE_69ea5383-cc5a-4ae9-a211-90c4c475614a">1,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTUtMS0xLTM4NzE_388b398d-115d-4bf5-b31e-4ea4ea859877">1,695</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTEtMS0xLTA_bd8e251e-db8f-4aa8-a70b-96b10c9e8f78">1,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTMtMS0xLTA_318a8035-ba6a-400a-ad02-de98d7d89dc1">1,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTUtMS0xLTA_2f57e64b-f6db-45f2-9f40-6a57baad44eb">1,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzExLTEtMS0xLTA_bcd41291-84af-4343-b1a5-6e8dd77d8c87">11,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzExLTMtMS0xLTA_5b8a7ddd-a969-4efb-80a3-c873a0ecf071">12,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzExLTUtMS0xLTA_662575fb-e021-4ba4-b869-f583f9d76999">9,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEzLTEtMS0xLTA_a371195b-9cf4-44d6-a8c3-82391b483653">661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEzLTMtMS0xLTA_2439418e-3d05-4284-8384-99777bbecd34">575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEzLTUtMS0xLTA_37006e78-aa82-403c-a198-8f49791ca533">626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE1LTEtMS0xLTA_8a9c7198-7531-4060-b63b-1132eb36d011">3,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE1LTMtMS0xLTA_2efcfd0e-4633-41b1-9894-cdf92ab29c12">4,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE1LTUtMS0xLTA_78b61106-def9-47ec-a6ba-da2bf3314cfd">4,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE2LTEtMS0xLTA_e894887f-69a0-4bfc-b28a-f917716e5f6b">13,879</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE2LTMtMS0xLTA_5c9bdda3-c6bc-4614-acff-14191901c70c">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE2LTUtMS0xLTA_9c12c885-26a8-40ef-bf9b-1722ed9a7e7e">7,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><ix:continuation id="i4f243d77dd954b60b5e1f35010142c1b"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NjU_bb99fe38-4e1b-4ddf-b099-5049db0f3e2b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity loss from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:37.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzMtMS0xLTEtMA_024c8590-1346-4b68-870e-6076985bdd8f">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzMtMy0xLTEtMA_ddc810c5-a5c0-4cb5-9bee-f0ba6c823caf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzMtNS0xLTEtMA_b0704adc-bfd4-4540-b2c4-81dd7c3306ca">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzMtNy0xLTEtMA_e4187bae-331e-44ca-bafc-6fda1be21ec0">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzQtMS0xLTEtMA_93647a16-79ab-4e4c-8dbf-476f15200aea">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzQtMy0xLTEtMA_5673668d-c3f1-4032-8711-1892763361de">158</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzQtNS0xLTEtMA_7608968a-8016-4ec4-b657-748433283eeb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzQtNy0xLTEtMA_7e967aad-3618-45c9-9265-1635d440719d">164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzctMS0xLTEtMA_0ae181f2-a351-438d-b6f0-ea7c8b1d0de3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzctMy0xLTEtMA_c6abc55f-c636-4a1f-ad91-99ccda610281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzctNS0xLTEtMA_78139a7d-deea-4730-ad21-76324523ee9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzctNy0xLTEtMA_cdf66ce9-16c4-4aea-85d5-b68fe49e5000">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzgtMS0xLTEtMA_7656ef3a-5f11-4f50-aeef-8e65aff0b3e8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzgtMy0xLTEtMA_cf93580e-85b4-44c0-86ce-efd33dca0970">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzgtNS0xLTEtMA_22f240d6-f433-481f-b1e7-0969fc998e26">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzgtNy0xLTEtMA_9ac71646-75f4-4510-86a2-0df3d648a06c">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzExLTEtMS0xLTA_6739157a-a9ee-4c1e-91b2-6f2ff553fb7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzExLTMtMS0xLTA_8fb8c594-cc00-42e3-8134-413095ff3634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzExLTUtMS0xLTA_398f0be6-d7ce-4e2d-aa5d-724c7467b06a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzExLTctMS0xLTA_fb044066-85d5-4dd0-8ee4-7a24407b083d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzEyLTEtMS0xLTA_785691ca-c087-4164-ab6e-047d339b7df3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzEyLTMtMS0xLTA_c871af83-7d1f-49e5-81d2-d5e9dad82935">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzEyLTUtMS0xLTA_b3c09eb4-3d93-44c2-8bbb-981be97d1d8b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzEyLTctMS0xLTA_87e475a5-da90-41ee-a53f-808133f1cacd">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NDI_5c0cc8ba-eb60-45a5-b364-12a26e89f3c9" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f96c6b07354101b83e5657c2f98734_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzEtMS0xLTEtMA_77d62b12-123f-4164-97e0-6f75aabaabd1">11,759</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77becba44594afaa9cd2ceb1fd401d7_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzEtMy0xLTEtMA_bb03349d-0761-43cf-a830-3e4f5be4a0d8">10,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0089f10a0e6b4fc399437bdbe0f24541_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzEtNS0xLTEtMA_8f3c6d46-3dbc-43dd-b5dc-6c93e090abef">8,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbc8434b69594d2faec9792cab27130a_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzItMS0xLTEtMA_3df553cf-8627-42e6-a83c-a02e76399ce3">6,081</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89793641482a462a8870d840e39282bd_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzItMy0xLTEtMA_a213ff84-bdc2-4369-acff-2297b96ae74a">5,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e29b586bba44708bb5e13fc1cccac7_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzItNS0xLTEtMA_0c8d6686-69fc-49b1-988b-c341555c940d">4,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52450a8e8d2546b5bd337d8497a5289c_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzMtMS0xLTEtMA_f2f865e9-2b9a-4e03-915e-28253a9e67dc">857</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69892ca182474febb07a4d42f2311e31_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzMtMy0xLTEtMA_d96a21e0-175c-4902-a961-8865611e4ea8">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db0658921f94c4da60d8ab9e661845b_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzMtNS0xLTEtMA_81240c8f-2e60-46bc-b349-4ff635d0e58a">692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i960c222e9b7d4a59927d7e6165657a27_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtMS0xLTEtNTAwODc_b2653619-7324-41f6-9c24-27f35457bef2">220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff168ce1b424a539e923a9b1865cba9_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtMy0xLTEtNTAwODc_3c539596-cd99-4f87-b039-23b705326651">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c65b2ff6c94bb8bcc3df47b62d5705_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtNS0xLTEtNTAwODc_7974031a-8a4a-4bfb-807e-8d49b95f423e">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7975455e654a058dcc8d1764cb18b9_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtMS0xLTEtMA_e2a531b5-cad1-4a54-8c1b-02c9c65f71e7">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2004b75c2c4673a8d52b5496f1f227_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtMy0xLTEtMA_e299f246-4971-4b58-abd5-bf6243c00255">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic467a8caacc54f36b9cd0bbb7b623a98_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtNS0xLTEtMA_710ae2d8-1c18-40c5-a762-30c419fa2577">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c87fa80f5a449daba8c6132b457304_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzYtMS0xLTEtMA_a0aab881-132f-45b9-aef6-ff8a2ec4fd09">159</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4457dd521ae041f5801d7bde8d26fffe_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzYtMy0xLTEtMA_dc49342c-cbd3-4fc1-9778-4ebc84f2733b">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib520017c77134d6d8203bb67065a1066_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzYtNS0xLTEtMA_7484249d-3c20-4903-99bf-9d0d197b5a84">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba482b7988f246148ad09c509cd17ccd_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzctMS0xLTEtMA_48fc91e6-58f5-4fd1-9b92-e7fe90739756">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd9499f0549458ca5c8d1f40663fd48_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzctMy0xLTEtMA_47bcf06c-55ff-478d-9f52-4363fb27b7c2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ace3e3f4dc49a9b53a1d8959fe23aa_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzctNS0xLTEtMA_f40cb2f9-20c7-4828-9053-519595a77d92">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzgtMS0xLTEtMA_bb4f850d-bcc7-4da4-9fe7-d079bf902279">19,279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzgtMy0xLTEtMA_966d0a8d-c985-4cc8-abff-3039ab752802">17,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071cda02b544795b02b9668d83532cf_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzgtNS0xLTEtMA_cd53beeb-313b-4e97-9a24-5bf631d842b6">14,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_202"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Merck &amp; Co., Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of Merck &amp; Co., Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Rebate Accruals - Medicaid, Managed Care and Medicare Part D </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, the Company records certain variable consideration including discounts, which are estimated at the time of sale generally using the expected value method. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. Certain of these discounts representing a portion of the accrual take the form of rebates, which are amounts owed based upon definitive contractual agreements or legal requirements with private sector (Managed Care) and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. Management uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. The accrued balance relative to the provision for rebates included in accrued and other current liabilities was $2.6 billion as of December 31, 2021, of which the majority relates to U.S. rebate accruals &#8211; Medicaid, Managed Care and Medicare Part D.   </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to U.S. rebate accruals - Medicaid, Managed Care, and Medicare Part D is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing the rebate accruals, as the accruals are based on assumptions developed using pricing information and historical customer segment utilization mix, and a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating evidence related to these assumptions.   </span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to U.S. rebate accruals - Medicaid, Managed Care, and Medicare Part D, including management&#8217;s controls over the assumptions used to estimate the corresponding rebate accruals. These procedures also included, among others (i) developing an independent estimate of the rebate accruals by utilizing third party data on historical customer segment utilization mix in the U.S., pricing information, the terms of the specific rebate programs, and the historical trend of actual rebate claims paid, (ii) comparing the independent estimate to the rebate accruals recorded by management, and (iii) testing rebate claims paid, including evaluating those claims for consistency with the contractual terms of the Company&#8217;s rebate agreements.</span></div><div style="text-align:justify"><img src="mrk-20211231_g2.gif" alt="mrk-20211231_g2.gif" style="height:51px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMDIvZnJhZzo4NWVkZDNhN2NmOGQ0YjI4ODUwZTBlZDRjY2QwYmE3Yy90ZXh0cmVnaW9uOjg1ZWRkM2E3Y2Y4ZDRiMjg4NTBlMGVkNGNjZDBiYTdjXzM4NDgyOTA3MDY3MDg_167833f7-b997-42f3-b7ea-e626a0d5f81c">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMDIvZnJhZzo4NWVkZDNhN2NmOGQ0YjI4ODUwZTBlZDRjY2QwYmE3Yy90ZXh0cmVnaW9uOjg1ZWRkM2E3Y2Y4ZDRiMjg4NTBlMGVkNGNjZDBiYTdjXzM4NDgyOTA3MDY3MDk_74342bb9-6181-4356-bac1-8792e3239b77">Florham Park, New Jersey</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2022</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2002.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_2170"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:24pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Supplementary Data</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Quarterly Financial Data (Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4th Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3rd Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2nd Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1st Q</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,627</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,648</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,298</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,428</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,567</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Loss) Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,567</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,545</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,179</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Loss) Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">1.49</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">1.81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">0.61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">1.51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">1.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">0.48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Loss) Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">0.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">1.48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">1.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">0.61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">1.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt 0 13pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross Profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (Loss) Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (Loss) Income Attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic (Loss) Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (Loss) Income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (Loss) Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.18&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amounts in the fourth quarter of 2020 include charges related to the acquisitions of VelosBio Inc. and OncoImmune (see Note 4) and an intangible asset impairment charge related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> (see Note 9).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amounts in the third quarter of 2020 include charges related to transactions with Seagen Inc (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amounts in the second quarter of 2021 include a charge related to the acquisition of Pandion Therapeutics, Inc. (see Note 4). </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Reflects the results of the businesses that were spun-off to Organon on June 2, 2021 as discontinued operations for all periods presented (see Note 3).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_205"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_208"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures. Based on their evaluation, as of the end of the period covered by this Form&#160;10-K, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that the Company&#8217;s disclosure controls and procedures (as defined in Rules&#160;13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Act)) are effective. For the fourth quarter of 2021, there have been no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) of the Act. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212;&#160;Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December&#160;31, 2021. PricewaterhouseCoopers LLP, an independent registered public accounting firm, has performed its own assessment of the effectiveness of the Company&#8217;s internal control over financial reporting and its attestation report is included in this Form 10-K filing.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_211"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Management&#8217;s Report</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Responsibility for Financial Statements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Responsibility for the integrity and objectivity of the Company&#8217;s financial statements rests with management. The financial statements report on management&#8217;s stewardship of Company assets. These statements are prepared in conformity with generally accepted accounting principles and, accordingly, include amounts that are based on management&#8217;s best estimates and judgments. Nonfinancial information included in the Annual Report on Form&#160;10-K has also been prepared by management and is consistent with the financial statements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To assure that financial information is reliable and assets are safeguarded, management maintains an effective system of internal controls and procedures, important elements of which include: careful selection, training and development of operating and financial managers; an organization that provides appropriate division of responsibility; and communications aimed at assuring that Company policies and procedures are understood throughout the organization. A staff of internal auditors regularly monitors the adequacy and application of internal controls on a worldwide basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To ensure that personnel continue to understand the system of internal controls and procedures, and policies concerning good and prudent business practices, annually all employees of the Company are required to complete Code of Conduct training. This training reinforces the importance and understanding of internal controls by reviewing key corporate policies, procedures and systems. In addition, the Company has compliance programs, including an ethical business practices program to reinforce the Company&#8217;s long-standing commitment to high ethical standards in the conduct of its business.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and other financial information included in the Annual Report on Form&#160;10-K fairly present, in all material respects, the Company&#8217;s financial condition, results of operations and cash flows. Our formal certification to the Securities and Exchange Commission is included in this Form&#160;10-K filing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212;&#160;Integrated </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="padding:0 1pt"><div><img src="mrk-20211231_g3.jpg" alt="mrk-20211231_g3.jpg" style="height:78px;margin-bottom:5pt;vertical-align:text-bottom;width:258px"/></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:69pt"><td colspan="3" style="padding:0 1pt"><div><img src="mrk-20211231_g4.jpg" alt="mrk-20211231_g4.jpg" style="height:78px;margin-bottom:5pt;vertical-align:text-bottom;width:258px"/></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert M. Davis</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caroline Litchfield</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and President</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_214"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_2380"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:9pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_217"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_220"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on directors and nominees is incorporated by reference from the discussion under Proposal&#160;1. Election of Directors of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022. Information on executive officers is set forth in Part&#160;I of this document on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_70">44</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on compliance with Section&#160;16(a) of the Securities Exchange Act of 1934, if applicable, is incorporated by reference from the discussion under the heading &#8220;Stock Ownership Information&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a Code of Conduct &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Values and Standards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applicable to all employees, including the principal executive officer, principal financial officer, principal accounting officer and Controller. The Code of Conduct is available on the Company&#8217;s website at merck.com/company-overview/culture-and-values/code-of-conduct/values-and-standards. The Company intends to disclose future amendments to certain provisions of the Code of Conduct, and waivers of the Code of Conduct granted to executive officers and directors, if any, on the website within four business days following the date of any amendment or waiver. Every Merck employee is responsible for adhering to business practices that are in accordance with the law and with ethical principles that reflect the highest standards of corporate and individual behavior.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on the identification of the audit committee and the audit committee financial expert is incorporated by reference from the discussion under the heading &#8220;Board Meetings and Committees&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_223"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Executive Compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required on executive compensation is incorporated by reference from the discussion under the headings &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Summary Compensation Table,&#8221; &#8220;All Other Compensation&#8221; table, &#8220;Grants of Plan-Based Awards&#8221; table, &#8220;Outstanding Equity Awards&#8221; table, &#8220;Option Exercises and Stock Vested&#8221; table, &#8220;Pension Benefits&#8221; table, &#8220;Nonqualified Deferred Compensation&#8221; table, and &#8220;Potential Payments Upon Termination or a Change in Control&#8221;, including the discussion under the subheadings &#8220;Separation&#8221; and &#8220;Change in Control,&#8221; as well as all footnote information to the various tables, of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on director compensation is incorporated by reference from the discussion under the heading &#8220;Director Compensation&#8221; and related &#8220;2021 Schedule of Director Fees&#8221; table and &#8220;2021 Director Compensation&#8221; table of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information under the headings &#8220;Compensation and Management Development Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation and Management Development Committee Report&#8221; is incorporated by reference from the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_226"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to security ownership of certain beneficial owners and management is incorporated by reference from the discussion under the heading &#8220;Stock Ownership Information&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the options, warrants and rights and other equity compensation under the Company&#8217;s equity compensation plans as of the close of business on December&#160;31, 2021. The table does not include information about tax qualified plans such as the Merck U.S. Savings Plan.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>securities&#160;to&#160;be<br/>issued upon<br/>exercise of<br/>outstanding<br/>options,&#160;warrants<br/>and rights<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price of<br/>outstanding<br/>options, warrants<br/>and rights<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>securities&#160;remaining<br/>available&#160;for&#160;future<br/>issuance&#160;under&#160;equity<br/>compensation plans<br/>(excluding<br/>securities<br/>reflected&#160;in&#160;column&#160;(a))<br/>(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,572,010</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,994,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,572,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.27&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,994,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.94pt">Includes options to purchase shares of Company Common Stock and other rights under the following shareholder-approved plans: the Merck &amp; Co., Inc. 2010 and 2019 Incentive Stock Plans, and the Merck&#160;&amp; Co., Inc. 2010 Non-Employee Directors Stock Option Plan.</span></div><div style="margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes approximately 11,790,206&#160;shares of restricted stock units and 1,965,983 performance share units (assuming maximum payouts) under the Merck Sharp&#160;&amp; Dohme 2010 and 2019 Incentive Stock Plans. Also excludes 193,107 shares of phantom stock deferred under the MSD Employee Deferral Program and 468,633 shares of phantom stock deferred under the Merck &amp; Co., Inc. Plan for Deferred Payment of Directors&#8217; Compensation.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_229"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on transactions with related persons is incorporated by reference from the discussion under the heading &#8220;Related Person Transactions&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required information on director independence is incorporated by reference from the discussion under the heading &#8220;Independence of Directors&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022.</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_232"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Principal Accountant Fees and Services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required for this item is incorporated by reference from the discussion under Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm for 2022 beginning with the caption &#8220;Pre-Approval Policy for Services of Independent Registered Public Accounting Firm&#8221; through &#8220;Fees for Services Provided by the Independent Registered Public Accounting Firm&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_235"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_238"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.02pt">Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The following documents are filed as part of this Form&#160;10-K</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_241"></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated statement of income for the years ended December&#160;31, 2021, 2020 and 2019 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated statement of comprehensive income for the years ended December&#160;31, 2021, 2020 and 2019 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated balance sheet as of December&#160;31, 2021 and 2020 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated statement of equity for the years ended December&#160;31, 2021, 2020 and 2019 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated statement of cash flows for the years ended December&#160;31, 2021, 2020 and 2019 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to consolidated financial statements</span></div><div style="margin-top:6pt;padding-left:81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report of PricewaterhouseCoopers LLP, independent registered public accounting firm (PCAOB ID <ix:nonNumeric contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yNDEvZnJhZzo3ZTliYjkyMjkwMzI0Nzk1YmVjNGUwNzE1NmYyY2IwNy90ZXh0cmVnaW9uOjdlOWJiOTIyOTAzMjQ3OTViZWM0ZTA3MTU2ZjJjYjA3XzEwOTk1MTE2MjgyOTY_1c554e82-561f-4a7e-b099-6e83fd9270e8">238</ix:nonNumeric>)</span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_244"></div><div style="margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Financial Statement Schedules</span></div><div style="margin-top:6pt;text-align:justify;text-indent:81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules are omitted because they are either not required or not applicable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statements of affiliates carried on the equity basis have been omitted because, considered individually or in the aggregate, such affiliates do not constitute a significant subsidiary.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_247"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-bottom:1pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex31.htm">Restated Certificate of Incorporation of Merck &amp; Co., Inc. (November 3, 2009)&#160;&#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed November 4, 2009 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015815000048/exhibit32-byxlawsxmerckcoi.htm">By-Laws of Merck &amp; Co., Inc. (effective July 22, 2015) &#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed July 28, 2015 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture, dated as of April 1, 1991, between Merck Sharp &amp; Dohme Corp. (f/k/a Schering Corporation) and U.S. Bank Trust National Association (as successor to Morgan Guaranty Trust Company of New York), as Trustee (the 1991 Indenture)&#160;&#8212;&#160;Incorporated by reference to Exhibit&#160;4 to MSD&#8217;s Registration Statement on Form S-3 (No. 33-39349)</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64978/0000950123-97-008101.txt">First Supplemental Indenture to the 1991 Indenture, dated as of October 1, 1997&#160;&#8212;&#160;Incorporated by reference to Exhibit 4(b) to MSD&#8217;s Registration Statement on Form S-3 filed September 25, 1997 (No.&#160;333-36383)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex43.htm">Second Supplemental Indenture to the 1991 Indenture, dated November 3, 2009&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.3 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed November 4, 2009 (No.1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312512216683/d318209dex41.htm">Third Supplemental Indenture to the 1991 Indenture, dated May 1, 2012&#160;&#8212; Incorporated by reference to Exhibit 4.1 to Merck &amp; Co., Inc.&#8217;s Form 10-Q Quarterly Report for the period ended March&#160;31, 2012 (No.&#160;1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012303013260/y92128exv4w1.txt">Indenture, dated November 26, 2003, between Merck &amp; Co., Inc. (f/k/a Schering-Plough Corporation) and The Bank of New York as Trustee (the 2003 Indenture)&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.1 to Schering-Plough&#8217;s Current Report on Form&#160;8&#8209;K filed November&#160;28, 2003 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012303013260/y92128exv4w3.txt">Second Supplemental Indenture to the 2003 Indenture (including Form of Note), dated November&#160;26, 2003&#160;&#8212; Incorporated by reference to Exhibit 4.3 to Schering-Plough&#8217;s Current Report on Form&#160;8&#8209;K filed November 28, 2003 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012307012711/y39738exv4w1.htm">Third Supplemental Indenture to the 2003 Indenture (including Form of Note), dated September 17, 2007&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.1 to Schering-Plough&#8217;s Current Report on Form 8&#8209;K filed September 17, 2007 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex44.htm">Fifth Supplemental Indenture to the 2003 Indenture, dated November 3, 2009&#160;&#8212;&#160;Incorporated by reference to Exhibit&#160;4.4 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed November 4, 2009 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312510278450/dex41.htm">Indenture, dated as of January 6, 2010, between Merck &amp; Co., Inc. and U.S. Bank Trust National Association, as Trustee&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.1 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed December 10, 2010 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/exhibit410-merckdescriptio.htm">Description of the Registrant&#8217;s Common Stock - Incorporated by reference to Exhibit 4.10 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/exhibit411-merckdescriptio.htm">Description of the Registrant&#8217;s 1.125% Notes due 2021, 1.875% Notes due 2026, and 2.500% Notes due 2034 - Incorporated by reference to Exhibit 4.11 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/exhibit412-merckdescriptio.htm">Description of the Registrant&#8217;s 0.500% Notes due 2024 and 1.375% Notes due 2036 - Incorporated by reference to Exhibit 4.12 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000130817915000131/lmrk2015_def14a.htm">Merck &amp; Co., Inc. Executive Incentive Plan (as amended and restated effective June 1, 2015)&#160;&#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Schedule 14A filed April 13, 2015 (No.&#160;1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015820000005/ex102deferralprograme.htm">Merck &amp; Co., Inc. Deferral Program Including the Base Salary Deferral Plan (Amended and Restated effective December 1, 2019) - Incorporated by reference to Exhibit 10.2 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2019 filed February 26, 2020 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000130817915000131/lmrk2015_def14a.htm">Merck &amp; Co., Inc. 2010 Incentive Stock Plan (as amended and restated June 1, 2015)&#160;&#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Schedule 14A filed April 13, 2015 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012311047041/y90523exv10w2.htm">Form of stock option terms for 2011 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.2 to Merck &amp; Co., Inc.&#8217;s Form 10&#8209;Q Quarterly Report for the period ended March 31, 2011 filed May 9, 2011  (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312512084319/d274705dex1020.htm">Form of stock option terms for 2012 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.20 to Merck &amp; Co., Inc.&#8217;s Form 10&#8209;K Annual Report for the fiscal year ended December 31, 2011 filed February&#160;28, 2012 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312513084618/d438975dex1019.htm">Form of stock option terms for 2013 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.19 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2012 filed February&#160;28, 2013 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015815000005/ex1018stockoptiontermsfor2.htm">Form of stock option terms for 2014 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.18 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December&#160;31, 2014 filed February&#160;27, 2015 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015816000063/ex10202015nqsograntsunderm.htm">Form of stock option terms for 2015 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.20 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December&#160;31, 2015 filed February&#160;26, 2016 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015818000005/ex1012_2018nqsogranttermsu.htm">Form of stock option terms for 2018 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan &#8212; Incorporated by referent to Exhibit 10.12 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2017 filed February 27, 2018 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015817000010/ex10192016nqsograntsunderm.htm">Form of stock option terms for 2016 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan &#8212;&#160;Incorporated by reference to Exhibit 10.19 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2016 filed February&#160;28, 2017 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015818000005/ex1017_2018restrictedstock.htm">Form of restricted stock unit terms for 2018 quarterly and annual grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan &#8212; Incorporated by reference to Exhibit 10.17 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2017 filed on February 28, 2018 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015818000011/exhibit10psuawardtermsunde.htm">2018 Performance Share Unit Award Terms under the Merck &amp; Co., Inc. 2010 Stock Incentive Plan &#8212; Incorporated by reference to Exhibit 10 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 10-Q Quarterly Report for the period ended March 31, 2018 filed May 8, 2018 (No. 1-6571)</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000114036119006720/mrk-def14a_052819.htm">Merck &amp; Co., Inc. 2019 Incentive Stock Plan - Incorporated by reference to Appendix C to Merck &amp; Co., Inc.&#8217;s Schedule 14A filed April 8, 2019 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312512485851/d445500dex101.htm">Merck &amp; Co., Inc. Change in Control Separation Benefits Plan (effective as amended and restated, as of January 1, 2013)&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.1 to Merck&#160;&amp; Co., Inc.&#8217;s Current Report on Form&#160;8&#8209;K filed November 29, 2012 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015819000014/ex1019merckusseparationben.htm">Merck &amp; Co., Inc. U.S. Separation Benefits Plan (amended and restated as of January 1, 2019) - Incorporated by reference to Exhibit 10.19 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2018 filed February 27, 2019 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64978/0000950123-96-004374.txt">Retirement Plan for the Directors of Merck &amp; Co., Inc. (amended and restated June 21, 1996)&#160;&#8212;Incorporated by reference to Exhibit 10.C to MSD&#8217;s Form 10-Q Quarterly Report for the period ended June&#160;30, 1996 filed August 13, 1996 (No. 1-3305)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1017-planfordeferre.htm">Merck &amp; Co., Inc. Plan for Deferred Payment of Directors&#8217; Compensation (Amended and Restated effective as of January 1, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1017-planfordeferre.htm">2022)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012304005617/y96428exv10wu.txt">Distribution agreement between Schering-Plough and Centocor, Inc., dated April 3, 1998&#160;&#8212;&#160;Incorporated by reference to Exhibit 10(u) to Schering-Plough&#8217;s Amended 10-K for the year ended December 31, 2003 filed May 3, 2004 (No. 1-6571)&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012307016977/y45185exv10w1.htm">Amendment Agreement to the Distribution Agreement between Centocor, Inc., CAN Development, LLC, and Schering-Plough (Ireland) Company&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.1 to Schering-Plough&#8217;s Current Report on Form 8-K filed December 21, 2007 (No. 1-6571)&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015819000014/a2018form10-k_exhibit1027x.htm">Severance Agreement and General Release between Merck &amp; Co., Inc. and Adam H. Schechter, dated December 1, 2018 - Incorporated by reference to Exhibit 10.27 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2018 filed February 27, 2019 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015819000014/a2018form10-k_ex1028xoffer.htm">Offer Letter between Merck &amp; Co., Inc. and Jennifer Zachary, dated March 16, 2018 - Incorporated by reference to Exhibit 10.28 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2018 filed February 27, 2019 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex1023-2021annualnqsoterms.htm">Form of stock option terms for 2021 annual non-qualified option grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex1023-2021annualnqsoterms.htm"> - </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex1023-2021annualnqsoterms.htm">Incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex1023-2021annualnqsoterms.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex1023-2021annualnqsoterms.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex1023-2021annualnqsoterms.htm">23</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex1023-2021annualnqsoterms.htm"> to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex10-24x2021annualrsuterms.htm">Form of restricted stock unit terms for 2021 annual grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex10-24x2021annualrsuterms.htm"> - </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex10-24x2021annualrsuterms.htm">Incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex10-24x2021annualrsuterms.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex10-24x2021annualrsuterms.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex10-24x2021annualrsuterms.htm">24</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex10-24x2021annualrsuterms.htm"> to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1024-2022annualnqso.htm">Form of stock option terms for 2022 annual non-qualified option grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1025-2022annualrsut.htm">Form of restricted stock unit terms for 2022 annual grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21-subsidiarylistas.htm">Subsidiaries of Merck &amp; Co., Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23-consentofindependentr.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex241-powerofattorney1.htm">Power of Attorney</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex242-certificationofboard.htm">Certified Resolution of Board of Directors</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311-rule13ax14a15dx14ace.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312-rule13ax14a15dx14ace.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321-section1350certifica.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322-section1350certifica.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Certain portions of the exhibit have been omitted pursuant to a request for confidential treatment. The non-public information has been filed separately with the Securities and Exchange Commission pursuant to rule&#160;24b-2 under the Securities Exchange Act of 1934, as amended.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of Merck &amp; Co., Inc.&#8217;s total consolidated assets are not filed as exhibits to this report. Merck &amp; Co., Inc. will furnish a copy of these agreements to the Securities and Exchange Commission on request.</span></td></tr></table></div><div><span><br/></span></div><div id="i1e1e934bfffd457891fb6e33dae50d64_250"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</span></div></div></div><div id="i1e1e934bfffd457891fb6e33dae50d64_253"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Table o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">f </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1e1e934bfffd457891fb6e33dae50d64_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:&#160;&#160;&#160;&#160;February&#160;25, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.801%"><tr><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK&#160;&amp; CO., INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Chief Executive Officer and President)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Attorney-in-Fact)</span></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:28.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President;</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Executive Officer; Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAROLINE LITCHFIELD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer; Principal Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RITA A. KARACHUN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance-Global Controller;</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accounting Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KENNETH C. FRAZIER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MARY ELLEN COE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAMELA J. CRAIG</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THOMAS H. GLOCER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RISA J. LAVIZZO-MOUREY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STEPHEN L. MAYO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAUL B. ROTHMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PATRICIA F. RUSSO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHRISTINE E. SEIDMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INGE G. THULIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KATHY J. WARDEN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PETER C. WENDELL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jennifer Zachary, by signing her name hereto, does hereby sign this document pursuant to powers of attorney duly executed by the persons named, filed with the Securities and Exchange Commission as an exhibit to this document, on behalf of such persons, all in the capacities and on the date stated, such persons including a majority of the directors of the Company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.371%"><tr><td style="width:1.0%"></td><td style="width:14.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Attorney-in-Fact)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>2
<FILENAME>exhibit1017-planfordeferre.htm
<DESCRIPTION>EXHIBIT-10.17 PLAN FOR DEFERRED PAYMENT OF DIRECTORS COMPENSATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i010e8b01fa9c42e1b3f88df1ef02ecbf_1"></div><div style="min-height:47.52pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.17</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PLAN FOR DEFERRED PAYMENT OF</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DIRECTORS' COMPENSATION</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Effective as Amended and Restated January 1, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:47.52pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article I &#160;&#160;&#160;&#160;Purpose&#160;&#160;&#160;&#160;  1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article II &#160;&#160;&#160;&#160;Election of Deferral, Investment Alternatives and Distribution Schedule&#160;&#160;&#160;&#160;  1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article III &#160;&#160;&#160;&#160;Valuation of Deferred Amounts&#160;&#160;&#160;&#160;  3</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article IV &#160;&#160;&#160;&#160;Redesignation Within a Deferral Account&#160;&#160;&#160;&#160;  5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article V &#160;&#160;&#160;&#160;Payment of Deferred Amounts&#160;&#160;&#160;&#160;  6</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article VI &#160;&#160;&#160;&#160;Designation of Beneficiary&#160;&#160;&#160;&#160;  6</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article VII &#160;&#160;&#160;&#160;Plan Amendment or Termination&#160;&#160;&#160;&#160;  7</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article VIII&#160;&#160;&#160;&#160;Section 409A Compliance&#160;&#160;&#160;&#160;  7</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Article IX&#160;&#160;&#160;&#160;Effective Date&#160;&#160;&#160;&#160;  7</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div></div><div id="i010e8b01fa9c42e1b3f88df1ef02ecbf_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PLAN FOR DEFERRED PAYMENT OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DIRECTORS' COMPENSATION</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.&#160;&#160;&#160;&#160;PURPOSE</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Merck &#38; Co., Inc. Plan for Deferred Payment of Directors&#8217; Compensation (&#8220;Plan&#8221;) provides an unfunded arrangement for directors of Merck &#38; Co., Inc., formerly known as Schering-Plough Corporation (&#8220;Merck&#8221; or the &#8220;Company&#8221;) prior to the closing date (&#8220;Closing Date&#8221;) of the Agreement and Plan of Merger dated as of March 8, 2009, as amended, by and among Merck &#38; Co., Inc., Schering-Plough Corporation, SP Merger Subsidiary One, Inc. and SP Merger Subsidiary Two, Inc. (the &#8220;Transactions&#8221;), other than directors that are current employees of the Company or its subsidiaries, to value, account for and ultimately distribute amounts deferred (i) voluntarily in case of annual retainers and Board and committee meeting fees, if any, and (ii) mandatorily in certain other cases as described herein.  Prior to the Closing Date, the predecessor to this Plan provided identical benefits to directors of Merck Sharp &#38; Dohme Corp. (formerly Merck &#38; Co, Inc. prior to the Closing Date) (&#8220;MSD&#8221;).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">II.&#160;&#160;&#160;&#160;ELECTION OF DEFERRAL, INVESTMENT ALTERNATIVES AND DISTRIBUTION SCHEDULE</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Election of Voluntary Deferral Amount</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Prior to December 31 of each year, each director may irrevocably elect (an &#8220;Initial Election&#8221;) to defer, until termination of service as a director or later, 50% or 100% of each of the following (together, the &#8220;Voluntary Deferral Amount&#8221;) with respect to the 12 months beginning April 1 of the next calendar year after such Initial Election&#58; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:122.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) Board retainer </font></div><div style="padding-left:122.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) Lead Director retainer </font></div><div style="padding-left:122.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c) Committee Chairperson retainer </font></div><div style="padding-left:122.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d) Audit Committee member retainer, and </font></div><div style="padding-left:122.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e) Board and committee meeting fees, if any. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Prior to commencement of duties as a director or within the first 30 days following commencement of services, a director newly elected or appointed to the Board during a calendar year may make an Initial Election for the portion of the Voluntary Deferral Amount applicable to such director's first year of service (or part thereof). </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;The Voluntary Deferral Amount shall be credited as follows&#58;  (1) Board and committee meeting fees, if any, that are deferred are credited as of the last business day of each calendar quarter&#59; (2) if the Board retainer, Lead Director retainer, Committee Chairperson retainer and&#47;or Audit Committee member retainer are deferred, a pro-rata share of the deferred retainer is credited as of the last business day of each calendar quarter.  The dates as of which the Voluntary Deferral Amount, or parts thereof, are credited to the director's deferred account are hereinafter referred to as the Voluntary Deferral Dates.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Once an Initial Election is made, including, effective December&#8217;s 2008, elections made by directors of MSD prior to the Transactions, it shall continue to apply in successive years on the same terms and conditions until the director makes a new Initial Election.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Certain directors (the &#8220;Schering Directors&#8221;) who were directors of Schering-Plough Corporation on the Closing Date of the Transactions continued service </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">following the Closing Date.  Anything in the Plan to the contrary notwithstanding, the Schering Directors were first eligible to elect Voluntary Deferrals by December 31 of the year that includes the Closing Date.  That initial election may not apply earlier than January 1 of the following year and shall continue through April 1 of the second year following the Closing Date. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Deferral Amount</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;As of the Friday following the Company&#8217;s Annual Meeting of Shareholders (the &#8220;Mandatory Deferral Date&#8221;), each director will be credited with an amount equivalent to the annual cash retainer for the 12 month period beginning on the April 1 preceding the Annual Meeting&#59; provided, however, that effective for the 12-month period beginning April 1, 2022 and thereafter, such credit shall instead equal $220,000 (the &#8220;Mandatory Deferral Amount&#8221;).  The Mandatory Deferral Amount will be measured by the Merck Common Stock account.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;A director newly elected or appointed to the Board after the Mandatory Deferral Date will be credited with a pro rata portion of the Mandatory Deferral Amount applicable to such director's first year of service (or part thereof).  Such pro rata portion shall be credited to the director's account as of the first day of such director's service.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;For purposes of the Mandatory Deferral Amount, the Schering Directors shall be treated as if newly elected or appointed to the Board as of the Closing Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Automatic Deferral of Executive Committee Fees</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Between June 2005, and April 2007, directors of MSD who served as either Chairperson or member of the Board&#8217;s Executive Committee, in lieu of any cash payment for such service, were credited with an amount provided by way of retainer or meeting fees (the &#8220;Automatic Deferral Amount&#8221;).  The Automatic Deferral Amount is measured by the Merck Common Stock account.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Election of Investment Alternatives</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Initial Election shall include an election as to the investment alternatives by which the value of amounts deferred will be measured in accordance with Article III, below.  Investment alternatives available under this Plan shall be the same as the investment alternatives available from time to time under the Merck &#38; Co., Inc. Deferral Program (the &#8220;Executive Deferral Program&#8221;)&#59; provided, however, that at all times there shall be a Merck Common Stock fund.  All investment alternatives other than Merck Common Stock are referred to herein as &#8220;Other Investment Alternatives.&#8221;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:3pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Election of Distribution Schedule</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">An Initial Election shall include an election of the year during which the Distribution Date (as defined below) shall occur and shall apply to all Voluntary Deferral Amounts, Mandatory Deferral Amounts and Automatic Deferral Amounts credited during the same period.  The Distribution Date shall be the 15th day of the month (or, if such day is not a business day, the next business day) of a calendar quarter following the Director&#8217;s termination of service as a director or such number of years thereafter as would be permitted for distributions elected under the Executive Deferral Program. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Changes to Distribution Schedule </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If and to the extent that participants in the Executive Deferral Program are permitted to make re-deferral elections from time to time, participants in this Plan </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">may elect to defer their Distribution Dates subject to the same restrictions applicable under the Executive Deferral Program&#59; provided, however, that no re-deferral election may have the effect of accelerating a distribution prior to a director&#8217;s termination of service or death.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Unforeseeable Emergency</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee shall distribute a participant's deferred amounts if and to the extent a participant applies to receive a distribution due to an Unforeseeable Emergency as defined in Treas. Reg. Sec. 1.409A-3(i) or successor thereto.  A participant wishing a hardship distribution must provide the Committee or its delegate with sufficient evidence to prove compliance with Treas. Reg. Sec. 1.409A-3(i).  Such a participant&#8217;s entire account balance may be distributed to satisfy such Unforeseeable Emergency without regard to whether it is invested wholly or partially in Merck Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VALUATION OF DEFERRED AMOUNTS</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Merck Common Stock</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Initial Crediting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The annual Mandatory Deferral Amount shall be used to determine the number of full and partial shares of Merck Common Stock that such amount would purchase at the closing price of the Common Stock on the New York Stock Exchange (&#8220;NYSE&#8221;) on the Mandatory Deferral Date.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Automatic Deferral Amount is used to determine the number of full and partial shares of Merck Common Stock that such amount would have purchased at the closing price of the Common Stock on the NYSE.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">That portion of the Voluntary Deferral Amount allocated to Merck Common Stock shall be used to determine the number of full and partial shares of Merck Common Stock that such amount would purchase at the closing price of the Common Stock on the NYSE on the applicable Voluntary Deferral Date. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Plan is unfunded&#58;  at no time will any shares of Merck Common Stock be purchased or earmarked for such deferred amounts nor will any rights of a shareholder exist with respect to such amounts.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Dividends.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each director's account will be credited with the additional number of full and partial shares of Merck Common Stock that would have been purchasable with the dividends on shares previously credited to the account at the closing price of the Common Stock on the NYSE on the date each dividend was paid. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Distributions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Distributions from the Merck Common Stock account will be valued at the closing price of Merck Common Stock on the NYSE as of the Distribution Date.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;For purposes of valuation of Merck Common Stock, if Merck Common Stock is no longer traded on the NYSE, but is publicly traded on any other exchange, references to NYSE shall mean such other exchange.  If Merck Common Stock is not publicly traded and if the Governance Committee of the Board of Directors (formerly known as the Committee on Corporate Governance) determines that a measurement of Merck Common Stock on any Mandatory or Voluntary Deferral Date or Distribution Date would not constitute fair market value, then the Committee shall decide on the date and method to determine fair market value, which shall be in accord with any requirements set forth under Section 409A or any successor thereto.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Other Investment Alternatives</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Initial Crediting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The amount allocated to each Other Investment Alternative shall be used to determine the full and partial Other Investment Alternative shares that such amount would purchase at the closing net asset value of the Other Investment Alternative shares on the Mandatory or Voluntary Deferral Date, whichever is applicable.  The director&#8217;s account will be credited with the number of full and partial Other Investment Alternative shares so determined.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">At no time will any Other Investment Alternative shares be purchased or earmarked for such deferred amounts nor will any rights of a shareholder exist with respect to such amounts.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Dividends.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each director&#8217;s account will be credited with the additional number of full and partial Other Investment Alternative shares that would have been purchasable, at the closing net asset value of the Other Investment Alternative shares as of the date each dividend is paid on the Other Investment Alternative shares, with the dividends that would have been paid on the number of shares previously credited to such account (including pro rata dividends on any partial shares).</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Distributions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Other Investment Alternative distributions will be valued based on the closing net asset value of the Other Investment Alternative shares as of the Distribution Date.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Adjustments</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In the event of a reorganization, recapitalization, stock split, stock dividend, combination of shares, merger, consolidation, rights offering or any other change in the corporate structure or shares of the Company or an Other Investment Alternative, the number and kind of shares or units shall be adjusted accordingly.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IV.&#160;&#160;&#160;&#160;REDESIGNATION WITHIN A DEFERRAL ACCOUNT</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">General</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A director may redesignate how his or her account is invested among the Other Investment Alternatives (a &#8220;Redesignation&#8221;).  A Redesignation affects only the Investment Alternatives&#59; it does not affect the timing of distributions from the Plan. Except as provided in Section G. of Article II, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">amounts deferred using the Merck Common Stock method and any earnings attributable to such deferrals may not be redesignated prior to the first anniversary of the termination of the director&#8217;s service.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The change will be effective at the closing price as of (i) the day when the redesignation request is received pursuant to administrative guidelines established by the Human Resources Financial Services area provided the request is received prior to the close of the NYSE on such day or (ii) the next following business day if the request is received when the NYSE is closed. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">When Redesignation May Occur</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">During Active Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. There is no limit on the number of times a director may Redesignate the portion of his&#47;her deferred account permitted to be Redesignated. Each such request shall be irrevocable and can be Redesignated in whole percentages or as a dollar amount.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">After Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Following the death of a director, the legal representative or beneficiary of such director may Redesignate subject to the same rules as for active directors set forth in Article IV, Section B.1.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Valuation of Amounts to be Redesignated </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The portion of the director's account to be Redesignated will be valued at its cash equivalent and such cash equivalent will be converted into shares or units of the Other Investment Alternatives.  For purposes of such Redesignations, the cash equivalent of the value of the Other Investment Alternative shares shall be the closing net asset value of such Other Investment Alternative as of (i) the day when the Redesignation request is received pursuant to administrative guidelines established by the Human Resources Financial Services area of the Treasury department, provided the request is received prior to the close of the NYSE on such day or (ii) the next following business day if the request is received when the NYSE is closed.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">V.&#160;&#160;&#160;&#160;PAYMENT OF DEFERRED AMOUNTS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payment</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;All payments to directors of amounts deferred will be in cash as of the Distribution Date.  Distributions shall be pro rata by investment alternative.  Distributions shall be paid as soon as administratively feasible after the Distribution Date.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Forfeitures</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;A director's deferred amount attributable to the Mandatory Deferral Amount and earnings thereon shall be forfeited upon his or her removal as a director or upon a determination by the Governance Committee, in its sole discretion that, a director has&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;joined the Board of, managed, operated, participated in a material way in, entered employment with, performed consulting (or any other) services for, or otherwise been connected in any material manner with a company, corporation, enterprise, firm, limited partnership, partnership, person, sole proprietorship or any other business entity determined by the Governance Committee in its sole discretion to be competitive with the business of the Company, its subsidiaries or its affiliates (a &#34;Competitor&#34;)&#59;</font></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><font><br></font></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;directly or indirectly acquired an equity interest of 5&#160;percent or greater in a Competitor&#59; or</font></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><font><br></font></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;disclosed any material trade secrets or other material confidential information, including customer lists, relating to the Company or to the business of the Company to others, including a Competitor.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VI.&#160;&#160;&#160;&#160;DESIGNATION OF BENEFICIARY</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of the death of a director&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;The deferred amount at the date of death shall be paid to the last named beneficiary or beneficiaries designated by the director, or, if no beneficiary has been designated, to the legal representative of the director's estate.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;A lump sum distribution of any remaining account balance will be made to the director&#8217;s beneficiary or estate&#8217;s legal representative as soon as administratively feasible </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">following such death, whether or not the director was in service at the time of death or has commenced to receive payments of his or her account balance.  The Distribution Date of such a distribution shall be the 15th day of the month (or, if such day is not a business day, the next business day) of the calendar quarter following the date the Company learns of such death.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VII.&#160;&#160;&#160;&#160;PLAN AMENDMENT OR TERMINATION</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Governance Committee shall have the right to amend or terminate this Plan at any time for any reason.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIII.&#160;&#160;&#160;&#160;SECTION 409A COMPLIANCE </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anything in the Plan to the contrary notwithstanding, the Plan shall comply with Section 409A of the Internal Revenue Code of 1986, as amended (or any successor thereto) (the &#8220;Code&#8221;) and shall be interpreted in accordance therewith.  Any payment called for under the Plan as of or as soon as administratively feasible on or after a designated date shall be made no later than a date within the same tax year of a director, or by March 15 of the following year, if later (or such other time as permitted in Treas. Reg. Sec. 1.409A-3(d) or any successor thereto)&#59; provided further, that the director is not permitted to change the taxable year of payment, except in accordance with Article II, Section F and Section 409A of the Code.  Where the Plan&#8217;s obligation to pay is unclear, including a dispute about who is the proper beneficiary of a director who dies, payment shall be made as soon as administratively feasible after the Program&#8217;s obligation becomes clear and at a time permitted by Treas. Reg. Sec. 1.409A-3(g)(4) or any successor thereto.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IX.&#160;&#160;&#160;&#160;EFFECTIVE DATE.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This amendment and restatement of this plan shall be effective as of January 1, 2022.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>exhibit1024-2022annualnqso.htm
<DESCRIPTION>EXHIBIT-10.24 2022 ANNUAL NQSO TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic53a4947ab3a48d9a9f71ba8d5c789d2_1"></div><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.24</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GLOBAL TERMS AND CONDITIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Grant Type&#58;    &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">NQSO &#8211; Annual </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Option Price&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  &#160;&#160;&#160;&#160;$XX.XX </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Grant Date&#58;     &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">May 3, 2022 </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Expiration Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">May 2, 2032 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Vesting Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Portion that Vests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">May 3, 2023                 First&#58;  33.333% </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">May 3, 2024                 Second&#58;  33.333% </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">May 3, 2025                 Third&#58;  Balance     </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">    </font></div><div style="margin-bottom:0.08pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:252pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:28.97pt">GENERAL</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Merck &#38; Co., Inc. (the &#8220;Company&#8221;) has granted to you the stock option specified in this document pursuant to the Merck &#38; Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the &#8220;Plan&#8221;).  This stock option is subject to the terms and conditions of the Plan and these Global Terms and Conditions, including any additional terms and conditions for your country in Appendix B (the &#8220;Terms&#8221;).  Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">IMPORTANT NOTICE&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This grant requires you to affirmatively accept it.  You </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> log onto the Morgan Stanley website at&#58; </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days.  Failure to accept the terms and conditions of your stock option within 90 days may result in Forfeiture of the stock option.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Vesting &#38; Expiration Dates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> This stock option becomes exercisable in equal installments (subject to a rounding process) on the Vesting Dates indicated in the box above. This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (&#8220;JV&#8221;) of the Company by which you are employed (the &#8220;Employer&#8221;) is terminated, your right to exercise this stock option will be determined according to the terms in Section II and for grantees outside the United States, also in paragraph 12 of Section A (&#8220;Nature of Grant&#8221;) of Appendix B, Part I.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;Subject to Recoupment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> This stock option will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.69pt">TERMINATION OF EMPLOYMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:7.31pt">General Rule.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">  If your employment is terminated for any reason other than those specified in the following paragraphs, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire unless exercised before the New York Stock Exchange closes (the &#8220;Close of Business&#8221;) on the day before the same day of the third </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">month (&#8220;Within Three Months&#8221;) after the date of the termination (but in no event after the expiration of the Option Period).  Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open.  Where there is no corresponding day of a month, the last day of the month is deemed to be the same day as a later date (e.g., November 28, 29 and 30 all correspond to February 28 in non-leap years).  If you are rehired by the Company or the Employer, as applicable, this option nevertheless will expire unless exercised Within Three Months, or the original Expiration Date if earlier. </font></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:7.92pt">Involuntary Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">  If the Company determines that your employment is involuntarily terminated, including the result of a restructuring or job elimination, but excluding non-performance of your duties and the reasons listed under paragraphs C through H, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire on the day before the one year anniversary of the date your employment ends, but in no event later than the original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:7.92pt">Sale.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> If your employment is terminated and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or JV, the following portion of this stock option award will vest and become exercisable immediately upon such termination&#58; if employment terminates on or after the Grant Date but before the first anniversary thereof, then one-third of this stock option award will vest and become exercisable&#59; if employment terminates on or after the first anniversary of the Grant Date, then all unvested stock options will vest and become exercisable. The remaining portion, if any, of this stock option that does not vest pursuant to the foregoing sentence will be forfeited on the date your employment terminates.  Whether already vested on the date your employment terminates or vested as a result of such sale, this stock option will expire the day before the first anniversary of the date your employment with the Company or the Employer, as applicable, ends, but in no event later than the original Expiration Date. Notwithstanding the foregoing, the Committee may determine, for purposes of this stock option grant, whether employment with an entity that is established from the Company&#8217;s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a&#160; termination of employment, and may make adjustments, if any, as it deems appropriate, and not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and&#47;or number of shares subject to this option, and&#47;or in the option price of such option.  If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:7.31pt">Retirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> If your employment terminates as the result of your retirement, the portion of this stock option that would have become exercisable according to its original schedule within one year of the date your employment terminates will vest and become exercisable on its applicable Vesting Date and the remainder will expire immediately.  Whether already vested on the date your employment terminates or vested as a result of such retirement, this option will expire on the earlier of (a) the day before the fifth anniversary of the termination date or (b) its original Expiration Date.  For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:8.54pt">Death.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. This stock option will expire on such earlier date than otherwise specified in this paragraph as may be required under applicable non-U.S. law (e.g., in France, six months from the date of death). If you die while any portion of this stock option remains outstanding, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in  paragraph B, C, D, G or H as applicable (and at least a year from your death in those jurisdictions where such extension is required by law).</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:9.14pt">Misconduct.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:7.31pt">Disability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If your employment is terminated and the Company determines that such termination resulted from your inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this stock option will continue to become exercisable on applicable Vesting Dates and will expire on the earlier of (a) the day before the fifth anniversary of the day your employment terminates and (b) its original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:7.31pt">Change in Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> If this stock option is assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is involuntarily terminated without Cause before the second anniversary after the closing of a Change in Control, each unvested stock option that is outstanding immediately prior to the Change in Control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a Change in Control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination by reasons of retirement, involuntary termination, sale, misconduct, death or disability, as described in paragraphs B through G above or termination prior to a Change in Control. If this stock option does not remain outstanding following the Change in Control and is not converted into a successor stock option, then each unvested stock option that is outstanding immediately prior to the Change in Control will lapse as of the Change in Control and at the election of the Company, you will be entitled to receive cash for this stock option in an amount at least equal to the difference between the price paid to stockholders in the Change in Control and the Option Price of this stock option. &#8220;Cause&#8221; and &#8220;Change in Control&#8221; are defined in the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:11.59pt">Transfer of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the &#8220;Company Group&#8221;) is not considered termination of employment for purposes of this stock option. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this stock option following a transfer of employment accordance with this section.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.41pt">TRANSFERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This stock option and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">TAX WITHHOLDING</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regardless of any action the Company and&#47;or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (&#8220;Tax-Related Items&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and&#47;or the Employer, if any. You further acknowledge that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the stock option or underlying shares of Common Stock, including, but not limited to, the grant, vesting or exercise of the stock option, the subsequent sale of shares of Common Stock acquired pursuant to such exercise and the receipt of any dividends&#59; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the stock option to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and&#47;or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following&#58; (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and&#47;or any subsidiary, affiliate or JV of the Company&#59; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at exercise of the stock option either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or (iii) withholding in shares of Common Stock to be issued at exercise of the stock option&#59; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Committee must approve any decision to satisfy the Tax-Related Items by the method described in (iii) above.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in common stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and&#47;or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the exercised stock options, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares, if you fail to comply with your obligations in connection with the Tax-Related Items.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">DATA PRIVACY</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company&#8217;s data processing practices and declare your consent. </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company&#8217;s legal basis for the processing of your personal data would be your consent.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company&#8217;s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company&#8217;s legal basis for the transfer of your personal data is your consent.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee&#59; you would merely forfeit the opportunities associated with the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.54pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and&#47;or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn&#58; Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.14pt">The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company&#8217;s Global Privacy and Data Protection Policy.  You also understand that the Company may, in the future, request you to provide another data privacy consent.&#160; If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and&#47;or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.&#160; You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and&#47;or the Employer.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">If you agree with the data processing practices described in this Section, you will declare your consent by clicking to &#34;Accept&#34; these Terms on the Morgan Stanley website.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">GOVERNING LAW</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">SEVERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.47pt">WAIVER</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">COUNTY-SPECIFIC APPENDIX</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This stock option shall be subject to any additional provisions set forth in Appendix B for your country, if any. If you relocate to one of the countries included in Appendix B during the life of this stock option, the additional provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">ADMINISTRATION</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Committee is responsible for construing and interpreting this stock option, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this stock option grant.  Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this stock option grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among Eligible Employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This stock option is subject to the provisions of the 2019 Incentive Stock Plan.  For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via Sync &#62; HR &#62; Money &#62; Long-Term Incentive Program.</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic53a4947ab3a48d9a9f71ba8d5c789d2_7"></div><hr style="page-break-after:always"><div style="min-height:18.72pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.252%"><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font><br></font></div><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:6.2pt"><font><br></font></div><div style="margin-top:2.5pt;padding-left:35.3pt;padding-right:35.3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX A</font></div><div style="padding-left:35.3pt;padding-right:35.3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results</font></div><div style="padding-right:10pt;text-align:justify"><font><br></font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:1.494%;min-width:0.494%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.254%"></div></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><div id="ic53a4947ab3a48d9a9f71ba8d5c789d2_10"></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Management Development Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company&#59; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">In addition, awards under the Executive Incentive Plan (&#8220;EIP&#8221;) and Performance Share Units (&#8220;PSU&#8221;) under the Merck &#38; Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company&#8217;s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">A &#8220;Material Violation&#8221; is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company&#8217;s overall goodwill or reputation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Executive&#8221; means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Fault&#8221; means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:100%">For Compliance Violations</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">Chief Executive Officer.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its </font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">For EIP Awards and PSUs Upon </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Significant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"> Restatement of Financial Results </font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EIP Awards and PSUs for Executives are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above)&#59; and</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee shall have sole discretion to make all determinations under this policy.  Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the &#8220;Applicable Rules&#8221;).  To the extent the Applicable Rules require recovery of any bonus and&#47;or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.</font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>4
<FILENAME>exhibit1025-2022annualrsut.htm
<DESCRIPTION>EXHIBIT-10.25 2022 ANNUAL RSU TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2a42ed085c32486c921348fdc9895252_1"></div><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.25</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GLOBAL TERMS AND CONDITIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022 RESTRICTED STOCK UNIT GRANTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Grant Type&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">    RSU - Annual</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Grant Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">    May 3, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Vesting Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Portion that Vests</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">May 3, 2023                 First&#58;  33.333%</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">May 3, 2024                 Second&#58;  33.333%</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">May 3, 2025                 Third&#58;  Balance</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:28.97pt">GENERAL. </font></div><div style="text-indent:-18pt"><font><br></font></div><div style="padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Merck &#38; Co., Inc. (the &#8220;Company&#8221;) has granted to you the Restricted Stock Unit (&#8220;RSU&#8221;) award specified in this document (&#8220;RSU Award&#8221;) pursuant to the Merck &#38; Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the &#8220;Plan&#8221;).  This RSU Award is subject to the terms and conditions of the Plan and these Global Terms and Conditions, including any additional terms and conditions for your country in Appendix B (the &#8220;Terms&#8221;).  Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  This grant requires you to affirmatively accept it.  You MUST log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.  </font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;padding-right:-3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days.  Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Restricted (Vesting) Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Restricted Period is the period during which this RSU Award is subject to forfeiture and is eligible to vest.  The RSU Award will vest with respect to one-third of this RSUs subject to the RSU Award on each of the First, Second, and Third anniversaries of the Grant Date (each a &#8220;Vesting Date&#8221;) as shown in the box above, except as otherwise provided in Article II below.  No voting rights apply to this RSU Award.  No fractional shares will be issued upon settlement of the RSU Award&#59; all calculations are subject to rounding.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (&#8220;you&#8221;) if and to the extent dividends are paid by the Company on Merck Common Stock.  Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs.  If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion.  Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Distribution (Settlement of RSU Award).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion&#59; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a &#8220;change in control event&#8221; within the meaning of U.S. Treasury Regulations Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the RSU Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">409A Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a &#8220;separation from service (as defined in Section 409A)&#8221; and any such payment to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.54pt">Subject to Recoupment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.69pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (&#8220;JV&#8221;) of the Company by which you are employed (the &#8220;Employer&#8221;) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II and for grantees outside the United States, also in paragraph 12 of Section A (&#8220;Nature of Grant&#8221;) of Appendix B, Part I.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Involuntary Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If the Company determines that your employment is involuntarily terminated during the Restricted Period on or after the first anniversary of the Grant Date, the RSU Award will vest on the next subsequent Vesting Date following your employment termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to the RSU Award (whether or not vested), multiplied by (ii) a fraction, numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion, if any, of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. An &#8220;involuntary termination&#8221; includes termination of your employment by the Company or the Employer, as applicable, as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs C through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Sale.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or JV, the RSU Award will continue to vest on the following original Vesting Date(s) set forth in paragraph I(A) with respect to the following unvested portion of your RSU Award and dividend equivalents that have accrued through the corresponding Vesting Dates&#58; if employment terminates on or after the Grant Date but before the first anniversary thereof, then one-third of your RSU Award will vest on the first Vesting Date&#59; if employment terminates on or after the first anniversary of the Grant Date, the portion of your RSU Award that was eligible to vest on the second and third Vesting Dates, respectively, will vest on the corresponding Vesting Dates. The remaining portion, if any, of the RSU Award that does not vest pursuant to the foregoing sentence will be forfeited on the date your employment terminates. Notwithstanding the foregoing, the Committee may determine, for purposes of this RSU Award, whether employment with an entity that is established from the Company&#8217;s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, and to the extent not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and&#47;or number of shares subject to this RSU Award.  If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Retirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment terminates by retirement during the Restricted Period, the RSU Award will vest on the next subsequent Vesting Date following your termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to this RSU Award (whether or not vested), multiplied by (ii) a fraction, the numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending on the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.54pt">Death.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, C, D, G or H, the RSU Award will immediately vest with respect to any portion of this RSU Award that has not vested as of your death and dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.14pt">Misconduct.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date.  If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If this RSU Award is assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is terminated during the Restricted Period without Cause before the second anniversary of the closing of the Change in Control, then the RSU Award will continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of the RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date. If this RSU Award does not remain outstanding following the Change in Control and is not converted into a successor RSU, then the RSU Award will immediately vest with respect to the portion of the RSU Award that is unvested as of the Change in Control and dividend equivalents that have accrued though such date and, at the election of the Company, you will be entitled to receive cash for such portion of this RSU Award in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire. &#8220;Cause&#8221; and &#8220;Change in Control&#8221; are defined in the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.59pt">Transfer of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the &#8220;Company Group&#8221;) is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this RSU Award following a transfer of employment accordance with this section.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.41pt">TRANSFERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">TAX WITHHOLDING</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regardless of any action the Company and&#47;or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (&#8220;Tax-Related Items&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and&#47;or the Employer, if any. You further acknowledge that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and&#47;or dividend equivalents&#59; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and&#47;or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following&#58; (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and&#47;or any subsidiary, affiliate or JV of the Company&#59; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period&#59; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and&#47;or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">DATA PRIVACY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company&#8217;s data processing practices and declare your consent. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company&#8217;s legal basis for the processing of your personal data would be your consent.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company&#8217;s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company&#8217;s legal basis for the transfer of your personal data is your consent.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee&#59; you would merely forfeit the opportunities associated with the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.54pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and&#47;or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn&#58; Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.14pt">The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company&#8217;s Global Privacy and Data Protection Policy.  You also understand that the Company may, in the future, request you to provide another data privacy consent.&#160; If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and&#47;or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.&#160; You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and&#47;or the Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you agree with the data processing practices described in this Article, you will declare your consent by clicking to &#34;Accept&#34; these Terms on the Morgan Stanley website.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">GOVERNING LAW</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">SEVERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.47pt">WAIVER</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">COUNTY-SPECIFIC APPENDIX</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The RSU Award shall be subject to any additional provisions set forth in Appendix B for your country, if any. If you relocate to one of the countries included in Appendix B during the life of the RSU Award, the additional provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">ADMINISTRATION</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync &#62; HR &#62; Money &#62; Long-Term Incentive Program </font></div><div style="margin-bottom:0.12pt;padding-left:5.95pt;text-indent:36pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2a42ed085c32486c921348fdc9895252_4"></div><hr style="page-break-after:always"><div style="min-height:18.72pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.286%"><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font><br></font></div><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font><br></font></div><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font><br></font></div><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font><br></font></div><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font><br></font></div><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font><br></font></div><div style="margin-top:2.5pt;padding-left:35.3pt;padding-right:35.3pt;text-align:center"><font><br></font></div><div style="margin-top:2.5pt;padding-left:35.3pt;padding-right:35.3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX A</font></div><div style="padding-left:35.3pt;padding-right:35.3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results</font></div><div style="padding-right:10pt;text-align:justify"><font><br></font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:1.427%;min-width:0.427%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.287%"></div></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2a42ed085c32486c921348fdc9895252_7"></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Management Development Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company&#59; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">In addition, awards under the Executive Incentive Plan (&#8220;EIP&#8221;) and Performance Share Units (&#8220;PSU&#8221;) under the Merck &#38; Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company&#8217;s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">A &#8220;Material Violation&#8221; is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company&#8217;s overall goodwill or reputation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Executive&#8221; means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Fault&#8221; means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:100%">For Compliance Violations</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">Chief Executive Officer.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking </font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">For EIP Awards and PSUs Upon Significant Restatement of Financial Results </font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EIP Awards and PSUs for Executives are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above)&#59; and</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee shall have sole discretion to make all determinations under this policy.  Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the &#8220;Applicable Rules&#8221;).  To the extent the Applicable Rules require recovery of any bonus and&#47;or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion</font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>5
<FILENAME>exhibit21-subsidiarylistas.htm
<DESCRIPTION>EXHIBIT-21 SUBSIDIARY LIST
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i74662f31c22d445ca51c113eedf56771_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 21</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK &#38; CO., INC. SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">as of 12&#47;31&#47;2021</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The following is a list of subsidiaries of the Company, doing business under the name stated.</font></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Country or State</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of Incorporation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7728026 Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abmaxis Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleron Holding Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:0.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleron Pharma Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada (BC)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleron Pharma Germany GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleron Pharma Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleron Pharma Netherlands BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleron Pharma Switzerland AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleron Securities Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Afferent Pharmaceuticals, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agrident GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agro Verhen B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aleis Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Argentina S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Australia Pty. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Avrasya Hayvan Kimlik Sistemleri Sanayi Ve Ticaret Limited Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex dan-mark ApS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Europe S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Group Germany GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Holdings 1 Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Holdings 2 Inc.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Holdings 3 Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex India Private Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex International do Brasil Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Maroc S.A.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex New Zealand Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Polska Spolka z ograniczona odpowiedzialnoscia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex SCR Vostok</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belarus</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Services S.A.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex UK Group Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex USA, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alta Plastic Muhendislik Sanayi Ve Ticaret Limited Sirketi</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal ID Australia Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antelliq Finance, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antelliq Holdings France S.A.S</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antimicrobial Stewardship LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ArQule, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing Allflex Plastic Products Co. Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing Protection Science and Technology Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biomark, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idaho</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRC Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burgwedel Biotech GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Calporta Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge Resonant Technologies Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canji, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cCam Biotherapeutics Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cherokee Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chevillot S.A.S.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controladora MSD Mexicana Sociedad de Responsabilidad Limitada de Capital Variable</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cooper Veterinary Products (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporation Allflex, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cosmas B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cubist Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Destron Fearing Corporation</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialstat Trading 91 Pty Ltd T&#47;A Allflex SA</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digital Angel S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digital Angel S.A.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diosynth Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diosynth Produtos Farmo-quimicos Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drovers ID Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DSD Holding A&#47;S</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elastec S.R.L</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Essex Pharmaceuticals, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Essexfarm, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ecuador</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farmacox - Companhia Farmaceutica, Lda </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farmasix-Produtos Farmaceuticos, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financiere MSD</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fontelabor-Produtos Farmaceuticos, Lda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frosst Laboratories, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frosst Portuguesa - Produtos Farmaceuticos, Lda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GlycoFi, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GT Acquisition Sub, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnesota</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hangzhou MSD Pharmaceutical Co., Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harrisvaccines, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hawk and Falcon L.L.C.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Services and Solutions, LLC</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heptafarma Companhia Farmaceutica, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hydrochemie GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idenix GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idenix SARL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN Canada Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN Czech s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN Deutschland GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN North America Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN Switzerland AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="background-color:#f3f1f1;color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune Design B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune Design Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insight Acquisition Holdings Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Indemnity Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (Ireland) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (Israel) Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (M) Sdn. Bhd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (Thailand) Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet AB</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Agencies B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Animal Health Taiwan Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Argentina S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Australia Pty Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Canada Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Central America S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Deutschland GmbH</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Ecuador S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ecuador</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Egypt for Animal Health SAE</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet GesmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Hellas A.E.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Holdings France SAS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Hungaria &#201;rt&#233;kes&#237;t&#337; Kft</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet India Pvt Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet International B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet International GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet International Sarl</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russian Federation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Maroc S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Mexico S.A. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Middle East Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyprus</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Nederland B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Philippines, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Productions S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Productions S.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Romania SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet SAS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Schering-Plough Animal Health Pty. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet South Africa (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Sp. z.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet UK Production Limited</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Venezolana S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Veterinaria Chile Ltda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Veteriner Ilaclari Pazarlama ve Ticaret Ltd. Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet, s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interveterinaria SA de CV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IOmet Pharma Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratoires Merck Sharp &#38; Dohme-Chibret</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Abello, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Chibret, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Frosst, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Quimico-Farmaceuticos Chibret, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lemifar S. A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maya Tibbi &#220;r&#252;nler Ticaret Limited Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCM Vaccine B.V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck and Company LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Capital Ventures, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Frosst Canada &#38; Co.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Frosst Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Global Health Innovation Fund, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Global Health Innovation, Private Equity, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck HDAC Research, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Holdings II Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Holdings III Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Holdings IV Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Holdings LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck International Holdings Corp.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Lumira Biosciences Fund L.P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Registry Holdings, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Research Investments LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Research Laboratories Massachusetts, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Argentina) LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Asia) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Australia) Pty. Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Chile) Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (China) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Enterprises) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Europe) Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Holdings) Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (I.A.) LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (International) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Israel - 1996) Company Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Malaysia) SDN. BHD.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (New Zealand) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Sweden) A.B.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Switzerland) GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (UK) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Animal Health, S.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Asia Pacific Services Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme BH d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bosnia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Bulgaria EOOD</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulgaria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Colombia S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Comercializadora, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Cyprus Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyprus</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme d.o.o. Belgrade</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme de Espana SAU</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Farmaceutica Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Finance Europe Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Gesellschaft m.b.H.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Holdings Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme IDEA GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme inovativna zdravila d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme International Services B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Ireland (Human Health) Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Latvija</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latvia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bolivia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Manufacturing Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme OU</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estonia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Peru SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:21.35pt;padding-right:2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Pharmaceutical Industrial and Commercial Societe Anonyme</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Research GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Romania SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Salud Animal Colombia S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Saude Animal Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Singapore Trading Pte. Ltd.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Tunisie SARL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunisia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme, Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme, s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp Dohme Ilaclari Limited Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Teknika LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merko Acquisition S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merko Dalton B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merko N.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ML Holdings (Canada) Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRL San Francisco, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRL Ventures Fund LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (I.A.) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (L-SP) Unterst&#252;tzungskasse GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Ningbo) Animal Health Technology Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Nippon Holdings) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Norge) AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Shanghai) Pharmaceuticals Consultancy Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Thailand) Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Agencies B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD AH Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health (Phils.), Inc</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health (Shanghai) Trading Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health A&#47;S</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Danube Biotech GmbH</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health FZ-LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Holdings BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Innovation AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Innovation GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Innovation Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Innovation SAS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health K.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Korea Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Norge AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Oy</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Pension Trustee Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health S.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health UK Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Vietnam Co. Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viet Nam</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health, Lda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Argentina Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Argentina SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Asia Holdings Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Belgium BV - SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Biotech B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Brazil Investments B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Central America Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD China (Investments) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD China B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD China Holding Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Cubist Holdings Unlimited Company</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Czech Republic s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Danmark ApS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Egypt LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD EIC Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Eurofinance</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Farmaceutica C.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD FI BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Finance B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Finance Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Finance Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Finland Oy</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD France</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Global Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Global Research GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD HH Vietnam Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Holdings (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Holdings 2 G.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Holdings G.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Human Health Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Human Health Holding II B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD IDEA Algerie SPA</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Algeria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD IDEA Pharmaceuticals Nigeria Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nigeria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD IDEA Tunisie SARL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunisia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Idenix Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Innovation &#38; Development GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International Business GmbH</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International Finance B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International Finance LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International Investment Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International Manufacturing GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Investment Holdings (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Investments (Holdings) GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Italia s.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Japan Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Japan Holdings GK</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD K.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Korea Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Laboratories India LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Latin America Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Latin America Services S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Luxembourg S.a.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Merck Sharp &#38; Dohme AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD NL 4 B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Overseas Manufacturing Co (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Panama International Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Participations B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharma (Singapore) Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharma GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharma Hungary Korlatolt Felelossegu Tarsasag</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals Investments 1 Unlimited Company</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals Investments 3 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals Ireland Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russian Federation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals Private Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Polska Dystrybucja Sp. z.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Polska Sp.z.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD R&#38;D (China) Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD R&#38;D Innovation Centre Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD RDC Costa Rica Sociedad de Responsabilidad Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Rica</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Regional Business Support Center GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Registry Holdings, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Shared Business Services EMEA Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4pt;padding-left:3.25pt;padding-right:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Sharp &#38; Dohme Gesellschaft mit beschr&#228;nkter Haftung</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4pt;padding-left:3.25pt;padding-right:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Switzerland Investments 1 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Switzerland Investments 4 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Switzerland Investments 5 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Ukraine Limited Liability Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukraine</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Unterstutzungskasse GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vaccines Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vaccins</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vaccins Holdings</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Venezuela Holding GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Ventures (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Verwaltungs GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vietnam Company Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vietnam Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vostok B.V.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSDIG Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSDRG Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSDRG LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSP Singapore Company, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSP Vaccine Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multilan AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nihon MSD G.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nourifarma - Produtos Quimicos e Farmaceuticos, Sociedade Uniperssoal, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O.PI.VI S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OBS Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncoethix GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OncoImmune, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Optimer Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon Argentina SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon Argentina Holdings BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon China B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon Egypt Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon Latin America S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon Limited Liability Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russian Federation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon Middle East S.A.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebanon</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS ID AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS ID Hellas M.I.K.E</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P.T. Merck Sharp &#38; Dohme Indonesia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pandion Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pandion Operations, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parlanca Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peloton Therapeutics, Inc.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polnet ID Spolka z ograniczona odpowiedzialnoscia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PrognostiX-Poultry Limited </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prondil Sociedad An&#243;nima</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Intervet Indonesia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Organon Indonesia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Merck Sharp Dohme Pharma Tbk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> 1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Putexin Investments Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigontec GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigontec, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rosetta Inpharmatics LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S.C. Allflex Romania S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S.C.R. (Engineers) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough, S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough (India) Private Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Animal Health Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Corporation</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Corporation, U.S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough del Peru S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Holdings Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paraguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Sante Animale</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCR Allflex Management, Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCR Dairy, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCR Europe S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCR Monitoring Mexico, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sentipharm AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Servicios Veternarios Servet, Sociedad An&#243;nima</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai MSD Pharmaceutical Trading Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sistemas de Identificacao Animal Ltda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SmartCells, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOL Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stallmastaren AB</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SureFlap (NZ) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SureFlap Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SureFlap LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag ID Investments, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Themis BioScience GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Theriak B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tilos Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trius Therapeutics LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAB Merck Sharp &#38; Dohme</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lithuania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaki Aquaculture Systems ehf.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iceland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaki Scotland Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vall&#233;e S.A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VelosBio Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VelosBio Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venco Farmaceutica S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venco Holding GmbH</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vet Pharma Friesoythe GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veterinaria Premium, Sociedad Anonima</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guatemala</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VetInvent, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vetrex B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vetrex Egypt L.L.C.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vilsan Veteriner Ilaclari Ticaret ve Sanayi Anonim Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viralytics Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vocaltag Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vree Health Italia S.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Werthenstein Biopharma GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zo&#246;pharm B.V.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:201%">___________</font></div><div style="padding-right:50.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:201%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:201%"> own less than 100%</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">17</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>6
<FILENAME>ex23-consentofindependentr.htm
<DESCRIPTION>EXHIBIT-23 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4cdc14421df248febbb23c0b309cda10_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form&#160;S-3 (Nos.&#160;333-254700 and 333-254703) and on Form&#160;S-8 (Nos. 333-173025, 333-173024, 333-162883, 333-162884, 333-162885, 333-162886, 333-121089, and 333-233226) of Merck&#160;&#38; Co., Inc. of our report dated February&#160;25, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form&#160;10-K.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.1
<SEQUENCE>7
<FILENAME>ex241-powerofattorney1.htm
<DESCRIPTION>EXHIBIT-24.1 POWER OF ATTORNEY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8dc74247fc6f420e969788ac84ed9744_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">Exhibit 24.1 </font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;text-decoration:underline">POWER OF ATTORNEY </font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Each of the undersigned does hereby appoint JENNIFER ZACHARY as his&#47;her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck&#160;&#38; Co., Inc. for the fiscal year ended December&#160;31, 2021 under the Securities Exchange Act of 1934, including amendments thereto and all exhibits and other documents in connection therewith. </font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">IN WITNESS WHEREOF, this instrument has been duly executed as of the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:138%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%"> day of February 2022. </font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">MERCK&#160;&#38; CO., Inc. </font></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:24.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert M. Davis</font></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer&#59; Director)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:24.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caroline Litchfield </font></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rita A. Karachun</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance&#8212;Global Controller</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rita A. Karachun</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</font></td></tr></table></div><div style="margin-top:13pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">DIRECTORS </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:42.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mary Ellen Coe</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paul B. Rothman</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mary Ellen Coe</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul B. Rothman</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Pamela J. Craig</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Patricia F. Russo</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pamela J. Craig</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia F. Russo</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth C. Frazier</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christine E. Seidman</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth C. Frazier</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine E. Seidman</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas H. Glocer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Inge G. Thulin</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas H. Glocer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inge G. Thulin</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Risa J. Lavizzo-Mourey</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathy J. Warden</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risa J. Lavizzo-Mourey</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathy J. Warden</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Stephen L. Mayo</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter C. Wendell</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen L. Mayo</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter C. Wendell</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.2
<SEQUENCE>8
<FILENAME>ex242-certificationofboard.htm
<DESCRIPTION>EXHIBIT-24.2 CERTIFICATION OF BOARD RESOLUTION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifbdb0be0511a40ba93afda1bcc12c4d8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">Exhibit 24.2 </font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">I, Kelly Grez, Deputy Corporate Secretary of Merck &#38; Co., Inc. (the &#8220;Company&#8221;), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 25, 2022 in accordance with the provisions of the By-Laws of the Company&#58; </font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;text-decoration:underline">&#8220;Special Resolution No. 13 &#8211; 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%"> </font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">RESOLVED, that the proposed form of the Annual Report on Form 10-K of the Company for the fiscal year ended December&#160;31, 2021, attached hereto, is hereby approved with such changes as the proper officers of the Company, with the advice of counsel, deem appropriate&#59; </font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">FURTHER RESOLVED, that each officer and director who may be required to execute the aforesaid Annual Report on Form 10-K or any amendments thereto (whether on behalf of the Company or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) is hereby authorized to execute a power of attorney appointing Jennifer Zachary as his&#47;her true and lawful attorney to execute in his&#47;her name, place and stead (in any such capacity) such Annual Report on Form&#160;10&#8209;K and any and all amendments thereto and any and all exhibits and other documents necessary or incidental in connection therewith and to file the same with the Securities and Exchange Commission, the attorney to have power to act and to have full power and authority to do and perform in the name and on behalf of each of said officers and directors, or both, as the case may be, every act whatsoever necessary or advisable to be done in the premises as fully and to all intents and purposes as any such officer or director might or could do in person&#59; and</font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">FURTHER RESOLVED that an executed copy of the Action by Unanimous Written Consent be filed with the minutes of the meetings of the Board of Directors of the Company.&#34;</font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:138%;position:relative;top:-2.62pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%"> day of February 2022. </font></div><div style="text-indent:24.75pt"><font><br></font></div><div style="text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:48.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.612%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Corporate Seal&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly Grez</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly Grez<br>Deputy Corporate Secretary</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>ex311-rule13ax14a15dx14ace.htm
<DESCRIPTION>EXHIBIT-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i95f3d6f591a44b5ea729551bf3d26ba5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert M. Davis, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2022 </font></div><div style="margin-top:15pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.321%"><tr><td style="width:1.0%"></td><td style="width:9.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS<br>Chief Executive Officer and President</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>ex312-rule13ax14a15dx14ace.htm
<DESCRIPTION>EXHIBIT-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9dd87d5f56ce4484a1c63090719d37bf_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Caroline Litchfield, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;February&#160;25, 2022 </font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.514%"><tr><td style="width:1.0%"></td><td style="width:9.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAROLINE LITCHFIELD<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>ex321-section1350certifica.htm
<DESCRIPTION>EXHIBIT-32.1 SECTION 1350 CERTIFICATION OF CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia33e6b050fe541ea92190749558182c1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  February 25, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;   ROBERT M. DAVIS</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;     Chief&#160;Executive&#160;Officer and President</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>ex322-section1350certifica.htm
<DESCRIPTION>EXHIBIT-32.2 SECTION 1350 CERTIFICATION OF CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7372b71c2fa345b69c5619d7327175d9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  February 25, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-45pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;    CAROLINE LITCHFIELD</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;      Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>mrk-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c2671c01-457c-407e-affb-5c2ec2e9dc08,g:df117aec-e688-48b3-9aac-3f4fd6688d4e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrk="http://www.merck.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.merck.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.merck.com/role/CoverPage">
        <link:definition>000010001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.merck.com/role/AuditInformation">
        <link:definition>000020002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofIncome" roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome">
        <link:definition>100010003 - Statement - Consolidated Statement of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofComprehensiveIncome" roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome">
        <link:definition>100020004 - Statement - Consolidated Statement of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheet" roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet">
        <link:definition>100030005 - Statement - Consolidated Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetParenthetical" roleURI="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical">
        <link:definition>100040006 - Statement - Consolidated Balance Sheet (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofEquity" roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity">
        <link:definition>100050007 - Statement - Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofEquityParenthetical" roleURI="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical">
        <link:definition>100060008 - Statement - Consolidated Statement of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlows" roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows">
        <link:definition>100070009 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlowsParenthetical" roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical">
        <link:definition>100080010 - Statement - Consolidated Statement of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://www.merck.com/role/NatureofOperations">
        <link:definition>210011001 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsDetails" roleURI="http://www.merck.com/role/NatureofOperationsDetails">
        <link:definition>240024001 - Disclosure - Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPolicies" roleURI="http://www.merck.com/role/SummaryofAccountingPolicies">
        <link:definition>210031002 - Disclosure - Summary of Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPoliciesPolicies" roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies">
        <link:definition>220042001 - Disclosure - Summary of Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPoliciesDetails" roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails">
        <link:definition>240054002 - Disclosure - Summary of Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCo" roleURI="http://www.merck.com/role/SpinOffofOrganonCo">
        <link:definition>210061003 - Disclosure - Spin-Off of Organon &amp; Co.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoTables" roleURI="http://www.merck.com/role/SpinOffofOrganonCoTables">
        <link:definition>230073001 - Disclosure - Spin-Off of Organon &amp; Co. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoNarrativeDetails" roleURI="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails">
        <link:definition>240084003 - Disclosure - Spin-Off of Organon &amp; Co. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" roleURI="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails">
        <link:definition>240094004 - Disclosure - Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails" roleURI="http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails">
        <link:definition>240104005 - Disclosure - Spin-Off of Organon &amp; Co. - Assets and Liabilities of Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreements" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements">
        <link:definition>210111004 - Disclosure - Acquisitions, Research Collaborations and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreementsTables" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables">
        <link:definition>230123002 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails">
        <link:definition>240134006 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>240144007 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangements" roleURI="http://www.merck.com/role/CollaborativeArrangements">
        <link:definition>210151005 - Disclosure - Collaborative Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsTables" roleURI="http://www.merck.com/role/CollaborativeArrangementsTables">
        <link:definition>230163003 - Disclosure - Collaborative Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsNarrativeDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails">
        <link:definition>240174008 - Disclosure - Collaborative Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsFinancialInformationDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails">
        <link:definition>240184009 - Disclosure - Collaborative Arrangements - Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.merck.com/role/Restructuring">
        <link:definition>210191006 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.merck.com/role/RestructuringTables">
        <link:definition>230203004 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.merck.com/role/RestructuringNarrativeDetails">
        <link:definition>240214010 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesActivitiesbyTypeofCostDetails" roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails">
        <link:definition>240224011 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivitiesbyProgramDetails" roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails">
        <link:definition>240234012 - Disclosure - Restructuring - Activities by Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.merck.com/role/FinancialInstruments">
        <link:definition>210241007 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.merck.com/role/FinancialInstrumentsTables">
        <link:definition>230253005 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>240264013 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectofNetInvestmentHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
        <link:definition>240274014 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationAboutInterestRateSwapsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails">
        <link:definition>240284015 - Disclosure - Financial Instruments - Information About Interest Rate Swaps (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails">
        <link:definition>240294016 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>240304017 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails">
        <link:definition>240314018 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails">
        <link:definition>240324019 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>240334020 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails">
        <link:definition>240344021 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>240354022 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
        <link:definition>240364023 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.merck.com/role/Inventories">
        <link:definition>210371008 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.merck.com/role/InventoriesTables">
        <link:definition>230383006 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesInventoriesDetails" roleURI="http://www.merck.com/role/InventoriesInventoriesDetails">
        <link:definition>240394024 - Disclosure - Inventories - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesInventoriesDetails_1" roleURI="http://www.merck.com/role/InventoriesInventoriesDetails_1">
        <link:definition>240394024 - Disclosure - Inventories - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.merck.com/role/InventoriesNarrativeDetails">
        <link:definition>240404025 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibles" roleURI="http://www.merck.com/role/GoodwillandOtherIntangibles">
        <link:definition>210411009 - Disclosure - Goodwill and Other Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesTables" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesTables">
        <link:definition>230423007 - Disclosure - Goodwill and Other Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails">
        <link:definition>240434026 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesNarrativeDetails" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails">
        <link:definition>240444027 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesOtherIntangiblesDetails" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails">
        <link:definition>240454028 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeases" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeases">
        <link:definition>210461010 - Disclosure - Loans Payable, Long-Term Debt and Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesTables" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables">
        <link:definition>230473008 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesNarrativeDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails">
        <link:definition>240484029 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesLongTermDebtDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails">
        <link:definition>240494030 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails">
        <link:definition>240504031 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails">
        <link:definition>240514032 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1">
        <link:definition>240514032 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandEnvironmentalLiabilities" roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities">
        <link:definition>210521011 - Disclosure - Contingencies and Environmental Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandEnvironmentalLiabilitiesDetails" roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails">
        <link:definition>240534033 - Disclosure - Contingencies and Environmental Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.merck.com/role/Equity">
        <link:definition>210541012 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.merck.com/role/EquityTables">
        <link:definition>230553009 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.merck.com/role/EquityNarrativeDetails">
        <link:definition>240564034 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityShareholdersEquityDetails" roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails">
        <link:definition>240574035 - Disclosure - Equity - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlans" roleURI="http://www.merck.com/role/ShareBasedCompensationPlans">
        <link:definition>210581013 - Disclosure - Share-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansTables" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables">
        <link:definition>230593010 - Disclosure - Share-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansNarrativeDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails">
        <link:definition>240604036 - Disclosure - Share-Based Compensation Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails">
        <link:definition>240614037 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails">
        <link:definition>240624038 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails">
        <link:definition>240634039 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails">
        <link:definition>240644040 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlans" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans">
        <link:definition>210651014 - Disclosure - Pension and Other Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansTables" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables">
        <link:definition>230663011 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansNarrativeDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails">
        <link:definition>240674041 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>240684042 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails">
        <link:definition>240694043 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1">
        <link:definition>240694043 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails">
        <link:definition>240704044 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails">
        <link:definition>240714045 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails">
        <link:definition>240724046 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails">
        <link:definition>240734047 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails">
        <link:definition>240744048 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails">
        <link:definition>240754049 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails">
        <link:definition>240764050 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails">
        <link:definition>240774051 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNet" roleURI="http://www.merck.com/role/OtherIncomeExpenseNet">
        <link:definition>210781015 - Disclosure - Other (Income) Expense, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetTables" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables">
        <link:definition>230793012 - Disclosure - Other (Income) Expense, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails">
        <link:definition>240804052 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetNarrativeDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails">
        <link:definition>240814053 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncome" roleURI="http://www.merck.com/role/TaxesonIncome">
        <link:definition>210821016 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeTables" roleURI="http://www.merck.com/role/TaxesonIncomeTables">
        <link:definition>230833013 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails">
        <link:definition>240844054 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeNarrativeDetails" roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails">
        <link:definition>240854055 - Disclosure - Taxes on Income - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeIncomeBeforeTaxesDetails" roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails">
        <link:definition>240864056 - Disclosure - Taxes on Income - Income Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeTaxesonIncomeDetails" roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails">
        <link:definition>240874057 - Disclosure - Taxes on Income - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeDeferredIncomeTaxesDetails" roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails">
        <link:definition>240884058 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeUnrecognizedTaxBenefitsDetails" roleURI="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails">
        <link:definition>240894059 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.merck.com/role/EarningsperShare">
        <link:definition>210901017 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.merck.com/role/EarningsperShareTables">
        <link:definition>230913014 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareCalculationsofEarningsPerShareDetails" roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails">
        <link:definition>240924060 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>240934061 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>210941018 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>230953015 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossDetails" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails">
        <link:definition>240964062 - Disclosure - Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.merck.com/role/SegmentReporting">
        <link:definition>210971019 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.merck.com/role/SegmentReportingTables">
        <link:definition>230983016 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails">
        <link:definition>240994063 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSalesofCompanysProductsDetails" roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails">
        <link:definition>241004064 - Disclosure - Segment Reporting - Sales of Company's Products (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails">
        <link:definition>241014065 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails">
        <link:definition>241024066 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" roleURI="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails">
        <link:definition>241034067 - Disclosure - Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails">
        <link:definition>241044068 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrk_PotentialFutureMilestonePaymentsSalesBased" abstract="false" name="PotentialFutureMilestonePaymentsSalesBased" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AdempasMember" abstract="true" name="AdempasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ScheduleOfOtherIntangiblesTable" abstract="true" name="ScheduleOfOtherIntangiblesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" abstract="true" name="MortgageAndAssetBackedSecuritiesInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" abstract="true" name="NotesSubjectToRepaymentAtOptionOfHolderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BelsomraMember" abstract="true" name="BelsomraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MovementinCommonStockandTreasuryStockRollForward" abstract="true" name="MovementinCommonStockandTreasuryStockRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_A3.90NotesDue2039Member" abstract="true" name="A3.90NotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_PremiumOnSharesAcquired" abstract="false" name="PremiumOnSharesAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AnimalHealthMember" abstract="true" name="AnimalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" abstract="true" name="CasesCompanyAgreedToTollStatuteOfLimitationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_HealthcareServicesSegmentMember" abstract="true" name="HealthcareServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PharmaceuticalsegmentMember" abstract="true" name="PharmaceuticalsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" abstract="false" name="AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LivestockMember" abstract="true" name="LivestockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A1.875Notesdue2026Member" abstract="true" name="A1.875Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" abstract="false" name="DeferredTaxAssetsUnrecognizedTaxBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A280NotesDue2023Member" abstract="true" name="A280NotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AcceleronPharmaIncMember" abstract="true" name="AcceleronPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentsAccruedSalesBased" abstract="false" name="MilestonePaymentsAccruedSalesBased" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_InvanzMember" abstract="true" name="InvanzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_TermForPayingOffEnvironmentalLiabilities" abstract="false" name="TermForPayingOffEnvironmentalLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_A190NotesDue2028Member" abstract="true" name="A190NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BridionMember" abstract="true" name="BridionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" abstract="false" name="ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" abstract="true" name="SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LossContingencyClaimsonAppealNumber" abstract="false" name="LossContingencyClaimsonAppealNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_ConsumercarebusinessMember" abstract="true" name="ConsumercarebusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ContingentPaymentsCollaborativeArrangement" abstract="false" name="ContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" abstract="false" name="RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_EmergingMarketsEquitiesInvestmentFundsMember" abstract="true" name="EmergingMarketsEquitiesInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrk_ContingentConsiderationPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_TransitionServicesAgreementMember" abstract="true" name="TransitionServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A0.50eurodenominatednotesdue2024Member" abstract="true" name="A0.50eurodenominatednotesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_MilestonePaymentsAccruedRegulatory" abstract="false" name="MilestonePaymentsAccruedRegulatory" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A275NotesDue2051Member" abstract="true" name="A275NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" abstract="false" name="PaymentsToAcquireBusinessFourNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IncomeTaxTable" abstract="true" name="IncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_DebtSecuritiesandEquitySecuritiesFVNI" abstract="false" name="DebtSecuritiesandEquitySecuritiesFVNI" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PandionTherapeuticsMember" abstract="true" name="PandionTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A290NotesDue2061Member" abstract="true" name="A290NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LegalDefenseCostsMember" abstract="true" name="LegalDefenseCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_TukysaMember" abstract="true" name="TukysaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" abstract="false" name="ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CommercialandOtherLitigationMember" abstract="true" name="CommercialandOtherLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" abstract="false" name="PaymentsToAcquireBusinessFiveNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" abstract="true" name="SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_FosamaxMember" abstract="true" name="FosamaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" abstract="true" name="MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" abstract="true" name="DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrk_VaqtaMember" abstract="true" name="VaqtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.40NotesDue2022Member" abstract="true" name="A2.40NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementProfitSharing" abstract="false" name="CollaborativeArrangementProfitSharing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DefinedBenefitPlanOtherChangesPlanAssets" abstract="false" name="DefinedBenefitPlanOtherChangesPlanAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired" abstract="false" name="PaymentsToAcquireBusinessSixNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AllianceRevenueKoselugoMember" abstract="true" name="AllianceRevenueKoselugoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AccrualForChargebacks" abstract="false" name="AccrualForChargebacks" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" abstract="true" name="DefinedBenefitPlanCashandOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OncoImmuneMember" abstract="true" name="OncoImmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_VerquvoMember" abstract="true" name="VerquvoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SivextroMember" abstract="true" name="SivextroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" abstract="true" name="EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" abstract="false" name="OffsettingAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_A3.875NotesDue2021Member" abstract="true" name="A3.875NotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A075NotesDue2026Member" abstract="true" name="A075NotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" abstract="true" name="FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrk_RoyaltyRatePercentage" abstract="false" name="RoyaltyRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_PelotonMember" abstract="true" name="PelotonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_VelosBioMember" abstract="true" name="VelosBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrk_Pneumovax23Member" abstract="true" name="Pneumovax23Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SupplyCommitmentQuantityDelivered" abstract="false" name="SupplyCommitmentQuantityDelivered" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_DeferredTaxLiabilitiesEquityMethodInvestment" abstract="false" name="DeferredTaxLiabilitiesEquityMethodInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" abstract="true" name="EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_IncomeTaxLineItems" abstract="true" name="IncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_CollaborativeArrangementsAbstract" abstract="true" name="CollaborativeArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_CorporateObligationsFixedIncomeSecuritiesMember" abstract="true" name="CorporateObligationsFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SegmentReportingUnallocatedOtherExpensesNet" abstract="false" name="SegmentReportingUnallocatedOtherExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SupplyCommitmentMinimumNumberOfMarkets" abstract="false" name="SupplyCommitmentMinimumNumberOfMarkets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_A215NotesDue2031Member" abstract="true" name="A215NotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IncomeTaxesPayableMember" abstract="true" name="IncomeTaxesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" abstract="false" name="CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_AcceleratedDepreciationMember" abstract="true" name="AcceleratedDepreciationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InternationalMember" abstract="true" name="InternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" abstract="false" name="AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" abstract="false" name="IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A63DebenturesDue2026Member" abstract="true" name="A63DebenturesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" abstract="true" name="OtherPostretirementBenefitPlanPriorServiceCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CancidasMember" abstract="true" name="CancidasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_A1.375eurodenominatednotesdue2036Member" abstract="true" name="A1.375eurodenominatednotesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IsentressIsentressHDMember" abstract="true" name="IsentressIsentressHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_KeytrudaMember" abstract="true" name="KeytrudaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AnimalHealthsegmentMember" abstract="true" name="AnimalHealthsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.75NotesDue2025Member" abstract="true" name="A2.75NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IntangibleAssetsExcludingGoodwillLineItems" abstract="true" name="IntangibleAssetsExcludingGoodwillLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_RotateqMember" abstract="true" name="RotateqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" abstract="true" name="InventoryNotExpectedtobeSoldWithinOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_FixedIncomeObligationsInvestmentFundsMember" abstract="true" name="FixedIncomeObligationsInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" abstract="false" name="UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SentinelMember" abstract="true" name="SentinelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.500Notesdue2034Member" abstract="true" name="A2.500Notesdue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MolnupiravirMember" abstract="true" name="MolnupiravirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ProQuadMMRIIVarivaxMember" abstract="true" name="ProQuadMMRIIVarivaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentsMadetoCollaborativePartner" abstract="false" name="MilestonePaymentsMadetoCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" abstract="true" name="FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_A170NotesDue2027Member" abstract="true" name="A170NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InsuranceContractsOtherInvestmentsMember" abstract="true" name="InsuranceContractsOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A235NotesDue2040Member" abstract="true" name="A235NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EurodominatedNotesMember" abstract="true" name="EurodominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach" abstract="false" name="NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_CommercialmilestoneMember" abstract="true" name="CommercialmilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A415NotesDue2043Member" abstract="true" name="A415NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" abstract="false" name="LicenseOptionPaymentRelatedToCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" abstract="false" name="RestructuringReserveIncreaseDecreaseNoncashActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PatentlitigationMember" abstract="true" name="PatentlitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ThemisMember" abstract="true" name="ThemisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" abstract="false" name="DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_NoxafilMember" abstract="true" name="NoxafilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_LynparzaMember" abstract="true" name="LynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrk_RidgebackBiotherapeuticsLPMember" abstract="true" name="RidgebackBiotherapeuticsLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ProfitShareCounterparty" abstract="false" name="ProfitShareCounterparty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SeagenMember" abstract="true" name="SeagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementSalesNet" abstract="false" name="CollaborativeArrangementSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SotaterceptMember" abstract="true" name="SotaterceptMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_JanuviaMember" abstract="true" name="JanuviaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InjectableFormulationMember" abstract="true" name="InjectableFormulationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoryTable" abstract="true" name="InventoryTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" abstract="false" name="DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_NemtabrutinibMember" abstract="true" name="NemtabrutinibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SimponiMember" abstract="true" name="SimponiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearThree" abstract="false" name="LongTermDebtInterestPayableYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ZerbaxaMember" abstract="true" name="ZerbaxaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" abstract="true" name="GovernmentAndAgencyObligationsInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A4.00NotesDue2049Member" abstract="true" name="A4.00NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AllianceRevenueAdempasVerquvoMember" abstract="true" name="AllianceRevenueAdempasVerquvoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherPostretirementBenefitPlanNetLossMember" abstract="true" name="OtherPostretirementBenefitPlanNetLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RevenuePerformanceObligationPaymentTerms" abstract="false" name="RevenuePerformanceObligationPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_SupplyCommitmentToJapanMember" abstract="true" name="SupplyCommitmentToJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A1.875EuroNotesDue2026Member" abstract="true" name="A1.875EuroNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrk_ArtivaBiotherapeuticsIncMember" abstract="true" name="ArtivaBiotherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" abstract="false" name="UpfrontPaymentsMadeToLicenseOrCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SupplyCommitmentToUnitedKingdomMember" abstract="true" name="SupplyCommitmentToUnitedKingdomMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DificidMember" abstract="true" name="DificidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ProfitShare" abstract="false" name="ProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_DevelopmentMilestonesMember" abstract="true" name="DevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PrevymisMember" abstract="true" name="PrevymisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearFive" abstract="false" name="LongTermDebtInterestPayableYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" abstract="true" name="FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SanofiPasteurMember" abstract="true" name="SanofiPasteurMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_GileadSciencesMember" abstract="true" name="GileadSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CompanionAnimalsMember" abstract="true" name="CompanionAnimalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LenvimaMember" abstract="true" name="LenvimaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DevelopedMarketsEquitySecuritiesMember" abstract="true" name="DevelopedMarketsEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ReblozylMember" abstract="true" name="ReblozylMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" abstract="true" name="SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OralAndInjectableFormulationsMember" abstract="true" name="OralAndInjectableFormulationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.5EuroNotesDue2034Member" abstract="true" name="A2.5EuroNotesDue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherNonoperatingIncomeExpenseOther" abstract="false" name="OtherNonoperatingIncomeExpenseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_JanumetMember" abstract="true" name="JanumetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ManufacturingAndSupplyAgreementsMember" abstract="true" name="ManufacturingAndSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IAVIMember" abstract="true" name="IAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ChargesRelatedToProgramDiscontinuation" abstract="false" name="ChargesRelatedToProgramDiscontinuation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ImmuneDesignMember" abstract="true" name="ImmuneDesignMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" abstract="false" name="ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" abstract="false" name="RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_A245NotesDue2050Member" abstract="true" name="A245NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AlliancerevenueLynparzaMember" abstract="true" name="AlliancerevenueLynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AntelliqMember" abstract="true" name="AntelliqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CostsExpensesAndOther" abstract="false" name="CostsExpensesAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrk_DevelopedMarketsEquitiesInvestmentFundsMember" abstract="true" name="DevelopedMarketsEquitiesInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A0.500Notesdue2024Member" abstract="true" name="A0.500Notesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SalesThreshold" abstract="false" name="SalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LongTermDebtCurrentMaturitiesMember" abstract="true" name="LongTermDebtCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SupplyCommitmentToUnitedNationsChildrensFundMember" abstract="true" name="SupplyCommitmentToUnitedNationsChildrensFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearFour" abstract="false" name="LongTermDebtInterestPayableYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" abstract="true" name="GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_PotentialFutureMilestonePaymentsRegulatory" abstract="false" name="PotentialFutureMilestonePaymentsRegulatory" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" abstract="true" name="ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OrganonCoMember" abstract="true" name="OrganonCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearTwo" abstract="false" name="LongTermDebtInterestPayableYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A145NotesDue2030Member" abstract="true" name="A145NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents" abstract="false" name="AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="dtr-types:noDecimalsMonetaryItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" abstract="false" name="IntangibleAssetProductsAndProductRightsMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrk_OtherPharmaceuticalMember" abstract="true" name="OtherPharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CorporateObligationsInvestmentFundsMember" abstract="true" name="CorporateObligationsInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.35NotesDue2022Member" abstract="true" name="A2.35NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RecognizedAsAbstract" abstract="true" name="RecognizedAsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_PensionPlanPriorServiceCostMember" abstract="true" name="PensionPlanPriorServiceCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PrimaxinMember" abstract="true" name="PrimaxinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationsDebt" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LongTermDebtExcludingCurrentMaturitiesMember" abstract="true" name="LongTermDebtExcludingCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FederalMember" abstract="true" name="FederalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoriesProducedinPreparationforProductLaunchesMember" abstract="true" name="InventoriesProducedinPreparationforProductLaunchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RealEstateInvestmentFundsMember" abstract="true" name="RealEstateInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherStateCourtMember" abstract="true" name="OtherStateCourtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotyetCommencedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PensionPlanNetLossMember" abstract="true" name="PensionPlanNetLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SalesDiscounts" abstract="false" name="SalesDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OralFormulationMember" abstract="true" name="OralFormulationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A1.375Notesdue2036Member" abstract="true" name="A1.375Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A3.70NotesDue2045Member" abstract="true" name="A3.70NotesDue2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DunboyneMember" abstract="true" name="DunboyneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SupplyCommitmentToUnitedStatesMember" abstract="true" name="SupplyCommitmentToUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrk_SupplyCommitmentQuantityCommitted" abstract="false" name="SupplyCommitmentQuantityCommitted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_AssetsandLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsandLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillBeNoncash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities" abstract="false" name="AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="dtr-types:noDecimalsMonetaryItemType"/>
  <xs:element id="mrk_GefapixantMember" abstract="true" name="GefapixantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RoyaltyRateDeductionPercentage" abstract="false" name="RoyaltyRateDeductionPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearOne" abstract="false" name="LongTermDebtInterestPayableYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AccrualForRebates" abstract="false" name="AccrualForRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OtherVariableRateDebtMember" abstract="true" name="OtherVariableRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" abstract="false" name="ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_ArQuleMember" abstract="true" name="ArQuleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_GardasilGardasil9Member" abstract="true" name="GardasilGardasil9Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" abstract="false" name="EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_IntangibleAssetMeasurementInput" abstract="false" name="IntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="mrk_IOmetPharmaLtdMember" abstract="true" name="IOmetPharmaLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired" abstract="false" name="PaymentsToAcquireBusinessSevenNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A2.90NotesDue2024Member" abstract="true" name="A2.90NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrk_A3.40NotesDue2029Member" abstract="true" name="A3.40NotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>mrk-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c2671c01-457c-407e-affb-5c2ec2e9dc08,g:df117aec-e688-48b3-9aac-3f4fd6688d4e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofIncome"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_58d6020e-90f9-4491-8249-e7846d432f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1a98a7d9-5594-4977-8ee4-ae632738b4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58d6020e-90f9-4491-8249-e7846d432f83" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1a98a7d9-5594-4977-8ee4-ae632738b4bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_51284a1e-b34a-467a-8c39-d4fc5b61eab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58d6020e-90f9-4491-8249-e7846d432f83" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_51284a1e-b34a-467a-8c39-d4fc5b61eab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6d10ddf9-f4f4-4546-9a62-5342bfe32197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c558cdc4-23f8-4f28-91fc-46f4f5847414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_6d10ddf9-f4f4-4546-9a62-5342bfe32197" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c558cdc4-23f8-4f28-91fc-46f4f5847414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_f8dee175-8556-498a-8fc5-4ee3e9aea746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_6d10ddf9-f4f4-4546-9a62-5342bfe32197" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_f8dee175-8556-498a-8fc5-4ee3e9aea746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9ebedb7e-0d6d-4c2d-a93c-b59dd912129d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_47a0f34b-3579-42f8-81a0-0f7d921f155b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_9ebedb7e-0d6d-4c2d-a93c-b59dd912129d" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_47a0f34b-3579-42f8-81a0-0f7d921f155b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_96cf27f0-1272-4a8c-9895-e6d20dbef788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_9ebedb7e-0d6d-4c2d-a93c-b59dd912129d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_96cf27f0-1272-4a8c-9895-e6d20dbef788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_280b1fe8-002c-4bb8-9504-0df2e96702f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_3319b024-8a65-4f88-8638-f632d9397644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_280b1fe8-002c-4bb8-9504-0df2e96702f7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_3319b024-8a65-4f88-8638-f632d9397644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_28f1b63e-bd93-4eeb-8530-8327ef5dd618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_280b1fe8-002c-4bb8-9504-0df2e96702f7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_28f1b63e-bd93-4eeb-8530-8327ef5dd618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_49696a69-41f8-45f4-991b-a0dc995fa8ed" xlink:href="mrk-20211231.xsd#mrk_CostsExpensesAndOther"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0f030719-4736-4b98-a9c0-d458de9de3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_49696a69-41f8-45f4-991b-a0dc995fa8ed" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0f030719-4736-4b98-a9c0-d458de9de3cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6e2e84d5-fc3b-4ff8-a4eb-245349251404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_49696a69-41f8-45f4-991b-a0dc995fa8ed" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6e2e84d5-fc3b-4ff8-a4eb-245349251404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8ee6e7f9-e946-46a0-9ad6-1d6f92c36551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_49696a69-41f8-45f4-991b-a0dc995fa8ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8ee6e7f9-e946-46a0-9ad6-1d6f92c36551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_21a01a5c-1f39-4e15-afa5-f2474c92529e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_49696a69-41f8-45f4-991b-a0dc995fa8ed" xlink:to="loc_us-gaap_RestructuringCharges_21a01a5c-1f39-4e15-afa5-f2474c92529e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7c2d95e4-03b1-4c0e-b9ac-00834f8daecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_49696a69-41f8-45f4-991b-a0dc995fa8ed" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7c2d95e4-03b1-4c0e-b9ac-00834f8daecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b6b913cc-b63d-443e-bc39-0d15beb9a8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7cb30a2f-7644-4464-97f9-3368b34086e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b6b913cc-b63d-443e-bc39-0d15beb9a8a0" xlink:to="loc_us-gaap_Revenues_7cb30a2f-7644-4464-97f9-3368b34086e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_4e54c7cb-7eb7-45e1-b613-d75b936bc404" xlink:href="mrk-20211231.xsd#mrk_CostsExpensesAndOther"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b6b913cc-b63d-443e-bc39-0d15beb9a8a0" xlink:to="loc_mrk_CostsExpensesAndOther_4e54c7cb-7eb7-45e1-b613-d75b936bc404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_770c5386-7ec2-4734-9fdd-fc109afaa7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33a2605d-8bce-4d3e-8565-6b7a4b840539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_770c5386-7ec2-4734-9fdd-fc109afaa7cd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33a2605d-8bce-4d3e-8565-6b7a4b840539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1b6c903a-854b-4d60-b764-0aa486cc6992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_770c5386-7ec2-4734-9fdd-fc109afaa7cd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1b6c903a-854b-4d60-b764-0aa486cc6992" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fa173df4-2c1b-431f-8786-e53bee9d665c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bdf2b5a4-1d7a-4c88-8122-bd3e25d0d2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fa173df4-2c1b-431f-8786-e53bee9d665c" xlink:to="loc_us-gaap_NetIncomeLoss_bdf2b5a4-1d7a-4c88-8122-bd3e25d0d2f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee9cd0e9-2459-4100-899b-cd345b3c8d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fa173df4-2c1b-431f-8786-e53bee9d665c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee9cd0e9-2459-4100-899b-cd345b3c8d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_67b4ccb1-653b-4b94-a3a9-162465683b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_316ca8f7-d6f8-4651-bb9c-21533e46331d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_67b4ccb1-653b-4b94-a3a9-162465683b7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_316ca8f7-d6f8-4651-bb9c-21533e46331d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e3ec9100-5a0d-4d4a-a72d-32b146520093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_67b4ccb1-653b-4b94-a3a9-162465683b7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e3ec9100-5a0d-4d4a-a72d-32b146520093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2af6362c-4963-4ac3-8aa7-2cd5f532c95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_67b4ccb1-653b-4b94-a3a9-162465683b7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2af6362c-4963-4ac3-8aa7-2cd5f532c95b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b8d11104-447b-43dc-95fc-8f379d8dad51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_67b4ccb1-653b-4b94-a3a9-162465683b7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b8d11104-447b-43dc-95fc-8f379d8dad51" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedBalanceSheet"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b6b41167-c56c-4de2-ba17-6b1a3647cbad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f090c2fb-9557-4705-b842-f3e75ee99b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b6b41167-c56c-4de2-ba17-6b1a3647cbad" xlink:to="loc_us-gaap_AssetsCurrent_f090c2fb-9557-4705-b842-f3e75ee99b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_da0d1502-3623-46dd-89dd-cb8bb2760218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b6b41167-c56c-4de2-ba17-6b1a3647cbad" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_da0d1502-3623-46dd-89dd-cb8bb2760218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_244f3cb1-5733-46c7-ae34-1ca41f03e86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b6b41167-c56c-4de2-ba17-6b1a3647cbad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_244f3cb1-5733-46c7-ae34-1ca41f03e86f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fa809c97-b223-4e6c-9224-5838a16b6c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b6b41167-c56c-4de2-ba17-6b1a3647cbad" xlink:to="loc_us-gaap_Goodwill_fa809c97-b223-4e6c-9224-5838a16b6c3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7b482044-3fb4-4c16-996a-320039ed7479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b6b41167-c56c-4de2-ba17-6b1a3647cbad" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7b482044-3fb4-4c16-996a-320039ed7479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_54776a5c-e1ca-4896-9841-cbe6f77cea25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b6b41167-c56c-4de2-ba17-6b1a3647cbad" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_54776a5c-e1ca-4896-9841-cbe6f77cea25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_0b6a8142-544d-41cf-827a-3da5bbc07c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b6b41167-c56c-4de2-ba17-6b1a3647cbad" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_0b6a8142-544d-41cf-827a-3da5bbc07c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3e193562-8936-42c2-aa4c-483b12c4fa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b2da2876-e58b-4ac5-ba43-f72fe6ae8238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3e193562-8936-42c2-aa4c-483b12c4fa8d" xlink:to="loc_us-gaap_CommonStockValue_b2da2876-e58b-4ac5-ba43-f72fe6ae8238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a6441be7-73a8-4cf4-b2b6-d940a937b17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3e193562-8936-42c2-aa4c-483b12c4fa8d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a6441be7-73a8-4cf4-b2b6-d940a937b17e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_87aebb75-6e7b-46d1-bfbf-d36de1fe0c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3e193562-8936-42c2-aa4c-483b12c4fa8d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_87aebb75-6e7b-46d1-bfbf-d36de1fe0c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa97a742-198e-4bcd-8ef2-7a17b49dca23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3e193562-8936-42c2-aa4c-483b12c4fa8d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa97a742-198e-4bcd-8ef2-7a17b49dca23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_31f78817-8410-4fa0-b48c-5329dabd3650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e7e79060-ca75-4f3f-bb24-9a73a308080b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_31f78817-8410-4fa0-b48c-5329dabd3650" xlink:to="loc_us-gaap_LiabilitiesCurrent_e7e79060-ca75-4f3f-bb24-9a73a308080b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_942f73b6-9fa0-42c7-9c82-ec2a98564303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_31f78817-8410-4fa0-b48c-5329dabd3650" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_942f73b6-9fa0-42c7-9c82-ec2a98564303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_76d9504f-066d-4074-aa91-527db2585155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_31f78817-8410-4fa0-b48c-5329dabd3650" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_76d9504f-066d-4074-aa91-527db2585155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8653069f-11bf-425d-b67a-7144a21aa51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_31f78817-8410-4fa0-b48c-5329dabd3650" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8653069f-11bf-425d-b67a-7144a21aa51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_267fecab-04aa-44e7-8ee4-18a88c8035ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_31f78817-8410-4fa0-b48c-5329dabd3650" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_267fecab-04aa-44e7-8ee4-18a88c8035ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_b3ba3e58-47cf-480f-a9c4-a049e4b08d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_31f78817-8410-4fa0-b48c-5329dabd3650" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_b3ba3e58-47cf-480f-a9c4-a049e4b08d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_36a48c07-eab7-491b-9c9f-e1b2f16ab2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_5ab6f78f-cb3d-4867-b473-2e5b688f43d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_36a48c07-eab7-491b-9c9f-e1b2f16ab2e6" xlink:to="loc_us-gaap_Land_5ab6f78f-cb3d-4867-b473-2e5b688f43d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_d1353ded-b085-422a-a836-a0b48ad35e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_36a48c07-eab7-491b-9c9f-e1b2f16ab2e6" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_d1353ded-b085-422a-a836-a0b48ad35e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_b1d72af3-e73b-4cdb-99e2-485791593f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_36a48c07-eab7-491b-9c9f-e1b2f16ab2e6" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_b1d72af3-e73b-4cdb-99e2-485791593f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_d1a3cf0b-8466-4d37-8ad5-3dbe5dff6904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_36a48c07-eab7-491b-9c9f-e1b2f16ab2e6" xlink:to="loc_us-gaap_ConstructionInProgressGross_d1a3cf0b-8466-4d37-8ad5-3dbe5dff6904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_90ad66f0-4153-4057-b34f-c45e4e4da9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_650761f8-2ef1-42ca-81d8-edaa2232bba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_90ad66f0-4153-4057-b34f-c45e4e4da9e9" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_650761f8-2ef1-42ca-81d8-edaa2232bba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d0436100-4c1b-4d6d-a400-6740235a66e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_90ad66f0-4153-4057-b34f-c45e4e4da9e9" xlink:to="loc_us-gaap_TreasuryStockValue_d0436100-4c1b-4d6d-a400-6740235a66e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6e67a955-6745-48d6-ab43-21954aceb080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c80ee3b6-d833-404b-8b90-7aa9e81cb93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6e67a955-6745-48d6-ab43-21954aceb080" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c80ee3b6-d833-404b-8b90-7aa9e81cb93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14dea52f-f1ca-44d6-b155-9cbf262aeebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6e67a955-6745-48d6-ab43-21954aceb080" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14dea52f-f1ca-44d6-b155-9cbf262aeebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_05825cd6-3e45-46f4-8852-387c296168f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f436c501-8cf2-4a69-afe0-5fae6766e4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05825cd6-3e45-46f4-8852-387c296168f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f436c501-8cf2-4a69-afe0-5fae6766e4ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7f88ff2d-3748-4726-911a-8bef97c89220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05825cd6-3e45-46f4-8852-387c296168f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7f88ff2d-3748-4726-911a-8bef97c89220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4d75bff6-f897-48f9-9611-74604f7899e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05825cd6-3e45-46f4-8852-387c296168f2" xlink:to="loc_us-gaap_InventoryNet_4d75bff6-f897-48f9-9611-74604f7899e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_60f471bf-83a8-4c41-82b9-5549926de49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05825cd6-3e45-46f4-8852-387c296168f2" xlink:to="loc_us-gaap_OtherAssetsCurrent_60f471bf-83a8-4c41-82b9-5549926de49a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_77b4dcc5-c2b4-44ec-9d9d-10d7dc685416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_05825cd6-3e45-46f4-8852-387c296168f2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_77b4dcc5-c2b4-44ec-9d9d-10d7dc685416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_88421b57-e305-40b2-bf0b-db0a6b107ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_ac11cdb3-7acf-43a5-9c26-d91399c533d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_88421b57-e305-40b2-bf0b-db0a6b107ca4" xlink:to="loc_us-gaap_DebtCurrent_ac11cdb3-7acf-43a5-9c26-d91399c533d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e1dbcdd2-56de-408d-a20b-45b01bea0b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_88421b57-e305-40b2-bf0b-db0a6b107ca4" xlink:to="loc_us-gaap_AccountsPayableCurrent_e1dbcdd2-56de-408d-a20b-45b01bea0b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_223bb17c-057f-490d-8a36-1869302e2511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_88421b57-e305-40b2-bf0b-db0a6b107ca4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_223bb17c-057f-490d-8a36-1869302e2511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_13b8f02b-78fc-47a5-9345-431cb0a133eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_88421b57-e305-40b2-bf0b-db0a6b107ca4" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_13b8f02b-78fc-47a5-9345-431cb0a133eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_f4fe2cbd-eba2-41f9-b30d-f02e787ade51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_88421b57-e305-40b2-bf0b-db0a6b107ca4" xlink:to="loc_us-gaap_DividendsPayableCurrent_f4fe2cbd-eba2-41f9-b30d-f02e787ade51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_b31f4e26-3780-415d-becd-54c6b5e84a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_88421b57-e305-40b2-bf0b-db0a6b107ca4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_b31f4e26-3780-415d-becd-54c6b5e84a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e2671af-57a1-4e1c-b530-da94f1813cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2aef24f9-630f-4a5d-81ae-7738d90f4407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e2671af-57a1-4e1c-b530-da94f1813cf7" xlink:to="loc_us-gaap_StockholdersEquity_2aef24f9-630f-4a5d-81ae-7738d90f4407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_7fc45ba4-ce3f-4285-a50c-386d561858e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e2671af-57a1-4e1c-b530-da94f1813cf7" xlink:to="loc_us-gaap_MinorityInterest_7fc45ba4-ce3f-4285-a50c-386d561858e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_76dc26d3-4cb5-467b-991b-307b26bd053a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_e488b119-690c-4b8b-9cdb-cc694ef3278a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_76dc26d3-4cb5-467b-991b-307b26bd053a" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_e488b119-690c-4b8b-9cdb-cc694ef3278a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_7a0ce700-f647-4ee9-8b6a-1f2162d3677a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_76dc26d3-4cb5-467b-991b-307b26bd053a" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_7a0ce700-f647-4ee9-8b6a-1f2162d3677a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_e2ae1151-fe19-4a76-8c61-9add14789861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_76dc26d3-4cb5-467b-991b-307b26bd053a" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_e2ae1151-fe19-4a76-8c61-9add14789861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_958e75e5-4699-47d7-ad66-a7e656797339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ab08b12-2709-4bc0-ac09-a29dc1f57811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_958e75e5-4699-47d7-ad66-a7e656797339" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ab08b12-2709-4bc0-ac09-a29dc1f57811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_681c49cf-7712-431b-9666-0d2eaf5a3213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_958e75e5-4699-47d7-ad66-a7e656797339" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_681c49cf-7712-431b-9666-0d2eaf5a3213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_13a56a3d-34a9-4912-9caf-5d129a89637d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_958e75e5-4699-47d7-ad66-a7e656797339" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_13a56a3d-34a9-4912-9caf-5d129a89637d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b0bb7a8-9492-4221-a736-ac861eb1883b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_958e75e5-4699-47d7-ad66-a7e656797339" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b0bb7a8-9492-4221-a736-ac861eb1883b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_5ff3a7ec-4dfd-4596-b0fd-389b7fc35d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_958e75e5-4699-47d7-ad66-a7e656797339" xlink:to="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_5ff3a7ec-4dfd-4596-b0fd-389b7fc35d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b8869e09-3f97-4f8d-8dc7-f1023fe88132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b8869e09-3f97-4f8d-8dc7-f1023fe88132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_bb0e7d25-ee69-46d7-8c84-9109faac2942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_bb0e7d25-ee69-46d7-8c84-9109faac2942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_40ce31aa-10da-4b64-9640-93185b843ba9" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_40ce31aa-10da-4b64-9640-93185b843ba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_02ae2af4-b9d3-4196-b26f-3b1a084e5ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_02ae2af4-b9d3-4196-b26f-3b1a084e5ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_3ab468fb-7256-4351-aad0-00ea8c9062cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_3ab468fb-7256-4351-aad0-00ea8c9062cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_702ef34d-f015-4bd4-9be2-741168788c40" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_702ef34d-f015-4bd4-9be2-741168788c40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_7f6be348-172b-433a-8ba0-9b2695fd1bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_7f6be348-172b-433a-8ba0-9b2695fd1bdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f2a4c2cc-66f7-450c-aaee-3a74711a499b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f2a4c2cc-66f7-450c-aaee-3a74711a499b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_632f64aa-0523-44ba-9514-54bb7a7ae149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_632f64aa-0523-44ba-9514-54bb7a7ae149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_2397ec9a-36c4-4394-b590-89bbc0414e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_2397ec9a-36c4-4394-b590-89bbc0414e2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired_9aa9a6f8-0377-49ff-9c65-064f3fd4b120" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired_9aa9a6f8-0377-49ff-9c65-064f3fd4b120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired_df3c624f-1629-4e7a-bdac-93758a779bbe" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_c19b7d7b-3086-4311-b771-05f4f538e6c2" xlink:to="loc_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired_df3c624f-1629-4e7a-bdac-93758a779bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_bdd7f664-5ec9-4502-9932-517149ddfa57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_dc7012c0-ada2-4c61-91b7-863520d73716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_bdd7f664-5ec9-4502-9932-517149ddfa57" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_dc7012c0-ada2-4c61-91b7-863520d73716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a89dcf6d-c5ba-47b7-870f-d1e0118f1b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_bdd7f664-5ec9-4502-9932-517149ddfa57" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a89dcf6d-c5ba-47b7-870f-d1e0118f1b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ca212ee5-c907-4cc1-a0d5-3c4a2e01fab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_bdd7f664-5ec9-4502-9932-517149ddfa57" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ca212ee5-c907-4cc1-a0d5-3c4a2e01fab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e7d92c9a-9105-48ba-9b08-7937ad00f383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_bdd7f664-5ec9-4502-9932-517149ddfa57" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e7d92c9a-9105-48ba-9b08-7937ad00f383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_3e02bcb1-4cb1-42ec-93ea-309ddb60e912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_bdd7f664-5ec9-4502-9932-517149ddfa57" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_3e02bcb1-4cb1-42ec-93ea-309ddb60e912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d3d2b16f-23eb-4ff7-b5ff-ef4b9b9d3789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_bdd7f664-5ec9-4502-9932-517149ddfa57" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d3d2b16f-23eb-4ff7-b5ff-ef4b9b9d3789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d6e38e32-410b-4650-897a-c119ff23ecc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_bdd7f664-5ec9-4502-9932-517149ddfa57" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d6e38e32-410b-4650-897a-c119ff23ecc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_615ce4b1-bc9e-4792-900f-dbeecb7beee2" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_bdd7f664-5ec9-4502-9932-517149ddfa57" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_615ce4b1-bc9e-4792-900f-dbeecb7beee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_29977bc9-1d5a-4e7e-9168-fdd5b6475c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_29977bc9-1d5a-4e7e-9168-fdd5b6475c5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_19151bf9-0ef8-4282-bd01-f79f4c593118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_19151bf9-0ef8-4282-bd01-f79f4c593118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f47dccbf-9ec6-487b-ba74-907c23f8baf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_ShareBasedCompensation_f47dccbf-9ec6-487b-ba74-907c23f8baf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d9f5f7d-cf10-47f0-a14f-b50383c187c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d9f5f7d-cf10-47f0-a14f-b50383c187c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6e479173-9909-4784-bf34-8c36db02f97b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6e479173-9909-4784-bf34-8c36db02f97b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree_83c1c2a4-589d-4a8c-af28-f8c6efb8bc21" xlink:href="mrk-20211231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree_83c1c2a4-589d-4a8c-af28-f8c6efb8bc21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_53c67956-7b7a-4353-908d-f3cc632efaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_53c67956-7b7a-4353-908d-f3cc632efaa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_2ff703a4-5c09-4f24-8460-04ef869f7503" xlink:href="mrk-20211231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_2ff703a4-5c09-4f24-8460-04ef869f7503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2793fa92-c56b-43e6-8300-e48cb4cef4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2793fa92-c56b-43e6-8300-e48cb4cef4ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_af3fcea1-4934-4916-9c9a-3b68ecd16704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_af3fcea1-4934-4916-9c9a-3b68ecd16704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_15b7dfba-e26e-4c96-a1b0-bd3a85152b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_15b7dfba-e26e-4c96-a1b0-bd3a85152b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_cd04f146-43a8-4f3b-b6ba-08344a1c3762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_AdjustmentForAmortization_cd04f146-43a8-4f3b-b6ba-08344a1c3762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0b2dcd0c-1fff-4704-8ab6-416826c27ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0b2dcd0c-1fff-4704-8ab6-416826c27ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_948f1295-1313-4f62-bb57-94f6d95c34f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_948f1295-1313-4f62-bb57-94f6d95c34f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_752b3d39-f11a-4bc8-baae-de6154e279a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_752b3d39-f11a-4bc8-baae-de6154e279a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2bfa9035-3bba-4e5a-b693-758aa591dafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_Depreciation_2bfa9035-3bba-4e5a-b693-758aa591dafc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_1b11830b-3067-4421-b1df-627dd843917f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_1b11830b-3067-4421-b1df-627dd843917f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_c3df2cdb-7258-461a-ac24-0da99d2d204b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2ba89d5b-6587-4d67-a913-4dc53009d48a" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_c3df2cdb-7258-461a-ac24-0da99d2d204b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_fa85c978-08bd-4673-b7b4-829c1a42c639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_ee6ae13d-ce65-4f04-ab6a-bfbb3db6c7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_fa85c978-08bd-4673-b7b4-829c1a42c639" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_ee6ae13d-ce65-4f04-ab6a-bfbb3db6c7eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8c78cc71-4778-4502-a2e3-36a17585c390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_fa85c978-08bd-4673-b7b4-829c1a42c639" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8c78cc71-4778-4502-a2e3-36a17585c390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c5547bb2-f907-46bf-87be-671babae174a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_2eacc212-819a-42a4-99e4-f5570c7e8bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c5547bb2-f907-46bf-87be-671babae174a" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_2eacc212-819a-42a4-99e4-f5570c7e8bcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_ffe8acd7-2eb2-47dd-af44-72b6afc20013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c5547bb2-f907-46bf-87be-671babae174a" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_ffe8acd7-2eb2-47dd-af44-72b6afc20013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_7b577e9c-6d96-4ed5-82dd-2ad47285b496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_0a300022-976a-4eb2-9c5e-bd977cbd8798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_7b577e9c-6d96-4ed5-82dd-2ad47285b496" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_0a300022-976a-4eb2-9c5e-bd977cbd8798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_6bb7ca37-2c91-420d-9bd5-67dc36719a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_7b577e9c-6d96-4ed5-82dd-2ad47285b496" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_6bb7ca37-2c91-420d-9bd5-67dc36719a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fec7ea5c-c358-43b2-972c-9284f63c8ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2844441b-c9e9-4c7b-bec4-91ee60050a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fec7ea5c-c358-43b2-972c-9284f63c8ac3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2844441b-c9e9-4c7b-bec4-91ee60050a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_b098b342-e3f7-46f9-bfb4-1e1a97ee434a" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fec7ea5c-c358-43b2-972c-9284f63c8ac3" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_b098b342-e3f7-46f9-bfb4-1e1a97ee434a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_6248e460-59c4-49fe-bc72-36fb85ec9e25" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fec7ea5c-c358-43b2-972c-9284f63c8ac3" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_6248e460-59c4-49fe-bc72-36fb85ec9e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_fa62e27c-da44-42a1-865d-f2735455b17e" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fec7ea5c-c358-43b2-972c-9284f63c8ac3" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_fa62e27c-da44-42a1-865d-f2735455b17e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_5c8cedcc-abdc-4c83-b8ac-ea891de81a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fec7ea5c-c358-43b2-972c-9284f63c8ac3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_5c8cedcc-abdc-4c83-b8ac-ea891de81a71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4363d801-b030-4c4e-955b-7b27f00e4be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent_327de959-39b9-4f88-8f97-b6c0977ba8d4" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4363d801-b030-4c4e-955b-7b27f00e4be5" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent_327de959-39b9-4f88-8f97-b6c0977ba8d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_11d70f42-fdd2-49e3-8898-8aaaba20739b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4363d801-b030-4c4e-955b-7b27f00e4be5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_11d70f42-fdd2-49e3-8898-8aaaba20739b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_b57b5100-e9e4-471c-a958-1fa3cb729bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4363d801-b030-4c4e-955b-7b27f00e4be5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_b57b5100-e9e4-471c-a958-1fa3cb729bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_3cb59b27-f26d-4bbe-9d76-dbe8a86dffd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_7614adb9-4623-4a17-baec-42298da4b849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_3cb59b27-f26d-4bbe-9d76-dbe8a86dffd8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_7614adb9-4623-4a17-baec-42298da4b849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_534f692d-6720-4ce6-a213-eb9410c3e21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_3cb59b27-f26d-4bbe-9d76-dbe8a86dffd8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_534f692d-6720-4ce6-a213-eb9410c3e21a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_8e6a88b6-1880-4a27-adcf-46fb1fb0dc29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_fc87d1ba-4938-4c43-86f4-3a07037928df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_8e6a88b6-1880-4a27-adcf-46fb1fb0dc29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_fc87d1ba-4938-4c43-86f4-3a07037928df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_13310942-9b83-4202-b7e9-5b68366ccca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_8e6a88b6-1880-4a27-adcf-46fb1fb0dc29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_13310942-9b83-4202-b7e9-5b68366ccca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_3232b1ee-09e9-4471-aea8-6f5e16da8d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_8e6a88b6-1880-4a27-adcf-46fb1fb0dc29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_3232b1ee-09e9-4471-aea8-6f5e16da8d4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_5a1dce6e-3bec-472e-8830-c26716b4a048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_8e6a88b6-1880-4a27-adcf-46fb1fb0dc29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_5a1dce6e-3bec-472e-8830-c26716b4a048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_32ce7bd6-b460-4ca1-a778-a909162c0c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_2a650e9f-7276-4d02-914d-792565789e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_32ce7bd6-b460-4ca1-a778-a909162c0c2c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_2a650e9f-7276-4d02-914d-792565789e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_e9711910-6b4c-485a-a2f7-5873b5711b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_32ce7bd6-b460-4ca1-a778-a909162c0c2c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_e9711910-6b4c-485a-a2f7-5873b5711b9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_a73ed3bc-93bf-4444-af29-129931e54639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_32ce7bd6-b460-4ca1-a778-a909162c0c2c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_a73ed3bc-93bf-4444-af29-129931e54639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_309eff0b-7066-477c-acb7-6fee7c1ef0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_32ce7bd6-b460-4ca1-a778-a909162c0c2c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_309eff0b-7066-477c-acb7-6fee7c1ef0f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8ae27a7f-3b04-4595-bc24-f732ac785774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c93f85de-5091-4868-8541-bc5c40de99ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8ae27a7f-3b04-4595-bc24-f732ac785774" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c93f85de-5091-4868-8541-bc5c40de99ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9b8bf248-3cda-4d56-be44-ec7db469e70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8ae27a7f-3b04-4595-bc24-f732ac785774" xlink:to="loc_us-gaap_Goodwill_9b8bf248-3cda-4d56-be44-ec7db469e70a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_352e508d-df0d-46c6-81c4-3ca8b9a398d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_352e508d-df0d-46c6-81c4-3ca8b9a398d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0213e8e1-9151-4f61-8672-43f945953239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0213e8e1-9151-4f61-8672-43f945953239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4372e4ea-36ab-4907-9ed4-e9022970e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4372e4ea-36ab-4907-9ed4-e9022970e00b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_fae7e9fa-daa8-456a-a35e-72f3d305201d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_fae7e9fa-daa8-456a-a35e-72f3d305201d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_33b80968-7e85-462c-913e-14db61184a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_33b80968-7e85-462c-913e-14db61184a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_24bbb2e3-3969-4c93-8ec2-b9d240b7ea27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_24bbb2e3-3969-4c93-8ec2-b9d240b7ea27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_695b526f-aa1e-4c47-8af5-8161668de37c" xlink:href="mrk-20211231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_695b526f-aa1e-4c47-8af5-8161668de37c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_bc0bda9c-a062-498b-acf3-1c7f5df399e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_bc0bda9c-a062-498b-acf3-1c7f5df399e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7095c207-93be-431f-869c-2ca6845b9100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7095c207-93be-431f-869c-2ca6845b9100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ac1b3283-ba82-4fa4-af2c-9fd22702223a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_98b459f3-5f53-4596-920b-f15bf68f1da1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ac1b3283-ba82-4fa4-af2c-9fd22702223a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6dab21e6-a17d-45e6-afc9-9b7846c61da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_34c396b7-2dfc-4227-9ee4-ede42918f3fe" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_6dab21e6-a17d-45e6-afc9-9b7846c61da7" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_34c396b7-2dfc-4227-9ee4-ede42918f3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_7f17f7be-4f80-442f-915c-df0221114252" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_6dab21e6-a17d-45e6-afc9-9b7846c61da7" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_7f17f7be-4f80-442f-915c-df0221114252" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1cb7a4f3-d694-4f12-8e32-0a230a9e2d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_11af8d90-d4d3-49db-aeea-c4ff4d3597b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1cb7a4f3-d694-4f12-8e32-0a230a9e2d14" xlink:to="loc_us-gaap_DerivativeAssets_11af8d90-d4d3-49db-aeea-c4ff4d3597b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_1e6999d2-108e-4a0c-aea0-9f819ad6cb78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1cb7a4f3-d694-4f12-8e32-0a230a9e2d14" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_1e6999d2-108e-4a0c-aea0-9f819ad6cb78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7d18a8e5-12ff-4cf2-87f6-3fe11140f309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1cb7a4f3-d694-4f12-8e32-0a230a9e2d14" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7d18a8e5-12ff-4cf2-87f6-3fe11140f309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_b9125b77-e0df-41ee-ae38-fc3c86eb969b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_dd4548e6-88e2-4050-921e-ebdcf5cf7971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_b9125b77-e0df-41ee-ae38-fc3c86eb969b" xlink:to="loc_us-gaap_DerivativeLiabilities_dd4548e6-88e2-4050-921e-ebdcf5cf7971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_559de465-c271-4a95-9784-a4ea15e97304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_b9125b77-e0df-41ee-ae38-fc3c86eb969b" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_559de465-c271-4a95-9784-a4ea15e97304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_1b096377-d58a-4825-89ab-5939cdeacdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_b9125b77-e0df-41ee-ae38-fc3c86eb969b" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_1b096377-d58a-4825-89ab-5939cdeacdeb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae52af45-65e4-4205-af32-9386439132a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de4257d7-54eb-4fe6-8712-46b396b777bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae52af45-65e4-4205-af32-9386439132a7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de4257d7-54eb-4fe6-8712-46b396b777bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d88c1c39-af63-4775-8220-110d541561f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae52af45-65e4-4205-af32-9386439132a7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d88c1c39-af63-4775-8220-110d541561f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b68984de-fb44-40b6-b4ff-5b9ad8064424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae52af45-65e4-4205-af32-9386439132a7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b68984de-fb44-40b6-b4ff-5b9ad8064424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_c8ebf384-5123-494c-b80b-e5f4d125bdde" xlink:href="mrk-20211231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aad0058e-f068-4d8f-a743-d21f0d48efe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_c8ebf384-5123-494c-b80b-e5f4d125bdde" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aad0058e-f068-4d8f-a743-d21f0d48efe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_51bf0cf9-4622-4f48-8894-25831673bf40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_c8ebf384-5123-494c-b80b-e5f4d125bdde" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_51bf0cf9-4622-4f48-8894-25831673bf40" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1959c350-8c2b-44e1-a436-3e053f1100de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4a4a6f3d-8b33-42eb-a29e-9c7abe453fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1959c350-8c2b-44e1-a436-3e053f1100de" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4a4a6f3d-8b33-42eb-a29e-9c7abe453fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_9abf080f-3c1c-4f54-b95b-433d42bf60a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1959c350-8c2b-44e1-a436-3e053f1100de" xlink:to="loc_us-gaap_DerivativeLiabilities_9abf080f-3c1c-4f54-b95b-433d42bf60a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_68bc59f2-b8b3-4f13-9af6-032985d1655b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0fd3aec5-99f2-448e-aebf-b6785eb68b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_68bc59f2-b8b3-4f13-9af6-032985d1655b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0fd3aec5-99f2-448e-aebf-b6785eb68b37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c42a3c10-6d14-4d49-99f0-b5b01077cf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_68bc59f2-b8b3-4f13-9af6-032985d1655b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c42a3c10-6d14-4d49-99f0-b5b01077cf1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6b3d1f83-9827-4b36-b562-64f64d1757bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_ae45cb3f-dfaa-4fb7-b121-5c46bde8a134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6b3d1f83-9827-4b36-b562-64f64d1757bd" xlink:to="loc_us-gaap_TradingSecurities_ae45cb3f-dfaa-4fb7-b121-5c46bde8a134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9d1a5e11-9311-4127-b369-6efa6874e800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6b3d1f83-9827-4b36-b562-64f64d1757bd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9d1a5e11-9311-4127-b369-6efa6874e800" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_096c403f-0b50-46ca-858d-b3c1b0dc14cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6b3d1f83-9827-4b36-b562-64f64d1757bd" xlink:to="loc_us-gaap_DerivativeAssets_096c403f-0b50-46ca-858d-b3c1b0dc14cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#InventoriesInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_351ce879-1937-4a4c-8f95-5415c942724e" xlink:href="mrk-20211231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_e91d80f2-fae1-4dc0-a0e9-e1a4a7248d43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_351ce879-1937-4a4c-8f95-5415c942724e" xlink:to="loc_us-gaap_InventoryLIFOReserve_e91d80f2-fae1-4dc0-a0e9-e1a4a7248d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_29813855-1d52-4a36-9147-4189b4114e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_351ce879-1937-4a4c-8f95-5415c942724e" xlink:to="loc_us-gaap_InventoryGross_29813855-1d52-4a36-9147-4189b4114e70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_9711b551-b96e-4dd7-95aa-4162167890e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_e6bb2129-7265-4ee5-9b7d-79ecc6eaf4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_9711b551-b96e-4dd7-95aa-4162167890e5" xlink:to="loc_us-gaap_InventoryFinishedGoods_e6bb2129-7265-4ee5-9b7d-79ecc6eaf4dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_e0d334cb-0c12-44d3-9770-8a4f27369c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_9711b551-b96e-4dd7-95aa-4162167890e5" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_e0d334cb-0c12-44d3-9770-8a4f27369c40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_f8db105f-55aa-458d-9447-ef985a7af659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_9711b551-b96e-4dd7-95aa-4162167890e5" xlink:to="loc_us-gaap_OtherInventorySupplies_f8db105f-55aa-458d-9447-ef985a7af659" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20211231.xsd#InventoriesInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_388c24d9-6308-4ec8-84cc-fdf5027a80b9" xlink:href="mrk-20211231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_be945957-9853-4927-aee5-7b7319007f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_388c24d9-6308-4ec8-84cc-fdf5027a80b9" xlink:to="loc_us-gaap_InventoryNet_be945957-9853-4927-aee5-7b7319007f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_bb6b0073-9f0d-4886-9c45-56de1066b224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_388c24d9-6308-4ec8-84cc-fdf5027a80b9" xlink:to="loc_us-gaap_InventoryNoncurrent_bb6b0073-9f0d-4886-9c45-56de1066b224" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#GoodwillandOtherIntangiblesOtherIntangiblesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_534e357e-74ef-4851-ba66-558a96730bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8d1ce39a-74ab-48c0-a63b-64d089c2fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_534e357e-74ef-4851-ba66-558a96730bc0" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8d1ce39a-74ab-48c0-a63b-64d089c2fed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_54ccb946-2bd7-4a43-a119-7470e6df8076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_534e357e-74ef-4851-ba66-558a96730bc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_54ccb946-2bd7-4a43-a119-7470e6df8076" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dba09396-3e32-4c9b-98ab-727c0f11b067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_aea77ee8-5159-4745-b450-0483561357ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_dba09396-3e32-4c9b-98ab-727c0f11b067" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_aea77ee8-5159-4745-b450-0483561357ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff560e8b-7569-4c2f-b01f-d17a5d3f067c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_dba09396-3e32-4c9b-98ab-727c0f11b067" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff560e8b-7569-4c2f-b01f-d17a5d3f067c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fbdafa0e-1fb6-4e19-bb2e-63febb78590c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_229c9226-fe5c-49ca-8803-5b9de49ef45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fbdafa0e-1fb6-4e19-bb2e-63febb78590c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_229c9226-fe5c-49ca-8803-5b9de49ef45e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c27604ac-a76f-4d3d-acf8-de6a41a286a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fbdafa0e-1fb6-4e19-bb2e-63febb78590c" xlink:to="loc_us-gaap_OperatingLeaseLiability_c27604ac-a76f-4d3d-acf8-de6a41a286a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70b76cc1-48a4-46a4-b857-217c93668cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e67acba0-fc7c-4138-aea3-824eb8c48c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70b76cc1-48a4-46a4-b857-217c93668cef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e67acba0-fc7c-4138-aea3-824eb8c48c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ffc3daa1-23f9-49cb-9c41-a210a7c9d159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70b76cc1-48a4-46a4-b857-217c93668cef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ffc3daa1-23f9-49cb-9c41-a210a7c9d159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_666d8d9a-db71-411a-815d-a5f22ba563f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70b76cc1-48a4-46a4-b857-217c93668cef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_666d8d9a-db71-411a-815d-a5f22ba563f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_17646e8c-aa54-49f7-a96a-0162067ca73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70b76cc1-48a4-46a4-b857-217c93668cef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_17646e8c-aa54-49f7-a96a-0162067ca73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45af59ad-3b57-44f6-bb38-3f981c77ecf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70b76cc1-48a4-46a4-b857-217c93668cef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45af59ad-3b57-44f6-bb38-3f981c77ecf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d6bfac8f-f1d5-4585-b298-2c09746b1cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70b76cc1-48a4-46a4-b857-217c93668cef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d6bfac8f-f1d5-4585-b298-2c09746b1cd8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f72c3287-283a-409d-9457-81a5b0f74f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_f00fabf0-9ca6-44dd-8360-e8dc5f6e04bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f72c3287-283a-409d-9457-81a5b0f74f70" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_f00fabf0-9ca6-44dd-8360-e8dc5f6e04bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_0f79df66-6464-4c3c-9dcb-a6797c7da6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f72c3287-283a-409d-9457-81a5b0f74f70" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_0f79df66-6464-4c3c-9dcb-a6797c7da6f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b917e2ac-c491-467e-836d-3017bf62ab45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f72c3287-283a-409d-9457-81a5b0f74f70" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b917e2ac-c491-467e-836d-3017bf62ab45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ea725d5b-f85e-4262-9b05-7395a69fc3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f72c3287-283a-409d-9457-81a5b0f74f70" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ea725d5b-f85e-4262-9b05-7395a69fc3d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_c7aef3ba-a6ff-404c-ba35-70dd2086c9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f72c3287-283a-409d-9457-81a5b0f74f70" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_c7aef3ba-a6ff-404c-ba35-70dd2086c9d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_022da062-6e41-4b32-b158-5ff1df89778d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f72c3287-283a-409d-9457-81a5b0f74f70" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_022da062-6e41-4b32-b158-5ff1df89778d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_0b2fcdaa-8a55-4822-9522-fccdb5fcb23c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f72c3287-283a-409d-9457-81a5b0f74f70" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_0b2fcdaa-8a55-4822-9522-fccdb5fcb23c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_fa08d446-2fd3-4adc-a8be-17e26ea8e7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f72c3287-283a-409d-9457-81a5b0f74f70" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_fa08d446-2fd3-4adc-a8be-17e26ea8e7a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_3f427fd1-642a-448d-8735-ec10110dd37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_e08a1e9a-a26c-4aa1-8e9e-1a3206fa2d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_3f427fd1-642a-448d-8735-ec10110dd37f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_e08a1e9a-a26c-4aa1-8e9e-1a3206fa2d3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_bd0cc8cd-2422-450f-9b10-36bf532a7262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_3f427fd1-642a-448d-8735-ec10110dd37f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_bd0cc8cd-2422-450f-9b10-36bf532a7262" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_182ea765-f6b6-490c-a898-d9dd51d5f563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_3f427fd1-642a-448d-8735-ec10110dd37f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_182ea765-f6b6-490c-a898-d9dd51d5f563" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_eb0916d8-18a8-4343-b39c-4978b1868083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b82b7269-7b39-4ec3-8d42-6b6240b2b9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_eb0916d8-18a8-4343-b39c-4978b1868083" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b82b7269-7b39-4ec3-8d42-6b6240b2b9a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_2a852bff-76b2-4223-bec3-f9429b583e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_eb0916d8-18a8-4343-b39c-4978b1868083" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_2a852bff-76b2-4223-bec3-f9429b583e89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_069b8b48-87eb-4e7c-a322-0ac67d21f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_a6757d4e-9ebe-4685-aba4-d355d8b3bc59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_069b8b48-87eb-4e7c-a322-0ac67d21f4c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_a6757d4e-9ebe-4685-aba4-d355d8b3bc59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c637e580-27a4-47e0-b2a8-4d1d6f09e2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_069b8b48-87eb-4e7c-a322-0ac67d21f4c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c637e580-27a4-47e0-b2a8-4d1d6f09e2fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_db7e09e5-a4f3-4977-b876-e67bb4df4c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_cc8cba98-8cfa-41fb-aa5e-8d742b67cee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_db7e09e5-a4f3-4977-b876-e67bb4df4c52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_cc8cba98-8cfa-41fb-aa5e-8d742b67cee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_b37ff789-1bb4-45a8-94c9-b1ec37747ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_db7e09e5-a4f3-4977-b876-e67bb4df4c52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_b37ff789-1bb4-45a8-94c9-b1ec37747ca5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a6c5e895-2dc9-4406-8a26-5e3c85d3b628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_810ab314-04d2-4752-a3cb-34e6ed051020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_a6c5e895-2dc9-4406-8a26-5e3c85d3b628" xlink:to="loc_us-gaap_InvestmentIncomeInterest_810ab314-04d2-4752-a3cb-34e6ed051020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_077c48a3-948a-4156-9365-f7b2b6c77fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_a6c5e895-2dc9-4406-8a26-5e3c85d3b628" xlink:to="loc_us-gaap_InterestExpense_077c48a3-948a-4156-9365-f7b2b6c77fa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_29e26851-0434-4a8a-b51e-0653be74306e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_a6c5e895-2dc9-4406-8a26-5e3c85d3b628" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_29e26851-0434-4a8a-b51e-0653be74306e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d014a862-5d68-4c6c-ad5c-01aa21785e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_a6c5e895-2dc9-4406-8a26-5e3c85d3b628" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d014a862-5d68-4c6c-ad5c-01aa21785e98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_d2e60946-6ba2-4821-8521-0a902041c0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_a6c5e895-2dc9-4406-8a26-5e3c85d3b628" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_d2e60946-6ba2-4821-8521-0a902041c0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_7bdd72f1-1564-4a93-8324-4a381e21485d" xlink:href="mrk-20211231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_a6c5e895-2dc9-4406-8a26-5e3c85d3b628" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_7bdd72f1-1564-4a93-8324-4a381e21485d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6c8d5663-367f-4153-8807-6e6cce384c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6c8d5663-367f-4153-8807-6e6cce384c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ec3fe49b-8186-40b2-be9d-c7d68daa64eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ec3fe49b-8186-40b2-be9d-c7d68daa64eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4c167d8f-7263-4f50-b2d1-48e571d5c501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4c167d8f-7263-4f50-b2d1-48e571d5c501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ae94093e-14cb-4813-85e7-0fa3ffd4cd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ae94093e-14cb-4813-85e7-0fa3ffd4cd36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_bd2217c8-9281-4283-b542-d9fb0a771360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_bd2217c8-9281-4283-b542-d9fb0a771360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_5f330076-19d2-4a25-ad3a-610b74d6d411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_5f330076-19d2-4a25-ad3a-610b74d6d411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_2eeb993b-f6ab-4055-89c9-208bc7c7bb0f" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_2eeb993b-f6ab-4055-89c9-208bc7c7bb0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_ba75c263-a61a-497a-b673-62b5e279952b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_ba75c263-a61a-497a-b673-62b5e279952b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_9769e8fb-28ab-45f1-b379-8149d7729d19" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_9769e8fb-28ab-45f1-b379-8149d7729d19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_0be56fa6-44b8-4456-b30c-9c43a8f7c8ae" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_0be56fa6-44b8-4456-b30c-9c43a8f7c8ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_e875792e-7ed0-4b5e-848d-4f37d69599af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_e875792e-7ed0-4b5e-848d-4f37d69599af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1a56469c-9a9a-4331-9e34-b170f11a2a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1a56469c-9a9a-4331-9e34-b170f11a2a6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_8ec30f16-f383-480b-8488-af922d9757e1" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_8ec30f16-f383-480b-8488-af922d9757e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_22fe89bf-879e-4244-b768-2e32e17fad9e" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_22fe89bf-879e-4244-b768-2e32e17fad9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_92b77c4a-b62f-460b-b395-61d74bbb3a20" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6d8de29e-1914-488c-9cab-7e5a231121ef" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_92b77c4a-b62f-460b-b395-61d74bbb3a20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b43ad182-ab4b-4b3d-a4b4-35cb71b71d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b43ad182-ab4b-4b3d-a4b4-35cb71b71d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1cc8c0ff-7d62-486d-b9bc-4c76b2477caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1cc8c0ff-7d62-486d-b9bc-4c76b2477caf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_1327011d-dd0b-4c4c-b89b-ad3414a4a71d" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_1327011d-dd0b-4c4c-b89b-ad3414a4a71d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_1d011d52-335e-4b52-8d51-d52c2fef36fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_1d011d52-335e-4b52-8d51-d52c2fef36fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d0cfdec1-75c0-4fd3-a903-931b07da9079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d0cfdec1-75c0-4fd3-a903-931b07da9079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_aaa354bc-20e6-4719-9870-cb1975702b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_aaa354bc-20e6-4719-9870-cb1975702b4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_f9a961c5-4e9d-4e28-9189-7e18b0efbe8b" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_f9a961c5-4e9d-4e28-9189-7e18b0efbe8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_9705eb4d-2934-4dc8-9479-88ebec671400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_9705eb4d-2934-4dc8-9479-88ebec671400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_bc55b173-b97c-4043-afcc-7030bf4a33bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_bc55b173-b97c-4043-afcc-7030bf4a33bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_39693aac-3372-4cf6-bd2a-01331a2757bb" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_39693aac-3372-4cf6-bd2a-01331a2757bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_217c6ba9-2915-494d-a569-afa1374eb53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_217c6ba9-2915-494d-a569-afa1374eb53b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_755df6fc-9ff4-4df4-9420-2559bc255447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_755df6fc-9ff4-4df4-9420-2559bc255447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_bfbeb6e3-fa08-46f5-a8bb-342a7b61fd50" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_bfbeb6e3-fa08-46f5-a8bb-342a7b61fd50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_cdb2381c-f302-4c2f-8c37-7261c0450579" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_cdb2381c-f302-4c2f-8c37-7261c0450579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_ffebccc3-2550-4cb2-9e26-f7a143a2b1f3" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6c72a9bb-e6c9-47a2-8cd3-a89d3ea4ed40" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_ffebccc3-2550-4cb2-9e26-f7a143a2b1f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeIncomeBeforeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4287ad20-bfe4-42cc-85ff-0c194a395761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fa057305-fa5b-494e-b9d3-7dac9143a790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4287ad20-bfe4-42cc-85ff-0c194a395761" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fa057305-fa5b-494e-b9d3-7dac9143a790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5cae45de-f837-4f20-b4d5-ffa1b7c8ea0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4287ad20-bfe4-42cc-85ff-0c194a395761" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5cae45de-f837-4f20-b4d5-ffa1b7c8ea0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeTaxesonIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2e0ac85c-47d8-4e4b-9e2f-4df7c025361a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9c408523-dd8b-44eb-aa05-6b9c02bed331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2e0ac85c-47d8-4e4b-9e2f-4df7c025361a" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9c408523-dd8b-44eb-aa05-6b9c02bed331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fa6bb91d-4d57-4f04-91a9-0fae75b852ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2e0ac85c-47d8-4e4b-9e2f-4df7c025361a" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fa6bb91d-4d57-4f04-91a9-0fae75b852ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1054ab58-fa0a-4d88-869c-4498a9f45ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2e0ac85c-47d8-4e4b-9e2f-4df7c025361a" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1054ab58-fa0a-4d88-869c-4498a9f45ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_98438fb3-b9ce-49ad-8248-eb7a5e02c031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_83b4c67e-54ad-4e71-b9f0-a6524f19103e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98438fb3-b9ce-49ad-8248-eb7a5e02c031" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_83b4c67e-54ad-4e71-b9f0-a6524f19103e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1e7439e6-d499-450e-a941-26ad72ac9ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98438fb3-b9ce-49ad-8248-eb7a5e02c031" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1e7439e6-d499-450e-a941-26ad72ac9ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_766756a4-5bb4-49d7-9fa2-94892f08b087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_885901e0-5a45-43cb-8cc9-6531276b1bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_766756a4-5bb4-49d7-9fa2-94892f08b087" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_885901e0-5a45-43cb-8cc9-6531276b1bee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e36080dd-b4ad-4381-ae08-3dd04b741d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_766756a4-5bb4-49d7-9fa2-94892f08b087" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e36080dd-b4ad-4381-ae08-3dd04b741d87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_59111aa7-c222-4f66-88a7-4af18da2782b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_766756a4-5bb4-49d7-9fa2-94892f08b087" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_59111aa7-c222-4f66-88a7-4af18da2782b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeDeferredIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_24485215-993d-4037-87ba-0148f4ae0e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_cb090601-5f8a-4738-a697-9da51353b63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_24485215-993d-4037-87ba-0148f4ae0e41" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_cb090601-5f8a-4738-a697-9da51353b63f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_e4c1f2ae-d094-4202-acf8-61df8644bddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_24485215-993d-4037-87ba-0148f4ae0e41" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_e4c1f2ae-d094-4202-acf8-61df8644bddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_03e697ec-2eee-4a22-ab0f-32a660ca335b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_24485215-993d-4037-87ba-0148f4ae0e41" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_03e697ec-2eee-4a22-ab0f-32a660ca335b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_517293c9-4795-4f0f-af8c-c46ba406eb10" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_24485215-993d-4037-87ba-0148f4ae0e41" xlink:to="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_517293c9-4795-4f0f-af8c-c46ba406eb10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_00e60100-9a38-4081-b6b1-0383943e7fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_24485215-993d-4037-87ba-0148f4ae0e41" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_00e60100-9a38-4081-b6b1-0383943e7fe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_84b1c423-80b7-4957-8b56-02b5ef46f45b" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_24485215-993d-4037-87ba-0148f4ae0e41" xlink:to="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_84b1c423-80b7-4957-8b56-02b5ef46f45b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_e5c0a22e-7df7-40c0-b11a-f4e1b7a03dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_79d857cf-fa55-4376-9664-27f60525ff4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_e5c0a22e-7df7-40c0-b11a-f4e1b7a03dec" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_79d857cf-fa55-4376-9664-27f60525ff4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_fa4a52eb-a082-46af-994d-e5c128329aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_e5c0a22e-7df7-40c0-b11a-f4e1b7a03dec" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_fa4a52eb-a082-46af-994d-e5c128329aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8e021c3d-8cdd-4887-8006-e47e9f0b3db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8e021c3d-8cdd-4887-8006-e47e9f0b3db5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_eb791e54-f15d-411a-a045-66c7cfd4c042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_eb791e54-f15d-411a-a045-66c7cfd4c042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_ab81c8a9-8628-4c67-ba0f-9b5c8a9ce85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_ab81c8a9-8628-4c67-ba0f-9b5c8a9ce85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_73d2a44c-f546-483f-bdd6-dab5e6115e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_73d2a44c-f546-483f-bdd6-dab5e6115e6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_35ca8c9c-a4f2-47d2-98d8-2c6b00158e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_35ca8c9c-a4f2-47d2-98d8-2c6b00158e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_70aeeeb2-c41f-412e-9510-426fa0ba4ab4" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:to="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_70aeeeb2-c41f-412e-9510-426fa0ba4ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_15195566-191d-4fb5-a13d-8f17d2457422" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:to="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_15195566-191d-4fb5-a13d-8f17d2457422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1e1f00ac-ce2e-4177-88fa-e9ee9095ee32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1e1f00ac-ce2e-4177-88fa-e9ee9095ee32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_0701fe7c-afbc-4a2d-89d7-686351554d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_032eb777-c839-4fad-a263-db2d72e21f50" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_0701fe7c-afbc-4a2d-89d7-686351554d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_89aea454-89fb-4773-95ac-d86576efea61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_934cfe5b-e3b8-4385-bdb9-6f447f8bbea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_89aea454-89fb-4773-95ac-d86576efea61" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_934cfe5b-e3b8-4385-bdb9-6f447f8bbea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f92fdec6-bde5-4e9d-aa02-b78a263cd930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_89aea454-89fb-4773-95ac-d86576efea61" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f92fdec6-bde5-4e9d-aa02-b78a263cd930" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8786c51c-1a74-40be-a8e7-b11125b8fd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bc1ef4c5-bcfd-4f6c-acdc-acb6af55a580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8786c51c-1a74-40be-a8e7-b11125b8fd4a" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bc1ef4c5-bcfd-4f6c-acdc-acb6af55a580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_3e3b1a99-545f-4656-8386-36ed8e5eb731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8786c51c-1a74-40be-a8e7-b11125b8fd4a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_3e3b1a99-545f-4656-8386-36ed8e5eb731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8489ee7f-20c2-4618-b40a-ffbb58df6eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_3dc8e2c3-fefa-40a6-8231-4a959297c0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8489ee7f-20c2-4618-b40a-ffbb58df6eef" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_3dc8e2c3-fefa-40a6-8231-4a959297c0fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_a48341b8-6eb1-4cc3-8a3e-d231787e34c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8489ee7f-20c2-4618-b40a-ffbb58df6eef" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_a48341b8-6eb1-4cc3-8a3e-d231787e34c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b3740fe-d313-4ca1-97eb-d92a152da745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_177cd8f1-2c42-4d1c-b1cc-84edf2087504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b3740fe-d313-4ca1-97eb-d92a152da745" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_177cd8f1-2c42-4d1c-b1cc-84edf2087504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1f517e0d-bbb2-4470-a50b-51bcce520588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b3740fe-d313-4ca1-97eb-d92a152da745" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1f517e0d-bbb2-4470-a50b-51bcce520588" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ea49672b-cd86-4e43-89e1-f31abf799acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_65742e3e-9641-458e-8b23-041e91a8ded3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ea49672b-cd86-4e43-89e1-f31abf799acb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_65742e3e-9641-458e-8b23-041e91a8ded3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_06ce3057-78f8-4bb5-8b12-dcb93a9fa0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ea49672b-cd86-4e43-89e1-f31abf799acb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_06ce3057-78f8-4bb5-8b12-dcb93a9fa0d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a94bd390-a8b0-44e2-9064-8b6d22e533a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e55f1761-a2c9-4624-b7eb-4f324b0bf923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a94bd390-a8b0-44e2-9064-8b6d22e533a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e55f1761-a2c9-4624-b7eb-4f324b0bf923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7fc47cd6-61aa-4da6-8691-4c400841d4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a94bd390-a8b0-44e2-9064-8b6d22e533a5" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7fc47cd6-61aa-4da6-8691-4c400841d4af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_382705b9-b883-4785-9c9f-19d7be3cc947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_ed959d9e-788d-4b24-9ea8-27f680eeb433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_382705b9-b883-4785-9c9f-19d7be3cc947" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_ed959d9e-788d-4b24-9ea8-27f680eeb433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_e307761f-de0b-404a-be8c-57fdfcf8ed23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_382705b9-b883-4785-9c9f-19d7be3cc947" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_e307761f-de0b-404a-be8c-57fdfcf8ed23" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>mrk-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c2671c01-457c-407e-affb-5c2ec2e9dc08,g:df117aec-e688-48b3-9aac-3f4fd6688d4e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20211231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended" id="i2b2cbbfcdd804b1caae9900ab36862d6_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5703317e-5cb5-4aa0-8007-a504ec2c02a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentType_5703317e-5cb5-4aa0-8007-a504ec2c02a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_208aeff5-7dff-43fb-b662-91bcfa48ca82" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentAnnualReport_208aeff5-7dff-43fb-b662-91bcfa48ca82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7849372e-de05-4b40-94b9-0b04e238a43a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentTransitionReport_7849372e-de05-4b40-94b9-0b04e238a43a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_35c6830f-c2f0-4d67-83bd-83e180bb10ec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityFileNumber_35c6830f-c2f0-4d67-83bd-83e180bb10ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5462d923-9be1-4c5d-9dbc-01f4e85e1258" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityRegistrantName_5462d923-9be1-4c5d-9dbc-01f4e85e1258" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_86658b9c-5e30-4900-aeca-7eda5f348c57" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_CityAreaCode_86658b9c-5e30-4900-aeca-7eda5f348c57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5c8d3b43-f65b-4123-804b-aa082a1bc58d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_LocalPhoneNumber_5c8d3b43-f65b-4123-804b-aa082a1bc58d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_51a9ed51-b436-4de9-9ccb-f044db71d4a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_51a9ed51-b436-4de9-9ccb-f044db71d4a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6aad0124-8ff9-41a3-a1c1-4bd6002445c8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityTaxIdentificationNumber_6aad0124-8ff9-41a3-a1c1-4bd6002445c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c7f8ee6c-5f03-4f30-900a-2e0de993e8ca" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityAddressAddressLine1_c7f8ee6c-5f03-4f30-900a-2e0de993e8ca" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_362d36b7-7dfa-4bab-96b5-cf367c788d4d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityAddressCityOrTown_362d36b7-7dfa-4bab-96b5-cf367c788d4d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b43e9a69-52f8-4f7a-bb76-9aabc6163cce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityAddressStateOrProvince_b43e9a69-52f8-4f7a-bb76-9aabc6163cce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0f5247a7-28f9-4465-87ae-0710af1f2157" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityAddressPostalZipCode_0f5247a7-28f9-4465-87ae-0710af1f2157" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_32c0b328-2f09-4aff-a233-87efb4ad39fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_Security12bTitle_32c0b328-2f09-4aff-a233-87efb4ad39fc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_52897dd9-167b-4a49-8718-d128ce3a0f4a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_TradingSymbol_52897dd9-167b-4a49-8718-d128ce3a0f4a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_af0c4268-36a7-4536-8e5d-ff78ea381ba1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_SecurityExchangeName_af0c4268-36a7-4536-8e5d-ff78ea381ba1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4e1a1886-4d10-4df8-943b-fc2534388751" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4e1a1886-4d10-4df8-943b-fc2534388751" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_fc25848c-7ca6-4c90-9a81-2f71ea504dcd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityPublicFloat_fc25848c-7ca6-4c90-9a81-2f71ea504dcd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_53f90cb4-51a7-43fa-a814-2c3df8a7c20b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_53f90cb4-51a7-43fa-a814-2c3df8a7c20b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_dd17c8e1-011f-4580-a083-2104388bb496" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityVoluntaryFilers_dd17c8e1-011f-4580-a083-2104388bb496" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6ebaaeb1-c05c-4c2f-99b9-2761257371ec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityCurrentReportingStatus_6ebaaeb1-c05c-4c2f-99b9-2761257371ec" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_aaae1572-672c-4349-8fe9-362e8092cd12" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityInteractiveDataCurrent_aaae1572-672c-4349-8fe9-362e8092cd12" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0ec391e7-567f-4414-969b-6c47fc281f53" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityFilerCategory_0ec391e7-567f-4414-969b-6c47fc281f53" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6fb533ee-9c65-4c90-b99b-55e75d3f7424" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntitySmallBusiness_6fb533ee-9c65-4c90-b99b-55e75d3f7424" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_754aedd9-a659-4337-9548-1d15977a7187" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityEmergingGrowthCompany_754aedd9-a659-4337-9548-1d15977a7187" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8b12570c-dd70-4256-8d12-57eaeca9c975" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8b12570c-dd70-4256-8d12-57eaeca9c975" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1f12b999-eece-4037-bba4-8145aec4798a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityShellCompany_1f12b999-eece-4037-bba4-8145aec4798a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fc271e61-0da3-4bbf-b0aa-f59b55b48173" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_AmendmentFlag_fc271e61-0da3-4bbf-b0aa-f59b55b48173" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_752d506c-ed7a-4c35-88a9-61989d3e01d9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentPeriodEndDate_752d506c-ed7a-4c35-88a9-61989d3e01d9" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3b893c49-acb5-4a30-821d-fb521fe4ab37" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentFiscalYearFocus_3b893c49-acb5-4a30-821d-fb521fe4ab37" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d597ebb2-9ea6-4b92-8bf9-2f7b45ae8c93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d597ebb2-9ea6-4b92-8bf9-2f7b45ae8c93" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ebfafac8-ccf2-4a46-83df-199006de3e10" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityCentralIndexKey_ebfafac8-ccf2-4a46-83df-199006de3e10" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c9051f33-58a5-4bee-a38d-341a9c4e5566" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_CurrentFiscalYearEndDate_c9051f33-58a5-4bee-a38d-341a9c4e5566" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e3675bf1-98d4-4e4a-872f-5da0e7b82a3f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e3675bf1-98d4-4e4a-872f-5da0e7b82a3f" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_3d57070f-6e26-4b15-82f2-bfd0656b2a73" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentInformationTable_3d57070f-6e26-4b15-82f2-bfd0656b2a73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c38194e2-795f-4bba-83c9-5f357d8a54d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3d57070f-6e26-4b15-82f2-bfd0656b2a73" xlink:to="loc_us-gaap_DebtInstrumentAxis_c38194e2-795f-4bba-83c9-5f357d8a54d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c38194e2-795f-4bba-83c9-5f357d8a54d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c38194e2-795f-4bba-83c9-5f357d8a54d1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c38194e2-795f-4bba-83c9-5f357d8a54d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c38194e2-795f-4bba-83c9-5f357d8a54d1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_becda756-5954-47d8-90c7-eacc3c4165dc" xlink:href="mrk-20211231.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:to="loc_mrk_A0.500Notesdue2024Member_becda756-5954-47d8-90c7-eacc3c4165dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_74fea867-7bc6-4936-b28e-2e54c4903bd8" xlink:href="mrk-20211231.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:to="loc_mrk_A1.875Notesdue2026Member_74fea867-7bc6-4936-b28e-2e54c4903bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_ae631153-2eac-4000-8f90-271eed6a57a1" xlink:href="mrk-20211231.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:to="loc_mrk_A2.500Notesdue2034Member_ae631153-2eac-4000-8f90-271eed6a57a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_a8c5898b-6a26-4e79-b96d-e77bf04a0c61" xlink:href="mrk-20211231.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:to="loc_mrk_A1.375Notesdue2036Member_a8c5898b-6a26-4e79-b96d-e77bf04a0c61" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="extended" id="ib210948f156349eda1f61f0c95486f71_ConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_983dd1b6-9772-48c5-8a50-e1968eb174ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_983dd1b6-9772-48c5-8a50-e1968eb174ec" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1b6f35c2-a843-4f3d-9222-328f70a9e68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1b6f35c2-a843-4f3d-9222-328f70a9e68b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3535d183-626e-4eaf-94fa-f4dafe5d318f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_NetIncomeLoss_3535d183-626e-4eaf-94fa-f4dafe5d318f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_686b547e-9b04-4f93-b14d-c08e3992ac35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_686b547e-9b04-4f93-b14d-c08e3992ac35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_53d90af8-f11f-4ce4-ae6b-2003b5197295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_DividendsCommonStockCash_53d90af8-f11f-4ce4-ae6b-2003b5197295" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_efd899dc-b7a6-4923-9410-5bd9f285cd51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_efd899dc-b7a6-4923-9410-5bd9f285cd51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_35339dd6-f68a-4345-a7df-449ccba3a2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_35339dd6-f68a-4345-a7df-449ccba3a2b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7db0beba-9bf9-4231-bf7d-1d8bccab0487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7db0beba-9bf9-4231-bf7d-1d8bccab0487" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_44f10182-e162-44f5-8538-788521951d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_44f10182-e162-44f5-8538-788521951d52" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_ba8cb40c-09a7-4e09-afd9-ef8fa0fe1ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_StockholdersEquityOther_ba8cb40c-09a7-4e09-afd9-ef8fa0fe1ea1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5397ed18-a87e-412b-a4e1-4d4a53c13081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9b43eb1b-839c-42b9-ba67-7d9e1421b7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_983dd1b6-9772-48c5-8a50-e1968eb174ec" xlink:to="loc_us-gaap_StatementTable_9b43eb1b-839c-42b9-ba67-7d9e1421b7f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_76211e0a-0c33-4537-889d-cfa82995d0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9b43eb1b-839c-42b9-ba67-7d9e1421b7f6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_76211e0a-0c33-4537-889d-cfa82995d0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76211e0a-0c33-4537-889d-cfa82995d0d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_76211e0a-0c33-4537-889d-cfa82995d0d8" xlink:to="loc_us-gaap_EquityComponentDomain_76211e0a-0c33-4537-889d-cfa82995d0d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_76211e0a-0c33-4537-889d-cfa82995d0d8" xlink:to="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_37e6abc5-849f-4817-8207-cf45c39242e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_CommonStockMember_37e6abc5-849f-4817-8207-cf45c39242e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0a153e10-e878-4d43-b68b-ce1a39c7f16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0a153e10-e878-4d43-b68b-ce1a39c7f16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_51642a80-d5f0-4a77-8c02-2313a555d9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_RetainedEarningsMember_51642a80-d5f0-4a77-8c02-2313a555d9b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019a1056-ee18-42b5-b409-89233125b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019a1056-ee18-42b5-b409-89233125b30c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_aac9e558-bb54-4b99-9f7a-e06581367472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_TreasuryStockMember_aac9e558-bb54-4b99-9f7a-e06581367472" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_934aec13-7288-437f-836e-f9173c0211f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_NoncontrollingInterestMember_934aec13-7288-437f-836e-f9173c0211f4" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SummaryofAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="extended" id="i8b262f76f5a046eaa3252917a1efd021_SummaryofAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:href="mrk-20211231.xsd#mrk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts_8296fdd9-bf0f-4c76-98bb-d76c02e57477" xlink:href="mrk-20211231.xsd#mrk_SalesDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_SalesDiscounts_8296fdd9-bf0f-4c76-98bb-d76c02e57477" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForChargebacks_58ca9b47-0c17-4ff2-8af8-fa1a6627b67b" xlink:href="mrk-20211231.xsd#mrk_AccrualForChargebacks"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_AccrualForChargebacks_58ca9b47-0c17-4ff2-8af8-fa1a6627b67b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForRebates_eb414982-b3b6-4f97-8009-9d28add09ba5" xlink:href="mrk-20211231.xsd#mrk_AccrualForRebates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_AccrualForRebates_eb414982-b3b6-4f97-8009-9d28add09ba5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_fd407a05-05bb-452e-b0aa-da7cd63b2d8a" xlink:href="mrk-20211231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_fd407a05-05bb-452e-b0aa-da7cd63b2d8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_8e8fc792-c895-4eb1-a547-d7b7a184055d" xlink:href="mrk-20211231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_8e8fc792-c895-4eb1-a547-d7b7a184055d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenuePerformanceObligationPaymentTerms_3214bd2e-8155-43b8-a5fc-fb8ca8b9d5fe" xlink:href="mrk-20211231.xsd#mrk_RevenuePerformanceObligationPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_RevenuePerformanceObligationPaymentTerms_3214bd2e-8155-43b8-a5fc-fb8ca8b9d5fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5fd0eb4-c99f-4ff5-8d4d-ba246e5739ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5fd0eb4-c99f-4ff5-8d4d-ba246e5739ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_147703ad-0d2f-475f-ae9d-19dcedf86bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_us-gaap_Depreciation_147703ad-0d2f-475f-ae9d-19dcedf86bb8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_26520310-29a1-46bc-b16b-b4d356bc213f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_us-gaap_AdvertisingExpense_26520310-29a1-46bc-b16b-b4d356bc213f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7682a17a-17d1-4212-ba56-db8b1880c1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7682a17a-17d1-4212-ba56-db8b1880c1ab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aec79a93-c107-4739-9530-3c93bc449baf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_srt_RangeAxis_aec79a93-c107-4739-9530-3c93bc449baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aec79a93-c107-4739-9530-3c93bc449baf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aec79a93-c107-4739-9530-3c93bc449baf" xlink:to="loc_srt_RangeMember_aec79a93-c107-4739-9530-3c93bc449baf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de735e29-fc02-4272-bbf9-b2c60e1675a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aec79a93-c107-4739-9530-3c93bc449baf" xlink:to="loc_srt_RangeMember_de735e29-fc02-4272-bbf9-b2c60e1675a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_17ebd44b-bebc-4037-b01a-8ccce9b19e28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_de735e29-fc02-4272-bbf9-b2c60e1675a3" xlink:to="loc_srt_MinimumMember_17ebd44b-bebc-4037-b01a-8ccce9b19e28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b255e8c2-cd42-4160-86b5-c77159b14518" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_de735e29-fc02-4272-bbf9-b2c60e1675a3" xlink:to="loc_srt_MaximumMember_b255e8c2-cd42-4160-86b5-c77159b14518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0399ef08-f116-403f-83f3-04f1b3589e6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_srt_StatementGeographicalAxis_0399ef08-f116-403f-83f3-04f1b3589e6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0399ef08-f116-403f-83f3-04f1b3589e6b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0399ef08-f116-403f-83f3-04f1b3589e6b" xlink:to="loc_srt_SegmentGeographicalDomain_0399ef08-f116-403f-83f3-04f1b3589e6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_34649fa4-0c2b-40e3-bd51-59b999854a15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0399ef08-f116-403f-83f3-04f1b3589e6b" xlink:to="loc_srt_SegmentGeographicalDomain_34649fa4-0c2b-40e3-bd51-59b999854a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2e380baa-80a8-405f-973e-692095930dfd" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_34649fa4-0c2b-40e3-bd51-59b999854a15" xlink:to="loc_country_US_2e380baa-80a8-405f-973e-692095930dfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ce5e7c94-f905-43c3-8001-76ec09a27a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_34649fa4-0c2b-40e3-bd51-59b999854a15" xlink:to="loc_us-gaap_NonUsMember_ce5e7c94-f905-43c3-8001-76ec09a27a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7c429d8c-2560-40a5-9485-18e2fce92950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7c429d8c-2560-40a5-9485-18e2fce92950" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7c429d8c-2560-40a5-9485-18e2fce92950_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7c429d8c-2560-40a5-9485-18e2fce92950" xlink:to="loc_us-gaap_SegmentDomain_7c429d8c-2560-40a5-9485-18e2fce92950_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3354817a-829c-4201-a8ae-06250de3361b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7c429d8c-2560-40a5-9485-18e2fce92950" xlink:to="loc_us-gaap_SegmentDomain_3354817a-829c-4201-a8ae-06250de3361b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_80ece693-f2bc-4ee6-b852-1c71780b4156" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3354817a-829c-4201-a8ae-06250de3361b" xlink:to="loc_mrk_PharmaceuticalsegmentMember_80ece693-f2bc-4ee6-b852-1c71780b4156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_0dc5eb6d-2547-43e0-b81f-06b9fefe2618" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3354817a-829c-4201-a8ae-06250de3361b" xlink:to="loc_mrk_AnimalHealthsegmentMember_0dc5eb6d-2547-43e0-b81f-06b9fefe2618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5b037193-745d-4609-8c6e-165d15d3e15f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5b037193-745d-4609-8c6e-165d15d3e15f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5b037193-745d-4609-8c6e-165d15d3e15f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5b037193-745d-4609-8c6e-165d15d3e15f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5b037193-745d-4609-8c6e-165d15d3e15f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc7fcf4f-92f1-4e54-9ea5-284437b6af86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5b037193-745d-4609-8c6e-165d15d3e15f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc7fcf4f-92f1-4e54-9ea5-284437b6af86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_74b3b3d2-040d-4333-9f3f-664858ebf438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc7fcf4f-92f1-4e54-9ea5-284437b6af86" xlink:to="loc_us-gaap_BuildingMember_74b3b3d2-040d-4333-9f3f-664858ebf438" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_29ef80bf-53d7-4096-8998-9b518a6fac06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc7fcf4f-92f1-4e54-9ea5-284437b6af86" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_29ef80bf-53d7-4096-8998-9b518a6fac06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63ffd68d-4351-4d0a-875f-db213cf965de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63ffd68d-4351-4d0a-875f-db213cf965de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_63ffd68d-4351-4d0a-875f-db213cf965de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63ffd68d-4351-4d0a-875f-db213cf965de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_63ffd68d-4351-4d0a-875f-db213cf965de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e27c37cb-c97a-44f2-be80-d01ac314aa00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63ffd68d-4351-4d0a-875f-db213cf965de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e27c37cb-c97a-44f2-be80-d01ac314aa00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a2b1bf5b-c1a0-4c6f-b7d2-d2d12f2ad2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e27c37cb-c97a-44f2-be80-d01ac314aa00" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a2b1bf5b-c1a0-4c6f-b7d2-d2d12f2ad2a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SpinOffofOrganonCoNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="extended" id="i42efe9e9c68d49e2ac292fceb55e1105_SpinOffofOrganonCoNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_605e54bb-2c12-4ddf-a856-a9a31be56cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_605e54bb-2c12-4ddf-a856-a9a31be56cd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bd27ad01-ff55-4d23-bde9-46be51c124f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bd27ad01-ff55-4d23-bde9-46be51c124f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2dc65ca9-f907-435e-8d20-ba5f7621784d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2dc65ca9-f907-435e-8d20-ba5f7621784d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_edd2b758-b083-4e9d-b4be-36431f7a9f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_edd2b758-b083-4e9d-b4be-36431f7a9f10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_3a831b55-d475-4e46-bf97-e89a0e3adcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_RevenueFromRelatedParties_3a831b55-d475-4e46-bf97-e89a0e3adcb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales_74e0a4c8-8b72-4b66-a0ba-cd03906258d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_RelatedPartiesAmountInCostOfSales_74e0a4c8-8b72-4b66-a0ba-cd03906258d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_8474ceae-6ab5-4fb3-a416-c70f2c35b565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_8474ceae-6ab5-4fb3-a416-c70f2c35b565" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_d43aa42c-da48-496f-9234-279cd85a1fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_d43aa42c-da48-496f-9234-279cd85a1fe4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_b264f5fd-d98a-4590-ac64-89960b7c4adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_b264f5fd-d98a-4590-ac64-89960b7c4adb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c8279a69-af24-4bfc-addc-2f6ee39a903b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c8279a69-af24-4bfc-addc-2f6ee39a903b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt_110fd182-a4ce-4665-8b50-981ffc219e8c" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt_110fd182-a4ce-4665-8b50-981ffc219e8c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_f6be046a-7539-46fc-96f9-433a32c9448f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_f6be046a-7539-46fc-96f9-433a32c9448f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6c1e8d73-eee5-4110-b24d-b62d59b28831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6c1e8d73-eee5-4110-b24d-b62d59b28831" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_f94c9003-b16e-40b8-864e-7f46f48a26a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_f94c9003-b16e-40b8-864e-7f46f48a26a0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_8d23c62b-c311-4821-bf87-3ae174b293ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_8d23c62b-c311-4821-bf87-3ae174b293ec" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_ddd24f00-7c5a-445d-a10f-8fb5129d2a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_ddd24f00-7c5a-445d-a10f-8fb5129d2a33" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_70406594-3f6c-4e65-9ee3-ba042ef74b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_70406594-3f6c-4e65-9ee3-ba042ef74b5a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_061c2043-ac0f-40fb-a680-f4a8f11f3a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_061c2043-ac0f-40fb-a680-f4a8f11f3a7f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_412abed5-8514-4de5-b647-26a308a3bf2b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_dei_LegalEntityAxis_412abed5-8514-4de5-b647-26a308a3bf2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_412abed5-8514-4de5-b647-26a308a3bf2b_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_412abed5-8514-4de5-b647-26a308a3bf2b" xlink:to="loc_dei_EntityDomain_412abed5-8514-4de5-b647-26a308a3bf2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bdf5a338-8cde-4161-9fdb-c4e69bb0ed40" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_412abed5-8514-4de5-b647-26a308a3bf2b" xlink:to="loc_dei_EntityDomain_bdf5a338-8cde-4161-9fdb-c4e69bb0ed40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_cf973d19-e3dc-4bab-a1d6-5de80707b2b2" xlink:href="mrk-20211231.xsd#mrk_OrganonCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bdf5a338-8cde-4161-9fdb-c4e69bb0ed40" xlink:to="loc_mrk_OrganonCoMember_cf973d19-e3dc-4bab-a1d6-5de80707b2b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_43d3476a-d7cf-4b2c-a6d1-1578d1c0bbe1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_srt_RangeAxis_43d3476a-d7cf-4b2c-a6d1-1578d1c0bbe1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43d3476a-d7cf-4b2c-a6d1-1578d1c0bbe1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_43d3476a-d7cf-4b2c-a6d1-1578d1c0bbe1" xlink:to="loc_srt_RangeMember_43d3476a-d7cf-4b2c-a6d1-1578d1c0bbe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e709eda8-3106-4706-ada9-aa5040d99bde" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_43d3476a-d7cf-4b2c-a6d1-1578d1c0bbe1" xlink:to="loc_srt_RangeMember_e709eda8-3106-4706-ada9-aa5040d99bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12bed9e9-8b41-4978-a63f-e5f33efbefd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e709eda8-3106-4706-ada9-aa5040d99bde" xlink:to="loc_srt_MaximumMember_12bed9e9-8b41-4978-a63f-e5f33efbefd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4d0eb203-dd82-4c82-b3d3-25589d5dd957" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e709eda8-3106-4706-ada9-aa5040d99bde" xlink:to="loc_srt_MinimumMember_4d0eb203-dd82-4c82-b3d3-25589d5dd957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_05eeb5cf-8e1c-4fcf-a3be-d360c57c829d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_05eeb5cf-8e1c-4fcf-a3be-d360c57c829d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_05eeb5cf-8e1c-4fcf-a3be-d360c57c829d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_05eeb5cf-8e1c-4fcf-a3be-d360c57c829d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_05eeb5cf-8e1c-4fcf-a3be-d360c57c829d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5ae3fa3f-c7ea-4b6e-a153-e897e372f5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_05eeb5cf-8e1c-4fcf-a3be-d360c57c829d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5ae3fa3f-c7ea-4b6e-a153-e897e372f5a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember_8042a19c-d0d3-40b7-8d2c-c5f9bd0b3e9b" xlink:href="mrk-20211231.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ae3fa3f-c7ea-4b6e-a153-e897e372f5a2" xlink:to="loc_mrk_TransitionServicesAgreementMember_8042a19c-d0d3-40b7-8d2c-c5f9bd0b3e9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember_96fe264e-2a84-4b9c-a21a-fa5745a0581e" xlink:href="mrk-20211231.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ae3fa3f-c7ea-4b6e-a153-e897e372f5a2" xlink:to="loc_mrk_ManufacturingAndSupplyAgreementsMember_96fe264e-2a84-4b9c-a21a-fa5745a0581e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a77df7ad-5d4b-4aa9-af88-19b4b99c445c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_srt_CounterpartyNameAxis_a77df7ad-5d4b-4aa9-af88-19b4b99c445c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a77df7ad-5d4b-4aa9-af88-19b4b99c445c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a77df7ad-5d4b-4aa9-af88-19b4b99c445c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a77df7ad-5d4b-4aa9-af88-19b4b99c445c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffd7e285-5f58-4a12-b793-33d868d01f8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a77df7ad-5d4b-4aa9-af88-19b4b99c445c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffd7e285-5f58-4a12-b793-33d868d01f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_ffff7862-7e19-40fb-98d0-3b31d0e15dca" xlink:href="mrk-20211231.xsd#mrk_OrganonCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffd7e285-5f58-4a12-b793-33d868d01f8b" xlink:to="loc_mrk_OrganonCoMember_ffff7862-7e19-40fb-98d0-3b31d0e15dca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_229e0fb2-2b18-4783-bb05-dacf49b7af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_us-gaap_AwardTypeAxis_229e0fb2-2b18-4783-bb05-dacf49b7af6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_229e0fb2-2b18-4783-bb05-dacf49b7af6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_229e0fb2-2b18-4783-bb05-dacf49b7af6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_229e0fb2-2b18-4783-bb05-dacf49b7af6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854a15b-1066-4c82-afef-31bada3c9674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_229e0fb2-2b18-4783-bb05-dacf49b7af6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854a15b-1066-4c82-afef-31bada3c9674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_50cadb5a-133d-48ae-bf90-8ac70b7cfd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854a15b-1066-4c82-afef-31bada3c9674" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_50cadb5a-133d-48ae-bf90-8ac70b7cfd56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ea93648b-b737-451d-b785-9412f2f56388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854a15b-1066-4c82-afef-31bada3c9674" xlink:to="loc_us-gaap_PerformanceSharesMember_ea93648b-b737-451d-b785-9412f2f56388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa83bc3f-57f6-49ae-9610-bbbfbbe4072c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa83bc3f-57f6-49ae-9610-bbbfbbe4072c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa83bc3f-57f6-49ae-9610-bbbfbbe4072c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa83bc3f-57f6-49ae-9610-bbbfbbe4072c" xlink:to="loc_us-gaap_EquityComponentDomain_fa83bc3f-57f6-49ae-9610-bbbfbbe4072c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa83bc3f-57f6-49ae-9610-bbbfbbe4072c" xlink:to="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d5ecea46-c3f0-4569-80b3-8b0cec9ad37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d5ecea46-c3f0-4569-80b3-8b0cec9ad37b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_1e8fbfcb-7cbe-4177-80c1-31a0389eb93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_1e8fbfcb-7cbe-4177-80c1-31a0389eb93b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8ac53b3f-472c-49c7-8e5e-f0da715d8c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8ac53b3f-472c-49c7-8e5e-f0da715d8c6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6d14710a-7cf3-402a-a613-a50ff670b332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6d14710a-7cf3-402a-a613-a50ff670b332" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails" xlink:type="extended" id="i8626ffe6f0bd4cfda5d38e6d842da6e0_AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8ab667dd-97c8-4ace-bc0d-366112c21c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8ab667dd-97c8-4ace-bc0d-366112c21c39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_79aff0ae-079f-47cb-916c-b57e2849afab" xlink:href="mrk-20211231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_RoyaltyRatePercentage_79aff0ae-079f-47cb-916c-b57e2849afab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_e3681b5d-6d8d-4965-b67f-eea1c16ddf05" xlink:href="mrk-20211231.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_e3681b5d-6d8d-4965-b67f-eea1c16ddf05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_fab6e0cd-1e44-48f1-a8a0-9497041f41f5" xlink:href="mrk-20211231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_fab6e0cd-1e44-48f1-a8a0-9497041f41f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_c7c05b19-399a-4093-8108-9c1f4e66f2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_c7c05b19-399a-4093-8108-9c1f4e66f2f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_94edb097-268b-4cb0-af03-332e0f4eda14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_94edb097-268b-4cb0-af03-332e0f4eda14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_5c4c9d6d-621a-4822-bace-8f2d096bbaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_5c4c9d6d-621a-4822-bace-8f2d096bbaaa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_afcf6f01-6ee0-469a-8819-2ae6a5f765e3" xlink:href="mrk-20211231.xsd#mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_afcf6f01-6ee0-469a-8819-2ae6a5f765e3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_efd99c51-ef55-4e7a-9fe6-1f7a7e042a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_efd99c51-ef55-4e7a-9fe6-1f7a7e042a9b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_ea67fd2e-bd50-46cc-a827-b744e3101e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_ea67fd2e-bd50-46cc-a827-b744e3101e81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_5ad7495e-28b2-41a2-aec9-7c2dc4bc9007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_5ad7495e-28b2-41a2-aec9-7c2dc4bc9007" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShareCounterparty_cfeec4f3-1ff4-4d5e-a8c0-e818f33f28bb" xlink:href="mrk-20211231.xsd#mrk_ProfitShareCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_ProfitShareCounterparty_cfeec4f3-1ff4-4d5e-a8c0-e818f33f28bb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShare_c0b3c62b-b973-4636-a955-ebaafceb79ac" xlink:href="mrk-20211231.xsd#mrk_ProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_ProfitShare_c0b3c62b-b973-4636-a955-ebaafceb79ac" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesThreshold_987d86db-f279-4602-b57e-ff00081a8b09" xlink:href="mrk-20211231.xsd#mrk_SalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_SalesThreshold_987d86db-f279-4602-b57e-ff00081a8b09" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_10102cf6-e5bc-4e20-aa74-47055148b15e" xlink:href="mrk-20211231.xsd#mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_10102cf6-e5bc-4e20-aa74-47055148b15e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_50298af1-ed8c-434b-aed2-c09eae4a9c38" xlink:href="mrk-20211231.xsd#mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_50298af1-ed8c-434b-aed2-c09eae4a9c38" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_cf363613-2d0b-43fb-975a-7194895a9575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_cf363613-2d0b-43fb-975a-7194895a9575" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0efc53d0-53ab-4ec8-8a12-15acb4d46be1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0efc53d0-53ab-4ec8-8a12-15acb4d46be1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_d00a5fcd-29ab-4ac2-ab5a-4e3bc4328984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_Investments_d00a5fcd-29ab-4ac2-ab5a-4e3bc4328984" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PremiumOnSharesAcquired_1db81467-19be-4527-b4cf-3d771d02e0d8" xlink:href="mrk-20211231.xsd#mrk_PremiumOnSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_PremiumOnSharesAcquired_1db81467-19be-4527-b4cf-3d771d02e0d8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_493b4f41-5935-45a2-9f7d-885439fdbc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_493b4f41-5935-45a2-9f7d-885439fdbc7b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation_2e288db1-9e3b-4d7f-9b99-4aac2417a19a" xlink:href="mrk-20211231.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_ChargesRelatedToProgramDiscontinuation_2e288db1-9e3b-4d7f-9b99-4aac2417a19a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_808f1572-5613-41de-8453-9ccc126df469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_808f1572-5613-41de-8453-9ccc126df469" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_4006cf47-fd43-492b-9be1-af3fa73029e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_SharePrice_4006cf47-fd43-492b-9be1-af3fa73029e9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a62e0302-d7d5-44e1-baea-5518af38aec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a62e0302-d7d5-44e1-baea-5518af38aec8" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_21eca2f8-f6a8-4e92-863c-8cc87483d241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_21eca2f8-f6a8-4e92-863c-8cc87483d241" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ba141d82-c3a5-43d4-ad81-790d69c23a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_InventoryNet_ba141d82-c3a5-43d4-ad81-790d69c23a2e" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9a9691a0-c349-460f-abc9-fbae9b60fdad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9a9691a0-c349-460f-abc9-fbae9b60fdad" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7fbf91ec-3967-48bc-83a9-c71556025b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7fbf91ec-3967-48bc-83a9-c71556025b33" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eff8dc29-3bcd-40c4-8bc4-52769e377636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eff8dc29-3bcd-40c4-8bc4-52769e377636" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a39f457a-7d96-4335-981a-68fdbac7b4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a39f457a-7d96-4335-981a-68fdbac7b4a2" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d5ed19cd-be8e-48ac-a2a6-fea0005719f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d5ed19cd-be8e-48ac-a2a6-fea0005719f5" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_b807f68f-7eee-4595-8b6f-59684fdf267c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_b807f68f-7eee-4595-8b6f-59684fdf267c" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_8306638b-81eb-430d-9604-8506a870ef8e" xlink:href="mrk-20211231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_8306638b-81eb-430d-9604-8506a870ef8e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d4ca0416-612c-4e3c-97ed-68925c2d1d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_Goodwill_d4ca0416-612c-4e3c-97ed-68925c2d1d7b" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_cde3cc1c-0ed1-4428-96fc-7b0f5102f7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_cde3cc1c-0ed1-4428-96fc-7b0f5102f7f9" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_31c5dc40-919c-4c9a-856b-c08f68d1c211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_31c5dc40-919c-4c9a-856b-c08f68d1c211" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_5f8fadae-9183-422a-a14e-c6d90676c99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_5f8fadae-9183-422a-a14e-c6d90676c99f" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_818bf71d-e708-4a6d-99ab-6f4da6d5b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_818bf71d-e708-4a6d-99ab-6f4da6d5b4a3" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents_e2238599-27d7-4382-8bf1-bb08f70ea09f" xlink:href="mrk-20211231.xsd#mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents_e2238599-27d7-4382-8bf1-bb08f70ea09f" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities_d0296166-2d9a-4a66-9476-dcd49bc8d57a" xlink:href="mrk-20211231.xsd#mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities_d0296166-2d9a-4a66-9476-dcd49bc8d57a" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_e015e22a-8d4e-42fc-8185-e424ea21dbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_e015e22a-8d4e-42fc-8185-e424ea21dbb9" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_82a0409b-e7ac-4216-ae09-ab68ca2048b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_82a0409b-e7ac-4216-ae09-ab68ca2048b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_82a0409b-e7ac-4216-ae09-ab68ca2048b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_82a0409b-e7ac-4216-ae09-ab68ca2048b0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_82a0409b-e7ac-4216-ae09-ab68ca2048b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_82a0409b-e7ac-4216-ae09-ab68ca2048b0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_4ff87e87-204c-4755-90a1-4d26504987b9" xlink:href="mrk-20211231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:to="loc_mrk_DevelopmentMilestonesMember_4ff87e87-204c-4755-90a1-4d26504987b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_b2f629a1-6f06-4911-88e0-3ae1fb2262e9" xlink:href="mrk-20211231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:to="loc_mrk_RegulatoryMilestonesMember_b2f629a1-6f06-4911-88e0-3ae1fb2262e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialmilestoneMember_368b0d70-dd22-4d27-84b5-d1b0cfd30ffe" xlink:href="mrk-20211231.xsd#mrk_CommercialmilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:to="loc_mrk_CommercialmilestoneMember_368b0d70-dd22-4d27-84b5-d1b0cfd30ffe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_3c509387-90de-450f-adb4-b3551fcfe67e" xlink:href="mrk-20211231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:to="loc_mrk_SalesBasedMilestonesMember_3c509387-90de-450f-adb4-b3551fcfe67e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_597aa4a9-d3f7-42e6-8d7b-c1634ce90adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_597aa4a9-d3f7-42e6-8d7b-c1634ce90adb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_597aa4a9-d3f7-42e6-8d7b-c1634ce90adb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_597aa4a9-d3f7-42e6-8d7b-c1634ce90adb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_597aa4a9-d3f7-42e6-8d7b-c1634ce90adb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_597aa4a9-d3f7-42e6-8d7b-c1634ce90adb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember_12399465-8510-496b-b313-fa1481743271" xlink:href="mrk-20211231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_AcceleronPharmaIncMember_12399465-8510-496b-b313-fa1481743271" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember_25a20e21-e69e-4232-ba0f-84714462af65" xlink:href="mrk-20211231.xsd#mrk_PandionTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_PandionTherapeuticsMember_25a20e21-e69e-4232-ba0f-84714462af65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_75473bd4-ce12-427c-824a-eef7445e0099" xlink:href="mrk-20211231.xsd#mrk_OncoImmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_OncoImmuneMember_75473bd4-ce12-427c-824a-eef7445e0099" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_7f4a2b70-9a5a-46e8-9e92-7a7e760c648e" xlink:href="mrk-20211231.xsd#mrk_VelosBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_VelosBioMember_7f4a2b70-9a5a-46e8-9e92-7a7e760c648e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_b7563b21-df8d-4dd5-a9ef-1cef6bed877e" xlink:href="mrk-20211231.xsd#mrk_DunboyneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_DunboyneMember_b7563b21-df8d-4dd5-a9ef-1cef6bed877e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember_f4830138-94cb-4c8f-8478-4337619e5b69" xlink:href="mrk-20211231.xsd#mrk_ThemisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_ThemisMember_f4830138-94cb-4c8f-8478-4337619e5b69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_46b4340f-0a02-46b1-81f6-2b0d5706a912" xlink:href="mrk-20211231.xsd#mrk_ArQuleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_ArQuleMember_46b4340f-0a02-46b1-81f6-2b0d5706a912" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember_6aa665a5-a062-4d6d-9571-0ca99fffcdc8" xlink:href="mrk-20211231.xsd#mrk_PelotonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_PelotonMember_6aa665a5-a062-4d6d-9571-0ca99fffcdc8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_f1d93c70-59c4-477c-b8a9-2358b4998617" xlink:href="mrk-20211231.xsd#mrk_AntelliqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_AntelliqMember_f1d93c70-59c4-477c-b8a9-2358b4998617" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImmuneDesignMember_38310fc1-913a-4ddb-ae64-302df4555ad9" xlink:href="mrk-20211231.xsd#mrk_ImmuneDesignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_ImmuneDesignMember_38310fc1-913a-4ddb-ae64-302df4555ad9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_76f2b89c-437d-445d-aa9b-467d7d8de32a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_srt_CounterpartyNameAxis_76f2b89c-437d-445d-aa9b-467d7d8de32a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2b89c-437d-445d-aa9b-467d7d8de32a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_76f2b89c-437d-445d-aa9b-467d7d8de32a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2b89c-437d-445d-aa9b-467d7d8de32a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_76f2b89c-437d-445d-aa9b-467d7d8de32a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GileadSciencesMember_0cfcc160-4e60-4b24-b2b8-07ae1d40c180" xlink:href="mrk-20211231.xsd#mrk_GileadSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_GileadSciencesMember_0cfcc160-4e60-4b24-b2b8-07ae1d40c180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember_bfec6764-0208-4626-a96a-b29bc1c5a108" xlink:href="mrk-20211231.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_ArtivaBiotherapeuticsIncMember_bfec6764-0208-4626-a96a-b29bc1c5a108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember_19b44671-3a8f-4e53-91e6-b6f6e4bc2a44" xlink:href="mrk-20211231.xsd#mrk_SeagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_SeagenMember_19b44671-3a8f-4e53-91e6-b6f6e4bc2a44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_0210b224-cb23-4472-ac8c-0ad5c6350b0b" xlink:href="mrk-20211231.xsd#mrk_SentinelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_SentinelMember_0210b224-cb23-4472-ac8c-0ad5c6350b0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember_016c812d-be4e-4228-9de2-4aed043a6bfc" xlink:href="mrk-20211231.xsd#mrk_IAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_IAVIMember_016c812d-be4e-4228-9de2-4aed043a6bfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_5eb5495e-e547-4478-8683-3e5be15dd4cc" xlink:href="mrk-20211231.xsd#mrk_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_BristolMyersSquibbMember_5eb5495e-e547-4478-8683-3e5be15dd4cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a5f7e823-116b-4fc1-83b0-3b4c098e83e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_srt_ProductOrServiceAxis_a5f7e823-116b-4fc1-83b0-3b4c098e83e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5f7e823-116b-4fc1-83b0-3b4c098e83e3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a5f7e823-116b-4fc1-83b0-3b4c098e83e3" xlink:to="loc_srt_ProductsAndServicesDomain_a5f7e823-116b-4fc1-83b0-3b4c098e83e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a5f7e823-116b-4fc1-83b0-3b4c098e83e3" xlink:to="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralAndInjectableFormulationsMember_a455d8d3-20eb-4825-b4df-1ea79916409c" xlink:href="mrk-20211231.xsd#mrk_OralAndInjectableFormulationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_OralAndInjectableFormulationsMember_a455d8d3-20eb-4825-b4df-1ea79916409c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralFormulationMember_cb874eed-f86a-44c9-ac27-13c140d2ad24" xlink:href="mrk-20211231.xsd#mrk_OralFormulationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_OralFormulationMember_cb874eed-f86a-44c9-ac27-13c140d2ad24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InjectableFormulationMember_aa646155-7969-42c7-bc3d-df4b50dd6ed3" xlink:href="mrk-20211231.xsd#mrk_InjectableFormulationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_InjectableFormulationMember_aa646155-7969-42c7-bc3d-df4b50dd6ed3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember_68acff93-a16c-43e1-a826-9ed7d7697e3a" xlink:href="mrk-20211231.xsd#mrk_TukysaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_TukysaMember_68acff93-a16c-43e1-a826-9ed7d7697e3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_0c384b19-5468-4825-b208-2ba3baf07339" xlink:href="mrk-20211231.xsd#mrk_SentinelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_SentinelMember_0c384b19-5468-4825-b208-2ba3baf07339" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_d62637b6-0f05-4938-9374-127ba3d63645" xlink:href="mrk-20211231.xsd#mrk_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_COVID19Member_d62637b6-0f05-4938-9374-127ba3d63645" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember_31e9d1e1-3d20-4cd7-b383-598d602de55b" xlink:href="mrk-20211231.xsd#mrk_NemtabrutinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_NemtabrutinibMember_31e9d1e1-3d20-4cd7-b383-598d602de55b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0c0aba98-ad66-418a-a48d-55427e31f794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0c0aba98-ad66-418a-a48d-55427e31f794" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0c0aba98-ad66-418a-a48d-55427e31f794_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0c0aba98-ad66-418a-a48d-55427e31f794" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0c0aba98-ad66-418a-a48d-55427e31f794_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f557e37f-35a1-4160-8996-6ff84eab3cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0c0aba98-ad66-418a-a48d-55427e31f794" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f557e37f-35a1-4160-8996-6ff84eab3cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7baa1309-a7f4-4970-8b49-83a968bddddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f557e37f-35a1-4160-8996-6ff84eab3cf6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7baa1309-a7f4-4970-8b49-83a968bddddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae6714d7-ee2f-4366-a218-ed573e575d72" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_srt_RangeAxis_ae6714d7-ee2f-4366-a218-ed573e575d72" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae6714d7-ee2f-4366-a218-ed573e575d72_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ae6714d7-ee2f-4366-a218-ed573e575d72" xlink:to="loc_srt_RangeMember_ae6714d7-ee2f-4366-a218-ed573e575d72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5636c264-635f-48ce-9d24-5bc92637dcdd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ae6714d7-ee2f-4366-a218-ed573e575d72" xlink:to="loc_srt_RangeMember_5636c264-635f-48ce-9d24-5bc92637dcdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46db4c6e-bb4c-4340-a22a-6014f81c2e3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5636c264-635f-48ce-9d24-5bc92637dcdd" xlink:to="loc_srt_MinimumMember_46db4c6e-bb4c-4340-a22a-6014f81c2e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b170150d-eb9a-4863-9214-bb77933dac09" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5636c264-635f-48ce-9d24-5bc92637dcdd" xlink:to="loc_srt_MaximumMember_b170150d-eb9a-4863-9214-bb77933dac09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81d89938-3766-4302-87ba-cc2974fd5ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81d89938-3766-4302-87ba-cc2974fd5ffa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81d89938-3766-4302-87ba-cc2974fd5ffa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81d89938-3766-4302-87ba-cc2974fd5ffa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81d89938-3766-4302-87ba-cc2974fd5ffa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_310a28a7-f7ec-4133-bfd2-fae3e06de5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81d89938-3766-4302-87ba-cc2974fd5ffa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_310a28a7-f7ec-4133-bfd2-fae3e06de5b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_c4e50385-5ade-43d5-9ef9-9e010d7f9aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_310a28a7-f7ec-4133-bfd2-fae3e06de5b1" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_c4e50385-5ade-43d5-9ef9-9e010d7f9aa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_26708ae6-9ba9-4fab-b28d-95b57f46194c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_AssetAcquisitionAxis_26708ae6-9ba9-4fab-b28d-95b57f46194c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_26708ae6-9ba9-4fab-b28d-95b57f46194c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_26708ae6-9ba9-4fab-b28d-95b57f46194c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_26708ae6-9ba9-4fab-b28d-95b57f46194c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_26708ae6-9ba9-4fab-b28d-95b57f46194c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember_fd4b5e28-d6af-4686-8fa4-8fef62f94a2a" xlink:href="mrk-20211231.xsd#mrk_PandionTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_PandionTherapeuticsMember_fd4b5e28-d6af-4686-8fa4-8fef62f94a2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_ab39515d-0109-47e0-abe5-637d0b37d4e1" xlink:href="mrk-20211231.xsd#mrk_OncoImmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_OncoImmuneMember_ab39515d-0109-47e0-abe5-637d0b37d4e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_b0bb25e8-89b1-4828-81ad-84dc0b3fccc4" xlink:href="mrk-20211231.xsd#mrk_VelosBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_VelosBioMember_b0bb25e8-89b1-4828-81ad-84dc0b3fccc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_900bdfda-965c-4722-a975-eb11235426db" xlink:href="mrk-20211231.xsd#mrk_DunboyneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_DunboyneMember_900bdfda-965c-4722-a975-eb11235426db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember_720c4f19-cc13-42db-b3c0-656156f99b0f" xlink:href="mrk-20211231.xsd#mrk_PelotonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_PelotonMember_720c4f19-cc13-42db-b3c0-656156f99b0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1b9a8dad-d081-4a70-91b6-df0ccce15d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1b9a8dad-d081-4a70-91b6-df0ccce15d92" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b9a8dad-d081-4a70-91b6-df0ccce15d92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1b9a8dad-d081-4a70-91b6-df0ccce15d92" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b9a8dad-d081-4a70-91b6-df0ccce15d92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_884896e6-a2f0-434f-80ec-c152ecec2c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1b9a8dad-d081-4a70-91b6-df0ccce15d92" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_884896e6-a2f0-434f-80ec-c152ecec2c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fde2d2d8-a6e9-46b3-bdb1-dd416c3bbacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_884896e6-a2f0-434f-80ec-c152ecec2c8f" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fde2d2d8-a6e9-46b3-bdb1-dd416c3bbacb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_2e44e9c2-5424-444b-8934-14fac08b7d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_884896e6-a2f0-434f-80ec-c152ecec2c8f" xlink:to="loc_us-gaap_LicensingAgreementsMember_2e44e9c2-5424-444b-8934-14fac08b7d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d2494d8e-d25a-413c-82df-17ff6bf97c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d2494d8e-d25a-413c-82df-17ff6bf97c7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d2494d8e-d25a-413c-82df-17ff6bf97c7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d2494d8e-d25a-413c-82df-17ff6bf97c7f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d2494d8e-d25a-413c-82df-17ff6bf97c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_51c38789-fb3f-43e4-9038-1a72ff2ca3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d2494d8e-d25a-413c-82df-17ff6bf97c7f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_51c38789-fb3f-43e4-9038-1a72ff2ca3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_771837a8-6445-4804-afa3-ca69079fbafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_51c38789-fb3f-43e4-9038-1a72ff2ca3b4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_771837a8-6445-4804-afa3-ca69079fbafa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i6dde7cf5e33243aab9c0785d6e29e9bd_AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d81a7625-b3d8-49ce-a831-3373a5a42bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d81a7625-b3d8-49ce-a831-3373a5a42bd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_066283aa-cfc4-46dd-8dd8-43ae67ccb829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_066283aa-cfc4-46dd-8dd8-43ae67ccb829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0f4afa5e-b142-45b2-8e75-d0f7eddec5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0f4afa5e-b142-45b2-8e75-d0f7eddec5ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad7720fb-1030-469d-9353-ee2aad9bc39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad7720fb-1030-469d-9353-ee2aad9bc39c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2f500a2b-1152-4036-bfdf-87d9a8ee01e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2f500a2b-1152-4036-bfdf-87d9a8ee01e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3990fbea-c074-40f2-831b-b0bac67b0a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3990fbea-c074-40f2-831b-b0bac67b0a69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0f44e18d-6bf9-43fa-9c11-9ec78c0c161e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0f44e18d-6bf9-43fa-9c11-9ec78c0c161e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ae2c3418-f273-4d5a-b34d-3dadf10c1967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ae2c3418-f273-4d5a-b34d-3dadf10c1967" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4f43e818-ddee-47e0-906b-c1f39b0c3626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4f43e818-ddee-47e0-906b-c1f39b0c3626" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47612334-4461-4af1-8d26-edeba542a468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47612334-4461-4af1-8d26-edeba542a468" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a5fc6497-84ca-4282-861f-7b35ffbf7de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a5fc6497-84ca-4282-861f-7b35ffbf7de7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_8eeb78e3-59fb-4611-80ce-9a4596102e4e" xlink:href="mrk-20211231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_8eeb78e3-59fb-4611-80ce-9a4596102e4e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9831e077-3ad2-4e2b-a623-a4b16ddc652e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9831e077-3ad2-4e2b-a623-a4b16ddc652e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5adba024-8f69-48e7-86e5-6da03bde28c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_Goodwill_5adba024-8f69-48e7-86e5-6da03bde28c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9ec0292c-196c-4422-a2b8-f3e63b8bc326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9ec0292c-196c-4422-a2b8-f3e63b8bc326" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_63ba6bc3-cfbf-43a6-86e3-fa8886c3c5a1" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_63ba6bc3-cfbf-43a6-86e3-fa8886c3c5a1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_2dbaa85e-dd8f-497a-b878-0c23da20bb89" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetProductsAndProductRightsMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_2dbaa85e-dd8f-497a-b878-0c23da20bb89" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2dd77d6c-70be-4f4f-b041-dc68b789bb5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:to="loc_srt_RangeAxis_2dd77d6c-70be-4f4f-b041-dc68b789bb5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2dd77d6c-70be-4f4f-b041-dc68b789bb5e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2dd77d6c-70be-4f4f-b041-dc68b789bb5e" xlink:to="loc_srt_RangeMember_2dd77d6c-70be-4f4f-b041-dc68b789bb5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0d2d0a5-25ba-4e43-8216-ebcbbf2aa5c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2dd77d6c-70be-4f4f-b041-dc68b789bb5e" xlink:to="loc_srt_RangeMember_e0d2d0a5-25ba-4e43-8216-ebcbbf2aa5c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ac3540b6-44bc-450f-9447-73cec4bbbb25" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0d2d0a5-25ba-4e43-8216-ebcbbf2aa5c1" xlink:to="loc_srt_MinimumMember_ac3540b6-44bc-450f-9447-73cec4bbbb25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdc9e877-7da8-4ffe-a98e-18c7309a165e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0d2d0a5-25ba-4e43-8216-ebcbbf2aa5c1" xlink:to="loc_srt_MaximumMember_fdc9e877-7da8-4ffe-a98e-18c7309a165e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_81ece920-7264-471f-83d4-b2ee226ec849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_81ece920-7264-471f-83d4-b2ee226ec849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81ece920-7264-471f-83d4-b2ee226ec849_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_81ece920-7264-471f-83d4-b2ee226ec849" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_81ece920-7264-471f-83d4-b2ee226ec849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_81ece920-7264-471f-83d4-b2ee226ec849" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember_45abcf0f-f0be-409b-b9ba-0b056c0a4271" xlink:href="mrk-20211231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:to="loc_mrk_AcceleronPharmaIncMember_45abcf0f-f0be-409b-b9ba-0b056c0a4271" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_20008a7d-4490-4bd1-a08e-4a7e3f1305c0" xlink:href="mrk-20211231.xsd#mrk_ArQuleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:to="loc_mrk_ArQuleMember_20008a7d-4490-4bd1-a08e-4a7e3f1305c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_2684bca1-2c81-4b46-9018-d2030e70fbb5" xlink:href="mrk-20211231.xsd#mrk_AntelliqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:to="loc_mrk_AntelliqMember_2684bca1-2c81-4b46-9018-d2030e70fbb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_59d97754-0a84-4606-82e6-4a4f6ecc0d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_59d97754-0a84-4606-82e6-4a4f6ecc0d99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_59d97754-0a84-4606-82e6-4a4f6ecc0d99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_59d97754-0a84-4606-82e6-4a4f6ecc0d99" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_59d97754-0a84-4606-82e6-4a4f6ecc0d99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_160e34e9-c4f9-4388-b9a6-ef61c3105c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_59d97754-0a84-4606-82e6-4a4f6ecc0d99" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_160e34e9-c4f9-4388-b9a6-ef61c3105c48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2285679c-5b5a-4933-a11b-c826b6e86c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_160e34e9-c4f9-4388-b9a6-ef61c3105c48" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2285679c-5b5a-4933-a11b-c826b6e86c15" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended" id="i4b939506be18494dac29e90a04c2edf2_CollaborativeArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_e1622e31-b63d-4ff8-8ac6-8431888b617f" xlink:href="mrk-20211231.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_e1622e31-b63d-4ff8-8ac6-8431888b617f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsAccruedSalesBased_04b14e1d-f391-46ae-ae0b-d754be394de3" xlink:href="mrk-20211231.xsd#mrk_MilestonePaymentsAccruedSalesBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_MilestonePaymentsAccruedSalesBased_04b14e1d-f391-46ae-ae0b-d754be394de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_5fe8fa07-1580-490d-9d0d-2456db6ccded" xlink:href="mrk-20211231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_5fe8fa07-1580-490d-9d0d-2456db6ccded" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d165a32e-8163-458a-8b2c-589cadf395b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d165a32e-8163-458a-8b2c-589cadf395b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsAccruedRegulatory_378afa96-2066-4d75-b87d-4aa49c536b9d" xlink:href="mrk-20211231.xsd#mrk_MilestonePaymentsAccruedRegulatory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_MilestonePaymentsAccruedRegulatory_378afa96-2066-4d75-b87d-4aa49c536b9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_24b2c570-b904-460f-9205-66b91d036783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_us-gaap_Liabilities_24b2c570-b904-460f-9205-66b91d036783" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_db4d689e-3543-4067-920c-4fd855232712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_us-gaap_AdjustmentForAmortization_db4d689e-3543-4067-920c-4fd855232712" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_077908aa-74cb-4406-8bc8-a637949e56dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_077908aa-74cb-4406-8bc8-a637949e56dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentQuantityCommitted_3a2b703e-be54-4e5e-89c2-13747510371e" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentQuantityCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_SupplyCommitmentQuantityCommitted_3a2b703e-be54-4e5e-89c2-13747510371e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentQuantityDelivered_364e04b5-9fe5-4bad-afc4-9c1e4744dc1b" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentQuantityDelivered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_SupplyCommitmentQuantityDelivered_364e04b5-9fe5-4bad-afc4-9c1e4744dc1b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets_ede680de-7a85-470e-a6a6-f62f5da6c31b" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentMinimumNumberOfMarkets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets_ede680de-7a85-470e-a6a6-f62f5da6c31b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach_4f1a7aaa-5da5-4066-acba-dc759ba0c015" xlink:href="mrk-20211231.xsd#mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach_4f1a7aaa-5da5-4066-acba-dc759ba0c015" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_05d50b25-4d5e-491d-9c9f-c1dc71a3b55d" xlink:href="mrk-20211231.xsd#mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_05d50b25-4d5e-491d-9c9f-c1dc71a3b55d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_32a20ed5-d36d-4287-84dd-3a12e83ac401" xlink:href="mrk-20211231.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_32a20ed5-d36d-4287-84dd-3a12e83ac401" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_f5678419-9331-4660-bb14-35831c8acaac" xlink:href="mrk-20211231.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_f5678419-9331-4660-bb14-35831c8acaac" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_51895016-9c6a-4ea0-b5b5-df7dbee26544" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_srt_CounterpartyNameAxis_51895016-9c6a-4ea0-b5b5-df7dbee26544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51895016-9c6a-4ea0-b5b5-df7dbee26544_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_51895016-9c6a-4ea0-b5b5-df7dbee26544" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51895016-9c6a-4ea0-b5b5-df7dbee26544_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_51895016-9c6a-4ea0-b5b5-df7dbee26544" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_fa88fbf8-bec6-4783-bad2-321628643b5a" xlink:href="mrk-20211231.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:to="loc_mrk_EisaiMember_fa88fbf8-bec6-4783-bad2-321628643b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_cf7a2112-0ab4-4ace-a4f6-6d4196ae31bf" xlink:href="mrk-20211231.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:to="loc_mrk_BayerAGMember_cf7a2112-0ab4-4ace-a4f6-6d4196ae31bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_718ee367-1f08-47eb-af3f-2b0f1b30795d" xlink:href="mrk-20211231.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:to="loc_mrk_AstraZenecaMember_718ee367-1f08-47eb-af3f-2b0f1b30795d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_4bad8bd5-488a-42c4-b14d-006d0d5ce73b" xlink:href="mrk-20211231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_4bad8bd5-488a-42c4-b14d-006d0d5ce73b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4cc8df4-e4fe-4974-b8e2-c2f1780bc62b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_srt_ProductOrServiceAxis_a4cc8df4-e4fe-4974-b8e2-c2f1780bc62b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4cc8df4-e4fe-4974-b8e2-c2f1780bc62b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a4cc8df4-e4fe-4974-b8e2-c2f1780bc62b" xlink:to="loc_srt_ProductsAndServicesDomain_a4cc8df4-e4fe-4974-b8e2-c2f1780bc62b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a4cc8df4-e4fe-4974-b8e2-c2f1780bc62b" xlink:to="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_f5bebf18-e831-4781-89e7-d9dabb2b1865" xlink:href="mrk-20211231.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_LenvimaMember_f5bebf18-e831-4781-89e7-d9dabb2b1865" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_65cc92ab-e7fa-4339-ac4f-d62a9dc59498" xlink:href="mrk-20211231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_AdempasMember_65cc92ab-e7fa-4339-ac4f-d62a9dc59498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_6cf320c9-a5d8-48b6-9c0a-b79289f7e9d4" xlink:href="mrk-20211231.xsd#mrk_VerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_VerquvoMember_6cf320c9-a5d8-48b6-9c0a-b79289f7e9d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_6049df68-8436-404f-a348-a63641bbeaf9" xlink:href="mrk-20211231.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_LynparzaMember_6049df68-8436-404f-a348-a63641bbeaf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MolnupiravirMember_d7441f97-b459-468c-aa44-8a6a1e262195" xlink:href="mrk-20211231.xsd#mrk_MolnupiravirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_MolnupiravirMember_d7441f97-b459-468c-aa44-8a6a1e262195" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d6b39e47-c68d-48ed-81b8-f48ba41bb786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d6b39e47-c68d-48ed-81b8-f48ba41bb786" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6b39e47-c68d-48ed-81b8-f48ba41bb786_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d6b39e47-c68d-48ed-81b8-f48ba41bb786" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6b39e47-c68d-48ed-81b8-f48ba41bb786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d6b39e47-c68d-48ed-81b8-f48ba41bb786" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_4c26a3ca-9e0f-48db-9e6e-6073dd9b84cf" xlink:href="mrk-20211231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_mrk_SalesBasedMilestonesMember_4c26a3ca-9e0f-48db-9e6e-6073dd9b84cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_17acc152-75d1-4cd6-a739-7b3047741aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_17acc152-75d1-4cd6-a739-7b3047741aa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_4833929d-f693-47ff-879f-b5ae416c4489" xlink:href="mrk-20211231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_mrk_RegulatoryMilestonesMember_4833929d-f693-47ff-879f-b5ae416c4489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_7add8b0d-b012-4284-995f-87549c704ff4" xlink:href="mrk-20211231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_mrk_DevelopmentMilestonesMember_7add8b0d-b012-4284-995f-87549c704ff4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_77174e1e-939a-4fca-a754-92f16ba0f5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_us-gaap_CollaborativeArrangementMember_77174e1e-939a-4fca-a754-92f16ba0f5fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706036d8-ef09-4e79-a9bd-b11c89fd1319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706036d8-ef09-4e79-a9bd-b11c89fd1319" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_706036d8-ef09-4e79-a9bd-b11c89fd1319_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706036d8-ef09-4e79-a9bd-b11c89fd1319" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_706036d8-ef09-4e79-a9bd-b11c89fd1319_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_38985097-4c84-4725-bdd9-9648ffa85976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706036d8-ef09-4e79-a9bd-b11c89fd1319" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_38985097-4c84-4725-bdd9-9648ffa85976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_15bb070d-3766-4191-a479-ed651bed285f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_38985097-4c84-4725-bdd9-9648ffa85976" xlink:to="loc_us-gaap_LicenseMember_15bb070d-3766-4191-a479-ed651bed285f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_41b5709d-678d-4af8-a449-95eb535395b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_41b5709d-678d-4af8-a449-95eb535395b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_41b5709d-678d-4af8-a449-95eb535395b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_41b5709d-678d-4af8-a449-95eb535395b4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_41b5709d-678d-4af8-a449-95eb535395b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_73d30e21-b124-4bbd-82d6-c503cd2033f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_41b5709d-678d-4af8-a449-95eb535395b4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_73d30e21-b124-4bbd-82d6-c503cd2033f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1ccdb691-b596-4f72-b487-aa395777550a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_73d30e21-b124-4bbd-82d6-c503cd2033f7" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1ccdb691-b596-4f72-b487-aa395777550a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c0b72f66-d4d8-4825-a137-60be7eef3dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c0b72f66-d4d8-4825-a137-60be7eef3dcd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c0b72f66-d4d8-4825-a137-60be7eef3dcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c0b72f66-d4d8-4825-a137-60be7eef3dcd" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c0b72f66-d4d8-4825-a137-60be7eef3dcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_be8f9704-4286-4f88-9461-6ab271233552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c0b72f66-d4d8-4825-a137-60be7eef3dcd" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_be8f9704-4286-4f88-9461-6ab271233552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_9599d506-8e50-4b3a-81b6-1a1ad009a522" xlink:href="mrk-20211231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_be8f9704-4286-4f88-9461-6ab271233552" xlink:to="loc_mrk_RegulatoryMilestonesMember_9599d506-8e50-4b3a-81b6-1a1ad009a522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_c2ad16c5-8850-41fd-b360-1fe56d81c9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_SupplyCommitmentAxis_c2ad16c5-8850-41fd-b360-1fe56d81c9da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_c2ad16c5-8850-41fd-b360-1fe56d81c9da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_c2ad16c5-8850-41fd-b360-1fe56d81c9da" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_c2ad16c5-8850-41fd-b360-1fe56d81c9da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_c2ad16c5-8850-41fd-b360-1fe56d81c9da" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToUnitedStatesMember_9bc91a56-8fce-4686-a2ae-1194da516985" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:to="loc_mrk_SupplyCommitmentToUnitedStatesMember_9bc91a56-8fce-4686-a2ae-1194da516985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToJapanMember_c5d59492-6670-4d78-9e45-52313825aad1" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:to="loc_mrk_SupplyCommitmentToJapanMember_c5d59492-6670-4d78-9e45-52313825aad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToUnitedKingdomMember_fca53a04-411c-461d-86e5-b5cd963e21e1" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToUnitedKingdomMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:to="loc_mrk_SupplyCommitmentToUnitedKingdomMember_fca53a04-411c-461d-86e5-b5cd963e21e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember_540ee70e-5964-46e8-a7bb-dcd29b974737" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToUnitedNationsChildrensFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:to="loc_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember_540ee70e-5964-46e8-a7bb-dcd29b974737" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended" id="id584e21777154637b74d5f6f798fac10_CollaborativeArrangementsFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_153f7058-e4dc-43f4-bbac-ce6b27104d8a" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_153f7058-e4dc-43f4-bbac-ce6b27104d8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_4815b786-0b8c-4ef2-9221-4219ae4cc6dd" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_4815b786-0b8c-4ef2-9221-4219ae4cc6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_06cfa9ff-d46d-4cad-84a0-2b39f3f7e344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_Revenues_06cfa9ff-d46d-4cad-84a0-2b39f3f7e344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_43d2ad35-0b82-4618-bae2-40764b2b508c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_43d2ad35-0b82-4618-bae2-40764b2b508c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4cbf072-2ff9-4561-b26d-ee6d4518482d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4cbf072-2ff9-4561-b26d-ee6d4518482d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f52a3a0a-a889-4c32-84d0-182246dfeffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f52a3a0a-a889-4c32-84d0-182246dfeffd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_451eb587-5c8a-47a6-8530-5ceb58126043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_ReceivablesNetCurrent_451eb587-5c8a-47a6-8530-5ceb58126043" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e1f837c-586e-408f-ad6d-9423eaa7d5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e1f837c-586e-408f-ad6d-9423eaa7d5be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_fa90988d-2cdf-49c9-ac89-a86817544d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_fa90988d-2cdf-49c9-ac89-a86817544d7f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5bd8e4df-0b09-4427-949a-840e11de3bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5bd8e4df-0b09-4427-949a-840e11de3bf7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_d7f07fbe-7035-4d8e-aaac-1bcaa3c911dc" xlink:href="mrk-20211231.xsd#mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_d7f07fbe-7035-4d8e-aaac-1bcaa3c911dc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24030d1e-5eca-4bd9-9ba7-69c53075c0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24030d1e-5eca-4bd9-9ba7-69c53075c0e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_24030d1e-5eca-4bd9-9ba7-69c53075c0e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24030d1e-5eca-4bd9-9ba7-69c53075c0e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_24030d1e-5eca-4bd9-9ba7-69c53075c0e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24030d1e-5eca-4bd9-9ba7-69c53075c0e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_efb93dab-356a-4f9e-9aa8-beb8d0abfa60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:to="loc_us-gaap_SalesMember_efb93dab-356a-4f9e-9aa8-beb8d0abfa60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_210fc4f5-8a30-49fa-a9ce-42b58b8bc378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:to="loc_us-gaap_CostOfSalesMember_210fc4f5-8a30-49fa-a9ce-42b58b8bc378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e9a1d52c-db13-46da-9392-bcaf743be2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e9a1d52c-db13-46da-9392-bcaf743be2c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d94d5b04-0b4e-47d4-a422-c6cc662863cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d94d5b04-0b4e-47d4-a422-c6cc662863cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7f66452b-d2a9-4f82-b209-dd27beb67369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7f66452b-d2a9-4f82-b209-dd27beb67369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7f66452b-d2a9-4f82-b209-dd27beb67369_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7f66452b-d2a9-4f82-b209-dd27beb67369" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7f66452b-d2a9-4f82-b209-dd27beb67369_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7f66452b-d2a9-4f82-b209-dd27beb67369" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_0c31351d-cab0-403f-8c44-a56792d4d4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_0c31351d-cab0-403f-8c44-a56792d4d4bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_bedfc75e-e29b-4183-85f8-cd2d947e245e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_bedfc75e-e29b-4183-85f8-cd2d947e245e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0db92503-7e34-4289-9845-e10a0bebf109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0db92503-7e34-4289-9845-e10a0bebf109" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e6ecc137-fe85-40ba-98c2-34c92a5b5c28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_srt_CounterpartyNameAxis_e6ecc137-fe85-40ba-98c2-34c92a5b5c28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6ecc137-fe85-40ba-98c2-34c92a5b5c28_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e6ecc137-fe85-40ba-98c2-34c92a5b5c28" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e6ecc137-fe85-40ba-98c2-34c92a5b5c28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e6ecc137-fe85-40ba-98c2-34c92a5b5c28" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_db85aefa-dece-4869-a4c2-4865191bd6f2" xlink:href="mrk-20211231.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:to="loc_mrk_AstraZenecaMember_db85aefa-dece-4869-a4c2-4865191bd6f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_67abdef1-52df-47c9-8795-b47ba95ba407" xlink:href="mrk-20211231.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:to="loc_mrk_EisaiMember_67abdef1-52df-47c9-8795-b47ba95ba407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_e042cd49-e706-441d-ba0a-aa63e92b025f" xlink:href="mrk-20211231.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:to="loc_mrk_BayerAGMember_e042cd49-e706-441d-ba0a-aa63e92b025f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_1137db7a-ed85-4316-aa68-a594576ff18c" xlink:href="mrk-20211231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_1137db7a-ed85-4316-aa68-a594576ff18c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a2d15efa-67a4-4228-ad88-fb4251b689cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a2d15efa-67a4-4228-ad88-fb4251b689cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2d15efa-67a4-4228-ad88-fb4251b689cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a2d15efa-67a4-4228-ad88-fb4251b689cf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2d15efa-67a4-4228-ad88-fb4251b689cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dab2baab-e09c-41fe-a2e9-67f76fdbe868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a2d15efa-67a4-4228-ad88-fb4251b689cf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dab2baab-e09c-41fe-a2e9-67f76fdbe868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e5274927-4d1f-440a-ba4a-cd63616449b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dab2baab-e09c-41fe-a2e9-67f76fdbe868" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e5274927-4d1f-440a-ba4a-cd63616449b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_55ed0274-f092-4306-8349-2e1047f95df7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_srt_ProductOrServiceAxis_55ed0274-f092-4306-8349-2e1047f95df7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55ed0274-f092-4306-8349-2e1047f95df7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_55ed0274-f092-4306-8349-2e1047f95df7" xlink:to="loc_srt_ProductsAndServicesDomain_55ed0274-f092-4306-8349-2e1047f95df7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_55ed0274-f092-4306-8349-2e1047f95df7" xlink:to="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_1f1677aa-2dfd-47ce-ac58-e336a83ae1a1" xlink:href="mrk-20211231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_1f1677aa-2dfd-47ce-ac58-e336a83ae1a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_364f4f57-02a1-458e-b8c8-1cd0b4bb19a5" xlink:href="mrk-20211231.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_364f4f57-02a1-458e-b8c8-1cd0b4bb19a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_aef6ce4b-3e8b-4ecb-9509-2793adc4117f" xlink:href="mrk-20211231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_AdempasMember_aef6ce4b-3e8b-4ecb-9509-2793adc4117f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_bc93d8f6-e1cf-4e73-bb91-7cf354c96c05" xlink:href="mrk-20211231.xsd#mrk_VerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_VerquvoMember_bc93d8f6-e1cf-4e73-bb91-7cf354c96c05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MolnupiravirMember_272aac72-d238-4c50-ac57-cf4349a14614" xlink:href="mrk-20211231.xsd#mrk_MolnupiravirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_MolnupiravirMember_272aac72-d238-4c50-ac57-cf4349a14614" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="ib716fb379ec746259a42b350b2ec1271_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_733ae536-3417-4549-b05f-3f45b07ccaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_733ae536-3417-4549-b05f-3f45b07ccaa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_4841ba7f-7948-454b-b33f-52aa34ab1126" xlink:href="mrk-20211231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_4841ba7f-7948-454b-b33f-52aa34ab1126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_575b5401-85b3-4e3c-ae20-d9c8c033219d" xlink:href="mrk-20211231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_575b5401-85b3-4e3c-ae20-d9c8c033219d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f3c674b2-a118-47c2-8fa2-dc07f95a2455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f3c674b2-a118-47c2-8fa2-dc07f95a2455" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_1f15c1ca-372e-4c5c-8c18-bd404a31c64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_1f15c1ca-372e-4c5c-8c18-bd404a31c64b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_51eb7584-0b8c-43d8-b4dc-63267f5cd8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_51eb7584-0b8c-43d8-b4dc-63267f5cd8e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bfecb2f0-531d-4887-b27a-21fe86b43d81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_51eb7584-0b8c-43d8-b4dc-63267f5cd8e7" xlink:to="loc_srt_StatementScenarioAxis_bfecb2f0-531d-4887-b27a-21fe86b43d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bfecb2f0-531d-4887-b27a-21fe86b43d81_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_bfecb2f0-531d-4887-b27a-21fe86b43d81" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bfecb2f0-531d-4887-b27a-21fe86b43d81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fa5bd354-9a0d-47ca-b7a0-d8017d789179" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_bfecb2f0-531d-4887-b27a-21fe86b43d81" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fa5bd354-9a0d-47ca-b7a0-d8017d789179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_25b56f20-fb69-46e6-96bf-d9905bd9a0f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fa5bd354-9a0d-47ca-b7a0-d8017d789179" xlink:to="loc_srt_ScenarioForecastMember_25b56f20-fb69-46e6-96bf-d9905bd9a0f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended" id="iff7110f50919476fb7a214c9458248cf_RestructuringChargesActivitiesbyTypeofCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8bee654d-8c32-40c1-b2ea-a0ad99d6de27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_80b7f86b-0aea-45ea-991a-8da53fca6d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8bee654d-8c32-40c1-b2ea-a0ad99d6de27" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_80b7f86b-0aea-45ea-991a-8da53fca6d63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ca35c9bc-78da-42a3-a0c2-f24476e9dc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8bee654d-8c32-40c1-b2ea-a0ad99d6de27" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ca35c9bc-78da-42a3-a0c2-f24476e9dc3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8db1abfe-c789-4d99-b8c3-cfd22a9715fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ca35c9bc-78da-42a3-a0c2-f24476e9dc3e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8db1abfe-c789-4d99-b8c3-cfd22a9715fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8db1abfe-c789-4d99-b8c3-cfd22a9715fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8db1abfe-c789-4d99-b8c3-cfd22a9715fe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8db1abfe-c789-4d99-b8c3-cfd22a9715fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8db1abfe-c789-4d99-b8c3-cfd22a9715fe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_e9c115d2-fe88-4b79-ae77-2c9567a47895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_e9c115d2-fe88-4b79-ae77-2c9567a47895" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_dce08745-1d8d-4794-9be8-fa5602690d85" xlink:href="mrk-20211231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:to="loc_mrk_AcceleratedDepreciationMember_dce08745-1d8d-4794-9be8-fa5602690d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_83a07efb-f67c-45ba-9bf5-0503491afd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:to="loc_us-gaap_OtherRestructuringMember_83a07efb-f67c-45ba-9bf5-0503491afd6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19fa5c6e-b629-464d-9214-8754e360f220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ca35c9bc-78da-42a3-a0c2-f24476e9dc3e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19fa5c6e-b629-464d-9214-8754e360f220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19fa5c6e-b629-464d-9214-8754e360f220_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19fa5c6e-b629-464d-9214-8754e360f220" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19fa5c6e-b629-464d-9214-8754e360f220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19fa5c6e-b629-464d-9214-8754e360f220" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_16f3a347-bce2-449c-b933-545c0a9f1806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:to="loc_us-gaap_CostOfSalesMember_16f3a347-bce2-449c-b933-545c0a9f1806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3f34607-c0e0-490d-b20d-447ade66edc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3f34607-c0e0-490d-b20d-447ade66edc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a8edee3-f9f3-460f-b21d-a4277c0cf735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a8edee3-f9f3-460f-b21d-a4277c0cf735" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_859c6148-b0dc-461e-a2c9-35758d6337b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:to="loc_us-gaap_RestructuringChargesMember_859c6148-b0dc-461e-a2c9-35758d6337b7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended" id="i5a85d4472f3e4707b4b1b8c8f9ff0ebe_RestructuringActivitiesbyProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b7b6694f-7152-46d3-a82b-65fdf10c3d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7b6694f-7152-46d3-a82b-65fdf10c3d6b" xlink:to="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_dd8612fa-a36f-4b95-a841-390e508a3f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:to="loc_us-gaap_RestructuringReserve_dd8612fa-a36f-4b95-a841-390e508a3f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0fe93f04-fd76-45ee-83aa-8030392500d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0fe93f04-fd76-45ee-83aa-8030392500d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_7a68f8ee-093a-449a-ad81-d0564beeb9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:to="loc_us-gaap_PaymentsForRestructuring_7a68f8ee-093a-449a-ad81-d0564beeb9c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_9f582c04-6334-4f78-923e-9abf5fd34abd" xlink:href="mrk-20211231.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:to="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_9f582c04-6334-4f78-923e-9abf5fd34abd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c1df4d46-c382-4618-9499-0b747b01f852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36c2cffe-9bd6-4fd5-a0f5-d85f63e824a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7b6694f-7152-46d3-a82b-65fdf10c3d6b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36c2cffe-9bd6-4fd5-a0f5-d85f63e824a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_38cd28f7-e6c6-4532-a599-b36950f89fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36c2cffe-9bd6-4fd5-a0f5-d85f63e824a6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_38cd28f7-e6c6-4532-a599-b36950f89fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_38cd28f7-e6c6-4532-a599-b36950f89fa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_38cd28f7-e6c6-4532-a599-b36950f89fa9" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_38cd28f7-e6c6-4532-a599-b36950f89fa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_38cd28f7-e6c6-4532-a599-b36950f89fa9" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_cdd2a060-60b4-479b-a91c-94f365080901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_cdd2a060-60b4-479b-a91c-94f365080901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_45bf811e-15b7-46a9-a802-dc63be6da609" xlink:href="mrk-20211231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:to="loc_mrk_AcceleratedDepreciationMember_45bf811e-15b7-46a9-a802-dc63be6da609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_cbae3675-8735-4f0d-8dab-f3f94f26a47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:to="loc_us-gaap_OtherRestructuringMember_cbae3675-8735-4f0d-8dab-f3f94f26a47c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i7a86895f91034ade8167a3ccd89e0fff_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_d96ca1b6-4011-4f19-b277-ab87ef1b9c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_d96ca1b6-4011-4f19-b277-ab87ef1b9c70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_f15c7f11-cec8-4d67-bf93-ed85223b615b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_f15c7f11-cec8-4d67-bf93-ed85223b615b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ad190f03-e40e-4830-b907-d0d9b1c08000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ad190f03-e40e-4830-b907-d0d9b1c08000" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_43b3714a-c91b-4461-98aa-4f189b6cbea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_43b3714a-c91b-4461-98aa-4f189b6cbea7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b30bdf8d-c3dd-4be2-b6d8-7f6cb76a3173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b30bdf8d-c3dd-4be2-b6d8-7f6cb76a3173" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_fd835f73-b25c-40db-ad4d-7fce26c63c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_fd835f73-b25c-40db-ad4d-7fce26c63c5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1f4dbc53-9210-4e2f-9dc5-6967578166d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1f4dbc53-9210-4e2f-9dc5-6967578166d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_2f5d65fe-10be-4262-94ab-9f22ba04f554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_2f5d65fe-10be-4262-94ab-9f22ba04f554" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_86cfa4be-d084-46d5-9a34-9c68601d289e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_86cfa4be-d084-46d5-9a34-9c68601d289e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_0f099fe4-adf2-4006-9166-a69e456c0164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_0f099fe4-adf2-4006-9166-a69e456c0164" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_ca3418fb-6793-45bd-97b9-46ea75d3954b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_ca3418fb-6793-45bd-97b9-46ea75d3954b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_5c0aea9f-5646-466f-bee4-80789467ce99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_5c0aea9f-5646-466f-bee4-80789467ce99" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ade22bc5-61a2-43a5-be03-17bf941ed4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ade22bc5-61a2-43a5-be03-17bf941ed4b8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_807e2c03-b856-4838-bff4-146029e6de5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_807e2c03-b856-4838-bff4-146029e6de5b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9e930004-7eea-41e9-9728-f4b9b6ce1f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9e930004-7eea-41e9-9728-f4b9b6ce1f99" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_ea3cbf2d-dc48-4275-8355-974f608dbd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_AccountsReceivableSale_ea3cbf2d-dc48-4275-8355-974f608dbd61" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_45c61867-5aa5-4131-a773-efb2ba33d0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_RestrictedCashCurrent_45c61867-5aa5-4131-a773-efb2ba33d0b8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_34f9564a-d570-4bf6-a124-dd4b9ab471a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_34f9564a-d570-4bf6-a124-dd4b9ab471a2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_0c5e5a09-871b-49b3-987d-586bedefbb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_0c5e5a09-871b-49b3-987d-586bedefbb1c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_813d7eea-18df-4165-ae32-73c9428bad1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_813d7eea-18df-4165-ae32-73c9428bad1d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_435e4fbf-022c-4228-8c46-e5ab36847c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_435e4fbf-022c-4228-8c46-e5ab36847c9f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_374c4adb-7ac9-4764-9a31-72af57eed054" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_srt_RangeAxis_374c4adb-7ac9-4764-9a31-72af57eed054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_374c4adb-7ac9-4764-9a31-72af57eed054_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_374c4adb-7ac9-4764-9a31-72af57eed054" xlink:to="loc_srt_RangeMember_374c4adb-7ac9-4764-9a31-72af57eed054_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03a91b36-5afe-4436-a887-4b377fbe2646" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_374c4adb-7ac9-4764-9a31-72af57eed054" xlink:to="loc_srt_RangeMember_03a91b36-5afe-4436-a887-4b377fbe2646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2e047012-150f-4d72-9e37-7229def4f411" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_03a91b36-5afe-4436-a887-4b377fbe2646" xlink:to="loc_srt_MaximumMember_2e047012-150f-4d72-9e37-7229def4f411" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5426cb25-17b7-42de-9938-7415649ed986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_HedgingDesignationAxis_5426cb25-17b7-42de-9938-7415649ed986" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5426cb25-17b7-42de-9938-7415649ed986_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5426cb25-17b7-42de-9938-7415649ed986" xlink:to="loc_us-gaap_HedgingDesignationDomain_5426cb25-17b7-42de-9938-7415649ed986_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8b57633b-9a9a-483d-914a-543ec262c8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5426cb25-17b7-42de-9938-7415649ed986" xlink:to="loc_us-gaap_HedgingDesignationDomain_8b57633b-9a9a-483d-914a-543ec262c8ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ba90ec12-bb18-441a-a995-2597a41c1c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8b57633b-9a9a-483d-914a-543ec262c8ef" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ba90ec12-bb18-441a-a995-2597a41c1c58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9a83ad2e-9436-4e4d-89d3-1bc196662d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8b57633b-9a9a-483d-914a-543ec262c8ef" xlink:to="loc_us-gaap_NondesignatedMember_9a83ad2e-9436-4e4d-89d3-1bc196662d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fcf9a69e-3ded-4bf7-845d-29524c1a3f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fcf9a69e-3ded-4bf7-845d-29524c1a3f42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fcf9a69e-3ded-4bf7-845d-29524c1a3f42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fcf9a69e-3ded-4bf7-845d-29524c1a3f42" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fcf9a69e-3ded-4bf7-845d-29524c1a3f42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_58ba8a59-cbd6-4c13-a2bb-102bb8396af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fcf9a69e-3ded-4bf7-845d-29524c1a3f42" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_58ba8a59-cbd6-4c13-a2bb-102bb8396af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_741b2b1c-7100-40d8-a168-e8837986938b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_58ba8a59-cbd6-4c13-a2bb-102bb8396af6" xlink:to="loc_us-gaap_InterestRateSwapMember_741b2b1c-7100-40d8-a168-e8837986938b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e1a7cd4-18a3-4fbe-8b35-fb0035d0e10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e1a7cd4-18a3-4fbe-8b35-fb0035d0e10d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1a7cd4-18a3-4fbe-8b35-fb0035d0e10d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e1a7cd4-18a3-4fbe-8b35-fb0035d0e10d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1a7cd4-18a3-4fbe-8b35-fb0035d0e10d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0dedc7e-c438-4ebd-81b1-52fcd9c3491e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e1a7cd4-18a3-4fbe-8b35-fb0035d0e10d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0dedc7e-c438-4ebd-81b1-52fcd9c3491e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4ab1fb25-687c-4ccb-aede-ca3f1c100f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0dedc7e-c438-4ebd-81b1-52fcd9c3491e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4ab1fb25-687c-4ccb-aede-ca3f1c100f2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_95890a2b-c626-4bcc-a162-cf1a6c66a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_95890a2b-c626-4bcc-a162-cf1a6c66a6f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_95890a2b-c626-4bcc-a162-cf1a6c66a6f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_95890a2b-c626-4bcc-a162-cf1a6c66a6f5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_95890a2b-c626-4bcc-a162-cf1a6c66a6f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c40229ff-fa88-484c-806f-177972cd47a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_95890a2b-c626-4bcc-a162-cf1a6c66a6f5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c40229ff-fa88-484c-806f-177972cd47a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0775822e-662d-4aa9-9c90-a3febcdb3f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c40229ff-fa88-484c-806f-177972cd47a4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0775822e-662d-4aa9-9c90-a3febcdb3f81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b54c874f-c82b-408c-bd83-32322b604d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b54c874f-c82b-408c-bd83-32322b604d48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b54c874f-c82b-408c-bd83-32322b604d48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b54c874f-c82b-408c-bd83-32322b604d48" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b54c874f-c82b-408c-bd83-32322b604d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d8b1f4c7-909f-4948-a103-1bd66a41329d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b54c874f-c82b-408c-bd83-32322b604d48" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d8b1f4c7-909f-4948-a103-1bd66a41329d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d3301347-a1cc-497a-a87b-3399e390d867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d8b1f4c7-909f-4948-a103-1bd66a41329d" xlink:to="loc_us-gaap_AccountsReceivableMember_d3301347-a1cc-497a-a87b-3399e390d867" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a9ccfe8c-d8b5-48ba-9813-206a78a818ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_srt_MajorCustomersAxis_a9ccfe8c-d8b5-48ba-9813-206a78a818ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a9ccfe8c-d8b5-48ba-9813-206a78a818ad_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a9ccfe8c-d8b5-48ba-9813-206a78a818ad" xlink:to="loc_srt_NameOfMajorCustomerDomain_a9ccfe8c-d8b5-48ba-9813-206a78a818ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a9ccfe8c-d8b5-48ba-9813-206a78a818ad" xlink:to="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_McKessonCorporationMember_dd7e1388-9ba3-46e3-ae67-d277738066b4" xlink:href="mrk-20211231.xsd#mrk_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:to="loc_mrk_McKessonCorporationMember_dd7e1388-9ba3-46e3-ae67-d277738066b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmerisourceBergenCorporationMember_6e7b5fba-6a74-48f0-9006-8109a04d9695" xlink:href="mrk-20211231.xsd#mrk_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:to="loc_mrk_AmerisourceBergenCorporationMember_6e7b5fba-6a74-48f0-9006-8109a04d9695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CardinalHealthIncMember_1037232e-6d7f-42ea-a2fa-aa776285e349" xlink:href="mrk-20211231.xsd#mrk_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:to="loc_mrk_CardinalHealthIncMember_1037232e-6d7f-42ea-a2fa-aa776285e349" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0db404f0-1799-4619-86be-6bb878dd4215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0db404f0-1799-4619-86be-6bb878dd4215" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0db404f0-1799-4619-86be-6bb878dd4215_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0db404f0-1799-4619-86be-6bb878dd4215" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0db404f0-1799-4619-86be-6bb878dd4215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_126a93b1-9a32-4cb5-9531-973d71615229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0db404f0-1799-4619-86be-6bb878dd4215" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_126a93b1-9a32-4cb5-9531-973d71615229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member_41cf72c6-36f6-46d3-9e46-18789f5c5350" xlink:href="mrk-20211231.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_126a93b1-9a32-4cb5-9531-973d71615229" xlink:to="loc_mrk_A3.875NotesDue2021Member_41cf72c6-36f6-46d3-9e46-18789f5c5350" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="ib61413022b334203a4c006cc137979f4_FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_533ed98d-d425-4c71-81fb-9f1b30381e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_82d2209a-1c38-46b3-9b22-1e54228263e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_533ed98d-d425-4c71-81fb-9f1b30381e9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_82d2209a-1c38-46b3-9b22-1e54228263e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_c7ef38bc-529c-402f-b08f-4f38cdfebc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_533ed98d-d425-4c71-81fb-9f1b30381e9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_c7ef38bc-529c-402f-b08f-4f38cdfebc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c37adc33-1270-431e-a478-78529434f1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_533ed98d-d425-4c71-81fb-9f1b30381e9f" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c37adc33-1270-431e-a478-78529434f1d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7e80dea5-2cc1-42de-b8e9-349088c302b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c37adc33-1270-431e-a478-78529434f1d0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7e80dea5-2cc1-42de-b8e9-349088c302b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7e80dea5-2cc1-42de-b8e9-349088c302b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7e80dea5-2cc1-42de-b8e9-349088c302b5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7e80dea5-2cc1-42de-b8e9-349088c302b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_70fab4f8-01af-42dd-b1ce-169bafb6cc73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7e80dea5-2cc1-42de-b8e9-349088c302b5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_70fab4f8-01af-42dd-b1ce-169bafb6cc73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_09aabbe2-8eab-4073-9416-8ba7181a5c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70fab4f8-01af-42dd-b1ce-169bafb6cc73" xlink:to="loc_us-gaap_ForeignExchangeContractMember_09aabbe2-8eab-4073-9416-8ba7181a5c18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_2eccbf32-ed3a-4ce8-aa45-3d012c28ba78" xlink:href="mrk-20211231.xsd#mrk_EurodominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70fab4f8-01af-42dd-b1ce-169bafb6cc73" xlink:to="loc_mrk_EurodominatedNotesMember_2eccbf32-ed3a-4ce8-aa45-3d012c28ba78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42061bc0-5d9d-483a-83cc-1493a245e3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c37adc33-1270-431e-a478-78529434f1d0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42061bc0-5d9d-483a-83cc-1493a245e3b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42061bc0-5d9d-483a-83cc-1493a245e3b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42061bc0-5d9d-483a-83cc-1493a245e3b3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42061bc0-5d9d-483a-83cc-1493a245e3b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b5b772f-237a-49d5-9c4a-c483bc3a840b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42061bc0-5d9d-483a-83cc-1493a245e3b3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b5b772f-237a-49d5-9c4a-c483bc3a840b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4a57e13d-e31f-4090-a19a-bbd57bfed51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b5b772f-237a-49d5-9c4a-c483bc3a840b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4a57e13d-e31f-4090-a19a-bbd57bfed51b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsInformationAboutInterestRateSwapsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="extended" id="i9368fbed467c41b19e8f5176a85ecd60_FinancialInstrumentsInformationAboutInterestRateSwapsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_36207bbf-07bf-402e-83b0-1c1edcc1a0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_36207bbf-07bf-402e-83b0-1c1edcc1a0c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9e07d35-6bb3-4f00-b4d0-31ac7c7be0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9e07d35-6bb3-4f00-b4d0-31ac7c7be0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f98e0b72-03c9-4912-a0b9-bb01bc74f29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f98e0b72-03c9-4912-a0b9-bb01bc74f29d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ca1d064f-8d1d-47a0-92ca-13f59948040d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ca1d064f-8d1d-47a0-92ca-13f59948040d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9e5baac9-6e35-4599-9dfd-1b460bcd8b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:to="loc_us-gaap_DerivativeTable_9e5baac9-6e35-4599-9dfd-1b460bcd8b64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_06d8f8a8-f8fb-4532-a042-bd877d465d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9e5baac9-6e35-4599-9dfd-1b460bcd8b64" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_06d8f8a8-f8fb-4532-a042-bd877d465d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_06d8f8a8-f8fb-4532-a042-bd877d465d3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_06d8f8a8-f8fb-4532-a042-bd877d465d3f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_06d8f8a8-f8fb-4532-a042-bd877d465d3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cdb2f134-3c52-4790-b140-67636a5805aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_06d8f8a8-f8fb-4532-a042-bd877d465d3f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cdb2f134-3c52-4790-b140-67636a5805aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_eb69e7d2-7fbf-4e98-b72a-0c1a03be7ead" xlink:href="mrk-20211231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cdb2f134-3c52-4790-b140-67636a5805aa" xlink:to="loc_mrk_A2.40NotesDue2022Member_eb69e7d2-7fbf-4e98-b72a-0c1a03be7ead" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_27b7c8bb-9460-4c17-8879-d9c0b57ac36f" xlink:href="mrk-20211231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cdb2f134-3c52-4790-b140-67636a5805aa" xlink:to="loc_mrk_A2.35NotesDue2022Member_27b7c8bb-9460-4c17-8879-d9c0b57ac36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5b6835c6-9823-4733-9bf8-4224de9bfed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9e5baac9-6e35-4599-9dfd-1b460bcd8b64" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5b6835c6-9823-4733-9bf8-4224de9bfed6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5b6835c6-9823-4733-9bf8-4224de9bfed6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5b6835c6-9823-4733-9bf8-4224de9bfed6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5b6835c6-9823-4733-9bf8-4224de9bfed6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e620d0a8-2c00-4573-a83e-4ad8ec79e46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5b6835c6-9823-4733-9bf8-4224de9bfed6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e620d0a8-2c00-4573-a83e-4ad8ec79e46b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8b6a96b4-10a6-437b-b405-1ad43ddc574c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e620d0a8-2c00-4573-a83e-4ad8ec79e46b" xlink:to="loc_us-gaap_InterestRateSwapMember_8b6a96b4-10a6-437b-b405-1ad43ddc574c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsFairValueofHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="extended" id="ic1a17cea95ee411cac7c8fa77e6f2e35_FinancialInstrumentsFairValueofHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_33024a86-a284-4374-884f-004a64b3dee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_ef3aa552-633a-4da5-9dfa-902dc379b651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_33024a86-a284-4374-884f-004a64b3dee7" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_ef3aa552-633a-4da5-9dfa-902dc379b651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_7873dae0-1712-471c-abe7-3b2df6e4457b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_33024a86-a284-4374-884f-004a64b3dee7" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_7873dae0-1712-471c-abe7-3b2df6e4457b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e4e0ef04-3ad1-44d6-a2bd-ce6436abb698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_33024a86-a284-4374-884f-004a64b3dee7" xlink:to="loc_us-gaap_DerivativeTable_e4e0ef04-3ad1-44d6-a2bd-ce6436abb698" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6797598d-5c42-43dc-a85c-cbb589fc11d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e4e0ef04-3ad1-44d6-a2bd-ce6436abb698" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6797598d-5c42-43dc-a85c-cbb589fc11d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6797598d-5c42-43dc-a85c-cbb589fc11d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6797598d-5c42-43dc-a85c-cbb589fc11d4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6797598d-5c42-43dc-a85c-cbb589fc11d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ba8b3d54-12f4-42c0-830c-8560c034f63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6797598d-5c42-43dc-a85c-cbb589fc11d4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ba8b3d54-12f4-42c0-830c-8560c034f63a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_fbf9bcec-cd63-4bf1-b9da-17297d4bbd78" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ba8b3d54-12f4-42c0-830c-8560c034f63a" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_fbf9bcec-cd63-4bf1-b9da-17297d4bbd78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_d69d201c-f7a7-45d2-8053-5e8830991fc6" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtExcludingCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ba8b3d54-12f4-42c0-830c-8560c034f63a" xlink:to="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_d69d201c-f7a7-45d2-8053-5e8830991fc6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="iad796a5a17fb4d0f8c1b840a000efc9f_FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_f598ba7e-6aa7-4278-a29c-86b4af7c3eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:to="loc_us-gaap_DerivativeAssets_f598ba7e-6aa7-4278-a29c-86b4af7c3eaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_214aa7e8-339f-4024-80f4-9f229b3a650c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:to="loc_us-gaap_DerivativeLiabilities_214aa7e8-339f-4024-80f4-9f229b3a650c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_eb593f06-9d8e-4009-a9f6-d0c139d3ca05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:to="loc_us-gaap_DerivativeNotionalAmount_eb593f06-9d8e-4009-a9f6-d0c139d3ca05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e9c3a998-c3f1-47c5-8672-23c046fd0119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e9c3a998-c3f1-47c5-8672-23c046fd0119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e9c3a998-c3f1-47c5-8672-23c046fd0119_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e9c3a998-c3f1-47c5-8672-23c046fd0119" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e9c3a998-c3f1-47c5-8672-23c046fd0119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c266ea64-8276-4407-b94b-509510506225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e9c3a998-c3f1-47c5-8672-23c046fd0119" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c266ea64-8276-4407-b94b-509510506225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_1be6e0c2-ad98-4391-97cc-b69b06cd30b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c266ea64-8276-4407-b94b-509510506225" xlink:to="loc_us-gaap_InterestRateContractMember_1be6e0c2-ad98-4391-97cc-b69b06cd30b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d3dad164-c7a4-4fd6-8df3-c7597717dcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c266ea64-8276-4407-b94b-509510506225" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d3dad164-c7a4-4fd6-8df3-c7597717dcd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b9e40c4e-0691-4f05-91c6-4f91e0349fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:to="loc_us-gaap_HedgingDesignationAxis_b9e40c4e-0691-4f05-91c6-4f91e0349fad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b9e40c4e-0691-4f05-91c6-4f91e0349fad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_b9e40c4e-0691-4f05-91c6-4f91e0349fad" xlink:to="loc_us-gaap_HedgingDesignationDomain_b9e40c4e-0691-4f05-91c6-4f91e0349fad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6641fcf3-cf3f-452f-a621-d05b4e9c4cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_b9e40c4e-0691-4f05-91c6-4f91e0349fad" xlink:to="loc_us-gaap_HedgingDesignationDomain_6641fcf3-cf3f-452f-a621-d05b4e9c4cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7c2c8476-62b3-4dc1-99ca-b54421cfa91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_6641fcf3-cf3f-452f-a621-d05b4e9c4cb7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7c2c8476-62b3-4dc1-99ca-b54421cfa91a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_4555af11-83fe-418d-aebe-acd5bb5c1cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_6641fcf3-cf3f-452f-a621-d05b4e9c4cb7" xlink:to="loc_us-gaap_NondesignatedMember_4555af11-83fe-418d-aebe-acd5bb5c1cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_813612eb-be5d-40cf-a6a0-45b21187b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_813612eb-be5d-40cf-a6a0-45b21187b4b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_813612eb-be5d-40cf-a6a0-45b21187b4b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_813612eb-be5d-40cf-a6a0-45b21187b4b8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_813612eb-be5d-40cf-a6a0-45b21187b4b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_813612eb-be5d-40cf-a6a0-45b21187b4b8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_bbbacdb6-a70b-4487-835a-0d38827f7356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_bbbacdb6-a70b-4487-835a-0d38827f7356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_b752df2c-4906-451d-897e-7d1bd1432e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:to="loc_us-gaap_OtherAssetsMember_b752df2c-4906-451d-897e-7d1bd1432e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_8e71b663-d6e9-4666-99a1-d7b85209f829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_8e71b663-d6e9-4666-99a1-d7b85209f829" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_35868ee5-98c4-407e-99eb-da4b09cf1186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_35868ee5-98c4-407e-99eb-da4b09cf1186" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="extended" id="i121fa8ceeec34087bd97b0a490e30a9a_FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4b5fa1b8-5c81-409e-b0be-67e754d2b7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_Revenues_4b5fa1b8-5c81-409e-b0be-67e754d2b7c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f81ab821-d6f5-4a2d-a104-3b593c907fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f81ab821-d6f5-4a2d-a104-3b593c907fbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_30a4b213-0896-4496-ad6f-d7b310d24fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_30a4b213-0896-4496-ad6f-d7b310d24fce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_f86424d5-f113-48c6-b451-f2d00ced4a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_f86424d5-f113-48c6-b451-f2d00ced4a72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f39649b3-07bc-4d5c-8670-7c678fe988f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f39649b3-07bc-4d5c-8670-7c678fe988f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_5735e4bc-f510-4980-aab0-6fdd35a13727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_5735e4bc-f510-4980-aab0-6fdd35a13727" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_dd8bb46f-a195-4320-b237-1353e0438c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_dd8bb46f-a195-4320-b237-1353e0438c2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_dbedb53e-6255-430b-8a69-9efc31fdf4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_dbedb53e-6255-430b-8a69-9efc31fdf4cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d4d3139a-d79a-44fb-8555-47e7b6c7b6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d4d3139a-d79a-44fb-8555-47e7b6c7b6e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d4d3139a-d79a-44fb-8555-47e7b6c7b6e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d4d3139a-d79a-44fb-8555-47e7b6c7b6e0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d4d3139a-d79a-44fb-8555-47e7b6c7b6e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1cd0af12-778d-4d56-b4c4-df523d202250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d4d3139a-d79a-44fb-8555-47e7b6c7b6e0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1cd0af12-778d-4d56-b4c4-df523d202250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_36d3c4c9-f754-45a4-b376-d67995c8a539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1cd0af12-778d-4d56-b4c4-df523d202250" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_36d3c4c9-f754-45a4-b376-d67995c8a539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_77412eb4-0297-475c-b6bf-66383cdc6a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_77412eb4-0297-475c-b6bf-66383cdc6a18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_77412eb4-0297-475c-b6bf-66383cdc6a18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_77412eb4-0297-475c-b6bf-66383cdc6a18" xlink:to="loc_us-gaap_EquityComponentDomain_77412eb4-0297-475c-b6bf-66383cdc6a18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_15cdc26c-7ab2-4603-8259-b9b335227388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_77412eb4-0297-475c-b6bf-66383cdc6a18" xlink:to="loc_us-gaap_EquityComponentDomain_15cdc26c-7ab2-4603-8259-b9b335227388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_fd402f04-c6d0-44cc-9ef1-e05039b0b0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15cdc26c-7ab2-4603-8259-b9b335227388" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_fd402f04-c6d0-44cc-9ef1-e05039b0b0d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8789bcb5-d1b7-4dc9-8e20-3b5d82b3c7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8789bcb5-d1b7-4dc9-8e20-3b5d82b3c7d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8789bcb5-d1b7-4dc9-8e20-3b5d82b3c7d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8789bcb5-d1b7-4dc9-8e20-3b5d82b3c7d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8789bcb5-d1b7-4dc9-8e20-3b5d82b3c7d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d64730d1-66ec-4dcb-893b-a46bd2e78ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8789bcb5-d1b7-4dc9-8e20-3b5d82b3c7d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d64730d1-66ec-4dcb-893b-a46bd2e78ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8f4f0669-bb91-4914-a815-8994716de1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d64730d1-66ec-4dcb-893b-a46bd2e78ccd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8f4f0669-bb91-4914-a815-8994716de1ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4d8e257e-14c4-4b1c-91c2-b18d7115977d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4d8e257e-14c4-4b1c-91c2-b18d7115977d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4d8e257e-14c4-4b1c-91c2-b18d7115977d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4d8e257e-14c4-4b1c-91c2-b18d7115977d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4d8e257e-14c4-4b1c-91c2-b18d7115977d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d32fe0cf-14e4-470e-b159-5361d7f7c4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4d8e257e-14c4-4b1c-91c2-b18d7115977d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d32fe0cf-14e4-470e-b159-5361d7f7c4d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_98d80641-ee97-4230-9f20-cbb7013a3b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d32fe0cf-14e4-470e-b159-5361d7f7c4d9" xlink:to="loc_us-gaap_InterestRateSwapMember_98d80641-ee97-4230-9f20-cbb7013a3b75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_93d515e4-6c2b-493a-9f3a-ba16fb8aba8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d32fe0cf-14e4-470e-b159-5361d7f7c4d9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_93d515e4-6c2b-493a-9f3a-ba16fb8aba8f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="ida05935f21cc474bbabc21d0f4c3e612_FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_217516e9-054f-4c28-989e-18e902176ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_f6ccc54d-bdf9-493e-803e-f81ccc6c5958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_217516e9-054f-4c28-989e-18e902176ecb" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_f6ccc54d-bdf9-493e-803e-f81ccc6c5958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a443d39f-637b-4147-972c-aa05fd0f11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_217516e9-054f-4c28-989e-18e902176ecb" xlink:to="loc_us-gaap_DerivativeTable_a443d39f-637b-4147-972c-aa05fd0f11e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d5e76863-46fc-4fa9-828c-565ae6dffc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a443d39f-637b-4147-972c-aa05fd0f11e2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d5e76863-46fc-4fa9-828c-565ae6dffc7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d5e76863-46fc-4fa9-828c-565ae6dffc7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5e76863-46fc-4fa9-828c-565ae6dffc7c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d5e76863-46fc-4fa9-828c-565ae6dffc7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5e76863-46fc-4fa9-828c-565ae6dffc7c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5c97bf82-edae-44d5-ad63-689f77b462c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5c97bf82-edae-44d5-ad63-689f77b462c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_44034c84-8e83-4079-bf74-263c8d52735c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:to="loc_us-gaap_InterestRateContractMember_44034c84-8e83-4079-bf74-263c8d52735c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_44dfbc49-3d12-47bd-999f-d81bc3b8a610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:to="loc_us-gaap_ForwardContractsMember_44dfbc49-3d12-47bd-999f-d81bc3b8a610" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d6102da1-f615-4528-b21c-b6e43f68803a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a443d39f-637b-4147-972c-aa05fd0f11e2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d6102da1-f615-4528-b21c-b6e43f68803a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d6102da1-f615-4528-b21c-b6e43f68803a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d6102da1-f615-4528-b21c-b6e43f68803a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d6102da1-f615-4528-b21c-b6e43f68803a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d6102da1-f615-4528-b21c-b6e43f68803a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4b1106de-75c0-4335-9987-936104c56147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4b1106de-75c0-4335-9987-936104c56147" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_46cf113e-c4d6-4a0b-bb61-3a8abd65b972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:to="loc_us-gaap_SalesMember_46cf113e-c4d6-4a0b-bb61-3a8abd65b972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7998d058-ac3c-4cfa-8508-fdf6e58b321c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7998d058-ac3c-4cfa-8508-fdf6e58b321c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="extended" id="id72f7ea9cd784bab806da7bfc2f0fe12_FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799ade49-4bed-48a6-9004-7e23430b2d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799ade49-4bed-48a6-9004-7e23430b2d4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d186a49b-5313-4c95-a5b7-3045178343bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d186a49b-5313-4c95-a5b7-3045178343bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae892fea-7c24-4611-a6e3-61d3564eeb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae892fea-7c24-4611-a6e3-61d3564eeb44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_845cd619-21e0-4444-8ff0-7cc2c6359693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_845cd619-21e0-4444-8ff0-7cc2c6359693" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9f8032ca-7712-4233-82d2-c821b359193e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9f8032ca-7712-4233-82d2-c821b359193e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f01516ee-feb8-469b-b741-5bf992edb7e5" xlink:href="mrk-20211231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f01516ee-feb8-469b-b741-5bf992edb7e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1ddc6f79-9179-4c5f-ba65-01fd29b576a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1ddc6f79-9179-4c5f-ba65-01fd29b576a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f431464a-fba3-4cb7-8378-8350b458d561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f431464a-fba3-4cb7-8378-8350b458d561" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9151edca-6769-4112-9c8e-ef5b6891a5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f431464a-fba3-4cb7-8378-8350b458d561" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9151edca-6769-4112-9c8e-ef5b6891a5dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9151edca-6769-4112-9c8e-ef5b6891a5dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9151edca-6769-4112-9c8e-ef5b6891a5dc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9151edca-6769-4112-9c8e-ef5b6891a5dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9151edca-6769-4112-9c8e-ef5b6891a5dc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_59316f00-8954-4459-876e-4f150d836438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_59316f00-8954-4459-876e-4f150d836438" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_90d3ee09-cfa4-4e03-8eb4-9df58d24ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_90d3ee09-cfa4-4e03-8eb4-9df58d24ac40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_969f7cb5-d5f0-4223-950d-faf3a2171d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_969f7cb5-d5f0-4223-950d-faf3a2171d29" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i5eedc346d6a44151bc03437d24c5876b_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_491719d2-6af7-474c-8d3b-f3401134cd38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_491719d2-6af7-474c-8d3b-f3401134cd38" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_192edcd2-c56a-4bf9-8339-6237255b31af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_192edcd2-c56a-4bf9-8339-6237255b31af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_08f0a9ee-eebc-4285-827b-8910da9f0e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_08f0a9ee-eebc-4285-827b-8910da9f0e5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_265f130e-ce6d-46e4-8ae1-5519342c60d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_TradingSecurities_265f130e-ce6d-46e4-8ae1-5519342c60d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3c229947-e69f-4c5e-bd53-665e4660bef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3c229947-e69f-4c5e-bd53-665e4660bef0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_8efbe280-f4c1-4e90-8000-6666d5ecc7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_DerivativeAssets_8efbe280-f4c1-4e90-8000-6666d5ecc7bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8b4f9483-42b4-42e6-936c-c5ff5b162b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8b4f9483-42b4-42e6-936c-c5ff5b162b84" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_491719d2-6af7-474c-8d3b-f3401134cd38" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_37b63945-6acc-4040-baa9-e94cc72c5912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_37b63945-6acc-4040-baa9-e94cc72c5912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_c8bdaf81-fe18-440b-9e14-47f122b2154e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:to="loc_us-gaap_DerivativeLiabilities_c8bdaf81-fe18-440b-9e14-47f122b2154e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5b5d7202-c714-4674-a47b-12eb13a4138f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5b5d7202-c714-4674-a47b-12eb13a4138f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_491719d2-6af7-474c-8d3b-f3401134cd38" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ea169f39-6299-4967-82d8-e630736d8642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ea169f39-6299-4967-82d8-e630736d8642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ea169f39-6299-4967-82d8-e630736d8642_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ea169f39-6299-4967-82d8-e630736d8642" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ea169f39-6299-4967-82d8-e630736d8642_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d33746f6-eb63-4d9d-8dad-e5bd783279cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ea169f39-6299-4967-82d8-e630736d8642" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d33746f6-eb63-4d9d-8dad-e5bd783279cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0d9aaa97-6a55-4acc-8e3e-dbecfbc1ef8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d33746f6-eb63-4d9d-8dad-e5bd783279cd" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0d9aaa97-6a55-4acc-8e3e-dbecfbc1ef8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d1924d1c-d689-4dfe-9421-14324eb5798a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d1924d1c-d689-4dfe-9421-14324eb5798a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1924d1c-d689-4dfe-9421-14324eb5798a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d1924d1c-d689-4dfe-9421-14324eb5798a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1924d1c-d689-4dfe-9421-14324eb5798a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d1924d1c-d689-4dfe-9421-14324eb5798a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_86fb1a69-2ce0-480e-9b56-ef7077f7db49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_86fb1a69-2ce0-480e-9b56-ef7077f7db49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0458f46a-6eed-4f8e-8b3a-db6730f8a995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0458f46a-6eed-4f8e-8b3a-db6730f8a995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a386258e-602c-4734-a25e-23c4b169a5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a386258e-602c-4734-a25e-23c4b169a5cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5b8ac573-4382-452c-b6f6-db9e8bb9dd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5b8ac573-4382-452c-b6f6-db9e8bb9dd41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b8ac573-4382-452c-b6f6-db9e8bb9dd41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5b8ac573-4382-452c-b6f6-db9e8bb9dd41" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b8ac573-4382-452c-b6f6-db9e8bb9dd41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5b8ac573-4382-452c-b6f6-db9e8bb9dd41" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_0d7c9aff-5084-42e6-9d66-331121b150a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_0d7c9aff-5084-42e6-9d66-331121b150a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5f06d7f8-7d2c-46ce-aa57-055ee86fe96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5f06d7f8-7d2c-46ce-aa57-055ee86fe96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_73a0fc8f-bea1-4745-a684-1a85abbd1a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_73a0fc8f-bea1-4745-a684-1a85abbd1a0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_14244e50-72ca-4734-903a-f22060da09ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:to="loc_us-gaap_EquitySecuritiesMember_14244e50-72ca-4734-903a-f22060da09ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0e5b48bc-b2ac-4d8b-9a7d-7b9d8e802514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0e5b48bc-b2ac-4d8b-9a7d-7b9d8e802514" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0e5b48bc-b2ac-4d8b-9a7d-7b9d8e802514_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0e5b48bc-b2ac-4d8b-9a7d-7b9d8e802514" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0e5b48bc-b2ac-4d8b-9a7d-7b9d8e802514_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0e5b48bc-b2ac-4d8b-9a7d-7b9d8e802514" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_27ff874a-010d-45b8-b47f-3501a8a6e863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:to="loc_us-gaap_ForeignExchangeContractMember_27ff874a-010d-45b8-b47f-3501a8a6e863" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_70b1fa26-e6e9-4a11-af4e-6388b1e63eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_70b1fa26-e6e9-4a11-af4e-6388b1e63eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_0fccbf71-9a66-403d-8dea-fb8f098e0b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:to="loc_us-gaap_InterestRateContractMember_0fccbf71-9a66-403d-8dea-fb8f098e0b28" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended" id="i0d27f93b651d4632a123e9aefa3a7acd_FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5cd6468a-efe0-4ad1-b44f-a5a708365d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5cd6468a-efe0-4ad1-b44f-a5a708365d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6c723649-031e-4e7d-b73f-5ff00dbb6c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6c723649-031e-4e7d-b73f-5ff00dbb6c29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fd120d66-a5f0-49ac-90f0-3104b56037be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fd120d66-a5f0-49ac-90f0-3104b56037be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b2e36be5-d88e-46c9-9850-b18d61171823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b2e36be5-d88e-46c9-9850-b18d61171823" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_c34ce83b-92c2-44df-bc52-fa0b510643c9" xlink:href="mrk-20211231.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_c34ce83b-92c2-44df-bc52-fa0b510643c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bca7ec3c-d625-4c76-ad50-13a9e497c56f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6e350f5d-bc12-439b-affe-6318d01c72f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6e350f5d-bc12-439b-affe-6318d01c72f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e8355138-c017-49ee-80bb-54cb4cbc7d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e8355138-c017-49ee-80bb-54cb4cbc7d14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1d8c5b6e-5f39-4c35-acd3-830a49b05de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1d8c5b6e-5f39-4c35-acd3-830a49b05de2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a015474c-6950-4ae8-846c-e794e023ed81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1d8c5b6e-5f39-4c35-acd3-830a49b05de2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a015474c-6950-4ae8-846c-e794e023ed81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a015474c-6950-4ae8-846c-e794e023ed81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a015474c-6950-4ae8-846c-e794e023ed81" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a015474c-6950-4ae8-846c-e794e023ed81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bf2dcf63-62de-4304-bbcf-ad385d88c204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a015474c-6950-4ae8-846c-e794e023ed81" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bf2dcf63-62de-4304-bbcf-ad385d88c204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_efa1ea1d-3321-4bfc-a2f8-a16263ca2131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_bf2dcf63-62de-4304-bbcf-ad385d88c204" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_efa1ea1d-3321-4bfc-a2f8-a16263ca2131" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4e487ea9-db3c-405e-b634-ab985557e080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1d8c5b6e-5f39-4c35-acd3-830a49b05de2" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4e487ea9-db3c-405e-b634-ab985557e080" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_4e487ea9-db3c-405e-b634-ab985557e080_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4e487ea9-db3c-405e-b634-ab985557e080" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_4e487ea9-db3c-405e-b634-ab985557e080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_b7733fef-b638-4025-9be4-115f2e72904a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4e487ea9-db3c-405e-b634-ab985557e080" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_b7733fef-b638-4025-9be4-115f2e72904a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_b75604b6-5e7b-45c8-99ae-c819323a4930" xlink:href="mrk-20211231.xsd#mrk_SanofiPasteurMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_b7733fef-b638-4025-9be4-115f2e72904a" xlink:to="loc_mrk_SanofiPasteurMember_b75604b6-5e7b-45c8-99ae-c819323a4930" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i3f45f389125645758e830f717a6eddde_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_52484879-5de9-4e32-af11-249ceb137d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount_3cbcd21a-52de-4212-96eb-45a369020812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_52484879-5de9-4e32-af11-249ceb137d68" xlink:to="loc_us-gaap_LIFOInventoryAmount_3cbcd21a-52de-4212-96eb-45a369020812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_1a6bd0c2-e371-4ef0-bf1b-84f797d88195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_52484879-5de9-4e32-af11-249ceb137d68" xlink:to="loc_us-gaap_InventoryNoncurrent_1a6bd0c2-e371-4ef0-bf1b-84f797d88195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_0eabf7e5-1c36-499c-96ad-a1e995cfab32" xlink:href="mrk-20211231.xsd#mrk_InventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_52484879-5de9-4e32-af11-249ceb137d68" xlink:to="loc_mrk_InventoryTable_0eabf7e5-1c36-499c-96ad-a1e995cfab32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_4e38f030-19ac-4d6c-b5de-8a131e6292f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_InventoryTable_0eabf7e5-1c36-499c-96ad-a1e995cfab32" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_4e38f030-19ac-4d6c-b5de-8a131e6292f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4e38f030-19ac-4d6c-b5de-8a131e6292f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_4e38f030-19ac-4d6c-b5de-8a131e6292f1" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_4e38f030-19ac-4d6c-b5de-8a131e6292f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_0db25076-789f-46de-81e9-ee5d6b742f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_4e38f030-19ac-4d6c-b5de-8a131e6292f1" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_0db25076-789f-46de-81e9-ee5d6b742f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_b27c5663-8727-4c89-9d11-6e43ffaaf41c" xlink:href="mrk-20211231.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_0db25076-789f-46de-81e9-ee5d6b742f05" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_b27c5663-8727-4c89-9d11-6e43ffaaf41c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_db20e33e-b85b-44de-9324-4d0af0b4e1c4" xlink:href="mrk-20211231.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_0db25076-789f-46de-81e9-ee5d6b742f05" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_db20e33e-b85b-44de-9324-4d0af0b4e1c4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="extended" id="i36e45390c0ce46eba5783186c2f47854_GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f44d85ae-b0ff-4603-923c-bb4292910411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_f44d85ae-b0ff-4603-923c-bb4292910411" xlink:to="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d57e720f-a926-4529-80b9-945338f5e432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:to="loc_us-gaap_Goodwill_d57e720f-a926-4529-80b9-945338f5e432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_22a1ec50-6203-45e8-8f36-3f214eb803e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_22a1ec50-6203-45e8-8f36-3f214eb803e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_79b3af64-40b7-444e-b4a3-e7d250438a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_79b3af64-40b7-444e-b4a3-e7d250438a7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_1dcc308e-fda9-4e49-bb07-6b12728ef1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_1dcc308e-fda9-4e49-bb07-6b12728ef1c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31ebea78-546f-4869-ae65-4eb8d6697bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fb9009ae-ee49-40f1-933b-513787cbb66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_f44d85ae-b0ff-4603-923c-bb4292910411" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fb9009ae-ee49-40f1-933b-513787cbb66c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c9159499-e0ad-44dd-8f15-45358c9c9200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_f44d85ae-b0ff-4603-923c-bb4292910411" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c9159499-e0ad-44dd-8f15-45358c9c9200" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fd136943-4d62-42c7-a8ac-8c30904488f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c9159499-e0ad-44dd-8f15-45358c9c9200" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fd136943-4d62-42c7-a8ac-8c30904488f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fd136943-4d62-42c7-a8ac-8c30904488f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fd136943-4d62-42c7-a8ac-8c30904488f9" xlink:to="loc_us-gaap_SegmentDomain_fd136943-4d62-42c7-a8ac-8c30904488f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fd136943-4d62-42c7-a8ac-8c30904488f9" xlink:to="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_e87a9fa9-b207-4633-9b54-0f0cebbe1bce" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:to="loc_mrk_PharmaceuticalsegmentMember_e87a9fa9-b207-4633-9b54-0f0cebbe1bce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_5a948a8a-2773-4d90-bd35-c901b96cc517" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:to="loc_mrk_AnimalHealthsegmentMember_5a948a8a-2773-4d90-bd35-c901b96cc517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_3c094e04-5257-452d-9730-74bb768b17c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:to="loc_us-gaap_AllOtherSegmentsMember_3c094e04-5257-452d-9730-74bb768b17c0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended" id="id9b1cbb67c6c4363bcea9074c9e88886_GoodwillandOtherIntangiblesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetsExcludingGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7f3e4f0-2f28-414e-a2c1-b5821fafd731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7f3e4f0-2f28-414e-a2c1-b5821fafd731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1ade6fae-7bda-49ff-a536-02153d77511b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1ade6fae-7bda-49ff-a536-02153d77511b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c54d80e7-3863-4337-a99a-4cfcb019a3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c54d80e7-3863-4337-a99a-4cfcb019a3d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_e41e6a67-5245-47c0-966f-65d691f3eb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_InventoryWriteDown_e41e6a67-5245-47c0-966f-65d691f3eb4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d118da77-5970-4815-a1c0-725e1f5c48d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d118da77-5970-4815-a1c0-725e1f5c48d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_3b23081b-9c18-442d-b29e-8441cd96e42d" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_3b23081b-9c18-442d-b29e-8441cd96e42d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_33b5b396-7c97-46be-ad57-abb229aa3428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_33b5b396-7c97-46be-ad57-abb229aa3428" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4d72d97e-ca98-4928-8380-30c6a9d314de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4d72d97e-ca98-4928-8380-30c6a9d314de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9a4e8c3d-ac9f-45f2-bbf4-777d04597e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9a4e8c3d-ac9f-45f2-bbf4-777d04597e6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b422010c-2032-463d-907b-14585ed4a9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b422010c-2032-463d-907b-14585ed4a9e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4658daca-c714-491d-93e2-39a492d0a3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4658daca-c714-491d-93e2-39a492d0a3e8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_efa81dea-5a3d-4e5e-a63f-b83b51d2d655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_efa81dea-5a3d-4e5e-a63f-b83b51d2d655" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b5a1abdc-d023-4721-a935-f3eefc29c3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b5a1abdc-d023-4721-a935-f3eefc29c3a4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:href="mrk-20211231.xsd#mrk_ScheduleOfOtherIntangiblesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_91d15d45-bf44-428f-8900-4f9b1899d799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_91d15d45-bf44-428f-8900-4f9b1899d799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91d15d45-bf44-428f-8900-4f9b1899d799_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_91d15d45-bf44-428f-8900-4f9b1899d799" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91d15d45-bf44-428f-8900-4f9b1899d799_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cabe2572-653d-41cf-819b-c83d70183eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_91d15d45-bf44-428f-8900-4f9b1899d799" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cabe2572-653d-41cf-819b-c83d70183eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_7871befa-1292-46a4-810d-3a959ecf8fd1" xlink:href="mrk-20211231.xsd#mrk_AntelliqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cabe2572-653d-41cf-819b-c83d70183eaf" xlink:to="loc_mrk_AntelliqMember_7871befa-1292-46a4-810d-3a959ecf8fd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6fe8527f-a47d-447d-bc3c-60e2dc8f7a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6fe8527f-a47d-447d-bc3c-60e2dc8f7a6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6fe8527f-a47d-447d-bc3c-60e2dc8f7a6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6fe8527f-a47d-447d-bc3c-60e2dc8f7a6c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6fe8527f-a47d-447d-bc3c-60e2dc8f7a6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6fe8527f-a47d-447d-bc3c-60e2dc8f7a6c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_fb8c422e-96ca-41ad-8984-9e995a59c7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_fb8c422e-96ca-41ad-8984-9e995a59c7f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_b381ebb6-4ac7-47d7-a84f-a31eed73a1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:to="loc_us-gaap_TradeNamesMember_b381ebb6-4ac7-47d7-a84f-a31eed73a1c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6c7ef2e4-7aab-4d46-b0d3-d32e755d1271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:to="loc_us-gaap_LicenseMember_6c7ef2e4-7aab-4d46-b0d3-d32e755d1271" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_14df3adc-7ba0-4e4f-ace1-0fcf3586de41" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_srt_ProductOrServiceAxis_14df3adc-7ba0-4e4f-ace1-0fcf3586de41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14df3adc-7ba0-4e4f-ace1-0fcf3586de41_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_14df3adc-7ba0-4e4f-ace1-0fcf3586de41" xlink:to="loc_srt_ProductsAndServicesDomain_14df3adc-7ba0-4e4f-ace1-0fcf3586de41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_14df3adc-7ba0-4e4f-ace1-0fcf3586de41" xlink:to="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember_3b2c2f69-b435-492b-9129-b8289e157f72" xlink:href="mrk-20211231.xsd#mrk_ReblozylMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_ReblozylMember_3b2c2f69-b435-492b-9129-b8289e157f72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_0ae22b0b-8998-46e3-9202-749f260d5141" xlink:href="mrk-20211231.xsd#mrk_ZerbaxaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_ZerbaxaMember_0ae22b0b-8998-46e3-9202-749f260d5141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_925acf36-e7f5-41f8-affb-3b9426f7a3e3" xlink:href="mrk-20211231.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_GardasilGardasil9Member_925acf36-e7f5-41f8-affb-3b9426f7a3e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_f606726d-7035-4a64-a468-067aa0ab5f70" xlink:href="mrk-20211231.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_BridionMember_f606726d-7035-4a64-a468-067aa0ab5f70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_61c1086c-94e0-40bb-8f3a-76e08dcf7328" xlink:href="mrk-20211231.xsd#mrk_DificidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_DificidMember_61c1086c-94e0-40bb-8f3a-76e08dcf7328" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember_0606d3a0-1195-47e8-a62d-77ba4feafd57" xlink:href="mrk-20211231.xsd#mrk_SivextroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_SivextroMember_0606d3a0-1195-47e8-a62d-77ba4feafd57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_9e913722-120e-44df-bef6-e7146d65d56b" xlink:href="mrk-20211231.xsd#mrk_SimponiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_SimponiMember_9e913722-120e-44df-bef6-e7146d65d56b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthMember_e018e175-b5af-4c66-b0e4-8675ae26dac1" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_AnimalHealthMember_e018e175-b5af-4c66-b0e4-8675ae26dac1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_807636d4-a10b-4373-b688-707b4b50ed09" xlink:href="mrk-20211231.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_LynparzaMember_807636d4-a10b-4373-b688-707b4b50ed09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_aa59df77-686c-4cc3-8a54-74035059e62e" xlink:href="mrk-20211231.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_LenvimaMember_aa59df77-686c-4cc3-8a54-74035059e62e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_580cb03e-aba6-4e9d-b24b-65b089759bb6" xlink:href="mrk-20211231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_AdempasMember_580cb03e-aba6-4e9d-b24b-65b089759bb6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_4c124c97-a4e8-43ae-aa73-72a321cbcc92" xlink:href="mrk-20211231.xsd#mrk_VerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_VerquvoMember_4c124c97-a4e8-43ae-aa73-72a321cbcc92" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_132c1353-2073-4fea-8cf8-03a9ad52deb9" xlink:href="mrk-20211231.xsd#mrk_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_COVID19Member_132c1353-2073-4fea-8cf8-03a9ad52deb9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IOmetPharmaLtdMember_8665ac4f-504d-4ab4-8dfd-c1ea84ed5935" xlink:href="mrk-20211231.xsd#mrk_IOmetPharmaLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_IOmetPharmaLtdMember_8665ac4f-504d-4ab4-8dfd-c1ea84ed5935" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SotaterceptMember_4fd4c106-18e3-4c8e-bd31-e8c684ab51cc" xlink:href="mrk-20211231.xsd#mrk_SotaterceptMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_SotaterceptMember_4fd4c106-18e3-4c8e-bd31-e8c684ab51cc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember_6d1a5ef4-3c4d-41b0-90bc-4c86d8c1ea20" xlink:href="mrk-20211231.xsd#mrk_NemtabrutinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_NemtabrutinibMember_6d1a5ef4-3c4d-41b0-90bc-4c86d8c1ea20" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GefapixantMember_c0ddf745-390b-46b2-bee5-a8b72816b44d" xlink:href="mrk-20211231.xsd#mrk_GefapixantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_GefapixantMember_c0ddf745-390b-46b2-bee5-a8b72816b44d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9b69a527-d2b4-4594-9a9d-5e0b0e6f3528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9b69a527-d2b4-4594-9a9d-5e0b0e6f3528" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9b69a527-d2b4-4594-9a9d-5e0b0e6f3528_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9b69a527-d2b4-4594-9a9d-5e0b0e6f3528" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9b69a527-d2b4-4594-9a9d-5e0b0e6f3528_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_74b55ade-caea-47c9-bc19-1aea0905fdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9b69a527-d2b4-4594-9a9d-5e0b0e6f3528" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_74b55ade-caea-47c9-bc19-1aea0905fdb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_a2e2ceea-45c9-4e10-83c3-08a9147985e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_74b55ade-caea-47c9-bc19-1aea0905fdb0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_a2e2ceea-45c9-4e10-83c3-08a9147985e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f87c532e-019a-4af0-a5b1-1d9665636d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f87c532e-019a-4af0-a5b1-1d9665636d62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f87c532e-019a-4af0-a5b1-1d9665636d62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f87c532e-019a-4af0-a5b1-1d9665636d62" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f87c532e-019a-4af0-a5b1-1d9665636d62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_84cf2858-ec2d-4c60-bec4-f20a23af8f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f87c532e-019a-4af0-a5b1-1d9665636d62" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_84cf2858-ec2d-4c60-bec4-f20a23af8f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_fe4d3887-df8c-4ebe-a059-1584c383ddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_84cf2858-ec2d-4c60-bec4-f20a23af8f4c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_fe4d3887-df8c-4ebe-a059-1584c383ddc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_70cc1217-1ae2-4e24-bb15-b2a4a4891dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_ValuationTechniqueAxis_70cc1217-1ae2-4e24-bb15-b2a4a4891dd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_70cc1217-1ae2-4e24-bb15-b2a4a4891dd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_70cc1217-1ae2-4e24-bb15-b2a4a4891dd5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_70cc1217-1ae2-4e24-bb15-b2a4a4891dd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_5b21f4e8-2d42-4927-8093-e5e8dcca2762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_70cc1217-1ae2-4e24-bb15-b2a4a4891dd5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_5b21f4e8-2d42-4927-8093-e5e8dcca2762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_13c47042-63f3-4098-b44d-145fa637bb18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_5b21f4e8-2d42-4927-8093-e5e8dcca2762" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_13c47042-63f3-4098-b44d-145fa637bb18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c89767f-47cd-4596-be48-f65753ac8a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c89767f-47cd-4596-be48-f65753ac8a28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c89767f-47cd-4596-be48-f65753ac8a28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c89767f-47cd-4596-be48-f65753ac8a28" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c89767f-47cd-4596-be48-f65753ac8a28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ecd1777-966c-4b78-8c08-d2a9ecfdb6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c89767f-47cd-4596-be48-f65753ac8a28" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ecd1777-966c-4b78-8c08-d2a9ecfdb6d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2d3b16fb-ab8e-4265-bc5d-6115eb306897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ecd1777-966c-4b78-8c08-d2a9ecfdb6d7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2d3b16fb-ab8e-4265-bc5d-6115eb306897" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf1cb912-3ca6-4002-be1f-5a85a9324d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf1cb912-3ca6-4002-be1f-5a85a9324d0a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bf1cb912-3ca6-4002-be1f-5a85a9324d0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf1cb912-3ca6-4002-be1f-5a85a9324d0a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bf1cb912-3ca6-4002-be1f-5a85a9324d0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd6456eb-ca3e-4512-8c8a-4300b0aee20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf1cb912-3ca6-4002-be1f-5a85a9324d0a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd6456eb-ca3e-4512-8c8a-4300b0aee20a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2109ba6d-3b1d-4a6f-b50f-eec98dc25276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd6456eb-ca3e-4512-8c8a-4300b0aee20a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2109ba6d-3b1d-4a6f-b50f-eec98dc25276" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#GoodwillandOtherIntangiblesOtherIntangiblesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="extended" id="i62190acbf0974219982932a2548c78e8_GoodwillandOtherIntangiblesOtherIntangiblesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_614b49ee-2181-4791-8fa5-1dea7a7fcc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_614b49ee-2181-4791-8fa5-1dea7a7fcc6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eadfe60b-73e9-4c22-b60a-04f0c6cf7a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eadfe60b-73e9-4c22-b60a-04f0c6cf7a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d74b43b4-b4af-4fc6-870f-2169d51ec5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d74b43b4-b4af-4fc6-870f-2169d51ec5c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9b457dd-3234-431a-8f31-b2d0e87ad861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9b457dd-3234-431a-8f31-b2d0e87ad861" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355e2649-5702-491f-8384-2d71f10c97ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9b457dd-3234-431a-8f31-b2d0e87ad861" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355e2649-5702-491f-8384-2d71f10c97ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355e2649-5702-491f-8384-2d71f10c97ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355e2649-5702-491f-8384-2d71f10c97ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355e2649-5702-491f-8384-2d71f10c97ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355e2649-5702-491f-8384-2d71f10c97ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_133efac8-d258-4db5-a8d8-ee57fc15200c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_133efac8-d258-4db5-a8d8-ee57fc15200c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_66fbaca6-11cd-404f-8e46-b38502948960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:to="loc_us-gaap_TradeNamesMember_66fbaca6-11cd-404f-8e46-b38502948960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ebe56579-ee88-4e42-914f-4f03baa46090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ebe56579-ee88-4e42-914f-4f03baa46090" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1c0d571a-e83f-4426-b17e-dd4b9a3afa46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:to="loc_us-gaap_LicenseMember_1c0d571a-e83f-4426-b17e-dd4b9a3afa46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbb33f8d-baae-4f50-97f3-37f6aef16d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9b457dd-3234-431a-8f31-b2d0e87ad861" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbb33f8d-baae-4f50-97f3-37f6aef16d44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bbb33f8d-baae-4f50-97f3-37f6aef16d44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbb33f8d-baae-4f50-97f3-37f6aef16d44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bbb33f8d-baae-4f50-97f3-37f6aef16d44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_27b0b832-8569-484b-9a7a-1b9faccc33b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbb33f8d-baae-4f50-97f3-37f6aef16d44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_27b0b832-8569-484b-9a7a-1b9faccc33b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_392c6c13-9626-41f5-bf19-66e2bdbd5e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_27b0b832-8569-484b-9a7a-1b9faccc33b3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_392c6c13-9626-41f5-bf19-66e2bdbd5e30" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="extended" id="ib2033a82a32c4cd483a2616f84f9e3c9_LoansPayableLongTermDebtandLeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_aa72abf6-df17-4343-995c-efa6df64c26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtCurrent_aa72abf6-df17-4343-995c-efa6df64c26d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_aff4f9cc-6ecb-4b93-aaee-08d7e5ff438d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_DebtCurrent_aff4f9cc-6ecb-4b93-aaee-08d7e5ff438d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_cd88d8c5-2c9f-46dc-9f4d-9e7cfd18db5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_cd88d8c5-2c9f-46dc-9f4d-9e7cfd18db5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f4d44d37-c78f-4e7a-ac42-f2e6fc89d2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f4d44d37-c78f-4e7a-ac42-f2e6fc89d2b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_a94089f9-6302-4a11-b03a-932fe705c5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_a94089f9-6302-4a11-b03a-932fe705c5be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e03e3806-982d-4ea8-8b8b-b5ebf9dd937f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e03e3806-982d-4ea8-8b8b-b5ebf9dd937f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_800559f6-dd73-4b6c-84ea-e844c19e0109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_800559f6-dd73-4b6c-84ea-e844c19e0109" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3fc8ef19-06b0-4ad0-8079-f2f4145071ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3fc8ef19-06b0-4ad0-8079-f2f4145071ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_03ca7204-095b-4b8d-b50c-c3214269bac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_03ca7204-095b-4b8d-b50c-c3214269bac1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_29b2f43f-3bcc-45eb-9a67-4085da03d726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_29b2f43f-3bcc-45eb-9a67-4085da03d726" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7a212335-7ae1-4031-b70e-4bd3230cf50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7a212335-7ae1-4031-b70e-4bd3230cf50c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_22a86d32-3a67-42cc-a1a8-7edefafeae78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_22a86d32-3a67-42cc-a1a8-7edefafeae78" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearOne_32e727ea-c94a-405c-81b5-d4d450197541" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearOne_32e727ea-c94a-405c-81b5-d4d450197541" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearTwo_8a285c60-1cff-40fa-b4b5-945ccc8aefda" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearTwo_8a285c60-1cff-40fa-b4b5-945ccc8aefda" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearThree_588c7c5d-cbd5-4fdb-9601-67769104375e" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearThree_588c7c5d-cbd5-4fdb-9601-67769104375e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFour_262b55ab-c323-4575-8bea-4eae0a3d9f07" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearFour_262b55ab-c323-4575-8bea-4eae0a3d9f07" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFive_669ba91e-d946-4faa-88ab-702e0682b78b" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearFive_669ba91e-d946-4faa-88ab-702e0682b78b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fb3572bd-f38f-4574-a0ab-1cb00b1096a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fb3572bd-f38f-4574-a0ab-1cb00b1096a2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b1c3b1a7-2f83-4591-b01b-f9648c5f1e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b1c3b1a7-2f83-4591-b01b-f9648c5f1e38" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_defdbfc6-20c5-44e2-a3ad-77dcd53726a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_defdbfc6-20c5-44e2-a3ad-77dcd53726a1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c54c218b-5260-4f98-b40d-8667e4b10cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_OperatingLeaseCost_c54c218b-5260-4f98-b40d-8667e4b10cf9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2cbcc0a6-f35b-4bed-b6fb-28013ff77e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_OperatingLeasePayments_2cbcc0a6-f35b-4bed-b6fb-28013ff77e11" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_49421db0-38c2-4f0a-949c-813dc71af73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_49421db0-38c2-4f0a-949c-813dc71af73b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_f66e1f19-7ff9-416c-9edc-1d1ba6ce2175" xlink:href="mrk-20211231.xsd#mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_f66e1f19-7ff9-416c-9edc-1d1ba6ce2175" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e4a3ac1d-0448-4b23-ae7d-003a70156ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e4a3ac1d-0448-4b23-ae7d-003a70156ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e4a3ac1d-0448-4b23-ae7d-003a70156ae5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e4a3ac1d-0448-4b23-ae7d-003a70156ae5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e4a3ac1d-0448-4b23-ae7d-003a70156ae5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64844baa-9811-42a0-a121-c19212a9e1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e4a3ac1d-0448-4b23-ae7d-003a70156ae5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64844baa-9811-42a0-a121-c19212a9e1eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9cb4a7d3-7ea6-4662-8492-d74344bcfabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64844baa-9811-42a0-a121-c19212a9e1eb" xlink:to="loc_us-gaap_BuildingMember_9cb4a7d3-7ea6-4662-8492-d74344bcfabc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_4b531aae-1aff-442e-a135-08f82e21ad0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64844baa-9811-42a0-a121-c19212a9e1eb" xlink:to="loc_us-gaap_VehiclesMember_4b531aae-1aff-442e-a135-08f82e21ad0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_6e00e928-e9e8-4a95-9ee0-011c17af7ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_6e00e928-e9e8-4a95-9ee0-011c17af7ae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6e00e928-e9e8-4a95-9ee0-011c17af7ae3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6e00e928-e9e8-4a95-9ee0-011c17af7ae3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6e00e928-e9e8-4a95-9ee0-011c17af7ae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_473d8755-ae8e-4e20-9277-d306dd2b03bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6e00e928-e9e8-4a95-9ee0-011c17af7ae3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_473d8755-ae8e-4e20-9277-d306dd2b03bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4f08d6d1-af9d-4890-b216-6cd192bd03f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_473d8755-ae8e-4e20-9277-d306dd2b03bc" xlink:to="loc_us-gaap_CommercialPaperMember_4f08d6d1-af9d-4890-b216-6cd192bd03f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_fd7973d4-b5ed-4383-8258-faf3def057ad" xlink:href="mrk-20211231.xsd#mrk_NotesSubjectToRepaymentAtOptionOfHolderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_473d8755-ae8e-4e20-9277-d306dd2b03bc" xlink:to="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_fd7973d4-b5ed-4383-8258-faf3def057ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_be825ea8-1a97-4abb-9682-e752cbb9e47a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:to="loc_us-gaap_DebtInstrumentAxis_be825ea8-1a97-4abb-9682-e752cbb9e47a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_be825ea8-1a97-4abb-9682-e752cbb9e47a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_be825ea8-1a97-4abb-9682-e752cbb9e47a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_be825ea8-1a97-4abb-9682-e752cbb9e47a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_be825ea8-1a97-4abb-9682-e752cbb9e47a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherVariableRateDebtMember_d8f92211-7025-42dc-9753-0ea4f6633db6" xlink:href="mrk-20211231.xsd#mrk_OtherVariableRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_OtherVariableRateDebtMember_d8f92211-7025-42dc-9753-0ea4f6633db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member_dd81b69e-93ea-429c-8ce1-f76da930e4c1" xlink:href="mrk-20211231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A63DebenturesDue2026Member_dd81b69e-93ea-429c-8ce1-f76da930e4c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member_b161ed3b-3826-4eba-bcc5-5a9c28a48afe" xlink:href="mrk-20211231.xsd#mrk_A170NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A170NotesDue2027Member_b161ed3b-3826-4eba-bcc5-5a9c28a48afe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member_27633518-34a0-4e30-aaf1-3564da80600f" xlink:href="mrk-20211231.xsd#mrk_A190NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A190NotesDue2028Member_27633518-34a0-4e30-aaf1-3564da80600f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member_ac1462a1-f67a-4d18-adf9-2af6b686874f" xlink:href="mrk-20211231.xsd#mrk_A215NotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A215NotesDue2031Member_ac1462a1-f67a-4d18-adf9-2af6b686874f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member_e4480d47-ed12-43be-823a-d4f4cb61cfab" xlink:href="mrk-20211231.xsd#mrk_A275NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A275NotesDue2051Member_e4480d47-ed12-43be-823a-d4f4cb61cfab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member_5fe2c933-0e0c-4dab-b4f4-3085a7fc1f7c" xlink:href="mrk-20211231.xsd#mrk_A290NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A290NotesDue2061Member_5fe2c933-0e0c-4dab-b4f4-3085a7fc1f7c" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="extended" id="if3f945e267a8489c8ba9548022415db4_LoansPayableLongTermDebtandLeasesLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0c0dc22a-2637-4fd0-a0c1-27162c6cc60c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_420b2720-148c-431a-8ab9-c4f4b9301631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0c0dc22a-2637-4fd0-a0c1-27162c6cc60c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_420b2720-148c-431a-8ab9-c4f4b9301631" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9e40a987-674f-40f0-adf5-614240061a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0c0dc22a-2637-4fd0-a0c1-27162c6cc60c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9e40a987-674f-40f0-adf5-614240061a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6599cd8a-93b6-4ff7-a048-6a10efab5a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0c0dc22a-2637-4fd0-a0c1-27162c6cc60c" xlink:to="loc_us-gaap_DebtInstrumentTable_6599cd8a-93b6-4ff7-a048-6a10efab5a6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca825367-a8ca-4866-844c-5bb4bcd7622c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6599cd8a-93b6-4ff7-a048-6a10efab5a6e" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca825367-a8ca-4866-844c-5bb4bcd7622c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ca825367-a8ca-4866-844c-5bb4bcd7622c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca825367-a8ca-4866-844c-5bb4bcd7622c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ca825367-a8ca-4866-844c-5bb4bcd7622c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca825367-a8ca-4866-844c-5bb4bcd7622c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.75NotesDue2025Member_f18ba5b0-b771-4f8f-a61f-37df8b72229e" xlink:href="mrk-20211231.xsd#mrk_A2.75NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.75NotesDue2025Member_f18ba5b0-b771-4f8f-a61f-37df8b72229e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member_6c23613c-4866-4646-8e00-d0c16c2f1e23" xlink:href="mrk-20211231.xsd#mrk_A215NotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A215NotesDue2031Member_6c23613c-4866-4646-8e00-d0c16c2f1e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member_c7dfee78-a803-47cc-ab5e-32b9a72c5064" xlink:href="mrk-20211231.xsd#mrk_A275NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A275NotesDue2051Member_c7dfee78-a803-47cc-ab5e-32b9a72c5064" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.70NotesDue2045Member_8b6724cd-00a7-4415-9d98-a136b0d83730" xlink:href="mrk-20211231.xsd#mrk_A3.70NotesDue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A3.70NotesDue2045Member_8b6724cd-00a7-4415-9d98-a136b0d83730" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A280NotesDue2023Member_578ed790-20a5-4e29-84fd-44efdcd4be27" xlink:href="mrk-20211231.xsd#mrk_A280NotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A280NotesDue2023Member_578ed790-20a5-4e29-84fd-44efdcd4be27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.40NotesDue2029Member_4e14d6a9-df8a-4980-bc4f-a1528896c044" xlink:href="mrk-20211231.xsd#mrk_A3.40NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A3.40NotesDue2029Member_4e14d6a9-df8a-4980-bc4f-a1528896c044" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member_04f99661-5e1a-436a-b967-db273281ac32" xlink:href="mrk-20211231.xsd#mrk_A170NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A170NotesDue2027Member_04f99661-5e1a-436a-b967-db273281ac32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member_48f376bd-0304-4b7a-a3eb-31372868c924" xlink:href="mrk-20211231.xsd#mrk_A290NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A290NotesDue2061Member_48f376bd-0304-4b7a-a3eb-31372868c924" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A4.00NotesDue2049Member_20e9a91b-ddbd-42f9-a0e5-85c7b16d2229" xlink:href="mrk-20211231.xsd#mrk_A4.00NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A4.00NotesDue2049Member_20e9a91b-ddbd-42f9-a0e5-85c7b16d2229" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A415NotesDue2043Member_0fc97eb8-c8fe-444e-88e3-1c0fe07b6622" xlink:href="mrk-20211231.xsd#mrk_A415NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A415NotesDue2043Member_0fc97eb8-c8fe-444e-88e3-1c0fe07b6622" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A145NotesDue2030Member_f4dbae18-ce0b-418f-8645-c7cfc80ec2b3" xlink:href="mrk-20211231.xsd#mrk_A145NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A145NotesDue2030Member_f4dbae18-ce0b-418f-8645-c7cfc80ec2b3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A245NotesDue2050Member_9d509aa4-170c-4ee2-86fa-73ea9cfc39b9" xlink:href="mrk-20211231.xsd#mrk_A245NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A245NotesDue2050Member_9d509aa4-170c-4ee2-86fa-73ea9cfc39b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875EuroNotesDue2026Member_d027cf27-e09f-4dbf-8969-bd174cd9bf97" xlink:href="mrk-20211231.xsd#mrk_A1.875EuroNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A1.875EuroNotesDue2026Member_d027cf27-e09f-4dbf-8969-bd174cd9bf97" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member_68725a6f-7633-4baa-8257-98195ff6eee1" xlink:href="mrk-20211231.xsd#mrk_A190NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A190NotesDue2028Member_68725a6f-7633-4baa-8257-98195ff6eee1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A075NotesDue2026Member_9d1abb75-2c10-406d-aeb9-eaef1ad1f82f" xlink:href="mrk-20211231.xsd#mrk_A075NotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A075NotesDue2026Member_9d1abb75-2c10-406d-aeb9-eaef1ad1f82f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.90NotesDue2039Member_a5973877-b520-4758-91be-2457549b8c00" xlink:href="mrk-20211231.xsd#mrk_A3.90NotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A3.90NotesDue2039Member_a5973877-b520-4758-91be-2457549b8c00" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A235NotesDue2040Member_947ebfc0-0b60-46f4-9501-c71c3d57b551" xlink:href="mrk-20211231.xsd#mrk_A235NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A235NotesDue2040Member_947ebfc0-0b60-46f4-9501-c71c3d57b551" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.90NotesDue2024Member_d801ccca-c4b7-42d7-8a55-7e44ca626e16" xlink:href="mrk-20211231.xsd#mrk_A2.90NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.90NotesDue2024Member_d801ccca-c4b7-42d7-8a55-7e44ca626e16" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_6337ac6d-5bbf-4bde-a359-8c9b24b79e2f" xlink:href="mrk-20211231.xsd#mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_6337ac6d-5bbf-4bde-a359-8c9b24b79e2f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.50eurodenominatednotesdue2024Member_2a9dc87c-818a-4dbd-9dfc-180643a2fe77" xlink:href="mrk-20211231.xsd#mrk_A0.50eurodenominatednotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A0.50eurodenominatednotesdue2024Member_2a9dc87c-818a-4dbd-9dfc-180643a2fe77" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375eurodenominatednotesdue2036Member_d1a813ed-75ef-4563-bf60-958eb6da4ee4" xlink:href="mrk-20211231.xsd#mrk_A1.375eurodenominatednotesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A1.375eurodenominatednotesdue2036Member_d1a813ed-75ef-4563-bf60-958eb6da4ee4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.5EuroNotesDue2034Member_b2323629-0b3e-4776-a1d1-d959f6ea74ed" xlink:href="mrk-20211231.xsd#mrk_A2.5EuroNotesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.5EuroNotesDue2034Member_b2323629-0b3e-4776-a1d1-d959f6ea74ed" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_7703a31a-9a9e-4dec-9e82-0d919a4b0549" xlink:href="mrk-20211231.xsd#mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_7703a31a-9a9e-4dec-9e82-0d919a4b0549" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_474f44cc-080c-4b4c-8ee0-0eb409929c05" xlink:href="mrk-20211231.xsd#mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_474f44cc-080c-4b4c-8ee0-0eb409929c05" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_4d4b0248-888f-4f57-9756-e7d81f9d9bc5" xlink:href="mrk-20211231.xsd#mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_4d4b0248-888f-4f57-9756-e7d81f9d9bc5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_e759f6a8-1c3f-4b43-b350-d419cc0da2b2" xlink:href="mrk-20211231.xsd#mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_e759f6a8-1c3f-4b43-b350-d419cc0da2b2" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_7eef6a20-5686-46f4-b4a7-04cb473696f9" xlink:href="mrk-20211231.xsd#mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_7eef6a20-5686-46f4-b4a7-04cb473696f9" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_d453ec36-206f-42fb-9ee1-f38970d8bf01" xlink:href="mrk-20211231.xsd#mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_d453ec36-206f-42fb-9ee1-f38970d8bf01" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member_fd19b664-285a-47a7-a856-400c396dea7c" xlink:href="mrk-20211231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A63DebenturesDue2026Member_fd19b664-285a-47a7-a856-400c396dea7c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_d0424a15-b7a4-49d5-9137-2f6a1896840f" xlink:href="mrk-20211231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.35NotesDue2022Member_d0424a15-b7a4-49d5-9137-2f6a1896840f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_8314880c-f30f-46f5-8153-90a09452cc84" xlink:href="mrk-20211231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.40NotesDue2022Member_8314880c-f30f-46f5-8153-90a09452cc84" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherLongTermDebtMember_a5d46610-e54f-4f19-bfcc-1881b49f4965" xlink:href="mrk-20211231.xsd#mrk_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_OtherLongTermDebtMember_a5d46610-e54f-4f19-bfcc-1881b49f4965" xlink:type="arc" order="31"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#ContingenciesandEnvironmentalLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" xlink:type="extended" id="ieb704d83aab54b879bc7daf8dd83118c_ContingenciesandEnvironmentalLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_d7adc971-a9d7-41b6-b79d-839d62d92e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_d7adc971-a9d7-41b6-b79d-839d62d92e22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_b0190c01-c8e5-4fc4-843c-c4fc9e7d7a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_b0190c01-c8e5-4fc4-843c-c4fc9e7d7a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber_a75e74b3-b10b-45b4-b2f8-47fdcd616042" xlink:href="mrk-20211231.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_mrk_LossContingencyClaimsonAppealNumber_a75e74b3-b10b-45b4-b2f8-47fdcd616042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ae0a6828-b066-48d4-bea5-e90c3270a780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ae0a6828-b066-48d4-bea5-e90c3270a780" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_82bff538-6536-4a5c-81ee-d1883166846d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_82bff538-6536-4a5c-81ee-d1883166846d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_c1298db1-6dfd-4e8f-a194-a7701433715e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LitigationReserve_c1298db1-6dfd-4e8f-a194-a7701433715e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies_e4808a98-9eb4-4215-900b-e36e9f4797da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForEnvironmentalLossContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_AccrualForEnvironmentalLossContingencies_e4808a98-9eb4-4215-900b-e36e9f4797da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TermForPayingOffEnvironmentalLiabilities_613a6ded-c195-4ac4-bfce-eacc624ad0b0" xlink:href="mrk-20211231.xsd#mrk_TermForPayingOffEnvironmentalLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_mrk_TermForPayingOffEnvironmentalLiabilities_613a6ded-c195-4ac4-bfce-eacc624ad0b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_4402b90a-24b9-4cab-9b49-074f5c7e26db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_4402b90a-24b9-4cab-9b49-074f5c7e26db" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c95e018-ba59-4972-a327-f7e99a3236ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:to="loc_srt_ProductOrServiceAxis_3c95e018-ba59-4972-a327-f7e99a3236ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c95e018-ba59-4972-a327-f7e99a3236ae_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3c95e018-ba59-4972-a327-f7e99a3236ae" xlink:to="loc_srt_ProductsAndServicesDomain_3c95e018-ba59-4972-a327-f7e99a3236ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3d78cfe6-e08e-4cc9-a5d8-73c0878cd237" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3c95e018-ba59-4972-a327-f7e99a3236ae" xlink:to="loc_srt_ProductsAndServicesDomain_3d78cfe6-e08e-4cc9-a5d8-73c0878cd237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember_d3923d72-615b-4a94-9a96-3b72b7adbedd" xlink:href="mrk-20211231.xsd#mrk_FosamaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3d78cfe6-e08e-4cc9-a5d8-73c0878cd237" xlink:to="loc_mrk_FosamaxMember_d3923d72-615b-4a94-9a96-3b72b7adbedd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_b4137915-4cec-4da4-83cb-3cad72522b99" xlink:href="mrk-20211231.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3d78cfe6-e08e-4cc9-a5d8-73c0878cd237" xlink:to="loc_mrk_JanuviaMember_b4137915-4cec-4da4-83cb-3cad72522b99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a972bfff-fbfb-4306-a3cc-c91ae6e6236f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:to="loc_srt_LitigationCaseAxis_a972bfff-fbfb-4306-a3cc-c91ae6e6236f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a972bfff-fbfb-4306-a3cc-c91ae6e6236f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a972bfff-fbfb-4306-a3cc-c91ae6e6236f" xlink:to="loc_srt_LitigationCaseTypeDomain_a972bfff-fbfb-4306-a3cc-c91ae6e6236f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6c0681e5-6a19-408e-8eb9-2544551568c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a972bfff-fbfb-4306-a3cc-c91ae6e6236f" xlink:to="loc_srt_LitigationCaseTypeDomain_6c0681e5-6a19-408e-8eb9-2544551568c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember_a0eb0d0b-115e-490f-a366-03ae86d1b89b" xlink:href="mrk-20211231.xsd#mrk_FederalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6c0681e5-6a19-408e-8eb9-2544551568c0" xlink:to="loc_mrk_FederalMember_a0eb0d0b-115e-490f-a366-03ae86d1b89b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherStateCourtMember_e4951a00-6077-4dbe-972f-7614eff3fa47" xlink:href="mrk-20211231.xsd#mrk_OtherStateCourtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6c0681e5-6a19-408e-8eb9-2544551568c0" xlink:to="loc_mrk_OtherStateCourtMember_e4951a00-6077-4dbe-972f-7614eff3fa47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_316dbb9d-b298-49cc-b2bd-b469b52111e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_316dbb9d-b298-49cc-b2bd-b469b52111e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_316dbb9d-b298-49cc-b2bd-b469b52111e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_316dbb9d-b298-49cc-b2bd-b469b52111e1" xlink:to="loc_us-gaap_LossContingencyNatureDomain_316dbb9d-b298-49cc-b2bd-b469b52111e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_316dbb9d-b298-49cc-b2bd-b469b52111e1" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_01c0ea0e-c6b2-488a-b87e-227c133a9bb7" xlink:href="mrk-20211231.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:to="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_01c0ea0e-c6b2-488a-b87e-227c133a9bb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialandOtherLitigationMember_9a6c547a-b37f-4600-97ce-7265d6a239f0" xlink:href="mrk-20211231.xsd#mrk_CommercialandOtherLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:to="loc_mrk_CommercialandOtherLitigationMember_9a6c547a-b37f-4600-97ce-7265d6a239f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember_77cfad88-b652-46f2-913b-18050e5bef1a" xlink:href="mrk-20211231.xsd#mrk_PatentlitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:to="loc_mrk_PatentlitigationMember_77cfad88-b652-46f2-913b-18050e5bef1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_bfe978ea-e261-41af-b4c7-d04f411f5a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_bfe978ea-e261-41af-b4c7-d04f411f5a78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_bfe978ea-e261-41af-b4c7-d04f411f5a78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_bfe978ea-e261-41af-b4c7-d04f411f5a78" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_bfe978ea-e261-41af-b4c7-d04f411f5a78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_44d689b8-3946-4399-b43f-211f650a61b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_bfe978ea-e261-41af-b4c7-d04f411f5a78" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_44d689b8-3946-4399-b43f-211f650a61b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_89ef080b-f657-4a20-b84a-64723fb3e1ab" xlink:href="mrk-20211231.xsd#mrk_LegalDefenseCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_44d689b8-3946-4399-b43f-211f650a61b9" xlink:to="loc_mrk_LegalDefenseCostsMember_89ef080b-f657-4a20-b84a-64723fb3e1ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#EquityShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="extended" id="i548a0a5c2dbd48d6a5c0dcd76f6692e1_EquityShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_efd29950-cbd2-48f6-87f3-1a8290e3c3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:href="mrk-20211231.xsd#mrk_MovementinCommonStockandTreasuryStockRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_efd29950-cbd2-48f6-87f3-1a8290e3c3c8" xlink:to="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_82d42fcf-7a32-4b4c-9d0e-3ab5c290fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:to="loc_us-gaap_CommonStockSharesIssued_82d42fcf-7a32-4b4c-9d0e-3ab5c290fc9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_218caaea-d3bb-4c61-bf95-a3ef6f2bb6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_218caaea-d3bb-4c61-bf95-a3ef6f2bb6af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_65b5c8e3-a7c2-45ad-8e06-fe40b0a81a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_65b5c8e3-a7c2-45ad-8e06-fe40b0a81a3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2e516700-f3a4-4da0-b28f-04724bfaa8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_664791a6-9f5c-47b1-a870-a91dcb24c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_efd29950-cbd2-48f6-87f3-1a8290e3c3c8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_664791a6-9f5c-47b1-a870-a91dcb24c79f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c154887e-eac8-41ed-b2ec-56a2a6b7ea77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_664791a6-9f5c-47b1-a870-a91dcb24c79f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c154887e-eac8-41ed-b2ec-56a2a6b7ea77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c154887e-eac8-41ed-b2ec-56a2a6b7ea77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c154887e-eac8-41ed-b2ec-56a2a6b7ea77" xlink:to="loc_us-gaap_EquityComponentDomain_c154887e-eac8-41ed-b2ec-56a2a6b7ea77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47d84557-96fa-4530-a122-f3c54b82e195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c154887e-eac8-41ed-b2ec-56a2a6b7ea77" xlink:to="loc_us-gaap_EquityComponentDomain_47d84557-96fa-4530-a122-f3c54b82e195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dd5cb4fd-3755-4c29-9f13-508440f3ab21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47d84557-96fa-4530-a122-f3c54b82e195" xlink:to="loc_us-gaap_CommonStockMember_dd5cb4fd-3755-4c29-9f13-508440f3ab21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_736ab481-75d1-40e7-98e1-ba0206f5b2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47d84557-96fa-4530-a122-f3c54b82e195" xlink:to="loc_us-gaap_TreasuryStockMember_736ab481-75d1-40e7-98e1-ba0206f5b2e2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended" id="i59cb0c111b99488e9bfa9ff2c6e9e2d2_ShareBasedCompensationPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1d23c3b4-d2ac-4924-a701-71c0f66e42f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1d23c3b4-d2ac-4924-a701-71c0f66e42f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5e1c0270-e30c-4c6e-83d4-dc453c7e38f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5e1c0270-e30c-4c6e-83d4-dc453c7e38f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_061c3b62-5ae4-4fe9-bc10-c77886512aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_061c3b62-5ae4-4fe9-bc10-c77886512aca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0a3a0aa4-9832-474d-afb5-6a1995b4104f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0a3a0aa4-9832-474d-afb5-6a1995b4104f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1f38bda8-ea5c-4e86-a3ea-b15d4116d9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1f38bda8-ea5c-4e86-a3ea-b15d4116d9a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c54563fe-5ed8-481c-8950-4062198896a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensation_c54563fe-5ed8-481c-8950-4062198896a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ca055c02-2ea1-4b06-8b29-4ad2b1b03942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ca055c02-2ea1-4b06-8b29-4ad2b1b03942" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5f9abb6f-65ea-4f36-843e-c4025a95b7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5f9abb6f-65ea-4f36-843e-c4025a95b7df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_768903b8-e795-4ef4-a047-001105464343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_768903b8-e795-4ef4-a047-001105464343" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24606a1a-f281-4801-9e41-5e919c836bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24606a1a-f281-4801-9e41-5e919c836bb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_418c45e5-3108-4c18-9a47-5e0aa287e06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_418c45e5-3108-4c18-9a47-5e0aa287e06c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb080a11-67a6-4a62-94ed-5a04953dc2e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_418c45e5-3108-4c18-9a47-5e0aa287e06c" xlink:to="loc_srt_RangeAxis_eb080a11-67a6-4a62-94ed-5a04953dc2e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb080a11-67a6-4a62-94ed-5a04953dc2e5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eb080a11-67a6-4a62-94ed-5a04953dc2e5" xlink:to="loc_srt_RangeMember_eb080a11-67a6-4a62-94ed-5a04953dc2e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c78831d-82af-4e6d-8dc8-33417a8f3788" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eb080a11-67a6-4a62-94ed-5a04953dc2e5" xlink:to="loc_srt_RangeMember_4c78831d-82af-4e6d-8dc8-33417a8f3788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a236be0b-2ad9-48fe-945f-238f5e6493f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4c78831d-82af-4e6d-8dc8-33417a8f3788" xlink:to="loc_srt_MinimumMember_a236be0b-2ad9-48fe-945f-238f5e6493f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ba257466-515f-4bf4-bdbb-277f22d9de38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4c78831d-82af-4e6d-8dc8-33417a8f3788" xlink:to="loc_srt_MaximumMember_ba257466-515f-4bf4-bdbb-277f22d9de38" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="extended" id="i55e7b7d7dd64448e9d1e2abe24f7bd70_ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9ff18790-f848-4a58-ac3a-900897e42bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9ff18790-f848-4a58-ac3a-900897e42bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ce38ea20-a131-42a6-927c-460ca72978d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ce38ea20-a131-42a6-927c-460ca72978d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1a77a54-7c45-4117-a752-3430eec9d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1a77a54-7c45-4117-a752-3430eec9d59e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f2b0894c-5448-475d-9a08-584022fd9d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f2b0894c-5448-475d-9a08-584022fd9d4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction_84b2a32b-7817-4e38-b401-0095e88c7845" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction_84b2a32b-7817-4e38-b401-0095e88c7845" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment_e50e0e14-6d2f-42c8-b9ef-0551d7da34b9" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment_e50e0e14-6d2f-42c8-b9ef-0551d7da34b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e91d5954-29e1-4c44-8568-badd6c6a0930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_d1e9333f-10a8-4352-bf4c-62d66ba73774" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_d1e9333f-10a8-4352-bf4c-62d66ba73774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8a39b51-cf4a-428a-9d9a-ab0020e81100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8a39b51-cf4a-428a-9d9a-ab0020e81100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d6990328-6999-45b0-93ab-b4da24fbe758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d6990328-6999-45b0-93ab-b4da24fbe758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3a12c850-8491-44d7-ae6b-c508c36f43b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3a12c850-8491-44d7-ae6b-c508c36f43b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_494e0e4f-fd60-4e53-8078-4b2b0bae86fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_494e0e4f-fd60-4e53-8078-4b2b0bae86fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_bfa617ac-9d7e-4135-addc-ff83f1b57413" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_bfa617ac-9d7e-4135-addc-ff83f1b57413" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_c52c005b-8016-4f8b-b03a-d71733e73442" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_c52c005b-8016-4f8b-b03a-d71733e73442" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_070c0dd0-5aaa-43c9-ba25-5ec94ad97319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_1e90e4a4-04fa-49b7-879d-e527960f35b1" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_1e90e4a4-04fa-49b7-879d-e527960f35b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9cc3ba4-6c1f-4761-86f1-04f1c03b0709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9cc3ba4-6c1f-4761-86f1-04f1c03b0709" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0db63366-d011-408a-bb9b-637bfb4a0b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9cc3ba4-6c1f-4761-86f1-04f1c03b0709" xlink:to="loc_us-gaap_AwardTypeAxis_0db63366-d011-408a-bb9b-637bfb4a0b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0db63366-d011-408a-bb9b-637bfb4a0b40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0db63366-d011-408a-bb9b-637bfb4a0b40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0db63366-d011-408a-bb9b-637bfb4a0b40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b04941bb-a650-4d45-a6b3-41e3f617e748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0db63366-d011-408a-bb9b-637bfb4a0b40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b04941bb-a650-4d45-a6b3-41e3f617e748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1d849aef-1ad7-4c49-ae7d-484b2dcf8655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b04941bb-a650-4d45-a6b3-41e3f617e748" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1d849aef-1ad7-4c49-ae7d-484b2dcf8655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1cd53633-f855-466a-8ff3-96e84c02ff6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b04941bb-a650-4d45-a6b3-41e3f617e748" xlink:to="loc_us-gaap_PerformanceSharesMember_1cd53633-f855-466a-8ff3-96e84c02ff6e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended" id="i3ce69fb4f40d4227941374e5cfc52fa1_PensionandOtherPostretirementBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_754f12d1-08d2-40b4-9566-a71b1bc8d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_754f12d1-08d2-40b4-9566-a71b1bc8d0de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1693d55b-e7ad-4d9d-95d7-73e79977a2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1693d55b-e7ad-4d9d-95d7-73e79977a2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_aba5d422-a215-4174-8b94-27fc05a966e3" xlink:href="mrk-20211231.xsd#mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_aba5d422-a215-4174-8b94-27fc05a966e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_7c3222e0-de66-496b-a582-34dd38905438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_7c3222e0-de66-496b-a582-34dd38905438" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_88b96c97-3f02-4eea-8bd4-ca39a913fc0c" xlink:href="mrk-20211231.xsd#mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_88b96c97-3f02-4eea-8bd4-ca39a913fc0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_b274e0ed-fadd-412d-b99b-820d1dbc292e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_b274e0ed-fadd-412d-b99b-820d1dbc292e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_984c81a2-0278-4787-a45c-5641ae82dc59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_984c81a2-0278-4787-a45c-5641ae82dc59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6bd4e6f3-6d23-444b-bc13-22bcd1eecd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6bd4e6f3-6d23-444b-bc13-22bcd1eecd88" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b02f1c33-7a4f-4933-9c33-8bed7bf8a30a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b02f1c33-7a4f-4933-9c33-8bed7bf8a30a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b02f1c33-7a4f-4933-9c33-8bed7bf8a30a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b02f1c33-7a4f-4933-9c33-8bed7bf8a30a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b02f1c33-7a4f-4933-9c33-8bed7bf8a30a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b3156859-b9df-42eb-914b-64d9ad5474a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b02f1c33-7a4f-4933-9c33-8bed7bf8a30a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b3156859-b9df-42eb-914b-64d9ad5474a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fe0bc28f-5b66-421a-9e9d-4a74ac9e3226" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b3156859-b9df-42eb-914b-64d9ad5474a6" xlink:to="loc_country_US_fe0bc28f-5b66-421a-9e9d-4a74ac9e3226" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f6044966-7119-4822-a2ca-c366445df685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b3156859-b9df-42eb-914b-64d9ad5474a6" xlink:to="loc_us-gaap_ForeignPlanMember_f6044966-7119-4822-a2ca-c366445df685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_48116b4d-f084-4358-be27-7214161292e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_48116b4d-f084-4358-be27-7214161292e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_48116b4d-f084-4358-be27-7214161292e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_48116b4d-f084-4358-be27-7214161292e0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_48116b4d-f084-4358-be27-7214161292e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_80ef40b6-35f7-4dd6-a03a-3c7a405a7705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_48116b4d-f084-4358-be27-7214161292e0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_80ef40b6-35f7-4dd6-a03a-3c7a405a7705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_35b9686f-27b1-409c-a8cf-854e5e96bb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_80ef40b6-35f7-4dd6-a03a-3c7a405a7705" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_35b9686f-27b1-409c-a8cf-854e5e96bb36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f21e23da-9da4-441b-b58a-49ed922d8db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_80ef40b6-35f7-4dd6-a03a-3c7a405a7705" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f21e23da-9da4-441b-b58a-49ed922d8db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_458a3a36-cbce-4456-a0c0-c86ef68f2d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_458a3a36-cbce-4456-a0c0-c86ef68f2d2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_458a3a36-cbce-4456-a0c0-c86ef68f2d2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_458a3a36-cbce-4456-a0c0-c86ef68f2d2f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_458a3a36-cbce-4456-a0c0-c86ef68f2d2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182829cb-a907-4123-a796-61c3ac652b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_458a3a36-cbce-4456-a0c0-c86ef68f2d2f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182829cb-a907-4123-a796-61c3ac652b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cff33f5d-57a5-44fe-a92f-196d501e0591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182829cb-a907-4123-a796-61c3ac652b68" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cff33f5d-57a5-44fe-a92f-196d501e0591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8bc2d37b-7992-4162-9087-5b33ae6ad955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8bc2d37b-7992-4162-9087-5b33ae6ad955" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8bc2d37b-7992-4162-9087-5b33ae6ad955_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8bc2d37b-7992-4162-9087-5b33ae6ad955" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8bc2d37b-7992-4162-9087-5b33ae6ad955_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8bc2d37b-7992-4162-9087-5b33ae6ad955" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_aa25394f-1e64-4700-ae76-8780d44a760d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_aa25394f-1e64-4700-ae76-8780d44a760d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_3fabe55f-9e48-4913-9a36-142ae8fa0674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_3fabe55f-9e48-4913-9a36-142ae8fa0674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeInvestmentsMember_8b875754-02e2-41e3-afdf-705e1f96ae36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:to="loc_us-gaap_FixedIncomeInvestmentsMember_8b875754-02e2-41e3-afdf-705e1f96ae36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_bb83006c-4a9a-4dd6-9484-9e2165ebf78b" xlink:href="mrk-20211231.xsd#mrk_DefinedBenefitPlanCashandOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:to="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_bb83006c-4a9a-4dd6-9484-9e2165ebf78b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17110b00-98c6-4902-9fa9-64ec5992eb8e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_srt_RangeAxis_17110b00-98c6-4902-9fa9-64ec5992eb8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17110b00-98c6-4902-9fa9-64ec5992eb8e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17110b00-98c6-4902-9fa9-64ec5992eb8e" xlink:to="loc_srt_RangeMember_17110b00-98c6-4902-9fa9-64ec5992eb8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57f682eb-ae49-4ce6-a91b-d81b1eecaba9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17110b00-98c6-4902-9fa9-64ec5992eb8e" xlink:to="loc_srt_RangeMember_57f682eb-ae49-4ce6-a91b-d81b1eecaba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fd7dd0bc-4e98-4935-bb5d-ccbdb12cb303" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57f682eb-ae49-4ce6-a91b-d81b1eecaba9" xlink:to="loc_srt_MinimumMember_fd7dd0bc-4e98-4935-bb5d-ccbdb12cb303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_541f030b-74d9-4325-8212-47207c0fd5fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57f682eb-ae49-4ce6-a91b-d81b1eecaba9" xlink:to="loc_srt_MaximumMember_541f030b-74d9-4325-8212-47207c0fd5fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7da0755d-7241-46ac-b348-187c2597de0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_srt_StatementScenarioAxis_7da0755d-7241-46ac-b348-187c2597de0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7da0755d-7241-46ac-b348-187c2597de0e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7da0755d-7241-46ac-b348-187c2597de0e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7da0755d-7241-46ac-b348-187c2597de0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_687f37b0-af67-423d-90fe-68feda1f1f6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7da0755d-7241-46ac-b348-187c2597de0e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_687f37b0-af67-423d-90fe-68feda1f1f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0bcfe42d-3419-4d62-88d1-0abac6bdeb16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_687f37b0-af67-423d-90fe-68feda1f1f6d" xlink:to="loc_srt_ScenarioForecastMember_0bcfe42d-3419-4d62-88d1-0abac6bdeb16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i41cb80389f154bb696c2fb8819eb68bc_PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_c14a51da-b7fb-4e82-bfcd-121a7bf1e268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_c14a51da-b7fb-4e82-bfcd-121a7bf1e268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_175a2364-3b93-43be-8a8a-a951924a650a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_175a2364-3b93-43be-8a8a-a951924a650a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_398e26ff-c1b1-49fe-84ea-5e8167d8a7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_398e26ff-c1b1-49fe-84ea-5e8167d8a7ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_895abffa-74f5-4a5d-acf9-c44fb9918bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_895abffa-74f5-4a5d-acf9-c44fb9918bba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7aff1387-e872-40ae-8763-0d1246b114a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7aff1387-e872-40ae-8763-0d1246b114a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_fc70fcca-a490-4875-bc57-35d14534095a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_fc70fcca-a490-4875-bc57-35d14534095a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_3c3faa32-88e0-4cdf-8bcb-b8f23f5e5f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_3c3faa32-88e0-4cdf-8bcb-b8f23f5e5f19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_625857ec-c113-4946-9be7-4292e0ea7e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_625857ec-c113-4946-9be7-4292e0ea7e30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d5a1e663-fee5-44ba-bbd2-511d32f51e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d5a1e663-fee5-44ba-bbd2-511d32f51e6e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9e83f4d7-6655-49ff-a460-348de1822713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9e83f4d7-6655-49ff-a460-348de1822713" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_67129f32-17cf-4537-b363-b9ae728a3e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9e83f4d7-6655-49ff-a460-348de1822713" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_67129f32-17cf-4537-b363-b9ae728a3e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_67129f32-17cf-4537-b363-b9ae728a3e33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_67129f32-17cf-4537-b363-b9ae728a3e33" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_67129f32-17cf-4537-b363-b9ae728a3e33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6d160a2e-23b3-4fa0-9a6f-868526d2bad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_67129f32-17cf-4537-b363-b9ae728a3e33" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6d160a2e-23b3-4fa0-9a6f-868526d2bad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0918d2e5-083c-4011-ae14-c82fb109db75" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6d160a2e-23b3-4fa0-9a6f-868526d2bad2" xlink:to="loc_country_US_0918d2e5-083c-4011-ae14-c82fb109db75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_20df7889-530e-4f97-b059-e674f5e0a26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6d160a2e-23b3-4fa0-9a6f-868526d2bad2" xlink:to="loc_us-gaap_ForeignPlanMember_20df7889-530e-4f97-b059-e674f5e0a26e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8445afd3-100e-4892-9d30-7505c555093d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9e83f4d7-6655-49ff-a460-348de1822713" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8445afd3-100e-4892-9d30-7505c555093d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8445afd3-100e-4892-9d30-7505c555093d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8445afd3-100e-4892-9d30-7505c555093d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8445afd3-100e-4892-9d30-7505c555093d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0e22947a-8d2b-4360-8aef-b55a83096419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8445afd3-100e-4892-9d30-7505c555093d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0e22947a-8d2b-4360-8aef-b55a83096419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_32402bc3-5977-46e6-b487-62724a30dd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0e22947a-8d2b-4360-8aef-b55a83096419" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_32402bc3-5977-46e6-b487-62724a30dd70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_547a8ba9-1f57-4eec-a157-0b66102817d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0e22947a-8d2b-4360-8aef-b55a83096419" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_547a8ba9-1f57-4eec-a157-0b66102817d0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="extended" id="ib355ff7bd1414897b75bf8d0f13251e0_PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2a10af77-7701-4f10-8676-6ee61800d558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2a10af77-7701-4f10-8676-6ee61800d558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_ba4750ed-7ddb-47b3-82a3-7617d3f2a9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_ba4750ed-7ddb-47b3-82a3-7617d3f2a9e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_74468598-07e4-4cee-ade2-c331bb9975f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_74468598-07e4-4cee-ade2-c331bb9975f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_1073ee4d-2bec-4c1f-869c-4502ffa1cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_1073ee4d-2bec-4c1f-869c-4502ffa1cd4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_9135895f-3caf-4e2a-aef2-b10171dfab99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_9135895f-3caf-4e2a-aef2-b10171dfab99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_190f669b-824d-47e1-ac7b-6a3125a59090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_190f669b-824d-47e1-ac7b-6a3125a59090" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_02582ee2-085e-4e7e-a7fa-c8ef61605b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_02582ee2-085e-4e7e-a7fa-c8ef61605b3b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_d46454fd-3f0b-4f13-85be-b8096a288e50" xlink:href="mrk-20211231.xsd#mrk_DefinedBenefitPlanOtherChangesPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_d46454fd-3f0b-4f13-85be-b8096a288e50" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e873bf9b-d150-4d2c-a270-3c78b10309f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ede18b47-1ebc-4bf7-b081-41724de7fb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ede18b47-1ebc-4bf7-b081-41724de7fb1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_e8126e31-9b6b-4751-8538-9accaa0c651b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_e8126e31-9b6b-4751-8538-9accaa0c651b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_0c6f18b2-655a-414f-80ab-6a510df9edf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_0c6f18b2-655a-414f-80ab-6a510df9edf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4c521a2e-d983-4b4c-99d3-cada94ffcc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4c521a2e-d983-4b4c-99d3-cada94ffcc1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_f2f298f7-bdb2-4e59-a056-7edeeeeb38aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_f2f298f7-bdb2-4e59-a056-7edeeeeb38aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4a698e72-639e-4559-9b07-bccf71e0f267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4a698e72-639e-4559-9b07-bccf71e0f267" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_a7bd3623-5645-4666-9937-b477ea56b105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_a7bd3623-5645-4666-9937-b477ea56b105" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_47c03ce2-5988-49b6-8168-e3967487015f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_47c03ce2-5988-49b6-8168-e3967487015f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_61aebb73-8ea9-44cb-89be-3bcc354e424a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_61aebb73-8ea9-44cb-89be-3bcc354e424a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_352d06f3-e093-47f8-a8ae-6d6f9357ff6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_352d06f3-e093-47f8-a8ae-6d6f9357ff6a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_f665c650-994e-4ef6-8c44-7189d625c669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_f665c650-994e-4ef6-8c44-7189d625c669" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherChanges_3a9baf5b-a120-4b05-92e5-383dd12d8b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherChanges_3a9baf5b-a120-4b05-92e5-383dd12d8b43" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_01ef78f3-45f4-4566-9763-ac6a7b90b31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_84926df1-081b-4fdd-be99-8926d8a849fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_84926df1-081b-4fdd-be99-8926d8a849fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_a77156e1-4002-4d20-bc58-8533ebf73fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_a77156e1-4002-4d20-bc58-8533ebf73fe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ae1e7d98-6285-4abe-a168-4e13b3d5b2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ae1e7d98-6285-4abe-a168-4e13b3d5b2ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3234b17c-cabb-44d2-a55a-dc348d8b24b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3234b17c-cabb-44d2-a55a-dc348d8b24b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7285fe46-645f-4738-b663-efa77fc86d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7285fe46-645f-4738-b663-efa77fc86d90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_45372be6-44f9-45ac-a452-3156db6493ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7285fe46-645f-4738-b663-efa77fc86d90" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_45372be6-44f9-45ac-a452-3156db6493ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_45372be6-44f9-45ac-a452-3156db6493ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_45372be6-44f9-45ac-a452-3156db6493ed" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_45372be6-44f9-45ac-a452-3156db6493ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_17a66500-3289-4ac8-b29e-0731efd22bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_45372be6-44f9-45ac-a452-3156db6493ed" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_17a66500-3289-4ac8-b29e-0731efd22bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f50bfeff-1276-4d64-9144-31dba3b38659" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_17a66500-3289-4ac8-b29e-0731efd22bd0" xlink:to="loc_country_US_f50bfeff-1276-4d64-9144-31dba3b38659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_bf6ee325-8602-4ee5-a51d-920928a4cf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_17a66500-3289-4ac8-b29e-0731efd22bd0" xlink:to="loc_us-gaap_ForeignPlanMember_bf6ee325-8602-4ee5-a51d-920928a4cf64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cff144ed-8346-49f3-898b-f75c32bed7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7285fe46-645f-4738-b663-efa77fc86d90" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cff144ed-8346-49f3-898b-f75c32bed7ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cff144ed-8346-49f3-898b-f75c32bed7ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cff144ed-8346-49f3-898b-f75c32bed7ad" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cff144ed-8346-49f3-898b-f75c32bed7ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1928c416-a68e-45e4-8dba-fae831df54e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cff144ed-8346-49f3-898b-f75c32bed7ad" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1928c416-a68e-45e4-8dba-fae831df54e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2c1ec579-209e-42d6-8f34-56e3aa6a598a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1928c416-a68e-45e4-8dba-fae831df54e0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2c1ec579-209e-42d6-8f34-56e3aa6a598a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_298e992a-9873-46b2-9409-b8abb8b447c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1928c416-a68e-45e4-8dba-fae831df54e0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_298e992a-9873-46b2-9409-b8abb8b447c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="extended" id="ia0a950fe46fe431e944db785defe51b5_PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_59fa8904-18eb-4786-80fc-40ef2d70e2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_59fa8904-18eb-4786-80fc-40ef2d70e2c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_a24e8d5c-3ac0-4adf-8109-b474ad5d1211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_a24e8d5c-3ac0-4adf-8109-b474ad5d1211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_4f67c0bb-f7ff-4ffb-be2c-6d99b337f6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_4f67c0bb-f7ff-4ffb-be2c-6d99b337f6c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_7ab60a30-ebab-4581-8161-41e31e6b175a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_7ab60a30-ebab-4581-8161-41e31e6b175a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_9fd93d12-f02e-41ab-a857-41e9644047df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_9fd93d12-f02e-41ab-a857-41e9644047df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_aecedd40-9487-44d8-827e-5dfa9153bfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_9fd93d12-f02e-41ab-a857-41e9644047df" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_aecedd40-9487-44d8-827e-5dfa9153bfdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_aecedd40-9487-44d8-827e-5dfa9153bfdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_aecedd40-9487-44d8-827e-5dfa9153bfdb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_aecedd40-9487-44d8-827e-5dfa9153bfdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5a3cd0b2-5c8a-4dba-87db-0a59fe5b51e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_aecedd40-9487-44d8-827e-5dfa9153bfdb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5a3cd0b2-5c8a-4dba-87db-0a59fe5b51e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4d87c011-8746-42b8-b438-a63434f22c67" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5a3cd0b2-5c8a-4dba-87db-0a59fe5b51e5" xlink:to="loc_country_US_4d87c011-8746-42b8-b438-a63434f22c67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9e7331fb-268c-46c5-96ce-2e9525499f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5a3cd0b2-5c8a-4dba-87db-0a59fe5b51e5" xlink:to="loc_us-gaap_ForeignPlanMember_9e7331fb-268c-46c5-96ce-2e9525499f4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_623413b7-547a-4e3f-b711-d1e91bc382f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_9fd93d12-f02e-41ab-a857-41e9644047df" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_623413b7-547a-4e3f-b711-d1e91bc382f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_623413b7-547a-4e3f-b711-d1e91bc382f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_623413b7-547a-4e3f-b711-d1e91bc382f1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_623413b7-547a-4e3f-b711-d1e91bc382f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ea7f6e37-ae87-4060-a8b1-44ac329e51f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_623413b7-547a-4e3f-b711-d1e91bc382f1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ea7f6e37-ae87-4060-a8b1-44ac329e51f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_289020eb-635c-48a0-b757-1ec8eb9061e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ea7f6e37-ae87-4060-a8b1-44ac329e51f1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_289020eb-635c-48a0-b757-1ec8eb9061e3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="extended" id="ib7016ed14f094c80be268c6c4f40d806_PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eae039ed-ce7e-4889-8135-aff9178dcaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b7a5644c-e1bb-4653-a27c-5e58d423ed35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eae039ed-ce7e-4889-8135-aff9178dcaf7" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b7a5644c-e1bb-4653-a27c-5e58d423ed35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eae039ed-ce7e-4889-8135-aff9178dcaf7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_9c8b5aee-e28f-4c89-aa60-dd992e1f2672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_9c8b5aee-e28f-4c89-aa60-dd992e1f2672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c8b5aee-e28f-4c89-aa60-dd992e1f2672_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_9c8b5aee-e28f-4c89-aa60-dd992e1f2672" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c8b5aee-e28f-4c89-aa60-dd992e1f2672_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_4540510f-170f-46b3-b980-f8861b4b935e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_9c8b5aee-e28f-4c89-aa60-dd992e1f2672" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_4540510f-170f-46b3-b980-f8861b4b935e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ac6c2cd9-df60-4e55-8ef9-becf52646371" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_4540510f-170f-46b3-b980-f8861b4b935e" xlink:to="loc_country_US_ac6c2cd9-df60-4e55-8ef9-becf52646371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e52c4883-5adb-4b69-8304-fbc063ad1309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_4540510f-170f-46b3-b980-f8861b4b935e" xlink:to="loc_us-gaap_ForeignPlanMember_e52c4883-5adb-4b69-8304-fbc063ad1309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_d7f06573-abab-48bb-9883-8c35c8fe9e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_d7f06573-abab-48bb-9883-8c35c8fe9e3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d7f06573-abab-48bb-9883-8c35c8fe9e3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d7f06573-abab-48bb-9883-8c35c8fe9e3e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d7f06573-abab-48bb-9883-8c35c8fe9e3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8aada899-d6a6-4b5b-9922-0c8f474beed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d7f06573-abab-48bb-9883-8c35c8fe9e3e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8aada899-d6a6-4b5b-9922-0c8f474beed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c529537b-51f1-49a0-9605-c2892a07980b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8aada899-d6a6-4b5b-9922-0c8f474beed9" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c529537b-51f1-49a0-9605-c2892a07980b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5be642ea-0a38-44c9-81e9-d9884ab6d70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5be642ea-0a38-44c9-81e9-d9884ab6d70f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be642ea-0a38-44c9-81e9-d9884ab6d70f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5be642ea-0a38-44c9-81e9-d9884ab6d70f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5be642ea-0a38-44c9-81e9-d9884ab6d70f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5be642ea-0a38-44c9-81e9-d9884ab6d70f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0d01e61a-4be3-48bf-a408-4cb1fae428b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0d01e61a-4be3-48bf-a408-4cb1fae428b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_73ded400-8ca2-449e-ae81-6873f51b5462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_73ded400-8ca2-449e-ae81-6873f51b5462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_299d75f4-6e0f-4079-8558-87165257ab80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_299d75f4-6e0f-4079-8558-87165257ab80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d1330d37-39de-4360-abee-5a00ec99368f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d1330d37-39de-4360-abee-5a00ec99368f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_48ab9264-92a4-48df-9dfd-203fd8bb04eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_48ab9264-92a4-48df-9dfd-203fd8bb04eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_48ab9264-92a4-48df-9dfd-203fd8bb04eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_48ab9264-92a4-48df-9dfd-203fd8bb04eb" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_48ab9264-92a4-48df-9dfd-203fd8bb04eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_48ab9264-92a4-48df-9dfd-203fd8bb04eb" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_07992da9-bed0-40ba-92dd-e26e4c44e118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_07992da9-bed0-40ba-92dd-e26e4c44e118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_82f1b020-d252-4378-9134-1da563e82ae7" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_82f1b020-d252-4378-9134-1da563e82ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_1634e655-a8b5-4ec6-8849-62be95ec3eb3" xlink:href="mrk-20211231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_1634e655-a8b5-4ec6-8849-62be95ec3eb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_7100adf7-cd24-4178-bd31-7818941eacdc" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_7100adf7-cd24-4178-bd31-7818941eacdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_2e63ac74-0c9f-448b-b410-5ee1813d18e4" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_2e63ac74-0c9f-448b-b410-5ee1813d18e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember_17c567e9-5507-4287-8830-5c1136bdccf3" xlink:href="mrk-20211231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_CorporateObligationsInvestmentFundsMember_17c567e9-5507-4287-8830-5c1136bdccf3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_45a14fcb-45f3-49ea-a75d-e8f043157346" xlink:href="mrk-20211231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_45a14fcb-45f3-49ea-a75d-e8f043157346" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_a3161f4d-0afe-4567-873d-3a07dd1aef4d" xlink:href="mrk-20211231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_a3161f4d-0afe-4567-873d-3a07dd1aef4d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_8baa0dbc-2731-47ec-9aee-dac59a648e27" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_8baa0dbc-2731-47ec-9aee-dac59a648e27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_4419e604-a3da-4a38-b00b-787a4b02314b" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_4419e604-a3da-4a38-b00b-787a4b02314b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_0147ed09-1a39-4cdc-8ff5-28ed49c855fa" xlink:href="mrk-20211231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_0147ed09-1a39-4cdc-8ff5-28ed49c855fa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_8a69ea3c-29ab-453b-9ad9-5d1cb50b34a0" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_8a69ea3c-29ab-453b-9ad9-5d1cb50b34a0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_c341c353-3128-4113-8014-c3bb4db5c98f" xlink:href="mrk-20211231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_c341c353-3128-4113-8014-c3bb4db5c98f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_b5451152-75e3-47fb-b1b9-80becce32d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_us-gaap_OtherInvestmentsMember_b5451152-75e3-47fb-b1b9-80becce32d67" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="extended" id="i901823dd935c45ec97a4fb15d22e642a_PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8591dfe7-0d18-4acd-8a94-2b2281825d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8591dfe7-0d18-4acd-8a94-2b2281825d06" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_159a2fdc-4c93-49e0-95f4-3e5fd9f7fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_159a2fdc-4c93-49e0-95f4-3e5fd9f7fc6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_cedb7173-0e21-4cbe-9002-ed7d13b54712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_cedb7173-0e21-4cbe-9002-ed7d13b54712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_f555893c-e486-4d68-9ec8-ef86db7ca2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_cedb7173-0e21-4cbe-9002-ed7d13b54712" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_f555893c-e486-4d68-9ec8-ef86db7ca2db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_2d1410eb-ee9d-44ed-9366-c38e323b5871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_cedb7173-0e21-4cbe-9002-ed7d13b54712" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_2d1410eb-ee9d-44ed-9366-c38e323b5871" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_37bf3cd8-230b-4b75-b4e8-fcf66fc1f8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_37bf3cd8-230b-4b75-b4e8-fcf66fc1f8c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_f5af0b1e-a826-43d0-a945-2710fbe7ac25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_f5af0b1e-a826-43d0-a945-2710fbe7ac25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7312d52b-eace-49f3-b263-cfb11b0ea236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8591dfe7-0d18-4acd-8a94-2b2281825d06" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_439aa0a7-466f-4720-93cd-52813d031d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_439aa0a7-466f-4720-93cd-52813d031d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_439aa0a7-466f-4720-93cd-52813d031d37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_439aa0a7-466f-4720-93cd-52813d031d37" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_439aa0a7-466f-4720-93cd-52813d031d37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9408670b-7211-45f0-a139-6c0917a72da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_439aa0a7-466f-4720-93cd-52813d031d37" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9408670b-7211-45f0-a139-6c0917a72da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7848ba85-6f6c-40b2-b96f-6c2366101bc1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9408670b-7211-45f0-a139-6c0917a72da7" xlink:to="loc_country_US_7848ba85-6f6c-40b2-b96f-6c2366101bc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8463ca46-1dc0-4bbf-a6ac-763413330817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9408670b-7211-45f0-a139-6c0917a72da7" xlink:to="loc_us-gaap_ForeignPlanMember_8463ca46-1dc0-4bbf-a6ac-763413330817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bb25ab7a-84d1-4402-878e-72cf91691904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bb25ab7a-84d1-4402-878e-72cf91691904" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bb25ab7a-84d1-4402-878e-72cf91691904_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bb25ab7a-84d1-4402-878e-72cf91691904" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bb25ab7a-84d1-4402-878e-72cf91691904_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_29676cb1-33d3-412f-a5c9-32280cf9e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bb25ab7a-84d1-4402-878e-72cf91691904" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_29676cb1-33d3-412f-a5c9-32280cf9e6fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5a118fec-6aa2-4ffc-b79e-ddb0c3aa2b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_29676cb1-33d3-412f-a5c9-32280cf9e6fe" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5a118fec-6aa2-4ffc-b79e-ddb0c3aa2b45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bd802a26-a5a9-4bd0-ac9e-6c9d82bdfbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bd802a26-a5a9-4bd0-ac9e-6c9d82bdfbf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bd802a26-a5a9-4bd0-ac9e-6c9d82bdfbf8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bd802a26-a5a9-4bd0-ac9e-6c9d82bdfbf8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bd802a26-a5a9-4bd0-ac9e-6c9d82bdfbf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3ab92276-09c3-48f6-8c87-303140b0cf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bd802a26-a5a9-4bd0-ac9e-6c9d82bdfbf8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3ab92276-09c3-48f6-8c87-303140b0cf5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e35a9027-2666-459b-9142-73d93e305dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3ab92276-09c3-48f6-8c87-303140b0cf5a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e35a9027-2666-459b-9142-73d93e305dff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_37f256fd-e12e-43c5-8794-69c8f1e6b049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_37f256fd-e12e-43c5-8794-69c8f1e6b049" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_37f256fd-e12e-43c5-8794-69c8f1e6b049_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_37f256fd-e12e-43c5-8794-69c8f1e6b049" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_37f256fd-e12e-43c5-8794-69c8f1e6b049_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_37f256fd-e12e-43c5-8794-69c8f1e6b049" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_edfedc0b-0024-494e-b5e3-16f74676d0b5" xlink:href="mrk-20211231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_edfedc0b-0024-494e-b5e3-16f74676d0b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_ddaa6268-edc9-45f6-b9a3-4e02797da8d6" xlink:href="mrk-20211231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_ddaa6268-edc9-45f6-b9a3-4e02797da8d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_1b349de8-c363-437d-b8a7-e46d3492e402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:to="loc_us-gaap_OtherInvestmentsMember_1b349de8-c363-437d-b8a7-e46d3492e402" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="extended" id="i7e57020ce147475381162e56ace85de0_PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dd3655b6-bff8-4e89-a179-4993c0b40fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cbd893e0-d2c0-40d8-85a2-ef177f6606a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dd3655b6-bff8-4e89-a179-4993c0b40fc3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cbd893e0-d2c0-40d8-85a2-ef177f6606a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dd3655b6-bff8-4e89-a179-4993c0b40fc3" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7e168730-a1fd-47f2-9e98-a7b5b3248453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7e168730-a1fd-47f2-9e98-a7b5b3248453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7e168730-a1fd-47f2-9e98-a7b5b3248453_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7e168730-a1fd-47f2-9e98-a7b5b3248453" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7e168730-a1fd-47f2-9e98-a7b5b3248453_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3eb2c5c3-c46a-4aa0-8377-309975959d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7e168730-a1fd-47f2-9e98-a7b5b3248453" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3eb2c5c3-c46a-4aa0-8377-309975959d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_738d0227-f47a-4a54-a359-334e6b57707e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3eb2c5c3-c46a-4aa0-8377-309975959d1b" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_738d0227-f47a-4a54-a359-334e6b57707e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a6b5c43-6170-40df-a2c1-36c6d6bf27e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a6b5c43-6170-40df-a2c1-36c6d6bf27e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a6b5c43-6170-40df-a2c1-36c6d6bf27e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a6b5c43-6170-40df-a2c1-36c6d6bf27e1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a6b5c43-6170-40df-a2c1-36c6d6bf27e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a6b5c43-6170-40df-a2c1-36c6d6bf27e1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b597943e-0284-46c9-b58c-0b62f5d69ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b597943e-0284-46c9-b58c-0b62f5d69ff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_14784ceb-d8e7-4a20-9f7e-c55958e33936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_14784ceb-d8e7-4a20-9f7e-c55958e33936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_add78ca4-103f-416a-964f-9ed22c35b3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_add78ca4-103f-416a-964f-9ed22c35b3a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_5d96640f-2029-4314-9cb9-615391f9efb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_5d96640f-2029-4314-9cb9-615391f9efb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d5bd7545-faf2-4d59-a724-9b9e8d0d3604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d5bd7545-faf2-4d59-a724-9b9e8d0d3604" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_d5bd7545-faf2-4d59-a724-9b9e8d0d3604_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d5bd7545-faf2-4d59-a724-9b9e8d0d3604" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_d5bd7545-faf2-4d59-a724-9b9e8d0d3604_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d5bd7545-faf2-4d59-a724-9b9e8d0d3604" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_3a6941f2-92ea-451d-8d01-959e93766c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_3a6941f2-92ea-451d-8d01-959e93766c7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_bec640ea-e8e0-463b-8352-e398964e0892" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_bec640ea-e8e0-463b-8352-e398964e0892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_ce09ef39-cfe7-43aa-aeee-e24a949adeed" xlink:href="mrk-20211231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_ce09ef39-cfe7-43aa-aeee-e24a949adeed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_e2344894-96fa-4004-b75b-ff67b0e30a47" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_e2344894-96fa-4004-b75b-ff67b0e30a47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_e9f3cf8b-b67f-4403-96e1-fad59ecaab27" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_e9f3cf8b-b67f-4403-96e1-fad59ecaab27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_9c39bcf7-4b4e-4944-894d-358dc6fab385" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_9c39bcf7-4b4e-4944-894d-358dc6fab385" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_ef9645b9-16b0-4816-a867-f9f1e31d2739" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_ef9645b9-16b0-4816-a867-f9f1e31d2739" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_c582e18d-d48d-483a-bac1-e8b4a22d46b6" xlink:href="mrk-20211231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_c582e18d-d48d-483a-bac1-e8b4a22d46b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_78129f04-bc7f-463b-90e4-7ce093e9cccf" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_78129f04-bc7f-463b-90e4-7ce093e9cccf" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="extended" id="i3d5dd5faf00241b3995c9d533f4aa8d4_PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_63ca232e-f355-48b4-a8cc-c7a4412870ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_63ca232e-f355-48b4-a8cc-c7a4412870ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_3d5af504-0aac-425f-91cf-3a14f937683e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_3d5af504-0aac-425f-91cf-3a14f937683e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_e1788c33-aad5-42ad-929e-6249eccf4e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_e1788c33-aad5-42ad-929e-6249eccf4e82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_e8d3f664-6ee6-42a2-a0d7-6ddfe1ffec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_e8d3f664-6ee6-42a2-a0d7-6ddfe1ffec8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_384f9e99-aa89-4458-b62f-76d37e9d11ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_384f9e99-aa89-4458-b62f-76d37e9d11ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_75f60fee-1df5-4787-aaed-f95da2aa34d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_75f60fee-1df5-4787-aaed-f95da2aa34d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_411ea74b-69b8-4db9-906c-7217926d2fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_411ea74b-69b8-4db9-906c-7217926d2fd5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_31eeeb01-2696-4bdc-bb62-92064f35662d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_411ea74b-69b8-4db9-906c-7217926d2fd5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_31eeeb01-2696-4bdc-bb62-92064f35662d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_31eeeb01-2696-4bdc-bb62-92064f35662d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_31eeeb01-2696-4bdc-bb62-92064f35662d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_31eeeb01-2696-4bdc-bb62-92064f35662d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a7b313-c01d-49d4-af56-1b60dabc945c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_31eeeb01-2696-4bdc-bb62-92064f35662d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a7b313-c01d-49d4-af56-1b60dabc945c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d2f0c73f-3e5c-4556-8822-5b60b2f57d20" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a7b313-c01d-49d4-af56-1b60dabc945c" xlink:to="loc_country_US_d2f0c73f-3e5c-4556-8822-5b60b2f57d20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_91a8946b-5807-48a2-ae69-6f45b8b6eba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a7b313-c01d-49d4-af56-1b60dabc945c" xlink:to="loc_us-gaap_ForeignPlanMember_91a8946b-5807-48a2-ae69-6f45b8b6eba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4d5b16eb-22e5-4f21-a06b-f6746033315c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_411ea74b-69b8-4db9-906c-7217926d2fd5" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4d5b16eb-22e5-4f21-a06b-f6746033315c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4d5b16eb-22e5-4f21-a06b-f6746033315c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4d5b16eb-22e5-4f21-a06b-f6746033315c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4d5b16eb-22e5-4f21-a06b-f6746033315c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e72e740e-546e-46b0-8f46-92c141a88119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4d5b16eb-22e5-4f21-a06b-f6746033315c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e72e740e-546e-46b0-8f46-92c141a88119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_e3987e3f-b448-4cb3-8d82-9b7839f1f3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e72e740e-546e-46b0-8f46-92c141a88119" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_e3987e3f-b448-4cb3-8d82-9b7839f1f3c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e763b38d-6d11-46dd-9bec-1ce9b83f4b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e72e740e-546e-46b0-8f46-92c141a88119" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e763b38d-6d11-46dd-9bec-1ce9b83f4b33" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="extended" id="i72823e24330a474aae46e06271bc72e8_PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_6f7d938b-fac9-44bf-bd5e-ef2243c26325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_6f7d938b-fac9-44bf-bd5e-ef2243c26325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_aa94ed66-9309-4ac2-a0aa-0c70ebb2a5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_aa94ed66-9309-4ac2-a0aa-0c70ebb2a5a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_3cf0d69c-c68f-483b-aeb9-6726e3686e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_3cf0d69c-c68f-483b-aeb9-6726e3686e64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_f0df9c3d-b7c8-4b83-be93-f9db88cab063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_f0df9c3d-b7c8-4b83-be93-f9db88cab063" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_cdddd843-0441-4d06-8dad-a6f8cf6fb74a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_cdddd843-0441-4d06-8dad-a6f8cf6fb74a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_5eaccfed-927e-446f-bdd4-5a70117c14bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_5eaccfed-927e-446f-bdd4-5a70117c14bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c126c87a-072b-4586-ace8-ba4201149f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c126c87a-072b-4586-ace8-ba4201149f74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e54ce76f-c6e8-4921-9df8-4b4b722947b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c126c87a-072b-4586-ace8-ba4201149f74" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e54ce76f-c6e8-4921-9df8-4b4b722947b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e54ce76f-c6e8-4921-9df8-4b4b722947b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e54ce76f-c6e8-4921-9df8-4b4b722947b9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e54ce76f-c6e8-4921-9df8-4b4b722947b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c10e41db-12e6-4eca-b700-80982d87b36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e54ce76f-c6e8-4921-9df8-4b4b722947b9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c10e41db-12e6-4eca-b700-80982d87b36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b45bb5c6-a798-4ffd-b0ed-fbbf4ce66cbc" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c10e41db-12e6-4eca-b700-80982d87b36c" xlink:to="loc_country_US_b45bb5c6-a798-4ffd-b0ed-fbbf4ce66cbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5c274209-0ea9-4092-ace6-dd6d80475137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c10e41db-12e6-4eca-b700-80982d87b36c" xlink:to="loc_us-gaap_ForeignPlanMember_5c274209-0ea9-4092-ace6-dd6d80475137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a87b2a44-a7f9-4229-a6ef-acf59ae5953a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c126c87a-072b-4586-ace8-ba4201149f74" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a87b2a44-a7f9-4229-a6ef-acf59ae5953a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a87b2a44-a7f9-4229-a6ef-acf59ae5953a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a87b2a44-a7f9-4229-a6ef-acf59ae5953a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a87b2a44-a7f9-4229-a6ef-acf59ae5953a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a7867a6a-7ba1-47a6-b972-9ce57a3c7c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a87b2a44-a7f9-4229-a6ef-acf59ae5953a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a7867a6a-7ba1-47a6-b972-9ce57a3c7c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4214a997-340c-4fc4-88fe-171fee3b1285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a7867a6a-7ba1-47a6-b972-9ce57a3c7c3e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4214a997-340c-4fc4-88fe-171fee3b1285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_df7dc808-114a-4c49-a776-11c0a9e1d5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a7867a6a-7ba1-47a6-b972-9ce57a3c7c3e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_df7dc808-114a-4c49-a776-11c0a9e1d5ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="extended" id="id6fb3f6548944af5a8235015849f1231_PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc1401f1-5333-4915-990e-03720321d8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc1401f1-5333-4915-990e-03720321d8b6" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_686a307d-b19d-45f2-a571-73d9d1026a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_686a307d-b19d-45f2-a571-73d9d1026a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3fe7521e-29ec-4b0c-87ea-854ce61a7272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3fe7521e-29ec-4b0c-87ea-854ce61a7272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_e4646dd5-0402-4e64-b7b5-aae4806707af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_e4646dd5-0402-4e64-b7b5-aae4806707af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_5e16517f-3eaf-48ac-b728-bc85c436e03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_5e16517f-3eaf-48ac-b728-bc85c436e03a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc1401f1-5333-4915-990e-03720321d8b6" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f9963f19-f1e9-422c-9111-c215ac2b2a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f9963f19-f1e9-422c-9111-c215ac2b2a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_06df836f-7a3c-4836-8158-f1a221d1b217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_06df836f-7a3c-4836-8158-f1a221d1b217" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_f72707a9-ccc4-4edf-90f0-6b1c6670bc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_f72707a9-ccc4-4edf-90f0-6b1c6670bc7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4a6dc6e4-48f5-4963-93e4-ec558fba5458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc1401f1-5333-4915-990e-03720321d8b6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4a6dc6e4-48f5-4963-93e4-ec558fba5458" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_a42bcece-4af8-4851-b11f-0395ab61901d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4a6dc6e4-48f5-4963-93e4-ec558fba5458" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_a42bcece-4af8-4851-b11f-0395ab61901d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_a42bcece-4af8-4851-b11f-0395ab61901d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_a42bcece-4af8-4851-b11f-0395ab61901d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_a42bcece-4af8-4851-b11f-0395ab61901d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3808b168-9fb7-45ed-aa2b-d20d5bd074f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_a42bcece-4af8-4851-b11f-0395ab61901d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3808b168-9fb7-45ed-aa2b-d20d5bd074f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d64b9115-d9b0-41a5-9dbc-c02de0df5026" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3808b168-9fb7-45ed-aa2b-d20d5bd074f1" xlink:to="loc_country_US_d64b9115-d9b0-41a5-9dbc-c02de0df5026" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_2219917f-bd26-427e-9a50-2473870227ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3808b168-9fb7-45ed-aa2b-d20d5bd074f1" xlink:to="loc_us-gaap_ForeignPlanMember_2219917f-bd26-427e-9a50-2473870227ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4cc914e7-4bc0-4a24-8ae9-232d0842b8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4a6dc6e4-48f5-4963-93e4-ec558fba5458" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4cc914e7-4bc0-4a24-8ae9-232d0842b8fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4cc914e7-4bc0-4a24-8ae9-232d0842b8fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4cc914e7-4bc0-4a24-8ae9-232d0842b8fc" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4cc914e7-4bc0-4a24-8ae9-232d0842b8fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fec943b8-9e41-4d43-a513-2eb16467d60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4cc914e7-4bc0-4a24-8ae9-232d0842b8fc" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fec943b8-9e41-4d43-a513-2eb16467d60f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ec4471ed-b6b6-497b-9bc2-aade14129871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fec943b8-9e41-4d43-a513-2eb16467d60f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ec4471ed-b6b6-497b-9bc2-aade14129871" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="extended" id="i9a5c7efc0eef401ba940abacf402ac66_PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c9fc3c2a-98cd-4484-8f7e-c4804faa8532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_f467c31f-d2d2-414e-a268-3e594e828d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c9fc3c2a-98cd-4484-8f7e-c4804faa8532" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_f467c31f-d2d2-414e-a268-3e594e828d06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_fbf86fbe-1523-403a-bfc5-90959317641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c9fc3c2a-98cd-4484-8f7e-c4804faa8532" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_fbf86fbe-1523-403a-bfc5-90959317641b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f54f429-bd97-4836-a195-10d06af9d1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c9fc3c2a-98cd-4484-8f7e-c4804faa8532" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f54f429-bd97-4836-a195-10d06af9d1b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7913341a-c92e-4ed5-8ce1-e587e350231f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f54f429-bd97-4836-a195-10d06af9d1b4" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7913341a-c92e-4ed5-8ce1-e587e350231f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7913341a-c92e-4ed5-8ce1-e587e350231f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7913341a-c92e-4ed5-8ce1-e587e350231f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7913341a-c92e-4ed5-8ce1-e587e350231f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_814f1367-9c73-4dd8-ab18-df4f518a3de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7913341a-c92e-4ed5-8ce1-e587e350231f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_814f1367-9c73-4dd8-ab18-df4f518a3de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4c627053-b6bf-4437-94bd-82c8bc7f7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_814f1367-9c73-4dd8-ab18-df4f518a3de9" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4c627053-b6bf-4437-94bd-82c8bc7f7e91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended" id="i8a6d7b6ab6614d29937e583e233cff4d_OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b4bc43ae-f9cb-4a6b-9fed-becae5a1beab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b4bc43ae-f9cb-4a6b-9fed-becae5a1beab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bf1ca1ff-a3c9-462c-9462-63557835af6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_InterestExpense_bf1ca1ff-a3c9-462c-9462-63557835af6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_538e8548-f53c-4b18-9d5a-f5b6e6d615af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_538e8548-f53c-4b18-9d5a-f5b6e6d615af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_182372be-8a04-4cfc-8d1f-6562b9f078eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_182372be-8a04-4cfc-8d1f-6562b9f078eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_5449b027-9a26-40f1-83a8-b2b0a2937c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_5449b027-9a26-40f1-83a8-b2b0a2937c6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_6da12b5b-5ed7-4951-a9b8-a9b36110e0d8" xlink:href="mrk-20211231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_6da12b5b-5ed7-4951-a9b8-a9b36110e0d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_01c9ae29-3f9d-4179-9749-d60a39a72cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_01c9ae29-3f9d-4179-9749-d60a39a72cbd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1352142f-69d3-4336-b977-bffb9c2d11a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1352142f-69d3-4336-b977-bffb9c2d11a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_8be83475-8a0b-404c-b8fa-5cda2505d4f6" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_8be83475-8a0b-404c-b8fa-5cda2505d4f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_49ea9a17-040e-4692-aee9-37af908e85c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_8be83475-8a0b-404c-b8fa-5cda2505d4f6" xlink:to="loc_srt_StatementScenarioAxis_49ea9a17-040e-4692-aee9-37af908e85c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_49ea9a17-040e-4692-aee9-37af908e85c0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_49ea9a17-040e-4692-aee9-37af908e85c0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_49ea9a17-040e-4692-aee9-37af908e85c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_29077029-db92-456d-8a8b-24edafe92b79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_49ea9a17-040e-4692-aee9-37af908e85c0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_29077029-db92-456d-8a8b-24edafe92b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f1f1130c-be60-4221-9bd2-7a037531614b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_29077029-db92-456d-8a8b-24edafe92b79" xlink:to="loc_srt_ScenarioForecastMember_f1f1130c-be60-4221-9bd2-7a037531614b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherIncomeExpenseNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="extended" id="i9e650f4125b04ef6826cf0c3972d33ae_OtherIncomeExpenseNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_b550d8f6-9d93-401a-8a38-128637ca55d2" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_78545582-823d-41d3-b86d-920e4e4bceb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_b550d8f6-9d93-401a-8a38-128637ca55d2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_78545582-823d-41d3-b86d-920e4e4bceb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_bc0b1215-33c0-406d-af56-22965ee3cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_b550d8f6-9d93-401a-8a38-128637ca55d2" xlink:to="loc_us-gaap_InterestPaid_bc0b1215-33c0-406d-af56-22965ee3cffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_e940f4c9-0e36-4bc4-a6b8-f454c9f3d0cf" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_b550d8f6-9d93-401a-8a38-128637ca55d2" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_e940f4c9-0e36-4bc4-a6b8-f454c9f3d0cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9755dc41-fe2c-4ce7-a691-e38743ca6daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_e940f4c9-0e36-4bc4-a6b8-f454c9f3d0cf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9755dc41-fe2c-4ce7-a691-e38743ca6daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9755dc41-fe2c-4ce7-a691-e38743ca6daf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9755dc41-fe2c-4ce7-a691-e38743ca6daf" xlink:to="loc_us-gaap_SegmentDomain_9755dc41-fe2c-4ce7-a691-e38743ca6daf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1ce93e01-8657-441c-8ada-e8006a4cd29f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9755dc41-fe2c-4ce7-a691-e38743ca6daf" xlink:to="loc_us-gaap_SegmentDomain_1ce93e01-8657-441c-8ada-e8006a4cd29f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_HealthcareServicesSegmentMember_c02469f8-5de6-44d2-ab3b-d19ea48a7de4" xlink:href="mrk-20211231.xsd#mrk_HealthcareServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1ce93e01-8657-441c-8ada-e8006a4cd29f" xlink:to="loc_mrk_HealthcareServicesSegmentMember_c02469f8-5de6-44d2-ab3b-d19ea48a7de4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="extended" id="i18328c5c4df74510873600f020059eba_TaxesonIncomeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_54f25b27-6793-4181-aebf-e0b659eabc28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_54f25b27-6793-4181-aebf-e0b659eabc28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_729a8065-ca4a-474e-92f0-822e01b0212b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_729a8065-ca4a-474e-92f0-822e01b0212b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_1ffbade7-337c-4907-b135-0e410fe530ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_1ffbade7-337c-4907-b135-0e410fe530ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_f4ee80d7-e54a-4200-8a5c-9e08c6305b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_f4ee80d7-e54a-4200-8a5c-9e08c6305b53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_abfd0ce3-078d-4a0c-8822-7c8f88aa5aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_abfd0ce3-078d-4a0c-8822-7c8f88aa5aea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_fa9aa050-6557-4bf4-9697-1521d8f3adae" xlink:href="mrk-20211231.xsd#mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_fa9aa050-6557-4bf4-9697-1521d8f3adae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3219b6a1-81ee-41d0-ad45-95dd6d1e3d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3219b6a1-81ee-41d0-ad45-95dd6d1e3d5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_d373eb68-f58d-46e5-be20-88bd834c158a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_IncomeTaxesPaid_d373eb68-f58d-46e5-be20-88bd834c158a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_ccf474c0-3193-4a3f-863c-6907c5d7ab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_ccf474c0-3193-4a3f-863c-6907c5d7ab7e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_12270d79-ee8b-4922-8cc1-a76e9db68a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_12270d79-ee8b-4922-8cc1-a76e9db68a43" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c4c414b9-c2e0-479c-bc32-be584b9b4d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c4c414b9-c2e0-479c-bc32-be584b9b4d5f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1f15408e-96e5-4171-8b14-08ed1ddf9813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1f15408e-96e5-4171-8b14-08ed1ddf9813" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ef22e8f5-e601-47a0-b105-99acb53b47a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ef22e8f5-e601-47a0-b105-99acb53b47a7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a1b7dedf-bab3-4136-8308-eb69e85b771f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a1b7dedf-bab3-4136-8308-eb69e85b771f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e63c7bc5-6117-4c39-9afc-303983d3c19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e63c7bc5-6117-4c39-9afc-303983d3c19f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_a735d404-124e-43fb-bc52-2e32c00af272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_a735d404-124e-43fb-bc52-2e32c00af272" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a09c4697-3cf5-484b-8784-9230d7135bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a09c4697-3cf5-484b-8784-9230d7135bca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a09c4697-3cf5-484b-8784-9230d7135bca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a09c4697-3cf5-484b-8784-9230d7135bca" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a09c4697-3cf5-484b-8784-9230d7135bca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0081bdd1-96ee-466e-9ed1-4aa0e2ecf9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a09c4697-3cf5-484b-8784-9230d7135bca" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0081bdd1-96ee-466e-9ed1-4aa0e2ecf9cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxesPayableMember_7c4f76da-f4a0-4d5f-8ebc-be1f69056db0" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0081bdd1-96ee-466e-9ed1-4aa0e2ecf9cc" xlink:to="loc_mrk_IncomeTaxesPayableMember_7c4f76da-f4a0-4d5f-8ebc-be1f69056db0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a4e25978-103e-4c1c-a167-5c180cc2e3da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0081bdd1-96ee-466e-9ed1-4aa0e2ecf9cc" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a4e25978-103e-4c1c-a167-5c180cc2e3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3c5d43ac-1c11-4f73-a56c-b7c6abe7682f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3c5d43ac-1c11-4f73-a56c-b7c6abe7682f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3c5d43ac-1c11-4f73-a56c-b7c6abe7682f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3c5d43ac-1c11-4f73-a56c-b7c6abe7682f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3c5d43ac-1c11-4f73-a56c-b7c6abe7682f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_855a1562-06b1-44e9-9f53-1fb4f888b447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3c5d43ac-1c11-4f73-a56c-b7c6abe7682f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_855a1562-06b1-44e9-9f53-1fb4f888b447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_46e18fda-734c-4e43-8b6c-aeb95a109956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_855a1562-06b1-44e9-9f53-1fb4f888b447" xlink:to="loc_us-gaap_ForeignCountryMember_46e18fda-734c-4e43-8b6c-aeb95a109956" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_069dae14-0221-46e0-a579-1735c634d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_855a1562-06b1-44e9-9f53-1fb4f888b447" xlink:to="loc_us-gaap_DomesticCountryMember_069dae14-0221-46e0-a579-1735c634d43f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_5344fbb9-108f-41c7-bbfd-02dc7cdcf47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_5344fbb9-108f-41c7-bbfd-02dc7cdcf47b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_5344fbb9-108f-41c7-bbfd-02dc7cdcf47b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5344fbb9-108f-41c7-bbfd-02dc7cdcf47b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_5344fbb9-108f-41c7-bbfd-02dc7cdcf47b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_367bc9f9-d72e-4d00-8dc7-bfce1b6d2717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5344fbb9-108f-41c7-bbfd-02dc7cdcf47b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_367bc9f9-d72e-4d00-8dc7-bfce1b6d2717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_955c91e2-c7c4-440d-b3b4-670a4ea2b04a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_367bc9f9-d72e-4d00-8dc7-bfce1b6d2717" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_955c91e2-c7c4-440d-b3b4-670a4ea2b04a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_fa95994d-e2dc-4d7f-bd7b-04910da5e66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_fa95994d-e2dc-4d7f-bd7b-04910da5e66a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_fa95994d-e2dc-4d7f-bd7b-04910da5e66a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_fa95994d-e2dc-4d7f-bd7b-04910da5e66a" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_fa95994d-e2dc-4d7f-bd7b-04910da5e66a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_653598bd-4f90-4517-b583-c7d7de63aa45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_fa95994d-e2dc-4d7f-bd7b-04910da5e66a" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_653598bd-4f90-4517-b583-c7d7de63aa45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_02e4dbe3-891c-42ed-bbc5-9b1a5cf2e45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_653598bd-4f90-4517-b583-c7d7de63aa45" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_02e4dbe3-891c-42ed-bbc5-9b1a5cf2e45b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_c76ca971-f929-4f1a-ab6e-2d6bd7ffe8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_653598bd-4f90-4517-b583-c7d7de63aa45" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_c76ca971-f929-4f1a-ab6e-2d6bd7ffe8dd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeDeferredIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="extended" id="i42fdff1ee7c44a1ca89d3fd88e159579_TaxesonIncomeDeferredIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a8cbc2bb-b151-42a1-8388-0ec8048a1301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a8cbc2bb-b151-42a1-8388-0ec8048a1301" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_659f1ebb-30d0-4f19-8891-4387bc91c8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_659f1ebb-30d0-4f19-8891-4387bc91c8cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_e65126fd-2a5a-4aa0-8a85-4001bfe3efeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_e65126fd-2a5a-4aa0-8a85-4001bfe3efeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_bde84e38-3e1f-4ef6-866f-777142dcb9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_bde84e38-3e1f-4ef6-866f-777142dcb9f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_048c85c9-932e-4e7f-b00e-8c339b069719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_048c85c9-932e-4e7f-b00e-8c339b069719" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_5407df83-7f16-4565-b4b5-dbd927712f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_5407df83-7f16-4565-b4b5-dbd927712f19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_2bb0f155-a86e-4da9-9a4a-704b1d33f959" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_2bb0f155-a86e-4da9-9a4a-704b1d33f959" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_2c89e368-fc96-42bf-9ffb-90e2ab226927" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_2c89e368-fc96-42bf-9ffb-90e2ab226927" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_64fd763e-21bb-4d12-8571-2db08e876a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_64fd763e-21bb-4d12-8571-2db08e876a0f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ca06c92a-da19-4aef-bfb3-5a2c1fe3de1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ca06c92a-da19-4aef-bfb3-5a2c1fe3de1b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_817c89db-c4e1-4f80-ad7c-418975a7f102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_817c89db-c4e1-4f80-ad7c-418975a7f102" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3e9ea663-3b24-45f8-98cb-7597b169b727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_3e9ea663-3b24-45f8-98cb-7597b169b727" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_73aa9976-a0df-4752-98e5-11c13ee3b3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_73aa9976-a0df-4752-98e5-11c13ee3b3ec" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_ff01be7d-a411-4f6b-bc6d-c193f22357d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_ff01be7d-a411-4f6b-bc6d-c193f22357d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a3355089-2c83-41cf-b7d5-01e75afedabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a3355089-2c83-41cf-b7d5-01e75afedabd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_3d470742-8037-4eb3-b9a0-c68d8a12b586" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_3d470742-8037-4eb3-b9a0-c68d8a12b586" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_ec2d9268-647a-4b00-845b-29e3862e8db5" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_ec2d9268-647a-4b00-845b-29e3862e8db5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d97c8a40-13a3-4684-82bb-d49d98cbd02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d97c8a40-13a3-4684-82bb-d49d98cbd02c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_71fac289-dfda-41ec-88df-46e9789d049a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_71fac289-dfda-41ec-88df-46e9789d049a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_da1da643-e6fb-4bdb-bd06-d4c0d37cbf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilities_da1da643-e6fb-4bdb-bd06-d4c0d37cbf5f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_12658488-317b-4655-bc8c-d0154115f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_12658488-317b-4655-bc8c-d0154115f25a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_bef3647f-e3c9-4181-baa0-0c8b0904b602" xlink:href="mrk-20211231.xsd#mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_bef3647f-e3c9-4181-baa0-0c8b0904b602" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_290b0900-33ae-4569-a7fb-d3dc5bce17bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_bef3647f-e3c9-4181-baa0-0c8b0904b602" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_290b0900-33ae-4569-a7fb-d3dc5bce17bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_290b0900-33ae-4569-a7fb-d3dc5bce17bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_290b0900-33ae-4569-a7fb-d3dc5bce17bf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_290b0900-33ae-4569-a7fb-d3dc5bce17bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_55dbb828-a96f-4a8e-8cb1-3a7d2824dff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_290b0900-33ae-4569-a7fb-d3dc5bce17bf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_55dbb828-a96f-4a8e-8cb1-3a7d2824dff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_4a4b6153-e3db-452d-82ea-377ea8fa1372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_55dbb828-a96f-4a8e-8cb1-3a7d2824dff3" xlink:to="loc_us-gaap_OtherAssetsMember_4a4b6153-e3db-452d-82ea-377ea8fa1372" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i0198368d825145fc8e74d59bd6177927_TaxesonIncomeUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_ec368ece-c7d7-44cb-8879-0d47d713e7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ec368ece-c7d7-44cb-8879-0d47d713e7e0" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d1590b07-b062-4473-85e7-d64c83f9a7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d1590b07-b062-4473-85e7-d64c83f9a7e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0e8878cf-2dfb-49d9-b587-aabe70460d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0e8878cf-2dfb-49d9-b587-aabe70460d12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a1a3c3c2-8a2b-4fb0-859e-c922c497981a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a1a3c3c2-8a2b-4fb0-859e-c922c497981a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_051d283f-b04a-4b51-a1f7-8acefff3b60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_051d283f-b04a-4b51-a1f7-8acefff3b60d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_236bbc56-34a8-496e-96b3-4ed6f480cfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_236bbc56-34a8-496e-96b3-4ed6f480cfe1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_03b3887f-8c4b-4d7b-b3c5-c2889d212a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_03b3887f-8c4b-4d7b-b3c5-c2889d212a37" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_77bad6d6-d65f-4ef1-9d2b-2be890d9846d" xlink:href="mrk-20211231.xsd#mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_77bad6d6-d65f-4ef1-9d2b-2be890d9846d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fc5da0d0-28b8-433b-b5b4-2f8116ca1c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_1d60a3fa-32f3-4c57-adfe-00844bd85fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_5ec0d711-a9b1-43cb-8ab0-3f676a38183d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ec368ece-c7d7-44cb-8879-0d47d713e7e0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_5ec0d711-a9b1-43cb-8ab0-3f676a38183d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7d47deaf-849c-4b3b-89e4-9694ad78528b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5ec0d711-a9b1-43cb-8ab0-3f676a38183d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7d47deaf-849c-4b3b-89e4-9694ad78528b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d47deaf-849c-4b3b-89e4-9694ad78528b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7d47deaf-849c-4b3b-89e4-9694ad78528b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7d47deaf-849c-4b3b-89e4-9694ad78528b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a5484e9-0553-4cd6-86ac-926938ad0a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7d47deaf-849c-4b3b-89e4-9694ad78528b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a5484e9-0553-4cd6-86ac-926938ad0a3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ConsumercarebusinessMember_81d934e9-63fb-4f35-968f-9d480c7a6198" xlink:href="mrk-20211231.xsd#mrk_ConsumercarebusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a5484e9-0553-4cd6-86ac-926938ad0a3e" xlink:to="loc_mrk_ConsumercarebusinessMember_81d934e9-63fb-4f35-968f-9d480c7a6198" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i9732b7d6939747d59901cf4051d78ca9_OtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6d386c98-368c-48d4-b827-8c2863a11c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6d386c98-368c-48d4-b827-8c2863a11c5e" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2fd3756-a597-4f8d-8f4a-3286e61e279d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2fd3756-a597-4f8d-8f4a-3286e61e279d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_94b23f09-d46a-4b7d-b719-5f77749d4e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_94b23f09-d46a-4b7d-b719-5f77749d4e70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_e4d61b0a-e907-43f6-a3d4-aafae70b19ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_e4d61b0a-e907-43f6-a3d4-aafae70b19ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ac3b5c8f-a9f6-41b6-b726-ac174b8400d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ac3b5c8f-a9f6-41b6-b726-ac174b8400d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_fb78560b-1085-4967-9e06-a9c77b81ddad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_fb78560b-1085-4967-9e06-a9c77b81ddad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_a59e810c-bf24-4363-aaa0-9fb8151de941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_a59e810c-bf24-4363-aaa0-9fb8151de941" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3741f0db-5ee2-4157-a2c3-f1b8c36f0843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3741f0db-5ee2-4157-a2c3-f1b8c36f0843" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a89372c0-da4e-4e4f-8d84-44623b6b6f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a89372c0-da4e-4e4f-8d84-44623b6b6f41" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_f5a90b43-c8df-437f-b0cc-bcc647d18e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_f5a90b43-c8df-437f-b0cc-bcc647d18e4c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c60ee20b-f8e2-47fa-9d44-45d91d7bcac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_e290546b-db5f-4802-8d8f-4fde5c44e8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6d386c98-368c-48d4-b827-8c2863a11c5e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_e290546b-db5f-4802-8d8f-4fde5c44e8bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_faf1bfd7-8207-437c-a3a4-c422a38c5752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6d386c98-368c-48d4-b827-8c2863a11c5e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_faf1bfd7-8207-437c-a3a4-c422a38c5752" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_56525603-77cd-4e7b-8464-03167d88bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_faf1bfd7-8207-437c-a3a4-c422a38c5752" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_56525603-77cd-4e7b-8464-03167d88bc23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56525603-77cd-4e7b-8464-03167d88bc23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56525603-77cd-4e7b-8464-03167d88bc23" xlink:to="loc_us-gaap_EquityComponentDomain_56525603-77cd-4e7b-8464-03167d88bc23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56525603-77cd-4e7b-8464-03167d88bc23" xlink:to="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f13147a6-522a-43c9-a4b0-2a989f7fd9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f13147a6-522a-43c9-a4b0-2a989f7fd9fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a3c8fd40-e275-4c2f-860f-f02d47becc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a3c8fd40-e275-4c2f-860f-f02d47becc17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanNetLossMember_d50dc625-bee1-4d98-8de6-7c907416c27e" xlink:href="mrk-20211231.xsd#mrk_PensionPlanNetLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:to="loc_mrk_PensionPlanNetLossMember_d50dc625-bee1-4d98-8de6-7c907416c27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_e2e95587-63c9-4ada-8bc2-4e0bd8b1aea9" xlink:href="mrk-20211231.xsd#mrk_OtherPostretirementBenefitPlanNetLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:to="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_e2e95587-63c9-4ada-8bc2-4e0bd8b1aea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanPriorServiceCostMember_6775308e-3df4-4f08-8ca7-fcff3daa3d55" xlink:href="mrk-20211231.xsd#mrk_PensionPlanPriorServiceCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:to="loc_mrk_PensionPlanPriorServiceCostMember_6775308e-3df4-4f08-8ca7-fcff3daa3d55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_c2ce540a-53fe-40ae-a09d-e25c53b92f79" xlink:href="mrk-20211231.xsd#mrk_OtherPostretirementBenefitPlanPriorServiceCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:to="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_c2ce540a-53fe-40ae-a09d-e25c53b92f79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5c4cdf79-aa5e-4918-821a-08e77946f881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5c4cdf79-aa5e-4918-821a-08e77946f881" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3e1b42a3-82ac-4ab1-8695-8b2f763bb104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3e1b42a3-82ac-4ab1-8695-8b2f763bb104" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended" id="i0e39994d63724b23853a862aeea273d8_SegmentReportingSalesofCompanysProductsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cca8fe4e-afd7-4901-92e9-1d08a71a822b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3e0c6e99-53cd-40e6-bb59-ae49079170b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cca8fe4e-afd7-4901-92e9-1d08a71a822b" xlink:to="loc_us-gaap_Revenues_3e0c6e99-53cd-40e6-bb59-ae49079170b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2cbcf8b4-01cf-424a-a049-2d0c3c8f5e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cca8fe4e-afd7-4901-92e9-1d08a71a822b" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2cbcf8b4-01cf-424a-a049-2d0c3c8f5e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cca8fe4e-afd7-4901-92e9-1d08a71a822b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9718d11b-80c2-407c-aa66-d3a77ea0d837" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:to="loc_srt_StatementGeographicalAxis_9718d11b-80c2-407c-aa66-d3a77ea0d837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9718d11b-80c2-407c-aa66-d3a77ea0d837_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9718d11b-80c2-407c-aa66-d3a77ea0d837" xlink:to="loc_srt_SegmentGeographicalDomain_9718d11b-80c2-407c-aa66-d3a77ea0d837_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d7eae7a3-c60d-4255-8fd7-e5aa2837f95e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9718d11b-80c2-407c-aa66-d3a77ea0d837" xlink:to="loc_srt_SegmentGeographicalDomain_d7eae7a3-c60d-4255-8fd7-e5aa2837f95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4f6581f4-9eb8-4a09-bed0-88e0bae86609" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d7eae7a3-c60d-4255-8fd7-e5aa2837f95e" xlink:to="loc_country_US_4f6581f4-9eb8-4a09-bed0-88e0bae86609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_3fea92bb-fba2-43fb-a165-267df81e9ee7" xlink:href="mrk-20211231.xsd#mrk_InternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d7eae7a3-c60d-4255-8fd7-e5aa2837f95e" xlink:to="loc_mrk_InternationalMember_3fea92bb-fba2-43fb-a165-267df81e9ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_82df3c9d-8b49-4421-a342-a19c13d747c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:to="loc_srt_ConsolidationItemsAxis_82df3c9d-8b49-4421-a342-a19c13d747c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_82df3c9d-8b49-4421-a342-a19c13d747c7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_82df3c9d-8b49-4421-a342-a19c13d747c7" xlink:to="loc_srt_ConsolidationItemsDomain_82df3c9d-8b49-4421-a342-a19c13d747c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_998095a2-33ee-4a9a-9e00-c265fa77f9a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_82df3c9d-8b49-4421-a342-a19c13d747c7" xlink:to="loc_srt_ConsolidationItemsDomain_998095a2-33ee-4a9a-9e00-c265fa77f9a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_b1e5c115-fa46-45e8-9c4e-7d91b0e0c344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_998095a2-33ee-4a9a-9e00-c265fa77f9a7" xlink:to="loc_us-gaap_OperatingSegmentsMember_b1e5c115-fa46-45e8-9c4e-7d91b0e0c344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_17cd8c22-fd4a-44e1-98f2-5cccc790d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_998095a2-33ee-4a9a-9e00-c265fa77f9a7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_17cd8c22-fd4a-44e1-98f2-5cccc790d6a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_62467811-6324-4bb1-9794-163bcfd063dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_62467811-6324-4bb1-9794-163bcfd063dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_62467811-6324-4bb1-9794-163bcfd063dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_62467811-6324-4bb1-9794-163bcfd063dc" xlink:to="loc_us-gaap_SegmentDomain_62467811-6324-4bb1-9794-163bcfd063dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_62467811-6324-4bb1-9794-163bcfd063dc" xlink:to="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_3aa4c858-a901-4cef-b912-5a1169a567ce" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:to="loc_mrk_PharmaceuticalsegmentMember_3aa4c858-a901-4cef-b912-5a1169a567ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_f71378c1-f54f-44f7-a34e-7bd0cac37039" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:to="loc_mrk_AnimalHealthsegmentMember_f71378c1-f54f-44f7-a34e-7bd0cac37039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1cc78377-748e-4cac-8e4a-2bcc1907f84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1cc78377-748e-4cac-8e4a-2bcc1907f84c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_276a5479-3980-4c01-8bb9-9ad647e672ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:to="loc_srt_ProductOrServiceAxis_276a5479-3980-4c01-8bb9-9ad647e672ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_276a5479-3980-4c01-8bb9-9ad647e672ce_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_276a5479-3980-4c01-8bb9-9ad647e672ce" xlink:to="loc_srt_ProductsAndServicesDomain_276a5479-3980-4c01-8bb9-9ad647e672ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_276a5479-3980-4c01-8bb9-9ad647e672ce" xlink:to="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_6177eb29-2a39-41bb-9706-492a8fc4513a" xlink:href="mrk-20211231.xsd#mrk_KeytrudaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_KeytrudaMember_6177eb29-2a39-41bb-9706-492a8fc4513a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_533a1043-883d-47bc-ae46-19dada8c055e" xlink:href="mrk-20211231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_533a1043-883d-47bc-ae46-19dada8c055e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_8003d545-0daf-49ae-9a7b-9c4a840e4e98" xlink:href="mrk-20211231.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_LenvimaMember_8003d545-0daf-49ae-9a7b-9c4a840e4e98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_33840e71-fd61-44f0-aff7-2c80be3a2d0b" xlink:href="mrk-20211231.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_GardasilGardasil9Member_33840e71-fd61-44f0-aff7-2c80be3a2d0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_e44bae47-e1a5-433d-a408-c4db98d48d3b" xlink:href="mrk-20211231.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_e44bae47-e1a5-433d-a408-c4db98d48d3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_84265f4d-ff60-41cf-bce8-d1419618da31" xlink:href="mrk-20211231.xsd#mrk_Pneumovax23Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_Pneumovax23Member_84265f4d-ff60-41cf-bce8-d1419618da31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_1c99ddd3-9c2b-4b09-a044-f317c53ee4ed" xlink:href="mrk-20211231.xsd#mrk_RotateqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_RotateqMember_1c99ddd3-9c2b-4b09-a044-f317c53ee4ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_caa006ea-6cf2-4023-a5af-c8d1b180ea7f" xlink:href="mrk-20211231.xsd#mrk_VaqtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_VaqtaMember_caa006ea-6cf2-4023-a5af-c8d1b180ea7f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_cbac08f8-061c-4b3b-ac51-62870b972453" xlink:href="mrk-20211231.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_BridionMember_cbac08f8-061c-4b3b-ac51-62870b972453" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_fa178529-b2b8-4321-a036-055bf21b71db" xlink:href="mrk-20211231.xsd#mrk_PrevymisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_PrevymisMember_fa178529-b2b8-4321-a036-055bf21b71db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_3795d35e-66c5-4eb8-b7d4-adf023a3d00a" xlink:href="mrk-20211231.xsd#mrk_PrimaxinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_PrimaxinMember_3795d35e-66c5-4eb8-b7d4-adf023a3d00a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_8ac90a99-adf0-44f5-bb05-2569dce8b5f6" xlink:href="mrk-20211231.xsd#mrk_NoxafilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_NoxafilMember_8ac90a99-adf0-44f5-bb05-2569dce8b5f6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_b6a2c6e9-1f5b-429c-aafd-fdf8fa8b62fa" xlink:href="mrk-20211231.xsd#mrk_CancidasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_CancidasMember_b6a2c6e9-1f5b-429c-aafd-fdf8fa8b62fa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_4e2f2a68-002f-45af-b136-4b6058dd53b0" xlink:href="mrk-20211231.xsd#mrk_InvanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_InvanzMember_4e2f2a68-002f-45af-b136-4b6058dd53b0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_33694737-ba7b-48ab-afc4-c46acee8ffb9" xlink:href="mrk-20211231.xsd#mrk_ZerbaxaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_ZerbaxaMember_33694737-ba7b-48ab-afc4-c46acee8ffb9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_2f838d05-af63-4c7a-991b-174bd07e88ba" xlink:href="mrk-20211231.xsd#mrk_SimponiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_SimponiMember_2f838d05-af63-4c7a-991b-174bd07e88ba" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_c1412d21-fd1e-4caf-b979-82620fc7ba50" xlink:href="mrk-20211231.xsd#mrk_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_RemicadeMember_c1412d21-fd1e-4caf-b979-82620fc7ba50" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_92728aa2-93fe-4082-88c1-0e98ef7c4824" xlink:href="mrk-20211231.xsd#mrk_BelsomraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_BelsomraMember_92728aa2-93fe-4082-88c1-0e98ef7c4824" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MolnupiravirMember_4dd4506f-3db0-49ee-a064-6d12bde3d2e2" xlink:href="mrk-20211231.xsd#mrk_MolnupiravirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_MolnupiravirMember_4dd4506f-3db0-49ee-a064-6d12bde3d2e2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_5cbe8671-ad20-48a5-89b2-5f1aa96a2d58" xlink:href="mrk-20211231.xsd#mrk_IsentressIsentressHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_IsentressIsentressHDMember_5cbe8671-ad20-48a5-89b2-5f1aa96a2d58" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember_5059a343-442f-4c96-a50c-bd4be861af5c" xlink:href="mrk-20211231.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_AllianceRevenueAdempasVerquvoMember_5059a343-442f-4c96-a50c-bd4be861af5c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_6547fd5a-dada-4e7a-a536-7760500a7ef5" xlink:href="mrk-20211231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_AdempasMember_6547fd5a-dada-4e7a-a536-7760500a7ef5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_7f30fa89-9aec-43ce-b929-cf8b8daa33fb" xlink:href="mrk-20211231.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_JanuviaMember_7f30fa89-9aec-43ce-b929-cf8b8daa33fb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_e3f7d497-1b39-42be-ba34-f212c6788c04" xlink:href="mrk-20211231.xsd#mrk_JanumetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_JanumetMember_e3f7d497-1b39-42be-ba34-f212c6788c04" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_ac366c60-b81e-475f-a782-dbd11196d0ef" xlink:href="mrk-20211231.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_OtherPharmaceuticalMember_ac366c60-b81e-475f-a782-dbd11196d0ef" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_0ad7b126-fa0d-49c0-a5a7-b4586365b1a7" xlink:href="mrk-20211231.xsd#mrk_LivestockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_LivestockMember_0ad7b126-fa0d-49c0-a5a7-b4586365b1a7" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_103d96b5-32e2-4d94-9ee5-9b3993555cf3" xlink:href="mrk-20211231.xsd#mrk_CompanionAnimalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_CompanionAnimalsMember_103d96b5-32e2-4d94-9ee5-9b3993555cf3" xlink:type="arc" order="26"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="extended" id="ic3fcf1c49e674a28bb4a7673d37205cb_SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5238ce20-72b0-479c-b826-f39cfce2945e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_32e0ea71-00c5-4ff3-992c-4e27b44e8fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5238ce20-72b0-479c-b826-f39cfce2945e" xlink:to="loc_us-gaap_Revenues_32e0ea71-00c5-4ff3-992c-4e27b44e8fdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d6120854-7430-4445-b916-4376070c45ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5238ce20-72b0-479c-b826-f39cfce2945e" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d6120854-7430-4445-b916-4376070c45ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8494d242-9c6f-4920-8718-be09e603c4ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d6120854-7430-4445-b916-4376070c45ae" xlink:to="loc_srt_StatementGeographicalAxis_8494d242-9c6f-4920-8718-be09e603c4ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8494d242-9c6f-4920-8718-be09e603c4ca_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8494d242-9c6f-4920-8718-be09e603c4ca" xlink:to="loc_srt_SegmentGeographicalDomain_8494d242-9c6f-4920-8718-be09e603c4ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8494d242-9c6f-4920-8718-be09e603c4ca" xlink:to="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_165f5d35-2089-4c41-8f04-7ba7dce79419" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_country_US_165f5d35-2089-4c41-8f04-7ba7dce79419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_ba01472f-e06c-4137-add0-7c9a1d637ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_us-gaap_EMEAMember_ba01472f-e06c-4137-add0-7c9a1d637ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_fbc0778f-ed65-4e17-974a-8ac5d289a5f9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_country_CN_fbc0778f-ed65-4e17-974a-8ac5d289a5f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_431af3b5-649e-4253-89a1-3c2a13cd180f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_country_JP_431af3b5-649e-4253-89a1-3c2a13cd180f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_ce620812-47d4-4b54-892b-ba17f39fcb3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_srt_AsiaPacificMember_ce620812-47d4-4b54-892b-ba17f39fcb3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_72e62e58-dd69-4bf6-94e6-da6531d3a5e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_srt_LatinAmericaMember_72e62e58-dd69-4bf6-94e6-da6531d3a5e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_b1ba6448-6c01-4f86-a8cf-28972fd06c90" xlink:href="mrk-20211231.xsd#mrk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_mrk_OtherCountriesMember_b1ba6448-6c01-4f86-a8cf-28972fd06c90" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="extended" id="i824289cfe90842cc87dfe3763714e23a_SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_dad0ebc2-360b-4e5a-ba95-92e24f42759e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_InvestmentIncomeInterest_dad0ebc2-360b-4e5a-ba95-92e24f42759e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_55b8420c-a60f-480a-ac39-c42dde21af3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_InterestExpense_55b8420c-a60f-480a-ac39-c42dde21af3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_6dbb112b-1c44-4e63-8c8c-72a6e61bf711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_AdjustmentForAmortization_6dbb112b-1c44-4e63-8c8c-72a6e61bf711" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9c244564-775a-498d-8930-898b74c03dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_Depreciation_9c244564-775a-498d-8930-898b74c03dbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4da8ef29-6133-4f83-96a6-436b50680212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4da8ef29-6133-4f83-96a6-436b50680212" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b9fe9b0a-4a1c-4984-b04f-7be3968c5d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_RestructuringCharges_b9fe9b0a-4a1c-4984-b04f-7be3968c5d21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_6dfee9f6-8e14-4fd1-839e-c4fd34e6d432" xlink:href="mrk-20211231.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_6dfee9f6-8e14-4fd1-839e-c4fd34e6d432" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13d93b76-01b1-4feb-9bec-acb1daa11bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13d93b76-01b1-4feb-9bec-acb1daa11bfe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ee2bb38-7349-4a42-be42-ef7fd8c041b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ee2bb38-7349-4a42-be42-ef7fd8c041b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3d4bb036-5248-41da-be65-95491678b95f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ee2bb38-7349-4a42-be42-ef7fd8c041b9" xlink:to="loc_srt_ConsolidationItemsAxis_3d4bb036-5248-41da-be65-95491678b95f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3d4bb036-5248-41da-be65-95491678b95f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_3d4bb036-5248-41da-be65-95491678b95f" xlink:to="loc_srt_ConsolidationItemsDomain_3d4bb036-5248-41da-be65-95491678b95f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_3d4bb036-5248-41da-be65-95491678b95f" xlink:to="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6ab9f426-c4f9-4cb5-a339-c5d347533d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:to="loc_us-gaap_OperatingSegmentsMember_6ab9f426-c4f9-4cb5-a339-c5d347533d23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_dd8619df-6c24-46a9-9fe7-bb01a859e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:to="loc_us-gaap_CorporateNonSegmentMember_dd8619df-6c24-46a9-9fe7-bb01a859e0a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_c60369dc-7d07-406c-be34-5bbb73078c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_c60369dc-7d07-406c-be34-5bbb73078c23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3a3f924b-9487-4388-bbac-8285f620792c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ee2bb38-7349-4a42-be42-ef7fd8c041b9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3a3f924b-9487-4388-bbac-8285f620792c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3a3f924b-9487-4388-bbac-8285f620792c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3a3f924b-9487-4388-bbac-8285f620792c" xlink:to="loc_us-gaap_SegmentDomain_3a3f924b-9487-4388-bbac-8285f620792c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3a3f924b-9487-4388-bbac-8285f620792c" xlink:to="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_bc340c4c-7545-4edd-8470-fe957758745d" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:to="loc_mrk_PharmaceuticalsegmentMember_bc340c4c-7545-4edd-8470-fe957758745d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_6a943e6d-8676-4e83-90a2-dd4c24e16bc7" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:to="loc_mrk_AnimalHealthsegmentMember_6a943e6d-8676-4e83-90a2-dd4c24e16bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f0450e2f-7082-4318-9331-1b4da49d3430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f0450e2f-7082-4318-9331-1b4da49d3430" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" xlink:type="extended" id="i63fe9739ff904e5ba11f2dab7d2e138f_SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_571fd684-0323-4f10-a117-12464a906cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a0b2b6f7-8489-45ed-8f9b-e8fd9e5ee237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_571fd684-0323-4f10-a117-12464a906cf2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a0b2b6f7-8489-45ed-8f9b-e8fd9e5ee237" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0a99b2e5-3da1-4a97-aca3-1c852b0bed45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_571fd684-0323-4f10-a117-12464a906cf2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0a99b2e5-3da1-4a97-aca3-1c852b0bed45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a46da3a-1ed6-48dc-8929-394bfc313c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_571fd684-0323-4f10-a117-12464a906cf2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a46da3a-1ed6-48dc-8929-394bfc313c90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e175315c-e172-4d07-b96d-648e457eb38b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a46da3a-1ed6-48dc-8929-394bfc313c90" xlink:to="loc_srt_ConsolidationItemsAxis_e175315c-e172-4d07-b96d-648e457eb38b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e175315c-e172-4d07-b96d-648e457eb38b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e175315c-e172-4d07-b96d-648e457eb38b" xlink:to="loc_srt_ConsolidationItemsDomain_e175315c-e172-4d07-b96d-648e457eb38b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a439439b-4faa-438a-a19c-ce519c8a327c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e175315c-e172-4d07-b96d-648e457eb38b" xlink:to="loc_srt_ConsolidationItemsDomain_a439439b-4faa-438a-a19c-ce519c8a327c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_02b3dea0-613d-4fad-85da-f5f792b79e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a439439b-4faa-438a-a19c-ce519c8a327c" xlink:to="loc_us-gaap_OperatingSegmentsMember_02b3dea0-613d-4fad-85da-f5f792b79e16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7a0b30cf-9535-467c-870b-ab09cb4317db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a46da3a-1ed6-48dc-8929-394bfc313c90" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7a0b30cf-9535-467c-870b-ab09cb4317db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7a0b30cf-9535-467c-870b-ab09cb4317db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7a0b30cf-9535-467c-870b-ab09cb4317db" xlink:to="loc_us-gaap_SegmentDomain_7a0b30cf-9535-467c-870b-ab09cb4317db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7a0b30cf-9535-467c-870b-ab09cb4317db" xlink:to="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_aeb38f7d-feb8-457e-a11f-779c3bcc91e7" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:to="loc_mrk_PharmaceuticalsegmentMember_aeb38f7d-feb8-457e-a11f-779c3bcc91e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_87410428-d10f-4bdb-9b4d-e3ddfb93b948" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:to="loc_mrk_AnimalHealthsegmentMember_87410428-d10f-4bdb-9b4d-e3ddfb93b948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1886ae03-ef72-4369-a6b9-91b82f424acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1886ae03-ef72-4369-a6b9-91b82f424acd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="extended" id="ia056eeb9a1414769953a2e03b391ee22_SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_dad11bb0-c46a-4578-9a47-c19c5279b464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3c9c0032-8cf9-4e95-ad11-e46685cff74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_dad11bb0-c46a-4578-9a47-c19c5279b464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3c9c0032-8cf9-4e95-ad11-e46685cff74d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_82635beb-37e2-4b0c-b786-011c056a19aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_dad11bb0-c46a-4578-9a47-c19c5279b464" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_82635beb-37e2-4b0c-b786-011c056a19aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ad17b895-a11d-4dd2-b58c-9076b05424cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_82635beb-37e2-4b0c-b786-011c056a19aa" xlink:to="loc_srt_StatementGeographicalAxis_ad17b895-a11d-4dd2-b58c-9076b05424cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ad17b895-a11d-4dd2-b58c-9076b05424cd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ad17b895-a11d-4dd2-b58c-9076b05424cd" xlink:to="loc_srt_SegmentGeographicalDomain_ad17b895-a11d-4dd2-b58c-9076b05424cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ad17b895-a11d-4dd2-b58c-9076b05424cd" xlink:to="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2b81dc97-30a3-4846-813c-7e0fc38a271f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_country_US_2b81dc97-30a3-4846-813c-7e0fc38a271f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_a2d1ac7e-94fd-4faa-8e1b-9187afec4e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_us-gaap_EMEAMember_a2d1ac7e-94fd-4faa-8e1b-9187afec4e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_8d1aece5-492c-4032-bfda-09c318e60d50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_srt_AsiaPacificMember_8d1aece5-492c-4032-bfda-09c318e60d50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_7ef1a0d8-4902-4a7b-aff8-ff418846917f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_country_CN_7ef1a0d8-4902-4a7b-aff8-ff418846917f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_a1f78acd-77bc-4fd6-9d8a-d90f16eace53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_srt_LatinAmericaMember_a1f78acd-77bc-4fd6-9d8a-d90f16eace53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_62668efa-d80d-4bb2-a86c-a9fe39d5a69e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_country_JP_62668efa-d80d-4bb2-a86c-a9fe39d5a69e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_f643f42d-e005-4b42-be73-d58190c84aab" xlink:href="mrk-20211231.xsd#mrk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_mrk_OtherCountriesMember_f643f42d-e005-4b42-be73-d58190c84aab" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>mrk-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c2671c01-457c-407e-affb-5c2ec2e9dc08,g:df117aec-e688-48b3-9aac-3f4fd6688d4e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f850fe71-ce1b-4419-ba2d-986ed4aa926d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5783de2f-8422-4c6f-a0f2-6aab46d3ad15_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_538e5758-1101-48e5-aa46-7d1e0280fe0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_4cc316f1-57fc-48d1-90f6-33d28167aaf0_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains) losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d09be45c-f13d-4799-9b0a-b9d872faa206_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_974a0a30-206d-4d39-951b-0c1b36561c22_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A170NotesDue2027Member_bb416ee1-8f79-4cd4-bdf6-26235649cd17_terseLabel_en-US" xlink:label="lab_mrk_A170NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.70% notes due 2027</link:label>
    <link:label id="lab_mrk_A170NotesDue2027Member_label_en-US" xlink:label="lab_mrk_A170NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.70% notes due 2027 [Member]</link:label>
    <link:label id="lab_mrk_A170NotesDue2027Member_documentation_en-US" xlink:label="lab_mrk_A170NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.70% notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member" xlink:href="mrk-20211231.xsd#mrk_A170NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A170NotesDue2027Member" xlink:to="lab_mrk_A170NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c020dc27-d3b2-425b-8606-656dfdfcfee9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A235NotesDue2040Member_ac5b79f0-292b-4007-ab4e-2a4b6e8b0ba3_terseLabel_en-US" xlink:label="lab_mrk_A235NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2040</link:label>
    <link:label id="lab_mrk_A235NotesDue2040Member_label_en-US" xlink:label="lab_mrk_A235NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2040 [Member]</link:label>
    <link:label id="lab_mrk_A235NotesDue2040Member_documentation_en-US" xlink:label="lab_mrk_A235NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A235NotesDue2040Member" xlink:href="mrk-20211231.xsd#mrk_A235NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A235NotesDue2040Member" xlink:to="lab_mrk_A235NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_1f08c004-ff8a-42eb-9afe-699f5d965d50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses and other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_8efd53fe-761d-4a7f-a0ea-eaa0f7a427bc_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_5869c1b5-e86a-40a9-98fe-8731915b338e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_40f8ba75-6605-4748-992a-be84b69fbd7f_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_afa19cf1-49cf-4caa-96b0-297be92ce831_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4d38f909-e689-440a-b38e-ce8346560582_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_486ca4c4-a80b-44de-8057-b3356894f2bd_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Awards transferred to Organon in the spin-off (in dollars per share)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_1e9f9031-2d2d-4287-8df7-93ae7cd943ee_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_a9e66774-d61c-43e5-86eb-f4017891526f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_c62bfe7f-3126-4120-add9-8d32838adb63_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_381e75b1-6050-43bd-a439-e2627942e980_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a7d4506d-77e0-4202-836b-e92734497fb7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5f4d781b-bc6d-4b17-bab3-f922be5ce9b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fa71b8d2-1b61-468b-90ea-cabd273cd19d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f91076d1-d85a-48e9-9d8d-6478f3e90a11_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_15deb915-a8f1-4c87-b38c-9fa7f2cb0344_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_055cd451-c149-40d5-9ca2-dcecca9fa93a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition tax for accumulated foreign earnings, liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa33e236-f2d0-4fa9-9974-361e9ca0a1b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_96229ef5-73e7-4bc3-a075-704c7aedbc3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares collectively authorized for future grants under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_91fc6ecf-7439-458f-81f1-683248c34c8d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_df66f941-13ab-462e-a083-8a2c6b0824d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9d0d43f5-fd01-46b9-b07b-fc3c0e75ccbb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ffad383b-bdd9-4d54-aa75-4e519ce718a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_539bfd34-8c27-47e0-a007-fd7f2aadc621_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product intangibles and licenses, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_db542ec9-ae34-4483-856b-61b969feddf8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9729c149-9dba-40e6-b8f5-bee365d279db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_cb36b185-4fd4-4e8f-9d63-91a39b468b02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_43483a17-e012-4fd9-988d-63804627b321_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_fedc5633-d898-43f4-95c2-f01f193afec7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges and Spending Relating to Restructuring Activities by Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_043404ad-4a2a-4c58-86c6-904d2db2051b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_13de13ad-67dc-42b2-b9b1-8e1d579cc57a_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of intangible assets, acquired</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_06b8f6d8-ba78-4ece-a529-27cdcc131e25_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions related to prior year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_ce452bff-bb07-4fd6-9bdd-2bd5e022498b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received from counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_0d129f7b-2992-4594-af17-03a823ab8ecf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7d122e26-a0a2-4c85-a371-255b7acfec2b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eb3ae135-e8cd-405e-831e-2c6f256eff95_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_cab57bd2-2bf2-4968-b5b0-81f1c9c64ba7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_f40a4c75-1f91-41de-957e-85d31f281399_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_595387b9-7994-4c41-b7f1-61d2281991a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_fc75f86c-d45f-42e4-8ec2-56e4984b2da5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SupplyCommitmentQuantityDelivered_9fb1ca1c-2cb7-4717-aceb-ed667072a7a9_terseLabel_en-US" xlink:label="lab_mrk_SupplyCommitmentQuantityDelivered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity delivered (in courses)</link:label>
    <link:label id="lab_mrk_SupplyCommitmentQuantityDelivered_label_en-US" xlink:label="lab_mrk_SupplyCommitmentQuantityDelivered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Quantity Delivered</link:label>
    <link:label id="lab_mrk_SupplyCommitmentQuantityDelivered_documentation_en-US" xlink:label="lab_mrk_SupplyCommitmentQuantityDelivered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Quantity Delivered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentQuantityDelivered" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentQuantityDelivered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SupplyCommitmentQuantityDelivered" xlink:to="lab_mrk_SupplyCommitmentQuantityDelivered" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_69531f72-b142-4c08-b358-6498bafeb342_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00d55bf7-3ea2-4834-820f-49c8d9f1c522_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_af21c1e5-24be-4d0e-b44e-b6882b55fee5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_1328c4af-0134-4384-8ab9-c81843f75073_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Hedged Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_95e9be93-0d19-4b79-84a8-99f7a8aeb416_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_4393ab76-a59f-4c62-9aa3-db1a09e2a515_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_841e162f-43ca-43a5-bbea-e1d937121fa1_terseLabel_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_label_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_4a72357c-9dd0-4990-ae68-e4cfd459a0c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ecd25662-323b-4fa5-9921-a3eb57ae3eee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_df80dc7c-c20b-4b97-9d03-8e14618fe871_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_9b7dc807-b8c1-493b-bcc7-1a3c8ca5b80b_terseLabel_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed To Toll Statute Of Limitations</link:label>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_label_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed ToToll Statute Of Limitations [Member]</link:label>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_documentation_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed To Toll Statute Of Limitations[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:href="mrk-20211231.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:to="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_87ef46a5-3d59-4fae-a582-1b0469b7a170_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_48d647fa-ba4e-4ef2-8489-51f2314676bf_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) amortization</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a76d79e9-41e0-4bdf-b278-8f13a5d0f982_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1a98acb8-1557-43d0-a076-b4d5b682865c_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_104d1110-97af-4e27-989a-7d24f4890f94_terseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_label_en-US" xlink:label="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Products and Product rights, Measurement Input</link:label>
    <link:label id="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_documentation_en-US" xlink:label="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Products and Product rights, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetProductsAndProductRightsMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:to="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_1d80615a-c1e3-4f85-8ce1-cfbcaac3a0cc_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember_7c76622b-e08c-4604-91a2-d53efc25af33_terseLabel_en-US" xlink:label="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets equities</link:label>
    <link:label id="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets Equities Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets equities investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:href="mrk-20211231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:to="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5bbc7bba-82c7-455a-837e-4fe2f3cce294_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_2b74af5f-7a1e-4c2e-8115-9f3b37ce0f47_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AntelliqMember_dc230151-ed7c-4f45-a623-3bfae017f786_terseLabel_en-US" xlink:label="lab_mrk_AntelliqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antelliq</link:label>
    <link:label id="lab_mrk_AntelliqMember_label_en-US" xlink:label="lab_mrk_AntelliqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antelliq [Member]</link:label>
    <link:label id="lab_mrk_AntelliqMember_documentation_en-US" xlink:label="lab_mrk_AntelliqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antelliq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember" xlink:href="mrk-20211231.xsd#mrk_AntelliqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AntelliqMember" xlink:to="lab_mrk_AntelliqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PensionPlanPriorServiceCostMember_6fa11783-1c76-497f-8e86-a93ffec8a366_terseLabel_en-US" xlink:label="lab_mrk_PensionPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Prior Service Credit</link:label>
    <link:label id="lab_mrk_PensionPlanPriorServiceCostMember_label_en-US" xlink:label="lab_mrk_PensionPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Prior Service Cost [Member]</link:label>
    <link:label id="lab_mrk_PensionPlanPriorServiceCostMember_documentation_en-US" xlink:label="lab_mrk_PensionPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanPriorServiceCostMember" xlink:href="mrk-20211231.xsd#mrk_PensionPlanPriorServiceCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PensionPlanPriorServiceCostMember" xlink:to="lab_mrk_PensionPlanPriorServiceCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_be34538e-b9f6-4381-993d-78d44071c652_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_67b8f3dc-7be9-4877-a398-c3dfc375153a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_caa488ac-29c9-4152-83a9-30e77445de70_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of loans payable and long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_e6b214a2-76fb-4266-8b90-602d4b7bbe88_terseLabel_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO inventory amount</link:label>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_label_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO Inventory Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LIFOInventoryAmount" xlink:to="lab_us-gaap_LIFOInventoryAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_2cd9df9c-2986-4d5b-98a8-7acd8d020b55_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_b988a26b-934a-4841-b63a-a5a9896cadbc_terseLabel_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts</link:label>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_bc85a903-b9b2-4d76-9309-a4ebf5ae0fd3_verboseLabel_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts</link:label>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_label_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts Other Investments [Member]</link:label>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_documentation_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember" xlink:href="mrk-20211231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InsuranceContractsOtherInvestmentsMember" xlink:to="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c1ba1ace-629f-417b-af67-2033ebbab26b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2cdfd202-5003-4b06-83fd-7fbe50f41714_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory related, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22794c52-1f8c-4da7-b96b-611ebe82feab_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_488886e9-938a-4db6-9fc2-347a49f3ccfd_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_6fa336ae-df10-49c2-8be8-61f4d3bbdda1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax settlements</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_472243a0-5ffb-4b5f-a00d-839ae3107432_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operations, property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_68bf14c0-02b5-48c6-9e00-b29674bc5e55_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_21dd54a0-569a-4fcc-8ccc-aab26b54593d_terseLabel_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_label_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_documentation_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AnimalHealthsegmentMember" xlink:to="lab_mrk_AnimalHealthsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FixedIncomeObligationsInvestmentFundsMember_14305d81-ac06-470b-801a-b091c314fc18_terseLabel_en-US" xlink:label="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other fixed income obligations</link:label>
    <link:label id="lab_mrk_FixedIncomeObligationsInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Obligations Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_FixedIncomeObligationsInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income obligations investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:href="mrk-20211231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:to="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_916ff0ed-dfc4-4ce5-a2b5-bd5b1eff5f7c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e13c28fe-7a3a-4c75-bca3-951828c0cabe_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e533a880-157c-4619-aada-bbca85edc684_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains) losses for equity securities held through ownership interests in investment funds</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_07198e17-dc8b-4895-a286-ee65c2f41ab0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Investing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_dd4ee263-e4b4-4468-aa57-66a89a2b33eb_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75a5c531-bc8f-4d55-aba1-1675d6f6a20a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Nonvested January 1 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c6af86b4-5c4d-459b-b5a3-88a48c5d17e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Nonvested December 31 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_96102256-7f13-4949-9019-5ccff7ced8c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_4ac7f1d3-86f1-44f9-8ad0-17e60725ee66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_a6454708-5741-45e0-99f2-420b8dd8c099_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_d9577c43-fc09-4761-b776-6a2399c20e7a_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_aca91fd0-0cbe-4129-bbdc-42f1ecbed6f5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_f8bd17e8-d1ba-46f3-bd87-29cef340c24a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_992b5196-65cc-4044-aac6-efd485c4973f_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, equipment and office furnishings</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_bc6a2ef5-4c33-4a45-8402-a9a8837b1982_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_95ecf5bc-161f-4437-bd7a-1726d5da0d8f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_075048e5-ceef-4fff-a186-1e604335dc99_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_b8bcc25a-f7fb-4ec9-99fe-934139d68f47_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_511d9ed9-81e9-4640-9736-c027970b7522_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7ef9cd73-cc41-4819-8bab-1b04e7c97f6c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain (loss) recognized in OCI on derivatives</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_e7471e14-b91c-4dce-bc40-cfa10faec067_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in Other current assets</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a4ab1197-e947-4561-8e25-be341cb3cab8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_cdb2ff00-161a-4edb-9f15-07688c4c7f1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_db52796f-afdc-41df-8f18-d4dc791423ba_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_eb829633-98b5-4050-a3af-fc4378e7e2dd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ac10b3d7-144b-4d46-8da4-97b48f9535b0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SanofiPasteurMember_f1155402-099a-4947-8786-a6f8bd934c07_terseLabel_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_label_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_documentation_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember" xlink:href="mrk-20211231.xsd#mrk_SanofiPasteurMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SanofiPasteurMember" xlink:to="lab_mrk_SanofiPasteurMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7c976e3c-9e68-427e-a5e9-db4df283ad9f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanuviaMember_f38066b2-89d2-4b78-98b2-8074f8fcb35f_terseLabel_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia</link:label>
    <link:label id="lab_mrk_JanuviaMember_label_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member]</link:label>
    <link:label id="lab_mrk_JanuviaMember_documentation_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember" xlink:href="mrk-20211231.xsd#mrk_JanuviaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanuviaMember" xlink:to="lab_mrk_JanuviaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e57fe4d8-c03c-4666-a638-0209b2e09b68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_35cc3a51-6c76-4615-854e-00349612c8b1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_f40ebcc7-3d60-495f-8ffb-6bfba3adc8c2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_68d12f92-5e7c-4627-ac6d-6193af04f9ae_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Differential arising from:</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8e4c71ad-e0f7-415e-83b4-73ee2fe720a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ed73785a-c4c3-4bc0-9a9e-272feb65791e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_945cd5d6-dc8a-4778-a331-714daa06613c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_8898c234-3cb1-42e7-87d0-2ff51c85e0c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OralFormulationMember_741dd84a-7046-49ea-96ea-607d5b5c504b_terseLabel_en-US" xlink:label="lab_mrk_OralFormulationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation</link:label>
    <link:label id="lab_mrk_OralFormulationMember_label_en-US" xlink:label="lab_mrk_OralFormulationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">oral formulation [Member]</link:label>
    <link:label id="lab_mrk_OralFormulationMember_documentation_en-US" xlink:label="lab_mrk_OralFormulationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">oral formulation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralFormulationMember" xlink:href="mrk-20211231.xsd#mrk_OralFormulationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OralFormulationMember" xlink:to="lab_mrk_OralFormulationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_068758ca-649b-40d9-8571-b504d0a08f7a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions related to current year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1df5bb74-4064-43d2-b52b-5b65ad52c9ff_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_6f95abd5-afe8-4d62-bc96-3fb45a970390_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_f6cdc495-98b0-403e-806b-a1bf71414889_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International equities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_19dab6bd-5f2d-4fae-a3cb-9738d20a36df_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_b8c6cdac-5708-4071-b080-96bad6c6fdf7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherStateCourtMember_1dad8487-84f8-40f8-bbad-27b2978528a0_terseLabel_en-US" xlink:label="lab_mrk_OtherStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other State Court</link:label>
    <link:label id="lab_mrk_OtherStateCourtMember_label_en-US" xlink:label="lab_mrk_OtherStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other State Court [Member]</link:label>
    <link:label id="lab_mrk_OtherStateCourtMember_documentation_en-US" xlink:label="lab_mrk_OtherStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other state court.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherStateCourtMember" xlink:href="mrk-20211231.xsd#mrk_OtherStateCourtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherStateCourtMember" xlink:to="lab_mrk_OtherStateCourtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a63c3e8d-21d7-4f42-80e1-b83f1b72092a_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45129a3d-ba5d-4e9e-b9a4-b25289e766cb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_bcf4892d-0a28-4230-b52b-51f467cc76b3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable net impact to income tax provision if unrecognized tax benefits were recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_HealthcareServicesSegmentMember_868857c7-3afb-4930-a0f2-1aa74a2660e1_terseLabel_en-US" xlink:label="lab_mrk_HealthcareServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Services</link:label>
    <link:label id="lab_mrk_HealthcareServicesSegmentMember_label_en-US" xlink:label="lab_mrk_HealthcareServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Services Segment [Member]</link:label>
    <link:label id="lab_mrk_HealthcareServicesSegmentMember_documentation_en-US" xlink:label="lab_mrk_HealthcareServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Services segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_HealthcareServicesSegmentMember" xlink:href="mrk-20211231.xsd#mrk_HealthcareServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_HealthcareServicesSegmentMember" xlink:to="lab_mrk_HealthcareServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_466f03a5-bca2-4a24-a940-e4c17d7f6f96_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_6b9b558c-f695-42ef-8747-0e637bbdaa34_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RotateqMember_996b0390-6c16-4449-acd8-a707dbd07ba7_terseLabel_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq</link:label>
    <link:label id="lab_mrk_RotateqMember_label_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rotateq [Member]</link:label>
    <link:label id="lab_mrk_RotateqMember_documentation_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember" xlink:href="mrk-20211231.xsd#mrk_RotateqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RotateqMember" xlink:to="lab_mrk_RotateqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_aa08eacd-91ef-4eae-af31-78b899c3c181_terseLabel_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement</link:label>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_label_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement [Member]</link:label>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_documentation_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember" xlink:href="mrk-20211231.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TransitionServicesAgreementMember" xlink:to="lab_mrk_TransitionServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_7bd901f5-282b-415a-b173-e85d28b1d56c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from investments in equity securities, net</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9faeae1f-f6f3-49b8-bd45-fb4165f0fdbd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2e3595c0-3c3b-453f-8347-c0edd7f95dc1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_ae2a2865-83a2-43c9-9303-1773f599c2d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Pandion Therapeutics, Inc., net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Three, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_7143a398-37cd-4dda-aea6-f6bcb3189303_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D tax credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_826fba5b-d529-4aa8-8ba6-4b603ef3a6c3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits from adjustments related to examination</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_283009c6-dda2-4888-918d-93391aac2cc2_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleronPharmaIncMember_bb28aaad-d7b6-4bd1-bf1e-eb775eacf733_terseLabel_en-US" xlink:label="lab_mrk_AcceleronPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acceleron Pharma Inc.</link:label>
    <link:label id="lab_mrk_AcceleronPharmaIncMember_label_en-US" xlink:label="lab_mrk_AcceleronPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acceleron Pharma Inc. [Member]</link:label>
    <link:label id="lab_mrk_AcceleronPharmaIncMember_documentation_en-US" xlink:label="lab_mrk_AcceleronPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acceleron Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember" xlink:href="mrk-20211231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleronPharmaIncMember" xlink:to="lab_mrk_AcceleronPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_078e8ba8-7505-4445-8c79-c1f28fdb16d1_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c40f6580-28db-4199-9ff4-c5c790bfc028_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1318dfa7-ad91-43a9-b27e-d8698bf26680_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_b79e2078-ee11-46b4-91a4-0a676b99ed30_terseLabel_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_label_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Pharmaceutical [Member]</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_documentation_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember" xlink:href="mrk-20211231.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPharmaceuticalMember" xlink:to="lab_mrk_OtherPharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_38236b61-6d2a-4a5b-adef-7cacbf441d32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of Organon</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_5ea9296e-7069-4812-8eb6-ce50bdc91565_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember_3b5de6ff-68c1-4f39-9ea8-a0410f048a98_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember_label_en-US" xlink:label="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Excluding Current Maturities [Member]</link:label>
    <link:label id="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Excluding Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtExcludingCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:to="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b38a28f6-3a3c-4646-b51b-cc3d7aadb05e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f4ce5346-f5e9-4a1d-85eb-ce8c8aea01a3_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance January&#160;1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0c9ef064-e0f3-491f-87b1-5f96d62b0bff_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance December&#160;31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_7ccd8db3-5ef8-4704-a103-d95dbd96458d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_b8a2c487-5416-496d-84c4-0bbe31500af2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_b5f31ae3-fcae-4e5f-9278-0a3de46912f2_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic defined benefit plan (credit) cost other than service cost</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_edf657ca-a1da-457d-b802-f8106ae0e313_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f03d5636-907d-44f0-8fbb-db0beed84dbe_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5b4ede2f-d7af-4f22-9765-f5f4421ec9c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_19d0a198-72e1-4a4a-aa9b-5c8eefbcbf34_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_dd4d0e04-5308-4d4d-8e81-8dabc5086166_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_9512574c-274d-4d0c-a90b-c9ecbc87017f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity before deduction for treasury stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_Pneumovax23Member_ccfbdc3d-d669-4347-92b4-14c97231f572_terseLabel_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_label_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23 [Member]</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_documentation_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23[Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member" xlink:href="mrk-20211231.xsd#mrk_Pneumovax23Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_Pneumovax23Member" xlink:to="lab_mrk_Pneumovax23Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b440e29f-ce04-466e-ab8a-1a1746f177d1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_db56bfd7-03b5-4d1e-8c4c-3979aa4fa84c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance on foreign NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_4ea91ec6-8b92-4ce6-873b-0ba9d30f8e7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_ec4a2f9c-d6ab-4c37-8334-4161aabe60ad_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from income tax refunds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f46c6a3b-bf10-436f-9ea3-11454a26ff95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_79666b50-8e69-4b4e-b548-68fe1095ed5b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_51f15328-62d1-4b75-b04a-d37a265b4770_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities for accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_23cfdecb-e6e9-49b2-a1fd-ecf78b8e9a62_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_52e2769c-cdab-4287-910f-d58b02a1a53c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_d11f2695-6dcf-48f8-a938-43fb0acbf918_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_f910127e-18a4-4714-b731-31ed396fa32d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government bonds</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2e998098-02ee-4a7d-a6ea-8a869f53beed_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_2ac25372-9a70-4920-9818-83336fdde7ba_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_0a43422f-fa5e-4bf0-88c4-83debe97e42f_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_05825802-cbe3-44f5-b154-d3c9e30cf488_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e4f7f03f-ee96-4c42-b2a4-263e228bc127_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2eb50f4a-8d79-48a6-a7a9-59c59c9e3380_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ce7bc11d-3f56-482e-a8bb-4fd1200eef0b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5ed6e546-76d8-4f75-a6d7-3f529171f8fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2021 and 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_ba1e5cbb-788a-4e68-b0a3-96933fa7a61f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_53dd95a8-d6b1-4473-9f7f-6a656cf2f89e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_530c10e5-a2ac-49cc-a222-570f0dbdc4e8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operations, liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a7f4b70d-3e6c-4586-aad3-dbe1f5aec7d2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ee79104-7f72-4211-bdb7-cc81c1f5a831_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5e53b2a7-7d0e-48db-babd-c2fa9691f859_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_06811a6b-a987-403c-be2f-9c127a8c95d4_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember_2fe1aaa8-f8d7-47b5-93a6-86df06230e53_terseLabel_en-US" xlink:label="lab_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to United Nations Children's Fund</link:label>
    <link:label id="lab_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember_label_en-US" xlink:label="lab_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to United Nations Children's Fund [Member]</link:label>
    <link:label id="lab_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember_documentation_en-US" xlink:label="lab_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to United Nations Children's Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToUnitedNationsChildrensFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember" xlink:to="lab_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_841c0be0-34ff-4807-b8a0-61e6edf144d1_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status December&#160;31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IsentressIsentressHDMember_7ad4df61-da4d-4088-bebb-a8ea7d1e63d8_terseLabel_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_label_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member]</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_documentation_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember" xlink:href="mrk-20211231.xsd#mrk_IsentressIsentressHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IsentressIsentressHDMember" xlink:to="lab_mrk_IsentressIsentressHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be26c8f3-3002-41b7-83be-b11fd3470070_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_4195f3a0-ffb8-4818-bbac-8a71c203090d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ba88d126-aca1-48e5-89f8-1b5cd0df60da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Determine Weighted-Average Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearThree_eb8aad7c-f424-4cef-8efc-65c51b7bf342_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2024</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearThree_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Three</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearThree_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearThree" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearThree" xlink:to="lab_mrk_LongTermDebtInterestPayableYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f8202bc3-6996-4112-a0e9-fe584e582427_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Nonvested RSU and PSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_60330854-4b30-4f24-b822-ce5e3e70d1db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service (cost) credit arising during the period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_47f12c6a-6ef5-41f6-bf7f-7787fdd833c7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_02a66a12-d569-4f94-aeb6-3bfeac5521dc_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_1a4a524b-ea3b-4a87-942c-a8afab80f263_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI and the foreign-derived intangible income deduction</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_5200108a-a12a-4eae-a9fe-3d3e92116b28_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_aca13ee0-91c1-4580-ad16-b7dd44175419_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care cost trend rate assumed for next year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_fc1e54d6-a149-48bc-a4b8-490e6143fe9e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_40f39292-8eb2-4d5f-ac78-f51ec85fdaef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_94e47750-ced2-412b-94b4-3f17a31b5a6d_terseLabel_en-US" xlink:label="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards</link:label>
    <link:label id="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_label_en-US" xlink:label="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets credit loss carryforwards and NOL carryforwards domestic</link:label>
    <link:label id="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_documentation_en-US" xlink:label="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets credit loss carryforwards and NOL carryforwards domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:href="mrk-20211231.xsd#mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:to="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_7c3fd533-aa9b-4f55-a903-45dec911cce6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_f5f594d2-656c-4f94-a01f-c35f9666dacf_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_faf27598-a8f2-4773-804c-62fe9101f842_negatedTerseLabel_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of VelosBio Inc., net of cash acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_label_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Four, Net of Cash Acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_documentation_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Four, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:to="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_dea8d000-b067-48fa-9f56-a71c18a9919a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_9a14771f-062d-4f41-98e6-b2330cf360dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeInvestmentsMember_6fba23db-7958-4db8-8934-4c1272a70041_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Investments</link:label>
    <link:label id="lab_us-gaap_FixedIncomeInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeInvestmentsMember" xlink:to="lab_us-gaap_FixedIncomeInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_79ea803a-d077-4283-ba4d-07fe81e8466e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_052d383e-a699-4b48-938b-2d9573b4358b_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3c15a8fd-d3f4-4cbc-8b3b-0ff62603287e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_14662f46-6ffe-4cdc-b692-3f9f1a917a2d_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_69913199-af8f-41ed-8e04-d686ecc92e02_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.70NotesDue2045Member_ab01b975-2192-4ef2-be92-aab0da51d60d_terseLabel_en-US" xlink:label="lab_mrk_A3.70NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% notes due 2045</link:label>
    <link:label id="lab_mrk_A3.70NotesDue2045Member_label_en-US" xlink:label="lab_mrk_A3.70NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes Due 2045 [Member]</link:label>
    <link:label id="lab_mrk_A3.70NotesDue2045Member_documentation_en-US" xlink:label="lab_mrk_A3.70NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes Due 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.70NotesDue2045Member" xlink:href="mrk-20211231.xsd#mrk_A3.70NotesDue2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.70NotesDue2045Member" xlink:to="lab_mrk_A3.70NotesDue2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_dd136fa0-44f5-4968-a6cd-730015776e3a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_a89a8d7d-5392-4521-af93-dce39c8fa3be_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e932991-7f5e-4806-80c0-7a706e793f14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_f9ce46f3-a878-4543-bd54-692c7ca7ba98_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_349f8855-9157-4a71-a92a-9fb6cf7ec43e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_f25f6370-3f68-4ba1-a614-f89b1c26fe3f_terseLabel_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_label_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember" xlink:href="mrk-20211231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopmentMilestonesMember" xlink:to="lab_mrk_DevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_cd7ac050-2ca3-4d33-a652-c756262c7d90_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_31381d0a-dec4-4205-9935-c7bc5e6b9203_terseLabel_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Sales-Based</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_label_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Sales-Based</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_documentation_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Sales-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:href="mrk-20211231.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:to="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_038ee114-428a-4cb4-86c5-84ad2eb4c573_terseLabel_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes Assets And Liabilities Net [Table]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_label_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes Assets And Liabilities Net [Table]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_documentation_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes Assets And Liabilities Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:href="mrk-20211231.xsd#mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:to="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_46894f09-10eb-424e-9d87-2495077f8f84_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherChanges_a1f0497d-fe2c-4ff3-9add-2fed00bb8ae9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherChanges_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanOtherChanges" xlink:to="lab_us-gaap_DefinedBenefitPlanOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_52d2256f-8698-423e-8582-a6321903df02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52834b11-4bb0-4363-b697-77171d98758e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e2750ee4-da42-46f8-a068-1e889a03c3c0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_888d92a7-88ca-4dc5-8e5d-6a495661695b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_1f8e0473-3163-4748-a671-d67d57b1452e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027&#160;&#8212;&#160;2031</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3e6f56a9-5ca2-412d-bc5c-c08aaeefcbdf_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CardinalHealthIncMember_f1faeb5b-8438-4189-a724-337df0883145_terseLabel_en-US" xlink:label="lab_mrk_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_mrk_CardinalHealthIncMember_label_en-US" xlink:label="lab_mrk_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_mrk_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_mrk_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CardinalHealthIncMember" xlink:href="mrk-20211231.xsd#mrk_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CardinalHealthIncMember" xlink:to="lab_mrk_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_c1fb94ca-4485-4b0d-9f78-a5a647cc2baa_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Expected to Vest (in shares)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SivextroMember_14b4bfd2-84dc-46d3-929d-29251431015d_terseLabel_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro</link:label>
    <link:label id="lab_mrk_SivextroMember_label_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro [Member]</link:label>
    <link:label id="lab_mrk_SivextroMember_documentation_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember" xlink:href="mrk-20211231.xsd#mrk_SivextroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SivextroMember" xlink:to="lab_mrk_SivextroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_45e6f987-fd82-484c-a7bc-868add0b2925_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GileadSciencesMember_96ebf29f-597e-4e5c-aab5-5bc93fbb8f06_terseLabel_en-US" xlink:label="lab_mrk_GileadSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences</link:label>
    <link:label id="lab_mrk_GileadSciencesMember_label_en-US" xlink:label="lab_mrk_GileadSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences [Member]</link:label>
    <link:label id="lab_mrk_GileadSciencesMember_documentation_en-US" xlink:label="lab_mrk_GileadSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GileadSciencesMember" xlink:href="mrk-20211231.xsd#mrk_GileadSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GileadSciencesMember" xlink:to="lab_mrk_GileadSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_accb159c-57b0-43fb-9426-e3af11dd87fb_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0db5808e-3510-4aab-a41b-22641371ba12_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_71b37840-f0d4-4eff-934d-de4c1f381755_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_7122081c-90cc-499d-85e9-98c85a2d2358_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs, including amortization</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Amortization Of Purchase Accounting Adjustments</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to the amortization of purchase accounting adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_74cc72f4-1cab-4cbc-9f47-11313beb6cd6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_90a47875-c2a2-4f9e-9053-7bd50465fae6_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_b916106b-9a7d-4d44-873a-f1af3e9f7d79_negatedTerseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A4.00NotesDue2049Member_12e3c4fc-08ba-45d2-92f5-c4a22d94cb62_terseLabel_en-US" xlink:label="lab_mrk_A4.00NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% notes due 2049</link:label>
    <link:label id="lab_mrk_A4.00NotesDue2049Member_label_en-US" xlink:label="lab_mrk_A4.00NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_mrk_A4.00NotesDue2049Member_documentation_en-US" xlink:label="lab_mrk_A4.00NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Notes Due 2049</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A4.00NotesDue2049Member" xlink:href="mrk-20211231.xsd#mrk_A4.00NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A4.00NotesDue2049Member" xlink:to="lab_mrk_A4.00NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_97185700-a825-4548-ba04-836ff0b54763_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Be Noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:href="mrk-20211231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_443c94b0-a401-4ab0-9e5c-331b196421e4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b6d649eb-9976-40f6-9796-fd3fc92aec21_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_312dfb46-0183-4f6b-8427-cb5ecde64cf7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax&#160;Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f0ee0a9-8d14-4bd4-8fbb-d9e7888e19ee_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SimponiMember_38c69333-d3f8-4e0b-b029-c7b76829cae5_terseLabel_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi</link:label>
    <link:label id="lab_mrk_SimponiMember_label_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member]</link:label>
    <link:label id="lab_mrk_SimponiMember_documentation_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember" xlink:href="mrk-20211231.xsd#mrk_SimponiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SimponiMember" xlink:to="lab_mrk_SimponiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_83323212-81e3-4436-a993-0f5984549010_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A415NotesDue2043Member_c9ef96f1-02ee-4d0e-b49e-8c8c84a57d6b_terseLabel_en-US" xlink:label="lab_mrk_A415NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% notes due 2043</link:label>
    <link:label id="lab_mrk_A415NotesDue2043Member_label_en-US" xlink:label="lab_mrk_A415NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2043 [Member]</link:label>
    <link:label id="lab_mrk_A415NotesDue2043Member_documentation_en-US" xlink:label="lab_mrk_A415NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A415NotesDue2043Member" xlink:href="mrk-20211231.xsd#mrk_A415NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A415NotesDue2043Member" xlink:to="lab_mrk_A415NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_59ab69fe-c708-4372-834f-4410a4330be0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_8b412e75-743b-4d42-af9b-a52e4ac47dae_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_87ac80ea-f704-495f-bd61-9e8d6841c11f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_139e1feb-22cc-4317-afa3-7ef397a0c027_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_68817b36-bb91-45d5-9f02-dc068ea35f52_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c043dc73-5abb-4068-86fb-99dd55e9e1da_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_bcf2bcea-aaba-4d06-9a7f-147d3a25b52c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d5a881b9-c02f-4136-a3e8-7d9aefce865c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FosamaxMember_9ed80736-508e-4091-b20f-a41edf180dd3_terseLabel_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax</link:label>
    <link:label id="lab_mrk_FosamaxMember_label_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax [Member]</link:label>
    <link:label id="lab_mrk_FosamaxMember_documentation_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember" xlink:href="mrk-20211231.xsd#mrk_FosamaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FosamaxMember" xlink:to="lab_mrk_FosamaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_7091984d-41f9-4da5-86dc-0a702e03fa7e_negatedLabel_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_label_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income Expense, Other</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_documentation_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other nonoperating income and expense items not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:href="mrk-20211231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:to="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_371f227a-99ac-4a9a-9295-4e04dbe92453_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_77eeea7a-5f98-43e2-8929-3a2b8dab7910_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58326438-5b9e-4e89-83d4-89a6fe08eb7e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_9fc9c40a-9bd9-4973-8354-617e6be50c92_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to the sale of the marketing rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_KeytrudaMember_08bba71b-22c8-44a1-a0cd-b58c754b6de4_terseLabel_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda</link:label>
    <link:label id="lab_mrk_KeytrudaMember_label_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:label id="lab_mrk_KeytrudaMember_documentation_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember" xlink:href="mrk-20211231.xsd#mrk_KeytrudaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_KeytrudaMember" xlink:to="lab_mrk_KeytrudaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_86ec989f-a8a2-4aee-9573-ee6299080840_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_510da86a-6db5-4361-bc45-d3860d5e4df2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_12ce56cb-cd7f-40e4-b40f-42e9d5f7ba9b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_ff8d3144-dc7e-4d0e-bb67-67d88c1aed2c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_f04515c1-ef0b-4252-9f87-f4ec93c0a63f_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_35499685-1d02-4dc8-9b48-22503a7e79df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_20b48956-c712-4832-980b-3f9aab30aca5_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember" xlink:href="mrk-20211231.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueAdempasVerquvoMember" xlink:to="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_c2b07654-d5ae-4e80-b430-6f2b686e8ab4_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ff423fe1-d1cd-429d-ae67-1af26efecdca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d378ccc5-365a-42a9-a74f-b6e5f413bd65_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par Value of Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f39010e5-1d44-4371-a14c-5274fc231b35_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_dfc9a626-d5ee-4ae3-81bf-f6b4a990e4c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise_21efc9c3-978e-45fa-a661-ddf36b7c4109_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Adjustment to Merck awards related to the spin-off of Organon (in dollars per share)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment, Weighted Average Exercise</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment, Weighted Average Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_2f69c7e5-1259-4e6b-9b1c-557d659f333a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_bce74edf-f544-4c8f-8c18-d898bfedd195_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefits related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_57523861-30c0-4a60-84c6-e238714c81c3_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_41f5f2e2-e79b-4ea2-9336-68b25dc6058e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_8577be08-73a0-4f76-a3a8-1d3077e760dc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total segment profits</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fc6247f8-ef64-416b-bc89-55796d60bf37_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_2e5ff98a-e452-40e1-864b-ee25da6524d4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_426c874c-f224-477d-a235-5944b39b6e3e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_b8eb7d96-7bc4-43f6-9337-5d9463de8e37_terseLabel_en-US" xlink:label="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_631e3047-4a75-454b-bd91-34a0f8831532_verboseLabel_en-US" xlink:label="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_label_en-US" xlink:label="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Made To License or Collaborative Partner</link:label>
    <link:label id="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made to partner as part of a licensing or collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:href="mrk-20211231.xsd#mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:to="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ed1bf682-e174-4780-b3bb-cefc9787400b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_23ebb4ba-e238-4552-ae47-c6a9b5b517d8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_65566891-dbdb-423d-8377-1874893d71fe_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_37603884-1188-4eb3-a3f0-05b96742dc2e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_711236cf-d6df-4209-99d5-e18832f9ad78_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Awards transferred to Organon in the spin-off of Organon (in dollars per share)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_219a0572-8169-4303-8d4a-3e6da2436062_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_11cb552f-ed67-4307-a1a9-c6dbe29bf070_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopedMarketsEquitySecuritiesMember_3567d8dd-205f-4020-a517-c2c7a8dbc46c_terseLabel_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitySecuritiesMember_label_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Markets Equity Securities [Member]</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitySecuritiesMember_documentation_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:to="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_b7bb9ff0-b978-490e-88d5-143b739b52e6_terseLabel_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements</link:label>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_label_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements [Member]</link:label>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember" xlink:href="mrk-20211231.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ManufacturingAndSupplyAgreementsMember" xlink:to="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5f849a9a-85a3-440d-8357-1f8f4688fded_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_2a379346-eae8-4785-93c3-a1a566a0d635_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_9d3033ec-0330-405b-ada1-b08111cc0637_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Differential arising from:</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_16d2aa27-1f6d-4109-8897-f3b75644cde2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_6b835c3e-4278-4308-aa1f-d40745b63754_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_246fb5bb-f0ff-46da-aa45-3cbce1a42e59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_73a44a2b-ad76-40c1-8f9d-491d1c6fb690_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c1ed4dcf-655b-44f4-b25a-869b590d3794_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_6e21bca4-b275-487b-bc68-da8c4603de88_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_f41ad37c-b944-4d31-b6f4-bfd11ffe9295_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8174e43b-4140-44b2-8927-7a17dafe5f83_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net of allowance for doubtful accounts of $62 in 2021 and $67 in 2020)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_fb9c4f06-11d1-4fde-98b8-18a963424fcd_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific (other than China and Japan)</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_b758e751-6571-4c1a-b1d8-606ae0acbd42_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory related, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_69454fbd-9787-4e8e-b6d9-c75174a1344a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims dismissed (in cases)</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_502b6ee6-d4c3-4ba6-97b0-a80fa9d15b24_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_78e2a157-0cc4-425b-b889-ea7071eeb394_terseLabel_en-US" xlink:label="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, lease not yet commenced, amount</link:label>
    <link:label id="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_label_en-US" xlink:label="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Amount</link:label>
    <link:label id="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_documentation_en-US" xlink:label="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:href="mrk-20211231.xsd#mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:to="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_ac59602c-ac0e-4665-8fad-7d990a78de32_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e1e073cf-e181-40f9-b0df-db995bffb062_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_096ec9f5-7e2b-4b6a-b26e-b552f71d330d_totalLabel_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current and noncurrent inventories</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of current and noncurrent inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:href="mrk-20211231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:to="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_454a4125-dd2e-460e-8f03-e176cb77da8d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_278cce17-ba28-4dd7-8f56-3e1169873032_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2a6921b1-22e5-4595-a118-002f60522f3e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_1c8bf1cd-9650-4e0c-893d-6809a3b69a49_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76ac9d46-edcb-4d34-baa0-e60bd377d59d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1a76e382-43ad-4a01-8ee5-b038aa8fcea2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_11eb82be-6d22-4f3a-b701-9320993e3cbb_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A275NotesDue2051Member_6239b1a7-4cb8-4594-8c2c-898329936ce4_terseLabel_en-US" xlink:label="lab_mrk_A275NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2051</link:label>
    <link:label id="lab_mrk_A275NotesDue2051Member_label_en-US" xlink:label="lab_mrk_A275NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2051 [Member]</link:label>
    <link:label id="lab_mrk_A275NotesDue2051Member_documentation_en-US" xlink:label="lab_mrk_A275NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member" xlink:href="mrk-20211231.xsd#mrk_A275NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A275NotesDue2051Member" xlink:to="lab_mrk_A275NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_04e15cc6-c698-45a6-9108-4d8aa72d02fd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in Sales as a result of AOCL reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ae6cd82e-9235-4703-b441-597fd042b96e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a5bdcd12-29ef-44f5-9398-20d1dec7231d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_4b23a7e3-2d4a-4f3d-98b7-d1e4324e0b44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Stock and Treasury Stock Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_ce86bbbb-96c3-4dd9-8628-d5fdd2077826_terseLabel_en-US" xlink:label="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Subject To Repayment At Option Of Holder</link:label>
    <link:label id="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_label_en-US" xlink:label="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Subject To Repayment At Option Of Holder [Member]</link:label>
    <link:label id="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_documentation_en-US" xlink:label="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Subject To Repayment At Option Of Holder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:href="mrk-20211231.xsd#mrk_NotesSubjectToRepaymentAtOptionOfHolderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:to="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4ac9d117-bd6b-4665-a3e4-9197e1d0965d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a56e1c64-ebcf-4fec-bd50-7e0a2d87352c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_88e52a95-e0b3-41d8-8b8b-4ce63354657b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operation, other liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A280NotesDue2023Member_2588e8f3-7867-4b92-b378-3162040331ce_terseLabel_en-US" xlink:label="lab_mrk_A280NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2023</link:label>
    <link:label id="lab_mrk_A280NotesDue2023Member_label_en-US" xlink:label="lab_mrk_A280NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Notes Due 2023 [Member]</link:label>
    <link:label id="lab_mrk_A280NotesDue2023Member_documentation_en-US" xlink:label="lab_mrk_A280NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Notes Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A280NotesDue2023Member" xlink:href="mrk-20211231.xsd#mrk_A280NotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A280NotesDue2023Member" xlink:to="lab_mrk_A280NotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_bbd2cef5-b865-4975-8344-4d7a714b08be_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_385247e6-00c6-49b7-8ad5-d8d6e260cc09_terseLabel_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_label_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_documentation_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member" xlink:href="mrk-20211231.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.375Notesdue2036Member" xlink:to="lab_mrk_A1.375Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_0a8b8146-45be-4ce5-beaf-479612aeecf9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_adfb67fb-d489-4f6b-a203-d5c409ffc4b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_0ed63064-0bbb-45f2-a54b-2ab8f50c6b0e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e90aca4c-9ed1-44b2-b981-796d5790df28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_249fa524-7e7d-4b21-9859-8c6c0abd7581_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_959fbbcd-f737-4746-b91d-6273b5fec348_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plans and other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f62f62db-3b21-46d4-a683-725661e2a2cb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CancidasMember_bdd4d396-e5c4-4fa7-9254-3e7434573935_terseLabel_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas</link:label>
    <link:label id="lab_mrk_CancidasMember_label_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member]</link:label>
    <link:label id="lab_mrk_CancidasMember_documentation_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember" xlink:href="mrk-20211231.xsd#mrk_CancidasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CancidasMember" xlink:to="lab_mrk_CancidasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_551f2147-1ca7-44b4-bccb-a8675fa2d2a3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired_247fd8bd-71f8-4ffc-87a4-ca1414d9504c_negatedLabel_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Antelliq Corporation, net of cash acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired_label_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Six, Net of Cash Acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired_documentation_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Six, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired" xlink:to="lab_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PelotonMember_9746131b-1437-4afe-8078-03d73f3816d9_terseLabel_en-US" xlink:label="lab_mrk_PelotonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peloton</link:label>
    <link:label id="lab_mrk_PelotonMember_label_en-US" xlink:label="lab_mrk_PelotonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peloton [Member]</link:label>
    <link:label id="lab_mrk_PelotonMember_documentation_en-US" xlink:label="lab_mrk_PelotonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peloton [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember" xlink:href="mrk-20211231.xsd#mrk_PelotonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PelotonMember" xlink:to="lab_mrk_PelotonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_853f7c56-a742-470b-ab60-5402b674e0a7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_30d2d09a-0289-4c2d-84ec-cb136b38a722_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_b218bd40-fc8a-4045-a619-b901c343655b_terseLabel_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets equities</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Markets Equities Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets equities investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:to="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_24fd60c9-c1a6-4424-b225-988773c865ad_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_73bf532e-4afa-44f0-a091-779c81561a11_terseLabel_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP</link:label>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_label_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP [Member]</link:label>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_documentation_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember" xlink:href="mrk-20211231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RidgebackBiotherapeuticsLPMember" xlink:to="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7e4e4733-2e38-4ff2-a6a7-30579ae9112f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charge related to marketed product</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CostsExpensesAndOther_ccffe4ac-3fe2-445c-a1ee-5dd864cd9221_totalLabel_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs, expenses and other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_label_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Expenses And Other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_documentation_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of cost of sales, operating expenses and nonoperating income or expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther" xlink:href="mrk-20211231.xsd#mrk_CostsExpensesAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CostsExpensesAndOther" xlink:to="lab_mrk_CostsExpensesAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_16c629e3-2aca-4184-bad1-573fa45fa78b_terseLabel_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset-backed securities</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and Asset-Backed Securities Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and Asset-Backed Securities Investment Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:to="lab_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_2984290f-3b26-4dc0-84e5-f789f0dbceea_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IOmetPharmaLtdMember_9eb5c95e-0b20-4f60-8405-69870ba644b7_terseLabel_en-US" xlink:label="lab_mrk_IOmetPharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOmet Pharma Ltd</link:label>
    <link:label id="lab_mrk_IOmetPharmaLtdMember_label_en-US" xlink:label="lab_mrk_IOmetPharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOmet Pharma Ltd [Member]</link:label>
    <link:label id="lab_mrk_IOmetPharmaLtdMember_documentation_en-US" xlink:label="lab_mrk_IOmetPharmaLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOmet Pharma Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IOmetPharmaLtdMember" xlink:href="mrk-20211231.xsd#mrk_IOmetPharmaLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IOmetPharmaLtdMember" xlink:to="lab_mrk_IOmetPharmaLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_edba290e-9477-41de-b942-8e277a953655_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pretax restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_98f285e0-148c-4838-8ad3-8f9ba7a29b56_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_53f8ae4c-aee4-4a72-88ae-fac04206bf6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BristolMyersSquibbMember_86ed4c7c-0e4c-465b-beb4-489f3badbf94_terseLabel_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb</link:label>
    <link:label id="lab_mrk_BristolMyersSquibbMember_label_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb [Member]</link:label>
    <link:label id="lab_mrk_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember" xlink:href="mrk-20211231.xsd#mrk_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BristolMyersSquibbMember" xlink:to="lab_mrk_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_bf09dff2-8f70-41ae-946d-5a6c2390c8df_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers in (out) of Level 3</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:to="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_dbdd1bd9-175c-4c34-bf83-1add11589443_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_191ca329-e5e1-4571-94ac-4252d493b136_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Information Pertaining to Stock Option Plans</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block]</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional information pertaining to stock option plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_4e66de31-9a3a-44ae-9fcb-f610762c5c93_terseLabel_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember" xlink:href="mrk-20211231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RegulatoryMilestonesMember" xlink:to="lab_mrk_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_822ca97d-2eaa-4cdb-9456-b833b9d10330_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of securities and other investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2822b816-22ae-48c7-9468-35fc282e2884_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6977fe62-61c7-4ac0-8d1b-94a7023dd93e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_184ca27f-3661-41eb-817f-841a32986171_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d118846a-f7f1-4f2d-856e-482b878ac652_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRatePercentage_6950afe2-8570-44b3-a6cc-e64b97a8d935_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate, percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage" xlink:href="mrk-20211231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRatePercentage" xlink:to="lab_mrk_RoyaltyRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_98dc6d7d-f832-4487-9a5c-8457a818054e_terseLabel_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate, Investment funds</link:label>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_b6ac9ce6-8768-4365-bd1f-b813e1871f8b_verboseLabel_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate</link:label>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember" xlink:href="mrk-20211231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RealEstateInvestmentFundsMember" xlink:to="lab_mrk_RealEstateInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DunboyneMember_e665c449-8d3e-45d2-a1c8-9eba2fb14fc5_terseLabel_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne</link:label>
    <link:label id="lab_mrk_DunboyneMember_label_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne [Member]</link:label>
    <link:label id="lab_mrk_DunboyneMember_documentation_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember" xlink:href="mrk-20211231.xsd#mrk_DunboyneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DunboyneMember" xlink:to="lab_mrk_DunboyneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_ae5113ac-ab6d-46d2-9fb0-599880d246c2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of securities and other investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fed31449-9f14-411c-bace-4df6877d074a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Continuing Operations Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a291b48-5942-4de5-870d-dfe281d59e50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5ca71ec8-54c0-4c04-81dc-33645a2a9a4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_63355249-4b21-4dea-8895-7585a25a2b77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_5efc107c-795a-4aee-bd65-3d0ec21a6df4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_5a50055b-345b-416d-a734-b0c763833bbf_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_b363994b-a26f-4315-96fc-a9fb84298f78_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain recognized in Other (income) expense, net on derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_a3785a47-1317-45d4-a079-214579f5cee9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_ae010b9f-23dc-4e6f-bdc7-c3b5b6ca77af_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxLineItems_3aff1608-89a1-4299-a262-2600d6b0fc6c_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_mrk_IncomeTaxLineItems_label_en-US" xlink:label="lab_mrk_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_mrk_IncomeTaxLineItems_documentation_en-US" xlink:label="lab_mrk_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxLineItems" xlink:to="lab_mrk_IncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6bebec09-4886-4510-8e67-c1389c7af89f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InjectableFormulationMember_7125d884-02e6-431a-ab67-aa8f5034d8c0_terseLabel_en-US" xlink:label="lab_mrk_InjectableFormulationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation</link:label>
    <link:label id="lab_mrk_InjectableFormulationMember_label_en-US" xlink:label="lab_mrk_InjectableFormulationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">injectable formulation [Member]</link:label>
    <link:label id="lab_mrk_InjectableFormulationMember_documentation_en-US" xlink:label="lab_mrk_InjectableFormulationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">injectable formulation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InjectableFormulationMember" xlink:href="mrk-20211231.xsd#mrk_InjectableFormulationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InjectableFormulationMember" xlink:to="lab_mrk_InjectableFormulationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_061bc7c7-e5cf-46db-b1fe-d8e5459f4a1b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_c2552705-3dc7-4f5b-ac8d-2f9eed507c4e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e9bb804d-717f-420f-9179-12b12a427430_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e73e9271-e5be-426c-b1dc-cc8457fadedf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculations of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_949f468a-a163-4067-a920-001753a69c3f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1b320106-a1b9-48b8-8780-110d6ab6a713_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ad6adeae-e80a-438e-9bfd-b771f497613d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_4088650f-0eae-4561-afd6-6a6177d807ae_terseLabel_en-US" xlink:label="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% notes due 2033</link:label>
    <link:label id="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_label_en-US" xlink:label="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Five Zero Percentage Notes Due On Two Thousand And Thirty Three [Member]</link:label>
    <link:label id="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_documentation_en-US" xlink:label="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point five zero percentage notes due on two thousand and thirty three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:href="mrk-20211231.xsd#mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:to="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_960ad1b1-6ec8-4f07-a8e8-e7f6debf029b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_ba6acb74-8805-448e-b157-1189b857febf_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative downward price adjustment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e02ffe58-a077-4793-87cf-fab498ad7cef_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck &amp; Co., Inc., diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProfitShare_dff680fa-cb89-4e0e-9efe-251cfde1d046_terseLabel_en-US" xlink:label="lab_mrk_ProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit share</link:label>
    <link:label id="lab_mrk_ProfitShare_label_en-US" xlink:label="lab_mrk_ProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Share</link:label>
    <link:label id="lab_mrk_ProfitShare_documentation_en-US" xlink:label="lab_mrk_ProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShare" xlink:href="mrk-20211231.xsd#mrk_ProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProfitShare" xlink:to="lab_mrk_ProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_c52a12d8-dd08-4857-8ba5-4cbffd136288_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax settlements</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39cad0e2-03b9-4bfe-b364-dfa83daf6e14_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck &amp; Co., Inc., basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0a4d3178-934a-4e64-bb2f-bb4815a34602_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_3c84618a-bb4f-44f2-9674-c397ccf05dca_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_39661450-35df-482c-984d-9915ec6ef7d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b8e42a8-598c-4fe2-ab35-1cb124bee20c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_4ca91154-8d10-4cbb-b47b-59f6581e538c_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_38a0d00d-455a-4ba6-98cf-90b3f54862e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_McKessonCorporationMember_097f2659-5052-416f-b41b-57af97ab3843_terseLabel_en-US" xlink:label="lab_mrk_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson</link:label>
    <link:label id="lab_mrk_McKessonCorporationMember_label_en-US" xlink:label="lab_mrk_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_mrk_McKessonCorporationMember_documentation_en-US" xlink:label="lab_mrk_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_McKessonCorporationMember" xlink:href="mrk-20211231.xsd#mrk_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_McKessonCorporationMember" xlink:to="lab_mrk_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9486b6a7-29c9-4659-9959-13269fda0b0f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a291cca8-65da-4876-aa2b-eac4104b7ef5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_87d4d4a2-3833-47e7-a1f2-dde063040566_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0fe3ab62-3e93-4dd8-9fc4-45c1eca3c2bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_59363ddd-11ab-4ab4-9db2-5a3d62278675_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0f66525c-e837-4701-b4a1-a28a79bc4798_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_02b2cc2a-47b3-4534-a976-041dd6387ce7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AccrualForChargebacks_6da8bf96-6feb-479e-8f46-172faa28ae41_terseLabel_en-US" xlink:label="lab_mrk_AccrualForChargebacks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for chargebacks reflected as direct reduction to accounts receivable</link:label>
    <link:label id="lab_mrk_AccrualForChargebacks_label_en-US" xlink:label="lab_mrk_AccrualForChargebacks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual For Chargebacks</link:label>
    <link:label id="lab_mrk_AccrualForChargebacks_documentation_en-US" xlink:label="lab_mrk_AccrualForChargebacks" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for chargebacks reflected as a direction reduction to accounts receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForChargebacks" xlink:href="mrk-20211231.xsd#mrk_AccrualForChargebacks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AccrualForChargebacks" xlink:to="lab_mrk_AccrualForChargebacks" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_81973bb6-1ab8-4480-b9f4-ae0c581d7467_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_c96ef472-b65e-4766-9ec1-bc67efbb9fca_verboseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_fe52ef22-eae8-4384-a4b1-639e7e1d4bea_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other segments</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_403dfabc-e205-4111-9662-0cf0c084dab1_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrevymisMember_37b98de6-ba44-42eb-aabd-88e3b375daa1_terseLabel_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis</link:label>
    <link:label id="lab_mrk_PrevymisMember_label_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis [Member]</link:label>
    <link:label id="lab_mrk_PrevymisMember_documentation_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember" xlink:href="mrk-20211231.xsd#mrk_PrevymisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrevymisMember" xlink:to="lab_mrk_PrevymisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5a1a168e-de66-4029-b193-477146f87c0f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_c2079146-bf07-4993-9b05-7f2c2d9b37f2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_32b98595-15de-4844-b53f-6117d0384570_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_db990348-b9af-4190-8ac5-823a064abf41_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_abe83625-ace6-4ed7-861d-f6bfd602f31f_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties, current</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FederalMember_3450a5f7-1c37-47b2-9687-b1e8a6ba75d9_terseLabel_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Court</link:label>
    <link:label id="lab_mrk_FederalMember_label_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_mrk_FederalMember_documentation_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember" xlink:href="mrk-20211231.xsd#mrk_FederalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FederalMember" xlink:to="lab_mrk_FederalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_0c6f0c25-2f32-46f9-ab1d-f72478bb8e9b_terseLabel_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_label_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_documentation_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member" xlink:href="mrk-20211231.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.500Notesdue2034Member" xlink:to="lab_mrk_A2.500Notesdue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_8ef8f109-0b01-478a-a7c4-5da20ea93e2c_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of VelosBio</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Three</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_365dad12-d0cd-4637-b756-444b9e55d96b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral advanced to counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_f203f409-d914-481a-bdc3-323a527e5c98_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Right to Reclaim Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_c4f427d3-b352-4e1d-9712-25b4a445647c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b6f7644f-8b17-4009-bd6c-1e7adc78c2bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_488f050c-3d33-45a1-b748-e59bf310ce0b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service credit amortization included in benefit cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_17f5ce71-5f11-4327-b62f-1d354f5f9e71_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_20c001ac-901e-4281-8900-8f39b8da93fb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less treasury stock, at cost: 1,049,499,023 shares in 2021 and 1,046,877,695 shares in 2020</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_16546a61-8f6e-46ef-8018-3c984269bf39_terseLabel_en-US" xlink:label="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% notes due 2036</link:label>
    <link:label id="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_label_en-US" xlink:label="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percentage Notes Due On Two Thousand And Thirty Six [Member]</link:label>
    <link:label id="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_documentation_en-US" xlink:label="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five point seven five percentage notes due on two thousand and thirty six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:href="mrk-20211231.xsd#mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:to="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_b6aa1241-0f75-4559-ac10-d98edb979531_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operation, cash</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_662b3f4d-8c52-4715-b745-1cbc97d5838c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_bfa89e4c-663e-40e3-9a2f-3ded36c69a15_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Restructuring Costs</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1296a935-44e5-4a29-a351-8a8458af0bad_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties associated with uncertain tax positions, expense (benefit)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_15247b24-2e43-47c6-aeac-765b17fc5617_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity loss from affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_69f227ef-9d4c-4015-abd4-4cc949f8e945_terseLabel_en-US" xlink:label="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated and Projected Benefit Obligation in Excess of Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:href="mrk-20211231.xsd#mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:to="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_b7748c6e-d673-4a41-a903-60daa28682c2_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI and the foreign-derived intangible income deduction</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_75f6df9b-417e-49c7-8507-6471fc70ecd0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_36008cf0-2225-466a-b8fa-a94c20ae6c77_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SupplyCommitmentToUnitedStatesMember_ff4b4b06-fe5c-4273-9842-018511611cfb_terseLabel_en-US" xlink:label="lab_mrk_SupplyCommitmentToUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to United States</link:label>
    <link:label id="lab_mrk_SupplyCommitmentToUnitedStatesMember_label_en-US" xlink:label="lab_mrk_SupplyCommitmentToUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to United States [Member]</link:label>
    <link:label id="lab_mrk_SupplyCommitmentToUnitedStatesMember_documentation_en-US" xlink:label="lab_mrk_SupplyCommitmentToUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToUnitedStatesMember" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SupplyCommitmentToUnitedStatesMember" xlink:to="lab_mrk_SupplyCommitmentToUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_fc6008f2-4c64-43be-bf9c-ddeb8b4c7cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_7f704c95-b356-4f9f-a093-db44508b47df_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b09e26c7-6d2a-4db2-a12d-def7b938967b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_ea699cdc-2f75-4019-bcd0-40e3d9733766_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Discontinued Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_022e88fb-2b7c-4f2d-b892-76401937ab57_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_39fd9332-729b-44a8-9c80-9e8f0ffd552c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_ba02eb00-5a2c-4573-96ba-18d3b1748fe0_terseLabel_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product return period and expiration</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_label_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period After to Expiration Date</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_documentation_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period After to Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:href="mrk-20211231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:to="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_b5dd9f7d-7f9a-4bde-90cc-56ddbc040968_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RevenuePerformanceObligationPaymentTerms_dfe62177-2dd6-43db-a511-b4716f3ce9cb_terseLabel_en-US" xlink:label="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_mrk_RevenuePerformanceObligationPaymentTerms_label_en-US" xlink:label="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:label id="lab_mrk_RevenuePerformanceObligationPaymentTerms_documentation_en-US" xlink:label="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenuePerformanceObligationPaymentTerms" xlink:href="mrk-20211231.xsd#mrk_RevenuePerformanceObligationPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RevenuePerformanceObligationPaymentTerms" xlink:to="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_55ad5cc3-2532-4132-b5c0-11ca4259e1a6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0d886b30-7141-4c6f-b611-5b96cbbe7162_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_04a0d883-13f1-452e-8d4b-8eb8ff1372c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MolnupiravirMember_52c44a97-7364-4209-b345-1d204c3869c0_terseLabel_en-US" xlink:label="lab_mrk_MolnupiravirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molnupiravir</link:label>
    <link:label id="lab_mrk_MolnupiravirMember_label_en-US" xlink:label="lab_mrk_MolnupiravirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molnupiravir [Member]</link:label>
    <link:label id="lab_mrk_MolnupiravirMember_documentation_en-US" xlink:label="lab_mrk_MolnupiravirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molnupiravir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MolnupiravirMember" xlink:href="mrk-20211231.xsd#mrk_MolnupiravirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MolnupiravirMember" xlink:to="lab_mrk_MolnupiravirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_f4995e28-786e-465c-97bb-7f0e76e74d43_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_759212de-e804-4d3f-a776-9aff8e986ae3_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aa58a282-0c00-4784-b964-16bcce20e51c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (loss) gain on investments, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableSale_4cfcf868-cb4d-4ace-8b24-d0537f796be4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Factored accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableSale_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableSale" xlink:to="lab_us-gaap_AccountsReceivableSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_afee1070-5c2a-498c-826d-ccc771cb0473_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of&#160;Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_332e3c22-5c57-4e92-9f9e-96635dca5b4e_verboseLabel_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and (liabilities), net</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_d04b6a69-00d1-4e67-8cb0-90990dd1cdd6_terseLabel_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:href="mrk-20211231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:to="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7d66ab91-f45b-4f08-b523-2638b4ee2fce_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5a08c5a9-733e-4b9e-97a6-9fb0c759337e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SupplyCommitmentToJapanMember_63e826d4-ef15-4b40-bbe6-74c775a83872_terseLabel_en-US" xlink:label="lab_mrk_SupplyCommitmentToJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to Japan</link:label>
    <link:label id="lab_mrk_SupplyCommitmentToJapanMember_label_en-US" xlink:label="lab_mrk_SupplyCommitmentToJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to Japan [Member]</link:label>
    <link:label id="lab_mrk_SupplyCommitmentToJapanMember_documentation_en-US" xlink:label="lab_mrk_SupplyCommitmentToJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to Japan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToJapanMember" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SupplyCommitmentToJapanMember" xlink:to="lab_mrk_SupplyCommitmentToJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_6b5da83e-1ea7-4937-b4e3-1a81aa40cb91_terseLabel_en-US" xlink:label="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests</link:label>
    <link:label id="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_label_en-US" xlink:label="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests</link:label>
    <link:label id="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_documentation_en-US" xlink:label="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:href="mrk-20211231.xsd#mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:to="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_23402df4-5780-41a1-a380-6ea1a48b8edc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_133fd959-e1fa-47d9-bf84-61082610f20f_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_12402cd3-1044-4adb-96cf-1c792aa94606_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AmerisourceBergenCorporationMember_f24dc5ef-f73c-460c-8028-3d4b50c541cd_terseLabel_en-US" xlink:label="lab_mrk_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_mrk_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_mrk_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:label id="lab_mrk_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_mrk_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmerisourceBergenCorporationMember" xlink:href="mrk-20211231.xsd#mrk_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AmerisourceBergenCorporationMember" xlink:to="lab_mrk_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanNetLossMember_45191412-b45f-43e0-8419-f92ab3550016_terseLabel_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Net Gain</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanNetLossMember_label_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Net Loss [Member]</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanNetLossMember_documentation_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Net Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:href="mrk-20211231.xsd#mrk_OtherPostretirementBenefitPlanNetLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:to="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_bb90a1e1-6393-4f9b-8c6c-a43c7c6d132c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_84be84b5-910f-4620-ab54-1f47ef7a6069_terseLabel_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government And Agency Obligations Fixed Income Securities [Member]</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations fixed income securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:to="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4e27f2c0-0ace-4341-ada3-99786dff436f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_79b5f7b5-7c58-4a02-865e-ea6f731b1361_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_82cb6031-9029-485b-b5c1-039097074f8b_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of VelosBio</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Three, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Three, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_f0aa2841-63bb-47a5-8fb2-b8b32da5f0c1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_92ef8b58-bddd-486b-979c-3388e41d60fd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_93dea4e4-4ac1-4638-ac1f-bc5537f30f7d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_85e1a340-544c-45ca-8801-324874e0ea36_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_84b86958-6f1a-4d7d-b770-8b6723d0f46b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains recognized on investments in equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_6e63d452-6fa3-411f-818e-810cfa9677f0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_208ff85c-172a-4697-b4fc-e9570b699c20_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment (at cost)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_7fcec0fb-c57d-46a5-8cbe-508882913d0b_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Pandion</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Four, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Four, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventorySupplies_e0e1ccc8-c115-4a99-87f6-081c0544c77f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_OtherInventorySupplies_label_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventorySupplies" xlink:to="lab_us-gaap_OtherInventorySupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_436d1c21-57a7-48d0-a5bc-8fadd24b3db5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_001b73e2-de48-4667-850e-6db7bcc1db85_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gains</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_081fb350-1ea9-4bd2-bb63-11c2172dd494_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_5199d64b-eaf0-4d32-8624-57c8964162a5_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f5fb8de7-eb6b-43a2-b14c-0af91df53bf0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A145NotesDue2030Member_0e8bcf9c-fc7b-49d1-b5e0-d0dee5bf81ca_terseLabel_en-US" xlink:label="lab_mrk_A145NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% notes due 2030</link:label>
    <link:label id="lab_mrk_A145NotesDue2030Member_label_en-US" xlink:label="lab_mrk_A145NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% Notes Due 2030 [Member]</link:label>
    <link:label id="lab_mrk_A145NotesDue2030Member_documentation_en-US" xlink:label="lab_mrk_A145NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A145NotesDue2030Member" xlink:href="mrk-20211231.xsd#mrk_A145NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A145NotesDue2030Member" xlink:to="lab_mrk_A145NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_f94bd73c-733e-451f-af7f-030327c7d756_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_5a27dc7c-1426-4920-9b69-d39906b0e9ac_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsAccruedRegulatory_cc8102a4-5586-478d-9e15-017009e9e60c_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsAccruedRegulatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued regulatory approval milestone payment</link:label>
    <link:label id="lab_mrk_MilestonePaymentsAccruedRegulatory_label_en-US" xlink:label="lab_mrk_MilestonePaymentsAccruedRegulatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Accrued Regulatory</link:label>
    <link:label id="lab_mrk_MilestonePaymentsAccruedRegulatory_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsAccruedRegulatory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Accrued Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsAccruedRegulatory" xlink:href="mrk-20211231.xsd#mrk_MilestonePaymentsAccruedRegulatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsAccruedRegulatory" xlink:to="lab_mrk_MilestonePaymentsAccruedRegulatory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_f6bf4b4f-2c9f-46a3-97e7-63c8b29121df_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46c1b9ef-d9fa-40de-8c16-5070512568bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_483cb8b4-ff50-479b-8525-31297e9a6533_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1deba6b4-d39f-44ae-8601-d7a803d1cf8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_b95728b3-9bb2-4309-a18e-a8fc173f6ca7_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, Expenses and Other</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_f92dc4f0-fb6c-4673-870d-013908d571de_terseLabel_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_label_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_documentation_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:href="mrk-20211231.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:to="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_153bd2ac-5b7d-409e-b88e-663c2cba280c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_53c3abc1-238b-4f78-ac27-2d6a84fdc804_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_069bc9b6-4ea6-4bb8-8122-a44217520e3a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_3f496aea-07e4-4868-a930-c9a9ce52e39b_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets January&#160;1</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1458c296-ee01-45e4-9ae2-7203b8f8b01b_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets December&#160;31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5ad4c7a6-1b04-4768-9fba-124bc04679e1_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets at fair value</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9bd4aba9-134a-4935-b46f-8400812c31c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_ed57eb93-b152-453d-963c-41b070d3354f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0b84451f-a13b-457d-8878-abbf3bfa1a67_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Tax Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_00d6a1fb-af7d-417b-8f5e-6280a04a9f0b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_b6fee31b-d859-4ebc-a08d-b9f9db246d72_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_0f652c9f-ef8a-4afc-bbc1-2a9465ec921a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and fixed assets write-offs</link:label>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_label_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Related Impairments or Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:to="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent_f395e191-8ac6-4914-8e1c-235d936a4b98_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrual (Reversal), Income Taxes Payable, Current</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrual (Reversal), Income Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9e21fc86-90d4-4dfd-b680-fa931c1dce4d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_4b888ecf-d989-4d84-bee2-d16ff5b6258d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_155e69cc-209f-4e41-95d9-f1661d6de937_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanumetMember_0fe01a24-e883-4b1c-bc76-0074f8f3665b_terseLabel_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet</link:label>
    <link:label id="lab_mrk_JanumetMember_label_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member]</link:label>
    <link:label id="lab_mrk_JanumetMember_documentation_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember" xlink:href="mrk-20211231.xsd#mrk_JanumetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanumetMember" xlink:to="lab_mrk_JanumetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2bf623b4-f2ef-4396-b5c2-ba79f5003900_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash and cash equivalents related to discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_fc7edc7e-ba73-4f9a-acbb-dcd5928cbf8c_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired_fafa72f5-f18f-49bc-bbf0-0e2b51e3c9f7_negatedLabel_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Peloton Therapeutics, Inc., net of cash acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired_label_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Seven, Net of Cash Acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired_documentation_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Seven, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired" xlink:to="lab_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_faa5d8e1-ab47-4e97-b435-f32bd1b12fd2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_62a36e34-68b2-4630-833a-125dd156f771_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f183e90f-29c5-4242-877c-a4ace231bf7b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_49c3ebed-017e-41d5-ba98-df71b904114e_terseLabel_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments to be made</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_label_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Milestone Payments to be Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Milestone Payments to be Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:href="mrk-20211231.xsd#mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:to="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_fd7b262c-9401-4e79-bf20-7d77ac8e27fb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory classified in Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_37e521ea-4c53-406a-b922-fbf245f266e0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6007b072-c467-42f1-9578-1dec598a6df9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_acad948b-a399-4614-bdda-1052b4583038_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding assuming dilution (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_9f98432d-6180-4601-b9c3-464182374153_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_99d5deca-6f0c-4fb0-8e98-aa50aa5299b6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_6e3cb0d6-2e33-4652-9de8-4b1f8cc5bdea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_423409bc-4e6d-4b4c-a6d6-4eada1e5e111_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TermForPayingOffEnvironmentalLiabilities_aa34652b-2b63-424c-a6eb-90b016b83c73_terseLabel_en-US" xlink:label="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for paying off environmental liabilities</link:label>
    <link:label id="lab_mrk_TermForPayingOffEnvironmentalLiabilities_label_en-US" xlink:label="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term For Paying Off Environmental Liabilities</link:label>
    <link:label id="lab_mrk_TermForPayingOffEnvironmentalLiabilities_documentation_en-US" xlink:label="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for paying off environmental liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:href="mrk-20211231.xsd#mrk_TermForPayingOffEnvironmentalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:to="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_00551964-a149-440e-bb02-8f56b49aa50c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Liabilities of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_e1d838d6-8762-4caf-93ea-aa544de93c0e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Liabilities of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_09d492c7-31a9-4717-aa6b-d614c628102a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Options</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeOptionMember" xlink:to="lab_us-gaap_ForeignExchangeOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b020efc9-013f-4028-ad9d-cd6256027691_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_34e0ebd5-f64b-43f3-93e6-21748147a88d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information Relative to Stock Option Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ScheduleOfOtherIntangiblesTable_71b26432-8109-4d26-a713-e23c9c80cc48_terseLabel_en-US" xlink:label="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangibles [Table]</link:label>
    <link:label id="lab_mrk_ScheduleOfOtherIntangiblesTable_label_en-US" xlink:label="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangibles [Table]</link:label>
    <link:label id="lab_mrk_ScheduleOfOtherIntangiblesTable_documentation_en-US" xlink:label="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangibles [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfOtherIntangiblesTable" xlink:href="mrk-20211231.xsd#mrk_ScheduleOfOtherIntangiblesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable" xlink:to="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_c3a9d4a7-eaa5-4428-9e02-af127ca6335a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8224292f-3df1-4387-a73f-3878033e4d7a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AdempasMember_27bc8d65-b5e7-47d0-bff2-43126695fd6e_terseLabel_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:label id="lab_mrk_AdempasMember_label_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas [Member]</link:label>
    <link:label id="lab_mrk_AdempasMember_documentation_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember" xlink:href="mrk-20211231.xsd#mrk_AdempasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AdempasMember" xlink:to="lab_mrk_AdempasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6fe9f45f-bc13-48f9-bc41-4eb21bc5899c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_30299bbe-01d7-4ed9-9505-64a7da8560ab_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1937c60-b70b-4695-932c-7798de47bcf4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7223b8c5-0714-4d04-9461-d2f2484cd62c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_b0ebeb5c-79ba-4035-aced-341d6669268a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_80276447-6d80-4257-8a8f-ce619ed12286_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach_1744e178-d80d-4353-ba94-2e2b0f5c269a_terseLabel_en-US" xlink:label="lab_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of low and middle income countries (more than)</link:label>
    <link:label id="lab_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach_label_en-US" xlink:label="lab_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Low and Middle Income Countries Reached Through Supply And Access Approach</link:label>
    <link:label id="lab_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach_documentation_en-US" xlink:label="lab_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Low and Middle Income Countries Reached Through Supply And Access Approach</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach" xlink:href="mrk-20211231.xsd#mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach" xlink:to="lab_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ab5df789-48f0-4697-9dbb-117237cd4ea3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_2b55a955-5a91-4bf8-9714-bec54fe4b575_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d8430d7e-ee40-4c30-bc54-294149acdaf5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_bdb122e9-282c-4831-bfcb-a5c9963a6aa3_terseLabel_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_label_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_documentation_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember" xlink:href="mrk-20211231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AlliancerevenueLynparzaMember" xlink:to="lab_mrk_AlliancerevenueLynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8f2fbea9-1b63-48ff-b7e5-036fb485c13c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_34d31c2d-6b37-478e-82cb-8c77bc57642d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NemtabrutinibMember_d769fa4c-06c9-4f93-9ac3-1d9e691c3f1c_terseLabel_en-US" xlink:label="lab_mrk_NemtabrutinibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nemtabrutinib</link:label>
    <link:label id="lab_mrk_NemtabrutinibMember_label_en-US" xlink:label="lab_mrk_NemtabrutinibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nemtabrutinib [Member]</link:label>
    <link:label id="lab_mrk_NemtabrutinibMember_documentation_en-US" xlink:label="lab_mrk_NemtabrutinibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nemtabrutinib</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember" xlink:href="mrk-20211231.xsd#mrk_NemtabrutinibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NemtabrutinibMember" xlink:to="lab_mrk_NemtabrutinibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c9c2ff42-37ad-4945-9094-5cfada6b0219_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_19b200b5-8155-414f-9e18-98ee70c4a2f0_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0fff1607-c1c6-4348-b965-943f427baf68_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_379c6e27-3a20-426c-af66-0a15740f1f6f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6e29c010-2c41-44cd-9b2a-3d1bead469b4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_089712c6-d025-49f1-ae03-76236b492160_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables included in Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_76a188dd-3715-4e0f-b6e7-da33eb932875_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_10aa1ea8-fbb3-4022-96ee-1217446817bb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_d77d67d2-9878-4004-956c-7fcdbde2edc4_negatedLabel_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other unallocated, net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_label_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Unallocated Other Expenses Net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_documentation_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net expenses not allocated to segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:href="mrk-20211231.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:to="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets_d8886444-f049-4986-b1e5-35d43e5de985_terseLabel_en-US" xlink:label="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of markets (more than)</link:label>
    <link:label id="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets_label_en-US" xlink:label="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Minimum, Number of Markets</link:label>
    <link:label id="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets_documentation_en-US" xlink:label="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Minimum, Number of Markets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentMinimumNumberOfMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:to="lab_mrk_SupplyCommitmentMinimumNumberOfMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_ae8abbf8-ea0f-462d-ab34-c0134ab4e7ae_terseLabel_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_label_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_documentation_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:href="mrk-20211231.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:to="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6cbbca37-ca3c-4377-861b-489a96a0d1de_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_44d23e89-ea55-4ca4-8928-dce03703193d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_40052166-103a-4aae-9c4b-096f3e90eaf3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0249d5db-f119-4eae-9a2b-984b43a1aaf0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2fe124b8-b523-4eb7-b862-6a237b8a790d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_0d0c291c-faa5-459a-b59b-bc99a8860b4a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3d984a8d-70ac-4abc-b05a-82ed1a62abb1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_de482be5-26fc-4cca-8f82-35e6c81ed4a5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.375eurodenominatednotesdue2036Member_10b95ee4-3312-43f2-8de2-219c406ba454_terseLabel_en-US" xlink:label="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro-denominated notes due 2036</link:label>
    <link:label id="lab_mrk_A1.375eurodenominatednotesdue2036Member_label_en-US" xlink:label="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro-denominated notes due 2036 [Member]</link:label>
    <link:label id="lab_mrk_A1.375eurodenominatednotesdue2036Member_documentation_en-US" xlink:label="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro-denominated notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375eurodenominatednotesdue2036Member" xlink:href="mrk-20211231.xsd#mrk_A1.375eurodenominatednotesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.375eurodenominatednotesdue2036Member" xlink:to="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFive_29c3155f-b568-4af7-8c30-6d7039714de2_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2026</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFive_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Five</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFive_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFive" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearFive" xlink:to="lab_mrk_LongTermDebtInterestPayableYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_619e9038-3a0e-4023-9838-7930fb6e018d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForEnvironmentalLossContingencies_1cf46d26-701c-404d-b4bb-a42f25313608_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities for environmental matters</link:label>
    <link:label id="lab_us-gaap_AccrualForEnvironmentalLossContingencies_label_en-US" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for Environmental Loss Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForEnvironmentalLossContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:to="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_602f9b6f-8101-4540-980d-18c680a6428d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_689e5d37-2e97-4085-862e-25d7ef4d356c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PandionTherapeuticsMember_1d588401-0c02-4ef4-97e8-1dadefa0bfcc_terseLabel_en-US" xlink:label="lab_mrk_PandionTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pandion Therapeutics</link:label>
    <link:label id="lab_mrk_PandionTherapeuticsMember_label_en-US" xlink:label="lab_mrk_PandionTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pandion Therapeutics [Member]</link:label>
    <link:label id="lab_mrk_PandionTherapeuticsMember_documentation_en-US" xlink:label="lab_mrk_PandionTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pandion Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember" xlink:href="mrk-20211231.xsd#mrk_PandionTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PandionTherapeuticsMember" xlink:to="lab_mrk_PandionTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c99ce4aa-994e-4d09-919f-0504a50ca895_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_7a0bec5b-ed03-48c0-b5f8-94371d4f1059_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_92fcb100-9cda-4ed2-8015-b64618fae010_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3877d313-09c1-4abe-8c46-418292b39893_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_12dfa960-a12f-4441-bf36-62282f77e4c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_26e68802-01b7-4002-8838-9b5c68f8dff2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1e48b7ae-a2e6-4b9c-b40e-ecc9c369d1e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets on NOL carryforwards relating to foreign jurisdictions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_5fb89d6b-8d4c-4d76-9ebd-c0a333fedbd5_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Research and Development Expenses</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_16c16601-7b48-4121-a8e7-e2e4e21f4763_terseLabel_en-US" xlink:label="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Company's pension investments categorized as level 3 assets</link:label>
    <link:label id="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_label_en-US" xlink:label="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Pension Investments Which Are Categorized As Level Three Assets Percentage</link:label>
    <link:label id="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_documentation_en-US" xlink:label="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company pension investments which are categorized as level three assets percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:href="mrk-20211231.xsd#mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:to="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9c272a35-44a1-4c55-9e5a-5fd812ff406e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4caf4c3b-c93d-4e5b-bf1d-022fa9e37270_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_2e16db96-25e7-4985-a9de-e0d4877a86c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_bed69d5f-eebd-4c05-a3b9-c4a34bd00482_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_8e51cc07-2b29-4b0c-9f84-4092f9f514b9_negatedTerseLabel_en-US" xlink:label="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of Organon</link:label>
    <link:label id="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_label_en-US" xlink:label="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction</link:label>
    <link:label id="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_documentation_en-US" xlink:label="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:href="mrk-20211231.xsd#mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:to="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_d9a7c87d-6730-442d-92e3-17edcdb0fb9b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_39816107-2658-4630-9458-c97739f68b32_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d918e418-0792-4f47-93ab-afa04b616a55_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d50d16d1-7dc3-4ce1-91a8-4c0b86a21553_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InvanzMember_01edbe7d-8bbe-4841-b661-2f332ad38b54_terseLabel_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz</link:label>
    <link:label id="lab_mrk_InvanzMember_label_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member]</link:label>
    <link:label id="lab_mrk_InvanzMember_documentation_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember" xlink:href="mrk-20211231.xsd#mrk_InvanzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InvanzMember" xlink:to="lab_mrk_InvanzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_2a9dc29b-64e9-42e7-b961-f5a8334acca1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_5ba7d1c0-f478-46b2-8a17-93d2a5626d84_terseLabel_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_label_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_documentation_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation" xlink:href="mrk-20211231.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ChargesRelatedToProgramDiscontinuation" xlink:to="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_e1392337-c295-45eb-a184-cf8255e67d76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Activity by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_89179d00-1a17-4c80-b63b-04bad06181a1_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_040d375d-9d24-44d1-9291-fdb8e9d8ff06_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OralAndInjectableFormulationsMember_366370d9-f8ae-4cb1-9173-ac4a062af8ef_terseLabel_en-US" xlink:label="lab_mrk_OralAndInjectableFormulationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral and Injectable Formulations</link:label>
    <link:label id="lab_mrk_OralAndInjectableFormulationsMember_label_en-US" xlink:label="lab_mrk_OralAndInjectableFormulationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">oral and injectable formulations [Member]</link:label>
    <link:label id="lab_mrk_OralAndInjectableFormulationsMember_documentation_en-US" xlink:label="lab_mrk_OralAndInjectableFormulationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">oral and injectable formulations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralAndInjectableFormulationsMember" xlink:href="mrk-20211231.xsd#mrk_OralAndInjectableFormulationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OralAndInjectableFormulationsMember" xlink:to="lab_mrk_OralAndInjectableFormulationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_00aeeb4a-167b-43d7-a243-d5b63f2fb9f7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_2b2eb474-c692-454e-97a4-a21efd1a7be8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a62f29a6-2ead-4c8c-b475-602906234c64_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_2ea6e449-1734-4f6c-a444-bb238b1eef10_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative upward price adjustment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_05664ab2-096f-4642-b5e3-7a6929d1e260_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_f079f1f1-22db-493f-9d9b-4521086d8807_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_6019e0c4-288c-4db1-8042-ad18bc0ae9cd_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, Assets</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_label_en-US" xlink:label="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Unrecognized Tax Benefits</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_documentation_en-US" xlink:label="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets unrecognized tax benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:to="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c5b32c1-bdc7-4196-a4f7-3c9a766ff5d7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7ccacc65-96ed-4358-9ccc-5a44606a7128_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_10f3921b-034e-47c5-9a53-76984ebc35a2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_656c63cb-d3ab-4de9-ba42-2b49224b13a3_terseLabel_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product return period</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_label_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_documentation_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:href="mrk-20211231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:to="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_7dc6cba8-1e23-4720-a009-c3558d4dea35_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637c030a-f72a-4280-bfae-baf4a76077aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_ca04e2a1-4cda-4a49-8c29-9bfd07fba4ba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_56c154bb-d997-4e87-963f-557620fa8729_negatedTerseLabel_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of ArQule, Inc., net of cash acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_label_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Five, Net of Cash Acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_documentation_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Five, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:to="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_71a3d953-cbde-4050-8ec3-29b8e0034978_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_322dc140-adec-4206-bf10-49883a094a93_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_6eafbd3d-c043-48c9-868f-e4b198e3ac06_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operations, goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3aaf5552-d981-4896-8fe5-d95897dfabdf_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3a96a05d-8a9d-4f21-a05c-5cca6dd4b127_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory rate applied to income from continuing operations before taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_13636d30-dcbf-4947-bd3b-ad4a61a92077_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, less allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_645ad80c-1c15-46ce-9714-cd94d73f73c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a502dba1-eb54-4b1a-9369-f999d8070bee_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck &amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_04a2746d-1e31-4321-961c-5418a17f6d45_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck &amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e01308ea-a233-44b9-86bc-1846125a3bf1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_3e1abaa2-2dce-49f6-94ad-fc9989938d69_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_12762bd6-d8b6-4aba-9e3d-67dddc2e575c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_7f29912d-cb6f-4745-a624-db1df6126287_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementsAbstract" xlink:to="lab_mrk_CollaborativeArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_ed15f4ac-dcfb-46a6-8790-22a584d52235_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5b50cc19-fd30-49f4-abd5-2112a97e6e55_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1918533b-b4ba-4a49-85cc-d832b86dac48_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_29c5652c-a22b-41d1-b4b5-b9053d439017_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_a2ba51ea-4c10-4ab9-9e01-d0d51cb838f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Revenues by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_49baaaed-ab0c-4b58-b7c9-cc11032eade8_terseLabel_en-US" xlink:label="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate possible expenditure on environmental matters in excess of amounts accrued</link:label>
    <link:label id="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_label_en-US" xlink:label="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Exit Costs, Reasonably Possible Additional Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:to="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_385c1dfa-ae80-48ba-9b8c-cd04918583bf_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_fbdfec69-674a-4c75-9cb5-48ab2b9d15e3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5d87ca47-81ee-4635-aaaf-dca2bdd9fdcd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f7d1ecfd-7719-48df-aabf-2f84fbfec61f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_32c5fc9a-f0c6-4e71-befe-966f6b74ce95_terseLabel_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs</link:label>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:to="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_f8c77bf6-8e77-4f13-9e9e-482c915d2564_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_43ed093b-2093-4758-9db2-283fa8324d53_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_7fac71a1-47e3-4131-b33d-022637948c92_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ac49cad1-426c-4a3a-a666-3adb43733cff_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f2c5d9be-ec7d-49fb-9a40-871d2a2d6beb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_76137897-6a06-442e-9bb5-7313d495bae0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_35ceaeb5-9852-479c-95b3-86b82260a93c_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearTwo_cd0e0d07-63e0-4f83-b43d-5d7f69b46c41_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2023</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearTwo_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Two</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearTwo_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearTwo" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearTwo" xlink:to="lab_mrk_LongTermDebtInterestPayableYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_aac1a1b7-348f-4738-aa7f-ccbe7d3d715b_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ea0206d2-3850-4a6c-880a-5aa8945106ca_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_693e36ae-c03e-4657-930c-e3e7aaeabfef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ReblozylMember_199676c0-fc3e-4f45-b7ae-2a418862b9b1_terseLabel_en-US" xlink:label="lab_mrk_ReblozylMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reblozyl</link:label>
    <link:label id="lab_mrk_ReblozylMember_label_en-US" xlink:label="lab_mrk_ReblozylMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reblozyl [Member]</link:label>
    <link:label id="lab_mrk_ReblozylMember_documentation_en-US" xlink:label="lab_mrk_ReblozylMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reblozyl</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember" xlink:href="mrk-20211231.xsd#mrk_ReblozylMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ReblozylMember" xlink:to="lab_mrk_ReblozylMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_ec7625bc-375e-47db-90d6-ea49202cb92a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Acceleron Pharma Inc., net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_ddd24cf1-1d01-437d-9846-7e98db7a3a7a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-Off of Organon &amp; Co.</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_b5fae864-433c-45b6-8c65-aa1c5fbb9734_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs, including amortization</link:label>
    <link:label id="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Amortization Of Purchase Accounting Adjustments</link:label>
    <link:label id="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to amortization of purchase accounting adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:to="lab_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_3ea5955f-72a4-4903-9c28-4e2cd4a3aa59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376a6599-c4bd-4b40-b1d3-a560637fd664_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8d2ac7d7-0a2e-45f6-839f-cbe85e15e775_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BayerAGMember_8e21b363-fd81-441e-8cf4-fa3e90e808af_terseLabel_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG</link:label>
    <link:label id="lab_mrk_BayerAGMember_label_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:label id="lab_mrk_BayerAGMember_documentation_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember" xlink:href="mrk-20211231.xsd#mrk_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BayerAGMember" xlink:to="lab_mrk_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_2f739e43-6cc1-428e-98e4-890f8b8a563a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsAccruedSalesBased_8f6ac58c-579c-4d04-a400-9c056223bc5f_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsAccruedSalesBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments accrued</link:label>
    <link:label id="lab_mrk_MilestonePaymentsAccruedSalesBased_label_en-US" xlink:label="lab_mrk_MilestonePaymentsAccruedSalesBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Accrued Sales Based</link:label>
    <link:label id="lab_mrk_MilestonePaymentsAccruedSalesBased_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsAccruedSalesBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Accrued Sales Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsAccruedSalesBased" xlink:href="mrk-20211231.xsd#mrk_MilestonePaymentsAccruedSalesBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsAccruedSalesBased" xlink:to="lab_mrk_MilestonePaymentsAccruedSalesBased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_02c83163-cc98-4920-a213-70b7b30eac81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_2c9521d8-5874-4f07-88f2-8bd3108e7b80_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and other postretirement benefits, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_07d8449d-e615-4961-8508-3d0ea56148b5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_eaabd071-c684-4307-a1e9-de256a434ead_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_37c821e9-fe12-4c99-a291-866903acfa0f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_743c204f-7a16-4a61-8d11-0d6c445db2e6_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_793c5b9f-80ea-477d-94ba-dcd4f601f486_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFour_1d846cfe-b9d3-43ef-aee1-01d8f2508fd0_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2025</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFour_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Four</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFour_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFour" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearFour" xlink:to="lab_mrk_LongTermDebtInterestPayableYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ArQuleMember_ef2d2121-8f16-4a8a-8ca7-02dd981daf28_terseLabel_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule</link:label>
    <link:label id="lab_mrk_ArQuleMember_label_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule [Member]</link:label>
    <link:label id="lab_mrk_ArQuleMember_documentation_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember" xlink:href="mrk-20211231.xsd#mrk_ArQuleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ArQuleMember" xlink:to="lab_mrk_ArQuleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7554adf-98ab-47eb-bdc3-c2826661d8a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_500d67c6-7cef-4077-91e8-05418e159a6a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3007f831-e963-40de-837c-0ca37f2b616b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_53be1745-fcb3-400e-8ffa-1af58131f8bc_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_18b63e02-786d-419d-83d5-5d815d33c368_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Derivative Pretax (Gain) Loss Recognized in Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_9794a28d-8bb1-44fb-944a-5fc8a1cf86c9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LegalDefenseCostsMember_c9554b53-5b89-48e6-ad0b-b4817929733b_terseLabel_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_label_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_documentation_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember" xlink:href="mrk-20211231.xsd#mrk_LegalDefenseCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LegalDefenseCostsMember" xlink:to="lab_mrk_LegalDefenseCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_291c397d-0303-44d1-96c3-688a279a9415_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_40e18287-6422-428c-9128-e579f823b3e4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d46c8ec1-b0fd-4a2d-8a01-182c27db8e0e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ea5f7dbe-f597-4eb2-8c3c-4a25a7c6e55d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_d8e33001-c672-4ace-9fb9-0019e7efce60_verboseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unallocated</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b9f0d8bd-8573-4d91-8842-3d8293acedd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction_dcb67226-c420-45cc-875c-420677a6ce7d_negatedTerseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Awards transferred to Organon in the spin-off</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred due to Spinoff Transaction</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred due to Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_996c9ccb-3e83-49c8-a777-153a261c2b5f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_97f35121-1912-4e01-8f76-24cd5a0ae44a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of accounts receivable represented by customers with largest balances (as percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesDiscounts_53e4073c-106b-468d-89ad-f219ad426aa0_terseLabel_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_label_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_documentation_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts" xlink:href="mrk-20211231.xsd#mrk_SalesDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesDiscounts" xlink:to="lab_mrk_SalesDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3675b269-1d00-4716-bd68-32d14108620f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Outstanding, January 1 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93e10607-0fc5-4c8d-bad8-e7c90ca51fb9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Outstanding, December 31 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_6317a5aa-b637-46f5-b5ef-90a4b821e7a2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_cc919e83-7006-47bd-813c-d8db3a3ff5ee_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AstraZenecaMember_7b6c14ee-67d2-4537-af6e-df53a41364ca_terseLabel_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_label_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_documentation_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember" xlink:href="mrk-20211231.xsd#mrk_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AstraZenecaMember" xlink:to="lab_mrk_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AuditInformationAbstract_label_en-US" xlink:label="lab_mrk_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_mrk_AuditInformationAbstract_documentation_en-US" xlink:label="lab_mrk_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AuditInformationAbstract" xlink:href="mrk-20211231.xsd#mrk_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AuditInformationAbstract" xlink:to="lab_mrk_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7ba06144-b29e-4304-be52-b31bf22b0686_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_0c2a171e-18d9-462f-8c3d-8650e8a75dea_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Promotion Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_268cd611-ed81-40f0-97b5-dd221a3b5f25_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3b6dbae5-19ad-44c8-b1ed-b3539b59eae8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Environmental Liabilities</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_2107dcd0-9b61-486f-9380-d25309859758_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_e8353805-2d18-4a7a-b1ee-ad5147250c47_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_50d3f911-fb63-4fad-aa2a-60656ea4b59e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of unrecognized prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a7e47f34-0306-4e16-a2be-db09cbf1b9dd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_9e837ce0-d513-4f06-ba87-7533c4d73342_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition tax liability, current</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_99fa0037-bfe7-4883-ba60-601eeb82d082_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_65e0a5a1-ad55-4732-8bd1-433ba569b74e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ad03b3cd-1962-4a35-ba12-e80e94357e3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d2d9654f-c4ec-4eb1-a444-34dd69d18650_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity of stock options that vest per year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dffb069b-95b5-40e1-adbc-109bf882d5f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_057617e7-b85e-4213-bf62-84a732e00808_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_827bf6fc-379f-4aa3-9520-4d76d25acf8d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) amortization included in benefit cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d453d172-6dbe-411b-858d-eb7b825af094_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_90e0bfc6-88d3-4cb4-9408-c46a678044ca_terseLabel_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation and Funded Status</link:label>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:to="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_8b4c84dc-de1c-4f32-8009-4a20e5167441_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swaps held</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_9fd4e4dd-6095-4e7e-a041-8e0087a7c116_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Swaps Held</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_eda5cd3b-127f-46da-bc34-4b6d98019940_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_77708796-ed8d-4e08-a940-2167d0dd1e57_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_5e9e0a80-2f98-4f83-858e-2c49ab0077d0_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember" xlink:href="mrk-20211231.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueKoselugoMember" xlink:to="lab_mrk_AllianceRevenueKoselugoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_7d5472fa-3e93-443c-b67c-a45eb8a81345_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, pending claims (in cases)</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_41588a9b-e77c-44ae-be41-0630f479e2b4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8d011bf-f41b-4f02-b0f3-afbbaf409e7c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan net gain (loss) and prior service credit (cost), net of amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7ecc2e61-77bc-48b0-87d6-633db2a53a50_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_256cfced-f337-4259-8b7f-7ff1b614e281_verboseLabel_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset-backed securities</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Asset Backed Securities Fixed Income Securities [Member]</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset backed securities fixed income securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:to="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.40NotesDue2029Member_5a8d33bf-69c6-426b-a829-7fe5c7b25b0e_terseLabel_en-US" xlink:label="lab_mrk_A3.40NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40% notes due 2029</link:label>
    <link:label id="lab_mrk_A3.40NotesDue2029Member_label_en-US" xlink:label="lab_mrk_A3.40NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40% Notes Due 2029 [Member]</link:label>
    <link:label id="lab_mrk_A3.40NotesDue2029Member_documentation_en-US" xlink:label="lab_mrk_A3.40NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40% Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.40NotesDue2029Member" xlink:href="mrk-20211231.xsd#mrk_A3.40NotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.40NotesDue2029Member" xlink:to="lab_mrk_A3.40NotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_0ed765d4-d153-4a73-8bc1-2e7459ce2951_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Seagen Inc. common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_6c73130a-e9df-427f-8a60-7d7f7b2bf3c3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_c7bf7ee6-8510-4a57-a003-5b7a576d10f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, other expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_02621058-a622-42c0-a334-055c82f36398_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Legal Defense Costs</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8089f3ee-b284-45cd-a05d-2a66257f8f65_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f6aeb0eb-925e-48d2-934b-3804c1e7a09a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_faa87862-94ed-4045-b71e-ce8add3cf954_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions to defined contribution savings plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_43712f2f-2164-4771-b408-7ae4ad4a1828_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7968ff4-204f-466d-bec9-e45f7e41ce43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6eda4670-d25e-4263-8319-40505d6d5a01_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and product rights - Reblozyl (12 year useful life)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_0d51ff92-4659-4704-ac1f-961d7a93cbd1_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, equipment and office furnishings</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_1b15721c-6b0b-49d4-8bd1-7eeff4272e2e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_c332032e-2518-40f8-9936-55d7669004cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_f2356d71-1bea-4e68-8e49-34cbe2294c2e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_3e758fba-6f14-47da-9cf7-c858cb2ea06f_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution from Organon &amp; Co.</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operations Distribution Received</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operations Distribution Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2ec8d9ef-3130-4758-aacc-9595d92a0e7d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A215NotesDue2031Member_3a79bd83-8108-4dfb-8ec9-934355310711_terseLabel_en-US" xlink:label="lab_mrk_A215NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.15% notes due 2031</link:label>
    <link:label id="lab_mrk_A215NotesDue2031Member_label_en-US" xlink:label="lab_mrk_A215NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.15% notes due 2031 [Member]</link:label>
    <link:label id="lab_mrk_A215NotesDue2031Member_documentation_en-US" xlink:label="lab_mrk_A215NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.15% notes due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member" xlink:href="mrk-20211231.xsd#mrk_A215NotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A215NotesDue2031Member" xlink:to="lab_mrk_A215NotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_c5496da9-da65-42aa-a77d-68dbfb808bd5_totalLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_d0774999-f1a4-44b0-8028-e351618e9d18_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments made to collaborative partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_label_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:href="mrk-20211231.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:to="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_92b19b10-4538-4e41-a02f-c65c7bb656d4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_cad99227-d5b0-48ab-ba60-e39f42588d68_terseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value discount rate</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_74d0bb10-b239-4ec5-a51c-6b3e05d8622b_verboseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IntangibleAssetMeasurementInput" xlink:to="lab_mrk_IntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_60405da5-3cf8-4c4c-abc8-9cb9f3d502bc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relating to assets sold during the year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_d21c00f5-f8a7-4a42-8743-9a4ae28e4ef9_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contract indexed to issuer's equity, indexed shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_label_en-US" xlink:label="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contract Indexed to Issuer's Equity, Indexed Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:to="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c66d1691-de14-4166-a02c-049a363aec3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Continuing Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_059b13cd-eb7a-4435-ae47-0a86d823bfb3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dd66e0e1-19a4-4558-aaec-f3346ae3ab90_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SentinelMember_90f4d696-f5f0-426c-8b9f-f1a68a7d05d2_terseLabel_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel</link:label>
    <link:label id="lab_mrk_SentinelMember_label_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel [Member]</link:label>
    <link:label id="lab_mrk_SentinelMember_documentation_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember" xlink:href="mrk-20211231.xsd#mrk_SentinelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SentinelMember" xlink:to="lab_mrk_SentinelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_851c6f55-196c-4738-aae1-3653736f22ad_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - profit sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementProfitSharing" xlink:to="lab_mrk_CollaborativeArrangementProfitSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_42ae4396-226c-49ed-a926-353763c684b7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3ee605e4-bfa1-4bb7-9980-df6dfb197596_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d9264173-2c24-4fa7-a4ec-971de4ba86bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on derivatives, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d7b2711a-b87f-43c3-9329-302efa532531_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Discontinued Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_72e6dc70-bce1-4c31-acc3-8b0a74fa72cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_51d57d5e-3c56-4cd2-a477-32e763d17736_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2c747163-ba98-495a-92fe-5fd7787e9412_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_2fdba7bf-90dd-4dc7-86db-0d668ebc53e6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_6deb356f-3b5f-40df-823f-c2b70bddd063_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ArtivaBiotherapeuticsIncMember_89e82e65-3413-40da-bf6c-83d435c85176_terseLabel_en-US" xlink:label="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Artiva Biotherapeutics, Inc.</link:label>
    <link:label id="lab_mrk_ArtivaBiotherapeuticsIncMember_label_en-US" xlink:label="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Artiva Biotherapeutics, Inc. [Member]</link:label>
    <link:label id="lab_mrk_ArtivaBiotherapeuticsIncMember_documentation_en-US" xlink:label="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Artiva Biotherapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember" xlink:href="mrk-20211231.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ArtivaBiotherapeuticsIncMember" xlink:to="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9ad8a24b-7793-4465-9636-53bf35944675_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_77a98322-f9de-4e7c-b778-ae339baa55ad_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_e19d07c6-d627-44c4-9c25-fb45b6d469a9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits relating to stock option exercises</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_0ec36b90-e425-4b20-9301-8413a48e4b33_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_4baead71-e3bf-4092-8900-c838b882f29d_terseLabel_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_184f0010-d8a8-4dfb-91d2-2915bda9826a_verboseLabel_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member" xlink:href="mrk-20211231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.40NotesDue2022Member" xlink:to="lab_mrk_A2.40NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_66df30c8-4c83-408e-95e4-de5568e5c8b4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases and sales, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:to="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_807b058e-03b6-4c03-af77-4c3f7b358cd0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_e56e491f-4476-49f4-a28b-cc9a2b46abde_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_8e0910d6-93c6-4426-8bf2-f36c238a9927_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Adjustment to Merck awards related to the spin-off of Organon (in dollars per share)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_f877cccb-ee4e-4561-96de-03c401e02fa3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_9b636025-625d-46fe-9417-a5e58aa21e53_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_89205fa9-d3bd-4ebc-a709-3635309cf481_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_d2c26a5a-dfba-45c7-92fc-c9b0c0ab5737_terseLabel_en-US" xlink:label="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net assets (liabilities)</link:label>
    <link:label id="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_label_en-US" xlink:label="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets and Liabilities Recognized, Net</link:label>
    <link:label id="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_documentation_en-US" xlink:label="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets and Liabilities Recognized, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:href="mrk-20211231.xsd#mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:to="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_3d3e4bf1-2a72-4bc2-930c-0825e3e1a697_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operations, other intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_f749128d-ef1f-4a71-bd60-e53715f87976_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_af9795bc-aa42-4959-b78b-2e8fd5b387ea_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_b2fc33d5-f446-4dc2-a8f9-32cd3e990c7d_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment_80bea70b-76f7-4314-987f-fec0ff6d1e94_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Adjustment to Merck awards related to the spin-off of Organon (in shares)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_a9437219-2bd8-4de1-8306-7f25a53fdd23_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_fe3cd973-457b-4d93-9421-8aa16532f245_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.5EuroNotesDue2034Member_0b80201c-f5d7-44a7-91f9-a848da32ad78_terseLabel_en-US" xlink:label="lab_mrk_A2.5EuroNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% euro-denominated notes due 2034</link:label>
    <link:label id="lab_mrk_A2.5EuroNotesDue2034Member_label_en-US" xlink:label="lab_mrk_A2.5EuroNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Euro Notes Due 2034 [Member]</link:label>
    <link:label id="lab_mrk_A2.5EuroNotesDue2034Member_documentation_en-US" xlink:label="lab_mrk_A2.5EuroNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Euro Notes Due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.5EuroNotesDue2034Member" xlink:href="mrk-20211231.xsd#mrk_A2.5EuroNotesDue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.5EuroNotesDue2034Member" xlink:to="lab_mrk_A2.5EuroNotesDue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SupplyCommitmentToUnitedKingdomMember_227871a0-b83c-4d41-bfd1-9f8a0259dfe1_terseLabel_en-US" xlink:label="lab_mrk_SupplyCommitmentToUnitedKingdomMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to United Kingdom</link:label>
    <link:label id="lab_mrk_SupplyCommitmentToUnitedKingdomMember_label_en-US" xlink:label="lab_mrk_SupplyCommitmentToUnitedKingdomMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to United Kingdom [Member]</link:label>
    <link:label id="lab_mrk_SupplyCommitmentToUnitedKingdomMember_documentation_en-US" xlink:label="lab_mrk_SupplyCommitmentToUnitedKingdomMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment to United Kingdom</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToUnitedKingdomMember" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToUnitedKingdomMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SupplyCommitmentToUnitedKingdomMember" xlink:to="lab_mrk_SupplyCommitmentToUnitedKingdomMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_ccce19d8-c578-4209-bf73-07b79236c14d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_46c7fded-3c73-4e8b-b4dc-967b4894e255_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_0b055d87-bdfd-4e12-87e7-376f636f601a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_01bfa247-f1c1-4cec-85b3-e6ad9c7b53d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c03a8c3-4012-496a-a350-956bc026a8e4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d1a74331-f2e0-4c1a-9c5b-8b91a8f8f87e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_3c4f8583-ff8b-4e7e-a3ca-fadb4309cd3d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_7b055ccc-c35b-4787-8edb-068d28da9881_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d270078b-ac1a-493c-ba89-857a60a1a076_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_108fe991-5166-4527-a047-6cb20e1d2020_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9321cf6d-0094-474b-99ff-2df2540d4ed9_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_202fb457-fa3a-40d8-8cf7-98f982070506_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition tax liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BelsomraMember_b4863808-11ae-45ba-8213-652b888d1a86_terseLabel_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra</link:label>
    <link:label id="lab_mrk_BelsomraMember_label_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:label id="lab_mrk_BelsomraMember_documentation_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember" xlink:href="mrk-20211231.xsd#mrk_BelsomraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BelsomraMember" xlink:to="lab_mrk_BelsomraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_3b9e3bfe-c39e-4db0-8bce-3bcef4385e17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_842ea549-4bc9-4224-a917-8e54e9918266_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to LIFO cost</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReserve" xlink:to="lab_us-gaap_InventoryLIFOReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_ba446aae-dcd3-4828-b9e0-bd3f5e83b3ac_terseLabel_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_label_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_documentation_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member" xlink:href="mrk-20211231.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.500Notesdue2024Member" xlink:to="lab_mrk_A0.500Notesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_fa0c4f39-e4d8-44f9-9ee6-4735bc9aaedd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LenvimaMember_1fa566f3-96ca-4d03-ae03-0bae49d837d7_verboseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_a60c6de5-35d4-49c4-81a4-7a706d444859_terseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_label_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:label id="lab_mrk_LenvimaMember_documentation_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember" xlink:href="mrk-20211231.xsd#mrk_LenvimaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LenvimaMember" xlink:to="lab_mrk_LenvimaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems_88d2e31d-ffea-495a-9a8a-e8f8a2a60ee0_terseLabel_en-US" xlink:label="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="mrk-20211231.xsd#mrk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_37907200-b728-46ff-beb3-e5fc344faabc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d9c9892a-94ed-4e5b-bd8d-aedd22c51431_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Long-Term Debt and Leases</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_c27dea5d-1674-406f-bbdd-70e48a9148c4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e054d9f4-e2b0-4a32-b8ad-42ebeea5aa07_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5fcadb8c-2cd3-415a-9c16-bc0848a7cbf7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_4712c34f-43d1-42c2-9815-100081b12936_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4304cc5f-3ec3-4c36-9a0d-8dcc4cd01547_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product intangibles and licenses, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c5a3a564-00d9-41cd-a72b-e325f8dd5e07_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_417ec2f0-6b4f-4b91-bc50-f9458c919fbb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_e75d555e-dd10-488d-8dbe-0e3deb149ec9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid to stockholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_90d59f9c-f409-4130-b361-ceb513e05331_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation payments to settle equity awards attributable to precombination service</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_8441d4e0-672a-438d-803f-263477dd5f42_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_b99c87c7-aea2-46ba-97cb-3d402d59a1fb_terseLabel_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_label_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_documentation_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member" xlink:href="mrk-20211231.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.875Notesdue2026Member" xlink:to="lab_mrk_A1.875Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_f24d1ac8-6ee7-4e47-a907-514267da8bdf_terseLabel_en-US" xlink:label="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% debentures due 2028</link:label>
    <link:label id="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_label_en-US" xlink:label="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Nine Five Percentage Debentures Due On Two Thousand And Twenty Eight [Member]</link:label>
    <link:label id="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_documentation_en-US" xlink:label="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five point nine five percentage debentures due on two thousand and twenty eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:href="mrk-20211231.xsd#mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:to="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_209ab154-20db-44c3-b691-64b7be4f6259_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of Company's Products</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_de354ca9-2620-411b-9b46-a6d4c8335d33_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_3d733de0-80ae-4f7f-b6bd-0c19c257bbd5_terseLabel_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims on appeal (in cases)</link:label>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_label_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims on Appeal, Number</link:label>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_documentation_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims on Appeal, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber" xlink:href="mrk-20211231.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LossContingencyClaimsonAppealNumber" xlink:to="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_110e7c40-f717-49ea-8f84-0447142dc96b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e398185-1029-4d91-8954-8fb829b00550_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_244a6d59-39e2-4048-9ac7-1923fb078894_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4df00302-c2ca-4c21-8182-e9c8b6500b0b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d2b3d2cd-8d42-4a5d-aade-7e9c962abaec_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_d89fbc36-10b4-489c-b075-a875eace5e2a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_201de1aa-e35f-4bb1-8330-de29ff296cee_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_f0e21c92-9a61-4409-87ea-593ceaf68a28_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_6eeb9e4c-87fb-49dc-99fa-24c3e5d32245_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of exchange rate changes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ImmuneDesignMember_4c119082-194d-4b23-81db-4740bb709799_terseLabel_en-US" xlink:label="lab_mrk_ImmuneDesignMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immune Design</link:label>
    <link:label id="lab_mrk_ImmuneDesignMember_label_en-US" xlink:label="lab_mrk_ImmuneDesignMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immune Design [Member]</link:label>
    <link:label id="lab_mrk_ImmuneDesignMember_documentation_en-US" xlink:label="lab_mrk_ImmuneDesignMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immune Design [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImmuneDesignMember" xlink:href="mrk-20211231.xsd#mrk_ImmuneDesignMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ImmuneDesignMember" xlink:to="lab_mrk_ImmuneDesignMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_83436c49-95cd-4348-984d-b32adac4c78f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Rate Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_COVID19Member_475755fa-5c40-4dc3-afdb-2dafe8959ee6_terseLabel_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_mrk_COVID19Member_label_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_mrk_COVID19Member_documentation_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member" xlink:href="mrk-20211231.xsd#mrk_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_COVID19Member" xlink:to="lab_mrk_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_91c67de3-9903-4d78-ab72-d0cce6a44555_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Peloton</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryTable_e3aae339-06b8-4d18-a600-2a4da1fbdc4a_terseLabel_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_label_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_documentation_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable" xlink:href="mrk-20211231.xsd#mrk_InventoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryTable" xlink:to="lab_mrk_InventoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_5abd71ab-23c9-4851-85f0-3b7da7e499be_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_88b19862-8853-4aa8-b48d-050f6473800b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_ff4d4e58-c61f-485f-a934-b891bee3adcc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims settled (in cases)</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_96c6dfa3-6c37-4219-ab36-1f08621e5bf0_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties, current</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b357c754-e751-4cd5-bbba-a6e71abd704f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_f2cd9c6d-3155-42d6-b015-cf76f745d0ad_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets_31cb8fff-48be-457a-a615-289f0c1fe35d_terseLabel_en-US" xlink:label="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets_label_en-US" xlink:label="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Other Changes Plan Assets</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets_documentation_en-US" xlink:label="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in plan assets, not otherwise separately disclosed in the financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:href="mrk-20211231.xsd#mrk_DefinedBenefitPlanOtherChangesPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:to="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fc86e316-be02-4046-8538-0667aefb5e82_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_7a4b087f-6fe0-4aa0-9599-5d16ab078568_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_7a9adc9c-ad66-4af1-b149-25754f3c42d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, carrying amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d2895f13-99e6-40ea-b903-0d7d95fd933c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_b4beb3b5-f871-4165-8b87-bf5d845b38c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_c112452e-89ee-49f8-b8c6-855b478d61e5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary growth rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_3cb70546-42df-4fac-a8ce-959287b12871_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RecognizedAsAbstract_a206c960-3405-4803-8629-e430b558a762_terseLabel_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_label_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized As [Abstract]</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_documentation_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract" xlink:href="mrk-20211231.xsd#mrk_RecognizedAsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RecognizedAsAbstract" xlink:to="lab_mrk_RecognizedAsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProfitShareCounterparty_97d641ee-e31f-4da6-b8e4-2e8e94cbb9a2_terseLabel_en-US" xlink:label="lab_mrk_ProfitShareCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit share by counterparty</link:label>
    <link:label id="lab_mrk_ProfitShareCounterparty_label_en-US" xlink:label="lab_mrk_ProfitShareCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Share Counterparty</link:label>
    <link:label id="lab_mrk_ProfitShareCounterparty_documentation_en-US" xlink:label="lab_mrk_ProfitShareCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Share Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShareCounterparty" xlink:href="mrk-20211231.xsd#mrk_ProfitShareCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProfitShareCounterparty" xlink:to="lab_mrk_ProfitShareCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrimaxinMember_6cecff22-b726-4f94-bb38-17de5875d26a_terseLabel_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin</link:label>
    <link:label id="lab_mrk_PrimaxinMember_label_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member]</link:label>
    <link:label id="lab_mrk_PrimaxinMember_documentation_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember" xlink:href="mrk-20211231.xsd#mrk_PrimaxinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrimaxinMember" xlink:to="lab_mrk_PrimaxinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5317fe27-a957-4d9a-9fdf-2ecf99db2b5e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems_8d0ab016-47e0-4e07-930e-ab9fdfd84a14_terseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:label id="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems_label_en-US" xlink:label="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:label id="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems_documentation_en-US" xlink:label="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetsExcludingGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:to="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_d9235d84-f904-4b06-bb33-06b6c2bbd7d1_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:href="mrk-20211231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_477bc41f-8214-477c-b285-dff755ad00b5_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment_cd452473-d98f-4a8c-ab76-f200d72c8ad1_negatedTerseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Adjustment to Merck awards related to the spin-off of Organon (in shares)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_e83db150-1289-4a1b-b6c6-9c39efb87df9_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Peloton</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_899fb18c-0b15-4edf-bd6b-7d8543c57051_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VaqtaMember_7f621b95-40a1-4821-884f-f80aa8a2cce1_terseLabel_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta</link:label>
    <link:label id="lab_mrk_VaqtaMember_label_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:label id="lab_mrk_VaqtaMember_documentation_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember" xlink:href="mrk-20211231.xsd#mrk_VaqtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VaqtaMember" xlink:to="lab_mrk_VaqtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_bcbbc9fc-d55b-4839-92ef-57ca6f1a851a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_5cfe2667-2d7a-46dc-ae00-f04543468846_negatedTerseLabel_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_label_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</link:label>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_documentation_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:href="mrk-20211231.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:to="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_07f0ff25-7216-416e-9db3-954a9fc83047_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_bc91602e-fe6f-4be0-9de9-001a965f4299_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum planning cycle of hedges (less than)</link:label>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Average Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_d557b58c-626e-42ee-ac7f-20ad5d64a242_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Payments) receipts, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_4ae7f11f-7009-4ef8-9619-cce18eaa3684_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_459edfce-44d8-4499-9d55-7a95063ffd4d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d92d070a-89df-4a64-ac0d-7b2ed8eddd53_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_6cfcda70-4015-4f93-95e5-1a47e9253c0b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operations, inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_f99693ff-445c-4a08-8690-c68c24e51a31_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NoxafilMember_b8cb9146-197d-4864-8c89-3844c42182e7_terseLabel_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil</link:label>
    <link:label id="lab_mrk_NoxafilMember_label_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member]</link:label>
    <link:label id="lab_mrk_NoxafilMember_documentation_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember" xlink:href="mrk-20211231.xsd#mrk_NoxafilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NoxafilMember" xlink:to="lab_mrk_NoxafilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bc398c02-0c3f-4200-a47e-cc87dfcadd37_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_3e8dd81a-afff-4957-a99d-55d5f8532f63_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ef2d8a98-f6d1-4f19-82e8-a299beb6aff6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5f9e3c94-d846-4bfd-b4df-c7a8983a2a27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f0c67fec-3535-43d1-978b-1c137993b29e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_fccab8be-0284-46fb-a4e0-d9e182ac0965_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_e2100cef-e104-469a-b71c-b6f5ec53491e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_f7e1aa77-de03-4270-9839-d262cedb80f4_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations before taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3b5488a9-93e3-4dd3-93fd-ff6351443ed8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_241417f5-be9d-494b-911b-df3625f6351b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax share-based compensation cost recorded, related to continuing operations</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a4171527-3675-47db-bf7d-f4cded817871_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_52b06d9b-22a6-4497-9284-e16ef0e2ed9b_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_ddecd8ed-1318-4b57-adad-0629b30edd0d_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_487c9cf7-7d9e-4bb2-994b-783b12119563_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_729609ee-f6ed-4848-88fa-7674c8aeb81e_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_139895a7-afc0-407a-848f-68db0807360f_negatedLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_4562fa0a-d4bb-49cf-be4a-976bec81007c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Flows Provided by Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_f7e44e6c-0966-4a1e-b587-7636f0bd68aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income of discontinued operations attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_a70de7c6-4feb-4f70-a5b0-ffd1febf0767_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0ce019b9-db35-41e6-900e-76ddcaac2de4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_62bd6ff4-5441-4777-8280-7086e23057e7_terseLabel_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_label_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad MMR II Varivax [Member]</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_documentation_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:href="mrk-20211231.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:to="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a942b08e-b5fa-42a9-bb20-40ad45ee8e1a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_87a0b815-44fc-44c8-99e5-e48f57c589a8_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of OncoImmune</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_24f0933d-19d2-4115-847e-f236120ab2ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a72c6cf4-ff04-4395-ba5f-8c05452adfe7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_d6a9615a-8e6e-4c9e-a1f1-41c73ad15f63_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount of derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_76553fba-fd57-454c-9177-94eb0e315999_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Swap Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_126a1bb5-a5fd-4e7e-b71c-d6fdc31fbfa1_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2f467c0b-c8c6-4bbf-bab7-91814abec1c6_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_ac53f24b-0ff6-4aa2-b1bd-4b93356bc020_terseLabel_en-US" xlink:label="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Other Investments</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_label_en-US" xlink:label="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Other Investments [Member]</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_documentation_en-US" xlink:label="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:href="mrk-20211231.xsd#mrk_DefinedBenefitPlanCashandOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:to="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_0ef79bf3-5e56-495e-bcc7-b9ef301517bd_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities held through ownership interests in investment funds</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_39a880fe-db66-47a3-97e2-2f842884f6da_terseLabel_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets And Liabilities [Table Text Block]</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:href="mrk-20211231.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_415ce2e1-6c67-454c-817f-8dc8c50e68a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for the acquisition of Pandion Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b6ca9692-4762-4f6f-b0b6-30c2f7fa9543_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_87e75791-e37f-4e99-9a68-0cff44eced3b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of exchange rate changes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ef33f9d3-4c29-47f5-ab33-d54a515567e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_329a678f-7d39-4b01-b09d-e050ce1ed31c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_dd6e8a84-57bd-44de-b978-77964fea56d1_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities_11be3ab1-5a88-4f0e-b197-32294280bfed_terseLabel_en-US" xlink:label="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities_label_en-US" xlink:label="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets and Liabilities, Deferred Tax Liabilities</link:label>
    <link:label id="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities_documentation_en-US" xlink:label="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets and Liabilities, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities" xlink:href="mrk-20211231.xsd#mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities" xlink:to="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_f3a6e410-5709-48ff-9e78-b5735fb08c62_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4157e652-d923-4c9a-91cc-6916fc36439d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_df0f98a1-6c3d-4008-a38f-a584beb578c6_totalLabel_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and publicly traded equity securities, fair value</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_label_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_documentation_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:href="mrk-20211231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:to="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CommercialandOtherLitigationMember_b7301643-2b0c-4dc7-af5a-a1a238c2ebf6_terseLabel_en-US" xlink:label="lab_mrk_CommercialandOtherLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Litigation</link:label>
    <link:label id="lab_mrk_CommercialandOtherLitigationMember_label_en-US" xlink:label="lab_mrk_CommercialandOtherLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and Other Litigation [Member]</link:label>
    <link:label id="lab_mrk_CommercialandOtherLitigationMember_documentation_en-US" xlink:label="lab_mrk_CommercialandOtherLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and Other Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialandOtherLitigationMember" xlink:href="mrk-20211231.xsd#mrk_CommercialandOtherLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CommercialandOtherLitigationMember" xlink:to="lab_mrk_CommercialandOtherLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a4ac3f18-f8ac-4380-9356-44e181583197_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b78010ef-a8d2-437b-9504-853109329acc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_7f9b67a6-a398-46b6-a6b6-34e20d4fb8d9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a4fe116e-a9e8-49b2-80af-f7dfc1888249_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a34a86f8-046f-4635-a7da-8cb9dab5726d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15fcc2ee-3543-4b05-bbfd-dab9474fb640_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.90NotesDue2039Member_be7e5a1d-03b1-4f06-92f3-35a4eaab92d6_terseLabel_en-US" xlink:label="lab_mrk_A3.90NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.90% notes due 2039</link:label>
    <link:label id="lab_mrk_A3.90NotesDue2039Member_label_en-US" xlink:label="lab_mrk_A3.90NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.90% Notes Due 2039 [Member]</link:label>
    <link:label id="lab_mrk_A3.90NotesDue2039Member_documentation_en-US" xlink:label="lab_mrk_A3.90NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.90% Notes Due 2039</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.90NotesDue2039Member" xlink:href="mrk-20211231.xsd#mrk_A3.90NotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.90NotesDue2039Member" xlink:to="lab_mrk_A3.90NotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_2b00d8bb-bb0d-485c-9f1e-98e3c669134b_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_081e9f74-e836-45e1-80fc-4199abf2c55c_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_label_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:to="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_1fe22483-57d6-4281-8a49-0e15c189b116_terseLabel_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_label_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Increase (Decrease) Noncash Activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_documentation_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash activity affecting the restructuring reserve, including accelerated depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:href="mrk-20211231.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:to="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_f5ed6940-0f7e-4089-91cd-0bdb0b1e5071_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A190NotesDue2028Member_e33379ab-dcf9-4520-8329-4699bf44f22b_terseLabel_en-US" xlink:label="lab_mrk_A190NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2028</link:label>
    <link:label id="lab_mrk_A190NotesDue2028Member_label_en-US" xlink:label="lab_mrk_A190NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2028 [Member]</link:label>
    <link:label id="lab_mrk_A190NotesDue2028Member_documentation_en-US" xlink:label="lab_mrk_A190NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member" xlink:href="mrk-20211231.xsd#mrk_A190NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A190NotesDue2028Member" xlink:to="lab_mrk_A190NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_cbc8a2b7-5e6c-4379-ae61-28f3acbeeff4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_43a96121-7c69-483d-9e8b-4dc7d1e85a76_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance January&#160;1 (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e254e27e-93f2-42d0-b394-c6a74db13eda_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance December&#160;31 (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b531ff38-9248-45da-9041-390b9e124354_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_69ccadec-dd1e-49ae-8d98-00eee7932ed0_terseLabel_en-US" xlink:label="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.55% notes due 2037</link:label>
    <link:label id="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_label_en-US" xlink:label="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Five Five Percentage Notes Due On Two Thousand And Thirty Seven [Member]</link:label>
    <link:label id="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_documentation_en-US" xlink:label="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point five five percentage notes due on two thousand and thirty seven.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:href="mrk-20211231.xsd#mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:to="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_e0053618-792a-48e3-a651-4030d4de9e51_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_613984db-a617-42b5-acbf-1fe3a11bc8fd_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_51bc52ff-b02f-49c1-81d5-16bc5ceed44f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d629dfdb-a863-48b1-bd02-373d2ebabffe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_43cabba3-182a-49b8-92d2-f374a536d2ff_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_0e47c33a-84e0-45fe-b33b-87dc34071b74_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A290NotesDue2061Member_4218e400-28de-45eb-b76b-7d6c09aa272a_terseLabel_en-US" xlink:label="lab_mrk_A290NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% notes due 2061</link:label>
    <link:label id="lab_mrk_A290NotesDue2061Member_label_en-US" xlink:label="lab_mrk_A290NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% notes due 2061 [Member]</link:label>
    <link:label id="lab_mrk_A290NotesDue2061Member_documentation_en-US" xlink:label="lab_mrk_A290NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% notes due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member" xlink:href="mrk-20211231.xsd#mrk_A290NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A290NotesDue2061Member" xlink:to="lab_mrk_A290NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_714e025a-9faa-406d-b1d3-60b78af05e59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in AOCI by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_02d758a2-e3e0-4ab5-a2d7-b9f868e75229_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1a1fb10a-a98d-4163-bb07-892121eb5e75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_11b54410-056a-464a-bbfd-56383af9f4ad_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PensionPlanNetLossMember_031d38d9-0421-4638-b6df-81d848434d44_terseLabel_en-US" xlink:label="lab_mrk_PensionPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Net Loss</link:label>
    <link:label id="lab_mrk_PensionPlanNetLossMember_label_en-US" xlink:label="lab_mrk_PensionPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Net Loss [Member]</link:label>
    <link:label id="lab_mrk_PensionPlanNetLossMember_documentation_en-US" xlink:label="lab_mrk_PensionPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Net Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanNetLossMember" xlink:href="mrk-20211231.xsd#mrk_PensionPlanNetLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PensionPlanNetLossMember" xlink:to="lab_mrk_PensionPlanNetLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_fe8db159-2b74-4a2a-a2b3-aeaa1b5e1ec5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_1c9cbbfb-9b93-47a2-847b-9286e329fe90_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_afd6dae7-1dd0-4eb8-a1b9-c414a389fb8b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_70b62b51-b733-40c3-bd52-65a30049c4cb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_f3d9dba6-4e62-497c-bac3-6f6bfca2f16c_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_980e0729-9e1d-45f2-82b7-3b1e0cd33064_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average interest rate of commercial paper</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_5578a09a-3c1a-4c43-8233-10becaac43ae_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7b815159-2e1a-4647-aec1-558f0003ecb5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_a6304f04-810e-42cc-a0cd-4f7f8ebdb25d_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_4f7bd57d-5786-4a16-9246-88275ece0d2f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_df27813d-7c39-49ea-80a1-d0379b26a5ea_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_41abab3e-876d-4996-b0fc-99a1bf7dd89b_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_301d8013-8db9-4d15-b0bf-b80de01527f1_terseLabel_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember" xlink:href="mrk-20211231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesBasedMilestonesMember" xlink:to="lab_mrk_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_9bfcceb5-5d90-468f-b52e-92705483e110_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_19319fb6-f529-4505-aabf-8ac2efa04768_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SotaterceptMember_099ce6c3-8aa5-4f6e-a326-7bdbadb1e62b_terseLabel_en-US" xlink:label="lab_mrk_SotaterceptMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">sotatercept</link:label>
    <link:label id="lab_mrk_SotaterceptMember_label_en-US" xlink:label="lab_mrk_SotaterceptMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">sotatercept [Member]</link:label>
    <link:label id="lab_mrk_SotaterceptMember_documentation_en-US" xlink:label="lab_mrk_SotaterceptMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">sotatercept</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SotaterceptMember" xlink:href="mrk-20211231.xsd#mrk_SotaterceptMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SotaterceptMember" xlink:to="lab_mrk_SotaterceptMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_a2eae4d2-ed73-4a63-a442-73bd8dad8566_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b82921f0-7c5b-4f24-b793-d3ac70742823_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_93e51529-bb22-479f-9099-9a19c29a83f8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_7f97877d-dc0b-4c98-b397-29888a54b3b3_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c8638061-5a51-449f-af89-87ab803f0a85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_b8d41f0b-d98e-4adc-87b4-edc8f511e5d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Location and Pretax Gain or Loss Amounts for Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PatentlitigationMember_73c27e51-9717-4501-8a35-e35596fadfc2_terseLabel_en-US" xlink:label="lab_mrk_PatentlitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent litigation</link:label>
    <link:label id="lab_mrk_PatentlitigationMember_label_en-US" xlink:label="lab_mrk_PatentlitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent litigation [Member]</link:label>
    <link:label id="lab_mrk_PatentlitigationMember_documentation_en-US" xlink:label="lab_mrk_PatentlitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember" xlink:href="mrk-20211231.xsd#mrk_PatentlitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PatentlitigationMember" xlink:to="lab_mrk_PatentlitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxesPayableMember_2d64c93c-bf65-4fb2-9681-e3078e01fa46_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable</link:label>
    <link:label id="lab_mrk_IncomeTaxesPayableMember_label_en-US" xlink:label="lab_mrk_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:label id="lab_mrk_IncomeTaxesPayableMember_documentation_en-US" xlink:label="lab_mrk_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxesPayableMember" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxesPayableMember" xlink:to="lab_mrk_IncomeTaxesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ThemisMember_bb20e7bd-d01f-4e13-8a74-4d4ed42475e8_terseLabel_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis</link:label>
    <link:label id="lab_mrk_ThemisMember_label_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis [Member]</link:label>
    <link:label id="lab_mrk_ThemisMember_documentation_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember" xlink:href="mrk-20211231.xsd#mrk_ThemisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ThemisMember" xlink:to="lab_mrk_ThemisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_705d0717-292b-4224-9ee4-98b4e9633855_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b7ea2e8f-627e-4df8-bc67-69482199053c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information about the Changes in Liabilities for Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_fa6f3371-96ee-4bbb-a9fb-bb30ac8efc32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net Income (Loss) Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1b1d650e-403a-4305-806f-736ebb182829_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_9d1f4a75-b23d-44b9-9543-25631e3b2c6f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IAVIMember_f105cbc9-aad3-4286-a808-7f3cb3b5f920_terseLabel_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI</link:label>
    <link:label id="lab_mrk_IAVIMember_label_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI [Member]</link:label>
    <link:label id="lab_mrk_IAVIMember_documentation_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember" xlink:href="mrk-20211231.xsd#mrk_IAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IAVIMember" xlink:to="lab_mrk_IAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesThreshold_680562f0-ff5b-4142-ae2d-b96f87cedd28_terseLabel_en-US" xlink:label="lab_mrk_SalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales threshold</link:label>
    <link:label id="lab_mrk_SalesThreshold_label_en-US" xlink:label="lab_mrk_SalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales threshold</link:label>
    <link:label id="lab_mrk_SalesThreshold_documentation_en-US" xlink:label="lab_mrk_SalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesThreshold" xlink:href="mrk-20211231.xsd#mrk_SalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesThreshold" xlink:to="lab_mrk_SalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LynparzaMember_dc3a832b-1bd8-494a-9c9b-304112c60db1_terseLabel_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza</link:label>
    <link:label id="lab_mrk_LynparzaMember_label_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:label id="lab_mrk_LynparzaMember_documentation_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember" xlink:href="mrk-20211231.xsd#mrk_LynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LynparzaMember" xlink:to="lab_mrk_LynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8add8d6f-1073-46d5-82a4-2f42e7d33630_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_98b04211-e25e-4c0c-8f3f-289ebfc4881e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2644a1a-35df-48ee-8270-130d312af84f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1a4eac41-45ff-4c01-8979-035520f6d624_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ff5dc628-ffd5-4453-b9f5-b6667363c210_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4ef0e27e-73f4-4909-8a76-04228ef3803f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_98cdcd27-f6e8-432d-90d8-d3141c94a994_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_289f21b9-3890-4565-8845-e41ed8a025ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_cf7b089b-3599-4cc9-aaf9-c0ae48d7f9ab_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e7a35fa4-c04e-4e67-bd83-0a3422c01d78_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (excludes inventories of $2,194 in 2021 and $2,070 in 2020 classified in Other assets - see Note&#160;8)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_b04cdcc6-fbec-412d-9e73-e1a3e13b1d26_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CommercialmilestoneMember_9cfb570d-0867-4d8f-8fbb-e2d78bc2625c_terseLabel_en-US" xlink:label="lab_mrk_CommercialmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone</link:label>
    <link:label id="lab_mrk_CommercialmilestoneMember_label_en-US" xlink:label="lab_mrk_CommercialmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">commercial milestone [Member]</link:label>
    <link:label id="lab_mrk_CommercialmilestoneMember_documentation_en-US" xlink:label="lab_mrk_CommercialmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">commercial milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialmilestoneMember" xlink:href="mrk-20211231.xsd#mrk_CommercialmilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CommercialmilestoneMember" xlink:to="lab_mrk_CommercialmilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_242524fe-bd95-43dc-86e9-ff6150f558cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Loss from Affiliates and Depreciation Included in Segment Profits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_49e24813-ab7f-4bb5-b7c4-f54fc84aa932_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherVariableRateDebtMember_41a75483-745e-44a9-98db-77cb38fc4062_terseLabel_en-US" xlink:label="lab_mrk_OtherVariableRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Rate Debt</link:label>
    <link:label id="lab_mrk_OtherVariableRateDebtMember_label_en-US" xlink:label="lab_mrk_OtherVariableRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Rate Debt [Member]</link:label>
    <link:label id="lab_mrk_OtherVariableRateDebtMember_documentation_en-US" xlink:label="lab_mrk_OtherVariableRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherVariableRateDebtMember" xlink:href="mrk-20211231.xsd#mrk_OtherVariableRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherVariableRateDebtMember" xlink:to="lab_mrk_OtherVariableRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_a7b0dac8-dec7-407b-a7c8-80f0d7e9090a_terseLabel_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Research Collaborations and License Agreements</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_label_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Research Collaborations And License Agreements [Text Block]</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to acquisitions, research collaborations and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:href="mrk-20211231.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:to="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b0d2aaaa-8082-4c0b-bdcd-60533c135b63_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d9cb2776-46e1-44cb-be5e-7dcf284573d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_65bf353e-9f62-446b-84d2-10176431a074_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_df720bcc-2579-4660-a062-ece2826bb238_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_6213a3a6-6864-4d59-a3ad-608dcd633ecd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_3b052734-9a9a-46bb-98d6-293bfc147b38_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_4ebb7205-4183-4454-81a5-cc05f14a9157_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_befd4611-0959-479c-a6ad-3f7a963f4696_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a7d8abd8-a226-4b42-ab20-5d58690ca294_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8260ea3c-3592-41ab-a0a2-3613f38a6cff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_9a8b9b2e-fca9-46c6-a232-c378114368b3_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and other postretirement benefits, Liabilities</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_label_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_documentation_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:to="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_34c17145-8d02-4ec4-8193-ab6691b28af8_terseLabel_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Regulatory</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_label_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Regulatory</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_documentation_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:href="mrk-20211231.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:to="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_06d1de96-176c-4b28-bf55-4f9d4788bd03_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_19bcb93f-60fc-4686-aacf-198eff1b626d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_dc8d8bf5-c108-4405-bdb4-cc3912975d70_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GefapixantMember_06d256a1-6c7c-40f2-be3b-c2938fad2807_terseLabel_en-US" xlink:label="lab_mrk_GefapixantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">gefapixant</link:label>
    <link:label id="lab_mrk_GefapixantMember_label_en-US" xlink:label="lab_mrk_GefapixantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">gefapixant [Member]</link:label>
    <link:label id="lab_mrk_GefapixantMember_documentation_en-US" xlink:label="lab_mrk_GefapixantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">gefapixant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GefapixantMember" xlink:href="mrk-20211231.xsd#mrk_GefapixantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GefapixantMember" xlink:to="lab_mrk_GefapixantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58c0caf8-63f7-4dc0-a6d3-c0b2306daab5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_e48838ff-8236-425f-a696-225e5bb98e17_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_d3793a1e-20f2-415e-bc0f-0facd11b8779_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_c99c1650-a7d2-463d-bf4a-d93f9f2c8d48_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_d389cacf-c32b-4405-bff8-6639632fe12b_terseLabel_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Capitalization</link:label>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_label_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_54093331-cc8a-48d0-8a4b-b0c677925bf5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa8db208-b78c-409e-89f8-934f22860eec_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government bonds</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_82bd561d-d500-4fb8-af2c-786feeceb920_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments, maximum</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4f65251e-1ef5-4c6f-8b6e-286659a6ba82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.90NotesDue2024Member_18fad421-7f16-49c8-a122-badb8e65b211_terseLabel_en-US" xlink:label="lab_mrk_A2.90NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% notes due 2024</link:label>
    <link:label id="lab_mrk_A2.90NotesDue2024Member_label_en-US" xlink:label="lab_mrk_A2.90NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A2.90NotesDue2024Member_documentation_en-US" xlink:label="lab_mrk_A2.90NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.90NotesDue2024Member" xlink:href="mrk-20211231.xsd#mrk_A2.90NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.90NotesDue2024Member" xlink:to="lab_mrk_A2.90NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_ffcd61cc-9ff7-4cbe-b611-7cbec308faa2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b31e02be-6b58-4219-b77c-66c4a7f8bbe2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9c57707b-9f1c-4959-89da-301aff303697_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit and operating loss carryforward, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8c1862df-e657-41ee-a890-9dd26e622276_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_202e84b1-bc9c-4931-a55d-305b5fb5076e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_47808716-1ed7-45fa-b771-80e94eda4f90_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_279f1a77-b6f6-47ef-87ed-0c3e99177011_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_d31f0afe-6b1d-4749-a27d-75312133d9a6_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other profits</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_1bf00632-6ef1-408a-abce-01b8d30b9ed4_terseLabel_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Prior Service Credit</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_label_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Prior Service Cost [Member]</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_documentation_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:href="mrk-20211231.xsd#mrk_OtherPostretirementBenefitPlanPriorServiceCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:to="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_d7009c24-d070-4b23-98ea-6103179bf469_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b5aac7d2-808f-450c-a2ff-3f61f0e17200_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_07a4c19b-2f24-4caa-853f-ac2eabca67f9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_cb1927f6-d805-459b-9b90-2e4a3ca73018_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_f0f5830d-f2f2-4320-9278-32304e2b7a2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a241da7-7d40-4005-97a1-0c676ec396bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_63f8a600-2e32-4ee3-8039-d0044557365d_terseLabel_en-US" xlink:label="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.40% debentures due 2028</link:label>
    <link:label id="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_label_en-US" xlink:label="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Percentage Debentures Due On Two Thousand And Twenty Eight [Member]</link:label>
    <link:label id="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_documentation_en-US" xlink:label="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point four percentage debentures due on two thousand and twenty eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:href="mrk-20211231.xsd#mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:to="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_2cdfd372-6140-4d39-916a-cec64cf28073_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherCountriesMember_56318830-f0f1-45cc-a82b-736c9acb1f00_terseLabel_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_label_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_documentation_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember" xlink:href="mrk-20211231.xsd#mrk_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherCountriesMember" xlink:to="lab_mrk_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_929d5755-7642-46dd-a8b0-1c69875e52d7_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_67d4f640-2f77-451f-b44e-5c0f5ab646b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt_2ff11b2f-1e4f-4ad5-9521-36ae5f86dd1b_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, including discontinued operations, debt</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Debt</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_db965daf-8025-487f-a14e-bcb77ea26fc0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_59e41ee8-9efa-4b27-89ac-5635131bcc6c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_1d11927f-ec80-4394-a630-56a0b3a192b4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion, and Amortization [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_7171627c-f700-4087-8575-3a8b4ae26db7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.&#160;equities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_a3cdfff1-0b1f-4297-9050-bf3a5ff14afc_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Pandion</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Four</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_82167090-1ccb-4c50-8b49-e4f0b0ae1f93_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected restructuring and related cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_10f3c19b-52bd-41e7-b625-46d437bfcf2a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_3d5d0119-a19c-479a-9582-4b5165151f17_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses and other tax credit carryforwards, Assets</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_label_en-US" xlink:label="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets operating loss carryforwards and other tax credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:to="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_5d5816b3-538a-4801-87ac-a9a3d13accd4_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6ac97815-1879-4334-a7c7-dde135883395_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_81cd8256-a47c-48e4-b63d-bdfe13df1a04_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartiesAmountInCostOfSales_3bfc45f2-ebdc-4517-87f6-d2159659c180_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party amount in cost of sales</link:label>
    <link:label id="lab_us-gaap_RelatedPartiesAmountInCostOfSales_label_en-US" xlink:label="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties Amount in Cost of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:to="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_78559e0e-7b79-440c-b009-2ae5d9205b13_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_31a7fd61-2b1c-4e49-b337-ff822fa15d21_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VelosBioMember_cf28e7b6-95d4-4b4d-a26d-040f4de2f7d3_terseLabel_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio</link:label>
    <link:label id="lab_mrk_VelosBioMember_label_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio [Member]</link:label>
    <link:label id="lab_mrk_VelosBioMember_documentation_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember" xlink:href="mrk-20211231.xsd#mrk_VelosBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VelosBioMember" xlink:to="lab_mrk_VelosBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_7d0e1421-a249-40ea-9252-c630e8671a1d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables included in Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_117327d8-4395-41fe-8c8a-e763808db930_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_86cb7739-b8ee-46e5-ad9e-6218fd32fe7b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1acb8bbe-8113-4168-87fb-fe2106cfbdab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_74c70211-a3c3-4cd2-b616-1c161b5aa339_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4c0406de-dfef-48d4-bcfb-74fc41825dc7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_f2a98d84-b8c9-4aca-8f3c-6c3456b8c08d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VerquvoMember_7e100765-e1a0-4086-9570-071971a0dea6_terseLabel_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo</link:label>
    <link:label id="lab_mrk_VerquvoMember_label_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo [Member]</link:label>
    <link:label id="lab_mrk_VerquvoMember_documentation_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember" xlink:href="mrk-20211231.xsd#mrk_VerquvoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VerquvoMember" xlink:to="lab_mrk_VerquvoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4659ab75-1a4c-4cdb-8404-1e502152d9d2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8d4952ab-ee8b-4a1e-97bb-9c53d5e1bab0_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_a72d05a9-69a7-45e7-923d-344281ea2537_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SupplyCommitmentQuantityCommitted_ae04942a-2c4f-454d-b2ba-579f4fe86caa_terseLabel_en-US" xlink:label="lab_mrk_SupplyCommitmentQuantityCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity committed (in courses)</link:label>
    <link:label id="lab_mrk_SupplyCommitmentQuantityCommitted_label_en-US" xlink:label="lab_mrk_SupplyCommitmentQuantityCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Quantity Committed</link:label>
    <link:label id="lab_mrk_SupplyCommitmentQuantityCommitted_documentation_en-US" xlink:label="lab_mrk_SupplyCommitmentQuantityCommitted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Quantity Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentQuantityCommitted" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentQuantityCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SupplyCommitmentQuantityCommitted" xlink:to="lab_mrk_SupplyCommitmentQuantityCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4b163228-829c-45b7-bab0-0a6ad8b00a7f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_3273c421-0fbd-4d65-9fc9-5403325c3c0f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherLongTermDebtMember_ea03f0ba-cacb-4cb0-8b5f-89b11dc5a243_terseLabel_en-US" xlink:label="lab_mrk_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_OtherLongTermDebtMember_label_en-US" xlink:label="lab_mrk_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_mrk_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_mrk_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherLongTermDebtMember" xlink:href="mrk-20211231.xsd#mrk_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherLongTermDebtMember" xlink:to="lab_mrk_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_09e24fd2-b79f-47df-845f-772640a5cfbf_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_4b33b525-151f-4e58-b3b1-c45666064707_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_9d877a82-2f82-4e2b-8fd6-964db7353a88_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_b71dd097-c59a-4e8d-a8d6-5db1702a5fe5_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of the United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d83e574d-8942-4473-9a66-e27738bce4ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6063a6d3-d992-4f12-bcc0-ecb1b5efa401_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_fea0005d-5dd3-4b9e-a48a-e0d909069e4d_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b51273a7-0288-416c-be33-f9b0d02a824c_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_38e6799a-e20f-4043-ae10-70045c6a998d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a0fdafa7-d489-4516-9646-0aa281d93dfe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) Net of Taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_80a47014-9b71-4b4d-baa8-d1d52bb23b46_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_fcf588f3-f573-426a-ae56-25c1e7eb2d04_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8bfcc2bb-0dac-47f5-ac50-30ddea7eaabd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_33778dd4-2d84-4733-9f67-e70060bf4f52_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_8c1b25d9-1e3c-412b-a4b3-1ef6c69b36e9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9400627e-f639-47cb-b0f1-51bb98f10e82_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_10488aa0-07d3-494f-99b0-b392f6c20c99_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Continuing Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_4e195541-d832-47ce-ab2e-83d1e1cf91f3_terseLabel_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government And Agency Obligations Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:to="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aa290845-22fb-48ea-9031-af7320b50721_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_964fe16f-7c84-452a-bf9d-104f80adb4dc_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5cfff514-90d9-4a91-8a96-24ce11a90c91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Between Effective Tax Rate and U.S. Statutory Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b0b11737-ddad-49d9-b799-18211fbbc545_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_c98ca4d4-68bb-4bbd-a4b2-b8f656de5653_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f73f0e57-4d72-4a3e-9e5a-ba45fabc27fd_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxTable_0bd79ba0-8af6-4daa-828f-faa529f2e8df_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_mrk_IncomeTaxTable_label_en-US" xlink:label="lab_mrk_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_mrk_IncomeTaxTable_documentation_en-US" xlink:label="lab_mrk_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxTable" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxTable" xlink:to="lab_mrk_IncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_d14e54b9-40bb-4a54-8724-aa30ccd78619_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses recognized on investments in equity securities without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6006770c-e558-4255-8f55-35ca96002386_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_a25138f8-db1f-418b-b07b-8ca8a058a3df_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relating to assets still held at December 31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EurodominatedNotesMember_8d27442b-364b-4408-95f0-259e104e016b_terseLabel_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-denominated notes</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_label_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_documentation_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember" xlink:href="mrk-20211231.xsd#mrk_EurodominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EurodominatedNotesMember" xlink:to="lab_mrk_EurodominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d066db65-0f8d-47c0-b1d8-a3f034da47f6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a7381648-fea4-4b2d-99ba-3c926787367c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember_1ef76fa7-a79d-4bb9-bc3f-52b932ea1be6_terseLabel_en-US" xlink:label="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations</link:label>
    <link:label id="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Obligations Fixed Income Securities [Member]</link:label>
    <link:label id="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations fixed income securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:href="mrk-20211231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:to="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8469c607-be8b-41e9-b859-61ef8ba93012_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_8388bd6d-843c-4fd1-9b46-72217f2cd194_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate, deduction, percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Deduction, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Deduction, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage" xlink:href="mrk-20211231.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRateDeductionPercentage" xlink:to="lab_mrk_RoyaltyRateDeductionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_8e898b41-a016-4955-89f9-fca3f4e10355_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges Related to Restructuring Program Activities by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c019b81-6a00-4c10-a9bf-123b740f112d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_11225b2d-6c17-4b83-8c44-1e605d2c480a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d02cc0ba-c780-4b12-8d4a-185692fa66c3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_bbe09835-ec00-4956-994a-1021e75ed1d7_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for the acquisition of VelosBio Inc.</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:href="mrk-20211231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:to="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BridionMember_7ef92897-ac4c-4bd8-9801-41ea2ed8a342_terseLabel_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion</link:label>
    <link:label id="lab_mrk_BridionMember_label_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member]</link:label>
    <link:label id="lab_mrk_BridionMember_documentation_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember" xlink:href="mrk-20211231.xsd#mrk_BridionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BridionMember" xlink:to="lab_mrk_BridionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_646fe590-fbfb-495c-8b17-33525aa08fce_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cb28c32a-aee5-40fb-b52b-d69c4679df1d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EisaiMember_69c9adc4-7e92-4ea1-b066-313e22971f92_terseLabel_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_mrk_EisaiMember_label_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_mrk_EisaiMember_documentation_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember" xlink:href="mrk-20211231.xsd#mrk_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EisaiMember" xlink:to="lab_mrk_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_762ed6a2-f932-4710-99fb-d0cdf34722a2_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_49ac6dc4-9c1f-485e-9620-6f7410406167_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SeagenMember_c1fff5c5-4a7b-4bf3-919c-1c1b7ca5cacf_terseLabel_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen</link:label>
    <link:label id="lab_mrk_SeagenMember_label_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen [Member]</link:label>
    <link:label id="lab_mrk_SeagenMember_documentation_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember" xlink:href="mrk-20211231.xsd#mrk_SeagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SeagenMember" xlink:to="lab_mrk_SeagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InternationalMember_bab2c4c2-a5ae-49be-9b60-6a0db5bd53cf_terseLabel_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Int&#8217;l</link:label>
    <link:label id="lab_mrk_InternationalMember_label_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_mrk_InternationalMember_documentation_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember" xlink:href="mrk-20211231.xsd#mrk_InternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InternationalMember" xlink:to="lab_mrk_InternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_828ac6b1-e0bf-4345-9e44-181247c01ac0_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of OncoImmune</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d3819457-cd63-4181-bbbc-bd50e5efca26_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree_8df71f75-fc5b-4aee-94db-4afb017b4020_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for the acquisition of Peloton Therapeutics, Inc.</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Three</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" xlink:href="mrk-20211231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" xlink:to="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_e93d56c0-108a-4228-9a44-b114238f5280_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_70aa6cdd-4bfa-4ec5-b0df-2dbfab480bc5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_a8bdae81-8cf4-4acc-9068-7b0da078a595_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of continuing involvement after disposal</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Period of Continuing Involvement after Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:to="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a63ef500-e267-488e-affe-ff4889215ed7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_dc18bfa8-27c3-4595-aa2a-a3ea0da95764_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_6162f1f6-bbf4-47df-824c-344ff5c3b616_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation January&#160;1</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_390b70b2-573b-4c31-a412-a3eda7116d4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation December&#160;31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MovementinCommonStockandTreasuryStockRollForward_3ce39b58-650a-42d0-82ac-2fac8a72b61f_terseLabel_en-US" xlink:label="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Common Stock and Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_mrk_MovementinCommonStockandTreasuryStockRollForward_label_en-US" xlink:label="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Common Stock and Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_mrk_MovementinCommonStockandTreasuryStockRollForward_documentation_en-US" xlink:label="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Common Stock and Treasury Stock [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:href="mrk-20211231.xsd#mrk_MovementinCommonStockandTreasuryStockRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:to="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d60c8fbc-4515-4d11-8fa8-c59fade00c06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment (at cost)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_0d08d998-d08d-483a-b3c8-1a975ca11f55_terseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_f067afef-be6d-4af4-ad66-88d2e7d5f4d3_verboseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_label_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment [Member]</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_documentation_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PharmaceuticalsegmentMember" xlink:to="lab_mrk_PharmaceuticalsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_0c794e86-e916-44a9-ab6a-6f37dfdd51ef_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_8bcc0d35-a643-4af6-90c7-37b4447c7ebb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e019db8b-171a-477e-b0c1-99398c414af7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_741d89fa-10e6-4932-9db5-ee04e8bfbb19_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_a4a297cc-2779-4574-88fb-6e8b7f477e32_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_0854a08c-628b-47d4-889e-eb55ef7ab5d5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_9a518979-c72b-4fa8-a355-51fb0d8ec0b4_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_ce0f8456-1241-42ef-a579-8663b1bc8a13_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (approximates current cost)</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_4d303de5-a7e5-44c0-95e4-c6baffb06df2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_a1a44d1d-5c5d-4bec-9cc8-05073dd8e5bc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AccrualForRebates_30160ab8-586d-44e9-a736-0c12fbc686e0_terseLabel_en-US" xlink:label="lab_mrk_AccrualForRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for rebates included in accrued and other current liabilities</link:label>
    <link:label id="lab_mrk_AccrualForRebates_label_en-US" xlink:label="lab_mrk_AccrualForRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual For Rebates</link:label>
    <link:label id="lab_mrk_AccrualForRebates_documentation_en-US" xlink:label="lab_mrk_AccrualForRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for rebates recorded as current liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForRebates" xlink:href="mrk-20211231.xsd#mrk_AccrualForRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AccrualForRebates" xlink:to="lab_mrk_AccrualForRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_d7df53a5-9370-4f9a-af1b-502c224bf259_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0db4efe0-01fc-4fae-9bbc-5a49815b6b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_725aaed3-805f-43d7-8690-14947fd1c715_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents_b121f093-2dc8-4c88-b605-491a86c52c98_terseLabel_en-US" xlink:label="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents_label_en-US" xlink:label="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets and Liabilities, Cash and Cash Equivalents</link:label>
    <link:label id="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents_documentation_en-US" xlink:label="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets and Liabilities, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents" xlink:href="mrk-20211231.xsd#mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents" xlink:to="lab_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A075NotesDue2026Member_ca94730e-294a-4f4a-86f8-a8a2ca0e95ff_terseLabel_en-US" xlink:label="lab_mrk_A075NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% notes due 2026</link:label>
    <link:label id="lab_mrk_A075NotesDue2026Member_label_en-US" xlink:label="lab_mrk_A075NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A075NotesDue2026Member_documentation_en-US" xlink:label="lab_mrk_A075NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Notes due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A075NotesDue2026Member" xlink:href="mrk-20211231.xsd#mrk_A075NotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A075NotesDue2026Member" xlink:to="lab_mrk_A075NotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_98b629f1-21fe-4495-9ced-55cbaa835ec8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) amortization included in benefit cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_dbaf51ab-eed0-4cce-885d-455b7dd78760_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A63DebenturesDue2026Member_0026946b-1343-46b6-86cf-ad7039ba0b14_terseLabel_en-US" xlink:label="lab_mrk_A63DebenturesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.30% debentures due 2026</link:label>
    <link:label id="lab_mrk_A63DebenturesDue2026Member_label_en-US" xlink:label="lab_mrk_A63DebenturesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.3% Debentures Due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A63DebenturesDue2026Member_documentation_en-US" xlink:label="lab_mrk_A63DebenturesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point three percentage debentures due on two thousand and twenty six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member" xlink:href="mrk-20211231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A63DebenturesDue2026Member" xlink:to="lab_mrk_A63DebenturesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f61490f8-4aa9-4cd4-aba6-a8e50ece0035_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9f018556-0746-45a1-82ef-16c08ceec1c6_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AnimalHealthMember_714ad699-33c0-444a-ab5b-3631b71ca212_terseLabel_en-US" xlink:label="lab_mrk_AnimalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health</link:label>
    <link:label id="lab_mrk_AnimalHealthMember_label_en-US" xlink:label="lab_mrk_AnimalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health [Member]</link:label>
    <link:label id="lab_mrk_AnimalHealthMember_documentation_en-US" xlink:label="lab_mrk_AnimalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthMember" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AnimalHealthMember" xlink:to="lab_mrk_AnimalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_2ba03d70-8fb2-4171-a22a-301d6a0563fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0ab554d7-a618-4588-b2dd-3ebdcd58ffb9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ead0e737-fef1-4e48-af81-67a09ad0be45_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax share-based compensation cost recorded</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a43cc441-dc91-419c-bc10-c12ec902a0db_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_df41d980-452d-4ea6-8d14-e77db665856c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_c2936fbb-2f23-4001-b5fb-da5afd8f86d1_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_ad8b91b1-148b-4578-b94a-8303aaea3683_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of Organon &amp; Co.</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_becc8949-e50b-4b20-9565-81e79913c44e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spinoff transaction</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cc93e650-5258-45e3-a5fc-526aa64dce06_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GardasilGardasil9Member_9b281d59-bfd8-4f32-b766-93e4ba376cac_terseLabel_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_label_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member]</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_documentation_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member" xlink:href="mrk-20211231.xsd#mrk_GardasilGardasil9Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GardasilGardasil9Member" xlink:to="lab_mrk_GardasilGardasil9Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_8327cf90-e9c7-4f39-8910-869bec0043d0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds collected from factoring of receivable, held in restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_d9ae6b69-fd0c-469c-ae79-e947ede8815f_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, Liabilities</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_label_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Equity Method Investment</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_documentation_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:to="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.75NotesDue2025Member_a8ce8d62-2470-46fc-bdfe-7e731a28f8c7_terseLabel_en-US" xlink:label="lab_mrk_A2.75NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2025</link:label>
    <link:label id="lab_mrk_A2.75NotesDue2025Member_label_en-US" xlink:label="lab_mrk_A2.75NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_mrk_A2.75NotesDue2025Member_documentation_en-US" xlink:label="lab_mrk_A2.75NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.75NotesDue2025Member" xlink:href="mrk-20211231.xsd#mrk_A2.75NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.75NotesDue2025Member" xlink:to="lab_mrk_A2.75NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_aac19c99-387e-4d10-8a9d-ae336abec1b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RemicadeMember_edd61781-2d0a-4de4-92e3-ccac81bd2a2a_terseLabel_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_mrk_RemicadeMember_label_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_mrk_RemicadeMember_documentation_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember" xlink:href="mrk-20211231.xsd#mrk_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RemicadeMember" xlink:to="lab_mrk_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a41b3bd0-dca6-41a8-b57d-83f8fb642d90_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $103 of restricted cash at January 1, 2021 included in Other Assets - see Note 7)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_504ff020-a52e-42bb-9598-68b8f43d9dbe_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Year (includes $71 of restricted cash at December 31, 2021 included in Other Assets - see Note 7)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d28d232c-b019-4df3-bb4f-8a2ced309a82_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OncoImmuneMember_fbfb1603-8a38-4471-98b1-502a0ee44a9a_terseLabel_en-US" xlink:label="lab_mrk_OncoImmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OncoImmune</link:label>
    <link:label id="lab_mrk_OncoImmuneMember_label_en-US" xlink:label="lab_mrk_OncoImmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OncoImmune [Member]</link:label>
    <link:label id="lab_mrk_OncoImmuneMember_documentation_en-US" xlink:label="lab_mrk_OncoImmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OncoImmune</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember" xlink:href="mrk-20211231.xsd#mrk_OncoImmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OncoImmuneMember" xlink:to="lab_mrk_OncoImmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_c0b0d54d-69ae-4897-9345-faf1df0dec1c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_161894c0-fb74-41fa-b76a-2adaa0bd4139_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fb0df93c-67c4-480d-a318-d8e35452e525_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_fa666756-afe9-445c-abb7-c666920b85d3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_d41d5d4d-0e4b-4111-8630-a6d789d1a986_terseLabel_en-US" xlink:label="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% notes due 2039</link:label>
    <link:label id="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_label_en-US" xlink:label="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Eight Five Percentage Notes Due On Two Thousand And Thirty Nine [Member]</link:label>
    <link:label id="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_documentation_en-US" xlink:label="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five point eight five percentage notes due on two thousand and thirty nine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:href="mrk-20211231.xsd#mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:to="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_e6400f98-3b7f-41d2-a247-f87908977f87_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.875EuroNotesDue2026Member_b2ef29d8-df9b-4b6e-ab36-e5958c52d09f_terseLabel_en-US" xlink:label="lab_mrk_A1.875EuroNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% euro-denominated notes due 2026</link:label>
    <link:label id="lab_mrk_A1.875EuroNotesDue2026Member_label_en-US" xlink:label="lab_mrk_A1.875EuroNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Euro Notes Due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A1.875EuroNotesDue2026Member_documentation_en-US" xlink:label="lab_mrk_A1.875EuroNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Euro Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875EuroNotesDue2026Member" xlink:href="mrk-20211231.xsd#mrk_A1.875EuroNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.875EuroNotesDue2026Member" xlink:to="lab_mrk_A1.875EuroNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_737fb88d-7f55-4994-b947-0eb4e242dc74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8d339581-b316-4759-8100-b3234d7635b5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0af915af-530e-471c-a2c6-75a755e62617_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e734ea6-630f-4d44-a1c5-97580345a816_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_06547fa2-1db9-4a5a-80a1-dabef5800bf1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_3b98ad73-81ac-44c2-a53d-57770024a856_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal defense costs reserve</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZerbaxaMember_9d7a1e67-4e7a-4a9a-bb68-bc8d9a47121c_terseLabel_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_label_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_documentation_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember" xlink:href="mrk-20211231.xsd#mrk_ZerbaxaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZerbaxaMember" xlink:to="lab_mrk_ZerbaxaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_976994aa-2399-447c-924f-91113b0b34a7_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_ede659c8-eb46-4849-a2c5-b7c81bb3e137_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which share-based payment awards vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DificidMember_b7f39a1a-48b2-4d39-929f-4e051d3fcf16_terseLabel_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid</link:label>
    <link:label id="lab_mrk_DificidMember_label_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid [Member]</link:label>
    <link:label id="lab_mrk_DificidMember_documentation_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember" xlink:href="mrk-20211231.xsd#mrk_DificidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DificidMember" xlink:to="lab_mrk_DificidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_22c6409f-4a47-4f96-bed3-8e22df67055e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Assets of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_ab9890b8-c10f-4e40-90a0-3e558c0b734f_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Assets of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e5892259-022b-4a62-9b7b-d33b67c26224_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_479cc666-2082-461b-b21a-4d0f6ad2e456_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_def85029-2e12-4c90-adb5-5c9328565a55_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_12a6ebb4-57ec-4ecb-856b-8c59cb4721b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, reduction resulting from divestiture of Merck's consumer care business</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TukysaMember_a5951a7b-f360-457f-a500-4c8bc930662c_terseLabel_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa</link:label>
    <link:label id="lab_mrk_TukysaMember_label_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa [Member]</link:label>
    <link:label id="lab_mrk_TukysaMember_documentation_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember" xlink:href="mrk-20211231.xsd#mrk_TukysaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TukysaMember" xlink:to="lab_mrk_TukysaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_837c3043-c41b-45a2-ba57-88f0f1f957ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction_ee4117a9-08ef-45ca-8f7d-e05db91a2d15_negatedTerseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Awards transferred to Organon in spin-off (in shares)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_9411de33-65ef-4e8a-8e6a-20d173f86b34_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_c26149d7-d9e0-4259-b619-10d7458e5263_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_353fc916-4139-4b33-9001-eea8077271a2_terseLabel_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_label_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_documentation_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember" xlink:href="mrk-20211231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleratedDepreciationMember" xlink:to="lab_mrk_AcceleratedDepreciationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_7908a8f7-1f68-4e97-af6a-e9a3708cc7cb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process and Raw Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_32db3d16-d46f-4e55-ad70-80a132e03e43_terseLabel_en-US" xlink:label="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.60% notes due 2042</link:label>
    <link:label id="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_label_en-US" xlink:label="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]</link:label>
    <link:label id="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_documentation_en-US" xlink:label="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:href="mrk-20211231.xsd#mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:to="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_63d9be8a-bb7d-4340-9638-ea4d1e784ce3_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Profits to Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_10a21f49-a683-4dec-bb58-760e015accab_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_892603ba-f125-4837-83fd-ba4ddda33b5c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_217d72ef-b392-4561-be84-ed2ce6b45f0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LivestockMember_94d2df09-cd08-4a80-9acf-d6711564a1cb_terseLabel_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock</link:label>
    <link:label id="lab_mrk_LivestockMember_label_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:label id="lab_mrk_LivestockMember_documentation_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember" xlink:href="mrk-20211231.xsd#mrk_LivestockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LivestockMember" xlink:to="lab_mrk_LivestockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A245NotesDue2050Member_d20f4160-2997-4311-b782-7a9250c9f42d_terseLabel_en-US" xlink:label="lab_mrk_A245NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2050</link:label>
    <link:label id="lab_mrk_A245NotesDue2050Member_label_en-US" xlink:label="lab_mrk_A245NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes Due 2050 [Member]</link:label>
    <link:label id="lab_mrk_A245NotesDue2050Member_documentation_en-US" xlink:label="lab_mrk_A245NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A245NotesDue2050Member" xlink:href="mrk-20211231.xsd#mrk_A245NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A245NotesDue2050Member" xlink:to="lab_mrk_A245NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_294d7333-e162-4c7c-862f-d4b26ba96c48_terseLabel_en-US" xlink:label="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:label id="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:label id="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:href="mrk-20211231.xsd#mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:to="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_2c162af2-24c5-4535-b9c7-9dc83a84e90d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, Expenses and Other</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_87fe9ed2-148c-47e6-a458-efe2962a23e4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition of business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ConsumercarebusinessMember_4c6239a1-363f-41e6-ac76-d0e88a415d66_terseLabel_en-US" xlink:label="lab_mrk_ConsumercarebusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">consumer care business</link:label>
    <link:label id="lab_mrk_ConsumercarebusinessMember_label_en-US" xlink:label="lab_mrk_ConsumercarebusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">consumer care business [Member]</link:label>
    <link:label id="lab_mrk_ConsumercarebusinessMember_documentation_en-US" xlink:label="lab_mrk_ConsumercarebusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">consumer care business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ConsumercarebusinessMember" xlink:href="mrk-20211231.xsd#mrk_ConsumercarebusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ConsumercarebusinessMember" xlink:to="lab_mrk_ConsumercarebusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bf90f042-5d93-4e0c-b015-20b2eed4922b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available borrowing capacity under credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_903325eb-4377-49be-8c6e-faeb806c769c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LatinAmericaMember_1bcb32db-bd9f-4a03-8ef1-bf77f9a194b6_terseLabel_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America</link:label>
    <link:label id="lab_srt_LatinAmericaMember_label_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LatinAmericaMember" xlink:to="lab_srt_LatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ContingentConsiderationPolicyTextBlock_914ba283-94a0-430d-9ede-3d5fb0ce6838_terseLabel_en-US" xlink:label="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_mrk_ContingentConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:label id="lab_mrk_ContingentConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discussion of the accounting policy for contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentConsiderationPolicyTextBlock" xlink:href="mrk-20211231.xsd#mrk_ContingentConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ContingentConsiderationPolicyTextBlock" xlink:to="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_82c315cd-e3ed-47d6-bf3a-cff60a27131b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_a72f601f-d1c3-468f-83fb-ef23742db4fc_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d1161474-aac5-483f-b40c-3004a6242235_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_462b1add-95a0-46dc-9456-caf0b59212b8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_1d877565-342e-45bb-9735-bb4874a0f2e8_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ee9af43e-5bd1-4948-b148-20e0ceec1ec3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_d34c0f6a-2efb-4e6a-8e29-8bcb13ce611c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_5780eb0f-a1cf-4a02-9029-1baea156008d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary growth rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_f6e85874-7b52-4f48-bc3d-b4eabb1340b1_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and promotion costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock_fe7dd217-8d00-42f5-a3f4-08ce18dd545e_terseLabel_en-US" xlink:label="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:href="mrk-20211231.xsd#mrk_AssetsandLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:to="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_7fa7bb1b-ff89-440d-829a-03b94885140c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative costs since program inception</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_8b5ba325-0f23-43e5-9566-bc6d132dbfa3_terseLabel_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_045726dc-04b2-4af0-ab49-3440b9a0423a_verboseLabel_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member" xlink:href="mrk-20211231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.35NotesDue2022Member" xlink:to="lab_mrk_A2.35NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0ef27588-bee3-43c7-83bb-7dc99a39b1f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory rate applied to income from continuing operations before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearOne_050ed6a9-179c-44e6-a8b1-bbfd1ee0fcdf_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2022</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearOne_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year One</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearOne_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearOne" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearOne" xlink:to="lab_mrk_LongTermDebtInterestPayableYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CompanionAnimalsMember_1fd364e2-f531-4cc6-895a-a86c8a87f3e9_terseLabel_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_label_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_documentation_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember" xlink:href="mrk-20211231.xsd#mrk_CompanionAnimalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CompanionAnimalsMember" xlink:to="lab_mrk_CompanionAnimalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CorporateObligationsInvestmentFundsMember_33c313ff-6c80-4823-bdf0-4e2c08324c2d_terseLabel_en-US" xlink:label="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations</link:label>
    <link:label id="lab_mrk_CorporateObligationsInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Obligations Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_CorporateObligationsInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember" xlink:href="mrk-20211231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CorporateObligationsInvestmentFundsMember" xlink:to="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.50eurodenominatednotesdue2024Member_6c2f9dbc-509e-411e-9608-758703a6403b_terseLabel_en-US" xlink:label="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro-denominated notes due 2024</link:label>
    <link:label id="lab_mrk_A0.50eurodenominatednotesdue2024Member_label_en-US" xlink:label="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro-denominated notes due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A0.50eurodenominatednotesdue2024Member_documentation_en-US" xlink:label="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro-denominated notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.50eurodenominatednotesdue2024Member" xlink:href="mrk-20211231.xsd#mrk_A0.50eurodenominatednotesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.50eurodenominatednotesdue2024Member" xlink:to="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_1d5336fb-caf6-478f-b1cc-3676a3ca9f7f_terseLabel_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments collaborative arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20211231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_ff113137-ac94-4d64-a546-296a26acfe57_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_1aebdba7-3407-4731-9a30-76ac2fca2f3e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_02cc48b9-6789-4373-a7d6-f48ad1beb34c_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_d8eab2b9-121f-4e18-a3c6-d78cf89bc6ca_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_1e43e17d-365a-4272-b915-ab18aecc8edc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_64a1e65a-47e1-4504-ab01-a819a2ccc6aa_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f5eece0-654d-4d69-b0aa-20cf36ad70b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_aecddc41-d28f-4e0f-afb2-189e26682a30_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_57257e8a-48a7-4973-94cd-45ee737d957a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_b148951e-0850-457c-90b0-3d9ce928d188_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_8469a86f-a823-4718-93c0-2eecab619f72_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefits</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.875NotesDue2021Member_d5ebb56e-9e9c-4255-9bdf-30c5d5d2c49e_terseLabel_en-US" xlink:label="lab_mrk_A3.875NotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2021</link:label>
    <link:label id="lab_mrk_A3.875NotesDue2021Member_label_en-US" xlink:label="lab_mrk_A3.875NotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2021 [Member]</link:label>
    <link:label id="lab_mrk_A3.875NotesDue2021Member_documentation_en-US" xlink:label="lab_mrk_A3.875NotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member" xlink:href="mrk-20211231.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.875NotesDue2021Member" xlink:to="lab_mrk_A3.875NotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PremiumOnSharesAcquired_8a706b8b-cde3-463c-9b42-18e931ca4a44_terseLabel_en-US" xlink:label="lab_mrk_PremiumOnSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on shares acquired</link:label>
    <link:label id="lab_mrk_PremiumOnSharesAcquired_label_en-US" xlink:label="lab_mrk_PremiumOnSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on shares acquired</link:label>
    <link:label id="lab_mrk_PremiumOnSharesAcquired_documentation_en-US" xlink:label="lab_mrk_PremiumOnSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on shares acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PremiumOnSharesAcquired" xlink:href="mrk-20211231.xsd#mrk_PremiumOnSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PremiumOnSharesAcquired" xlink:to="lab_mrk_PremiumOnSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_167d38d4-67aa-4dd3-82ed-11f5e3f2a8fa_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and product rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4009116c-cabd-4192-8a41-1b4bc79416f5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OrganonCoMember_6541671a-447b-40a3-a54e-9f967b162b38_terseLabel_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co.</link:label>
    <link:label id="lab_mrk_OrganonCoMember_label_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co. [Member]</link:label>
    <link:label id="lab_mrk_OrganonCoMember_documentation_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember" xlink:href="mrk-20211231.xsd#mrk_OrganonCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OrganonCoMember" xlink:to="lab_mrk_OrganonCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c4eb27e-e430-4597-b54a-ce3b55aebbe1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_be7e94e4-96e7-4117-9529-31d3341e6243_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of Organon</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_68123b30-5003-443a-9347-2d2b3737f78b_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales by Merck</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementSalesNet" xlink:to="lab_mrk_CollaborativeArrangementSalesNet" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>mrk-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c2671c01-457c-407e-affb-5c2ec2e9dc08,g:df117aec-e688-48b3-9aac-3f4fd6688d4e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_55b71563-51d9-4891-9cfb-6a2e64082fc1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_3d57070f-6e26-4b15-82f2-bfd0656b2a73" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55b71563-51d9-4891-9cfb-6a2e64082fc1" xlink:to="loc_dei_DocumentInformationTable_3d57070f-6e26-4b15-82f2-bfd0656b2a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c38194e2-795f-4bba-83c9-5f357d8a54d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3d57070f-6e26-4b15-82f2-bfd0656b2a73" xlink:to="loc_us-gaap_DebtInstrumentAxis_c38194e2-795f-4bba-83c9-5f357d8a54d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c38194e2-795f-4bba-83c9-5f357d8a54d1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_becda756-5954-47d8-90c7-eacc3c4165dc" xlink:href="mrk-20211231.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:to="loc_mrk_A0.500Notesdue2024Member_becda756-5954-47d8-90c7-eacc3c4165dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_74fea867-7bc6-4936-b28e-2e54c4903bd8" xlink:href="mrk-20211231.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:to="loc_mrk_A1.875Notesdue2026Member_74fea867-7bc6-4936-b28e-2e54c4903bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_ae631153-2eac-4000-8f90-271eed6a57a1" xlink:href="mrk-20211231.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:to="loc_mrk_A2.500Notesdue2034Member_ae631153-2eac-4000-8f90-271eed6a57a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_a8c5898b-6a26-4e79-b96d-e77bf04a0c61" xlink:href="mrk-20211231.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc1fa86d-2bea-40b7-b103-3be3d4da134b" xlink:to="loc_mrk_A1.375Notesdue2036Member_a8c5898b-6a26-4e79-b96d-e77bf04a0c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3d57070f-6e26-4b15-82f2-bfd0656b2a73" xlink:to="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5703317e-5cb5-4aa0-8007-a504ec2c02a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentType_5703317e-5cb5-4aa0-8007-a504ec2c02a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_208aeff5-7dff-43fb-b662-91bcfa48ca82" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentAnnualReport_208aeff5-7dff-43fb-b662-91bcfa48ca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7849372e-de05-4b40-94b9-0b04e238a43a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentTransitionReport_7849372e-de05-4b40-94b9-0b04e238a43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_35c6830f-c2f0-4d67-83bd-83e180bb10ec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityFileNumber_35c6830f-c2f0-4d67-83bd-83e180bb10ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5462d923-9be1-4c5d-9dbc-01f4e85e1258" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityRegistrantName_5462d923-9be1-4c5d-9dbc-01f4e85e1258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_86658b9c-5e30-4900-aeca-7eda5f348c57" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_CityAreaCode_86658b9c-5e30-4900-aeca-7eda5f348c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5c8d3b43-f65b-4123-804b-aa082a1bc58d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_LocalPhoneNumber_5c8d3b43-f65b-4123-804b-aa082a1bc58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_51a9ed51-b436-4de9-9ccb-f044db71d4a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_51a9ed51-b436-4de9-9ccb-f044db71d4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6aad0124-8ff9-41a3-a1c1-4bd6002445c8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityTaxIdentificationNumber_6aad0124-8ff9-41a3-a1c1-4bd6002445c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c7f8ee6c-5f03-4f30-900a-2e0de993e8ca" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityAddressAddressLine1_c7f8ee6c-5f03-4f30-900a-2e0de993e8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_362d36b7-7dfa-4bab-96b5-cf367c788d4d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityAddressCityOrTown_362d36b7-7dfa-4bab-96b5-cf367c788d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b43e9a69-52f8-4f7a-bb76-9aabc6163cce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityAddressStateOrProvince_b43e9a69-52f8-4f7a-bb76-9aabc6163cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0f5247a7-28f9-4465-87ae-0710af1f2157" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityAddressPostalZipCode_0f5247a7-28f9-4465-87ae-0710af1f2157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_32c0b328-2f09-4aff-a233-87efb4ad39fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_Security12bTitle_32c0b328-2f09-4aff-a233-87efb4ad39fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_52897dd9-167b-4a49-8718-d128ce3a0f4a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_TradingSymbol_52897dd9-167b-4a49-8718-d128ce3a0f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_af0c4268-36a7-4536-8e5d-ff78ea381ba1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_SecurityExchangeName_af0c4268-36a7-4536-8e5d-ff78ea381ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4e1a1886-4d10-4df8-943b-fc2534388751" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4e1a1886-4d10-4df8-943b-fc2534388751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_fc25848c-7ca6-4c90-9a81-2f71ea504dcd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityPublicFloat_fc25848c-7ca6-4c90-9a81-2f71ea504dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_53f90cb4-51a7-43fa-a814-2c3df8a7c20b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_53f90cb4-51a7-43fa-a814-2c3df8a7c20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_dd17c8e1-011f-4580-a083-2104388bb496" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityVoluntaryFilers_dd17c8e1-011f-4580-a083-2104388bb496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6ebaaeb1-c05c-4c2f-99b9-2761257371ec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityCurrentReportingStatus_6ebaaeb1-c05c-4c2f-99b9-2761257371ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_aaae1572-672c-4349-8fe9-362e8092cd12" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityInteractiveDataCurrent_aaae1572-672c-4349-8fe9-362e8092cd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0ec391e7-567f-4414-969b-6c47fc281f53" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityFilerCategory_0ec391e7-567f-4414-969b-6c47fc281f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6fb533ee-9c65-4c90-b99b-55e75d3f7424" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntitySmallBusiness_6fb533ee-9c65-4c90-b99b-55e75d3f7424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_754aedd9-a659-4337-9548-1d15977a7187" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityEmergingGrowthCompany_754aedd9-a659-4337-9548-1d15977a7187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8b12570c-dd70-4256-8d12-57eaeca9c975" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8b12570c-dd70-4256-8d12-57eaeca9c975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1f12b999-eece-4037-bba4-8145aec4798a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityShellCompany_1f12b999-eece-4037-bba4-8145aec4798a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fc271e61-0da3-4bbf-b0aa-f59b55b48173" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_AmendmentFlag_fc271e61-0da3-4bbf-b0aa-f59b55b48173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_752d506c-ed7a-4c35-88a9-61989d3e01d9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentPeriodEndDate_752d506c-ed7a-4c35-88a9-61989d3e01d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3b893c49-acb5-4a30-821d-fb521fe4ab37" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentFiscalYearFocus_3b893c49-acb5-4a30-821d-fb521fe4ab37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d597ebb2-9ea6-4b92-8bf9-2f7b45ae8c93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d597ebb2-9ea6-4b92-8bf9-2f7b45ae8c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ebfafac8-ccf2-4a46-83df-199006de3e10" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_EntityCentralIndexKey_ebfafac8-ccf2-4a46-83df-199006de3e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c9051f33-58a5-4bee-a38d-341a9c4e5566" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_CurrentFiscalYearEndDate_c9051f33-58a5-4bee-a38d-341a9c4e5566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e3675bf1-98d4-4e4a-872f-5da0e7b82a3f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4e3408ff-c206-49dc-a76f-05fe41b49eb7" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e3675bf1-98d4-4e4a-872f-5da0e7b82a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AuditInformation" xlink:type="simple" xlink:href="mrk-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AuditInformationAbstract_18c75945-f2c6-49b4-ac7b-5ba93207dd30" xlink:href="mrk-20211231.xsd#mrk_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_585bc6fc-b259-4172-9fd2-86f4fe6a4ddc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_AuditInformationAbstract_18c75945-f2c6-49b4-ac7b-5ba93207dd30" xlink:to="loc_dei_AuditorName_585bc6fc-b259-4172-9fd2-86f4fe6a4ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_71a3e383-96ec-4b7d-ac71-f2dc1be8acaa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_AuditInformationAbstract_18c75945-f2c6-49b4-ac7b-5ba93207dd30" xlink:to="loc_dei_AuditorLocation_71a3e383-96ec-4b7d-ac71-f2dc1be8acaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c77002f2-60f7-4f9b-89fa-7de10b183865" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_AuditInformationAbstract_18c75945-f2c6-49b4-ac7b-5ba93207dd30" xlink:to="loc_dei_AuditorFirmId_c77002f2-60f7-4f9b-89fa-7de10b183865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_92f29500-7da7-45d2-a8ba-507af920b46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_Revenues_92f29500-7da7-45d2-a8ba-507af920b46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_e11bede4-7121-486e-9f38-d8c53cc76b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_e11bede4-7121-486e-9f38-d8c53cc76b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_90f5f2e7-f7cc-4237-a735-729c6aadf723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e11bede4-7121-486e-9f38-d8c53cc76b4a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_90f5f2e7-f7cc-4237-a735-729c6aadf723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_018bd2fe-b17a-474b-8aec-53e647c4a585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e11bede4-7121-486e-9f38-d8c53cc76b4a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_018bd2fe-b17a-474b-8aec-53e647c4a585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d7a41641-8e9f-4b75-b308-02348d7aa32b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e11bede4-7121-486e-9f38-d8c53cc76b4a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d7a41641-8e9f-4b75-b308-02348d7aa32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_09d48b3c-2fc7-435d-a971-ed25de497127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e11bede4-7121-486e-9f38-d8c53cc76b4a" xlink:to="loc_us-gaap_RestructuringCharges_09d48b3c-2fc7-435d-a971-ed25de497127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_172d84af-bd43-423b-8184-82a42d30d8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e11bede4-7121-486e-9f38-d8c53cc76b4a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_172d84af-bd43-423b-8184-82a42d30d8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_f871dff5-6437-4b46-a4a8-2cc804c13d87" xlink:href="mrk-20211231.xsd#mrk_CostsExpensesAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e11bede4-7121-486e-9f38-d8c53cc76b4a" xlink:to="loc_mrk_CostsExpensesAndOther_f871dff5-6437-4b46-a4a8-2cc804c13d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b32e0858-4bf4-4f0c-87c2-b4e2801d0e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b32e0858-4bf4-4f0c-87c2-b4e2801d0e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_96621ea8-2a4a-4062-8556-7249eb6feb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_96621ea8-2a4a-4062-8556-7249eb6feb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6528e213-0eb5-4819-9bc2-040e079b38d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6528e213-0eb5-4819-9bc2-040e079b38d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_e0813ce9-396a-42c8-84af-2c1d9ecea6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_e0813ce9-396a-42c8-84af-2c1d9ecea6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_08a5dd3f-0bd9-40a2-829f-aa049c296779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_08a5dd3f-0bd9-40a2-829f-aa049c296779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2fb447c1-2b6c-4ca4-a59b-772db896c5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2fb447c1-2b6c-4ca4-a59b-772db896c5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f151cf85-6007-45ef-80c4-43312dd1287e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_NetIncomeLoss_f151cf85-6007-45ef-80c4-43312dd1287e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_38dd93c3-a4d6-4b56-88db-630d8fc033d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_38dd93c3-a4d6-4b56-88db-630d8fc033d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_10637c0f-403f-4a5b-8faa-3b8b03419138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_38dd93c3-a4d6-4b56-88db-630d8fc033d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_10637c0f-403f-4a5b-8faa-3b8b03419138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_5b388e63-55b8-4fb4-ad64-fb74208140e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_38dd93c3-a4d6-4b56-88db-630d8fc033d1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_5b388e63-55b8-4fb4-ad64-fb74208140e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0e4438a2-df71-4ad3-b0f4-b3177c8f8b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_38dd93c3-a4d6-4b56-88db-630d8fc033d1" xlink:to="loc_us-gaap_EarningsPerShareBasic_0e4438a2-df71-4ad3-b0f4-b3177c8f8b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_6b085017-459b-4a2f-b703-3d6a569ab0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a149dcf9-af85-452b-94a9-6d4c809c6bd2" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_6b085017-459b-4a2f-b703-3d6a569ab0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_885921bf-19dd-45f9-8c66-7e2aa6470ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_6b085017-459b-4a2f-b703-3d6a569ab0a6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_885921bf-19dd-45f9-8c66-7e2aa6470ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d7b68af3-f045-4ae5-9f06-1ad4a01ef9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_6b085017-459b-4a2f-b703-3d6a569ab0a6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d7b68af3-f045-4ae5-9f06-1ad4a01ef9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8fb88872-0ecb-46e8-a0f1-08c900b2c2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_6b085017-459b-4a2f-b703-3d6a569ab0a6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8fb88872-0ecb-46e8-a0f1-08c900b2c2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_682b3342-863e-4e9c-9f6e-b34a0bef879e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d3ec7513-98d3-4b3d-b0e0-0c2c6d4c3979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_682b3342-863e-4e9c-9f6e-b34a0bef879e" xlink:to="loc_us-gaap_NetIncomeLoss_d3ec7513-98d3-4b3d-b0e0-0c2c6d4c3979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_66e7d35f-52d7-4a19-ac9e-220e54454521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_682b3342-863e-4e9c-9f6e-b34a0bef879e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_66e7d35f-52d7-4a19-ac9e-220e54454521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f925fcfd-9fec-4a62-a739-1a0d3514aefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_66e7d35f-52d7-4a19-ac9e-220e54454521" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f925fcfd-9fec-4a62-a739-1a0d3514aefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a1465abc-cb5d-4cb9-828f-ef611c15d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_66e7d35f-52d7-4a19-ac9e-220e54454521" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a1465abc-cb5d-4cb9-828f-ef611c15d4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5910df9d-398b-4b07-9a54-4e3c8b2e8eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_66e7d35f-52d7-4a19-ac9e-220e54454521" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5910df9d-398b-4b07-9a54-4e3c8b2e8eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cc0416a7-e363-49af-b52a-c395c753abfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_66e7d35f-52d7-4a19-ac9e-220e54454521" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cc0416a7-e363-49af-b52a-c395c753abfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c0477517-d6ab-4ffd-abc3-ebcbc9576874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_66e7d35f-52d7-4a19-ac9e-220e54454521" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c0477517-d6ab-4ffd-abc3-ebcbc9576874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2f0e38a1-2460-4967-b4b0-fbc57b4fe07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_682b3342-863e-4e9c-9f6e-b34a0bef879e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2f0e38a1-2460-4967-b4b0-fbc57b4fe07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedBalanceSheet"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c47fcd72-1d59-44ee-a275-57adf7bcdacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c47fcd72-1d59-44ee-a275-57adf7bcdacb" xlink:to="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e50354e7-7fe4-4ea8-aacd-33ee33747bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e50354e7-7fe4-4ea8-aacd-33ee33747bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8caed9f3-4512-47d2-a970-c57fb59de0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e50354e7-7fe4-4ea8-aacd-33ee33747bf7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8caed9f3-4512-47d2-a970-c57fb59de0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_28f3525a-66df-4c01-a3c4-5fcaa3895b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e50354e7-7fe4-4ea8-aacd-33ee33747bf7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_28f3525a-66df-4c01-a3c4-5fcaa3895b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e94c543a-0427-4d29-80ab-f30c3e30f4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e50354e7-7fe4-4ea8-aacd-33ee33747bf7" xlink:to="loc_us-gaap_InventoryNet_e94c543a-0427-4d29-80ab-f30c3e30f4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ec62b46a-4640-4027-809f-cd9bf01bef02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e50354e7-7fe4-4ea8-aacd-33ee33747bf7" xlink:to="loc_us-gaap_OtherAssetsCurrent_ec62b46a-4640-4027-809f-cd9bf01bef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_829d8724-31c4-415d-a9eb-7cfea8161baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e50354e7-7fe4-4ea8-aacd-33ee33747bf7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_829d8724-31c4-415d-a9eb-7cfea8161baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0531a086-5a71-44ec-9e05-63f70d9f52be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e50354e7-7fe4-4ea8-aacd-33ee33747bf7" xlink:to="loc_us-gaap_AssetsCurrent_0531a086-5a71-44ec-9e05-63f70d9f52be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_00fcd5bc-7895-4098-b3bd-5d6acc0f1a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_00fcd5bc-7895-4098-b3bd-5d6acc0f1a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_39fb1190-53c8-4e39-bfe4-2d737f62cd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_39fb1190-53c8-4e39-bfe4-2d737f62cd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_c72c72ee-7c1b-4b37-a10b-7817dc37e2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_39fb1190-53c8-4e39-bfe4-2d737f62cd8d" xlink:to="loc_us-gaap_Land_c72c72ee-7c1b-4b37-a10b-7817dc37e2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_49ce47d0-f643-44e7-bea7-8952c5b21722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_39fb1190-53c8-4e39-bfe4-2d737f62cd8d" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_49ce47d0-f643-44e7-bea7-8952c5b21722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_2ba54228-ae49-4dc4-ac56-8f429e09f029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_39fb1190-53c8-4e39-bfe4-2d737f62cd8d" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_2ba54228-ae49-4dc4-ac56-8f429e09f029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_c008c38c-05cd-478a-9225-6dc1c2a2628c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_39fb1190-53c8-4e39-bfe4-2d737f62cd8d" xlink:to="loc_us-gaap_ConstructionInProgressGross_c008c38c-05cd-478a-9225-6dc1c2a2628c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bc3fb0a1-1853-432d-93a9-d96680636c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_39fb1190-53c8-4e39-bfe4-2d737f62cd8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bc3fb0a1-1853-432d-93a9-d96680636c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8aedf425-6fe5-4534-9ea8-1f0dc9a6749c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8aedf425-6fe5-4534-9ea8-1f0dc9a6749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bb7771db-ef45-43ce-9d9d-f54a3a45f6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bb7771db-ef45-43ce-9d9d-f54a3a45f6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5c8db619-2ebb-4679-ba2c-4ea6aa14a9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_Goodwill_5c8db619-2ebb-4679-ba2c-4ea6aa14a9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7aaf685d-c70b-4c68-8610-992cb1a676ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7aaf685d-c70b-4c68-8610-992cb1a676ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_a92b2ba4-37ee-45bc-be14-3ddb9c591a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_a92b2ba4-37ee-45bc-be14-3ddb9c591a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_306fd04c-5038-4872-a49a-1fb9b4178a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_306fd04c-5038-4872-a49a-1fb9b4178a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8ffb39fc-eef3-43ff-bc9d-e91156e84de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ef5c814-5abd-4e7e-ad76-e32f11f0d8f1" xlink:to="loc_us-gaap_Assets_8ffb39fc-eef3-43ff-bc9d-e91156e84de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c47fcd72-1d59-44ee-a275-57adf7bcdacb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9e0dbdea-95dc-4697-958f-f16aed8feb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9e0dbdea-95dc-4697-958f-f16aed8feb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_051b3ca9-983d-4c6c-933c-e8f7a7b24821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9e0dbdea-95dc-4697-958f-f16aed8feb88" xlink:to="loc_us-gaap_DebtCurrent_051b3ca9-983d-4c6c-933c-e8f7a7b24821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_29ff2ceb-8ab9-4627-bc2b-419a0a218a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9e0dbdea-95dc-4697-958f-f16aed8feb88" xlink:to="loc_us-gaap_AccountsPayableCurrent_29ff2ceb-8ab9-4627-bc2b-419a0a218a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0d83b475-ea2f-4a3e-b3cc-5bd59dc60a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9e0dbdea-95dc-4697-958f-f16aed8feb88" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0d83b475-ea2f-4a3e-b3cc-5bd59dc60a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_734394fd-13c2-42ba-b62e-6fef14e54907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9e0dbdea-95dc-4697-958f-f16aed8feb88" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_734394fd-13c2-42ba-b62e-6fef14e54907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_7c5a7e9a-1bec-4885-8dda-dae1ff1b7798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9e0dbdea-95dc-4697-958f-f16aed8feb88" xlink:to="loc_us-gaap_DividendsPayableCurrent_7c5a7e9a-1bec-4885-8dda-dae1ff1b7798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_d2e57cf6-d493-48fa-89ba-09a216500661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9e0dbdea-95dc-4697-958f-f16aed8feb88" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_d2e57cf6-d493-48fa-89ba-09a216500661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_55f3eafd-ef1e-4066-8d90-659e03dd0c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9e0dbdea-95dc-4697-958f-f16aed8feb88" xlink:to="loc_us-gaap_LiabilitiesCurrent_55f3eafd-ef1e-4066-8d90-659e03dd0c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fddc210d-72a0-47e4-b280-87c5e786cd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fddc210d-72a0-47e4-b280-87c5e786cd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_156f8954-fc1a-4ea6-829c-4314174a90c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_156f8954-fc1a-4ea6-829c-4314174a90c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8f630101-ad15-4813-b71f-a8ccd19bda1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8f630101-ad15-4813-b71f-a8ccd19bda1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_de6606a0-3d75-430e-ae6f-56936a7d78ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_de6606a0-3d75-430e-ae6f-56936a7d78ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_70677a1f-26b1-4f26-b84f-0c7e4638a24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:to="loc_us-gaap_StockholdersEquityAbstract_70677a1f-26b1-4f26-b84f-0c7e4638a24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_004c25e8-0453-45eb-9616-22803ca2ba96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_70677a1f-26b1-4f26-b84f-0c7e4638a24f" xlink:to="loc_us-gaap_CommonStockValue_004c25e8-0453-45eb-9616-22803ca2ba96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9d0d4876-54f5-469e-afdf-b7cc534ceb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_70677a1f-26b1-4f26-b84f-0c7e4638a24f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9d0d4876-54f5-469e-afdf-b7cc534ceb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8a990700-f983-404b-9829-4e9ec0919388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_70677a1f-26b1-4f26-b84f-0c7e4638a24f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8a990700-f983-404b-9829-4e9ec0919388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b804d024-7878-4349-9dec-7c738587acaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_70677a1f-26b1-4f26-b84f-0c7e4638a24f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b804d024-7878-4349-9dec-7c738587acaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_e5158f3e-245c-4e32-af93-d3ea69e1f971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_70677a1f-26b1-4f26-b84f-0c7e4638a24f" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_e5158f3e-245c-4e32-af93-d3ea69e1f971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_633901be-3b23-4188-b6ff-ff7a98198965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_70677a1f-26b1-4f26-b84f-0c7e4638a24f" xlink:to="loc_us-gaap_TreasuryStockValue_633901be-3b23-4188-b6ff-ff7a98198965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7fd90790-8b62-4eb6-9acb-00328ae5e063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_70677a1f-26b1-4f26-b84f-0c7e4638a24f" xlink:to="loc_us-gaap_StockholdersEquity_7fd90790-8b62-4eb6-9acb-00328ae5e063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1db8fa5e-f934-4427-a65c-265aa2997a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:to="loc_us-gaap_MinorityInterest_1db8fa5e-f934-4427-a65c-265aa2997a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e76fcc9-ec60-49b4-bb0d-5df3660b6666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e76fcc9-ec60-49b4-bb0d-5df3660b6666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3ca1ba2-9c6f-4730-b2d5-8ea58d179fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_151b21f1-26c2-4930-bc95-775d7a6af735" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b3ca1ba2-9c6f-4730-b2d5-8ea58d179fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedBalanceSheetParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f23c7b15-580c-4f8d-86ca-79cfb1519851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ae678a4c-79d1-4c0a-a54a-8f6a02fe1d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f23c7b15-580c-4f8d-86ca-79cfb1519851" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ae678a4c-79d1-4c0a-a54a-8f6a02fe1d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_76474feb-103b-4504-a070-330ebd3f62b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f23c7b15-580c-4f8d-86ca-79cfb1519851" xlink:to="loc_us-gaap_InventoryNoncurrent_76474feb-103b-4504-a070-330ebd3f62b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8835a616-8c7e-431a-852b-f08c6f880a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f23c7b15-580c-4f8d-86ca-79cfb1519851" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8835a616-8c7e-431a-852b-f08c6f880a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_540c97dd-ace7-4abf-8863-071ee7175bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f23c7b15-580c-4f8d-86ca-79cfb1519851" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_540c97dd-ace7-4abf-8863-071ee7175bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ea5c457d-188f-4ab5-a8d1-5b643a6278c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f23c7b15-580c-4f8d-86ca-79cfb1519851" xlink:to="loc_us-gaap_CommonStockSharesIssued_ea5c457d-188f-4ab5-a8d1-5b643a6278c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_ed90c861-9363-41b0-81d9-834a4219b9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f23c7b15-580c-4f8d-86ca-79cfb1519851" xlink:to="loc_us-gaap_TreasuryStockShares_ed90c861-9363-41b0-81d9-834a4219b9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_02952b70-8a4a-4004-b4c9-c659344cb211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9b43eb1b-839c-42b9-ba67-7d9e1421b7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_02952b70-8a4a-4004-b4c9-c659344cb211" xlink:to="loc_us-gaap_StatementTable_9b43eb1b-839c-42b9-ba67-7d9e1421b7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_76211e0a-0c33-4537-889d-cfa82995d0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9b43eb1b-839c-42b9-ba67-7d9e1421b7f6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_76211e0a-0c33-4537-889d-cfa82995d0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_76211e0a-0c33-4537-889d-cfa82995d0d8" xlink:to="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_37e6abc5-849f-4817-8207-cf45c39242e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_CommonStockMember_37e6abc5-849f-4817-8207-cf45c39242e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0a153e10-e878-4d43-b68b-ce1a39c7f16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0a153e10-e878-4d43-b68b-ce1a39c7f16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_51642a80-d5f0-4a77-8c02-2313a555d9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_RetainedEarningsMember_51642a80-d5f0-4a77-8c02-2313a555d9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019a1056-ee18-42b5-b409-89233125b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019a1056-ee18-42b5-b409-89233125b30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_aac9e558-bb54-4b99-9f7a-e06581367472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_TreasuryStockMember_aac9e558-bb54-4b99-9f7a-e06581367472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_934aec13-7288-437f-836e-f9173c0211f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33420efd-c8d0-49cd-a069-881a8406e566" xlink:to="loc_us-gaap_NoncontrollingInterestMember_934aec13-7288-437f-836e-f9173c0211f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_983dd1b6-9772-48c5-8a50-e1968eb174ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9b43eb1b-839c-42b9-ba67-7d9e1421b7f6" xlink:to="loc_us-gaap_StatementLineItems_983dd1b6-9772-48c5-8a50-e1968eb174ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_983dd1b6-9772-48c5-8a50-e1968eb174ec" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1b6f35c2-a843-4f3d-9222-328f70a9e68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1b6f35c2-a843-4f3d-9222-328f70a9e68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3535d183-626e-4eaf-94fa-f4dafe5d318f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_NetIncomeLoss_3535d183-626e-4eaf-94fa-f4dafe5d318f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_686b547e-9b04-4f93-b14d-c08e3992ac35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_686b547e-9b04-4f93-b14d-c08e3992ac35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_53d90af8-f11f-4ce4-ae6b-2003b5197295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_DividendsCommonStockCash_53d90af8-f11f-4ce4-ae6b-2003b5197295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_efd899dc-b7a6-4923-9410-5bd9f285cd51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_efd899dc-b7a6-4923-9410-5bd9f285cd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_35339dd6-f68a-4345-a7df-449ccba3a2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_35339dd6-f68a-4345-a7df-449ccba3a2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7db0beba-9bf9-4231-bf7d-1d8bccab0487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7db0beba-9bf9-4231-bf7d-1d8bccab0487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_44f10182-e162-44f5-8538-788521951d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_44f10182-e162-44f5-8538-788521951d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_ba8cb40c-09a7-4e09-afd9-ef8fa0fe1ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_StockholdersEquityOther_ba8cb40c-09a7-4e09-afd9-ef8fa0fe1ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5397ed18-a87e-412b-a4e1-4d4a53c13081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1e63927-604f-47c6-8a04-2442dff38367" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5397ed18-a87e-412b-a4e1-4d4a53c13081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_88b2ca1f-2274-4203-857d-f4bc9be8f85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_e599f7f4-baac-423f-b087-a2aca7eb5d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_88b2ca1f-2274-4203-857d-f4bc9be8f85a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_e599f7f4-baac-423f-b087-a2aca7eb5d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7cad5d1e-b587-410d-bb12-99266bdfdd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7cad5d1e-b587-410d-bb12-99266bdfdd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ace803b9-c7ba-4c20-b1f6-41becab9f958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7cad5d1e-b587-410d-bb12-99266bdfdd7c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ace803b9-c7ba-4c20-b1f6-41becab9f958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7cad5d1e-b587-410d-bb12-99266bdfdd7c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_e8093df2-3d4e-49b4-b56a-bf8ca2f14957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_us-gaap_AdjustmentForAmortization_e8093df2-3d4e-49b4-b56a-bf8ca2f14957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bc85fec1-1d6d-4cb9-ab2b-e7600ff21da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_us-gaap_Depreciation_bc85fec1-1d6d-4cb9-ab2b-e7600ff21da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_7b520f28-90c2-4683-a37c-4ba1c40a8961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_7b520f28-90c2-4683-a37c-4ba1c40a8961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_60e07080-d6f9-4a7c-a604-dee54688ad6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_60e07080-d6f9-4a7c-a604-dee54688ad6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_3c37fbf2-7b7f-4c58-8c5e-2ec78f72f232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_3c37fbf2-7b7f-4c58-8c5e-2ec78f72f232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_d95d69c9-ef7e-4f97-89d5-f53239d41249" xlink:href="mrk-20211231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_d95d69c9-ef7e-4f97-89d5-f53239d41249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree_a219205a-ea1b-4688-927b-3080c9f56b74" xlink:href="mrk-20211231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree_a219205a-ea1b-4688-927b-3080c9f56b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91ad57be-bbf0-46f2-888b-828e90de38c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91ad57be-bbf0-46f2-888b-828e90de38c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d0c29e9b-de58-4cac-bf03-36a64f0d43ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_us-gaap_ShareBasedCompensation_d0c29e9b-de58-4cac-bf03-36a64f0d43ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_620fe36b-c5b7-4d49-b2bb-fb4477314852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_620fe36b-c5b7-4d49-b2bb-fb4477314852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1479098c-62c5-4ebe-bd20-0aa8b448b710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9566af4d-02b2-4755-b7de-7795a8cf7e3c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1479098c-62c5-4ebe-bd20-0aa8b448b710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_baf301e6-68af-40b1-b0f9-380479af9187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1479098c-62c5-4ebe-bd20-0aa8b448b710" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_baf301e6-68af-40b1-b0f9-380479af9187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c7e92ed8-5403-4fcf-baa6-ca2d7b4357a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1479098c-62c5-4ebe-bd20-0aa8b448b710" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c7e92ed8-5403-4fcf-baa6-ca2d7b4357a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ec965fb3-2bb7-4280-acf8-608bc05c3736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1479098c-62c5-4ebe-bd20-0aa8b448b710" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ec965fb3-2bb7-4280-acf8-608bc05c3736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7df3cf8b-350b-468a-ab1d-59ae4fc9afd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1479098c-62c5-4ebe-bd20-0aa8b448b710" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7df3cf8b-350b-468a-ab1d-59ae4fc9afd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_98809b2a-da3e-47a0-86d5-46660f64974f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1479098c-62c5-4ebe-bd20-0aa8b448b710" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_98809b2a-da3e-47a0-86d5-46660f64974f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8df1933a-570f-427a-a444-41364df5759a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1479098c-62c5-4ebe-bd20-0aa8b448b710" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8df1933a-570f-427a-a444-41364df5759a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5c2efc3d-db88-4a4a-9302-656566f9be2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1479098c-62c5-4ebe-bd20-0aa8b448b710" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5c2efc3d-db88-4a4a-9302-656566f9be2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5603f0f6-2e1c-4067-b50e-803234cf5442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7cad5d1e-b587-410d-bb12-99266bdfdd7c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5603f0f6-2e1c-4067-b50e-803234cf5442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_83c3d973-9675-4971-b4d5-11861ca8d8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_83c3d973-9675-4971-b4d5-11861ca8d8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_9215563f-d6e4-4a30-94dd-960c17ddd2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_9215563f-d6e4-4a30-94dd-960c17ddd2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dc51ddce-fb22-4bd3-8bb8-9de5f61d2913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dc51ddce-fb22-4bd3-8bb8-9de5f61d2913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0012e903-3d62-4db3-a39d-939ae6717ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0012e903-3d62-4db3-a39d-939ae6717ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_32c56500-5162-4bcc-81dc-93d8258ab1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_32c56500-5162-4bcc-81dc-93d8258ab1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_e04cc33e-7824-486b-abef-b1bc9f9ceb04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_e04cc33e-7824-486b-abef-b1bc9f9ceb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_15141a19-7451-4320-89a5-382388e903f7" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_15141a19-7451-4320-89a5-382388e903f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_0b1c77cf-eb10-400a-8b0b-776496569fb7" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_0b1c77cf-eb10-400a-8b0b-776496569fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired_7e3d2250-3490-4375-b8b5-7abffb3c8bf4" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired_7e3d2250-3490-4375-b8b5-7abffb3c8bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired_d9ac9461-99d1-4abd-a715-db0ac49ab8b4" xlink:href="mrk-20211231.xsd#mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired_d9ac9461-99d1-4abd-a715-db0ac49ab8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_03912a7c-4a87-4430-947d-c1be114f6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_03912a7c-4a87-4430-947d-c1be114f6f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3d0845ba-a28c-436d-a88e-4cafc18d3c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3d0845ba-a28c-436d-a88e-4cafc18d3c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_a57f679e-e0dd-4382-a891-96d032e1c699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_124caef9-85a5-4106-84ad-e29cee528e1c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_a57f679e-e0dd-4382-a891-96d032e1c699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_7e90578c-681e-46d2-9419-12d8d8db4632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_7e90578c-681e-46d2-9419-12d8d8db4632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_977137fc-e983-4e93-b171-e1c00c6ff9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_977137fc-e983-4e93-b171-e1c00c6ff9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f055d172-9109-4cc5-83a0-c365231689c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f055d172-9109-4cc5-83a0-c365231689c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_94a5b69c-3213-4ee8-9984-bff34e9ccec4" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_94a5b69c-3213-4ee8-9984-bff34e9ccec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5b200173-4a3b-4d1b-8d6e-263831b042bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5b200173-4a3b-4d1b-8d6e-263831b042bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_cca25ff2-1450-4159-b86e-15ab3ae40a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_cca25ff2-1450-4159-b86e-15ab3ae40a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_40f758ac-2533-4a97-a21b-bd9f09a2296c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_40f758ac-2533-4a97-a21b-bd9f09a2296c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3cfa1b2d-0720-47f1-bfc9-c02b391e5e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3cfa1b2d-0720-47f1-bfc9-c02b391e5e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0be4cd1f-9463-4951-8c78-02dcdff7c07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af1d99c9-d2bd-4003-ad72-4cb31e93dbfb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0be4cd1f-9463-4951-8c78-02dcdff7c07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0f96c6d4-d622-4530-8b7f-8bf3def2bd31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0f96c6d4-d622-4530-8b7f-8bf3def2bd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_7f805183-132c-4c3f-9f12-55d6c9ba9eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0f96c6d4-d622-4530-8b7f-8bf3def2bd31" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_7f805183-132c-4c3f-9f12-55d6c9ba9eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_236b0262-e4eb-40f5-8b74-296541e34a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0f96c6d4-d622-4530-8b7f-8bf3def2bd31" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_236b0262-e4eb-40f5-8b74-296541e34a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_ac570de8-8ca2-48d9-886f-5af69aeb3fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0f96c6d4-d622-4530-8b7f-8bf3def2bd31" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_ac570de8-8ca2-48d9-886f-5af69aeb3fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_3786e054-f92e-4eb6-8ee0-2eeadb3fbe77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_0f96c6d4-d622-4530-8b7f-8bf3def2bd31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_3786e054-f92e-4eb6-8ee0-2eeadb3fbe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e845bd5-5065-475e-b326-253183c779b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e845bd5-5065-475e-b326-253183c779b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_97989a12-296d-4f9e-b51d-1344a78ad60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_97989a12-296d-4f9e-b51d-1344a78ad60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c7c434d-35cf-44bc-b6d4-3686e3766551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c7c434d-35cf-44bc-b6d4-3686e3766551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_4c9fa055-9a38-485f-bd0c-ff2e1789f8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_4c9fa055-9a38-485f-bd0c-ff2e1789f8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf78b736-694f-4c9f-8c26-3c9c238cc5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b141483e-7f67-49a5-872c-0c6f88e52a00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf78b736-694f-4c9f-8c26-3c9c238cc5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="simple" xlink:href="mrk-20211231.xsd#ConsolidatedStatementofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5effbc50-b625-4cd3-ad65-d2e86089a4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_fa175a11-2e33-458d-b5fa-422ab2d5f726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5effbc50-b625-4cd3-ad65-d2e86089a4f4" xlink:to="loc_us-gaap_RestrictedCash_fa175a11-2e33-458d-b5fa-422ab2d5f726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperations" xlink:type="simple" xlink:href="mrk-20211231.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47e9ff10-7e57-4ffd-bbac-75dffe62ecb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_6bdc447e-65db-43f6-a8a2-8bfdcfbf63e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47e9ff10-7e57-4ffd-bbac-75dffe62ecb6" xlink:to="loc_us-gaap_NatureOfOperations_6bdc447e-65db-43f6-a8a2-8bfdcfbf63e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#NatureofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a71a8abb-8ce5-4451-bd81-9b67f3bcc1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2a765342-33e0-4433-9b08-7e8cfbcb83d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a71a8abb-8ce5-4451-bd81-9b67f3bcc1b9" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2a765342-33e0-4433-9b08-7e8cfbcb83d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="simple" xlink:href="mrk-20211231.xsd#SummaryofAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1f9027d3-b700-41f5-90c8-c417f89e7c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_03fad583-1195-47e8-b8b4-478bb970009b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1f9027d3-b700-41f5-90c8-c417f89e7c00" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_03fad583-1195-47e8-b8b4-478bb970009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrk-20211231.xsd#SummaryofAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_da8f3cf8-dd88-494a-a298-152445ae5ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_da8f3cf8-dd88-494a-a298-152445ae5ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_6fac184e-b97e-4d27-9c2e-171da6611b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_6fac184e-b97e-4d27-9c2e-171da6611b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_db48d031-b645-4cbe-9914-cf8e0dbd61bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_db48d031-b645-4cbe-9914-cf8e0dbd61bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_39acd762-abd6-4cb1-8f38-9dd2821cce42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_39acd762-abd6-4cb1-8f38-9dd2821cce42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_28aef753-8ba0-400e-b0d2-59f605544261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_28aef753-8ba0-400e-b0d2-59f605544261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_930c9019-f31c-470e-91de-9ff1f1b0f64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_930c9019-f31c-470e-91de-9ff1f1b0f64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_119f7b58-b612-4b7b-a3eb-3795d0eb13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_119f7b58-b612-4b7b-a3eb-3795d0eb13d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_a49dd2da-fa57-4e0c-8c5d-8ae6e6694ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_a49dd2da-fa57-4e0c-8c5d-8ae6e6694ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_3919892a-0380-4080-af93-3bc9d67ea19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_3919892a-0380-4080-af93-3bc9d67ea19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_946cea2f-328a-406c-acb4-5229b06c58f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_946cea2f-328a-406c-acb4-5229b06c58f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_82272b2c-aa4a-4b8c-b0a5-58520e00a8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_82272b2c-aa4a-4b8c-b0a5-58520e00a8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_3ef6f402-5016-4c0a-9362-3e61eed691c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_3ef6f402-5016-4c0a-9362-3e61eed691c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_ee9abdae-801a-4824-bbf7-2aa2b0098048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_ee9abdae-801a-4824-bbf7-2aa2b0098048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentConsiderationPolicyTextBlock_7a69c5d0-c736-4790-a575-67b0a20116cc" xlink:href="mrk-20211231.xsd#mrk_ContingentConsiderationPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_mrk_ContingentConsiderationPolicyTextBlock_7a69c5d0-c736-4790-a575-67b0a20116cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9bdcc45c-260c-4ac3-af13-0c750347bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9bdcc45c-260c-4ac3-af13-0c750347bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_2f0b3890-20f5-4bbd-b3eb-e6c4ee80b33b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_2f0b3890-20f5-4bbd-b3eb-e6c4ee80b33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2b2d0381-793c-42f6-84d9-bdcc92c5134d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2b2d0381-793c-42f6-84d9-bdcc92c5134d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_051f953a-dca0-43fd-afcc-ea2c72fc8988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_051f953a-dca0-43fd-afcc-ea2c72fc8988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e7df5be1-92aa-4066-9bc2-6fb2d7a519d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e7df5be1-92aa-4066-9bc2-6fb2d7a519d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_769b2274-a48c-44f5-8bad-43bb4b66dd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_769b2274-a48c-44f5-8bad-43bb4b66dd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e0939625-3649-4002-8e64-95c9161b75a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_UseOfEstimates_e0939625-3649-4002-8e64-95c9161b75a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8bec7345-2155-4ba1-9132-1b374f2f4a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8bec7345-2155-4ba1-9132-1b374f2f4a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e5e5232-e6cf-42cc-8a96-ef489f416a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ab80c83-921d-43e5-a8f0-bf27de0870d4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e5e5232-e6cf-42cc-8a96-ef489f416a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SummaryofAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fb6d1d49-17e8-41ae-9335-eb6d5371ceff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fb6d1d49-17e8-41ae-9335-eb6d5371ceff" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aec79a93-c107-4739-9530-3c93bc449baf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_srt_RangeAxis_aec79a93-c107-4739-9530-3c93bc449baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de735e29-fc02-4272-bbf9-b2c60e1675a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aec79a93-c107-4739-9530-3c93bc449baf" xlink:to="loc_srt_RangeMember_de735e29-fc02-4272-bbf9-b2c60e1675a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_17ebd44b-bebc-4037-b01a-8ccce9b19e28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_de735e29-fc02-4272-bbf9-b2c60e1675a3" xlink:to="loc_srt_MinimumMember_17ebd44b-bebc-4037-b01a-8ccce9b19e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b255e8c2-cd42-4160-86b5-c77159b14518" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_de735e29-fc02-4272-bbf9-b2c60e1675a3" xlink:to="loc_srt_MaximumMember_b255e8c2-cd42-4160-86b5-c77159b14518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0399ef08-f116-403f-83f3-04f1b3589e6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_srt_StatementGeographicalAxis_0399ef08-f116-403f-83f3-04f1b3589e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_34649fa4-0c2b-40e3-bd51-59b999854a15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0399ef08-f116-403f-83f3-04f1b3589e6b" xlink:to="loc_srt_SegmentGeographicalDomain_34649fa4-0c2b-40e3-bd51-59b999854a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2e380baa-80a8-405f-973e-692095930dfd" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_34649fa4-0c2b-40e3-bd51-59b999854a15" xlink:to="loc_country_US_2e380baa-80a8-405f-973e-692095930dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ce5e7c94-f905-43c3-8001-76ec09a27a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_34649fa4-0c2b-40e3-bd51-59b999854a15" xlink:to="loc_us-gaap_NonUsMember_ce5e7c94-f905-43c3-8001-76ec09a27a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7c429d8c-2560-40a5-9485-18e2fce92950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7c429d8c-2560-40a5-9485-18e2fce92950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3354817a-829c-4201-a8ae-06250de3361b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7c429d8c-2560-40a5-9485-18e2fce92950" xlink:to="loc_us-gaap_SegmentDomain_3354817a-829c-4201-a8ae-06250de3361b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_80ece693-f2bc-4ee6-b852-1c71780b4156" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3354817a-829c-4201-a8ae-06250de3361b" xlink:to="loc_mrk_PharmaceuticalsegmentMember_80ece693-f2bc-4ee6-b852-1c71780b4156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_0dc5eb6d-2547-43e0-b81f-06b9fefe2618" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3354817a-829c-4201-a8ae-06250de3361b" xlink:to="loc_mrk_AnimalHealthsegmentMember_0dc5eb6d-2547-43e0-b81f-06b9fefe2618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5b037193-745d-4609-8c6e-165d15d3e15f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5b037193-745d-4609-8c6e-165d15d3e15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc7fcf4f-92f1-4e54-9ea5-284437b6af86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5b037193-745d-4609-8c6e-165d15d3e15f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc7fcf4f-92f1-4e54-9ea5-284437b6af86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_74b3b3d2-040d-4333-9f3f-664858ebf438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc7fcf4f-92f1-4e54-9ea5-284437b6af86" xlink:to="loc_us-gaap_BuildingMember_74b3b3d2-040d-4333-9f3f-664858ebf438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_29ef80bf-53d7-4096-8998-9b518a6fac06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc7fcf4f-92f1-4e54-9ea5-284437b6af86" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_29ef80bf-53d7-4096-8998-9b518a6fac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63ffd68d-4351-4d0a-875f-db213cf965de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63ffd68d-4351-4d0a-875f-db213cf965de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e27c37cb-c97a-44f2-be80-d01ac314aa00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63ffd68d-4351-4d0a-875f-db213cf965de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e27c37cb-c97a-44f2-be80-d01ac314aa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a2b1bf5b-c1a0-4c6f-b7d2-d2d12f2ad2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e27c37cb-c97a-44f2-be80-d01ac314aa00" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a2b1bf5b-c1a0-4c6f-b7d2-d2d12f2ad2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:href="mrk-20211231.xsd#mrk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2037b056-d54e-4ef5-9e27-20479043ea64" xlink:to="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts_8296fdd9-bf0f-4c76-98bb-d76c02e57477" xlink:href="mrk-20211231.xsd#mrk_SalesDiscounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_SalesDiscounts_8296fdd9-bf0f-4c76-98bb-d76c02e57477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForChargebacks_58ca9b47-0c17-4ff2-8af8-fa1a6627b67b" xlink:href="mrk-20211231.xsd#mrk_AccrualForChargebacks"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_AccrualForChargebacks_58ca9b47-0c17-4ff2-8af8-fa1a6627b67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForRebates_eb414982-b3b6-4f97-8009-9d28add09ba5" xlink:href="mrk-20211231.xsd#mrk_AccrualForRebates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_AccrualForRebates_eb414982-b3b6-4f97-8009-9d28add09ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_fd407a05-05bb-452e-b0aa-da7cd63b2d8a" xlink:href="mrk-20211231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_fd407a05-05bb-452e-b0aa-da7cd63b2d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_8e8fc792-c895-4eb1-a547-d7b7a184055d" xlink:href="mrk-20211231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_8e8fc792-c895-4eb1-a547-d7b7a184055d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenuePerformanceObligationPaymentTerms_3214bd2e-8155-43b8-a5fc-fb8ca8b9d5fe" xlink:href="mrk-20211231.xsd#mrk_RevenuePerformanceObligationPaymentTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_mrk_RevenuePerformanceObligationPaymentTerms_3214bd2e-8155-43b8-a5fc-fb8ca8b9d5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5fd0eb4-c99f-4ff5-8d4d-ba246e5739ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5fd0eb4-c99f-4ff5-8d4d-ba246e5739ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_147703ad-0d2f-475f-ae9d-19dcedf86bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_us-gaap_Depreciation_147703ad-0d2f-475f-ae9d-19dcedf86bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_26520310-29a1-46bc-b16b-b4d356bc213f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_us-gaap_AdvertisingExpense_26520310-29a1-46bc-b16b-b4d356bc213f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7682a17a-17d1-4212-ba56-db8b1880c1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_1c8b9c0c-00a4-4903-bd91-abb6c6ba2446" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7682a17a-17d1-4212-ba56-db8b1880c1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCo" xlink:type="simple" xlink:href="mrk-20211231.xsd#SpinOffofOrganonCo"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCo" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_855abe6f-9563-4d77-a061-eb5db2ea70d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_eb390412-6ead-4283-a78a-3622229f985a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_855abe6f-9563-4d77-a061-eb5db2ea70d8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_eb390412-6ead-4283-a78a-3622229f985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#SpinOffofOrganonCoTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4e6b7158-c315-4ad8-81f0-bab27e0c1f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_21a4789c-83d4-433d-8b3b-18fcc6161a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4e6b7158-c315-4ad8-81f0-bab27e0c1f27" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_21a4789c-83d4-433d-8b3b-18fcc6161a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SpinOffofOrganonCoNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cff924fb-de38-469b-b729-d9182408d288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cff924fb-de38-469b-b729-d9182408d288" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_412abed5-8514-4de5-b647-26a308a3bf2b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_dei_LegalEntityAxis_412abed5-8514-4de5-b647-26a308a3bf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bdf5a338-8cde-4161-9fdb-c4e69bb0ed40" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_412abed5-8514-4de5-b647-26a308a3bf2b" xlink:to="loc_dei_EntityDomain_bdf5a338-8cde-4161-9fdb-c4e69bb0ed40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_cf973d19-e3dc-4bab-a1d6-5de80707b2b2" xlink:href="mrk-20211231.xsd#mrk_OrganonCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bdf5a338-8cde-4161-9fdb-c4e69bb0ed40" xlink:to="loc_mrk_OrganonCoMember_cf973d19-e3dc-4bab-a1d6-5de80707b2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_43d3476a-d7cf-4b2c-a6d1-1578d1c0bbe1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_srt_RangeAxis_43d3476a-d7cf-4b2c-a6d1-1578d1c0bbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e709eda8-3106-4706-ada9-aa5040d99bde" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_43d3476a-d7cf-4b2c-a6d1-1578d1c0bbe1" xlink:to="loc_srt_RangeMember_e709eda8-3106-4706-ada9-aa5040d99bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12bed9e9-8b41-4978-a63f-e5f33efbefd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e709eda8-3106-4706-ada9-aa5040d99bde" xlink:to="loc_srt_MaximumMember_12bed9e9-8b41-4978-a63f-e5f33efbefd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4d0eb203-dd82-4c82-b3d3-25589d5dd957" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e709eda8-3106-4706-ada9-aa5040d99bde" xlink:to="loc_srt_MinimumMember_4d0eb203-dd82-4c82-b3d3-25589d5dd957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_05eeb5cf-8e1c-4fcf-a3be-d360c57c829d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_05eeb5cf-8e1c-4fcf-a3be-d360c57c829d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5ae3fa3f-c7ea-4b6e-a153-e897e372f5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_05eeb5cf-8e1c-4fcf-a3be-d360c57c829d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5ae3fa3f-c7ea-4b6e-a153-e897e372f5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember_8042a19c-d0d3-40b7-8d2c-c5f9bd0b3e9b" xlink:href="mrk-20211231.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ae3fa3f-c7ea-4b6e-a153-e897e372f5a2" xlink:to="loc_mrk_TransitionServicesAgreementMember_8042a19c-d0d3-40b7-8d2c-c5f9bd0b3e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember_96fe264e-2a84-4b9c-a21a-fa5745a0581e" xlink:href="mrk-20211231.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5ae3fa3f-c7ea-4b6e-a153-e897e372f5a2" xlink:to="loc_mrk_ManufacturingAndSupplyAgreementsMember_96fe264e-2a84-4b9c-a21a-fa5745a0581e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a77df7ad-5d4b-4aa9-af88-19b4b99c445c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_srt_CounterpartyNameAxis_a77df7ad-5d4b-4aa9-af88-19b4b99c445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffd7e285-5f58-4a12-b793-33d868d01f8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a77df7ad-5d4b-4aa9-af88-19b4b99c445c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffd7e285-5f58-4a12-b793-33d868d01f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_ffff7862-7e19-40fb-98d0-3b31d0e15dca" xlink:href="mrk-20211231.xsd#mrk_OrganonCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffd7e285-5f58-4a12-b793-33d868d01f8b" xlink:to="loc_mrk_OrganonCoMember_ffff7862-7e19-40fb-98d0-3b31d0e15dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_229e0fb2-2b18-4783-bb05-dacf49b7af6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_us-gaap_AwardTypeAxis_229e0fb2-2b18-4783-bb05-dacf49b7af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854a15b-1066-4c82-afef-31bada3c9674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_229e0fb2-2b18-4783-bb05-dacf49b7af6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854a15b-1066-4c82-afef-31bada3c9674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_50cadb5a-133d-48ae-bf90-8ac70b7cfd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854a15b-1066-4c82-afef-31bada3c9674" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_50cadb5a-133d-48ae-bf90-8ac70b7cfd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ea93648b-b737-451d-b785-9412f2f56388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b854a15b-1066-4c82-afef-31bada3c9674" xlink:to="loc_us-gaap_PerformanceSharesMember_ea93648b-b737-451d-b785-9412f2f56388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa83bc3f-57f6-49ae-9610-bbbfbbe4072c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa83bc3f-57f6-49ae-9610-bbbfbbe4072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa83bc3f-57f6-49ae-9610-bbbfbbe4072c" xlink:to="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d5ecea46-c3f0-4569-80b3-8b0cec9ad37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d5ecea46-c3f0-4569-80b3-8b0cec9ad37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_1e8fbfcb-7cbe-4177-80c1-31a0389eb93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_1e8fbfcb-7cbe-4177-80c1-31a0389eb93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8ac53b3f-472c-49c7-8e5e-f0da715d8c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8ac53b3f-472c-49c7-8e5e-f0da715d8c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6d14710a-7cf3-402a-a613-a50ff670b332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57a15837-b5b9-4fc8-8b96-bf4c7668b4fc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6d14710a-7cf3-402a-a613-a50ff670b332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9a45621b-980e-4ff4-9107-4e17a1e6de27" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_605e54bb-2c12-4ddf-a856-a9a31be56cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_605e54bb-2c12-4ddf-a856-a9a31be56cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bd27ad01-ff55-4d23-bde9-46be51c124f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bd27ad01-ff55-4d23-bde9-46be51c124f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2dc65ca9-f907-435e-8d20-ba5f7621784d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2dc65ca9-f907-435e-8d20-ba5f7621784d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_edd2b758-b083-4e9d-b4be-36431f7a9f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_edd2b758-b083-4e9d-b4be-36431f7a9f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_3a831b55-d475-4e46-bf97-e89a0e3adcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_RevenueFromRelatedParties_3a831b55-d475-4e46-bf97-e89a0e3adcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales_74e0a4c8-8b72-4b66-a0ba-cd03906258d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_RelatedPartiesAmountInCostOfSales_74e0a4c8-8b72-4b66-a0ba-cd03906258d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_8474ceae-6ab5-4fb3-a416-c70f2c35b565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_8474ceae-6ab5-4fb3-a416-c70f2c35b565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_d43aa42c-da48-496f-9234-279cd85a1fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_d43aa42c-da48-496f-9234-279cd85a1fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_b264f5fd-d98a-4590-ac64-89960b7c4adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_b264f5fd-d98a-4590-ac64-89960b7c4adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c8279a69-af24-4bfc-addc-2f6ee39a903b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c8279a69-af24-4bfc-addc-2f6ee39a903b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt_110fd182-a4ce-4665-8b50-981ffc219e8c" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt_110fd182-a4ce-4665-8b50-981ffc219e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_f6be046a-7539-46fc-96f9-433a32c9448f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_f6be046a-7539-46fc-96f9-433a32c9448f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6c1e8d73-eee5-4110-b24d-b62d59b28831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_6c1e8d73-eee5-4110-b24d-b62d59b28831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_f94c9003-b16e-40b8-864e-7f46f48a26a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_f94c9003-b16e-40b8-864e-7f46f48a26a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_8d23c62b-c311-4821-bf87-3ae174b293ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_8d23c62b-c311-4821-bf87-3ae174b293ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_ddd24f00-7c5a-445d-a10f-8fb5129d2a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_ddd24f00-7c5a-445d-a10f-8fb5129d2a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_70406594-3f6c-4e65-9ee3-ba042ef74b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_70406594-3f6c-4e65-9ee3-ba042ef74b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_061c2043-ac0f-40fb-a680-f4a8f11f3a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9d13a077-17cc-45fd-a301-f8345ca69d61" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_061c2043-ac0f-40fb-a680-f4a8f11f3a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c03f16f-fa76-4567-be02-1e5e0ac4d56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_c84659f8-7e30-424c-93b5-546c025faca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c03f16f-fa76-4567-be02-1e5e0ac4d56c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_c84659f8-7e30-424c-93b5-546c025faca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_40df9e07-6c7f-4724-adda-5f34b2166261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c03f16f-fa76-4567-be02-1e5e0ac4d56c" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_40df9e07-6c7f-4724-adda-5f34b2166261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_37b9f887-254b-4252-b4ba-f61da331fced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_40df9e07-6c7f-4724-adda-5f34b2166261" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_37b9f887-254b-4252-b4ba-f61da331fced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_7f5af3d3-8dce-49dc-bdc2-3d3594c66670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_40df9e07-6c7f-4724-adda-5f34b2166261" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_7f5af3d3-8dce-49dc-bdc2-3d3594c66670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_8d4ddc5e-d6dc-4006-a0c2-354cc9065138" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_40df9e07-6c7f-4724-adda-5f34b2166261" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_8d4ddc5e-d6dc-4006-a0c2-354cc9065138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_5a039857-1b05-47e6-a4c5-a0ffc61ba5fc" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_40df9e07-6c7f-4724-adda-5f34b2166261" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_5a039857-1b05-47e6-a4c5-a0ffc61ba5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_f661fa90-bf44-494a-b19b-6448d50ac832" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_40df9e07-6c7f-4724-adda-5f34b2166261" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_f661fa90-bf44-494a-b19b-6448d50ac832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_739069d4-7e77-48ec-a9f3-b39a357d851a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_40df9e07-6c7f-4724-adda-5f34b2166261" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_739069d4-7e77-48ec-a9f3-b39a357d851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_9bd665e6-aa9d-48d5-9ae2-9ec37464c1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c03f16f-fa76-4567-be02-1e5e0ac4d56c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_9bd665e6-aa9d-48d5-9ae2-9ec37464c1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_f763f848-c303-462d-ad8f-404863dbc14c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c03f16f-fa76-4567-be02-1e5e0ac4d56c" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_f763f848-c303-462d-ad8f-404863dbc14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1ef82811-a2f9-4651-9d9a-894cf8d75150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c03f16f-fa76-4567-be02-1e5e0ac4d56c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1ef82811-a2f9-4651-9d9a-894cf8d75150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_7c9ecde0-5c6e-4f81-bc18-7a3b5975779e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c03f16f-fa76-4567-be02-1e5e0ac4d56c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_7c9ecde0-5c6e-4f81-bc18-7a3b5975779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8da840a7-02c8-4794-93d5-11f9249dfa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4c03f16f-fa76-4567-be02-1e5e0ac4d56c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8da840a7-02c8-4794-93d5-11f9249dfa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_0282de33-c59a-4c51-bf1d-f7373b59a052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_0282de33-c59a-4c51-bf1d-f7373b59a052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0f27827b-ba51-475e-9f3e-e2bb47e49848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0f27827b-ba51-475e-9f3e-e2bb47e49848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_367308c5-e281-4b4d-8ff7-fe08c8b8556c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_367308c5-e281-4b4d-8ff7-fe08c8b8556c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_0db889c8-6e0e-48be-903d-1a743853fe22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_0db889c8-6e0e-48be-903d-1a743853fe22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8dce88b5-aa7a-40dd-9572-8ad06a0e0db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8dce88b5-aa7a-40dd-9572-8ad06a0e0db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_9db10048-ab6f-476d-81d6-3e148e5b7f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_9db10048-ab6f-476d-81d6-3e148e5b7f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_99ce45fb-946e-415e-881c-3d5a77928f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_99ce45fb-946e-415e-881c-3d5a77928f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_d8278a8e-cbcc-4531-9005-2c74a1fadc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_d8278a8e-cbcc-4531-9005-2c74a1fadc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_ea5c5569-edf8-45fa-8a2e-cc525f14eee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_ea5c5569-edf8-45fa-8a2e-cc525f14eee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_08d3da37-ddf2-4e10-971c-91b0f0b67d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_08d3da37-ddf2-4e10-971c-91b0f0b67d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_0ca6fc42-18d2-4523-a57a-ae1204e87eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_0ca6fc42-18d2-4523-a57a-ae1204e87eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c37cd334-56a3-4c35-9115-6664d3c56331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c37cd334-56a3-4c35-9115-6664d3c56331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent_a07572ba-95d0-4c47-959d-030e54c2672e" xlink:href="mrk-20211231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent_a07572ba-95d0-4c47-959d-030e54c2672e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_31a33285-6cff-4560-a395-8e7c8b8ec6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_31a33285-6cff-4560-a395-8e7c8b8ec6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_22075e9e-4d4d-4c12-90d6-d8e8c7442cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_22075e9e-4d4d-4c12-90d6-d8e8c7442cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_edb554fb-5cd6-4228-a8b9-003b103cbca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_edb554fb-5cd6-4228-a8b9-003b103cbca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_13853404-cd04-4074-83eb-4209238c69ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1aea6ae1-9675-4bcf-ae62-e0bbd517744c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_13853404-cd04-4074-83eb-4209238c69ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="simple" xlink:href="mrk-20211231.xsd#AcquisitionsResearchCollaborationsandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_75a9ddc7-847a-4b9e-8665-a35243f4565f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_0e2ac356-6952-4700-bda7-106beb4b9cca" xlink:href="mrk-20211231.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_75a9ddc7-847a-4b9e-8665-a35243f4565f" xlink:to="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_0e2ac356-6952-4700-bda7-106beb4b9cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8d37fb85-8bc7-4989-92f7-9727ac272a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4e337fbe-75f1-4aae-a5d3-5440f3600733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8d37fb85-8bc7-4989-92f7-9727ac272a74" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4e337fbe-75f1-4aae-a5d3-5440f3600733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_32da22b4-4ec2-40c1-aa89-d2ef853de1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_32da22b4-4ec2-40c1-aa89-d2ef853de1c3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_82a0409b-e7ac-4216-ae09-ab68ca2048b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_82a0409b-e7ac-4216-ae09-ab68ca2048b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_82a0409b-e7ac-4216-ae09-ab68ca2048b0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_4ff87e87-204c-4755-90a1-4d26504987b9" xlink:href="mrk-20211231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:to="loc_mrk_DevelopmentMilestonesMember_4ff87e87-204c-4755-90a1-4d26504987b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_b2f629a1-6f06-4911-88e0-3ae1fb2262e9" xlink:href="mrk-20211231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:to="loc_mrk_RegulatoryMilestonesMember_b2f629a1-6f06-4911-88e0-3ae1fb2262e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialmilestoneMember_368b0d70-dd22-4d27-84b5-d1b0cfd30ffe" xlink:href="mrk-20211231.xsd#mrk_CommercialmilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:to="loc_mrk_CommercialmilestoneMember_368b0d70-dd22-4d27-84b5-d1b0cfd30ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_3c509387-90de-450f-adb4-b3551fcfe67e" xlink:href="mrk-20211231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9830ecda-31cf-46a2-8476-ed02be0d5a76" xlink:to="loc_mrk_SalesBasedMilestonesMember_3c509387-90de-450f-adb4-b3551fcfe67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_597aa4a9-d3f7-42e6-8d7b-c1634ce90adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_597aa4a9-d3f7-42e6-8d7b-c1634ce90adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_597aa4a9-d3f7-42e6-8d7b-c1634ce90adb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember_12399465-8510-496b-b313-fa1481743271" xlink:href="mrk-20211231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_AcceleronPharmaIncMember_12399465-8510-496b-b313-fa1481743271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember_25a20e21-e69e-4232-ba0f-84714462af65" xlink:href="mrk-20211231.xsd#mrk_PandionTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_PandionTherapeuticsMember_25a20e21-e69e-4232-ba0f-84714462af65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_75473bd4-ce12-427c-824a-eef7445e0099" xlink:href="mrk-20211231.xsd#mrk_OncoImmuneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_OncoImmuneMember_75473bd4-ce12-427c-824a-eef7445e0099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_7f4a2b70-9a5a-46e8-9e92-7a7e760c648e" xlink:href="mrk-20211231.xsd#mrk_VelosBioMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_VelosBioMember_7f4a2b70-9a5a-46e8-9e92-7a7e760c648e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_b7563b21-df8d-4dd5-a9ef-1cef6bed877e" xlink:href="mrk-20211231.xsd#mrk_DunboyneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_DunboyneMember_b7563b21-df8d-4dd5-a9ef-1cef6bed877e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember_f4830138-94cb-4c8f-8478-4337619e5b69" xlink:href="mrk-20211231.xsd#mrk_ThemisMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_ThemisMember_f4830138-94cb-4c8f-8478-4337619e5b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_46b4340f-0a02-46b1-81f6-2b0d5706a912" xlink:href="mrk-20211231.xsd#mrk_ArQuleMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_ArQuleMember_46b4340f-0a02-46b1-81f6-2b0d5706a912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember_6aa665a5-a062-4d6d-9571-0ca99fffcdc8" xlink:href="mrk-20211231.xsd#mrk_PelotonMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_PelotonMember_6aa665a5-a062-4d6d-9571-0ca99fffcdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_f1d93c70-59c4-477c-b8a9-2358b4998617" xlink:href="mrk-20211231.xsd#mrk_AntelliqMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_AntelliqMember_f1d93c70-59c4-477c-b8a9-2358b4998617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImmuneDesignMember_38310fc1-913a-4ddb-ae64-302df4555ad9" xlink:href="mrk-20211231.xsd#mrk_ImmuneDesignMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5fd842b-e4a4-4287-a5f4-2ad6db674a7e" xlink:to="loc_mrk_ImmuneDesignMember_38310fc1-913a-4ddb-ae64-302df4555ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_76f2b89c-437d-445d-aa9b-467d7d8de32a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_srt_CounterpartyNameAxis_76f2b89c-437d-445d-aa9b-467d7d8de32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_76f2b89c-437d-445d-aa9b-467d7d8de32a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GileadSciencesMember_0cfcc160-4e60-4b24-b2b8-07ae1d40c180" xlink:href="mrk-20211231.xsd#mrk_GileadSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_GileadSciencesMember_0cfcc160-4e60-4b24-b2b8-07ae1d40c180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember_bfec6764-0208-4626-a96a-b29bc1c5a108" xlink:href="mrk-20211231.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_ArtivaBiotherapeuticsIncMember_bfec6764-0208-4626-a96a-b29bc1c5a108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember_19b44671-3a8f-4e53-91e6-b6f6e4bc2a44" xlink:href="mrk-20211231.xsd#mrk_SeagenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_SeagenMember_19b44671-3a8f-4e53-91e6-b6f6e4bc2a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_0210b224-cb23-4472-ac8c-0ad5c6350b0b" xlink:href="mrk-20211231.xsd#mrk_SentinelMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_SentinelMember_0210b224-cb23-4472-ac8c-0ad5c6350b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember_016c812d-be4e-4228-9de2-4aed043a6bfc" xlink:href="mrk-20211231.xsd#mrk_IAVIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_IAVIMember_016c812d-be4e-4228-9de2-4aed043a6bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_5eb5495e-e547-4478-8683-3e5be15dd4cc" xlink:href="mrk-20211231.xsd#mrk_BristolMyersSquibbMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ac29bb-d340-4cb5-9db5-ca9ff39e3f96" xlink:to="loc_mrk_BristolMyersSquibbMember_5eb5495e-e547-4478-8683-3e5be15dd4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a5f7e823-116b-4fc1-83b0-3b4c098e83e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_srt_ProductOrServiceAxis_a5f7e823-116b-4fc1-83b0-3b4c098e83e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a5f7e823-116b-4fc1-83b0-3b4c098e83e3" xlink:to="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralAndInjectableFormulationsMember_a455d8d3-20eb-4825-b4df-1ea79916409c" xlink:href="mrk-20211231.xsd#mrk_OralAndInjectableFormulationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_OralAndInjectableFormulationsMember_a455d8d3-20eb-4825-b4df-1ea79916409c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralFormulationMember_cb874eed-f86a-44c9-ac27-13c140d2ad24" xlink:href="mrk-20211231.xsd#mrk_OralFormulationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_OralFormulationMember_cb874eed-f86a-44c9-ac27-13c140d2ad24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InjectableFormulationMember_aa646155-7969-42c7-bc3d-df4b50dd6ed3" xlink:href="mrk-20211231.xsd#mrk_InjectableFormulationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_InjectableFormulationMember_aa646155-7969-42c7-bc3d-df4b50dd6ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember_68acff93-a16c-43e1-a826-9ed7d7697e3a" xlink:href="mrk-20211231.xsd#mrk_TukysaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_TukysaMember_68acff93-a16c-43e1-a826-9ed7d7697e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_0c384b19-5468-4825-b208-2ba3baf07339" xlink:href="mrk-20211231.xsd#mrk_SentinelMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_SentinelMember_0c384b19-5468-4825-b208-2ba3baf07339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_d62637b6-0f05-4938-9374-127ba3d63645" xlink:href="mrk-20211231.xsd#mrk_COVID19Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_COVID19Member_d62637b6-0f05-4938-9374-127ba3d63645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember_31e9d1e1-3d20-4cd7-b383-598d602de55b" xlink:href="mrk-20211231.xsd#mrk_NemtabrutinibMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_486ff5d1-345e-4243-a687-0e6a2b9992a2" xlink:to="loc_mrk_NemtabrutinibMember_31e9d1e1-3d20-4cd7-b383-598d602de55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0c0aba98-ad66-418a-a48d-55427e31f794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0c0aba98-ad66-418a-a48d-55427e31f794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f557e37f-35a1-4160-8996-6ff84eab3cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0c0aba98-ad66-418a-a48d-55427e31f794" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f557e37f-35a1-4160-8996-6ff84eab3cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7baa1309-a7f4-4970-8b49-83a968bddddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f557e37f-35a1-4160-8996-6ff84eab3cf6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7baa1309-a7f4-4970-8b49-83a968bddddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae6714d7-ee2f-4366-a218-ed573e575d72" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_srt_RangeAxis_ae6714d7-ee2f-4366-a218-ed573e575d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5636c264-635f-48ce-9d24-5bc92637dcdd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ae6714d7-ee2f-4366-a218-ed573e575d72" xlink:to="loc_srt_RangeMember_5636c264-635f-48ce-9d24-5bc92637dcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46db4c6e-bb4c-4340-a22a-6014f81c2e3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5636c264-635f-48ce-9d24-5bc92637dcdd" xlink:to="loc_srt_MinimumMember_46db4c6e-bb4c-4340-a22a-6014f81c2e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b170150d-eb9a-4863-9214-bb77933dac09" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5636c264-635f-48ce-9d24-5bc92637dcdd" xlink:to="loc_srt_MaximumMember_b170150d-eb9a-4863-9214-bb77933dac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81d89938-3766-4302-87ba-cc2974fd5ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81d89938-3766-4302-87ba-cc2974fd5ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_310a28a7-f7ec-4133-bfd2-fae3e06de5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81d89938-3766-4302-87ba-cc2974fd5ffa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_310a28a7-f7ec-4133-bfd2-fae3e06de5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_c4e50385-5ade-43d5-9ef9-9e010d7f9aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_310a28a7-f7ec-4133-bfd2-fae3e06de5b1" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_c4e50385-5ade-43d5-9ef9-9e010d7f9aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_26708ae6-9ba9-4fab-b28d-95b57f46194c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_AssetAcquisitionAxis_26708ae6-9ba9-4fab-b28d-95b57f46194c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_26708ae6-9ba9-4fab-b28d-95b57f46194c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember_fd4b5e28-d6af-4686-8fa4-8fef62f94a2a" xlink:href="mrk-20211231.xsd#mrk_PandionTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_PandionTherapeuticsMember_fd4b5e28-d6af-4686-8fa4-8fef62f94a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_ab39515d-0109-47e0-abe5-637d0b37d4e1" xlink:href="mrk-20211231.xsd#mrk_OncoImmuneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_OncoImmuneMember_ab39515d-0109-47e0-abe5-637d0b37d4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_b0bb25e8-89b1-4828-81ad-84dc0b3fccc4" xlink:href="mrk-20211231.xsd#mrk_VelosBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_VelosBioMember_b0bb25e8-89b1-4828-81ad-84dc0b3fccc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_900bdfda-965c-4722-a975-eb11235426db" xlink:href="mrk-20211231.xsd#mrk_DunboyneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_DunboyneMember_900bdfda-965c-4722-a975-eb11235426db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember_720c4f19-cc13-42db-b3c0-656156f99b0f" xlink:href="mrk-20211231.xsd#mrk_PelotonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ddb59a48-2cc8-4e93-94be-1b701c08095b" xlink:to="loc_mrk_PelotonMember_720c4f19-cc13-42db-b3c0-656156f99b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1b9a8dad-d081-4a70-91b6-df0ccce15d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1b9a8dad-d081-4a70-91b6-df0ccce15d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_884896e6-a2f0-434f-80ec-c152ecec2c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1b9a8dad-d081-4a70-91b6-df0ccce15d92" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_884896e6-a2f0-434f-80ec-c152ecec2c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fde2d2d8-a6e9-46b3-bdb1-dd416c3bbacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_884896e6-a2f0-434f-80ec-c152ecec2c8f" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fde2d2d8-a6e9-46b3-bdb1-dd416c3bbacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_2e44e9c2-5424-444b-8934-14fac08b7d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_884896e6-a2f0-434f-80ec-c152ecec2c8f" xlink:to="loc_us-gaap_LicensingAgreementsMember_2e44e9c2-5424-444b-8934-14fac08b7d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d2494d8e-d25a-413c-82df-17ff6bf97c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d2494d8e-d25a-413c-82df-17ff6bf97c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_51c38789-fb3f-43e4-9038-1a72ff2ca3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d2494d8e-d25a-413c-82df-17ff6bf97c7f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_51c38789-fb3f-43e4-9038-1a72ff2ca3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_771837a8-6445-4804-afa3-ca69079fbafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_51c38789-fb3f-43e4-9038-1a72ff2ca3b4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_771837a8-6445-4804-afa3-ca69079fbafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0adfee3f-db6a-4be2-8e85-a788f67cd449" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8ab667dd-97c8-4ace-bc0d-366112c21c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8ab667dd-97c8-4ace-bc0d-366112c21c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_79aff0ae-079f-47cb-916c-b57e2849afab" xlink:href="mrk-20211231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_RoyaltyRatePercentage_79aff0ae-079f-47cb-916c-b57e2849afab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_e3681b5d-6d8d-4965-b67f-eea1c16ddf05" xlink:href="mrk-20211231.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_e3681b5d-6d8d-4965-b67f-eea1c16ddf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_fab6e0cd-1e44-48f1-a8a0-9497041f41f5" xlink:href="mrk-20211231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_fab6e0cd-1e44-48f1-a8a0-9497041f41f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_c7c05b19-399a-4093-8108-9c1f4e66f2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_c7c05b19-399a-4093-8108-9c1f4e66f2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_94edb097-268b-4cb0-af03-332e0f4eda14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_94edb097-268b-4cb0-af03-332e0f4eda14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_5c4c9d6d-621a-4822-bace-8f2d096bbaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_5c4c9d6d-621a-4822-bace-8f2d096bbaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_afcf6f01-6ee0-469a-8819-2ae6a5f765e3" xlink:href="mrk-20211231.xsd#mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_afcf6f01-6ee0-469a-8819-2ae6a5f765e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_efd99c51-ef55-4e7a-9fe6-1f7a7e042a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_efd99c51-ef55-4e7a-9fe6-1f7a7e042a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_ea67fd2e-bd50-46cc-a827-b744e3101e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_ea67fd2e-bd50-46cc-a827-b744e3101e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_5ad7495e-28b2-41a2-aec9-7c2dc4bc9007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_5ad7495e-28b2-41a2-aec9-7c2dc4bc9007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShareCounterparty_cfeec4f3-1ff4-4d5e-a8c0-e818f33f28bb" xlink:href="mrk-20211231.xsd#mrk_ProfitShareCounterparty"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_ProfitShareCounterparty_cfeec4f3-1ff4-4d5e-a8c0-e818f33f28bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShare_c0b3c62b-b973-4636-a955-ebaafceb79ac" xlink:href="mrk-20211231.xsd#mrk_ProfitShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_ProfitShare_c0b3c62b-b973-4636-a955-ebaafceb79ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesThreshold_987d86db-f279-4602-b57e-ff00081a8b09" xlink:href="mrk-20211231.xsd#mrk_SalesThreshold"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_SalesThreshold_987d86db-f279-4602-b57e-ff00081a8b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_10102cf6-e5bc-4e20-aa74-47055148b15e" xlink:href="mrk-20211231.xsd#mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_10102cf6-e5bc-4e20-aa74-47055148b15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_50298af1-ed8c-434b-aed2-c09eae4a9c38" xlink:href="mrk-20211231.xsd#mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_50298af1-ed8c-434b-aed2-c09eae4a9c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_cf363613-2d0b-43fb-975a-7194895a9575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_cf363613-2d0b-43fb-975a-7194895a9575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0efc53d0-53ab-4ec8-8a12-15acb4d46be1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0efc53d0-53ab-4ec8-8a12-15acb4d46be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_d00a5fcd-29ab-4ac2-ab5a-4e3bc4328984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_Investments_d00a5fcd-29ab-4ac2-ab5a-4e3bc4328984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PremiumOnSharesAcquired_1db81467-19be-4527-b4cf-3d771d02e0d8" xlink:href="mrk-20211231.xsd#mrk_PremiumOnSharesAcquired"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_PremiumOnSharesAcquired_1db81467-19be-4527-b4cf-3d771d02e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_493b4f41-5935-45a2-9f7d-885439fdbc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_493b4f41-5935-45a2-9f7d-885439fdbc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation_2e288db1-9e3b-4d7f-9b99-4aac2417a19a" xlink:href="mrk-20211231.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_ChargesRelatedToProgramDiscontinuation_2e288db1-9e3b-4d7f-9b99-4aac2417a19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_808f1572-5613-41de-8453-9ccc126df469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_808f1572-5613-41de-8453-9ccc126df469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_4006cf47-fd43-492b-9be1-af3fa73029e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_SharePrice_4006cf47-fd43-492b-9be1-af3fa73029e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a62e0302-d7d5-44e1-baea-5518af38aec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a62e0302-d7d5-44e1-baea-5518af38aec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_21eca2f8-f6a8-4e92-863c-8cc87483d241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_21eca2f8-f6a8-4e92-863c-8cc87483d241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ba141d82-c3a5-43d4-ad81-790d69c23a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_InventoryNet_ba141d82-c3a5-43d4-ad81-790d69c23a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9a9691a0-c349-460f-abc9-fbae9b60fdad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9a9691a0-c349-460f-abc9-fbae9b60fdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7fbf91ec-3967-48bc-83a9-c71556025b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7fbf91ec-3967-48bc-83a9-c71556025b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eff8dc29-3bcd-40c4-8bc4-52769e377636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eff8dc29-3bcd-40c4-8bc4-52769e377636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a39f457a-7d96-4335-981a-68fdbac7b4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a39f457a-7d96-4335-981a-68fdbac7b4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d5ed19cd-be8e-48ac-a2a6-fea0005719f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d5ed19cd-be8e-48ac-a2a6-fea0005719f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_b807f68f-7eee-4595-8b6f-59684fdf267c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_b807f68f-7eee-4595-8b6f-59684fdf267c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_8306638b-81eb-430d-9604-8506a870ef8e" xlink:href="mrk-20211231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_8306638b-81eb-430d-9604-8506a870ef8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d4ca0416-612c-4e3c-97ed-68925c2d1d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_Goodwill_d4ca0416-612c-4e3c-97ed-68925c2d1d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_cde3cc1c-0ed1-4428-96fc-7b0f5102f7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_cde3cc1c-0ed1-4428-96fc-7b0f5102f7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_31c5dc40-919c-4c9a-856b-c08f68d1c211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_31c5dc40-919c-4c9a-856b-c08f68d1c211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_5f8fadae-9183-422a-a14e-c6d90676c99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_5f8fadae-9183-422a-a14e-c6d90676c99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_818bf71d-e708-4a6d-99ab-6f4da6d5b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_818bf71d-e708-4a6d-99ab-6f4da6d5b4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents_e2238599-27d7-4382-8bf1-bb08f70ea09f" xlink:href="mrk-20211231.xsd#mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents_e2238599-27d7-4382-8bf1-bb08f70ea09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities_d0296166-2d9a-4a66-9476-dcd49bc8d57a" xlink:href="mrk-20211231.xsd#mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities_d0296166-2d9a-4a66-9476-dcd49bc8d57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_e015e22a-8d4e-42fc-8185-e424ea21dbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_444b34bf-a6c8-481c-800b-e4dfd45a2dcb" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_e015e22a-8d4e-42fc-8185-e424ea21dbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9d602625-4586-4b06-b92e-2041554a0f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9d602625-4586-4b06-b92e-2041554a0f2b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2dd77d6c-70be-4f4f-b041-dc68b789bb5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:to="loc_srt_RangeAxis_2dd77d6c-70be-4f4f-b041-dc68b789bb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0d2d0a5-25ba-4e43-8216-ebcbbf2aa5c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2dd77d6c-70be-4f4f-b041-dc68b789bb5e" xlink:to="loc_srt_RangeMember_e0d2d0a5-25ba-4e43-8216-ebcbbf2aa5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ac3540b6-44bc-450f-9447-73cec4bbbb25" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0d2d0a5-25ba-4e43-8216-ebcbbf2aa5c1" xlink:to="loc_srt_MinimumMember_ac3540b6-44bc-450f-9447-73cec4bbbb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdc9e877-7da8-4ffe-a98e-18c7309a165e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0d2d0a5-25ba-4e43-8216-ebcbbf2aa5c1" xlink:to="loc_srt_MaximumMember_fdc9e877-7da8-4ffe-a98e-18c7309a165e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_81ece920-7264-471f-83d4-b2ee226ec849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_81ece920-7264-471f-83d4-b2ee226ec849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_81ece920-7264-471f-83d4-b2ee226ec849" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember_45abcf0f-f0be-409b-b9ba-0b056c0a4271" xlink:href="mrk-20211231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:to="loc_mrk_AcceleronPharmaIncMember_45abcf0f-f0be-409b-b9ba-0b056c0a4271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_20008a7d-4490-4bd1-a08e-4a7e3f1305c0" xlink:href="mrk-20211231.xsd#mrk_ArQuleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:to="loc_mrk_ArQuleMember_20008a7d-4490-4bd1-a08e-4a7e3f1305c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_2684bca1-2c81-4b46-9018-d2030e70fbb5" xlink:href="mrk-20211231.xsd#mrk_AntelliqMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57586c8e-d8b4-4812-972f-8d1391311634" xlink:to="loc_mrk_AntelliqMember_2684bca1-2c81-4b46-9018-d2030e70fbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_59d97754-0a84-4606-82e6-4a4f6ecc0d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_59d97754-0a84-4606-82e6-4a4f6ecc0d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_160e34e9-c4f9-4388-b9a6-ef61c3105c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_59d97754-0a84-4606-82e6-4a4f6ecc0d99" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_160e34e9-c4f9-4388-b9a6-ef61c3105c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2285679c-5b5a-4933-a11b-c826b6e86c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_160e34e9-c4f9-4388-b9a6-ef61c3105c48" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2285679c-5b5a-4933-a11b-c826b6e86c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a6313be7-1bed-4c53-ba15-b487dd9632e3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d81a7625-b3d8-49ce-a831-3373a5a42bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d81a7625-b3d8-49ce-a831-3373a5a42bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_066283aa-cfc4-46dd-8dd8-43ae67ccb829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_066283aa-cfc4-46dd-8dd8-43ae67ccb829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0f4afa5e-b142-45b2-8e75-d0f7eddec5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0f4afa5e-b142-45b2-8e75-d0f7eddec5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad7720fb-1030-469d-9353-ee2aad9bc39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad7720fb-1030-469d-9353-ee2aad9bc39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2f500a2b-1152-4036-bfdf-87d9a8ee01e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2f500a2b-1152-4036-bfdf-87d9a8ee01e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3990fbea-c074-40f2-831b-b0bac67b0a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3990fbea-c074-40f2-831b-b0bac67b0a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0f44e18d-6bf9-43fa-9c11-9ec78c0c161e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0f44e18d-6bf9-43fa-9c11-9ec78c0c161e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ae2c3418-f273-4d5a-b34d-3dadf10c1967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ae2c3418-f273-4d5a-b34d-3dadf10c1967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4f43e818-ddee-47e0-906b-c1f39b0c3626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4f43e818-ddee-47e0-906b-c1f39b0c3626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47612334-4461-4af1-8d26-edeba542a468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47612334-4461-4af1-8d26-edeba542a468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a5fc6497-84ca-4282-861f-7b35ffbf7de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a5fc6497-84ca-4282-861f-7b35ffbf7de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_8eeb78e3-59fb-4611-80ce-9a4596102e4e" xlink:href="mrk-20211231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_8eeb78e3-59fb-4611-80ce-9a4596102e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9831e077-3ad2-4e2b-a623-a4b16ddc652e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9831e077-3ad2-4e2b-a623-a4b16ddc652e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5adba024-8f69-48e7-86e5-6da03bde28c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_Goodwill_5adba024-8f69-48e7-86e5-6da03bde28c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9ec0292c-196c-4422-a2b8-f3e63b8bc326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9ec0292c-196c-4422-a2b8-f3e63b8bc326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_63ba6bc3-cfbf-43a6-86e3-fa8886c3c5a1" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_63ba6bc3-cfbf-43a6-86e3-fa8886c3c5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_2dbaa85e-dd8f-497a-b878-0c23da20bb89" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetProductsAndProductRightsMeasurementInput"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9710c155-57df-4b9b-af07-217119aec336" xlink:to="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_2dbaa85e-dd8f-497a-b878-0c23da20bb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20211231.xsd#CollaborativeArrangements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_b24d975d-5be5-48d3-bca1-528a49b97b25" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_df7094e4-5439-4c31-b104-b3b47d3fa5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_b24d975d-5be5-48d3-bca1-528a49b97b25" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_df7094e4-5439-4c31-b104-b3b47d3fa5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#CollaborativeArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_bca9dfba-71f4-4071-acc6-bacf3009ed58" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_87381779-7246-4b34-977d-8402aa9836bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_bca9dfba-71f4-4071-acc6-bacf3009ed58" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_87381779-7246-4b34-977d-8402aa9836bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9aae9543-f3bb-4637-926c-eee05f48dd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9aae9543-f3bb-4637-926c-eee05f48dd5b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_51895016-9c6a-4ea0-b5b5-df7dbee26544" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_srt_CounterpartyNameAxis_51895016-9c6a-4ea0-b5b5-df7dbee26544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_51895016-9c6a-4ea0-b5b5-df7dbee26544" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_fa88fbf8-bec6-4783-bad2-321628643b5a" xlink:href="mrk-20211231.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:to="loc_mrk_EisaiMember_fa88fbf8-bec6-4783-bad2-321628643b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_cf7a2112-0ab4-4ace-a4f6-6d4196ae31bf" xlink:href="mrk-20211231.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:to="loc_mrk_BayerAGMember_cf7a2112-0ab4-4ace-a4f6-6d4196ae31bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_718ee367-1f08-47eb-af3f-2b0f1b30795d" xlink:href="mrk-20211231.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:to="loc_mrk_AstraZenecaMember_718ee367-1f08-47eb-af3f-2b0f1b30795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_4bad8bd5-488a-42c4-b14d-006d0d5ce73b" xlink:href="mrk-20211231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4506a37b-ba7f-4b00-8e9e-e282f0ababac" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_4bad8bd5-488a-42c4-b14d-006d0d5ce73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4cc8df4-e4fe-4974-b8e2-c2f1780bc62b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_srt_ProductOrServiceAxis_a4cc8df4-e4fe-4974-b8e2-c2f1780bc62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a4cc8df4-e4fe-4974-b8e2-c2f1780bc62b" xlink:to="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_f5bebf18-e831-4781-89e7-d9dabb2b1865" xlink:href="mrk-20211231.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_LenvimaMember_f5bebf18-e831-4781-89e7-d9dabb2b1865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_65cc92ab-e7fa-4339-ac4f-d62a9dc59498" xlink:href="mrk-20211231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_AdempasMember_65cc92ab-e7fa-4339-ac4f-d62a9dc59498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_6cf320c9-a5d8-48b6-9c0a-b79289f7e9d4" xlink:href="mrk-20211231.xsd#mrk_VerquvoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_VerquvoMember_6cf320c9-a5d8-48b6-9c0a-b79289f7e9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_6049df68-8436-404f-a348-a63641bbeaf9" xlink:href="mrk-20211231.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_LynparzaMember_6049df68-8436-404f-a348-a63641bbeaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MolnupiravirMember_d7441f97-b459-468c-aa44-8a6a1e262195" xlink:href="mrk-20211231.xsd#mrk_MolnupiravirMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f5b07f8c-1b8f-4af5-b8c8-37d056fc1379" xlink:to="loc_mrk_MolnupiravirMember_d7441f97-b459-468c-aa44-8a6a1e262195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d6b39e47-c68d-48ed-81b8-f48ba41bb786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d6b39e47-c68d-48ed-81b8-f48ba41bb786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d6b39e47-c68d-48ed-81b8-f48ba41bb786" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_4c26a3ca-9e0f-48db-9e6e-6073dd9b84cf" xlink:href="mrk-20211231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_mrk_SalesBasedMilestonesMember_4c26a3ca-9e0f-48db-9e6e-6073dd9b84cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_17acc152-75d1-4cd6-a739-7b3047741aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_17acc152-75d1-4cd6-a739-7b3047741aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_4833929d-f693-47ff-879f-b5ae416c4489" xlink:href="mrk-20211231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_mrk_RegulatoryMilestonesMember_4833929d-f693-47ff-879f-b5ae416c4489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_7add8b0d-b012-4284-995f-87549c704ff4" xlink:href="mrk-20211231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_mrk_DevelopmentMilestonesMember_7add8b0d-b012-4284-995f-87549c704ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_77174e1e-939a-4fca-a754-92f16ba0f5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a5fe6940-9175-4574-be64-51ad36cfba59" xlink:to="loc_us-gaap_CollaborativeArrangementMember_77174e1e-939a-4fca-a754-92f16ba0f5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706036d8-ef09-4e79-a9bd-b11c89fd1319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706036d8-ef09-4e79-a9bd-b11c89fd1319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_38985097-4c84-4725-bdd9-9648ffa85976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_706036d8-ef09-4e79-a9bd-b11c89fd1319" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_38985097-4c84-4725-bdd9-9648ffa85976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_15bb070d-3766-4191-a479-ed651bed285f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_38985097-4c84-4725-bdd9-9648ffa85976" xlink:to="loc_us-gaap_LicenseMember_15bb070d-3766-4191-a479-ed651bed285f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_41b5709d-678d-4af8-a449-95eb535395b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_41b5709d-678d-4af8-a449-95eb535395b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_73d30e21-b124-4bbd-82d6-c503cd2033f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_41b5709d-678d-4af8-a449-95eb535395b4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_73d30e21-b124-4bbd-82d6-c503cd2033f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1ccdb691-b596-4f72-b487-aa395777550a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_73d30e21-b124-4bbd-82d6-c503cd2033f7" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1ccdb691-b596-4f72-b487-aa395777550a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c0b72f66-d4d8-4825-a137-60be7eef3dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c0b72f66-d4d8-4825-a137-60be7eef3dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_be8f9704-4286-4f88-9461-6ab271233552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c0b72f66-d4d8-4825-a137-60be7eef3dcd" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_be8f9704-4286-4f88-9461-6ab271233552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_9599d506-8e50-4b3a-81b6-1a1ad009a522" xlink:href="mrk-20211231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_be8f9704-4286-4f88-9461-6ab271233552" xlink:to="loc_mrk_RegulatoryMilestonesMember_9599d506-8e50-4b3a-81b6-1a1ad009a522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_c2ad16c5-8850-41fd-b360-1fe56d81c9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_SupplyCommitmentAxis_c2ad16c5-8850-41fd-b360-1fe56d81c9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_c2ad16c5-8850-41fd-b360-1fe56d81c9da" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToUnitedStatesMember_9bc91a56-8fce-4686-a2ae-1194da516985" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:to="loc_mrk_SupplyCommitmentToUnitedStatesMember_9bc91a56-8fce-4686-a2ae-1194da516985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToJapanMember_c5d59492-6670-4d78-9e45-52313825aad1" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:to="loc_mrk_SupplyCommitmentToJapanMember_c5d59492-6670-4d78-9e45-52313825aad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToUnitedKingdomMember_fca53a04-411c-461d-86e5-b5cd963e21e1" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToUnitedKingdomMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:to="loc_mrk_SupplyCommitmentToUnitedKingdomMember_fca53a04-411c-461d-86e5-b5cd963e21e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember_540ee70e-5964-46e8-a7bb-dcd29b974737" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentToUnitedNationsChildrensFundMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_2ad4f1ab-3ffd-4d8b-9225-e092c1ab42f6" xlink:to="loc_mrk_SupplyCommitmentToUnitedNationsChildrensFundMember_540ee70e-5964-46e8-a7bb-dcd29b974737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cbbf5e4-2635-4b13-ba65-4ff43484d65f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_e1622e31-b63d-4ff8-8ac6-8431888b617f" xlink:href="mrk-20211231.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_e1622e31-b63d-4ff8-8ac6-8431888b617f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsAccruedSalesBased_04b14e1d-f391-46ae-ae0b-d754be394de3" xlink:href="mrk-20211231.xsd#mrk_MilestonePaymentsAccruedSalesBased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_MilestonePaymentsAccruedSalesBased_04b14e1d-f391-46ae-ae0b-d754be394de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_5fe8fa07-1580-490d-9d0d-2456db6ccded" xlink:href="mrk-20211231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_5fe8fa07-1580-490d-9d0d-2456db6ccded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d165a32e-8163-458a-8b2c-589cadf395b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d165a32e-8163-458a-8b2c-589cadf395b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsAccruedRegulatory_378afa96-2066-4d75-b87d-4aa49c536b9d" xlink:href="mrk-20211231.xsd#mrk_MilestonePaymentsAccruedRegulatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_MilestonePaymentsAccruedRegulatory_378afa96-2066-4d75-b87d-4aa49c536b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_24b2c570-b904-460f-9205-66b91d036783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_us-gaap_Liabilities_24b2c570-b904-460f-9205-66b91d036783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_db4d689e-3543-4067-920c-4fd855232712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_us-gaap_AdjustmentForAmortization_db4d689e-3543-4067-920c-4fd855232712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_077908aa-74cb-4406-8bc8-a637949e56dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_077908aa-74cb-4406-8bc8-a637949e56dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentQuantityCommitted_3a2b703e-be54-4e5e-89c2-13747510371e" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentQuantityCommitted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_SupplyCommitmentQuantityCommitted_3a2b703e-be54-4e5e-89c2-13747510371e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentQuantityDelivered_364e04b5-9fe5-4bad-afc4-9c1e4744dc1b" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentQuantityDelivered"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_SupplyCommitmentQuantityDelivered_364e04b5-9fe5-4bad-afc4-9c1e4744dc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets_ede680de-7a85-470e-a6a6-f62f5da6c31b" xlink:href="mrk-20211231.xsd#mrk_SupplyCommitmentMinimumNumberOfMarkets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_SupplyCommitmentMinimumNumberOfMarkets_ede680de-7a85-470e-a6a6-f62f5da6c31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach_4f1a7aaa-5da5-4066-acba-dc759ba0c015" xlink:href="mrk-20211231.xsd#mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach_4f1a7aaa-5da5-4066-acba-dc759ba0c015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_05d50b25-4d5e-491d-9c9f-c1dc71a3b55d" xlink:href="mrk-20211231.xsd#mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_05d50b25-4d5e-491d-9c9f-c1dc71a3b55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_32a20ed5-d36d-4287-84dd-3a12e83ac401" xlink:href="mrk-20211231.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_32a20ed5-d36d-4287-84dd-3a12e83ac401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_f5678419-9331-4660-bb14-35831c8acaac" xlink:href="mrk-20211231.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a36ddf5-eab9-4677-83ab-3f445ab1a04c" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_f5678419-9331-4660-bb14-35831c8acaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_58e91a62-35a2-43cb-8a61-58bb8121ee55" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_58e91a62-35a2-43cb-8a61-58bb8121ee55" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24030d1e-5eca-4bd9-9ba7-69c53075c0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24030d1e-5eca-4bd9-9ba7-69c53075c0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24030d1e-5eca-4bd9-9ba7-69c53075c0e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_efb93dab-356a-4f9e-9aa8-beb8d0abfa60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:to="loc_us-gaap_SalesMember_efb93dab-356a-4f9e-9aa8-beb8d0abfa60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_210fc4f5-8a30-49fa-a9ce-42b58b8bc378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:to="loc_us-gaap_CostOfSalesMember_210fc4f5-8a30-49fa-a9ce-42b58b8bc378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e9a1d52c-db13-46da-9392-bcaf743be2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e9a1d52c-db13-46da-9392-bcaf743be2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d94d5b04-0b4e-47d4-a422-c6cc662863cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0c6c74f1-3316-4296-8297-d580063d349c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d94d5b04-0b4e-47d4-a422-c6cc662863cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7f66452b-d2a9-4f82-b209-dd27beb67369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7f66452b-d2a9-4f82-b209-dd27beb67369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7f66452b-d2a9-4f82-b209-dd27beb67369" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_0c31351d-cab0-403f-8c44-a56792d4d4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_0c31351d-cab0-403f-8c44-a56792d4d4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_bedfc75e-e29b-4183-85f8-cd2d947e245e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_bedfc75e-e29b-4183-85f8-cd2d947e245e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0db92503-7e34-4289-9845-e10a0bebf109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_905ff436-1f26-4f74-947d-f715423186d1" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0db92503-7e34-4289-9845-e10a0bebf109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e6ecc137-fe85-40ba-98c2-34c92a5b5c28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_srt_CounterpartyNameAxis_e6ecc137-fe85-40ba-98c2-34c92a5b5c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e6ecc137-fe85-40ba-98c2-34c92a5b5c28" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_db85aefa-dece-4869-a4c2-4865191bd6f2" xlink:href="mrk-20211231.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:to="loc_mrk_AstraZenecaMember_db85aefa-dece-4869-a4c2-4865191bd6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_67abdef1-52df-47c9-8795-b47ba95ba407" xlink:href="mrk-20211231.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:to="loc_mrk_EisaiMember_67abdef1-52df-47c9-8795-b47ba95ba407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_e042cd49-e706-441d-ba0a-aa63e92b025f" xlink:href="mrk-20211231.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:to="loc_mrk_BayerAGMember_e042cd49-e706-441d-ba0a-aa63e92b025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_1137db7a-ed85-4316-aa68-a594576ff18c" xlink:href="mrk-20211231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676812ab-dc18-4083-a3ad-2320ea76bba0" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_1137db7a-ed85-4316-aa68-a594576ff18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a2d15efa-67a4-4228-ad88-fb4251b689cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a2d15efa-67a4-4228-ad88-fb4251b689cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dab2baab-e09c-41fe-a2e9-67f76fdbe868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a2d15efa-67a4-4228-ad88-fb4251b689cf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dab2baab-e09c-41fe-a2e9-67f76fdbe868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e5274927-4d1f-440a-ba4a-cd63616449b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dab2baab-e09c-41fe-a2e9-67f76fdbe868" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e5274927-4d1f-440a-ba4a-cd63616449b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_55ed0274-f092-4306-8349-2e1047f95df7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_srt_ProductOrServiceAxis_55ed0274-f092-4306-8349-2e1047f95df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_55ed0274-f092-4306-8349-2e1047f95df7" xlink:to="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_1f1677aa-2dfd-47ce-ac58-e336a83ae1a1" xlink:href="mrk-20211231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_1f1677aa-2dfd-47ce-ac58-e336a83ae1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_364f4f57-02a1-458e-b8c8-1cd0b4bb19a5" xlink:href="mrk-20211231.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_364f4f57-02a1-458e-b8c8-1cd0b4bb19a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_aef6ce4b-3e8b-4ecb-9509-2793adc4117f" xlink:href="mrk-20211231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_AdempasMember_aef6ce4b-3e8b-4ecb-9509-2793adc4117f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_bc93d8f6-e1cf-4e73-bb91-7cf354c96c05" xlink:href="mrk-20211231.xsd#mrk_VerquvoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_VerquvoMember_bc93d8f6-e1cf-4e73-bb91-7cf354c96c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MolnupiravirMember_272aac72-d238-4c50-ac57-cf4349a14614" xlink:href="mrk-20211231.xsd#mrk_MolnupiravirMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5417754b-22c4-4421-8bfb-7be2ee75d208" xlink:to="loc_mrk_MolnupiravirMember_272aac72-d238-4c50-ac57-cf4349a14614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_676af717-c68e-42c3-8543-2231421785a3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_153f7058-e4dc-43f4-bbac-ce6b27104d8a" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_153f7058-e4dc-43f4-bbac-ce6b27104d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_4815b786-0b8c-4ef2-9221-4219ae4cc6dd" xlink:href="mrk-20211231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_4815b786-0b8c-4ef2-9221-4219ae4cc6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_06cfa9ff-d46d-4cad-84a0-2b39f3f7e344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_Revenues_06cfa9ff-d46d-4cad-84a0-2b39f3f7e344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_43d2ad35-0b82-4618-bae2-40764b2b508c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_43d2ad35-0b82-4618-bae2-40764b2b508c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4cbf072-2ff9-4561-b26d-ee6d4518482d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4cbf072-2ff9-4561-b26d-ee6d4518482d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f52a3a0a-a889-4c32-84d0-182246dfeffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f52a3a0a-a889-4c32-84d0-182246dfeffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_451eb587-5c8a-47a6-8530-5ceb58126043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_ReceivablesNetCurrent_451eb587-5c8a-47a6-8530-5ceb58126043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e1f837c-586e-408f-ad6d-9423eaa7d5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e1f837c-586e-408f-ad6d-9423eaa7d5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_fa90988d-2cdf-49c9-ac89-a86817544d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_fa90988d-2cdf-49c9-ac89-a86817544d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5bd8e4df-0b09-4427-949a-840e11de3bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5bd8e4df-0b09-4427-949a-840e11de3bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_d7f07fbe-7035-4d8e-aaac-1bcaa3c911dc" xlink:href="mrk-20211231.xsd#mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b6bc3337-d7f7-420a-8ff4-1a5b3918447a" xlink:to="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_d7f07fbe-7035-4d8e-aaac-1bcaa3c911dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20211231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_96ba7982-fe0f-44ae-8c3c-4a4180396a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_69cb567c-d20e-40e9-aebb-4483c2fb327b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_96ba7982-fe0f-44ae-8c3c-4a4180396a44" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_69cb567c-d20e-40e9-aebb-4483c2fb327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a6a777b3-bf41-43d7-9417-d9ef33ef65e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3b7b36a5-e77f-4714-b881-9d434914e849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a6a777b3-bf41-43d7-9417-d9ef33ef65e0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3b7b36a5-e77f-4714-b881-9d434914e849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_c02890e9-2962-46de-886d-24cf572905ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a6a777b3-bf41-43d7-9417-d9ef33ef65e0" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_c02890e9-2962-46de-886d-24cf572905ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_317ad7d2-ab9c-41cb-9151-df2398bb278c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_51eb7584-0b8c-43d8-b4dc-63267f5cd8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_317ad7d2-ab9c-41cb-9151-df2398bb278c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_51eb7584-0b8c-43d8-b4dc-63267f5cd8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bfecb2f0-531d-4887-b27a-21fe86b43d81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_51eb7584-0b8c-43d8-b4dc-63267f5cd8e7" xlink:to="loc_srt_StatementScenarioAxis_bfecb2f0-531d-4887-b27a-21fe86b43d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fa5bd354-9a0d-47ca-b7a0-d8017d789179" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_bfecb2f0-531d-4887-b27a-21fe86b43d81" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fa5bd354-9a0d-47ca-b7a0-d8017d789179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_25b56f20-fb69-46e6-96bf-d9905bd9a0f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fa5bd354-9a0d-47ca-b7a0-d8017d789179" xlink:to="loc_srt_ScenarioForecastMember_25b56f20-fb69-46e6-96bf-d9905bd9a0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_51eb7584-0b8c-43d8-b4dc-63267f5cd8e7" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_733ae536-3417-4549-b05f-3f45b07ccaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_733ae536-3417-4549-b05f-3f45b07ccaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_4841ba7f-7948-454b-b33f-52aa34ab1126" xlink:href="mrk-20211231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_4841ba7f-7948-454b-b33f-52aa34ab1126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_575b5401-85b3-4e3c-ae20-d9c8c033219d" xlink:href="mrk-20211231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_575b5401-85b3-4e3c-ae20-d9c8c033219d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f3c674b2-a118-47c2-8fa2-dc07f95a2455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f3c674b2-a118-47c2-8fa2-dc07f95a2455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_1f15c1ca-372e-4c5c-8c18-bd404a31c64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f8bab5a9-436d-4d0a-819f-71023f2d1238" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_1f15c1ca-372e-4c5c-8c18-bd404a31c64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ee519099-d5b2-45b1-8f2d-2b006021caef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ca35c9bc-78da-42a3-a0c2-f24476e9dc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ee519099-d5b2-45b1-8f2d-2b006021caef" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ca35c9bc-78da-42a3-a0c2-f24476e9dc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8db1abfe-c789-4d99-b8c3-cfd22a9715fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ca35c9bc-78da-42a3-a0c2-f24476e9dc3e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8db1abfe-c789-4d99-b8c3-cfd22a9715fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8db1abfe-c789-4d99-b8c3-cfd22a9715fe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_e9c115d2-fe88-4b79-ae77-2c9567a47895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_e9c115d2-fe88-4b79-ae77-2c9567a47895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_dce08745-1d8d-4794-9be8-fa5602690d85" xlink:href="mrk-20211231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:to="loc_mrk_AcceleratedDepreciationMember_dce08745-1d8d-4794-9be8-fa5602690d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_83a07efb-f67c-45ba-9bf5-0503491afd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_42ff4784-5a7e-44ff-8442-e9f6c60a3b02" xlink:to="loc_us-gaap_OtherRestructuringMember_83a07efb-f67c-45ba-9bf5-0503491afd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19fa5c6e-b629-464d-9214-8754e360f220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ca35c9bc-78da-42a3-a0c2-f24476e9dc3e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19fa5c6e-b629-464d-9214-8754e360f220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19fa5c6e-b629-464d-9214-8754e360f220" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_16f3a347-bce2-449c-b933-545c0a9f1806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:to="loc_us-gaap_CostOfSalesMember_16f3a347-bce2-449c-b933-545c0a9f1806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3f34607-c0e0-490d-b20d-447ade66edc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3f34607-c0e0-490d-b20d-447ade66edc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a8edee3-f9f3-460f-b21d-a4277c0cf735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a8edee3-f9f3-460f-b21d-a4277c0cf735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_859c6148-b0dc-461e-a2c9-35758d6337b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_adde7883-d1a6-4aaf-9f99-fee364387b1e" xlink:to="loc_us-gaap_RestructuringChargesMember_859c6148-b0dc-461e-a2c9-35758d6337b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8bee654d-8c32-40c1-b2ea-a0ad99d6de27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ca35c9bc-78da-42a3-a0c2-f24476e9dc3e" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8bee654d-8c32-40c1-b2ea-a0ad99d6de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_80b7f86b-0aea-45ea-991a-8da53fca6d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8bee654d-8c32-40c1-b2ea-a0ad99d6de27" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_80b7f86b-0aea-45ea-991a-8da53fca6d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_396f9d9a-2215-44f6-9237-199caf66b7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36c2cffe-9bd6-4fd5-a0f5-d85f63e824a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_396f9d9a-2215-44f6-9237-199caf66b7bb" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36c2cffe-9bd6-4fd5-a0f5-d85f63e824a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_38cd28f7-e6c6-4532-a599-b36950f89fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36c2cffe-9bd6-4fd5-a0f5-d85f63e824a6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_38cd28f7-e6c6-4532-a599-b36950f89fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_38cd28f7-e6c6-4532-a599-b36950f89fa9" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_cdd2a060-60b4-479b-a91c-94f365080901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_cdd2a060-60b4-479b-a91c-94f365080901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_45bf811e-15b7-46a9-a802-dc63be6da609" xlink:href="mrk-20211231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:to="loc_mrk_AcceleratedDepreciationMember_45bf811e-15b7-46a9-a802-dc63be6da609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_cbae3675-8735-4f0d-8dab-f3f94f26a47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d69e8a0f-5720-4219-8ed5-e1fc9cc4cacf" xlink:to="loc_us-gaap_OtherRestructuringMember_cbae3675-8735-4f0d-8dab-f3f94f26a47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b7b6694f-7152-46d3-a82b-65fdf10c3d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36c2cffe-9bd6-4fd5-a0f5-d85f63e824a6" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_b7b6694f-7152-46d3-a82b-65fdf10c3d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7b6694f-7152-46d3-a82b-65fdf10c3d6b" xlink:to="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_dd8612fa-a36f-4b95-a841-390e508a3f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:to="loc_us-gaap_RestructuringReserve_dd8612fa-a36f-4b95-a841-390e508a3f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0fe93f04-fd76-45ee-83aa-8030392500d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0fe93f04-fd76-45ee-83aa-8030392500d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_7a68f8ee-093a-449a-ad81-d0564beeb9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:to="loc_us-gaap_PaymentsForRestructuring_7a68f8ee-093a-449a-ad81-d0564beeb9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_9f582c04-6334-4f78-923e-9abf5fd34abd" xlink:href="mrk-20211231.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:to="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_9f582c04-6334-4f78-923e-9abf5fd34abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c1df4d46-c382-4618-9499-0b747b01f852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c22ef454-0b5c-479c-b61c-ed2feb236c77" xlink:to="loc_us-gaap_RestructuringReserve_c1df4d46-c382-4618-9499-0b747b01f852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1d055352-5a09-43e3-9ea0-87a84ad6d2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_79e4ea00-7bf1-4ef4-9a61-cc8b26e27e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1d055352-5a09-43e3-9ea0-87a84ad6d2c7" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_79e4ea00-7bf1-4ef4-9a61-cc8b26e27e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f52c425e-ad6a-4858-aa37-4ca0cff3e57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f52c425e-ad6a-4858-aa37-4ca0cff3e57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_9d09f4eb-5d93-4c35-a290-dd7af23e5ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_9d09f4eb-5d93-4c35-a290-dd7af23e5ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_3b41783e-e786-4999-8ab8-46f533e2355e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_3b41783e-e786-4999-8ab8-46f533e2355e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e5e57c34-7bfd-4809-b6dc-289a5a592270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e5e57c34-7bfd-4809-b6dc-289a5a592270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_ea6bcb2c-dec6-4e36-bc83-c3174ecad255" xlink:href="mrk-20211231.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_ea6bcb2c-dec6-4e36-bc83-c3174ecad255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0fb8c1f5-e9e1-42c7-9972-9f99a27f7292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0fb8c1f5-e9e1-42c7-9972-9f99a27f7292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_901a647f-126f-46b0-8c31-ffd49bcc65ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_901a647f-126f-46b0-8c31-ffd49bcc65ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e324c5a9-81cf-4039-966d-827592b4907d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e324c5a9-81cf-4039-966d-827592b4907d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_562bffed-9b40-49d5-aa12-aeaaca03e2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_562bffed-9b40-49d5-aa12-aeaaca03e2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ee578858-e2f9-4c89-89bd-d8800ec65d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c132586-8ad5-4f51-b6a5-7f6551736f7b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ee578858-e2f9-4c89-89bd-d8800ec65d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fb806dc5-7e2b-4604-8acb-fee0155710cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fb806dc5-7e2b-4604-8acb-fee0155710cd" xlink:to="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_374c4adb-7ac9-4764-9a31-72af57eed054" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_srt_RangeAxis_374c4adb-7ac9-4764-9a31-72af57eed054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03a91b36-5afe-4436-a887-4b377fbe2646" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_374c4adb-7ac9-4764-9a31-72af57eed054" xlink:to="loc_srt_RangeMember_03a91b36-5afe-4436-a887-4b377fbe2646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2e047012-150f-4d72-9e37-7229def4f411" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_03a91b36-5afe-4436-a887-4b377fbe2646" xlink:to="loc_srt_MaximumMember_2e047012-150f-4d72-9e37-7229def4f411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5426cb25-17b7-42de-9938-7415649ed986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_HedgingDesignationAxis_5426cb25-17b7-42de-9938-7415649ed986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8b57633b-9a9a-483d-914a-543ec262c8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5426cb25-17b7-42de-9938-7415649ed986" xlink:to="loc_us-gaap_HedgingDesignationDomain_8b57633b-9a9a-483d-914a-543ec262c8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ba90ec12-bb18-441a-a995-2597a41c1c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8b57633b-9a9a-483d-914a-543ec262c8ef" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ba90ec12-bb18-441a-a995-2597a41c1c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9a83ad2e-9436-4e4d-89d3-1bc196662d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8b57633b-9a9a-483d-914a-543ec262c8ef" xlink:to="loc_us-gaap_NondesignatedMember_9a83ad2e-9436-4e4d-89d3-1bc196662d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fcf9a69e-3ded-4bf7-845d-29524c1a3f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fcf9a69e-3ded-4bf7-845d-29524c1a3f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_58ba8a59-cbd6-4c13-a2bb-102bb8396af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fcf9a69e-3ded-4bf7-845d-29524c1a3f42" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_58ba8a59-cbd6-4c13-a2bb-102bb8396af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_741b2b1c-7100-40d8-a168-e8837986938b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_58ba8a59-cbd6-4c13-a2bb-102bb8396af6" xlink:to="loc_us-gaap_InterestRateSwapMember_741b2b1c-7100-40d8-a168-e8837986938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e1a7cd4-18a3-4fbe-8b35-fb0035d0e10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e1a7cd4-18a3-4fbe-8b35-fb0035d0e10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0dedc7e-c438-4ebd-81b1-52fcd9c3491e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e1a7cd4-18a3-4fbe-8b35-fb0035d0e10d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0dedc7e-c438-4ebd-81b1-52fcd9c3491e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4ab1fb25-687c-4ccb-aede-ca3f1c100f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0dedc7e-c438-4ebd-81b1-52fcd9c3491e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4ab1fb25-687c-4ccb-aede-ca3f1c100f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_95890a2b-c626-4bcc-a162-cf1a6c66a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_95890a2b-c626-4bcc-a162-cf1a6c66a6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c40229ff-fa88-484c-806f-177972cd47a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_95890a2b-c626-4bcc-a162-cf1a6c66a6f5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c40229ff-fa88-484c-806f-177972cd47a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0775822e-662d-4aa9-9c90-a3febcdb3f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c40229ff-fa88-484c-806f-177972cd47a4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0775822e-662d-4aa9-9c90-a3febcdb3f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b54c874f-c82b-408c-bd83-32322b604d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b54c874f-c82b-408c-bd83-32322b604d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d8b1f4c7-909f-4948-a103-1bd66a41329d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b54c874f-c82b-408c-bd83-32322b604d48" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d8b1f4c7-909f-4948-a103-1bd66a41329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d3301347-a1cc-497a-a87b-3399e390d867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d8b1f4c7-909f-4948-a103-1bd66a41329d" xlink:to="loc_us-gaap_AccountsReceivableMember_d3301347-a1cc-497a-a87b-3399e390d867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a9ccfe8c-d8b5-48ba-9813-206a78a818ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_srt_MajorCustomersAxis_a9ccfe8c-d8b5-48ba-9813-206a78a818ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a9ccfe8c-d8b5-48ba-9813-206a78a818ad" xlink:to="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_McKessonCorporationMember_dd7e1388-9ba3-46e3-ae67-d277738066b4" xlink:href="mrk-20211231.xsd#mrk_McKessonCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:to="loc_mrk_McKessonCorporationMember_dd7e1388-9ba3-46e3-ae67-d277738066b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmerisourceBergenCorporationMember_6e7b5fba-6a74-48f0-9006-8109a04d9695" xlink:href="mrk-20211231.xsd#mrk_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:to="loc_mrk_AmerisourceBergenCorporationMember_6e7b5fba-6a74-48f0-9006-8109a04d9695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CardinalHealthIncMember_1037232e-6d7f-42ea-a2fa-aa776285e349" xlink:href="mrk-20211231.xsd#mrk_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d6d499cc-7f85-44f2-a7f8-1252a7258911" xlink:to="loc_mrk_CardinalHealthIncMember_1037232e-6d7f-42ea-a2fa-aa776285e349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0db404f0-1799-4619-86be-6bb878dd4215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0db404f0-1799-4619-86be-6bb878dd4215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_126a93b1-9a32-4cb5-9531-973d71615229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0db404f0-1799-4619-86be-6bb878dd4215" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_126a93b1-9a32-4cb5-9531-973d71615229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member_41cf72c6-36f6-46d3-9e46-18789f5c5350" xlink:href="mrk-20211231.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_126a93b1-9a32-4cb5-9531-973d71615229" xlink:to="loc_mrk_A3.875NotesDue2021Member_41cf72c6-36f6-46d3-9e46-18789f5c5350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f6fcae16-c7da-4bc1-9608-ded5409ade19" xlink:to="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_d96ca1b6-4011-4f19-b277-ab87ef1b9c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_d96ca1b6-4011-4f19-b277-ab87ef1b9c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_f15c7f11-cec8-4d67-bf93-ed85223b615b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_f15c7f11-cec8-4d67-bf93-ed85223b615b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ad190f03-e40e-4830-b907-d0d9b1c08000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ad190f03-e40e-4830-b907-d0d9b1c08000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_43b3714a-c91b-4461-98aa-4f189b6cbea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_43b3714a-c91b-4461-98aa-4f189b6cbea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b30bdf8d-c3dd-4be2-b6d8-7f6cb76a3173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b30bdf8d-c3dd-4be2-b6d8-7f6cb76a3173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_fd835f73-b25c-40db-ad4d-7fce26c63c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_fd835f73-b25c-40db-ad4d-7fce26c63c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1f4dbc53-9210-4e2f-9dc5-6967578166d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1f4dbc53-9210-4e2f-9dc5-6967578166d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_2f5d65fe-10be-4262-94ab-9f22ba04f554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_2f5d65fe-10be-4262-94ab-9f22ba04f554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_86cfa4be-d084-46d5-9a34-9c68601d289e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_86cfa4be-d084-46d5-9a34-9c68601d289e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_0f099fe4-adf2-4006-9166-a69e456c0164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_0f099fe4-adf2-4006-9166-a69e456c0164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_ca3418fb-6793-45bd-97b9-46ea75d3954b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_ca3418fb-6793-45bd-97b9-46ea75d3954b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_5c0aea9f-5646-466f-bee4-80789467ce99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_5c0aea9f-5646-466f-bee4-80789467ce99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ade22bc5-61a2-43a5-be03-17bf941ed4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ade22bc5-61a2-43a5-be03-17bf941ed4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_807e2c03-b856-4838-bff4-146029e6de5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_807e2c03-b856-4838-bff4-146029e6de5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9e930004-7eea-41e9-9728-f4b9b6ce1f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9e930004-7eea-41e9-9728-f4b9b6ce1f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_ea3cbf2d-dc48-4275-8355-974f608dbd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableSale"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_AccountsReceivableSale_ea3cbf2d-dc48-4275-8355-974f608dbd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_45c61867-5aa5-4131-a773-efb2ba33d0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_RestrictedCashCurrent_45c61867-5aa5-4131-a773-efb2ba33d0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_34f9564a-d570-4bf6-a124-dd4b9ab471a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_34f9564a-d570-4bf6-a124-dd4b9ab471a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_0c5e5a09-871b-49b3-987d-586bedefbb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_0c5e5a09-871b-49b3-987d-586bedefbb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_813d7eea-18df-4165-ae32-73c9428bad1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_813d7eea-18df-4165-ae32-73c9428bad1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_435e4fbf-022c-4228-8c46-e5ab36847c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2c4a750d-380f-4f33-9f8e-d7e6fade97d6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_435e4fbf-022c-4228-8c46-e5ab36847c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f1942dc8-d2f6-402b-891d-16944f88240f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c37adc33-1270-431e-a478-78529434f1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f1942dc8-d2f6-402b-891d-16944f88240f" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c37adc33-1270-431e-a478-78529434f1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7e80dea5-2cc1-42de-b8e9-349088c302b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c37adc33-1270-431e-a478-78529434f1d0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7e80dea5-2cc1-42de-b8e9-349088c302b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_70fab4f8-01af-42dd-b1ce-169bafb6cc73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7e80dea5-2cc1-42de-b8e9-349088c302b5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_70fab4f8-01af-42dd-b1ce-169bafb6cc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_09aabbe2-8eab-4073-9416-8ba7181a5c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70fab4f8-01af-42dd-b1ce-169bafb6cc73" xlink:to="loc_us-gaap_ForeignExchangeContractMember_09aabbe2-8eab-4073-9416-8ba7181a5c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_2eccbf32-ed3a-4ce8-aa45-3d012c28ba78" xlink:href="mrk-20211231.xsd#mrk_EurodominatedNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_70fab4f8-01af-42dd-b1ce-169bafb6cc73" xlink:to="loc_mrk_EurodominatedNotesMember_2eccbf32-ed3a-4ce8-aa45-3d012c28ba78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42061bc0-5d9d-483a-83cc-1493a245e3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c37adc33-1270-431e-a478-78529434f1d0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42061bc0-5d9d-483a-83cc-1493a245e3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b5b772f-237a-49d5-9c4a-c483bc3a840b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42061bc0-5d9d-483a-83cc-1493a245e3b3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b5b772f-237a-49d5-9c4a-c483bc3a840b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4a57e13d-e31f-4090-a19a-bbd57bfed51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b5b772f-237a-49d5-9c4a-c483bc3a840b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4a57e13d-e31f-4090-a19a-bbd57bfed51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_533ed98d-d425-4c71-81fb-9f1b30381e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c37adc33-1270-431e-a478-78529434f1d0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_533ed98d-d425-4c71-81fb-9f1b30381e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_82d2209a-1c38-46b3-9b22-1e54228263e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_533ed98d-d425-4c71-81fb-9f1b30381e9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_82d2209a-1c38-46b3-9b22-1e54228263e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_c7ef38bc-529c-402f-b08f-4f38cdfebc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_533ed98d-d425-4c71-81fb-9f1b30381e9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_c7ef38bc-529c-402f-b08f-4f38cdfebc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsInformationAboutInterestRateSwapsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c3c5ce88-5869-4af0-a582-72bd933f1881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9e5baac9-6e35-4599-9dfd-1b460bcd8b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c3c5ce88-5869-4af0-a582-72bd933f1881" xlink:to="loc_us-gaap_DerivativeTable_9e5baac9-6e35-4599-9dfd-1b460bcd8b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_06d8f8a8-f8fb-4532-a042-bd877d465d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9e5baac9-6e35-4599-9dfd-1b460bcd8b64" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_06d8f8a8-f8fb-4532-a042-bd877d465d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cdb2f134-3c52-4790-b140-67636a5805aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_06d8f8a8-f8fb-4532-a042-bd877d465d3f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cdb2f134-3c52-4790-b140-67636a5805aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_eb69e7d2-7fbf-4e98-b72a-0c1a03be7ead" xlink:href="mrk-20211231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cdb2f134-3c52-4790-b140-67636a5805aa" xlink:to="loc_mrk_A2.40NotesDue2022Member_eb69e7d2-7fbf-4e98-b72a-0c1a03be7ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_27b7c8bb-9460-4c17-8879-d9c0b57ac36f" xlink:href="mrk-20211231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cdb2f134-3c52-4790-b140-67636a5805aa" xlink:to="loc_mrk_A2.35NotesDue2022Member_27b7c8bb-9460-4c17-8879-d9c0b57ac36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5b6835c6-9823-4733-9bf8-4224de9bfed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9e5baac9-6e35-4599-9dfd-1b460bcd8b64" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5b6835c6-9823-4733-9bf8-4224de9bfed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e620d0a8-2c00-4573-a83e-4ad8ec79e46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5b6835c6-9823-4733-9bf8-4224de9bfed6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e620d0a8-2c00-4573-a83e-4ad8ec79e46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8b6a96b4-10a6-437b-b405-1ad43ddc574c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e620d0a8-2c00-4573-a83e-4ad8ec79e46b" xlink:to="loc_us-gaap_InterestRateSwapMember_8b6a96b4-10a6-437b-b405-1ad43ddc574c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9e5baac9-6e35-4599-9dfd-1b460bcd8b64" xlink:to="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_36207bbf-07bf-402e-83b0-1c1edcc1a0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_36207bbf-07bf-402e-83b0-1c1edcc1a0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9e07d35-6bb3-4f00-b4d0-31ac7c7be0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9e07d35-6bb3-4f00-b4d0-31ac7c7be0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f98e0b72-03c9-4912-a0b9-bb01bc74f29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f98e0b72-03c9-4912-a0b9-bb01bc74f29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ca1d064f-8d1d-47a0-92ca-13f59948040d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0a4c68c6-b8be-4785-b8cd-5ea14090684d" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ca1d064f-8d1d-47a0-92ca-13f59948040d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsFairValueofHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_593715e2-2732-4352-9551-473c3dc23702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e4e0ef04-3ad1-44d6-a2bd-ce6436abb698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_593715e2-2732-4352-9551-473c3dc23702" xlink:to="loc_us-gaap_DerivativeTable_e4e0ef04-3ad1-44d6-a2bd-ce6436abb698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6797598d-5c42-43dc-a85c-cbb589fc11d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e4e0ef04-3ad1-44d6-a2bd-ce6436abb698" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6797598d-5c42-43dc-a85c-cbb589fc11d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ba8b3d54-12f4-42c0-830c-8560c034f63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6797598d-5c42-43dc-a85c-cbb589fc11d4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ba8b3d54-12f4-42c0-830c-8560c034f63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_fbf9bcec-cd63-4bf1-b9da-17297d4bbd78" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ba8b3d54-12f4-42c0-830c-8560c034f63a" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_fbf9bcec-cd63-4bf1-b9da-17297d4bbd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_d69d201c-f7a7-45d2-8053-5e8830991fc6" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtExcludingCurrentMaturitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ba8b3d54-12f4-42c0-830c-8560c034f63a" xlink:to="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_d69d201c-f7a7-45d2-8053-5e8830991fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_33024a86-a284-4374-884f-004a64b3dee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e4e0ef04-3ad1-44d6-a2bd-ce6436abb698" xlink:to="loc_us-gaap_DerivativeLineItems_33024a86-a284-4374-884f-004a64b3dee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_ef3aa552-633a-4da5-9dfa-902dc379b651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_33024a86-a284-4374-884f-004a64b3dee7" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_ef3aa552-633a-4da5-9dfa-902dc379b651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_7873dae0-1712-471c-abe7-3b2df6e4457b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_33024a86-a284-4374-884f-004a64b3dee7" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_7873dae0-1712-471c-abe7-3b2df6e4457b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_90f57d93-16f8-4b26-aea9-1d37a7ea48ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_90f57d93-16f8-4b26-aea9-1d37a7ea48ae" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e9c3a998-c3f1-47c5-8672-23c046fd0119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e9c3a998-c3f1-47c5-8672-23c046fd0119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c266ea64-8276-4407-b94b-509510506225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e9c3a998-c3f1-47c5-8672-23c046fd0119" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c266ea64-8276-4407-b94b-509510506225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_1be6e0c2-ad98-4391-97cc-b69b06cd30b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c266ea64-8276-4407-b94b-509510506225" xlink:to="loc_us-gaap_InterestRateContractMember_1be6e0c2-ad98-4391-97cc-b69b06cd30b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d3dad164-c7a4-4fd6-8df3-c7597717dcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c266ea64-8276-4407-b94b-509510506225" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d3dad164-c7a4-4fd6-8df3-c7597717dcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b9e40c4e-0691-4f05-91c6-4f91e0349fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:to="loc_us-gaap_HedgingDesignationAxis_b9e40c4e-0691-4f05-91c6-4f91e0349fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6641fcf3-cf3f-452f-a621-d05b4e9c4cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_b9e40c4e-0691-4f05-91c6-4f91e0349fad" xlink:to="loc_us-gaap_HedgingDesignationDomain_6641fcf3-cf3f-452f-a621-d05b4e9c4cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7c2c8476-62b3-4dc1-99ca-b54421cfa91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_6641fcf3-cf3f-452f-a621-d05b4e9c4cb7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7c2c8476-62b3-4dc1-99ca-b54421cfa91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_4555af11-83fe-418d-aebe-acd5bb5c1cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_6641fcf3-cf3f-452f-a621-d05b4e9c4cb7" xlink:to="loc_us-gaap_NondesignatedMember_4555af11-83fe-418d-aebe-acd5bb5c1cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_813612eb-be5d-40cf-a6a0-45b21187b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_813612eb-be5d-40cf-a6a0-45b21187b4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_813612eb-be5d-40cf-a6a0-45b21187b4b8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_bbbacdb6-a70b-4487-835a-0d38827f7356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_bbbacdb6-a70b-4487-835a-0d38827f7356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_b752df2c-4906-451d-897e-7d1bd1432e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:to="loc_us-gaap_OtherAssetsMember_b752df2c-4906-451d-897e-7d1bd1432e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_8e71b663-d6e9-4666-99a1-d7b85209f829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_8e71b663-d6e9-4666-99a1-d7b85209f829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_35868ee5-98c4-407e-99eb-da4b09cf1186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_335a324c-68df-4938-97ca-efdedb847298" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_35868ee5-98c4-407e-99eb-da4b09cf1186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b24405d5-af9e-4039-92d2-4c88f5e3f5e7" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_f598ba7e-6aa7-4278-a29c-86b4af7c3eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:to="loc_us-gaap_DerivativeAssets_f598ba7e-6aa7-4278-a29c-86b4af7c3eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_214aa7e8-339f-4024-80f4-9f229b3a650c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:to="loc_us-gaap_DerivativeLiabilities_214aa7e8-339f-4024-80f4-9f229b3a650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_eb593f06-9d8e-4009-a9f6-d0c139d3ca05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_422adf00-191d-46f7-90e2-db1dcb6f0e25" xlink:to="loc_us-gaap_DerivativeNotionalAmount_eb593f06-9d8e-4009-a9f6-d0c139d3ca05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6aba7aeb-a2d4-40fc-adf8-3f0b4ad7e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_71c352d1-41e2-447a-b752-f1bee6fe39db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6aba7aeb-a2d4-40fc-adf8-3f0b4ad7e89d" xlink:to="loc_us-gaap_DerivativeAssets_71c352d1-41e2-447a-b752-f1bee6fe39db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_357486f1-8f2d-4299-8458-2537cb9f23d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6aba7aeb-a2d4-40fc-adf8-3f0b4ad7e89d" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_357486f1-8f2d-4299-8458-2537cb9f23d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_3bc024d7-46f5-4c09-8d93-d08d00a51f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6aba7aeb-a2d4-40fc-adf8-3f0b4ad7e89d" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_3bc024d7-46f5-4c09-8d93-d08d00a51f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_127ba784-8318-40c0-abb6-20b348db3d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6aba7aeb-a2d4-40fc-adf8-3f0b4ad7e89d" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_127ba784-8318-40c0-abb6-20b348db3d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_e8d4d523-7d57-422f-a197-db1fa8062552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6aba7aeb-a2d4-40fc-adf8-3f0b4ad7e89d" xlink:to="loc_us-gaap_DerivativeLiabilities_e8d4d523-7d57-422f-a197-db1fa8062552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_cd1c54fa-7642-48e6-a72b-34d26fed8827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6aba7aeb-a2d4-40fc-adf8-3f0b4ad7e89d" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_cd1c54fa-7642-48e6-a72b-34d26fed8827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_e4c22d9b-d0d2-4680-933d-d8a38343bf08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6aba7aeb-a2d4-40fc-adf8-3f0b4ad7e89d" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_e4c22d9b-d0d2-4680-933d-d8a38343bf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_08795214-525d-47d5-b5d3-6e0527920b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6aba7aeb-a2d4-40fc-adf8-3f0b4ad7e89d" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_08795214-525d-47d5-b5d3-6e0527920b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1934b5a9-8f51-4294-be0a-1a68b303feec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1934b5a9-8f51-4294-be0a-1a68b303feec" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d4d3139a-d79a-44fb-8555-47e7b6c7b6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d4d3139a-d79a-44fb-8555-47e7b6c7b6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1cd0af12-778d-4d56-b4c4-df523d202250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d4d3139a-d79a-44fb-8555-47e7b6c7b6e0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1cd0af12-778d-4d56-b4c4-df523d202250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_36d3c4c9-f754-45a4-b376-d67995c8a539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1cd0af12-778d-4d56-b4c4-df523d202250" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_36d3c4c9-f754-45a4-b376-d67995c8a539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_77412eb4-0297-475c-b6bf-66383cdc6a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_77412eb4-0297-475c-b6bf-66383cdc6a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_15cdc26c-7ab2-4603-8259-b9b335227388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_77412eb4-0297-475c-b6bf-66383cdc6a18" xlink:to="loc_us-gaap_EquityComponentDomain_15cdc26c-7ab2-4603-8259-b9b335227388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_fd402f04-c6d0-44cc-9ef1-e05039b0b0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15cdc26c-7ab2-4603-8259-b9b335227388" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_fd402f04-c6d0-44cc-9ef1-e05039b0b0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8789bcb5-d1b7-4dc9-8e20-3b5d82b3c7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8789bcb5-d1b7-4dc9-8e20-3b5d82b3c7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d64730d1-66ec-4dcb-893b-a46bd2e78ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8789bcb5-d1b7-4dc9-8e20-3b5d82b3c7d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d64730d1-66ec-4dcb-893b-a46bd2e78ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8f4f0669-bb91-4914-a815-8994716de1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d64730d1-66ec-4dcb-893b-a46bd2e78ccd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8f4f0669-bb91-4914-a815-8994716de1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4d8e257e-14c4-4b1c-91c2-b18d7115977d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4d8e257e-14c4-4b1c-91c2-b18d7115977d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d32fe0cf-14e4-470e-b159-5361d7f7c4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4d8e257e-14c4-4b1c-91c2-b18d7115977d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d32fe0cf-14e4-470e-b159-5361d7f7c4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_98d80641-ee97-4230-9f20-cbb7013a3b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d32fe0cf-14e4-470e-b159-5361d7f7c4d9" xlink:to="loc_us-gaap_InterestRateSwapMember_98d80641-ee97-4230-9f20-cbb7013a3b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_93d515e4-6c2b-493a-9f3a-ba16fb8aba8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d32fe0cf-14e4-470e-b159-5361d7f7c4d9" xlink:to="loc_us-gaap_ForeignExchangeContractMember_93d515e4-6c2b-493a-9f3a-ba16fb8aba8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1d98acaf-3ee4-4705-8b0d-15033a14494a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4b5fa1b8-5c81-409e-b0be-67e754d2b7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_Revenues_4b5fa1b8-5c81-409e-b0be-67e754d2b7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f81ab821-d6f5-4a2d-a104-3b593c907fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f81ab821-d6f5-4a2d-a104-3b593c907fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_30a4b213-0896-4496-ad6f-d7b310d24fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_30a4b213-0896-4496-ad6f-d7b310d24fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_f86424d5-f113-48c6-b451-f2d00ced4a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_f86424d5-f113-48c6-b451-f2d00ced4a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f39649b3-07bc-4d5c-8670-7c678fe988f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f39649b3-07bc-4d5c-8670-7c678fe988f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_5735e4bc-f510-4980-aab0-6fdd35a13727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_5735e4bc-f510-4980-aab0-6fdd35a13727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_dd8bb46f-a195-4320-b237-1353e0438c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_dd8bb46f-a195-4320-b237-1353e0438c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_dbedb53e-6255-430b-8a69-9efc31fdf4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_d211613a-b4ef-4461-b0a0-62a3b455a5a1" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_dbedb53e-6255-430b-8a69-9efc31fdf4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_98f83ffd-2343-400c-a12e-387bd82a3e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a443d39f-637b-4147-972c-aa05fd0f11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_98f83ffd-2343-400c-a12e-387bd82a3e5c" xlink:to="loc_us-gaap_DerivativeTable_a443d39f-637b-4147-972c-aa05fd0f11e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d5e76863-46fc-4fa9-828c-565ae6dffc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a443d39f-637b-4147-972c-aa05fd0f11e2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d5e76863-46fc-4fa9-828c-565ae6dffc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5e76863-46fc-4fa9-828c-565ae6dffc7c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5c97bf82-edae-44d5-ad63-689f77b462c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5c97bf82-edae-44d5-ad63-689f77b462c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_44034c84-8e83-4079-bf74-263c8d52735c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:to="loc_us-gaap_InterestRateContractMember_44034c84-8e83-4079-bf74-263c8d52735c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_44dfbc49-3d12-47bd-999f-d81bc3b8a610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_00530694-0a5a-42f5-9049-f2a828dce0ac" xlink:to="loc_us-gaap_ForwardContractsMember_44dfbc49-3d12-47bd-999f-d81bc3b8a610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d6102da1-f615-4528-b21c-b6e43f68803a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a443d39f-637b-4147-972c-aa05fd0f11e2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d6102da1-f615-4528-b21c-b6e43f68803a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d6102da1-f615-4528-b21c-b6e43f68803a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4b1106de-75c0-4335-9987-936104c56147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4b1106de-75c0-4335-9987-936104c56147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_46cf113e-c4d6-4a0b-bb61-3a8abd65b972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:to="loc_us-gaap_SalesMember_46cf113e-c4d6-4a0b-bb61-3a8abd65b972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7998d058-ac3c-4cfa-8508-fdf6e58b321c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_abe8cf33-657d-4a4c-b87e-0cabdd180cf7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7998d058-ac3c-4cfa-8508-fdf6e58b321c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_217516e9-054f-4c28-989e-18e902176ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a443d39f-637b-4147-972c-aa05fd0f11e2" xlink:to="loc_us-gaap_DerivativeLineItems_217516e9-054f-4c28-989e-18e902176ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_f6ccc54d-bdf9-493e-803e-f81ccc6c5958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_217516e9-054f-4c28-989e-18e902176ecb" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_f6ccc54d-bdf9-493e-803e-f81ccc6c5958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_493e4fc5-630f-4ffe-b87f-6e22a529abf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f431464a-fba3-4cb7-8378-8350b458d561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_493e4fc5-630f-4ffe-b87f-6e22a529abf6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f431464a-fba3-4cb7-8378-8350b458d561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9151edca-6769-4112-9c8e-ef5b6891a5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f431464a-fba3-4cb7-8378-8350b458d561" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9151edca-6769-4112-9c8e-ef5b6891a5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9151edca-6769-4112-9c8e-ef5b6891a5dc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_59316f00-8954-4459-876e-4f150d836438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_59316f00-8954-4459-876e-4f150d836438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_90d3ee09-cfa4-4e03-8eb4-9df58d24ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_90d3ee09-cfa4-4e03-8eb4-9df58d24ac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_969f7cb5-d5f0-4223-950d-faf3a2171d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89346fef-540b-4461-9792-d77e8dc2ce13" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_969f7cb5-d5f0-4223-950d-faf3a2171d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f431464a-fba3-4cb7-8378-8350b458d561" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799ade49-4bed-48a6-9004-7e23430b2d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_799ade49-4bed-48a6-9004-7e23430b2d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d186a49b-5313-4c95-a5b7-3045178343bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d186a49b-5313-4c95-a5b7-3045178343bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae892fea-7c24-4611-a6e3-61d3564eeb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae892fea-7c24-4611-a6e3-61d3564eeb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_845cd619-21e0-4444-8ff0-7cc2c6359693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_845cd619-21e0-4444-8ff0-7cc2c6359693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9f8032ca-7712-4233-82d2-c821b359193e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9f8032ca-7712-4233-82d2-c821b359193e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f01516ee-feb8-469b-b741-5bf992edb7e5" xlink:href="mrk-20211231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f01516ee-feb8-469b-b741-5bf992edb7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1ddc6f79-9179-4c5f-ba65-01fd29b576a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230e71df-6d32-4e96-bfa5-448567a809a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1ddc6f79-9179-4c5f-ba65-01fd29b576a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_541588b0-bc23-44df-bd9e-e23872a6c0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_541588b0-bc23-44df-bd9e-e23872a6c0ef" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ea169f39-6299-4967-82d8-e630736d8642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ea169f39-6299-4967-82d8-e630736d8642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d33746f6-eb63-4d9d-8dad-e5bd783279cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ea169f39-6299-4967-82d8-e630736d8642" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d33746f6-eb63-4d9d-8dad-e5bd783279cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0d9aaa97-6a55-4acc-8e3e-dbecfbc1ef8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d33746f6-eb63-4d9d-8dad-e5bd783279cd" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0d9aaa97-6a55-4acc-8e3e-dbecfbc1ef8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d1924d1c-d689-4dfe-9421-14324eb5798a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d1924d1c-d689-4dfe-9421-14324eb5798a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d1924d1c-d689-4dfe-9421-14324eb5798a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_86fb1a69-2ce0-480e-9b56-ef7077f7db49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_86fb1a69-2ce0-480e-9b56-ef7077f7db49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0458f46a-6eed-4f8e-8b3a-db6730f8a995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0458f46a-6eed-4f8e-8b3a-db6730f8a995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a386258e-602c-4734-a25e-23c4b169a5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035ce0f4-398f-4460-ab4d-8b5a9fffd6d4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a386258e-602c-4734-a25e-23c4b169a5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5b8ac573-4382-452c-b6f6-db9e8bb9dd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5b8ac573-4382-452c-b6f6-db9e8bb9dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5b8ac573-4382-452c-b6f6-db9e8bb9dd41" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_0d7c9aff-5084-42e6-9d66-331121b150a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_0d7c9aff-5084-42e6-9d66-331121b150a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5f06d7f8-7d2c-46ce-aa57-055ee86fe96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5f06d7f8-7d2c-46ce-aa57-055ee86fe96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_73a0fc8f-bea1-4745-a684-1a85abbd1a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_73a0fc8f-bea1-4745-a684-1a85abbd1a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_14244e50-72ca-4734-903a-f22060da09ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e5a71d1-d83c-4519-9a80-5a9bc68474fe" xlink:to="loc_us-gaap_EquitySecuritiesMember_14244e50-72ca-4734-903a-f22060da09ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0e5b48bc-b2ac-4d8b-9a7d-7b9d8e802514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0e5b48bc-b2ac-4d8b-9a7d-7b9d8e802514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0e5b48bc-b2ac-4d8b-9a7d-7b9d8e802514" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_27ff874a-010d-45b8-b47f-3501a8a6e863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:to="loc_us-gaap_ForeignExchangeContractMember_27ff874a-010d-45b8-b47f-3501a8a6e863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_70b1fa26-e6e9-4a11-af4e-6388b1e63eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_70b1fa26-e6e9-4a11-af4e-6388b1e63eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_0fccbf71-9a66-403d-8dea-fb8f098e0b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa5d6d19-3191-4709-b988-a72d62cfd764" xlink:to="loc_us-gaap_InterestRateContractMember_0fccbf71-9a66-403d-8dea-fb8f098e0b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_491719d2-6af7-474c-8d3b-f3401134cd38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e50c503-d664-4948-a4b3-d449e6413625" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_491719d2-6af7-474c-8d3b-f3401134cd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_491719d2-6af7-474c-8d3b-f3401134cd38" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_192edcd2-c56a-4bf9-8339-6237255b31af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_192edcd2-c56a-4bf9-8339-6237255b31af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_08f0a9ee-eebc-4285-827b-8910da9f0e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_08f0a9ee-eebc-4285-827b-8910da9f0e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_265f130e-ce6d-46e4-8ae1-5519342c60d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_TradingSecurities_265f130e-ce6d-46e4-8ae1-5519342c60d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3c229947-e69f-4c5e-bd53-665e4660bef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3c229947-e69f-4c5e-bd53-665e4660bef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_8efbe280-f4c1-4e90-8000-6666d5ecc7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_DerivativeAssets_8efbe280-f4c1-4e90-8000-6666d5ecc7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8b4f9483-42b4-42e6-936c-c5ff5b162b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_26fc68eb-cc61-41bd-afc3-de42adb80b18" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8b4f9483-42b4-42e6-936c-c5ff5b162b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_491719d2-6af7-474c-8d3b-f3401134cd38" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_37b63945-6acc-4040-baa9-e94cc72c5912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_37b63945-6acc-4040-baa9-e94cc72c5912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_c8bdaf81-fe18-440b-9e14-47f122b2154e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:to="loc_us-gaap_DerivativeLiabilities_c8bdaf81-fe18-440b-9e14-47f122b2154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5b5d7202-c714-4674-a47b-12eb13a4138f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d7330e7-0d39-4fa2-a31d-81cfe9558f62" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5b5d7202-c714-4674-a47b-12eb13a4138f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b24978e9-9d71-4f89-afa1-daf9475d94b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1d8c5b6e-5f39-4c35-acd3-830a49b05de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b24978e9-9d71-4f89-afa1-daf9475d94b4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1d8c5b6e-5f39-4c35-acd3-830a49b05de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a015474c-6950-4ae8-846c-e794e023ed81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1d8c5b6e-5f39-4c35-acd3-830a49b05de2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a015474c-6950-4ae8-846c-e794e023ed81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bf2dcf63-62de-4304-bbcf-ad385d88c204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a015474c-6950-4ae8-846c-e794e023ed81" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bf2dcf63-62de-4304-bbcf-ad385d88c204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_efa1ea1d-3321-4bfc-a2f8-a16263ca2131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_bf2dcf63-62de-4304-bbcf-ad385d88c204" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_efa1ea1d-3321-4bfc-a2f8-a16263ca2131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4e487ea9-db3c-405e-b634-ab985557e080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1d8c5b6e-5f39-4c35-acd3-830a49b05de2" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4e487ea9-db3c-405e-b634-ab985557e080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_b7733fef-b638-4025-9be4-115f2e72904a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4e487ea9-db3c-405e-b634-ab985557e080" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_b7733fef-b638-4025-9be4-115f2e72904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_b75604b6-5e7b-45c8-99ae-c819323a4930" xlink:href="mrk-20211231.xsd#mrk_SanofiPasteurMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_b7733fef-b638-4025-9be4-115f2e72904a" xlink:to="loc_mrk_SanofiPasteurMember_b75604b6-5e7b-45c8-99ae-c819323a4930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1d8c5b6e-5f39-4c35-acd3-830a49b05de2" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5cd6468a-efe0-4ad1-b44f-a5a708365d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5cd6468a-efe0-4ad1-b44f-a5a708365d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6c723649-031e-4e7d-b73f-5ff00dbb6c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6c723649-031e-4e7d-b73f-5ff00dbb6c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fd120d66-a5f0-49ac-90f0-3104b56037be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fd120d66-a5f0-49ac-90f0-3104b56037be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b2e36be5-d88e-46c9-9850-b18d61171823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b2e36be5-d88e-46c9-9850-b18d61171823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_c34ce83b-92c2-44df-bc52-fa0b510643c9" xlink:href="mrk-20211231.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_c34ce83b-92c2-44df-bc52-fa0b510643c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bca7ec3c-d625-4c76-ad50-13a9e497c56f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c14e3e5-a8ef-4ffd-b45d-37a9d85660d9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bca7ec3c-d625-4c76-ad50-13a9e497c56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6e350f5d-bc12-439b-affe-6318d01c72f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6e350f5d-bc12-439b-affe-6318d01c72f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e8355138-c017-49ee-80bb-54cb4cbc7d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5ae5aeff-9847-4bef-bc68-e9fb25438816" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e8355138-c017-49ee-80bb-54cb4cbc7d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20211231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_491c2ac0-d3cd-42e1-ba02-9464ba4f7ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_42675799-a5b6-4a1d-b881-1ce266d29d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_491c2ac0-d3cd-42e1-ba02-9464ba4f7ad0" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_42675799-a5b6-4a1d-b881-1ce266d29d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_38ebd30b-0b9f-4961-9f4f-e289ea5fee9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_46b56644-dc91-4575-80e2-5035515270e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_38ebd30b-0b9f-4961-9f4f-e289ea5fee9f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_46b56644-dc91-4575-80e2-5035515270e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#InventoriesInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a8d0954e-3e8a-447f-a3cf-04e0f3dd30a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_0c2219b5-89ef-4b42-ab4a-fa1a46c4fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8d0954e-3e8a-447f-a3cf-04e0f3dd30a5" xlink:to="loc_us-gaap_InventoryFinishedGoods_0c2219b5-89ef-4b42-ab4a-fa1a46c4fabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_6384c3c0-7994-4f40-8964-7bf058e7a5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8d0954e-3e8a-447f-a3cf-04e0f3dd30a5" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_6384c3c0-7994-4f40-8964-7bf058e7a5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_62fe4f54-9656-4f62-9949-1e731fefdf92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8d0954e-3e8a-447f-a3cf-04e0f3dd30a5" xlink:to="loc_us-gaap_OtherInventorySupplies_62fe4f54-9656-4f62-9949-1e731fefdf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_5759cb9a-5ad3-4c59-b301-08d5d6af5215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8d0954e-3e8a-447f-a3cf-04e0f3dd30a5" xlink:to="loc_us-gaap_InventoryGross_5759cb9a-5ad3-4c59-b301-08d5d6af5215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_92b6d88c-05ae-47a1-b6f3-9bd8e675df34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8d0954e-3e8a-447f-a3cf-04e0f3dd30a5" xlink:to="loc_us-gaap_InventoryLIFOReserve_92b6d88c-05ae-47a1-b6f3-9bd8e675df34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_a81977a0-ab6f-4452-9c05-b19d4bb048fe" xlink:href="mrk-20211231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8d0954e-3e8a-447f-a3cf-04e0f3dd30a5" xlink:to="loc_mrk_InventoryNetAndInventoryNoncurrent_a81977a0-ab6f-4452-9c05-b19d4bb048fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract_ce4d064c-b9e3-4da3-9795-71e0f9ee2cbe" xlink:href="mrk-20211231.xsd#mrk_RecognizedAsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8d0954e-3e8a-447f-a3cf-04e0f3dd30a5" xlink:to="loc_mrk_RecognizedAsAbstract_ce4d064c-b9e3-4da3-9795-71e0f9ee2cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8f958975-392e-4cd8-aef1-4cf2fb44496c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_ce4d064c-b9e3-4da3-9795-71e0f9ee2cbe" xlink:to="loc_us-gaap_InventoryNet_8f958975-392e-4cd8-aef1-4cf2fb44496c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_4af03fc5-335d-42cd-b04d-ea1183adcd74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_ce4d064c-b9e3-4da3-9795-71e0f9ee2cbe" xlink:to="loc_us-gaap_InventoryNoncurrent_4af03fc5-335d-42cd-b04d-ea1183adcd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20211231.xsd#InventoriesInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_cffab02d-c7b1-4c3e-a9e6-635a6d45d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_0eabf7e5-1c36-499c-96ad-a1e995cfab32" xlink:href="mrk-20211231.xsd#mrk_InventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_cffab02d-c7b1-4c3e-a9e6-635a6d45d0e0" xlink:to="loc_mrk_InventoryTable_0eabf7e5-1c36-499c-96ad-a1e995cfab32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_4e38f030-19ac-4d6c-b5de-8a131e6292f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_0eabf7e5-1c36-499c-96ad-a1e995cfab32" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_4e38f030-19ac-4d6c-b5de-8a131e6292f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_0db25076-789f-46de-81e9-ee5d6b742f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_4e38f030-19ac-4d6c-b5de-8a131e6292f1" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_0db25076-789f-46de-81e9-ee5d6b742f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_b27c5663-8727-4c89-9d11-6e43ffaaf41c" xlink:href="mrk-20211231.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_0db25076-789f-46de-81e9-ee5d6b742f05" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_b27c5663-8727-4c89-9d11-6e43ffaaf41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_db20e33e-b85b-44de-9324-4d0af0b4e1c4" xlink:href="mrk-20211231.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_0db25076-789f-46de-81e9-ee5d6b742f05" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_db20e33e-b85b-44de-9324-4d0af0b4e1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_52484879-5de9-4e32-af11-249ceb137d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_0eabf7e5-1c36-499c-96ad-a1e995cfab32" xlink:to="loc_us-gaap_InventoryLineItems_52484879-5de9-4e32-af11-249ceb137d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount_3cbcd21a-52de-4212-96eb-45a369020812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_52484879-5de9-4e32-af11-249ceb137d68" xlink:to="loc_us-gaap_LIFOInventoryAmount_3cbcd21a-52de-4212-96eb-45a369020812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_1a6bd0c2-e371-4ef0-bf1b-84f797d88195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_52484879-5de9-4e32-af11-249ceb137d68" xlink:to="loc_us-gaap_InventoryNoncurrent_1a6bd0c2-e371-4ef0-bf1b-84f797d88195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="mrk-20211231.xsd#GoodwillandOtherIntangibles"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a40f072-02c2-4421-8f8f-98937f02c4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a97215f8-ea0c-4550-ba9e-44d0455e598c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a40f072-02c2-4421-8f8f-98937f02c4b3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a97215f8-ea0c-4550-ba9e-44d0455e598c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ce95194a-e213-462d-9ad7-2c97e9fb9a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0ca61aec-2956-45f5-92f9-2b56d26495f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ce95194a-e213-462d-9ad7-2c97e9fb9a7f" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_0ca61aec-2956-45f5-92f9-2b56d26495f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_0e6e5d2b-783f-4051-9fa9-b45fa1d2ea46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ce95194a-e213-462d-9ad7-2c97e9fb9a7f" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_0e6e5d2b-783f-4051-9fa9-b45fa1d2ea46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5695acdd-c357-4082-83b9-c32d4fd0ce51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c9159499-e0ad-44dd-8f15-45358c9c9200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5695acdd-c357-4082-83b9-c32d4fd0ce51" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c9159499-e0ad-44dd-8f15-45358c9c9200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fd136943-4d62-42c7-a8ac-8c30904488f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c9159499-e0ad-44dd-8f15-45358c9c9200" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fd136943-4d62-42c7-a8ac-8c30904488f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fd136943-4d62-42c7-a8ac-8c30904488f9" xlink:to="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_e87a9fa9-b207-4633-9b54-0f0cebbe1bce" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:to="loc_mrk_PharmaceuticalsegmentMember_e87a9fa9-b207-4633-9b54-0f0cebbe1bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_5a948a8a-2773-4d90-bd35-c901b96cc517" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:to="loc_mrk_AnimalHealthsegmentMember_5a948a8a-2773-4d90-bd35-c901b96cc517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_3c094e04-5257-452d-9730-74bb768b17c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d71a5a44-223c-41c6-a64e-db540362a2c8" xlink:to="loc_us-gaap_AllOtherSegmentsMember_3c094e04-5257-452d-9730-74bb768b17c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f44d85ae-b0ff-4603-923c-bb4292910411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c9159499-e0ad-44dd-8f15-45358c9c9200" xlink:to="loc_us-gaap_GoodwillLineItems_f44d85ae-b0ff-4603-923c-bb4292910411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_f44d85ae-b0ff-4603-923c-bb4292910411" xlink:to="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d57e720f-a926-4529-80b9-945338f5e432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:to="loc_us-gaap_Goodwill_d57e720f-a926-4529-80b9-945338f5e432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_22a1ec50-6203-45e8-8f36-3f214eb803e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_22a1ec50-6203-45e8-8f36-3f214eb803e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_79b3af64-40b7-444e-b4a3-e7d250438a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_79b3af64-40b7-444e-b4a3-e7d250438a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_1dcc308e-fda9-4e49-bb07-6b12728ef1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_1dcc308e-fda9-4e49-bb07-6b12728ef1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31ebea78-546f-4869-ae65-4eb8d6697bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_adae5ebd-283f-416c-b533-7695299085fb" xlink:to="loc_us-gaap_Goodwill_31ebea78-546f-4869-ae65-4eb8d6697bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fb9009ae-ee49-40f1-933b-513787cbb66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_f44d85ae-b0ff-4603-923c-bb4292910411" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fb9009ae-ee49-40f1-933b-513787cbb66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09e81ad1-5a8a-46f7-b5aa-6b7879f1834a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:href="mrk-20211231.xsd#mrk_ScheduleOfOtherIntangiblesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09e81ad1-5a8a-46f7-b5aa-6b7879f1834a" xlink:to="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_91d15d45-bf44-428f-8900-4f9b1899d799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_91d15d45-bf44-428f-8900-4f9b1899d799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cabe2572-653d-41cf-819b-c83d70183eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_91d15d45-bf44-428f-8900-4f9b1899d799" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cabe2572-653d-41cf-819b-c83d70183eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_7871befa-1292-46a4-810d-3a959ecf8fd1" xlink:href="mrk-20211231.xsd#mrk_AntelliqMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cabe2572-653d-41cf-819b-c83d70183eaf" xlink:to="loc_mrk_AntelliqMember_7871befa-1292-46a4-810d-3a959ecf8fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6fe8527f-a47d-447d-bc3c-60e2dc8f7a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6fe8527f-a47d-447d-bc3c-60e2dc8f7a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6fe8527f-a47d-447d-bc3c-60e2dc8f7a6c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_fb8c422e-96ca-41ad-8984-9e995a59c7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_fb8c422e-96ca-41ad-8984-9e995a59c7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_b381ebb6-4ac7-47d7-a84f-a31eed73a1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:to="loc_us-gaap_TradeNamesMember_b381ebb6-4ac7-47d7-a84f-a31eed73a1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6c7ef2e4-7aab-4d46-b0d3-d32e755d1271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0da142b7-4da6-4e5b-a60d-54d5db8154be" xlink:to="loc_us-gaap_LicenseMember_6c7ef2e4-7aab-4d46-b0d3-d32e755d1271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_14df3adc-7ba0-4e4f-ace1-0fcf3586de41" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_srt_ProductOrServiceAxis_14df3adc-7ba0-4e4f-ace1-0fcf3586de41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_14df3adc-7ba0-4e4f-ace1-0fcf3586de41" xlink:to="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember_3b2c2f69-b435-492b-9129-b8289e157f72" xlink:href="mrk-20211231.xsd#mrk_ReblozylMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_ReblozylMember_3b2c2f69-b435-492b-9129-b8289e157f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_0ae22b0b-8998-46e3-9202-749f260d5141" xlink:href="mrk-20211231.xsd#mrk_ZerbaxaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_ZerbaxaMember_0ae22b0b-8998-46e3-9202-749f260d5141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_925acf36-e7f5-41f8-affb-3b9426f7a3e3" xlink:href="mrk-20211231.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_GardasilGardasil9Member_925acf36-e7f5-41f8-affb-3b9426f7a3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_f606726d-7035-4a64-a468-067aa0ab5f70" xlink:href="mrk-20211231.xsd#mrk_BridionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_BridionMember_f606726d-7035-4a64-a468-067aa0ab5f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_61c1086c-94e0-40bb-8f3a-76e08dcf7328" xlink:href="mrk-20211231.xsd#mrk_DificidMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_DificidMember_61c1086c-94e0-40bb-8f3a-76e08dcf7328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember_0606d3a0-1195-47e8-a62d-77ba4feafd57" xlink:href="mrk-20211231.xsd#mrk_SivextroMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_SivextroMember_0606d3a0-1195-47e8-a62d-77ba4feafd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_9e913722-120e-44df-bef6-e7146d65d56b" xlink:href="mrk-20211231.xsd#mrk_SimponiMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_SimponiMember_9e913722-120e-44df-bef6-e7146d65d56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthMember_e018e175-b5af-4c66-b0e4-8675ae26dac1" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_AnimalHealthMember_e018e175-b5af-4c66-b0e4-8675ae26dac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_807636d4-a10b-4373-b688-707b4b50ed09" xlink:href="mrk-20211231.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_LynparzaMember_807636d4-a10b-4373-b688-707b4b50ed09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_aa59df77-686c-4cc3-8a54-74035059e62e" xlink:href="mrk-20211231.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_LenvimaMember_aa59df77-686c-4cc3-8a54-74035059e62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_580cb03e-aba6-4e9d-b24b-65b089759bb6" xlink:href="mrk-20211231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_AdempasMember_580cb03e-aba6-4e9d-b24b-65b089759bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_4c124c97-a4e8-43ae-aa73-72a321cbcc92" xlink:href="mrk-20211231.xsd#mrk_VerquvoMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_VerquvoMember_4c124c97-a4e8-43ae-aa73-72a321cbcc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_132c1353-2073-4fea-8cf8-03a9ad52deb9" xlink:href="mrk-20211231.xsd#mrk_COVID19Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_COVID19Member_132c1353-2073-4fea-8cf8-03a9ad52deb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IOmetPharmaLtdMember_8665ac4f-504d-4ab4-8dfd-c1ea84ed5935" xlink:href="mrk-20211231.xsd#mrk_IOmetPharmaLtdMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_IOmetPharmaLtdMember_8665ac4f-504d-4ab4-8dfd-c1ea84ed5935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SotaterceptMember_4fd4c106-18e3-4c8e-bd31-e8c684ab51cc" xlink:href="mrk-20211231.xsd#mrk_SotaterceptMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_SotaterceptMember_4fd4c106-18e3-4c8e-bd31-e8c684ab51cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember_6d1a5ef4-3c4d-41b0-90bc-4c86d8c1ea20" xlink:href="mrk-20211231.xsd#mrk_NemtabrutinibMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_NemtabrutinibMember_6d1a5ef4-3c4d-41b0-90bc-4c86d8c1ea20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GefapixantMember_c0ddf745-390b-46b2-bee5-a8b72816b44d" xlink:href="mrk-20211231.xsd#mrk_GefapixantMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37584d4f-660f-4340-bfec-40b3956440cc" xlink:to="loc_mrk_GefapixantMember_c0ddf745-390b-46b2-bee5-a8b72816b44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9b69a527-d2b4-4594-9a9d-5e0b0e6f3528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9b69a527-d2b4-4594-9a9d-5e0b0e6f3528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_74b55ade-caea-47c9-bc19-1aea0905fdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9b69a527-d2b4-4594-9a9d-5e0b0e6f3528" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_74b55ade-caea-47c9-bc19-1aea0905fdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_a2e2ceea-45c9-4e10-83c3-08a9147985e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_74b55ade-caea-47c9-bc19-1aea0905fdb0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_a2e2ceea-45c9-4e10-83c3-08a9147985e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f87c532e-019a-4af0-a5b1-1d9665636d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f87c532e-019a-4af0-a5b1-1d9665636d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_84cf2858-ec2d-4c60-bec4-f20a23af8f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f87c532e-019a-4af0-a5b1-1d9665636d62" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_84cf2858-ec2d-4c60-bec4-f20a23af8f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_fe4d3887-df8c-4ebe-a059-1584c383ddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_84cf2858-ec2d-4c60-bec4-f20a23af8f4c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_fe4d3887-df8c-4ebe-a059-1584c383ddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_70cc1217-1ae2-4e24-bb15-b2a4a4891dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_ValuationTechniqueAxis_70cc1217-1ae2-4e24-bb15-b2a4a4891dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_5b21f4e8-2d42-4927-8093-e5e8dcca2762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_70cc1217-1ae2-4e24-bb15-b2a4a4891dd5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_5b21f4e8-2d42-4927-8093-e5e8dcca2762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_13c47042-63f3-4098-b44d-145fa637bb18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_5b21f4e8-2d42-4927-8093-e5e8dcca2762" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_13c47042-63f3-4098-b44d-145fa637bb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c89767f-47cd-4596-be48-f65753ac8a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c89767f-47cd-4596-be48-f65753ac8a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ecd1777-966c-4b78-8c08-d2a9ecfdb6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c89767f-47cd-4596-be48-f65753ac8a28" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ecd1777-966c-4b78-8c08-d2a9ecfdb6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2d3b16fb-ab8e-4265-bc5d-6115eb306897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ecd1777-966c-4b78-8c08-d2a9ecfdb6d7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2d3b16fb-ab8e-4265-bc5d-6115eb306897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf1cb912-3ca6-4002-be1f-5a85a9324d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf1cb912-3ca6-4002-be1f-5a85a9324d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd6456eb-ca3e-4512-8c8a-4300b0aee20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf1cb912-3ca6-4002-be1f-5a85a9324d0a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd6456eb-ca3e-4512-8c8a-4300b0aee20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2109ba6d-3b1d-4a6f-b50f-eec98dc25276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd6456eb-ca3e-4512-8c8a-4300b0aee20a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2109ba6d-3b1d-4a6f-b50f-eec98dc25276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetsExcludingGoodwillLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_0a9f2c76-1775-44bb-84b7-e4ee0a2a7051" xlink:to="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7f3e4f0-2f28-414e-a2c1-b5821fafd731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7f3e4f0-2f28-414e-a2c1-b5821fafd731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1ade6fae-7bda-49ff-a536-02153d77511b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1ade6fae-7bda-49ff-a536-02153d77511b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c54d80e7-3863-4337-a99a-4cfcb019a3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c54d80e7-3863-4337-a99a-4cfcb019a3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_e41e6a67-5245-47c0-966f-65d691f3eb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_InventoryWriteDown_e41e6a67-5245-47c0-966f-65d691f3eb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d118da77-5970-4815-a1c0-725e1f5c48d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d118da77-5970-4815-a1c0-725e1f5c48d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_3b23081b-9c18-442d-b29e-8441cd96e42d" xlink:href="mrk-20211231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_3b23081b-9c18-442d-b29e-8441cd96e42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_33b5b396-7c97-46be-ad57-abb229aa3428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_33b5b396-7c97-46be-ad57-abb229aa3428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4d72d97e-ca98-4928-8380-30c6a9d314de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4d72d97e-ca98-4928-8380-30c6a9d314de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9a4e8c3d-ac9f-45f2-bbf4-777d04597e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9a4e8c3d-ac9f-45f2-bbf4-777d04597e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b422010c-2032-463d-907b-14585ed4a9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b422010c-2032-463d-907b-14585ed4a9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4658daca-c714-491d-93e2-39a492d0a3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4658daca-c714-491d-93e2-39a492d0a3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_efa81dea-5a3d-4e5e-a63f-b83b51d2d655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_efa81dea-5a3d-4e5e-a63f-b83b51d2d655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b5a1abdc-d023-4721-a935-f3eefc29c3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_59c57afa-5507-4ac8-b565-30f5d28b3b67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b5a1abdc-d023-4721-a935-f3eefc29c3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#GoodwillandOtherIntangiblesOtherIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4f2d5628-4c35-4323-9c9d-51203f71028f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9b457dd-3234-431a-8f31-b2d0e87ad861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4f2d5628-4c35-4323-9c9d-51203f71028f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9b457dd-3234-431a-8f31-b2d0e87ad861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355e2649-5702-491f-8384-2d71f10c97ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9b457dd-3234-431a-8f31-b2d0e87ad861" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355e2649-5702-491f-8384-2d71f10c97ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_355e2649-5702-491f-8384-2d71f10c97ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_133efac8-d258-4db5-a8d8-ee57fc15200c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_133efac8-d258-4db5-a8d8-ee57fc15200c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_66fbaca6-11cd-404f-8e46-b38502948960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:to="loc_us-gaap_TradeNamesMember_66fbaca6-11cd-404f-8e46-b38502948960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ebe56579-ee88-4e42-914f-4f03baa46090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ebe56579-ee88-4e42-914f-4f03baa46090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1c0d571a-e83f-4426-b17e-dd4b9a3afa46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8154a288-f39a-442a-983c-ff8f75028d09" xlink:to="loc_us-gaap_LicenseMember_1c0d571a-e83f-4426-b17e-dd4b9a3afa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbb33f8d-baae-4f50-97f3-37f6aef16d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9b457dd-3234-431a-8f31-b2d0e87ad861" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbb33f8d-baae-4f50-97f3-37f6aef16d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_27b0b832-8569-484b-9a7a-1b9faccc33b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbb33f8d-baae-4f50-97f3-37f6aef16d44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_27b0b832-8569-484b-9a7a-1b9faccc33b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_392c6c13-9626-41f5-bf19-66e2bdbd5e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_27b0b832-8569-484b-9a7a-1b9faccc33b3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_392c6c13-9626-41f5-bf19-66e2bdbd5e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9b457dd-3234-431a-8f31-b2d0e87ad861" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_614b49ee-2181-4791-8fa5-1dea7a7fcc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_614b49ee-2181-4791-8fa5-1dea7a7fcc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eadfe60b-73e9-4c22-b60a-04f0c6cf7a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eadfe60b-73e9-4c22-b60a-04f0c6cf7a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d74b43b4-b4af-4fc6-870f-2169d51ec5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73d55f03-269a-4217-8e76-4d78626f49ce" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d74b43b4-b4af-4fc6-870f-2169d51ec5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeases"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_15ab65ec-8258-4391-b34c-f049698312cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d6f323a7-6159-4d57-acc1-df41836f09b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_15ab65ec-8258-4391-b34c-f049698312cd" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d6f323a7-6159-4d57-acc1-df41836f09b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_17ae388d-41a6-43c6-ae1a-8306cddcad51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_6fec9c69-00b7-451c-a85b-7a33b7ca1466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_17ae388d-41a6-43c6-ae1a-8306cddcad51" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_6fec9c69-00b7-451c-a85b-7a33b7ca1466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock_c22b1de3-6a2a-4eaa-a4a1-eb95f6039de9" xlink:href="mrk-20211231.xsd#mrk_AssetsandLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_17ae388d-41a6-43c6-ae1a-8306cddcad51" xlink:to="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock_c22b1de3-6a2a-4eaa-a4a1-eb95f6039de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_18fabfb8-277e-4c9a-bf61-f7194e495a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_17ae388d-41a6-43c6-ae1a-8306cddcad51" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_18fabfb8-277e-4c9a-bf61-f7194e495a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b3b1d943-57b3-4737-8d58-26c07848f787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b3b1d943-57b3-4737-8d58-26c07848f787" xlink:to="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e4a3ac1d-0448-4b23-ae7d-003a70156ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e4a3ac1d-0448-4b23-ae7d-003a70156ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64844baa-9811-42a0-a121-c19212a9e1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e4a3ac1d-0448-4b23-ae7d-003a70156ae5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64844baa-9811-42a0-a121-c19212a9e1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9cb4a7d3-7ea6-4662-8492-d74344bcfabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64844baa-9811-42a0-a121-c19212a9e1eb" xlink:to="loc_us-gaap_BuildingMember_9cb4a7d3-7ea6-4662-8492-d74344bcfabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_4b531aae-1aff-442e-a135-08f82e21ad0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64844baa-9811-42a0-a121-c19212a9e1eb" xlink:to="loc_us-gaap_VehiclesMember_4b531aae-1aff-442e-a135-08f82e21ad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_6e00e928-e9e8-4a95-9ee0-011c17af7ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_6e00e928-e9e8-4a95-9ee0-011c17af7ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_473d8755-ae8e-4e20-9277-d306dd2b03bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6e00e928-e9e8-4a95-9ee0-011c17af7ae3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_473d8755-ae8e-4e20-9277-d306dd2b03bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4f08d6d1-af9d-4890-b216-6cd192bd03f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_473d8755-ae8e-4e20-9277-d306dd2b03bc" xlink:to="loc_us-gaap_CommercialPaperMember_4f08d6d1-af9d-4890-b216-6cd192bd03f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_fd7973d4-b5ed-4383-8258-faf3def057ad" xlink:href="mrk-20211231.xsd#mrk_NotesSubjectToRepaymentAtOptionOfHolderMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_473d8755-ae8e-4e20-9277-d306dd2b03bc" xlink:to="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_fd7973d4-b5ed-4383-8258-faf3def057ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_be825ea8-1a97-4abb-9682-e752cbb9e47a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:to="loc_us-gaap_DebtInstrumentAxis_be825ea8-1a97-4abb-9682-e752cbb9e47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_be825ea8-1a97-4abb-9682-e752cbb9e47a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherVariableRateDebtMember_d8f92211-7025-42dc-9753-0ea4f6633db6" xlink:href="mrk-20211231.xsd#mrk_OtherVariableRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_OtherVariableRateDebtMember_d8f92211-7025-42dc-9753-0ea4f6633db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member_dd81b69e-93ea-429c-8ce1-f76da930e4c1" xlink:href="mrk-20211231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A63DebenturesDue2026Member_dd81b69e-93ea-429c-8ce1-f76da930e4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member_b161ed3b-3826-4eba-bcc5-5a9c28a48afe" xlink:href="mrk-20211231.xsd#mrk_A170NotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A170NotesDue2027Member_b161ed3b-3826-4eba-bcc5-5a9c28a48afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member_27633518-34a0-4e30-aaf1-3564da80600f" xlink:href="mrk-20211231.xsd#mrk_A190NotesDue2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A190NotesDue2028Member_27633518-34a0-4e30-aaf1-3564da80600f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member_ac1462a1-f67a-4d18-adf9-2af6b686874f" xlink:href="mrk-20211231.xsd#mrk_A215NotesDue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A215NotesDue2031Member_ac1462a1-f67a-4d18-adf9-2af6b686874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member_e4480d47-ed12-43be-823a-d4f4cb61cfab" xlink:href="mrk-20211231.xsd#mrk_A275NotesDue2051Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A275NotesDue2051Member_e4480d47-ed12-43be-823a-d4f4cb61cfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member_5fe2c933-0e0c-4dab-b4f4-3085a7fc1f7c" xlink:href="mrk-20211231.xsd#mrk_A290NotesDue2061Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb644efe-4102-4eaf-95a5-6a7bf5205a91" xlink:to="loc_mrk_A290NotesDue2061Member_5fe2c933-0e0c-4dab-b4f4-3085a7fc1f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8468be81-613f-47fe-8844-7ee8554b0c72" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_aa72abf6-df17-4343-995c-efa6df64c26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtCurrent_aa72abf6-df17-4343-995c-efa6df64c26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_aff4f9cc-6ecb-4b93-aaee-08d7e5ff438d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_DebtCurrent_aff4f9cc-6ecb-4b93-aaee-08d7e5ff438d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_cd88d8c5-2c9f-46dc-9f4d-9e7cfd18db5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_cd88d8c5-2c9f-46dc-9f4d-9e7cfd18db5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f4d44d37-c78f-4e7a-ac42-f2e6fc89d2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f4d44d37-c78f-4e7a-ac42-f2e6fc89d2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_a94089f9-6302-4a11-b03a-932fe705c5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_a94089f9-6302-4a11-b03a-932fe705c5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e03e3806-982d-4ea8-8b8b-b5ebf9dd937f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e03e3806-982d-4ea8-8b8b-b5ebf9dd937f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_800559f6-dd73-4b6c-84ea-e844c19e0109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_800559f6-dd73-4b6c-84ea-e844c19e0109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3fc8ef19-06b0-4ad0-8079-f2f4145071ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3fc8ef19-06b0-4ad0-8079-f2f4145071ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_03ca7204-095b-4b8d-b50c-c3214269bac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_03ca7204-095b-4b8d-b50c-c3214269bac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_29b2f43f-3bcc-45eb-9a67-4085da03d726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_29b2f43f-3bcc-45eb-9a67-4085da03d726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7a212335-7ae1-4031-b70e-4bd3230cf50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7a212335-7ae1-4031-b70e-4bd3230cf50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_22a86d32-3a67-42cc-a1a8-7edefafeae78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_22a86d32-3a67-42cc-a1a8-7edefafeae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearOne_32e727ea-c94a-405c-81b5-d4d450197541" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearOne"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearOne_32e727ea-c94a-405c-81b5-d4d450197541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearTwo_8a285c60-1cff-40fa-b4b5-945ccc8aefda" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearTwo"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearTwo_8a285c60-1cff-40fa-b4b5-945ccc8aefda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearThree_588c7c5d-cbd5-4fdb-9601-67769104375e" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearThree"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearThree_588c7c5d-cbd5-4fdb-9601-67769104375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFour_262b55ab-c323-4575-8bea-4eae0a3d9f07" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearFour"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearFour_262b55ab-c323-4575-8bea-4eae0a3d9f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFive_669ba91e-d946-4faa-88ab-702e0682b78b" xlink:href="mrk-20211231.xsd#mrk_LongTermDebtInterestPayableYearFive"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LongTermDebtInterestPayableYearFive_669ba91e-d946-4faa-88ab-702e0682b78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fb3572bd-f38f-4574-a0ab-1cb00b1096a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fb3572bd-f38f-4574-a0ab-1cb00b1096a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b1c3b1a7-2f83-4591-b01b-f9648c5f1e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b1c3b1a7-2f83-4591-b01b-f9648c5f1e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_defdbfc6-20c5-44e2-a3ad-77dcd53726a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_defdbfc6-20c5-44e2-a3ad-77dcd53726a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c54c218b-5260-4f98-b40d-8667e4b10cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_OperatingLeaseCost_c54c218b-5260-4f98-b40d-8667e4b10cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2cbcc0a6-f35b-4bed-b6fb-28013ff77e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_OperatingLeasePayments_2cbcc0a6-f35b-4bed-b6fb-28013ff77e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_49421db0-38c2-4f0a-949c-813dc71af73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_49421db0-38c2-4f0a-949c-813dc71af73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_f66e1f19-7ff9-416c-9edc-1d1ba6ce2175" xlink:href="mrk-20211231.xsd#mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0000193e-3e50-4a32-9463-c3189cd92333" xlink:to="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_f66e1f19-7ff9-416c-9edc-1d1ba6ce2175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c583b99b-6c54-4321-8732-d91ae844e4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6599cd8a-93b6-4ff7-a048-6a10efab5a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c583b99b-6c54-4321-8732-d91ae844e4d0" xlink:to="loc_us-gaap_DebtInstrumentTable_6599cd8a-93b6-4ff7-a048-6a10efab5a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca825367-a8ca-4866-844c-5bb4bcd7622c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6599cd8a-93b6-4ff7-a048-6a10efab5a6e" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca825367-a8ca-4866-844c-5bb4bcd7622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca825367-a8ca-4866-844c-5bb4bcd7622c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.75NotesDue2025Member_f18ba5b0-b771-4f8f-a61f-37df8b72229e" xlink:href="mrk-20211231.xsd#mrk_A2.75NotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.75NotesDue2025Member_f18ba5b0-b771-4f8f-a61f-37df8b72229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member_6c23613c-4866-4646-8e00-d0c16c2f1e23" xlink:href="mrk-20211231.xsd#mrk_A215NotesDue2031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A215NotesDue2031Member_6c23613c-4866-4646-8e00-d0c16c2f1e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member_c7dfee78-a803-47cc-ab5e-32b9a72c5064" xlink:href="mrk-20211231.xsd#mrk_A275NotesDue2051Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A275NotesDue2051Member_c7dfee78-a803-47cc-ab5e-32b9a72c5064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.70NotesDue2045Member_8b6724cd-00a7-4415-9d98-a136b0d83730" xlink:href="mrk-20211231.xsd#mrk_A3.70NotesDue2045Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A3.70NotesDue2045Member_8b6724cd-00a7-4415-9d98-a136b0d83730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A280NotesDue2023Member_578ed790-20a5-4e29-84fd-44efdcd4be27" xlink:href="mrk-20211231.xsd#mrk_A280NotesDue2023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A280NotesDue2023Member_578ed790-20a5-4e29-84fd-44efdcd4be27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.40NotesDue2029Member_4e14d6a9-df8a-4980-bc4f-a1528896c044" xlink:href="mrk-20211231.xsd#mrk_A3.40NotesDue2029Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A3.40NotesDue2029Member_4e14d6a9-df8a-4980-bc4f-a1528896c044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member_04f99661-5e1a-436a-b967-db273281ac32" xlink:href="mrk-20211231.xsd#mrk_A170NotesDue2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A170NotesDue2027Member_04f99661-5e1a-436a-b967-db273281ac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member_48f376bd-0304-4b7a-a3eb-31372868c924" xlink:href="mrk-20211231.xsd#mrk_A290NotesDue2061Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A290NotesDue2061Member_48f376bd-0304-4b7a-a3eb-31372868c924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A4.00NotesDue2049Member_20e9a91b-ddbd-42f9-a0e5-85c7b16d2229" xlink:href="mrk-20211231.xsd#mrk_A4.00NotesDue2049Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A4.00NotesDue2049Member_20e9a91b-ddbd-42f9-a0e5-85c7b16d2229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A415NotesDue2043Member_0fc97eb8-c8fe-444e-88e3-1c0fe07b6622" xlink:href="mrk-20211231.xsd#mrk_A415NotesDue2043Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A415NotesDue2043Member_0fc97eb8-c8fe-444e-88e3-1c0fe07b6622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A145NotesDue2030Member_f4dbae18-ce0b-418f-8645-c7cfc80ec2b3" xlink:href="mrk-20211231.xsd#mrk_A145NotesDue2030Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A145NotesDue2030Member_f4dbae18-ce0b-418f-8645-c7cfc80ec2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A245NotesDue2050Member_9d509aa4-170c-4ee2-86fa-73ea9cfc39b9" xlink:href="mrk-20211231.xsd#mrk_A245NotesDue2050Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A245NotesDue2050Member_9d509aa4-170c-4ee2-86fa-73ea9cfc39b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875EuroNotesDue2026Member_d027cf27-e09f-4dbf-8969-bd174cd9bf97" xlink:href="mrk-20211231.xsd#mrk_A1.875EuroNotesDue2026Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A1.875EuroNotesDue2026Member_d027cf27-e09f-4dbf-8969-bd174cd9bf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member_68725a6f-7633-4baa-8257-98195ff6eee1" xlink:href="mrk-20211231.xsd#mrk_A190NotesDue2028Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A190NotesDue2028Member_68725a6f-7633-4baa-8257-98195ff6eee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A075NotesDue2026Member_9d1abb75-2c10-406d-aeb9-eaef1ad1f82f" xlink:href="mrk-20211231.xsd#mrk_A075NotesDue2026Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A075NotesDue2026Member_9d1abb75-2c10-406d-aeb9-eaef1ad1f82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.90NotesDue2039Member_a5973877-b520-4758-91be-2457549b8c00" xlink:href="mrk-20211231.xsd#mrk_A3.90NotesDue2039Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A3.90NotesDue2039Member_a5973877-b520-4758-91be-2457549b8c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A235NotesDue2040Member_947ebfc0-0b60-46f4-9501-c71c3d57b551" xlink:href="mrk-20211231.xsd#mrk_A235NotesDue2040Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A235NotesDue2040Member_947ebfc0-0b60-46f4-9501-c71c3d57b551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.90NotesDue2024Member_d801ccca-c4b7-42d7-8a55-7e44ca626e16" xlink:href="mrk-20211231.xsd#mrk_A2.90NotesDue2024Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.90NotesDue2024Member_d801ccca-c4b7-42d7-8a55-7e44ca626e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_6337ac6d-5bbf-4bde-a359-8c9b24b79e2f" xlink:href="mrk-20211231.xsd#mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_6337ac6d-5bbf-4bde-a359-8c9b24b79e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.50eurodenominatednotesdue2024Member_2a9dc87c-818a-4dbd-9dfc-180643a2fe77" xlink:href="mrk-20211231.xsd#mrk_A0.50eurodenominatednotesdue2024Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A0.50eurodenominatednotesdue2024Member_2a9dc87c-818a-4dbd-9dfc-180643a2fe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375eurodenominatednotesdue2036Member_d1a813ed-75ef-4563-bf60-958eb6da4ee4" xlink:href="mrk-20211231.xsd#mrk_A1.375eurodenominatednotesdue2036Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A1.375eurodenominatednotesdue2036Member_d1a813ed-75ef-4563-bf60-958eb6da4ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.5EuroNotesDue2034Member_b2323629-0b3e-4776-a1d1-d959f6ea74ed" xlink:href="mrk-20211231.xsd#mrk_A2.5EuroNotesDue2034Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.5EuroNotesDue2034Member_b2323629-0b3e-4776-a1d1-d959f6ea74ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_7703a31a-9a9e-4dec-9e82-0d919a4b0549" xlink:href="mrk-20211231.xsd#mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_7703a31a-9a9e-4dec-9e82-0d919a4b0549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_474f44cc-080c-4b4c-8ee0-0eb409929c05" xlink:href="mrk-20211231.xsd#mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_474f44cc-080c-4b4c-8ee0-0eb409929c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_4d4b0248-888f-4f57-9756-e7d81f9d9bc5" xlink:href="mrk-20211231.xsd#mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_4d4b0248-888f-4f57-9756-e7d81f9d9bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_e759f6a8-1c3f-4b43-b350-d419cc0da2b2" xlink:href="mrk-20211231.xsd#mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_e759f6a8-1c3f-4b43-b350-d419cc0da2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_7eef6a20-5686-46f4-b4a7-04cb473696f9" xlink:href="mrk-20211231.xsd#mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_7eef6a20-5686-46f4-b4a7-04cb473696f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_d453ec36-206f-42fb-9ee1-f38970d8bf01" xlink:href="mrk-20211231.xsd#mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_d453ec36-206f-42fb-9ee1-f38970d8bf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member_fd19b664-285a-47a7-a856-400c396dea7c" xlink:href="mrk-20211231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A63DebenturesDue2026Member_fd19b664-285a-47a7-a856-400c396dea7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_d0424a15-b7a4-49d5-9137-2f6a1896840f" xlink:href="mrk-20211231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.35NotesDue2022Member_d0424a15-b7a4-49d5-9137-2f6a1896840f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_8314880c-f30f-46f5-8153-90a09452cc84" xlink:href="mrk-20211231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_A2.40NotesDue2022Member_8314880c-f30f-46f5-8153-90a09452cc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherLongTermDebtMember_a5d46610-e54f-4f19-bfcc-1881b49f4965" xlink:href="mrk-20211231.xsd#mrk_OtherLongTermDebtMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2af21827-c915-4284-8c9b-8531b0dec7e5" xlink:to="loc_mrk_OtherLongTermDebtMember_a5d46610-e54f-4f19-bfcc-1881b49f4965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0c0dc22a-2637-4fd0-a0c1-27162c6cc60c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6599cd8a-93b6-4ff7-a048-6a10efab5a6e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0c0dc22a-2637-4fd0-a0c1-27162c6cc60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_420b2720-148c-431a-8ab9-c4f4b9301631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0c0dc22a-2637-4fd0-a0c1-27162c6cc60c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_420b2720-148c-431a-8ab9-c4f4b9301631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9e40a987-674f-40f0-adf5-614240061a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0c0dc22a-2637-4fd0-a0c1-27162c6cc60c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9e40a987-674f-40f0-adf5-614240061a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a0db9b1-ec86-4e12-a380-8c558c32de66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a0db9b1-ec86-4e12-a380-8c558c32de66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_db345190-485a-4619-bc58-73a9489c8ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_db345190-485a-4619-bc58-73a9489c8ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_39bdacf6-c9d9-42e3-8e5b-d373bf273c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_39bdacf6-c9d9-42e3-8e5b-d373bf273c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_13815eb3-02fa-4553-9adf-46cce3f2d09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_13815eb3-02fa-4553-9adf-46cce3f2d09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d32469d-2b94-4ddc-b12d-430c6032d4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d32469d-2b94-4ddc-b12d-430c6032d4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_3370f002-18fd-42c6-8927-d4f491656ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_3370f002-18fd-42c6-8927-d4f491656ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_431bc159-e912-4a79-84aa-6058f97ab8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:to="loc_us-gaap_OperatingLeaseLiability_431bc159-e912-4a79-84aa-6058f97ab8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0fe26d12-950b-4bb6-b88f-087f9ac598d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0fe26d12-950b-4bb6-b88f-087f9ac598d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eed814c1-da1c-409b-9cc0-dd9a5a7ebeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6405c2fe-e774-4dfa-9fff-33fa35d40aea" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eed814c1-da1c-409b-9cc0-dd9a5a7ebeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c8ec5282-ca3d-45e3-8d99-62913d7468ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c8ec5282-ca3d-45e3-8d99-62913d7468ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_90bc81d3-6899-4ad2-a77c-009b08909633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_90bc81d3-6899-4ad2-a77c-009b08909633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d8e24e1f-a7c8-4892-bec2-aa4c3bfeaf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d8e24e1f-a7c8-4892-bec2-aa4c3bfeaf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cf8a041e-a02c-4c2d-bbf6-1c2a4acc891e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cf8a041e-a02c-4c2d-bbf6-1c2a4acc891e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f5dd9cb1-96f8-48f1-8c85-319f20f67b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f5dd9cb1-96f8-48f1-8c85-319f20f67b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7e3b4d64-0265-451b-af7d-729b9e017c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7e3b4d64-0265-451b-af7d-729b9e017c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e128960e-0329-4ba8-9ad0-ac3c3c2d5baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e128960e-0329-4ba8-9ad0-ac3c3c2d5baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b54b29b1-f238-4f8d-8aab-294f30486dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b54b29b1-f238-4f8d-8aab-294f30486dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_457ce308-09da-4ea5-a1ec-37c3ea25f0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0995864-9700-435d-a7ff-8be14cfa35f9" xlink:to="loc_us-gaap_OperatingLeaseLiability_457ce308-09da-4ea5-a1ec-37c3ea25f0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="simple" xlink:href="mrk-20211231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="simple" xlink:href="mrk-20211231.xsd#ContingenciesandEnvironmentalLiabilities"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa08de21-3654-4f74-983f-88264d4d68df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_22426ea8-89fd-4334-9a0c-95173f11b565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa08de21-3654-4f74-983f-88264d4d68df" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_22426ea8-89fd-4334-9a0c-95173f11b565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#ContingenciesandEnvironmentalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_493d29fd-d984-4c0b-91c6-d86489a9ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_493d29fd-d984-4c0b-91c6-d86489a9ec70" xlink:to="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c95e018-ba59-4972-a327-f7e99a3236ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:to="loc_srt_ProductOrServiceAxis_3c95e018-ba59-4972-a327-f7e99a3236ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3d78cfe6-e08e-4cc9-a5d8-73c0878cd237" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3c95e018-ba59-4972-a327-f7e99a3236ae" xlink:to="loc_srt_ProductsAndServicesDomain_3d78cfe6-e08e-4cc9-a5d8-73c0878cd237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember_d3923d72-615b-4a94-9a96-3b72b7adbedd" xlink:href="mrk-20211231.xsd#mrk_FosamaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3d78cfe6-e08e-4cc9-a5d8-73c0878cd237" xlink:to="loc_mrk_FosamaxMember_d3923d72-615b-4a94-9a96-3b72b7adbedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_b4137915-4cec-4da4-83cb-3cad72522b99" xlink:href="mrk-20211231.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3d78cfe6-e08e-4cc9-a5d8-73c0878cd237" xlink:to="loc_mrk_JanuviaMember_b4137915-4cec-4da4-83cb-3cad72522b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a972bfff-fbfb-4306-a3cc-c91ae6e6236f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:to="loc_srt_LitigationCaseAxis_a972bfff-fbfb-4306-a3cc-c91ae6e6236f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6c0681e5-6a19-408e-8eb9-2544551568c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a972bfff-fbfb-4306-a3cc-c91ae6e6236f" xlink:to="loc_srt_LitigationCaseTypeDomain_6c0681e5-6a19-408e-8eb9-2544551568c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember_a0eb0d0b-115e-490f-a366-03ae86d1b89b" xlink:href="mrk-20211231.xsd#mrk_FederalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6c0681e5-6a19-408e-8eb9-2544551568c0" xlink:to="loc_mrk_FederalMember_a0eb0d0b-115e-490f-a366-03ae86d1b89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherStateCourtMember_e4951a00-6077-4dbe-972f-7614eff3fa47" xlink:href="mrk-20211231.xsd#mrk_OtherStateCourtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6c0681e5-6a19-408e-8eb9-2544551568c0" xlink:to="loc_mrk_OtherStateCourtMember_e4951a00-6077-4dbe-972f-7614eff3fa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_316dbb9d-b298-49cc-b2bd-b469b52111e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_316dbb9d-b298-49cc-b2bd-b469b52111e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_316dbb9d-b298-49cc-b2bd-b469b52111e1" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_01c0ea0e-c6b2-488a-b87e-227c133a9bb7" xlink:href="mrk-20211231.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:to="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_01c0ea0e-c6b2-488a-b87e-227c133a9bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialandOtherLitigationMember_9a6c547a-b37f-4600-97ce-7265d6a239f0" xlink:href="mrk-20211231.xsd#mrk_CommercialandOtherLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:to="loc_mrk_CommercialandOtherLitigationMember_9a6c547a-b37f-4600-97ce-7265d6a239f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember_77cfad88-b652-46f2-913b-18050e5bef1a" xlink:href="mrk-20211231.xsd#mrk_PatentlitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ad4e470d-9894-42f3-bb3d-9743bead9b40" xlink:to="loc_mrk_PatentlitigationMember_77cfad88-b652-46f2-913b-18050e5bef1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_bfe978ea-e261-41af-b4c7-d04f411f5a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_bfe978ea-e261-41af-b4c7-d04f411f5a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_44d689b8-3946-4399-b43f-211f650a61b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_bfe978ea-e261-41af-b4c7-d04f411f5a78" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_44d689b8-3946-4399-b43f-211f650a61b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_89ef080b-f657-4a20-b84a-64723fb3e1ab" xlink:href="mrk-20211231.xsd#mrk_LegalDefenseCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_44d689b8-3946-4399-b43f-211f650a61b9" xlink:to="loc_mrk_LegalDefenseCostsMember_89ef080b-f657-4a20-b84a-64723fb3e1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7eab2357-3d83-48ca-8845-e0f7be90ba08" xlink:to="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_d7adc971-a9d7-41b6-b79d-839d62d92e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_d7adc971-a9d7-41b6-b79d-839d62d92e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_b0190c01-c8e5-4fc4-843c-c4fc9e7d7a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_b0190c01-c8e5-4fc4-843c-c4fc9e7d7a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber_a75e74b3-b10b-45b4-b2f8-47fdcd616042" xlink:href="mrk-20211231.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_mrk_LossContingencyClaimsonAppealNumber_a75e74b3-b10b-45b4-b2f8-47fdcd616042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ae0a6828-b066-48d4-bea5-e90c3270a780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ae0a6828-b066-48d4-bea5-e90c3270a780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_82bff538-6536-4a5c-81ee-d1883166846d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_82bff538-6536-4a5c-81ee-d1883166846d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_c1298db1-6dfd-4e8f-a194-a7701433715e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_LitigationReserve_c1298db1-6dfd-4e8f-a194-a7701433715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies_e4808a98-9eb4-4215-900b-e36e9f4797da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForEnvironmentalLossContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_AccrualForEnvironmentalLossContingencies_e4808a98-9eb4-4215-900b-e36e9f4797da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TermForPayingOffEnvironmentalLiabilities_613a6ded-c195-4ac4-bfce-eacc624ad0b0" xlink:href="mrk-20211231.xsd#mrk_TermForPayingOffEnvironmentalLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_mrk_TermForPayingOffEnvironmentalLiabilities_613a6ded-c195-4ac4-bfce-eacc624ad0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_4402b90a-24b9-4cab-9b49-074f5c7e26db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b7a7acbc-2406-43a0-8838-257307615279" xlink:to="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_4402b90a-24b9-4cab-9b49-074f5c7e26db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20211231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_03ca9da4-a171-4881-a5f1-833690f67dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b7c5cf9a-d7bb-457b-ad5d-9d315d619ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_03ca9da4-a171-4881-a5f1-833690f67dc9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b7c5cf9a-d7bb-457b-ad5d-9d315d619ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2db3ffaa-972c-4bbc-99b9-66f7e081783f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_b6968188-e612-4f6a-b982-e7f16c4eb2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2db3ffaa-972c-4bbc-99b9-66f7e081783f" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_b6968188-e612-4f6a-b982-e7f16c4eb2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8eeaf824-bb8b-4d1e-b5b9-cce68f3a15ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_34fa16d1-5c9b-4991-b0c2-e622bd1fbba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8eeaf824-bb8b-4d1e-b5b9-cce68f3a15ec" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_34fa16d1-5c9b-4991-b0c2-e622bd1fbba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_967dd1e7-4565-4767-971c-8d6079b9e272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8eeaf824-bb8b-4d1e-b5b9-cce68f3a15ec" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_967dd1e7-4565-4767-971c-8d6079b9e272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#EquityShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4a9e8cad-4b48-494c-8bd1-0770b25825dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_664791a6-9f5c-47b1-a870-a91dcb24c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4a9e8cad-4b48-494c-8bd1-0770b25825dc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_664791a6-9f5c-47b1-a870-a91dcb24c79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c154887e-eac8-41ed-b2ec-56a2a6b7ea77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_664791a6-9f5c-47b1-a870-a91dcb24c79f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c154887e-eac8-41ed-b2ec-56a2a6b7ea77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47d84557-96fa-4530-a122-f3c54b82e195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c154887e-eac8-41ed-b2ec-56a2a6b7ea77" xlink:to="loc_us-gaap_EquityComponentDomain_47d84557-96fa-4530-a122-f3c54b82e195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dd5cb4fd-3755-4c29-9f13-508440f3ab21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47d84557-96fa-4530-a122-f3c54b82e195" xlink:to="loc_us-gaap_CommonStockMember_dd5cb4fd-3755-4c29-9f13-508440f3ab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_736ab481-75d1-40e7-98e1-ba0206f5b2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47d84557-96fa-4530-a122-f3c54b82e195" xlink:to="loc_us-gaap_TreasuryStockMember_736ab481-75d1-40e7-98e1-ba0206f5b2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_efd29950-cbd2-48f6-87f3-1a8290e3c3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_664791a6-9f5c-47b1-a870-a91dcb24c79f" xlink:to="loc_us-gaap_ClassOfStockLineItems_efd29950-cbd2-48f6-87f3-1a8290e3c3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:href="mrk-20211231.xsd#mrk_MovementinCommonStockandTreasuryStockRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_efd29950-cbd2-48f6-87f3-1a8290e3c3c8" xlink:to="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_82d42fcf-7a32-4b4c-9d0e-3ab5c290fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:to="loc_us-gaap_CommonStockSharesIssued_82d42fcf-7a32-4b4c-9d0e-3ab5c290fc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_218caaea-d3bb-4c61-bf95-a3ef6f2bb6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_218caaea-d3bb-4c61-bf95-a3ef6f2bb6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_65b5c8e3-a7c2-45ad-8e06-fe40b0a81a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_65b5c8e3-a7c2-45ad-8e06-fe40b0a81a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2e516700-f3a4-4da0-b28f-04724bfaa8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_902f00ab-e1e7-48da-bf9d-ce06dacce963" xlink:to="loc_us-gaap_CommonStockSharesIssued_2e516700-f3a4-4da0-b28f-04724bfaa8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="simple" xlink:href="mrk-20211231.xsd#ShareBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b8adae9-018c-45b7-93ef-e3a5bddb4239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9a6d628d-6b6f-4d4c-b027-4d9bde745c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b8adae9-018c-45b7-93ef-e3a5bddb4239" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9a6d628d-6b6f-4d4c-b027-4d9bde745c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#ShareBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4167ddba-26bf-4a21-a651-005edbc990d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4e7c89e6-38e6-49cf-b22b-1775d4e21f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4167ddba-26bf-4a21-a651-005edbc990d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4e7c89e6-38e6-49cf-b22b-1775d4e21f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6f636409-c272-47e3-91e3-50b012baf942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4167ddba-26bf-4a21-a651-005edbc990d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6f636409-c272-47e3-91e3-50b012baf942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_4c94d563-3ad7-4b67-872f-b477854c2358" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4167ddba-26bf-4a21-a651-005edbc990d5" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_4c94d563-3ad7-4b67-872f-b477854c2358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_c9e59625-0332-422b-a29f-f6db87d3f3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4167ddba-26bf-4a21-a651-005edbc990d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_c9e59625-0332-422b-a29f-f6db87d3f3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3480e58-141a-401d-86e9-0f7ff1a4cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_418c45e5-3108-4c18-9a47-5e0aa287e06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3480e58-141a-401d-86e9-0f7ff1a4cf46" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_418c45e5-3108-4c18-9a47-5e0aa287e06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb080a11-67a6-4a62-94ed-5a04953dc2e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_418c45e5-3108-4c18-9a47-5e0aa287e06c" xlink:to="loc_srt_RangeAxis_eb080a11-67a6-4a62-94ed-5a04953dc2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c78831d-82af-4e6d-8dc8-33417a8f3788" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eb080a11-67a6-4a62-94ed-5a04953dc2e5" xlink:to="loc_srt_RangeMember_4c78831d-82af-4e6d-8dc8-33417a8f3788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a236be0b-2ad9-48fe-945f-238f5e6493f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4c78831d-82af-4e6d-8dc8-33417a8f3788" xlink:to="loc_srt_MinimumMember_a236be0b-2ad9-48fe-945f-238f5e6493f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ba257466-515f-4bf4-bdbb-277f22d9de38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4c78831d-82af-4e6d-8dc8-33417a8f3788" xlink:to="loc_srt_MaximumMember_ba257466-515f-4bf4-bdbb-277f22d9de38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_418c45e5-3108-4c18-9a47-5e0aa287e06c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1d23c3b4-d2ac-4924-a701-71c0f66e42f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1d23c3b4-d2ac-4924-a701-71c0f66e42f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5e1c0270-e30c-4c6e-83d4-dc453c7e38f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5e1c0270-e30c-4c6e-83d4-dc453c7e38f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_061c3b62-5ae4-4fe9-bc10-c77886512aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_061c3b62-5ae4-4fe9-bc10-c77886512aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0a3a0aa4-9832-474d-afb5-6a1995b4104f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0a3a0aa4-9832-474d-afb5-6a1995b4104f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1f38bda8-ea5c-4e86-a3ea-b15d4116d9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1f38bda8-ea5c-4e86-a3ea-b15d4116d9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c54563fe-5ed8-481c-8950-4062198896a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensation_c54563fe-5ed8-481c-8950-4062198896a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ca055c02-2ea1-4b06-8b29-4ad2b1b03942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ca055c02-2ea1-4b06-8b29-4ad2b1b03942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5f9abb6f-65ea-4f36-843e-c4025a95b7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5f9abb6f-65ea-4f36-843e-c4025a95b7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_768903b8-e795-4ef4-a047-001105464343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_768903b8-e795-4ef4-a047-001105464343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24606a1a-f281-4801-9e41-5e919c836bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4bb05c1-1286-447d-9645-4cc7b6833eeb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24606a1a-f281-4801-9e41-5e919c836bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ad2432a-b355-4ec7-a26d-653cc8fa4165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60e7ddb1-cbcf-479c-b3e6-efba923be57c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ad2432a-b355-4ec7-a26d-653cc8fa4165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60e7ddb1-cbcf-479c-b3e6-efba923be57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_85f37d96-6016-4a94-a9b2-b8bd06be06f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ad2432a-b355-4ec7-a26d-653cc8fa4165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_85f37d96-6016-4a94-a9b2-b8bd06be06f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5f9fb43c-4d64-483e-9943-7b46dc6b28ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ad2432a-b355-4ec7-a26d-653cc8fa4165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5f9fb43c-4d64-483e-9943-7b46dc6b28ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6b842725-2930-4620-a85e-99e422e006ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ad2432a-b355-4ec7-a26d-653cc8fa4165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6b842725-2930-4620-a85e-99e422e006ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2ad9964-7571-48ef-a482-90b51380086a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ad2432a-b355-4ec7-a26d-653cc8fa4165" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2ad9964-7571-48ef-a482-90b51380086a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d942863e-b8bc-4908-8804-be87bb53ec76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d942863e-b8bc-4908-8804-be87bb53ec76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73546e36-4593-42dc-8f70-8034f7f46597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d942863e-b8bc-4908-8804-be87bb53ec76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73546e36-4593-42dc-8f70-8034f7f46597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2625a891-77fb-47ae-844a-9e36f4cd2483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d942863e-b8bc-4908-8804-be87bb53ec76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2625a891-77fb-47ae-844a-9e36f4cd2483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3b0f30aa-9dc9-4def-b522-1a2515e45297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d942863e-b8bc-4908-8804-be87bb53ec76" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3b0f30aa-9dc9-4def-b522-1a2515e45297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_26787755-2e65-4ba1-ab09-2bcd39451888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d942863e-b8bc-4908-8804-be87bb53ec76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_26787755-2e65-4ba1-ab09-2bcd39451888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction_b1b15dea-dc70-4fda-9358-171eb6dbe73f" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d942863e-b8bc-4908-8804-be87bb53ec76" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction_b1b15dea-dc70-4fda-9358-171eb6dbe73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment_2210b4d3-d885-4112-a829-bb375ac1e8c8" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d942863e-b8bc-4908-8804-be87bb53ec76" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment_2210b4d3-d885-4112-a829-bb375ac1e8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_361285e3-cd83-4131-8855-11c758753ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d942863e-b8bc-4908-8804-be87bb53ec76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_361285e3-cd83-4131-8855-11c758753ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5f8199fa-1deb-4a63-aae7-bbd1d153160c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5f8199fa-1deb-4a63-aae7-bbd1d153160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_88bf6060-0ca8-4522-af73-a5bcb6f33653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_88bf6060-0ca8-4522-af73-a5bcb6f33653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa95412a-8ff1-4e84-9939-a767fcbf5781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa95412a-8ff1-4e84-9939-a767fcbf5781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7220886c-1616-460c-84dd-a693ee1f4e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa95412a-8ff1-4e84-9939-a767fcbf5781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7220886c-1616-460c-84dd-a693ee1f4e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fe939ec0-fadc-4e96-ba98-8df10e261b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa95412a-8ff1-4e84-9939-a767fcbf5781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fe939ec0-fadc-4e96-ba98-8df10e261b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d762755c-7fe7-4ca6-aff7-103545bc4a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa95412a-8ff1-4e84-9939-a767fcbf5781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d762755c-7fe7-4ca6-aff7-103545bc4a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_490bfd8e-eeac-4079-8969-349cf5b21a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa95412a-8ff1-4e84-9939-a767fcbf5781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_490bfd8e-eeac-4079-8969-349cf5b21a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_40bf9557-12ed-4a17-b340-0258aebe3310" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa95412a-8ff1-4e84-9939-a767fcbf5781" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_40bf9557-12ed-4a17-b340-0258aebe3310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise_d3265f52-3944-42fb-a520-2f3a643586ec" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa95412a-8ff1-4e84-9939-a767fcbf5781" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise_d3265f52-3944-42fb-a520-2f3a643586ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e73a9110-0c5b-4f22-8f98-d85f4fcfe806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa95412a-8ff1-4e84-9939-a767fcbf5781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e73a9110-0c5b-4f22-8f98-d85f4fcfe806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_db175db1-a1d0-4321-a19e-7c0b54bd41a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_db175db1-a1d0-4321-a19e-7c0b54bd41a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_73110bb3-98a5-4868-a37b-b3c25d177948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_73110bb3-98a5-4868-a37b-b3c25d177948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f865975b-1908-4dab-9aba-686e3b1e69c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f865975b-1908-4dab-9aba-686e3b1e69c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b24f4d70-0a8c-4c99-b375-f3e04c2c7e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b24f4d70-0a8c-4c99-b375-f3e04c2c7e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_73e07840-4be1-461b-8efc-5f41913ee109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_73e07840-4be1-461b-8efc-5f41913ee109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_119f52fc-4d79-42e8-bee4-bd3f0cb143d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_119f52fc-4d79-42e8-bee4-bd3f0cb143d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_92010438-b2be-42d6-80ef-3fbc21a18ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_92010438-b2be-42d6-80ef-3fbc21a18ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9e51b904-883e-4948-a436-1cefffa00609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaca0857-a12f-4d1a-95a5-c0a56a20e254" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9e51b904-883e-4948-a436-1cefffa00609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40a6647c-707c-4db7-98d5-a5de28c7bee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ebf09a13-e5bd-4014-a9a9-356cdceb27f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40a6647c-707c-4db7-98d5-a5de28c7bee8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ebf09a13-e5bd-4014-a9a9-356cdceb27f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2e8947e9-16e6-47e7-be1f-bfc2a33d02fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40a6647c-707c-4db7-98d5-a5de28c7bee8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2e8947e9-16e6-47e7-be1f-bfc2a33d02fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fcea9f45-f9b0-4ebd-941a-5250e23be7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40a6647c-707c-4db7-98d5-a5de28c7bee8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fcea9f45-f9b0-4ebd-941a-5250e23be7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_957af4d2-5324-48e0-ae3d-9e0ee0118a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9cc3ba4-6c1f-4761-86f1-04f1c03b0709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_957af4d2-5324-48e0-ae3d-9e0ee0118a24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9cc3ba4-6c1f-4761-86f1-04f1c03b0709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0db63366-d011-408a-bb9b-637bfb4a0b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9cc3ba4-6c1f-4761-86f1-04f1c03b0709" xlink:to="loc_us-gaap_AwardTypeAxis_0db63366-d011-408a-bb9b-637bfb4a0b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b04941bb-a650-4d45-a6b3-41e3f617e748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0db63366-d011-408a-bb9b-637bfb4a0b40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b04941bb-a650-4d45-a6b3-41e3f617e748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1d849aef-1ad7-4c49-ae7d-484b2dcf8655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b04941bb-a650-4d45-a6b3-41e3f617e748" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1d849aef-1ad7-4c49-ae7d-484b2dcf8655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1cd53633-f855-466a-8ff3-96e84c02ff6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b04941bb-a650-4d45-a6b3-41e3f617e748" xlink:to="loc_us-gaap_PerformanceSharesMember_1cd53633-f855-466a-8ff3-96e84c02ff6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9cc3ba4-6c1f-4761-86f1-04f1c03b0709" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9ff18790-f848-4a58-ac3a-900897e42bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9ff18790-f848-4a58-ac3a-900897e42bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ce38ea20-a131-42a6-927c-460ca72978d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ce38ea20-a131-42a6-927c-460ca72978d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1a77a54-7c45-4117-a752-3430eec9d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1a77a54-7c45-4117-a752-3430eec9d59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f2b0894c-5448-475d-9a08-584022fd9d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f2b0894c-5448-475d-9a08-584022fd9d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction_84b2a32b-7817-4e38-b401-0095e88c7845" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction_84b2a32b-7817-4e38-b401-0095e88c7845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment_e50e0e14-6d2f-42c8-b9ef-0551d7da34b9" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment_e50e0e14-6d2f-42c8-b9ef-0551d7da34b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e91d5954-29e1-4c44-8568-badd6c6a0930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d9a2aac6-c3c0-4fc4-be82-f3f55d9ea6b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e91d5954-29e1-4c44-8568-badd6c6a0930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_d1e9333f-10a8-4352-bf4c-62d66ba73774" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_d1e9333f-10a8-4352-bf4c-62d66ba73774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8a39b51-cf4a-428a-9d9a-ab0020e81100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8a39b51-cf4a-428a-9d9a-ab0020e81100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d6990328-6999-45b0-93ab-b4da24fbe758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d6990328-6999-45b0-93ab-b4da24fbe758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3a12c850-8491-44d7-ae6b-c508c36f43b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3a12c850-8491-44d7-ae6b-c508c36f43b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_494e0e4f-fd60-4e53-8078-4b2b0bae86fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_494e0e4f-fd60-4e53-8078-4b2b0bae86fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_bfa617ac-9d7e-4135-addc-ff83f1b57413" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue_bfa617ac-9d7e-4135-addc-ff83f1b57413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_c52c005b-8016-4f8b-b03a-d71733e73442" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_c52c005b-8016-4f8b-b03a-d71733e73442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_070c0dd0-5aaa-43c9-ba25-5ec94ad97319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56abd53e-0abe-4a96-b248-16bb8f6fe4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_070c0dd0-5aaa-43c9-ba25-5ec94ad97319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_1e90e4a4-04fa-49b7-879d-e527960f35b1" xlink:href="mrk-20211231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a91d7416-cb14-4edc-8827-9229cd003ee5" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_1e90e4a4-04fa-49b7-879d-e527960f35b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c2018bec-b92c-4090-a495-fb76301a1d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0fb7a102-7af4-458e-93ed-148e274eb4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c2018bec-b92c-4090-a495-fb76301a1d3d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0fb7a102-7af4-458e-93ed-148e274eb4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_519026bb-b96e-405b-9219-3b7290344da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_519026bb-b96e-405b-9219-3b7290344da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_bf14964f-723c-4ec1-9825-7282d2e79289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:to="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_bf14964f-723c-4ec1-9825-7282d2e79289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_9b26f75e-06b4-4291-a405-da3fdda882ec" xlink:href="mrk-20211231.xsd#mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:to="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_9b26f75e-06b4-4291-a405-da3fdda882ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_4b3dc37a-a946-4a56-a029-98305d0d0f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_4b3dc37a-a946-4a56-a029-98305d0d0f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_3cea7f16-0453-49e5-aaa1-5b457e3d720e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:to="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_3cea7f16-0453-49e5-aaa1-5b457e3d720e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_84921899-5e38-470b-a3f2-2a29a8d2ea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_84921899-5e38-470b-a3f2-2a29a8d2ea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_2a5fc070-5c62-4dac-9f42-088f1224da20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_2a5fc070-5c62-4dac-9f42-088f1224da20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_0b100a8f-fd3e-4aba-9602-2b95bf93b794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_0b100a8f-fd3e-4aba-9602-2b95bf93b794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_2daf48ca-fecd-4fd9-9392-25085d0260bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_14130334-718c-4551-a9d7-1bdb44e59cdf" xlink:to="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_2daf48ca-fecd-4fd9-9392-25085d0260bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_18069758-eb4f-4946-95fe-97386263a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_18069758-eb4f-4946-95fe-97386263a13b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b02f1c33-7a4f-4933-9c33-8bed7bf8a30a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b02f1c33-7a4f-4933-9c33-8bed7bf8a30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b3156859-b9df-42eb-914b-64d9ad5474a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b02f1c33-7a4f-4933-9c33-8bed7bf8a30a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b3156859-b9df-42eb-914b-64d9ad5474a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fe0bc28f-5b66-421a-9e9d-4a74ac9e3226" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b3156859-b9df-42eb-914b-64d9ad5474a6" xlink:to="loc_country_US_fe0bc28f-5b66-421a-9e9d-4a74ac9e3226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f6044966-7119-4822-a2ca-c366445df685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b3156859-b9df-42eb-914b-64d9ad5474a6" xlink:to="loc_us-gaap_ForeignPlanMember_f6044966-7119-4822-a2ca-c366445df685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_48116b4d-f084-4358-be27-7214161292e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_48116b4d-f084-4358-be27-7214161292e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_80ef40b6-35f7-4dd6-a03a-3c7a405a7705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_48116b4d-f084-4358-be27-7214161292e0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_80ef40b6-35f7-4dd6-a03a-3c7a405a7705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_35b9686f-27b1-409c-a8cf-854e5e96bb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_80ef40b6-35f7-4dd6-a03a-3c7a405a7705" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_35b9686f-27b1-409c-a8cf-854e5e96bb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f21e23da-9da4-441b-b58a-49ed922d8db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_80ef40b6-35f7-4dd6-a03a-3c7a405a7705" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f21e23da-9da4-441b-b58a-49ed922d8db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_458a3a36-cbce-4456-a0c0-c86ef68f2d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_458a3a36-cbce-4456-a0c0-c86ef68f2d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182829cb-a907-4123-a796-61c3ac652b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_458a3a36-cbce-4456-a0c0-c86ef68f2d2f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182829cb-a907-4123-a796-61c3ac652b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cff33f5d-57a5-44fe-a92f-196d501e0591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182829cb-a907-4123-a796-61c3ac652b68" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cff33f5d-57a5-44fe-a92f-196d501e0591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8bc2d37b-7992-4162-9087-5b33ae6ad955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8bc2d37b-7992-4162-9087-5b33ae6ad955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8bc2d37b-7992-4162-9087-5b33ae6ad955" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_aa25394f-1e64-4700-ae76-8780d44a760d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_aa25394f-1e64-4700-ae76-8780d44a760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_3fabe55f-9e48-4913-9a36-142ae8fa0674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_3fabe55f-9e48-4913-9a36-142ae8fa0674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeInvestmentsMember_8b875754-02e2-41e3-afdf-705e1f96ae36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:to="loc_us-gaap_FixedIncomeInvestmentsMember_8b875754-02e2-41e3-afdf-705e1f96ae36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_bb83006c-4a9a-4dd6-9484-9e2165ebf78b" xlink:href="mrk-20211231.xsd#mrk_DefinedBenefitPlanCashandOtherInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_0df966fc-41b7-4277-a003-378fbe78cc40" xlink:to="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_bb83006c-4a9a-4dd6-9484-9e2165ebf78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17110b00-98c6-4902-9fa9-64ec5992eb8e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_srt_RangeAxis_17110b00-98c6-4902-9fa9-64ec5992eb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57f682eb-ae49-4ce6-a91b-d81b1eecaba9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_17110b00-98c6-4902-9fa9-64ec5992eb8e" xlink:to="loc_srt_RangeMember_57f682eb-ae49-4ce6-a91b-d81b1eecaba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fd7dd0bc-4e98-4935-bb5d-ccbdb12cb303" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57f682eb-ae49-4ce6-a91b-d81b1eecaba9" xlink:to="loc_srt_MinimumMember_fd7dd0bc-4e98-4935-bb5d-ccbdb12cb303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_541f030b-74d9-4325-8212-47207c0fd5fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57f682eb-ae49-4ce6-a91b-d81b1eecaba9" xlink:to="loc_srt_MaximumMember_541f030b-74d9-4325-8212-47207c0fd5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7da0755d-7241-46ac-b348-187c2597de0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_srt_StatementScenarioAxis_7da0755d-7241-46ac-b348-187c2597de0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_687f37b0-af67-423d-90fe-68feda1f1f6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7da0755d-7241-46ac-b348-187c2597de0e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_687f37b0-af67-423d-90fe-68feda1f1f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0bcfe42d-3419-4d62-88d1-0abac6bdeb16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_687f37b0-af67-423d-90fe-68feda1f1f6d" xlink:to="loc_srt_ScenarioForecastMember_0bcfe42d-3419-4d62-88d1-0abac6bdeb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_320aead2-249a-4bca-8e0b-d25558d0398f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_754f12d1-08d2-40b4-9566-a71b1bc8d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_754f12d1-08d2-40b4-9566-a71b1bc8d0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1693d55b-e7ad-4d9d-95d7-73e79977a2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1693d55b-e7ad-4d9d-95d7-73e79977a2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_aba5d422-a215-4174-8b94-27fc05a966e3" xlink:href="mrk-20211231.xsd#mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_aba5d422-a215-4174-8b94-27fc05a966e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_7c3222e0-de66-496b-a582-34dd38905438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_7c3222e0-de66-496b-a582-34dd38905438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_88b96c97-3f02-4eea-8bd4-ca39a913fc0c" xlink:href="mrk-20211231.xsd#mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_88b96c97-3f02-4eea-8bd4-ca39a913fc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_b274e0ed-fadd-412d-b99b-820d1dbc292e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_b274e0ed-fadd-412d-b99b-820d1dbc292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_984c81a2-0278-4787-a45c-5641ae82dc59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_984c81a2-0278-4787-a45c-5641ae82dc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6bd4e6f3-6d23-444b-bc13-22bcd1eecd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6642db30-dbe9-4c6a-aedf-765e0112f021" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6bd4e6f3-6d23-444b-bc13-22bcd1eecd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b639933e-534b-4954-8018-c17e8726fbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9e83f4d7-6655-49ff-a460-348de1822713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b639933e-534b-4954-8018-c17e8726fbe1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9e83f4d7-6655-49ff-a460-348de1822713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_67129f32-17cf-4537-b363-b9ae728a3e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9e83f4d7-6655-49ff-a460-348de1822713" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_67129f32-17cf-4537-b363-b9ae728a3e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6d160a2e-23b3-4fa0-9a6f-868526d2bad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_67129f32-17cf-4537-b363-b9ae728a3e33" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6d160a2e-23b3-4fa0-9a6f-868526d2bad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0918d2e5-083c-4011-ae14-c82fb109db75" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6d160a2e-23b3-4fa0-9a6f-868526d2bad2" xlink:to="loc_country_US_0918d2e5-083c-4011-ae14-c82fb109db75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_20df7889-530e-4f97-b059-e674f5e0a26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6d160a2e-23b3-4fa0-9a6f-868526d2bad2" xlink:to="loc_us-gaap_ForeignPlanMember_20df7889-530e-4f97-b059-e674f5e0a26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8445afd3-100e-4892-9d30-7505c555093d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9e83f4d7-6655-49ff-a460-348de1822713" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8445afd3-100e-4892-9d30-7505c555093d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0e22947a-8d2b-4360-8aef-b55a83096419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8445afd3-100e-4892-9d30-7505c555093d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0e22947a-8d2b-4360-8aef-b55a83096419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_32402bc3-5977-46e6-b487-62724a30dd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0e22947a-8d2b-4360-8aef-b55a83096419" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_32402bc3-5977-46e6-b487-62724a30dd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_547a8ba9-1f57-4eec-a157-0b66102817d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0e22947a-8d2b-4360-8aef-b55a83096419" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_547a8ba9-1f57-4eec-a157-0b66102817d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9e83f4d7-6655-49ff-a460-348de1822713" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_c14a51da-b7fb-4e82-bfcd-121a7bf1e268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_c14a51da-b7fb-4e82-bfcd-121a7bf1e268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_175a2364-3b93-43be-8a8a-a951924a650a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_175a2364-3b93-43be-8a8a-a951924a650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_398e26ff-c1b1-49fe-84ea-5e8167d8a7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_398e26ff-c1b1-49fe-84ea-5e8167d8a7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_895abffa-74f5-4a5d-acf9-c44fb9918bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_895abffa-74f5-4a5d-acf9-c44fb9918bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7aff1387-e872-40ae-8763-0d1246b114a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7aff1387-e872-40ae-8763-0d1246b114a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_fc70fcca-a490-4875-bc57-35d14534095a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_fc70fcca-a490-4875-bc57-35d14534095a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_3c3faa32-88e0-4cdf-8bcb-b8f23f5e5f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_3c3faa32-88e0-4cdf-8bcb-b8f23f5e5f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_625857ec-c113-4946-9be7-4292e0ea7e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_625857ec-c113-4946-9be7-4292e0ea7e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d5a1e663-fee5-44ba-bbd2-511d32f51e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f2e182a1-5628-4f4d-ad5c-7ec3fb23ebd7" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d5a1e663-fee5-44ba-bbd2-511d32f51e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f968ae82-eb45-4295-94e9-cca57caec7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7285fe46-645f-4738-b663-efa77fc86d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f968ae82-eb45-4295-94e9-cca57caec7c6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7285fe46-645f-4738-b663-efa77fc86d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_45372be6-44f9-45ac-a452-3156db6493ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7285fe46-645f-4738-b663-efa77fc86d90" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_45372be6-44f9-45ac-a452-3156db6493ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_17a66500-3289-4ac8-b29e-0731efd22bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_45372be6-44f9-45ac-a452-3156db6493ed" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_17a66500-3289-4ac8-b29e-0731efd22bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f50bfeff-1276-4d64-9144-31dba3b38659" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_17a66500-3289-4ac8-b29e-0731efd22bd0" xlink:to="loc_country_US_f50bfeff-1276-4d64-9144-31dba3b38659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_bf6ee325-8602-4ee5-a51d-920928a4cf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_17a66500-3289-4ac8-b29e-0731efd22bd0" xlink:to="loc_us-gaap_ForeignPlanMember_bf6ee325-8602-4ee5-a51d-920928a4cf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cff144ed-8346-49f3-898b-f75c32bed7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7285fe46-645f-4738-b663-efa77fc86d90" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cff144ed-8346-49f3-898b-f75c32bed7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1928c416-a68e-45e4-8dba-fae831df54e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cff144ed-8346-49f3-898b-f75c32bed7ad" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1928c416-a68e-45e4-8dba-fae831df54e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2c1ec579-209e-42d6-8f34-56e3aa6a598a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1928c416-a68e-45e4-8dba-fae831df54e0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2c1ec579-209e-42d6-8f34-56e3aa6a598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_298e992a-9873-46b2-9409-b8abb8b447c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1928c416-a68e-45e4-8dba-fae831df54e0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_298e992a-9873-46b2-9409-b8abb8b447c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7285fe46-645f-4738-b663-efa77fc86d90" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2a10af77-7701-4f10-8676-6ee61800d558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2a10af77-7701-4f10-8676-6ee61800d558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_ba4750ed-7ddb-47b3-82a3-7617d3f2a9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_ba4750ed-7ddb-47b3-82a3-7617d3f2a9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_74468598-07e4-4cee-ade2-c331bb9975f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_74468598-07e4-4cee-ade2-c331bb9975f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_1073ee4d-2bec-4c1f-869c-4502ffa1cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_1073ee4d-2bec-4c1f-869c-4502ffa1cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_9135895f-3caf-4e2a-aef2-b10171dfab99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_9135895f-3caf-4e2a-aef2-b10171dfab99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_190f669b-824d-47e1-ac7b-6a3125a59090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_190f669b-824d-47e1-ac7b-6a3125a59090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_02582ee2-085e-4e7e-a7fa-c8ef61605b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_02582ee2-085e-4e7e-a7fa-c8ef61605b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_d46454fd-3f0b-4f13-85be-b8096a288e50" xlink:href="mrk-20211231.xsd#mrk_DefinedBenefitPlanOtherChangesPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_d46454fd-3f0b-4f13-85be-b8096a288e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e873bf9b-d150-4d2c-a270-3c78b10309f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_ef993c0e-42d5-4bcb-8218-705afe1f2f26" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e873bf9b-d150-4d2c-a270-3c78b10309f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ede18b47-1ebc-4bf7-b081-41724de7fb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ede18b47-1ebc-4bf7-b081-41724de7fb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_e8126e31-9b6b-4751-8538-9accaa0c651b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_e8126e31-9b6b-4751-8538-9accaa0c651b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_0c6f18b2-655a-414f-80ab-6a510df9edf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_0c6f18b2-655a-414f-80ab-6a510df9edf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4c521a2e-d983-4b4c-99d3-cada94ffcc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_4c521a2e-d983-4b4c-99d3-cada94ffcc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_f2f298f7-bdb2-4e59-a056-7edeeeeb38aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_f2f298f7-bdb2-4e59-a056-7edeeeeb38aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4a698e72-639e-4559-9b07-bccf71e0f267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4a698e72-639e-4559-9b07-bccf71e0f267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_a7bd3623-5645-4666-9937-b477ea56b105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_a7bd3623-5645-4666-9937-b477ea56b105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_47c03ce2-5988-49b6-8168-e3967487015f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_47c03ce2-5988-49b6-8168-e3967487015f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_61aebb73-8ea9-44cb-89be-3bcc354e424a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_61aebb73-8ea9-44cb-89be-3bcc354e424a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_352d06f3-e093-47f8-a8ae-6d6f9357ff6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_352d06f3-e093-47f8-a8ae-6d6f9357ff6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_f665c650-994e-4ef6-8c44-7189d625c669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_f665c650-994e-4ef6-8c44-7189d625c669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherChanges_3a9baf5b-a120-4b05-92e5-383dd12d8b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherChanges_3a9baf5b-a120-4b05-92e5-383dd12d8b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_01ef78f3-45f4-4566-9763-ac6a7b90b31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc596c96-1f8d-42b1-9f09-54bb457dd48d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_01ef78f3-45f4-4566-9763-ac6a7b90b31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_84926df1-081b-4fdd-be99-8926d8a849fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_84926df1-081b-4fdd-be99-8926d8a849fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d2ce2e00-7cdc-477f-bbff-9aae6f8d305e" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_a77156e1-4002-4d20-bc58-8533ebf73fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_a77156e1-4002-4d20-bc58-8533ebf73fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ae1e7d98-6285-4abe-a168-4e13b3d5b2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ae1e7d98-6285-4abe-a168-4e13b3d5b2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3234b17c-cabb-44d2-a55a-dc348d8b24b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_768f1c3a-57a5-482d-904d-bfa516d78790" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3234b17c-cabb-44d2-a55a-dc348d8b24b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_97748224-e979-4045-9335-6aff9e14329f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_9fd93d12-f02e-41ab-a857-41e9644047df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_97748224-e979-4045-9335-6aff9e14329f" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_9fd93d12-f02e-41ab-a857-41e9644047df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_aecedd40-9487-44d8-827e-5dfa9153bfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_9fd93d12-f02e-41ab-a857-41e9644047df" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_aecedd40-9487-44d8-827e-5dfa9153bfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5a3cd0b2-5c8a-4dba-87db-0a59fe5b51e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_aecedd40-9487-44d8-827e-5dfa9153bfdb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5a3cd0b2-5c8a-4dba-87db-0a59fe5b51e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4d87c011-8746-42b8-b438-a63434f22c67" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5a3cd0b2-5c8a-4dba-87db-0a59fe5b51e5" xlink:to="loc_country_US_4d87c011-8746-42b8-b438-a63434f22c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9e7331fb-268c-46c5-96ce-2e9525499f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5a3cd0b2-5c8a-4dba-87db-0a59fe5b51e5" xlink:to="loc_us-gaap_ForeignPlanMember_9e7331fb-268c-46c5-96ce-2e9525499f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_623413b7-547a-4e3f-b711-d1e91bc382f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_9fd93d12-f02e-41ab-a857-41e9644047df" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_623413b7-547a-4e3f-b711-d1e91bc382f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ea7f6e37-ae87-4060-a8b1-44ac329e51f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_623413b7-547a-4e3f-b711-d1e91bc382f1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ea7f6e37-ae87-4060-a8b1-44ac329e51f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_289020eb-635c-48a0-b757-1ec8eb9061e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ea7f6e37-ae87-4060-a8b1-44ac329e51f1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_289020eb-635c-48a0-b757-1ec8eb9061e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_9fd93d12-f02e-41ab-a857-41e9644047df" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_59fa8904-18eb-4786-80fc-40ef2d70e2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_59fa8904-18eb-4786-80fc-40ef2d70e2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_a24e8d5c-3ac0-4adf-8109-b474ad5d1211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_a24e8d5c-3ac0-4adf-8109-b474ad5d1211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_4f67c0bb-f7ff-4ffb-be2c-6d99b337f6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_4f67c0bb-f7ff-4ffb-be2c-6d99b337f6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_7ab60a30-ebab-4581-8161-41e31e6b175a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_dda7d5e7-6d4a-49b2-9a2e-4a35b69d6203" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_7ab60a30-ebab-4581-8161-41e31e6b175a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fbc91e6d-4cfe-4b06-ba98-4d56e2476754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fbc91e6d-4cfe-4b06-ba98-4d56e2476754" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_9c8b5aee-e28f-4c89-aa60-dd992e1f2672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_9c8b5aee-e28f-4c89-aa60-dd992e1f2672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_4540510f-170f-46b3-b980-f8861b4b935e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_9c8b5aee-e28f-4c89-aa60-dd992e1f2672" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_4540510f-170f-46b3-b980-f8861b4b935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ac6c2cd9-df60-4e55-8ef9-becf52646371" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_4540510f-170f-46b3-b980-f8861b4b935e" xlink:to="loc_country_US_ac6c2cd9-df60-4e55-8ef9-becf52646371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e52c4883-5adb-4b69-8304-fbc063ad1309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_4540510f-170f-46b3-b980-f8861b4b935e" xlink:to="loc_us-gaap_ForeignPlanMember_e52c4883-5adb-4b69-8304-fbc063ad1309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_d7f06573-abab-48bb-9883-8c35c8fe9e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_d7f06573-abab-48bb-9883-8c35c8fe9e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8aada899-d6a6-4b5b-9922-0c8f474beed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d7f06573-abab-48bb-9883-8c35c8fe9e3e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8aada899-d6a6-4b5b-9922-0c8f474beed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c529537b-51f1-49a0-9605-c2892a07980b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8aada899-d6a6-4b5b-9922-0c8f474beed9" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c529537b-51f1-49a0-9605-c2892a07980b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5be642ea-0a38-44c9-81e9-d9884ab6d70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5be642ea-0a38-44c9-81e9-d9884ab6d70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5be642ea-0a38-44c9-81e9-d9884ab6d70f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0d01e61a-4be3-48bf-a408-4cb1fae428b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0d01e61a-4be3-48bf-a408-4cb1fae428b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_73ded400-8ca2-449e-ae81-6873f51b5462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_73ded400-8ca2-449e-ae81-6873f51b5462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_299d75f4-6e0f-4079-8558-87165257ab80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_299d75f4-6e0f-4079-8558-87165257ab80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d1330d37-39de-4360-abee-5a00ec99368f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_872ba498-7ea6-4bc0-9243-85b80c3aebfe" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d1330d37-39de-4360-abee-5a00ec99368f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_48ab9264-92a4-48df-9dfd-203fd8bb04eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_48ab9264-92a4-48df-9dfd-203fd8bb04eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_48ab9264-92a4-48df-9dfd-203fd8bb04eb" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_07992da9-bed0-40ba-92dd-e26e4c44e118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_07992da9-bed0-40ba-92dd-e26e4c44e118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_82f1b020-d252-4378-9134-1da563e82ae7" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_82f1b020-d252-4378-9134-1da563e82ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_1634e655-a8b5-4ec6-8849-62be95ec3eb3" xlink:href="mrk-20211231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_1634e655-a8b5-4ec6-8849-62be95ec3eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_7100adf7-cd24-4178-bd31-7818941eacdc" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_7100adf7-cd24-4178-bd31-7818941eacdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_2e63ac74-0c9f-448b-b410-5ee1813d18e4" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_2e63ac74-0c9f-448b-b410-5ee1813d18e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember_17c567e9-5507-4287-8830-5c1136bdccf3" xlink:href="mrk-20211231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_CorporateObligationsInvestmentFundsMember_17c567e9-5507-4287-8830-5c1136bdccf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_45a14fcb-45f3-49ea-a75d-e8f043157346" xlink:href="mrk-20211231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_45a14fcb-45f3-49ea-a75d-e8f043157346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_a3161f4d-0afe-4567-873d-3a07dd1aef4d" xlink:href="mrk-20211231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_a3161f4d-0afe-4567-873d-3a07dd1aef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_8baa0dbc-2731-47ec-9aee-dac59a648e27" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_8baa0dbc-2731-47ec-9aee-dac59a648e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_4419e604-a3da-4a38-b00b-787a4b02314b" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_4419e604-a3da-4a38-b00b-787a4b02314b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_0147ed09-1a39-4cdc-8ff5-28ed49c855fa" xlink:href="mrk-20211231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_0147ed09-1a39-4cdc-8ff5-28ed49c855fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_8a69ea3c-29ab-453b-9ad9-5d1cb50b34a0" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_8a69ea3c-29ab-453b-9ad9-5d1cb50b34a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_c341c353-3128-4113-8014-c3bb4db5c98f" xlink:href="mrk-20211231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_c341c353-3128-4113-8014-c3bb4db5c98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_b5451152-75e3-47fb-b1b9-80becce32d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_422e4896-0c67-4ea8-94cb-965d0752e04a" xlink:to="loc_us-gaap_OtherInvestmentsMember_b5451152-75e3-47fb-b1b9-80becce32d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eae039ed-ce7e-4889-8135-aff9178dcaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ef0b6e94-3f6f-4329-bdf8-e7941b0656bc" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eae039ed-ce7e-4889-8135-aff9178dcaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b7a5644c-e1bb-4653-a27c-5e58d423ed35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eae039ed-ce7e-4889-8135-aff9178dcaf7" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b7a5644c-e1bb-4653-a27c-5e58d423ed35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a14ca604-6f48-4fee-87c9-62eb43765985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a14ca604-6f48-4fee-87c9-62eb43765985" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_439aa0a7-466f-4720-93cd-52813d031d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_439aa0a7-466f-4720-93cd-52813d031d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9408670b-7211-45f0-a139-6c0917a72da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_439aa0a7-466f-4720-93cd-52813d031d37" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9408670b-7211-45f0-a139-6c0917a72da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7848ba85-6f6c-40b2-b96f-6c2366101bc1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9408670b-7211-45f0-a139-6c0917a72da7" xlink:to="loc_country_US_7848ba85-6f6c-40b2-b96f-6c2366101bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8463ca46-1dc0-4bbf-a6ac-763413330817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9408670b-7211-45f0-a139-6c0917a72da7" xlink:to="loc_us-gaap_ForeignPlanMember_8463ca46-1dc0-4bbf-a6ac-763413330817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bb25ab7a-84d1-4402-878e-72cf91691904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bb25ab7a-84d1-4402-878e-72cf91691904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_29676cb1-33d3-412f-a5c9-32280cf9e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bb25ab7a-84d1-4402-878e-72cf91691904" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_29676cb1-33d3-412f-a5c9-32280cf9e6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5a118fec-6aa2-4ffc-b79e-ddb0c3aa2b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_29676cb1-33d3-412f-a5c9-32280cf9e6fe" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5a118fec-6aa2-4ffc-b79e-ddb0c3aa2b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bd802a26-a5a9-4bd0-ac9e-6c9d82bdfbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bd802a26-a5a9-4bd0-ac9e-6c9d82bdfbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3ab92276-09c3-48f6-8c87-303140b0cf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bd802a26-a5a9-4bd0-ac9e-6c9d82bdfbf8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3ab92276-09c3-48f6-8c87-303140b0cf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e35a9027-2666-459b-9142-73d93e305dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3ab92276-09c3-48f6-8c87-303140b0cf5a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e35a9027-2666-459b-9142-73d93e305dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_37f256fd-e12e-43c5-8794-69c8f1e6b049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_37f256fd-e12e-43c5-8794-69c8f1e6b049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_37f256fd-e12e-43c5-8794-69c8f1e6b049" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_edfedc0b-0024-494e-b5e3-16f74676d0b5" xlink:href="mrk-20211231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_edfedc0b-0024-494e-b5e3-16f74676d0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_ddaa6268-edc9-45f6-b9a3-4e02797da8d6" xlink:href="mrk-20211231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_ddaa6268-edc9-45f6-b9a3-4e02797da8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_1b349de8-c363-437d-b8a7-e46d3492e402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_1f52d48b-3274-494b-9e40-b3a0072a42f0" xlink:to="loc_us-gaap_OtherInvestmentsMember_1b349de8-c363-437d-b8a7-e46d3492e402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8591dfe7-0d18-4acd-8a94-2b2281825d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_993ca7d4-781c-43ac-8e98-6e5cb52ec7d8" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8591dfe7-0d18-4acd-8a94-2b2281825d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8591dfe7-0d18-4acd-8a94-2b2281825d06" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_159a2fdc-4c93-49e0-95f4-3e5fd9f7fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_159a2fdc-4c93-49e0-95f4-3e5fd9f7fc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_cedb7173-0e21-4cbe-9002-ed7d13b54712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_cedb7173-0e21-4cbe-9002-ed7d13b54712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_f555893c-e486-4d68-9ec8-ef86db7ca2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_cedb7173-0e21-4cbe-9002-ed7d13b54712" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_f555893c-e486-4d68-9ec8-ef86db7ca2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_2d1410eb-ee9d-44ed-9366-c38e323b5871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_cedb7173-0e21-4cbe-9002-ed7d13b54712" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_2d1410eb-ee9d-44ed-9366-c38e323b5871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_37bf3cd8-230b-4b75-b4e8-fcf66fc1f8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_37bf3cd8-230b-4b75-b4e8-fcf66fc1f8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_f5af0b1e-a826-43d0-a945-2710fbe7ac25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_f5af0b1e-a826-43d0-a945-2710fbe7ac25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7312d52b-eace-49f3-b263-cfb11b0ea236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_8b643013-9463-4e4d-8e71-956146839350" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7312d52b-eace-49f3-b263-cfb11b0ea236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d86193f4-8098-4d8f-90cd-aff792ebbdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d86193f4-8098-4d8f-90cd-aff792ebbdc3" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7e168730-a1fd-47f2-9e98-a7b5b3248453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7e168730-a1fd-47f2-9e98-a7b5b3248453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3eb2c5c3-c46a-4aa0-8377-309975959d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7e168730-a1fd-47f2-9e98-a7b5b3248453" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3eb2c5c3-c46a-4aa0-8377-309975959d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_738d0227-f47a-4a54-a359-334e6b57707e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3eb2c5c3-c46a-4aa0-8377-309975959d1b" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_738d0227-f47a-4a54-a359-334e6b57707e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a6b5c43-6170-40df-a2c1-36c6d6bf27e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a6b5c43-6170-40df-a2c1-36c6d6bf27e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a6b5c43-6170-40df-a2c1-36c6d6bf27e1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b597943e-0284-46c9-b58c-0b62f5d69ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b597943e-0284-46c9-b58c-0b62f5d69ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_14784ceb-d8e7-4a20-9f7e-c55958e33936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_14784ceb-d8e7-4a20-9f7e-c55958e33936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_add78ca4-103f-416a-964f-9ed22c35b3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_add78ca4-103f-416a-964f-9ed22c35b3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_5d96640f-2029-4314-9cb9-615391f9efb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3d3d8ba-dedd-4f8f-a78e-30964d701354" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_5d96640f-2029-4314-9cb9-615391f9efb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d5bd7545-faf2-4d59-a724-9b9e8d0d3604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d5bd7545-faf2-4d59-a724-9b9e8d0d3604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d5bd7545-faf2-4d59-a724-9b9e8d0d3604" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_3a6941f2-92ea-451d-8d01-959e93766c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_3a6941f2-92ea-451d-8d01-959e93766c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_bec640ea-e8e0-463b-8352-e398964e0892" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_bec640ea-e8e0-463b-8352-e398964e0892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_ce09ef39-cfe7-43aa-aeee-e24a949adeed" xlink:href="mrk-20211231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_ce09ef39-cfe7-43aa-aeee-e24a949adeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_e2344894-96fa-4004-b75b-ff67b0e30a47" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_e2344894-96fa-4004-b75b-ff67b0e30a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_e9f3cf8b-b67f-4403-96e1-fad59ecaab27" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember_e9f3cf8b-b67f-4403-96e1-fad59ecaab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_9c39bcf7-4b4e-4944-894d-358dc6fab385" xlink:href="mrk-20211231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_9c39bcf7-4b4e-4944-894d-358dc6fab385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_ef9645b9-16b0-4816-a867-f9f1e31d2739" xlink:href="mrk-20211231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_ef9645b9-16b0-4816-a867-f9f1e31d2739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_c582e18d-d48d-483a-bac1-e8b4a22d46b6" xlink:href="mrk-20211231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_c582e18d-d48d-483a-bac1-e8b4a22d46b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_78129f04-bc7f-463b-90e4-7ce093e9cccf" xlink:href="mrk-20211231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8c76d15b-cb59-4b5d-8698-34779671933c" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_78129f04-bc7f-463b-90e4-7ce093e9cccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dd3655b6-bff8-4e89-a179-4993c0b40fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55641109-631c-49a0-a422-af22f734c284" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dd3655b6-bff8-4e89-a179-4993c0b40fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cbd893e0-d2c0-40d8-85a2-ef177f6606a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dd3655b6-bff8-4e89-a179-4993c0b40fc3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cbd893e0-d2c0-40d8-85a2-ef177f6606a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fe84fe1a-38fe-4862-a4e6-58b1cb61eb56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_411ea74b-69b8-4db9-906c-7217926d2fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fe84fe1a-38fe-4862-a4e6-58b1cb61eb56" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_411ea74b-69b8-4db9-906c-7217926d2fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_31eeeb01-2696-4bdc-bb62-92064f35662d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_411ea74b-69b8-4db9-906c-7217926d2fd5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_31eeeb01-2696-4bdc-bb62-92064f35662d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a7b313-c01d-49d4-af56-1b60dabc945c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_31eeeb01-2696-4bdc-bb62-92064f35662d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a7b313-c01d-49d4-af56-1b60dabc945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d2f0c73f-3e5c-4556-8822-5b60b2f57d20" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a7b313-c01d-49d4-af56-1b60dabc945c" xlink:to="loc_country_US_d2f0c73f-3e5c-4556-8822-5b60b2f57d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_91a8946b-5807-48a2-ae69-6f45b8b6eba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a7b313-c01d-49d4-af56-1b60dabc945c" xlink:to="loc_us-gaap_ForeignPlanMember_91a8946b-5807-48a2-ae69-6f45b8b6eba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4d5b16eb-22e5-4f21-a06b-f6746033315c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_411ea74b-69b8-4db9-906c-7217926d2fd5" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4d5b16eb-22e5-4f21-a06b-f6746033315c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e72e740e-546e-46b0-8f46-92c141a88119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4d5b16eb-22e5-4f21-a06b-f6746033315c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e72e740e-546e-46b0-8f46-92c141a88119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_e3987e3f-b448-4cb3-8d82-9b7839f1f3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e72e740e-546e-46b0-8f46-92c141a88119" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_e3987e3f-b448-4cb3-8d82-9b7839f1f3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e763b38d-6d11-46dd-9bec-1ce9b83f4b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e72e740e-546e-46b0-8f46-92c141a88119" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e763b38d-6d11-46dd-9bec-1ce9b83f4b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_411ea74b-69b8-4db9-906c-7217926d2fd5" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_63ca232e-f355-48b4-a8cc-c7a4412870ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_63ca232e-f355-48b4-a8cc-c7a4412870ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_3d5af504-0aac-425f-91cf-3a14f937683e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_3d5af504-0aac-425f-91cf-3a14f937683e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_e1788c33-aad5-42ad-929e-6249eccf4e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_e1788c33-aad5-42ad-929e-6249eccf4e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_e8d3f664-6ee6-42a2-a0d7-6ddfe1ffec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_e8d3f664-6ee6-42a2-a0d7-6ddfe1ffec8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_384f9e99-aa89-4458-b62f-76d37e9d11ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_384f9e99-aa89-4458-b62f-76d37e9d11ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_75f60fee-1df5-4787-aaed-f95da2aa34d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a6d3bfa4-c5e3-47d5-9fa6-986c1693263b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_75f60fee-1df5-4787-aaed-f95da2aa34d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8ad29be5-893f-4507-9e6a-a58039938203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c126c87a-072b-4586-ace8-ba4201149f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8ad29be5-893f-4507-9e6a-a58039938203" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c126c87a-072b-4586-ace8-ba4201149f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e54ce76f-c6e8-4921-9df8-4b4b722947b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c126c87a-072b-4586-ace8-ba4201149f74" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e54ce76f-c6e8-4921-9df8-4b4b722947b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c10e41db-12e6-4eca-b700-80982d87b36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e54ce76f-c6e8-4921-9df8-4b4b722947b9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c10e41db-12e6-4eca-b700-80982d87b36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b45bb5c6-a798-4ffd-b0ed-fbbf4ce66cbc" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c10e41db-12e6-4eca-b700-80982d87b36c" xlink:to="loc_country_US_b45bb5c6-a798-4ffd-b0ed-fbbf4ce66cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5c274209-0ea9-4092-ace6-dd6d80475137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c10e41db-12e6-4eca-b700-80982d87b36c" xlink:to="loc_us-gaap_ForeignPlanMember_5c274209-0ea9-4092-ace6-dd6d80475137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a87b2a44-a7f9-4229-a6ef-acf59ae5953a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c126c87a-072b-4586-ace8-ba4201149f74" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a87b2a44-a7f9-4229-a6ef-acf59ae5953a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a7867a6a-7ba1-47a6-b972-9ce57a3c7c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a87b2a44-a7f9-4229-a6ef-acf59ae5953a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a7867a6a-7ba1-47a6-b972-9ce57a3c7c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4214a997-340c-4fc4-88fe-171fee3b1285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a7867a6a-7ba1-47a6-b972-9ce57a3c7c3e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4214a997-340c-4fc4-88fe-171fee3b1285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_df7dc808-114a-4c49-a776-11c0a9e1d5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a7867a6a-7ba1-47a6-b972-9ce57a3c7c3e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_df7dc808-114a-4c49-a776-11c0a9e1d5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c126c87a-072b-4586-ace8-ba4201149f74" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_6f7d938b-fac9-44bf-bd5e-ef2243c26325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_6f7d938b-fac9-44bf-bd5e-ef2243c26325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_aa94ed66-9309-4ac2-a0aa-0c70ebb2a5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_aa94ed66-9309-4ac2-a0aa-0c70ebb2a5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_3cf0d69c-c68f-483b-aeb9-6726e3686e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_3cf0d69c-c68f-483b-aeb9-6726e3686e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_f0df9c3d-b7c8-4b83-be93-f9db88cab063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_f0df9c3d-b7c8-4b83-be93-f9db88cab063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_cdddd843-0441-4d06-8dad-a6f8cf6fb74a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_cdddd843-0441-4d06-8dad-a6f8cf6fb74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_5eaccfed-927e-446f-bdd4-5a70117c14bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb00aecc-b7a0-4b46-97aa-013c1fb0a69e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_5eaccfed-927e-446f-bdd4-5a70117c14bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8aed8ab4-5b15-427f-8364-3bed7ef478b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4a6dc6e4-48f5-4963-93e4-ec558fba5458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8aed8ab4-5b15-427f-8364-3bed7ef478b7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4a6dc6e4-48f5-4963-93e4-ec558fba5458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_a42bcece-4af8-4851-b11f-0395ab61901d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4a6dc6e4-48f5-4963-93e4-ec558fba5458" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_a42bcece-4af8-4851-b11f-0395ab61901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3808b168-9fb7-45ed-aa2b-d20d5bd074f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_a42bcece-4af8-4851-b11f-0395ab61901d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3808b168-9fb7-45ed-aa2b-d20d5bd074f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d64b9115-d9b0-41a5-9dbc-c02de0df5026" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3808b168-9fb7-45ed-aa2b-d20d5bd074f1" xlink:to="loc_country_US_d64b9115-d9b0-41a5-9dbc-c02de0df5026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_2219917f-bd26-427e-9a50-2473870227ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3808b168-9fb7-45ed-aa2b-d20d5bd074f1" xlink:to="loc_us-gaap_ForeignPlanMember_2219917f-bd26-427e-9a50-2473870227ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4cc914e7-4bc0-4a24-8ae9-232d0842b8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4a6dc6e4-48f5-4963-93e4-ec558fba5458" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4cc914e7-4bc0-4a24-8ae9-232d0842b8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fec943b8-9e41-4d43-a513-2eb16467d60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4cc914e7-4bc0-4a24-8ae9-232d0842b8fc" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fec943b8-9e41-4d43-a513-2eb16467d60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ec4471ed-b6b6-497b-9bc2-aade14129871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fec943b8-9e41-4d43-a513-2eb16467d60f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ec4471ed-b6b6-497b-9bc2-aade14129871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc1401f1-5333-4915-990e-03720321d8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4a6dc6e4-48f5-4963-93e4-ec558fba5458" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc1401f1-5333-4915-990e-03720321d8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc1401f1-5333-4915-990e-03720321d8b6" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_686a307d-b19d-45f2-a571-73d9d1026a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_686a307d-b19d-45f2-a571-73d9d1026a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3fe7521e-29ec-4b0c-87ea-854ce61a7272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3fe7521e-29ec-4b0c-87ea-854ce61a7272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_e4646dd5-0402-4e64-b7b5-aae4806707af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_e4646dd5-0402-4e64-b7b5-aae4806707af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_5e16517f-3eaf-48ac-b728-bc85c436e03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_cce4e880-3274-4dbe-86d6-89b27ac16bf5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_5e16517f-3eaf-48ac-b728-bc85c436e03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc1401f1-5333-4915-990e-03720321d8b6" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f9963f19-f1e9-422c-9111-c215ac2b2a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f9963f19-f1e9-422c-9111-c215ac2b2a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_06df836f-7a3c-4836-8158-f1a221d1b217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_06df836f-7a3c-4836-8158-f1a221d1b217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_f72707a9-ccc4-4edf-90f0-6b1c6670bc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_863c9a0a-22a4-4af8-8e24-e25f888e0f14" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_f72707a9-ccc4-4edf-90f0-6b1c6670bc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b14b5694-8f95-4886-a4da-45771cb73fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f54f429-bd97-4836-a195-10d06af9d1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b14b5694-8f95-4886-a4da-45771cb73fa1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f54f429-bd97-4836-a195-10d06af9d1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7913341a-c92e-4ed5-8ce1-e587e350231f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f54f429-bd97-4836-a195-10d06af9d1b4" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7913341a-c92e-4ed5-8ce1-e587e350231f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_814f1367-9c73-4dd8-ab18-df4f518a3de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7913341a-c92e-4ed5-8ce1-e587e350231f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_814f1367-9c73-4dd8-ab18-df4f518a3de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4c627053-b6bf-4437-94bd-82c8bc7f7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_814f1367-9c73-4dd8-ab18-df4f518a3de9" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4c627053-b6bf-4437-94bd-82c8bc7f7e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c9fc3c2a-98cd-4484-8f7e-c4804faa8532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0f54f429-bd97-4836-a195-10d06af9d1b4" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c9fc3c2a-98cd-4484-8f7e-c4804faa8532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_f467c31f-d2d2-414e-a268-3e594e828d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c9fc3c2a-98cd-4484-8f7e-c4804faa8532" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_f467c31f-d2d2-414e-a268-3e594e828d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_fbf86fbe-1523-403a-bfc5-90959317641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c9fc3c2a-98cd-4484-8f7e-c4804faa8532" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_fbf86fbe-1523-403a-bfc5-90959317641b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherIncomeExpenseNet"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_415367aa-f22f-4f27-ac62-3db8e9bdd0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_c344a61b-3aa9-4854-b703-1480e9acd270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_415367aa-f22f-4f27-ac62-3db8e9bdd0b2" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_c344a61b-3aa9-4854-b703-1480e9acd270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherIncomeExpenseNetTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_26045416-b02a-4962-9774-25b65ebb8df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_86860119-35fc-4d54-9f77-1708ddd91f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_26045416-b02a-4962-9774-25b65ebb8df0" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_86860119-35fc-4d54-9f77-1708ddd91f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_dbcc6b84-f4a1-4fee-a7ce-e7b54e13cbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_8be83475-8a0b-404c-b8fa-5cda2505d4f6" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dbcc6b84-f4a1-4fee-a7ce-e7b54e13cbb6" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_8be83475-8a0b-404c-b8fa-5cda2505d4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_49ea9a17-040e-4692-aee9-37af908e85c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_8be83475-8a0b-404c-b8fa-5cda2505d4f6" xlink:to="loc_srt_StatementScenarioAxis_49ea9a17-040e-4692-aee9-37af908e85c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_29077029-db92-456d-8a8b-24edafe92b79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_49ea9a17-040e-4692-aee9-37af908e85c0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_29077029-db92-456d-8a8b-24edafe92b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f1f1130c-be60-4221-9bd2-7a037531614b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_29077029-db92-456d-8a8b-24edafe92b79" xlink:to="loc_srt_ScenarioForecastMember_f1f1130c-be60-4221-9bd2-7a037531614b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_8be83475-8a0b-404c-b8fa-5cda2505d4f6" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b4bc43ae-f9cb-4a6b-9fed-becae5a1beab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b4bc43ae-f9cb-4a6b-9fed-becae5a1beab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bf1ca1ff-a3c9-462c-9462-63557835af6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_InterestExpense_bf1ca1ff-a3c9-462c-9462-63557835af6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_538e8548-f53c-4b18-9d5a-f5b6e6d615af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_538e8548-f53c-4b18-9d5a-f5b6e6d615af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_182372be-8a04-4cfc-8d1f-6562b9f078eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_182372be-8a04-4cfc-8d1f-6562b9f078eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_5449b027-9a26-40f1-83a8-b2b0a2937c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_5449b027-9a26-40f1-83a8-b2b0a2937c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_6da12b5b-5ed7-4951-a9b8-a9b36110e0d8" xlink:href="mrk-20211231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_6da12b5b-5ed7-4951-a9b8-a9b36110e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_01c9ae29-3f9d-4179-9749-d60a39a72cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_01c9ae29-3f9d-4179-9749-d60a39a72cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1352142f-69d3-4336-b977-bffb9c2d11a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_fdabb09f-cd66-4762-b941-ea663e271d6c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1352142f-69d3-4336-b977-bffb9c2d11a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherIncomeExpenseNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_50f2030b-aac6-4bc3-932f-5f1a896748bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_e940f4c9-0e36-4bc4-a6b8-f454c9f3d0cf" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_50f2030b-aac6-4bc3-932f-5f1a896748bf" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_e940f4c9-0e36-4bc4-a6b8-f454c9f3d0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9755dc41-fe2c-4ce7-a691-e38743ca6daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_e940f4c9-0e36-4bc4-a6b8-f454c9f3d0cf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9755dc41-fe2c-4ce7-a691-e38743ca6daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1ce93e01-8657-441c-8ada-e8006a4cd29f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9755dc41-fe2c-4ce7-a691-e38743ca6daf" xlink:to="loc_us-gaap_SegmentDomain_1ce93e01-8657-441c-8ada-e8006a4cd29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_HealthcareServicesSegmentMember_c02469f8-5de6-44d2-ab3b-d19ea48a7de4" xlink:href="mrk-20211231.xsd#mrk_HealthcareServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1ce93e01-8657-441c-8ada-e8006a4cd29f" xlink:to="loc_mrk_HealthcareServicesSegmentMember_c02469f8-5de6-44d2-ab3b-d19ea48a7de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_b550d8f6-9d93-401a-8a38-128637ca55d2" xlink:href="mrk-20211231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_e940f4c9-0e36-4bc4-a6b8-f454c9f3d0cf" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_b550d8f6-9d93-401a-8a38-128637ca55d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_78545582-823d-41d3-b86d-920e4e4bceb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_b550d8f6-9d93-401a-8a38-128637ca55d2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_78545582-823d-41d3-b86d-920e4e4bceb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_bc0b1215-33c0-406d-af56-22965ee3cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_b550d8f6-9d93-401a-8a38-128637ca55d2" xlink:to="loc_us-gaap_InterestPaid_bc0b1215-33c0-406d-af56-22965ee3cffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e6d60ced-5f60-4635-ad00-514973f8653c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_87fffc10-daf3-4585-a251-9c1277f48152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e6d60ced-5f60-4635-ad00-514973f8653c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_87fffc10-daf3-4585-a251-9c1277f48152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d0185810-fb35-4c83-b3df-26713fbb87f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2f271639-6ec3-4d91-8542-45e92ba02b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0185810-fb35-4c83-b3df-26713fbb87f5" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2f271639-6ec3-4d91-8542-45e92ba02b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_29cc8f5e-2e61-47b0-ad84-77f586efaae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0185810-fb35-4c83-b3df-26713fbb87f5" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_29cc8f5e-2e61-47b0-ad84-77f586efaae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b1340b09-8f5f-448b-90f6-34b064144f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0185810-fb35-4c83-b3df-26713fbb87f5" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b1340b09-8f5f-448b-90f6-34b064144f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b53997f9-ccbf-407d-9e50-21902476eeab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0185810-fb35-4c83-b3df-26713fbb87f5" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b53997f9-ccbf-407d-9e50-21902476eeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_168ad28c-7c90-4a00-9391-ee9a1c89586d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0185810-fb35-4c83-b3df-26713fbb87f5" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_168ad28c-7c90-4a00-9391-ee9a1c89586d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8d50c438-75af-4453-83de-ab4763b63d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_7af6a34f-1595-4fc1-8626-318155410927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d50c438-75af-4453-83de-ab4763b63d87" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_7af6a34f-1595-4fc1-8626-318155410927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_aceafc3b-6b96-46d5-a72b-a27a8ea6d67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_7af6a34f-1595-4fc1-8626-318155410927" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_aceafc3b-6b96-46d5-a72b-a27a8ea6d67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_7af6a34f-1595-4fc1-8626-318155410927" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7f1291db-77fc-40f5-b005-81d3080bc027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7f1291db-77fc-40f5-b005-81d3080bc027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_f1088ebc-0a9a-4b74-9c2f-bb8aa6d70bb5" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_f1088ebc-0a9a-4b74-9c2f-bb8aa6d70bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_ef3b35f4-1cdb-4996-933c-21d6d74ff68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_ef3b35f4-1cdb-4996-933c-21d6d74ff68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_049e7bbb-eb30-4a45-a2bb-25c74d7d133a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_049e7bbb-eb30-4a45-a2bb-25c74d7d133a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_38622e59-6678-4bd6-8088-faef7f84ac2f" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree_38622e59-6678-4bd6-8088-faef7f84ac2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_0463a7b5-2906-4b41-932e-f2dc0bb7ca0f" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_0463a7b5-2906-4b41-932e-f2dc0bb7ca0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c1013f7b-d555-454e-812d-5d5814caae29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c1013f7b-d555-454e-812d-5d5814caae29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_049c29a5-f1eb-4ea2-9c73-3e6baaf26ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_049c29a5-f1eb-4ea2-9c73-3e6baaf26ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_191b2e29-e254-4073-bb12-e6862a779b39" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments_191b2e29-e254-4073-bb12-e6862a779b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_e8447426-7ddd-41e3-b326-76f1c1d6f8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_e8447426-7ddd-41e3-b326-76f1c1d6f8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_8e878205-96ad-4531-9c90-3c8998faeca4" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_8e878205-96ad-4531-9c90-3c8998faeca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_6d34d53e-0d19-465a-9f63-a223d02c4a89" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination_6d34d53e-0d19-465a-9f63-a223d02c4a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_394ec9ac-1902-453b-acc5-983a1f47d13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_394ec9ac-1902-453b-acc5-983a1f47d13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_564c5979-41d7-4dc5-84fc-94883f86f16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_870b47f7-69f6-4204-9c37-4f35425ba815" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_564c5979-41d7-4dc5-84fc-94883f86f16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5103f830-8d56-45ab-ad11-bae477af29b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_7af6a34f-1595-4fc1-8626-318155410927" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5103f830-8d56-45ab-ad11-bae477af29b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_129a1885-a28e-4cc5-86c4-78d26942b42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d50c438-75af-4453-83de-ab4763b63d87" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_129a1885-a28e-4cc5-86c4-78d26942b42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_19ccd215-cec4-4dd8-91a6-66739f685e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_129a1885-a28e-4cc5-86c4-78d26942b42e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_19ccd215-cec4-4dd8-91a6-66739f685e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_129a1885-a28e-4cc5-86c4-78d26942b42e" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_54d27a4a-7917-472e-867b-a7a5ab571af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_54d27a4a-7917-472e-867b-a7a5ab571af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_c32aa8d2-160c-4717-94b3-3aeb36470afd" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_c32aa8d2-160c-4717-94b3-3aeb36470afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_f0d5ae9e-b651-4551-83c4-7f1dd3ddd4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_f0d5ae9e-b651-4551-83c4-7f1dd3ddd4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_97a23627-6001-4fc0-afc8-dd78439a5ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_97a23627-6001-4fc0-afc8-dd78439a5ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_7f8fe660-c036-49c4-8d91-802cfb462566" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent_7f8fe660-c036-49c4-8d91-802cfb462566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_6599ce6f-03e5-4d73-b39c-ed38110eec3a" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_6599ce6f-03e5-4d73-b39c-ed38110eec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a6cbfdb0-b253-409f-a8ee-35a9ec569e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a6cbfdb0-b253-409f-a8ee-35a9ec569e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_b716c0be-1278-41a7-b50b-4814d31020c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_b716c0be-1278-41a7-b50b-4814d31020c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_38e3d1f4-c1ad-445a-9068-60372a49ba01" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments_38e3d1f4-c1ad-445a-9068-60372a49ba01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e46069e1-249b-4b3b-926c-194060e3c513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e46069e1-249b-4b3b-926c-194060e3c513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_60471f69-9ef0-472e-ac29-7ea7c724fe41" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_60471f69-9ef0-472e-ac29-7ea7c724fe41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_1c646cd6-4ed0-4b23-9004-692c60dcd5af" xlink:href="mrk-20211231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent_1c646cd6-4ed0-4b23-9004-692c60dcd5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_3c17b17e-e046-45a1-a9f6-ccd6576e0891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_3c17b17e-e046-45a1-a9f6-ccd6576e0891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2108abb4-aaaf-4a36-aaa6-1c0c424ba02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_81d4f820-e593-4f2a-8b9b-f518911a84dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2108abb4-aaaf-4a36-aaa6-1c0c424ba02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9df1143c-8a14-4abf-9f19-bcb39130b6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_129a1885-a28e-4cc5-86c4-78d26942b42e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9df1143c-8a14-4abf-9f19-bcb39130b6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f4180c4a-ab3d-4f48-846f-2ee35ccfe728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f4180c4a-ab3d-4f48-846f-2ee35ccfe728" xlink:to="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a09c4697-3cf5-484b-8784-9230d7135bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a09c4697-3cf5-484b-8784-9230d7135bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0081bdd1-96ee-466e-9ed1-4aa0e2ecf9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a09c4697-3cf5-484b-8784-9230d7135bca" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0081bdd1-96ee-466e-9ed1-4aa0e2ecf9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxesPayableMember_7c4f76da-f4a0-4d5f-8ebc-be1f69056db0" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0081bdd1-96ee-466e-9ed1-4aa0e2ecf9cc" xlink:to="loc_mrk_IncomeTaxesPayableMember_7c4f76da-f4a0-4d5f-8ebc-be1f69056db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a4e25978-103e-4c1c-a167-5c180cc2e3da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0081bdd1-96ee-466e-9ed1-4aa0e2ecf9cc" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a4e25978-103e-4c1c-a167-5c180cc2e3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3c5d43ac-1c11-4f73-a56c-b7c6abe7682f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3c5d43ac-1c11-4f73-a56c-b7c6abe7682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_855a1562-06b1-44e9-9f53-1fb4f888b447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3c5d43ac-1c11-4f73-a56c-b7c6abe7682f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_855a1562-06b1-44e9-9f53-1fb4f888b447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_46e18fda-734c-4e43-8b6c-aeb95a109956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_855a1562-06b1-44e9-9f53-1fb4f888b447" xlink:to="loc_us-gaap_ForeignCountryMember_46e18fda-734c-4e43-8b6c-aeb95a109956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_069dae14-0221-46e0-a579-1735c634d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_855a1562-06b1-44e9-9f53-1fb4f888b447" xlink:to="loc_us-gaap_DomesticCountryMember_069dae14-0221-46e0-a579-1735c634d43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_5344fbb9-108f-41c7-bbfd-02dc7cdcf47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_5344fbb9-108f-41c7-bbfd-02dc7cdcf47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_367bc9f9-d72e-4d00-8dc7-bfce1b6d2717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5344fbb9-108f-41c7-bbfd-02dc7cdcf47b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_367bc9f9-d72e-4d00-8dc7-bfce1b6d2717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_955c91e2-c7c4-440d-b3b4-670a4ea2b04a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_367bc9f9-d72e-4d00-8dc7-bfce1b6d2717" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_955c91e2-c7c4-440d-b3b4-670a4ea2b04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_fa95994d-e2dc-4d7f-bd7b-04910da5e66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_fa95994d-e2dc-4d7f-bd7b-04910da5e66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_653598bd-4f90-4517-b583-c7d7de63aa45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_fa95994d-e2dc-4d7f-bd7b-04910da5e66a" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_653598bd-4f90-4517-b583-c7d7de63aa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_02e4dbe3-891c-42ed-bbc5-9b1a5cf2e45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_653598bd-4f90-4517-b583-c7d7de63aa45" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_02e4dbe3-891c-42ed-bbc5-9b1a5cf2e45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_c76ca971-f929-4f1a-ab6e-2d6bd7ffe8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_653598bd-4f90-4517-b583-c7d7de63aa45" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_c76ca971-f929-4f1a-ab6e-2d6bd7ffe8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxTable_ba818561-03c1-45f8-aad4-a3939c30014d" xlink:to="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_54f25b27-6793-4181-aebf-e0b659eabc28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_54f25b27-6793-4181-aebf-e0b659eabc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_729a8065-ca4a-474e-92f0-822e01b0212b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_729a8065-ca4a-474e-92f0-822e01b0212b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_1ffbade7-337c-4907-b135-0e410fe530ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_1ffbade7-337c-4907-b135-0e410fe530ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_f4ee80d7-e54a-4200-8a5c-9e08c6305b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_f4ee80d7-e54a-4200-8a5c-9e08c6305b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_abfd0ce3-078d-4a0c-8822-7c8f88aa5aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_abfd0ce3-078d-4a0c-8822-7c8f88aa5aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_fa9aa050-6557-4bf4-9697-1521d8f3adae" xlink:href="mrk-20211231.xsd#mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_fa9aa050-6557-4bf4-9697-1521d8f3adae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3219b6a1-81ee-41d0-ad45-95dd6d1e3d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3219b6a1-81ee-41d0-ad45-95dd6d1e3d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_d373eb68-f58d-46e5-be20-88bd834c158a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_IncomeTaxesPaid_d373eb68-f58d-46e5-be20-88bd834c158a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_ccf474c0-3193-4a3f-863c-6907c5d7ab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_ccf474c0-3193-4a3f-863c-6907c5d7ab7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_12270d79-ee8b-4922-8cc1-a76e9db68a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_12270d79-ee8b-4922-8cc1-a76e9db68a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c4c414b9-c2e0-479c-bc32-be584b9b4d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c4c414b9-c2e0-479c-bc32-be584b9b4d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1f15408e-96e5-4171-8b14-08ed1ddf9813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1f15408e-96e5-4171-8b14-08ed1ddf9813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ef22e8f5-e601-47a0-b105-99acb53b47a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ef22e8f5-e601-47a0-b105-99acb53b47a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a1b7dedf-bab3-4136-8308-eb69e85b771f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a1b7dedf-bab3-4136-8308-eb69e85b771f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e63c7bc5-6117-4c39-9afc-303983d3c19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e63c7bc5-6117-4c39-9afc-303983d3c19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_a735d404-124e-43fb-bc52-2e32c00af272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_e5f8ab72-5f7a-4239-a456-4633fda3a43a" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_a735d404-124e-43fb-bc52-2e32c00af272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeIncomeBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_08a53a7b-e8c0-47af-b82b-fab39cf87927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_50e1f081-0058-4566-be10-a5b6ecb362a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_08a53a7b-e8c0-47af-b82b-fab39cf87927" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_50e1f081-0058-4566-be10-a5b6ecb362a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_67b95cb5-c74d-4561-91aa-a3596a8b3026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_08a53a7b-e8c0-47af-b82b-fab39cf87927" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_67b95cb5-c74d-4561-91aa-a3596a8b3026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_60e0a17b-8a30-4bbf-91df-1337df71c802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_08a53a7b-e8c0-47af-b82b-fab39cf87927" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_60e0a17b-8a30-4bbf-91df-1337df71c802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeTaxesonIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_643615d7-34cc-4b40-9af1-869425f87608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_59330863-4b96-4aa2-8dad-7333bd9f7083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_643615d7-34cc-4b40-9af1-869425f87608" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_59330863-4b96-4aa2-8dad-7333bd9f7083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cc9d576f-a0d4-4644-82d2-7cc1ca008e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_59330863-4b96-4aa2-8dad-7333bd9f7083" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cc9d576f-a0d4-4644-82d2-7cc1ca008e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0f3bcbd8-7d45-4283-aeeb-9b37dfe31bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_59330863-4b96-4aa2-8dad-7333bd9f7083" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0f3bcbd8-7d45-4283-aeeb-9b37dfe31bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0b64eece-81fe-4769-a44b-746bb5a12a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_59330863-4b96-4aa2-8dad-7333bd9f7083" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0b64eece-81fe-4769-a44b-746bb5a12a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_385b9bac-5758-4587-b069-6aa5a93d1070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_59330863-4b96-4aa2-8dad-7333bd9f7083" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_385b9bac-5758-4587-b069-6aa5a93d1070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e7c074c-7bc2-4dfc-8c0f-724b18b8861f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_643615d7-34cc-4b40-9af1-869425f87608" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e7c074c-7bc2-4dfc-8c0f-724b18b8861f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2897d658-4300-4629-99af-3498911c2375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e7c074c-7bc2-4dfc-8c0f-724b18b8861f" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2897d658-4300-4629-99af-3498911c2375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a19edf4b-80ee-455d-9b08-94e491fbe05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e7c074c-7bc2-4dfc-8c0f-724b18b8861f" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a19edf4b-80ee-455d-9b08-94e491fbe05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3039ce44-55e4-4c39-af18-5f8c675491ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e7c074c-7bc2-4dfc-8c0f-724b18b8861f" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3039ce44-55e4-4c39-af18-5f8c675491ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aef7330a-3419-46de-a751-23fbb9a4522b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e7c074c-7bc2-4dfc-8c0f-724b18b8861f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aef7330a-3419-46de-a751-23fbb9a4522b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3ee521be-d309-404a-b536-ca0298dc7e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_643615d7-34cc-4b40-9af1-869425f87608" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3ee521be-d309-404a-b536-ca0298dc7e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeDeferredIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9f5f8b8b-443d-46a6-beda-4a8351530f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_bef3647f-e3c9-4181-baa0-0c8b0904b602" xlink:href="mrk-20211231.xsd#mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9f5f8b8b-443d-46a6-beda-4a8351530f93" xlink:to="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_bef3647f-e3c9-4181-baa0-0c8b0904b602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_290b0900-33ae-4569-a7fb-d3dc5bce17bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_bef3647f-e3c9-4181-baa0-0c8b0904b602" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_290b0900-33ae-4569-a7fb-d3dc5bce17bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_55dbb828-a96f-4a8e-8cb1-3a7d2824dff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_290b0900-33ae-4569-a7fb-d3dc5bce17bf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_55dbb828-a96f-4a8e-8cb1-3a7d2824dff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_4a4b6153-e3db-452d-82ea-377ea8fa1372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_55dbb828-a96f-4a8e-8cb1-3a7d2824dff3" xlink:to="loc_us-gaap_OtherAssetsMember_4a4b6153-e3db-452d-82ea-377ea8fa1372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:href="mrk-20211231.xsd#mrk_IncomeTaxLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_bef3647f-e3c9-4181-baa0-0c8b0904b602" xlink:to="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a8cbc2bb-b151-42a1-8388-0ec8048a1301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a8cbc2bb-b151-42a1-8388-0ec8048a1301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_659f1ebb-30d0-4f19-8891-4387bc91c8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_659f1ebb-30d0-4f19-8891-4387bc91c8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_e65126fd-2a5a-4aa0-8a85-4001bfe3efeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_e65126fd-2a5a-4aa0-8a85-4001bfe3efeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_bde84e38-3e1f-4ef6-866f-777142dcb9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_bde84e38-3e1f-4ef6-866f-777142dcb9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_048c85c9-932e-4e7f-b00e-8c339b069719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_048c85c9-932e-4e7f-b00e-8c339b069719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_5407df83-7f16-4565-b4b5-dbd927712f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_5407df83-7f16-4565-b4b5-dbd927712f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_2bb0f155-a86e-4da9-9a4a-704b1d33f959" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_2bb0f155-a86e-4da9-9a4a-704b1d33f959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_2c89e368-fc96-42bf-9ffb-90e2ab226927" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_2c89e368-fc96-42bf-9ffb-90e2ab226927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_64fd763e-21bb-4d12-8571-2db08e876a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_64fd763e-21bb-4d12-8571-2db08e876a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ca06c92a-da19-4aef-bfb3-5a2c1fe3de1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ca06c92a-da19-4aef-bfb3-5a2c1fe3de1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_817c89db-c4e1-4f80-ad7c-418975a7f102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_817c89db-c4e1-4f80-ad7c-418975a7f102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3e9ea663-3b24-45f8-98cb-7597b169b727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_3e9ea663-3b24-45f8-98cb-7597b169b727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_73aa9976-a0df-4752-98e5-11c13ee3b3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_73aa9976-a0df-4752-98e5-11c13ee3b3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_ff01be7d-a411-4f6b-bc6d-c193f22357d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_ff01be7d-a411-4f6b-bc6d-c193f22357d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a3355089-2c83-41cf-b7d5-01e75afedabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a3355089-2c83-41cf-b7d5-01e75afedabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_3d470742-8037-4eb3-b9a0-c68d8a12b586" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_3d470742-8037-4eb3-b9a0-c68d8a12b586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_ec2d9268-647a-4b00-845b-29e3862e8db5" xlink:href="mrk-20211231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_ec2d9268-647a-4b00-845b-29e3862e8db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d97c8a40-13a3-4684-82bb-d49d98cbd02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d97c8a40-13a3-4684-82bb-d49d98cbd02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_71fac289-dfda-41ec-88df-46e9789d049a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_71fac289-dfda-41ec-88df-46e9789d049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_da1da643-e6fb-4bdb-bd06-d4c0d37cbf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredTaxLiabilities_da1da643-e6fb-4bdb-bd06-d4c0d37cbf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_12658488-317b-4655-bc8c-d0154115f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_236e8646-551e-4572-b738-b6b5c62722e5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_12658488-317b-4655-bc8c-d0154115f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#TaxesonIncomeUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_20fd7d7a-9f65-4f44-953e-c3e149dd9847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_5ec0d711-a9b1-43cb-8ab0-3f676a38183d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_20fd7d7a-9f65-4f44-953e-c3e149dd9847" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_5ec0d711-a9b1-43cb-8ab0-3f676a38183d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7d47deaf-849c-4b3b-89e4-9694ad78528b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5ec0d711-a9b1-43cb-8ab0-3f676a38183d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7d47deaf-849c-4b3b-89e4-9694ad78528b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a5484e9-0553-4cd6-86ac-926938ad0a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7d47deaf-849c-4b3b-89e4-9694ad78528b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a5484e9-0553-4cd6-86ac-926938ad0a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ConsumercarebusinessMember_81d934e9-63fb-4f35-968f-9d480c7a6198" xlink:href="mrk-20211231.xsd#mrk_ConsumercarebusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a5484e9-0553-4cd6-86ac-926938ad0a3e" xlink:to="loc_mrk_ConsumercarebusinessMember_81d934e9-63fb-4f35-968f-9d480c7a6198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_ec368ece-c7d7-44cb-8879-0d47d713e7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_5ec0d711-a9b1-43cb-8ab0-3f676a38183d" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_ec368ece-c7d7-44cb-8879-0d47d713e7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ec368ece-c7d7-44cb-8879-0d47d713e7e0" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d1590b07-b062-4473-85e7-d64c83f9a7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d1590b07-b062-4473-85e7-d64c83f9a7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0e8878cf-2dfb-49d9-b587-aabe70460d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0e8878cf-2dfb-49d9-b587-aabe70460d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a1a3c3c2-8a2b-4fb0-859e-c922c497981a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a1a3c3c2-8a2b-4fb0-859e-c922c497981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_051d283f-b04a-4b51-a1f7-8acefff3b60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_051d283f-b04a-4b51-a1f7-8acefff3b60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_236bbc56-34a8-496e-96b3-4ed6f480cfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_236bbc56-34a8-496e-96b3-4ed6f480cfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_03b3887f-8c4b-4d7b-b3c5-c2889d212a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_03b3887f-8c4b-4d7b-b3c5-c2889d212a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_77bad6d6-d65f-4ef1-9d2b-2be890d9846d" xlink:href="mrk-20211231.xsd#mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_77bad6d6-d65f-4ef1-9d2b-2be890d9846d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fc5da0d0-28b8-433b-b5b4-2f8116ca1c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8049262b-b3cf-4ef5-ab92-37ba5558a786" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fc5da0d0-28b8-433b-b5b4-2f8116ca1c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_1d60a3fa-32f3-4c57-adfe-00844bd85fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ec368ece-c7d7-44cb-8879-0d47d713e7e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_1d60a3fa-32f3-4c57-adfe-00844bd85fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShare" xlink:type="simple" xlink:href="mrk-20211231.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f0110e6b-be0b-4a2b-9663-f27bcc8e3353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_66b3e48a-e40b-40f2-9650-ee24d9dd7dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f0110e6b-be0b-4a2b-9663-f27bcc8e3353" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_66b3e48a-e40b-40f2-9650-ee24d9dd7dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a1089713-0820-44e3-ad91-e8aa8938008f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c190e9d8-5b3a-4499-adba-76737b8969e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a1089713-0820-44e3-ad91-e8aa8938008f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c190e9d8-5b3a-4499-adba-76737b8969e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_0f1ed3b7-f322-4588-8c43-cdf16c33233b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_0f1ed3b7-f322-4588-8c43-cdf16c33233b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_eb67fa1f-0db3-4f9f-980d-1823ba18995e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_eb67fa1f-0db3-4f9f-980d-1823ba18995e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a02477a4-2142-492e-be15-13672a17fa46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a02477a4-2142-492e-be15-13672a17fa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c9b48b2c-a362-449f-ab6d-01cab5e80444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c9b48b2c-a362-449f-ab6d-01cab5e80444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56d95a38-8f2d-4baa-873f-eeeb44e79a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56d95a38-8f2d-4baa-873f-eeeb44e79a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1752da5f-94d5-4455-bad8-0ff6ece987cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1752da5f-94d5-4455-bad8-0ff6ece987cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_78e1bbf8-dafb-4041-be5d-cbae89e02e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_78e1bbf8-dafb-4041-be5d-cbae89e02e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_7698fa62-00a6-4f75-95f3-ae17ed661c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_7698fa62-00a6-4f75-95f3-ae17ed661c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b5597a7b-420e-495c-9f90-716e7b9ff762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7698fa62-00a6-4f75-95f3-ae17ed661c00" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b5597a7b-420e-495c-9f90-716e7b9ff762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_7e3ff6e3-2763-4204-92d8-f60ee436f6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7698fa62-00a6-4f75-95f3-ae17ed661c00" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_7e3ff6e3-2763-4204-92d8-f60ee436f6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5e4c083f-0db0-4846-9a37-e2ea316c061c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7698fa62-00a6-4f75-95f3-ae17ed661c00" xlink:to="loc_us-gaap_EarningsPerShareBasic_5e4c083f-0db0-4846-9a37-e2ea316c061c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_06aaef81-ce64-48a5-9ecb-b5f1a5786cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e07d7ae0-46e6-4b2b-8886-1a542c6402e2" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_06aaef81-ce64-48a5-9ecb-b5f1a5786cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ce394f76-9aa8-4dc1-b449-da6ab7d566ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_06aaef81-ce64-48a5-9ecb-b5f1a5786cac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ce394f76-9aa8-4dc1-b449-da6ab7d566ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_16f8416e-a3fb-44e4-ba1c-35026fee33fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_06aaef81-ce64-48a5-9ecb-b5f1a5786cac" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_16f8416e-a3fb-44e4-ba1c-35026fee33fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cdca5deb-7b2a-4ad7-abab-8378bfd9dee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_06aaef81-ce64-48a5-9ecb-b5f1a5786cac" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cdca5deb-7b2a-4ad7-abab-8378bfd9dee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9161c686-3366-4723-90bb-9619705267de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7320076a-1b5d-49ad-9e69-a1ce447475ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9161c686-3366-4723-90bb-9619705267de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7320076a-1b5d-49ad-9e69-a1ce447475ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fcf4b1ce-4d79-48bb-9287-94a4f7b587b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_26ac74aa-40df-48b8-9147-232f206e071a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fcf4b1ce-4d79-48bb-9287-94a4f7b587b4" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_26ac74aa-40df-48b8-9147-232f206e071a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e2609bf0-a19e-4109-bbcf-e542e2e0314d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8d7948d5-748e-4904-8eb0-dad2c6471d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e2609bf0-a19e-4109-bbcf-e542e2e0314d" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8d7948d5-748e-4904-8eb0-dad2c6471d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c9174385-3cb5-4188-a831-4f7844b70e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_faf1bfd7-8207-437c-a3a4-c422a38c5752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c9174385-3cb5-4188-a831-4f7844b70e9d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_faf1bfd7-8207-437c-a3a4-c422a38c5752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_56525603-77cd-4e7b-8464-03167d88bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_faf1bfd7-8207-437c-a3a4-c422a38c5752" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_56525603-77cd-4e7b-8464-03167d88bc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56525603-77cd-4e7b-8464-03167d88bc23" xlink:to="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f13147a6-522a-43c9-a4b0-2a989f7fd9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f13147a6-522a-43c9-a4b0-2a989f7fd9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a3c8fd40-e275-4c2f-860f-f02d47becc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a3c8fd40-e275-4c2f-860f-f02d47becc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanNetLossMember_d50dc625-bee1-4d98-8de6-7c907416c27e" xlink:href="mrk-20211231.xsd#mrk_PensionPlanNetLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:to="loc_mrk_PensionPlanNetLossMember_d50dc625-bee1-4d98-8de6-7c907416c27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_e2e95587-63c9-4ada-8bc2-4e0bd8b1aea9" xlink:href="mrk-20211231.xsd#mrk_OtherPostretirementBenefitPlanNetLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:to="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_e2e95587-63c9-4ada-8bc2-4e0bd8b1aea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanPriorServiceCostMember_6775308e-3df4-4f08-8ca7-fcff3daa3d55" xlink:href="mrk-20211231.xsd#mrk_PensionPlanPriorServiceCostMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:to="loc_mrk_PensionPlanPriorServiceCostMember_6775308e-3df4-4f08-8ca7-fcff3daa3d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_c2ce540a-53fe-40ae-a09d-e25c53b92f79" xlink:href="mrk-20211231.xsd#mrk_OtherPostretirementBenefitPlanPriorServiceCostMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c9bb947b-64b7-44ce-8ef8-e0842a7dbeda" xlink:to="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_c2ce540a-53fe-40ae-a09d-e25c53b92f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5c4cdf79-aa5e-4918-821a-08e77946f881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5c4cdf79-aa5e-4918-821a-08e77946f881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3e1b42a3-82ac-4ab1-8695-8b2f763bb104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_952fcd6e-cced-436b-9861-3b0bbd144e86" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3e1b42a3-82ac-4ab1-8695-8b2f763bb104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6d386c98-368c-48d4-b827-8c2863a11c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_faf1bfd7-8207-437c-a3a4-c422a38c5752" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6d386c98-368c-48d4-b827-8c2863a11c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6d386c98-368c-48d4-b827-8c2863a11c5e" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2fd3756-a597-4f8d-8f4a-3286e61e279d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2fd3756-a597-4f8d-8f4a-3286e61e279d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_94b23f09-d46a-4b7d-b719-5f77749d4e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_94b23f09-d46a-4b7d-b719-5f77749d4e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_e4d61b0a-e907-43f6-a3d4-aafae70b19ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_e4d61b0a-e907-43f6-a3d4-aafae70b19ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ac3b5c8f-a9f6-41b6-b726-ac174b8400d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ac3b5c8f-a9f6-41b6-b726-ac174b8400d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_fb78560b-1085-4967-9e06-a9c77b81ddad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_fb78560b-1085-4967-9e06-a9c77b81ddad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_a59e810c-bf24-4363-aaa0-9fb8151de941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_a59e810c-bf24-4363-aaa0-9fb8151de941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3741f0db-5ee2-4157-a2c3-f1b8c36f0843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3741f0db-5ee2-4157-a2c3-f1b8c36f0843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a89372c0-da4e-4e4f-8d84-44623b6b6f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a89372c0-da4e-4e4f-8d84-44623b6b6f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_f5a90b43-c8df-437f-b0cc-bcc647d18e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_f5a90b43-c8df-437f-b0cc-bcc647d18e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c60ee20b-f8e2-47fa-9d44-45d91d7bcac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_0228e247-b85a-4f9e-96be-4b6e01a6cb8c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c60ee20b-f8e2-47fa-9d44-45d91d7bcac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_e290546b-db5f-4802-8d8f-4fde5c44e8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6d386c98-368c-48d4-b827-8c2863a11c5e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_e290546b-db5f-4802-8d8f-4fde5c44e8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_98d650c9-fca0-41d1-826b-2cccd008c720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_06bb15fa-0e9e-4f5f-92c8-35a845b139cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_98d650c9-fca0-41d1-826b-2cccd008c720" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_06bb15fa-0e9e-4f5f-92c8-35a845b139cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4e24f130-d813-43fd-85f8-9254e70059e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2b08f843-9e24-4a0b-a652-dde3fd865725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e24f130-d813-43fd-85f8-9254e70059e2" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2b08f843-9e24-4a0b-a652-dde3fd865725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_4b73fb3f-a913-4814-b189-1a2109696381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e24f130-d813-43fd-85f8-9254e70059e2" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_4b73fb3f-a913-4814-b189-1a2109696381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_36c2f7cd-00d6-4b3c-a0ca-1d7af4fb31ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e24f130-d813-43fd-85f8-9254e70059e2" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_36c2f7cd-00d6-4b3c-a0ca-1d7af4fb31ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_16b05eb5-ca56-4d1c-9a61-0cbfe11a7d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e24f130-d813-43fd-85f8-9254e70059e2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_16b05eb5-ca56-4d1c-9a61-0cbfe11a7d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_6cbadcfa-1ec3-41e9-876d-27d4c629ab0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e24f130-d813-43fd-85f8-9254e70059e2" xlink:to="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_6cbadcfa-1ec3-41e9-876d-27d4c629ab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_66add024-f42d-42b8-89da-00562e230510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c44b639d-1536-4767-8a79-ec7d3216f458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_66add024-f42d-42b8-89da-00562e230510" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c44b639d-1536-4767-8a79-ec7d3216f458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_dc659108-84d7-4a7b-a607-0abca50622f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_dc659108-84d7-4a7b-a607-0abca50622f7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9718d11b-80c2-407c-aa66-d3a77ea0d837" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:to="loc_srt_StatementGeographicalAxis_9718d11b-80c2-407c-aa66-d3a77ea0d837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d7eae7a3-c60d-4255-8fd7-e5aa2837f95e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9718d11b-80c2-407c-aa66-d3a77ea0d837" xlink:to="loc_srt_SegmentGeographicalDomain_d7eae7a3-c60d-4255-8fd7-e5aa2837f95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4f6581f4-9eb8-4a09-bed0-88e0bae86609" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d7eae7a3-c60d-4255-8fd7-e5aa2837f95e" xlink:to="loc_country_US_4f6581f4-9eb8-4a09-bed0-88e0bae86609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_3fea92bb-fba2-43fb-a165-267df81e9ee7" xlink:href="mrk-20211231.xsd#mrk_InternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d7eae7a3-c60d-4255-8fd7-e5aa2837f95e" xlink:to="loc_mrk_InternationalMember_3fea92bb-fba2-43fb-a165-267df81e9ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_82df3c9d-8b49-4421-a342-a19c13d747c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:to="loc_srt_ConsolidationItemsAxis_82df3c9d-8b49-4421-a342-a19c13d747c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_998095a2-33ee-4a9a-9e00-c265fa77f9a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_82df3c9d-8b49-4421-a342-a19c13d747c7" xlink:to="loc_srt_ConsolidationItemsDomain_998095a2-33ee-4a9a-9e00-c265fa77f9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_b1e5c115-fa46-45e8-9c4e-7d91b0e0c344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_998095a2-33ee-4a9a-9e00-c265fa77f9a7" xlink:to="loc_us-gaap_OperatingSegmentsMember_b1e5c115-fa46-45e8-9c4e-7d91b0e0c344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_17cd8c22-fd4a-44e1-98f2-5cccc790d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_998095a2-33ee-4a9a-9e00-c265fa77f9a7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_17cd8c22-fd4a-44e1-98f2-5cccc790d6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_62467811-6324-4bb1-9794-163bcfd063dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_62467811-6324-4bb1-9794-163bcfd063dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_62467811-6324-4bb1-9794-163bcfd063dc" xlink:to="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_3aa4c858-a901-4cef-b912-5a1169a567ce" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:to="loc_mrk_PharmaceuticalsegmentMember_3aa4c858-a901-4cef-b912-5a1169a567ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_f71378c1-f54f-44f7-a34e-7bd0cac37039" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:to="loc_mrk_AnimalHealthsegmentMember_f71378c1-f54f-44f7-a34e-7bd0cac37039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1cc78377-748e-4cac-8e4a-2bcc1907f84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9513e32a-b631-49f5-aac2-8c712c190d11" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1cc78377-748e-4cac-8e4a-2bcc1907f84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_276a5479-3980-4c01-8bb9-9ad647e672ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:to="loc_srt_ProductOrServiceAxis_276a5479-3980-4c01-8bb9-9ad647e672ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_276a5479-3980-4c01-8bb9-9ad647e672ce" xlink:to="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_6177eb29-2a39-41bb-9706-492a8fc4513a" xlink:href="mrk-20211231.xsd#mrk_KeytrudaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_KeytrudaMember_6177eb29-2a39-41bb-9706-492a8fc4513a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_533a1043-883d-47bc-ae46-19dada8c055e" xlink:href="mrk-20211231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_533a1043-883d-47bc-ae46-19dada8c055e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_8003d545-0daf-49ae-9a7b-9c4a840e4e98" xlink:href="mrk-20211231.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_LenvimaMember_8003d545-0daf-49ae-9a7b-9c4a840e4e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_33840e71-fd61-44f0-aff7-2c80be3a2d0b" xlink:href="mrk-20211231.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_GardasilGardasil9Member_33840e71-fd61-44f0-aff7-2c80be3a2d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_e44bae47-e1a5-433d-a408-c4db98d48d3b" xlink:href="mrk-20211231.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_e44bae47-e1a5-433d-a408-c4db98d48d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_84265f4d-ff60-41cf-bce8-d1419618da31" xlink:href="mrk-20211231.xsd#mrk_Pneumovax23Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_Pneumovax23Member_84265f4d-ff60-41cf-bce8-d1419618da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_1c99ddd3-9c2b-4b09-a044-f317c53ee4ed" xlink:href="mrk-20211231.xsd#mrk_RotateqMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_RotateqMember_1c99ddd3-9c2b-4b09-a044-f317c53ee4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_caa006ea-6cf2-4023-a5af-c8d1b180ea7f" xlink:href="mrk-20211231.xsd#mrk_VaqtaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_VaqtaMember_caa006ea-6cf2-4023-a5af-c8d1b180ea7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_cbac08f8-061c-4b3b-ac51-62870b972453" xlink:href="mrk-20211231.xsd#mrk_BridionMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_BridionMember_cbac08f8-061c-4b3b-ac51-62870b972453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_fa178529-b2b8-4321-a036-055bf21b71db" xlink:href="mrk-20211231.xsd#mrk_PrevymisMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_PrevymisMember_fa178529-b2b8-4321-a036-055bf21b71db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_3795d35e-66c5-4eb8-b7d4-adf023a3d00a" xlink:href="mrk-20211231.xsd#mrk_PrimaxinMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_PrimaxinMember_3795d35e-66c5-4eb8-b7d4-adf023a3d00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_8ac90a99-adf0-44f5-bb05-2569dce8b5f6" xlink:href="mrk-20211231.xsd#mrk_NoxafilMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_NoxafilMember_8ac90a99-adf0-44f5-bb05-2569dce8b5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_b6a2c6e9-1f5b-429c-aafd-fdf8fa8b62fa" xlink:href="mrk-20211231.xsd#mrk_CancidasMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_CancidasMember_b6a2c6e9-1f5b-429c-aafd-fdf8fa8b62fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_4e2f2a68-002f-45af-b136-4b6058dd53b0" xlink:href="mrk-20211231.xsd#mrk_InvanzMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_InvanzMember_4e2f2a68-002f-45af-b136-4b6058dd53b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_33694737-ba7b-48ab-afc4-c46acee8ffb9" xlink:href="mrk-20211231.xsd#mrk_ZerbaxaMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_ZerbaxaMember_33694737-ba7b-48ab-afc4-c46acee8ffb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_2f838d05-af63-4c7a-991b-174bd07e88ba" xlink:href="mrk-20211231.xsd#mrk_SimponiMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_SimponiMember_2f838d05-af63-4c7a-991b-174bd07e88ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_c1412d21-fd1e-4caf-b979-82620fc7ba50" xlink:href="mrk-20211231.xsd#mrk_RemicadeMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_RemicadeMember_c1412d21-fd1e-4caf-b979-82620fc7ba50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_92728aa2-93fe-4082-88c1-0e98ef7c4824" xlink:href="mrk-20211231.xsd#mrk_BelsomraMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_BelsomraMember_92728aa2-93fe-4082-88c1-0e98ef7c4824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MolnupiravirMember_4dd4506f-3db0-49ee-a064-6d12bde3d2e2" xlink:href="mrk-20211231.xsd#mrk_MolnupiravirMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_MolnupiravirMember_4dd4506f-3db0-49ee-a064-6d12bde3d2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_5cbe8671-ad20-48a5-89b2-5f1aa96a2d58" xlink:href="mrk-20211231.xsd#mrk_IsentressIsentressHDMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_IsentressIsentressHDMember_5cbe8671-ad20-48a5-89b2-5f1aa96a2d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember_5059a343-442f-4c96-a50c-bd4be861af5c" xlink:href="mrk-20211231.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_AllianceRevenueAdempasVerquvoMember_5059a343-442f-4c96-a50c-bd4be861af5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_6547fd5a-dada-4e7a-a536-7760500a7ef5" xlink:href="mrk-20211231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_AdempasMember_6547fd5a-dada-4e7a-a536-7760500a7ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_7f30fa89-9aec-43ce-b929-cf8b8daa33fb" xlink:href="mrk-20211231.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_JanuviaMember_7f30fa89-9aec-43ce-b929-cf8b8daa33fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_e3f7d497-1b39-42be-ba34-f212c6788c04" xlink:href="mrk-20211231.xsd#mrk_JanumetMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_JanumetMember_e3f7d497-1b39-42be-ba34-f212c6788c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_ac366c60-b81e-475f-a782-dbd11196d0ef" xlink:href="mrk-20211231.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_OtherPharmaceuticalMember_ac366c60-b81e-475f-a782-dbd11196d0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_0ad7b126-fa0d-49c0-a5a7-b4586365b1a7" xlink:href="mrk-20211231.xsd#mrk_LivestockMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_LivestockMember_0ad7b126-fa0d-49c0-a5a7-b4586365b1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_103d96b5-32e2-4d94-9ee5-9b3993555cf3" xlink:href="mrk-20211231.xsd#mrk_CompanionAnimalsMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1119e5e-10fd-45c3-a055-9cb11e8d4c2b" xlink:to="loc_mrk_CompanionAnimalsMember_103d96b5-32e2-4d94-9ee5-9b3993555cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cca8fe4e-afd7-4901-92e9-1d08a71a822b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e68dcac0-a803-477d-835d-d86e8468cdc2" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_cca8fe4e-afd7-4901-92e9-1d08a71a822b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3e0c6e99-53cd-40e6-bb59-ae49079170b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cca8fe4e-afd7-4901-92e9-1d08a71a822b" xlink:to="loc_us-gaap_Revenues_3e0c6e99-53cd-40e6-bb59-ae49079170b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2cbcf8b4-01cf-424a-a049-2d0c3c8f5e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cca8fe4e-afd7-4901-92e9-1d08a71a822b" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2cbcf8b4-01cf-424a-a049-2d0c3c8f5e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1e1876ea-1105-4157-9c97-a85d0bf3b338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d6120854-7430-4445-b916-4376070c45ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1e1876ea-1105-4157-9c97-a85d0bf3b338" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d6120854-7430-4445-b916-4376070c45ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8494d242-9c6f-4920-8718-be09e603c4ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d6120854-7430-4445-b916-4376070c45ae" xlink:to="loc_srt_StatementGeographicalAxis_8494d242-9c6f-4920-8718-be09e603c4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8494d242-9c6f-4920-8718-be09e603c4ca" xlink:to="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_165f5d35-2089-4c41-8f04-7ba7dce79419" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_country_US_165f5d35-2089-4c41-8f04-7ba7dce79419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_ba01472f-e06c-4137-add0-7c9a1d637ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_us-gaap_EMEAMember_ba01472f-e06c-4137-add0-7c9a1d637ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_fbc0778f-ed65-4e17-974a-8ac5d289a5f9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_country_CN_fbc0778f-ed65-4e17-974a-8ac5d289a5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_431af3b5-649e-4253-89a1-3c2a13cd180f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_country_JP_431af3b5-649e-4253-89a1-3c2a13cd180f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_ce620812-47d4-4b54-892b-ba17f39fcb3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_srt_AsiaPacificMember_ce620812-47d4-4b54-892b-ba17f39fcb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_72e62e58-dd69-4bf6-94e6-da6531d3a5e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_srt_LatinAmericaMember_72e62e58-dd69-4bf6-94e6-da6531d3a5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_b1ba6448-6c01-4f86-a8cf-28972fd06c90" xlink:href="mrk-20211231.xsd#mrk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ceaa9ff-df3f-4f2c-83ce-f227fe023e00" xlink:to="loc_mrk_OtherCountriesMember_b1ba6448-6c01-4f86-a8cf-28972fd06c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5238ce20-72b0-479c-b826-f39cfce2945e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d6120854-7430-4445-b916-4376070c45ae" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5238ce20-72b0-479c-b826-f39cfce2945e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_32e0ea71-00c5-4ff3-992c-4e27b44e8fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5238ce20-72b0-479c-b826-f39cfce2945e" xlink:to="loc_us-gaap_Revenues_32e0ea71-00c5-4ff3-992c-4e27b44e8fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0f26717a-e9c0-49f4-939a-b4b67b8d078d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ee2bb38-7349-4a42-be42-ef7fd8c041b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0f26717a-e9c0-49f4-939a-b4b67b8d078d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ee2bb38-7349-4a42-be42-ef7fd8c041b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3d4bb036-5248-41da-be65-95491678b95f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ee2bb38-7349-4a42-be42-ef7fd8c041b9" xlink:to="loc_srt_ConsolidationItemsAxis_3d4bb036-5248-41da-be65-95491678b95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_3d4bb036-5248-41da-be65-95491678b95f" xlink:to="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6ab9f426-c4f9-4cb5-a339-c5d347533d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:to="loc_us-gaap_OperatingSegmentsMember_6ab9f426-c4f9-4cb5-a339-c5d347533d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_dd8619df-6c24-46a9-9fe7-bb01a859e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:to="loc_us-gaap_CorporateNonSegmentMember_dd8619df-6c24-46a9-9fe7-bb01a859e0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_c60369dc-7d07-406c-be34-5bbb73078c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_89cf3dc7-498c-4eef-acf5-3f32fff56cfe" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_c60369dc-7d07-406c-be34-5bbb73078c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3a3f924b-9487-4388-bbac-8285f620792c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ee2bb38-7349-4a42-be42-ef7fd8c041b9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3a3f924b-9487-4388-bbac-8285f620792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3a3f924b-9487-4388-bbac-8285f620792c" xlink:to="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_bc340c4c-7545-4edd-8470-fe957758745d" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:to="loc_mrk_PharmaceuticalsegmentMember_bc340c4c-7545-4edd-8470-fe957758745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_6a943e6d-8676-4e83-90a2-dd4c24e16bc7" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:to="loc_mrk_AnimalHealthsegmentMember_6a943e6d-8676-4e83-90a2-dd4c24e16bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f0450e2f-7082-4318-9331-1b4da49d3430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_90128903-6fae-4c77-b4ad-83b513249f52" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f0450e2f-7082-4318-9331-1b4da49d3430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ee2bb38-7349-4a42-be42-ef7fd8c041b9" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_dad0ebc2-360b-4e5a-ba95-92e24f42759e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_InvestmentIncomeInterest_dad0ebc2-360b-4e5a-ba95-92e24f42759e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_55b8420c-a60f-480a-ac39-c42dde21af3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_InterestExpense_55b8420c-a60f-480a-ac39-c42dde21af3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_6dbb112b-1c44-4e63-8c8c-72a6e61bf711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_AdjustmentForAmortization_6dbb112b-1c44-4e63-8c8c-72a6e61bf711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9c244564-775a-498d-8930-898b74c03dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_Depreciation_9c244564-775a-498d-8930-898b74c03dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4da8ef29-6133-4f83-96a6-436b50680212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4da8ef29-6133-4f83-96a6-436b50680212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b9fe9b0a-4a1c-4984-b04f-7be3968c5d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_RestructuringCharges_b9fe9b0a-4a1c-4984-b04f-7be3968c5d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_6dfee9f6-8e14-4fd1-839e-c4fd34e6d432" xlink:href="mrk-20211231.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_6dfee9f6-8e14-4fd1-839e-c4fd34e6d432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13d93b76-01b1-4feb-9bec-acb1daa11bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f0c5bc53-0b45-49ca-a8f9-e167942d2629" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13d93b76-01b1-4feb-9bec-acb1daa11bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_afcb0743-82fc-4b4a-a43c-b4eb1bb16c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a46da3a-1ed6-48dc-8929-394bfc313c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_afcb0743-82fc-4b4a-a43c-b4eb1bb16c0e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a46da3a-1ed6-48dc-8929-394bfc313c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e175315c-e172-4d07-b96d-648e457eb38b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a46da3a-1ed6-48dc-8929-394bfc313c90" xlink:to="loc_srt_ConsolidationItemsAxis_e175315c-e172-4d07-b96d-648e457eb38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a439439b-4faa-438a-a19c-ce519c8a327c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e175315c-e172-4d07-b96d-648e457eb38b" xlink:to="loc_srt_ConsolidationItemsDomain_a439439b-4faa-438a-a19c-ce519c8a327c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_02b3dea0-613d-4fad-85da-f5f792b79e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a439439b-4faa-438a-a19c-ce519c8a327c" xlink:to="loc_us-gaap_OperatingSegmentsMember_02b3dea0-613d-4fad-85da-f5f792b79e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7a0b30cf-9535-467c-870b-ab09cb4317db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a46da3a-1ed6-48dc-8929-394bfc313c90" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7a0b30cf-9535-467c-870b-ab09cb4317db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7a0b30cf-9535-467c-870b-ab09cb4317db" xlink:to="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_aeb38f7d-feb8-457e-a11f-779c3bcc91e7" xlink:href="mrk-20211231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:to="loc_mrk_PharmaceuticalsegmentMember_aeb38f7d-feb8-457e-a11f-779c3bcc91e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_87410428-d10f-4bdb-9b4d-e3ddfb93b948" xlink:href="mrk-20211231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:to="loc_mrk_AnimalHealthsegmentMember_87410428-d10f-4bdb-9b4d-e3ddfb93b948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1886ae03-ef72-4369-a6b9-91b82f424acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cccabf02-22a9-4e46-a79c-c76fa44f2265" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1886ae03-ef72-4369-a6b9-91b82f424acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_571fd684-0323-4f10-a117-12464a906cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a46da3a-1ed6-48dc-8929-394bfc313c90" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_571fd684-0323-4f10-a117-12464a906cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a0b2b6f7-8489-45ed-8f9b-e8fd9e5ee237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_571fd684-0323-4f10-a117-12464a906cf2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a0b2b6f7-8489-45ed-8f9b-e8fd9e5ee237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0a99b2e5-3da1-4a97-aca3-1c852b0bed45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_571fd684-0323-4f10-a117-12464a906cf2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0a99b2e5-3da1-4a97-aca3-1c852b0bed45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20211231.xsd#SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b63fe47a-07e1-4574-8ab4-9d3e577af316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_82635beb-37e2-4b0c-b786-011c056a19aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b63fe47a-07e1-4574-8ab4-9d3e577af316" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_82635beb-37e2-4b0c-b786-011c056a19aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ad17b895-a11d-4dd2-b58c-9076b05424cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_82635beb-37e2-4b0c-b786-011c056a19aa" xlink:to="loc_srt_StatementGeographicalAxis_ad17b895-a11d-4dd2-b58c-9076b05424cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ad17b895-a11d-4dd2-b58c-9076b05424cd" xlink:to="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2b81dc97-30a3-4846-813c-7e0fc38a271f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_country_US_2b81dc97-30a3-4846-813c-7e0fc38a271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_a2d1ac7e-94fd-4faa-8e1b-9187afec4e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_us-gaap_EMEAMember_a2d1ac7e-94fd-4faa-8e1b-9187afec4e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_8d1aece5-492c-4032-bfda-09c318e60d50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_srt_AsiaPacificMember_8d1aece5-492c-4032-bfda-09c318e60d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_7ef1a0d8-4902-4a7b-aff8-ff418846917f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_country_CN_7ef1a0d8-4902-4a7b-aff8-ff418846917f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_a1f78acd-77bc-4fd6-9d8a-d90f16eace53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_srt_LatinAmericaMember_a1f78acd-77bc-4fd6-9d8a-d90f16eace53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_62668efa-d80d-4bb2-a86c-a9fe39d5a69e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_country_JP_62668efa-d80d-4bb2-a86c-a9fe39d5a69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_f643f42d-e005-4b42-be73-d58190c84aab" xlink:href="mrk-20211231.xsd#mrk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a84e29c5-fcc6-4022-88ce-290b82fdde73" xlink:to="loc_mrk_OtherCountriesMember_f643f42d-e005-4b42-be73-d58190c84aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_dad11bb0-c46a-4578-9a47-c19c5279b464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_82635beb-37e2-4b0c-b786-011c056a19aa" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_dad11bb0-c46a-4578-9a47-c19c5279b464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3c9c0032-8cf9-4e95-ad11-e46685cff74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_dad11bb0-c46a-4578-9a47-c19c5279b464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3c9c0032-8cf9-4e95-ad11-e46685cff74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mrk-20211231_g1.jpg
<TEXT>
begin 644 mrk-20211231_g1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M, 3@ P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ ^/?V'_V'_P!N3_@KK^W)\=_A1\*/V[O$'@C_ (0CQ!J%^[ZM
MX@U.6*6)]3FA6*-891MVX^F.*^P/^(3;_@J9_P!)=O\ RH:Y_P#'J/\ @TV_
MY2F?M=_]O'_I\GK]_J /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_T
MEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O
M_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH
M:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?
M_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZ
MOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_
MJ* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@
M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHRB[--/1GZ7A\SR[%T(UJ-6,HR5TTUJF=517*_\ "]?@C_T6/PK_ .%#;?\
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M5\!? 7CKX%^$M5T+Q'\#=?O=>T2^T&"2TU.Z@DNC%//"5V32IGAV!88'/RC
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M"3R2*\#_ ."R_P 5OAG\*_\ @G'\3[OXD^/]'T)+_P .M;V']JZC' ;J4S1
M1Q!R#(V6'RKD\U]1T5YE6K5K5'4J2<I/5MN[;\VSTZ5*E0IJG3BHQ6B25DEV
M26Q^6?\ P5 \'?'KX-_MV?!K_@J;_P $R+72?%VI_%?3KCX0>,?[,O%N--O&
MO5D_L?5II(=ZO%:W<>Z:3^Y:11;E#$CCO^"G\O[-G['W[6__  3C_9NLOB]H
M=M%\.?BC*FM2:MK<*W<2-;V:G4+_ '/F-[B:4RM+)@.\K-DY)K]?:*@T/RC_
M ."R_P"TM^S-HG_!6K]@+4O%GQT\%6^FZ!XK\57OB.YO?$=H+?3+6ZT_3UM9
M[IF?;!%*2/+>0A7P2I(!KZH\2_MV_P#!,^U^._@K7_@9\9_AEX_^+7B:7_A"
M_"N@_#_Q;87M]=6M]=VL]R\_V-I&CM;=+3[2\KC:B12!,O(%;ZTHH _'SQI)
M^PK^U3_P<Q_$;X1?'K6_AYXN\,Z[^R1'X;%GJ^HVD\3ZJ^K6Q:U@D+?N[T6\
MKLHC(F4%BN,$UZ7_ ,$]/VFY?^"37QQO/^"-?[>WQ5M=/\.:9 VH?LR?%/Q3
M>1VMKX@\.-(0-'N+ARL:7MHQ\I5)&]<*H51 )/TXHH _*7]F7Q!X<_X(M?\
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M",A@0V""#D&I?^'>/[$__1N/AS_OP_\ \576?LV?";Q-\"O@MH?PD\4_$/\
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M0WWBOXE^$+R.\T[[!>Z7+91:*+Z$F*XGDN)UG,"LY@CMY2XB,T?F<-^PK=>
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M'_@]Y_Y-9^!__90-1_\ 2$4 >?\ _!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\
MP:;?\I3/VN_^WC_T^3U^_P!0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?B#_P>\_\FL_ _P#[*!J/_I"*_;ZOQ!_X/>?^36?@?_V4#4?_
M $A% 'G_ /P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]
M?O\ 4 %%%% !1110 4444 %0V.HZ?JD)N-,OX;B-9&1G@E#@,IPRY!Z@\$=J
M\\_:E_9STS]JOX;P_!?QAXLU73O">HZI&WC33]%OYK.XUO34CD+:=]I@=)8(
MI9O(\TQL&>%)(L@2DCX'\"_L%_#7_@G;_P %R/@KX4_X)SZ1>^$?!/Q&^&OB
MJ^^.OP]T[5+B?2XK.PA@CTS4S%-(_E2R7US'"&!'$+A0-\NX _4&BOR._P""
MU_Q%^#^N?M9)I_\ P4\_8 ^-_B?]F?P-HUG'H'Q%\!WMW'I6G:M=G??ZG?+I
M]Q%,T*(;2V0R']VT5R420S+7;_\ !0/XD?!W]BG_ ()%?"+X!_\ !+[Q0=!\
M)_'3XD>'_ O@+Q3X=UJ>YN+6QURXFNKJ^ANIG>8S/$LZ"1V,D;3C&UD7: ?I
MK;7MG>&06EW%*893'+Y<@;8XZJ<=",C@^M2U^<_[<^E?#G_@EG^U/^R/\5OV
M6_ >E>"_#_CGXJ6OPE\?Z#H%FMM;:YI^IPD64]VJ >=/:7$)FCG;,O[V92Q$
MK@_HQ0 445Y?\5OCS\2OA]XN?PYX7_9E\4>*;18$D&K:3/"L+,PY3#G.1WH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OQ!_X/>?^36?@?_V4#4?_ $A%?M]7X@_\'O/_
M ":S\#_^R@:C_P"D(H \_P#^#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG
M[7?_ &\?^GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** /"_P!K
M#_DMGP/_ .Q[E_\ 29J]TKPO]K#_ )+9\#_^Q[E_])FKW2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\R_;!_:%TS]F#]GW7_ (M7;1M>VUM]GT2VD_Y>+Z3*PICN
M ?G8?W$8]J]-K\J?^"S'[3G_  L_XV6WP'\,ZAOT;P3G^T/+?*SZG(H\S/KY
M28C'<,THKX[COB-<,\.U<3%_O)>Y#_$^O_;JO+Y6ZG!F.*^J85S6[T7K_P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ^
MK:OI6@:9/K6NZG;V5G:Q&2YN[N98XH4 R69F("@=R3BOG77_ -M#Q_\ '/6;
MGX??L(?#Y/$TD,I@U'XAZZKV^@::W0[&P'NW']U!CD,-ZYKS<PS;!98HJM*\
MY?#"*<IR_P ,5J_-[+=M(QJUZ=&W,]7LEJW\CVOXL_&;X7? OPG+XW^+/C:Q
MT/38L@37DN&E;&=D:#+RO_LH"?:O"/\ A:/[7'[8_P#HOP'T.X^%7@"?A_'/
MB.S#:QJ41[V5H3B%6'21SD@AE8$%:Z?X3?L+^%='\61?&']HCQ==_$[QX,,F
ML>((Q]CTXYSLL[0?NX5!Y!P2",C;DBO=Z\SZKG&<:XN3H4O^?<'^\DO[]1?#
M_AIN_P#T\>QER5Z_Q^['LM_F^GHOO/,O@!^R1\&?V<TGU+P=HLU_X@O\G5_%
MNNSF[U._<_>:2=N0">2J;5)&2">:]-HHKW,)@\)@*"HX:"A!;)*R_P"'?5[O
MJ=$*<*<>6"L@HHHKI+"BBB@ HHHH **** "BBB@ HHHH **** "OQ!_X/>?^
M36?@?_V4#4?_ $A%?M]7X@_\'O/_ ":S\#_^R@:C_P"D(H \_P#^#3;_ )2F
M?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H **** "BBB@ HHHH
M **** "BBB@ HHHH **** /"_P!K#_DMGP/_ .Q[E_\ 29J]TKPO]K#_ )+9
M\#_^Q[E_])FKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBNB2-:5"G1U6[W;U;^?](****],V"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**
M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M K\0?^#WG_DUGX'_ /90-1_](17[?5^(/_![S_R:S\#_ /LH&H_^D(H \_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***;--#;PM<7$JI&BEG=VP% ZDD]!1L ZBO&/B7_P % ?V4?AEJ'_"/S_%&
MWU[66;9#H?A*%M3NI9/^>8$ 95;V=EKC]8_:B_;'^(6DW6M?!_\ 97M_!>AV
MUL\\WBOXO:G]D6"%5+-(]C!F90J@MG)%>#7XER>C-TX5/:36\::=1K_%RIJ/
MK)I>9S2Q="+LG=]EK^6WS.)_X+,?M.?\*P^"=M\!_#.H;-9\;9_M#RWPT&F1
ML/,SZ>:^(QV*K**_/#]D[]HO7OV6/CIHWQAT2V>ZBLW:'5=.679]MLY!MEBS
MR <89200'13VK,_:"^.?Q#_:(^*%]\2?B7XF&JW\H$$%Q':B"-+>/(C2.,?Z
MM<9..3EB2222>*K^5.*^,,5G?%/]J8:3@J;7LMKQ47=/JKMW;W6MM4?&8W'3
MQ&,]M#2VWR/U_P!$^!O[0?[:VG6GC3]J7QVGAOP'J4$=UIWPT\$ZD2+VW<!T
M-_?)S,"I!*1_*<@@H17T7X ^'7@3X5>%[?P5\./"5AHNE6BX@L=.MQ&@/=CC
M[S'NQR2>22:^3/\ @C/^TY_PL_X)W/P'\3:AOUGP3C^S_,?+3Z9(Q\O'KY3Y
MC/8*T0K[-K^F^#WEF8952S6A>=2K'WIR?-.Z^*-^B4KVC%1CU2/KL#[&K15:
M.K:U;U?I_P !:!1117UQW!1110 445RWQ7^-OPB^!?AUO%GQA^(^C^'+  [)
M]5ODB,I'58U)W2-_LH"?:IG.%.+E-V2ZLVPV&Q&,KQHT(.<Y:*,4VV^R2U?R
M.II))(XHVEE<*J@EF8X  [FOEB3]OSXO_'UVTS]@[]E_5_%%HY*IX_\ &ROI
M&@H/^>D8?$UVHXRJ!&&>E$?[ 'Q:^/DBZG^WE^T_K'BNU<AG\ >"V?2-!3_I
MG)Y>)KH#L[E'&>M>=_:/MM,+!U//X8?^!/?_ +=4C[#_ %.66^]GV)AA?^G?
M\2OZ>RB_<?E6G2.G^*W_  4J_9N\">(F^'?PZO=4^)GC Y6'PM\.; ZG/N''
M[R6/]U& >&R^Y>?EXKE_['_X*:?M1<Z[K>A_ 'PK/UL]+*:QXCFC/9ICB"WR
M,89,2(<Y!Q7T#\*?@I\(_@9X=7PG\'_ASH_AS3QC?!I-BD7FD=&D8#=(W^TQ
M)]ZZBCZGBL1_O-73^6%XKYR^)_)Q7D'^L.0Y1IDV"3FO^7N(M5GZQI6]C#TE
M&K)=)GA?P6_X)U?LP?!S7?\ A.KKPK=>,O%SN)+CQEX]O3JNHR2#^,-+\D;?
M[2(I]S7NE%%=E##8?"PY:45%>2_/N_,^<S3.<VSO$>WQ]>56>R<FW9=E?1)=
M$K)=$%%%%;GF!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH \+_:P_Y+9\#_\ L>Y?_29J]TKPO]K#_DMGP/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!OR_$;_@F+-J,"??U'P9\3+"ZW>NVW=1)^9KI_U5XJS#5X[#PC_+2G#F_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\=XV//A\JK\O\TJ<XQ^]Q_.Q]/\ B?\ X*1?L\0ZO)X4^$<7B'XEZVG']F>
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M.3YNN:B__H5R<5J6W_!*/_@G=:,6B_93\-DD8_>F=Q_X](:Q]CPRO^7U9_\
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MK%GRM_PV_P#MO77.E_\ !*GQBZ],W?CW3(#N^A!XZ<_X4?\ #7O_  4EN?\
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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M;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
MP+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
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MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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MTKPO]K#_ )+9\#_^Q[E_])FKW2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?^%X?"
M'_A;W_"@O^%BZ5_PF?\ 97]I?\(Y]J'VK[+G'F;?UV_>V_-C'-?-?_!4G_@J
M1X0_8=\(/X!\ S6FK_$S5[3=INFL0\6DQ,,"[N0/S2+JY&3A02?Q#_X7C\7_
M /A;_P#POW_A8NJ_\)G_ &K_ &E_PD?VH_:OM6<^9N_3;]W;\N,<5^E\)>&^
M.XCP,\76E[*#3]G=?$^]OY//=]#\PXO\3,!PUCX8.A#VLTU[2STC'M?^?RV7
M4_IZHK\W/V3_ /@L;^U)^V!INE_!'X)?L^^$KOXEPZ69=:UWQ/XK6STPA"%-
MQ':(!/-D$,\<3$IR?N]/<?\ A@K]J#X]?Z5^VI^W#XAN[&7F;P1\+81H>F =
MXI)P#/=1_P"^%;ISQ7SN,X6KY/B'2S6M"BUTOSS:[J,;V3Z<[A<^DP7%=#.<
M.JN4T9UD^MN2"?9RG:[77D4['J/QY_;[_9"_9LF?3/BM\<='M]51MB^']-D-
M]J+/T"?9K</(I)X!8*,]Z\N_X;-_;;_:!_T?]D+]B"^T73)N(?&OQHNSI5L
M>CK81$W$J'J&5NG4<U[#\!?V*OV5OV9(4'P2^!VA:+=(NTZJ+7S[YQWW74Q>
M9A[%\<]*]1KE^N9%@_\ =Z#JR_FJNR^5.#5O^WIR7D=7U//L;_O.(5*/\M)7
M?SJ33O\ ]NTX/S/DW_AWO\??CL/M?[;O[;?BG7[27F;P5\/5&@Z/CO#*T>9;
MI/=]K>_%>U? K]C_ /9B_9GLUMO@;\$M \/RK'L;4+>S$EY(N,8>YDW3./\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/F>]-YYZS!_F1U:/"A HL_\ !4SPW\$];_8+^)6K_'-[2VL?#_AJYU?0=8D
M%UI.M6\9?3KNR?[R7J78A\G9\[2%4 ;?M/P%_P %A_@K^Q7^QA\9]2^.'PT_
MX+3^*OV.O&WCVX;5_%'@SPHEYKFG^(+ICAM3?0K)Q)#+*5(>XQY;LI.W?YA:
MM_P2'_9W_8L_;B^,VF?''XK_ /!:OQ7^V/XL\ 7::QX:\"^*$O-$T[0[I& 3
M4O[#O9&EFDB8KLGP(U8J2I;85 /UW\'SZ_=>$M+NO%=LD.J2:= VI0Q_=CN#
M&ID4>P;(K1HHH **** "BBB@ HHHH **** /"_VL/^2V? __ +'N7_TF:O=*
M\+_:P_Y+9\#_ /L>Y?\ TF:O=* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK*\:>.?!7PX\.7'C#X
M@^+M,T/2;1=UUJ6KWT=M!$/]J20A1^=?,NL?\%,[[XP:K/X,_P""?W[/NO\
MQ9OXI3#/XJFC;2_#=D_0E[R< RE>3L0#<!\K&O1P.4YAF*<J,/=6\FU&$?\
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M ,"E9?\ D@?7.!<N_@86KBI=ZTU2@_6E2YI_=B$?+HT__@K%\:/^/S7?AO\
M!?3)>BV5L_B#5X<^I?%JV/48YIT/_!+KP%X[E6__ &J?C[\1_BM,6#2:?KOB
M22TTL,.<QVEJ4\L9[;R*^H*R/&WC[P/\-=!E\4_$+Q?INB:;#_K+[5;U((@?
M3<Y )/8#D]JB>78*,'/%2<TMW.7N_-:07W"EQYG6%5LNC3P:[T(1A-?]QGS5
MOOJ,Y_X4?LV?L_\ P+MU@^$'P;\.>'F5=IN-,TF*.=Q_MS8\Q_JS&NWKYQO?
MV^[_ .*-Y+X?_8S^!6O_ !&G5S&_B.XB.FZ' W0EKF< R$<G8JC<!\I-1?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\SXT>%/[-T&U@/A;P_IL!L='Q&O^AP$W!W11?ZM6S@A 0 #@-_:!_P""#_\
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M$Z/J^F>(-)M=>T2^CNK*]MDN+2YA;*2Q.H9'4]P000?>OPQ_;!_:%U/]I_\
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MX.CT^)S[/),>/?%'_#6G[?OB#Y?!?_!,;4(HVZ77B+XG:=9[/<Q;"Q_ U/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?B#_P>\_\
M)K/P/_[*!J/_ *0BOV^K\0?^#WG_ )-9^!__ &4#4?\ TA% 'G__  :;?\I3
M/VN_^WC_ -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'A?[6'_);/@?\ ]CW+_P"DS5[I7A?[6'_);/@?
M_P!CW+_Z3-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%([I&ADD<*JC+,QP /6@!:*\L^)?[;7[)WPC,D7CKX]>'
M8)XL^9965[]LN%/H8;<.X/U6O'_B'_P5G^'?A^V\_P "_!KQ)?QNN;;5?%5S
M;>'=-G';9<7KC/TV9KP\7Q-D."FX5,1%R7V8^_+_ ,!AS2_ FE+ZQ75&BG.;
MVC%.4GZ1C=_@?6=%?F]KG_!5GX_?%#4G\/\ PR\0Z!93YQ_9?PY\'7_BK5XR
M>@#.L=E)[;7ZU3'PE_;Y_:(&[Q#\(?BAKUK.?FG^)OQ @\.Z8<_W])L@9A_P
M&3@<5Y+XO>)=L!A*E3S?NQ^=N::^=,^IAP3Q<XJ=?"?5XOKB9T\,K=TJTHS?
M_;L6WT3/NSXF?M7?LV?![S(_B1\;O#FF3Q9WV3ZFDER/^V$9:0_@M>8W'_!2
M#PGXKA=OV??@'\0_'Z!24U6QT!K'3 !W>ZN=OECW*^M>1?#3_@F!^TE9>7-?
M_%+X7_#=006A^'?P_&IW8']U=0U5FN(S_M*3R*].M_\ @E'\!/$LR7O[0/Q)
M^)'Q2G#!RGC7QM<O;JP_N16YB"J.RY([4N?C/';*%%>2N_\ P*3?XT2O]7<E
MPO\ O^;T_..'I5*TE_V]4]A3?RE)'E_Q/_X*0_&2P,D7B7XK?!+X4P#/GVMU
MXC?Q1K,'TATX.F[V=17QC^UWKOPD\?ZPOQ&/C/Q=XN\;ZM.DUUXHU7X?VWA[
M3KNU"LN^*-1YL[[@BB0A0%4@Y. /U]^&/[*?[-/P8\N3X6? CPKHDT6-MY9:
M)"+DXZ9F*F1OQ8U^<W[;'['G_!07]H3X[Z]\9]8^ 5Z=/NK^.RT.TAUW3YY+
M>S$@BMU\N*X9A][S)#C:I>1V(4$CX7Q R?.Z>2<J]KBJLW:R4Y**6KDU#EIK
MLOW:>KL]&>7G6+R' Y;4P^24\5.O57)[25517*VG)>QI0L^:UK2J26M[71\9
MU)8Z=I&K:C:Z=X@U6ZL+"6ZC6]O;&/?-!%O&]T7(W,%R0N1GID=:^A?^'4'[
M?O\ T03_ ,NG2O\ Y*JK??\ !+?]O+3KRSL;GX 7)>^G:*!H==T^1%8(S_O'
M2X*Q+A2 SE5+%5!+,H/X?3X7XKH5(U%@*UTT]:4__D3\SR^&;X#&T\5AJ<E4
MIM3B^6]G'WKV:::5KM--6WT/K/PI_P $0?@EXGT#3]3UG]I'Q/JMA<6<4MI=
M:#I6F60GA904</\ 9Y"V5(.XDDYSS7<>&_\ @BC^QCH.W^T9O&.L;3S_ &EX
M@4;OKY$4==U_P3?\*_M)?#7]GV'X2_M)^!)-(O?#ER;?0KE]5M;K[38M\R)F
MWEDVF([DPV/D\L#.#CZ K^J<IX<X;S#+J6)JY?&$I13<9P]Z+ZIJ:OH^^ZU/
MTW%<29EG-!/%0IZ[KV%&&O72-.)\QZA_P1__ &#[Z(1Q_"^_@./OQ>([LD_]
M]R,/TKGKS_@B5^Q;-.+G3&\6Z=(IRDEEK,6Y3[%X6-?7M%>A+@[A:7_,%37I
M%1_*QY=&=3#_ ,&3A_A;C^31\M^'?^"7VD> -O\ PK+]K'XJ:/L.8]VK6LNW
M\K=??]/2MO\ X9%_:KT__D7?^"B?BV+'3^TO"MC>?^A8SW_R*^B:*J/"N2P5
MJ<91_P -6K'_ -)FC"K1C7GS5)2;[N4K_F?.W_"A/^"ANE_\@_\ ;YTG4P.B
MZG\+;*'/L3$]'_"%_P#!4#2_^/#XU_"?5<=/[3\-W<&[Z^2W'_US7T37%_&S
M]HGX&_LX^&3XO^./Q2T?PU8X)B;4KL+)<$=5BB&9)F_V45C[5M1X5I5ZJIX>
MI7<GLE6JR;]%*4KG-6IX;#4G4J5'&*W;FTEZMNQY5_:7_!5;2O\ C[\-? O5
M5'3[#>:M S#W\P8!X^G(]#5/Q#\>O^"@WP^T6Y\2>.?V9_AZVG641DO+]/B-
M'90Q(.K,]RH5![L>XKG3^W#^U5^U%_Q+_P!@G]E^XAT2?A/BC\5EDTW2RI_Y
M:VUHO^D72D'(88 (PRU<\/\ _!,2R^)NLVWCO]O3XZ>(?C'K$,@F@T.[D.G^
M'K&3_IE80$*Q'3<YPX W)7N?ZCO ZX_,ZM%_R1=.I4^<7!QC_P!ORB_[K/"_
MM/$8W3*XSJ+^>3Y*?RE*+E/_ +<C)/\ F1Y_\-_^"P'Q;^->OZEX'^"O[$EW
MXLU73I##/>^'O%QO=-BDQPSW<5F80O3'[S#=C7 >-_\ AX-^T!X@G7]L;P'\
M7;/P>S$?\(%\&M+@L;>X3^[<79G>>=",!D.!U*E:_1GPIX0\*>!- MO"G@CP
MQI^C:79ILM--TNS2W@@7T2.,!5'T%:-<\(9GEU>4LLQU6*Z.I##5)KS35"'*
M_P##JOYF=$\DQ./P\89C7<VMU&\(/RDD_>7^)V?\J/CKX$?'']G#]E?P]_PB
M_P *O^"</QA\%6Y0+<W,/PS+R7..AEN?.:6<CCEV)!.*[S_AYS^SK:?\C%X:
M\?Z/C[W]I^!KM=OUVJU?1-%>97H<45ZKJU,>IR>[G2YF_5J<6SU*&#GA*2I4
M'&,5LE%)+T2:1\]VG_!5#]A.XE^S7/QM:SF[Q7WAO48B/J3;X_6M[3/^"AO[
M%&KX^R?M'^'$W=/M4[P>G_/15QU_SBO8;NQLM0B\B_LXIT_N31AA^1K!U/X/
M?"36P1K/PM\.7>[[WVK1+>3/_?2'U/YUE[#BJ/\ R_HR_P"X4X_^YI&O+C%]
MJ+_[=:_]N9SNE_M??LHZS@:;^TMX#D9ND9\6V:O_ -\F0'OZ5T.F?&3X0ZW@
MZ-\5?#=WN^[]EURWDS_WRYKG]4_9$_93UG)U/]FKP'*S=9#X2LP_?^(1@]SW
MKGM3_P"">G[%.KY^U?LX>&TSU^RVS0?^BV7%'-Q5'[-&7_;TX_\ ML@OC5TB
M_FU^C/7[._L-1C\[3[V&=/[\,@8?F*FKY\O/^"6'["5U)]HA^!WV64?=ELO$
M>HQ$?0+<8_2H?^'8G[.-I_R+NO\ CS2/3^S?'-XN/^^F;W_,T?6^)X_%A*3]
M*\OUH+\PY\8MX+_P)_\ R)[/\6_B=X9^#'PSUSXJ^,;CR]-T+3I+NYP0&DVC
MY8USU9VVHH[LP%?B%_PTY\3?^&F?^&J?[0_XJ/\ X2+^UOOG9][_ (]_7RO+
M_=8_N<5[O_P5)TG0?@3XJT_]G[P!\=_B1KXFLEO?%&F>)O&4E[9Q98-;1^5M
M4>9\K2'=G :,CK7R'7\\^)W%^/S'.*>#BO9_5G=VES?O-[W27PK1=GS'S&;X
MZI5KJFM.3SOK_P  _;/5/^"B?[*.A_#O0_'NI?$JWDN/$&G0W6G^'-,4WFI,
MTB@B$P0Y9'#93Y]J[E(S7._\+=_;M_:(_=?!3X-V?PL\/S?=\4?$5?-U-T/\
M46GID1N..)B5/K7S+_P0]^*7P\L_&WB#X/Z_X7TE/$-Y"=1\/ZX]E']KEC10
ML]KYI&_:%VR*@.,"4U^EM?LG#./S#C/)J>-JXGV<'HX4ERRYEHU*;O)7W2@H
M-)KWF>[A*E7'T%4<[+LM'\W_ )6/GWPI_P $[_AC>ZY#XX_:0\9:[\6?$,1W
M)<^+[HFQ@;N(;)#Y4:'^XV\5[UI6DZ5H6G0Z/HFF6]G:6\82WM;6%8XXE'15
M50 H]A5BBOLL!E6798G]6IJ+>[WE+SE)WE)^;;9WTZ-*C\"M^?S>["BBBO0-
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *_$'_@]Y_Y-9^!_P#V4#4?_2$5^WU?B#_P>\_\FL_
M_P#[*!J/_I"* //_ /@TV_Y2F?M=_P#;Q_Z?)Z_?ZOP!_P"#3;_E*9^UW_V\
M?^GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** /"_VL/^2V? __
M +'N7_TF:O=*\+_:P_Y+9\#_ /L>Y?\ TF:O=* "BBB@ HHHH **** "BBB@
M HHJIK^NZ/X6T*]\3>(=0CM-/TZTDNKZ[F.$AAC4N[L>P"@D_2E*48IMNR0%
MNBJF@:[H_BG0K+Q-X>U".[T_4;2.ZL;N$Y2:&10Z.I[@J01]:MT1E&233NF
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M.>PKZE_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@"76/
M&G@[P]="QU_Q9IEC.R!Q#>7\<3E22 <,0<<'GVKXK_X*Y?MN^"-(^#I_9\^$
M_CFQU/6?%!4:[-I%\DRV6GJ<F-WC)"O,P"[>IC$F0 RY]._X*0?LY^'/VHOV
M:_$-OJ7PLL&\3:+I$]WX9U[5YQ!_9TB#>Q,R<K&54[E;*$X+#@$?C1H.F#2-
M*BLRHWA<RD=V/7_/M7Y1XJ\28S(\E>%IJ-\1>":E[R2MSMQM>S3Y4[VU?56-
M,]J\-T.&5*EB*GUZ4DG2=/W.1\UYQJJ33:LDXN*DN:ZNM3]2?^"1O[;O@C5_
M@Z/V?/BQXYL=,UGPN6&A3:O?)"M[I['(C1Y" SPL2NWJ(S'@$*V/L#5_C;\&
M?#]FVHZ]\7/#%C;H,O/>:_;Q(H]2S. .HK^?O4K5;NS>/[-%*X!:))URI8#C
M-?8OP<_X)*_M7VGA32O&,=A\(M9;4+2*\@AU:/5988TD4.N#;31QRC!'52IS
MQG@UGX69]GO$F3_4:"HJ6'48N=:JXW3ORVC&G.3LE9O1:*\KL\#!YO@J64PC
MR5:E=-IJ,591TY7=O5ZM6O':Y]M_$G_@JO\ L3_#J22Q@^*,GB.^1MJV/AC3
MI+HRGL$E(6%OPDKCKG_@H%^UA\4F:V_9F_X)^^++F*09M-9\:2?V? X/0[7V
M1L/<3UR_P^^"G_!4GX/1LOPJ\%?LS:09%VR'3_!=_9EAZEH2&<_[V:Z@:O\
M\%NK7_4Z?^SG=;NOVFSUU-OTV/S^/I7ZF^$>(,7_ !\XH07:BN7_ ,FJJ;^:
MC'R".>4H_P 3"XA^D(Q7HTI3;7I)/T*<_P )_P#@K_\ &WGQK\=_!GPSTZ<?
MO+'PW;&>ZB^A"L>/]FY_QIFF_P#!&WP+XKU!->_:0_:6^('CW4%.6>:^6VB?
MUSYGGS#\)16@/%O_  6WMN+CP%^SG<D]#;/KJ!?KO;FG#XA?\%I+8;;CX+_
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M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM6M*U6]U"1TNM$GM0JY#2D8;VXH O5^(/_![
MS_R:S\#_ /LH&H_^D(K]OJ_$'_@]Y_Y-9^!__90-1_\ 2$4 >?\ _!IM_P I
M3/VN_P#MX_\ 3Y/7[_5^ /\ P:;?\I3/VN_^WC_T^3U^_P!0 4444 %%%% !
M1110!!JEW<:?IEQ?VFESWTL$#R165JT8EN&"DB-#(R(&8C +,JY(RP&37Q5_
MP1[^"O[3?P'\;?M,)^T'^S5KW@NT^)G[2/B3Q_X2U'4->T6\BGTR^6TC@BD6
MPO[B2*XQ S,I78!_&3Q7VY10!\4_!_X ?&K_ ()Y?M;_ !_\>?"CX!:Y\1O
M'QTUV#QMHMEX6U'3X+G1_$[0M%J-K="]N8 (;IQ#/'<(65,2I(!B,R>3M_P1
M$^(J?\$GY/@#'XNT/_A?)^+!^,Z:X)'_ ++'CC[9]J$.\KO^S^1_H/F[=V/W
MNW_EG7Z744 ?%/Q>_9^^-'_!1+]JG]GWXA?%CX!ZW\-_ GP-\03>-M:L/%6I
M:?/=ZOXF6!8]/M+46-Q.IAM9#+-)<.560B)8U;<[)]K444 %%%% 'A?[6'_)
M;/@?_P!CW+_Z3-7NE>%_M8?\EL^!_P#V/<O_ *3-7NE !1110 4444 %%%%
M!1110!\9?\%F/VG/^%8?!.V^ _AG4-FL^-L_VAY;X:#3(V'F9]/-?$8[%5E%
M?E17[C?&7]@[]E3]H+QM)\1?C!\,)-9UB2VCMS=OXAU"$+$@PJ+'%<*B 9)P
MJC)))R237*?\.H/V O\ H@G_ )=.J_\ R57X9QKX=<6<5Y[/&*M25-)1@G*=
MU%=[4VKMW;U>]KNQ\[F&5XW&XEU.:-MEJ]ON/QDK]5_^",_[3G_"S_@G<_ ?
MQ-J&_6?!./[/\Q\M/IDC'R\>OE/F,]@K1"O1/^'4'[ 7_1!/_+IU7_Y*KJ_@
MU^P=^RI^S[XVC^(OP?\ AA)HVL1VTEN+M/$.H3!HG&&1HY;AD<' .&4X(!&"
M :."O#KBSA3/88QUJ3IM.,TI3NXOM>FE=.S6JVM=7#+\KQN"Q*J<T;;/5[?<
M>O4445^YGT04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65XX\#
M^$/B7X0U'P#X^\.VFKZ-J]H]MJ6FWT0>*>)A@JP/Y@]00",$ UJT54)RIR4H
MNS6J:Z$SA"I!QDKIZ-/9H_"__@HA_P $?OB]^S3\7K'_ (4%X7U7Q;X,\6ZJ
MMIX<^R0F:ZL+J0_+97&/QV2G"LH.X@@Y_1+_ ();_P#!+?PA^P[X03Q]X^AM
M-7^)FKVFW4M24!XM)B89-I;$_D\O5R,#"@ _7U%?;YOX@9_G.2PRZM*R6DY+
M>IVYOUM\3U9\+D_AWP_DN=U,RHQNWK"+^&F^O+^E_A6B"BBBOAC[P**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\0?^#WG_DUGX'_]
ME U'_P!(17[?5^(/_![S_P FL_ __LH&H_\ I"* //\ _@TV_P"4IG[7?_;Q
M_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#PO\ :P_Y+9\#_P#L>Y?_ $F:O=*\+_:P_P"2V? __L>Y
M?_29J]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ.,2"3[5H **** /"_VL/^2V? __ +'N7_TF:O=*\+_:P_Y+9\#_ /L>Y?\
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MT?\ #NKX'_\ 0W>._P#PKYZ]ZHH \%_X=U? _P#Z&[QW_P"%?/1_P[J^!_\
MT-WCO_PKYZ]ZHH \%_X=U? __H;O'?\ X5\]'_#NKX'_ /0W>.__  KYZ]ZH
MH \%_P"'=7P/_P"AN\=_^%?/1_P[J^!__0W>._\ PKYZ]ZHH ^,OV1/V./AG
M\6?AGJ'B3Q5XJ\7K<P>*M2LHQ9>)IHD\J&<HF0.K8ZGO7J?_  [J^!__ $-W
MCO\ \*^>NY_9K^#.I_ SP%>^$-5UJ"_DNO$-]J*S6\;*JK/*7"8/< X->@T
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MYZ/^'=7P/_Z&[QW_ .%?/7O5% '@O_#NKX'_ /0W>.__  KYZ/\ AW5\#_\
MH;O'?_A7SU[U10!X+_P[J^!__0W>._\ PKYZ/^'=7P/_ .AN\=_^%?/7O5%
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M*^>O>J* /!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO_P *^>O>J* /!?\
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MH \%_P"'=7P/_P"AN\=_^%?/1_P[J^!__0W>._\ PKYZ]ZHH \%_X=U? _\
MZ&[QW_X5\]'_  [J^!__ $-WCO\ \*^>O>J* /!?^'=7P/\ ^AN\=_\ A7ST
M?\.ZO@?_ -#=X[_\*^>O>J* /!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO
M_P *^>O>J* /!?\ AW5\#_\ H;O'?_A7SUVOP5_9B^'_ ,!]6O=8\':UXANI
M;^W6&9=9UN2Z15#;@5#_ '3GO7HM% !7X@_\'O/_ ":S\#_^R@:C_P"D(K]O
MJ_$'_@]Y_P"36?@?_P!E U'_ -(10!Y__P &FW_*4S]KO_MX_P#3Y/7[_5^
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MP14.F:7IFB:=!I&C:=!:6EM$L=M:VL*QQQ(!@*JJ % '  XH GHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .?\ BK\5?AQ\#?AOK7Q?^+WC.P\.
M^&/#NGR7VMZUJDXC@M+=!EG9C^0 R6)  )(%?F;X2_X+Z?\ !'CXK_%:V_:O
M^/\ ^V#IEL_A5;J/X5?#]?#>JW5QI"RHT,NISI%:LLFIW,9,:*I86UO(T2G?
M-<$_JE10!^>GQC\/3?L[?\%L?A3_ ,%(_'NG3^&_ 'Q8^ MS\-?$^I:ZR0Q>
M&=9%Y'JME'?R[C';FX"?948L4,T(3=F1-VC^Q5\.+C]H'_@LY\?/^"D/A:5;
MOX?6'P]TCX9> _$ENV^U\121O%>ZG/:R#B:""XCCM_.7*/(LH5CY;5][7EE9
MZC:26&H6D4\$R%)89HPR.IZ@@\$>QIT$$-M"EM;0K''&H6.-% 55 P  .@H
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M^D_X)M_L0Z%\ ?$.M6NJ>+M0U"Z\1?$'5K%-L%WK=ZP>?RA@9CC58H$; +)
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M.ZCDGFOL076I7]Q<00QO<W$LX"0Q [$C"(D<,*A? ?V8_BU)^R=_P08\<_\
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M@ HHHH **** "OQ!_P"#WG_DUGX'_P#90-1_](17[?5^(/\ P>\_\FL_ _\
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MWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\ T8]\0/\
MPHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]\0/_  HK
M'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PHK'_"C_B-
MY_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\ "C_B-Y_9
M9_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(WG]EG_HQ
M[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6?^C'OB!_
MX45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\ A16/
M^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X45C_A0!^W
MU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?
MB#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_P#$
M;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1O/[+
M/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\ T8]\
M0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]\0/_
M  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PHK'_"
MC_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\ "C_B
M-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(WG]E
MG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6?^C'
MOB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\
MA16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X45C_A
M0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^
MWU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@
M_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1
MO/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\
MT8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]
M\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PH
MK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\
M"C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(
MWG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6
M?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X
M@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X4
M5C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\
MA0!^WU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]
M17X@_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#
M_P 1O/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[
M+/\ T8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_
M $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$
M#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"B
ML?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH
M_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC
M>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\
MHQ[X@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB
M!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A1
M6/\ A0!^WU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4
M ?M]17X@_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU
M%?B#_P 1O/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\
M1O/[+/\ T8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/
M[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]
M&/?$#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0
M/_"BL?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**
MQ_PH_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_P
MH_XC>?V6?^C'OB!_X45C_A0!^WU?B#_P>\_\FL_ _P#[*!J/_I"*/^(WG]EG
M_HQ[X@?^%%8_X5\!_P#!?3_@OI\(O^"PGPB\ ?#?X;_ 'Q)X.G\'>)+K4KFY
4US4[>=+A);<1!%$0R"",Y- '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mrk-20211231_g2.gif
<TEXT>
begin 644 mrk-20211231_g2.gif
M1TE&.#EA>@%  '   "'Y! D  /\ +     !Z 4  A____^_W]^_OY@ ("
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MP@I%^^1 %7HV6,($!2!!O@$(IT "!CRDJ5ZQGE*/ @BN>E&$<Z[2;KXLKUA
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M !5XRE#D*1 #3* >)/I/A (@C#R4H![]R)@J(-,N]?@#BI&#&\<T0O^3=!U
M+8E9:][J<0 ]! M:.:F0JQ2R2PNIKGM81:N:=K;( /421/HJA12!.*&2*9%3
M>@3 O'"K"F'0R287H$TXPW2339DQ!@;HYF1U>UHUS1,G-$.MZ@JP"MI(1@'G
MVI2:DG.3M3VM*,/1@S2%,UN8.F@W9B2B[SH3H4) !@%3-<4O2P"Q;H5$ *5
M0 E"Q0":I,]9MA5C%3ERP8NH<#@EL-1KEVN1@TD&05$A+@'I1.$MK5<@!!I
M4R=PX>\6(C1U2 A?3RNL=ZT($*9 A<\.$+E%RL1K$\2N*1D@3W\$()4E"+%!
M]',DF$4W)PY6KW,$+ S9$@ 537V;(?PTOXW_V,B0IH2(;74SD=(>Y',J;*!
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MK" RC^44_N!\H0-'5&@@A\5&<5,C]6 ;B%$<O@-"2"89+W, \(%K(D$4PKB
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MLWZ+@<$;XC&ED"]M!C(S)#T)(Q,:E ?"1!?N62E*)"OL-P (0##=(6XZ<"_
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ME\+4-)LR*=^*8;;DAF/"&E*_(A2Y#51]X7*=01>]E!Q14:O]$=W]R*04T!;
M=RFO8UL28*.V\3=<(2IF,TJ39: I(3576 \=;=:DQ8B>!6DG,Y2!HXG!K-L.
M4A-T$AZ\')W]P8+&H<);01[ZXDY?0RCX'3S=C6>:K2"$3=0%0]IGP@H-T$R@
M(MT\ <SL;1)OMYO0:=Y=,E9]01=?O!-XO!6_X4D>DBZ)@R BE^$68LQC%12:
M$D'\#3J-!.&;<7?U\.!\Z.+-P<083A(3DAY![A-4@>.906\HT-%%[N,[D=I.
9?MX% !8"$![E5AXGH]?D5[[E7/XA 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>mrk-20211231_g3.jpg
<TEXT>
begin 644 mrk-20211231_g3.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X19,17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    F    <@$R  (    4    F(=I  0    !    K    -@ +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($5L96UE;G1S(#$P+C @5VEN9&]W
M<P R,#$T.C W.C(U(#$Q.C$Q.C0Y   #H $  P    '__P  H ( !     $
M  + H , !     $   #9          8! P #     0 &   !&@ %     0
M 28!&P %     0   2X!*  #     0 "   " 0 $     0   38" @ $
M 0  %0X         2     $   !(     ?_8_^  $$I&248  0(  $@ 2
M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(                  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
M^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+
M 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"
M2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M
M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$
M2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&
M!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'
M!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ
M"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*
MF JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG
M#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/
M"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,
M$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4
M:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E
M%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:
MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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M_2G]NOY+_MS_;?___^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          (X0DE- _0      !( -0    $ +0    8       $X0DE-
M _<      !P  /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M X<    &              #9   "P    "D 4@ @ $0 80!V &D <P @ &4
M; !E &, = !R &\ ;@!I &, ( !S &D 9P!N &$ = !U '( 90 @ "T ( !W
M &@ ;P!L &4 ( !N &$ ;0!E     0                         !
M          +     V0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    V0    !29VAT;&]N9P   L     &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -D
M    4F=H=&QO;F<   +      W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3004       $
M 3A"24T$#      5*@    $   "@    ,0   >   %O@   5#@ 8  '_V/_@
M !!*1DE&  $"  !( $@  /_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M                  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 !_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ ,0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ ]2JJKIK954QM=5;0UC&@-:UK1M:QC6^UK6M4TDDE*267
MU3JSZ,FCI>#MLZIE@OK8X%S*J6D"_.RFL<QWH5SZ=3/4K^U9/IT,_P +=2WU
M8ZED=4Z)CYN26/M>;6&RL%K+!7;917D5L<7;69-=3+V_\8DIU4DDDE*22224
MI))))2DDDDE*22224I))))2DDDDE*22224__T/55SOU]ZMF=+^KF3;AUV>I<
M!2[(KT-#;2VAV0W])2]U[?5_565.]3[1L71+E?K;U*EG6>D=/N)&)0;NK]1<
MTG<RK!8;L8NK9_.5OS-C_P"OCI*85XW4,/I[,5KK6=?Z]MKWN>;W8F-4T,W.
MOW,<]O3,5_\ /;_UKK67ZG_:U=/B8M&%BTX>,ST\?&K;52R2=K& 5UMW/+GN
MVL;^<O/.H]5^LO2^MU?66ZML9.&]UG3,B:VT83<C#II9ZM0L<W/8_,^UYMMU
M>S'KLMJ_P2Z+K.+]:NJ=)RV6NKZ6P46$8V&\WWW/#+=E+LRVG&9C4O?Z6YE&
M/9?9_P!RJ$E-GZI]6ZCUJC*ZKD 5]/R+W-Z55MAYQZ_T?VFUT[OUE_N]-[/T
M?\NNQ;R\RKSOK1=TYO5/J[5=9B7X-?3,!E#!#+*&TV_;W47O96REUKNI8/J^
ME^C]#'_TJZWIWUF/46Y&!CU6XW5JJ0[&9U*IV*,@[?Z0RG6[[.R\?I_29^C2
M4Z[^H83,^KIS[0,RZM]U=.LEE98RQ_[OTK&_ZUV*RO-0SZV=3RG_ %HQL7%Z
MI;BY-56!D8E@H+J<5V15U#[/7DMR_6Q,_P"U9>-O^W5VO?53D5T_HZ%W6'UO
M#S.D'J](M^SM98]];JW"YII+F9%#L>/4]>JRJRKTV_G_ ,VDIN7WT8]+[\BQ
MM--8+K++'!K6M'TG/>Z&M:L^OKIR&^IA=/S,JJ 6V"ME =/[C>HVX5CF_P O
MT]BXJ^KZS7XS,3*=E.S.LW5=6Z2!/I8N07O?9T[/=D,R?U+I=+L/-^SV8E?J
M74W>A^G5^CZU=<HP,S"S,;)HS\3I.5EOS,QC&;\S%#&75XE=%;,;(PZW6,NJ
MOK_G:_[:2G?QOK'DY3[OL_1LVRNAYI?8'8@'JMTOK9OSF-L]!_Z*RRMSV>NR
MZGZ=**?K)BTZY^-EX#=/?=2YU8DQ-F3A_:L:EO\ QUU:N=+Z=C=+Z=C=.Q6A
MM&+6VI@  G:-7NC\^QWOL_EJTDI%C96+ET-R,2YF10^=EM3@]A@[';7L+FNV
MN;M15@=2HHZ-U/$ZKAM]%N=E,Q>HTL]K+OM!-=&2ZOZ'VNK+=3^G_G;<=]U=
MOJ?H?3WTE*5*GIGI=5OZD<O)L]=C:QB/LG'K#8]]&.UK=MK]OOL>ZQ74DE*2
M2224I))))3__T?550/1L3]NCKLO^UC%.%MD>F:C8,F=FW=ZGJ-_?5]))3E=<
M^K?3NN.QCFFT#&?NVUOVMM8XL?;B9+2'>KB7/HH=;5_P2U4DDE+ !H#6B -
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MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0      >P
M  $!    & !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $4 ; !E
M &T 90!N '0 <P   !T 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !% &P 90!M &4 ;@!T ', (  Q #  +@ P     0 X0DE-! 8       <
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M4D%96%E:( ?/  8  P       &%C<W!-4T94     &YO;F4
M       !  #VU@ !     -,M041"10
M                                !6-P<G0   #     3&1E<V,   $,
M    :7=T<'0   %X    %&)K<'0   &,    %&M44D,   &@    #G1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DY($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A
M=&5D+B!!;&P@4FEG:'1S(%)E<V5R=F5D+@!D97-C          ]'<F%Y($=A
M;6UA(#(N,@
M                                                          !8
M65H@        \U0  0    $6SUA96B                      8W5R=@
M       ! C,  /_N  Y!9&]B90!D      #_VP!#  8$! 0%! 8%!08)!@4&
M"0L(!@8("PP*"@L*"@P0# P,# P,$ P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  +" #9 L ! 1$ _]T ! !8_\0 T@    <! 0$! 0
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MD=U;A\/+[/J+]K.+_P#.%'E@1:5YA\S.M#=31:?;$BA"P*)I:5)^%FEB_P"
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MR" "C*'D+GCRWV"?\,V3BS_(3R/%IT5C<12W*0@A"7*E>7@PH1]!PSB_)?\
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MGVO'U& Y.SN0JHB=6=F;M@#R!^9WDSSY:75SY:OOK:63K'=1NCQ2(9 2A9'
M-'XMQ;[+<6R6U%:5WRN2UI45\/\ /Y9>;-FS&F<2_P"<L_-C:+^5DVFQ#_2/
M,-Q'9ANA6)/W\K?=&D/_ #TY9X[M[?S%Y5N?+OF>$?5Y+FFJ:/<$<@/JMT\5
M2*$;26Y)0_:B9?V6SZ-^5]=L]?\ +^FZS:2*]OJ-O'<+P8.H+J&9>0VJC-Q;
M_*7#;-FS9L"WNJZ98(CWUY!:)*>,;3R)&&:E:*6(J<$\E(J"*'<'(C^9_G[2
M_('D^^\R7BK(\0$=G9LX0W-S)M'$#N?V2S45N,:N_P"SGDS\M/(7F[\\O.UW
MYA\RW4AT2"<-J%T2W$ECZGU*T!-(_@/Q4;]Q%QY?&R^I[3T71M-T;3;;3=,@
M6"RMD6.&-=J*HVW[G!]1XYLQV!.<7_YR;_-"X\F>2?T?IC^GK&N%[>&85!AA
M I-(I_GH>"?\'A5_SBO^4TOEGR^_F36[,P^8-39EA$H^.&U^'B*'[+2,&9J?
ML,F=]S9LV;,0*=*^V%.N>5/+6O1"/6=+MM011Q47$:O0?Y)()&<N\\_\XX>7
M]3TBXC\OL;/47 2)KB1GMU0_;'IA6VIV7_@LX_I.O_G=^1VJ'3M5A.H>77D5
M;6WG=YK6<#=EM+H+_HDGI@MZ<B<?VOJ[YZ9_+G\RO+/G[1%U/1)2&B(2^L9*
M+-;2FOP2*/&AXNO[N3]EOV<EU1TS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;
M-FS9L__5]4YLV;-F/0YQG_G*+\P(?*_Y<3Z?#*1JWF/E96:JS*5B !N9?AI6
MB.L?VOMS1_:56R(?\X4^73#Y;U[S%+#Q>^NDLX)SL6CMTYN%_P GG*-_YDST
MH2*'?/.O_.5WYO'0M(/DO1;J+]+:O$1JY4$R063]%#!@JO/]GBRLWH<W^#U(
MWSR)IM_=:=J=GJ%K,UO=6DT<\%Q&/B1XW#HZCQ5@&&?2[0?-7EC7O5;1-7L]
M46"@G-G<17' M\2\C$SC??#BHS5'7MFJ#TWSF?YI_GMY(_+^T:.XF74M:!I%
MHUJX]45-"92.2P**?[L^+^56SRKY^T?\S//?EW5/S9\SL+32;<PQ:59S<HRU
MO<2A$2TC*T:&,R\O59N4WQO^\^-E]"?\X>6PA_*,R ?[TZE=2L?<+''^I,*?
M^<T=9TR'R#I&CS!VO[_4/K-GQ)"JMK$5E9O'_>E%"_Y?^1D$_P"<*-1@A\Y>
M8-/>8I-<V"2QP_LMZ,P#'_67U%I_D\\[U^>OYK2_EKY1@U6TMHKV_O+I;2UM
MIG*+0QO(TA"_$ZIZ>]/YT_FSF7_..7_.0'F[SIYTO/+_ )H:"X^L0RWFG2PQ
M"$Q,CH6MP$^U%P+,K2<I>4?Q2R<\]+9LV474"I(IXXF]S;)(D+RHLLO+THRP
M#-Q^UQ!W/'OGC3_G*G7[_P V?FMIWD[3.-P=+$5G;P1C=K_4"C.I>G7^Y3C\
M2IP?]MY%SL?YW?E#::C^2T6DZ7;)/J'E6WADTJ5J!S%;(L<PY#XOWMNO+T_V
MI8T_U\B/_.&_YBO=Z?>^0[V0E].#7VDD_P#+/(X]>*NWV)I%D3X?]VR_RYZ;
MJ,V;-E5'$FNWCG@;_G)WS*^M_G!K*+*9+32O3L(%))"F)%]=1NR_[T-+_+G=
M_P#G$7\Q;K7O*ESY6U&0/>^7^ L2Q'-K&3X46GVF^KO&8^?+X8WB3]E>1+_S
MF7Y8\X:G#H6J6%O+>:%8"6.>*!6=HIYB")'517@R(J"3]A_A_P!V9Q;RG_SD
M!Y_\I^3[;RSY?-G8VT$SS?75@YW,@D<O(DAD+Q%233FL2RJB?#)G7/R[_P"<
MG/S)U32;:PM_*<WF75+9A'>7\!<!P>C,$0HDG^L>+9W?\O-8_,;5X9+WS9I%
MKHMM(H-E9PR/)<"I_P!W<OA4A<F=1MOUZ9CT/;WSR+YLAD_-K_G)9-!2>230
MM!DX7$3D%%6S8"X"@?[]FHF>MXHTC1410J( J*.R@8_-FS9LV;,:TVZX1>:O
M)^A>:M';1];MC<Z<\D<CV_)D!,1JJG@P^&GPN/\ @?CSRS^87DCS1^2OFG3/
M,7E&::?2YYB8YW),I 7]Y8WO$>C-ZB'_ $>3CS;X_P#=T:O)Z9_+?S[H_GKR
MI9^8=+;X)QPNK:H+V]P@'JPO3C\2%MB1\<7!_P#=F2K-FS9LV;-FS9LV;-FS
M9LV;-FS9LV;-FS9LV;-G_];U3FS9LV8],\%_\Y1>=/\ $GYKW]K$Q>TT%1I<
M(!V,D+,UPW'LWKLT?^K$N>I?^<;]!ET;\G/+\<U#+>PM?D\0OPW;M*E>Y_=L
MGQ8-_.7\UM-_+GRH^J3<9]6N"T.CV35_>S#J6I0B*($-,?\ GFOQNN>-/R]\
M@^:OS>\\7?[\@SR->:WJLOQK$LCU9N)-9)&)*QQC_A45FP;^>'E73]/_ #8/
MD[RQIY3ZG#I^FVL"<3-<3SPHZL[ #G-,TZ^H_P"V_P#DY%O)WG?S?^7OF=M3
MTIVLM5@+6M[;7"&C@./4@N(V ?[:?$OP2*Z\OA;/3/E?_G,_RG<PHGF32+O3
M;GB?4FM>%S 7%*\02DB@_*3##5/^<S?RRMN2V.GZI?OQJKB*&)">M"S2\_\
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M4\E>5Y+O3[*QN/JL5OIBL+VYEC6C.9(.4O%ZMPCC9/W7#U5Y9RS6/RN_-O\
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MB_)S2KM+I=$:\FC*M$;RXFF52N]2A<1-O_,C9U*"WA@C2*!!%"@ 2- %4 ;
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M%[JRW_ERV?U19/&1,Y'V8W/V"JO1N?'XOY,])P6\-O$L4$:Q0H J1HO%0H%
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MFZ</'IMS:@#^[BO+@C;_ (S/*<C.K?\ .&'D:17;2=:U2QE;F4]8PW$25^R
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MG'_.O_.&VN1ZM$/)]\DVFR@!_P!(O22)_=HDHZ#_ %.7^MGHK\J_RXTO\O\
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>;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mrk-20211231_g4.jpg
<TEXT>
begin 644 mrk-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0 !+ $L  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        $L     0   2P    !  .@ 0 #     0 !  "@
M @ $     0   C>@ P $     0   *      _^T .%!H;W1O<VAO<" S+C
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MW0 $ "3_V@ , P$  A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]#]_**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'V'3'T[Q!IT,&D)-;;H(SB2>RNKX %!=))+$KE8P0#^EZBBB@ HHHH ****
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M+W \)VOA>&VU1%N0MN=4N;R)].,EOO!DD$$-]Y<@1A$I=2R^: X!_2=1110
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MUXOU.Z;='X@T_1-1MQY%Q%MBCT^"R(WSPQ1S?O+5SOMVFB&=AD$R2Q1^H?\
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MX:^ ?#7PYT*6XGTWPKH]AHEG+=LKW$EOIT"6\32LB1HTC)&"Q5%4MG"@<5^
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MX:XUF\EMYUD8N4,:IIL)C 16#,^YF!4+_2=7\P7_  6K_P"3IO"W_9/]._\
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MP-)MD:WDW1[T /[?*X_XA>-=*^&O@'Q+\1M=BN)]-\*Z/?ZW>16BJ]Q);Z=
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M0U--"BBU&SO]8O$CM]+M[*Y@\R2YN(HYKA7CMR8RUPB$O,C)#X!\;H?VR?\
M@I!>2_'30OA%Y?A;PMI]U#IDFEVD<,MQIRW%U)Y<=Y=-'=:W<0M$\31V@9$E
M!\NVADG82\__ ,$U/B%^RI\/?C)'J'[1NE[M:DU#3&\':_>9;1]#O(UNA-/?
M SI&F^1[;R)Y()EMI%$Q> (90 ?TG?LA?"&Y^!'[-'P]^%NH1W$&I:3H\<VJ
M07,T-P]OJFHN]]?PB2W'E-'#=W$L<94L/+5?G<Y=OH^L_2=6TK7]*L]=T*\M
M]1TW4;>*[L[RTE6>WN;>=0\4L4J%DDCD1@RLI*LI!!(-:% ''_$+P5I7Q*\
M^)?ASKLMQ!IOBK1[_1+R6T94N([?48'MY6B9TD19%20E2R,H;&5(XK^&/Q_X
M \9?"SQEJWP^^(.DW&A^(=#N#;7UC<@!XG #*0REDDCD1E>.1&:.6-E=&9&5
MC_9;\=/VR?V<?V=K/4?^%C>,]/76M.PC>'-.E2^UQYY+=KJ&(V43&2#SXP-D
MMQY-N"\>^5 ZD_SH_%CQ)X^_X*I?M@06'PMT6WT"W@T>73=)DU/S]EKHVEM<
M70N]6FM8[H0R3SW!C'EH8DDFA@W.W[Z0 _:[]A[XJ? +X0_L;?"O1?$?Q(\'
MZ-OT^X:07OBBP?;J-U(-2O+9I)!9[+BW_M"(S6IC+VGF)$\DV!/+XA^V)_P5
M>^%_@;P;J'A3]F76[?Q9X[NKBZTTZK';2MI>B" ['NTDGC6#4)&)/V3R3-;,
M099&:-4BN/#_  G_ ,$.O^0->>.OBW_SZR:QI^DZ'_NFY@M+Z>\_WDBGDL_1
MV@ZQU]G_  O_ ."3/['_ ,.-5.L:GI>L>.;B.XM;FT3Q1?K-;VSVK,^/L]E#
M907$<Q*^;'=)/&RH%VA2X< _G1\-6O[07[%_COX:?'G^Q/[%N]7T^/Q)X6N[
MU(;[3M5TR^@,<J,8I&4>;:W&R:+?%=0I,C_NF:-Z_LM\ >/_  ;\4_!ND_$'
MX?:M;ZYX>URW%S8WUL24E0DJP*L%>.2-U9)(W59(I%9'575E'S!^W'^R+I7[
M7WPC7PI!=V^C^+-!N&U+PYJL\*NB7!C*26EQ((WG2SNAM\WR2&62.&4K+Y0B
M?\D/^"9G[5?BK]GGXCO^R'^T#9^(-(M/$&H65MX<LM4MI8I= UC43N6VDM)8
MENHK?5&N(G4@^7%*1+Y86XGG4 _H^HHHH __U?U-_;F^%^J_&+]DOXF> ]"-
MP=2GT?\ M*S@M+5KVXN[C1IXM2BM(H$97>2[>U$"[=S*T@8*Y&QOQ0_X(Y_M
M'Z%\._B/XB^!OC75?L%AX\^R7&@->7CI9KKEL6B-K%"4,*W&HPRJ!*SQEVM8
MH!YCO$H_I>K^3+]N#]E7QE^Q!\>=.^*7PHL[C3_ DNL6FK>#=6+C41I>J6FR
MZ^PW)GB($D,\;26R3B436RC,DTD=QL /ZS:*_,#]E'_@J+\#OCCH2:3\5=2T
M_P"&WC/3=/BGU(:Q=0V.AWLH<Q2-IUW<3_[DAMYRLJ"3;&;A8I)A^G] !17@
M'BS]JW]F7P-_;,?BGXJ^#[*[\/\ VI=1L/[:M)=1@ELMPG@^Q12O=/<(R,GD
M)$TI<; A; KXO\:_\%A?V/\ PKJL6GZ$_BCQC;R6ZS-?:)I*PV\;LSJ8675)
M]/G,BA0Q*Q-'M=<.6W*H!^$/P;\2:K^P;^VEI^I_%+1;C4+CX=:QJ.FZM:66
MZ%Y[>[M9[(W=G]JCA,L;P7 NK;S%B6XC*?-&LF]?Z+O^'HW["?\ T4S_ ,H&
MN?\ ROK\@?BCJGQ'_P""J&NZ->_!7]GK3_"%_8ZA(NO^/9;TO%,NRSMQ!>:@
M+6RAF^RPO%(T!CO+T1*IMD1!*LOU_P# O_@BY\.-*T+3M3_:'\1ZAK?B2'4#
M<7.F^&[L6^AO9QNOEVKRS6BWTOFJI,LL;VK*)-D>#&)G /G_ /;E_P""BOPX
M_:D\(:E^S;\(?A[J'BG^U]0T^/1/$5VH2\&JV]^%1],TT03W#_:[<>3$YDM[
MDK<O&T*\J_PA^QM^T-<_L7_M"S>,/&>@ZQ*D%O=>&]>TB%H;*]A1[F'[2LT-
MW;2.TEL\&\6ZR6DC3QHKSI'YJ/\ UN_"_P""GPC^"NE'1_A1X0T?PM;R6]K;
M7#Z;:1PW%XEDK) ;NX \^ZD0._[R=Y)"SLQ8LS$\A\:_V6/V??VB?LLGQC\$
MZ?X@N[+RU@O\S66HI%%YI2#[;9R071MPT\C^093$7;>4W $ 'Q__ ,/>?V-O
M^$$_X2[^TO$']J_]"M_8\G]L?Z_RO];O_LS[G[__ (_O]7Q_K?W5?A#^W]^U
M)X5_:V^.-I\0_!6CZAH^BZ5X?L]"MEU0Q"\N/)FN;J2:2*%Y8X?WETT:HLLN
M5C#EE+F-/Z+M)_X)E_L.:+JMGK%G\,+>2XL+B*YB2[U;5KRW9X6#J);>XO9(
M)HR1\T<J/&ZY5U920??X_P!F3]FV'2KC0H?A1X'33;RXM[NXLU\.:<+>:XM5
MF2"62(6^QI(4N)EC8@LBRN%(#MD ^$/"?A;7?VP/^"2^C>"O"UK_ &9K5WX/
MM=+TZV\Q)_M=YX,O5A@C\R5K6.+^T9-+5=SL%M_/R3((R6_%']EK]M;XN?L/
MW/C#P9I?A/1[I]3N)8]3LM<L)+35++5+&&>WA22:,PW'EV]PRM-:3[@ DB0F
MVDFEE/\ 8;10!_.#)X-_;S_X*:Z[\/=2^+WAK_A#_@[;ZA;S73V!.AV<MJZ"
MXEU*WMK^:[O+RXGLY?)LKD136BL^%V*URY_H.^'O@K2OAKX!\-?#G0I;B?3?
M"NCV&B6<MVRO<26^G0);Q-*R)&C2,D8+%452V<*!Q7844 >/_'[X.:%^T!\&
M_%GP=\1R?9[3Q-I[6\=SM=_LEY&RS6=UY<<L+2_9KJ.*;RC(JR;-C_*Q!_E"
M^"GQ(^(__!/+]KBZB\1V^V3P_J$GAOQ;:):&7^T-#DN(I)WLA=?99/WT<45W
M8REH1)B)GS"[HW]CM?,'[2G['_P._:IT(:9\3-'\G58?LZVGB32UAM]<M(K=
MW<01W<D,NZW;S90T$J219D+A!*$D4 _(#_@IA_P4&^$_QD^#>F_!W]GWQ%_;
M]IXAU 7'B>Y^PW5GY-GIK1S6UKY=_91,WVBZ*3>;!(K1_9=C968BON_]DS]B
MGP:?V(?#'P9_:(\-6^LG7;C_ (2S4=,N(#I]QIU[=L)+=/.@@L;^*\@MMD-P
MTLCSJQEMA*UJ$B7G_A/_ ,$B/V7/AQXRG\5^(7UCQY;P7$4NDZ5K\T1LK81"
MW<&YCM8H!?2>?%-E90+9H)A%);NR>:_ZGT ?D#\;OV6_^&1_^";WQE^&_P (
M=8\0:W)J6H-KMQ< ;;Q-.N;^P@NH6%HB$V\6D6Y6\<_)(HGD98X7\J/Y/_X(
MP_!?XH:=\2];^.^H>'[BU\":IX7U+0;'6)GBC2ZOUU#3I&2&)G$\D8$,JF98
MS")(WCW^8K*/Z+J* /QQ_;C_ ."6-M\>O&2_%;X"7FC^%?$^K7#/XEL=4::W
MTN_=P6-_$UM!</#>,^!.HC\NX+><2DPD:X_-#0/A;_P57_9RT[4O!'@_3/B!
MIFE1^'Y]VGZ-<#6].M['4KQ8I?[/6UDN[>#4#<.9/]#VW\*,]P-D1DDK^KVB
M@#^:'P+_ ,$O/VR?VAO%5]J_[5?BW4/"_P#9FGQ6VGZIKNH1^,-1NLRNZVT*
MQ:BWE6\6Z1W,DZ8>11'&^^1HS2/V</V__P#@G#\1[OQE\$-*_P"%D^&]8S83
MQZ/9W.J6>HQ$W/V7^T=(MW2^@N(%3SA-"6B@:7R1=2"62.3^EZB@#\P/@Y^W
MS\<?B/\ &3PO\)_&/[,/C#P5'XC^U2MJ5[<S+]DL[-4\^\:*^TW3XWMX))H%
MF83AE\U%C669XH9?T_HHH **** "BBB@ HHHH _G!_X+-_LZ?\(UX[T+]I?0
M(<6'B_RM"\0?-]S6+. _8YOWD[,?M-C"8]D4*QQ_8]SL7GY_2_\ X)C_ +0.
ME?&_]ESP]H3-;P>(?AQ;VWA75+.(JA%O91*FG70B\^:7R[BT55:5Q&LES%<"
M- B"OK_XT?"'P;\>OA?X@^$?Q CN)-"\16Z0W!M)C!<1/#*D\$T3@$"2&>-)
M5#J\;,H$B.A9&_$'Q;_P0^U7_A(2W@3XIVYT*>XD8)J^E-]MM+=KNW5(R\$W
MEW4B6;W#M)MME>>&*,(B3O);@'E_[:OCJS_X*"?MJ_#[]G[X*Z]_:GAO2-^C
MC4HH;=[..\ED>XUO4;.1I86O;>"QMHBH,JK,ULWV;<)%DE^<++4_BY_P2P_;
M O[6!+?Q EE;K;3&:VDM+7Q)X:U!HIP87E1GMY-\2@R0F58+N!XRUQ&DB2?T
M/?LB?L.?"/\ 9!TJ[G\*-<:]XLUBWA@U7Q'J2QBX=$6,R6]I&B@6MF\Z&;RM
MTDC-M$LTOE1%/?\ XO?!?X7_ !Z\&R> /BYX?M_$6A27$-V+>9Y87BN("2DL
M,\#QSPR %D+12*S1N\;$H[JP!\8>%O\ @K!^Q+X@T*UU?5O%^H>&;NX\SS-+
MU31-0DO+?8[(/,:P@O+4[U4.OESO\K#=M;<J_*'Q0_X+<> ;72A#\%_A[K&I
MZE/;W2FX\430:=;V=QM46LGD6<MX]W'O+&6/SK5MJA5?+ED^GX_^"2?[%J>)
MKC7F\/ZQ)8SW%O,FBMK-U]@@2&VF@>&-U87ACFDD6YD+W+R":%!&Z0&2&3Z@
M^$/[(7[-'P(N8]0^%OP]T?2=2@N)KF#5)HWU'5+=[B$6\@AO[Y[B[BC:+*F.
M.58\,_RY=RP!_/CIO[.G[>?_  45\=Z5\2_B?#J&C^#-8U!IK?5-68VNCZ+I
MUU!!,9-'TB>=;B6WEMUA6&2!"EU(%,UR6$LR_N]\6?V*/@W\7/@%H'P+\1V7
MVO\ X0KP^NB^$M?O0TFHZ5/#8"Q@NV:U>T\_&R*6:W)2WG>--Z?*FWZ_HH _
MGQ_95_9/_;2_8Q_; L]+\-:1<>*OAGK=P]IK6IV-]:V>EZCHB-'&E[<0SO(]
MO>:>]XLZ6^W[1*8[F&VDE@,TI_H.HHH Y_Q3X3\*^.="NO"WC71M/\0:+>^7
M]IT[5+6*]LY_*=98_,@F5XWV2(KKN4X901R :X_P5\$?@O\ #759==^'/@'P
MOX5U*>W:TEO-$T:STZXDMW9':)I;>&-VC9XT8J3M+*IQD#'J%% ''^/_  !X
M-^*?@W5OA]\0=)M]<\/:Y;FVOK&Y!*2H2&4AE*O')&ZJ\<B,LD4BJZ,KJK#\
MT/#G_!&W]D?1+QKK4[SQAX@C;R,6^HZI;QQ+Y5Q#.^#96=K)^^CB>W?+G$4T
MA39,(I8_U?HH *_*#_@L%\'-"\<_LP'XJW$GV?6OAIJ%M<6<FUW\^SUJYMK"
MZM<"5(TWR/;S^:R2,/L_EKM$CM7ZOUGZMI.E:_I5YH6NV=OJ.FZC;RVEY9W<
M2SV]S;SJ4EBEB<,DD<B,596!5E)!!!H _"'_ ((L?M ZKJ-MXK_9HUQKBZM]
M+MW\5:!*Q:1+6W::*WU"U+/.1'&9YH)X(HH0IDDNGD?<R@_O=7\B7[1WP0\?
M?\$W?VH_#?B;P'J=QJ&FV]Q'XA\)ZK<I/"+FWBE*7&F7\D'V=)I%3]S>)!(J
MS6TZ,PB$_E)_1]^RK^V)\(_VK_!MGK/@_4+?3O$ZV[R:OX3N;F-M4TYX#&DS
MB/Y7N+/?-'Y=VB"-PZJPCF#PH >7_P#!13]E'0OVF/@=?ZM&FH?\)G\/]/U3
M6/#)TZ-[N6[E\E99].-HI_??;OL\<:%!YL<HC9-R^9#+\H?\$D/VQ+;QOX-C
M_9A^(.H6\/B'PK;Y\*37-S,]UK&E@RRRVH$VY#)IB!1&B2 FTVA(0EK+(?VN
MK^8+XE_\6?\ ^"R5G_PKK_B4_;_B!X<^T?\ +SO_ .$MM[+^U_\ CX\W'VK^
MT+GICRO,_=>7M3: '_!0#]@WXXR_M5ZMXD^#O@+4-?\ #?Q*U!-1L9M'$U[%
M:ZG=B(:@-1EDRMAYE]))<!YG2U$4OR2*(I4A_HM^'ND^)M?^"_AK0OC?9V^H
M^(=1\+V%IXOL[N*VGM[F_GLT34HI8H0UI)')*TBLL8,+*2%!0BO4** /A#5O
M^"9?[#FM:K>:Q>?#"WCN+^XEN94M-6U:SMU>9B["*WM[V."&,$_+'$B1HN%1
M54 #YP_X<J?LL_\ 0T_$#_P8Z7_\J:_7ZB@#\D-)_P"",/[*&G:K9ZA>:WXX
MU2WM;B*:6QN]3L5M[I(V#-#*UOIT$XCD VL8I8Y I.QU;##[0^&G[%G[*GPB
M\B3P+\,/#]O=VFH)JEK?ZA;'5]1M;R/RS');WNHM<W4/EM$KQK'*JH^74!F8
MGZ?HH *^(/VG?^"?_P"S[^T[_;7B37])_L3Q]J6GQ6=MXKT]YEGAEMO^/>6X
MM%E2UO-J@12&5/-:W C26/9$\?V_10!_/C9?\$G_ -KOX17-^O[/'QTM])M]
M2N%6\>&^U;PP]U;V\,36\DR:>+P/(L\UV@C9F6.-4D5RT[QP]!'_ ,$YO^"A
M_B;2KC0OB!^TE</INI7%O8:A9KXE\0:G;SZ-=+,FH-)%.ENDLBIY:QVK@17"
MNXDFA"#S/WNHH _%'P5_P1'^"]AI4L/Q&^(7BC7-2-PS17&B0V>C6ZVY5 L;
M07$6INT@<.3()E4JRKL!4LWZW?#3X5?#CX-^%8/!7PM\.:?X9T6WV-]FT^$1
M^=*D4</GW$G,EQ<-'$BR3S,\LFT%W8\UZ!10 4444 %?$'[:O[$WA7]L'PKI
M6F_VAI_A+Q)IFH6\_P#PDW]BQ:EJ,FG6\5VO]G^9YUK,MNTUUYVWS2@=<["3
MN'V_10!S_A/0/^$4\*Z-X6_M+4-8_L?3[73_ .T=6G^U:C>?98EB^T7<^U?-
MN)=N^63:-[DG SBN@HHH __6_?RN/\?^ /!OQ3\&ZM\/OB#I-OKGA[7+<VU]
M8W()25"0RD,I5XY(W57CD1EDBD571E=58=A10!^(/Q+_ .")?PX\0>*I]6^%
MOQ$U#P?HMQOD_LC4-,&M_9Y7ED?9;W/VNSD%ND;)'&DPFE^0L\SEOE\__P"'
M&/\ U6S_ ,M3_P"^]?O]10!^(/@7_@B'\+-/^W?\++^)?B#7O,\K[%_85E:Z
M)Y.-_F^=]I_M3SM^4V;?*V;6SOW#;]W_  O_ .">_P"Q_P#"K2CI^F?#;1]?
MN)K>UAN[[Q1"NO7%P]JK+YVV]$L%O)*79I1:Q01NQ'R!415^SZ* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_ .)?PJ^'
M'QD\*S^"OBEX<T_Q-HMQO;[-J$(D\F5XI(?/MY.)+>X6.5UCGA9)8]Q*.IYK
M\$?BA_P2,^//P<U4?$;]DOQ]<:QJ5C<736=H+C_A'?$%I;W#+!%';:@DZ6]Q
M)]GFE%S(SV*LB'8C&3RE_HNHH _G!_X67_P6T_MC^POL?B#[3_?_ .$<\/\
MV7_D(_V7_P ?7V/[/_Q\?/\ ZS_CT_TW_CS_ ']=A^S)_P $]OVJ/'7[4</[
M1/[7]Q<:-/H6L67B8S-?V&H7^MZI:2K+:P1BSEN(+6SMS"@D4A L(2WMXU4F
M2#^@ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]?]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH __0_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025011912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-6571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merck&#160;& Co., Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">740-4000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1918501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 Galloping Hill Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Kenilworth<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock ($0.50&#160;par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,527,733,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196,870,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000310158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022, to be filed with the </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities and Exchange Commission within 120&#160;days after the close of the fiscal year covered by this report</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A0.500Notesdue2024Member', window );">0.500% Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.875Notesdue2026Member', window );">1.875% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.875% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.500Notesdue2034Member', window );">2.500% Notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.500% Notes due 2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.375Notesdue2036Member', window );">1.375% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 36A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A0.500Notesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A0.500Notesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.875Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.875Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.500Notesdue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.500Notesdue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.375Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.375Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229032804152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Florham Park, New Jersey<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229031385448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
<td class="nump">$ 39,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">13,626<span></span>
</td>
<td class="nump">13,618<span></span>
</td>
<td class="nump">12,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">9,634<span></span>
</td>
<td class="nump">8,955<span></span>
</td>
<td class="nump">9,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,245<span></span>
</td>
<td class="nump">13,397<span></span>
</td>
<td class="nump">9,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(1,341)<span></span>
</td>
<td class="num">(890)<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CostsExpensesAndOther', window );">Total costs, expenses and other</a></td>
<td class="nump">34,825<span></span>
</td>
<td class="nump">35,655<span></span>
</td>
<td class="nump">31,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from Continuing Operations Before Taxes</a></td>
<td class="nump">13,879<span></span>
</td>
<td class="nump">5,863<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on Income from Continuing Operations</a></td>
<td class="nump">1,521<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net Income from Continuing Operations</a></td>
<td class="nump">12,358<span></span>
</td>
<td class="nump">4,523<span></span>
</td>
<td class="nump">5,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net Income (Loss) Attributable to Noncontrolling Interests</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">12,345<span></span>
</td>
<td class="nump">4,519<span></span>
</td>
<td class="nump">5,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
<td class="nump">4,153<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">$ 13,049<span></span>
</td>
<td class="nump">$ 7,067<span></span>
</td>
<td class="nump">$ 9,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">1.01<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Income (in dollars per share)</a></td>
<td class="nump">5.16<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">4.86<span></span>
</td>
<td class="nump">1.78<span></span>
</td>
<td class="nump">2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="nump">1.61<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Income (in dollars per share)</a></td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CostsExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of cost of sales, operating expenses and nonoperating income or expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CostsExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229031054424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">$ 13,049<span></span>
</td>
<td class="nump">$ 7,067<span></span>
</td>
<td class="nump">$ 9,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive Income (Loss) Net of Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized gain (loss) on derivatives, net of reclassifications</a></td>
<td class="nump">410<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized (loss) gain on investments, net of reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Benefit plan net gain (loss) and prior service credit (cost), net of amortization</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="num">(423)<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="num">(441)<span></span>
</td>
<td class="num">(648)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 14,805<span></span>
</td>
<td class="nump">$ 6,626<span></span>
</td>
<td class="nump">$ 9,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229030881880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,096<span></span>
</td>
<td class="nump">$ 8,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable (net of allowance for doubtful accounts of $62 in 2021 and $67 in 2020)</a></td>
<td class="nump">9,230<span></span>
</td>
<td class="nump">6,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (excludes inventories of $2,194 in 2021 and $2,070 in 2020 classified in Other assets - see Note&#160;8)</a></td>
<td class="nump">5,953<span></span>
</td>
<td class="nump">5,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6,987<span></span>
</td>
<td class="nump">4,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">30,266<span></span>
</td>
<td class="nump">27,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property, Plant and Equipment (at cost)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">12,529<span></span>
</td>
<td class="nump">11,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery, equipment and office furnishings</a></td>
<td class="nump">16,303<span></span>
</td>
<td class="nump">15,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">8,313<span></span>
</td>
<td class="nump">6,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment (at cost)</a></td>
<td class="nump">37,471<span></span>
</td>
<td class="nump">35,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="nump">18,192<span></span>
</td>
<td class="nump">18,162<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">19,279<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,264<span></span>
</td>
<td class="nump">18,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other Intangibles, Net</a></td>
<td class="nump">22,933<span></span>
</td>
<td class="nump">14,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">11,582<span></span>
</td>
<td class="nump">9,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Noncurrent Assets of Discontinued Operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">105,694<span></span>
</td>
<td class="nump">91,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">2,412<span></span>
</td>
<td class="nump">6,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="nump">4,609<span></span>
</td>
<td class="nump">4,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">13,859<span></span>
</td>
<td class="nump">12,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,768<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">23,872<span></span>
</td>
<td class="nump">27,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">30,690<span></span>
</td>
<td class="nump">25,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Taxes</a></td>
<td class="nump">3,441<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="nump">9,434<span></span>
</td>
<td class="nump">12,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Noncurrent Liabilities of Discontinued Operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2021 and 2020</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Other paid-in capital</a></td>
<td class="nump">44,238<span></span>
</td>
<td class="nump">39,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">53,696<span></span>
</td>
<td class="nump">47,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,429)<span></span>
</td>
<td class="num">(6,634)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' equity before deduction for treasury stock</a></td>
<td class="nump">95,293<span></span>
</td>
<td class="nump">82,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less treasury stock, at cost: 1,049,499,023 shares in 2021 and 1,046,877,695 shares in 2020</a></td>
<td class="nump">57,109<span></span>
</td>
<td class="nump">56,787<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</a></td>
<td class="nump">38,184<span></span>
</td>
<td class="nump">25,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interests</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">38,257<span></span>
</td>
<td class="nump">25,404<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">$ 105,694<span></span>
</td>
<td class="nump">$ 91,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026649384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory classified in Other assets</a></td>
<td class="nump">$ 2,194<span></span>
</td>
<td class="nump">$ 2,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">6,500,000,000<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">1,049,499,023<span></span>
</td>
<td class="nump">1,046,877,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023082760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Other Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- controlling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 26,882<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 38,808<span></span>
</td>
<td class="nump">$ 42,579<span></span>
</td>
<td class="num">$ (5,545)<span></span>
</td>
<td class="num">$ (50,929)<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">9,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(5,820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">(4,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">26,001<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">39,660<span></span>
</td>
<td class="nump">46,602<span></span>
</td>
<td class="num">(6,193)<span></span>
</td>
<td class="num">(55,950)<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">7,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(6,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">25,404<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">39,588<span></span>
</td>
<td class="nump">47,362<span></span>
</td>
<td class="num">(6,634)<span></span>
</td>
<td class="num">(56,787)<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">13,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(6,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">(840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">5,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 38,257<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 44,238<span></span>
</td>
<td class="nump">$ 53,696<span></span>
</td>
<td class="num">$ (4,429)<span></span>
</td>
<td class="num">$ (57,109)<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229033095992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="nump">$ 2.64<span></span>
</td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229022625448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities of Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations</a></td>
<td class="nump">$ 12,358<span></span>
</td>
<td class="nump">$ 4,523<span></span>
</td>
<td class="nump">$ 5,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,578<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Intangible asset impairment charges</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Income from investments in equity securities, net</a></td>
<td class="num">(1,940)<span></span>
</td>
<td class="num">(1,338)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Charge for the acquisition of Pandion Therapeutics, Inc.</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo', window );">Charge for the acquisition of VelosBio Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,660<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree', window );">Charge for the acquisition of Peloton Therapeutics, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">187<span></span>
</td>
<td class="num">(566)<span></span>
</td>
<td class="num">(560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,033)<span></span>
</td>
<td class="num">(1,002)<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(674)<span></span>
</td>
<td class="num">(895)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">277<span></span>
</td>
<td class="num">(1,152)<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(540)<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="num">(1,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Noncurrent liabilities</a></td>
<td class="nump">484<span></span>
</td>
<td class="num">(617)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="num">(1,758)<span></span>
</td>
<td class="num">(2,433)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net Cash Provided by Operating Activities of Continuing Operations</a></td>
<td class="nump">13,122<span></span>
</td>
<td class="nump">7,617<span></span>
</td>
<td class="nump">8,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities of Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(4,448)<span></span>
</td>
<td class="num">(4,429)<span></span>
</td>
<td class="num">(3,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchase of Seagen Inc. common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of securities and other investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(3,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales of securities and other investments</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
<td class="nump">8,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisition of Acceleron Pharma Inc., net of cash acquired</a></td>
<td class="num">(11,174)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired', window );">Acquisition of Pandion Therapeutics, Inc., net of cash acquired</a></td>
<td class="num">(1,554)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired', window );">Acquisition of VelosBio Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,696)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired', window );">Acquisition of ArQule, Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,545)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired', window );">Acquisition of Antelliq Corporation, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired', window );">Acquisition of Peloton Therapeutics, Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Other acquisitions, net of cash acquired</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(1,365)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(91)<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net Cash Used in Investing Activities of Continuing Operations</a></td>
<td class="num">(16,421)<span></span>
</td>
<td class="num">(9,193)<span></span>
</td>
<td class="num">(2,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities of Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="num">(3,986)<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
<td class="num">(3,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on debt</a></td>
<td class="num">(2,319)<span></span>
</td>
<td class="num">(1,957)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">7,936<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived', window );">Distribution from Organon &amp; Co.</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(840)<span></span>
</td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">(4,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid to stockholders</a></td>
<td class="num">(6,610)<span></span>
</td>
<td class="num">(6,215)<span></span>
</td>
<td class="num">(5,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net Cash Provided by (Used in) Financing Activities of Continuing Operations</a></td>
<td class="nump">3,097<span></span>
</td>
<td class="num">(2,832)<span></span>
</td>
<td class="num">(8,861)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by operating activities</a></td>
<td class="nump">987<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
<td class="nump">4,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(134)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in financing activities</a></td>
<td class="num">(504)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations', window );">Net Cash Flows Provided by Discontinued Operations</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">4,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(133)<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $103 of restricted cash at January 1, 2021 included in Other Assets - see Note 7)</a></td>
<td class="nump">8,153<span></span>
</td>
<td class="nump">9,934<span></span>
</td>
<td class="nump">7,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Less: Cash and cash equivalents related to discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Year (includes $71 of restricted cash at December 31, 2021 included in Other Assets - see Note 7)</a></td>
<td class="nump">$ 8,167<span></span>
</td>
<td class="nump">$ 8,153<span></span>
</td>
<td class="nump">$ 9,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Including Discontinued Operations Distribution Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business Five, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business Four, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business Seven, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business Six, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in cash associated with the entity's discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025008824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026886600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#8217;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin-Off of Organon &amp; Co. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off (see Note 3).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026420760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Accounting Policies</a></td>
<td class="text">Summary of Accounting Policies<div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#8217; interests are shown as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#8217;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#8217;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2021, $11.4 billion in 2020 and $9.9 billion in 2019. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $207 </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and $2.6 billion, respectively, at December&#160;31, 2021 and were $208 million and $2.6 billion, respectively, at December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzUz_b48cccc3-76a0-476d-bb80-193b05cdb46c">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for disaggregated revenue disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and from 3 to 15&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Depreciation expense was $1.6 billion in 2021, $1.7 billion in 2020 and $1.6 billion in 2019.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion Costs &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.0 billion in 2021, $1.8 billion in 2020 and $1.9 billion in 2019.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income from Continuing Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued amended guidance on the accounting for convertible instruments and contracts in an entity&#8217;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The amended guidance is effective for interim and annual periods in 2022. The application of the amendments in the new guidance are to be applied either on a modified retrospective or a retrospective basis. There was no impact to the Company&#8217;s consolidated financial statements upon adoption on January 1, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards&#160;Not Yet Adopted &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements. The Company is progressing in its evaluation of LIBOR cessation exposures, including the review of debt-related contracts, leases, business development and licensing arrangements, royalty and other agreements. The Company has amended certain agreements and continues to review other agreements for potential impacts. With regard to debt-related exposures in particular, all existing interest rate swaps linked to LIBOR will mature in 2022. The Company is still evaluating the impact to its LIBOR-based debt. Based on its evaluation thus far, the Company does not anticipate a material impact to its consolidated financial statements as a result of reference rate reform. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have a material impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div>In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to the company&#8217;s financial statements. The guidance is effective for annual periods beginning in 2022 and is to be applied on either a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026521208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Spin-Off of Organon &amp; Co.</a></td>
<td class="text">Spin-Off of Organon &amp; Co.On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one-tenth of a share of Organon&#8217;s common stock for each share of Merck common stock held by such shareholder. The <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5&#160;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0&#160;billion were distributed by Organon to Merck in connection with the spin-off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture and supply certain formulated pharmaceutical products for Organon, and (c) package and label certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in the consolidated statement of income for the above MSAs include sales of $219&#160;million and related cost of sales of $195&#160;million in 2021. Amounts included in the consolidated statement of income for the TSAs was immaterial in 2021. The amount due from Organon under the above agreements was $964&#160;million at December&#160;31, 2021 and is reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount due to Organon under these agreements was $400&#160;million at December&#160;31, 2021 and is included in A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ccrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the women&#8217;s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company&#8217;s consolidated statement of income as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through June 2, 2021, the date of the spin-off. Prior periods have been recast to reflect this presentation. As a result of the spin-off of Organon, Merck incurred separation costs of $556&#160;million in 2021 and $743&#160;million in 2020, which are also included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. As of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">789</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of assets and liabilities of discontinued operations are as follows:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, less allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent Assets of Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent Liabilities of Discontinued Operations</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the spin-off of Organon, Merck distributed net liabilities of $5.1&#160;billion as of June 2, 2021 consisting of debt of $9.4&#160;billion (described above), goodwill of $1.4&#160;billion, property, plant and equipment of $981&#160;million, cash of $929&#160;million, inventory of $815&#160;million, other intangibles, net, of $519&#160;million and other net liabilities of $328&#160;million. The spin-off also resulted in a net decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $449 million consisting of $421 million for the derecognition of net losses on foreign currency translation adjustments and $28 million associated with employee benefit plans. The distribution of the net liabilities and reduction to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulted in a net $4.6 billion increase to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>Expenses for curtailments, settlements and termination benefits provided to certain employees were incurred in connection with the spin-off (see Note 14). Additionally, all outstanding Merck stock options, restricted stock units (RSUs) and performance share units (PSUs) (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees (see Note 13).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026906312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock', window );">Acquisitions, Research Collaborations and License Agreements</a></td>
<td class="text">Acquisitions, Research Collaborations and License Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $11.5&#160;billion. Acceleron is evaluating the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron&#8217;s lead therapeutic candidate, sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. Under a previous agreement assumed by Merck, Bristol Myers Squibb (BMS) was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay 22% royalties on future sales of sotatercept in the PH field to BMS. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to sotatercept, Acceleron&#8217;s portfolio includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated in Phase 2 and Phase 3 trials for additional indications for hematology therapies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is being developed and commercialized through a global collaboration with BMS. In connection with this ongoing collaboration, Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Merck is eligible to receive future contingent milestone payments including up to $20&#160;million in regulatory milestones and up to $80&#160;million in sales-based milestones. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as a business combination. The Company incurred $280&#160;million of costs directly related to the acquisition of Acceleron, consisting primarily of share-based compensation payments to settle non-vested equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs in 2021. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Acceleron is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D - sotatercept </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and product rights - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reblozyl </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12 year useful life)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,832)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,092&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Total consideration paid of $1.9 billion included $147&#160;million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $1.7 billion in 2021 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead&#8217;s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Merck and Gilead will share operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. Global development and commercialization costs will be shared 60% Gilead and 40% Merck across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation revenue tiers. Upon passing $2.0&#160;billion a year in net product sales for the oral combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold. Upon passing $3.5&#160;billion a year in net product sales for the injectable combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the U.S. Food and Drug Administration (FDA) placed full or partial clinical holds on investigational new drug applications for certain oral, implant and injectable formulations of islatravir based on </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. As a result of these holds, Merck and Gilead made the decision to stop all dosing of participants in a Phase 2 clinical study evaluating islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. The two companies are assessing whether a different dosing of islatravir in combination with lenacapavir may provide a once-weekly oral therapy option for people living with HIV. Merck and Gilead remain committed to their collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva&#8217;s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30&#160;million, which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15&#160;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5&#160;million in developmental milestones, $570&#160;million in regulatory milestones, and $1.05&#160;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423&#160;million. OncoImmune&#8217;s lead therapeutic candidate (MK-7110) was being evaluated for the treatment of patients hospitalized with COVID-19. The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50&#160;million for a 20% ownership interest in the new entity, which was valued at $33&#160;million resulting in a $17&#160;million premium. Merck also recognized other net liabilities of $22&#160;million. The Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $462&#160;million in 2020 related to this transaction. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential Emergency Use Authorization (EUA) application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#8217;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207&#160;million in 2021, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio&#8217;s lead investigational candidate is zilovertamab vedotin (MK-2140), an antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180&#160;million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $2.7 billion in 2020 related to the transaction. During 2021, the Company recorded adjustments to these amounts which resulted in a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $43&#160;million, an increase to total consideration paid of $47&#160;million, and an increase to net assets recorded of $90&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen) announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. Merck recorded $616&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020 related to this transaction reflecting the upfront payment as well as a $16&#160;million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6&#160;billion, including $850&#160;million in development milestones and $1.75&#160;billion in sales-based milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million, which were recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65&#160;million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#8364;256&#160;million ($302&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289&#160;million and other net assets of $13&#160;million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410&#160;million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401&#160;million related to currently marketed products and inventory of $9&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. See Note 5 for additional information related to this collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make additional contingent payments of up to $740&#160;million. The transaction was accounted for as a business combination. The Company determined the fair value of the contingent consideration was $85&#160;million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;D of $113&#160;million, cash of $59&#160;million, deferred tax assets of $72&#160;million and other net liabilities of $32&#160;million. The excess of the consideration transferred over the fair value of net assets acquired of $239&#160;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;D impairment charge of $90&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. The Company also recorded a reduction in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses resulting from a decrease in the related liability for contingent consideration of $45&#160;million since future contingent milestone payments have been reduced to $450&#160;million in the aggregate, including up to $60&#160;million for development milestones, up to $196&#160;million for regulatory approval milestones, and up to $194&#160;million for commercial milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $6.5&#160;million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#8217;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305&#160;million in 2020, of which $260&#160;million was reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The remaining $45&#160;million of costs were reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138&#160;million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95&#160;million of costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2020. ArQule&#8217;s lead investigational candidate, nemtabrutinib (MK-1026), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as a business combination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D - nemtabrutinib </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Merck recorded a $275 million intangible asset impairment charge related to nemtabrutinib (see Note 9).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2&#945; (HIF-2&#945;) for the treatment of patients with cancer and other non-oncology diseases. Merck made an upfront payment of $1.2 billion. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $157 million, deferred tax liabilities of $52 million, and other net liabilities of $4 million at the acquisition </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $993 million in 2019 related to the transaction. Former Peloton shareholders received a $50 million milestone payment from Merck in 2021 upon first commercial sale of Peloton&#8217;s lead candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (belzutifan), which was approved as monotherapy in the U.S. in August 2021. Former Peloton shareholders are also eligible to receive $50 million upon U.S. regulatory approval as a combination therapy, as well as up to $1.05 billion of sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq&#8217;s debt. The transaction was accounted for as a business combination. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:1pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.721%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from 18-24 years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in 2019.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span> approaches to enable the body&#8217;s immune system to fight disease, for $301 million in cash. The transaction was accounted for as a business combination. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets of $42 million. The excess of the consideration transferred over the fair value of net assets acquired of $20 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to acquisitions, research collaborations and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026451240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangements</a></td>
<td class="text">Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below.</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing AstraZeneca&#8217;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. Merck made sales-based milestone payments to AstraZeneca aggregating $550 million and $200 million in 2020 and 2019, respectively. As of December&#160;31, 2021, sales-based milestone payments accrued but not yet paid totaled $400&#160;million. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019, Lynparza received regulatory approvals triggering capitalized milestone payments of $160&#160;million and $60 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at December&#160;31, 2021 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ccounts payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. Merck made sales-based milestone payments to Eisai aggregating $200&#160;million, $500 million and $50 million&#160;in 2021, 2020 and 2019, respectively. As of December&#160;31, 2021, sales-based milestone payments accrued but not yet paid totaled $600&#160;million. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $75&#160;million and $10&#160;million, respectively, from Merck to Eisai. As of December&#160;31, 2021, a regulatory approval milestone payment of $25&#160;million was accrued but not yet paid. Potential future regulatory milestone payments of $25 million remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.0 billion at December&#160;31, 2021 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#8217;s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales of Adempas and Verquvo in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375&#160;million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment that was outstanding under this agreement. Accordingly, Merck recorded a liability of $400&#160;million and a corresponding increase to the intangible assets related to this collaboration. Merck also recognized $153&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in 2021. In January 2022, Merck made this final milestone payment to Bayer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $806 million and $68 million, respectively, at December&#160;31, 2021 and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">424</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense as noted above. In addition, cost of sales in all periods now includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued milestone payment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck and Ridgeback, a closely held biotechnology company, entered into a collaboration agreement to develop molnupiravir (MK-4482), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit share calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#8217;s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the FDA granted EUA for molnupiravir. Under a previously announced procurement agreement with the U.S. government, Merck agreed to supply 3.1&#160;million courses of molnupiravir to the U.S. government upon EUA or approval from the FDA, of which approximately 888,000 courses were delivered in 2021. This procurement of molnupiravir is being supported in whole or in part with federal funds. Additionally, in December 2021, Japan&#8217;s Ministry of Health, Labor and Welfare granted Special Approval for Emergency in Japan for molnupiravir. Under a supply agreement, the Japanese government will purchase 1.6&#160;million courses of molnupiravir, of which approximately 200,000 courses were delivered in 2021. Also, in November 2021, the Medicines and Healthcare products Regulatory Agency in the United Kingdom (UK) granted conditional marketing authorization for molnupiravir. The UK government has committed to purchase a total of 2.23&#160;million courses of molnupiravir, of which approximately 152,000 courses were delivered in 2021. Merck has entered into advance purchase and supply agreements for molnupiravir in more than 30 markets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and Ridgeback are committed to providing timely access to molnupiravir globally through a comprehensive supply and access approach, which includes investing at risk to produce millions of courses of therapy; tiered pricing based on the ability of governments to finance health care; entering into supply agreements with governments as noted above; allocating up to 3&#160;million courses of therapy to the United Nations Children&#8217;s Fund (UNICEF) for use in adults; and granting voluntary licenses to generic manufacturers and to the Medicines Patent Pool (MPP) to make generic molnupiravir available in more than 100 low- and middle-income countries following local regulatory authorizations or approvals. Merck, Ridgeback and Emory University will not receive royalties for sales of molnupiravir under the MPP agreement (molnupiravir was invented at Emory University and licensed to Ridgeback) for as long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molnupiravir sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount in 2020 includes upfront payment.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued royalty and milestone payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026909112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $868 million in 2021, $880 million in 2020 and $915 million in 2019 related to restructuring program activities. Since inception of the Restructuring Program through December&#160;31, 2021, Merck has recorded total pretax accumulated costs of approximately $2.7 billion. The Company expects to record charges of approximately $400 million in 2022 related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">661</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2021, 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;14) and share-based compensation. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:45.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December&#160;31, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">637</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be substantially completed by the end of 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026509496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:35.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.745%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(296)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021,&#160;five interest rate swaps with a total notional amount of&#160;$1.15&#160;billion&#160;matured. These swaps effectively converted the Company&#8217;s&#160;$1.15&#160;billion,&#160;3.875%&#160;fixed-rate notes due 2021 to variable rate debt. At December&#160;31, 2021, the Company was a party to nine pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These interest rate swaps matured in February 2022.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. See Note 2 for a discussion of the pending discontinuation of LIBOR as part of reference rate reform. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:43.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,073</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,713</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32,958</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:59.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collateral posted/received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,756</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:41.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company estimates $170 million of pretax net unrealized gains on derivatives maturing within the next 12&#160;months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December&#160;31 is as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,733</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2021 were $232 million during 2021. Unrealized net gains recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2020 were $163 million during 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, the Company also had $596 million and $586 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During 2021, the Company recorded unrealized gains of $110 million and unrealized losses of $1 million related to certain of these equity investments still held at December&#160;31, 2021. During 2020, the Company recorded unrealized gains of $62 million and unrealized losses of $3 million related to certain of these investments still held at December&#160;31, 2020. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December&#160;31, 2021 were $234 million and $7 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, the Company also had $1.7&#160;billion and $800&#160;million, respectively, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. (Gains) losses recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating to these investment funds were $(1.4)&#160;billion, $(583)&#160;million and $113&#160;million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,363</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,363</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include cash equivalents of $6.8 billion (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)(3)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Balance at December&#160;31, 2021 includes $151 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At December&#160;31, 2021 and 2020, $620 million and $711 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 4). The payments of contingent consideration in both years relate to the Sanofi Pasteur MSD liabilities described above. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at December&#160;31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion and at December&#160;31, 2020, was $36.0 billion compared with a carrying value of $31.8 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately 20%, 15% and 10%, respectively, of total accounts receivable at December&#160;31, 2021. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.8 billion and $2.1 billion of accounts receivable as of December&#160;31, 2021 and 2020, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2021 and 2020, the Company had collected $62 million and $102&#160;million, </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in January 2022 and 2021, respectively. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $164 million at December&#160;31, 2021. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>. Cash collateral advanced by the Company to counterparties was $36 million at December&#160;31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026520088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,147</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,624&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised approximately $3.3 billion and $2.8 billion at December&#160;31, 2021 and 2020, respectively. Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At December&#160;31, 2021 and 2020, these amounts included $1.9 billion and $1.8 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $256 million and $279 million at December&#160;31, 2021 and 2020, respectively, of inventories produced in preparation for product launches.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026425272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangibles</a></td>
<td class="text">Goodwill and Other Intangibles<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,431</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,997</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2021 and 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The additions to goodwill in the Pharmaceutical segment in 2021 were primarily related to the acquisition of Acceleron. The additions to goodwill in the Pharmaceutical segment in 2020 were primarily related to the acquisitions of ArQule and Themis. See Note 4 for more information on these acquisitions. </span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other acquired intangibles at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,671</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,776</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, IPR&amp;D, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. Some of the more significant acquired intangibles, on a net basis, related to human health marketed products (included in products and product rights above) at December&#160;31, 2021 include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $3.8 billion; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $478 million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, $191 million; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $145 million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Dificid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $145 million;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $138 million; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $101 million. Additionally, the Company had $5.0 billion of net acquired intangibles related to animal health marketed products at December&#160;31, 2021, of which $2.3&#160;billion relate primarily to trade names obtained through the 2019 acquisition of Antelliq (see Note 4). At December&#160;31, 2021, IPR&amp;D primarily relates to MK-7962 (sotatercept), $6.4 billion, obtained through the acquisition of Acceleron in 2021 (see Note 4); MK-1026 (nemtabrutinib), $2.0 billion, obtained through the acquisition of ArQule in 2020 (see below and Note 4); and MK-7264 (gefapixant) $832 million, obtained through the acquisition of Afferent Pharmaceuticals in 2016. Some of the more significant net intangible assets included in licenses and other above at December&#160;31, 2021 include Lynparza, $1.1 billion, related to a collaboration with AstraZeneca; Lenvima, $1.0 billion, related to a collaboration with Eisai; Adempas, $806 million related to a collaboration with Bayer; and Verquvo, $68 million, also related to a collaboration with Bayer. See Note 5 for additional information related to the intangible assets associated with these collaborations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company recorded an impairment charge of $1.6&#160;billion within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset for impairment. The Company revised its cash flow forecasts for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120&#160;million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2020 related to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recall. A phased resupply of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was initiated in the fourth quarter of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company recorded impairment charges related to marketed products and other intangibles of $705 million. Of this amount, $612 million related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible Gram-positive organisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company recorded a $275 million IPR&amp;D impairment charge within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies, obtained in connection with the acquisition of ArQule (see Note 4). As part of Merck&#8217;s annual impairment assessment of IPR&amp;D intangible assets, the Company estimated the current fair value of nemtabrutinib utilizing projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect the current competitive landscape for nemtabrutinib, including increased expected development costs for additional clinical trial data needed to develop nemtabrutinib, as well as a delay in the anticipated launch date for nemtabrutinib, which collectively reduced the projected future cash flows and estimated fair value. Additionally, the discount rate utilized to determine the current fair value of the asset was reduced to 8.5% to reflect the current risk profile of the asset. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;D impairment charge noted above. The remaining IPR&amp;D intangible asset related to nemtabrutinib is $2.0 billion. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company recorded a $90 million IPR&amp;D impairment charge related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck&#8217;s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $45&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company recorded $172 million of IPR&amp;D impairment charges. Of this amount, $155 million relates to the write-off of the intangible asset balance for programs obtained in connection with the acquisition of IOmet Pharma Ltd following a review of clinical trial results conducted by Merck, along with external clinical trial results for similar compounds. The discontinuation of this clinical development program also resulted in a reversal of the related liability for contingent consideration of $11 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense primarily recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $1.6 billion in 2021, $1.8 billion in 2020 and $1.7 billion in 2019. The estimated aggregate amortization expense for each of the next five years is as follows: 2022, $1.7 billion; 2023, $1.6 billion; 2024, $1.6 billion; 2025, $1.4 billion; 2026, $1.4 billion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026422840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loans Payable, Long-Term Debt and Leases</a></td>
<td class="text">Loans Payable, Long-Term Debt and Leases<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans Payable</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans payable at December&#160;31, 2021 included $2.3 billion of notes due in 2022 and $149 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December&#160;31, 2020 included $2.3 billion of notes due in 2021, $4.0 billion of commercial paper borrowings and $73 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 0.08% and 0.79% for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,495</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75% notes due 2051</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,749</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,736</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70% notes due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90% notes due 2061</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90% notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">715</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">559</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">558</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of zero and 0.45% for 2021 and 2020, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck&#8217;s option at any time, at varying redemption prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company issued $8.0&#160;billion principal amount of senior unsecured notes consisting of $1.5&#160;billion of 1.70% notes due 2027, $1.0&#160;billion of 1.90% notes due 2028, $2.0&#160;billion of 2.15% notes due 2031, $2.0&#160;billion of 2.75% notes due 2051 and $1.5&#160;billion of 2.90% notes due 2061. Merck used the net proceeds from the offering of the 2027 notes, the 2031 notes, the 2051 notes and the 2061 notes for general corporate purposes, including the repayment of outstanding commercial paper borrowings (including commercial paper borrowings in connection with Merck&#8217;s acquisition of Acceleron), and other indebtedness. Merck allocated an amount equal to the net proceeds of the offering of the notes due in 2028 to finance or refinance, in whole or in part, projects and partnerships in the Company&#8217;s priority environmental, social and governance (ESG) areas. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s borrowings require that Merck comply with covenants and, at December&#160;31, 2021, the Company was in compliance with these covenants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate maturities of long-term debt for each of the next five years are as follows: 2022, $2.3 billion; 2023, $1.7 billion; 2024, $1.3 billion; 2025, $2.5 billion; 2026, $2.3 billion. Interest payments related to these debt obligations are as follows: 2022, $910 million; 2023, $875 million; 2024, $838 million; 2025, $771 million; 2026, $743 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of seven years, which include options to extend the leases for up to four years where applicable. Vehicle leases are generally in effect for four years. The Company does not record short-term leases (leases with an initial term of 12 months or less) on the balance sheet; however, Merck currently has no short-term leases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company&#8217;s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company&#8217;s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost was $343&#160;million in 2021, $340&#160;million in 2020 and $333&#160;million in 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $340 million in 2021, $334&#160;million in 2020 and $275&#160;million in 2019. Operating lease assets obtained in exchange for lease obligations were $117 million in 2021, $473 million in 2020 and $125 million in 2019. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_16a2eb8c-e452-4c08-a1c1-253a7ae69d38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_51a0e69b-3d06-4866-8735-b4018eea9421"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_a62e225e-815f-4743-87ec-8f20071b70d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_f733f0e1-fc32-4cc4-af08-cafbad4247b5">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_640b8294-5ffb-4269-b064-66281ca04383"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_7eda0372-d2d2-488c-a2da-c5fb07ed06fd">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Includes prepaid leases that have no related lease liability.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $86 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026899880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Environmental Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Environmental Liabilities</a></td>
<td class="text">Contingencies and Environmental Liabilities <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fosamax</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (Fosamax Litigation). As of December&#160;31, 2021, approximately 3,470 cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#8217;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#8217;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#8217; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December&#160;31, 2021, Merck is aware of approximately 675 product users alleging that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the development of pancreatic cancer and other injuries. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). On March 9, 2021, the MDL Court issued an omnibus order granting defendants&#8217; summary judgment motions based on preemption and failure to establish general causation, as well as granting defendants&#8217; motions to exclude plaintiffs&#8217; expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and on October 5, 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants&#8217; summary judgment motions and also granting defendants&#8217; motions to exclude plaintiffs&#8217; expert witnesses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck&#8217;s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(relating to the Fosamax matter discussed above). Merck filed the opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that preemption presents a legal question to be resolved by the court. In May 2020, the Illinois Appellate Court issued a mandate to the state trial court, which, as of December 31, 2021, had not scheduled a case management conference or otherwise taken action.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against any remaining lawsuits.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney&#8217;s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government&#8217;s information request by seeking information relating to Merck&#8217;s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company&#8217;s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General&#8217;s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck&#8217;s development of an insulin glargine product, and its subsequent termination, as well as Merck&#8217;s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government&#8217;s investigation and intends to produce information and/or documents as necessary in response to the CID.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Company&#8217;s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S.&#160;These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings.&#160;Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants&#8217; motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants&#8217; motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants&#8217; motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. In December 2019, the district court granted the Merck Defendants&#8217; motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of 35 direct purchasers. In August 2020, the Fourth Circuit vacated the district court&#8217;s class certification order and remanded for further proceedings consistent with the court&#8217;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. Briefing on these objections is ongoing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court has heard argument on certain of the motions. The court may hold additional hearings on the other motions. Trial in this matter has been adjourned. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in August 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. In August 2021, the district court granted certification of a class of indirect purchasers. In September 2021, the Merck Defendants petitioned to appeal the class certification decision to the Fourth Circuit. The Fourth Circuit denied that petition on September 30, 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, United Healthcare Services, Inc. filed a lawsuit in the U.S. District Court for the District of Minnesota against the Merck Defendants and others (the UHC Action). The UHC Action makes similar allegations as those made in the Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class action, as well as allegations about Vytorin. In September 2020, the U.S. Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict Zetia litigation already in progress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Humana Inc. filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against Merck and others, alleging defendants violated state antitrust laws in multiple states. Also, in December 2020, Centene Corporation and others filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana. Both lawsuits allege similar anticompetitive acts to those alleged in the Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class action. In July 2021, the California Court ruled on defendants&#8217; Motion to Quash for lack of personal jurisdiction, granting the motion as to the out-of-state claims against defendants, and ordering limited jurisdictional discovery with regard to the California claims.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on July 16, 2021, Humana and Centene filed actions against the Merck Defendants in New Jersey in the Bergen County Superior Court, re-asserting the claims that were dismissed in their California action. In September 2021, the parties reached an agreement that Humana and Centene would file their claims in New Jersey federal court, seek a transfer of those claims to the multidistrict Zetia litigation already in progress, and subsequently dismiss the actions previously filed in California and New Jersey state courts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Kaiser Foundation Health Plan, Inc. similarly filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana and Centene. The Kaiser lawsuit alleges similar anticompetitive acts to those alleged in the Zetia class action. The Kaiser action was removed to the U.S. District Court for the Northern District of California on July 16, 2021. In September 2021, the U.S. Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict Zetia litigation already in progress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 2021, all of the insurer plaintiffs (Kaiser, Humana, and Centene) are part of the multidistrict Zetia litigation, and are proceeding with discovery in that action. On February 9, 2022, United Healthcare, Kaiser, and Humana each filed an amended complaint.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rotavirus Vaccines Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, MSD is a defendant in putative class action lawsuits filed in 2018 on behalf of direct purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, alleging violations of federal antitrust laws. The cases were consolidated in the Eastern District of Pennsylvania. In January 2019, the court denied MSD&#8217;s motions to compel arbitration and to dismiss the consolidated complaint. In February 2019, MSD appealed the court&#8217;s order on arbitration to the Third Circuit. In October 2019, the Third Circuit vacated the district court&#8217;s order and remanded for limited discovery on the issue of </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arbitrability. On July 6, 2020, MSD filed a renewed motion to compel arbitration, and plaintiffs filed a cross motion for summary judgment as to arbitrability. On November 20, 2020, the district court denied MSD&#8217;s motion and granted plaintiffs&#8217; motion. On December 4, 2020, MSD filed a notice of appeal to the Third Circuit. MSD&#8217;s appeal is fully briefed, and the Third Circuit heard argument on September 24, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal on February 7, 2022 and took the matter under advisement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M&#8209;M&#8209;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;II vaccine, which charge that the Company misrepresented the efficacy of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck&#8217;s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits have proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck KGaA Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name &#8220;Merck&#8221; in the U.S. KGaA has filed suit against the Company in France, the UK, Germany, Switzerland, Mexico, India, Australia, Singapore, Hong Kong, SAR, PRC, and China alleging, among other things, unfair competition, trademark infringement and/or corporate name infringement. In the UK, Australia, Singapore, Hong Kong, SAR, PRC, and India, KGaA also alleges breach of the parties&#8217; coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in numerous jurisdictions outside of the U.S.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with four generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against one generic company, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As previously disclosed, the FDA has granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. The Company currently anticipates that sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. will decline significantly after this date. However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin (2027 salt/polymorph patent), which, if determined to be valid, would preclude generic manufacturers from making sitagliptin phosphate salt and polymorphic forms until 2027 with the expiration of that patent, plus pediatric exclusivity. In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity, ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#8217;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, with closing arguments scheduled for April 13, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company has settled with 21 generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan has appealed the USPTO&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#8217;s application seeking approval of its sitagliptin tablets. The U.S. District Court for the District of Delaware has set a three-day bench trial in this matter beginning on October 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Germany, generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the generic companies are successful, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could lose market exclusivity in Germany at the same time as the expiry of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pediatric market exclusivity in September 2022. A hearing was held in June 2021 and the court decided that the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is invalid, which decision the Company has appealed. Challenges to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPC have also occurred in the following European countries: Austria, Czech Republic, Finland, France, Hungary, Italy, Portugal, Romania, Slovakia, and Sweden.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2021 and 2020 of approximately $230 million and $235 million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company&#8217;s potential liability varies greatly from site to site. For some sites the potential liability is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $40 million and $43 million at December&#160;31, 2021 and 2020, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $40 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#8217;s financial condition, results of operations or liquidity for any year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026902696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merck certificate of incorporation authorizes 6,500,000,000&#160;shares of common stock and 20,000,000&#160;shares of preferred stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Stock</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229034751864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation Plans</a></td>
<td class="text">Share-Based Compensation Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company&#8217;s shareholders.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, 93 million shares collectively were authorized for future grants under the Company&#8217;s share-based compensation plans. These awards are settled with treasury shares.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10&#160;years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company&#8217;s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company&#8217;s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company&#8217;s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total pretax share-based compensation cost recorded in 2021, 2020 and 2019 was $498&#160;million, $475&#160;million and $417&#160;million, respectively, including $479 million, $441 million and $388 million, respectively, related to continuing operations. Income tax benefits for share-based compensation expense recognized in 2021, 2020 and 2019 were $69 million, $65 million and $57 million, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company&#8217;s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price of options granted in 2021, 2020 and 2019 was $75.99, $77.67 and $80.05 per option, respectively. The weighted average fair value of options granted in 2021, 2020 and 2019 was $9.80, $9.93 and $10.63 per option, respectively, and were determined using the following assumptions:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding January&#160;1, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75.99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,728)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards transferred to Organon in the spin-off</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,947)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustment to Merck awards related to the spin-off of Organon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,829</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,136</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60.41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Activity prior to the Organon spin-off has not been restated.</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  In connection with the spin-off of Organon, all outstanding Merck stock options (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div><div style="margin-bottom:3pt;margin-top:7pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested January 1, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,897</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,066)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards transferred to Organon in the spin-off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustment to Merck awards related to the spin-off of Organon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.88</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,966</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected to vest December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,832</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Activity prior to the Organon spin-off has not been restated.</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  In connection with the spin-off of Organon, all outstanding Merck RSUs and PSUs (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, there was $699 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026395704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefit Plans</a></td>
<td class="text">Pension and Other Postretirement Benefit Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S.&#160;retirees and their dependents, through its other postretirement benefit plans. The Company uses December&#160;31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic Benefit Cost</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other&#160;Postretirement&#160;Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">403</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">298</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit) for pension and other postretirement benefit plans in 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;6), termination charges were recorded in 2021, 2020 and 2019 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain pension plans. An increase in lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if related to the spin-off of Organon (each as noted above).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obligations and Funded Status</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.453%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation January&#160;1</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,613</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,003&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,458</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,558&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">403</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,999</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,575</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funded status December&#160;31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(932)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,941)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(249)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(877)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,859)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,377)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(377)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Actuarial (gains) losses primarily reflect changes in discount rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, the accumulated benefit obligation was $24.9 billion and $26.3 billion, respectively, for all pension plans, of which $13.8 billion and $14.4 billion, respectively, related to U.S. pension plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:63.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,916</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,723</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plan Assets</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December&#160;31, 2021 and 2020, $943 million and $942 million, respectively, or approximately 4% of the Company&#8217;s pension investments were categorized as Level&#160;3 assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s pension plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:18.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,799</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">919</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">919</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,672&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,944</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">369</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">369</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">591</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The plans&#8217; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#8217;s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:25.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.629%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.279%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers in (out) of Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:18.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S.&#160;pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans is allocated 30% to 45% in U.S.&#160;equities, 15% to 30% in international equities, 35% to 45% in fixed-income investments, and up to 5% in cash and other investments. The portfolio&#8217;s equity weighting is consistent with the long-term nature of the plans&#8217; benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 11%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Contributions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions during 2022 are expected to be approximately $280 million for U.S. pension plans, approximately $150 million for international pension plans and approximately $50 million for other postretirement benefit plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Benefit Payments</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027&#160;&#8212;&#160;2031</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amounts Recognized in Other Comprehensive Income</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:28.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.990%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gain (loss) arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,048</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(816)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">786</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">298</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(105)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Actuarial Assumptions</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:33.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;Pension&#160;and&#160;Other<br/>Postretirement&#160;Benefit&#160;Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan&#8217;s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2022, the expected rate of return for the Company&#8217;s U.S. pension and other postretirement benefit plans will be 6.70%, as compared to a range of 6.50% to 6.70% in 2021. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Savings Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2021, 2020 and 2019 were $158 million, $158 million and $143 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026504104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text">Other (Income) Expense, Net<div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">806</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,940)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates losses of approximately $500&#160;million will be recorded in the first quarter of 2022 from ownership interests in investment funds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net (as presented in the table above) in 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment, which were fully divested by the first quarter of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid was $779 million in 2021, $822 million in 2020 and $841 million in 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026572920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes on Income</a></td>
<td class="text">Taxes on Income<div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:35.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Pandion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs, including amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Peloton</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (TCJA) was enacted in December 2017 and the Company reflected the impact of the TCJA in its 2017 financial statements. However, since application of certain provisions of the TCJA </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remained subject to further interpretation, in certain instances the Company made reasonable estimates of the effects of the TCJA, which were since finalized and resulted in additional income tax expense in 2018 and 2019. The Company&#8217;s remaining transition tax liability under the TCJA, which has been reduced by payments and the utilization of foreign tax credits, was $2.6 billion at December&#160;31, 2021, of which $390 million is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the remainder of $2.2 billion is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the U.S., particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2022), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. Beginning in 2021, the Company has an additional tax incentive in the form of a tax holiday in Switzerland for a newly active legal entity which is effective through 2030. </span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on income from continuing operations consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,996</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,749</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">692</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,441</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December&#160;31, 2021, $181 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $164 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $686 million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards. Valuation allowances of $123&#160;million have been established on these U.S. tax credit carryforwards and NOL carryforwards. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid in 2021, 2020 and 2019 (including amounts attributable to discontinued operations) were $2.4 billion, $2.7 billion and $4.5 billion, respectively. Tax benefits relating to stock option exercises were $21 million in 2021, $12 million in 2020 and $65 million in 2019. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Amounts in 2021 and 2019 reflect settlements with the IRS discussed below. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  Amount in 2019 includes $78 million related to the divestiture of Merck&#8217;s Consumer Care business in 2014.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to recognize the unrecognized tax benefits of $1.5 billion at December&#160;31, 2021, the income tax provision would reflect a favorable net impact of $1.5 billion.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December&#160;31, 2021 could decrease by up to approximately $11 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company&#8217;s </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties associated with uncertain tax positions amounted to a (benefit) expense of $(37) million in 2021, $16 million in 2020 and $(53) million in 2019. These amounts reflect the beneficial impacts of various tax settlements, including the settlements discussed below. Liabilities for accrued interest and penalties were $192 million and $205 million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190&#160;million (of which $172&#160;million related to continuing operations and $18&#160;million related to discontinued operations). The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236&#160;million net tax benefit in 2021 (of which $207&#160;million related to continuing operations and $29&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the IRS concluded its examinations of Merck&#8217;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million (of which $142&#160;million related to discontinued operations with an offsetting credit of $35&#160;million related to continuing operations). The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $364 million net tax benefit in 2019 (of which $106&#160;million related to continuing operations and $258&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS is currently conducting examinations of the Company&#8217;s tax returns for the years 2017 and 2018. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company&#8217;s income tax returns are open for examination for the period 2003 through 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026426488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share<div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.88</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div>In 2021, 2020 and 2019, 9 million, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026422840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:37.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.903%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1, 2019, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(631)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,922</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,383</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,769</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,756</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Spin-off of Organon (see Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">449</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,830)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,429)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 14).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $3.6 billion and $5.4 billion at December 31, 2021 and 2020, respectively, and other postretirement benefit plan net gain of $473 million and $391 million at December 31, 2021 and 2020, respectively, as well as pension plan prior service credit of $190 million and $255 million at December 31, 2021 and 2020, respectively, and other postretirement benefit plan prior service credit of $181 million and $244 million at December 31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229116979320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S.&#160;government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2021, the amortization of intangible assets previously included as part of the calculation of segment profits is now included in unallocated non-segment corporate expenses. Prior period Pharmaceutical and Animal Health segment profits have been recast to reflect this change on a comparable basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:30.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">515</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,792</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">506</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">547</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">893</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">807</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">179</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">318</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Molnupiravir</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">632</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">474</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">769</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">342</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,964</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,310</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">42,754</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">36,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">34,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">667</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,628</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,568</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">26,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">48,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">19,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">21,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">116</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">382</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">26,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">48,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">21,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">39,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales (including sales to Organon). Other for 2021 also includes $185&#160;million related to the achievement of milestones for an out-licensed product that triggered contingent payments to Merck.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,927</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity loss from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,759</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229031307064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#8217; interests are shown as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is </span>defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#8217;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#8217;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2021, $11.4 billion in 2020 and $9.9 billion in 2019. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $207 </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and $2.6 billion, respectively, at December&#160;31, 2021 and were $208 million and $2.6 billion, respectively, at December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzUz_b48cccc3-76a0-476d-bb80-193b05cdb46c">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for disaggregated revenue disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock', window );">Depreciation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and from 3 to 15&#160;years for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Promotion Costs</a></td>
<td class="text">Advertising and Promotion Costs &#8212; Advertising and promotion costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Software Capitalization</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Acquired Intangibles</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangibles include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted </span>future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration&#160;&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">Research and Development&#160;&#8212;&#160;Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring Costs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies and Legal Defense Costs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Taxes on Income</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income from Continuing Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Reclassifications&#160;&#8212;&#160;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards&#160;&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued amended guidance on the accounting for convertible instruments and contracts in an entity&#8217;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The amended guidance is effective for interim and annual periods in 2022. The application of the amendments in the new guidance are to be applied either on a modified retrospective or a retrospective basis. There was no impact to the Company&#8217;s consolidated financial statements upon adoption on January 1, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards&#160;Not Yet Adopted &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements. The Company is progressing in its evaluation of LIBOR cessation exposures, including the review of debt-related contracts, leases, business development and licensing arrangements, royalty and other agreements. The Company has amended certain agreements and continues to review other agreements for potential impacts. With regard to debt-related exposures in particular, all existing interest rate swaps linked to LIBOR will mature in 2022. The Company is still evaluating the impact to its LIBOR-based debt. Based on its evaluation thus far, the Company does not anticipate a material impact to its consolidated financial statements as a result of reference rate reform. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have a material impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div>In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to the company&#8217;s financial statements. The guidance is effective for annual periods beginning in 2022 and is to be applied on either a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discussion of the accounting policy for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229032776872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">789</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of assets and liabilities of discontinued operations are as follows:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, less allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent Assets of Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent Liabilities of Discontinued Operations</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026455992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Acceleron is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D - sotatercept </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and product rights - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reblozyl </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12 year useful life)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,832)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,092&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D - nemtabrutinib </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:1pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.721%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from 18-24 years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026496328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ccounts payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued milestone payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">424</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense as noted above. In addition, cost of sales in all periods now includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued milestone payment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molnupiravir sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount in 2020 includes upfront payment.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued royalty and milestone payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023051528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Charges Related to Restructuring Program Activities by Type of Cost</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">661</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and Spending Relating to Restructuring Activities by Program</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:45.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December&#160;31, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">637</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be substantially completed by the end of 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026715496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Effect of Net Investment Hedges</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:35.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.745%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(296)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Summary of Interest Rate Derivatives</a></td>
<td class="text">At December&#160;31, 2021, the Company was a party to nine pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: <div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These interest rate swaps matured in February 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:43.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,073</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,260&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,713</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32,958</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock', window );">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</a></td>
<td class="text">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:59.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collateral posted/received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Location and Pretax Gain or Loss Amounts for Derivatives</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,756</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:41.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Information on Investments in Debt and Equity Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December&#160;31 is as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,733</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2021 were $232 million during 2021. Unrealized net gains recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at December&#160;31, 2020 were $163 million during 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.224%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,363</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,363</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summarized Information about the Changes in Liabilities for Contingent Consideration</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)(3)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Balance at December&#160;31, 2021 includes $151 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At December&#160;31, 2021 and 2020, $620 million and $711 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OffsettingAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026902136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,747</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,147</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,624&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025864952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill Activity by Segment</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,431</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,997</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div>(2) Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2021 and 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Other Intangibles</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other acquired intangibles at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,671</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,776</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229031045368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,495</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75% notes due 2051</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,979</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,749</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,736</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70% notes due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90% notes due 2061</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,235</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90% notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">748</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">715</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">559</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">558</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AssetsandLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_16a2eb8c-e452-4c08-a1c1-253a7ae69d38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_51a0e69b-3d06-4866-8735-b4018eea9421"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_a62e225e-815f-4743-87ec-8f20071b70d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_f733f0e1-fc32-4cc4-af08-cafbad4247b5">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_640b8294-5ffb-4269-b064-66281ca04383"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_7eda0372-d2d2-488c-a2da-c5fb07ed06fd">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Includes prepaid leases that have no related lease liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetsandLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetsandLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026391272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Summary of Common Stock and Treasury Stock Transactions</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027494344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Determine Weighted-Average Fair Value of Options Granted</a></td>
<td class="text">The weighted average fair value of options granted in 2021, 2020 and 2019 was $9.80, $9.93 and $10.63 per option, respectively, and were determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information Relative to Stock Option Plan Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding January&#160;1, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75.99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,728)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards transferred to Organon in the spin-off</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,947)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustment to Merck awards related to the spin-off of Organon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,829</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,136</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60.41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Activity prior to the Organon spin-off has not been restated.</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  In connection with the spin-off of Organon, all outstanding Merck stock options (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock', window );">Additional Information Pertaining to Stock Option Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:7pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Nonvested RSU and PSU Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested January 1, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,897</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,066)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards transferred to Organon in the spin-off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustment to Merck awards related to the spin-off of Organon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.88</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,966</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected to vest December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,832</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Activity prior to the Organon spin-off has not been restated.</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  In connection with the spin-off of Organon, all outstanding Merck RSUs and PSUs (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional information pertaining to stock option plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023330200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other&#160;Postretirement&#160;Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">403</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">298</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock', window );">Obligation and Funded Status</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.453%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation January&#160;1</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,613</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,003&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,458</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,558&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,607</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">403</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit obligation December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,999</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,575</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funded status December&#160;31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(932)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,941)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(249)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(877)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,859)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,377)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(377)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Actuarial (gains) losses primarily reflect changes in discount rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock', window );">Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:63.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,916</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,723</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,995&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s pension plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:18.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,799</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">919</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">919</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,672&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,944</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">369</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">369</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">591</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">982</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The plans&#8217; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-top:1pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:18.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock', window );">Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#8217;s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:25.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.629%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.279%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers in (out) of Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Summary of Expected Benefit Payments</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027&#160;&#8212;&#160;2031</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Other Comprehensive Income</a></td>
<td class="text">The following amounts were reflected as components of <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:28.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.990%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gain (loss) arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,048</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(816)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">786</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">298</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(105)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:33.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;Pension&#160;and&#160;Other<br/>Postretirement&#160;Benefit&#160;Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(b)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229029144984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">806</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,940)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates losses of approximately $500&#160;million will be recorded in the first quarter of 2022 from ownership interests in investment funds.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026773560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Effective Tax Rate and U.S. Statutory Rate</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:35.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Pandion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs, including amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Peloton</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Income Before Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Taxes on Income</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on income from continuing operations consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">301</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,996</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,749</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">692</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,441</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Amounts in 2021 and 2019 reflect settlements with the IRS discussed below. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  Amount in 2019 includes $78 million related to the divestiture of Merck&#8217;s Consumer Care business in 2014.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026396824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculations of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.88</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026580840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in AOCI by Component</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:37.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.903%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1, 2019, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(915)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(631)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,922</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,383</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">192</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,769</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,756</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Spin-off of Organon (see Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">449</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,830)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,429)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 14).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $3.6 billion and $5.4 billion at December 31, 2021 and 2020, respectively, and other postretirement benefit plan net gain of $473 million and $391 million at December 31, 2021 and 2020, respectively, as well as pension plan prior service credit of $190 million and $255 million at December 31, 2021 and 2020, respectively, and other postretirement benefit plan prior service credit of $181 million and $244 million at December 31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024982232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Sales of Company's Products</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:30.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">515</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,792</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">506</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">547</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">893</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">807</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">179</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">318</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Molnupiravir</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">632</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">474</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">769</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">342</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,964</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,310</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">42,754</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">36,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">34,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">667</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,628</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,568</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">26,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">48,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">19,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">21,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">116</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">382</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">26,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">48,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">21,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">39,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales (including sales to Organon). Other for 2021 also includes $185&#160;million related to the achievement of milestones for an out-licensed product that triggered contingent payments to Merck.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Consolidated Revenues by Geographic Area</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Segment Profits to Income Before Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,977</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,927</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Equity Loss from Affiliates and Depreciation Included in Segment Profits</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity loss from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock', window );">Property, Plant and Equipment, Net by Geographic Area</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,759</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026422840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229022910584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SalesDiscounts', window );">Customer discounts</a></td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AccrualForChargebacks', window );">Accrual for chargebacks reflected as direct reduction to accounts receivable</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AccrualForRebates', window );">Accrual for rebates included in accrued and other current liabilities</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate', window );">Product return period and expiration</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1,578<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising and promotion costs</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate', window );">Product return period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Capitalized Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery, equipment and office furnishings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | United States | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">36 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | United States | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate', window );">Product return period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">24 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Capitalized Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">45 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery, equipment and office furnishings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AccrualForChargebacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrual for chargebacks reflected as a direction reduction to accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AccrualForChargebacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AccrualForRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrual for rebates recorded as current liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AccrualForRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RevenuePerformanceObligationPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RevenuePerformanceObligationPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Goods, Goods Return Period After to Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SalesDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SalesDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025347752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration received</a></td>
<td class="nump">$ 9,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Disposal group, other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,000,000<span></span>
</td>
<td class="nump">$ 743,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal group, including discontinued operations, liabilities</a></td>
<td class="nump">5,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt', window );">Disposal group, including discontinued operations, debt</a></td>
<td class="nump">9,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Disposal group, including discontinued operations, goodwill</a></td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,356,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Disposal group, including discontinued operations, property, plant and equipment</a></td>
<td class="nump">981,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash', window );">Disposal group, including discontinued operation, cash</a></td>
<td class="nump">929,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Disposal group, including discontinued operations, inventory</a></td>
<td class="nump">815,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Disposal group, including discontinued operations, other intangible assets</a></td>
<td class="nump">519,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 503,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Disposal group, including discontinued operation, other liabilities</a></td>
<td class="nump">328,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spinoff transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,091,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spinoff transaction</a></td>
<td class="nump">449,000,000<span></span>
</td>
<td class="nump">449,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spinoff transaction</a></td>
<td class="nump">421,000,000<span></span>
</td>
<td class="nump">421,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spinoff transaction</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Other Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spinoff transaction</a></td>
<td class="nump">$ 4,600,000,000<span></span>
</td>
<td class="nump">4,643,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrganonCoMember', window );">Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartiesAmountInCostOfSales', window );">Related party amount in cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">964,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Transition services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Manufacturing and supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Manufacturing and supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mrk_OrganonCoMember', window );">Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 9,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationsDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationsDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand, demand deposits with banks or financial institutions, and  other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartiesAmountInCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartiesAmountInCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_OrganonCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_OrganonCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrk_TransitionServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrk_TransitionServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrk_ManufacturingAndSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrk_ManufacturingAndSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mrk_OrganonCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mrk_OrganonCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025231384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Sales</a></td>
<td class="nump">$ 2,512<span></span>
</td>
<td class="nump">$ 6,476<span></span>
</td>
<td class="nump">$ 7,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Costs, Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">1,867<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">3,548<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax', window );">Income from discontinued operations before taxes</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
<td class="nump">4,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod', window );">Tax provision</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of taxes</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">2,559<span></span>
</td>
<td class="nump">4,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Income of discontinued operations attributable to noncontrolling interests</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 2,548<span></span>
</td>
<td class="nump">$ 4,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Research and Development Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Restructuring Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229022882312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. - Assets and Liabilities of Discontinued Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, less allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">981<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Other intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Noncurrent Assets of Discontinued Operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable', window );">Trade accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Noncurrent Liabilities of Discontinued Operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accrual (Reversal), Income Taxes Payable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228939873336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements - Narrative (Details)<br> $ / shares in Units, &#8364; in Millions, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="14">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,245.0<span></span>
</td>
<td class="nump">$ 13,397.0<span></span>
</td>
<td class="nump">$ 9,724.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,556.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,953.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,554.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,953.0<span></span>
</td>
<td class="nump">5,554.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777.0<span></span>
</td>
<td class="nump">841.0<span></span>
</td>
<td class="nump">767.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,264.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,882.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,264.0<span></span>
</td>
<td class="nump">18,882.0<span></span>
</td>
<td class="nump">18,069.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57.0)<span></span>
</td>
<td class="num">(83.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember', window );">Pandion Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Other net assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_OncoImmuneMember', window );">OncoImmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Other net assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to acquire investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PremiumOnSharesAcquired', window );">Premium on shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_VelosBioMember', window );">VelosBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Other net assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">2,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_DunboyneMember', window );">Dunboyne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302.0<span></span>
</td>
<td class="nump">&#8364; 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Other net assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_PelotonMember', window );">Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Other net assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 993.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PremiumOnSharesAcquired', window );">Premium on shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SentinelMember', window );">Sentinel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SentinelMember', window );">Sentinel | Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 401.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ChargesRelatedToProgramDiscontinuation', window );">Charges related to program discontinuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207.0<span></span>
</td>
<td class="nump">305.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Inventory and fixed assets write-offs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember', window );">nemtabrutinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_GileadSciencesMember', window );">Gilead Sciences | Oral and Injectable Formulations | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProfitShareCounterparty', window );">Profit share by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProfitShare', window );">Profit share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_GileadSciencesMember', window );">Gilead Sciences | Oral Formulation | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProfitShareCounterparty', window );">Profit share by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProfitShare', window );">Profit share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SalesThreshold', window );">Sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_GileadSciencesMember', window );">Gilead Sciences | Injectable Formulation | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProfitShareCounterparty', window );">Profit share by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProfitShare', window );">Profit share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SalesThreshold', window );">Sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner', window );">Upfront and milestone payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Maximum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to acquire investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares', window );">Forward contract indexed to issuer's equity, indexed shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SentinelMember', window );">Sentinel | Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible assets, acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_IAVIMember', window );">IAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRateDeductionPercentage', window );">Royalty rate, deduction, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Maximum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember', window );">Acceleron Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible assets, acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,380.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and (liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,422.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember', window );">Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and (liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember', window );">Themis | COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,280.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and (liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 512.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed', window );">Share-based compensation payments to settle equity awards attributable to precombination service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Debt assumed</a></td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">31.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and (liabilities), net</a></td>
<td class="num">(82.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,376.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ImmuneDesignMember', window );">Immune Design</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember', window );">Development Milestones | Artiva Biotherapeutics, Inc. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember', window );">Development Milestones | Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember', window );">Development Milestones | Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Artiva Biotherapeutics, Inc. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Seagen | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Bristol Myers Squibb | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_CommercialmilestoneMember', window );">Commercial Milestone | Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Artiva Biotherapeutics, Inc. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Bristol Myers Squibb | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Potential future milestone payments, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Other Assets and Liabilities Recognized, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Recognized Identifiable Assets and Liabilities, Cash and Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:noDecimalsMonetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Recognized Identifiable Assets and Liabilities, Deferred Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:noDecimalsMonetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ChargesRelatedToProgramDiscontinuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges related to program discontinuation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ChargesRelatedToProgramDiscontinuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PremiumOnSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on shares acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PremiumOnSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ProfitShareCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Share Counterparty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ProfitShareCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRateDeductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Deduction, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRateDeductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and Milestone Payments to be Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments made to partner as part of a licensing or collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of issuer's shares to which the forward contract is indexed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_OncoImmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_OncoImmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_VelosBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_VelosBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_DunboyneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_DunboyneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_PelotonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_PelotonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SentinelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SentinelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NemtabrutinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_GileadSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_GileadSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OralAndInjectableFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OralAndInjectableFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OralFormulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OralFormulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_InjectableFormulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_InjectableFormulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SeagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SeagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_TukysaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_TukysaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SentinelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SentinelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_IAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_IAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ImmuneDesignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ImmuneDesignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_CommercialmilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_CommercialmilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024425640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember', window );">Acceleron Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Products and product rights - Reblozyl (12 year useful life)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible assets, acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember', window );">Acceleron Pharma Inc. | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">2,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="num">(589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Consideration transferred</a></td>
<td class="nump">$ 3,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="nump">0.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">24 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Products and Product rights, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetProductsAndProductRightsMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229019834744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Narrative (Details)<br> course in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>course</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>course</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>course </div>
<div>market </div>
<div>country</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 22,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,933<span></span>
</td>
<td class="nump">$ 14,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="nump">$ 1,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SupplyCommitmentMinimumNumberOfMarkets', window );">Number of markets (more than) | market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach', window );">Number of low and middle income countries (more than) | country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToUnitedStatesMember', window );">Supply Commitment to United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SupplyCommitmentQuantityCommitted', window );">Quantity committed (in courses) | course</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SupplyCommitmentQuantityDelivered', window );">Quantity delivered (in courses) | course</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToJapanMember', window );">Supply Commitment to Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SupplyCommitmentQuantityCommitted', window );">Quantity committed (in courses) | course</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SupplyCommitmentQuantityDelivered', window );">Quantity delivered (in courses) | course</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToUnitedKingdomMember', window );">Supply Commitment to United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SupplyCommitmentQuantityCommitted', window );">Quantity committed (in courses) | course</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SupplyCommitmentQuantityDelivered', window );">Quantity delivered (in courses) | course</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToUnitedNationsChildrensFundMember', window );">Supply Commitment to United Nations Children's Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SupplyCommitmentQuantityCommitted', window );">Quantity committed (in courses) | course</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 3,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,368<span></span>
</td>
<td class="nump">3,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Licenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_VerquvoMember', window );">Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_VerquvoMember', window );">Verquvo | Licenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement', window );">License option payment related to collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Lenvima | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Lenvima | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsAccruedSalesBased', window );">Milestone payments accrued</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsAccruedRegulatory', window );">Accrued regulatory approval milestone payment</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsSalesBased', window );">Potential Future Milestone Payments Sales-Based</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsRegulatory', window );">Potential Future Milestone Payments Regulatory</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Lenvima | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsAccruedSalesBased', window );">Milestone payments accrued</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Adempas | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Lynparza | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsAccruedSalesBased', window );">Milestone payments accrued</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsSalesBased', window );">Potential Future Milestone Payments Sales-Based</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsRegulatory', window );">Potential Future Milestone Payments Regulatory</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Lynparza | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License option payment related to collaborative arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsAccruedRegulatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Accrued Regulatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsAccruedRegulatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsAccruedSalesBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Accrued Sales Based</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsAccruedSalesBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsMadetoCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsMadetoCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Low and Middle Income Countries Reached Through Supply And Access Approach</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PotentialFutureMilestonePaymentsRegulatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments Regulatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PotentialFutureMilestonePaymentsRegulatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PotentialFutureMilestonePaymentsSalesBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments Sales-Based</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PotentialFutureMilestonePaymentsSalesBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SupplyCommitmentMinimumNumberOfMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply Commitment, Minimum, Number of Markets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SupplyCommitmentMinimumNumberOfMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SupplyCommitmentQuantityCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply Commitment, Quantity Committed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SupplyCommitmentQuantityCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SupplyCommitmentQuantityDelivered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply Commitment, Quantity Delivered</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SupplyCommitmentQuantityDelivered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToUnitedKingdomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToUnitedKingdomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToUnitedNationsChildrensFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=mrk_SupplyCommitmentToUnitedNationsChildrensFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024565800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
<td class="nump">$ 39,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">13,626<span></span>
</td>
<td class="nump">13,618<span></span>
</td>
<td class="nump">12,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">9,634<span></span>
</td>
<td class="nump">8,955<span></span>
</td>
<td class="nump">9,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,245<span></span>
</td>
<td class="nump">13,397<span></span>
</td>
<td class="nump">9,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">23,872<span></span>
</td>
<td class="nump">27,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Payables included in Other Noncurrent Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">733<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Bayer AG | Collaborative Arrangement | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Net sales by Merck</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Bayer AG | Collaborative Arrangement | Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Net sales by Merck</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Molnupiravir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Profit Sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Sales, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_RidgebackBiotherapeuticsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_RidgebackBiotherapeuticsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_MolnupiravirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_MolnupiravirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025319624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays', window );">Estimate of cumulative pre tax costs that will result in cash outlays</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash', window );">Estimate of cumulative pre tax costs that will be noncash</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative costs since program inception</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will be noncash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025163864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Charges Activities by Type of Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025094952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Activities by Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">$ 586<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(608)<span></span>
</td>
<td class="num">(779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(422)<span></span>
</td>
<td class="num">(508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(186)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(118)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash activity affecting the restructuring reserve, including accelerated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RestructuringReserveIncreaseDecreaseNoncashActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229019726824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 32,958,000,000<span></span>
</td>
<td class="nump">$ 32,784,000,000<span></span>
</td>
<td class="nump">$ 32,958,000,000<span></span>
</td>
<td class="nump">$ 32,784,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">8,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">596,000,000<span></span>
</td>
<td class="nump">586,000,000<span></span>
</td>
<td class="nump">596,000,000<span></span>
</td>
<td class="nump">586,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Unrealized gains recognized on investments in equity securities without readily determinable fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Unrealized losses recognized on investments in equity securities without readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative upward price adjustment</a></td>
<td class="nump">234,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative downward price adjustment</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of loans payable and long-term debt, including current portion</a></td>
<td class="nump">35,700,000,000<span></span>
</td>
<td class="nump">36,000,000,000<span></span>
</td>
<td class="nump">35,700,000,000<span></span>
</td>
<td class="nump">36,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, carrying amount</a></td>
<td class="nump">33,100,000,000<span></span>
</td>
<td class="nump">31,800,000,000<span></span>
</td>
<td class="nump">33,100,000,000<span></span>
</td>
<td class="nump">31,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableSale', window );">Factored accounts receivable</a></td>
<td class="nump">2,800,000,000<span></span>
</td>
<td class="nump">2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Funds collected from factoring of receivable, held in restricted cash</a></td>
<td class="nump">62,000,000<span></span>
</td>
<td class="nump">102,000,000<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="nump">102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received from counterparties</a></td>
<td class="nump">164,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">164,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral advanced to counterparties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities held through ownership interests in investment funds</a></td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">(Gains) losses for equity securities held through ownership interests in investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,400,000,000)<span></span>
</td>
<td class="num">(583,000,000)<span></span>
</td>
<td class="nump">$ 113,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A3.875NotesDue2021Member', window );">3.875% Notes Due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | McKesson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of accounts receivable represented by customers with largest balances (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of accounts receivable represented by customers with largest balances (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of accounts receivable represented by customers with largest balances (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 6,800,000,000<span></span>
</td>
<td class="nump">6,800,000,000<span></span>
</td>
<td class="nump">$ 6,800,000,000<span></span>
</td>
<td class="nump">6,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps held | interest_rate_swap</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 12,245,000,000<span></span>
</td>
<td class="nump">13,714,000,000<span></span>
</td>
<td class="nump">$ 12,245,000,000<span></span>
</td>
<td class="nump">13,714,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 20,713,000,000<span></span>
</td>
<td class="nump">$ 19,070,000,000<span></span>
</td>
<td class="nump">$ 20,713,000,000<span></span>
</td>
<td class="nump">$ 19,070,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum planning cycle of hedges (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum planning cycle of hedges (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease from sale of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A3.875NotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A3.875NotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrk_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrk_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrk_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrk_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrk_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrk_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229028690904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="num">$ (49)<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="num">(296)<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025356312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Information About Interest Rate Swaps (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="nump">$ 8,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total Swap Notional Amount</a></td>
<td class="nump">$ 32,958,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,784,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held | interest_rate_swap</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total Swap Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member', window );">2.40% notes due 2022 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held | interest_rate_swap</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total Swap Notional Amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member', window );">2.35% notes due 2022 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held | interest_rate_swap</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total Swap Notional Amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229028601080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember', window );">Loans payable and current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Hedged Liabilities</a></td>
<td class="nump">$ 2,263<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtExcludingCurrentMaturitiesMember', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Hedged Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtExcludingCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtExcludingCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229019650696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">32,958<span></span>
</td>
<td class="nump">32,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">12,245<span></span>
</td>
<td class="nump">13,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">20,713<span></span>
</td>
<td class="nump">19,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">6,778<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">2,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">5,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">10,073<span></span>
</td>
<td class="nump">7,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 10,640<span></span>
</td>
<td class="nump">$ 11,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024974952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Gross amounts recognized in the consolidated balance sheet, asset</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received, asset</a></td>
<td class="num">(164)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, asset</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Gross amounts recognized in the consolidated balance sheet, liability</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral received, liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, liability</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026800392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
<td class="nump">$ 39,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(1,341)<span></span>
</td>
<td class="num">(890)<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="num">(441)<span></span>
</td>
<td class="num">(648)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of gain (loss) recognized in OCI on derivatives</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of gain (loss) recognized in OCI on derivatives</a></td>
<td class="nump">333<span></span>
</td>
<td class="num">(383)<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">(Decrease) increase in Sales as a result of AOCL reclassifications</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (income) expense, net | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged items</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Derivatives designated as hedging instruments</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of gain recognized in Other (income) expense, net on derivatives</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="num">$ (194)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024442184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025155192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information on Debt and Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities, fair value</a></td>
<td class="nump">1,647<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI', window );">Total debt and publicly traded equity securities, fair value</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized (loss) gains</a></td>
<td class="num">(232)<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities and Equity Securities, FV-NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DebtSecuritiesandEquitySecuritiesFVNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229018394552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,647<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">$ 767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,282<span></span>
</td>
<td class="nump">2,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Currency Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,279<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Currency Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,279<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Currency Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Currency Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229030903208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, beginning balance</a></td>
<td class="nump">$ 841<span></span>
</td>
<td class="nump">$ 767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration liability, changes in estimated fair value</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther', window );">Other</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, ending balance</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration, liability, current</a></td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember', window );">Sanofi Pasteur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, beginning balance</a></td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, ending balance</a></td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">$ 711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, measurement input, discount rate</a></td>
<td class="nump">0.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Sanofi Pasteur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, measurement input, discount rate</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024422280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work in process</a></td>
<td class="nump">6,220<span></span>
</td>
<td class="nump">5,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Supplies</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total (approximates current cost)</a></td>
<td class="nump">8,163<span></span>
</td>
<td class="nump">7,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Decrease to LIFO cost</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_InventoryNetAndInventoryNoncurrent', window );">Total current and noncurrent inventories</a></td>
<td class="nump">8,147<span></span>
</td>
<td class="nump">7,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RecognizedAsAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">5,953<span></span>
</td>
<td class="nump">5,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 2,194<span></span>
</td>
<td class="nump">$ 2,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of current and noncurrent inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RecognizedAsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognized as.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RecognizedAsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product.  Includes supplies used directly or indirectly in the manufacturing or production process.  This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027823640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LIFOInventoryAmount', window );">LIFO inventory amount</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory classified in Other assets</a></td>
<td class="nump">2,194<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember', window );">Inventory Not Expected to be Sold Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory classified in Other assets</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember', window );">Inventories Produced in Preparation for Product Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory classified in Other assets</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LIFOInventoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LIFOInventoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023911624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 18,882<span></span>
</td>
<td class="nump">$ 18,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">2,436<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(54)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">21,264<span></span>
</td>
<td class="nump">18,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment losses</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">15,614<span></span>
</td>
<td class="nump">14,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">2,431<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">17,997<span></span>
</td>
<td class="nump">15,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">3,268<span></span>
</td>
<td class="nump">3,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">3,267<span></span>
</td>
<td class="nump">3,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023657000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 22,933<span></span>
</td>
<td class="nump">$ 14,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge related to marketed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration liability, changes in estimated fair value</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense, 2022</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense, 2023</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense, 2024</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense, 2025</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated aggregate amortization expense, 2026</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">9,281<span></span>
</td>
<td class="nump">3,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember', window );">Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge related to marketed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SivextroMember', window );">Sivextro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge related to marketed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AnimalHealthMember', window );">Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Licenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_VerquvoMember', window );">Verquvo | Licenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration liability, changes in estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_IOmetPharmaLtdMember', window );">IOmet Pharma Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration liability, changes in estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SotaterceptMember', window );">sotatercept | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember', window );">nemtabrutinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember', window );">nemtabrutinib | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember', window );">nemtabrutinib | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GefapixantMember', window );">gefapixant | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">7,895<span></span>
</td>
<td class="nump">4,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Reblozyl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Dificid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Sivextro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">2,389<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">3,368<span></span>
</td>
<td class="nump">$ 3,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License | Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License | Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq | Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetsExcludingGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Excluding Goodwill [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetsExcludingGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZerbaxaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SivextroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SivextroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AnimalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AnimalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_IOmetPharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_IOmetPharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SotaterceptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SotaterceptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NemtabrutinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GefapixantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GefapixantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ReblozylMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ReblozylMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_DificidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_DificidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SimponiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SimponiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229028846472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Other Intangibles (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 42,438<span></span>
</td>
<td class="nump">$ 33,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">19,505<span></span>
</td>
<td class="nump">19,136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">22,933<span></span>
</td>
<td class="nump">14,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">9,281<span></span>
</td>
<td class="nump">3,228<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">9,281<span></span>
</td>
<td class="nump">3,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">23,671<span></span>
</td>
<td class="nump">20,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">15,776<span></span>
</td>
<td class="nump">16,138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">7,895<span></span>
</td>
<td class="nump">4,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">2,389<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">6,604<span></span>
</td>
<td class="nump">6,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,236<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">$ 3,368<span></span>
</td>
<td class="nump">$ 3,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024495208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current maturities</a></td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">2,412,000,000<span></span>
</td>
<td class="nump">6,431,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">30,690,000,000<span></span>
</td>
<td class="nump">$ 25,360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">8,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Long-term debt, maturities, repayments of principal in 2022</a></td>
<td class="nump">2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long-term debt, maturities, repayments of principal in 2023</a></td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long-term debt, maturities, repayments of principal in 2024</a></td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-term debt, maturities, repayments of principal in 2025</a></td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Long-term debt, maturities, repayments of principal in 2026</a></td>
<td class="nump">2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearOne', window );">Long-term debt, interest payments in 2022</a></td>
<td class="nump">910,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearTwo', window );">Long-term debt, interest payments in 2023</a></td>
<td class="nump">875,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearThree', window );">Long-term debt, interest payments in 2024</a></td>
<td class="nump">838,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearFour', window );">Long-term debt, interest payments in 2025</a></td>
<td class="nump">771,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearFive', window );">Long-term debt, interest payments in 2026</a></td>
<td class="nump">743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Available borrowing capacity under credit facility</a></td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease, cost</a></td>
<td class="nump">$ 343,000,000<span></span>
</td>
<td class="nump">$ 340,000,000<span></span>
</td>
<td class="nump">$ 333,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">340,000,000<span></span>
</td>
<td class="nump">334,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">117,000,000<span></span>
</td>
<td class="nump">$ 473,000,000<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount', window );">Lessee, operating lease, lease not yet commenced, amount</a></td>
<td class="nump">$ 86,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_OtherVariableRateDebtMember', window );">Other Variable Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member', window );">6.30% debentures due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member', window );">1.70% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,493,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member', window );">1.90% notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 994,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member', window );">2.15% notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,986,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member', window );">2.75% notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,979,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member', window );">2.90% notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,484,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Weighted-average interest rate of commercial paper</a></td>
<td class="nump">0.08%<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=mrk_NotesSubjectToRepaymentAtOptionOfHolderMember', window );">Notes Subject To Repayment At Option Of Holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">$ 149,000,000<span></span>
</td>
<td class="nump">$ 73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_OtherVariableRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_OtherVariableRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=mrk_NotesSubjectToRepaymentAtOptionOfHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=mrk_NotesSubjectToRepaymentAtOptionOfHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229019844824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 30,690<span></span>
</td>
<td class="nump">$ 25,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.75NotesDue2025Member', window );">2.75% notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 2,495<span></span>
</td>
<td class="nump">2,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member', window );">2.15% notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member', window );">2.75% notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,979<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.70NotesDue2045Member', window );">3.70% notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,977<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A280NotesDue2023Member', window );">2.80% notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.40NotesDue2029Member', window );">3.40% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">1,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member', window );">1.70% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,493<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member', window );">2.90% notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,484<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A4.00NotesDue2049Member', window );">4.00% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A415NotesDue2043Member', window );">4.15% notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,239<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A145NotesDue2030Member', window );">1.45% notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,235<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A245NotesDue2050Member', window );">2.45% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,212<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.875EuroNotesDue2026Member', window );">1.875% euro-denominated notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,123<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member', window );">1.90% notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A075NotesDue2026Member', window );">0.75% notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.90NotesDue2039Member', window );">3.90% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A235NotesDue2040Member', window );">2.35% notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.90NotesDue2024Member', window );">2.90% notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember', window );">6.50% notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A0.50eurodenominatednotesdue2024Member', window );">0.50% euro-denominated notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.375eurodenominatednotesdue2036Member', window );">1.375% euro-denominated notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.5EuroNotesDue2034Member', window );">2.50% euro-denominated notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 558<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember', window );">3.60% notes due 2042</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 491<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember', window );">6.55% notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember', window );">5.75% notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember', window );">5.95% debentures due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember', window );">5.85% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember', window );">6.40% debentures due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member', window );">6.30% debentures due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member', window );">2.35% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member', window );">2.40% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_OtherLongTermDebtMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.75NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.75NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.70NotesDue2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.70NotesDue2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A280NotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A280NotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.40NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.40NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A4.00NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A4.00NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A415NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A415NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A145NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A145NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A245NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A245NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.875EuroNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.875EuroNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A075NotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A075NotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.90NotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.90NotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A235NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A235NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.90NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.90NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A0.50eurodenominatednotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A0.50eurodenominatednotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.375eurodenominatednotesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.375eurodenominatednotesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.5EuroNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.5EuroNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027931704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other Assets</a></td>
<td class="nump">$ 1,586<span></span>
</td>
<td class="nump">$ 1,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets<span></span>
</td>
<td class="text">Other Assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="nump">$ 1,225<span></span>
</td>
<td class="nump">$ 1,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,529<span></span>
</td>
<td class="nump">$ 1,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027950456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,529<span></span>
</td>
<td class="nump">$ 1,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027740024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Environmental Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>case</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>case </div>
<div>claim </div>
<div>Plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForEnvironmentalLossContingencies', window );">Accrued liabilities for environmental matters | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_TermForPayingOffEnvironmentalLiabilities', window );">Term for paying off environmental liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss', window );">Aggregate possible expenditure on environmental matters in excess of amounts accrued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember', window );">Legal Defense Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Legal defense costs reserve | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CommercialandOtherLitigationMember', window );">Commercial Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims (in cases)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss contingency, number of plaintiffs | Plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember', window );">Patent litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss contingency, claims settled (in cases)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims (in cases)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | Federal Court</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Loss contingency, claims dismissed (in cases)</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LossContingencyClaimsonAppealNumber', window );">Loss contingency, claims on appeal (in cases)</a></td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims (in cases)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia | Cases Company Agreed To Toll Statute Of Limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims (in cases) | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia | Other State Court</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims (in cases)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LossContingencyClaimsonAppealNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims on Appeal, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LossContingencyClaimsonAppealNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_TermForPayingOffEnvironmentalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term for paying off environmental liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_TermForPayingOffEnvironmentalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForEnvironmentalLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs accrued as of the balance sheet date for environmental loss contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6395460&amp;loc=d3e13647-108346<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13207-110859<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForEnvironmentalLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of reasonably possible loss exposure in excess of amount accrued for remediation, site restoration, postclosure, monitoring commitments, or other exit costs associated with the sale, disposal or abandonment of a particular property resulting from unanticipated contamination of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.Y.Q4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14394-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CommercialandOtherLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CommercialandOtherLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_FosamaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_FosamaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_OtherStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_OtherStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026934424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Narrative (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">6,500,000,000<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024553272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Shareholders' Equity (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MovementinCommonStockandTreasuryStockRollForward', window );"><strong>Movement in Common Stock and Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance January&#160;1 (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance December&#160;31 (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MovementinCommonStockandTreasuryStockRollForward', window );"><strong>Movement in Common Stock and Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance January&#160;1 (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance December&#160;31 (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MovementinCommonStockandTreasuryStockRollForward', window );"><strong>Movement in Common Stock and Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance January&#160;1 (in shares)</a></td>
<td class="nump">1,047,000,000<span></span>
</td>
<td class="nump">1,038,000,000<span></span>
</td>
<td class="nump">985,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">66,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances (in shares)</a></td>
<td class="num">(9,000,000)<span></span>
</td>
<td class="num">(7,000,000)<span></span>
</td>
<td class="num">(13,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance December&#160;31 (in shares)</a></td>
<td class="nump">1,049,000,000<span></span>
</td>
<td class="nump">1,047,000,000<span></span>
</td>
<td class="nump">1,038,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MovementinCommonStockandTreasuryStockRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Movement in Common Stock and Treasury Stock [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MovementinCommonStockandTreasuryStockRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024013512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares collectively authorized for future grants under share-based compensation plans (in shares)</a></td>
<td class="nump">93,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Quantity of stock options that vest per year</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Period over which share-based payment awards vest</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pretax share-based compensation cost recorded</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Pretax share-based compensation cost recorded, related to continuing operations</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefits related to share-based compensation</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of options granted (in dollars per share)</a></td>
<td class="nump">$ 75.99<span></span>
</td>
<td class="nump">$ 77.67<span></span>
</td>
<td class="nump">$ 80.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards</a></td>
<td class="nump">$ 699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Contractual term of options</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Contractual term of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027794728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 9.80<span></span>
</td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="nump">$ 10.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">20.90%<span></span>
</td>
<td class="nump">22.10%<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023240536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of&#160;Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, January 1 (in shares)</a></td>
<td class="nump">19,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted (in shares)</a></td>
<td class="nump">4,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised (in shares)</a></td>
<td class="num">(3,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited (in shares)</a></td>
<td class="num">(626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction', window );">Number of Options, Awards transferred to Organon in spin-off (in shares)</a></td>
<td class="num">(1,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment', window );">Number of Options, Adjustment to Merck awards related to the spin-off of Organon (in shares)</a></td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, December 31 (in shares)</a></td>
<td class="nump">18,572<span></span>
</td>
<td class="nump">19,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">17,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable (in shares)</a></td>
<td class="nump">12,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)</a></td>
<td class="nump">$ 63.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">75.99<span></span>
</td>
<td class="nump">$ 77.67<span></span>
</td>
<td class="nump">$ 80.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">54.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited (in dollars per share)</a></td>
<td class="nump">73.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Awards transferred to Organon in the spin-off (in dollars per share)</a></td>
<td class="nump">72.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise', window );">Weighted Average Exercise Price, Adjustment to Merck awards related to the spin-off of Organon (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)</a></td>
<td class="nump">65.27<span></span>
</td>
<td class="nump">$ 63.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">64.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 60.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment, Weighted Average Exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024950952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from the exercise of stock options</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027746632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested January 1 (in shares) | shares</a></td>
<td class="nump">11,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted (in shares) | shares</a></td>
<td class="nump">7,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested (in shares) | shares</a></td>
<td class="num">(6,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited (in shares) | shares</a></td>
<td class="num">(1,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction', window );">Number of Shares, Awards transferred to Organon in the spin-off | shares</a></td>
<td class="num">(1,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment', window );">Number of Shares, Adjustment to Merck awards related to the spin-off of Organon (in shares) | shares</a></td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested December 31 (in shares) | shares</a></td>
<td class="nump">11,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber', window );">Number of Shares, Expected to Vest (in shares) | shares</a></td>
<td class="nump">10,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 74.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">76.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">70.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">76.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Awards transferred to Organon in the spin-off of Organon (in dollars per share) | $ / shares</a></td>
<td class="nump">76.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Adjustment to Merck awards related to the spin-off of Organon (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares</a></td>
<td class="nump">74.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 74.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested January 1 (in shares) | shares</a></td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted (in shares) | shares</a></td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested (in shares) | shares</a></td>
<td class="num">(1,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited (in shares) | shares</a></td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction', window );">Number of Shares, Awards transferred to Organon in the spin-off | shares</a></td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment', window );">Number of Shares, Adjustment to Merck awards related to the spin-off of Organon (in shares) | shares</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested December 31 (in shares) | shares</a></td>
<td class="nump">1,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber', window );">Number of Shares, Expected to Vest (in shares) | shares</a></td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 75.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">69.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">57.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">79.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Awards transferred to Organon in the spin-off of Organon (in dollars per share) | $ / shares</a></td>
<td class="nump">77.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Adjustment to Merck awards related to the spin-off of Organon (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares</a></td>
<td class="nump">77.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 77.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred due to Spinoff Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228939855736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="nump">$ 26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contributions to defined contribution savings plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage', window );">Percentage of Company's pension investments categorized as level 3 assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
<td class="nump">$ 942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests', window );">Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | U.S.&#160;equities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | U.S.&#160;equities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | International equities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | International equities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Fixed Income Investments | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Fixed Income Investments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Cash And Other Investments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">$ 11,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,195<span></span>
</td>
<td class="nump">$ 12,009<span></span>
</td>
<td class="nump">$ 10,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company pension investments which are categorized as level three assets percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DefinedBenefitPlanCashandOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DefinedBenefitPlanCashandOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024479144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service cost</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss (gain) amortization</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(755)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
<td class="num">(817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service cost</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss (gain) amortization</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(416)<span></span>
</td>
<td class="num">(414)<span></span>
</td>
<td class="num">(425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service cost</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss (gain) amortization</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="num">(26)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229022928408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets', window );">Other</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation January&#160;1</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effects of exchange rate changes</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Other</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation December&#160;31</a></td>
<td class="nump">1,541<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status December&#160;31</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="num">(241)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(941)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation January&#160;1</a></td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">13,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="num">(332)<span></span>
</td>
<td class="nump">1,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effects of exchange rate changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(941)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation December&#160;31</a></td>
<td class="nump">13,999<span></span>
</td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">13,003<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status December&#160;31</a></td>
<td class="num">(932)<span></span>
</td>
<td class="num">(1,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other Assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="num">(877)<span></span>
</td>
<td class="num">(1,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">12,009<span></span>
</td>
<td class="nump">10,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="num">(671)<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets', window );">Spin-off of Organon</a></td>
<td class="num">(55)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets', window );">Other</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">12,195<span></span>
</td>
<td class="nump">12,009<span></span>
</td>
<td class="nump">10,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation January&#160;1</a></td>
<td class="nump">12,458<span></span>
</td>
<td class="nump">10,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="num">(240)<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effects of exchange rate changes</a></td>
<td class="num">(678)<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation', window );">Spin-off of Organon</a></td>
<td class="num">(118)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Other</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation December&#160;31</a></td>
<td class="nump">11,575<span></span>
</td>
<td class="nump">12,458<span></span>
</td>
<td class="nump">$ 10,558<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status December&#160;31</a></td>
<td class="nump">620<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other Assets</a></td>
<td class="nump">1,395<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="num">$ (753)<span></span>
</td>
<td class="num">$ (1,377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in plan assets, not otherwise separately disclosed in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DefinedBenefitPlanOtherChangesPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in benefit obligation of defined benefit plan from disposal or classification as held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDivestituresBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in plan assets of defined benefit plan from disposal or classification as held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDivestituresPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027634088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) - Pension Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation</a></td>
<td class="nump">$ 13,013<span></span>
</td>
<td class="nump">$ 14,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">12,072<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation</a></td>
<td class="nump">12,916<span></span>
</td>
<td class="nump">13,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">12,072<span></span>
</td>
<td class="nump">11,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation</a></td>
<td class="nump">2,507<span></span>
</td>
<td class="nump">8,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">7,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation</a></td>
<td class="nump">2,462<span></span>
</td>
<td class="nump">4,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="nump">$ 2,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228940543176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) - Pension Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 943<span></span>
</td>
<td class="nump">$ 942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">$ 11,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,035<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">919<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,915<span></span>
</td>
<td class="nump">2,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,870<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,156<span></span>
</td>
<td class="nump">3,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,915<span></span>
</td>
<td class="nump">2,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,898<span></span>
</td>
<td class="nump">4,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,870<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5,007<span></span>
</td>
<td class="nump">5,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,799<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">919<span></span>
</td>
<td class="nump">927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">12,195<span></span>
</td>
<td class="nump">12,009<span></span>
</td>
<td class="nump">10,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,944<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,436<span></span>
</td>
<td class="nump">4,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">2,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">9,293<span></span>
</td>
<td class="nump">7,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,292<span></span>
</td>
<td class="nump">4,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,025<span></span>
</td>
<td class="nump">2,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">937<span></span>
</td>
<td class="nump">935<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">937<span></span>
</td>
<td class="nump">935<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Real estate, Investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_FixedIncomeObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_FixedIncomeObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229019227816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) - Pension Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">$ 942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">$ 942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Insurance Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">12,009<span></span>
</td>
<td class="nump">10,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">12,195<span></span>
</td>
<td class="nump">12,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Insurance Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers in (out) of Level 3</a></td>
<td class="nump">78<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">937<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Insurance Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers in (out) of Level 3</a></td>
<td class="nump">78<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">937<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers in (out) of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers in (out) of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(C)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023663432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) - Other Postretirement Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026719704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027&#160;&#8212;&#160;2031</a></td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027&#160;&#8212;&#160;2031</a></td>
<td class="nump">4,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027&#160;&#8212;&#160;2031</a></td>
<td class="nump">$ 1,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023432152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) credit arising during the period</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax', window );">Total</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Prior service credit amortization included in benefit cost</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax', window );">Total</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="num">(448)<span></span>
</td>
<td class="num">(816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) credit arising during the period</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax', window );">Total</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="num">(820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Prior service credit amortization included in benefit cost</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax', window );">Total</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">815<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) credit arising during the period</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax', window );">Total</a></td>
<td class="nump">786<span></span>
</td>
<td class="num">(345)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Prior service credit amortization included in benefit cost</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax', window );">Total</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023914072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025016824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) - Other Postretirement Benefits<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Health care cost trend rate assumed for next year</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Rate to which the cost trend rate is assumed to decline</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229028837144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
<td class="num">$ (274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Income from investments in equity securities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,940)<span></span>
</td>
<td class="num">(1,338)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic defined benefit plan (credit) cost other than service cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="num">(545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_OtherNonoperatingIncomeExpenseOther', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,341)<span></span>
</td>
<td class="num">(890)<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized (loss) gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (232)<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized (loss) gains</a></td>
<td class="num">$ (500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OtherNonoperatingIncomeExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income and expense items not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OtherNonoperatingIncomeExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229023099528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_HealthcareServicesSegmentMember', window );">Healthcare Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_HealthcareServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_HealthcareServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024730824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate applied to income from continuing operations before taxes</a></td>
<td class="nump">$ 2,915<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="nump">$ 1,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract', window );"><strong>Differential arising from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings</a></td>
<td class="num">(1,446)<span></span>
</td>
<td class="num">(965)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount', window );">GILTI and the foreign-derived intangible income deduction</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlements', window );">Tax settlements</a></td>
<td class="num">(275)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R&amp;D tax credit</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree', window );">Acquisition of VelosBio</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour', window );">Acquisition of Pandion</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Restructuring</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments', window );">Acquisition-related costs, including amortization</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo', window );">Acquisition of OncoImmune</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination', window );">Acquisition of Peloton</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount', window );">Tax Cuts and Jobs Act of 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">$ 1,521<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Tax&#160;Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate applied to income from continuing operations before taxes</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract', window );"><strong>Differential arising from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings</a></td>
<td class="num">(10.40%)<span></span>
</td>
<td class="num">(16.50%)<span></span>
</td>
<td class="num">(6.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent', window );">GILTI and the foreign-derived intangible income deduction</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax settlements</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credit</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent', window );">Acquisition of VelosBio</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent', window );">Acquisition of Pandion</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges', window );">Restructuring</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments', window );">Acquisition-related costs, including amortization</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent', window );">Acquisition of OncoImmune</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent', window );">Acquisition of Peloton</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent', window );">Tax Cuts and Jobs Act of 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total, Tax Rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">22.90%<span></span>
</td>
<td class="nump">21.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to the amortization of purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Four, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Three, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Two, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to amortization of purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229022642984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Transition tax for accumulated foreign earnings, liability</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred tax assets on NOL carryforwards relating to foreign jurisdictions</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic', window );">Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards</a></td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Tax credit and operating loss carryforward, valuation allowance</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefits relating to stock option exercises</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,529<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">$ 1,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Favorable net impact to income tax provision if unrecognized tax benefits were recognized</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties associated with uncertain tax positions, expense (benefit)</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Liabilities for accrued interest and penalties</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Valuation allowance on foreign NOL carryforwards</a></td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Valuation allowance on foreign NOL carryforwards</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service (IRS) | Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Proceeds from income tax refunds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service (IRS) | Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrk_IncomeTaxesPayableMember', window );">Income Taxes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent', window );">Transition tax liability, current</a></td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent', window );">Transition tax liability, noncurrent</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets credit loss carryforwards and NOL carryforwards domestic</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_IncomeTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_IncomeTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229028675640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Income Before Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 1,854<span></span>
</td>
<td class="num">$ (3,814)<span></span>
</td>
<td class="num">$ (66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">12,025<span></span>
</td>
<td class="nump">9,677<span></span>
</td>
<td class="nump">7,237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from Continuing Operations Before Taxes</a></td>
<td class="nump">$ 13,879<span></span>
</td>
<td class="nump">$ 5,863<span></span>
</td>
<td class="nump">$ 7,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024870472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Taxes on Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">240<span></span>
</td>
<td class="num">(605)<span></span>
</td>
<td class="num">(328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(77)<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision</a></td>
<td class="nump">187<span></span>
</td>
<td class="num">(566)<span></span>
</td>
<td class="num">(560)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">$ 1,521<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229025229784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income - Deferred Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Product intangibles and licenses, Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory related, Assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Accelerated depreciation, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Equity Method Investments, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Pensions and other postretirement benefits, Assets</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Compensation related, Assets</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits', window );">Unrecognized tax benefits, Assets</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards', window );">Net operating losses and other tax credit carryforwards, Assets</a></td>
<td class="nump">867<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, Assets</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal, Assets</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance, Assets</a></td>
<td class="num">(287)<span></span>
</td>
<td class="num">(404)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred taxes</a></td>
<td class="nump">1,996<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Product intangibles and licenses, Liabilities</a></td>
<td class="nump">2,933<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts', window );">Inventory related, Liabilities</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Accelerated depreciation, Liabilities</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredTaxLiabilitiesEquityMethodInvestment', window );">Equity method investments, Liabilities</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans', window );">Pensions and other postretirement benefits, Liabilities</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other, Liabilities</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Subtotal, Liabilities</a></td>
<td class="nump">4,745<span></span>
</td>
<td class="nump">2,656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred income taxes, Liabilities</a></td>
<td class="nump">2,749<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">3,441<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred taxes</a></td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards and other tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxAssetsUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxLiabilitiesEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxLiabilitiesEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027717208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance January&#160;1</a></td>
<td class="nump">$ 1,537<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
<td class="nump">$ 1,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions related to current year positions</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions related to prior year positions</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction', window );">Spin-off of Organon</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance December&#160;31</a></td>
<td class="nump">1,529<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Unrecognized tax benefits, reduction resulting from divestiture of Merck's consumer care business</a></td>
<td class="num">$ (58)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_ConsumercarebusinessMember', window );">consumer care business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Unrecognized tax benefits, reduction resulting from divestiture of Merck's consumer care business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_ConsumercarebusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_ConsumercarebusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027503112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 12,345<span></span>
</td>
<td class="nump">$ 4,519<span></span>
</td>
<td class="nump">$ 5,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
<td class="nump">4,153<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Merck &amp; Co., Inc., basic</a></td>
<td class="nump">13,049<span></span>
</td>
<td class="nump">7,067<span></span>
</td>
<td class="nump">9,843<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Merck &amp; Co., Inc., diluted</a></td>
<td class="nump">$ 13,049<span></span>
</td>
<td class="nump">$ 7,067<span></span>
</td>
<td class="nump">$ 9,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average common shares outstanding (in shares)</a></td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common shares issuable (in shares)</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average common shares outstanding assuming dilution (in shares)</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">1.01<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Income (in dollars per share)</a></td>
<td class="nump">5.16<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">4.86<span></span>
</td>
<td class="nump">1.78<span></span>
</td>
<td class="nump">2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="nump">1.61<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Income (in dollars per share)</a></td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229026524056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228939713400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,404<span></span>
</td>
<td class="nump">$ 26,001<span></span>
</td>
<td class="nump">$ 26,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951<span></span>
</td>
<td class="num">(915)<span></span>
</td>
<td class="num">(610)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(568)<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
<td class="num">(441)<span></span>
</td>
<td class="num">(648)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,257<span></span>
</td>
<td class="nump">25,404<span></span>
</td>
<td class="nump">26,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="num">(383)<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="num">(299)<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,540)<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
<td class="num">(3,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
<td class="num">(599)<span></span>
</td>
<td class="num">(948)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(374)<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="num">(488)<span></span>
</td>
<td class="num">(756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,743)<span></span>
</td>
<td class="num">(4,540)<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanNetLossMember', window );">Pension Plan Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanNetLossMember', window );">Other Postretirement Benefit Plan Net Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanPriorServiceCostMember', window );">Pension Plan Prior Service Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanPriorServiceCostMember', window );">Other Postretirement Benefit Plan Prior Service Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,828)<span></span>
</td>
<td class="num">(1,981)<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,830)<span></span>
</td>
<td class="num">(1,828)<span></span>
</td>
<td class="num">(1,981)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,634)<span></span>
</td>
<td class="num">(6,193)<span></span>
</td>
<td class="num">(5,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,429)<span></span>
</td>
<td class="num">$ (6,634)<span></span>
</td>
<td class="num">$ (6,193)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanNetLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanNetLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanNetLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanNetLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanPriorServiceCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanPriorServiceCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanPriorServiceCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanPriorServiceCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229029404776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228941418376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Sales of Company's Products (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
<td class="nump">$ 39,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Revenue related to the sale of the marketing rights</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">48,322<span></span>
</td>
<td class="nump">41,336<span></span>
</td>
<td class="nump">38,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">42,754<span></span>
</td>
<td class="nump">36,610<span></span>
</td>
<td class="nump">34,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">17,186<span></span>
</td>
<td class="nump">14,380<span></span>
</td>
<td class="nump">11,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,673<span></span>
</td>
<td class="nump">3,938<span></span>
</td>
<td class="nump">3,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,135<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">2,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Molnupiravir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">857<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,324<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,964<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">2,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,568<span></span>
</td>
<td class="nump">4,703<span></span>
</td>
<td class="nump">4,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">2,939<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">22,425<span></span>
</td>
<td class="nump">19,588<span></span>
</td>
<td class="nump">18,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">22,159<span></span>
</td>
<td class="nump">19,517<span></span>
</td>
<td class="nump">18,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">20,401<span></span>
</td>
<td class="nump">18,010<span></span>
</td>
<td class="nump">16,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">9,765<span></span>
</td>
<td class="nump">8,352<span></span>
</td>
<td class="nump">6,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,881<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">1,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,629<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">583<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Molnupiravir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">984<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,758<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Animal Health | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">667<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Animal Health | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">872<span></span>
</td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">26,279<span></span>
</td>
<td class="nump">21,930<span></span>
</td>
<td class="nump">20,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">26,163<span></span>
</td>
<td class="nump">21,819<span></span>
</td>
<td class="nump">20,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">22,353<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
<td class="nump">17,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7,421<span></span>
</td>
<td class="nump">6,028<span></span>
</td>
<td class="nump">4,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,792<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Molnupiravir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,597<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,810<span></span>
</td>
<td class="nump">3,219<span></span>
</td>
<td class="nump">3,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Animal Health | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,628<span></span>
</td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Animal Health | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">892<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_KeytrudaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_KeytrudaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_Pneumovax23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_Pneumovax23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RotateqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RotateqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VaqtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VaqtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrevymisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrevymisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrimaxinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrimaxinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NoxafilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NoxafilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CancidasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CancidasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_InvanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_InvanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZerbaxaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SimponiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SimponiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BelsomraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BelsomraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_MolnupiravirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_MolnupiravirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanumetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanumetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LivestockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LivestockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228939860568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Consolidated Revenues by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
<td class="nump">$ 39,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">22,425<span></span>
</td>
<td class="nump">19,588<span></span>
</td>
<td class="nump">18,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">13,341<span></span>
</td>
<td class="nump">11,547<span></span>
</td>
<td class="nump">10,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4,378<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,726<span></span>
</td>
<td class="nump">2,602<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific (other than China and Japan)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,206<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
<td class="nump">2,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="nump">$ 1,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229024259128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(806)<span></span>
</td>
<td class="num">(831)<span></span>
</td>
<td class="num">(893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="num">(1,636)<span></span>
</td>
<td class="num">(1,817)<span></span>
</td>
<td class="num">(1,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="num">(1,578)<span></span>
</td>
<td class="num">(1,669)<span></span>
</td>
<td class="num">(1,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(12,245)<span></span>
</td>
<td class="num">(13,397)<span></span>
</td>
<td class="num">(9,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(661)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">13,879<span></span>
</td>
<td class="nump">5,863<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">32,927<span></span>
</td>
<td class="nump">27,776<span></span>
</td>
<td class="nump">25,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">30,977<span></span>
</td>
<td class="nump">26,106<span></span>
</td>
<td class="nump">23,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Unallocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(806)<span></span>
</td>
<td class="num">(831)<span></span>
</td>
<td class="num">(893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="num">(1,636)<span></span>
</td>
<td class="num">(1,817)<span></span>
</td>
<td class="num">(1,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="num">(1,414)<span></span>
</td>
<td class="num">(1,519)<span></span>
</td>
<td class="num">(1,491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(11,692)<span></span>
</td>
<td class="num">(12,911)<span></span>
</td>
<td class="num">(9,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(661)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SegmentReportingUnallocatedOtherExpensesNet', window );">Other unallocated, net</a></td>
<td class="num">$ (3,031)<span></span>
</td>
<td class="num">$ (4,394)<span></span>
</td>
<td class="num">$ (4,395)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SegmentReportingUnallocatedOtherExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other net expenses not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SegmentReportingUnallocatedOtherExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027908856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details) - Operating Segments - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss from affiliates</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss from affiliates</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss from affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss from affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140229027846152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 19,279<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 14,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">11,759<span></span>
</td>
<td class="nump">10,394<span></span>
</td>
<td class="nump">8,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">6,081<span></span>
</td>
<td class="nump">5,314<span></span>
</td>
<td class="nump">4,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific (other than China and Japan)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">737<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>mrk-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrk="http://www.merck.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrk-20211231.xsd" xlink:type="simple"/>
    <context id="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i19fa39a0158d4ac3a19217bc596e4123_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46992b35b0554da8a6375df5c7dc327e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1852627ad8f34be7a1cca870e27e5bae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a98152d3a5b419398f05b5c58fb8024_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7d3d9b0d798490eb3d016707f5c8fb3_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ie0f012095b0b4d82a0ee2d4237014df1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib8b85b81b3df4143813c92eac8590ae3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i296a96e660db43169f0376b184f4d3fc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i241c8aa1377540ad88e44cceb968c204_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia2112d614d9a45828458276b54ac3348_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifd9336867cce49919c9a776ee62bc1b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1b062550448c4f5b877548d6eda89d15_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib908a2ace6f544bd91b2adcb40f2f0af_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8b25cba6160a4486b14740ddd2b481ef_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8e94e814bd0149bd847f2783d90c9d48_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i40203e52d1c440a6b89559fa168b081a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0171e54cbd894628b6188119563a887e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3acd7fea33f491a9299de32f18ce21a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e784cab819d451499c362b12111a27a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01dd7de0cf6f4ace976de5b22d6ba095_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5a5580f8dad412cb034d3e6ad78653f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a458b3d31d042a4bb104dc181064e79_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e651f0bdf0a4e5c85db0a3c85be51f1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5734fc741d6d4e0480d4a89bf0739099_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7071cda02b544795b02b9668d83532cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89ce079367344ee799a79a4d8a61dcdf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia95480df7b48466b8fe2970840b6d96e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1468cd3ea95419fb66e7dd8d3547410_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1dd27579d0594b8c836cf9cb029ccdb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if91e41b657e142838655904b6ffc2b4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i747b6da151fd47548889dcf4acf9f07e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i629510fd09f5448784fc756b630535b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d1f8e2c09b84254b99b8e105564e52b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44fbc319828d43888404b362300c8719_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22154b3c72564c4184ae4a06c41144ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49673c36f67e4d93b4ebbe225a478e72_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52711b1bf6764fd78c0ef6f9e7df950f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5889b314dc6846e99dfdc5dd5b0d4d4d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fb199531c9a4be79a55f354540b66f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5771d34675734e438d53901618ffd853_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a2a1e33e2f04030829641bc2c24a05c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e9a7df047274290ad191b1e08bfc7ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i333ee6c0baa94ce7a67cc850a8d3a772_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10c6f9da4227441da8480f88901779b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i020c181c0f60421080b1a0cdcce948b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1a2739cca2046f0abc863ed20b48d0b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idbf378454e1d4b12a87f05c8d4852a45_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48e19dcf50aa4fd1ae7e9d3a8ea60763_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ef868a5ade24c99b03f00ffa9481beb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3844e8babf814713b968b4e3c289a5c6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42166b8ad497486faa87ed01b29e3d22_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74c24ba602a542c0b8c9b0ef7ed35ee3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad274281f336490a9ef2ec84cddc2518_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f1aaf80bf5248b6b6375fd958a9e703_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib66800d952274b52b8a0a168fe298ecc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b1ac66b90724fe18f56ea110536b64b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8be0b42ed8034d95ba4e13ab6fbbf535_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b030dcad117451495b0cce71d1a6fc8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1098dc170e941f38477fba57b8cf5ae_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="if2498efe88024feb8dbf6cebe7b9e1c4_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="id35e3e3e253f4a6eb98018307707afde_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i16aa05ee3ee141d2ace6ce8e2e932362_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="iaeb5df78dae84a27b551e06a2a2ae854_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i162cf24607d24678bb2c7252e0441829_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11ebf3cfa71a410e931e1ac91fd56a8d_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i5475fea5427a4a45a8d0f7c70cc2edc1_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="iad3694ffb88a4c26905566a5aadc567e_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="if35f0cdded8a441882d65448ee48c8ed_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i84ebf0636d2b4c2daa4201ebca56405d_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="iab98fe0036ab490284530f0ef5a067b9_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i6c67fcd89a8b4082808554b5f0549fc8_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i5c62b473540e4792973e3e5eff8e852b_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i700f5502bfe547d29c56588dcd1c2a57_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i078bab656180438fb5b9e6e2b822296a_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i2ad6313c93cd46b38072ff32e2d4d398_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="if845b3b4c08c45efbf34f152a3076b6b_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="i66e156b81e874c37998b4260b293e32d_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i691918582c3344e899b4df21192718a3_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ib5e47ab987cd4d3abdc343a64acdfcdc_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i363a34970b28487fb538f79d80bd5c63_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i3dbe981b0dce44c7b9140f5b1e642a2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62ab2e68dea743c09e757b18af5181e8_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OralAndInjectableFormulationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i85efbd1b835b4a8e8e7140e9b606ea82_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OralFormulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if1ab7dec508142c597fc9e631c500889_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InjectableFormulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0caff53de00b40f0b2a4242ec4f7b853_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i6a13694e029b4e109b43b40ab0e2f486_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ie4df9ebe39004e61b4723b8728950ca9_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="iee08b09a26eb4dbf9c1fc7400dd403eb_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i8782918165654defab8aad5b032f7b4e_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i8b7f6216f9b24aefaf5499aeeae375cb_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i65036a0df1a24e1286b3b620969af227_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifbd4e250c5234f40a49f0424a7b9ca39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a2125d5f6f642d48b2728270ed20dcf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87d5e8e876a74d78b9b4adb360ed3859_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4bb721c83cb4d6baf3edaee991beff8_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i154453efc9bf49d9b6c2e7bdb4a3667d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i887204908c64421d9da59e4d3c3099b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e331a60d4604a2b9a0563cb2271e112_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic5c941f925d9424e9b42b6b4bb3d68b8_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2bd91e11abc48aeac94ddad807d22c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i090c4ce27a88432b994b5cd38555a37b_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie34faa097b834cfa9a5bcfcaf8c87262_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6f789b2accd9484992688f3f01dfdf11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48c7436c3f434009bc43ed8fb64f30db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37947affd59e45db9bf4247d22ef2445_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0a44796f0e99454095c4177490b7a1fc_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id735e23c835a42d7a629be7b46a33b70_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia094e3f9230741fb85ffb13181d20935_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i22dbddf74d0346e2bcda039fb5251dc8_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibd702d7339fc4907beb6de920d2ebfcb_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i94eccca165db4204b5fe7cd15369ff52_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0772900bf1714a1286b8a8be67ef1352_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i46379c7182e540b2828bf31f0181f842_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="id62a4bb25fc844f59220aa4a94682bd9_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="iffce628751d64772b2c55aabb65ac5b4_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="iaf228ffc1f9146219d66ae63268e5646_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i253e7eb6731846cd8297aa6fff74e2a7_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7c2134703ab44a17a75303f1e2bbc346_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idd20b1fb1b1840cd97ca9a25e317e07f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia72336269c0e4853bb62f08578a8703e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41279252c9624ed8a4c7a81861188d80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5bd531bb0694347bbaa1de33894a3f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d06568f20aa4404ac1d16b234d39d17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d3b73f821cd4774aad66eb73f3a5f66_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:IAVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i38be38fc4a954d74a422539b6c013245_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia80b8fd970c84658b490d1b62ee60672_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i00f0fb0e68c34bcc9ac14ca5a1d30e3e_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i863cd316ea5d4a879ae66467e3f51ad8_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="i02d468ad359d4b3c907fa0ca583c3707_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="i02366c725d8e4b61a487fbc509afa833_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if3aa932f580f42fba20f4fb291aa005d_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i2c7c2e213af64bed83c7c5be126fe2b5_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i0b43da370e844376a5ef3e3c317c068c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4d46d7a5f1d84985a8798afe9a116fcd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:CommercialmilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i094e0d6dfc6e43d8a71ef15cc8afa929_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i73b1a5803b6e4bb1b34750d30eaca4d0_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i2b06079ce243471f80c224e28eca9bc0_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="i178e3b5f7ea940f3ac5c975609fe189a_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="i6bb86c75b69646909c1e731b110cd594_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="i353be6859e8a4c909dc868bb55fa96ef_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="ib1fd1624d0a447a0a77222b18fdb866f_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="i38900b44f49245e2a2fe07fe9834a8cc_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ib3255f0f1f154600bc059456bba5499d_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i14319073e5c3479eb00e19929756ed79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5702456494b740da8508f5b853110e3d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida96075caa59419780179c2f9b3c3546_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa55a231791b4a4c9b8b8459d1b149dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98306b224b47475488e911e85f203624_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a357f883cf8403d91477b70cff00a8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i642c3ff7f9414f5392688e1239f63e01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica0a3fd966314c5dac24c390abc72914_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8bd0a10b28b427cb9d90dfe3a600d6c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic810a621774c4c99983badd39ea9eba9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03aabfbe2af64606bfcdc9b7244adddb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46c263ae58e241119936ff1e15d0ea2a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id016daaee2884b7f93108c6df370f620_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76cfcf2bfbe4407ca26ac87fbf3ba4d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42d4f6c2d4ef45beaae183fe55dbf354_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ica857d506be742ee8d273ccfcb812e2a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i93d60c48bbfb4999a5474c6c5295cf07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6bc366f05419417e83c83213cac8477c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib054f661c3f042f99541982143ad5e6f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia8e6351182024603b7f62da8e5b885f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iafe4a4c0ebe0439a803c537ea10a6d6a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b90e12bc9ba43f7abb9022574ae4b38_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7365ef92cc904089a49a56598ef8d5e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i109c40ef87d24d13bd2b5cc4cf386752_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6154dfd2961f4f43916c01e33c8d1386_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56b97e6d098246129353599999e69659_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if375a5c48628477c973fbc4fd1d1b133_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie381877a89e94c45bc4b63e6dc00f506_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3c672ce6ee24fd083c1fcaea23ee2bd_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3303c07747a54842b62042d5a21e6f09_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56a431121ab94fd3aeaeff71b65fbed1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if502cf4525474a359d96f230ac724e3f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7239a77febd64e6582c7bd34411f3af6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i328e047b1fe9465cba44b2312c36a1f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie554c78a55284e71b4e43682b58e067e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8e076f12b4342f1b585a7f637e3c832_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bd44ea5d24342129e8b6ebb5a4efdb2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia98a6294caf44811bdfc230489f05f54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1775b6c3bb3245dfa916e2e3ecfac7c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4981e17b20a547c8bc03157a8ea2bd94_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if383a9214fb545e98c021a08266ee37c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78dcd3d033904438964f0f1e38a578c6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibdb3a0fe626d42bd8f53d27a0a6cc6c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i19ffe322d7c84b43864b069f78e9b3e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d6795e1450e497ea457f40aeb36be13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0db97feaad864168aa38dfed369a69a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b9860090665459d8fec0ff943a45f30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31bedff9aa684372b0af5c1ba6c41467_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if064fdd725ea4a7c982907c44a941df6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19adf582d06f45aca49da637284ec35a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2cbdb424aa5944669afe3610141ee5d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56eee0d6468b4e67837ceae0dbff2f9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie04e36743dcd41d3b045117f4f3b8170_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4e1a080606b4e4592e4f4733ceb6c81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if90b8c08c37a41ffa4f6848991b4a7da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1570e7027e0e496ab090442e8a8be4af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17edb9f092f7485f9426b08af9218bf2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00f8c65ee807407dab9ca51108c58857_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id18a472cdb414425a36e2fc4fc858400_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0a967edb06f4521aaaaa2ecf0a9b105_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia746274f620f40c1851d95a52bb1fec0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7e96dc6c32d41be85aaddf645d42386_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic78cbe3c61444fe491dc47f1246975d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96d7ebb400b14b728855eecc7c992f50_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07c74b59b3824b859e175ea5af3e1de3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3a2d934adf3844c9948a3c90a53001de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia59c375a867e43f387fc23f684540a1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic524b8d83ef44a209ae2f8d59984ad9f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie861385c736d4571ac97d10e57900db0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i891ef023d6cf4c1594a15170a05474b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id72f5afaff1c4203b2ae637d11fe6fb6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81e1fc699103401fbce35712191d910b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i30e3a1eb707a4bc0b1578b9e4e15f60b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ideff38e8d1af4d7ca70fc010025279b6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia185bf2a1911407099126af09d6781da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i342fe69beb814c41a97a7aef4c9ac973_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0452510b6e3c4fbd81f8cddba0a9d033_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0003ff4798514c25a8591c162be15992_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfd82ed31d7346f58d217331940bd0d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i817d4a5d455b48e0835d76a3e57a68b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8063a63e130649cd85c2717196b54dde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50e584cc2eff43599af7e4d668e4568c_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5bf2c56c247444b38c99429fcfcc161e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b951c64d4e94488b0076bc63024ee64_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i756ba880ce0840268980b9aab4635b5a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3dce085486ee43df951fdeb7914c2311_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedKingdomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="ibc01fdd92ce142b8bd16ad6681f5c303_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedKingdomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9796277d9ba47be91cb5b887f734e7e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">mrk:SupplyCommitmentToUnitedNationsChildrensFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32e28bb8b9aa4b7293ac191de6dddfe4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia356d15f44884231bebbcd7fcdd11f4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i097bcd95db4c4868880f6e0af7fcc0c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib15900e9713c45c48f0b905cb6dda370_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00fb66ab96ce42d89c8d0763fcc77ddb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b31b8b00cfe47f490681a6d81cd140b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i737ff51dc12248dfac6273aae238abff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a1726f56cf343c482a8f9ccb64bd59a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13200a779dce464f80cba863cea9e407_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1fde0285ad7451a9e92d2f80b91240f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e67b3bb86584dab8782e051cf58baff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5aaca85009704ba19f1513e1e6c78715_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31dc8ec6b8e445b7b1b2b75aa10c997f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida45dba4790a481d8b49ae4d99983799_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia73cb7250e044a5f85e091f1f1ddae2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i946b15bf33724eab9cd37c967a566b18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i41ee296e8eeb43419e7163aaf951d1c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf3f8d9415a448c18444c1d1d8b1fe42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31323381bed94598b8252be522569bca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id56683f71b6048a5b950676e5147ddf6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib8e2c2edc5a34bdb938b2ab9082b4ef0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ac2c9d18fc948e3b3936a9c1745217a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i59278b50186c44eea02cd1646e7b396b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfe328f6c7a841e2b8499cc76eb20e1a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icbbd36fe79ec4490af6d95ad286eece6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice0f65c662794b7c9441b60c88d828a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a62cdc5b588461686edf03bf5ad6825_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4caa478726464d649c33751164cc0d70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iebd95b3f5d7d4a40ada1f89d7f2b3807_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba6383149a1b416d85737bb951015359_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16cf5190146b4f96b1360695ccb6edd8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i30f607f077f64c3daf4b01cf7298bfcd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50bddbb672804072ba20c9dda2af5613_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i380e21df60bd41249e37f76c96e5b370_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0297bc36963248d48192cc37c891ebd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa96945711e74e16af5a510b6ad45e87_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i310042e57f8648c1910a64c356d6e4e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46fa1a240c9641f582948709782ebebb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9e16f47e6744b63b974f8c45a0aebce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib320e53fbe8f4a71a079672c21ab5589_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i403dfea81e9b44b38f3a6469fc84c66b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie002d0c48a3741839131c30916e5272c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3f343081e674fb6824fe0f6ea3f51b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67a74b90c27a4d51bc7a5b722f81b3b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id19696965a5c496d8add86515a1be5ec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic2d842b6322f4be89cdc492a4a169002_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iacdb4cd333404a72ab7e9c4a06cbe2c1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iebf1ad6c7e2d42f2b67fbb17e45f48ff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idb3f09c566f04978a062c5b475fcb376_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d31ca3c243847fca3ff1222d83159af_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i111c43d6a309499f9624c33e82a4ffc9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4ccf2924ac4f40168f4b02f65db200ee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf00dc1bbf9946288b16b5451fe51cd5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3ce6215e57c2458a9afd417343c63d14_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd0c801111b849889a3cb1999277404a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16730c4a678e4c64b56d69ad77692225_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8f15ce626aad44f58292eedaa374a985_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic5f02c13fd4747fc989b60fd784585bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id069b94a80af42e4888ed8c2211e56e1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9199f48459144d88986872e9ce83bcc8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3b1a06d7e97b4f2da011319e92c97eb9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6560744cffdb44c6a15e0de8cb3125c5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6aa2324a7bd9442db621352f34648867_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iffb507ac1c0b432293ffd49cc271e612_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if561463c4bc4425caa176dc7d55ee265_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6bc98ae55b3748a19a4a059028c47b39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5bbf238dd6a44468ac376288e4e1add_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id389b623812d474ea6c5ac6b16c29504_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb664c71c0594335bb3a3f87041223a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20b9087bb1864779b2109ddd342e45f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d11003c0d414a6e8d574694e9ec9dea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6e9ec1cceb94d9bae732843b25cdb75_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ee26aaae9074659993d6d84e4de1ffb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02721ef0aaab4a4caee301f22e9386ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84bb7bc1ceda4f948a3090842627e654_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3e1bd075f93491e9df5f7f32bd7ad1f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib65521c997c84ef8b37cc9b21ffd59d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie72e897aad094644a983458bfe8704d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibeeff8ebe3be4a60ab7c727335780af7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9352e4c6900b48a3965ce12d07bf3a06_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie137bb0fd9d44320bee063d82bfcf668_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic4e9d32d55204511bafd6a9816b6f024_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a496974bc6443bb93bb621dd56fc567_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4df804136d5442df9b3d7abea422a604_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia2bbb9db2c294c3ba3a6368380f2e03e_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i8fe94b07a3fc4572a433b1102b900e44_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i310109d6898342d49bc826875e191ad6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9de5cdef0a234eefaec97bc914e30cc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i591a75ce070d4aaf981adbe405971c39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i752aeb3870ee4f6bbfd196995b6998d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6611393547d42b1bc24ebbbb98dc51d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2ac86e44601419fa50cb8bfba8997cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd3c2b08bde54d01b9032cf85c1bae1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99c86a1b952c48f7861dbe9b5aeab121_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia36b163f3e8e43d6ae5f69d6957c282f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28e71a0f38b8445fad18e25a0d495afe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0bd1d54e2d34252a1c972fe50060600_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c7da2a453a443a3976d58aac76e2b44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09985e2ea91f4c08a1fb3fe016edfca0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70cfa0f51218476493154e53e8b1dbb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ab442d7528e4761a37ccabe79942355_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if30aa462731e489cadd31a7b7aa3f2c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98d4a664ab5b4b76bf159dc924348812_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19fc35655fc94795bae5c9b1bf8ef198_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9731ca41dc5346328715b1b72d90d14a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bfc38d37e5a42ac8fc03da3a897894d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i516472e36f9d496aa8c94bb0c311f117_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ccd34269c794e22960b8ccb14c99461_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e2b59714c6844d68d8390e2770ef044_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia90d34918e9842f5b8088721b0df39e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5b7d60396c746879acbf1477ac19434_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idee6fff4646d4707a2a06f61ed411ffe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20fbc9f911a54d23b75ffedfccc36c36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib59169c0f6834a5a9361dc5a5dd9fb50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12ea01dfaf7b4584b7cb6e99f32d5f16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i733145edccf544dba291d9978b2c7899_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1efd7da37e42404d934244b631380e00_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6696a02570e049eead17b64f1424b15f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib57b83c73b584975acd4aa8663d43dd8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5e1d3b1cd3244e0aad923e07c063a9cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i539bde58e63e4ef48c1df31dfc07d91a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02bd2346097c4b3b9fe8e30de60e2cf3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e4641a8e98d45b995aa58ccc3163f5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88c61111e751460c82200beada745607_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i713d31c07f5a4005843f4d9cf95d467d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3a88bace3aac440ea9b4d06c6c356839_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief07c343564f4087b2e4707c3e91f20e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4fe1bc7905c64eee8380775080e0e9ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i71d6586ddd354fdab6d1c9bcba27020f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c020fbadbb34c96a252288c30f7d10c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b6efd6ed9184294a5fe275ff87e45f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1883b0f48cea47939cd4e2cd6084fd78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32737545f1ac4e5788d077690a87566c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8165d1112e047829b04b7cf5d434fdc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b37f94f01344d068373b8eadf59831f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a5e799c31be4b2b97f3af704a0044b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7088d09c4094d16b9f7a4d53c7aa102_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief2d0cb66d6843a2b24234f1871d47d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7753d387d18e460ba9fe6aa0c2630a87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2278c012f1844a228077b20f27d2ee75_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfb2266cfce24ebfb26a77e0821736a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c3ce1e7833a43afb07fd5c57894ed59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9eec4c9abea402cbed26716dfe0330c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fe99227a96e498abb64a74bdc78ffa9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d46b377a489415a9f6e4c66fe01bf48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie06b300d5fc54b4b9783aa98a7eb7558_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bd24ccfb9ef45e5b7c7e11d85d3c5a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4831a0db655443696586e7bf7801c3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5cd4dd6f92f4fb4aeba7cc718e0b003_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98b812ad7f9c4916b7d12f5ddf65dea2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if476e20ccbac40da9954263fe92cc4a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i380f7c1970374c70a7b006dd0d7d14d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48cd974a9dc24b368f72dbb106104fdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if49bf71bb091429a952fad2e1c3ff77b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64f9cfb107d04007a2a989ea4edc5d95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d0972f005da4b289e0431985712cca1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fc26049b03349d5a347c39c0b1c2d52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia75d16e884674d4b891ec0ff23d5093a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd6d94719de4466686b830a0d3f35adc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67eac5db6f054e3180b3bf214875c398_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f2922f1eb3341d59ffc36b1dec737f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6772ab94dd5b401f86bc3a27f2707c7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief19c5f56cee4d83ac0c396c293b6749_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65dd20d822a044fa906443ea329c9a4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6df1f9215da4dd8b4038a15c4d03869_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e2c14bb74904e8c96d89c5cd96c9212_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c7f502712974d0099042d3487baaba4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5e50550f1a1441eb77bd65c2709b78d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10944a8fad9a45dbad295162e3f81b90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a924a8c7478492599a96afaa7e429bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id51fe3efcb094b65bcae5a4a5eb91051_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07ddf9e42a484a8ab8fe46200c4b1460_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id87fd36653fe4e028384eb4df59b37d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87476d0b8816403891dc417aaa9709e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaab118969b6042d18ed16e3ea6721990_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i137f81c1d5584d34869c5b39909172a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96634206fbd44c669c42fbc69576e46c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedcde32f3e3347d6ad26d923ef7bf728_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i023622ad5898409ea6e74a7865b4ad94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00b4c1c59dd545679bbdd8960724fdb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd18623cbffe4173b5c074fecac0d9ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89f7d706f0cb44e4b3153791e14d9f6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i374759bb016f41888888e78791dd4ab0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib68fef76e57547f7bdc2cbb70b67de87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f9444d5b1664f58a02728dfddbf063e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i040ff5ea36d3484ea651ef737fdff71a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if97446d23ecf43389079d10a5ca90ec7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f2ba44854df404fa52145c11e69cd99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id66a61dac3da49dcaba07eaff95d4ed3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a6ab54db1664800b50dfbdaff4462cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i833b3ba93d614377a2cfecac4c5866e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0dbc4d9a77694d4e882a111f60ec428f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ec83c194e1744edba2a8a35ddd3a21f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45f95df00da14c09af18c27401b54ae3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i132e97951baa4113bcc1bae3044eb719_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb83adad926e453482286d737c575b36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93d7907189bb4207bb49c42bee6f1dfd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6fabc58b05ff44ed9522b607c9a248bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i774c5a342b514fc886c9641360c25a17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70b17ce920094858a99911bb86e14711_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if376a86c326f475d9363b305b989f5ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32c6fca8f8164d468cff272eeba8634f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if47597a8ab7540518bde99ada02a6412_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iba40621af6f34b0c95e94ed7710c5944_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70af15b795b3483b886c630cdd41133d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie64824a2ab1d473089f51fd77c18511b_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4fe9a0ab54434720b0cf1a566885c13a_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if11ef0dcf23f4836b169d65009b32b67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9281f223aedf4b3bb8e9b4c609a7ffcd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3aec1ab29624b00ae21ee1541745253_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i603759dc019d4b2a92e63a7c43c81202_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f1e538358a0404a97553c780f46ab33_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1acd2394418419a847e9c266f2fd96b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2263f3e53dbf46e49603498a02a8dd4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc491b98f87c48fb9a82e390d80b4690_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07617b881607408cb61cf2b2cf92be00_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i052ad8a1361041b1a1e984ec500adab0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb26ec2f5da740a3bc8fbb26528a6eba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2606072a417c44aca18c5c159c178685_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a27173a90934ada9d520eceda174831_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaed00c6f79924c5aac07fb1cde0defe2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i088cc2519a19414c8e3186d5e4e8a023_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4dbb367e3e5946fdae5de683a45bd0da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47d1b633d5da4aafad19b8e301c01923_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife16e0d66c324162af7d23d581f9e520_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic859cf2414014f41b9ff0a1bc9a8edca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i922da6ff675f4e36b395123bd41f860c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bf7db39f15a4eb598543794b5cb18d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0418b77d11494b49b8670d97efc20a6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9287dd64826c40ae9176320df60031ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4679263e59f543019e17c0b7fc2182cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62b877fdaf564761be440e19be29b2c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b8899dd9c654bfbac46b393cd7d3264_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice2377a28ca84de48887e30dfe2d5537_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i332ad40fc06246e8899471a208f82f55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25cf501ae0374a8db4041a26e5ccaba7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1235021626ea40d68c48483cac1e238e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i571d3003c339474b8a92cd20e397f126_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24d884f9483546dcbadd8236be97f3a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib27e295e010541d7a58a958648701bed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie81297921b384692b3eb61bf4efc821e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34d6a0c4542c41ffa80fc7096731b88f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1188336496264ef18e60cdee67b0cb7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e8562560c434644bad56e82266c221a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SotaterceptMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie71ea2fb304b4cf08e846d2e023c3048_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e62506b0ff84122affab840c3ae7e5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GefapixantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i321bbe1dae804437a98c0bfa6c5e9802_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60c730eccd1b44f8962e3a3b83bcdaf7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3df148b8481d43589980b5d43c439d34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf91833342104fa49cf3cfd60cca2c5c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IOmetPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia4f5157cdcdc4b5fb735395ee19116dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94c025ef9d554744b2deaf2bb4227962_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifae9f90a84a045708d897dad62fa6f48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia85becd9ff8a491c842d4ef0416f1bfa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17dae8a27f274a1f9b71d7a871389f36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb06f869aee84648b3f08b5c22658045_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A215NotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieee399b5bb9e4f7382fa9bed6063f3e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A215NotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i666ad1c871a5437daefbf379c3ae7a1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A275NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03f677306c544591b8bdc15d6568cad1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A275NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4603067c37764e92871db7d73bb6a41e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ab29f77d5a54d36880055884c3d208a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if25f9151edb34efe9659838c9851b5e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f198e2b6c8242329a2d6cce74447c22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6eb70a7318804000a0b25e0954dccccc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if272cc9ec9314c9b954ca02afdf19912_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i330c8b376f0845b981e104e9da711b0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A170NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1d4c4db752a47e1929b1bd9b0221ef3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A170NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e29e43c73b04d478539ff08737d0321_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A290NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifce508fabf274d7fa48a9d9ef29611c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A290NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if938e22e704043879505c140022bccd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69c90a6837f441e4b263d84bf547260b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75a2923a86ee4187a9d8e30f1302bad4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd6dc540edbe4a84988990cbdefe13d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i178e4bc051044e76b42ccbb46d917f9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i325a7820086449098f9f5e7c422cda0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i333858d5ddd54903ba67c9eaba12bf2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95bb17180d994e87ab3f841a7c846700_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic23e62f8001740b7b380115c4ba260c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7d7bae96e8b46fe83ce2a84bc3c0cb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i449243770d5a4a3aadefa2f9bb07dd48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A190NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i186f6c50dad74e3a8ea966fe8407b0d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A190NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0adefdd4fd64c70843942c5ea526307_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c3307530aa44190849bb1be7e10ad8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76684c6e7e7941fd886f959ebdf9684b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id60a350fed0a495da16890e319f026be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i311636cf40db4f85b916067268059c87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e284b03ac364d3e8d78fbfa391cb0be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7435768c60e4451a21d4ba610ecc268_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee70c6efaceb4bd8a3f32437df0c8a5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a4e8734f76f48d190b8676cdac0c206_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a04e2cfd3a641758e42b169902efdc5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i130360c441d842fda96aa1a87003755c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4181b1f1a852487da488d837c8158ebd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1267e41a13d4a82939639506b0b47e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if189170ce36b4eafb6f7201a9ca6ae4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84ae7163839e44318d2e1239dac4e116_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idcc406a9bf2f434eafd58f22ac831620_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a64ddf383234fde89422eb58d5a04d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5f2f1899dbf46acb52be81d989d18b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0065ecadcbc4c46aedfe9502ae528f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i674f0f6f35ce404ca1e28b4ade93aafa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic84be8ae9e69454eb62cd343daebc684_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida0900466410461fadb2b25dacab282a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i443dc9e5f3c14c26b4627206e39cb2d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie314f63b9375416f8539d5d713836ce5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ed29c8d391249e7b1ab655051fd96a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if16c9874988749a6b9d4de2a351876c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6381683a577b43b3a4f20e5ee2a42a23_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i774de7dc3f4a439e9ef258e52ad97260_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6230e83c438e4a4b8ad400ee569ba5e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A63DebenturesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5cc9da918f54ffe9561a30e890c176e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A63DebenturesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf3fd779ab0345a4b5682f42d4df167e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9334d22b30c34db685a58c5c19efc4c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6615a4b358b4458cb9f301a9917387a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83ff4d5f08ad4af5886628a1bbba25b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief565eb90eb64c95925824555f9e9d46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87c57d8615014148a065e980841d3dc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida73e3479c1f4e4687a0d8cc7ff79ca9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a6dee25ec5f47f0b9d50258c662b2e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7bd0a9a37e0245ff9bf9f6ac947f019f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic816dee0d6f44f3e9271509aa2068b19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0836d3b184984272bd57f286fc63992e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d2e8bc60a0148298d49f7245816f760_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="if4692914ed0347bb9847781d8d6fbef2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46200e06c7a04756a48759eed40c9e41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89ee4600a50543649e2d1a72ee56c5dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ce296e507f349c6bd47b0823480f591_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95ea257d9c4d4c4fbbd6847991aa1d0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica45cfeeb70a4e189cf234b69c9b1ed3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:PatentlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c06720f33624299898d274fe0bf9d14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8826f2e082a14b209b4b18a5290f7a91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b9c3612f056401fb72e41a133ef96aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbc6c432152d469a9be95a1902906f56_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide665a6ad8774e8695a7587e4b025cb3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i00edd76d055e4b64afd262bffa0b265e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96029d87c50446529e49db206d363e3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28d604caa6ad46098194a9214fb47727_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7408e11850240218278c7eae714eb3a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba967fbd75634791abd5af201082537c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i178e704826a843dfa1384049fd999736_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i20446a0c4abb418588d30ab024ada07f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfd71cacd403473c93f86070341b371c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i382c108bc8474154b35a6d4fdd79419a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67b6db65c6024850a158f13f22048bf4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cfd3d09310f4317b6f6249083ad8378_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe10670a16e24ae9ace40787b5ce2a22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0aeb1e3ef794674a96fff2b9d26c8e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id17c6f956a4e491bb84b7d1e3a57f150_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7718651d7bc40ef9616b0d6567d4a64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie27d33c6ed3449c6bf53ce5acffed5d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4b9083971f54521ad14c9f68c6611c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia76d34893501497c8338c478a45c7b0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2203d4639810407383286a40f8685df1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2f1c43c814b41b488e8134de602f0f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37e1626071144092beaba6babfdd27fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb4792b128164e4abdf42d752f6b3c2f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f0f6b50d341424ab17a88ac1dabec97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5089b458f08249059c8517844cbfc375_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ca7b42ee03e4960a864194df69e164a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fbbeaa396c141b0a6b6351e2f4827c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifae2b18472b24703bb9488d9d606bcb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib222fc4bb6d643ceb99b004ab5acd309_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i395bb955653e420e886491134570b658_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a1c560946da41119cf3ed20ed9a3a21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf83da73f5164932a265dca954005724_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9243705e6b154b6aa3bd6af2236836e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63dd5c670a0c459fae41752f3906d605_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6774d1da76d4da2b5a0219216a610e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6eb9748ba281494181282cff265c56e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa42d6dd3f814707bc449ce9962c43dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8baeeb84552840538a8162507d1d3a8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11a079dfc52a4a6497a425eeb1403e8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ba0e181a34f4aaba795297286899f6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12d3fc8ceebe427fb6bd5603436c2c53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibdb1065a32e34de0b0f43368d0777874_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i784c90e7bd294dc88132ba65ade89e56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ee628429c5b4b66bb61ce127cc28e2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49fb7d46a5334d3bac5d2d4116e11efc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62c401195a1c4761a19b5cdadde85849_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01b501a9ec7d4dea8f9112a428ef72c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief1c7c92675e40b1b1e2ca3fc8e0d851_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5141bbf8e94b49f7a0aa873c881c5fd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f48949b908e47e1864aa29acc116ec4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39f58f3724274bc6b0bf3a72767dec82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae3975a126cb44be9d32abdad7ef4792_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02abcc69be99452c8ce2101132639629_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e3b50b3dba44aadb2c0ce56a935394e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd9e94b26ed5494abf5baee5b79b943f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63f253095b9d4d2cae95926ac75da379_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e82a23e98a7447f8a12f4ab996a88c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1df7467a741d426880031a7209c24355_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i981b91cc3e4e423692ebf62688a6e073_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7e2e5a9fcaf49569cbade9e54075f58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1edc21c2cd0343e5b7e3413d27bf3fc2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i878cc16768774bbaaf020a38a72e6aff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc8c49f9da2e48ee9aa0dad038b7bb6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6edfb93331994daaad9ccbd6a3ff2d16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5141467dce724a88a3c16a16dc6e57bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id687b7cf31b44549a0832f1284c3b22e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e01ea44f0044e7d91022ca6977facea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e7bb1d9889a46a389725e7f47bc44e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf4a94a0a6d04223852740fc12c45b3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d79d8008eed47b6bfe7d6f012412074_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibff79da55ddf46a8a205167e0e830e71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife3fd5de6b3642078db592881517d635_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2dfeb6b2ea94e89a81b426dff17a96d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6be5d66271948aa8671b0ef9f628d22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7c9bf0ebd284c25b3cb345c5806e946_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if550fbbab92e4a0393c402773c5a53c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b79ac72fb4241bc81c3ec6b5b6328b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab77361384864106be3cf07dc9d4c939_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i780cd04510ba457c89c22dffb8ea2e1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia22749de8cf749bdbeef2616d2d8d6ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie831c58af1194dadafaceb30180cdd0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i336582d966b84b16b300a96248672867_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06dd0193192145d6a6d7021a9dd8f817_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21bbf4eeebfb45518c50300f370d3966_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2778b4fbd1b45ffb87524b7514583a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8ec4cb354474da4bbd6842b97202f41_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c9b0274b7734fcfbb1b0c73ee0c7da0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f74d89c62ca43fc8d49c4f183628eb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5a1db66bff04574a73feba1773e8409_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02446a35871f4693b8e5acc1f9a5b7de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0989ca72ed7543d093e13b1133771ff6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ce6426bb9e749e9bcd7521d23f5c407_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib65644eadb2b4fa1a6c40d00289f4f35_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i962f8425aa3040a69e84e834f0b0f346_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7b57daa317543c6a71e4c01cbe79b46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b98f27bd3184965a9bc7698e47ad89d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95e86bd2f96d4a0c9cc3b9f4e0850708_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if74bfe6b3728464e8f867a4499a49cf9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ecf6e1df51340bbaba2f059fec3465a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i796214cf8fae486795991741a4067066_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1637d8c529464e04832eabd1d29ad359_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fa69b52074c40c6919a723ecff07d91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77f365cc16f54180a306da2bc7aee6a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffbd9fca0edc4beb8128fe8f2eaab268_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75257cca48cb459382be06af1340c22d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i400ddc9234554cba8b43aea81b2f3b12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe56286d4ea44f1aae537601d99ea7ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4cf65bb3ba540209a17504e51e8e63c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6941b80bcbf5486ca983dfe0369cd741_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic97d1993aeff4c979b35dd2e4f863df4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fd3b14d2a9c494aa14fbdcb6fb11f9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9790f5a9551417380bff30595e606aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ded4752a21d440a80630cbd004ec39b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c179b8078b940dc99ef97ff0435620f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibaa64b0d1dd44c1ca28cecbd821aa477_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1ffbcf1eb5b41d7b00120fe3ee1352e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9db319e5ae454d27afcda3fd19764a79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i706ca6f052df467cb8f58b4806f630c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30f0da2cf5e1450d9c71192c487952c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44fe692f8a764fea898fec5aa9111d12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i379e05b6692f4dd48df63d0606e10804_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac502293aa264b42aa9d2b66841da851_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i29262e1dfa004785a42f1051bb310323_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9f9aca5533a45719f02ea5e54e22cbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48ac8e7222dd4ad2875cdd76fbdbf312_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib92ab01903744a8bb55dfac3169a2f28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ce94dcb4f694c35afda081b8f7df941_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d5cd6c26a754923b47fb82b1d835e26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie809e18ae31c4a759d00ca9258dfe590_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0670034fe75f4d2192a609e94de300e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05abcec58f8e487c81199b7f51eaef9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id147c2024aff4ce09865ffaf7bfc6e1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1a7f9d852f245d68f1669370ba8ea37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c3b3f7029dc4097b2e2fe7e1e985e18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fbca24807fc45728ae28f4fe314fa94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia92db765e927452a886deda18e0ec49e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c7e60832cf84f69b1d73b1f05f3a237_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc9294e66deb48e4a276489e2d5fbdd9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad21e08ece0443f09e98d2df051b2720_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81d4508410614547944dd3263008dfa1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d27a90fefee49c6bd2314841eaac836_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14f445cef0a94f3d858a4e92b44e53dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib402ec846ebb4646b9e19d44aa463e42_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib23f4c405736447893c2ed0ba5129d03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5c0e35ee479451baa6f3dffbdb78a83_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6099682544f4ab6885c0649f5ab634e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9499680b2a3b46c692bbfca28d92fa99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icadc8586f8c14f1599940106a4a639f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i137b41dccc2a451a8661523b56e79847_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3e264e35d0845cb9d3d40717095240c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbdc9d92cae54e3388f07afc57b2e738_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27b7acb7de364282992d39b44d6c732b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ddd68d8b0db49c6b4809aa72bf47d60_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19f7fa74b02f420fa18a1752a0f640d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6074254ef5dd404ab34a3d26ea726aa1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9f0c02f2b3e4264bec1d52a63e9ad74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4eb2ef278f5044ea82584e0170c78683_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e92e9adedd8495e89c3a894377ecdd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74519ccd850f450985a56ff14ca4b7b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fbcea62d0ed4955ac41d050862b0e34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic56cac3dd6c044c78e322e9ef1a9d386_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1f6500c95d2415997c537d9ec576b14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a23ebdda2d14f27ba9a6dff74a6bb93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie263eba552824ca8b7bc26dc2b1e3c03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i500f88f01cbb476cbf8d0869fa88f998_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife7b52747c1c4adbb18078f65218a7b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb20ddb11d8244308c74bbd88c09e832_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4b5c61354004941911815be12a06d46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i575c68e47b1441f4b370a4373fcd38ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb56ee6d545047549d0817e0e372530e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33d81e4466bd41e4b377ed1df2ea8e56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4e0f2f727aa4b97ac781a4fed704c4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7739919ef6a3464e8636dba4a13f4976_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia616155b2f954117981e48d2681acb1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ff224138dc04bb5bcb654572597d15c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i299c4edd1f2c40aaaf1ba172f892df50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d6be1fc79ba48d990cd4dda9a8296c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2b4299473e14a998ff1749df6fabbad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieda8181c2b92463f832b2b807385e1fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica5c9a82e7a14132ae1bc5575aa82c6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib45b430cbec34f7ab97e3b77aa48d4b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88665ad826e641d683cd947d6542e94a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e4eed3d574f4c3b90b6ec3fbf015cbc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9092910402714a39aa0adcd1cdc3fd8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0977763dab53428ea24d011484e19d42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e6aaee1f8734728ad3f49f6e109d45e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i646ea08b951e47a28a3b3a458d5f19c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7376c87bfaef4564894e5aa0078bf290_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i707265f378224c11812d0a38d0ca7c46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d671f19e027414790d54572de238e8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i976895874b4548edab0975dff614e53a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia948bae53d494c0fa79a34e4feab974b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0c88c3aebd6403fb5e73ba3df2752da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3101abbfd6104bf9961e4797c1fc7a59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8f53799ef4a489f9b8523196b414ed1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd54b143c2f54e0b899d7f7221b49435_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50d4f261c68445c8ae56f66fe852bae3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81fb3f5ab0be4cb8be61559da9ba2513_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8688a36baca47b99958cbc03224ade5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib528900af6b84f9f883fce50d5d90e15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i597378302fc14c5688b47d18bf9609ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c35baef64594afe9308f4038d2cc019_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b32ee0e7ad4477d84343a59721b904a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10aa657ebd0f4ff8bde707e6da253978_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40e1b8d26f324b76a4c50b0c70101c62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12fb9df356b24a28a7100d667bfecc3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30cd90083da946e2867764d0280e60ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46c1df4974f5423196b196d52fcb54a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1056686abda14133bbb25a974481bf51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i777644be6c2f496cb431e433227cf5e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaadae92a049a4d5c988b6a3155d0fea9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67cdc14fb7854ae6ab8daac50bf5b18a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4e4116135e74738941265923fae287e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba72f924d50f448995676c787615f080_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6335958a344a435583e593f08493ef84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc7e70eb2b30488facea1f9b7925c9d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if61638e78d26452fbd7dcb3dc3b0b9a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29c3faf60ab14164abe7ec068a5e8acc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i392677707f7e41c59c65694477a60d86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71d1b3b11ab744479c9bf01ef20dc759_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i331730bf6efb44d682e209f3086f5deb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0aed454000324ddfb59ec630f8ca840d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if44f8b9ae40243fdab6b2eeea80bdadb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53221686a07c4c2692910544bf9e5f7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7f304228c0b47459eb2df8092a19197_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35aa130d32044270a7ca14c1c500e128_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffd5948864f247fb8240d73efa22974a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id79d1d134fab4804b1f8916d27f270bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica51247083bc45349d5f1aa4494688cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67efbd0183464528a19f2f2370692b97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f3d2bbb957c495e8f423ace831f825b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7032f825e9148319be784239d5dc247_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9375a5e955a43e4b015b97beb369e80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad73c6a4016949568ba9ffec4920197d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99736db639604a3b9e19d5223863228a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0989033959b24547b6d2f0250223be9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i062dd5eba1074bd9b7e1f64bbe49f973_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b4fa5b2309b4501b0b66a49e6b61e2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22f5c0ebcbab4a01a984c3b118e581fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8f1f45c17984c09b0569f1408b068a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d7b39df984e4cc8a43284b6c372e087_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if87e1269e4974cacb4df9177b0d52da2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0038c792d634a9ba8b15407c89e2895_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec324fd291e244f2a0f252da445766bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacb4e5f9e58140afb021278770b30523_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e89844fc4dc4df08d07363b5b09c838_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf01a553998e486db4187f11f6c70b9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i431015c47e6d427ab97b03d0f8688df5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e027fa8d0004e2f893102d1de5efaf0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbed2e49029849b3943ac5cbdb11cfcf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02f3afa788a448f7a63c0f0ccc99339e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2ea805daaef473299b9ae21f484efbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35f7bd0fb86b414a9c2c97debb06568e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54f9f4e4430546bd9a3b6f9954b477dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0543e0d9beb449b8a879873310de464a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08c5624edf264ef78c72a7cc903e4d53_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3cf767adb1b441a08fdbf662ead15031_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae0b2dd3b32941cc92817703c2a4e429_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c9c0618cec84c088e773da09a42ef8f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb24ab962e0d4ce68a8f9e970430d6d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib51e5e37dd5440398f596d5a49edb8c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icdeac8350d854b17860499847d42ea25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88cb35a2c8a0448c83339d1060a7a9cf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ica6c5629485f4afeb50f9607d49405b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib03dc9f34fcb49d685cc8f077e1f7d9b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd4a51131f4d4e358c9cecca8b9026d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6008424e527d4605b76b5c541489c471_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f6924e6dd4542c39440e5e6128bd0b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48869176aa064f5b84788a6a483e5d0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6b32614e3a94518839d5155b07abd5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4193bedff7b5470093b4777d0ca284e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86abfbda1f9146a4a6851f8c322ef63a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5b1148bd1f04038a1852875553f8c89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f0a39a74efd4a798069f6dc88d2753f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e83024d7d194652beabf70b37e52087_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9efddc2c4eb4b51ac27ed6cd9f54f5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c24038538054e02b5a035f3e61a08dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a0ff66d0a1341e8afc7ed8586d8a024_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e6daeaa1d88470ca8bab0e45dcff6cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieaa6e26e2efe4d9ea09bc81d737de0e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id06d07a27e9045a094b87e5c189c3954_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6a22f408073435e909cf7aa033ebc6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice177b53b8bf471bbf10d5357f0e823f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51e1329bd56243e18e983e2de609a849_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0a5086b5128478aa64899a4b8b33cf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b13ef32d5364a38917129aff9fec7b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica90cf7838a7461289b9ba848c17f909_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id626f58b4ed04285b83a1f5f564106f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85b5f8a81b5d42fbb063b001b277bd2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i121d0ae7b5584cf08889319e21df6f00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ab8af9defb944fcb4a112b4a4fd3754_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica3c0900036b4c57b95574ad6d4370aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia23692c19eb34a1f8e06494fa27cd511_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8677bf18cb544efa1b2a3272f0a47a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d6b068cf6ab41fb9bfee3a5fd9d9251_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12f2b2c632f44cd1a8f7e0b0d9bb1c56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if643fb5543124a6894df897dc47be455_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4df17beca4f4aae9917df8f72802d26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96b69b9758d9428fa6eee4787db14eb3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f07f5009ef24afdb2515077be35b2c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if47b6f8be3a54363980225411f0cde09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd4eb7c2144745c5a54d9ff57aeffc3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03afe5c2d65644bf8233215d9ed8ce21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i667292d025a9462f937f9e358ff4597b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e7a58a77c914de6a53aea5b50437da4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8888c94d17e84a6c8685bb3aa616ceab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabf411e7ed154695860581e937aea220_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib427fd64730a44df9cddac5399f38153_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26c47a65b46544c38b3b012501b67980_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1da62d5a32854107a7b16eacacfd2bc5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd7f6d0dd3ee4a929304b9754f6827b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a86ee5eed134b6c89a7d0fa2be8b6b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88d73446659a4e33b8b0a661934a44b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf7ccf80013542b487ab201e6f185f08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a9e21c8c54c43daa17d22d749c695e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5e32729f23f4e5dbbc51b849d911757_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07b0f77300a243acb6a9ebbfcb1aaa2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b86fee24be648ad94520f4a1978a1cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5c501dddf974f5abc029b567480dbee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i091b7006b6ea46b3b61e3eecc932c387_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b5b17f159a845539e0a01013b211052_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bdda57c7bdb4c5bb74a961da2c1d8aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica17e9ff742a40d783b5644277161e30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0ef3d891cbc4cd69295e9cecc6d5a62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e02936176ce456aaf00f889622803e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i483bd58d24394b3b80eb5b353b8efbdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i793918a7fdaf491fb0c1dbcd66331c49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4bc268366729489591fd438b0fe8fe17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd69e0aa38ac4ec7b4f7d1c9516ad2e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icebfe327fd3d4adab637ef455f461fcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b3c817820c64372aa410440be5205a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic83f94a689444e288ae0dbed266bd406_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b704682926148cc84a8db8efc5c796a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e4628916abc4126927023ae15fd0a85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie15d37d6fcf94f1d962a65444ddad466_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia130b62a5f43450aa1a3339b37134132_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3df7f246cf14229afdd2685344a7de4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2807f56dcaab490eac85b298b86298c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib26b7b22b4244d81b6f3cc21118aec61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bf9ac56392a463fac3b411b9205a0a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6a02cc27c7c4c2f8ba5429f74eab5dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee3239325c8c46efac7fc183d07c9374_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia63554eec91f4d6ab395b9acc70717d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i287ca8ea377b4ed080264796be545504_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8db09a55de19497b9b70d729546fbb1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14d98b7a9bf04af8884803848570265d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7e091f2feda475987d31a21e338c4f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bf7c43c5492487a99e3564c60260e5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39f74f7cbb854caba1a1c57ac918a3ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc35b4c7594d4187a5cb7cc2d7f4d264_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90407e0949ed436885a9125ae3ff3616_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i728b0c1d082a441b95dd386a599c8098_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fc07cc2ffcc4a07b93ab604fa085182_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3750cadf46e42dfb107576386473746_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb00f009ed984b3e9d7ce65a1632e458_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6dd6a6d63e54e938c5a72c294269cc1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08fc130457454a08b3f267225ed6ed27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6467d1906b2f4d7e8bf6f78423b52659_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7de3243e532c4de2852c89993a892b41_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76e47c270d1243bab3c87f29d058155f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iecf563768fe14889b1e01fe62524d07f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a491066de6b4e4792fdd0a3377e0b54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdb93f5076a643298235176fc92ef07c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7e1bd81b4d648f3b5b45923274ecfc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e40afe1730c4117941b66edb4d40d3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1910fb48ae8b47d59024291ba45240d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i149179b3d497412eaee0ad158abcd1d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1e84e538d73498da4853df1d5a84ecf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i495b7eb9aafb434b88ff4e62c501d012_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2370d975c61e4aaa91def0aa9732dfc1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfbfb9218ab84c998baded784956a8d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3eb3c9e8db1400ab82cf431989eeb20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0f174f676614246ac5cc662923bd7de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1deac4fc07e246e48d31f4bb339ce199_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied9cc57e45454c60a2afcf99a471a7a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea250ccc936041e7a2dfb8b6d72e949b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc0707765e4e4b9ea9465ed6da91604f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib36b1192c28e46a9bc24708ace77b04c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa625a65fc9249b88c46cf2eac079bb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec626e4bae224a9f838923e9721430eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf509bb5a7f240e8bfdf5c3c69c7f006_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad12fdc5a7d14e5ea50cf778b94402fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9213c4b474fe4561ae99450da35e89eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i755061a1bfda44be8dce382e25583fc2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95e72546c73c4aa4ae96105aad140dd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DefinedBenefitPlanCashandOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb0d794972b549a0b3f947ab5849bf7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74135854883f44a0bb9ee84c11306656_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i818016db2b54406e88278d77b05a6d54_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i42dbde811d0f43b89555c0b2477f1fac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i58dc9cde42be4f269b8259f1f6a7f155_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifaf22a93cc2d4d0a814975c167a0a1fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9977d228ad648dea6127cc9cf399ac2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3cb2ff06220a49eb8adeb3181d31932d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:HealthcareServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4d3b1868b07e42d9beeb1de061d22b1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:IncomeTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb2506788d4645da9386ce90a8f1d696_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7418d8deee94241a890cc5e06e3fb35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i412ceb3578cd4323882f96bffbb8f4c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee0d42255922420582e8788d38817637_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6a9a13cd0a149fd8df342c997fb0ade_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i622d15e154f84cc28b01ef17d5fe85b8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mrk:ConsumercarebusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib84dc814a0974bf0836891662899fabc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9efea9cf6b604686982b9cdfac42f3df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76e98608767a40d2a24b489eafd3e853_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9158afc2f18a4d47b2a3ce049a91f164_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i85b88606a448480e91ccbb985a641950_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i836d57ab500a430aa624c66b51480417_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i67716ab8d95d41c1918c1fd2f92b31b0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i53553e2c388c408a80697cd5600f2014_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0a24da076c044d1fa1d2d467928316c3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic2d1a929ea734ccb8df8f7b64219510e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e3b8b15d7e64a8f9877988ce4a10017_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i125b2cdaed7c4239afe4d7fce006c0b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c54f5a5a29a410190d2348b3cb74190_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice3199f2dd06439293c869fd20ba1ae5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib83101efb98444978fff619393569f09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i144b086740d64654bd9a30061c1a7812_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51564faf2000464284c4a9cae610de81_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id16d9426fdca4a16a4bd46315c4d4084_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4063360a866a4d7484c9f7904b09eb53_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6168466248344c884d7d9bc139939b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i615fa016c2ed4e2383a651cb2aab2822_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id92ec4a36cf94e91ae66e6a887ecd413_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i192fe0af931a48ed803ea8f1c256afe9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf472479cca849d1b21d8c0dc0ed9d69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb6c7a465398473797dd31962d89b8c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9f5696787284d468844d796e307282b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i306e82501fa8410bb91080177d50d682_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib425c1e1a40c4df8944d884d3d307ad0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i924ea9183ae449d796b1a0a7b05f0e67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if225d2f0b77c4d51944e158ac6b67edc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a311768e0b74998947f7049aaba9c79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8de7afcf6cd04006ba705dd72d2915dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia855c9dc8c7e44ce9dc6bc2b51ed6d1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief0fabdbe30d4ec8b1cd71e2cd64c3ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03c80f2ba2ae4750bb0b2f180be80c68_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a1ce584193c48a6b0103a7644f7ef6f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic54db7d5cebb4ef48b74f960b41c1c27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5639e6827db9445ca99ec3429d38514b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i585f62c2af3048dab19b2ccec8904d68_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i118a055047184fcfaf92090074d7ad4b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1ed4f4d9b9f84b11afd909432b51fa6b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7ee5ac9fe1248559264115ca0ce8e31_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i38ca7fbd199642df8e35c5b087f2f181_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i412a988a09de489e882e0bf3f1cdad5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9b7bca2629345b48bdf4ab1a9cc002a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58b89ac54cd84d5f97104114e72eb401_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacf7482af6de46c1b860e27aaab98d93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6dcf9b8bc9de4148a0ee6c3a5a6f2815_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2464e70d7ef4f7bb40db6173462adaf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d5e11e3ccd6431c909fb49ed639bb98_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3890b29d4919406994442f1b5b0164b3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i126a4a0ccf3f40efaba2835b745502dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifec348f46f8349989fde334c3a0e6693_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie62a9ffa2b864eba96a15816fc03a298_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96bd5d4591c74fc59a16a07549d1b809_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedd13c82855e45e18ee1bcb4674461b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48dea599db224c139d74cfb868f7ca31_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if671aaa852bb4d1cafc2487adea83e34_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i06e29a49f9e146509c3cb1014ab81958_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idbecde3516774ea4a214f44d642a3ea4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i30ab7314f4724a408939aecfacc08cdb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67504f9dc2414b458ecaaf3418bf800b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7410d9a99f3144d289bb5915b56f611f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i30070b5abd3a408f95c70d3b9328afa1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c07bfb932384999b083744d5271f56b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d896fcb2b074166b1af7ecd1df7ecc5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4449be5f9f4d4dd7bb5f71f197d1195e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia24b2aefb0cd4d1b92b0312679c47a00_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i18ad66ab734b47e3b0b68f6d3ecd75cf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i092a9a3dd77c432aa3fd0dfe58c9fc24_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifee03932a98f4e90a47a62b45b98473d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f84682c651e42369b0be205d5dc544b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d55e46f9c6a4d77998096a6a91e85c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69815c97a5284f8892611939d8f5ebb7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8887b54a6020401cafc8b73bf4852968_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc8d5492cb544bc9894b3d738712a155_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie8f17a778d3d46d6a0f56138bb37401e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f8600b39d154c5299e9b719a4e65eff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f6ea600d207424d9ebdc43381b8d663_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb046a0ba0c04045b30d5722effaafb2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae5bfe0049f14a07b613d265fd540357_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i350b1e0896d840898c101f9718c2c2f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icdcd82740163451e95d5ef31c1a6f103_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie59e38a3f1f14f8c99ea483759e328a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iafb83f4e70884ababc7ef0c9ff8f1f20_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3921cbd5aeac4547b3df48439ab8f6d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia9ce69f481d241f28a3dee75585ddbbc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifbceb0e389804da8ae6d0759d4119f73_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14e8ffa354eb405b9df85f225faa97a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie6825addbac14de89b7448f21f1dbe0d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7528d7d63d24a0ebc48ba15ef1742c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3e69f638636462c981930e509c9d3c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17a52444ed7149d9a832be8c913ccfb2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2262179634dd4d6eb718ea17322c0302_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i290541092ab24a35bbac3de5b7d6757f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9cb120af06d848bd9bd55575768c0454_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie68cf814d8754d468098e25c4faec59e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec491afd16ff4fe9ac6ba8cce69bdefc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3727a4b434224ffab2d1dd6ab2a31446_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie09b13d69e694ea999debfb5ba7aa578_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic347c94c641d49f6b9ce87d0eac2090f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6d75f1dea9e4e668d532d7b2c10b2e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ec4b2a3d76b4364b2d56779a19fa6ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i43bc6db40c0145fa82725faf6c749c89_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if76ee5e9706c4379b1703add36dffafe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ddb209f66734519ba2f0f9440875f4c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i287f086f0a1348718abecee8bf3fbdbf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d92ef43e74548739e46fef213a2b691_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96a4d1d25cbb48a890bf52a4c3b2ce24_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c9956b24fe747cead1ba231ba98dfdc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i621acda9e95e42d49d9d543db91d4937_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4146bb447d743da9ee890800435e8b8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6e080a31cc484b33b1889bec0d989641_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f25ff9318914fa99b0b7fc3b0911f02_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc9f572a206f4619a83415208462c648_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib14128500dc8496a9a941b07e7570826_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24b4e19b01d14af2b9e7a5be87b0ba14_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i680941386a504ccaa708270ef21bba50_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3351be1b9677432389243aef036d0f4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7339a2912de4accacec0a80f0cbde96_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2c9827e87644e79a48ea79d80420a22_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i99ea00653e9e4cee964d9489c3bd0732_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i26d42dde9fe44012ad67da4ad05352c6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5022ef10f96e4b7aa61a055fd68efe83_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icef9b40b31044eefab0cf6ddf301bf11_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6cc9260dfb142b3ae1b4e51b2636178_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2985d0dd5ea145ce8d2f0ef7df6b36cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c0ac23a8c384de6a68683e097588935_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ica9555c3b16d4029b0bdd2a58b8ca117_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0e00b0f2a574b709afc847e290d1f4d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifcc00e8952a6492f83da929648c7859c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7bb2f997ceca4c2db0eb415936f392d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i588ccd376cce4c459b89838c0dc320a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c2ca26bde454c769f7a36998e53e53c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibe6c4413e27f4dbdaed582d92345ee15_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3fe52f351a8d4153a56a10fd4e76f488_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82d4d56c6b614201adb1944e0e9e1c92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i044a677ce7ed4b15a2562a43b2b9abd8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idbe73e300fe4433fa589eb9c59eef229_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b81951a30894213954768ae743f31a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2cd822d77da04087961e1a434edc2bdb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i919922d6658d4bf094bffc6057c2d318_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id2a5bec58714422fbaf00a68687b7d72_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f251d58dc4741a5b4bc331916be0226_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i238867c42030496c888ff5fec0f238f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic05c8e25b2f143a6a83cd529f6a9edb3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3caea6cd27384755bedf9d283e539fe4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie49045b590b94189b3ba82d3341d8dc1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib08607411f484218996fb2684f207c26_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i57867663740a4d66a1abfa217c854234_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i17685f23777c4777b25d05b30847170a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if341417b19c14b84884a2711d11c29c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id336dc1a92684f6d959130b607011823_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic49ea5e6124f4cb291979ada6f6e1d4a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i360f6b57fbae4cd3a936581cb768c93c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i790f602712d84379bed540b6f76fc57b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id141d171a5bb4e19948360b7c1265792_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i41a6fdd6f73f41219529c1d7d8607b4d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ide35d7caf43044a8842880c9892d8610_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3b2ade8ccf2247a083b1043ad7d0e5a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf3d0c3a557a4c4a845f4c3c31bf35fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0948681bcbfe41be84f9be49d7bee81b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id628e1c6911e4ad79edefc7fbd510f4c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2ceda0300e794bddb9081944d2f35ec9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9682639f648451a9580e7c6106d6bea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibcfe45979c5843819de5fd1faa5f6164_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5014f16e8514b5fa48152d56fdf4acb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iab537984b5264cc6ab6b179f58898f76_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i653304b28e3a4aba996ff5ad6455596d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbc699a519cd4da6b9151325ddcc9476_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6522f24b64a418290e82b61d41d2138_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id497588ccac6414284ef2d78c4360759_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id57de4669b2c404ba2df9d8c63350b95_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05c9b8eb51bf4bfdb4aa84f8464b6ad4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib4c5d62997704e51815fd6ff6a3f63f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e966b911fc84965a21f483f48ad5f9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i670abf0ceee14b2bb45e1d0361ced108_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ide0875049533455190662cb3270eca92_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1e34030eb894f44a8c12d5525d6bd13_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d3bc8edf0b84232bcf558d786724b9e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08867c31927d455abd0c72bb2f6dd29f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibca75dc6c120487cab23cf75b4de21d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i573ac9203d854868906b1f2a5afd90e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0d492c360fb47b893486098bafc98b4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i75797ab2cf2f4e1ca746e1ac560446c3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5527cbc51fe7422dbd7d4c2cf6cfcd9f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i53d4058d922d48bfa4f4476cc78aa40d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibff774d7ca444bf697bf7b5e3ab1a652_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib54e43721fb14ed08c10d118aa1018f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic7e35d6b25834f2f8c64c46be0b8e79b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1399a756a222419cb0f46fbcf7b54698_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id72757c16e414c11b68254cb75195b3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia75b7a5a1281432abceddda5981a31d6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8971c73b69b24487819c96119033483f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5fe780ac69be4298a4650d36dd0c8e48_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9af6d5d2383c47e9b7f3aae3de39cd9c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic36b66816cc44e4b89e9cca0a8e2fc39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2128d2249b5433c8c29182a6113f86a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6802fc4302e74a7fb1b161db797c4710_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i335b959ce3ae469ea04ba9f29a1064b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4eca5885fc0477bb9a10919f5131fce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58ef4256ffaa4cf08d46414850e9f302_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0fc97751676240338ec6973bc3f4329b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f098b0847574bfaa047e6960ba579da_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:MolnupiravirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic789d859ce7147209a488fcef20e508a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icad804308bbf473898a71229679ec50c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib8fd691878ec45c88dccd5fc5b741c66_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d83bf3c10424ac1b31714923c7c7222_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idbd7b557051941028e48d4c7979df2d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1f22b920f0142a7a77c93888483253f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a08aa9a691f42a684ca26528ec547e8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89c5034ed9c54f56861f85fb06ac04b8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i20da1a75201d44228058bec6bb25681c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc21603e76ba43718a1da2416c551b71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i860379b9e6694ee69337ca4a63a63ee9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79ad805324a7466aaa2adf87437b786d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49c259f812e0493c9a80f73147db4d87_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie334b2fb8b4f428eae8891ba5428e8ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b03e2bf2dfd474289cfb9e6b903b9e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib19f798e233b445dad2d45692dd72895_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2747d6aa809047c68d271b385afc8f32_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i362f6d1d48a4452382e6007cfe8aba1e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e40e495bd0b4d74a40b380b6538afee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3bfcb3bbc22441859e766a0bf136e8f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7844fb1fab6b467795efe381ddc3d257_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i077c0c6c35484b8d80c194006e499277_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaad4da76bf1442ad9c12d29fa802065d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6abee35368bc428188fc163b9c321692_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia410bb854da34475906908a70e1b9ddd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7d519f01b8384c2bbf73455aae73e495_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifb7e2aa6c1ea4be2baa790c8abd97c73_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida5e0a42af0a415dbc7ac173403c6c0f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1120f19a2bf44abbb0c3dc54b2a33858_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibe420bf94cdc4e508956f70224f4c347_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i875bb4453f9346a9889252db74a91e92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id52da847ebfb42a892f32e61b9768325_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31403cbad4be41ff806afb334c3cc801_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5e7beb95553472b82caa89c381f3e73_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id707418566a14de9abb8afa077ffcce7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3dbba2c093f84e089af32d87b1ea49e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4359fa8ee9ae4e1ca5acfc1ef3d4769a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i855aacd97879416694b822d5b5a4e61f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i053d6ba1ed2841b3916017660c6df7d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib04c71c3f757454aa800a15a8010af43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8c1036618754c889e448fee724b87f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if22268e596b0476aa1a363dc33a72e0c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5fc3ab73c2d4c188100a9ccbc477ac4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0eddcbbe421b4d6fb2d8b67f56b5b5f7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ade6018d32b4458a32138623c4dd828_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i05f4bd9b10014321983b0401d103bbd4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f952e92f0ca4e6483f30550b71d62ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic9a7a6ab9b3e4c83ba2682007c4d5f5a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i409834fa971041c59a9219af6cc8a8fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab2f301fabb64c4b9a1224b62e33cf45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84e8d6fd87284f119ad6bbeb297f087b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f80c96aec434110897f030eab369d00_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia05ecde19c334fc3869d0a13c50b3d91_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8b51fa1e63844c0a772c0468f3aecc2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i31f4c85d94b444cc93caffa1905c6ad7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec26147c7b0f4628a255c9ed76696470_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82c0463faf174f59a03cfbd4c245e30b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac282dd562d44386a140bff679bd6312_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8227972e5ae047dcb65cacbe11fda43e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief9e718c9899485dac81e79d2b65a8c1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i902f509e24c5427593e3c70a397619cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c92b7d768b04f0496a1e4096d91ca45_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1b64b45d21a43908135485c4336af56_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b007460a32c4c97a79e96fba3124285_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa79b78c2ca447ee97688bc48b4bb2a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a7e4a72b7eb4ea4aa580f1844e390d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67bce372466c44158bf7d70262025e3c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i53fdee9f2db04a4ab37654bf8ad3ce55_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibcecb7d348a3418fb83648e67423787b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d3835e3db0c4b86b4b85421ffd621a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i391af24746af409e98e68c04fd6b1a6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie6f76e1d339d419f8e388024ded2d57c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5bd674a922374a05b288a846e7656f8f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice28c52b471c4e2990f1d5fda9a6605a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8dd74afd8fe9493dbddd22f40067b822_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if84e446473224b92a8e962c9c6661bef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie92e22bab44c4a8585d741cb84b22e0b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i17d4f819332f4489a002b37af48a6b7b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1f07294b8d184726bdd9f9431afa7552_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic659ca2172564f53a729023707985665_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8410cf640294595a9c6c3993a24c454_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice06d069455f4c78a72b7a22c07b369f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9405751ff5f547cb86645a579c2708c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i84c516c5302941878e7cd4bc6ff5a4be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i980d80d9d41b4b498a1d29eae232be01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d40fffde89545dba8648608f3dae7f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2fa1c27df5144fb9b2e20a19423662bc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14452d35763c4c49b6af96a9eedff2c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c19fc0232664dbb82ab1947769dbc56_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie3c67e1533834abb9370666fb82dabbe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie42b1731f9424c6490b9e6d7083ba158_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i700c5af718dc4cc7a9afb37161495201_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i244f5c86b05d45859ccbbae1bc5a1e4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia07ef034ee544842829927be984fee2c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieaa0b2b1f7064efc9056cdd5245618a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9887835dab646e18759f89f0b92d691_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f650db9484346c99e5ce03c627df6a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2dd5fc45690468599bc819ec36baa72_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb0c9180eaed41789a00b00eaa6420dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee23680a9ed04180b885349d2534edf5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib47cf1b70e6843698113f3bbfd683a3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i485ba6b68e3543b6a383a01f55dc222e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91f4520623a2490cb524e95878a17cbb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i97c7636f13a047af99200a56c856358a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icdb5826a89fe434cacb3a48a5d577261_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i51b6e713277c47e29642541d538d06f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c78a1f59ce94b479267d48bca0bdcf7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5553318c17394c7c86186b52781cbbf1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3887d92fb9d4538b9b8882d8131625e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1126352971dd46669a405313ec339037_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idefdfd681b4e4b51923fd6feb08020aa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd29895771bf4e55817628fdfec5709d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0dbed4d7248d48c98107ad18eed29ce9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifba4578f496546feae50404f7c94acf7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icb727fa4e7aa4178a7b1e42c772bdcb7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fcd9e2f534e45aeaf0506c607d7115c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f39fabecb0945059db383224430a917_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3d71201413c34bac8b783c4fe7712fce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id86c1551379c460aa0a9da151aab63c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf5faa00c2fd48289d394fa06ad542e8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i702054b971f24d8d84a6e2447ac82145_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i80d78a41cef745c09b4167941714950f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia83ef2bbdf9d4c628f48c7199364718a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie65d141d77524275b769848de141bc4a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18e4eed626644fac94b8f8c13407308e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0317b49ef7a406ab77915a805d48780_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iadfd209928014784a6e2ed68f848e3da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f86df598e9d4df4b133bb5dfcb2e6c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b351db0a29943e88f99348848e492c8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74f96c6b07354101b83e5657c2f98734_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic77becba44594afaa9cd2ceb1fd401d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0089f10a0e6b4fc399437bdbe0f24541_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idbc8434b69594d2faec9792cab27130a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89793641482a462a8870d840e39282bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i59e29b586bba44708bb5e13fc1cccac7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i52450a8e8d2546b5bd337d8497a5289c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69892ca182474febb07a4d42f2311e31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6db0658921f94c4da60d8ab9e661845b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i960c222e9b7d4a59927d7e6165657a27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ff168ce1b424a539e923a9b1865cba9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61c65b2ff6c94bb8bcc3df47b62d5705_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibb7975455e654a058dcc8d1764cb18b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc2004b75c2c4673a8d52b5496f1f227_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic467a8caacc54f36b9cd0bbb7b623a98_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81c87fa80f5a449daba8c6132b457304_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4457dd521ae041f5801d7bde8d26fffe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib520017c77134d6d8203bb67065a1066_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba482b7988f246148ad09c509cd17ccd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8dd9499f0549458ca5c8d1f40663fd48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77ace3e3f4dc49a9b53a1d8959fe23aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mrk:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="course">
        <measure>mrk:course</measure>
    </unit>
    <unit id="market">
        <measure>mrk:market</measure>
    </unit>
    <unit id="country">
        <measure>mrk:country</measure>
    </unit>
    <unit id="interest_rate_swap">
        <measure>mrk:interest_rate_swap</measure>
    </unit>
    <unit id="case">
        <measure>mrk:case</measure>
    </unit>
    <unit id="claim">
        <measure>mrk:claim</measure>
    </unit>
    <unit id="plaintiff">
        <measure>mrk:Plaintiff</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF80L2ZyYWc6NGE5ODExMmM1OGUxNDI4NTkwZTFlMWI3MjdiYzlhMjMvdGFibGU6ZGM0YWExNGIwMDZmNDljOGEwYTExZjQ5YjE2NDQzMzcvdGFibGVyYW5nZTpkYzRhYTE0YjAwNmY0OWM4YTBhMTFmNDliMTY0NDMzN180LTEtMS0xLTA_9f648663-3ae2-4d67-83bc-a4faca6ac860">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF80L2ZyYWc6NGE5ODExMmM1OGUxNDI4NTkwZTFlMWI3MjdiYzlhMjMvdGFibGU6ZGM0YWExNGIwMDZmNDljOGEwYTExZjQ5YjE2NDQzMzcvdGFibGVyYW5nZTpkYzRhYTE0YjAwNmY0OWM4YTBhMTFmNDliMTY0NDMzN181LTEtMS0xLTA_970fdfbc-3571-4f6f-9871-4ce8604434ad">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF80L2ZyYWc6NGE5ODExMmM1OGUxNDI4NTkwZTFlMWI3MjdiYzlhMjMvdGFibGU6ZGM0YWExNGIwMDZmNDljOGEwYTExZjQ5YjE2NDQzMzcvdGFibGVyYW5nZTpkYzRhYTE0YjAwNmY0OWM4YTBhMTFmNDliMTY0NDMzN182LTEtMS0xLTA_4f443312-89f1-487d-802a-dd56214e36c6">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF80L2ZyYWc6NGE5ODExMmM1OGUxNDI4NTkwZTFlMWI3MjdiYzlhMjMvdGFibGU6ZGM0YWExNGIwMDZmNDljOGEwYTExZjQ5YjE2NDQzMzcvdGFibGVyYW5nZTpkYzRhYTE0YjAwNmY0OWM4YTBhMTFmNDliMTY0NDMzN185LTEtMS0xLTA_c19bef8e-358a-4165-ad6a-b97672265e2f">0000310158</dei:EntityCentralIndexKey>
    <mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate
      contextRef="ic1a2739cca2046f0abc863ed20b48d0b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzUz_b48cccc3-76a0-476d-bb80-193b05cdb46c">P3M</mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i84ebf0636d2b4c2daa4201ebca56405d_D20210602-20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTQyL2ZyYWc6OWMyYTgzYmIwZmRmNDg1MTlhMmVhMGUxMTJkZTUyN2UvdGV4dHJlZ2lvbjo5YzJhODNiYjBmZGY0ODUxOWEyZWEwZTExMmRlNTI3ZV8xMDk5NTExNjI3ODUz_9a2e852b-01a5-4ae0-8700-9bfbf262caa7"
      unitRef="number">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_16a2eb8c-e452-4c08-a1c1-253a7ae69d38">http://fasb.org/us-gaap/2021-01-31#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_51a0e69b-3d06-4866-8735-b4018eea9421">http://fasb.org/us-gaap/2021-01-31#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_a62e225e-815f-4743-87ec-8f20071b70d4">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_f733f0e1-fc32-4cc4-af08-cafbad4247b5">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_640b8294-5ffb-4269-b064-66281ca04383">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_7eda0372-d2d2-488c-a2da-c5fb07ed06fd">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODEvZnJhZzowMzY4NWYzNDU3OTg0ZmI2YjQ3MGIyZDY4NmUwNzY0Mi90YWJsZTo2NTZjZDY2ZDQxOGY0MTUzOTBiNTU4MWNjYmI4ZjhiNi90YWJsZXJhbmdlOjY1NmNkNjZkNDE4ZjQxNTM5MGI1NTgxY2NiYjhmOGI2XzEtMS0xLTEtMA_c216bd1c-8a80-4aa3-8a45-60b560e04012"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjYw_adf26d85-adc3-45d1-969e-69efa6b15aa7">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6OTkxM2FkZGU1ZTFlNDg1NmI2ZTNmNzhhNmEyOTgxOWMvdGFibGVyYW5nZTo5OTEzYWRkZTVlMWU0ODU2YjZlM2Y3OGE2YTI5ODE5Y18wLTEtMS0xLTA_a10e8944-d8c6-4656-8d7b-83cb14e766bb">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yMjY_8fa38186-a478-4092-9102-78dc60cb3417">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yMjY_5309e26d-3654-4fb6-b35f-2c0217d9c0fe">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6NDdjNmJjMmNiZjMxNDhhMmJmNTAyYmY4OTE5M2VlNGMvdGFibGVyYW5nZTo0N2M2YmMyY2JmMzE0OGEyYmY1MDJiZjg5MTkzZWU0Y18wLTEtMS0xLTA_6298d2e7-3eb6-4762-99af-38fa113dabbb">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjY2_0dbff403-e753-4178-9616-88c269c6a203">1-6571</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjYx_acda676d-8481-4151-a7de-e69ca0888822">Merck&#160;&amp; Co., Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YzQyNjVjOTU1NzA1NGYxOGIyMzc5MWYwN2YzMGFhYmIvdGFibGVyYW5nZTpjNDI2NWM5NTU3MDU0ZjE4YjIzNzkxZjA3ZjMwYWFiYl8wLTAtMS0xLTA_f7e7c263-fdc0-4764-91f2-28722554deab">2000 Galloping Hill Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YzQyNjVjOTU1NzA1NGYxOGIyMzc5MWYwN2YzMGFhYmIvdGFibGVyYW5nZTpjNDI2NWM5NTU3MDU0ZjE4YjIzNzkxZjA3ZjMwYWFiYl8xLTAtMS0xLTA_f0a7d6c5-ff7a-459f-8ee3-00d89ac5b46e">Kenilworth</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YzQyNjVjOTU1NzA1NGYxOGIyMzc5MWYwN2YzMGFhYmIvdGFibGVyYW5nZTpjNDI2NWM5NTU3MDU0ZjE4YjIzNzkxZjA3ZjMwYWFiYl8xLTItMS0xLTA_250b7312-fba7-42a5-a28e-79835bd48ebd">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YzQyNjVjOTU1NzA1NGYxOGIyMzc5MWYwN2YzMGFhYmIvdGFibGVyYW5nZTpjNDI2NWM5NTU3MDU0ZjE4YjIzNzkxZjA3ZjMwYWFiYl8xLTMtMS0xLTA_1a6bfd4b-132a-40bf-8c3c-df44b2c05432">07033</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjU3_89d848c0-4647-40ac-8a6d-f44250c414bd">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjYy_a366f45e-2a59-4f8b-8e1c-745db56a3941">740-4000</dei:LocalPhoneNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YmU1NjBkZTVmNjVjNDQwY2JiNGFiYmIxY2YxZDM2ZTIvdGFibGVyYW5nZTpiZTU2MGRlNWY2NWM0NDBjYmI0YWJiYjFjZjFkMzZlMl8wLTAtMS0xLTA_db1f4447-fdbe-4502-a23e-c4764ef925ef">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6YmU1NjBkZTVmNjVjNDQwY2JiNGFiYmIxY2YxZDM2ZTIvdGFibGVyYW5nZTpiZTU2MGRlNWY2NWM0NDBjYmI0YWJiYjFjZjFkMzZlMl8wLTEtMS0xLTA_97266e6d-e005-4ae8-96b2-9bf2923e0fba">22-1918501</dei:EntityTaxIdentificationNumber>
    <dei:Security12bTitle
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF8yLTAtMS0xLTA_cd02ec22-7c68-41a4-9b9f-e845e92d7591">Common Stock ($0.50&#160;par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF8yLTEtMS0xLTA_ef9d20b2-3685-4eae-85ee-6939d1597270">MRK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF8yLTItMS0xLTA_cc273aaa-9ea0-4b70-ac04-042ff3deaf19">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i19fa39a0158d4ac3a19217bc596e4123_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF80LTAtMS0xLTA_36320325-959f-4970-87cc-547305ba1f2e">0.500% Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i19fa39a0158d4ac3a19217bc596e4123_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF80LTEtMS0xLTA_e03d87a4-b51b-4273-9620-fca27719673e">MRK 24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i19fa39a0158d4ac3a19217bc596e4123_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF80LTItMS0xLTA_d5183acc-7d94-4e94-b470-962b151cdfa1">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i46992b35b0554da8a6375df5c7dc327e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF81LTAtMS0xLTA_c25fc072-213f-451d-8f5c-f2ec631a9fae">1.875% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i46992b35b0554da8a6375df5c7dc327e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF81LTEtMS0xLTA_2cc03c42-c670-40a8-960f-326f79891c77">MRK/26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i46992b35b0554da8a6375df5c7dc327e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF81LTItMS0xLTA_bd472cf8-e357-4a0b-a89b-e0373394f299">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i1852627ad8f34be7a1cca870e27e5bae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF82LTAtMS0xLTA_982e4f90-96e3-4c35-8929-99cd5826f63a">2.500% Notes due 2034</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1852627ad8f34be7a1cca870e27e5bae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF82LTEtMS0xLTA_dc75a312-585b-47d4-877e-09235403e445">MRK/34</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1852627ad8f34be7a1cca870e27e5bae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF82LTItMS0xLTA_ba8646be-36cf-4d8b-9739-3c88dfa6d62e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i3a98152d3a5b419398f05b5c58fb8024_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF83LTAtMS0xLTA_57b337d2-a07b-47d2-abe7-903d2fce72ea">1.375% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3a98152d3a5b419398f05b5c58fb8024_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF83LTEtMS0xLTA_06d81c9c-72ec-408f-ad7e-c98212cac986">MRK 36A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3a98152d3a5b419398f05b5c58fb8024_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MzBkM2E5YTAzM2I2NDdjM2JlMTEyNzM1MTgxZTMxNjAvdGFibGVyYW5nZTozMGQzYTlhMDMzYjY0N2MzYmUxMTI3MzUxODFlMzE2MF83LTItMS0xLTA_53ce0c18-6f40-44ce-bde2-dcbcc1c537df">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib7d3d9b0d798490eb3d016707f5c8fb3_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl80ODM_4279d827-7bb2-499b-b406-361439faa852"
      unitRef="shares">2527733606</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat
      contextRef="ie0f012095b0b4d82a0ee2d4237014df1_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl82MDM_ed227440-64e7-4b91-b410-755d5c630960"
      unitRef="usd">196870000000</dei:EntityPublicFloat>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjU4_243cd5d7-7b8e-47aa-9623-d63ab8bf19b7">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjYz_f377839b-0375-4c14-98e8-740e48e1eed6">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjY0_08f6215a-00f3-4597-900f-11c0a2abeba7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjU1_effe8213-acd8-46a8-b16b-91b9572a4663">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MTU2OWM4MTExNmM2NGZhOWFlMjg0Y2ZkZjg1M2ZlMDcvdGFibGVyYW5nZToxNTY5YzgxMTE2YzY0ZmE5YWUyODRjZmRmODUzZmUwN18wLTAtMS0xLTA_fd89efa6-d675-4912-94a1-dd2cbc80e8d8">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MTU2OWM4MTExNmM2NGZhOWFlMjg0Y2ZkZjg1M2ZlMDcvdGFibGVyYW5nZToxNTY5YzgxMTE2YzY0ZmE5YWUyODRjZmRmODUzZmUwN18xLTMtMS0xLTA_774a323c-84ff-423c-98d1-6d34c8e3acd3">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6MTU2OWM4MTExNmM2NGZhOWFlMjg0Y2ZkZjg1M2ZlMDcvdGFibGVyYW5nZToxNTY5YzgxMTE2YzY0ZmE5YWUyODRjZmRmODUzZmUwN18yLTMtMS0xLTA_dbcaaaee-66f2-4062-b9cb-d5b7cd7b9e4e">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8yNjU5_f5d1206f-bfc0-473f-8953-bfdf1913dda4">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGV4dHJlZ2lvbjphNTU5MTRlZmMwMjI0NzMyYjI5MmM2NjVjYzNiNjYzMl8zODQ4MjkwNjk5OTEz_7f45d3b6-9328-48a4-9f60-b8ef2387eec0">false</dei:EntityShellCompany>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xL2ZyYWc6YTU1OTE0ZWZjMDIyNDczMmIyOTJjNjY1Y2MzYjY2MzIvdGFibGU6OTZhMDAxN2M1NmVlNDA4NGFjYzIyZmRlZjdlYWY3ODAvdGFibGVyYW5nZTo5NmEwMDE3YzU2ZWU0MDg0YWNjMjJmZGVmN2VhZjc4MF8yLTAtMS0xLTA_be14877a-67de-4246-916f-11cc3fe7eb00">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;24, 2022, to be filed with the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities and Exchange Commission within 120&#160;days after the close of the fiscal year covered by this report&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:Revenues
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEtMS0xLTEtMA_e9ba35a1-796a-4918-8a31-563f710742c7"
      unitRef="usd">48704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEtMy0xLTEtMA_5d4fe67b-5bc5-41e9-9c6a-cfdfc2a60b24"
      unitRef="usd">41518000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEtNS0xLTEtMA_8321d7e8-dee6-4216-9684-6e006ea722b5"
      unitRef="usd">39121000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzMtMS0xLTEtMA_17d43010-6c6a-4f90-af90-e56054600278"
      unitRef="usd">13626000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzMtMy0xLTEtMA_0df2c995-12ec-48c1-bc74-5d167864d049"
      unitRef="usd">13618000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzMtNS0xLTEtMA_f600dbdd-76bf-493d-9617-9b6fca060895"
      unitRef="usd">12016000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzQtMS0xLTEtMA_71a42e63-a99d-4409-b948-35a9177e8a12"
      unitRef="usd">9634000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzQtMy0xLTEtMA_889c1fd4-07aa-407d-9b50-d871855fc7e4"
      unitRef="usd">8955000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzQtNS0xLTEtMA_a832c3c5-69da-4a85-9f2f-8e69c57806e3"
      unitRef="usd">9455000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzUtMS0xLTEtMA_f496c194-20ee-4a69-8e5b-b9864cf00059"
      unitRef="usd">12245000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzUtMy0xLTEtMA_d847a44a-aee5-47aa-b911-c2725a7727f2"
      unitRef="usd">13397000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzUtNS0xLTEtMA_196c1a45-a1f2-4eab-88d9-3f7feb4226e6"
      unitRef="usd">9724000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzYtMS0xLTEtMA_f35d5eae-2038-4f07-b966-5c61edc076a2"
      unitRef="usd">661000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzYtMy0xLTEtMA_06e293e5-e311-49dc-bf90-bcbf63c47c70"
      unitRef="usd">575000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzYtNS0xLTEtMA_753c1b48-89ad-4949-9cd4-e96f30f35406"
      unitRef="usd">626000000</us-gaap:RestructuringCharges>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzctMS0xLTEtMA_f86853c3-579f-4c7a-9a52-011609aea341"
      unitRef="usd">1341000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzctMy0xLTEtMA_a99eca07-7b63-4e79-a856-07713a5afb32"
      unitRef="usd">890000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzctNS0xLTEtMA_0bfea1ba-1532-4ff9-8b6c-d14343e9d14d"
      unitRef="usd">-129000000</us-gaap:OtherNonoperatingIncomeExpense>
    <mrk:CostsExpensesAndOther
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzgtMS0xLTEtMA_a488a162-91de-490e-9ac9-58ed9d212031"
      unitRef="usd">34825000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzgtMy0xLTEtMA_6985870e-b086-4ae3-ad43-23324d516db9"
      unitRef="usd">35655000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzgtNS0xLTEtMA_208627e9-1756-4379-a7c9-98809e4b180b"
      unitRef="usd">31950000000</mrk:CostsExpensesAndOther>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzktMS0xLTEtMA_cc6bcfb1-a5a3-452c-9818-33adde30fac2"
      unitRef="usd">13879000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzktMy0xLTEtMA_a5a2a19a-4e03-48c9-9e0b-28bd60ea1ce4"
      unitRef="usd">5863000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzktNS0xLTEtMA_9efdec63-62df-46d5-9df0-de3e6ca1632d"
      unitRef="usd">7171000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEwLTEtMS0xLTA_cfaac8ab-57e6-48ee-accd-58c70a1fe153"
      unitRef="usd">1521000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEwLTMtMS0xLTA_868578af-081d-4c75-9043-a91a337e9602"
      unitRef="usd">1340000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEwLTUtMS0xLTA_885b2339-18dc-41e0-8fba-42bcf46f4c05"
      unitRef="usd">1565000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzExLTEtMS0xLTA_a48daa18-150b-4cc7-8a99-e5b31066f9c8"
      unitRef="usd">12358000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzExLTMtMS0xLTA_89bf656b-704b-4c0f-a2af-b3f0c0d205d6"
      unitRef="usd">4523000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzExLTUtMS0xLTA_8d7daa28-6724-4f16-ad93-d922d3069248"
      unitRef="usd">5606000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEyLTEtMS0xLTA_e44cf497-5815-4e4d-8754-75f319134778"
      unitRef="usd">13000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEyLTMtMS0xLTA_a9ad8a8f-ee5b-4d9e-8eed-d4f8e29f2889"
      unitRef="usd">4000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEyLTUtMS0xLTA_7aa2f02f-28e4-4a80-89d5-1e07a5a60569"
      unitRef="usd">-84000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEzLTEtMS0xLTA_1da5a490-6afc-44e5-b58b-8dd963f88930"
      unitRef="usd">12345000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEzLTMtMS0xLTA_157a8de2-def9-447c-9e6d-d1ed0eb0da4f"
      unitRef="usd">4519000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzEzLTUtMS0xLTA_804b8665-0a8f-43e3-9d96-1d707242653a"
      unitRef="usd">5690000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE0LTEtMS0xLTgy_4d19ddd7-a246-43c9-a0d9-8f332591202a"
      unitRef="usd">704000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE0LTMtMS0xLTgy_83acf2cd-4baa-4f05-bb14-b4c2badb3b81"
      unitRef="usd">2548000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE0LTUtMS0xLTgy_e74cfd78-0295-427e-aca6-0f46d4fa507d"
      unitRef="usd">4153000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE1LTEtMS0xLTExNw_d6fb79df-7b47-43ed-8a07-d8539ccc2699"
      unitRef="usd">13049000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE1LTMtMS0xLTExOQ_08540730-c04d-433c-a68d-f75ce6d4e98c"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE1LTUtMS0xLTEyMQ_37880ec2-7f82-4a95-b3fe-7681183e9730"
      unitRef="usd">9843000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE3LTEtMS0xLTkz_444163db-27e7-4b03-bda9-1f48be58b3c7"
      unitRef="usdPerShare">4.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE3LTMtMS0xLTkz_ee7c4a06-b07e-4899-ab67-5d8d0bf01053"
      unitRef="usdPerShare">1.79</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE3LTUtMS0xLTkz_3d3924f1-8718-4489-8ced-4962479732ca"
      unitRef="usdPerShare">2.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE4LTEtMS0xLTkz_97f1064b-48f0-4074-bfa9-deeecd0a4270"
      unitRef="usdPerShare">0.28</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE4LTMtMS0xLTkz_a5a39938-057a-4c52-a9f8-39cf73533dda"
      unitRef="usdPerShare">1.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE4LTUtMS0xLTkz_dfc2bc28-51e9-4707-8953-36e8ad8f08a9"
      unitRef="usdPerShare">1.62</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE5LTEtMS0xLTkz_61c5ac76-3545-4a4b-93e5-ff074d6f98fd"
      unitRef="usdPerShare">5.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE5LTMtMS0xLTkz_823db72e-99e7-49e1-8add-cf82b94a33a7"
      unitRef="usdPerShare">2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzE5LTUtMS0xLTkz_c28ca42d-1c30-46d6-a827-f37dd36c9193"
      unitRef="usdPerShare">3.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIxLTEtMS0xLTkz_7e6f5f10-bb3e-48b8-b9ed-38f76547e401"
      unitRef="usdPerShare">4.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIxLTMtMS0xLTkz_b638bd4b-37c9-4773-99dd-eaf625f27893"
      unitRef="usdPerShare">1.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIxLTUtMS0xLTkz_1c4b19b3-5418-49d6-b987-d1a1627d2d1a"
      unitRef="usdPerShare">2.21</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIyLTEtMS0xLTkz_ffd6ba73-f4ce-4e69-9c62-d2e248cad854"
      unitRef="usdPerShare">0.28</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIyLTMtMS0xLTkz_8c6f1e3a-eb5d-4157-a897-092f3e25489a"
      unitRef="usdPerShare">1.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIyLTUtMS0xLTkz_f8ff745e-2021-44c3-a5c1-bfcd58467f4a"
      unitRef="usdPerShare">1.61</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIzLTEtMS0xLTkz_e0f2f41a-1738-4d46-80f0-9198dc142463"
      unitRef="usdPerShare">5.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIzLTMtMS0xLTkz_cb05a712-703f-43f1-9fc9-5ea1dfd9269b"
      unitRef="usdPerShare">2.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZTo4NWYxZDJjODdlNGM0ZTJiYjc0MmRmYzg0NmQ3MWQ0ZS90YWJsZXJhbmdlOjg1ZjFkMmM4N2U0YzRlMmJiNzQyZGZjODQ2ZDcxZDRlXzIzLTUtMS0xLTkz_d646b9dd-4944-412a-8d37-edbf27d590ea"
      unitRef="usdPerShare">3.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzEtMS0xLTEtMA_521f1f22-1cbc-40ec-892e-db367184cb0c"
      unitRef="usd">13049000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzEtMy0xLTEtMA_382c7b0f-172f-41fc-810b-86da0797b552"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzEtNS0xLTEtMA_639334cb-fc98-4814-9805-df33921b88a1"
      unitRef="usd">9843000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzMtMS0xLTEtMA_ad9fc7d8-44a5-439a-bdc7-c7b56c04e173"
      unitRef="usd">410000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzMtMy0xLTEtMA_0d349181-0c49-47d7-a300-cbceda974528"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzMtNS0xLTEtMA_14ea9195-63c2-40a6-b979-690be23ad27b"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzQtMS0xLTEtMA_6af2a394-7922-446c-a635-45035d6251f2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzQtMy0xLTEtMA_31aa3cbd-ba96-4fa6-a9de-21d4b57e7fe0"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzQtNS0xLTEtMA_94e995f1-b454-431a-97c4-ca8bdf920b3a"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzUtMS0xLTEtMA_4df18903-d2f8-42ff-9e17-f5dc37607fd8"
      unitRef="usd">-1769000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzUtMy0xLTEtMA_8531386b-2cc3-4a5a-86f4-354843d3568b"
      unitRef="usd">279000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzUtNS0xLTEtMA_f057e166-aec8-428a-812d-f654ba72e260"
      unitRef="usd">705000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzYtMS0xLTEtMA_b1e1a232-e5e9-46ae-b24d-286587b221ee"
      unitRef="usd">-423000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzYtMy0xLTEtMA_6e41a195-eaad-412e-bc49-518198bc031c"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzYtNS0xLTEtMA_34470082-e5bb-4f14-b4ae-cd0d3851c218"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzctMS0xLTEtMA_d7cdd2a5-182f-4b9c-9e9f-5b3f305a885f"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzctMy0xLTEtMA_22a69c9d-b8a2-449e-8063-32e8d1537e19"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzctNS0xLTEtMA_31cc660f-fd8a-42c2-a52c-ee82533e48e5"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzgtMS0xLTEtMA_d86d73fd-90d9-4c86-ad86-c091a9c17d0f"
      unitRef="usd">14805000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzgtMy0xLTEtMA_14fe7302-8ff2-4e9c-9f6e-0238d285cc84"
      unitRef="usd">6626000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzAvZnJhZzo3Yjc2YTZhYWFjMzE0YzhiOTgyZjI1MjI4YzQ1MjAyZS90YWJsZToyM2I1NzIyOGY3MWI0MGMyYjQ3Nzk3ZjIwYTZlMjE3OS90YWJsZXJhbmdlOjIzYjU3MjI4ZjcxYjQwYzJiNDc3OTdmMjBhNmUyMTc5XzgtNS0xLTEtMA_5b068ca7-e5b8-4b13-af7e-62ec0408f0b7"
      unitRef="usd">9195000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMtMS0xLTEtMA_ebebfa54-f656-4433-a39b-55585c424c67"
      unitRef="usd">8096000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMtMy0xLTEtMA_89b7c4f8-55cf-4ec2-b3b7-b22bf6b5e1ab"
      unitRef="usd">8050000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjUxN2UyMzlmMGM3OTQwMmRhNmNkOTE3Zjk5OGY4NjlmXzY4_5a32a1d4-6f07-430d-a805-3f3ad58cd972"
      unitRef="usd">62000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjUxN2UyMzlmMGM3OTQwMmRhNmNkOTE3Zjk5OGY4NjlmXzgz_0217a804-65e5-460b-93aa-82aa597fee90"
      unitRef="usd">67000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzUtMS0xLTEtMA_4431ac25-7ded-46f6-97b2-6fd2ea3f68e9"
      unitRef="usd">9230000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzUtMy0xLTEtMA_4e91e170-f7bb-4132-ab04-8d412e585805"
      unitRef="usd">6803000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjBkNDc5YjQ4ZTNiODRlYmRiNDJkMDg1Y2Q2MWY2YjhhXzQy_6e6ad75e-3cf2-4ff5-8bd3-d3b4264768e8"
      unitRef="usd">2194000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjBkNDc5YjQ4ZTNiODRlYmRiNDJkMDg1Y2Q2MWY2YjhhXzU3_24845acb-5bf3-4c9c-bcc0-8f34b7df91a5"
      unitRef="usd">2070000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzYtMS0xLTEtMA_5ac94e46-6cb6-4df4-960d-cc069639d365"
      unitRef="usd">5953000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzYtMy0xLTEtMA_c545f58b-144d-412c-b950-fa267a3715b2"
      unitRef="usd">5554000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzctMS0xLTEtMA_b9b8715b-3413-4466-90fd-6bc1a25a7b22"
      unitRef="usd">6987000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzctMy0xLTEtMA_e2a5b587-cf77-42f8-92b3-af12639d741b"
      unitRef="usd">4674000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzgtMS0xLTEtMjE5_80f0151e-33d3-4ff2-970d-70312b8712ff"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzgtMy0xLTEtMjE5_c9a6126d-a7f9-4647-8988-e4e4bdb24080"
      unitRef="usd">2683000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzgtMS0xLTEtMA_c27f01b7-6e85-434a-b456-41e5b2236199"
      unitRef="usd">30266000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzgtMy0xLTEtMA_2efae1d0-0bad-4db3-8eaa-df40defc0707"
      unitRef="usd">27764000000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzktMS0xLTEtMA_a8dd747c-cc1c-4881-8f41-823b53198064"
      unitRef="usd">370000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzktMy0xLTEtMA_dc14356e-07ab-4908-9140-c4b47d1823c5"
      unitRef="usd">785000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:Land
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzExLTEtMS0xLTA_57b239d5-9b4a-48c4-a7d3-231b7f35227d"
      unitRef="usd">326000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzExLTMtMS0xLTA_3d9c77a0-84d2-41e8-b0a6-2d74559fd947"
      unitRef="usd">336000000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzEyLTEtMS0xLTA_464bd42e-03e7-413d-a279-742a1f787f18"
      unitRef="usd">12529000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzEyLTMtMS0xLTA_bea89b63-2a9c-4a40-ab40-b21edfc9bd68"
      unitRef="usd">11998000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzEzLTEtMS0xLTA_1af9bce8-a6ca-47de-bb90-9f751ce9f833"
      unitRef="usd">16303000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzEzLTMtMS0xLTA_a4849aef-033d-4b82-83c8-057f7d89351b"
      unitRef="usd">15860000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE0LTEtMS0xLTA_69cf5fdb-03c8-436b-ac31-eadfece8731b"
      unitRef="usd">8313000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE0LTMtMS0xLTA_d8b6613d-61cb-4447-81f7-e6e07ab7db41"
      unitRef="usd">6968000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE1LTEtMS0xLTA_bb4cec65-8a5d-49a1-8746-12fa5bbb724d"
      unitRef="usd">37471000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE1LTMtMS0xLTA_cb0fce7f-61a2-4b72-95c2-b42f4446f6ca"
      unitRef="usd">35162000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE2LTEtMS0xLTA_8126faf8-d41f-4c7f-83c7-3c538d4111b7"
      unitRef="usd">18192000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE2LTMtMS0xLTA_355f969a-cb99-45fc-9143-71740046122e"
      unitRef="usd">18162000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE3LTEtMS0xLTA_7fdae8e1-042a-4b8a-9f19-640de42a5454"
      unitRef="usd">19279000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE3LTMtMS0xLTA_2e9a779e-8090-4520-9ab3-85f903b2bc47"
      unitRef="usd">17000000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE4LTEtMS0xLTA_5e21be3a-52f2-425e-9763-4d06b28c6bfe"
      unitRef="usd">21264000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE4LTMtMS0xLTA_c7f02453-1e92-451f-9501-ce92bcfe4ece"
      unitRef="usd">18882000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE5LTEtMS0xLTA_860886f0-9209-4bb8-b91a-a6f97b7f01dd"
      unitRef="usd">22933000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzE5LTMtMS0xLTA_fe62178f-6f8d-46a5-87ad-fb32f463f2a2"
      unitRef="usd">14101000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIwLTEtMS0xLTA_ab37fd1d-2053-42f1-8e3e-2e5fd3098c24"
      unitRef="usd">11582000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIwLTMtMS0xLTA_3e06a069-609b-472f-b652-91cf226563f8"
      unitRef="usd">9881000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIyLTEtMS0xLTIyNQ_ebb85da5-a215-49ab-8e69-1d96ce0d5c7a"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIyLTMtMS0xLTIyNQ_448a0e3d-f56c-41a7-9e8d-5a5674ab8321"
      unitRef="usd">3175000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIxLTEtMS0xLTA_546e4f98-373f-4a69-b235-67ed2fefc9c1"
      unitRef="usd">105694000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzIxLTMtMS0xLTA_16d46af4-916d-4e3c-86a7-ade069fbcdc0"
      unitRef="usd">91588000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI0LTEtMS0xLTA_e1f5e3a6-c871-4af0-8c3a-3e1182e5c560"
      unitRef="usd">2412000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI0LTMtMS0xLTA_757c0ca1-e915-40f8-93ed-316cb68d23d4"
      unitRef="usd">6431000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI1LTEtMS0xLTA_23ab7f59-6683-40e8-9f99-1cacde0d34b8"
      unitRef="usd">4609000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI1LTMtMS0xLTA_0a83687c-7b2c-4053-8ec1-3c00907c4093"
      unitRef="usd">4327000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI2LTEtMS0xLTA_5af407b3-3a32-4d5c-bc26-42f268ac8f91"
      unitRef="usd">13859000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI2LTMtMS0xLTA_ab8cfb62-ee8e-4bed-9cea-0633b4dbadc3"
      unitRef="usd">12212000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI3LTEtMS0xLTA_7c8bddea-0901-4b6c-b2ae-72620784b191"
      unitRef="usd">1224000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI3LTMtMS0xLTA_5d064474-804f-469d-9ba6-9e811165a3a2"
      unitRef="usd">1597000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI4LTEtMS0xLTA_b35c3071-388f-46d8-9286-02ff0884ac06"
      unitRef="usd">1768000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI4LTMtMS0xLTA_89b838d4-c65f-4269-b635-eb755ed00213"
      unitRef="usd">1674000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMxLTEtMS0xLTIzMg_41cf10f7-a24b-4bc4-a442-2db3865930bf"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMxLTMtMS0xLTIzMg_8e498149-9f14-4d84-9215-8f3145175619"
      unitRef="usd">1086000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI5LTEtMS0xLTA_a80c1640-8639-4ae1-9b64-2ec48b150a09"
      unitRef="usd">23872000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzI5LTMtMS0xLTA_ac47419d-58ce-479b-9d74-0d5af8105d8b"
      unitRef="usd">27327000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMwLTEtMS0xLTA_b152454c-5f69-4b97-8a39-25f44266826a"
      unitRef="usd">30690000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMwLTMtMS0xLTA_59cbcdad-54c3-4e07-8910-2662c8220341"
      unitRef="usd">25360000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMxLTEtMS0xLTA_843e9e4a-b6e8-427c-8a9c-c0b87110cee2"
      unitRef="usd">3441000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMxLTMtMS0xLTA_1a576a8b-28b4-4eed-807b-0965441c899f"
      unitRef="usd">1005000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMyLTEtMS0xLTA_9dc79f90-d553-45b3-b044-d9f4e1cf2213"
      unitRef="usd">9434000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzMyLTMtMS0xLTA_2f654fdd-3509-49a5-b82c-06c655c5eefa"
      unitRef="usd">12306000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM2LTEtMS0xLTIzNg_f42015ac-cb6b-4b65-aba1-abbacaf8ba9b"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM2LTMtMS0xLTIzNg_23e8618f-ac23-4122-95b4-b662b71554db"
      unitRef="usd">186000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV8xOQ_2c8287c4-47f4-4c17-a172-f5c5291d4a10"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV8xOQ_aeaf67c6-fc4c-47fe-ae65-dcd620621416"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV80NQ_04e7169c-aae2-4a7c-b1da-a869de70a375"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV80NQ_d9b49194-1b02-42fc-813b-4ad339937dee"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV82NA_03bfcdb2-b4f0-4c7c-8072-bc9deff64e9a"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjo0NWM2MmJjNGZlZTg0YzNiYjIzNjI2Yjc0ZjI5YWMxZV82NA_5e519b5b-2694-442b-bb3a-3f4ed3f0d8ca"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTEtMS0xLTA_6a5edc83-4a70-41b5-897c-63ecbb8c537c"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM0LTMtMS0xLTA_14d698ba-2839-43a1-b161-3ba3e6c5587c"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM1LTEtMS0xLTA_895822f1-f017-4a20-a3a3-046e85e3c3da"
      unitRef="usd">44238000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM1LTMtMS0xLTA_f0242c1d-175b-4a8d-8c15-3e24b6a50488"
      unitRef="usd">39588000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM2LTEtMS0xLTA_c7a7d05f-2d74-427c-a2db-435c02a53049"
      unitRef="usd">53696000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM2LTMtMS0xLTA_8e3d1cb5-1228-4e67-b2ae-9db1473e5f47"
      unitRef="usd">47362000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM3LTEtMS0xLTA_bc25d9e4-812c-40c7-a95f-5f9e0740fa3c"
      unitRef="usd">-4429000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM3LTMtMS0xLTA_cd02bbf9-ce2b-43bc-976e-5bfe54e24326"
      unitRef="usd">-6634000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM4LTEtMS0xLTA_ed8c971f-9fb4-46a3-9362-00ea468501bd"
      unitRef="usd">95293000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM4LTMtMS0xLTA_08650af9-a791-4541-88ef-078d6f999f5d"
      unitRef="usd">82104000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockShares
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjphM2QzZGZkMmQ3MzM0MDZiODI0OTU2YWVhYTAxMzlmNV8zNQ_6a423aa5-a9b3-48fd-b356-0c2badc9de7b"
      unitRef="shares">1049499023</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM5LTAtMS0xLTAvdGV4dHJlZ2lvbjphM2QzZGZkMmQ3MzM0MDZiODI0OTU2YWVhYTAxMzlmNV81Nw_023f3329-6bf0-4fd8-9788-d35b79a2bed9"
      unitRef="shares">1046877695</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM5LTEtMS0xLTA_7fac78ab-b185-4fd5-b0bb-98acf29e9254"
      unitRef="usd">57109000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzM5LTMtMS0xLTA_817aa7ae-647a-45de-b9b5-a53bcb5c1660"
      unitRef="usd">56787000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQwLTEtMS0xLTA_5898af42-c355-43c3-9742-7a36e1bb90d0"
      unitRef="usd">38184000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQwLTMtMS0xLTA_e06188b3-d7af-4138-954f-b4ebcf2ac4aa"
      unitRef="usd">25317000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQxLTEtMS0xLTA_446eb612-5fa5-4b43-b11e-15eb206ad9d6"
      unitRef="usd">73000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQxLTMtMS0xLTA_7aff6a1d-e29c-47c5-b118-3db2c3c62f0b"
      unitRef="usd">87000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQyLTEtMS0xLTA_d1cdc249-d400-445e-8123-8e998f476bbc"
      unitRef="usd">38257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQyLTMtMS0xLTA_93722287-8f46-4a2d-8293-1d7423c256dc"
      unitRef="usd">25404000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQzLTEtMS0xLTA_86578844-6e1a-4045-9c1e-8e605260bcae"
      unitRef="usd">105694000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzMvZnJhZzplMjhlOTE5YThjNWU0MGRkYjlmZmRkZGI2NjA4Y2U1YS90YWJsZTpmYTE1ZDkyNmM4OWY0MmViOGFhMjI4ZTZkZjM2ODZiOC90YWJsZXJhbmdlOmZhMTVkOTI2Yzg5ZjQyZWI4YWEyMjhlNmRmMzY4NmI4XzQzLTMtMS0xLTA_9af57dbe-3d28-497a-bd61-19b0fce22224"
      unitRef="usd">91588000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i296a96e660db43169f0376b184f4d3fc_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtMS0xLTEtMA_89e5df36-634a-40a3-974c-b4c0e603412e"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i241c8aa1377540ad88e44cceb968c204_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtMy0xLTEtMA_489fb923-2cd2-43fb-bbac-cb549fe757ce"
      unitRef="usd">38808000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2112d614d9a45828458276b54ac3348_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtNS0xLTEtMA_2144a647-db54-469b-b7e9-bd7b56d3dee9"
      unitRef="usd">42579000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd9336867cce49919c9a776ee62bc1b2_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtNy0xLTEtMA_d040d4fb-5fad-410b-aa29-c98a8b49dc6b"
      unitRef="usd">-5545000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b062550448c4f5b877548d6eda89d15_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtOS0xLTEtMA_af67db55-006c-4262-a3b6-60710d0fd0d1"
      unitRef="usd">-50929000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib908a2ace6f544bd91b2adcb40f2f0af_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtMTEtMS0xLTA_990d7078-8999-4b97-8a44-147ff436512e"
      unitRef="usd">181000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b25cba6160a4486b14740ddd2b481ef_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEtMTMtMS0xLTA_fc71de36-fec6-4609-af53-e2f66716879a"
      unitRef="usd">26882000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8e94e814bd0149bd847f2783d90c9d48_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzItNS0xLTEtMA_02bd8560-91da-428f-8b3d-3c816a060f73"
      unitRef="usd">9843000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzItMTMtMS0xLTA_7f1a3f6e-f5b6-49ef-9330-1f04526a16b7"
      unitRef="usd">9843000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i40203e52d1c440a6b89559fa168b081a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzQtNy0xLTEtMA_f7cbb7ab-30bf-4b4a-9312-272c6ec2decd"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzQtMTMtMS0xLTA_33235937-09cd-4d32-8d18-aa6253054af7"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYzE3NzQ4MGIxMDQ1ZTY4NDcwZjhhNWEyMDVhYWMyXzQ1_3cf5dfe6-8346-4db1-a6ae-f06901532e01"
      unitRef="usdPerShare">2.26</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8e94e814bd0149bd847f2783d90c9d48_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzUtNS0xLTEtMA_3ed79eff-fb7a-491b-9ffc-c911348e760a"
      unitRef="usd">5820000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzUtMTMtMS0xLTA_527d74bf-2987-49ef-81bd-a8a8952e4b93"
      unitRef="usd">5820000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0171e54cbd894628b6188119563a887e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzYtMy0xLTEtMA_1fcd5d67-4f55-4c64-936a-4a95f0a9a284"
      unitRef="usd">-1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzYtOS0xLTEtMA_878254da-5f5c-4935-9d46-989471c1bfbf"
      unitRef="usd">5780000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzYtMTMtMS0xLTA_67ef27ac-59b9-4017-88c5-f87ba1c0a50c"
      unitRef="usd">4780000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if3acd7fea33f491a9299de32f18ce21a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzctMTEtMS0xLTA_5b8b8582-73c9-48ee-9ecc-01c97afe39d2"
      unitRef="usd">-66000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzctMTMtMS0xLTA_4bf8399e-dbc8-4d6e-b28a-27010f637a38"
      unitRef="usd">-66000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if3acd7fea33f491a9299de32f18ce21a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzgtMTEtMS0xLTA_78c3a021-0739-4eb3-a469-5dbcf16b6864"
      unitRef="usd">21000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzgtMTMtMS0xLTA_86222da5-7526-41ff-a7b0-0a1c0eeb29f6"
      unitRef="usd">21000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i0171e54cbd894628b6188119563a887e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzktMy0xLTEtMA_2832d499-92c8-42b2-8501-18aebf4cc644"
      unitRef="usd">148000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzktOS0xLTEtMA_6c188337-5bb9-47c1-8b53-ad8789a43409"
      unitRef="usd">-759000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzktMTMtMS0xLTA_cdc49d7f-a8c5-4313-a9ff-68e3647982d6"
      unitRef="usd">-611000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e784cab819d451499c362b12111a27a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTEtMS0xLTA_35175175-0f36-4c33-b83f-22303572fbd1"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01dd7de0cf6f4ace976de5b22d6ba095_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTMtMS0xLTA_0ecd0bde-6e81-4767-8be2-6e1ad7d0786a"
      unitRef="usd">39660000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5a5580f8dad412cb034d3e6ad78653f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTUtMS0xLTA_a83caba9-3c80-4755-9c56-48d7dfff9159"
      unitRef="usd">46602000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a458b3d31d042a4bb104dc181064e79_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTctMS0xLTA_a5ffc2a2-781a-4f46-af83-a2a9b0b64f1d"
      unitRef="usd">-6193000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e651f0bdf0a4e5c85db0a3c85be51f1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTktMS0xLTA_baa97b90-6f44-42d1-ba3a-31d698f1613b"
      unitRef="usd">-55950000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5734fc741d6d4e0480d4a89bf0739099_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTExLTEtMS0w_99fdedc4-8e13-458b-9806-e9bb98a1a72e"
      unitRef="usd">94000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEwLTEzLTEtMS0w_9bdba587-e8ad-4394-8400-cda103285036"
      unitRef="usd">26001000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i89ce079367344ee799a79a4d8a61dcdf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzExLTUtMS0xLTA_d637576e-f41b-4527-bf51-0f040cbe1add"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzExLTEzLTEtMS0w_04cef684-4f37-4f94-993d-710a5c580e14"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia95480df7b48466b8fe2970840b6d96e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEyLTctMS0xLTA_55a746da-61a7-48b8-8c8c-2267417b87eb"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEyLTEzLTEtMS0w_c32dfbe0-903c-43e9-9e16-a70bc5a7d637"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjpjZGEwZTM0OGZmYTU0YTY5YmUxZjZkYmM0ZDY5Y2Y2MV80NQ_b774ebbf-dbf2-49e1-8a5b-c848e09eba59"
      unitRef="usdPerShare">2.48</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i89ce079367344ee799a79a4d8a61dcdf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEzLTUtMS0xLTA_d22a887a-8c74-45ad-964a-6e7f05e1cb1c"
      unitRef="usd">6307000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzEzLTEzLTEtMS0w_9233d961-84f7-4cd3-a4bb-fcec38559a54"
      unitRef="usd">6307000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE0LTktMS0xLTA_a75989e0-1df4-4d84-9ca2-3e3d835697e3"
      unitRef="usd">1281000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE0LTEzLTEtMS0w_d4ffe6c1-790c-4118-98e3-e3307f7a3f63"
      unitRef="usd">1281000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic1468cd3ea95419fb66e7dd8d3547410_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE1LTExLTEtMS0w_3c0c641a-4540-49c8-8882-55766c41280d"
      unitRef="usd">15000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE1LTEzLTEtMS0w_8a553ef6-9758-4956-b91f-1ee85d8b722a"
      unitRef="usd">15000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic1468cd3ea95419fb66e7dd8d3547410_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE2LTExLTEtMS0w_a78bf35b-94ac-4507-855f-fa186159063f"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE2LTEzLTEtMS0w_e2827e7d-6194-40af-85bc-269f7b7a8534"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i1dd27579d0594b8c836cf9cb029ccdb8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE3LTMtMS0xLTA_fe73d54b-9321-43e6-97f9-95244131fe1e"
      unitRef="usd">72000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE3LTktMS0xLTA_738174e3-a4ac-4a94-97da-7a2e214d8d33"
      unitRef="usd">-444000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE3LTEzLTEtMS0w_afebef70-fae5-469b-af13-06bf27711104"
      unitRef="usd">-372000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if91e41b657e142838655904b6ffc2b4c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTEtMS0xLTA_5fc42eed-084f-4115-baaf-c7391dc06a07"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i747b6da151fd47548889dcf4acf9f07e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTMtMS0xLTA_cab66bfa-5058-43cd-b210-5fbbfc434de0"
      unitRef="usd">39588000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i629510fd09f5448784fc756b630535b7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTUtMS0xLTA_418ebc26-6054-4657-8d9e-c8925d03b543"
      unitRef="usd">47362000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d1f8e2c09b84254b99b8e105564e52b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTctMS0xLTA_8e6d93a5-6dde-47d6-8992-96cfab3f9258"
      unitRef="usd">-6634000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44fbc319828d43888404b362300c8719_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTktMS0xLTA_ae93175a-198d-47ca-a1d8-fa673f2f12c7"
      unitRef="usd">-56787000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22154b3c72564c4184ae4a06c41144ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTExLTEtMS0w_b057d3b7-4fd5-49b2-a36d-904d3f8154ec"
      unitRef="usd">87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE4LTEzLTEtMS0w_56f8b8c5-d835-4cd1-8d13-0fefb849bcc9"
      unitRef="usd">25404000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i49673c36f67e4d93b4ebbe225a478e72_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE5LTUtMS0xLTA_2b71ac16-c59f-45b6-9a0c-d5a3657f0cfd"
      unitRef="usd">13049000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzE5LTEzLTEtMS0w_fa974938-c923-4a95-b26e-099e0b3ace91"
      unitRef="usd">13049000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i52711b1bf6764fd78c0ef6f9e7df950f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIwLTctMS0xLTA_ae4094b5-00d9-40e2-87f8-63829b296783"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIwLTEzLTEtMS0w_65715aea-edd4-4fa7-b33f-a8cc03ed45a4"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjozYjkwNThlODM4YTY0ZTdkOWEzYWU5NjI2OGNkMTdlZl80NQ_61e68984-0e78-49f7-ac72-e92cb5fbc451"
      unitRef="usdPerShare">2.64</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i49673c36f67e4d93b4ebbe225a478e72_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIxLTUtMS0xLTA_83ac3102-9fef-46a6-84a4-49aa843a6f57"
      unitRef="usd">6715000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIxLTEzLTEtMS0w_d534b2e5-4f8b-4a2a-8d97-fa53c5233756"
      unitRef="usd">6715000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTktMS0xLTA_ddb00d4f-3ca5-45a9-bc13-abf4f13599c6"
      unitRef="usd">840000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTEzLTEtMS0w_6962bc0b-d25f-407b-bd3b-a63b42315d88"
      unitRef="usd">840000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i5889b314dc6846e99dfdc5dd5b0d4d4d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTMtMS0xLTM5Nzk_0114f0dc-e91d-4fd2-a0c6-d911662a294b"
      unitRef="usd">4643000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i52711b1bf6764fd78c0ef6f9e7df950f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTctMS0xLTM5ODI_1ad466d9-f128-4e20-a4bc-b9b79970d07e"
      unitRef="usd">449000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i5fb199531c9a4be79a55f354540b66f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTExLTEtMS0zOTg4_4e112ff7-e5c9-4e44-916a-a4938b992bb3"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIyLTEzLTEtMS0zOTg4_510092d7-0021-477c-a2ba-3af38692f1e6"
      unitRef="usd">5091000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5fb199531c9a4be79a55f354540b66f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIzLTExLTEtMS0w_2b344edc-1a07-4a75-a0d3-225f13211a63"
      unitRef="usd">16000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzIzLTEzLTEtMS0w_27063127-842a-4bb0-8403-315213acdae4"
      unitRef="usd">16000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5fb199531c9a4be79a55f354540b66f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI0LTExLTEtMS0w_6c59251f-aa07-4873-859d-08652e6571b3"
      unitRef="usd">29000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI0LTEzLTEtMS0w_6d38de5f-e0d6-447a-b76a-06401c12f241"
      unitRef="usd">29000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i5889b314dc6846e99dfdc5dd5b0d4d4d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI1LTMtMS0xLTA_bf736118-7cf2-49d7-916a-201e4a262881"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI1LTktMS0xLTA_699e879e-05cf-40e2-90e6-c217c1da0f1f"
      unitRef="usd">-518000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI1LTEzLTEtMS0w_c3c07038-e321-4110-aa4d-9d4dd0923c69"
      unitRef="usd">-525000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5771d34675734e438d53901618ffd853_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTEtMS0xLTA_2af6cbbe-f076-456c-b6c0-15b127c14d02"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a2a1e33e2f04030829641bc2c24a05c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTMtMS0xLTA_c880487d-dc9d-414d-b5bd-20f04a8c99c9"
      unitRef="usd">44238000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e9a7df047274290ad191b1e08bfc7ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTUtMS0xLTA_84c06c69-6b07-4b72-9dd2-8629c8d79365"
      unitRef="usd">53696000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i333ee6c0baa94ce7a67cc850a8d3a772_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTctMS0xLTA_5f8b8515-7ca9-4ae5-91fb-6d9ff7f9967f"
      unitRef="usd">-4429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10c6f9da4227441da8480f88901779b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTktMS0xLTA_d87c8e83-028e-4a68-8d44-350304968543"
      unitRef="usd">-57109000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i020c181c0f60421080b1a0cdcce948b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTExLTEtMS0w_a91e2cb1-806f-40fd-a1d9-d44c78e99f0d"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzYvZnJhZzo5NTA5ODVhZjY0OGU0MTY2OWIzMTU4YThjOTA4YjYwZi90YWJsZTo4NzdjNWM4NmQ5MWU0OTMyODcyOWE4NmMyZmJlMWIwNi90YWJsZXJhbmdlOjg3N2M1Yzg2ZDkxZTQ5MzI4NzI5YTg2YzJmYmUxYjA2XzI2LTEzLTEtMS0w_7cc276d9-f8db-4834-b501-e39ef1027b20"
      unitRef="usd">38257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzItMS0xLTEtMA_18521275-470d-49c9-863a-b2a27105df60"
      unitRef="usd">12358000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzItMy0xLTEtMA_63699d28-e2d4-4de4-99d8-1f7cfd9ae34c"
      unitRef="usd">4523000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzItNS0xLTEtMA_617814d0-b732-4e36-ac2d-5a57c6a98c0f"
      unitRef="usd">5606000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentForAmortization
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQtMS0xLTEtMA_ac13e178-3522-4756-aa89-c461e0e3064b"
      unitRef="usd">1636000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQtMy0xLTEtMA_d07a2ba3-8559-4b64-802e-b92d3650d16f"
      unitRef="usd">1817000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQtNS0xLTEtMA_47a039d4-50ff-4e5c-a021-93fe8065fb19"
      unitRef="usd">1695000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:Depreciation
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUtMS0xLTEtMA_862dfdab-ff7c-4ba5-9341-1717ea119954"
      unitRef="usd">1578000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUtMy0xLTEtMA_ca28db63-b4c9-4840-aa00-50dd28fecbd6"
      unitRef="usd">1669000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUtNS0xLTEtMA_b7b35b8f-befd-40ce-bcde-37f973833ffe"
      unitRef="usd">1615000000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzYtMS0xLTEtMA_d651607f-d1d7-478b-a5c8-f01111c5047c"
      unitRef="usd">302000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzYtMy0xLTEtMA_ff46211a-95a0-48fc-98d5-eb0f1a2c1a3c"
      unitRef="usd">1718000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzYtNS0xLTEtMA_3931e30a-c319-4834-98a5-0955ddb17791"
      unitRef="usd">1040000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMS0xLTEtMjcyMDI_cc0d0dcb-cf38-4eb6-9548-7cb0a41c2e65"
      unitRef="usd">1940000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMy0xLTEtMjcyMDI_e31ec640-fcaf-4f2c-9567-9ca7490e9163"
      unitRef="usd">1338000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctNS0xLTEtMjcyMDI_e3fb56bd-5552-4821-9af7-048e954dd174"
      unitRef="usd">170000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMS0xLTEtMzQ5_d5a7ade7-f3ef-486e-bab1-72f0d3f9538a"
      unitRef="usd">1556000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMy0xLTEtMzQ5_e96a60e6-e230-4b19-a0e0-aca9307958ac"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctNS0xLTEtMzQ5_83184db3-c661-487a-857d-c8fb8d7c7180"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMS0xLTEtMA_1b4f5c14-e0fc-47db-bbb6-2bd091062ebc"
      unitRef="usd">0</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctMy0xLTEtMA_61d6bd96-31bc-4e2a-b8ef-529e83cece25"
      unitRef="usd">2660000000</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzctNS0xLTEtMA_3ad4b2bf-4d93-4416-b4b3-35198a613d6d"
      unitRef="usd">0</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzgtMS0xLTEtMA_06cdbc4f-2f00-4938-a379-f80a3cdd9611"
      unitRef="usd">0</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzgtMy0xLTEtMA_2d468631-03e9-4a70-9095-37569c013059"
      unitRef="usd">0</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzgtNS0xLTEtMA_9f15e317-2a40-4774-ba1f-dbcd338a3faa"
      unitRef="usd">993000000</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEwLTEtMS0xLTA_73e3c463-9a1f-4c94-9088-6e4046ae020b"
      unitRef="usd">187000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEwLTMtMS0xLTA_2279143b-ace1-4f21-9274-ff76b4a59fbe"
      unitRef="usd">-566000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEwLTUtMS0xLTA_e0190d70-84e7-4581-b40f-580bb9bcd6ff"
      unitRef="usd">-560000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzExLTEtMS0xLTA_1a9d1a00-7129-4d20-ba1b-97fe5a22e804"
      unitRef="usd">479000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzExLTMtMS0xLTA_44ffe05e-d348-444e-b32e-f936e846931e"
      unitRef="usd">441000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzExLTUtMS0xLTA_4b1405ea-e0ac-4353-a220-0a199f679515"
      unitRef="usd">388000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEyLTEtMS0xLTA_f6451dc0-9b84-4442-be0b-a33263299558"
      unitRef="usd">-805000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEyLTMtMS0xLTA_73d638c4-e278-41fc-a341-da5e4f22275e"
      unitRef="usd">-1294000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzEyLTUtMS0xLTA_09e9735a-0881-43f6-a3e9-024a0cbd18a4"
      unitRef="usd">-354000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE0LTEtMS0xLTA_cb162f52-95cf-40ab-85f3-ac768aa338c5"
      unitRef="usd">2033000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE0LTMtMS0xLTA_305151f9-37cb-493c-b8e0-51ed3ea103da"
      unitRef="usd">1002000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE0LTUtMS0xLTA_d463f052-b10e-44d3-b5c2-de8a8c00fdbe"
      unitRef="usd">-92000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE1LTEtMS0xLTA_984d44b2-eeef-4433-a102-00a80be65649"
      unitRef="usd">674000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE1LTMtMS0xLTA_e2c166e0-a306-4163-b266-e300a460cc24"
      unitRef="usd">895000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE1LTUtMS0xLTA_1142218e-c6c4-4a05-968e-e41959bd51c2"
      unitRef="usd">473000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE2LTEtMS0xLTA_c4f27af8-048b-4d2f-885c-a2c17582c384"
      unitRef="usd">405000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE2LTMtMS0xLTA_6190d1ba-86e1-4771-a431-dbbe37ef812e"
      unitRef="usd">684000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE2LTUtMS0xLTA_632edd88-c489-4a6f-b7a2-8205628f453b"
      unitRef="usd">443000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE3LTEtMS0xLTA_c08e8c2c-ae6f-499b-98e1-b7fda5f9d72f"
      unitRef="usd">277000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE3LTMtMS0xLTA_4d3c53e0-f1cd-4604-9043-781056457057"
      unitRef="usd">-1152000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE3LTUtMS0xLTA_ad8f6f0f-914c-48b9-923e-aaac0ebfaa4d"
      unitRef="usd">413000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE4LTEtMS0xLTA_52be77c6-44cf-4a90-8bc3-347f22f2ef3c"
      unitRef="usd">-540000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE4LTMtMS0xLTA_e6ce017d-4067-4410-9b49-4d72118834f3"
      unitRef="usd">814000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE4LTUtMS0xLTA_5fef6116-7aef-4d82-85a7-12b5012b0c97"
      unitRef="usd">-1889000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE5LTEtMS0xLTA_1fef4eba-a691-4396-a0d8-60371060db99"
      unitRef="usd">484000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE5LTMtMS0xLTA_58b673d9-82c5-43cd-aa48-9c19cc718f9e"
      unitRef="usd">-617000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzE5LTUtMS0xLTA_52adc9a2-8e06-4c21-b8ad-bb816910bdd6"
      unitRef="usd">-733000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIwLTEtMS0xLTA_11dbc501-3801-4a00-94cb-a62460a949eb"
      unitRef="usd">1758000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIwLTMtMS0xLTA_51539ed5-6ed1-4e81-ab9b-e3f7daa0e6b6"
      unitRef="usd">2433000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIwLTUtMS0xLTA_0fc8c323-9846-48e9-8845-609f61f154e9"
      unitRef="usd">-70000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIxLTEtMS0xLTA_e0a4fcca-7ccd-4159-8c36-fbcbc2226b5b"
      unitRef="usd">13122000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIxLTMtMS0xLTA_d10b5db1-a276-43d4-8037-ca9793263b64"
      unitRef="usd">7617000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIxLTUtMS0xLTA_0c9bad9d-5ae8-4a17-9fd9-d47e5755ab97"
      unitRef="usd">8884000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIzLTEtMS0xLTA_2bba2918-5ae3-4e1f-9a7c-78fa40992f35"
      unitRef="usd">4448000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIzLTMtMS0xLTA_ddaa5983-3525-442b-a173-867ebead8518"
      unitRef="usd">4429000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzIzLTUtMS0xLTA_f46cf3a0-3575-45ff-9e5e-c70dc6d32384"
      unitRef="usd">3369000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI0LTEtMS0xLTA_6d0ec6c0-af3c-490e-8e8a-03d9fd9a0d4b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI0LTMtMS0xLTA_9f9efb07-5333-4e5b-bc08-d2ee37e5f474"
      unitRef="usd">1000000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI0LTUtMS0xLTA_72b0da84-864e-40f0-8d89-bbd0bb963994"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI1LTEtMS0xLTA_d17b03b1-3fe5-4a1e-b744-8852ac9f6770"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI1LTMtMS0xLTA_7cb51c6a-7f70-4104-a873-71ec0e11d879"
      unitRef="usd">95000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI1LTUtMS0xLTA_9f21bc94-fbfc-481c-aead-77ec9f90085b"
      unitRef="usd">3202000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI2LTEtMS0xLTA_88b61f0b-5508-4ab7-8250-c40bbd282912"
      unitRef="usd">1026000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI2LTMtMS0xLTA_788c709a-00c9-494d-9ad9-b5dd08943202"
      unitRef="usd">2812000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI2LTUtMS0xLTA_586f5360-dc58-40bc-b709-1f310d8be0d7"
      unitRef="usd">8622000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTEtMS0xLTMwODI1_d1dfe9ae-b6c2-4b14-b9b5-0eb11ed7ad30"
      unitRef="usd">11174000000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTMtMS0xLTMwODI1_97ed436c-2fda-4b3a-bc4f-1bd47fed0a1d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTUtMS0xLTMwODI1_a2da1116-9eaa-4062-8d51-144089f68e8d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTEtMS0xLTM2MQ_244777cd-d0aa-4064-a05e-faf76db990df"
      unitRef="usd">1554000000</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTMtMS0xLTM2MQ_64e41939-af7a-413c-9190-55d3ee409b9f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTUtMS0xLTM2MQ_2d7de3bf-f7f5-49b2-8f44-a49be6877c9a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTEtMS0xLTA_977cc2d8-b2d0-48a1-a04a-01d04418d39a"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTMtMS0xLTA_4be79c44-c78d-4484-990b-3913a2539d74"
      unitRef="usd">2696000000</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI3LTUtMS0xLTA_0a4b6000-5a56-4117-96a0-a8d79d4f3060"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTEtMS0xLTA_296a7926-7b42-43a7-9d43-d06a3a6065bb"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTMtMS0xLTA_3557826c-9e99-42ed-9cee-7b9ec3828437"
      unitRef="usd">2545000000</mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI4LTUtMS0xLTA_f4c2f99f-4306-400f-81ba-925388e26b3f"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessSixNetOfCashAcquired
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI5LTEtMS0xLTA_7ad61afc-905f-4562-ac7a-edc38ab4f234"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessSixNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessSixNetOfCashAcquired
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI5LTMtMS0xLTA_17a7fcaa-5919-4b6d-9563-29c81abec790"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessSixNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessSixNetOfCashAcquired
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzI5LTUtMS0xLTA_5bd84aad-d174-4453-8e00-8ff56410bd62"
      unitRef="usd">3620000000</mrk:PaymentsToAcquireBusinessSixNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessSevenNetOfCashAcquired
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMwLTEtMS0xLTA_21f016e6-c7bb-4ac0-bc00-1e0fca0937cf"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessSevenNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessSevenNetOfCashAcquired
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMwLTMtMS0xLTA_ab828225-3844-4e74-95cb-03d8eb05cae4"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessSevenNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessSevenNetOfCashAcquired
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMwLTUtMS0xLTA_7d20f158-3bd3-49a9-bb7c-5c39e3194524"
      unitRef="usd">1040000000</mrk:PaymentsToAcquireBusinessSevenNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMxLTEtMS0xLTA_85012c7d-b156-435d-a153-f855fe512d14"
      unitRef="usd">179000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMxLTMtMS0xLTA_d72a8b81-35c5-4e92-9f17-40e4f4cf1327"
      unitRef="usd">1365000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMxLTUtMS0xLTA_a28109f9-0cc9-4e13-b816-fc859d441f15"
      unitRef="usd">294000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMyLTEtMS0xLTA_39f0a70f-32ca-47cf-82e0-6e5eb9a0638f"
      unitRef="usd">91000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMyLTMtMS0xLTA_1210635d-4493-4b01-9d43-301338f165e1"
      unitRef="usd">-125000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMyLTUtMS0xLTA_bf0c0dac-e92c-4297-9da3-55116ec00b7d"
      unitRef="usd">-374000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMzLTEtMS0xLTA_cf9a6e32-d997-43aa-96a0-64de0014c4f6"
      unitRef="usd">-16421000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMzLTMtMS0xLTA_1dda5f7f-4f1c-4e0c-b426-f4613c1c565c"
      unitRef="usd">-9193000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzMzLTUtMS0xLTA_5946b379-d804-4a9d-925f-f604900db97a"
      unitRef="usd">-2529000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM1LTEtMS0xLTA_f075454f-315f-4d95-af14-0f50822e7702"
      unitRef="usd">-3986000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM1LTMtMS0xLTA_8f44f53a-866c-416c-886f-003ccc2de11c"
      unitRef="usd">2549000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM1LTUtMS0xLTA_86cd2179-cd70-4a47-a663-01cb702ff597"
      unitRef="usd">-3710000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM2LTEtMS0xLTA_c5187021-3f97-4ee7-a655-91ee0f44fe62"
      unitRef="usd">2319000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM2LTMtMS0xLTA_0a08f0d1-6e05-4709-b604-f5a76e3ee381"
      unitRef="usd">1957000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM2LTUtMS0xLTA_b994d496-9581-4cc8-a651-52b895835aea"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM3LTEtMS0xLTA_d7f84f0c-1722-4e42-880f-6084e65adf28"
      unitRef="usd">7936000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM3LTMtMS0xLTA_6fff5615-7286-4dc6-abd5-6dfec8cf0d9b"
      unitRef="usd">4419000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM3LTUtMS0xLTA_0495f626-b6c2-4300-8e0b-5dc1a671a0f2"
      unitRef="usd">4958000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTEtMS0xLTI3MjM5_5e2843be-9fca-4142-b274-bca9061b0b68"
      unitRef="usd">9000000000</mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTMtMS0xLTI3MjM5_84441b2a-3955-4a25-92d2-dea8dbfcd687"
      unitRef="usd">0</mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTUtMS0xLTI3MjM5_2543d47f-b099-4b39-b8c3-b24ee475dbee"
      unitRef="usd">0</mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM4LTEtMS0xLTA_0aab910c-b95f-4e80-815a-fe72a7d6bd4c"
      unitRef="usd">840000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM4LTMtMS0xLTA_067a3151-6d65-4fac-bc97-d54c97558867"
      unitRef="usd">1281000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM4LTUtMS0xLTA_136c3624-19cd-45f0-8c6b-e86109b072b4"
      unitRef="usd">4780000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM5LTEtMS0xLTA_fb91928e-d6b7-4e01-b7ec-893c6845214b"
      unitRef="usd">6610000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM5LTMtMS0xLTA_ab087481-ec6d-4077-9b00-277ee5878d0b"
      unitRef="usd">6215000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzM5LTUtMS0xLTA_39ab1d13-630f-47fe-9220-c76202b78666"
      unitRef="usd">5695000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTEtMS0xLTA_600c9a76-0ce7-46ab-a301-93860cffe7cd"
      unitRef="usd">202000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTMtMS0xLTA_7dfdc3be-dca0-4858-bcd6-b8837979e8c0"
      unitRef="usd">89000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQwLTUtMS0xLTA_984cd637-fc1c-433e-a42b-69a8bb3088aa"
      unitRef="usd">361000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQxLTEtMS0xLTA_3f7a0a78-6efa-4768-bf02-b3b9d972d7fe"
      unitRef="usd">-286000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQxLTMtMS0xLTA_4cc87bd7-05e0-434d-9e85-205188b69166"
      unitRef="usd">-436000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQxLTUtMS0xLTA_0dd1e382-6946-4c70-81d1-6145eea6b66c"
      unitRef="usd">5000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQyLTEtMS0xLTA_00d19f7e-003f-42bc-97a4-9d24cb514517"
      unitRef="usd">3097000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQyLTMtMS0xLTA_23c54f83-a95d-4662-8b14-019ceac13178"
      unitRef="usd">-2832000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQyLTUtMS0xLTA_d0acc823-92c5-4c1c-abbe-9a3671a44376"
      unitRef="usd">-8861000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTEtMS0xLTI3Mzcy_920eaa2e-6850-43ce-8862-8042be8fcb67"
      unitRef="usd">987000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTMtMS0xLTI3Mzcy_b441fab9-7c9c-4469-9c35-23d905199335"
      unitRef="usd">2636000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTUtMS0xLTI3Mzcy_c4579d23-2394-4b43-b490-c826cf49d4d5"
      unitRef="usd">4556000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ3LTEtMS0xLTI3Mzcy_385ba00c-b2ae-4fe4-b234-4486f9e18fbd"
      unitRef="usd">-134000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ3LTMtMS0xLTI3Mzcy_3012af77-cd80-4d10-a6ae-27c072bf9a05"
      unitRef="usd">-250000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ3LTUtMS0xLTI3Mzcy_a2c1847e-af84-49c9-ac5f-205aaa81c254"
      unitRef="usd">-100000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ4LTEtMS0xLTI3Mzcy_c6320ddc-7515-4426-8c54-09d5ab6bcd0a"
      unitRef="usd">-504000000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ4LTMtMS0xLTI3Mzcy_56313de4-a9ef-4ba3-874c-6ad4c964e5da"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ4LTUtMS0xLTI3Mzcy_73dd4689-932d-49fc-bb8c-32e52f0431d3"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUwLTEtMS0xLTI3NDA5_e089510b-a880-4ffe-814e-b02a508b55b0"
      unitRef="usd">349000000</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUwLTMtMS0xLTI3NDEy_3db7b2c3-0e0e-4e2c-812f-35746ccc140e"
      unitRef="usd">2386000000</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzUwLTUtMS0xLTI3NDE1_46aaa6e1-1643-40a4-9f9f-1d007f28d882"
      unitRef="usd">4456000000</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQzLTEtMS0xLTA_f0d638dd-4f62-4166-9709-851519570aed"
      unitRef="usd">-133000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQzLTMtMS0xLTA_7b8b2446-e46c-48cb-ae5e-2bb058a26cfb"
      unitRef="usd">253000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQzLTUtMS0xLTA_0e0e4241-281b-462e-8c96-cd4b79d05d71"
      unitRef="usd">17000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ0LTEtMS0xLTA_80859024-76d9-4794-87c4-afc05eb9ad30"
      unitRef="usd">14000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ0LTMtMS0xLTA_520c44bc-12e1-4ad9-8205-0ec97bac474f"
      unitRef="usd">-1769000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ0LTUtMS0xLTA_51194b29-8883-45b2-8f20-d3f77b4e0532"
      unitRef="usd">1967000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:RestrictedCash
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjozMmJjNTc4NjJjMGI0MTkxOGE4NWRkYzIzMDUyMjZlNl83OA_d18a870a-e489-48cd-a4dd-518633fcbc27"
      unitRef="usd">103000000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ1LTEtMS0xLTA_3e222830-3ecf-4146-ba89-50d518dcc9d5"
      unitRef="usd">8153000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ1LTMtMS0xLTA_e0903fe4-43d2-4550-9526-f36ba9c8fd11"
      unitRef="usd">9934000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8b25cba6160a4486b14740ddd2b481ef_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ1LTUtMS0xLTA_0eb5cb76-9a91-4784-bd40-45d93d44f3ae"
      unitRef="usd">7967000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzU0LTEtMS0xLTI3NTU1_9a3fb545-1fa0-46f4-a968-63da1233a067"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzU0LTMtMS0xLTI3NTU1_b8ad4163-81e2-482d-91d6-53e857848c70"
      unitRef="usd">12000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzU0LTUtMS0xLTI3NTU1_a2f58079-ecbb-4fe3-816e-56f8d1c7ef5e"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:RestrictedCash
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ZDM1MWRjNGE4Y2Y0MWEyOThlZmU5NGIzZGFhOTUxZV83Mg_7b55fd53-9c23-48a9-ac32-4f00200ecc99"
      unitRef="usd">71000000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTEtMS0xLTA_71942e21-bbb9-41be-bed5-4ca795183046"
      unitRef="usd">8167000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTMtMS0xLTA_289ae0cb-57c0-48c1-ae43-cd09d279aaca"
      unitRef="usd">8153000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xMzkvZnJhZzo0NTkxZmY1ZjA2MzE0MWYxYThlNDA5NzY3ZDFhZDU2Zi90YWJsZTowNThlOTFmNzY0NGM0OWM5OTU3ZDhlN2U4ODMyMzM4YS90YWJsZXJhbmdlOjA1OGU5MWY3NjQ0YzQ5Yzk5NTdkOGU3ZTg4MzIzMzhhXzQ2LTUtMS0xLTA_ef4b5a9c-63c7-4e93-8ac1-a8feb705f302"
      unitRef="usd">9934000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDUvZnJhZzpmNmJlNjA3MzFkODA0NmE1OTM4MDg4NTIwNDVmMDlkNy90ZXh0cmVnaW9uOmY2YmU2MDczMWQ4MDQ2YTU5MzgwODg1MjA0NWYwOWQ3XzM2Mjk_661fe58e-576e-4426-b093-abe03342aab0">Nature of Operations&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck&#160;&amp;amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company&#x2019;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Spin-Off of Organon &amp;amp; Co. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, Merck completed the spin-off of products from its women&#x2019;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp;amp; Co. (Organon) through a distribution of Organon&#x2019;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#x2019;s diversified brands franchise. Merck&#x2019;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#x2019;s consolidated financial statements through the date of the spin-off (see Note 3).&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDUvZnJhZzpmNmJlNjA3MzFkODA0NmE1OTM4MDg4NTIwNDVmMDlkNy90ZXh0cmVnaW9uOmY2YmU2MDczMWQ4MDQ2YTU5MzgwODg1MjA0NWYwOWQ3XzMyMQ_7275f4f7-3683-45e4-961b-f351e907f254"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjQw_b77b6bcd-7f01-4767-b266-e8702fc391b1">Summary of Accounting Policies&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#x2019; interests are shown as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#x2019;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#x2019;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Equivalents&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#x2019;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Comprehensive Income (OCI)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for debt securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or similar investments, minus impairments. Such adjustments are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for equity securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#x2019;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#x2019;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The nature of the Company&#x2019;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2021, $11.4 billion in 2020 and $9.9 billion in 2019. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#x2019;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were $207 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million and $2.6 billion, respectively, at December&#160;31, 2021 and were $208 million and $2.6 billion, respectively, at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#x2019;s total unbudgeted spending and the Company&#x2019;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzUz_b48cccc3-76a0-476d-bb80-193b05cdb46c"&gt;three&lt;/span&gt; to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck&#x2019;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 19 for disaggregated revenue disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Depreciation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Buildings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and from 3 to 15&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Machinery, equipment and office furnishings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Depreciation expense was $1.6 billion in 2021, $1.7 billion in 2020 and $1.6 billion in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advertising and Promotion Costs &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.0 billion in 2021, $1.8 billion in 2020 and $1.9 billion in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Capitalization&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired Intangibles&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired intangibles include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired In-Process Research and Development&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&#160;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; over its remaining useful life, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Compensation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring Costs&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies and Legal Defense Costs&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income from Continuing Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#x2019;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued amended guidance on the accounting for convertible instruments and contracts in an entity&#x2019;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The amended guidance is effective for interim and annual periods in 2022. The application of the amendments in the new guidance are to be applied either on a modified retrospective or a retrospective basis. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption on January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards&#160;Not Yet Adopted &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements. The Company is progressing in its evaluation of LIBOR cessation exposures, including the review of debt-related contracts, leases, business development and licensing arrangements, royalty and other agreements. The Company has amended certain agreements and continues to review other agreements for potential impacts. With regard to debt-related exposures in particular, all existing interest rate swaps linked to LIBOR will mature in 2022. The Company is still evaluating the impact to its LIBOR-based debt. Based on its evaluation thus far, the Company does not anticipate a material impact to its consolidated financial statements as a result of reference rate reform. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have a material impact on the Company&#x2019;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.&lt;/span&gt;&lt;/div&gt;In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to the company&#x2019;s financial statements. The guidance is effective for annual periods beginning in 2022 and is to be applied on either a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTYy_ca27e6c2-a2c2-4404-97e7-15833e6537f4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#x2019; interests are shown as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTQx_f715607d-57af-4be7-988a-1916d55da175">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is &lt;/span&gt;defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#x2019;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#x2019;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTA5_c32c77a4-cf79-43b4-ad1e-b55fe2e76a10">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and reflected as a separate component of equity. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NDY2_a32fa0e1-a15d-431b-a40d-d0f2a6013d3c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Equivalents&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTMx_a16ee105-a551-452e-866a-31f98168c83e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. pharmaceutical and vaccine inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered to have a high probability of regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.&lt;/span&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTAy_ad01a300-1e70-4d65-aac9-893f02373be7">&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#x2019;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Comprehensive Income (OCI)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for debt securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or similar investments, minus impairments. Such adjustments are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for equity securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTg3_1a88ee29-bc03-40dd-84aa-b849222fb6b2">&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#x2019;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#x2019;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The nature of the Company&#x2019;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2021, $11.4 billion in 2020 and $9.9 billion in 2019. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#x2019;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were $207 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million and $2.6 billion, respectively, at December&#160;31, 2021 and were $208 million and $2.6 billion, respectively, at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#x2019;s total unbudgeted spending and the Company&#x2019;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzUz_b48cccc3-76a0-476d-bb80-193b05cdb46c"&gt;three&lt;/span&gt; to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck&#x2019;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 19 for disaggregated revenue disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <mrk:SalesDiscounts
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzk2MTg_a2cfeae7-8173-46ff-929d-3e80b440fc76"
      unitRef="usd">12300000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzk2Mjg_10ffe377-75f6-4253-840d-e5c582239270"
      unitRef="usd">11400000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzk2NDE_31ca5b07-f4c0-4edb-a367-c348522face7"
      unitRef="usd">9900000000</mrk:SalesDiscounts>
    <mrk:AccrualForChargebacks
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzExMzg3_9528a693-e419-4546-b46a-5255ba2fdd88"
      unitRef="usd">207000000</mrk:AccrualForChargebacks>
    <mrk:AccrualForRebates
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzExMzk0_af85f9cc-8da2-4b45-9c12-c0a74048f004"
      unitRef="usd">2600000000</mrk:AccrualForRebates>
    <mrk:AccrualForChargebacks
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzExNDI3_358c693a-954b-4acc-84b1-d31b6171145c"
      unitRef="usd">208000000</mrk:AccrualForChargebacks>
    <mrk:AccrualForRebates
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzExNDM0_54ca717f-9f96-4923-a17e-6ac8b4705965"
      unitRef="usd">2600000000</mrk:AccrualForRebates>
    <mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate
      contextRef="idbf378454e1d4b12a87f05c8d4852a45_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzU5_f1105399-c44b-47b8-a665-2bb3affb85a8">P6M</mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate>
    <mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyMzcz_356a7fd8-93c8-420f-9280-d8946dbb7551">P12M</mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i48e19dcf50aa4fd1ae7e9d3a8ea60763_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEyOTc5_335d8d3d-20c0-4c38-b71f-61c735df76ba">P36D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i3ef868a5ade24c99b03f00ffa9481beb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzMDYy_439acd79-2f01-43eb-880c-a8b8bada9526">P30D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i3844e8babf814713b968b4e3c289a5c6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzMTkz_cefb6577-e390-441e-b987-7dfa8f716f98">P90D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i42166b8ad497486faa87ed01b29e3d22_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzMjYw_9f1b9660-e6e9-4113-9ed3-4fde1b4d0f01">P30D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i74c24ba602a542c0b8c9b0ef7ed35ee3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzMjcx_55135472-a634-4125-8f07-31762d3eea1d">P90D</mrk:RevenuePerformanceObligationPaymentTerms>
    <us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTU2_447bd28c-61a0-4a6d-9b12-889a8cb3571a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Depreciation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Buildings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and from 3 to 15&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Machinery, equipment and office furnishings&lt;/span&gt;.</us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iad274281f336490a9ef2ec84cddc2518_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNjE0_45386768-4340-4d43-9a48-0758ecffe08c">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5f1aaf80bf5248b6b6375fd958a9e703_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNjIw_550b6b84-3630-4fce-88cd-92f01abca183">P45Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib66800d952274b52b8a0a168fe298ecc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNjUz_f5180bb5-206a-4eca-b93b-d73387bb74e4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0b1ac66b90724fe18f56ea110536b64b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNjU5_88984db1-0a67-4435-ac07-48dece48e515">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNzQy_5db35aa1-58d2-4767-9f2f-0eeb567527f5"
      unitRef="usd">1600000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNzUy_ed7c909d-4690-4a14-828e-8c3dd3cbb3de"
      unitRef="usd">1700000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzNzY1_f33a1246-4eb3-4c6c-ba4a-d030f830eb17"
      unitRef="usd">1600000000</us-gaap:Depreciation>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTAz_791fee9a-282c-4a4e-af85-956fc4bebe61">Advertising and Promotion Costs &#x2014; Advertising and promotion costs are expensed as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzOTI2_2544828b-456e-42c3-974b-2ad6ad826677"
      unitRef="usd">2000000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzOTM2_62df5e15-f01c-4911-bf22-644ef11fce5d"
      unitRef="usd">1800000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzEzOTQ5_9b44e284-578b-40bb-be1e-0a47b5d6e57a"
      unitRef="usd">1900000000</us-gaap:AdvertisingExpense>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjA5_0ad92a21-4589-4f7a-b29e-ef6994b30cd5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Capitalization&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8be0b42ed8034d95ba4e13ab6fbbf535_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzE0NTQ3_2754b76f-0085-41b6-b62a-82528384df48">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4b030dcad117451495b0cce71d1a6fc8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzE0NTUz_80c3f5a9-e923-4259-84cc-8d13cf155fd8">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NDkw_e9e4ccba-b707-4b0c-b7dc-9302346ada73">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).&lt;/span&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjU2_7297affe-ec23-4bc8-aa8d-10d190e0ebf2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired Intangibles&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired intangibles include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted &lt;/span&gt;future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic1a2739cca2046f0abc863ed20b48d0b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzE1OTA1_8742aa42-a567-4db9-b08f-1d3a3522031e">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idbf378454e1d4b12a87f05c8d4852a45_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzE1OTEx_a0a077b8-b81e-437b-8abe-b0dc4117ca5a">P24Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTM2_1ba5373c-fd07-4feb-a973-e8f20205c35b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired In-Process Research and Development&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <mrk:ContingentConsiderationPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTU4_1edac947-ac1b-4dba-8353-a52503aa4b68">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&#160;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. If the transaction is accounted for as an acquisition of an asset rather than a business, contingent consideration is not recognized at the acquisition date. In these instances, product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable by the Company of being achieved.&lt;/span&gt;</mrk:ContingentConsiderationPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjQ0_6b604580-e25c-404c-8b88-26d1570542c2">Research and Development&#160;&#x2014;&#160;Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTkz_4877d869-5133-48e1-80a5-3c4ca39ef2f4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when probable of being achieved. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; over its remaining useful life, subject to impairment testing.&lt;/span&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjIw_bbbadda6-196f-4fdb-9499-390b798ab326">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Compensation&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NDg4_ee265a1e-3bec-4020-9741-ac4f5b7547da">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring Costs&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.&lt;/span&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjYw_d696f261-833d-4c5d-8220-2febebbb5ef2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies and Legal Defense Costs&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTA3_36e622a6-0dcb-4570-a330-fbb3f8fd0924">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income from Continuing Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NDk5_c7582492-d9f7-4c7c-8047-f342b1573f1a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#x2019;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities (primarily IPR&amp;amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NTc1_3f21053e-bf55-412a-8547-75c6baaee524">Reclassifications&#160;&#x2014;&#160;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNDgvZnJhZzpjNzRlOWFiNmQ0YTQ0OGMxOGE3MzE4NWU0MWE3YTU2Yi90ZXh0cmVnaW9uOmM3NGU5YWI2ZDRhNDQ4YzE4YTczMTg1ZTQxYTdhNTZiXzI5NjEy_3e780737-fec6-40dd-8323-b1ab6b91bedc">&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued amended guidance on the accounting for convertible instruments and contracts in an entity&#x2019;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The amended guidance is effective for interim and annual periods in 2022. The application of the amendments in the new guidance are to be applied either on a modified retrospective or a retrospective basis. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption on January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards&#160;Not Yet Adopted &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements. The Company is progressing in its evaluation of LIBOR cessation exposures, including the review of debt-related contracts, leases, business development and licensing arrangements, royalty and other agreements. The Company has amended certain agreements and continues to review other agreements for potential impacts. With regard to debt-related exposures in particular, all existing interest rate swaps linked to LIBOR will mature in 2022. The Company is still evaluating the impact to its LIBOR-based debt. Based on its evaluation thus far, the Company does not anticipate a material impact to its consolidated financial statements as a result of reference rate reform. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have a material impact on the Company&#x2019;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.&lt;/span&gt;&lt;/div&gt;In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to the company&#x2019;s financial statements. The guidance is effective for annual periods beginning in 2022 and is to be applied on either a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM3NjQ0_726e36a1-ec5f-476f-a44b-a32025ef5865">Spin-Off of Organon &amp;amp; Co.On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#x2019;s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one-tenth of a share of Organon&#x2019;s common stock for each share of Merck common stock held by such shareholder. The &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5&#160;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0&#160;billion were distributed by Organon to Merck in connection with the spin-off. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture and supply certain formulated pharmaceutical products for Organon, and (c) package and label certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in the consolidated statement of income for the above MSAs include sales of $219&#160;million and related cost of sales of $195&#160;million in 2021. Amounts included in the consolidated statement of income for the TSAs was immaterial in 2021. The amount due from Organon under the above agreements was $964&#160;million at December&#160;31, 2021 and is reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount due to Organon under these agreements was $400&#160;million at December&#160;31, 2021 and is included in A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ccrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of the women&#x2019;s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company&#x2019;s consolidated statement of income as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through June 2, 2021, the date of the spin-off. Prior periods have been recast to reflect this presentation. As a result of the spin-off of Organon, Merck incurred separation costs of $556&#160;million in 2021 and $743&#160;million in 2020, which are also included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. As of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs, Expenses and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;877&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income of discontinued operations attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reflects amounts through the June 2, 2021 spin-off date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of assets and liabilities of discontinued operations are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent Assets of Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent Liabilities of Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the spin-off of Organon, Merck distributed net liabilities of $5.1&#160;billion as of June 2, 2021 consisting of debt of $9.4&#160;billion (described above), goodwill of $1.4&#160;billion, property, plant and equipment of $981&#160;million, cash of $929&#160;million, inventory of $815&#160;million, other intangibles, net, of $519&#160;million and other net liabilities of $328&#160;million. The spin-off also resulted in a net decrease to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of $449 million consisting of $421 million for the derecognition of net losses on foreign currency translation adjustments and $28 million associated with employee benefit plans. The distribution of the net liabilities and reduction to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; resulted in a net $4.6 billion increase to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other paid-in capital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;Expenses for curtailments, settlements and termination benefits provided to certain employees were incurred in connection with the spin-off (see Note 14). Additionally, all outstanding Merck stock options, restricted stock units (RSUs) and performance share units (PSUs) (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees (see Note 13).</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib1098dc170e941f38477fba57b8cf5ae_I20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NTEx_5b9972f3-1da7-4c4e-b282-a7c6870ec0fd"
      unitRef="usd">9500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NTI1_c7aa325b-ec98-4212-8e15-b91dd1fddda5"
      unitRef="usd">9000000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="if2498efe88024feb8dbf6cebe7b9e1c4_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NTU4_613fd8f2-0d08-483f-baa0-a00cdf1e5766">P25M</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="id35e3e3e253f4a6eb98018307707afde_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NjA1_a7f8a2b7-0062-48c8-97bf-11db18177e20">P4Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i16aa05ee3ee141d2ace6ce8e2e932362_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0NjI0_878a62a1-be7f-4113-9fa7-3c49b2fe3641">P10Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:RevenueFromRelatedParties
      contextRef="iaeb5df78dae84a27b551e06a2a2ae854_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF80Mzk4MDQ2NTMyMjc5_a110911a-b550-40f4-b75f-053f60f2f467"
      unitRef="usd">219000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartiesAmountInCostOfSales
      contextRef="iaeb5df78dae84a27b551e06a2a2ae854_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF80Mzk4MDQ2NTMyMjkz_900758ce-2a02-44e1-b2b5-feb9572a87be"
      unitRef="usd">195000000</us-gaap:RelatedPartiesAmountInCostOfSales>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i162cf24607d24678bb2c7252e0441829_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0Nzkz_a0c7792a-708e-4b4c-8dc2-f2e1f2fc977d"
      unitRef="usd">964000000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i162cf24607d24678bb2c7252e0441829_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM0ODA3_85a5f271-0115-4447-b3a4-a6213d4e7fcb"
      unitRef="usd">400000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM3NTcx_7953811b-f545-42a8-8358-d945f301b28b"
      unitRef="usd">556000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM3NTg1_816e071d-1fd5-4aa8-84fd-ffa7d4aa1170"
      unitRef="usd">743000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM3NjQz_24da022f-e7ce-4446-8376-7764605d662c">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs, Expenses and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;877&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income of discontinued operations attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reflects amounts through the June 2, 2021 spin-off date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of assets and liabilities of discontinued operations are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent Assets of Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent Liabilities of Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xLTEtMS0xLTMzODk_73d1a0d4-5c8c-4a8f-b088-9d0968e8dbc5"
      unitRef="usd">2512000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xLTMtMS0xLTMzOTM_960e501a-8382-4674-8386-1563384ff9e0"
      unitRef="usd">6476000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xLTUtMS0xLTM3MzE3_00a5c606-571a-4f34-9c50-12b26f3b25d2"
      unitRef="usd">7719000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8zLTEtMS0xLTMzODk_259122f4-6242-4c92-9ef9-cde1eb8262a5"
      unitRef="usd">789000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8zLTMtMS0xLTMzOTM_1c5e8360-7466-472c-9c11-83639a88aff1"
      unitRef="usd">1867000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8zLTUtMS0xLTM3MzE3_c9415951-ebcd-44c6-9434-54c90f60abf7"
      unitRef="usd">2096000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV80LTEtMS0xLTMzODk_1e3ae89a-6df1-4427-b956-fef2c8fba300"
      unitRef="usd">877000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV80LTMtMS0xLTMzOTM_2a2ee812-b06c-4b39-9f61-100f6ad033b1"
      unitRef="usd">1513000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV80LTUtMS0xLTM3MzE3_b4f9e08c-fb9f-4abc-8754-0a53d010a86d"
      unitRef="usd">1160000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV81LTEtMS0xLTMzODk_338217a2-d112-4358-800f-8f10478e714f"
      unitRef="usd">103000000</mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV81LTMtMS0xLTMzOTM_459aac6c-75c5-4492-90fc-7bd98e2eab53"
      unitRef="usd">161000000</mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV81LTUtMS0xLTM3MzE3_777f72f4-c0b2-4cda-a9e2-51e43a2f6daa"
      unitRef="usd">148000000</mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV82LTEtMS0xLTMzODk_df399f66-ad41-41ce-9a17-5da9e73032d5"
      unitRef="usd">1000000</mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV82LTMtMS0xLTMzOTM_c04e042f-7416-4316-b7b0-e8b0a73b1e8f"
      unitRef="usd">3000000</mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV82LTUtMS0xLTM3MzE3_13bd04d9-aa0e-447c-9f18-a32589d643bc"
      unitRef="usd">12000000</mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts>
    <mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV83LTEtMS0xLTMzODk_6cb0c61f-22e8-4952-8c51-50b7d7175a64"
      unitRef="usd">15000000</mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV83LTMtMS0xLTMzOTM_0b3e7d06-0646-4341-951d-b624756834e7"
      unitRef="usd">-4000000</mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV83LTUtMS0xLTM3MzE3_1581a32a-8be3-44ff-a8cc-ab13fde1b295"
      unitRef="usd">-10000000</mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV84LTEtMS0xLTMzODk_d34d5d4d-3055-48d1-87c5-12bb4032e2aa"
      unitRef="usd">1755000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV84LTMtMS0xLTMzOTM_0e334052-f920-4fd7-ac1b-c477a128287e"
      unitRef="usd">3548000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV84LTUtMS0xLTM3MzE3_2820105e-4e34-49a2-98fe-d1975c59b95a"
      unitRef="usd">3426000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV85LTEtMS0xLTMzODk_41a1b392-6a58-4b25-b69e-514527a21398"
      unitRef="usd">757000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV85LTMtMS0xLTMzOTM_ce0624d4-c86d-473d-b0fc-e6b5a3b8d982"
      unitRef="usd">2928000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV85LTUtMS0xLTM3MzE3_22b23ec6-7093-46c2-ae47-4658ad8abace"
      unitRef="usd">4293000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMC0xLTEtMS0zMzg5_3d106c51-1a51-4543-b133-2fd4319e1fd2"
      unitRef="usd">50000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMC0zLTEtMS0zMzkz_41274616-8fb0-4a86-bd79-9fee40d17eb2"
      unitRef="usd">369000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMC01LTEtMS0zNzMxNw_c01ff7fa-e7f4-4531-92bf-fed5b4d73f20"
      unitRef="usd">122000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMS0xLTEtMS0zMzg5_a27dbf8b-286d-4abe-bb24-2b2756098054"
      unitRef="usd">707000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMS0zLTEtMS0zMzkz_358d3f6a-4826-4040-ba2f-44481284bc48"
      unitRef="usd">2559000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMS01LTEtMS0zNzMxNw_acf65e3c-386f-4f84-91ab-199aab551a45"
      unitRef="usd">4171000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMi0xLTEtMS0zMzg5_516dc4d8-1dee-4c0b-84f0-997b32965f73"
      unitRef="usd">3000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMi0zLTEtMS0zMzkz_475b5730-83b8-4753-b528-634197361ff7"
      unitRef="usd">11000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMi01LTEtMS0zNzMxNw_373897ec-27b9-4d0a-9fc6-764151f48b42"
      unitRef="usd">18000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMy0xLTEtMS0zMzg5_1de5e53c-765d-44b6-bf97-8f77191ea21d"
      unitRef="usd">704000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMy0zLTEtMS0zMzkz_7b5b6dc1-6f95-417d-a47c-e8481554a89d"
      unitRef="usd">2548000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTI2OTk0ZjJlNzYxNDgxMWE1YjE2YTk5YTNlNzMxZTEvdGFibGVyYW5nZToxMjY5OTRmMmU3NjE0ODExYTViMTZhOTlhM2U3MzFlMV8xMy01LTEtMS0zNzMxNw_6dc18e90-a5f1-42e5-bbae-4b6304d06218"
      unitRef="usd">4153000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xLTItMS0xLTMzNDY_fa35abd7-72a9-4142-ac43-404c957e4b5c"
      unitRef="usd">12000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8yLTItMS0xLTMzNDY_7d93dda5-b5e7-4366-b9cf-e3f32f801c74"
      unitRef="usd">1048000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8zLTItMS0xLTMzNDY_3e3e9f78-a21f-40d1-97c5-df1a0e60b5e3"
      unitRef="usd">756000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF80LTItMS0xLTMzNDY_ab89e891-ad96-499b-b850-a1cce5024cf7"
      unitRef="usd">867000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF81LTItMS0xLTMzNDY_da9f616b-d0bc-4552-8957-652186f57466"
      unitRef="usd">2683000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF83LTItMS0xLTMzNDY_c2f8a387-965a-40b1-80f4-64d7afd2ad14"
      unitRef="usd">986000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF84LTItMS0xLTMzNDY_9b85b5f4-387f-49a0-bb64-e7bd5971f40c"
      unitRef="usd">1356000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF85LTItMS0xLTMzNDY_b496767e-24cf-47c7-ab2f-c29def86e31a"
      unitRef="usd">503000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xMC0yLTEtMS0zMzQ2_414eccb7-87a8-417d-86ce-0bc10cce59db"
      unitRef="usd">330000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xMS0yLTEtMS0zMzQ2_dee8a8d7-966b-4a65-bf25-14ba1fdc6861"
      unitRef="usd">3175000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xMy0yLTEtMS0zMzQ2_1de27d65-d1dd-4bb0-a569-6bced204ac7d"
      unitRef="usd">267000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xNC0yLTEtMS0zMzQ2_3b3a4cf8-acdb-422c-9bdc-a106c1b45282"
      unitRef="usd">841000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <mrk:DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xNS0yLTEtMS0zMzQ2_06ff2f42-4365-44e5-9686-b178e6dcd0be"
      unitRef="usd">-22000000</mrk:DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xNi0yLTEtMS0zMzQ2_8b27f816-ebfa-4857-a183-9c28a2e3b764"
      unitRef="usd">1086000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xOC0yLTEtMS0zMzQ2_abac63ae-66fc-4d60-9a2e-fcf48379be3b"
      unitRef="usd">10000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8xOS0yLTEtMS0zMzQ2_794ba03e-7e64-48d9-9813-042e0aeaff28"
      unitRef="usd">176000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGFibGU6MTkxNTNlODEzZDVmNGQ0ZDllMDJlZmViNDNjODQwNTAvdGFibGVyYW5nZToxOTE1M2U4MTNkNWY0ZDRkOWUwMmVmZWI0M2M4NDA1MF8yMC0yLTEtMS0zMzQ2_03268d7d-354b-477b-acc8-cbf983a40759"
      unitRef="usd">186000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NjM4_c09cd35e-abe8-4899-a97c-a80e523b208c"
      unitRef="usd">5100000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsDebt
      contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NjUy_9e36f837-7f7d-41e5-9803-9010784fd7a9"
      unitRef="usd">9400000000</mrk:DisposalGroupIncludingDiscontinuedOperationsDebt>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NjY2_d67bd2ad-9093-45d6-8988-b07600e18e35"
      unitRef="usd">1400000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4Njgw_4e369f5a-2e1b-4687-b0c8-4746810c7c03"
      unitRef="usd">981000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCash
      contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4Njk0_3cc2cd12-c8d1-41ff-8862-10297dda2065"
      unitRef="usd">929000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCash>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NzA4_0e22eee4-723a-44d1-83c0-14f80ec47c98"
      unitRef="usd">815000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NzIy_ece8563e-c392-4a5b-ac92-e2fe411c3ba0"
      unitRef="usd">519000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
      contextRef="i0f0a6dd04b8e4082a9f04724e68b1605_I20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4NzM2_282d11b8-3bc6-43b4-b06d-c0cb6c5478b2"
      unitRef="usd">328000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i11ebf3cfa71a410e931e1ac91fd56a8d_D20210602-20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4ODQz_683511c4-38c6-4150-a794-8d35000bef3e"
      unitRef="usd">449000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i5475fea5427a4a45a8d0f7c70cc2edc1_D20210602-20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4ODI3_940496b7-982b-4026-aeea-9e8912de17f1"
      unitRef="usd">421000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="iad3694ffb88a4c26905566a5aadc567e_D20210602-20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4ODIy_8d3d391c-abd2-44e1-9e96-dd1559601762"
      unitRef="usd">28000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="if35f0cdded8a441882d65448ee48c8ed_D20210602-20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMTAyL2ZyYWc6Zjc2MTBkYjY4NDU0NGJkMTlhY2RjMGM1OTA1Mjg4MTQvdGV4dHJlZ2lvbjpmNzYxMGRiNjg0NTQ0YmQxOWFjZGMwYzU5MDUyODgxNF8xMDk5NTExNjM4ODU5_732d9b5e-4539-44f3-9bcb-d218f8aac1f8"
      unitRef="usd">4600000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4NDgyOTA3NTYzMTc_7b84aa6c-0341-42d9-9268-1d57a363e1c5">Acquisitions, Research Collaborations and License Agreements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#x2019;s financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $11.5&#160;billion. Acceleron is evaluating the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron&#x2019;s lead therapeutic candidate, sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. Under a previous agreement assumed by Merck, Bristol Myers Squibb (BMS) was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay 22% royalties on future sales of sotatercept in the PH field to BMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to sotatercept, Acceleron&#x2019;s portfolio includes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated in Phase 2 and Phase 3 trials for additional indications for hematology therapies. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is being developed and commercialized through a global collaboration with BMS. In connection with this ongoing collaboration, Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Merck is eligible to receive future contingent milestone payments including up to $20&#160;million in regulatory milestones and up to $80&#160;million in sales-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction was accounted for as a business combination. The Company incurred $280&#160;million of costs directly related to the acquisition of Acceleron, consisting primarily of share-based compensation payments to settle non-vested equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; costs in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Acceleron is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 19, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - sotatercept &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products and product rights - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reblozyl &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12 year useful life)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Total consideration paid of $1.9 billion included $147&#160;million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $1.7 billion in 2021 related to the transaction. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck&#x2019;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead&#x2019;s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Merck and Gilead will share operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. Global development and commercialization costs will be shared 60% Gilead and 40% Merck across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation revenue tiers. Upon passing $2.0&#160;billion a year in net product sales for the oral combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold. Upon passing $3.5&#160;billion a year in net product sales for the injectable combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck&#x2019;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#x2019;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the U.S. Food and Drug Administration (FDA) placed full or partial clinical holds on investigational new drug applications for certain oral, implant and injectable formulations of islatravir based on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. As a result of these holds, Merck and Gilead made the decision to stop all dosing of participants in a Phase 2 clinical study evaluating islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. The two companies are assessing whether a different dosing of islatravir in combination with lenacapavir may provide a once-weekly oral therapy option for people living with HIV. Merck and Gilead remain committed to their collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva&#x2019;s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30&#160;million, which was included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15&#160;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5&#160;million in developmental milestones, $570&#160;million in regulatory milestones, and $1.05&#160;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423&#160;million. OncoImmune&#x2019;s lead therapeutic candidate (MK-7110) was being evaluated for the treatment of patients hospitalized with COVID-19. The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50&#160;million for a 20% ownership interest in the new entity, which was valued at $33&#160;million resulting in a $17&#160;million premium. Merck also recognized other net liabilities of $22&#160;million. The Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $462&#160;million in 2020 related to this transaction. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential Emergency Use Authorization (EUA) application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#x2019;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207&#160;million in 2021, which are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio&#x2019;s lead investigational candidate is zilovertamab vedotin (MK-2140), an antibody-drug conjugate targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180&#160;million (primarily cash) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $2.7 billion in 2020 related to the transaction. During 2021, the Company recorded adjustments to these amounts which resulted in a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $43&#160;million, an increase to total consideration paid of $47&#160;million, and an increase to net assets recorded of $90&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, Merck and Seagen Inc. (Seagen) announced an oncology collaboration to globally develop and commercialize Seagen&#x2019;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. Merck recorded $616&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2020 related to this transaction reflecting the upfront payment as well as a $16&#160;million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6&#160;billion, including $850&#160;million in development milestones and $1.75&#160;billion in sales-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million, which were recorded as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65&#160;million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck&#x2019;s territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#x20ac;256&#160;million ($302&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289&#160;million and other net assets of $13&#160;million. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410&#160;million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401&#160;million related to currently marketed products and inventory of $9&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. See Note 5 for additional information related to this collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make additional contingent payments of up to $740&#160;million. The transaction was accounted for as a business combination. The Company determined the fair value of the contingent consideration was $85&#160;million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;amp;D of $113&#160;million, cash of $59&#160;million, deferred tax assets of $72&#160;million and other net liabilities of $32&#160;million. The excess of the consideration transferred over the fair value of net assets acquired of $239&#160;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;amp;D impairment charge of $90&#160;million within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. The Company also recorded a reduction in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expenses resulting from a decrease in the related liability for contingent consideration of $45&#160;million since future contingent milestone payments have been reduced to $450&#160;million in the aggregate, including up to $60&#160;million for development milestones, up to $196&#160;million for regulatory approval milestones, and up to $194&#160;million for commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $6.5&#160;million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#x2019;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305&#160;million in 2020, of which $260&#160;million was reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and related to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The remaining $45&#160;million of costs were reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138&#160;million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95&#160;million of costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2020. ArQule&#x2019;s lead investigational candidate, nemtabrutinib (MK-1026), is a novel, oral Bruton&#x2019;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - nemtabrutinib &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangement for ARQ 087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, Merck recorded a $275 million intangible asset impairment charge related to nemtabrutinib (see Note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2&#x3b1; (HIF-2&#x3b1;) for the treatment of patients with cancer and other non-oncology diseases. Merck made an upfront payment of $1.2 billion. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $157 million, deferred tax liabilities of $52 million, and other net liabilities of $4 million at the acquisition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;date, as well as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $993 million in 2019 related to the transaction. Former Peloton shareholders received a $50 million milestone payment from Merck in 2021 upon first commercial sale of Peloton&#x2019;s lead candidate, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Welireg&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (belzutifan), which was approved as monotherapy in the U.S. in August 2021. Former Peloton shareholders are also eligible to receive $50 million upon U.S. regulatory approval as a combination therapy, as well as up to $1.05 billion of sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq&#x2019;s debt. The transaction was accounted for as a business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets (useful lives ranging from 18-24 years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in 2019.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt; approaches to enable the body&#x2019;s immune system to fight disease, for $301 million in cash. The transaction was accounted for as a business combination. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets of $42 million. The excess of the consideration transferred over the fair value of net assets acquired of $20 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed.</mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iab98fe0036ab490284530f0ef5a067b9_D20211101-20211130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk2NTU_1fae82f0-f066-49ab-88ff-3fdaa5af8dda"
      unitRef="usd">11500000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <mrk:RoyaltyRatePercentage
      contextRef="i6c67fcd89a8b4082808554b5f0549fc8_D20211101-20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1Nzc0MjU_0f4aa386-da2f-4450-862a-4f5039ddf76c"
      unitRef="number">0.22</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i5c62b473540e4792973e3e5eff8e852b_D20211101-20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2OTQ4MTU_908f8982-1911-4b8a-97ea-bd3d972ba605"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i700f5502bfe547d29c56588dcd1c2a57_D20211101-20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NzUxMTM_50e2148b-ec86-4f6e-8ec3-69211d595e7d"
      unitRef="number">0.24</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRateDeductionPercentage
      contextRef="i6c67fcd89a8b4082808554b5f0549fc8_D20211101-20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1Nzc2MDQ_0d791c6f-a2f4-4697-9c25-05738202c37a"
      unitRef="number">0.50</mrk:RoyaltyRateDeductionPercentage>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i078bab656180438fb5b9e6e2b822296a_D20211101-20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE2NDkyNjc1MjgyMTI_867ecd4c-1de0-4684-8230-823e4836c056"
      unitRef="usd">20000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i2ad6313c93cd46b38072ff32e2d4d398_D20211101-20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE2NDkyNjc1MjgyNTE_d449a8f4-9cb2-40d6-a0b0-2964b328fa40"
      unitRef="usd">80000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="if845b3b4c08c45efbf34f152a3076b6b_I20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2OTAwNzI_a7624876-6940-46b2-862b-4314cc869474"
      unitRef="usd">280000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4NDgyOTA3NDUxNjY_97fb74f6-b214-47e9-8ca7-4b2cbb374751">&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Acceleron is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 19, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - sotatercept &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products and product rights - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reblozyl &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12 year useful life)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - nemtabrutinib &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangement for ARQ 087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets (useful lives ranging from 18-24 years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i66e156b81e874c37998b4260b293e32d_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzEtMS0xLTEtMzU5MzA_35cd0f11-8545-4401-bcbd-b597ee484170"
      unitRef="usd">340000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="i66e156b81e874c37998b4260b293e32d_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzItMS0xLTEtMzU5NzU_9b180cd2-237d-4bd5-a9db-d42de0e57e46"
      unitRef="usd">285000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i66e156b81e874c37998b4260b293e32d_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzQtMS0xLTEtMzU5MzM_a0bceda1-151d-4a4d-9c22-5e72bdaffc54"
      unitRef="usd">6380000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="iab98fe0036ab490284530f0ef5a067b9_D20211101-20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzYtMC0xLTEtMzYzMTQvdGV4dHJlZ2lvbjo4NzQwM2Q2MmM5ZDE0MThmYmJlMTk0NzNhZTMxNzJhM18xMDk5NTExNjI3ODg4_7114d30d-e34f-4c90-b346-957768fe7242">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i66e156b81e874c37998b4260b293e32d_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzYtMS0xLTEtMzU5Mzg_b7dfccd1-5745-4035-a915-3e0acd9d700c"
      unitRef="usd">3830000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i66e156b81e874c37998b4260b293e32d_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzctMS0xLTEtMzU5NDA_0e380877-e9d5-4c6c-8d09-2c30c6956ba8"
      unitRef="usd">1832000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i66e156b81e874c37998b4260b293e32d_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzgtMS0xLTEtMzU5NDc_bf235d40-260c-4ea1-a8c3-cdb40ebd382e"
      unitRef="usd">89000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i66e156b81e874c37998b4260b293e32d_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzgtMi0xLTEtNDI3NTU_8f89e0e3-2d1c-4de1-b895-a552b6e3d19a"
      unitRef="usd">9092000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i66e156b81e874c37998b4260b293e32d_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzEwLTEtMS0xLTM1OTQ5_ef8a229c-13ec-4ac1-9850-2102ee1849e3"
      unitRef="usd">2422000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i66e156b81e874c37998b4260b293e32d_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTphMzc1YzcxNTEyZmY0NjJkYjJlMmY5Y2IzYTFjMTg2OS90YWJsZXJhbmdlOmEzNzVjNzE1MTJmZjQ2MmRiMmUyZjljYjNhMWMxODY5XzExLTEtMS0xLTM1OTUx_c7f157b2-9af7-4025-ac5e-d38bd8c5b608"
      unitRef="usd">11514000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="i691918582c3344e899b4df21192718a3_I20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE2NDkyNjc1MDQ2NDU_a44dd9a3-9efc-45b6-a838-9d3df2746e7d"
      unitRef="number">0.075</mrk:IntangibleAssetMeasurementInput>
    <mrk:IntangibleAssetProductsAndProductRightsMeasurementInput
      contextRef="i691918582c3344e899b4df21192718a3_I20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NzQ0MTI_64c859fe-4580-4aad-bc35-da5924978d9a"
      unitRef="number">0.060</mrk:IntangibleAssetProductsAndProductRightsMeasurementInput>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="ib5e47ab987cd4d3abdc343a64acdfcdc_D20210401-20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3MjU_446d0d6b-9300-46d0-9fa9-80fd3f81cdff"
      unitRef="usd">1900000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="ib5e47ab987cd4d3abdc343a64acdfcdc_D20210401-20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3MTE_93d44bea-5493-4099-a4a5-be68a9c8ed44"
      unitRef="usd">147000000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="i363a34970b28487fb538f79d80bd5c63_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3NDI_dd4e64f8-b5cc-4594-8c71-3aa8848978a3"
      unitRef="usd">156000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3dbe981b0dce44c7b9140f5b1e642a2d_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3NTk_20027b2f-3727-49c6-a4f8-b50ae837ae80"
      unitRef="usd">1700000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:ProfitShareCounterparty
      contextRef="i62ab2e68dea743c09e757b18af5181e8_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3NjM_ec29d711-f0b7-4b08-998c-4ba044d249e7"
      unitRef="number">0.60</mrk:ProfitShareCounterparty>
    <mrk:ProfitShare
      contextRef="i62ab2e68dea743c09e757b18af5181e8_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3Njg_cf2c8328-417e-44ed-a517-4ea601c0cfba"
      unitRef="number">0.40</mrk:ProfitShare>
    <mrk:SalesThreshold
      contextRef="i85efbd1b835b4a8e8e7140e9b606ea82_D20210301-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NTMyMjU_bcd1754f-db26-46fa-868f-304f40d0df63"
      unitRef="usd">2000000000</mrk:SalesThreshold>
    <mrk:ProfitShareCounterparty
      contextRef="i85efbd1b835b4a8e8e7140e9b606ea82_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3NzQ_f23836a0-5731-4f78-a31a-4752eee73735"
      unitRef="number">0.65</mrk:ProfitShareCounterparty>
    <mrk:ProfitShare
      contextRef="i85efbd1b835b4a8e8e7140e9b606ea82_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3Nzk_0708065e-c0b4-4292-980e-6b185bb8934c"
      unitRef="number">0.35</mrk:ProfitShare>
    <mrk:SalesThreshold
      contextRef="if1ab7dec508142c597fc9e631c500889_D20210301-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3ODQ_a2a59343-7d1b-45aa-be0c-91345ecc84ae"
      unitRef="usd">3500000000</mrk:SalesThreshold>
    <mrk:ProfitShareCounterparty
      contextRef="if1ab7dec508142c597fc9e631c500889_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk3OTg_1f5961e9-0a28-4a3f-bc4a-eb7b1efa1439"
      unitRef="number">0.65</mrk:ProfitShareCounterparty>
    <mrk:ProfitShare
      contextRef="if1ab7dec508142c597fc9e631c500889_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NTMyNDI_2891b8a3-2c18-43a9-acdf-f1002e220f18"
      unitRef="number">0.35</mrk:ProfitShare>
    <mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner
      contextRef="i0caff53de00b40f0b2a4242ec4f7b853_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4MDQ_4c272e74-7b19-4d06-96b2-e460ffeb7c6e"
      unitRef="usd">30000000</mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner>
    <mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner
      contextRef="i0caff53de00b40f0b2a4242ec4f7b853_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4MTc_9bd3c246-014d-4594-aa1b-a3a1590dda64"
      unitRef="usd">15000000</mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i6a13694e029b4e109b43b40ab0e2f486_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4MzA_a28b222d-2e2f-4e74-b426-855ab84462b0"
      unitRef="usd">217500000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ie4df9ebe39004e61b4723b8728950ca9_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4NDY_02a8ae10-ccbb-4226-b989-113b6206540e"
      unitRef="usd">570000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="iee08b09a26eb4dbf9c1fc7400dd403eb_D20210101-20210131"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4NjA_a468362e-fa00-46ef-a90e-eb760a154c2a"
      unitRef="usd">1050000000.00</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:RoyaltyRatePercentage
      contextRef="i8782918165654defab8aad5b032f7b4e_D20210101-20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2NzYwMTA_0639f13a-89a4-4c72-b50e-4d36dc54f160"
      unitRef="number">0.07</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i8782918165654defab8aad5b032f7b4e_D20210101-20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2NzYwMTA_28f7b126-a603-4d33-8a34-a9217a2d4348"
      unitRef="number">0.07</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i8b7f6216f9b24aefaf5499aeeae375cb_D20210101-20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDk4NzY_b073c687-b6f8-48e6-a883-4b795f9e8a0f"
      unitRef="number">0.14</mrk:RoyaltyRatePercentage>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i65036a0df1a24e1286b3b620969af227_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2ODAwOTY_fad8f390-96d5-4096-8d22-e9a12246aad8"
      unitRef="usd">423000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i65036a0df1a24e1286b3b620969af227_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE4MjU_dbd4f272-24ba-4051-a2d1-0d9a45eb8830"
      unitRef="usd">50000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifbd4e250c5234f40a49f0424a7b9ca39_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE4MzQ_5d9da416-40b5-4efa-bad9-bb05f9cffebb"
      unitRef="number">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:Investments
      contextRef="ifbd4e250c5234f40a49f0424a7b9ca39_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE4OTU_a8307574-8f94-4970-bb53-120cfffb6dfd"
      unitRef="usd">33000000</us-gaap:Investments>
    <mrk:PremiumOnSharesAcquired
      contextRef="i65036a0df1a24e1286b3b620969af227_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE5MTM_a9dee810-531f-4fc8-bfdd-6c1db567c8cd"
      unitRef="usd">17000000</mrk:PremiumOnSharesAcquired>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="ifbd4e250c5234f40a49f0424a7b9ca39_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2NzgwNTM_892a6c21-5988-426c-86a8-d263069a06b7"
      unitRef="usd">-22000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i1a2125d5f6f642d48b2728270ed20dcf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2NzgxNTQ_1cb4a073-83f1-470d-bd46-d83a980bceaf"
      unitRef="usd">462000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <mrk:ChargesRelatedToProgramDiscontinuation
      contextRef="i87d5e8e876a74d78b9b4adb360ed3859_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2Nzk5MDI_7d70c210-c386-469c-b276-375ec7b2d6c7"
      unitRef="usd">207000000</mrk:ChargesRelatedToProgramDiscontinuation>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="id4bb721c83cb4d6baf3edaee991beff8_D20201201-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzIyMDI_dcd4f0d1-b0a3-4013-adde-f83f427eab04"
      unitRef="usd">2800000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="i154453efc9bf49d9b6c2e7bdb4a3667d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzI1ODY_cc2b0751-269d-4571-af29-68168aa9c4a8"
      unitRef="usd">180000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i887204908c64421d9da59e4d3c3099b6_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzI2NDc_69116e4c-86f6-4323-a361-9bf7d3f022f5"
      unitRef="usd">2700000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1e331a60d4604a2b9a0563cb2271e112_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDkyNzQ_e6630ba5-cf5f-4b04-8524-2697f643836e"
      unitRef="usd">43000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="ic5c941f925d9424e9b42b6b4bb3d68b8_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQ5NDc4MDI0MTAyNjc_136bb662-a778-4c7f-b47d-5aa5c5b9ec01"
      unitRef="usd">47000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="if2bd91e11abc48aeac94ddad807d22c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQzOTgwNDY1NDkzOTA_43c7add9-816a-41bb-9a1a-6a9eda6e1920"
      unitRef="usd">90000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner
      contextRef="i090c4ce27a88432b994b5cd38555a37b_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM0Mzg_091c51fb-7496-438f-8936-2f355ba53ec7"
      unitRef="usd">600000000</mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i090c4ce27a88432b994b5cd38555a37b_D20200901-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM0NDc_c9f8dc0c-161a-4f96-b52d-661bbce6e8df"
      unitRef="usd">1000000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares
      contextRef="ie34faa097b834cfa9a5bcfcaf8c87262_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM0NzE_b61fd713-3d58-43a3-aafd-f1b65c03325c"
      unitRef="shares">5000000</us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares>
    <us-gaap:SharePrice
      contextRef="ie34faa097b834cfa9a5bcfcaf8c87262_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM1MTg_c55a70e7-a4c7-4c4b-aa6b-5f69c2b476bd"
      unitRef="usdPerShare">200</us-gaap:SharePrice>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6f789b2accd9484992688f3f01dfdf11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM1NDc_5d22b64c-3d71-4d7a-b1df-e8dd9137fa10"
      unitRef="usd">616000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:PremiumOnSharesAcquired
      contextRef="i48c7436c3f434009bc43ed8fb64f30db_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM2Njc_1b96dd8d-1e41-4aef-97e5-6565f9e7d95a"
      unitRef="usd">16000000</mrk:PremiumOnSharesAcquired>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i090c4ce27a88432b994b5cd38555a37b_D20200901-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4NTI_4485c0cf-7786-462c-96e3-963c85012f4a"
      unitRef="usd">2600000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i37947affd59e45db9bf4247d22ef2445_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4NjY_df0bf359-3ad1-4c1e-8d60-f50a425187d2"
      unitRef="usd">850000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i0a44796f0e99454095c4177490b7a1fc_D20200901-20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzM4OTk_0764fecf-849c-4123-853f-905f50f15682"
      unitRef="usd">1750000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner
      contextRef="id735e23c835a42d7a629be7b46a33b70_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzQ4ODU_bbc513d0-5bbd-473b-adb0-835b150f27b3"
      unitRef="usd">210000000</mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ia094e3f9230741fb85ffb13181d20935_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUwNDg_e6c52387-dd26-4813-9600-7d70d47887fd"
      unitRef="usd">65000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:RoyaltyRatePercentage
      contextRef="i22dbddf74d0346e2bcda039fb5251dc8_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUwOTg_0ea61b9b-c3c8-4bbb-aa14-41f578d54baf"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="ibd702d7339fc4907beb6de920d2ebfcb_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUxMDQ_c467a0d4-9eaa-4187-888c-6fa593d38cfc"
      unitRef="number">0.33</mrk:RoyaltyRatePercentage>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i94eccca165db4204b5fe7cd15369ff52_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUzMjg_5989a3ac-fa47-4d8f-9530-b9d9fce14354"
      unitRef="eur">256000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i94eccca165db4204b5fe7cd15369ff52_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzUzMzI_0c4f31af-601e-4024-8fde-46f83c3cc7b9"
      unitRef="usd">302000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i0772900bf1714a1286b8a8be67ef1352_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU0NTA_b9ae82da-180a-41a9-9f71-177d9fe6a98b"
      unitRef="usd">289000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="i0772900bf1714a1286b8a8be67ef1352_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU0Nzc_6b1f62a7-7fa2-42b9-bc73-ada2841e0a88"
      unitRef="usd">13000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i46379c7182e540b2828bf31f0181f842_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU2Nzk_f5e031e0-e94e-43d1-b35b-656f71e323f0"
      unitRef="usd">410000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="id62a4bb25fc844f59220aa4a94682bd9_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU4NTc_263aa086-1421-475d-8925-2b60a2e5ae92"
      unitRef="usd">401000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:InventoryNet
      contextRef="iffce628751d64772b2c55aabb65ac5b4_I20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzU5MTY_3e25215e-e6e6-4615-a5d4-5c52012a5dcd"
      unitRef="usd">9000000</us-gaap:InventoryNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="iaf228ffc1f9146219d66ae63268e5646_D20200701-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzYyNzA_411018cd-dd6e-4689-8b9f-bda637866195">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i253e7eb6731846cd8297aa6fff74e2a7_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc0NzU_908a6276-42f5-400b-9bf3-76db568873b3"
      unitRef="usd">366000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc1NzM_4a95b9b6-a8e7-477b-b74a-10562912e4b1"
      unitRef="usd">740000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc3MTg_f4c595fe-b00d-4d38-b180-7187bc0a30de"
      unitRef="usd">85000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc5NTA_e1011dfa-a3e6-484d-8f21-7b0abc22b14e"
      unitRef="usd">113000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc5NjI_6aa34bbe-177b-43ca-a65c-56a7efb33740"
      unitRef="usd">59000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzc5ODk_da9c97f5-8a8f-4d08-9cb7-0f44d5719249"
      unitRef="usd">72000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzgwMjE_c06a3268-a35b-400e-8a06-d4f659004ae2"
      unitRef="usd">-32000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:Goodwill
      contextRef="i7c2134703ab44a17a75303f1e2bbc346_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzgxMTU_86e6fdad-f391-4631-a3b5-e5def0a1b441"
      unitRef="usd">239000000</us-gaap:Goodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="idd20b1fb1b1840cd97ca9a25e317e07f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg1ODM_2dc5f94d-d3c5-465d-a67f-688fc8132e82"
      unitRef="usd">90000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="idd20b1fb1b1840cd97ca9a25e317e07f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg3ODY_4f5b1a24-a327-435a-876f-d5e245572449"
      unitRef="usd">-45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ia72336269c0e4853bb62f08578a8703e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg4NTM_3d4ad195-6db9-4a92-bf75-af284fae84f4"
      unitRef="usd">450000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i41279252c9624ed8a4c7a81861188d80_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg4OTA_d516c855-4e89-437a-a7e5-c78d37fdfb2f"
      unitRef="usd">60000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="if5bd531bb0694347bbaa1de33894a3f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg5Mjc_fe53d1e3-86e6-41fa-b79e-f2938087fc5e"
      unitRef="usd">196000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i7d06568f20aa4404ac1d16b234d39d17_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3Xzg5NzY_5a847f4e-c854-4f04-bf09-bbce304f3028"
      unitRef="usd">194000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner
      contextRef="i8d3b73f821cd4774aad66eb73f3a5f66_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzkzODc_a75c2114-f632-4b96-a722-8c20a4a02b9b"
      unitRef="usd">6500000</mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner>
    <mrk:ChargesRelatedToProgramDiscontinuation
      contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwMzY4_427180ee-839a-44e5-9c21-c696f3d605ba"
      unitRef="usd">305000000</mrk:ChargesRelatedToProgramDiscontinuation>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwMzg5_e19f75d1-d64d-463e-be7a-934925918d38"
      unitRef="usd">260000000</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwNTU4_ececa6d0-ea66-490b-8703-2630f2a1b3fd"
      unitRef="usd">45000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ia80b8fd970c84658b490d1b62ee60672_D20200101-20200131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzExMDUw_cb85e4d6-47cc-4188-acbf-723346fdeadb"
      unitRef="usd">2700000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed
      contextRef="i00f0fb0e68c34bcc9ac14ca5a1d30e3e_I20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzExMDYy_0fb6e3ed-e07e-42eb-870c-98fb83695e79"
      unitRef="usd">138000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="i00f0fb0e68c34bcc9ac14ca5a1d30e3e_I20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzExMjQz_4dd8f6c3-85b6-497b-9b7e-aa6d524b6a96"
      unitRef="usd">95000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzEtMS0xLTEtMA_9faa2c26-5462-4a12-8d4b-612df1e62e31"
      unitRef="usd">145000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzItMS0xLTEtMA_8acf2faf-45dc-4f5c-95a2-6131d2aca421"
      unitRef="usd">2280000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzMtMS0xLTEtMA_a971c178-2d25-4f07-850c-e22f0a251d6a"
      unitRef="usd">80000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzQtMS0xLTEtMA_ff20b942-3c2b-437a-81eb-0ffcd4225e3c"
      unitRef="usd">361000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzUtMS0xLTEtMA_5c706159-f41f-4d45-affa-1a605c7505bc"
      unitRef="usd">34000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzYtMS0xLTEtMA_f5e68e10-4545-4d40-973d-fbc1b2cf406d"
      unitRef="usd">2178000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzctMS0xLTEtMA_8f2b40f4-a5d7-4fd3-be94-354a687a963a"
      unitRef="usd">512000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i863cd316ea5d4a879ae66467e3f51ad8_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTpjNWVhZjI5YWQ3Mzk0YzdkOWM0YTAzNWYwMDRhZGQ3NC90YWJsZXJhbmdlOmM1ZWFmMjlhZDczOTRjN2Q5YzRhMDM1ZjAwNGFkZDc0XzgtMS0xLTEtMA_92a680ae-296f-4a5e-bd18-14e88feceab5"
      unitRef="usd">2690000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="i02d468ad359d4b3c907fa0ca583c3707_I20200116"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEyMTE4_67a9db57-79e0-4445-a01a-f558581f9643"
      unitRef="number">0.125</mrk:IntangibleAssetMeasurementInput>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i02366c725d8e4b61a487fbc509afa833_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE3MTQwMzA_e967f4a0-730e-4589-8f80-5b7fe4e9fdfd"
      unitRef="usd">275000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="if3aa932f580f42fba20f4fb291aa005d_D20190701-20190731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEyODA5_ba9cbd6f-7953-446c-89bb-cf0b78bdc61e"
      unitRef="usd">1200000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <mrk:AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents
      contextRef="i2c7c2e213af64bed83c7c5be126fe2b5_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzMDk3_49ecb352-881d-4382-b2a1-e1230c65b2c7"
      unitRef="usd">157000000</mrk:AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents>
    <mrk:AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities
      contextRef="i2c7c2e213af64bed83c7c5be126fe2b5_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzMTI5_211a3b4a-ac63-4ac6-9ebc-8d84ec2a5890"
      unitRef="usd">52000000</mrk:AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="i2c7c2e213af64bed83c7c5be126fe2b5_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzMTYy_fbfb33a0-a445-40d1-99fd-ff327b226780"
      unitRef="usd">4000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0b43da370e844376a5ef3e3c317c068c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzMjM4_d7e2dcb5-7625-41a5-9d8d-f93f96fa8708"
      unitRef="usd">993000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i4d46d7a5f1d84985a8798afe9a116fcd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2ODMzMDA_2eddb61e-75e6-4fdf-8f2c-f748de88f8ee"
      unitRef="usd">50000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i094e0d6dfc6e43d8a71ef15cc8afa929_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2ODM1Mzg_bd6ceed9-3c8e-4626-b4f6-bf5a229162c1"
      unitRef="usd">50000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i73b1a5803b6e4bb1b34750d30eaca4d0_D20190701-20190731"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEwOTk1MTE2ODM2MTU_886aa262-9c2d-4aa4-add7-b6428dd7ba26"
      unitRef="usd">1050000000.00</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i2b06079ce243471f80c224e28eca9bc0_D20190401-20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzNTg0_26a8348a-b23c-4034-b2ff-104039d6dbcb"
      unitRef="usd">2300000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzEzNjQz_83e81ee9-06aa-4bad-bf51-ee80657e1212"
      unitRef="usd">1300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzEtMS0xLTEtMA_79ae8c64-2700-4473-82c4-a0872de71355"
      unitRef="usd">31000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzItMS0xLTEtMA_4d7834ae-8884-4445-84bc-e216b212ebaa"
      unitRef="usd">73000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzMtMS0xLTEtMA_0a9fe23b-eb0a-4f5f-a153-048e2f62645e"
      unitRef="usd">93000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzQtMS0xLTEtMA_f01f87c3-3162-4567-b353-81523d5f77b1"
      unitRef="usd">60000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6bb86c75b69646909c1e731b110cd594_D20190401-20190401"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1YWQwZjUyZDZiMzQ4N2I5YjY1NGRjNDRhN2VjMWRlXzYy_3db0565a-709e-468a-903a-bf9a9163f4a5">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i353be6859e8a4c909dc868bb55fa96ef_D20190401-20190401"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1YWQwZjUyZDZiMzQ4N2I5YjY1NGRjNDRhN2VjMWRlXzY1_737a0945-f46e-4f9e-ab20-0e007908920f">P24Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzUtMS0xLTEtMA_ea04608e-a05f-472f-8c2c-ff384596f446"
      unitRef="usd">2689000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzYtMS0xLTEtMA_de178ab4-b428-4970-a6c8-960691a1ed39"
      unitRef="usd">589000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzctMS0xLTEtMA_ae171dc3-7081-4007-96a5-07f8c8692f95"
      unitRef="usd">-82000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzgtMS0xLTEtMA_a9034f1a-ffdc-4c04-a4c3-63a3e606517b"
      unitRef="usd">2275000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzktMS0xLTEtMA_cffbb12b-f07e-4390-8f31-8a776260ae2b"
      unitRef="usd">1376000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90YWJsZTowMzNiZjk1NjFhYmY0OTk0YWI1OWU4ZGJkM2Y0YzIwNS90YWJsZXJhbmdlOjAzM2JmOTU2MWFiZjQ5OTRhYjU5ZThkYmQzZjRjMjA1XzEwLTEtMS0xLTA_ab3765b6-5c9d-4003-8c95-a413d8a87a11"
      unitRef="usd">3651000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="ib1fd1624d0a447a0a77222b18fdb866f_I20190401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE0MDY5_a9e03221-129b-4190-8971-a409dba1631e"
      unitRef="number">0.115</mrk:IntangibleAssetMeasurementInput>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="i178e3b5f7ea940f3ac5c975609fe189a_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE0NTIw_eef5e1c5-534a-4654-a3c3-de8cc746c596"
      unitRef="usd">47000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i38900b44f49245e2a2fe07fe9834a8cc_D20190401-20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE0ODk0_c2bec6c1-2450-4d03-9b95-4eeab8c3c302"
      unitRef="usd">301000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ib3255f0f1f154600bc059456bba5499d_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE1MDEx_9edf74fa-844d-4691-8f7d-0727a43c2b62"
      unitRef="usd">156000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ib3255f0f1f154600bc059456bba5499d_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE1MDIz_a8902768-b7ed-4b2c-987a-041cc6069e88"
      unitRef="usd">83000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="ib3255f0f1f154600bc059456bba5499d_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE1MDUw_c79ccad5-b2c3-4fb2-87b1-4abee0b4d752"
      unitRef="usd">42000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:Goodwill
      contextRef="ib3255f0f1f154600bc059456bba5499d_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTEvZnJhZzo3YTI0ZjA2ODNiNjM0YTkyOTNhYTkxZThhNDE1ZjMyNy90ZXh0cmVnaW9uOjdhMjRmMDY4M2I2MzRhOTI5M2FhOTFlOGE0MTVmMzI3XzE1MTQ0_57b02eca-626e-4e60-850c-e4259c62bef1"
      unitRef="usd">20000000</us-gaap:Goodwill>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwNjI3_2ab11239-647b-4105-8063-ffea2291893e">Collaborative Arrangements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#x2019;s more significant collaborative arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#x2019;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Imfinzi. The companies are also jointly developing and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercializing AstraZeneca&#x2019;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. Merck made sales-based milestone payments to AstraZeneca aggregating $550 million and $200 million in 2020 and 2019, respectively. As of December&#160;31, 2021, sales-based milestone payments accrued but not yet paid totaled $400&#160;million. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020 and 2019, Lynparza received regulatory approvals triggering capitalized milestone payments of $160&#160;million and $60 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at December&#160;31, 2021 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trade &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;ccounts payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Eisai&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expenses. Certain expenses incurred solely by Merck or Eisai are not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Lenvima.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. Merck made sales-based milestone payments to Eisai aggregating $200&#160;million, $500 million and $50 million&#160;in 2021, 2020 and 2019, respectively. As of December&#160;31, 2021, sales-based milestone payments accrued but not yet paid totaled $600&#160;million. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $75&#160;million and $10&#160;million, respectively, from Merck to Eisai. As of December&#160;31, 2021, a regulatory approval milestone payment of $25&#160;million was accrued but not yet paid. Potential future regulatory milestone payments of $25 million remain under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.0 billion at December&#160;31, 2021 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone and future option payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bayer AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#x2019;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#x2019;s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#x2019;s share of profits from sales of Adempas and Verquvo in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#x2019;s share of profits from sales in Merck&#x2019;s marketing territories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made a sales-based milestone payment to Bayer of $375&#160;million in 2020. In 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payment that was outstanding under this agreement. Accordingly, Merck recorded a liability of $400&#160;million and a corresponding increase to the intangible assets related to this collaboration. Merck also recognized $153&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in 2021. In January 2022, Merck made this final milestone payment to Bayer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $806 million and $68 million, respectively, at December&#160;31, 2021 and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Verquvo recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;424&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; Accrued and other current Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense as noted above. In addition, cost of sales in all periods now includes Bayer&#x2019;s share of profits from sales in Merck&#x2019;s marketing territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ridgeback Biotherapeutics LP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, Merck and Ridgeback, a closely held biotechnology company, entered into a collaboration agreement to develop molnupiravir (MK-4482), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit share calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#x2019;s share of profits) are reflected as decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the FDA granted EUA for molnupiravir. Under a previously announced procurement agreement with the U.S. government, Merck agreed to supply 3.1&#160;million courses of molnupiravir to the U.S. government upon EUA or approval from the FDA, of which approximately 888,000 courses were delivered in 2021. This procurement of molnupiravir is being supported in whole or in part with federal funds. Additionally, in December 2021, Japan&#x2019;s Ministry of Health, Labor and Welfare granted Special Approval for Emergency in Japan for molnupiravir. Under a supply agreement, the Japanese government will purchase 1.6&#160;million courses of molnupiravir, of which approximately 200,000 courses were delivered in 2021. Also, in November 2021, the Medicines and Healthcare products Regulatory Agency in the United Kingdom (UK) granted conditional marketing authorization for molnupiravir. The UK government has committed to purchase a total of 2.23&#160;million courses of molnupiravir, of which approximately 152,000 courses were delivered in 2021. Merck has entered into advance purchase and supply agreements for molnupiravir in more than 30 markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck and Ridgeback are committed to providing timely access to molnupiravir globally through a comprehensive supply and access approach, which includes investing at risk to produce millions of courses of therapy; tiered pricing based on the ability of governments to finance health care; entering into supply agreements with governments as noted above; allocating up to 3&#160;million courses of therapy to the United Nations Children&#x2019;s Fund (UNICEF) for use in adults; and granting voluntary licenses to generic manufacturers and to the Medicines Patent Pool (MPP) to make generic molnupiravir available in more than 100 low- and middle-income countries following local regulatory authorizations or approvals. Merck, Ridgeback and Emory University will not receive royalties for sales of molnupiravir under the MPP agreement (molnupiravir was invented at Emory University and licensed to Ridgeback) for as long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molnupiravir sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Payables to Ridgeback included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes royalty expense and amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Amount in 2020 includes upfront payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued royalty and milestone payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i14319073e5c3479eb00e19929756ed79_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM1ODg_cafb3c19-21e7-4b39-be86-a755c52be526"
      unitRef="usd">550000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i5702456494b740da8508f5b853110e3d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM1OTU_691a7d17-61da-4cbe-9fc8-677266e4a321"
      unitRef="usd">200000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsAccruedSalesBased
      contextRef="ida96075caa59419780179c2f9b3c3546_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwOTk1MTE2NTUxMDI_0d5ab1fb-eb52-4138-9f74-ddb89211e833"
      unitRef="usd">400000000</mrk:MilestonePaymentsAccruedSalesBased>
    <mrk:PotentialFutureMilestonePaymentsSalesBased
      contextRef="ida96075caa59419780179c2f9b3c3546_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM3MTE_cf5c2c25-5770-4f40-8adf-2064d81127d1"
      unitRef="usd">2700000000</mrk:PotentialFutureMilestonePaymentsSalesBased>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="ifa55a231791b4a4c9b8b8459d1b149dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM5MTU_ebddb720-5357-4dec-b0a8-62767eb2cd83"
      unitRef="usd">160000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i98306b224b47475488e911e85f203624_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM5MTk_a132c184-4230-469f-92ca-d3f17e664f35"
      unitRef="usd">60000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:PotentialFutureMilestonePaymentsRegulatory
      contextRef="ida96075caa59419780179c2f9b3c3546_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQwMzg_389223d5-fb52-4ece-a420-382e368c55ef"
      unitRef="usd">1400000000</mrk:PotentialFutureMilestonePaymentsRegulatory>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4a357f883cf8403d91477b70cff00a8b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQxOTc_92ef5404-3f58-432d-98e6-27b253527225"
      unitRef="usd">1100000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwNjIx_7b430b7a-d6e9-405c-bb3b-ee111287d345">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trade &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;ccounts payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone and future option payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Verquvo recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;424&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; Accrued and other current Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense as noted above. In addition, cost of sales in all periods now includes Bayer&#x2019;s share of profits from sales in Merck&#x2019;s marketing territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molnupiravir sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Payables to Ridgeback included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes royalty expense and amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Amount in 2020 includes upfront payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Includes accrued royalty and milestone payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i642c3ff7f9414f5392688e1239f63e01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEtMS0xLTEtMA_b51580d6-04f4-467d-ac12-23752259f15c"
      unitRef="usd">989000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ica0a3fd966314c5dac24c390abc72914_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEtMy0xLTEtMA_1e15561b-27e2-4f05-966e-f253f46f6d51"
      unitRef="usd">725000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ia8bd0a10b28b427cb9d90dfe3a600d6c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEtNS0xLTEtMA_2e9c0b39-eff3-4cf6-a864-f844576aeaaf"
      unitRef="usd">444000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ic810a621774c4c99983badd39ea9eba9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzItMS0xLTEtMA_5da69606-67f5-4480-abfe-0442a57d69d8"
      unitRef="usd">29000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i03aabfbe2af64606bfcdc9b7244adddb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzItMy0xLTEtMA_3faf38a2-5613-4bf6-902b-57401d8e8051"
      unitRef="usd">8000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i46c263ae58e241119936ff1e15d0ea2a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzItNS0xLTEtMA_14f6f093-2756-4f92-a280-3b481bdfbd76"
      unitRef="usd">0</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="id016daaee2884b7f93108c6df370f620_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzMtMS0xLTEtMA_5231b1ae-2b26-422c-814e-968d47afdb9a"
      unitRef="usd">1018000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i76cfcf2bfbe4407ca26ac87fbf3ba4d9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzMtMy0xLTEtMA_239752a8-b2a7-4e8d-9867-b4b7961b49cb"
      unitRef="usd">733000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i42d4f6c2d4ef45beaae183fe55dbf354_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzMtNS0xLTEtMA_97175544-cd56-4e9a-965c-640e1b51ecc3"
      unitRef="usd">444000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ica857d506be742ee8d273ccfcb812e2a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzUtMS0xLTEtMA_0cfe65cd-3177-4fe1-a7c2-59c8d253bf97"
      unitRef="usd">167000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i93d60c48bbfb4999a5474c6c5295cf07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzUtMy0xLTEtMA_a10bcb46-dc41-4649-8ad1-c68abbdc861c"
      unitRef="usd">247000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6bc366f05419417e83c83213cac8477c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzUtNS0xLTEtMA_9dfd1ed7-d188-4071-8de4-8d16a73d1f16"
      unitRef="usd">148000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib054f661c3f042f99541982143ad5e6f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzYtMS0xLTEtMA_afcf76d8-26b9-47db-8096-6e331c960f99"
      unitRef="usd">178000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia8e6351182024603b7f62da8e5b885f4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzYtMy0xLTEtMA_fbf8c18e-36aa-4106-b982-0ad0e47a015d"
      unitRef="usd">160000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iafe4a4c0ebe0439a803c537ea10a6d6a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzYtNS0xLTEtMA_2a555955-c77c-4ed7-b0d2-a3768362338f"
      unitRef="usd">138000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9b90e12bc9ba43f7abb9022574ae4b38_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzctMS0xLTEtMA_a51ff3bc-92bb-49f5-8129-5cd5bfb5496d"
      unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7365ef92cc904089a49a56598ef8d5e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzctMy0xLTEtMA_e1a28f95-3d26-497d-b7f4-9e467a7181a1"
      unitRef="usd">133000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i109c40ef87d24d13bd2b5cc4cf386752_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzctNS0xLTEtMA_528a08de-e755-4bf5-b3dc-f151a5d9253f"
      unitRef="usd">168000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i6154dfd2961f4f43916c01e33c8d1386_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEwLTEtMS0xLTA_601689e0-0f9c-4503-9b01-d9afafe46d92"
      unitRef="usd">271000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i56b97e6d098246129353599999e69659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzEwLTMtMS0xLTA_2c8aebe6-ec14-40d7-9bf9-a73dca8c25c9"
      unitRef="usd">215000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if375a5c48628477c973fbc4fd1d1b133_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzExLTEtMS0xLTA_b146a083-cd31-4320-8d89-6570eb25f81b"
      unitRef="usd">415000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie381877a89e94c45bc4b63e6dc00f506_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTplNTZlYWRjNjIwNTQ0Y2VhYjZkYjRlNmY5NmZjNGFlNy90YWJsZXJhbmdlOmU1NmVhZGM2MjA1NDRjZWFiNmRiNGU2Zjk2ZmM0YWU3XzExLTMtMS0xLTA_003318d0-d27c-4848-938d-b419eec28943"
      unitRef="usd">423000000</us-gaap:LiabilitiesCurrent>
    <mrk:LicenseOptionPaymentRelatedToCollaborativeArrangement
      contextRef="ie3c672ce6ee24fd083c1fcaea23ee2bd_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzYxNTI_9def2650-7822-45de-9028-c5cde7bb103c"
      unitRef="usd">125000000</mrk:LicenseOptionPaymentRelatedToCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i3303c07747a54842b62042d5a21e6f09_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwOTk1MTE2NTcxOTE_84872507-238a-442d-922b-9001672b9473"
      unitRef="usd">200000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i56a431121ab94fd3aeaeff71b65fbed1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzY4OTc_95ac13e2-2974-438d-aa42-d0c8f16a8fce"
      unitRef="usd">500000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="if502cf4525474a359d96f230ac724e3f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzY5MDQ_f122a8f0-1cf2-4a81-a04d-6a905ef4eb04"
      unitRef="usd">50000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsAccruedSalesBased
      contextRef="i7239a77febd64e6582c7bd34411f3af6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwOTk1MTE2NTcyMzk_4864eddd-325f-4509-926f-9511df5dda18"
      unitRef="usd">600000000</mrk:MilestonePaymentsAccruedSalesBased>
    <mrk:PotentialFutureMilestonePaymentsSalesBased
      contextRef="i7239a77febd64e6582c7bd34411f3af6_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzcwMDg_e6c63a04-bf40-43ad-854f-9d0ff0e5e5f6"
      unitRef="usd">2600000000</mrk:PotentialFutureMilestonePaymentsSalesBased>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i328e047b1fe9465cba44b2312c36a1f0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwOTk1MTE2NTczMzc_1aa7798d-5391-4a29-95b9-6c47ec10a802"
      unitRef="usd">75000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="ie554c78a55284e71b4e43682b58e067e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzcyMDU_7f7a757e-f938-44a4-a420-fae05a79eb79"
      unitRef="usd">10000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsAccruedRegulatory
      contextRef="i7239a77febd64e6582c7bd34411f3af6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQzOTgwNDY1NTczNzI_0e4c5e86-1f57-4998-a7b1-7488df7183dc"
      unitRef="usd">25000000</mrk:MilestonePaymentsAccruedRegulatory>
    <mrk:PotentialFutureMilestonePaymentsRegulatory
      contextRef="i7239a77febd64e6582c7bd34411f3af6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzczMDE_7ec18d96-f094-467b-a28b-d48166487ae4"
      unitRef="usd">25000000</mrk:PotentialFutureMilestonePaymentsRegulatory>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia8e076f12b4342f1b585a7f637e3c832_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzc0NTk_ef74dc73-b249-4f88-b2d1-a4679dbc982d"
      unitRef="usd">1000000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i0bd44ea5d24342129e8b6ebb5a4efdb2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEtMS0xLTEtMA_46496585-3fc2-4f46-b0e0-660e8839ac7c"
      unitRef="usd">704000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ia98a6294caf44811bdfc230489f05f54_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEtMy0xLTEtMA_a5433ae7-fc1b-4e27-a029-959032a078c8"
      unitRef="usd">580000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i1775b6c3bb3245dfa916e2e3ecfac7c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEtNS0xLTEtMA_7baa1032-d5e0-49b4-be85-e1679e04efda"
      unitRef="usd">404000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4981e17b20a547c8bc03157a8ea2bd94_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzMtMS0xLTEtMA_0fdf18d8-91d8-4376-8828-c36d2e7a48ae"
      unitRef="usd">195000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if383a9214fb545e98c021a08266ee37c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzMtMy0xLTEtMA_99cc20e5-18ee-4ed9-9f18-673c7f87c3a9"
      unitRef="usd">271000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i78dcd3d033904438964f0f1e38a578c6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzMtNS0xLTEtMA_2b162a1d-3a42-484a-9b52-e5810f101dd0"
      unitRef="usd">206000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibdb3a0fe626d42bd8f53d27a0a6cc6c3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzQtMS0xLTEtMA_123dc721-8cbd-4821-b790-83f798065bdb"
      unitRef="usd">127000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i19ffe322d7c84b43864b069f78e9b3e7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzQtMy0xLTEtMA_66e62494-f2f7-4f98-a3f3-4de2a4b50f0c"
      unitRef="usd">73000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8d6795e1450e497ea457f40aeb36be13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzQtNS0xLTEtMA_17ef0ade-3678-4e84-aca5-65bc1a80f4dd"
      unitRef="usd">80000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0db97feaad864168aa38dfed369a69a9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzUtMS0xLTEtMA_d65de57c-af7e-448f-9721-5c4de03fa83c"
      unitRef="usd">173000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8b9860090665459d8fec0ff943a45f30_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzUtMy0xLTEtMA_2a3b13d6-1b54-44b5-83e6-de3cd081b1e7"
      unitRef="usd">185000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i31bedff9aa684372b0af5c1ba6c41467_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzUtNS0xLTEtMA_1b2de13c-c5dd-40a9-9174-6524cbf2a3fd"
      unitRef="usd">189000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if064fdd725ea4a7c982907c44a941df6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzgtMS0xLTEtMA_b8495c7a-7496-4144-9610-5d141f74feb3"
      unitRef="usd">200000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i19adf582d06f45aca49da637284ec35a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzgtMy0xLTEtMA_2c0361e4-a5d0-4180-92a7-5fc9ed09a9c5"
      unitRef="usd">157000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2cbdb424aa5944669afe3610141ee5d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzktMS0xLTEtMA_d6576095-e1cb-4395-9bbc-f2df5fe3e5d0"
      unitRef="usd">625000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i56eee0d6468b4e67837ceae0dbff2f9c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzktMy0xLTEtMA_bfd5ce2a-b77c-493a-ad11-fb7aab5c8494"
      unitRef="usd">335000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie04e36743dcd41d3b045117f4f3b8170_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEwLTEtMS0xLTA_7991742b-034a-4c79-b4ec-f68549d026ea"
      unitRef="usd">0</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ia4e1a080606b4e4592e4f4733ceb6c81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpjZThjODg5YTM3YzI0NzJhYjZmYzI0NzM5NjQyYWMzNi90YWJsZXJhbmdlOmNlOGM4ODlhMzdjMjQ3MmFiNmZjMjQ3Mzk2NDJhYzM2XzEwLTMtMS0xLTA_3827b100-ade1-4dd2-8964-d1d0bad98bb5"
      unitRef="usd">600000000</us-gaap:LiabilitiesNoncurrent>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="if90b8c08c37a41ffa4f6848991b4a7da_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzk2NTI_531d32db-16e4-4f9d-9404-eae438b8571d"
      unitRef="usd">375000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsAccruedSalesBased
      contextRef="i1570e7027e0e496ab090442e8a8be4af_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzk4Nzc_d6a3673a-4dc3-4d6b-a4a8-dbaae33eda5e"
      unitRef="usd">400000000</mrk:MilestonePaymentsAccruedSalesBased>
    <us-gaap:Liabilities
      contextRef="i1570e7027e0e496ab090442e8a8be4af_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzk5NTc_69d889ce-4a82-4b64-bb6e-2529eea6e89f"
      unitRef="usd">400000000</us-gaap:Liabilities>
    <us-gaap:AdjustmentForAmortization
      contextRef="i17edb9f092f7485f9426b08af9218bf2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQzOTgwNDY1MjUzMjI_987d928e-c904-4e32-8838-0af513ea538d"
      unitRef="usd">153000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i00f8c65ee807407dab9ca51108c58857_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzEwMjQz_1a16843a-0cc1-451b-ab25-981e28ce233a"
      unitRef="usd">806000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id18a472cdb414425a36e2fc4fc858400_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQzOTgwNDY1NTg3OTc_c812a141-b965-44ae-a9b4-4451e758a5ab"
      unitRef="usd">68000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ic0a967edb06f4521aaaaa2ecf0a9b105_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEtMS0xLTEtMA_126282e8-bf1f-42f0-b52c-a6e4deb1342b"
      unitRef="usd">342000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ia746274f620f40c1851d95a52bb1fec0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEtMy0xLTEtMA_40faa826-424b-4301-ad59-2ba8f7c68539"
      unitRef="usd">281000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ie7e96dc6c32d41be85aaddf645d42386_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEtNS0xLTEtMA_31d95906-c04e-472a-8e43-a2aa81983f1c"
      unitRef="usd">204000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ic78cbe3c61444fe491dc47f1246975d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzItMS0xLTEtMA_5a9e931e-e2d3-4abf-85ef-74474201b530"
      unitRef="usd">252000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i96d7ebb400b14b728855eecc7c992f50_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzItMy0xLTEtMA_99a01f3b-6404-4b56-a860-4cfd9ddb203e"
      unitRef="usd">220000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i07c74b59b3824b859e175ea5af3e1de3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzItNS0xLTEtMA_8a85bce1-e637-4de8-bd5d-fb6b973cb859"
      unitRef="usd">215000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i3a2d934adf3844c9948a3c90a53001de_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtMS0xLTEtMzUyMw_db2690e8-d410-4211-95c5-ff0ee7e7ceb0"
      unitRef="usd">7000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ia59c375a867e43f387fc23f684540a1c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtMy0xLTEtMzUyMw_115bfe4f-808f-4a98-93de-9ead65ad84dc"
      unitRef="usd">0</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ic524b8d83ef44a209ae2f8d59984ad9f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtNS0xLTEtMzUyMw_82a57025-f354-441a-8a31-91f9be390452"
      unitRef="usd">0</mrk:CollaborativeArrangementSalesNet>
    <us-gaap:Revenues
      contextRef="ic0a967edb06f4521aaaaa2ecf0a9b105_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtMS0xLTEtMA_d07ee806-4dc3-4799-bd84-af5b01737b84"
      unitRef="usd">601000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia746274f620f40c1851d95a52bb1fec0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtMy0xLTEtMA_bc03429b-5f4e-40ff-a633-dfa9aeb32c77"
      unitRef="usd">501000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7e96dc6c32d41be85aaddf645d42386_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzMtNS0xLTEtMA_8645d51e-f2f9-4e72-a722-9df287f87a89"
      unitRef="usd">419000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie861385c736d4571ac97d10e57900db0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzUtMS0xLTEtMA_9f6e6e93-072f-4435-b774-7c99d8b19351"
      unitRef="usd">424000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i891ef023d6cf4c1594a15170a05474b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzUtMy0xLTEtMA_43fcdab5-3685-4900-828f-04bdf6f87d49"
      unitRef="usd">196000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id72f5afaff1c4203b2ae637d11fe6fb6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzUtNS0xLTEtMA_00973f30-5de6-4313-b029-5826d64a566c"
      unitRef="usd">188000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i81e1fc699103401fbce35712191d910b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzYtMS0xLTEtMA_148ef678-9200-419b-88d2-9a7ae527d3e7"
      unitRef="usd">126000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i30e3a1eb707a4bc0b1578b9e4e15f60b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzYtMy0xLTEtMA_ca65fc84-2f26-49b3-b910-ac624f492684"
      unitRef="usd">47000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ideff38e8d1af4d7ca70fc010025279b6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzYtNS0xLTEtMA_3ef71f4d-b02d-48aa-a787-3e548d6328ad"
      unitRef="usd">34000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia185bf2a1911407099126af09d6781da_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzctMS0xLTEtMA_0c539bb6-09f4-4017-89eb-968d0bfa1a80"
      unitRef="usd">53000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i342fe69beb814c41a97a7aef4c9ac973_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzctMy0xLTEtMA_08445fac-db15-4fe0-9e39-4ac204a2d3dc"
      unitRef="usd">63000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0452510b6e3c4fbd81f8cddba0a9d033_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzctNS0xLTEtMA_17a99ff2-0502-460b-947a-6865ed02be92"
      unitRef="usd">126000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i0003ff4798514c25a8591c162be15992_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEwLTEtMS0xLTA_9240c5d0-6a9b-4411-96a4-c3283f5af165"
      unitRef="usd">114000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idfd82ed31d7346f58d217331940bd0d2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzEwLTMtMS0xLTA_3ec1c469-9b86-43d4-ac68-31183dddea85"
      unitRef="usd">65000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i817d4a5d455b48e0835d76a3e57a68b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzExLTEtMS0xLTA_20b91db1-2193-46a8-9159-eec2e674a3f6"
      unitRef="usd">472000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8063a63e130649cd85c2717196b54dde_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTowZTZhZmZjZGQ3ZDk0YzQ0YjVjM2Q2MzRlMTY2ZWUwZC90YWJsZXJhbmdlOjBlNmFmZmNkZDdkOTRjNDRiNWMzZDYzNGUxNjZlZTBkXzExLTMtMS0xLTA_c0957017-18de-4587-9471-ef2af8199d6b"
      unitRef="usd">0</us-gaap:LiabilitiesCurrent>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie861385c736d4571ac97d10e57900db0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzQzOTgwNDY1MjU1ODQ_dbf474cf-4fb8-4146-9803-5f10fd303497"
      unitRef="usd">153000000</us-gaap:AmortizationOfIntangibleAssets>
    <mrk:SupplyCommitmentQuantityCommitted
      contextRef="i50e584cc2eff43599af7e4d668e4568c_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg2Njc_997ff1e0-b02e-4a9d-a922-fa57e5994de0"
      unitRef="course">3100000</mrk:SupplyCommitmentQuantityCommitted>
    <mrk:SupplyCommitmentQuantityDelivered
      contextRef="i5bf2c56c247444b38c99429fcfcc161e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg2ODA_0b68eb4c-8155-466d-90d6-eaed2a5b9232"
      unitRef="course">888000</mrk:SupplyCommitmentQuantityDelivered>
    <mrk:SupplyCommitmentQuantityCommitted
      contextRef="i5b951c64d4e94488b0076bc63024ee64_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg2ODk_37b3ccb0-3ace-44b3-87c2-0e6bc86633fe"
      unitRef="course">1600000</mrk:SupplyCommitmentQuantityCommitted>
    <mrk:SupplyCommitmentQuantityDelivered
      contextRef="i756ba880ce0840268980b9aab4635b5a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3MDI_adbede86-463c-4a72-b229-db41a668265a"
      unitRef="course">200000</mrk:SupplyCommitmentQuantityDelivered>
    <mrk:SupplyCommitmentQuantityCommitted
      contextRef="i3dce085486ee43df951fdeb7914c2311_D20211101-20211130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3MTE_9eac7fb0-58ef-4528-ac2a-fbf94038beaa"
      unitRef="course">2230000</mrk:SupplyCommitmentQuantityCommitted>
    <mrk:SupplyCommitmentQuantityDelivered
      contextRef="ibc01fdd92ce142b8bd16ad6681f5c303_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3MjU_8aefb98a-ddf3-4177-af0a-adae4e2677c0"
      unitRef="course">152000</mrk:SupplyCommitmentQuantityDelivered>
    <mrk:SupplyCommitmentMinimumNumberOfMarkets
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3MzQ_3a754709-95f3-45bf-b7a6-08f1bc2ad8a0"
      unitRef="market">30</mrk:SupplyCommitmentMinimumNumberOfMarkets>
    <mrk:SupplyCommitmentQuantityCommitted
      contextRef="if9796277d9ba47be91cb5b887f734e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3Mzk_9d92f7ce-ed80-43c3-bd8d-4c8c4e2da8b7"
      unitRef="course">3000000</mrk:SupplyCommitmentQuantityCommitted>
    <mrk:NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90ZXh0cmVnaW9uOjc4ODhkY2IyNTZiZDQyOTY4NzU3MjdkOTdjMDQyOGJlXzM4NDgyOTA3NDg3NTA_a4440c30-805f-4b8f-8fd5-ad68f0f641d0"
      unitRef="country">100</mrk:NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach>
    <us-gaap:Revenues
      contextRef="i32e28bb8b9aa4b7293ac191de6dddfe4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzEtMS0xLTEtMzQ3NzI_db95e199-2263-4384-a9bb-292a147746f0"
      unitRef="usd">952000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia356d15f44884231bebbcd7fcdd11f4e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzEtMy0xLTEtMzk4ODk_f662943d-face-4024-a9d5-0ce0b97a30bb"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i097bcd95db4c4868880f6e0af7fcc0c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzUtMS0xLTEtMzQ3NzI_9a76a85b-2a63-43b1-9d13-9c95afb62b32"
      unitRef="usd">494000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib15900e9713c45c48f0b905cb6dda370_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzMtMy0xLTEtMzk5MTI_65ab3bc4-9128-4861-b918-0280548e435e"
      unitRef="usd">13000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i00fb66ab96ce42d89c8d0763fcc77ddb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzYtMS0xLTEtMzQ3NzI_df8dd18d-6045-432f-a336-500c5b845c1e"
      unitRef="usd">33000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1b31b8b00cfe47f490681a6d81cd140b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzQtMy0xLTEtMzk5MTI_2c5f56c3-411a-4151-b595-b66a083447ab"
      unitRef="usd">6000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i737ff51dc12248dfac6273aae238abff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzctMS0xLTEtMzQ3NzI_7e7824a5-02e8-424b-ba26-e443351eb9ea"
      unitRef="usd">60000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7a1726f56cf343c482a8f9ccb64bd59a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzUtMy0xLTEtMzk5MTI_a975a27e-9a7e-4e19-b140-2b312f3b50ef"
      unitRef="usd">323000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LiabilitiesCurrent
      contextRef="i13200a779dce464f80cba863cea9e407_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzExLTEtMS0xLTM0Nzcy_b8bf238e-aec2-4226-afc7-c6fb6eba5214"
      unitRef="usd">283000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie1fde0285ad7451a9e92d2f80b91240f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTQvZnJhZzo3ODg4ZGNiMjU2YmQ0Mjk2ODc1NzI3ZDk3YzA0MjhiZS90YWJsZTpiYThjZDIxZmRlMmM0ZGVmOGQxZDBjZWY0NTFkN2I2My90YWJsZXJhbmdlOmJhOGNkMjFmZGUyYzRkZWY4ZDFkMGNlZjQ1MWQ3YjYzXzgtMy0xLTEtMzk5Mjg_09c428a7-3bde-49d0-bd33-76e0269a7026"
      unitRef="usd">3000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzM2MTM_6423e94c-2ec5-4188-a231-f78f1264c53b">Restructuring&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#x2019;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#x2019;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded total pretax costs of $868 million in 2021, $880 million in 2020 and $915 million in 2019 related to restructuring program activities. Since inception of the Restructuring Program through December&#160;31, 2021, Merck has recorded total pretax accumulated costs of approximately $2.7 billion. The Company expects to record charges of approximately $400 million in 2022 related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;91&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other activity in 2021, 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;14) and share-based compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;91&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring reserves December&#160;31, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;637&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be substantially completed by the end of 2023.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzkzNg_a4baa16f-9d6d-4e4a-8712-dfd9d6fcbec5"
      unitRef="usd">3500000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4Xzk4MQ_ff9edca5-ed74-4085-8ddb-101d9999cf61"
      unitRef="number">0.70</mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzExMzc_55c09a3a-858a-4a81-b391-327a16f6b7c1"
      unitRef="number">0.30</mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzE1MTM_d481f1c6-f422-41f7-8b44-b8952368a39a"
      unitRef="usd">868000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzE1MjM_bbd0422c-19b8-4e4a-9199-f3c5fa024d00"
      unitRef="usd">880000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzE1MzY_4dd5f5aa-c62c-4802-aa4b-75d32f3d8e4e"
      unitRef="usd">915000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzE3MTQ_e0fdec6e-213f-48fc-b7e8-61616a4dcea2"
      unitRef="usd">2700000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i2e67b3bb86584dab8782e051cf58baff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzEwOTk1MTE2MzI0NTQ_a421f0e4-8b2e-4764-a3b2-305ca469ca72"
      unitRef="usd">400000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzM2MTU_9551b5c9-1147-4b32-b77c-17530abfa0f5">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;91&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5aaca85009704ba19f1513e1e6c78715_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzItMS0xLTEtMA_38f3d1b0-86e2-4b6e-b7e3-9e1b8042a223"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i31dc8ec6b8e445b7b1b2b75aa10c997f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzItMy0xLTEtMA_acc0d44c-b106-4712-af6f-c4ed3f7bcb50"
      unitRef="usd">52000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ida45dba4790a481d8b49ae4d99983799_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzItNS0xLTEtMA_054b9fab-f3f1-4ec9-81a9-2a55d86d32d5"
      unitRef="usd">108000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia73cb7250e044a5f85e091f1f1ddae2d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzItNy0xLTEtMA_e352d8d9-09f7-4d80-bbfa-2b32b85225f6"
      unitRef="usd">160000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i946b15bf33724eab9cd37c967a566b18_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzMtMS0xLTEtMA_cc814c09-d476-47a5-87f5-01008d15d826"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i41ee296e8eeb43419e7163aaf951d1c2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzMtMy0xLTEtMA_c616a465-cc27-4d87-bfe2-208ab6866ad1"
      unitRef="usd">12000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaf3f8d9415a448c18444c1d1d8b1fe42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzMtNS0xLTEtMA_1bd3234c-4356-4e8e-81ae-f746858f03cb"
      unitRef="usd">7000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i31323381bed94598b8252be522569bca_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzMtNy0xLTEtMA_d5ec6457-b85d-4fd4-8bb8-2699ea18af82"
      unitRef="usd">19000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id56683f71b6048a5b950676e5147ddf6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzQtMS0xLTEtMA_6716b54b-9fcc-45f3-b6b0-65fc43588129"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib8e2c2edc5a34bdb938b2ab9082b4ef0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzQtMy0xLTEtMA_dd276064-6801-4911-97d8-b8a2fd7b36c5"
      unitRef="usd">27000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9ac2c9d18fc948e3b3936a9c1745217a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzQtNS0xLTEtMA_485d1994-74a4-4bc4-b11d-c47ebecbb27f"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i59278b50186c44eea02cd1646e7b396b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzQtNy0xLTEtMA_1e2d82bb-cd90-423b-a3fc-edd696f9ffff"
      unitRef="usd">28000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="icfe328f6c7a841e2b8499cc76eb20e1a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzUtMS0xLTEtMA_e09d7612-7466-440a-b7b7-a9faf74f82b1"
      unitRef="usd">451000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="icbbd36fe79ec4490af6d95ad286eece6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzUtMy0xLTEtMA_27c8be14-3a9c-460e-985d-cff06a37a742"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ice0f65c662794b7c9441b60c88d828a8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzUtNS0xLTEtMA_4a6912dd-3a7a-4d0c-9fc6-161d1d22221e"
      unitRef="usd">210000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3a62cdc5b588461686edf03bf5ad6825_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzUtNy0xLTEtMA_00176531-e01c-4396-9933-7af561c8e2d3"
      unitRef="usd">661000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4caa478726464d649c33751164cc0d70_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzYtMS0xLTEtMA_533b4a05-4047-4684-b037-e3041a14f23e"
      unitRef="usd">451000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzYtMy0xLTEtMA_4ecb69f7-6f8d-4621-abc7-50f11b495ed4"
      unitRef="usd">91000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzYtNS0xLTEtMA_1e91cbf4-8e5f-4df3-9c06-4dd160007de8"
      unitRef="usd">326000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzYtNy0xLTEtMA_08e11146-6463-408f-bf70-fe55735892a2"
      unitRef="usd">868000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iebd95b3f5d7d4a40ada1f89d7f2b3807_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzgtMS0xLTEtMA_f8a2d2e3-c824-4b49-821a-5bf72f43259f"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iba6383149a1b416d85737bb951015359_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzgtMy0xLTEtMA_bfe63798-9d5a-45df-a494-5d31dc3e9c0e"
      unitRef="usd">143000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i16cf5190146b4f96b1360695ccb6edd8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzgtNS0xLTEtMA_455a707c-3519-4f49-b869-e860cb7eed36"
      unitRef="usd">32000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i30f607f077f64c3daf4b01cf7298bfcd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzgtNy0xLTEtMA_b70e4b79-c968-4f54-9737-abde5eb2e474"
      unitRef="usd">175000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i50bddbb672804072ba20c9dda2af5613_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzktMS0xLTEtMA_37b59fde-b3ca-4d06-b5cd-0522496bb722"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i380e21df60bd41249e37f76c96e5b370_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzktMy0xLTEtMA_04eae235-e91f-40ed-b743-ae20517cf52a"
      unitRef="usd">44000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0297bc36963248d48192cc37c891ebd4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzktNS0xLTEtMA_c871cacb-7753-4673-9d8f-f15bac770a58"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaa96945711e74e16af5a510b6ad45e87_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzktNy0xLTEtMA_2a3090ca-5592-49c2-8f8d-8066d0cbd0e3"
      unitRef="usd">47000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i310042e57f8648c1910a64c356d6e4e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEwLTEtMS0xLTA_bf0d6abd-76c0-4cfb-a34e-ddc59c06ca3e"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i46fa1a240c9641f582948709782ebebb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEwLTMtMS0xLTA_14af2165-a968-41ef-9b01-36931c856397"
      unitRef="usd">81000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic9e16f47e6744b63b974f8c45a0aebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEwLTUtMS0xLTA_2d50afb3-ba4d-4254-9e3d-7423543e84d4"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i48c7436c3f434009bc43ed8fb64f30db_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEwLTctMS0xLTA_86afdce2-088a-4c15-bce8-1197fdf5abc8"
      unitRef="usd">83000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib320e53fbe8f4a71a079672c21ab5589_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzExLTEtMS0xLTA_7169d962-34c1-4329-a339-af9e9f03eeef"
      unitRef="usd">385000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i403dfea81e9b44b38f3a6469fc84c66b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzExLTMtMS0xLTA_4de9c858-1462-4962-8e69-258e3b05d8db"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie002d0c48a3741839131c30916e5272c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzExLTUtMS0xLTA_10b1296b-3e15-4123-9f03-8a086a456ba2"
      unitRef="usd">190000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id3f343081e674fb6824fe0f6ea3f51b3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzExLTctMS0xLTA_5ba13bca-83d2-4fa5-a433-294330778bec"
      unitRef="usd">575000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEyLTEtMS0xLTA_8366fcb5-991a-4169-8a19-34c53b1f419a"
      unitRef="usd">385000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEyLTMtMS0xLTA_840e12bc-40b6-4d5a-a969-ed1119e56178"
      unitRef="usd">268000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEyLTUtMS0xLTA_9a562958-a908-4e9c-9678-faaf95627a8c"
      unitRef="usd">227000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzEyLTctMS0xLTA_f5b1c8b5-7a85-4fe7-9895-46a83ce839b4"
      unitRef="usd">880000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i67a74b90c27a4d51bc7a5b722f81b3b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE0LTEtMS0xLTA_fc5d2746-f352-490c-85e1-a7f3fa6438e2"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id19696965a5c496d8add86515a1be5ec_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE0LTMtMS0xLTA_70e886c1-9517-4dfa-b3a2-167e09e52151"
      unitRef="usd">198000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic2d842b6322f4be89cdc492a4a169002_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE0LTUtMS0xLTA_45ff26ed-4f25-4e18-9ecf-c95790f4cc25"
      unitRef="usd">53000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iacdb4cd333404a72ab7e9c4a06cbe2c1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE0LTctMS0xLTA_822a0435-ee8c-4ecf-ab28-052b2d0529fc"
      unitRef="usd">251000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iebf1ad6c7e2d42f2b67fbb17e45f48ff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE1LTEtMS0xLTA_74eef182-cb1d-4b41-a931-d249c9e9221b"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="idb3f09c566f04978a062c5b475fcb376_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE1LTMtMS0xLTA_67ce0f83-25c9-43ea-b5ae-c964d8554f95"
      unitRef="usd">33000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6d31ca3c243847fca3ff1222d83159af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE1LTUtMS0xLTA_ab937252-33b4-4bad-914a-629e3b736ce3"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i111c43d6a309499f9624c33e82a4ffc9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE1LTctMS0xLTA_e65e11f6-a7dc-4298-ae28-49dd5372094e"
      unitRef="usd">34000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4ccf2924ac4f40168f4b02f65db200ee_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE2LTEtMS0xLTA_4f88d3ef-6078-47da-9540-8a31df88c926"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="idf00dc1bbf9946288b16b5451fe51cd5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE2LTMtMS0xLTA_85181c25-54c9-49d4-a24c-f5d603a7b339"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3ce6215e57c2458a9afd417343c63d14_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE2LTUtMS0xLTA_ec32e9ad-9c84-4879-95be-33639accdb0a"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ifd0c801111b849889a3cb1999277404a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE2LTctMS0xLTA_775b69cd-bc5e-4833-91eb-b59fc621cbca"
      unitRef="usd">4000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i16730c4a678e4c64b56d69ad77692225_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE3LTEtMS0xLTA_64c81241-288e-4ab1-9acb-deda1247f731"
      unitRef="usd">572000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8f15ce626aad44f58292eedaa374a985_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE3LTMtMS0xLTA_af97b001-d779-4fb8-a29b-c7a24c6e49ce"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic5f02c13fd4747fc989b60fd784585bb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE3LTUtMS0xLTA_7f02e7c9-6504-4ee7-9ecc-d2879da5892f"
      unitRef="usd">54000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id069b94a80af42e4888ed8c2211e56e1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE3LTctMS0xLTA_f0a2f193-4ce7-4ddc-ae48-b45e5fd91616"
      unitRef="usd">626000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9199f48459144d88986872e9ce83bcc8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE4LTEtMS0xLTA_8d8fc983-e8bd-45a1-8a5c-cbb39f1cd269"
      unitRef="usd">572000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3b1a06d7e97b4f2da011319e92c97eb9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE4LTMtMS0xLTA_6ac4b385-e693-4ec9-92b5-e700f2386331"
      unitRef="usd">233000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6560744cffdb44c6a15e0de8cb3125c5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE4LTUtMS0xLTA_178b3ac4-c9b6-4286-a499-864675bfb006"
      unitRef="usd">110000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTo2NzUwMDhiMTQ2ODY0NDIyODRhZmYxZWRhMTdkODkyMi90YWJsZXJhbmdlOjY3NTAwOGIxNDY4NjQ0MjI4NGFmZjFlZGExN2Q4OTIyXzE4LTctMS0xLTA_98a3d94c-ab01-4596-9420-1a7ad72730da"
      unitRef="usd">915000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90ZXh0cmVnaW9uOjMxZDIyYjJiMDI4YTQ0ZTc4ZGZlMGY2N2ZjNDJiYjA4XzM2MjM_ffe30eea-fcf6-4678-858d-961ad6614744">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;91&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring reserves December&#160;31, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;637&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be substantially completed by the end of 2023.</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i6aa2324a7bd9442db621352f34648867_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzEtMS0xLTEtMA_b664fb15-3114-4d5b-ab83-4fd071481c66"
      unitRef="usd">690000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iffb507ac1c0b432293ffd49cc271e612_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzEtMy0xLTEtMA_152796ee-2282-423b-a6d6-15eeca2734b8"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if561463c4bc4425caa176dc7d55ee265_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzEtNS0xLTEtMA_5480ef5d-0dc8-446b-9ef2-e15923bd196c"
      unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzEtNy0xLTEtMA_5cf43290-c3c8-45a0-80f4-085571309891"
      unitRef="usd">715000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzItMS0xLTEtMA_7cc6aaae-005a-4105-b22f-68b98a49a1ce"
      unitRef="usd">385000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzItMy0xLTEtMA_2e9ad7cb-17a6-48d5-b67c-bc81ce0ba3bc"
      unitRef="usd">268000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzItNS0xLTEtMA_8cbc0132-494b-42aa-a851-83813f55dddc"
      unitRef="usd">227000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzItNy0xLTEtMA_41dd39a5-69be-4e54-871b-6fe3e47b45ed"
      unitRef="usd">880000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzMtMS0xLTEtMA_fc68d80b-1a2a-4d9d-85e8-fd855f59671c"
      unitRef="usd">508000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzMtMy0xLTEtMA_88a5e51e-65e7-4e1e-98f1-9157d0be4e2b"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzMtNS0xLTEtMA_8b6e6090-7925-4d29-acc2-e22f2dd5cf96"
      unitRef="usd">271000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzMtNy0xLTEtMA_726585aa-d0a2-47b6-9765-56cc3942ed9f"
      unitRef="usd">779000000</us-gaap:PaymentsForRestructuring>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i16ce3f9944fc4b3b85b42c862fe89567_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzQtMS0xLTEtMA_8591f54e-03a1-4a99-a618-b7ba2f735ffb"
      unitRef="usd">0</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i29f21dfff07c410e80ee8014125034c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzQtMy0xLTEtMA_4b555799-c7bd-4a20-ae20-7954fe8a99d4"
      unitRef="usd">-268000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i7a022d537b3b4517830b92a2a10ac1d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzQtNS0xLTEtMA_e8cb63e9-8105-49d9-b7e4-89458b99571b"
      unitRef="usd">38000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzQtNy0xLTEtMA_d936144e-0ac8-4a57-9608-83c9125923ab"
      unitRef="usd">-230000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <us-gaap:RestructuringReserve
      contextRef="i6bc98ae55b3748a19a4a059028c47b39_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzUtMS0xLTEtMA_0d42a94f-7621-4b2c-8015-138c8f3048c1"
      unitRef="usd">567000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib5bbf238dd6a44468ac376288e4e1add_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzUtMy0xLTEtMA_92a71058-31a1-4101-b399-559621b505be"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id389b623812d474ea6c5ac6b16c29504_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzUtNS0xLTEtMA_f893bf46-13fe-4f04-9a6d-3f24bfbd3bd7"
      unitRef="usd">19000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzUtNy0xLTEtMA_e8bd5ca1-c52f-4aa5-a8db-e6eb8ec5ba17"
      unitRef="usd">586000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4caa478726464d649c33751164cc0d70_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzYtMS0xLTEtMA_29ddf8c2-edb4-4b48-9337-6ea12589cfc6"
      unitRef="usd">451000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzYtMy0xLTEtMA_038b55fa-1c7e-415b-90f1-1b38d1e9d0a1"
      unitRef="usd">91000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzYtNS0xLTEtMA_c194e780-4234-415a-a998-11f7aff73216"
      unitRef="usd">326000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzYtNy0xLTEtMA_038b8a8b-6510-4865-b32a-3c1c675d2416"
      unitRef="usd">868000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4caa478726464d649c33751164cc0d70_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzctMS0xLTEtMA_9edaa43e-b0b5-4ada-8a75-3d63e69c73de"
      unitRef="usd">422000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzctMy0xLTEtMA_933c3d4d-170d-465a-a5fa-4a3a530b584b"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzctNS0xLTEtMA_e0e5de5f-6a21-420b-965e-2ad441c8630e"
      unitRef="usd">186000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzctNy0xLTEtMA_ea94b252-9038-46ba-a9aa-cfc0fcafbd37"
      unitRef="usd">608000000</us-gaap:PaymentsForRestructuring>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i4caa478726464d649c33751164cc0d70_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzgtMS0xLTEtMA_289245df-8bdb-4d62-afd1-4a308210cce7"
      unitRef="usd">0</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="id3a953502d1a42fd8b0a4086954bb8f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzgtMy0xLTEtMA_b586fd59-e618-41ad-908d-a49e7abc7375"
      unitRef="usd">-91000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i489027060b71477d8b7b24e04c3cc60b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzgtNS0xLTEtMA_8b871717-21e0-4175-90dd-622b1c447a84"
      unitRef="usd">-118000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzgtNy0xLTEtMA_a46b9b8e-2aff-498f-8ff7-f0fb1b612120"
      unitRef="usd">-209000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <us-gaap:RestructuringReserve
      contextRef="icb664c71c0594335bb3a3f87041223a1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzktMS0xLTEtMA_e50d78ce-8bbb-4941-ac01-4cd9a99c4c5f"
      unitRef="usd">596000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i20b9087bb1864779b2109ddd342e45f4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzktMy0xLTEtMA_a44b0e9b-dd9f-44cc-80d0-8b1dca4f65e9"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5d11003c0d414a6e8d574694e9ec9dea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzktNS0xLTEtMA_3ff7b0f5-7ce5-4c6d-9336-44401fdece32"
      unitRef="usd">41000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNTcvZnJhZzozMWQyMmIyYjAyOGE0NGU3OGRmZTBmNjdmYzQyYmIwOC90YWJsZTpkOTJiNzllYmEwNGM0OGU3ODZjMDI4OWYyODFhZGIwNy90YWJsZXJhbmdlOmQ5MmI3OWViYTA0YzQ4ZTc4NmMwMjg5ZjI4MWFkYjA3XzktNy0xLTEtMA_754d404a-343f-488c-8afa-6d0895e64057"
      unitRef="usd">637000000</us-gaap:RestructuringReserve>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjU1_742d56c7-41d9-469d-98b2-eeb40d7e093f">Financial Instruments&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of the Company&#x2019;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#x2019;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and reclassified into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#x2019;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The forward contracts are not designated as hedges and are marked to market through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and remain in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#x2019;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; No amounts were reclassified from AOCL into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021,&#160;five interest rate swaps with a total notional amount of&#160;$1.15&#160;billion&#160;matured. These swaps effectively converted the Company&#x2019;s&#160;$1.15&#160;billion,&#160;3.875%&#160;fixed-rate notes due 2021 to variable rate debt. At December&#160;31, 2021, the Company was a party to nine pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par Value of Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of Interest Rate Swaps Held&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Swap Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These interest rate swaps matured in February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. See Note 2 for a discussion of the pending discontinuation of LIBOR as part of reference rate reform. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-Term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,073&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20,713&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32,958&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below). The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash collateral posted/received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,756&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of gain (loss) recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Decrease) increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;313&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivatives serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivatives serve as economic hedges against rising treasury rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the Company estimates $170 million of pretax net unrealized gains on derivatives maturing within the next 12&#160;months that hedge foreign currency denominated sales over that same period will be reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount ultimately reclassified to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments in Debt and Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net losses recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at December&#160;31, 2021 were $232 million during 2021. Unrealized net gains recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at December&#160;31, 2020 were $163 million during 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021 and 2020, the Company also had $596 million and $586 million, respectively, of equity investments without readily determinable fair values included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During 2021, the Company recorded unrealized gains of $110 million and unrealized losses of $1 million related to certain of these equity investments still held at December&#160;31, 2021. During 2020, the Company recorded unrealized gains of $62 million and unrealized losses of $3 million related to certain of these investments still held at December&#160;31, 2020. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December&#160;31, 2021 were $234 million and $7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021 and 2020, the Company also had $1.7&#160;billion and $800&#160;million, respectively, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for equity securities held through ownership interests in investment funds. (Gains) losses recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; relating to these investment funds were $(1.4)&#160;billion, $(583)&#160;million and $113&#160;million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;370&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,363&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,363&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160; Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; include cash equivalents of $6.8 billion (which would be considered Level 2 in the fair value hierarchy). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Balance at December&#160;31, 2021 includes $151 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; At December&#160;31, 2021 and 2020, $620 million and $711 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 4). The payments of contingent consideration in both years relate to the Sanofi Pasteur MSD liabilities described above. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of loans payable and long-term debt (including current portion) at December&#160;31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion and at December&#160;31, 2020, was $36.0 billion compared with a carrying value of $31.8 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company&#x2019;s investment policy guidelines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately 20%, 15% and 10%, respectively, of total accounts receivable at December&#160;31, 2021. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.8 billion and $2.1 billion of accounts receivable as of December&#160;31, 2021 and 2020, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2021 and 2020, the Company had collected $62 million and $102&#160;million, &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, on behalf of the financial institutions, which is reflected as restricted cash in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the related obligation to remit the cash within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company remitted the cash to the financial institutions in January 2022 and 2021, respectively. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#x2019;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#x2019;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $164 million at December&#160;31, 2021. The obligation to return such collateral is recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;. Cash collateral advanced by the Company to counterparties was $36 million at December&#160;31, 2020.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="if6e9ec1cceb94d9bae732843b25cdb75_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE0ODU_6156b8ed-c157-4b97-a28a-ec2fb5952f17">P2Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="i1ee26aaae9074659993d6d84e4de1ffb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzQ5MTc_9dccba6b-9226-4df2-8e97-c29e6166d953">P1Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjI0_b9c7970e-dc2c-4e47-839f-fe45d6abae9c">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; No amounts were reclassified from AOCL into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtMS0xLTEtMA_f5d41a5d-587d-4c75-aaef-a4feae77aecd"
      unitRef="usd">49000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i02721ef0aaab4a4caee301f22e9386ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtMy0xLTEtMA_8c8e78bb-8647-4ad6-80f2-9bd30a2013e2"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i84bb7bc1ceda4f948a3090842627e654_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtNS0xLTEtMA_4dad5742-bfee-4cf0-b8e9-8aa3c2409f91"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ia3e1bd075f93491e9df5f7f32bd7ad1f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtNy0xLTEtMA_44f6931a-d44c-411c-a065-20eeb4717d70"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ib65521c997c84ef8b37cc9b21ffd59d6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtOS0xLTEtMA_6f2651dd-6f01-4ce0-b92f-591d89772a02"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ie72e897aad094644a983458bfe8704d2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzMtMTEtMS0xLTA_ea42e8fa-a16d-4a38-9e88-a3633fad40cf"
      unitRef="usd">31000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ibeeff8ebe3be4a60ab7c727335780af7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtMS0xLTEtMA_58b6fa85-8f6f-4dd9-ac9e-d03adbabb235"
      unitRef="usd">296000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9352e4c6900b48a3965ce12d07bf3a06_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtMy0xLTEtMA_c0dd7a45-6ee9-454c-9f09-0dd16b7542a4"
      unitRef="usd">-385000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie137bb0fd9d44320bee063d82bfcf668_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtNS0xLTEtMA_08615bf4-e93b-4929-a12c-6b245cbd96cb"
      unitRef="usd">75000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ic4e9d32d55204511bafd6a9816b6f024_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtNy0xLTEtMA_9fe0b64a-0bd1-46ff-8458-3efe5e0e9ed8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i9a496974bc6443bb93bb621dd56fc567_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtOS0xLTEtMA_df682006-d29f-4c2d-823d-6a0d7c964e2d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i4df804136d5442df9b3d7abea422a604_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTpmZDEyYzA1MjBmMzU0OWJhYTVhYjFlZTQ5NjYzZjc0MC90YWJsZXJhbmdlOmZkMTJjMDUyMGYzNTQ5YmFhNWFiMWVlNDk2NjNmNzQwXzQtMTEtMS0xLTA_1c74e6f4-3cea-4e10-8fbc-e1f026585c23"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="ia2bbb9db2c294c3ba3a6368380f2e03e_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzY5ODU_726114e9-392e-4ce2-8cd4-da0d217314a8"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia2bbb9db2c294c3ba3a6368380f2e03e_I20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzcwMzM_a174e0db-f5a9-4ba3-a430-6b21059d2dc8"
      unitRef="usd">1150000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8fe94b07a3fc4572a433b1102b900e44_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzcwOTg_219af197-c1d9-42af-99c7-ea5dd8994f10"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8fe94b07a3fc4572a433b1102b900e44_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzcxMDI_9bb1bdb9-3248-4159-9591-51ccd59c2238"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjIx_cc5a9e60-1c9b-464d-8c7a-426bcd63c292">At December&#160;31, 2021, the Company was a party to nine pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below: &lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par Value of Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of Interest Rate Swaps Held&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Swap Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These interest rate swaps matured in February 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i310109d6898342d49bc826875e191ad6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzcxODg_c53d1f80-c2b2-40ec-8550-d2d5555f40dc"
      unitRef="interest_rate_swap">9</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9de5cdef0a234eefaec97bc914e30cc3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjM0MGI4YzBmYjdmODQyMWViN2Y3OTEyZWRkMTM2N2I2XzQ_f67ee628-b64d-474f-adc8-49b6db118324"
      unitRef="number">0.0240</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9de5cdef0a234eefaec97bc914e30cc3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzMtMS0xLTEtMA_cf8c2519-2cdd-4131-8e8a-be18cdfdf8b6"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i9de5cdef0a234eefaec97bc914e30cc3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzMtMy0xLTEtMA_3bf678c7-0945-40d0-9ebe-e8ef1cd9852e"
      unitRef="interest_rate_swap">4</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9de5cdef0a234eefaec97bc914e30cc3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzMtNS0xLTEtMA_7d909550-3bdf-4775-b465-10e6de57c6bc"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i591a75ce070d4aaf981adbe405971c39_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJjYzExOWI0NGNhMTQ1YjBiNjU4MjE1NjE0Mzg0MWU2XzQ_0a55091e-00db-43e1-bba0-5feede995d9f"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i591a75ce070d4aaf981adbe405971c39_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzQtMS0xLTEtMA_09e44543-cf20-4652-900b-aa31fe82f71a"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i591a75ce070d4aaf981adbe405971c39_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzQtMy0xLTEtMA_935e82c7-86ad-43a1-9f9e-af6937cb897e"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i591a75ce070d4aaf981adbe405971c39_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2YzgzOGJjNzUzOGU0MjY5ODhjOTVlODY2MjI3MjJhNC90YWJsZXJhbmdlOjZjODM4YmM3NTM4ZTQyNjk4OGM5NWU4NjYyMjcyMmE0XzQtNS0xLTEtMA_83d8dec2-44ee-4b96-a2b7-c71ce1fab4ec"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjQ4_0e660cdc-0981-478f-b76b-d9946980d845">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-Term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i752aeb3870ee4f6bbfd196995b6998d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzMtMS0xLTEtMA_8451d6d0-7371-4e53-bf7f-666a8930685c"
      unitRef="usd">2263000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ib6611393547d42b1bc24ebbbb98dc51d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzMtMy0xLTEtMA_0e4f7c29-4c47-4a97-9397-64d1e2865554"
      unitRef="usd">1150000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i752aeb3870ee4f6bbfd196995b6998d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzMtNS0xLTEtMA_650d4393-9033-4273-9189-8c40abf0bbdb"
      unitRef="usd">13000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ib6611393547d42b1bc24ebbbb98dc51d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzMtNy0xLTEtMA_1758b38f-d181-4a0f-83ae-70828d300f2f"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ic2ac86e44601419fa50cb8bfba8997cc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzQtMS0xLTEtMA_244d2f19-2798-4001-9f13-8172db82d9b6"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="idd3c2b08bde54d01b9032cf85c1bae1b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzQtMy0xLTEtMA_9dce19ec-da54-4374-bed1-7f5e101c2dfd"
      unitRef="usd">2301000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ic2ac86e44601419fa50cb8bfba8997cc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzQtNS0xLTEtMA_e60c8cbe-9636-4b3f-b838-f64eaf467821"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="idd3c2b08bde54d01b9032cf85c1bae1b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowZTE4YmFjYTcxNTg0OTVlODRlNjE2OGI4MWE0MWNhZi90YWJsZXJhbmdlOjBlMThiYWNhNzE1ODQ5NWU4NGU2MTY4YjgxYTQxY2FmXzQtNy0xLTEtMA_cdbc9e9f-96d1-4e62-b155-8ca5b2c3337e"
      unitRef="usd">53000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5Mjg3_291c576a-83bb-4cb8-8348-90441e7f5739">&lt;div style="margin-top:1pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,073&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20,713&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32,958&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="i99c86a1b952c48f7861dbe9b5aeab121_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzQtMy0xLTEtMA_da7c6964-16e3-4c24-af1d-5b3292012ff5"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i99c86a1b952c48f7861dbe9b5aeab121_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzQtNy0xLTEtMA_a2ac2c2b-6344-4bba-9375-a7ed54d55f26"
      unitRef="usd">2250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ia36b163f3e8e43d6ae5f69d6957c282f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzQtOS0xLTEtMA_157f634b-3e70-4e28-bae9-03e206b37681"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia36b163f3e8e43d6ae5f69d6957c282f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzQtMTMtMS0xLTA_00e387dc-0c4c-428f-83ea-ddf2cb0b1d13"
      unitRef="usd">1150000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i28e71a0f38b8445fad18e25a0d495afe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzUtMy0xLTEtMA_8d2c2ba2-f261-45b0-810e-3e05bfe3dc55"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i28e71a0f38b8445fad18e25a0d495afe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzUtNy0xLTEtMA_f8390a0a-6d67-4421-9941-3130f5262684"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ic0bd1d54e2d34252a1c972fe50060600_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzUtOS0xLTEtMA_7e466cb9-a07b-438c-8957-80f2116741ba"
      unitRef="usd">54000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic0bd1d54e2d34252a1c972fe50060600_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzUtMTMtMS0xLTA_5ba6007d-c379-41e7-b963-d146dffe7d84"
      unitRef="usd">2250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i7c7da2a453a443a3976d58aac76e2b44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzctMy0xLTEtMA_e4c3e696-9660-4468-8836-a72238281d6f"
      unitRef="usd">271000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7c7da2a453a443a3976d58aac76e2b44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzctNy0xLTEtMA_47133da6-0e2e-4657-ba9b-cf8534687adc"
      unitRef="usd">6778000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i09985e2ea91f4c08a1fb3fe016edfca0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzctOS0xLTEtMA_12a637d8-439e-4fdd-963e-136d8a85e867"
      unitRef="usd">12000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i09985e2ea91f4c08a1fb3fe016edfca0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzctMTMtMS0xLTA_8b3f3b5d-3356-4cc6-9be4-a5223ee6e1a0"
      unitRef="usd">3183000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i70cfa0f51218476493154e53e8b1dbb5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzgtMy0xLTEtMA_e126b43e-3122-4043-b484-52d6e6f88357"
      unitRef="usd">43000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i70cfa0f51218476493154e53e8b1dbb5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzgtNy0xLTEtMA_f17454fc-c553-4225-8b1f-97400f357913"
      unitRef="usd">1551000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i6ab442d7528e4761a37ccabe79942355_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzgtOS0xLTEtMA_f7b57715-d6a4-4dee-8ea8-f296df6c6008"
      unitRef="usd">45000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6ab442d7528e4761a37ccabe79942355_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzgtMTMtMS0xLTA_a97b8568-b7c4-4a5f-904d-3a3ad0ca689c"
      unitRef="usd">2030000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="if30aa462731e489cadd31a7b7aa3f2c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzktNS0xLTEtMA_84e8c669-d0cf-46ee-9f95-f5eeed15b240"
      unitRef="usd">24000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if30aa462731e489cadd31a7b7aa3f2c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzktNy0xLTEtMA_fe864114-af7c-4a35-9594-f3398bc3c079"
      unitRef="usd">1623000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i98d4a664ab5b4b76bf159dc924348812_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzktMTEtMS0xLTA_a18a33f5-7d49-405b-864d-db9ce7bcb66f"
      unitRef="usd">217000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i98d4a664ab5b4b76bf159dc924348812_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzktMTMtMS0xLTA_96e70d4f-f80b-40b6-9112-094436a92469"
      unitRef="usd">5049000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i19fc35655fc94795bae5c9b1bf8ef198_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEwLTUtMS0xLTA_174f689a-9bf4-4090-aff3-773a2d7f876d"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i19fc35655fc94795bae5c9b1bf8ef198_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEwLTctMS0xLTA_6758db49-1770-4dee-8c03-ec620065fe2f"
      unitRef="usd">43000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i9731ca41dc5346328715b1b72d90d14a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEwLTExLTEtMS0w_57984d03-3158-4240-af24-2a32986135e8"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9731ca41dc5346328715b1b72d90d14a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEwLTEzLTEtMS0w_bc3d8bd4-99af-4bd9-bbba-edbd5cf37ef6"
      unitRef="usd">52000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i0bfc38d37e5a42ac8fc03da3a897894d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTMtMS0xLTA_974dcd0e-baf8-4594-8be7-ff71885de6f2"
      unitRef="usd">328000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i0bfc38d37e5a42ac8fc03da3a897894d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTUtMS0xLTA_8c6d3927-17a9-4b61-a8e6-cfc7ec40695f"
      unitRef="usd">25000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0bfc38d37e5a42ac8fc03da3a897894d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTctMS0xLTA_cfb0690a-fb23-4fa2-ba82-4fc695684433"
      unitRef="usd">12245000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i516472e36f9d496aa8c94bb0c311f117_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTktMS0xLTA_c2ecfc60-7eb8-4624-b2d5-bbb3372700d2"
      unitRef="usd">112000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i516472e36f9d496aa8c94bb0c311f117_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTExLTEtMS0w_420cedcd-db3b-4429-ad3a-b73ad5cf23b7"
      unitRef="usd">218000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i516472e36f9d496aa8c94bb0c311f117_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzExLTEzLTEtMS0w_792551aa-70d4-406d-a673-073784880308"
      unitRef="usd">13714000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i9ccd34269c794e22960b8ccb14c99461_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEzLTMtMS0xLTA_5442c90e-33d4-4e1b-bd5d-d688e2ddb519"
      unitRef="usd">221000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9ccd34269c794e22960b8ccb14c99461_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEzLTctMS0xLTA_b5de9704-d409-461a-b893-c8aa9996afda"
      unitRef="usd">10073000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i7e2b59714c6844d68d8390e2770ef044_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEzLTktMS0xLTA_626da3d0-0dc2-4a77-95b4-0e6f7c82dbc3"
      unitRef="usd">70000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7e2b59714c6844d68d8390e2770ef044_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzEzLTEzLTEtMS0w_44356b0b-962d-4591-90e9-fec6953b4e35"
      unitRef="usd">7260000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ia90d34918e9842f5b8088721b0df39e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE0LTUtMS0xLTA_6e05dd7c-a8c3-4874-aadc-d5cb479e78c2"
      unitRef="usd">96000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia90d34918e9842f5b8088721b0df39e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE0LTctMS0xLTA_ee50e669-14c2-4812-a5a3-2bf96ee3d637"
      unitRef="usd">10640000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ib5b7d60396c746879acbf1477ac19434_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE0LTExLTEtMS0w_c1e42dc6-864d-4a6b-92a1-b2c6737e44ce"
      unitRef="usd">307000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib5b7d60396c746879acbf1477ac19434_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE0LTEzLTEtMS0w_f8c829f5-6571-4030-9d73-b68d01891fe7"
      unitRef="usd">11810000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="idee6fff4646d4707a2a06f61ed411ffe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTMtMS0xLTA_19dcfa72-be26-485e-a504-5ccf013b4762"
      unitRef="usd">221000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="idee6fff4646d4707a2a06f61ed411ffe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTUtMS0xLTA_3f8da9c8-8e24-4416-89be-6974e49211e1"
      unitRef="usd">96000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idee6fff4646d4707a2a06f61ed411ffe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTctMS0xLTA_b18f19db-4e20-43f1-84ad-458a4a682e21"
      unitRef="usd">20713000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i20fbc9f911a54d23b75ffedfccc36c36_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTktMS0xLTA_dbb0064e-d15e-4868-91ff-e8477a83b286"
      unitRef="usd">70000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i20fbc9f911a54d23b75ffedfccc36c36_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTExLTEtMS0w_4b9d157a-e1b2-4401-b5a4-b700c83df089"
      unitRef="usd">307000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i20fbc9f911a54d23b75ffedfccc36c36_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE1LTEzLTEtMS0w_01618452-a571-45ce-b2a8-6bd502e564fb"
      unitRef="usd">19070000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTMtMS0xLTA_6f0248b2-4a66-4969-8ea1-1fbd342f8c30"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTUtMS0xLTA_af7d8371-09d2-4d7d-b914-9f6f66f1c3c3"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTctMS0xLTA_11c2df32-09b1-4d51-a794-71d44dacbcec"
      unitRef="usd">32958000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTktMS0xLTA_0e676790-14f0-4f25-b969-28dc56047aa9"
      unitRef="usd">182000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTExLTEtMS0w_5d706834-ff3e-4207-af03-7e2924dfd465"
      unitRef="usd">525000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZToyNzNkNGE0NzQyNTE0N2FlYjQxNGRlOTczMTE2MTJjNC90YWJsZXJhbmdlOjI3M2Q0YTQ3NDI1MTQ3YWViNDE0ZGU5NzMxMTYxMmM0XzE2LTEzLTEtMS0w_c29ea7e4-dfac-470a-9721-8d659f631a53"
      unitRef="usd">32784000000</us-gaap:DerivativeNotionalAmount>
    <mrk:OffsettingAssetsAndLiabilitiesTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjE0_3769cf90-2014-44be-b761-fcd6a40054bc">The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash collateral posted/received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mrk:OffsettingAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzItMS0xLTEtMA_3f5b7322-8819-4967-8d73-96864daedbc6"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzItMy0xLTEtMA_95271355-c601-4738-b1ba-2211cb1d9969"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzItNS0xLTEtMA_5528fb0e-d4d8-48f3-b025-08c50b18c7e2"
      unitRef="usd">182000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzItNy0xLTEtMA_ea698cf3-8af6-4cdc-8539-ecd84484d5c1"
      unitRef="usd">525000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzMtMS0xLTEtMA_181a6533-45a5-437f-b2e5-a02249e924c6"
      unitRef="usd">110000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzMtMy0xLTEtMA_33224fc9-2fc2-40c3-b228-2edae0cea09c"
      unitRef="usd">110000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzMtNS0xLTEtMA_2359984b-00b0-4e51-8c07-be7e0001fb45"
      unitRef="usd">156000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzMtNy0xLTEtMA_994990f2-7b33-436d-b4a1-9ae1a18aa540"
      unitRef="usd">156000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzQtMS0xLTEtMA_b485f4d6-42c6-4f0c-9067-4c301788613d"
      unitRef="usd">164000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzQtMy0xLTEtMA_43a852a7-7e94-4826-9a35-82f51d338348"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzQtNS0xLTEtMA_f2a1f580-3ad8-4dc8-a101-92a7196a9d6b"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzQtNy0xLTEtMA_58198cd9-7b98-4ddb-9c89-307d52f8ca54"
      unitRef="usd">36000000</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzUtMS0xLTEtMA_950d2b30-cf00-4ee0-800a-a02a130ed1e4"
      unitRef="usd">275000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzUtMy0xLTEtMA_c7ef1d0b-4fe2-445f-89ff-832b3de8d4b4"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzUtNS0xLTEtMA_1e83e8b3-15f9-4677-8a92-11383103cb22"
      unitRef="usd">26000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTowNWJlZjAwODg0ODk0OTRiODk1NGJiZTA3ZTBmMWZlMC90YWJsZXJhbmdlOjA1YmVmMDA4ODQ4OTQ5NGI4OTU0YmJlMDdlMGYxZmUwXzUtNy0xLTEtMA_f33228be-0293-4a0a-bcb5-aca4a5b0809e"
      unitRef="usd">333000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjQy_847cb678-db82-4bb5-9e10-f7c709c90cac">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,756&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of gain (loss) recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Decrease) increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:Revenues
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMS0xLTEtMA_e9ba35a1-796a-4918-8a31-563f710742c7"
      unitRef="usd">48704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMy0xLTEtMA_5d4fe67b-5bc5-41e9-9c6a-cfdfc2a60b24"
      unitRef="usd">41518000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItNS0xLTEtMA_8321d7e8-dee6-4216-9684-6e006ea722b5"
      unitRef="usd">39121000000</us-gaap:Revenues>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItNy0xLTEtMA_f86853c3-579f-4c7a-9a52-011609aea341"
      unitRef="usd">1341000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItOS0xLTEtMA_a99eca07-7b63-4e79-a856-07713a5afb32"
      unitRef="usd">890000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMTEtMS0xLTA_0bfea1ba-1532-4ff9-8b6c-d14343e9d14d"
      unitRef="usd">-129000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMTMtMS0xLTA_91d06469-023f-4ab7-808c-1c5a8ba9946d"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMTUtMS0xLTA_2f3e958e-1094-43a0-8543-bbbb764e562e"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzItMTctMS0xLTA_e0d435cf-2c56-4f5f-bbe7-5d972fc3f489"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ib59169c0f6834a5a9361dc5a5dd9fb50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzUtNy0xLTEtMA_72fbcbba-8c18-4d0c-9b51-21b1e2720a80"
      unitRef="usd">40000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i12ea01dfaf7b4584b7cb6e99f32d5f16_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzUtOS0xLTEtMA_35d523a1-83f4-4092-b85c-e491acaedd07"
      unitRef="usd">-40000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i733145edccf544dba291d9978b2c7899_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzUtMTEtMS0xLTA_83ce2b9a-8346-4bbd-910b-0476783a6c0e"
      unitRef="usd">-95000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ib59169c0f6834a5a9361dc5a5dd9fb50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzYtNy0xLTEtMA_3ecc9d4c-7c86-4285-9924-d5b32a8440c4"
      unitRef="usd">-1000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i12ea01dfaf7b4584b7cb6e99f32d5f16_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzYtOS0xLTEtMA_4a19ec6f-6fbf-40ae-b61a-bc6372587953"
      unitRef="usd">76000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i733145edccf544dba291d9978b2c7899_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzYtMTEtMS0xLTA_d25514ea-b23a-4648-a206-0e7a49582565"
      unitRef="usd">65000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzktMTMtMS0xLTA_68b6ed04-9639-499c-9865-19485a345e78"
      unitRef="usd">333000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i02721ef0aaab4a4caee301f22e9386ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzktMTUtMS0xLTA_cd48f40a-a98c-46a8-962a-32ec092b8bb3"
      unitRef="usd">-383000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i84bb7bc1ceda4f948a3090842627e654_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzktMTctMS0xLTA_45fa81ea-9bef-46cb-a359-be5c51c27ba4"
      unitRef="usd">87000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:Revenues
      contextRef="i1efd7da37e42404d934244b631380e00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTEtMS0xLTA_a2447880-7b33-46ca-8098-623b3cf9258f"
      unitRef="usd">-194000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6696a02570e049eead17b64f1424b15f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTMtMS0xLTA_2424d00a-9e35-4032-b039-4b3210e5f195"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib57b83c73b584975acd4aa8663d43dd8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTUtMS0xLTA_c088cb72-a2d3-4164-a7e2-6d3121e7d169"
      unitRef="usd">255000000</us-gaap:Revenues>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTEzLTEtMS0w_583f1f68-b336-4e9f-a6b9-2ce275cf2e7a"
      unitRef="usd">194000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i02721ef0aaab4a4caee301f22e9386ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTE1LTEtMS0w_ff396b28-f565-4991-9363-639c10333376"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i84bb7bc1ceda4f948a3090842627e654_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEwLTE3LTEtMS0w_c3ae838f-11ec-472c-b4a9-0ab3f9f09e1c"
      unitRef="usd">-255000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib59169c0f6834a5a9361dc5a5dd9fb50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEyLTctMS0xLTA_b66f5d90-8b5d-471f-bcb3-8acfc9ccb1f3"
      unitRef="usd">-2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i12ea01dfaf7b4584b7cb6e99f32d5f16_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEyLTktMS0xLTA_202042e5-4530-44ac-a5e5-6a2d95aaf5cb"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i733145edccf544dba291d9978b2c7899_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEyLTExLTEtMS0w_526f0968-5f6a-40ac-85c1-61fdbfe188b3"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5e1d3b1cd3244e0aad923e07c063a9cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEzLTEzLTEtMS0w_ddd9d787-6933-4d50-8918-506f55d8cdaa"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i539bde58e63e4ef48c1df31dfc07d91a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEzLTE1LTEtMS0w_a06d29fd-7542-4fe6-b45f-f6fe764bea92"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i02bd2346097c4b3b9fe8e30de60e2cf3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo2Nzg0YTgwZTYzODE0YWUyODlhNWU1YWM5OWQxODFmMS90YWJsZXJhbmdlOjY3ODRhODBlNjM4MTRhZTI4OWE1ZTVhYzk5ZDE4MWYxXzEzLTE3LTEtMS0w_fed4aa30-20b5-4cef-a0f4-89e9cd9d5125"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjY5_022d539a-f117-4763-b39a-5a54f6ca4318">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;313&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivatives serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivatives serve as economic hedges against rising treasury rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ia3e1bd075f93491e9df5f7f32bd7ad1f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzMtMy0xLTEtMA_9d7ae229-2bf0-47a6-be99-802e810797b5"
      unitRef="usd">-313000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ib65521c997c84ef8b37cc9b21ffd59d6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzMtNS0xLTEtMA_cf2da042-fbd9-4430-afa4-f3ae39c504e8"
      unitRef="usd">12000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ie72e897aad094644a983458bfe8704d2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzMtNy0xLTEtMA_2eaaca5f-1a14-4bbb-8a41-a2ae9070c663"
      unitRef="usd">-174000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i3e4641a8e98d45b995aa58ccc3163f5d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzQtMy0xLTEtMA_9236409c-5676-487c-9ec8-c53414fabc8f"
      unitRef="usd">-9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i88c61111e751460c82200beada745607_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzQtNS0xLTEtMA_eaa9d696-a647-433e-ae77-7e9d58b9d5bf"
      unitRef="usd">-13000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i713d31c07f5a4005843f4d9cf95d467d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzQtNy0xLTEtMA_e472f7c9-ff25-4234-9ca5-a727055fcf10"
      unitRef="usd">-1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i3a88bace3aac440ea9b4d06c6c356839_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzUtMy0xLTEtMA_4c36caf3-21f1-495f-bda1-f2cbd793f7d5"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ief07c343564f4087b2e4707c3e91f20e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzUtNS0xLTEtMA_89953910-2401-49fe-826c-d19f84e68a86"
      unitRef="usd">-9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i4fe1bc7905c64eee8380775080e0e9ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzUtNy0xLTEtMA_508665f9-5ea2-4fd7-8841-af4147a79b28"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i71d6586ddd354fdab6d1c9bcba27020f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzYtMy0xLTEtMA_44e9b5e6-90e8-441a-bed3-7f7b87924c49"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i8c020fbadbb34c96a252288c30f7d10c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzYtNS0xLTEtMA_0b8e5335-3d98-477a-85be-8941960b59a4"
      unitRef="usd">-15000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i2b6efd6ed9184294a5fe275ff87e45f2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo4NTIyMWNkNjRhYjU0MzU3YjU5OTU5NjI1NDAyNDMwOS90YWJsZXJhbmdlOjg1MjIxY2Q2NGFiNTQzNTdiNTk5NTk2MjU0MDI0MzA5XzYtNy0xLTEtMA_52fcd90a-fbde-4c39-ad69-0c7ac785bbd1"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzk2NzA_78e24d41-f1e1-42c3-841a-ac6efa6c01e4"
      unitRef="usd">170000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5Mjc3_3b0244a5-66de-4d20-81f1-8a129cdff389">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net losses recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at December&#160;31, 2021 were $232 million during 2021. Unrealized net gains recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at December&#160;31, 2020 were $163 million during 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1883b0f48cea47939cd4e2cd6084fd78_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMS0xLTEtMA_3a294c60-4c94-4fcd-85b6-b1e8395cad26"
      unitRef="usd">80000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1883b0f48cea47939cd4e2cd6084fd78_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMy0xLTEtMA_fe565491-20e8-4157-881c-0112b5b54db3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1883b0f48cea47939cd4e2cd6084fd78_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtNS0xLTEtMA_a8e2c8cf-0e4a-49ba-b7ca-b66559689f22"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1883b0f48cea47939cd4e2cd6084fd78_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtNy0xLTEtMA_1c351bb5-41ce-4c87-877b-e5611522d380"
      unitRef="usd">80000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i32737545f1ac4e5788d077690a87566c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtOS0xLTEtMA_b6d758d8-1239-44d7-83cb-d27e78035ef5"
      unitRef="usd">84000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i32737545f1ac4e5788d077690a87566c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMTEtMS0xLTA_1d6417a3-a350-43a7-a997-c4b9a33a0440"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i32737545f1ac4e5788d077690a87566c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMTMtMS0xLTA_6a570fef-f239-48a7-ba35-30e44e5cd96a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32737545f1ac4e5788d077690a87566c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzMtMTUtMS0xLTA_0691cd98-4567-4430-a16b-56f9c4190b69"
      unitRef="usd">84000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMS0xLTEtMA_23ce1236-7083-4915-82bb-0210015be1a8"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMy0xLTEtMA_45aae2bc-5fb2-4d38-b224-4528ed610090"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtNS0xLTEtMA_1c92a30c-95f9-42c2-a4e2-d58229f7d616"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79a92c9fc7f34e1fb7c22d0ed49dcd4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtNy0xLTEtMA_c470d4ff-a1de-4068-99bd-fe53a43a523d"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtOS0xLTEtMA_bbe50853-a766-4aad-9164-10a534bb5d8a"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMTEtMS0xLTA_df6862e8-d8ec-4503-94a7-86d287ea6706"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMTMtMS0xLTA_8d3c814c-6936-4385-9c51-09aa3a3bb04b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2b53aab6cd84f8d92aa62ac37bee419_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzQtMTUtMS0xLTA_c9ba656f-e74d-47d6-988c-aad19afd969c"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie8165d1112e047829b04b7cf5d434fdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMS0xLTEtMA_cb6066c9-3b8c-421f-b5f1-1c3d129cd90c"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie8165d1112e047829b04b7cf5d434fdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMy0xLTEtMA_561166d7-c5d2-4427-bc97-e2eacdd9b637"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie8165d1112e047829b04b7cf5d434fdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtNS0xLTEtMA_7364ad4f-ef4d-46f8-80ac-4dfbdabcab51"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie8165d1112e047829b04b7cf5d434fdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtNy0xLTEtMA_51d6951d-70ef-4a00-acef-3cf36d0c89df"
      unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2b37f94f01344d068373b8eadf59831f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtOS0xLTEtMA_a9c806b5-04ff-43da-a244-96be63953590"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2b37f94f01344d068373b8eadf59831f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMTEtMS0xLTA_e8b031df-9be4-42e5-a00b-fa3325e25ce7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2b37f94f01344d068373b8eadf59831f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMTMtMS0xLTA_593a4657-221d-4106-8d7a-ea7430527c41"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b37f94f01344d068373b8eadf59831f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzYtMTUtMS0xLTA_59dbaa56-f282-43e3-907f-2ce5002b4324"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMS0xLTEtMA_a232a1a5-b747-4f02-a12e-acffcb49cb70"
      unitRef="usd">86000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMy0xLTEtMA_a3cf6b9f-5932-4426-9b4a-5ebdc1fd4f65"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtNS0xLTEtMA_cc6a3fdd-8f22-4688-b322-36e80c08ed6b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtNy0xLTEtMA_c86892ef-0197-4069-8f63-9044e1801225"
      unitRef="usd">86000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtOS0xLTEtMA_ffc9214c-d8cc-494b-9383-2676c59a15a5"
      unitRef="usd">89000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMTEtMS0xLTA_20ace1e4-68b7-4271-ba5e-eb44b2bbae32"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMTMtMS0xLTA_86d92783-1b0a-41f2-b2a7-2cb2ee83f1ea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzgtMTUtMS0xLTA_e7b1d932-0241-4c56-85eb-73f8ad724cba"
      unitRef="usd">89000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzktNy0xLTEtMA_00198171-6c50-47c1-b287-56a1eb0ba312"
      unitRef="usd">1647000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzktMTUtMS0xLTA_46298776-07a1-46dc-b4da-7eeb817df849"
      unitRef="usd">1787000000</us-gaap:EquitySecuritiesFvNi>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzEwLTctMS0xLTA_e44f6621-5e4b-45f8-a5bd-7eed6a5da91a"
      unitRef="usd">1733000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTo3YzlmMDc2ZjkxY2I0NWU0YWI1NjUxNTQzMTMzMzFjYy90YWJsZXJhbmdlOjdjOWYwNzZmOTFjYjQ1ZTRhYjU2NTE1NDMxMzMzMWNjXzEwLTE1LTEtMS0w_be035657-1e5a-4a20-839a-b9be77851ff5"
      unitRef="usd">1876000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwMjg4_c1601801-e4d9-437f-bd95-d12b62230b87"
      unitRef="usd">-232000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwNDA4_3589bda4-db2a-4b36-b53e-01708a366ce0"
      unitRef="usd">163000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwNDU3_b9db6412-f9b4-4a64-bd9f-004fc6608360"
      unitRef="usd">596000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwNDY0_f85487e9-46d1-4abf-a6d4-c3abd511bfc9"
      unitRef="usd">586000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwNjMy_16a47a63-662d-48ea-bcbe-11958cb92735"
      unitRef="usd">110000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwOTk1MTE2NDkxMzU_b6b36c01-f6eb-4be9-8cbd-7edc4f5702aa"
      unitRef="usd">1000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwOTk1MTE2NDkxNTY_95a0b586-71a7-4a52-baf7-a4d53a6cb54d"
      unitRef="usd">62000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEwOTI0_8d83aa02-a595-4b56-90dd-ad8e8a19f821"
      unitRef="usd">3000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzExMjQx_3bf8904b-fb19-4f1d-8f73-9bf76161aace"
      unitRef="usd">234000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzExMjQ4_40a486dc-d41e-4b0b-a896-cd9d56c76d5a"
      unitRef="usd">7000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjczNjU_c9223316-cee1-4d5d-9af4-fbc58004c918"
      unitRef="usd">1700000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjczNzk_085ec0b1-2b3a-4804-978a-b9c5388637fb"
      unitRef="usd">800000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjczOTM_316f0acb-33b5-4c1e-b2bb-3c03506349ae"
      unitRef="usd">1400000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0Njc0MDc_b353a358-c127-4f3f-8374-842fea1b99ee"
      unitRef="usd">583000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0Njc0MjE_7a25735b-711a-4520-9dc2-1d8e81e97de1"
      unitRef="usd">-113000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjI5_bcbd594f-4cb7-408a-a775-0746d132f0ca">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;370&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,363&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,363&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160; Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a5e799c31be4b2b97f3af704a0044b9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMS0xLTEtMA_c5f0683b-3194-40d6-a3e7-ca780d4d72e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic7088d09c4094d16b9f7a4d53c7aa102_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMy0xLTEtMA_afc17bb4-0520-47a1-a566-379ce6df4ad1"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief2d0cb66d6843a2b24234f1871d47d9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtNS0xLTEtMA_abbe834b-9baf-409b-acfe-577c905dc98b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7753d387d18e460ba9fe6aa0c2630a87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtNy0xLTEtMA_1a355c67-7827-4b75-94f7-bea1f6e7fe1d"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2278c012f1844a228077b20f27d2ee75_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtOS0xLTEtMA_38d95664-8069-4767-bdab-469bcf814dfc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfb2266cfce24ebfb26a77e0821736a3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMTEtMS0xLTA_eee724b4-5910-4106-aa52-3db3ee6b7319"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c3ce1e7833a43afb07fd5c57894ed59_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMTMtMS0xLTA_bbffade5-6ccc-47f6-b612-3d76dd07055d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9eec4c9abea402cbed26716dfe0330c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzUtMTUtMS0xLTA_394e7751-f44e-4614-bce6-a85afa1e28ae"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4fe99227a96e498abb64a74bdc78ffa9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTEtMS0xLTA_da35f57e-15e4-465c-b197-a90c4590cfb7"
      unitRef="usd">368000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7d46b377a489415a9f6e4c66fe01bf48_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTMtMS0xLTA_2235b091-4372-444b-9554-5ed80efe153e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie06b300d5fc54b4b9783aa98a7eb7558_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTUtMS0xLTA_c1422ced-893a-47ca-88eb-ac0641583624"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4bd24ccfb9ef45e5b7c7e11d85d3c5a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTctMS0xLTA_bd68c5bb-b9b5-41af-b7f3-9395eccf7f84"
      unitRef="usd">368000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id4831a0db655443696586e7bf7801c3a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTktMS0xLTA_cd5fe5f4-d24e-48a5-8d18-f4ed689632dd"
      unitRef="usd">780000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if5cd4dd6f92f4fb4aeba7cc718e0b003_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTExLTEtMS0w_7dcbc4be-786f-4e1b-9040-802ef6697876"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i98b812ad7f9c4916b7d12f5ddf65dea2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTEzLTEtMS0w_f23b4443-d1b1-4eb6-bc2b-841423dc4214"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if476e20ccbac40da9954263fe92cc4a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEwLTE1LTEtMS0w_0d1e4768-3f8e-4d75-924a-ec1b3fdf9f6b"
      unitRef="usd">780000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:TradingSecurities
      contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTEtMS0xLTA_f4e651cd-d5ca-47bd-91f7-5da370e6d826"
      unitRef="usd">368000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTMtMS0xLTA_a1cb33f3-5b15-4b6e-81da-5e5f7505b15f"
      unitRef="usd">2000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTUtMS0xLTA_fa3bfbbc-aa76-4bec-bbd4-b924dfa4daa3"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTctMS0xLTA_3b81c51d-bdba-4d13-a474-e7048281d58e"
      unitRef="usd">370000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTktMS0xLTA_f18913b2-f2c1-48e1-bdb3-6bae102c2cb4"
      unitRef="usd">780000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i9d0972f005da4b289e0431985712cca1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTExLTEtMS0w_cb4ccd9f-d623-404a-b83d-cf50eea4d91d"
      unitRef="usd">5000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTEzLTEtMS0w_c41971f5-90a1-495a-bc4f-0815b8cc5389"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzExLTE1LTEtMS0w_be7a0cba-dde7-4763-b486-18b78b2cfe9f"
      unitRef="usd">785000000</us-gaap:TradingSecurities>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia75d16e884674d4b891ec0ff23d5093a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTEtMS0xLTA_28b411b6-4a40-4bdb-af8d-b3c62be3f85d"
      unitRef="usd">80000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifd6d94719de4466686b830a0d3f35adc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTMtMS0xLTA_956d25ae-d150-46f2-830a-933265da057c"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i67eac5db6f054e3180b3bf214875c398_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTUtMS0xLTA_878df8d6-d574-48b8-a937-e83c76b5795d"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1f2922f1eb3341d59ffc36b1dec737f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTctMS0xLTA_c16db914-b6a5-4f79-a172-5267bf1fa8ff"
      unitRef="usd">80000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6772ab94dd5b401f86bc3a27f2707c7f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTktMS0xLTA_3deec615-1b4c-4a44-a900-244d6a2d9eab"
      unitRef="usd">84000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ief19c5f56cee4d83ac0c396c293b6749_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTExLTEtMS0w_5ffa7021-a1a3-4588-a9dc-575e303e3781"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i65dd20d822a044fa906443ea329c9a4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTEzLTEtMS0w_d3ed0176-9f56-4d65-9f53-bea8f7957972"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if6df1f9215da4dd8b4038a15c4d03869_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzEzLTE1LTEtMS0w_46417332-bbd8-46f4-8f1b-42aca3717bc7"
      unitRef="usd">84000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0e2c14bb74904e8c96d89c5cd96c9212_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTEtMS0xLTM4Njky_84538a72-f430-4fa8-a075-b78d51d4a540"
      unitRef="usd">4000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6c7f502712974d0099042d3487baaba4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTMtMS0xLTM4NzAx_a36514c0-6fb0-4703-acec-1e0c0873bc26"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia5e50550f1a1441eb77bd65c2709b78d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTUtMS0xLTM4NzAx_29c6c0bc-c6c4-4ea2-9282-bed0acab8d3b"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i10944a8fad9a45dbad295162e3f81b90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTctMS0xLTM4NzEy_f28a5abc-4396-4dee-adb2-aa4dcc80d050"
      unitRef="usd">4000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0a924a8c7478492599a96afaa7e429bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTktMS0xLTM4NzA4_3059343d-de43-48d2-9111-5ff43541a641"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id51fe3efcb094b65bcae5a4a5eb91051_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTExLTEtMS0zODcwOA_a40e391b-6bef-4f4b-ac18-e20ec554ada7"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i07ddf9e42a484a8ab8fe46200c4b1460_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTEzLTEtMS0zODcwOA_b5fdbfab-f9d9-4993-ba2e-ce3477a5b84b"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id87fd36653fe4e028384eb4df59b37d6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTE1LTEtMS0zODcxMg_8e689044-bf16-4b81-973c-261de3be77d4"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4fe99227a96e498abb64a74bdc78ffa9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTEtMS0xLTA_e025b02a-39ad-44f5-8626-b3102718edc2"
      unitRef="usd">1279000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7d46b377a489415a9f6e4c66fe01bf48_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTMtMS0xLTA_35d7b1af-318d-4028-ab70-97e790f9ecc3"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie06b300d5fc54b4b9783aa98a7eb7558_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTUtMS0xLTA_dcccd37a-360a-457e-83aa-fce6cec08696"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4bd24ccfb9ef45e5b7c7e11d85d3c5a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTctMS0xLTA_c6324188-a72a-460e-90bb-86cc25f2bccc"
      unitRef="usd">1279000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id4831a0db655443696586e7bf7801c3a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTktMS0xLTA_51b0861d-8e13-476e-b6e0-80ba726ee3d0"
      unitRef="usd">1007000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if5cd4dd6f92f4fb4aeba7cc718e0b003_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTExLTEtMS0w_2363732d-4106-4497-a026-3a996668a112"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i98b812ad7f9c4916b7d12f5ddf65dea2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTEzLTEtMS0w_56ca71e2-20a5-4815-b5eb-c034135bf4bf"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if476e20ccbac40da9954263fe92cc4a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE0LTE1LTEtMS0w_b94e5702-b670-4511-a136-899f7a4d873e"
      unitRef="usd">1007000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTEtMS0xLTA_1844f958-958e-4b19-a2e4-c4430c3199b7"
      unitRef="usd">1363000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTMtMS0xLTA_808fafdb-1f3d-407b-aa4b-0a292451fbad"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTUtMS0xLTA_ac557872-f728-4608-ab36-bc53472238a0"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTctMS0xLTA_fdbe25a5-556b-47d8-86f5-9b08e9e8d0a3"
      unitRef="usd">1363000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTktMS0xLTA_8d1a2ef1-8abd-4525-b056-d41584c25143"
      unitRef="usd">1091000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9d0972f005da4b289e0431985712cca1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTExLTEtMS0w_e207744d-b14e-4f55-9878-54d5389b941f"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTEzLTEtMS0w_3debc0d5-2f26-4411-b384-040c3a77cabb"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTE1LTEtMS0w_5a46d699-6827-4515-8eb8-e3f0802903b6"
      unitRef="usd">1091000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DerivativeAssets
      contextRef="i87476d0b8816403891dc417aaa9709e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTEtMS0xLTA_908ae9d4-b8f0-4440-acce-7f5901bf69ba"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iaab118969b6042d18ed16e3ea6721990_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTMtMS0xLTA_f2e90347-c054-45a9-a8dd-64e66a83a3fa"
      unitRef="usd">351000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i137f81c1d5584d34869c5b39909172a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTUtMS0xLTA_1ce7e848-be48-4e92-986e-ae287ea1b825"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i96634206fbd44c669c42fbc69576e46c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTctMS0xLTA_e0ae27b2-4daa-40d4-86fc-9a1c83cead4c"
      unitRef="usd">351000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iedcde32f3e3347d6ad26d923ef7bf728_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTktMS0xLTA_b27bbe7e-c8b3-4429-baf9-f8368a3286a5"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i023622ad5898409ea6e74a7865b4ad94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTExLTEtMS0w_26bb37c5-b03a-49ba-87f4-dd6746263815"
      unitRef="usd">90000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i00b4c1c59dd545679bbdd8960724fdb8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTEzLTEtMS0w_71d57a49-6dc9-4284-af87-8c705775a3b1"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idd18623cbffe4173b5c074fecac0d9ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE3LTE1LTEtMS0w_26b5b871-5e61-441a-99ac-c3cf7c067635"
      unitRef="usd">90000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i89f7d706f0cb44e4b3153791e14d9f6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTEtMS0xLTUwMDQ1_b1ee4890-efa6-434c-99b6-295732d92ea8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i374759bb016f41888888e78791dd4ab0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTMtMS0xLTUwMDQ1_3a829142-8d9e-4915-9522-18d9dd947c90"
      unitRef="usd">184000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib68fef76e57547f7bdc2cbb70b67de87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTUtMS0xLTUwMDQ1_e157a018-c41a-41be-a6ae-bf3badc53604"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3f9444d5b1664f58a02728dfddbf063e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTctMS0xLTUwMDQ1_efc30a49-85a1-4a28-aba7-29430afc4760"
      unitRef="usd">184000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i040ff5ea36d3484ea651ef737fdff71a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTktMS0xLTUwMDQ1_574498d9-69ad-4079-82f9-920176baf565"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if97446d23ecf43389079d10a5ca90ec7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTExLTEtMS01MDA0NQ_afa0c9ff-c707-4496-bd20-cc027467a1f5"
      unitRef="usd">37000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4f2ba44854df404fa52145c11e69cd99_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTEzLTEtMS01MDA0NQ_6506e091-0f91-47b0-aa4e-44bbd13b4422"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id66a61dac3da49dcaba07eaff95d4ed3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE1LTE1LTEtMS01MDA0NQ_4c4e3272-c9fb-43d7-afa0-25e793a7e71c"
      unitRef="usd">37000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7a6ab54db1664800b50dfbdaff4462cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTEtMS0xLTA_ee7b80cc-11fb-4421-8783-913de2b4ac29"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i833b3ba93d614377a2cfecac4c5866e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTMtMS0xLTA_09b0f4b8-e9f3-48ef-93f5-4f94b557eb02"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0dbc4d9a77694d4e882a111f60ec428f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTUtMS0xLTA_e459fcef-109c-44d0-ae7d-9a0b04d389fb"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8ec83c194e1744edba2a8a35ddd3a21f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTctMS0xLTA_564b2c3d-ef3b-40cc-82cd-99b6c5f0d5fa"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i45f95df00da14c09af18c27401b54ae3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTktMS0xLTA_483d9e05-d9b2-4de6-810f-5219f9d1e370"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i132e97951baa4113bcc1bae3044eb719_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTExLTEtMS0w_151b9a32-7774-4c91-b753-f6d178c99959"
      unitRef="usd">55000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ieb83adad926e453482286d737c575b36_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTEzLTEtMS0w_5217b5e9-fd2e-4400-afbc-c1274e08b2dd"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i93d7907189bb4207bb49c42bee6f1dfd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzE4LTE1LTEtMS0w_a8b5177a-f361-4a59-845a-35baf39ddf89"
      unitRef="usd">55000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTEtMS0xLTA_8fe2598f-2b32-43a8-b09c-85d7a48ca6ac"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTMtMS0xLTA_44076a15-c71a-4fdf-86cb-31a8401e04d6"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTUtMS0xLTA_b6c98a36-68f6-4734-a901-35ee7d5ad302"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTctMS0xLTA_3ce3bc38-90ca-42af-9733-77c2867fafad"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTktMS0xLTA_a7d43569-63d3-4d82-9280-8e680dc7a413"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9d0972f005da4b289e0431985712cca1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTExLTEtMS0w_4717fea5-8470-44db-aecb-dadf6bde377e"
      unitRef="usd">182000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTEzLTEtMS0w_fbef2681-423b-45c7-bbd8-a4f241ed62c2"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIwLTE1LTEtMS0w_763dcf9b-625f-4c38-a4ee-f924b81f17dd"
      unitRef="usd">182000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTEtMS0xLTA_42c08107-978f-4815-ba72-acbae1f433ec"
      unitRef="usd">1731000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTMtMS0xLTA_9aa7fe45-bdba-4e9f-a302-4357aab5834d"
      unitRef="usd">551000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTUtMS0xLTA_78e690a0-5ea0-4df7-817c-2044fcdabee9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTctMS0xLTA_9ef20c9f-45bc-4039-a92e-4f4cd7481d59"
      unitRef="usd">2282000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTktMS0xLTA_93f01b94-5d46-4ff1-8dfa-151083789598"
      unitRef="usd">1871000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9d0972f005da4b289e0431985712cca1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTExLTEtMS0w_e9cc52d1-fda3-4e19-b6e5-48ba30696072"
      unitRef="usd">187000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTEzLTEtMS0w_ec67f072-7593-4a5a-bb05-53dada3d5954"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzIxLTE1LTEtMS0w_14c84454-51fb-4b94-ae7e-53636cd63b13"
      unitRef="usd">2058000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTEtMS0xLTA_cf9359ad-0563-454c-9bf5-151b70c92248"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTMtMS0xLTA_e46d301f-061e-4bb4-bba8-192fed5f8db9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTUtMS0xLTA_f3f5c16c-d9dc-498b-8345-5b372189f3a3"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTctMS0xLTA_17c4164d-472a-4d1b-a802-5e68a3617440"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTktMS0xLTA_b29a199e-19a2-40b0-998f-07fc2a561a8a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9d0972f005da4b289e0431985712cca1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTExLTEtMS0w_310a82ac-3bad-402a-8895-4ba589131065"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTEzLTEtMS0w_ee3a9cc6-573b-4ec0-b91e-73938b929a69"
      unitRef="usd">841000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI0LTE1LTEtMS0w_6f67912e-0c40-4b05-8d86-dd71cea1d0fe"
      unitRef="usd">841000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="i87476d0b8816403891dc417aaa9709e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTEtMS0xLTA_0c10c765-fc8b-47ed-889d-5a552dda807c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iaab118969b6042d18ed16e3ea6721990_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTMtMS0xLTA_707cac5e-4b7f-404d-be57-8ea76b75a278"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i137f81c1d5584d34869c5b39909172a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTUtMS0xLTA_24a6b2f2-2f97-4745-8674-53462e341bdb"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i96634206fbd44c669c42fbc69576e46c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTctMS0xLTA_460f4272-da18-4691-81fb-40b3d5eed747"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iedcde32f3e3347d6ad26d923ef7bf728_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTktMS0xLTA_bdd3606d-245a-4f78-a2c8-8c9a7978edf9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i023622ad5898409ea6e74a7865b4ad94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTExLTEtMS0w_b879d195-8285-4a84-a3e9-dbb49c7f2d38"
      unitRef="usd">505000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i00b4c1c59dd545679bbdd8960724fdb8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTEzLTEtMS0w_28f362fb-0c57-42e8-80cd-6382a339afe8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="idd18623cbffe4173b5c074fecac0d9ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI2LTE1LTEtMS0w_7fa1ca56-34c8-4162-ae0a-d2e05fc6ad9c"
      unitRef="usd">505000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i89f7d706f0cb44e4b3153791e14d9f6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTEtMS0xLTA_a09a2883-7a87-4079-b975-078f90489c81"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i374759bb016f41888888e78791dd4ab0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTMtMS0xLTA_f9589d8f-8f20-422e-9cd7-f242720829f2"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib68fef76e57547f7bdc2cbb70b67de87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTUtMS0xLTA_6084e9db-90f1-48d3-bc53-4042504ec717"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3f9444d5b1664f58a02728dfddbf063e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTctMS0xLTA_d17b352a-a31b-4212-917c-f9f1aaa01167"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i040ff5ea36d3484ea651ef737fdff71a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTktMS0xLTA_53c0144c-61a3-4391-867b-d0f608b8614e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if97446d23ecf43389079d10a5ca90ec7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTExLTEtMS0w_350e5120-8820-4af0-9511-bb136ce3f0bf"
      unitRef="usd">20000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4f2ba44854df404fa52145c11e69cd99_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTEzLTEtMS0w_68dae751-061a-42a0-91f1-cd178a719e37"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id66a61dac3da49dcaba07eaff95d4ed3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI3LTE1LTEtMS0w_225d575f-ac71-4d57-ba56-882e34c908ff"
      unitRef="usd">20000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTEtMS0xLTA_bd029d7f-416d-483e-8070-c76b5cd14f50"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTMtMS0xLTA_09338bfb-02c3-4a3c-a095-717d0dedcb42"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTUtMS0xLTA_cbb8ec59-72f9-4119-a672-786755d37a12"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTctMS0xLTA_aa26241b-bbc6-4cf0-86d3-20cde2f7c44b"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTktMS0xLTA_ce7eb526-4689-4716-bbbe-51a23249eb95"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9d0972f005da4b289e0431985712cca1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTExLTEtMS0w_b84752ac-d571-4b63-8b73-fe19ebfcedaf"
      unitRef="usd">525000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTEzLTEtMS0w_511eb2f1-5980-47b1-a7b7-6ae048c11ea5"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzI5LTE1LTEtMS0w_987697f7-ef86-4802-8131-bb022686895a"
      unitRef="usd">525000000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i380f7c1970374c70a7b006dd0d7d14d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTEtMS0xLTA_06ed4381-0098-4618-b30d-059f646a7eee"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i48cd974a9dc24b368f72dbb106104fdb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTMtMS0xLTA_8eabe1fb-627f-4cfa-8be1-80db84e44679"
      unitRef="usd">121000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if49bf71bb091429a952fad2e1c3ff77b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTUtMS0xLTA_8b207591-5a8e-4eb4-b9e0-7e15422f095a"
      unitRef="usd">777000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTctMS0xLTA_0274097c-6654-4716-9637-f12cb13a170e"
      unitRef="usd">898000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i64f9cfb107d04007a2a989ea4edc5d95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTktMS0xLTA_fff62128-173e-46ea-b26c-324e0a8c5c99"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9d0972f005da4b289e0431985712cca1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTExLTEtMS0w_4e0522bd-10ae-4c37-bb76-a519725f5e50"
      unitRef="usd">525000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3fc26049b03349d5a347c39c0b1c2d52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTEzLTEtMS0w_7b661ce7-758a-4978-a487-9eaf2e14bc3e"
      unitRef="usd">841000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6c54ecd1eedd4c9f9f563dd70056b333_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplMGZmNzY5NDA0NzQ0MTk0OWUyNjI5ODAwMTU5ZWYxYS90YWJsZXJhbmdlOmUwZmY3Njk0MDQ3NDQxOTQ5ZTI2Mjk4MDAxNTllZjFhXzMwLTE1LTEtMS0w_8bdf0277-2dd2-44ef-8b2a-61851b31dd4d"
      unitRef="usd">1366000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i6fabc58b05ff44ed9522b607c9a248bc_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzNDIz_3182fc8b-66e5-46a8-9fc7-15e60d525eb5"
      unitRef="usd">6800000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i774c5a342b514fc886c9641360c25a17_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzNDIz_5b396db0-8092-4527-ba09-90cc5012f547"
      unitRef="usd">6800000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE5MjEx_bbd377a3-e881-428d-afa2-a9588dd2e833">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Balance at December&#160;31, 2021 includes $151 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; At December&#160;31, 2021 and 2020, $620 million and $711 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzEtMS0xLTEtMA_bfc255ab-aae5-4618-8870-1c22bce8b5ef"
      unitRef="usd">841000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzEtMy0xLTEtMA_46f75c70-01dd-494f-9fb7-32a8ae4614b1"
      unitRef="usd">767000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzItMS0xLTEtMA_2ab323e4-d270-4341-b956-a8d8f5bd2c9e"
      unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzItMy0xLTEtMA_6d80a68b-1d64-46d6-8767-d2c0f7804424"
      unitRef="usd">97000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzMtMS0xLTEtMA_d5594988-50bd-4de1-9876-dd5ca4bda562"
      unitRef="usd">57000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzMtMy0xLTEtMA_3b063d17-a524-44b3-bf25-4bc41de202f3"
      unitRef="usd">83000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzQtMS0xLTEtMA_f3bcaaf1-f6e5-4c61-a9a3-493689646195"
      unitRef="usd">109000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzQtMy0xLTEtMA_1b10895c-e6c0-459d-80a9-9005715d6167"
      unitRef="usd">106000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzUtMS0xLTEtMzg0NTQ_434610f5-987f-4428-a793-878620d3cd39"
      unitRef="usd">12000000</mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther>
    <mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzUtMy0xLTEtMzg0NTQ_6b47162d-f0e9-49df-b752-1df4bac1db9a"
      unitRef="usd">0</mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzUtMS0xLTEtMA_df996d54-9903-40b3-ad74-caf603cd703f"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90YWJsZTplZDQ0MWQzZDlkYzk0YzYyYmIwM2EwYTNiNzdiNzY0ZS90YWJsZXJhbmdlOmVkNDQxZDNkOWRjOTRjNjJiYjAzYTBhM2I3N2I3NjRlXzUtMy0xLTEtMA_c602407d-0bde-48d4-885d-c81b2a6b5887"
      unitRef="usd">841000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzODcx_03a1a45d-b930-4e34-ab50-a9e865f68b76"
      unitRef="usd">151000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i70b17ce920094858a99911bb86e14711_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzOTgz_746fb80b-3d91-4e4f-94a3-4fe8e3485c62"
      unitRef="usd">620000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if376a86c326f475d9363b305b989f5ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzEzOTkw_315b6320-cb8c-4dac-be23-a197d8d2d48e"
      unitRef="usd">711000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i70b17ce920094858a99911bb86e14711_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE0MTk5_7fd7e507-8504-4b0d-9f35-bfdd4aad4917"
      unitRef="number">0.115</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i32c6fca8f8164d468cff272eeba8634f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE0NDYx_3d51cf08-a809-4619-9d50-9c827e502b16"
      unitRef="number">0.08</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE1NDY0_6cfddb1c-4cbf-4a0e-96fe-2efe3aad69ff"
      unitRef="usd">35700000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE1NTAx_9fe193ea-561b-4606-be93-68d5788d2e3c"
      unitRef="usd">33100000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE1NTE5_27a83acd-5a43-433f-a486-73b4deb8d9cb"
      unitRef="usd">36000000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE1NTU2_57fad1bc-c6da-4c7e-a228-942b05d23b62"
      unitRef="usd">31800000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if47597a8ab7540518bde99ada02a6412_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzM4NDgyOTA3MjE5OTg_fb9cccfd-9980-40d1-93df-3d54fc6528d6"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iba40621af6f34b0c95e94ed7710c5944_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzM4NDgyOTA3MjIwMDM_5e24cf80-f6b7-42ed-97f7-a16a7d069878"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i70af15b795b3483b886c630cdd41133d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzM4NDgyOTA3MjIwMDg_630fd87f-7370-40a6-95d7-a57d2df6bb97"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableSale
      contextRef="ie64824a2ab1d473089f51fd77c18511b_D20211001-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE3NDQz_f618a00a-9056-4fb5-930e-d6b2fd07a065"
      unitRef="usd">2800000000</us-gaap:AccountsReceivableSale>
    <us-gaap:AccountsReceivableSale
      contextRef="i4fe9a0ab54434720b0cf1a566885c13a_D20201001-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE3NDUw_a37ddbca-60ca-4116-82ae-debdfb3cae82"
      unitRef="usd">2100000000</us-gaap:AccountsReceivableSale>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE3OTg4_b080deb5-9699-46c7-b97c-41876c03878e"
      unitRef="usd">62000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE3OTk1_b343a710-e006-42c3-8665-aa34eeff8dff"
      unitRef="usd">102000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjE2MDc_87f811eb-7d75-43cb-878c-6fe25063bf43"
      unitRef="usd">164000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjAvZnJhZzo5NzdhNjgyOWYyYTk0YWUzOWI4MDU0ODU5YjUxNWQyMy90ZXh0cmVnaW9uOjk3N2E2ODI5ZjJhOTRhZTM5YjgwNTQ4NTliNTE1ZDIzXzE2NDkyNjc0NjE0Mzg_b6f900ff-79ad-40ce-bfec-8397b4e91ba0"
      unitRef="usd">36000000</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzU0Mg_a9e90795-a5c9-47f6-9b4c-24c336ba00f2">Inventories&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,953&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories valued under the LIFO method comprised approximately $3.3 billion and $2.8 billion at December&#160;31, 2021 and 2020, respectively. Amounts recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are comprised almost entirely of raw materials and work in process inventories. At December&#160;31, 2021 and 2020, these amounts included $1.9 billion and $1.8 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $256 million and $279 million at December&#160;31, 2021 and 2020, respectively, of inventories produced in preparation for product launches.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzU0NQ_0f221c21-5492-4277-a766-5faa090a86d1">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,953&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzEtMS0xLTEtMA_38b54029-9be3-4f3f-bac6-4e05e2a616af"
      unitRef="usd">1747000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzEtMy0xLTEtMA_83b25cc6-9a94-4d7a-9307-903b55536152"
      unitRef="usd">1610000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzItMS0xLTEtMA_5647ec3d-5a77-4c55-be2f-20b0ef6518df"
      unitRef="usd">6220000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzItMy0xLTEtMA_d5638c43-2abf-4844-a65d-45fa50a33dd6"
      unitRef="usd">5949000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:OtherInventorySupplies
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzMtMS0xLTEtMA_26051a24-ed99-4bec-8376-63a86b17143d"
      unitRef="usd">196000000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzMtMy0xLTEtMA_d7530144-3711-4a1e-a682-c4663cee2959"
      unitRef="usd">146000000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryGross
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzQtMS0xLTEtMA_3024d344-5491-47c3-9873-ce86b77686ba"
      unitRef="usd">8163000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzQtMy0xLTEtMA_2db94539-6598-41fc-8a6d-0e10222241bc"
      unitRef="usd">7705000000</us-gaap:InventoryGross>
    <us-gaap:InventoryLIFOReserve
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzUtMS0xLTEtMA_a3cd3bbf-8af8-47c1-b8ec-5c059fc82b2a"
      unitRef="usd">16000000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryLIFOReserve
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzUtMy0xLTEtMA_fbbc0db6-af74-4429-9d9d-d20c70cf82b2"
      unitRef="usd">81000000</us-gaap:InventoryLIFOReserve>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzYtMS0xLTEtMA_5bc94dab-42f2-4276-a724-8867147575aa"
      unitRef="usd">8147000000</mrk:InventoryNetAndInventoryNoncurrent>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzYtMy0xLTEtMA_7e4efb17-f9ba-4874-858d-90b019fcbb2a"
      unitRef="usd">7624000000</mrk:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzgtMS0xLTEtMA_d2cd7aa5-38b2-424a-9d8e-8646d46c4c00"
      unitRef="usd">5953000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzgtMy0xLTEtMA_89ff8182-848f-40af-b0ae-4cf86e27d145"
      unitRef="usd">5554000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzktMS0xLTEtMA_6a53971d-ad4d-47a4-8228-00e7a99d472e"
      unitRef="usd">2194000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90YWJsZTo5MmFhM2JmNmQxNzg0ZTEzYjA2ZDE0OWJmZjkyODQ0My90YWJsZXJhbmdlOjkyYWEzYmY2ZDE3ODRlMTNiMDZkMTQ5YmZmOTI4NDQzXzktMy0xLTEtMA_8fd49b83-e033-4b5e-a8b0-d7ae035b8b4a"
      unitRef="usd">2070000000</us-gaap:InventoryNoncurrent>
    <us-gaap:LIFOInventoryAmount
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzEzMQ_58f6f3cc-00a0-4023-a0dd-db03d90038f1"
      unitRef="usd">3300000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:LIFOInventoryAmount
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzEzOA_1145578e-b633-4581-87a3-a5ae452cc4a4"
      unitRef="usd">2800000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:InventoryNoncurrent
      contextRef="if11ef0dcf23f4836b169d65009b32b67_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzMyMQ_191c0c37-6841-4d22-85f0-870d27e854cf"
      unitRef="usd">1900000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i9281f223aedf4b3bb8e9b4c609a7ffcd_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzMyOA_fd78f08e-8875-449f-8ec2-546adf82a48b"
      unitRef="usd">1800000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="if3aec1ab29624b00ae21ee1541745253_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzQzOA_93d50847-afd7-4ac7-b466-49d59d0e3960"
      unitRef="usd">256000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i603759dc019d4b2a92e63a7c43c81202_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjMvZnJhZzo5MmY4NjI3ODg2MTM0YTZlOWJmMzZmNmQwNTIxNjExNS90ZXh0cmVnaW9uOjkyZjg2Mjc4ODYxMzRhNmU5YmYzNmY2ZDA1MjE2MTE1XzQ0NQ_f8e9bdb1-8f86-49c8-a064-9d2c98387ce7"
      unitRef="usd">279000000</us-gaap:InventoryNoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMTY_c0f30196-5f1c-46d7-9f31-17f8d9912fed">Goodwill and Other Intangibles&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes goodwill activity by segment:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,997&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,264&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments on goodwill balances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The additions to goodwill in the Pharmaceutical segment in 2021 were primarily related to the acquisition of Acceleron. The additions to goodwill in the Pharmaceutical segment in 2020 were primarily related to the acquisitions of ArQule and Themis. See Note 4 for more information on these acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other acquired intangibles at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products and product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,776&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,895&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,389&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,604&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired intangibles include products and product rights, IPR&amp;amp;D, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. Some of the more significant acquired intangibles, on a net basis, related to human health marketed products (included in products and product rights above) at December&#160;31, 2021 include &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $3.8 billion; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $478 million;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Gardasil/Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 9, $191 million; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $145 million;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Dificid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $145 million;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $138 million; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simponi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $101 million. Additionally, the Company had $5.0 billion of net acquired intangibles related to animal health marketed products at December&#160;31, 2021, of which $2.3&#160;billion relate primarily to trade names obtained through the 2019 acquisition of Antelliq (see Note 4). At December&#160;31, 2021, IPR&amp;amp;D primarily relates to MK-7962 (sotatercept), $6.4 billion, obtained through the acquisition of Acceleron in 2021 (see Note 4); MK-1026 (nemtabrutinib), $2.0 billion, obtained through the acquisition of ArQule in 2020 (see below and Note 4); and MK-7264 (gefapixant) $832 million, obtained through the acquisition of Afferent Pharmaceuticals in 2016. Some of the more significant net intangible assets included in licenses and other above at December&#160;31, 2021 include Lynparza, $1.1 billion, related to a collaboration with AstraZeneca; Lenvima, $1.0 billion, related to a collaboration with Eisai; Adempas, $806 million related to a collaboration with Bayer; and Verquvo, $68 million, also related to a collaboration with Bayer. See Note 5 for additional information related to the intangible assets associated with these collaborations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company recorded an impairment charge of $1.6&#160;billion within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible asset for impairment. The Company revised its cash flow forecasts for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120&#160;million to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in 2020 related to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recall. A phased resupply of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was initiated in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company recorded impairment charges related to marketed products and other intangibles of $705 million. Of this amount, $612 million related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible Gram-positive organisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which indicated that the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; that, when compared with its related carrying value, resulted in the impairment charge noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;completion or abandonment of the projects. Upon successful completion of each IPR&amp;amp;D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company recorded a $275 million IPR&amp;amp;D impairment charge within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies, obtained in connection with the acquisition of ArQule (see Note 4). As part of Merck&#x2019;s annual impairment assessment of IPR&amp;amp;D intangible assets, the Company estimated the current fair value of nemtabrutinib utilizing projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect the current competitive landscape for nemtabrutinib, including increased expected development costs for additional clinical trial data needed to develop nemtabrutinib, as well as a delay in the anticipated launch date for nemtabrutinib, which collectively reduced the projected future cash flows and estimated fair value. Additionally, the discount rate utilized to determine the current fair value of the asset was reduced to 8.5% to reflect the current risk profile of the asset. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;amp;D impairment charge noted above. The remaining IPR&amp;amp;D intangible asset related to nemtabrutinib is $2.0 billion. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company recorded a $90 million IPR&amp;amp;D impairment charge related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck&#x2019;s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $45&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company recorded $172 million of IPR&amp;amp;D impairment charges. Of this amount, $155 million relates to the write-off of the intangible asset balance for programs obtained in connection with the acquisition of IOmet Pharma Ltd following a review of clinical trial results conducted by Merck, along with external clinical trial results for similar compounds. The discontinuation of this clinical development program also resulted in a reversal of the related liability for contingent consideration of $11 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IPR&amp;amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;amp;D programs and profitably commercialize the underlying product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense primarily recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was $1.6 billion in 2021, $1.8 billion in 2020 and $1.7 billion in 2019. The estimated aggregate amortization expense for each of the next five years is as follows: 2022, $1.7 billion; 2023, $1.6 billion; 2024, $1.6 billion; 2025, $1.4 billion; 2026, $1.4 billion.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMTM_60086d61-b14c-43c4-b5d5-e39eae78f6f4">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes goodwill activity by segment:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,997&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,264&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments on goodwill balances.&lt;/span&gt;&lt;/div&gt;(2) Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2021 and 2020.</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i5f1e538358a0404a97553c780f46ab33_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzEtMS0xLTEtMA_c5ee31e3-7e93-40d3-8d07-5b50df6ee39d"
      unitRef="usd">14825000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if1acd2394418419a847e9c266f2fd96b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzEtMy0xLTEtMA_d4b8fdbd-7b46-4611-89c6-8346f97d4f4a"
      unitRef="usd">3192000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2263f3e53dbf46e49603498a02a8dd4b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzEtNS0xLTEtMA_a194ee36-823a-43e4-adac-0b8ddabf340e"
      unitRef="usd">52000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzEtNy0xLTEtMA_dba67900-1ac0-48dd-8514-7e4a9f05445e"
      unitRef="usd">18069000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="idc491b98f87c48fb9a82e390d80b4690_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzItMS0xLTEtMA_d4ccf3a8-3dd0-4985-bf77-3fd18118b588"
      unitRef="usd">742000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i07617b881607408cb61cf2b2cf92be00_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzItMy0xLTEtMA_01e5a8f5-f9f9-481e-8517-e4d9e00879d3"
      unitRef="usd">105000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i052ad8a1361041b1a1e984ec500adab0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzItNS0xLTEtMA_92b39a45-b262-4116-9f5e-1575b634a1be"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzItNy0xLTEtMA_b43591bd-6536-4afc-9332-0c3482fc7090"
      unitRef="usd">847000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="idc491b98f87c48fb9a82e390d80b4690_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzMtMS0xLTEtMA_f22e0926-7f17-4c33-ab35-7254a7cf6662"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i07617b881607408cb61cf2b2cf92be00_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzMtMy0xLTEtMA_adb132ff-66b4-4ef1-aae6-fa9384b123cf"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i052ad8a1361041b1a1e984ec500adab0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzMtNS0xLTEtMA_3b8e7f11-8140-4422-8b03-f26c4b96fc1d"
      unitRef="usd">54000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzMtNy0xLTEtMA_7fdc242b-f611-458d-8e60-892caca5bebb"
      unitRef="usd">54000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="idc491b98f87c48fb9a82e390d80b4690_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzQtMS0xLTEtMA_7299a87c-43c9-4c87-b437-b5bf28dbeec1"
      unitRef="usd">47000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i07617b881607408cb61cf2b2cf92be00_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzQtMy0xLTEtMA_2f187da2-8465-45d4-90f5-900237da9d3a"
      unitRef="usd">-29000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i052ad8a1361041b1a1e984ec500adab0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzQtNS0xLTEtMA_34c7f5d3-bc5d-47c0-aa2f-327ba82c2649"
      unitRef="usd">2000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzQtNy0xLTEtMA_db5e2ad7-cd4f-4323-8b9d-52effb060984"
      unitRef="usd">20000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="idb26ec2f5da740a3bc8fbb26528a6eba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzUtMS0xLTEtMA_79b44d5e-a8c8-4a3b-b362-ef72226447a9"
      unitRef="usd">15614000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2606072a417c44aca18c5c159c178685_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzUtMy0xLTEtMA_bef1d02a-fd49-4cd9-bc2b-0da915ddab05"
      unitRef="usd">3268000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8a27173a90934ada9d520eceda174831_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzUtNS0xLTEtMA_ca26e1b0-5f1a-454b-82cf-1fa15a1cb470"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzUtNy0xLTEtMA_8fcf037b-9dc7-42bf-808d-843092a7a14f"
      unitRef="usd">18882000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iaed00c6f79924c5aac07fb1cde0defe2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzYtMS0xLTEtMA_952badba-4c82-4114-9e60-5565249155d6"
      unitRef="usd">2431000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i088cc2519a19414c8e3186d5e4e8a023_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzYtMy0xLTEtMA_bcc29e44-416a-4cb6-90aa-3a2c9abe02a5"
      unitRef="usd">5000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i4dbb367e3e5946fdae5de683a45bd0da_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzYtNS0xLTEtMA_8fba0e9f-a1fa-4bec-af72-35b6636af077"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzYtNy0xLTEtMA_202f6542-8f56-497a-8bae-7d39da54063e"
      unitRef="usd">2436000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="iaed00c6f79924c5aac07fb1cde0defe2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzgtMS0xLTEtMA_adff89ca-ebeb-4461-b864-5d30f9ae50b5"
      unitRef="usd">-48000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i088cc2519a19414c8e3186d5e4e8a023_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzgtMy0xLTEtMA_cd4fbc98-5c3c-49ee-ba6f-490c1878411f"
      unitRef="usd">-6000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4dbb367e3e5946fdae5de683a45bd0da_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzgtNS0xLTEtMA_845e85e0-4f8f-47be-9727-11bf53482bb0"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzgtNy0xLTEtMA_af208d8f-2dd5-4ce9-8c5f-2993ab79c6a4"
      unitRef="usd">-54000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i47d1b633d5da4aafad19b8e301c01923_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzktMS0xLTEtMA_c255f47b-8167-4f2b-be1c-2ae47075004f"
      unitRef="usd">17997000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ife16e0d66c324162af7d23d581f9e520_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzktMy0xLTEtMA_180a1256-a4a9-4724-9b52-9364c9038c54"
      unitRef="usd">3267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic859cf2414014f41b9ff0a1bc9a8edca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzktNS0xLTEtMA_bc1c06b5-e415-4c36-8a09-75450b148c72"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTo4ZDRlM2E0OWEzMTI0MmI0YWQyMDYyNjI5YTIxYzQ2NS90YWJsZXJhbmdlOjhkNGUzYTQ5YTMxMjQyYjRhZDIwNjI2MjlhMjFjNDY1XzktNy0xLTEtMA_bf5752d4-28b4-4f63-b0f8-c980a75185ec"
      unitRef="usd">21264000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzI2Mg_06835680-266f-4ee6-be19-a32460c0cb0f"
      unitRef="usd">531000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzI2Mg_8db071cf-1b1c-462f-bf06-459ed5c6b85a"
      unitRef="usd">531000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMzc_1990fc21-fe29-4576-9be0-93fe19f96794">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other acquired intangibles at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products and product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,776&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,895&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,389&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,604&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i922da6ff675f4e36b395123bd41f860c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItMS0xLTEtMA_8912fe7c-78fb-417d-853f-67a528a2fa4a"
      unitRef="usd">23671000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i922da6ff675f4e36b395123bd41f860c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItMy0xLTEtMA_393cd957-1378-4d88-893d-d0c07a434955"
      unitRef="usd">15776000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i922da6ff675f4e36b395123bd41f860c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItNS0xLTEtMA_eb87a0ba-a6fe-4935-b7f4-2959ba33b309"
      unitRef="usd">7895000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i5bf7db39f15a4eb598543794b5cb18d4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItNy0xLTEtMA_12ebbcd6-a4e6-450a-b628-d0192a6604b8"
      unitRef="usd">20928000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5bf7db39f15a4eb598543794b5cb18d4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItOS0xLTEtMA_3efc9251-4274-40f8-a333-28c2e4ec5f0a"
      unitRef="usd">16138000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5bf7db39f15a4eb598543794b5cb18d4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzItMTEtMS0xLTA_6c281c07-4aea-4d4f-a6b1-3fbe5f7a2774"
      unitRef="usd">4790000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i0418b77d11494b49b8670d97efc20a6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzQtMS0xLTEtMA_d6fd4153-5cd2-4c5a-b54e-8a6836bb2634"
      unitRef="usd">9281000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0418b77d11494b49b8670d97efc20a6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzQtNS0xLTEtMA_d0bb64c2-f872-4707-aad5-426dea7c39cc"
      unitRef="usd">9281000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i9287dd64826c40ae9176320df60031ab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzQtNy0xLTEtMA_b137af48-55a5-40b8-ae9b-e85be27fa971"
      unitRef="usd">3228000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9287dd64826c40ae9176320df60031ab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzQtMTEtMS0xLTA_1d23980a-4f22-4044-aad0-50e5a9be36b2"
      unitRef="usd">3228000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i4679263e59f543019e17c0b7fc2182cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtMS0xLTEtMA_134a7715-aa8c-458d-a8d3-2dcb91f20297"
      unitRef="usd">2882000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4679263e59f543019e17c0b7fc2182cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtMy0xLTEtMA_cab3d6ab-d947-4505-a5a3-55145cae97ea"
      unitRef="usd">493000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4679263e59f543019e17c0b7fc2182cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtNS0xLTEtMA_1c521e14-3883-4f03-b14f-14820eb36842"
      unitRef="usd">2389000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i62b877fdaf564761be440e19be29b2c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtNy0xLTEtMA_d0743b46-f423-4a9c-a5dd-30866c70e27c"
      unitRef="usd">2882000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i62b877fdaf564761be440e19be29b2c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtOS0xLTEtMA_ec49d73f-772a-415c-b1ad-7b30e16bdc13"
      unitRef="usd">352000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i62b877fdaf564761be440e19be29b2c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzUtMTEtMS0xLTA_82c7e3af-2bb6-4e85-9073-531c24ec2b91"
      unitRef="usd">2530000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2b8899dd9c654bfbac46b393cd7d3264_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtMS0xLTEtMA_4e585a3f-ddef-4c4b-aa5d-12c55cb1d07a"
      unitRef="usd">6604000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2b8899dd9c654bfbac46b393cd7d3264_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtMy0xLTEtMA_1feb0e05-9bca-4c1b-95aa-0f6b1699cba9"
      unitRef="usd">3236000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2b8899dd9c654bfbac46b393cd7d3264_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtNS0xLTEtMA_5441f6a2-332b-44a5-831e-e5e8195a71fa"
      unitRef="usd">3368000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ice2377a28ca84de48887e30dfe2d5537_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtNy0xLTEtMA_87d5b399-8e2a-4109-b9cf-9501fff1b19d"
      unitRef="usd">6199000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ice2377a28ca84de48887e30dfe2d5537_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtOS0xLTEtMA_5a5f5024-4931-44f2-9cd6-d5cc9fc73d38"
      unitRef="usd">2646000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ice2377a28ca84de48887e30dfe2d5537_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzYtMTEtMS0xLTA_2d9ddc20-40ea-4963-bdfc-fcb84163fa4c"
      unitRef="usd">3553000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctMS0xLTEtMA_b2e4085e-cd43-411b-858c-6776ddc9ea6e"
      unitRef="usd">42438000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctMy0xLTEtMA_08c97df1-5b2e-4277-b9dd-98209e78ca17"
      unitRef="usd">19505000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctNS0xLTEtMA_b2f3018c-bd09-40f3-8405-4d9ad7d0abae"
      unitRef="usd">22933000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctNy0xLTEtMA_e2ab50cb-4703-4917-bf0c-07906c2254cc"
      unitRef="usd">33237000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctOS0xLTEtMA_4e104ef2-ffc2-4b85-a1b0-9132de8d16fe"
      unitRef="usd">19136000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90YWJsZTpmYzU4MWNiNzVkOGM0ZTllOWJiNzc0ODNmYjkwODBiMi90YWJsZXJhbmdlOmZjNTgxY2I3NWQ4YzRlOWU5YmI3NzQ4M2ZiOTA4MGIyXzctMTEtMS0xLTA_6d1883d4-5f4d-4aeb-9a06-81a847fe3886"
      unitRef="usd">14101000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i332ad40fc06246e8899471a208f82f55_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDM3NjA_9b51b6ac-baeb-4faf-b498-5d062fbe79f2"
      unitRef="usd">3800000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i25cf501ae0374a8db4041a26e5ccaba7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEyNzY_1b68586e-c17c-45fa-89fa-f7cbae39e2a6"
      unitRef="usd">478000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1235021626ea40d68c48483cac1e238e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE2NDkyNjc0NjExMzM_2efb215d-8293-4c46-84bd-908a774cd0a5"
      unitRef="usd">191000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i571d3003c339474b8a92cd20e397f126_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE2NDkyNjc0NTc3MzU_408c7d49-cd1b-4225-b5f5-e8b07fcb133a"
      unitRef="usd">145000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i24d884f9483546dcbadd8236be97f3a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEzMzg_3fb6eff2-e549-4371-bbb9-5dc1bc181d54"
      unitRef="usd">145000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib27e295e010541d7a58a958648701bed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEzNjU_34277fde-00c1-4187-81cd-ba3f49c1a258"
      unitRef="usd">138000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie81297921b384692b3eb61bf4efc821e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEzODI_bb602d3c-7e33-455f-9e28-4582118280d7"
      unitRef="usd">101000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i34d6a0c4542c41ffa80fc7096731b88f_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE0MTY_9df5d22f-4f24-4c43-8933-d0cb3461f6f4"
      unitRef="usd">5000000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1188336496264ef18e60cdee67b0cb7e_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE1MDY_fdbdb381-9d00-4949-9486-ce076635e784"
      unitRef="usd">2300000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7e8562560c434644bad56e82266c221a_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDgyMjM_7d366802-c94d-4aa4-9078-a43ad2d7f115"
      unitRef="usd">6400000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie71ea2fb304b4cf08e846d2e023c3048_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDgyMzQ_23dfaff0-2071-423e-9f92-4806c1b59590"
      unitRef="usd">2000000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5e62506b0ff84122affab840c3ae7e5f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDgyNDA_00ede734-a2bb-4e74-a1fe-60ef02fbd42e"
      unitRef="usd">832000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4a357f883cf8403d91477b70cff00a8b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDk1MDE_92ef5404-3f58-432d-98e6-27b253527225"
      unitRef="usd">1100000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia8e076f12b4342f1b585a7f637e3c832_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDk1MTg_ef74dc73-b249-4f88-b2d1-a4679dbc982d"
      unitRef="usd">1000000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i00f8c65ee807407dab9ca51108c58857_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2MzYzMzk_1a16843a-0cc1-451b-ab25-981e28ce233a"
      unitRef="usd">806000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id18a472cdb414425a36e2fc4fc858400_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2MzYzNDQ_c812a141-b965-44ae-a9b4-4451e758a5ab"
      unitRef="usd">68000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i321bbe1dae804437a98c0bfa6c5e9802_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzIyMjk_a5d564f7-92cc-4d76-b563-4aad0c5bf6f0"
      unitRef="usd">1600000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:InventoryWriteDown
      contextRef="i321bbe1dae804437a98c0bfa6c5e9802_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzMyNzg_ebbfd8cf-c0d5-4b83-b502-2774905e90bc"
      unitRef="usd">120000000</us-gaap:InventoryWriteDown>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzM1Mjc_1b01f01d-5bf4-494f-af04-ab5401c325ef"
      unitRef="usd">705000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i60c730eccd1b44f8962e3a3b83bcdaf7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzM1NDc_e18f97fa-8d05-46bf-a0b5-7137440304d1"
      unitRef="usd">612000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i02366c725d8e4b61a487fbc509afa833_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzE2NDkyNjc0NTA0MTY_e967f4a0-730e-4589-8f80-5b7fe4e9fdfd"
      unitRef="usd">275000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="i3df148b8481d43589980b5d43c439d34_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzM4NDgyOTA3MTMxNzM_532b38ce-fc8a-4d78-b5df-7c2b4097d69a"
      unitRef="number">0.085</mrk:IntangibleAssetMeasurementInput>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie71ea2fb304b4cf08e846d2e023c3048_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2NDg0MDU_23dfaff0-2071-423e-9f92-4806c1b59590"
      unitRef="usd">2000000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2MzYwMzM_d1cd5afe-20ab-4e79-8ae7-55a91441c076"
      unitRef="usd">90000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i38be38fc4a954d74a422539b6c013245_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzU0NTY_741f1e7d-f570-4d3e-8db2-31e2376b0ec6"
      unitRef="usd">-45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzEwOTk1MTE2MzYwMjY_34422a2c-0a2f-47a1-bd4e-609d84b960a9"
      unitRef="usd">172000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="idf91833342104fa49cf3cfd60cca2c5c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzU1NTE_032e7ccb-f879-429c-aed9-a2b3f1fc7007"
      unitRef="usd">155000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="idf91833342104fa49cf3cfd60cca2c5c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzU5NjE_e8a49afe-1a87-4b5f-8602-a11ceed47634"
      unitRef="usd">-11000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzY5NDg_6488d598-0b14-42f6-a076-f1457547e517"
      unitRef="usd">1600000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzY5NTg_0d4035a0-e74a-4e07-a140-66f0792d3489"
      unitRef="usd">1800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzY5NzE_29548b7d-da20-4d7f-bc3d-3fa9f610bf4e"
      unitRef="usd">1700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcwNzc_585ece78-7071-4edf-b596-895bd28c30a2"
      unitRef="usd">1700000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcwODU_bf0ac298-2ad6-4e29-953c-eaebcc8a9a0d"
      unitRef="usd">1600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcwOTM_6b8fc779-9bdd-4090-98c4-beb23b0a42d4"
      unitRef="usd">1600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMDE_3ce12c56-1cbe-4345-ab04-a5bc2bea3854"
      unitRef="usd">1400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjYvZnJhZzoyOTZiYzk3M2M4MWY0ZjI4OGZiNWJiNDdiN2FkNmMyZS90ZXh0cmVnaW9uOjI5NmJjOTczYzgxZjRmMjg4ZmI1YmI0N2I3YWQ2YzJlXzcxMDk_69b08474-3fea-4479-9d48-4c917c371874"
      unitRef="usd">1400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3NzY_cfecc3ce-7210-49f4-8b23-0da3d4364c6f">Loans Payable, Long-Term Debt and Leases&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loans Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loans payable at December&#160;31, 2021 included $2.3 billion of notes due in 2022 and $149 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December&#160;31, 2020 included $2.3 billion of notes due in 2021, $4.0 billion of commercial paper borrowings and $73 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 0.08% and 0.79% for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.15% notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,977&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,749&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,736&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2061&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15% notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45% notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,235&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.875% euro-denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75% notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;748&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50% notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;715&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50% euro-denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375% euro-denominated notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50% euro-denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;558&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60% notes due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.30% debentures due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30,690&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of zero and 0.45% for 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck&#x2019;s option at any time, at varying redemption prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company issued $8.0&#160;billion principal amount of senior unsecured notes consisting of $1.5&#160;billion of 1.70% notes due 2027, $1.0&#160;billion of 1.90% notes due 2028, $2.0&#160;billion of 2.15% notes due 2031, $2.0&#160;billion of 2.75% notes due 2051 and $1.5&#160;billion of 2.90% notes due 2061. Merck used the net proceeds from the offering of the 2027 notes, the 2031 notes, the 2051 notes and the 2061 notes for general corporate purposes, including the repayment of outstanding commercial paper borrowings (including commercial paper borrowings in connection with Merck&#x2019;s acquisition of Acceleron), and other indebtedness. Merck allocated an amount equal to the net proceeds of the offering of the notes due in 2028 to finance or refinance, in whole or in part, projects and partnerships in the Company&#x2019;s priority environmental, social and governance (ESG) areas. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp;amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s borrowings require that Merck comply with covenants and, at December&#160;31, 2021, the Company was in compliance with these covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate maturities of long-term debt for each of the next five years are as follows: 2022, $2.3 billion; 2023, $1.7 billion; 2024, $1.3 billion; 2025, $2.5 billion; 2026, $2.3 billion. Interest payments related to these debt obligations are as follows: 2022, $910 million; 2023, $875 million; 2024, $838 million; 2025, $771 million; 2026, $743 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#x2019;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of seven years, which include options to extend the leases for up to four years where applicable. Vehicle leases are generally in effect for four years. The Company does not record short-term leases (leases with an initial term of 12 months or less) on the balance sheet; however, Merck currently has no short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company&#x2019;s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company&#x2019;s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost was $343&#160;million in 2021, $340&#160;million in 2020 and $333&#160;million in 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $340 million in 2021, $334&#160;million in 2020 and $275&#160;million in 2019. Operating lease assets obtained in exchange for lease obligations were $117 million in 2021, $473 million in 2020 and $125 million in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_16a2eb8c-e452-4c08-a1c1-253a7ae69d38"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_51a0e69b-3d06-4866-8735-b4018eea9421"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,586&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_a62e225e-815f-4743-87ec-8f20071b70d4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_f733f0e1-fc32-4cc4-af08-cafbad4247b5"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_640b8294-5ffb-4269-b064-66281ca04383"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_7eda0372-d2d2-488c-a2da-c5fb07ed06fd"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Includes prepaid leases that have no related lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating leases liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $86 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzk1_414b7de8-ddb0-463b-9db8-e86df84beb36"
      unitRef="usd">2300000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ia4f5157cdcdc4b5fb735395ee19116dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzE0Nw_a93bfb35-c5ca-4922-889a-f2861d27b466"
      unitRef="usd">149000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzI1OQ_117c796d-a8bf-448a-95f9-0ef5915535bd"
      unitRef="usd">2300000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i94c025ef9d554744b2deaf2bb4227962_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzI4NA_9bf966e1-85af-40d2-b303-d25cbeaf547d"
      unitRef="usd">4000000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ifae9f90a84a045708d897dad62fa6f48_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzMxMQ_162954b6-cc01-4bda-a399-2c9245f1b0ae"
      unitRef="usd">73000000</us-gaap:DebtCurrent>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="ia85becd9ff8a491c842d4ef0416f1bfa_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQ2NA_7cad4344-03cb-4654-bc97-6666a1642a33"
      unitRef="number">0.0008</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="i94c025ef9d554744b2deaf2bb4227962_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQ3MQ_192c783d-86aa-4ebc-89cf-d8f17522a825"
      unitRef="number">0.0079</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3ODA_d788e0df-1ad5-4f56-b0f5-d3cd448ebe4e">&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.15% notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,977&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,749&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,736&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2061&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15% notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45% notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,235&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.875% euro-denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75% notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;748&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50% notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;715&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50% euro-denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.375% euro-denominated notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50% euro-denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;558&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60% notes due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.30% debentures due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30,690&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i17dae8a27f274a1f9b71d7a871389f36_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEtMC0xLTEtMC90ZXh0cmVnaW9uOjY1MTI2MGE1NDVmNjQxMDhiNmNiYzIxYjU3ZGZjMzgyXzQ_e33987e9-f96b-40d8-9229-9022f57a6152"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i17dae8a27f274a1f9b71d7a871389f36_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEtMS0xLTEtMA_55d695d3-9c85-4340-8072-845c77ad12ee"
      unitRef="usd">2495000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifb06f869aee84648b3f08b5c22658045_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEtMy0xLTEtMA_dde19294-eead-46b6-a24d-b2c831c34344"
      unitRef="usd">2493000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMC0xLTEtMzE1OTQvdGV4dHJlZ2lvbjpjZGY4NmE3OTQ4OTM0MmNhOGU5MzQ2MmNlMWZiYzgzN18xMDk5NTExNjI3ODA3_05df83c8-5c6d-4657-a211-7d960590a212"
      unitRef="number">0.0215</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMS0xLTEtMzE1NjY_31808f78-1e47-44bd-aaaf-9614fba4a1e2"
      unitRef="usd">1986000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ieee399b5bb9e4f7382fa9bed6063f3e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMy0xLTEtMzE1NzM_abf58752-f4c7-41fd-8479-e2ed0507d9f6"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i666ad1c871a5437daefbf379c3ae7a1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMC0xLTEtMzE3MjcvdGV4dHJlZ2lvbjo0ZTE1NTk2Y2Y1OTI0ZTA0YmFjMTRmMzFiMDdhYTQ4Y18xMDk5NTExNjI3ODA1_e3a83f01-ec50-458c-a7da-dd64dccf473e"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i666ad1c871a5437daefbf379c3ae7a1e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMS0xLTEtMzE1ODA_a79cc7bc-d389-4309-8fbf-ebc876bbfb83"
      unitRef="usd">1979000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i03f677306c544591b8bdc15d6568cad1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMy0xLTEtMzE1ODc_4460fc86-f19b-4a10-b6ce-01a392e91f6a"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4603067c37764e92871db7d73bb6a41e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMC0xLTEtMC90ZXh0cmVnaW9uOmY1ZGI0YjJkYjY2ZjRiMDRhMTY5ZTZlNzZjNGYyYmFlXzQ_a919b2ae-d051-4efb-b10d-519a59a7a652"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4603067c37764e92871db7d73bb6a41e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMS0xLTEtMA_5f2ee038-d7fa-4597-bae8-f6a326e0dae6"
      unitRef="usd">1977000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8ab29f77d5a54d36880055884c3d208a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzItMy0xLTEtMA_649ac7bc-74b8-4444-93a1-47768c836066"
      unitRef="usd">1976000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if25f9151edb34efe9659838c9851b5e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMC0xLTEtMC90ZXh0cmVnaW9uOmQyNmUwNWQzNTJkOTQ5ZThiOGZjN2YyN2JkMTIxZDYzXzQ_f3fd7cf6-6992-4e4e-9bfb-19880942f39b"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if25f9151edb34efe9659838c9851b5e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMS0xLTEtMA_2582fbc4-c6d5-4fed-b177-fabb42824fc5"
      unitRef="usd">1749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3f198e2b6c8242329a2d6cce74447c22_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMtMy0xLTEtMA_edcc19ac-dfdf-4325-b944-61d4d8542993"
      unitRef="usd">1748000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6eb70a7318804000a0b25e0954dccccc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMjAxMmNkMjRhMDRlMTRiMGIzNzNlNTQ1ZmE2OWEwXzQ_a6d5ad17-f5b5-4f65-8068-04c684deaf42"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6eb70a7318804000a0b25e0954dccccc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzQtMS0xLTEtMA_45429096-e66c-41ee-9629-09bca3c46af5"
      unitRef="usd">1736000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if272cc9ec9314c9b954ca02afdf19912_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzQtMy0xLTEtMA_bbd522d3-74d1-4ca9-a109-2306f8a10b29"
      unitRef="usd">1734000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i330c8b376f0845b981e104e9da711b0e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMC0xLTEtMzE3NDUvdGV4dHJlZ2lvbjoxYmU4MjMwZWM1NWM0Y2U2OWIwYjZjMzcxZTQ2YmQ4M180Mzk4MDQ2NTExMTMz_b1bbf6ad-8310-4c7d-8a9c-5447e89d97f1"
      unitRef="number">0.0170</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i330c8b376f0845b981e104e9da711b0e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMS0xLTEtMzE2MTY_440b037f-558a-41ae-898d-bb2686d32d5e"
      unitRef="usd">1493000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia1d4c4db752a47e1929b1bd9b0221ef3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMy0xLTEtMzE2MjM_429a2a40-71f2-42f5-aa86-0ec00ea173ea"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e29e43c73b04d478539ff08737d0321_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMC0xLTEtMzE3ODcvdGV4dHJlZ2lvbjpjMzhjYjczNzljOTg0YzFmODYyNmJiOGEwY2FlYTRkNF80Mzk4MDQ2NTExMTM0_9a05b8c7-65ad-4a15-b2cc-da3eaea19ce0"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7e29e43c73b04d478539ff08737d0321_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMS0xLTEtMzE2MzA_97f26a95-940a-47ca-a587-e093ffeddceb"
      unitRef="usd">1484000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifce508fabf274d7fa48a9d9ef29611c3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMy0xLTEtMzE2Mzc_1c3de1da-41e2-4ce2-9022-9ee3b3aee594"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if938e22e704043879505c140022bccd0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjJjZmY0ZjVmZGY1NTRjZWQ4MjBiMTBhZWM5NGU3MWUzXzQ_3dc0287c-dd65-4190-8745-5d78c4aebcb1"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if938e22e704043879505c140022bccd0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzUtMS0xLTEtMA_60b4fb97-2f0d-412e-8a07-c89ef52eea21"
      unitRef="usd">1470000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i69c90a6837f441e4b263d84bf547260b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzUtMy0xLTEtMA_b86c4f99-7248-418b-9111-f69dd32c2af0"
      unitRef="usd">1469000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i75a2923a86ee4187a9d8e30f1302bad4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMC0xLTEtMC90ZXh0cmVnaW9uOjI0NTNiODgyMGI4MzQ0NDliOTAxZGI5MmFlOGNhYzg5XzQ_b301991e-e562-4b76-b539-2a5735a49936"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i75a2923a86ee4187a9d8e30f1302bad4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMS0xLTEtMA_0969d52d-5862-406c-bafa-9a0a0cfd881f"
      unitRef="usd">1239000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idd6dc540edbe4a84988990cbdefe13d5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzctMy0xLTEtMA_bd7b932a-efe5-4b81-a043-230eeed13453"
      unitRef="usd">1238000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i178e4bc051044e76b42ccbb46d917f9e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMC0xLTEtMC90ZXh0cmVnaW9uOmY2N2I2YzRkMGFmMjRjOTE4NDJlMTFjZTY2OTNiYjY1XzQ_d0200852-2718-4761-a601-3ef0a84d261f"
      unitRef="number">0.0145</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i178e4bc051044e76b42ccbb46d917f9e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMS0xLTEtMA_24686d07-e3c5-46a2-958b-32ee3ff3d462"
      unitRef="usd">1235000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i325a7820086449098f9f5e7c422cda0d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzgtMy0xLTEtMA_d285e8ad-c9d4-4b42-8951-991a0996adbf"
      unitRef="usd">1233000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i333858d5ddd54903ba67c9eaba12bf2a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTAtMS0xLTM5MzgyL3RleHRyZWdpb246MjQ2M2U1YmViYzdhNDAxYTllN2MzNzBiMWZiNGM3YmNfNA_84f83448-5ba6-4aad-9bf7-24d4a40bc043"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i333858d5ddd54903ba67c9eaba12bf2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTEtMS0xLTM5Mzgy_84b7cc0c-018d-428b-a367-4e7ee6870152"
      unitRef="usd">1212000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i95bb17180d994e87ab3f841a7c846700_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTMtMS0xLTM5Mzgy_9d2410cb-6312-4dc2-9cd1-beb01f198ccf"
      unitRef="usd">1211000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic23e62f8001740b7b380115c4ba260c4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzktMC0xLTEtMC90ZXh0cmVnaW9uOjZjYWMwZmE4NTVlMzQwODJiNzkzZGE3MjAyNzVjYWZiXzQ_09e4eb0e-1fbe-45d5-881d-1ff0475696ec"
      unitRef="number">0.01875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic23e62f8001740b7b380115c4ba260c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzktMS0xLTEtMA_6d987a05-2f50-4d6d-bc18-5f1f973ab9e5"
      unitRef="usd">1123000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic7d7bae96e8b46fe83ce2a84bc3c0cb6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzktMy0xLTEtMA_cb22b193-26b3-4f70-8564-ea6c8c644fdb"
      unitRef="usd">1218000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i449243770d5a4a3aadefa2f9bb07dd48_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEwLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMmY0OWI4YTA5NWY0ZTkwYWU4NTNkYWM3NDA1NTMzYV80Mzk4MDQ2NTExMTMz_e62b03d1-f029-4a36-b3db-1438f4229a75"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i449243770d5a4a3aadefa2f9bb07dd48_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEwLTEtMS0xLTA_15ae47c5-0f71-4ffc-8559-ea3168af194c"
      unitRef="usd">994000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i186f6c50dad74e3a8ea966fe8407b0d2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEwLTMtMS0xLTA_e9932375-029e-406f-9752-69450c4987f6"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0adefdd4fd64c70843942c5ea526307_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTAtMS0xLTAvdGV4dHJlZ2lvbjozMzJkMTlhOTc3NjQ0NTRjOGE1NDlhODdiZDA1MGE0MF80_39c34e61-b358-4168-8a42-91a7300291c9"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia0adefdd4fd64c70843942c5ea526307_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTEtMS0xLTA_80f53093-b8db-4495-b6d3-8208fb849449"
      unitRef="usd">993000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7c3307530aa44190849bb1be7e10ad8d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEyLTMtMS0xLTA_50354229-7eb2-44bf-a4b7-2ae8498d1bb0"
      unitRef="usd">991000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i76684c6e7e7941fd886f959ebdf9684b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEzLTAtMS0xLTAvdGV4dHJlZ2lvbjpkODAxMzc3NTRhMTM0NGYyYTU1NzMyZjRkZWQ5M2QxMl80_583dbc08-5e28-44ae-b4aa-d4165fbfaf31"
      unitRef="number">0.0390</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i76684c6e7e7941fd886f959ebdf9684b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEzLTEtMS0xLTA_e5c92a2e-e2fc-40bd-b8e3-80ff3f21e99c"
      unitRef="usd">984000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id60a350fed0a495da16890e319f026be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzEzLTMtMS0xLTA_8da399b3-4429-4352-a105-6e11476dacfa"
      unitRef="usd">983000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i311636cf40db4f85b916067268059c87_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmYzI5ZjliMzBlY2Y0MjI0YTEwZjA3NGRmZDA5YmM4YV80_a5c80b6d-c04f-431c-b80f-3f90271b8da6"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i311636cf40db4f85b916067268059c87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE0LTEtMS0xLTA_41a8fa77-e806-409e-bed6-ebfd2ec32f12"
      unitRef="usd">983000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9e284b03ac364d3e8d78fbfa391cb0be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE0LTMtMS0xLTA_4d786c9d-3947-451e-9d08-1c524e2eddbb"
      unitRef="usd">982000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib7435768c60e4451a21d4ba610ecc268_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE1LTAtMS0xLTAvdGV4dHJlZ2lvbjozMTNhMTI4YTZmMWQ0YWM1YTVhMDA5YTQyM2ZjNmJmMl80_f83dd2d0-ba3c-4b76-86f6-abc3f67be875"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib7435768c60e4451a21d4ba610ecc268_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE1LTEtMS0xLTA_fb44c434-393a-4bb1-bf5d-9d57f912153e"
      unitRef="usd">748000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iee70c6efaceb4bd8a3f32437df0c8a5b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE1LTMtMS0xLTA_012867bb-ceda-4575-ae4c-c73008217a2b"
      unitRef="usd">746000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3a4e8734f76f48d190b8676cdac0c206_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZGEwN2Y3ZWViNWQ0NzdlOTk4MDVjYmYyNjFhYTEwOF80_028cd4f8-e389-47f2-865e-e8ba42070d0b"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3a4e8734f76f48d190b8676cdac0c206_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE2LTEtMS0xLTA_c00ab300-5e03-4187-a481-5d3dd7c48403"
      unitRef="usd">715000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7a04e2cfd3a641758e42b169902efdc5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE2LTMtMS0xLTA_d09bdbe7-fa5e-4c15-a3fb-a62c4b9868c3"
      unitRef="usd">719000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i130360c441d842fda96aa1a87003755c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE3LTAtMS0xLTAvdGV4dHJlZ2lvbjo4N2VlMGQwOTEzMzg0NmQ3YTA5MzIxYmU5YTIwNGEyM180_df779c8d-238f-46c6-b565-050200b07380"
      unitRef="number">0.0050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i130360c441d842fda96aa1a87003755c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE3LTEtMS0xLTA_706a1de4-6d2b-446a-a028-6b368d537d3f"
      unitRef="usd">563000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4181b1f1a852487da488d837c8158ebd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE3LTMtMS0xLTA_dbc33078-b491-4080-8617-7a46b0055e93"
      unitRef="usd">611000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic1267e41a13d4a82939639506b0b47e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE4LTAtMS0xLTAvdGV4dHJlZ2lvbjpiOWIxNTA5OTRkYzI0YWNkYmQxNDM1MDFiNTk1YWNhMF80_3dc6aa76-05b8-409f-8289-53ac6d068ab4"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic1267e41a13d4a82939639506b0b47e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE4LTEtMS0xLTA_01e84d5c-038c-48d0-92c9-ca61e0f6e74f"
      unitRef="usd">559000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if189170ce36b4eafb6f7201a9ca6ae4b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE4LTMtMS0xLTA_0fbc8fbb-49d8-4482-92b0-9cd4b2cc0336"
      unitRef="usd">606000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i84ae7163839e44318d2e1239dac4e116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE5LTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmJhYjE2Njc4NDY0NDcyYjFhNWUwZDhmZDdlZDIxMF80_8ec48738-e702-482a-bdc0-d2454013af0f"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i84ae7163839e44318d2e1239dac4e116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE5LTEtMS0xLTA_62164bc7-739a-4418-8682-800e056fa435"
      unitRef="usd">558000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idcc406a9bf2f434eafd58f22ac831620_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzE5LTMtMS0xLTA_fc0c5192-2b9b-42bb-bdf5-1190f8528503"
      unitRef="usd">605000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4a64ddf383234fde89422eb58d5a04d0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIwLTAtMS0xLTAvdGV4dHJlZ2lvbjo0Nzk0YjVkYzA0OTA0ZWM3ODliMTA1ZWNjYmIyMmI5Y180_110b2900-c0d9-4045-9c33-eda29601f02c"
      unitRef="number">0.0360</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4a64ddf383234fde89422eb58d5a04d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIwLTEtMS0xLTA_791ed217-5ca7-4bf9-a279-d295c2454e6d"
      unitRef="usd">491000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if5f2f1899dbf46acb52be81d989d18b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIwLTMtMS0xLTA_e7347554-14db-467f-8d23-f93b5b0eb8ff"
      unitRef="usd">491000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib0065ecadcbc4c46aedfe9502ae528f5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIxLTAtMS0xLTAvdGV4dHJlZ2lvbjplY2M5MWY2YWVmZjQ0MmE0Yjg4ZmQ2N2JlZThmMzUwNF80_c7a474f5-fca2-401b-ad03-9be87628767b"
      unitRef="number">0.0655</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib0065ecadcbc4c46aedfe9502ae528f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIxLTEtMS0xLTA_987cbd9d-1148-46ce-9198-27c610038b69"
      unitRef="usd">409000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i674f0f6f35ce404ca1e28b4ade93aafa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIxLTMtMS0xLTA_45c82ad5-8801-4a2b-bf1a-5d79df2b8017"
      unitRef="usd">411000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic84be8ae9e69454eb62cd343daebc684_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNTM3Y2NmYzJmNzk0MTVjYjRlMDY4Mjk4N2YyOGZkY180_129ec326-6063-4cbe-b25f-c9fc53217564"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic84be8ae9e69454eb62cd343daebc684_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIyLTEtMS0xLTA_4a73615f-496b-4b1f-be4a-eee955908298"
      unitRef="usd">338000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ida0900466410461fadb2b25dacab282a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIyLTMtMS0xLTA_fb046c93-d4fd-4665-b579-f357c8f80846"
      unitRef="usd">338000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i443dc9e5f3c14c26b4627206e39cb2d8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIzLTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTNkMzg0ZWMzODI0MmZlOTVjNjVkODUwNmQ1ZmY1MF80_9a75814e-dfe6-41fc-b36b-e8198da009e9"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i443dc9e5f3c14c26b4627206e39cb2d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIzLTEtMS0xLTA_41f631b6-84e4-4d42-9066-1f0239bd392c"
      unitRef="usd">306000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie314f63b9375416f8539d5d713836ce5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzIzLTMtMS0xLTA_be94e42c-596b-4c57-9c94-fb0db7e25431"
      unitRef="usd">306000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2ed29c8d391249e7b1ab655051fd96a3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpkOGIxYTI5YzE5ZWQ0ZDU0YjA5ZWM0NTczODQ1YzRjMF80_0647b257-4fc1-4e63-a4f6-de69d6cc6a9a"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2ed29c8d391249e7b1ab655051fd96a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI0LTEtMS0xLTA_d311fc83-03c7-4ea4-9e7a-e654929a3035"
      unitRef="usd">271000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if16c9874988749a6b9d4de2a351876c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI0LTMtMS0xLTA_0faee997-4a5b-4d99-998e-2594072cb8c5"
      unitRef="usd">271000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6381683a577b43b3a4f20e5ee2a42a23_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjo0YTAxZTAxNWQ3Y2I0MjZhYjQyY2ZlMTc3NWM2NjliOF80_9c4b009a-bc26-4a2d-bb12-dd22732668ee"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6381683a577b43b3a4f20e5ee2a42a23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI1LTEtMS0xLTA_9206db4d-96ed-4873-a390-cadb7bab618f"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i774de7dc3f4a439e9ef258e52ad97260_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI1LTMtMS0xLTA_386e4d5e-ad3b-41b3-9737-bea1ed6329e8"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6230e83c438e4a4b8ad400ee569ba5e6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjpjYTFiY2VhNGY0ZmE0YWU1OTNiMjQzODBmMzM1ZjlmMl80_6c4d5c80-7d1d-4d37-b72a-85cda36c3dae"
      unitRef="number">0.0630</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6230e83c438e4a4b8ad400ee569ba5e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI2LTEtMS0xLTA_9008c909-2d37-48fb-967c-6925a969ccff"
      unitRef="usd">135000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id5cc9da918f54ffe9561a30e890c176e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI2LTMtMS0xLTA_fc02752c-ef4f-44be-9602-0baa83b61741"
      unitRef="usd">135000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf3fd779ab0345a4b5682f42d4df167e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI3LTAtMS0xLTkyMi90ZXh0cmVnaW9uOmEyNWY3NDBiY2NkZTQ4YjdiZjk1MjQ5MjcxNDJiNjY4XzQ_04ccd0e8-a89e-4e7a-87f1-f34fcf5ddca9"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idf3fd779ab0345a4b5682f42d4df167e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI3LTEtMS0xLTkyMg_b967eb40-f39e-4127-9d30-614c045eacfe"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9334d22b30c34db685a58c5c19efc4c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI3LTMtMS0xLTkyMg_0952de51-cc2f-402a-88c9-ccb6fbf83dc5"
      unitRef="usd">1269000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6615a4b358b4458cb9f301a9917387a1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI4LTAtMS0xLTkyOS90ZXh0cmVnaW9uOmQ2MTZhODc0ZjhmZDRjODU4YjMzZjQ4MzhmYzY3YzJjXzQ_613ef628-428f-4ee7-8909-b344c237dbe5"
      unitRef="number">0.0240</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6615a4b358b4458cb9f301a9917387a1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI4LTEtMS0xLTkyOQ_d3a856ca-06d2-40f6-82ef-d64c7891d981"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i83ff4d5f08ad4af5886628a1bbba25b7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzI4LTMtMS0xLTkyOQ_136c7cb1-33b2-4cbe-b2f9-b83bcad1d66c"
      unitRef="usd">1032000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ief565eb90eb64c95925824555f9e9d46_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMxLTEtMS0xLTA_a86bb319-6bfa-4381-b24a-5df7e7d8dd70"
      unitRef="usd">215000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i87c57d8615014148a065e980841d3dc9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMxLTMtMS0xLTA_2fed0ca7-df09-4083-81ac-db866a74dc38"
      unitRef="usd">294000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMyLTEtMS0xLTA_5f388d2f-7a83-414f-bb64-48c7bf477566"
      unitRef="usd">30690000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTphZGZjN2VlMmVjY2I0YTFkYjQ3N2M3MThmMzViNzBiOC90YWJsZXJhbmdlOmFkZmM3ZWUyZWNjYjRhMWRiNDc3YzcxOGYzNWI3MGI4XzMyLTMtMS0xLTA_c70cf9b1-6834-4d97-9d37-67bc23167bd4"
      unitRef="usd">25360000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="ida73e3479c1f4e4687a0d8cc7ff79ca9_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzc0Ng_fa6d16e1-bd64-44ab-90f1-c95b165c11f2"
      unitRef="number">0</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i5a6dee25ec5f47f0b9d50258c662b2e5_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzc1Mw_8b205f00-9468-4b82-9aad-61c93dc5c6c8"
      unitRef="number">0.0045</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6230e83c438e4a4b8ad400ee569ba5e6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzgxMg_1c03360e-9b2e-4e04-9a26-909742275b45"
      unitRef="number">0.0630</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjAzNTE_6cbca659-b553-426f-8634-4209ac8a45ef"
      unitRef="usd">8000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i330c8b376f0845b981e104e9da711b0e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjAzNjU_a9439923-c25f-4ddb-883a-78f60aeca0a0"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i330c8b376f0845b981e104e9da711b0e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjAzNzk_38f112c4-eaac-4d83-88bc-f7550c62deea"
      unitRef="number">0.0170</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i449243770d5a4a3aadefa2f9bb07dd48_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjAzODY_1d55c1d9-b185-4b9f-a936-264d83093f5f"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i449243770d5a4a3aadefa2f9bb07dd48_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0MDA_da4c7114-63a7-4d99-ac87-6a441a4e1b7f"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0MDc_a38dd06d-c78c-481e-a109-739ca29bcbf4"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaf33d8bf1b8141879f1fc2cf8709c6cb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0MjE_55224837-2e9e-4d26-85e3-2e1587bb80ea"
      unitRef="number">0.0215</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i666ad1c871a5437daefbf379c3ae7a1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0Mjg_5444e73b-1f7b-46a7-8902-9ce7ddaa1f3b"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i666ad1c871a5437daefbf379c3ae7a1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0NDI_5fb5c56e-3703-4526-add5-76505ff4da1c"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7e29e43c73b04d478539ff08737d0321_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0NDk_fd5d656b-8dc0-45ac-89c9-05dfca51b49e"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e29e43c73b04d478539ff08737d0321_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzQzOTgwNDY1MjA0NjM_7a07c507-6228-4a75-95f3-7f7a0c50fcab"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwMjQ_16fc9362-d7cc-40be-b6d3-7656628c6556"
      unitRef="usd">2300000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwMzI_8e107027-fa3b-48f4-ba61-6d8a40f8e18d"
      unitRef="usd">1700000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwNDA_868b213c-e228-48bc-b5a8-16b09d7c6ab9"
      unitRef="usd">1300000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwNDg_b77f1bd9-9f99-4968-b936-d5eedcfb9ee0"
      unitRef="usd">2500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwNTY_4d48b8f0-2d80-4ae4-8ba4-04ebadfa5669"
      unitRef="usd">2300000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <mrk:LongTermDebtInterestPayableYearOne
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk4NTg_59ab90f0-8b42-40ba-a0a4-1ea9805769b0"
      unitRef="usd">910000000</mrk:LongTermDebtInterestPayableYearOne>
    <mrk:LongTermDebtInterestPayableYearTwo
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk4ODk_ca1bd0d9-ca90-4ed8-aee6-362ea319e6ae"
      unitRef="usd">875000000</mrk:LongTermDebtInterestPayableYearTwo>
    <mrk:LongTermDebtInterestPayableYearThree
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk5MDI_2dc96cd8-408b-4730-b66d-511afe9bc887"
      unitRef="usd">838000000</mrk:LongTermDebtInterestPayableYearThree>
    <mrk:LongTermDebtInterestPayableYearFour
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk5MTU_f9a4e3bb-820e-4ae2-bc91-baa0dd778420"
      unitRef="usd">771000000</mrk:LongTermDebtInterestPayableYearFour>
    <mrk:LongTermDebtInterestPayableYearFive
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2Mzk5Mjg_f5923ebb-1d3c-4e0f-8c96-e5252ea6b350"
      unitRef="usd">743000000</mrk:LongTermDebtInterestPayableYearFive>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzIwNzk_f5b2a188-f8dd-4fa2-8d8f-cc9cc1588ea3"
      unitRef="usd">6000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7bd0a9a37e0245ff9bf9f6ac947f019f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzMwODM_50db9953-b9c8-41b4-8abc-718d82f2089d">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i7bd0a9a37e0245ff9bf9f6ac947f019f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzMxNDA_1c30babb-efbe-4ff0-aae9-5246be5adfd2">P4Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic816dee0d6f44f3e9271509aa2068b19_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzMyMDQ_1b7ffc84-12e4-4afb-baf2-9b42171291d1">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseCost
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzUzNTY_3838219b-84cb-401d-832b-82c752a53136"
      unitRef="usd">343000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzUzNDg_8e6b5575-4937-4a61-871f-8c0c465a2469"
      unitRef="usd">340000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzUzNDE_17725f60-6bf9-40b9-b476-ec0acc74f867"
      unitRef="usd">333000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU1MTI_4a069ca9-72bc-4f4a-9509-d6f3086e8770"
      unitRef="usd">340000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU0OTA_d95736a8-4360-4865-9918-e431584a7e97"
      unitRef="usd">334000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU0OTQ_c0da4395-a8c6-4b89-a465-002e0ba640a7"
      unitRef="usd">275000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU1MzM_556e314d-29f8-49f1-a19f-c36fab3bd582"
      unitRef="usd">117000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU1Mjc_c6c102e3-4697-40dc-b1c4-2250fc77fac3"
      unitRef="usd">473000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzEwOTk1MTE2MzU1MjA_65945ce4-3756-41d6-87ae-a0076365a1f4"
      unitRef="usd">125000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mrk:AssetsandLiabilitiesLesseeTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3NzE_cb1212e7-a788-4c66-b125-96b1f83337ed">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_16a2eb8c-e452-4c08-a1c1-253a7ae69d38"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMC0xLTEtMA_51a0e69b-3d06-4866-8735-b4018eea9421"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,586&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_a62e225e-815f-4743-87ec-8f20071b70d4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMC0xLTEtMA_f733f0e1-fc32-4cc4-af08-cafbad4247b5"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_640b8294-5ffb-4269-b064-66281ca04383"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMC0xLTEtMA_7eda0372-d2d2-488c-a2da-c5fb07ed06fd"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Includes prepaid leases that have no related lease liability.&lt;/span&gt;&lt;/div&gt;</mrk:AssetsandLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMS0xLTEtMA_c765b9bd-b6cd-4d9f-89e9-b82097bf32c0"
      unitRef="usd">1586000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzItMy0xLTEtMA_aab52b14-7cb2-4bf3-9df8-66bd397ccd6a"
      unitRef="usd">1688000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMS0xLTEtMA_95f841c5-cbb1-42e0-af15-6a386eeb06b4"
      unitRef="usd">304000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzQtMy0xLTEtMA_fa77bd76-3daf-49e4-9ced-f993214a868c"
      unitRef="usd">291000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMS0xLTEtMA_9e2f8ee0-7b23-466b-904f-9f20640cebef"
      unitRef="usd">1225000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzUtMy0xLTEtMA_86759fc6-9123-40fc-a720-b9fffbf33e75"
      unitRef="usd">1335000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzYtMS0xLTEtMA_ebf21154-b9f4-47c7-9eef-172291e1e1a1"
      unitRef="usd">1529000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzYtMy0xLTEtMA_ffbd0f73-bea1-4ff4-8daa-d24a73dd7dac"
      unitRef="usd">1626000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzctMS0xLTEtMA_47f601a5-211f-4edc-820a-067dd63a59e4">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzctMy0xLTEtMA_aadbc99d-c9aa-4f7a-8c60-d4a4be7540dc">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzgtMS0xLTEtMA_94ecfaf5-856a-472d-bd29-fddf880e692f"
      unitRef="number">0.026</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZTplZjQ3MDVkMzdiYWU0NzY1OTA2N2EwNmU2YjNmMWJiNi90YWJsZXJhbmdlOmVmNDcwNWQzN2JhZTQ3NjU5MDY3YTA2ZTZiM2YxYmI2XzgtMy0xLTEtMA_dc1e9ae3-46ca-4974-8ad7-5da9884a2d32"
      unitRef="number">0.028</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3Nzg_dba7c05c-2536-41f8-997a-5fd68e2c4330">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating leases liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzAtMS0xLTEtMA_d9706393-5775-4c6a-a250-84eae16add1a"
      unitRef="usd">336000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzEtMS0xLTEtMA_2ee9cae9-e321-44d3-bf64-9e88876fa491"
      unitRef="usd">292000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzItMS0xLTEtMA_4fb10e63-9516-4fb7-8d96-dfce9c0de5a3"
      unitRef="usd">242000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzMtMS0xLTEtMA_0862f214-c2cd-40cb-beba-2860578ac065"
      unitRef="usd">178000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzQtMS0xLTEtMA_659b4b9b-2216-406c-ac85-7a88afe7d6cd"
      unitRef="usd">146000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzUtMS0xLTEtMA_5a183668-8787-4471-bc5a-5f9f7900357e"
      unitRef="usd">511000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzYtMS0xLTEtMA_e6098350-5a32-4522-b9c8-94aec7523ea9"
      unitRef="usd">1705000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzctMS0xLTEtMA_2d6af179-9a77-4b91-86ba-3b815118fa39"
      unitRef="usd">176000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90YWJsZToxOTA1NzQwOGM0MmQ0NjM1OGIzODlhNmZmN2ZlNTVjOS90YWJsZXJhbmdlOjE5MDU3NDA4YzQyZDQ2MzU4YjM4OWE2ZmY3ZmU1NWM5XzgtMS0xLTEtMA_2999e7e2-2efd-4496-86ad-47a52881b4d9"
      unitRef="usd">1529000000</us-gaap:OperatingLeaseLiability>
    <mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNjkvZnJhZzpmNmIxMDAwNDgxZjc0ZWM3YTExYTc5NzQ4NThkYzQ1Zi90ZXh0cmVnaW9uOmY2YjEwMDA0ODFmNzRlYzdhMTFhNzk3NDg1OGRjNDVmXzU3NjM_4ac1142e-d6e9-4395-903a-554084d8d287"
      unitRef="usd">86000000</mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzMxNDQ5_c626aacc-191b-4f12-8778-85e711648bba">Contingencies and Environmental Liabilities &lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#x2019;s financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (Fosamax Litigation). As of December&#160;31, 2021, approximately 3,470 cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#x2019;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#x2019;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#x2019; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia/Janumet&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December&#160;31, 2021, Merck is aware of approximately 675 product users alleging that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the development of pancreatic cancer and other injuries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). On March 9, 2021, the MDL Court issued an omnibus order granting defendants&#x2019; summary judgment motions based on preemption and failure to establish general causation, as well as granting defendants&#x2019; motions to exclude plaintiffs&#x2019; expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and on October 5, 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants&#x2019; summary judgment motions and also granting defendants&#x2019; motions to exclude plaintiffs&#x2019; expert witnesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck&#x2019;s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Merck Sharp &amp;amp; Dohme Corp. v. Albrecht &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(relating to the Fosamax matter discussed above). Merck filed the opinion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Albrecht&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Albrecht&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, that preemption presents a legal question to be resolved by the court. In May 2020, the Illinois Appellate Court issued a mandate to the state trial court, which, as of December 31, 2021, had not scheduled a case management conference or otherwise taken action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against any remaining lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney&#x2019;s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government&#x2019;s information request by seeking information relating to Merck&#x2019;s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company&#x2019;s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General&#x2019;s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck&#x2019;s development of an insulin glargine product, and its subsequent termination, as well as Merck&#x2019;s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government&#x2019;s investigation and intends to produce information and/or documents as necessary in response to the CID.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, the Company&#x2019;s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#x2019;s policy is to cooperate with these authorities and to provide responses as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S.&#160;These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings.&#160;Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial and Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants&#x2019; motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants&#x2019; motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants&#x2019; motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. In December 2019, the district court granted the Merck Defendants&#x2019; motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#x2019; motion for class certification and certified a class of 35 direct purchasers. In August 2020, the Fourth Circuit vacated the district court&#x2019;s class certification order and remanded for further proceedings consistent with the court&#x2019;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. Briefing on these objections is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court has heard argument on certain of the motions. The court may hold additional hearings on the other motions. Trial in this matter has been adjourned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, in August 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. In August 2021, the district court granted certification of a class of indirect purchasers. In September 2021, the Merck Defendants petitioned to appeal the class certification decision to the Fourth Circuit. The Fourth Circuit denied that petition on September 30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, United Healthcare Services, Inc. filed a lawsuit in the U.S. District Court for the District of Minnesota against the Merck Defendants and others (the UHC Action). The UHC Action makes similar allegations as those made in the Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;class action, as well as allegations about Vytorin. In September 2020, the U.S. Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict Zetia litigation already in progress.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, Humana Inc. filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against Merck and others, alleging defendants violated state antitrust laws in multiple states. Also, in December 2020, Centene Corporation and others filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana. Both lawsuits allege similar anticompetitive acts to those alleged in the Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;class action. In July 2021, the California Court ruled on defendants&#x2019; Motion to Quash for lack of personal jurisdiction, granting the motion as to the out-of-state claims against defendants, and ordering limited jurisdictional discovery with regard to the California claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, on July 16, 2021, Humana and Centene filed actions against the Merck Defendants in New Jersey in the Bergen County Superior Court, re-asserting the claims that were dismissed in their California action. In September 2021, the parties reached an agreement that Humana and Centene would file their claims in New Jersey federal court, seek a transfer of those claims to the multidistrict Zetia litigation already in progress, and subsequently dismiss the actions previously filed in California and New Jersey state courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, Kaiser Foundation Health Plan, Inc. similarly filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana and Centene. The Kaiser lawsuit alleges similar anticompetitive acts to those alleged in the Zetia class action. The Kaiser action was removed to the U.S. District Court for the Northern District of California on July 16, 2021. In September 2021, the U.S. Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict Zetia litigation already in progress.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 2021, all of the insurer plaintiffs (Kaiser, Humana, and Centene) are part of the multidistrict Zetia litigation, and are proceeding with discovery in that action. On February 9, 2022, United Healthcare, Kaiser, and Humana each filed an amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rotavirus Vaccines Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, MSD is a defendant in putative class action lawsuits filed in 2018 on behalf of direct purchasers of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RotaTeq&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, alleging violations of federal antitrust laws. The cases were consolidated in the Eastern District of Pennsylvania. In January 2019, the court denied MSD&#x2019;s motions to compel arbitration and to dismiss the consolidated complaint. In February 2019, MSD appealed the court&#x2019;s order on arbitration to the Third Circuit. In October 2019, the Third Circuit vacated the district court&#x2019;s order and remanded for limited discovery on the issue of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;arbitrability. On July 6, 2020, MSD filed a renewed motion to compel arbitration, and plaintiffs filed a cross motion for summary judgment as to arbitrability. On November 20, 2020, the district court denied MSD&#x2019;s motion and granted plaintiffs&#x2019; motion. On December 4, 2020, MSD filed a notice of appeal to the Third Circuit. MSD&#x2019;s appeal is fully briefed, and the Third Circuit heard argument on September 24, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal on February 7, 2022 and took the matter under advisement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;M-M-R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;M&#x2011;M&#x2011;R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;II vaccine, which charge that the Company misrepresented the efficacy of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;M-M-R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck&#x2019;s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits have proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Merck KGaA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name &#x201c;Merck&#x201d; in the U.S. KGaA has filed suit against the Company in France, the UK, Germany, Switzerland, Mexico, India, Australia, Singapore, Hong Kong, SAR, PRC, and China alleging, among other things, unfair competition, trademark infringement and/or corporate name infringement. In the UK, Australia, Singapore, Hong Kong, SAR, PRC, and India, KGaA also alleges breach of the parties&#x2019; coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in numerous jurisdictions outside of the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#x2019;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#x2019;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has settled with four generic companies providing that these generic companies can bring their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against one generic company, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia, Janumet, Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; As previously disclosed, the FDA has granted pediatric exclusivity with respect to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#x2019;s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. The Company currently anticipates that sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. will decline significantly after this date. However, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin (2027 salt/polymorph patent), which, if determined to be valid, would preclude generic manufacturers from making sitagliptin phosphate salt and polymorphic forms until 2027 with the expiration of that patent, plus pediatric exclusivity. In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; formulation where its term plus the pediatric exclusivity, ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#x2019;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#x2019;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, with closing arguments scheduled for April 13, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company has settled with 21 generic companies providing that these generic companies can bring their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the market in May 2026 or earlier under certain circumstances, and their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the market in July 2026 or earlier under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in 2019, Mylan filed a petition for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inter Partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan has appealed the USPTO&#x2019;s decision to the U.S. Court of Appeals for the Federal Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#x2019;s application seeking approval of its sitagliptin tablets. The U.S. District Court for the District of Delaware has set a three-day bench trial in this matter beginning on October 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Germany, generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. If the generic companies are successful, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; could lose market exclusivity in Germany at the same time as the expiry of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; pediatric market exclusivity in September 2022. A hearing was held in June 2021 and the court decided that the SPC for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is invalid, which decision the Company has appealed. Challenges to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SPC have also occurred in the following European countries: Austria, Czech Republic, Finland, France, Hungary, Italy, Portugal, Romania, Slovakia, and Sweden.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#x2019;s financial condition, results of operations or cash flows either individually or in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Defense Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#x2019;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2021 and 2020 of approximately $230 million and $235 million, respectively, represents the Company&#x2019;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company&#x2019;s potential liability varies greatly from site to site. For some sites the potential liability is &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In management&#x2019;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $40 million and $43 million at December&#160;31, 2021 and 2020, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $40 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#x2019;s financial condition, results of operations or liquidity for any year.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i0836d3b184984272bd57f286fc63992e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzI0NzA_33b64fd3-ce45-446c-88e5-b1829359fa6f"
      unitRef="case">3470</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i4d2e8bc60a0148298d49f7245816f760_D20140301-20140331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzM2NzA_d0ec63d5-1927-46ae-a760-67415c46d27f"
      unitRef="case">650</us-gaap:LossContingencyClaimsDismissedNumber>
    <mrk:LossContingencyClaimsonAppealNumber
      contextRef="i4d2e8bc60a0148298d49f7245816f760_D20140301-20140331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzM3MzA_f7a4f6b2-78b2-4229-a677-f5892ee08877"
      unitRef="case">515</mrk:LossContingencyClaimsonAppealNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="if4692914ed0347bb9847781d8d6fbef2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzU4MTY_e5135806-3deb-42eb-a4b2-f7c225eeca22"
      unitRef="case">675</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i46200e06c7a04756a48759eed40c9e41_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzcwNzA_d70c0d00-20cf-4315-a894-e324f16c55c3"
      unitRef="case">6</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i89ee4600a50543649e2d1a72ee56c5dc_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzgzOTg_4160af14-d069-4dd2-a8ef-538c45e3ca29"
      unitRef="claim">50</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i7ce296e507f349c6bd47b0823480f591_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzE3ODUx_b7674a90-03dc-481d-a755-0ee9080a22ec"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i7ce296e507f349c6bd47b0823480f591_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzE4MzAz_b7674a90-03dc-481d-a755-0ee9080a22ec"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i95ea257d9c4d4c4fbbd6847991aa1d0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzE4NDM0_adbec6fa-af7e-4b18-9056-14e54e9a082c"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="ica45cfeeb70a4e189cf234b69c9b1ed3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzI0ODY5_a630b960-d4db-4602-9955-0b191485ebca"
      unitRef="case">21</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LitigationReserve
      contextRef="i2c06720f33624299898d274fe0bf9d14_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzI4MTU2_8b0477b2-8eb5-4a5a-8a30-2be83fa9b770"
      unitRef="usd">230000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="i8826f2e082a14b209b4b18a5290f7a91_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzI4MTYz_c2293764-1a19-4564-8372-5d217e5735a0"
      unitRef="usd">235000000</us-gaap:LitigationReserve>
    <us-gaap:AccrualForEnvironmentalLossContingencies
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzMwNzAy_fce77768-a0c6-428e-8e47-b0bc87ff0831"
      unitRef="usd">40000000</us-gaap:AccrualForEnvironmentalLossContingencies>
    <us-gaap:AccrualForEnvironmentalLossContingencies
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzEwOTk1MTE2NTk1NDg_7f0ed01b-a3e4-404f-9819-84c0e3dc6794"
      unitRef="usd">43000000</us-gaap:AccrualForEnvironmentalLossContingencies>
    <mrk:TermForPayingOffEnvironmentalLiabilities
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzMwOTQ3_f0e0d89d-6aad-4a22-a14b-1af7dbd949a5">P15Y</mrk:TermForPayingOffEnvironmentalLiabilities>
    <us-gaap:EnvironmentalExitCostsReasonablyPossibleAdditionalLoss
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzIvZnJhZzpjMzM0OTdiYjczZjk0M2Y5OTI0ODFhYTkyMDEwNGJhZS90ZXh0cmVnaW9uOmMzMzQ5N2JiNzNmOTQzZjk5MjQ4MWFhOTIwMTA0YmFlXzMxMjM1_ee2db8f7-5245-45f6-a587-a4aa00639c87"
      unitRef="usd">40000000</us-gaap:EnvironmentalExitCostsReasonablyPossibleAdditionalLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90ZXh0cmVnaW9uOjc2YzUwOTgxNzRlOTRmN2JiODJiOTAxOTIzNGEzMzExXzExMzk_ec15ec6a-c390-4035-b597-04f61fa2cc07">Equity&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merck certificate of incorporation authorizes 6,500,000,000&#160;shares of common stock and 20,000,000&#160;shares of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock and treasury stock transactions (shares in millions) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,047&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances primarily reflect activity under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90ZXh0cmVnaW9uOjc2YzUwOTgxNzRlOTRmN2JiODJiOTAxOTIzNGEzMzExXzcw_22b70d7f-1e83-4426-8b72-6f33ed88dcc8"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90ZXh0cmVnaW9uOjc2YzUwOTgxNzRlOTRmN2JiODJiOTAxOTIzNGEzMzExXzEwMA_0178042a-0cf1-41a8-a55a-86545ed4e220"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90ZXh0cmVnaW9uOjc2YzUwOTgxNzRlOTRmN2JiODJiOTAxOTIzNGEzMzExXzExMzY_1a4f5e89-e518-41d1-86f2-255e25cffb93">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock and treasury stock transactions (shares in millions) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,047&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances primarily reflect activity under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="if91e41b657e142838655904b6ffc2b4c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItMS0xLTEtMA_fd0b25d9-d2b6-496e-82e2-3a588855f8f5"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i44fbc319828d43888404b362300c8719_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItMy0xLTEtMA_50bfcb7c-24bf-489f-bb3a-ba1141cc2447"
      unitRef="shares">1047000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4e784cab819d451499c362b12111a27a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItNS0xLTEtMA_9e775635-a2df-4133-a03c-6f1f9062da8c"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5e651f0bdf0a4e5c85db0a3c85be51f1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItNy0xLTEtMA_78d2d664-1fed-43cd-a838-04328af2539b"
      unitRef="shares">1038000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i296a96e660db43169f0376b184f4d3fc_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItOS0xLTEtMA_e745e541-2d31-4cbc-9bdb-a9f46b3f665a"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1b062550448c4f5b877548d6eda89d15_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzItMTEtMS0xLTA_a9b9182e-033f-4554-9a8f-311e76e82cb5"
      unitRef="shares">985000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i6b9c3612f056401fb72e41a133ef96aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtMS0xLTEtMA_eec53348-1b1b-41cd-a418-cbb92f37d3fe"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtMy0xLTEtMA_8622b436-06f4-4468-bff8-2e3f8e94e9b8"
      unitRef="shares">11000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibbc6c432152d469a9be95a1902906f56_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtNS0xLTEtMA_eb34d683-1430-4cad-87ca-759c403209b7"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtNy0xLTEtMA_a144dcf9-44d7-4895-9276-5a5f24f2d2b6"
      unitRef="shares">16000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ide665a6ad8774e8695a7587e4b025cb3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtOS0xLTEtMA_cf9817a9-1b26-4114-882a-e90a7cd70874"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzMtMTEtMS0xLTA_4907cf00-9cb4-49f2-8bde-01f4d0a283d1"
      unitRef="shares">66000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6b9c3612f056401fb72e41a133ef96aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtMS0xLTEtMA_bfbe7f4a-5406-4298-9e58-fbbef7c49a91"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i99757db5aa8f46fb8ccc136260d10c44_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtMy0xLTEtMA_2fdf1a20-3ec8-4230-925b-c49e8afb35d3"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ibbc6c432152d469a9be95a1902906f56_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtNS0xLTEtMA_8682a503-26aa-4e9c-933d-1c81f758411f"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5059e96eddae4ef3aea324a3759a4f3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtNy0xLTEtMA_9325f6cc-34ba-4597-a880-7548c7fca6c0"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ide665a6ad8774e8695a7587e4b025cb3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtOS0xLTEtMA_84f5559f-e8ef-4bfe-b9c1-a660a8492bc4"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0e8b34f6270f4609b9345f69907b380c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzQtMTEtMS0xLTA_0d3b3ab8-bfdc-4259-afa5-3319b3998991"
      unitRef="shares">13000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5771d34675734e438d53901618ffd853_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtMS0xLTEtMA_c48067ee-8b4a-4442-ba03-6e2a738d1b8b"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i10c6f9da4227441da8480f88901779b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtMy0xLTEtMA_218b85d0-42bd-464f-822e-1e75001f5176"
      unitRef="shares">1049000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="if91e41b657e142838655904b6ffc2b4c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtNS0xLTEtMA_c224dc18-5f62-4041-97ab-2eae57099679"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i44fbc319828d43888404b362300c8719_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtNy0xLTEtMA_422f1d72-6f65-4b04-967c-a29a594f0d90"
      unitRef="shares">1047000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4e784cab819d451499c362b12111a27a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtOS0xLTEtMA_f12c97b6-272b-4c1e-8cf8-75328270cb40"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5e651f0bdf0a4e5c85db0a3c85be51f1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzUvZnJhZzo3NmM1MDk4MTc0ZTk0ZjdiYjgyYjkwMTkyMzRhMzMxMS90YWJsZTphODNmNTdmYjlmOTA0NzUzYmQyYWM0ZGI1ZTUzNTAzYi90YWJsZXJhbmdlOmE4M2Y1N2ZiOWY5MDQ3NTNiZDJhYzRkYjVlNTM1MDNiXzUtMTEtMS0xLTA_52e59c76-f48e-48df-b60d-3afaa488cac2"
      unitRef="shares">1038000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMjc_86cd8095-b860-40fc-b6d6-acc038f9ba7e">Share-Based Compensation Plans&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company&#x2019;s shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, 93 million shares collectively were authorized for future grants under the Company&#x2019;s share-based compensation plans. These awards are settled with treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10&#160;years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company&#x2019;s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company&#x2019;s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company&#x2019;s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total pretax share-based compensation cost recorded in 2021, 2020 and 2019 was $498&#160;million, $475&#160;million and $417&#160;million, respectively, including $479 million, $441 million and $388 million, respectively, related to continuing operations. Income tax benefits for share-based compensation expense recognized in 2021, 2020 and 2019 were $69 million, $65 million and $57 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company&#x2019;s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average exercise price of options granted in 2021, 2020 and 2019 was $75.99, $77.67 and $80.05 per option, respectively. The weighted average fair value of options granted in 2021, 2020 and 2019 was $9.80, $9.93 and $10.63 per option, respectively, and were determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:4pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information relative to stock option plan activity (options in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding January&#160;1, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards transferred to Organon in the spin-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustment to Merck awards related to the spin-off of Organon &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and expected to vest December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,829&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,136&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60.41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Activity prior to the Organon spin-off has not been restated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  In connection with the spin-off of Organon, all outstanding Merck stock options (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:7pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information pertaining to stock option plans is provided in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested January 1, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,897&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;69.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70.25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;79.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards transferred to Organon in the spin-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustment to Merck awards related to the spin-off of Organon &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74.88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expected to vest December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74.93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,832&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Activity prior to the Organon spin-off has not been restated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  In connection with the spin-off of Organon, all outstanding Merck RSUs and PSUs (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, there was $699 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQ1Mg_e5bbb2d5-f932-46a5-a7ad-0c338d58d5e5"
      unitRef="shares">93000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwNTc_c5c0fb5d-3b7a-4beb-bcd7-503b33b694b6">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic1a2739cca2046f0abc863ed20b48d0b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzgyNA_930d60de-1516-4666-b91e-db7d50c0990a">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="idbf378454e1d4b12a87f05c8d4852a45_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzgyNw_d87e8837-bbab-44dc-bb76-c7d590a0ba31">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMTQ_8b2862bb-8117-47ae-a526-b746ab2ed6d1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwNTQ_f6892708-9217-4f4c-813f-faccd11f9a84">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzEwOTk1MTE2MzcwNzA_6d6df354-34ea-4dca-aeda-ed9d68d838cd"
      unitRef="usd">498000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzEwOTk1MTE2MzcwODU_6cf64489-c06a-4a9b-9140-d5c4ec559fc6"
      unitRef="usd">475000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzEwOTk1MTE2MzcwOTk_fca5b699-fc80-4af0-9cd3-721b3f4234b2"
      unitRef="usd">417000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIwNzY_d18856a6-26be-419a-94f2-89e9686f73ba"
      unitRef="usd">479000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIwODA_142d7a18-2e5b-47d3-94e5-c853ce8c6c4b"
      unitRef="usd">441000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIwODc_7c98212c-8ef6-491e-a073-9284e5ccabc6"
      unitRef="usd">388000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIxNDE_780954fc-17f7-4124-9167-485db8f5a963"
      unitRef="usd">69000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIxNDU_24f9b0bf-3dc2-47a4-8b1e-84f48fc8f9d7"
      unitRef="usd">65000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzIxNTI_ecec5f12-137b-40dc-967f-de13e1dbf3dd"
      unitRef="usd">57000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMyNjA_3ca203e5-f321-432a-a079-fda9685e190d"
      unitRef="usdPerShare">75.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMyNjQ_e81e5a89-c1bc-4572-9b7a-57c0b0ce6dfb"
      unitRef="usdPerShare">77.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMyNzE_dca48bc7-649f-40ef-92e1-bff8254f57c0"
      unitRef="usdPerShare">80.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwNTE_d9254a80-76b8-4ba9-9c6d-05afd1258251">The weighted average fair value of options granted in 2021, 2020 and 2019 was $9.80, $9.93 and $10.63 per option, respectively, and were determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMzNzI_7db41141-c3bc-4d80-9970-911b87c8f1d2"
      unitRef="usdPerShare">9.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMzNzY_82e6d2f8-9684-4c16-9cd7-db1224f9fc73"
      unitRef="usdPerShare">9.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzMzODM_bc772e49-7a72-4a18-8284-ec25d2e04aef"
      unitRef="usdPerShare">10.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzEtMS0xLTEtMA_099dadb2-c8fc-4267-8f18-fa0144a6baf9"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzEtMy0xLTEtMA_0ac51050-de86-42d6-96f7-4193697039e2"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzEtNS0xLTEtMA_799fd7b2-6478-4be4-b832-bc6e7f07f0f6"
      unitRef="number">0.032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzItMS0xLTEtMA_6cff7007-6826-4576-94c5-9dadcb644ab6"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzItMy0xLTEtMA_c2146642-fa9f-473b-b291-cbe8bb847d22"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzItNS0xLTEtMA_f80712c3-6b61-4fc9-a831-e9014c45f5e2"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzMtMS0xLTEtMA_335026e8-e632-4b47-a4ad-e17a1565ec61"
      unitRef="number">0.209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzMtMy0xLTEtMA_702f731a-bd67-4c56-87db-41c98e66785b"
      unitRef="number">0.221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzMtNS0xLTEtMA_0f743638-5bfe-41e2-a2d9-97a357f5a255"
      unitRef="number">0.187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzQtMS0xLTEtMA_341336e9-cbdd-47aa-947f-1543084c425a">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzQtMy0xLTEtMA_bf2c00e6-7be9-4f2f-9ac2-b4ad1270ce53">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTplZjI0N2VlOWYyZjA0YjAxOWZjNjdhMDRhMWI5MjJhOC90YWJsZXJhbmdlOmVmMjQ3ZWU5ZjJmMDRiMDE5ZmM2N2EwNGExYjkyMmE4XzQtNS0xLTEtMA_660dbaa0-e5c9-42d3-9bce-8624dee0302d">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMjM_6fbc57aa-8af7-4c92-a0ed-81d80f72cc5d">&lt;div style="margin-bottom:3pt;margin-top:4pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information relative to stock option plan activity (options in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding January&#160;1, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards transferred to Organon in the spin-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustment to Merck awards related to the spin-off of Organon &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and expected to vest December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,829&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,136&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60.41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Activity prior to the Organon spin-off has not been restated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  In connection with the spin-off of Organon, all outstanding Merck stock options (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzEtMS0xLTEtMA_4e9485ab-e7a3-4e33-8022-7084c36effbf"
      unitRef="shares">19446000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzEtMy0xLTEtMA_7143702b-bc04-4eef-a5e6-2df459f93f63"
      unitRef="usdPerShare">63.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzItMS0xLTEtMA_8de57e51-8d55-4574-b3eb-a2ced64ff4ee"
      unitRef="shares">4781000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzItMy0xLTEtMA_27ca6611-815b-4378-80e3-63f93039900e"
      unitRef="usdPerShare">75.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzMtMS0xLTEtMA_55f82d57-1679-456f-9f06-216b6d52b815"
      unitRef="shares">3728000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzMtMy0xLTEtMA_6259bece-efb3-4d96-a579-f7f0d4deacd1"
      unitRef="usdPerShare">54.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzQtMS0xLTEtMA_af95357c-1da9-4f84-9109-c0862ed6a6f9"
      unitRef="shares">626000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzQtMy0xLTEtMA_54cd72db-4438-4eea-954b-4462f8b322e4"
      unitRef="usdPerShare">73.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMS0xLTEtNDMxMjk_a50c9393-4985-45c8-ab64-5c903220311f"
      unitRef="shares">1947000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMy0xLTEtNDMxMjk_89e85dd0-eecc-4d6f-8821-050e2c6b11c8"
      unitRef="usdPerShare">72.15</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMS0xLTEtMzY1MQ_b557037f-8e41-4661-9dcb-7bef1e2c1a19"
      unitRef="shares">646000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMy0xLTEtMzY1MQ_85ccb66e-3404-4cf6-8b7b-6dffb070ddbe"
      unitRef="usdPerShare">0</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMS0xLTEtMA_8135c20c-0dcf-4208-86f5-7bbd9258c1ec"
      unitRef="shares">18572000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtMy0xLTEtMA_9edaa11b-1a53-4a72-acc7-0d57b21dc9b8"
      unitRef="usdPerShare">65.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtNS0xLTEtMA_fb12c0e4-f844-4e27-868c-55fbc401bbb6">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzUtNy0xLTEtMA_553fc3a0-6c69-4993-b40c-96a6acf2fd41"
      unitRef="usd">213000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzgtMS0xLTEtNDc3ODE_13d327d8-46e0-4532-a2dc-9273a4d2be2a"
      unitRef="shares">17829000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzgtMy0xLTEtNDc3ODE_d98fe5e0-bddd-4359-9f70-7495bccb8890"
      unitRef="usdPerShare">64.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzgtNS0xLTEtNDc3ODE_3b58149f-8365-4af1-b7ca-5b76dccdbd91">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzgtNy0xLTEtNDc3ODE_bb81f8d2-3e6d-44de-b54a-ea3b06e6aa5a"
      unitRef="usd">212000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzYtMS0xLTEtMA_e920c8ad-d933-44e5-9fab-1e0e18c9af05"
      unitRef="shares">12136000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzYtMy0xLTEtMA_055475ef-3920-4cf7-beb9-5280e025ded4"
      unitRef="usdPerShare">60.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzYtNS0xLTEtMA_c6d2ca18-0ffe-44e9-b997-ff3604c25cf3">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTo4YmY4OGFmNTU4NDE0NTcwODY5MWY5YzA5YzU0ZDYzYy90YWJsZXJhbmdlOjhiZjg4YWY1NTg0MTQ1NzA4NjkxZjljMDljNTRkNjNjXzYtNy0xLTEtMA_42239e75-3892-48ae-bbf8-0726036b77ed"
      unitRef="usd">198000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMzY_bf291260-5d41-4f69-a5d1-31f834baa119">&lt;div style="margin-bottom:3pt;margin-top:7pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information pertaining to stock option plans is provided in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzEtMS0xLTEtMA_db802309-b0ba-4ce9-b1e3-62ae37268288"
      unitRef="usd">106000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzEtMy0xLTEtMA_0612eaf3-2550-49e0-b562-630493e8cd4d"
      unitRef="usd">51000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzEtNS0xLTEtMA_f72b4fdb-b7bd-4768-a753-aa632a8c4bc2"
      unitRef="usd">295000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzItMS0xLTEtMA_a9e80790-dcda-49b8-99cc-88edafe2e3ec"
      unitRef="usd">27000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzItMy0xLTEtMA_e0babddc-3db7-4695-805f-8f8c89edf20a"
      unitRef="usd">25000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzItNS0xLTEtMA_d1ea3a42-63e8-4e98-8cc5-984c16f849cf"
      unitRef="usd">27000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzMtMS0xLTEtMA_3d54e30a-cd1b-4dcd-bcca-42a1ff3e7500"
      unitRef="usd">202000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzMtMy0xLTEtMA_d6050a38-32c8-4b06-8eb7-a94fc6a04490"
      unitRef="usd">89000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTpmZjk2YTMwZmUzMDU0OTZkYWE1ZWY1YTZlYjg5NDQ2Ni90YWJsZXJhbmdlOmZmOTZhMzBmZTMwNTQ5NmRhYTVlZjVhNmViODk0NDY2XzMtNS0xLTEtMA_974bfc49-7f47-4891-abda-a72560fd7384"
      unitRef="usd">361000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzQwMzQ_3c888da8-8d8a-4b29-a8ca-41c443535eb6">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested January 1, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,897&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;69.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70.25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;79.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Awards transferred to Organon in the spin-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustment to Merck awards related to the spin-off of Organon &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74.88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expected to vest December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74.93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,832&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Activity prior to the Organon spin-off has not been restated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  In connection with the spin-off of Organon, all outstanding Merck RSUs and PSUs (whether vested or unvested) were converted into adjusted Merck awards for current and former Merck employees or Organon awards for Organon employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i00edd76d055e4b64afd262bffa0b265e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzItMi0xLTEtMA_c672ad8e-9d7f-452a-a527-33e4b89f77b1"
      unitRef="shares">11915000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i00edd76d055e4b64afd262bffa0b265e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzItNC0xLTEtMA_54529939-eeaf-4823-bb26-9682a4c7a320"
      unitRef="usdPerShare">74.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i96029d87c50446529e49db206d363e3e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzItNi0xLTEtMA_97782cf6-b806-4a90-aff9-6ed595384f02"
      unitRef="shares">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i96029d87c50446529e49db206d363e3e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzItOC0xLTEtMA_bf28f809-fab2-4bd9-8b86-ed07e9456a85"
      unitRef="usdPerShare">75.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzMtMi0xLTEtMA_51c3b8fa-a2d8-4f3c-8f6b-13fee497bf5e"
      unitRef="shares">7897000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzMtNC0xLTEtMA_b743928f-b96a-4d28-bc15-65f120c99d97"
      unitRef="usdPerShare">76.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzMtNi0xLTEtMA_ac7caa9c-54b7-4030-ab0e-06fbcd7d59d5"
      unitRef="shares">1487000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzMtOC0xLTEtMA_d0873383-af0b-45fa-94a4-2723ff45107e"
      unitRef="usdPerShare">69.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzQtMi0xLTEtMA_14c2245b-5360-4a86-873e-a62aea41b064"
      unitRef="shares">6066000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzQtNC0xLTEtMA_1afc2cab-34b5-42c3-8f12-2e1a20925e4f"
      unitRef="usdPerShare">70.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzQtNi0xLTEtMA_c5d8fd4b-e387-454f-9992-b8a3443c75a7"
      unitRef="shares">1284000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzQtOC0xLTEtMA_cb9002b6-5451-41e5-ac27-7342250e5da2"
      unitRef="usdPerShare">57.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzUtMi0xLTEtMA_99a5eb3d-70dd-4132-a3f8-ce9f78a69ad8"
      unitRef="shares">1015000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzUtNC0xLTEtMA_ece58ba0-08dc-4e7f-855f-60fdc31b2e57"
      unitRef="usdPerShare">76.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzUtNi0xLTEtMA_454174d5-80a5-4674-8955-6f2d0b3d05d6"
      unitRef="shares">149000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzUtOC0xLTEtMA_42d605b5-4161-4353-a828-c95435040421"
      unitRef="usdPerShare">79.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtMi0xLTEtNDMxMDU_1e8cc3f9-ee85-4794-94aa-3770b27cda4d"
      unitRef="shares">1309000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNC0xLTEtNDMxMDU_0dd914e3-3c44-4a48-b985-eb85347e1803"
      unitRef="usdPerShare">76.99</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNi0xLTEtNDMxMDU_7dadb4b2-88d6-4794-91cf-3bbf9a5d23ef"
      unitRef="shares">248000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtOC0xLTEtNDMxMDU_41b0f013-acbe-4385-b533-8fd7dfe180cd"
      unitRef="usdPerShare">77.39</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtMi0xLTEtMzY2NA_7325fab4-226a-4b6c-a0e8-55a3f31314da"
      unitRef="shares">-368000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue
      contextRef="i279bd7bbb0414ee698c427aa91b76f9f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNC0xLTEtMzY2NA_8fdf9d36-b16a-4737-abf2-608d961e12d4"
      unitRef="usdPerShare">0</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNi0xLTEtMzY2NA_a8161099-320e-446b-bce0-25cf3370030b"
      unitRef="shares">-60000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue
      contextRef="i28d604caa6ad46098194a9214fb47727_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtOC0xLTEtMzY2NA_bce31136-dd31-4178-8874-3c0975bda50f"
      unitRef="usdPerShare">0</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtMi0xLTEtMA_edfb313b-e0fb-4cdd-83e5-7bf445e16dc5"
      unitRef="shares">11790000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNC0xLTEtMA_f6cf284d-ef4b-4902-aedf-ffbec3630a56"
      unitRef="usdPerShare">74.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtNi0xLTEtMA_4319a3a6-ff27-4f9e-aef7-a2dda02588eb"
      unitRef="shares">1966000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzYtOC0xLTEtMA_cdbd9793-8b7e-4139-9fa9-c00746862610"
      unitRef="usdPerShare">77.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber
      contextRef="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzktMi0xLTEtNDc4MjE_dddddcdb-1e2f-4c2d-8ac6-14c67b8eca91"
      unitRef="shares">10499000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="ib3aede1471dd4afcaa4cd3fcd463a9fa_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzktNC0xLTEtNDc4MjE_410f5831-2a5e-48ee-975d-a951bad9c8fe"
      unitRef="usdPerShare">74.93</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber
      contextRef="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzktNi0xLTEtNDc4MjE_c093619d-6d51-44b4-9469-b9bd1c0559e8"
      unitRef="shares">1832000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="ia66e60c053e0417e99f2bbb2eee4dc0a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90YWJsZTphMGI3MjExNWNhMDM0M2I4YjczZThjMWQ2M2NmMDc5OS90YWJsZXJhbmdlOmEwYjcyMTE1Y2EwMzQzYjhiNzNlOGMxZDYzY2YwNzk5XzktOC0xLTEtNDc4MjE_9e8595f8-7170-4514-adcd-928a954e8a9c"
      unitRef="usdPerShare">77.40</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzM3NTk_ff828096-f036-48a9-9461-bce3dcd2a6ee"
      unitRef="usd">699000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xNzgvZnJhZzowYTc2OTE2MDMzNzE0MzNjOWQ2ZGQwYjZmMzg0NzU1Yi90ZXh0cmVnaW9uOjBhNzY5MTYwMzM3MTQzM2M5ZDZkZDBiNmYzODQ3NTViXzM5MjY_d5cb85e8-9879-4a71-a819-87f4bc58e139">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxMTA_8772921f-bf30-411a-84e0-662cc0f3a734">Pension and Other Postretirement Benefit Plans&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S.&#160;retirees and their dependents, through its other postretirement benefit plans. The Company uses December&#160;31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&#160;Postretirement&#160;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;403&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit cost (credit) for pension and other postretirement benefit plans in 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with restructuring actions (see Note&#160;6), termination charges were recorded in 2021, 2020 and 2019 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;certain pension plans. An increase in lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost (credit) other than the service cost component are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (see Note 15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if related to the spin-off of Organon (each as noted above).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Obligations and Funded Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit obligation January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,458&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;403&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit obligation December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,999&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11,575&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funded status December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(386)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Actuarial (gains) losses primarily reflect changes in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021 and 2020, the accumulated benefit obligation was $24.9 billion and $26.3 billion, respectively, for all pension plans, of which $13.8 billion and $14.4 billion, respectively, related to U.S. pension plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to the funded status of selected pension plans at December 31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension plans with a projected benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension plans with an accumulated benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,916&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,723&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December&#160;31, 2021 and 2020, $943 million and $942 million, respectively, or approximately 4% of the Company&#x2019;s pension investments were categorized as Level&#160;3 assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s pension plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,799&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;919&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;919&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,944&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other fixed income obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;369&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;369&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;982&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;578&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The plans&#x2019; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#x2019;s pension plan assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets sold during the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers in (out) of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established investment guidelines for its U.S.&#160;pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#x2019;s U.S.&#160;pension and other postretirement benefit plans is allocated 30% to 45% in U.S.&#160;equities, 15% to 30% in international equities, 35% to 45% in fixed-income investments, and up to 5% in cash and other investments. The portfolio&#x2019;s equity weighting is consistent with the long-term nature of the plans&#x2019; benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 11%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Contributions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contributions during 2022 are expected to be approximately $280 million for U.S. pension plans, approximately $150 million for international pension plans and approximately $50 million for other postretirement benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Benefit Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&#160;&#x2014;&#160;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amounts Recognized in Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Postretirement&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gain (loss) arising during the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,048&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (cost) credit arising during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,045&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;786&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization included in benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service credit amortization included in benefit cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Actuarial Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Pension&#160;and&#160;Other&lt;br/&gt;Postretirement&#160;Benefit&#160;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan&#x2019;s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2022, the expected rate of return for the Company&#x2019;s U.S. pension and other postretirement benefit plans will be 6.70%, as compared to a range of 6.50% to 6.70% in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The health care cost trend rate assumptions for other postretirement benefit plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year that the trend rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Savings Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee&#x2019;s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2021, 2020 and 2019 were $158 million, $158 million and $143 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxNDM_a17c2ad7-515b-4212-b070-e4acceac5d6b">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&#160;Postretirement&#160;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;403&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMS0xLTEtMA_38bfc288-3cc7-4aa5-8f65-458abe49fa4a"
      unitRef="usd">403000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMy0xLTEtMA_dae2ca25-99dd-4603-ae60-46ef162602e7"
      unitRef="usd">360000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtNS0xLTEtMA_ba416c0f-ff26-4b79-8f36-7ad2bde111aa"
      unitRef="usd">293000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtNy0xLTEtMA_d2cf5e51-1f2c-440f-bf71-8c442806ac18"
      unitRef="usd">328000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtOS0xLTEtMA_c0ac3d5f-5ec7-4832-b5f2-419ca6f0b05c"
      unitRef="usd">297000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMTEtMS0xLTA_1aec4223-ea61-4a6c-9e21-06e841087789"
      unitRef="usd">235000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMTMtMS0xLTA_a9f8535c-9a6d-47f9-aacd-f64d1c5c9dab"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMTUtMS0xLTA_256e388b-59ca-42a8-a86b-fcec2a3eccf2"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzMtMTctMS0xLTA_66ddb272-e4dc-426a-8890-817fc9ee2032"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMS0xLTEtMA_81f75b0c-d12a-4bf0-a136-2c574a786a2d"
      unitRef="usd">404000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMy0xLTEtMA_dd28af45-24f4-4b2c-9d8e-14561f3edfdd"
      unitRef="usd">431000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtNS0xLTEtMA_c0a0cb17-4f6d-40d1-a427-d7f71e58c409"
      unitRef="usd">458000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtNy0xLTEtMA_544a2380-d604-482d-af09-d052bc549fbf"
      unitRef="usd">123000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtOS0xLTEtMA_484c938b-6b43-4b3a-b469-0849f57ae818"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMTEtMS0xLTA_d215d2f5-e0b6-4b7e-9032-02e0c97c1b5b"
      unitRef="usd">176000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMTMtMS0xLTA_4a5025c9-c2e3-4830-ba28-251233f7199f"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMTUtMS0xLTA_14500fa9-be87-42af-9a68-97d3bba3dfb1"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzQtMTctMS0xLTA_59112e65-4d69-47a8-b507-af2b068d85d1"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMS0xLTEtMA_52687bd7-d851-4a7d-ad66-511bd3a63cee"
      unitRef="usd">755000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMy0xLTEtMA_d3b565c2-aeb1-4bba-9bab-747535d41723"
      unitRef="usd">774000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtNS0xLTEtMA_304f6e64-bbd0-4807-8b71-af5ed5b0cfd0"
      unitRef="usd">817000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtNy0xLTEtMA_5a6d9862-5465-474a-90ef-57fa492d197f"
      unitRef="usd">416000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtOS0xLTEtMA_90c60965-b082-4f8c-9ead-63c41e12e988"
      unitRef="usd">414000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMTEtMS0xLTA_e0d56780-760a-403f-8312-f0d808449e40"
      unitRef="usd">425000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMTMtMS0xLTA_3334b745-1930-4036-b355-2c0d741e796a"
      unitRef="usd">79000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMTUtMS0xLTA_03cfa5e1-5268-45ef-9ee1-e24923c5e0ba"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzUtMTctMS0xLTA_6a4c1538-0a2a-40cb-a020-a53f297186f9"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMS0xLTEtMA_87752797-5cad-4cd3-af40-bbb4f68aebbf"
      unitRef="usd">-38000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMy0xLTEtMA_36c3feeb-230c-4ec9-abeb-81b6dc689587"
      unitRef="usd">-49000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtNS0xLTEtMA_f9092907-5569-49b2-8ef2-0a3ab157282e"
      unitRef="usd">-49000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtNy0xLTEtMA_ff9fe4ad-e660-49cc-a7bb-4d35cab0d408"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtOS0xLTEtMA_523c2dd7-408b-43ec-b321-0f7819266ea2"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMTEtMS0xLTA_034dbd9f-fed4-4f6b-948a-3bbdfc45eed9"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMTMtMS0xLTA_d7f806c0-793a-4792-8179-709863934238"
      unitRef="usd">-63000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMTUtMS0xLTA_a2d8a7bf-f012-46c7-8ad8-53c9fe596bba"
      unitRef="usd">-73000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzYtMTctMS0xLTA_33b779b4-8339-4384-ad14-561f8b869822"
      unitRef="usd">-78000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMS0xLTEtMA_3012bfd3-2cd3-4186-90bc-c19cb0ab909c"
      unitRef="usd">-298000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMy0xLTEtMA_424b9fa5-6be5-4e69-940c-d0e973f13dc2"
      unitRef="usd">-303000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctNS0xLTEtMA_613d205e-c607-48e7-b655-c8d7a7839336"
      unitRef="usd">-151000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctNy0xLTEtMA_831addd9-2f72-4d28-a68d-2685b780f555"
      unitRef="usd">-142000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctOS0xLTEtMA_f4b92e6c-d3c9-48d6-8c2d-a9def6e00a36"
      unitRef="usd">-127000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMTEtMS0xLTA_6b59eb0a-3d39-4c12-a3a1-c285e92b3c07"
      unitRef="usd">-64000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMTMtMS0xLTA_32b1ed41-836b-4b63-9682-3f317b5c7ba4"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMTUtMS0xLTA_5ceb65c7-db6b-498e-aef1-ea212ae66961"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzctMTctMS0xLTA_ab28a77e-2601-4d8f-91f7-45b76b5662fc"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMS0xLTEtMA_c0377e9f-7fd2-4b5c-a3f9-2828e36600a0"
      unitRef="usd">56000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMy0xLTEtMA_47eda253-874e-4b8b-ac83-100e8043ede3"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtNS0xLTEtMA_361af269-34ef-4302-9138-7a8defac2073"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtNy0xLTEtMA_33c95fab-d774-457b-b73e-2d7b39481d18"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtOS0xLTEtMA_de12d239-6d21-4c36-9ab9-96caa3d3fa24"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMTEtMS0xLTA_85c53a2f-5c32-4a15-9116-f5825f2e3698"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMTMtMS0xLTA_7155d639-664e-46b6-8481-a6bbd101d68f"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMTUtMS0xLTA_5d6544b9-ad2a-4bbd-a385-f6c550589b15"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzgtMTctMS0xLTA_231c2575-e3b9-4a70-bc2a-b4d4f6809bb5"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMS0xLTEtMA_58559f48-89b9-4a0d-bf1f-c228d8389881"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMy0xLTEtMA_0001a123-66ae-4cfd-af85-44a0ef567d28"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktNS0xLTEtMA_c7766a01-4e2f-46c2-a25f-b8bccf5eae65"
      unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktNy0xLTEtMA_c0b2af23-06ad-4f70-a922-c49d339e8974"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktOS0xLTEtMA_6f64336f-5f7d-4c02-8207-e9962c2fad07"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMTEtMS0xLTA_b4d198a0-9f7f-4b6e-b740-ffe953f9ba33"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMTMtMS0xLTA_3eae051a-05be-4907-b081-658f1381110a"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMTUtMS0xLTA_01d65a10-8dfd-47f0-b1cd-24fe464ea589"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzktMTctMS0xLTA_e57bddc6-8564-422b-a49e-9f5665632bc7"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTEtMS0xLTA_1bc28b5e-e79d-46d7-9a71-3074d7628b98"
      unitRef="usd">-216000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTMtMS0xLTA_1a7e5c3c-cdca-4616-a699-bff56f865fd6"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTUtMS0xLTA_2d93dd7e-1bc6-4456-9ac0-bf706511d6a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTctMS0xLTA_31b6da1e-c550-4d84-aa7d-946242a97a7d"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTktMS0xLTA_838ce371-0fd0-4060-a505-9549ba1550df"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTExLTEtMS0w_f0dedbf8-6851-436a-87c5-35a7be972d6a"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTEzLTEtMS0w_0a3eeebf-eed0-4ee2-a598-9cdb9968e67f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTE1LTEtMS0w_6ece5481-28c6-4e74-b361-5ed44adcbd8d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzEwLTE3LTEtMS0w_ad87dbdd-a890-4fc0-979b-94ba087f01a8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTEtMS0xLTA_a1741e2e-4ddc-434d-aa8f-c4c76abed172"
      unitRef="usd">600000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTMtMS0xLTA_091e7767-b9d4-42ee-a7b8-6937e0b9f6b7"
      unitRef="usd">304000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTUtMS0xLTA_4ea9238b-280d-45c7-8fdd-72d45dc363b7"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTctMS0xLTA_1536c838-d155-439d-a9b2-666fc0c0be94"
      unitRef="usd">148000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTktMS0xLTA_ca78a50e-70ad-4742-95e1-8fc10380d66f"
      unitRef="usd">146000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTExLTEtMS0w_0fda5c76-c9f3-408e-a2c2-0a1c479b48d7"
      unitRef="usd">53000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTEzLTEtMS0w_67ddb2cb-b978-45b9-96fb-8aa446880a80"
      unitRef="usd">-83000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTE1LTEtMS0w_22520852-8ccb-48ed-bcb1-feb4c32f3adc"
      unitRef="usd">-59000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTowYjQ2MDZmOTFhZTE0NmY0OWQwZjJjOTYwM2RmMDU3NS90YWJsZXJhbmdlOjBiNDYwNmY5MWFlMTQ2ZjQ5ZDBmMmM5NjAzZGYwNTc1XzExLTE3LTEtMS0w_e81285e2-6f27-49ae-b5a6-b99a0743d1bc"
      unitRef="usd">-49000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwNzM_848ae41f-86a8-4730-a5e6-3a864271ec02">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit obligation January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,458&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;403&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit obligation December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,999&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11,575&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funded status December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(386)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Actuarial (gains) losses primarily reflect changes in discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtMS0xLTEtMA_7b0fb724-6b72-4e03-aa9d-30e71d339a9e"
      unitRef="usd">12672000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i178e704826a843dfa1384049fd999736_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtMy0xLTEtMA_a333ee48-a2e5-40bb-ae31-441b4061206b"
      unitRef="usd">11361000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtNS0xLTEtMA_8a63fe50-044d-4f54-8bdc-7cd85699addb"
      unitRef="usd">12009000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtNy0xLTEtMA_ea04257b-ff8e-4367-a8d0-c025d355b586"
      unitRef="usd">10135000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtOS0xLTEtMA_7f03c2d4-806d-4814-aadf-f0dc0c7bc3ed"
      unitRef="usd">1221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibfd71cacd403473c93f86070341b371c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzMtMTEtMS0xLTA_ac8e5c39-3b29-4a29-9918-b8bcf459a7de"
      unitRef="usd">1102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtMS0xLTEtMA_38dbeed3-684b-4ef4-87cd-c0ce58ea6662"
      unitRef="usd">1250000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtMy0xLTEtMA_804f63a1-631f-4b21-ab11-ea96e8ca047f"
      unitRef="usd">1908000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtNS0xLTEtMA_67145e75-8e5e-4f0c-9f40-4bb6d7e0ad41"
      unitRef="usd">891000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtNy0xLTEtMA_5c3bd1e7-8ea5-4d17-85cf-60f15683f630"
      unitRef="usd">1026000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtOS0xLTEtMA_0975dfc8-47b6-4c56-a2a6-64ad3fcc4987"
      unitRef="usd">118000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzQtMTEtMS0xLTA_c79f0f81-d7ae-413b-a2fe-672e503bee09"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtMS0xLTEtMA_cb275f6c-771a-45f7-a815-014ad49bb215"
      unitRef="usd">305000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtMy0xLTEtMA_46f0aa25-b278-4c2b-8a02-c450ae3cfc54"
      unitRef="usd">199000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtNS0xLTEtMA_0e994128-e9b1-4dec-9c0c-f6dd66a8df14"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtNy0xLTEtMA_7ef087a4-1ba7-46a8-8c65-5f6a4c298602"
      unitRef="usd">383000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtOS0xLTEtMA_90ef3fa0-6e27-41ba-8ca4-26172da9ce85"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzUtMTEtMS0xLTA_8f9bfcba-20c9-4b57-a1db-22a0c2994a81"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtMS0xLTEtMA_1d742b4c-33aa-4616-8277-9df48d894a3e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtMy0xLTEtMA_3bc70cb4-3129-43e5-8fa7-dde159a69edd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtNS0xLTEtMA_6e245e7d-f1bf-4e1c-840b-a976fd5572f7"
      unitRef="usd">-671000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtNy0xLTEtMA_cdf5f0a6-7d05-414e-9010-1cf0d25d8ddf"
      unitRef="usd">743000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtOS0xLTEtMA_d6ec066c-f8ad-4e5a-93f4-b9a9446b49c4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzYtMTEtMS0xLTA_f2bb5bca-74da-4346-a66e-aa5bbf469166"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctMS0xLTEtMA_63147b88-5e1a-42c2-b8d5-c660620f6b71"
      unitRef="usd">219000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctMy0xLTEtMA_a8c04d85-ed14-4631-b62b-ae52dd2d1342"
      unitRef="usd">751000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctNS0xLTEtMA_b595ac0d-c1f0-488b-9e2e-17cd3655a605"
      unitRef="usd">233000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctNy0xLTEtMA_ab0b4e95-e29a-4a37-9409-13deb7397fed"
      unitRef="usd">214000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctOS0xLTEtMA_831afa8e-3458-4bd4-8eab-6eab4800bf67"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzctMTEtMS0xLTA_4249ad79-bf00-4e6e-b33c-3e6e71f9751c"
      unitRef="usd">93000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtMS0xLTEtMA_05b186dc-a743-4355-9938-d637cd35833e"
      unitRef="usd">941000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtMy0xLTEtMA_3649f8b9-df81-4423-8d07-9315acb6eefc"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtNS0xLTEtMA_b1520d04-1279-4f34-864c-af6685c6cf18"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtNy0xLTEtMA_b19f2b13-9b6f-4e0b-a283-4810922b10a8"
      unitRef="usd">117000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtOS0xLTEtMA_0d565137-1c6f-4160-81ae-5389f4565ce0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzgtMTEtMS0xLTA_7678ef80-261a-4f58-9896-1e8b6d4f9227"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMS0xLTEtNDEyNA_874445bf-0386-4920-85fd-f8c9291ab447"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMy0xLTEtNDEyNA_ff11d3cc-8279-49b9-a708-770e52ccd33a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktNS0xLTEtNDEyNA_433b562b-e205-4968-a2cf-06ba8b2fb57c"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktNy0xLTEtNDEyNA_6492b905-8307-41c7-b1f6-7b2ba3b639fb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktOS0xLTEtNDEyNA_8438b7be-181d-40d9-ae2a-834e02ff0ddb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMTEtMS0xLTQxMjQ_9b94d4dc-281c-43f7-89ef-a5295db1a6ab"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMS0xLTEtMA_ecd12859-ee4f-482d-bd52-e318af26f6a0"
      unitRef="usd">0</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMy0xLTEtMA_3399fe89-d475-4b88-9408-29b011e55b74"
      unitRef="usd">0</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktNS0xLTEtMA_aeccd92e-6064-405e-a23f-45fd10ac3a7b"
      unitRef="usd">120000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktNy0xLTEtMA_81052285-d0d7-4ba5-858c-09bccdfa2a29"
      unitRef="usd">53000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktOS0xLTEtMA_ba01d4af-08b6-4fe6-a2bf-dbe895fac9c5"
      unitRef="usd">6000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzktMTEtMS0xLTA_eafd0d10-e9d6-49a6-94fa-ca794eaf87d0"
      unitRef="usd">18000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTEtMS0xLTA_3760292d-f44e-4af3-93bd-ecb8b0f82bc1"
      unitRef="usd">13067000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTMtMS0xLTA_8133020d-2ad6-47cf-9518-e32f013490ce"
      unitRef="usd">12672000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTUtMS0xLTA_6d34026d-1d09-4ac9-b855-9506304c1bc6"
      unitRef="usd">12195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTctMS0xLTA_3d3aa934-3561-4463-a378-05d08ad25548"
      unitRef="usd">12009000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTktMS0xLTA_dd1d7076-5305-4866-85fc-963bbbad9965"
      unitRef="usd">1292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEwLTExLTEtMS0w_c807a184-f6fd-4ceb-8f29-c9724956c34e"
      unitRef="usd">1221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTEtMS0xLTA_17193b87-e2b6-4e0b-ba7c-2ba42c6a5426"
      unitRef="usd">14613000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i178e704826a843dfa1384049fd999736_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTMtMS0xLTA_b06581ed-89ca-4f6f-b91f-ebf2cb886c9d"
      unitRef="usd">13003000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTUtMS0xLTA_287d33c7-5475-4743-9e0f-e43ef172f56a"
      unitRef="usd">12458000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTctMS0xLTA_a77a79ac-00c8-4685-8517-c46941004a29"
      unitRef="usd">10558000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTktMS0xLTA_3e9f18bb-6d5a-4110-a049-6185f3a92c47"
      unitRef="usd">1607000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ibfd71cacd403473c93f86070341b371c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzExLTExLTEtMS0w_fb093bf3-ebc4-47ef-9b29-4ee522552d22"
      unitRef="usd">1673000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTEtMS0xLTA_12969d70-aa0d-4801-aa9e-ab2200623d31"
      unitRef="usd">403000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTMtMS0xLTA_22a22104-0e8c-4825-bdf1-5964916dac09"
      unitRef="usd">360000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTUtMS0xLTA_8651ceb3-f5e2-4ec7-9536-c2dd7ebe361e"
      unitRef="usd">328000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTctMS0xLTA_bd3dce93-02ba-4a23-a2f1-85aed858dd06"
      unitRef="usd">297000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTktMS0xLTA_fa9f33f0-1eb4-48c8-99b2-e4cba462b82c"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEyLTExLTEtMS0w_8603426f-9fda-47ad-b584-4297c43db11c"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTEtMS0xLTA_071533db-1ed6-401f-9783-8f7e9874ad2d"
      unitRef="usd">404000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTMtMS0xLTA_6e3fdf68-8b91-4729-aab3-166e187cd8d1"
      unitRef="usd">431000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTUtMS0xLTA_dbbccfe4-a070-405d-9fb7-427f1bda0a0c"
      unitRef="usd">123000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTctMS0xLTA_aa1bb324-e88f-4f55-90ec-139033de7fd6"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTktMS0xLTA_e9c46d2c-68ac-42a3-b865-122040a71040"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzEzLTExLTEtMS0w_fac6b6e4-bb1b-47d7-99d8-a53c079033a6"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTEtMS0xLTA_47f89771-8a4e-4535-913a-4622de356253"
      unitRef="usd">332000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTMtMS0xLTA_9cfc4f11-aa22-4b13-9bfe-c5a6205a39dc"
      unitRef="usd">-1594000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTUtMS0xLTA_8e952d29-9c3b-4ddc-9345-b25b5d4b311c"
      unitRef="usd">240000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTctMS0xLTA_40f87bae-4f4a-4529-9f45-30e9ffb763e9"
      unitRef="usd">-1032000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTktMS0xLTA_7d10c6a5-615b-498b-8251-d019e9f025a8"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE0LTExLTEtMS0w_3f21940f-1bfc-4627-9ae6-ef701e1349ed"
      unitRef="usd">98000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTEtMS0xLTA_8029123c-05a8-4fb4-af07-315018c002bb"
      unitRef="usd">219000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTMtMS0xLTA_2b5c2a87-367a-4eb3-aeef-2910d7d7b7c5"
      unitRef="usd">751000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTUtMS0xLTA_6699caa7-b489-42a3-91a4-fef4f4cf50e3"
      unitRef="usd">233000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTctMS0xLTA_5949d360-6eb2-4f3a-8cd1-bbb6cb4a880f"
      unitRef="usd">214000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTktMS0xLTA_5c35ac51-4945-41ba-80c7-49ab9dca933c"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE1LTExLTEtMS0w_e5d986ad-9db9-411e-afa2-7e689b349db8"
      unitRef="usd">93000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTEtMS0xLTA_e6d9200a-8333-4b01-963d-782b83d4fcab"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTMtMS0xLTA_d72c749c-28e0-4bdf-829d-85bae81c987b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTUtMS0xLTA_123f3c84-7dc3-4b53-9a15-83a00bc31784"
      unitRef="usd">-678000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTctMS0xLTA_298b7284-ebd1-4142-9aa0-6c955599e10f"
      unitRef="usd">788000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTktMS0xLTA_baa36d0f-5177-48d3-8651-613ef80bf0e5"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE2LTExLTEtMS0w_2b0f637e-c3eb-4d4b-9e6f-b9db8b8fd411"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTEtMS0xLTA_631420e5-1640-4077-9b9b-a000e314fc11"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTMtMS0xLTA_8e1bab53-6718-4980-b22f-355c13f6f848"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTUtMS0xLTA_a5bedb1d-214c-4f29-b0f8-d107a9a80644"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTctMS0xLTA_45fd259a-a6b8-4836-b379-adcb88c94539"
      unitRef="usd">-64000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTktMS0xLTA_0ad9ff21-013c-465a-a01d-583166deaf82"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE3LTExLTEtMS0w_d56dbe96-f1f3-4a2d-94a5-59a0d1628941"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTEtMS0xLTA_b236bf3d-6d4a-492b-9d4f-d1d5d556c264"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTMtMS0xLTA_1a97a5fc-f46b-46fb-80c1-09b342143126"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTUtMS0xLTA_0e6ff932-ece4-4fd6-9190-18bbd6b5bb59"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTctMS0xLTA_5dad6faf-2005-4e2c-ac59-ae50ca60d169"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTktMS0xLTA_55035dd7-a076-4dcb-a6c3-2fc197af3501"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE4LTExLTEtMS0w_6ab5c96b-6dfc-4313-be10-b8a360caebb0"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTEtMS0xLTA_55279712-32ac-4245-9503-d55797b95aaf"
      unitRef="usd">56000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTMtMS0xLTA_35ba9a47-6824-4e5f-9dbc-170be03af516"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTUtMS0xLTA_69589fc1-fe69-4f78-981f-d48644839eba"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTctMS0xLTA_6ce0cef4-8151-4c3e-bd79-9a4ddb19c642"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTktMS0xLTA_299660ac-9dfa-47aa-a48b-70a5fe0ed66f"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzE5LTExLTEtMS0w_b27f96bc-42a6-4880-91a0-37a159e48f3e"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTEtMS0xLTA_52610c1a-176a-4259-b255-3fa902318918"
      unitRef="usd">941000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTMtMS0xLTA_c01d71da-e1ed-46c5-96ed-e133efe91ac1"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTUtMS0xLTA_e644d1c4-f6ff-4f69-80c4-4690d9a3b18f"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTctMS0xLTA_f6823642-dfdc-4b19-84d9-9d61188df9d1"
      unitRef="usd">117000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTktMS0xLTA_d8c1110c-0b19-4267-ac46-69bd4af15965"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIwLTExLTEtMS0w_415f0287-1541-4641-9cc1-a42d6ee42bc8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTEtMS0xLTQxMzA_93a5c12d-f5b1-4587-858a-c6aa3799b837"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTMtMS0xLTQxMzA_61e39b48-5606-448b-be02-ca517427d414"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTUtMS0xLTQxMzA_efe27c0b-d66e-46df-bae7-4730820748f5"
      unitRef="usd">118000000</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTctMS0xLTQxMzA_f3f42981-58a2-40e6-8e12-f745b2be83aa"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTktMS0xLTQxMzA_b898b239-1399-405a-8a51-dd801a6396b9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTExLTEtMS00MTMw_f834f934-aa13-431b-908a-a792a2634e48"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTEtMS0xLTA_2d511862-a589-4a51-8084-8db2378831ed"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTMtMS0xLTA_8ee20fc8-11fe-4016-b38d-5e8b6e84dc6a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTUtMS0xLTA_cc215c82-dd26-4124-8ad6-a716cac61544"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTctMS0xLTA_f834cb27-735b-426e-b206-eecb6e741334"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTktMS0xLTA_4a2c7a63-5df9-45bc-9d87-9161920374f1"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIxLTExLTEtMS0w_8ac04772-eeb4-4a3c-b426-008be15e582a"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTEtMS0xLTA_b1aa2934-4cd0-4be0-b5a8-7000a3992254"
      unitRef="usd">13999000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTMtMS0xLTA_fc6bafc9-f191-439b-9075-9b7edf16504e"
      unitRef="usd">14613000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTUtMS0xLTA_a8ad0823-a63d-4738-a66b-c636acd5ae57"
      unitRef="usd">11575000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTctMS0xLTA_abb5c9a7-f289-4c25-b4d7-36e5523d92ec"
      unitRef="usd">12458000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTktMS0xLTA_7d9c2b46-c011-4c57-89d6-37ff403bb577"
      unitRef="usd">1541000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIyLTExLTEtMS0w_f2fccce0-65d1-44eb-8213-2aa1b82c6453"
      unitRef="usd">1607000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTEtMS0xLTA_c156ef90-27c1-4e5e-ab2a-e5e3e933dd9a"
      unitRef="usd">-932000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTMtMS0xLTA_e4c8f2ef-21fc-4190-9a75-604e6a93533a"
      unitRef="usd">-1941000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTUtMS0xLTA_efad6cae-8abf-47ba-b0b4-6a100838762b"
      unitRef="usd">620000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTctMS0xLTA_7f4172e0-cfb0-4f76-adeb-81611c0243f7"
      unitRef="usd">-449000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTktMS0xLTA_ccb1a83b-1be9-4483-84ac-8abb0b2e6ec3"
      unitRef="usd">-249000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzIzLTExLTEtMS0w_b965bbdf-c31f-474f-a557-52dcf4d22a41"
      unitRef="usd">-386000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTEtMS0xLTA_7cca40ed-3dbe-4cd5-a5ac-11477cb8ad3a"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTMtMS0xLTA_f0314b0f-18de-46bb-b312-501fad763bf9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTUtMS0xLTA_9b849444-7174-4b42-80aa-56cf5066801f"
      unitRef="usd">1395000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTctMS0xLTA_f5d10ebd-d6a6-4c20-8366-32e5abbb36b9"
      unitRef="usd">941000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTktMS0xLTA_ca58b0ed-07e1-488f-bbbe-232867616763"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI1LTExLTEtMS0w_b265937f-6ced-4cdf-854d-53ce8298ec96"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTEtMS0xLTA_30bb5940-9229-428f-a733-329bf74d534d"
      unitRef="usd">64000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTMtMS0xLTA_680e3930-afa2-4c28-bd40-3eb78cee91f9"
      unitRef="usd">82000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTUtMS0xLTA_e09cc928-1076-4627-ad9d-3096932f0fa5"
      unitRef="usd">22000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTctMS0xLTA_56b92ea4-63cf-492b-885d-14021f1b30ba"
      unitRef="usd">13000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTktMS0xLTA_ab105b89-b615-46bd-b31f-461e2339ef97"
      unitRef="usd">8000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI2LTExLTEtMS0w_a4714e6e-5771-413e-b29a-a4b03346bd80"
      unitRef="usd">9000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTEtMS0xLTA_397977be-947e-47dc-9397-dc4225316f7d"
      unitRef="usd">877000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTMtMS0xLTA_90274a2d-3897-4d4c-9f12-25bc2f8fb1a5"
      unitRef="usd">1859000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTUtMS0xLTA_f588a35d-d91a-496c-a07f-bb6924b6cb3f"
      unitRef="usd">753000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTctMS0xLTA_315d2700-6010-46b2-8838-5d08ceb9a6b6"
      unitRef="usd">1377000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTktMS0xLTA_291cbd56-001a-41d7-8d79-a741c997440c"
      unitRef="usd">241000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4ZTFkYjVmNzQzZjE0ZTM0ODU0MDU2YWQzMzk1NjBjOS90YWJsZXJhbmdlOjhlMWRiNWY3NDNmMTRlMzQ4NTQwNTZhZDMzOTU2MGM5XzI3LTExLTEtMS0w_984f8cd3-a212-4057-bc3a-03db5376e1ba"
      unitRef="usd">377000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzIwMjU_be68cf8f-518a-43a3-b7f1-af6c52938c5d"
      unitRef="usd">24900000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzIwMzI_23049880-9e28-45e8-89cc-fd103d52dc4a"
      unitRef="usd">26300000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzIwODI_6bc0f503-f7b7-4538-ae05-ae3085f30b0f"
      unitRef="usd">13800000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzIwODk_7758bc7b-f28b-41c8-a99e-5a6eef78e61e"
      unitRef="usd">14400000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxNDU_ed1c2ac7-1f71-4bc1-8dbe-c34166f3b8ef">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to the funded status of selected pension plans at December 31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension plans with a projected benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension plans with an accumulated benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,916&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,723&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzMtMS0xLTEtMA_14ba045f-0251-40ef-8536-591bc6c3a19d"
      unitRef="usd">13013000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzMtMy0xLTEtMA_6c3c80d2-f2cd-40c7-b055-20dcee64b0ac"
      unitRef="usd">14613000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzMtNS0xLTEtMA_7e566071-5dad-4315-a5cd-6eee8f1bbb5a"
      unitRef="usd">2507000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzMtNy0xLTEtMA_9302d597-abcb-41e3-bf64-176e631ee4bb"
      unitRef="usd">8875000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzQtMS0xLTEtMA_b451bb27-7ab2-44ea-905c-a7599e973ead"
      unitRef="usd">12072000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzQtMy0xLTEtMA_266c9ab2-fe12-4892-b0ab-85b6154fa2aa"
      unitRef="usd">12672000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzQtNS0xLTEtMA_cde94849-4405-4022-b61c-f1f14999fc10"
      unitRef="usd">1731000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzQtNy0xLTEtMA_79cb3180-4e37-4118-bb28-3299283d6ad9"
      unitRef="usd">7488000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzYtMS0xLTEtMA_362a133b-ab87-4fa7-a707-1b7850846d1d"
      unitRef="usd">12916000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzYtMy0xLTEtMA_f7dda8dc-a7cf-424a-a237-ff653b7b28dd"
      unitRef="usd">13489000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzYtNS0xLTEtMA_6ad68e06-10b1-4e0e-b99d-7415402976b5"
      unitRef="usd">2462000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzYtNy0xLTEtMA_b0e8e1cc-3bad-4bb8-919f-381ab2b4f245"
      unitRef="usd">4234000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzctMS0xLTEtMA_a76b3022-ff47-4fc5-94a7-669a058f2001"
      unitRef="usd">12072000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzctMy0xLTEtMA_18bd30df-a7a5-4213-932c-7ffa42712ac6"
      unitRef="usd">11685000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzctNS0xLTEtMA_5e2b319d-3005-48b6-bb8f-a9e9284a8888"
      unitRef="usd">1723000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo5Y2ZmYjQwZTQ4NDI0YmFlOGIzMzY4YjA4MzkwNmQxNi90YWJsZXJhbmdlOjljZmZiNDBlNDg0MjRiYWU4YjMzNjhiMDgzOTA2ZDE2XzctNy0xLTEtMA_c77d43fa-ccab-4e96-9110-65b38d3c1681"
      unitRef="usd">2995000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe10670a16e24ae9ace40787b5ce2a22_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzMyODg_48e8fdc6-ae11-4059-8a50-7c086503fce1"
      unitRef="usd">943000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id0aeb1e3ef794674a96fff2b9d26c8e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzMyOTU_b5a7ea2a-0c82-4abb-946d-3293ac481308"
      unitRef="usd">942000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage
      contextRef="id17c6f956a4e491bb84b7d1e3a57f150_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzMzMzA_4cc829c8-40cb-4157-85d5-f01f7bc48a96"
      unitRef="number">0.04</mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage>
    <mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage
      contextRef="ia7718651d7bc40ef9616b0d6567d4a64_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzMzMzA_722c9b37-eb55-41ae-9ed0-378e3995e5b6"
      unitRef="number">0.04</mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwODI_51eefd68-3745-465f-97a8-bcc9834327c9">&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s pension plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,799&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;919&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;919&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,944&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other fixed income obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;369&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;369&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;982&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;578&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The plans&#x2019; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie27d33c6ed3449c6bf53ce5acffed5d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMS0xLTEtMA_47df0cba-e721-4e18-974c-d9832aa62807"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib4b9083971f54521ad14c9f68c6611c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMy0xLTEtMA_4e1c00a3-88ba-44a0-89da-d183e0efeaf8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia76d34893501497c8338c478a45c7b0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtNS0xLTEtMA_ea245755-c4ae-4905-8db2-60e6671f3b7a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2203d4639810407383286a40f8685df1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtNy0xLTEtMA_c477938b-198a-4e5e-91b7-08d3e386c824"
      unitRef="usd">289000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2f1c43c814b41b488e8134de602f0f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtOS0xLTEtMA_66688750-015c-453b-98c6-233eb2744997"
      unitRef="usd">292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37e1626071144092beaba6babfdd27fd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTEtMS0xLTA_a6ef4454-1185-4de8-a7f2-5948524569b4"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifb4792b128164e4abdf42d752f6b3c2f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTMtMS0xLTA_87a67da1-8d73-4ad9-bfb7-3b576b602d10"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1f0f6b50d341424ab17a88ac1dabec97_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTUtMS0xLTA_ff87ed36-76b7-4411-b0e6-8304f5d05f73"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5089b458f08249059c8517844cbfc375_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTctMS0xLTA_64f3ca37-b065-4efe-a934-385d784fcd7d"
      unitRef="usd">303000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8ca7b42ee03e4960a864194df69e164a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzQtMTktMS0xLTA_270b0e7c-ed05-4076-a36e-0bca1ee2e2f0"
      unitRef="usd">308000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8fbbeaa396c141b0a6b6351e2f4827c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMS0xLTEtMA_11c72f37-f8c2-4425-b6a6-e5854f58b32c"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifae2b18472b24703bb9488d9d606bcb1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMy0xLTEtMA_30251a5e-76ff-4f3c-bac1-150241f34027"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib222fc4bb6d643ceb99b004ab5acd309_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtNS0xLTEtMA_a2fb3dbd-8de9-4319-9ef6-01d719f163a7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i395bb955653e420e886491134570b658_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtNy0xLTEtMA_4a8d5e45-d35d-4bd8-be71-876a7215268c"
      unitRef="usd">3799000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4a1c560946da41119cf3ed20ed9a3a21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtOS0xLTEtMA_4753d3ea-7cc4-4170-9835-8bd58b4980ca"
      unitRef="usd">4035000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf83da73f5164932a265dca954005724_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTEtMS0xLTA_650ea152-183b-493b-8364-d1c2b7e8c347"
      unitRef="usd">206000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9243705e6b154b6aa3bd6af2236836e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTMtMS0xLTA_dd162692-41d2-441d-9531-b5ee3f6133e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i63dd5c670a0c459fae41752f3906d605_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTUtMS0xLTA_5c6c7a9f-c72d-4b02-8362-e3f4fd6b5ee8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if6774d1da76d4da2b5a0219216a610e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTctMS0xLTA_c74ede5f-98c6-402d-938e-3fb27ba08183"
      unitRef="usd">3884000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6eb9748ba281494181282cff265c56e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzYtMTktMS0xLTA_57ab3eb5-2203-4c12-ad3d-ea67a42d7a8a"
      unitRef="usd">4090000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaa42d6dd3f814707bc449ce9962c43dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMS0xLTEtMA_ec3e108e-6ff4-4b37-b948-3ede6b8f6aa6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8baeeb84552840538a8162507d1d3a8f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMy0xLTEtMA_643f29b3-20b0-4293-b0b8-06bded404569"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i11a079dfc52a4a6497a425eeb1403e8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctNS0xLTEtMA_70d8ec71-3cdd-4790-b02b-425d686b3b89"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ba0e181a34f4aaba795297286899f6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctNy0xLTEtMA_27aa388e-d769-416a-b861-c4412980b457"
      unitRef="usd">919000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i12d3fc8ceebe427fb6bd5603436c2c53_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctOS0xLTEtMA_47cd0822-1abd-4d7d-8572-2029502712c7"
      unitRef="usd">919000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibdb1065a32e34de0b0f43368d0777874_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTEtMS0xLTA_5f696db0-37d2-474d-86d2-c00dc31e036e"
      unitRef="usd">169000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i784c90e7bd294dc88132ba65ade89e56_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTMtMS0xLTA_422539f2-2a0d-4a6b-baf6-37ca7b770602"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ee628429c5b4b66bb61ce127cc28e2e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTUtMS0xLTA_61edf370-f680-4ca7-8eb4-350ca2fc508e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i49fb7d46a5334d3bac5d2d4116e11efc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTctMS0xLTA_5988da9d-f9a9-4568-ba45-18a70aebcff6"
      unitRef="usd">927000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i62c401195a1c4761a19b5cdadde85849_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzctMTktMS0xLTA_67677383-4d93-491d-bcb7-e8ede29f8ab6"
      unitRef="usd">1096000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i01b501a9ec7d4dea8f9112a428ef72c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMS0xLTEtMA_659dcc76-60eb-431c-a2f0-08a980ba3139"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ief1c7c92675e40b1b1e2ca3fc8e0d851_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMy0xLTEtMA_166e5370-7a78-43df-831a-c3fc9bc827ba"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5141bbf8e94b49f7a0aa873c881c5fd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtNS0xLTEtMA_5af3a5bf-f90e-4fdc-abf3-e4bced7fdb9c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7f48949b908e47e1864aa29acc116ec4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtNy0xLTEtMA_d67f2e2d-6534-42b4-89d5-a7b8e953dc42"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i39f58f3724274bc6b0bf3a72767dec82_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtOS0xLTEtMA_6749bba8-e68c-4c3a-bc33-a7f664646fc4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iae3975a126cb44be9d32abdad7ef4792_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTEtMS0xLTA_00692a78-e144-4432-aec6-104f60499faa"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02abcc69be99452c8ce2101132639629_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTMtMS0xLTA_ac9aa665-8fcc-46a4-96f0-7c0dde3c4766"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3e3b50b3dba44aadb2c0ce56a935394e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTUtMS0xLTA_3aa3fba1-2657-4b1b-9cee-bd7a9ff0ff0b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd9e94b26ed5494abf5baee5b79b943f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTctMS0xLTA_42d3fedc-9d4a-4594-b48f-0e4c4fe8166d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i63f253095b9d4d2cae95926ac75da379_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzgtMTktMS0xLTA_7282e92f-265e-44f4-b713-edb71e85f90d"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e82a23e98a7447f8a12f4ab996a88c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTEtMS0xLTA_199a0b4f-0df2-42a8-a5c6-7d05c581f461"
      unitRef="usd">2915000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1df7467a741d426880031a7209c24355_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTMtMS0xLTA_625457a1-bbaf-4dc1-bd95-3680948c2605"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i981b91cc3e4e423692ebf62688a6e073_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTUtMS0xLTA_b45efa99-a8a5-49e5-a7f9-f3b36d7c1f09"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib7e2e5a9fcaf49569cbade9e54075f58_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTctMS0xLTA_43d0187a-a3bc-453c-9cba-3caabf98d855"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1edc21c2cd0343e5b7e3413d27bf3fc2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTktMS0xLTA_604029a9-9882-4283-be6a-a75a07de3bf0"
      unitRef="usd">2915000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i878cc16768774bbaaf020a38a72e6aff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTExLTEtMS0w_15d4dbdc-ec04-4712-940f-693da57ec59f"
      unitRef="usd">2819000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icc8c49f9da2e48ee9aa0dad038b7bb6d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTEzLTEtMS0w_f5dce15c-7281-4ee5-8d0a-886040f25a71"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6edfb93331994daaad9ccbd6a3ff2d16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTE1LTEtMS0w_108cd19f-8b19-43f0-bd18-fad127c22eb7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5141467dce724a88a3c16a16dc6e57bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTE3LTEtMS0w_ee9075ec-25af-481c-b6a1-d87e7ec0fb55"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id687b7cf31b44549a0832f1284c3b22e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzExLTE5LTEtMS0w_1b6f78ea-d24c-48a2-afef-986b5e57600f"
      unitRef="usd">2819000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e01ea44f0044e7d91022ca6977facea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTEtMS0xLTA_015342e8-1ab8-4732-b3bd-f6e66b8dfe51"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5e7bb1d9889a46a389725e7f47bc44e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTMtMS0xLTA_6505288b-2b1c-496c-b07e-55d6cda61354"
      unitRef="usd">2870000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idf4a94a0a6d04223852740fc12c45b3e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTUtMS0xLTA_b693cb46-a546-4a76-847c-089b481a75c6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1d79d8008eed47b6bfe7d6f012412074_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTctMS0xLTA_c5bfbde0-450d-4a00-8927-846e48b21b6d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibff79da55ddf46a8a205167e0e830e71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTktMS0xLTA_bb64e647-c057-4234-8dcf-2a07f3431c2b"
      unitRef="usd">2870000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ife3fd5de6b3642078db592881517d635_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTExLTEtMS0w_a23f00d2-e959-475a-9418-63517696a8f2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id2dfeb6b2ea94e89a81b426dff17a96d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTEzLTEtMS0w_a2a5553c-aebf-473a-b97c-b698cee2c1b9"
      unitRef="usd">2236000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie6be5d66271948aa8671b0ef9f628d22_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTE1LTEtMS0w_2fe9e966-0f61-4ce5-8130-999519af5bb1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie7c9bf0ebd284c25b3cb345c5806e946_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTE3LTEtMS0w_364a398c-075e-4012-b91a-595b8cb07e30"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if550fbbab92e4a0393c402773c5a53c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzEzLTE5LTEtMS0w_0a94f0c9-7f12-4191-87f9-62e6733868ad"
      unitRef="usd">2236000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3b79ac72fb4241bc81c3ec6b5b6328b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTEtMS0xLTA_ecc22743-a3e0-4fde-b3d9-1d678b623e82"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iab77361384864106be3cf07dc9d4c939_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTMtMS0xLTA_e3e810ee-a6c1-4428-b7d2-90761cf7ec2d"
      unitRef="usd">2005000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i780cd04510ba457c89c22dffb8ea2e1a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTUtMS0xLTA_1e0cccb9-99d3-49d8-9d03-2846d3832734"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia22749de8cf749bdbeef2616d2d8d6ab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTctMS0xLTA_ca5952ca-3312-4ddb-bbaf-3404223f6611"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie831c58af1194dadafaceb30180cdd0d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTktMS0xLTA_ac285761-03c1-42a5-a8bb-e27a3e6cd69d"
      unitRef="usd">2005000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i336582d966b84b16b300a96248672867_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTExLTEtMS0w_5a3b0a80-a3b8-4f6b-8ced-26d9bcbae420"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i06dd0193192145d6a6d7021a9dd8f817_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTEzLTEtMS0w_e2e2b0ca-9af4-43fd-b424-ea5e52aeeab1"
      unitRef="usd">1994000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i21bbf4eeebfb45518c50300f370d3966_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTE1LTEtMS0w_d6ce2378-f9f3-4149-b524-7f415aaf5c91"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id2778b4fbd1b45ffb87524b7514583a6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTE3LTEtMS0w_589ccbe3-2d70-4246-95c8-d82879fc8e1f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia8ec4cb354474da4bbd6842b97202f41_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE0LTE5LTEtMS0w_2a7e7cf5-ed28-4d58-9c87-746168d91d42"
      unitRef="usd">1994000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7c9b0274b7734fcfbb1b0c73ee0c7da0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTEtMS0xLTA_6f42ce9d-af35-47e3-8a84-a66eaeb2ec91"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0f74d89c62ca43fc8d49c4f183628eb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTMtMS0xLTA_c28b8424-27c2-4ffd-a84a-c93aea734703"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic5a1db66bff04574a73feba1773e8409_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTUtMS0xLTA_3a85ee2f-1b23-4902-9844-0b11da442f22"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02446a35871f4693b8e5acc1f9a5b7de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTctMS0xLTA_49cdb48b-b1d2-438a-b383-d1d067f935eb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0989ca72ed7543d093e13b1133771ff6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTktMS0xLTA_ec440f10-39e8-4763-a741-c4be9abc4f7c"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9ce6426bb9e749e9bcd7521d23f5c407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTExLTEtMS0w_f7c7f27b-e652-4545-808f-26b84c96570e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib65644eadb2b4fa1a6c40d00289f4f35_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTEzLTEtMS0w_219e0a87-bdc0-49dc-a971-3b245a5fa41e"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i962f8425aa3040a69e84e834f0b0f346_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTE1LTEtMS0w_769e52af-c7ae-494f-829e-ccdcdbc40bfb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie7b57daa317543c6a71e4c01cbe79b46_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTE3LTEtMS0w_2e756834-ba83-4760-9ead-19a72d76020a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5b98f27bd3184965a9bc7698e47ad89d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE1LTE5LTEtMS0w_6f99ca0a-ba35-4e48-a793-2fbd3d743bf1"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i95e86bd2f96d4a0c9cc3b9f4e0850708_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTEtMS0xLTA_1e762626-485b-428c-87e9-8571eff0f893"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if74bfe6b3728464e8f867a4499a49cf9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTMtMS0xLTA_fdbb245d-d474-4d9d-a1bb-2652e017f93f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ecf6e1df51340bbaba2f059fec3465a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTUtMS0xLTA_c13c2688-7fb3-4538-9120-a3932745b34e"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i796214cf8fae486795991741a4067066_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTctMS0xLTA_4739e620-41ca-4633-b4af-e7eeb847869b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1637d8c529464e04832eabd1d29ad359_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTktMS0xLTA_8770030e-7f3c-4516-9a50-943580236e9a"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6fa69b52074c40c6919a723ecff07d91_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTExLTEtMS0w_82c3e2bd-4ec9-4e50-bcb2-513738e9b464"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i77f365cc16f54180a306da2bc7aee6a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTEzLTEtMS0w_9d8d8818-0ace-46b0-9597-8d73f5f77695"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iffbd9fca0edc4beb8128fe8f2eaab268_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTE1LTEtMS0w_3659aa20-4666-435e-9552-dae973e872e5"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i75257cca48cb459382be06af1340c22d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTE3LTEtMS0w_1aee205d-d092-42f3-a8db-e129c8a2ac4a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i400ddc9234554cba8b43aea81b2f3b12_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE2LTE5LTEtMS0w_521f4476-b9a7-4160-94d0-01dac77ddbf1"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe56286d4ea44f1aae537601d99ea7ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTEtMS0xLTA_279fa912-42a8-4157-9421-02006e366bd6"
      unitRef="usd">3156000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie4cf65bb3ba540209a17504e51e8e63c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTMtMS0xLTA_5771ef33-2f77-43c5-974e-f6f63e6ce42d"
      unitRef="usd">4898000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6941b80bcbf5486ca983dfe0369cd741_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTUtMS0xLTA_ff6d34cd-a6d3-4cd1-9986-34603a759901"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic97d1993aeff4c979b35dd2e4f863df4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTctMS0xLTA_1277f309-6633-4dc3-84af-cf3f3b73a196"
      unitRef="usd">5007000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTktMS0xLTA_8b5fa451-be13-4b56-8926-e09f1cf141db"
      unitRef="usd">13067000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8fd3b14d2a9c494aa14fbdcb6fb11f9e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTExLTEtMS0w_1a342f11-d902-4c51-af02-f703d45ed59a"
      unitRef="usd">3199000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id9790f5a9551417380bff30595e606aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTEzLTEtMS0w_ff0d5f41-b948-40a0-bd82-fe4d1cf4dc51"
      unitRef="usd">4352000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4ded4752a21d440a80630cbd004ec39b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTE1LTEtMS0w_a215a09d-ef9a-49c3-8be3-37d2dd71c02d"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3c179b8078b940dc99ef97ff0435620f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTE3LTEtMS0w_c052bac5-1414-47e2-af8e-9642d6d257e6"
      unitRef="usd">5114000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie469ebe67bcd4e9397318e0a7f364bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE3LTE5LTEtMS0w_02c839ec-aa47-4f67-ae42-10fabc4b38c9"
      unitRef="usd">12672000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibaa64b0d1dd44c1ca28cecbd821aa477_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTEtMS0xLTA_88bee902-ec4d-4e22-b9b1-370f087e926c"
      unitRef="usd">82000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if1ffbcf1eb5b41d7b00120fe3ee1352e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTMtMS0xLTA_19542870-c87e-445c-b5a1-a2fc1a28970f"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9db319e5ae454d27afcda3fd19764a79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTUtMS0xLTA_169a4bb7-8dba-408c-b4d3-3e2ce3067022"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i706ca6f052df467cb8f58b4806f630c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTctMS0xLTA_8175d9b0-ca7b-4cce-9446-d55ee94d380a"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i30f0da2cf5e1450d9c71192c487952c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTktMS0xLTA_31b7ad6f-06ce-42c4-afd4-61aa02baf2e6"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i44fe692f8a764fea898fec5aa9111d12_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTExLTEtMS0w_2b1ce910-0169-4860-9328-7e6b52c45727"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i379e05b6692f4dd48df63d0606e10804_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTEzLTEtMS0w_560d3803-f70c-4572-9423-d2a2227db4b6"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iac502293aa264b42aa9d2b66841da851_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTE1LTEtMS0w_aff0bd57-d1c9-457b-84db-982115fa8d67"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29262e1dfa004785a42f1051bb310323_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTE3LTEtMS0w_34504de3-b90f-4710-b7f6-d0a67be28062"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic9f9aca5533a45719f02ea5e54e22cbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzE5LTE5LTEtMS0w_bbe55d7f-3daf-4ba3-a545-52a57cf3fce7"
      unitRef="usd">131000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i48ac8e7222dd4ad2875cdd76fbdbf312_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTEtMS0xLTA_39014c0f-c03c-485c-b4f6-e53f5b4206ff"
      unitRef="usd">531000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib92ab01903744a8bb55dfac3169a2f28_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTMtMS0xLTA_ac6dc6db-8f2c-4a4d-8bde-21f724f21273"
      unitRef="usd">4292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9ce94dcb4f694c35afda081b8f7df941_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTUtMS0xLTA_ce59906e-c348-4025-b541-4a0a49a62bc8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0d5cd6c26a754923b47fb82b1d835e26_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTctMS0xLTA_decea34e-3de4-428d-bb9f-ac7aeb25c5a6"
      unitRef="usd">121000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie809e18ae31c4a759d00ca9258dfe590_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTktMS0xLTA_6c3a7811-30d8-4832-adae-b04898614f93"
      unitRef="usd">4944000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0670034fe75f4d2192a609e94de300e2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTExLTEtMS0w_387dabae-011b-4777-a3eb-d1bee7200415"
      unitRef="usd">475000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i05abcec58f8e487c81199b7f51eaef9d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTEzLTEtMS0w_21dc399e-9015-4546-ab8b-68d4670c00f4"
      unitRef="usd">4286000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id147c2024aff4ce09865ffaf7bfc6e1a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTE1LTEtMS0w_e9d9a4d4-b0ba-4a8f-b75c-a8d28e24e6ee"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib1a7f9d852f245d68f1669370ba8ea37_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTE3LTEtMS0w_b20f3f3b-0386-46f3-ab92-3b5aa7579e85"
      unitRef="usd">118000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5c3b3f7029dc4097b2e2fe7e1e985e18_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIxLTE5LTEtMS0w_fa246f48-cee5-4a6f-805e-2c3679e5f9e3"
      unitRef="usd">4879000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7fbca24807fc45728ae28f4fe314fa94_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTEtMS0xLTA_6969da00-ebba-4be5-9714-694dfafbfcf3"
      unitRef="usd">240000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia92db765e927452a886deda18e0ec49e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTMtMS0xLTA_98e0a1ee-e7f8-4bbd-87a5-fa89dc345abd"
      unitRef="usd">4025000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8c7e60832cf84f69b1d73b1f05f3a237_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTUtMS0xLTA_03fb1b1e-26e1-4bda-b8c2-d79d2a70cd69"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icc9294e66deb48e4a276489e2d5fbdd9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTctMS0xLTA_f517298a-306b-4563-a71b-c50f61a0e809"
      unitRef="usd">171000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iad21e08ece0443f09e98d2df051b2720_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTktMS0xLTA_d5ca843c-74cd-4047-830d-65632a375120"
      unitRef="usd">4436000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i81d4508410614547944dd3263008dfa1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTExLTEtMS0w_ec9c1cb3-d703-4679-b982-7bdda1a3f7dc"
      unitRef="usd">1516000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9d27a90fefee49c6bd2314841eaac836_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTEzLTEtMS0w_e50b4f06-8834-4dcb-a07a-6bdfc5834a98"
      unitRef="usd">2614000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i14f445cef0a94f3d858a4e92b44e53dd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTE1LTEtMS0w_ada34a5a-05dd-4126-a634-1615936fee1d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib402ec846ebb4646b9e19d44aa463e42_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTE3LTEtMS0w_d2b65b65-ebf3-4d09-97be-956a204e57ee"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib23f4c405736447893c2ed0ba5129d03_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIyLTE5LTEtMS0w_bb5bd317-3b93-47e0-a148-ad906f637398"
      unitRef="usd">4302000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5c0e35ee479451baa6f3dffbdb78a83_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTEtMS0xLTA_cfae29c5-f87c-449f-b5ea-50ef479c29d8"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if6099682544f4ab6885c0649f5ab634e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTMtMS0xLTA_0e6c9cbf-07c9-483f-a86e-a7f99287babb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9499680b2a3b46c692bbfca28d92fa99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTUtMS0xLTA_fb30736d-7a61-4574-a8a7-97d646b46912"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icadc8586f8c14f1599940106a4a639f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTctMS0xLTA_1c1346a5-fbe0-4ebd-acda-1b5712f20cfd"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i137b41dccc2a451a8661523b56e79847_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTktMS0xLTA_c0adce39-2ef5-4f41-a1ca-e52f5dba91a8"
      unitRef="usd">209000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib3e264e35d0845cb9d3d40717095240c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTExLTEtMS0w_ca52e016-77e0-4024-a0c0-eafbebb5b174"
      unitRef="usd">154000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idbdc9d92cae54e3388f07afc57b2e738_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTEzLTEtMS0w_6ef91729-10e8-4965-9d2a-894ff001b4ae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27b7acb7de364282992d39b44d6c732b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTE1LTEtMS0w_f4033353-6876-45ce-a0eb-a9e1024c2367"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9ddd68d8b0db49c6b4809aa72bf47d60_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTE3LTEtMS0w_4ac1cd45-02fc-4f09-8f7c-af302a10bd50"
      unitRef="usd">92000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i19f7fa74b02f420fa18a1752a0f640d9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzIzLTE5LTEtMS0w_08b2e81a-dab0-4287-b45d-c1d5b32d2f7a"
      unitRef="usd">246000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6074254ef5dd404ab34a3d26ea726aa1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTEtMS0xLTA_e3bc38a8-9ec7-46ca-9a60-7733086483cf"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if9f0c02f2b3e4264bec1d52a63e9ad74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTMtMS0xLTA_fcd9a978-e71d-4bc0-9088-8640a9a7ed55"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4eb2ef278f5044ea82584e0170c78683_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTUtMS0xLTA_b9bd47d1-83e1-46e6-9eed-62d0b8df24b6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8e92e9adedd8495e89c3a894377ecdd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTctMS0xLTA_fdbe674f-c94c-4c5e-8e39-e27485119b61"
      unitRef="usd">171000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i74519ccd850f450985a56ff14ca4b7b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTktMS0xLTA_32c58799-d457-47df-b748-a0028d922455"
      unitRef="usd">188000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7fbcea62d0ed4955ac41d050862b0e34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTExLTEtMS0w_12e353eb-e767-4f97-aa0f-178f35ba58c6"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic56cac3dd6c044c78e322e9ef1a9d386_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTEzLTEtMS0w_064d2711-d2d9-46cd-946f-1cb2ead6d323"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if1f6500c95d2415997c537d9ec576b14_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTE1LTEtMS0w_0ba7a0e4-8cd0-4b62-97cc-70d7fff7797b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0a23ebdda2d14f27ba9a6dff74a6bb93_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTE3LTEtMS0w_84adc4c8-a62b-4832-aeda-c9eb4e98ca91"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie263eba552824ca8b7bc26dc2b1e3c03_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI0LTE5LTEtMS0w_1a0e9928-5d6d-4387-997f-ae4bffd942fe"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i500f88f01cbb476cbf8d0869fa88f998_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTEtMS0xLTA_85a1c09d-4e45-406c-8c47-1db7b47ec9e4"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ife7b52747c1c4adbb18078f65218a7b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTMtMS0xLTA_ec7aa0a8-88df-4646-b9b1-9fcab8e96d44"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idb20ddb11d8244308c74bbd88c09e832_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTUtMS0xLTA_71c4fec0-9f67-4316-a255-50655f3d1a1a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic4b5c61354004941911815be12a06d46_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTctMS0xLTA_6c570393-d712-4611-83c4-378e6712ea12"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i575c68e47b1441f4b370a4373fcd38ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTktMS0xLTA_5cceb729-c4ab-423e-ac7e-eb73a05121da"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb56ee6d545047549d0817e0e372530e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTExLTEtMS0w_3b827485-adf7-4e4f-911d-c91c24c53e21"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i33d81e4466bd41e4b377ed1df2ea8e56_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTEzLTEtMS0w_f155995e-32ba-4e2b-a62a-73da1cbc5b5d"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie4e0f2f727aa4b97ac781a4fed704c4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTE1LTEtMS0w_319d3fd1-3401-42f0-b8d2-a23d95809486"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7739919ef6a3464e8636dba4a13f4976_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTE3LTEtMS0w_63d54453-8b08-462e-ba47-24284996b60c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia616155b2f954117981e48d2681acb1b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI1LTE5LTEtMS0w_5d03e4de-9c68-4343-85c2-85cf0a058943"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7ff224138dc04bb5bcb654572597d15c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTEtMS0xLTA_a5347fa3-b9da-4b3b-ab4e-5b3a5c974191"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i299c4edd1f2c40aaaf1ba172f892df50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTMtMS0xLTA_eb22d1ab-fa9d-41f0-98c7-5622d3734503"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1d6be1fc79ba48d990cd4dda9a8296c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTUtMS0xLTA_fcfd830d-223a-4587-8f4f-2799e9b67fe3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia2b4299473e14a998ff1749df6fabbad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTctMS0xLTA_7c61edf9-4af5-4970-bf33-fef6acd4f54d"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieda8181c2b92463f832b2b807385e1fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTktMS0xLTA_b1832787-add7-4a2f-ace0-a905d1f49906"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica5c9a82e7a14132ae1bc5575aa82c6c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTExLTEtMS0w_0db7eef8-19fc-4b4c-aeca-cf76645282d6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib45b430cbec34f7ab97e3b77aa48d4b0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTEzLTEtMS0w_bf76e35c-6653-4075-98c6-562e4c59fd22"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i88665ad826e641d683cd947d6542e94a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTE1LTEtMS0w_a0c40815-1d99-459d-a928-cea760b4c308"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3e4eed3d574f4c3b90b6ec3fbf015cbc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTE3LTEtMS0w_876e4f8f-96b5-46e4-b776-ad500cfef0e0"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9092910402714a39aa0adcd1cdc3fd8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI2LTE5LTEtMS0w_e5087dbf-dec9-4c0d-b21a-d61e64ffd363"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0977763dab53428ea24d011484e19d42_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTEtMS0xLTA_23dc9e1a-071e-4766-835b-84003153c07a"
      unitRef="usd">369000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e6aaee1f8734728ad3f49f6e109d45e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTMtMS0xLTA_776e6c36-61d3-47f6-9e60-ee42de7fcc73"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i646ea08b951e47a28a3b3a458d5f19c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTUtMS0xLTA_c391df4f-4924-468c-9038-27d82aba0fc7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7376c87bfaef4564894e5aa0078bf290_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTctMS0xLTA_4a152857-74c1-4799-a697-a9d9b72fc6b4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i707265f378224c11812d0a38d0ca7c46_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTktMS0xLTA_afda75f7-3145-4371-b93e-5729390320e3"
      unitRef="usd">369000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d671f19e027414790d54572de238e8e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTExLTEtMS0w_4bc36e17-4a41-4ef7-8f88-024cc246b72c"
      unitRef="usd">505000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i976895874b4548edab0975dff614e53a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTEzLTEtMS0w_ae9505f5-c525-4a01-a613-b16ae20c3e3e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia948bae53d494c0fa79a34e4feab974b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTE1LTEtMS0w_8f0004a7-a00d-43cb-9cf3-f9cedb4e8251"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic0c88c3aebd6403fb5e73ba3df2752da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTE3LTEtMS0w_4fc2fb4a-81e7-42b5-a44a-726e8d748d3c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3101abbfd6104bf9961e4797c1fc7a59_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzI4LTE5LTEtMS0w_8231f6eb-27c0-41ea-b62e-d9d9e58974c4"
      unitRef="usd">505000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8f53799ef4a489f9b8523196b414ed1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTEtMS0xLTA_0a8ef9ea-367c-4dfe-b387-8594c4245d24"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd54b143c2f54e0b899d7f7221b49435_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTMtMS0xLTA_8253fd34-0e6e-4249-9c5f-8af34618ea9a"
      unitRef="usd">591000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i50d4f261c68445c8ae56f66fe852bae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTUtMS0xLTA_6b84ec80-1a7c-4e87-88e3-23d0c92376b8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i81fb3f5ab0be4cb8be61559da9ba2513_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTctMS0xLTA_2d37e23f-8b45-4c76-9b95-a128af7fc2da"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib8688a36baca47b99958cbc03224ade5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTktMS0xLTA_11bce96e-e191-4916-8873-3ce616c3dbcb"
      unitRef="usd">597000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib528900af6b84f9f883fce50d5d90e15_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTExLTEtMS0w_084726f3-e568-4d6c-b212-946437c97c8c"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i597378302fc14c5688b47d18bf9609ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTEzLTEtMS0w_b22308fb-a967-4d87-8200-511b2cc88a36"
      unitRef="usd">481000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9c35baef64594afe9308f4038d2cc019_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTE1LTEtMS0w_2421f360-d567-4878-a860-db0427f0933e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5b32ee0e7ad4477d84343a59721b904a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTE3LTEtMS0w_7e35ee9a-c637-43db-ae42-a01c77ca98ec"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i10aa657ebd0f4ff8bde707e6da253978_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMwLTE5LTEtMS0w_db027d99-7a3d-4d8a-b13d-fee52a9c1ee2"
      unitRef="usd">487000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i40e1b8d26f324b76a4c50b0c70101c62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTEtMS0xLTA_b50706fc-5d46-46ac-b70c-8fb0a44221e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i12fb9df356b24a28a7100d667bfecc3d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTMtMS0xLTA_f6d9ef6d-cb98-42d2-88de-d151257ca6a5"
      unitRef="usd">223000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i30cd90083da946e2867764d0280e60ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTUtMS0xLTA_212b9846-8440-48d8-804e-e1c10299b9ca"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i46c1df4974f5423196b196d52fcb54a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTctMS0xLTA_3759d910-a5b3-481d-b924-f4876311fbca"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1056686abda14133bbb25a974481bf51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTktMS0xLTA_bae4f5b9-03e1-41bf-a8a4-48bea74b4997"
      unitRef="usd">225000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i777644be6c2f496cb431e433227cf5e2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTExLTEtMS0w_4866a400-e92c-40ad-b49a-79d48d9d508f"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaadae92a049a4d5c988b6a3155d0fea9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTEzLTEtMS0w_2bed42c3-7a86-4571-bf4c-14f931726f6b"
      unitRef="usd">174000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i67cdc14fb7854ae6ab8daac50bf5b18a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTE1LTEtMS0w_ce8d3eef-e0d1-4b2b-84d2-5b9293fecc22"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id4e4116135e74738941265923fae287e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTE3LTEtMS0w_98162b2a-cba1-452d-bf15-8c8d02d86038"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iba72f924d50f448995676c787615f080_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMxLTE5LTEtMS0w_e38ba651-69f2-4e81-9efa-c4a1d249bd4a"
      unitRef="usd">177000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6335958a344a435583e593f08493ef84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTEtMS0xLTA_f3919839-281f-460e-b9c2-88a0e38525dc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idc7e70eb2b30488facea1f9b7925c9d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTMtMS0xLTA_0612662e-5c91-431d-962e-a33a8160584a"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if61638e78d26452fbd7dcb3dc3b0b9a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTUtMS0xLTA_c31da82e-cce0-43d2-a8a1-856913df6f6a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29c3faf60ab14164abe7ec068a5e8acc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTctMS0xLTA_5114a190-f1b5-42c5-a4a7-191d9c1d0e76"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i392677707f7e41c59c65694477a60d86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTktMS0xLTA_d73358c4-9ce9-466f-8ec6-bd4eeb48f8e9"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i71d1b3b11ab744479c9bf01ef20dc759_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTExLTEtMS0w_ab1adfcb-d121-42a6-bbff-3a3824adbb77"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i331730bf6efb44d682e209f3086f5deb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTEzLTEtMS0w_641bf74f-d3f0-4958-8759-c1749b1feff8"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0aed454000324ddfb59ec630f8ca840d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTE1LTEtMS0w_cc5af041-b665-4124-8a4c-09ffdccc4945"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if44f8b9ae40243fdab6b2eeea80bdadb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTE3LTEtMS0w_ec7f1df4-05ab-45c5-a13b-ffe0f7d58b62"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i53221686a07c4c2692910544bf9e5f7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzMyLTE5LTEtMS0w_ff2a565b-8cfe-480b-9d5b-4d23263cc5b8"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7f304228c0b47459eb2df8092a19197_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTEtMS0xLTA_81360f2c-d597-41f4-bd36-5696fa29ee86"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i35aa130d32044270a7ca14c1c500e128_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTMtMS0xLTA_8cb0b9dc-eabf-4db6-b75f-ad63d9e322df"
      unitRef="usd">44000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iffd5948864f247fb8240d73efa22974a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTUtMS0xLTA_1d17df35-3010-4b59-98aa-c5c2c2944a5c"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id79d1d134fab4804b1f8916d27f270bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTctMS0xLTA_4e05bb8c-5456-49b7-8916-1e157ff9af9d"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica51247083bc45349d5f1aa4494688cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTktMS0xLTA_4c904536-f11b-4f2f-b1b1-34005f06b61b"
      unitRef="usd">982000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i67efbd0183464528a19f2f2370692b97_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTExLTEtMS0w_c1c50ee3-6c8d-44ad-b124-6f7c3b10b3db"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9f3d2bbb957c495e8f423ace831f825b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTEzLTEtMS0w_6a40f7fc-9ea7-44b6-bab9-9f1115d76ee4"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib7032f825e9148319be784239d5dc247_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTE1LTEtMS0w_bbcd26c7-c068-44ba-8a4f-3e58c6c45e31"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia9375a5e955a43e4b015b97beb369e80_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTE3LTEtMS0w_6d9df258-b456-429e-bc29-7fa208a48e70"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iad73c6a4016949568ba9ffec4920197d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM0LTE5LTEtMS0w_0b5e06c3-cd47-45a1-bf68-4a3cb20c773c"
      unitRef="usd">978000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i99736db639604a3b9e19d5223863228a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTEtMS0xLTA_8bc843c7-efd9-4ed0-b681-835b1ee827f1"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0989033959b24547b6d2f0250223be9b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTMtMS0xLTA_14eefa02-e543-49a8-9964-8bb767f1c47b"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i062dd5eba1074bd9b7e1f64bbe49f973_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTUtMS0xLTA_62bbfe21-6a01-4972-aedc-19238f811225"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1b4fa5b2309b4501b0b66a49e6b61e2f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTctMS0xLTA_5cb002f9-0b32-40e9-aee0-cb463aeda75d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i22f5c0ebcbab4a01a984c3b118e581fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTktMS0xLTA_0546df86-6abe-4e37-bbc1-ecf1de7d9ac4"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie8f1f45c17984c09b0569f1408b068a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTExLTEtMS0w_515f3e5d-38c7-4f89-a6fa-a3da09d68d12"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6d7b39df984e4cc8a43284b6c372e087_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTEzLTEtMS0w_ccc5547e-9387-4477-b88b-999d01d2142b"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if87e1269e4974cacb4df9177b0d52da2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTE1LTEtMS0w_a4884b37-7f3c-4b69-9c55-e50f840b7a96"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie0038c792d634a9ba8b15407c89e2895_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTE3LTEtMS0w_d0239321-4006-4511-adf9-3aafafe18810"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iec324fd291e244f2a0f252da445766bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM1LTE5LTEtMS0w_52905454-be4b-4bf8-bfcd-34f74219eaf0"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iacb4e5f9e58140afb021278770b30523_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTEtMS0xLTA_f07d7a53-ee40-46fe-942f-211713a6cd49"
      unitRef="usd">1387000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3e89844fc4dc4df08d07363b5b09c838_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTMtMS0xLTA_8322c2bc-e4dd-42aa-86b7-6e0cf7579b5d"
      unitRef="usd">9293000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibf01a553998e486db4187f11f6c70b9a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTUtMS0xLTA_2d102eb1-ab9b-467f-ad15-41d64a89efaa"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i431015c47e6d427ab97b03d0f8688df5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTctMS0xLTA_85aaeb0a-bdf5-4ca7-947d-62b27e5bb6ef"
      unitRef="usd">578000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTktMS0xLTA_25f9b845-0dbe-4c8a-a95e-0a8808464a6b"
      unitRef="usd">12195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8e027fa8d0004e2f893102d1de5efaf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTExLTEtMS0w_3b618927-d15f-4c3c-8021-2dde15814861"
      unitRef="usd">2779000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbed2e49029849b3943ac5cbdb11cfcf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTEzLTEtMS0w_19088271-615b-4608-8a84-3a8331312bf8"
      unitRef="usd">7696000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02f3afa788a448f7a63c0f0ccc99339e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTE1LTEtMS0w_ca8954a2-3cb9-48ba-a006-778e9a245e19"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib2ea805daaef473299b9ae21f484efbe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTE3LTEtMS0w_f6726600-4840-4e6b-9c66-40c7957a33d6"
      unitRef="usd">599000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1OWMwMDY3ODkwNjE0YzE2YjU1OWZiNmQ5N2RiOWMxYy90YWJsZXJhbmdlOjU5YzAwNjc4OTA2MTRjMTZiNTU5ZmI2ZDk3ZGI5YzFjXzM2LTE5LTEtMS0w_fa800acc-68eb-4b5e-b553-0867f44e7f93"
      unitRef="usd">12009000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwODM_cf73b261-8fcc-4b00-b9e6-9ad1165dfeba">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#x2019;s pension plan assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets sold during the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers in (out) of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i35f7bd0fb86b414a9c2c97debb06568e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMS0xLTEtMA_c31b0d10-1870-487a-bc0d-c5955a65728d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54f9f4e4430546bd9a3b6f9954b477dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMy0xLTEtMA_3fe54daf-bfe7-4fa8-a559-2f3fd1ea4c4c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iffbd9fca0edc4beb8128fe8f2eaab268_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtNS0xLTEtMA_9abd40e8-c4e3-4a53-ba17-7a57ed853215"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4ded4752a21d440a80630cbd004ec39b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtNy0xLTEtMA_58539ed7-a611-43d7-817d-e4001d49242d"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0543e0d9beb449b8a879873310de464a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtOS0xLTEtMA_babaeca2-b5c8-4208-8186-4654bcb85e80"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i08c5624edf264ef78c72a7cc903e4d53_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMTEtMS0xLTA_9d6b19e1-fbe8-419c-aac8-882d197a9c08"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3cf767adb1b441a08fdbf662ead15031_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMTMtMS0xLTA_1a534f0d-0bf7-4903-bbbb-4283687e46b3"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iae0b2dd3b32941cc92817703c2a4e429_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzMtMTUtMS0xLTA_b9b75974-e2f5-4d53-b15c-490a95c89b57"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i0c9c0618cec84c088e773da09a42ef8f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMS0xLTEtMA_0ab35b39-63d7-4526-9960-1c571f593d6f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ibb24ab962e0d4ce68a8f9e970430d6d4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMy0xLTEtMA_a5579f18-b81d-4c94-b95d-8c92a20988b4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ib51e5e37dd5440398f596d5a49edb8c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtNS0xLTEtMA_9c4c0936-5aa3-45a4-a26b-294393c502c9"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="icdeac8350d854b17860499847d42ea25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtNy0xLTEtMA_ae4b64be-1fd8-4bee-aed9-b7211c907e54"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i88cb35a2c8a0448c83339d1060a7a9cf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtOS0xLTEtMA_df363943-ef8f-41fa-a9be-0e0993aa5acf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ica6c5629485f4afeb50f9607d49405b7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMTEtMS0xLTA_1f919702-4d37-462e-a7b4-0865e7f1890b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ib03dc9f34fcb49d685cc8f077e1f7d9b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMTMtMS0xLTA_38b100e5-c6ba-46a8-8034-eae494e28a11"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ibd4a51131f4d4e358c9cecca8b9026d2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzUtMTUtMS0xLTA_43de9337-8d8b-4c86-94d8-55a639babc0f"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i0c9c0618cec84c088e773da09a42ef8f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMS0xLTEtMA_925ef3fe-380f-4c86-b90d-996a088d5caf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="ibb24ab962e0d4ce68a8f9e970430d6d4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMy0xLTEtMA_dbdd5c33-d566-4ad4-bf37-aceed97f8e39"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="ib51e5e37dd5440398f596d5a49edb8c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtNS0xLTEtMA_8e9fd7ab-156c-41fa-bb50-e7875df6537d"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="icdeac8350d854b17860499847d42ea25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtNy0xLTEtMA_a6a60560-65ea-442f-a585-c21ed3966d2a"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i88cb35a2c8a0448c83339d1060a7a9cf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtOS0xLTEtMA_ec6ba653-39eb-4764-821c-ed2e54c019e5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="ica6c5629485f4afeb50f9607d49405b7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMTEtMS0xLTA_08654202-baaf-4261-ad85-4782548922a9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="ib03dc9f34fcb49d685cc8f077e1f7d9b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMTMtMS0xLTA_50c9c086-7725-41bd-809b-6d12cf66fe23"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="ibd4a51131f4d4e358c9cecca8b9026d2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzYtMTUtMS0xLTA_0f7ae651-5751-4aa6-8fcc-c585d4a46cca"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i0c9c0618cec84c088e773da09a42ef8f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMS0xLTEtMA_514866d9-ab12-4ff1-aea9-7a2c92caa701"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ibb24ab962e0d4ce68a8f9e970430d6d4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMy0xLTEtMA_38297886-c24b-4207-8d7d-6d0561c2c9c1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ib51e5e37dd5440398f596d5a49edb8c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctNS0xLTEtMA_6752afab-7c7b-4555-8b28-10ce0d4a4206"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="icdeac8350d854b17860499847d42ea25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctNy0xLTEtMA_0f82dac1-1d3f-4db9-8ffd-2633c35f3dfc"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i88cb35a2c8a0448c83339d1060a7a9cf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctOS0xLTEtMA_c0ec2dd7-c08f-4f0c-98eb-343337863877"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ica6c5629485f4afeb50f9607d49405b7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMTEtMS0xLTA_de786924-40aa-41bd-8806-0cde9d6fe99a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ib03dc9f34fcb49d685cc8f077e1f7d9b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMTMtMS0xLTA_db95d43d-c618-4d44-bc39-a15ac17584d3"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ibd4a51131f4d4e358c9cecca8b9026d2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzctMTUtMS0xLTA_5043b3d0-1c9e-4959-a3eb-97daba1b6b30"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6008424e527d4605b76b5c541489c471_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMS0xLTEtMA_9d7465b3-052c-4a89-a4a3-7504911bd4f8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9f6924e6dd4542c39440e5e6128bd0b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMy0xLTEtMA_66e751f4-4d0d-4ce3-8fb6-083b63cc6901"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ecf6e1df51340bbaba2f059fec3465a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtNS0xLTEtMA_43b575fb-5080-4673-9385-1845a7f4591b"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6941b80bcbf5486ca983dfe0369cd741_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtNy0xLTEtMA_ad4a9074-cfa8-4546-97fa-ebb1a137a4fe"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i35f7bd0fb86b414a9c2c97debb06568e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtOS0xLTEtMA_e4510f97-7756-4d33-b416-e0557414052a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54f9f4e4430546bd9a3b6f9954b477dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMTEtMS0xLTA_3f61a66a-6821-4c25-ab7d-8ab8f7ffefdc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iffbd9fca0edc4beb8128fe8f2eaab268_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMTMtMS0xLTA_159e787c-77ec-4056-8e51-2debe78ca8dd"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4ded4752a21d440a80630cbd004ec39b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzgtMTUtMS0xLTA_20c824f2-9b90-4370-a8c5-865c4c08106a"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib7032f825e9148319be784239d5dc247_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTEtMS0xLTA_8a4238cb-cb8b-46e4-afea-8d6e1ec600d7"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i88665ad826e641d683cd947d6542e94a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTMtMS0xLTA_289bdec2-d3a5-43f0-a0aa-6d072c4ec813"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if87e1269e4974cacb4df9177b0d52da2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTUtMS0xLTA_d973ded1-8f54-4f89-8d19-00ab1e37220e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02f3afa788a448f7a63c0f0ccc99339e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTctMS0xLTA_f1a8313d-179d-41a6-aeb4-0eaa5df938a3"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i48869176aa064f5b84788a6a483e5d0d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTktMS0xLTA_aaa20415-f1f6-4552-8c90-d341dfbb3199"
      unitRef="usd">851000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic6b32614e3a94518839d5155b07abd5b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTExLTEtMS0w_c28c27bd-ca8b-4d04-bbd3-d104f96012ba"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4193bedff7b5470093b4777d0ca284e3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTEzLTEtMS0w_c7441ec7-41c2-449d-8625-509cc0be2c94"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i86abfbda1f9146a4a6851f8c322ef63a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEwLTE1LTEtMS0w_f040f283-93d9-4335-8ac2-692683669fe2"
      unitRef="usd">851000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="id5b1148bd1f04038a1852875553f8c89_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTEtMS0xLTA_37d521ba-e12c-4655-a3b1-c69f01836cd2"
      unitRef="usd">-34000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i8f0a39a74efd4a798069f6dc88d2753f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTMtMS0xLTA_681197eb-00f0-4ee6-b47b-77f1b5819ec2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i5e83024d7d194652beabf70b37e52087_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTUtMS0xLTA_78e36bd4-a3d1-4c25-acaf-fec6d0306276"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ib9efddc2c4eb4b51ac27ed6cd9f54f5d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTctMS0xLTA_8bc170b7-8844-44f8-ab56-8014fca86986"
      unitRef="usd">-34000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i8c24038538054e02b5a035f3e61a08dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTktMS0xLTA_90124fcd-47a7-407b-8911-7e67f07d39c1"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i4a0ff66d0a1341e8afc7ed8586d8a024_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTExLTEtMS0w_8cb68556-c90a-42d3-b5d5-7c3d1883fa28"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i7e6daeaa1d88470ca8bab0e45dcff6cc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTEzLTEtMS0w_1f7fe28d-c380-4523-8f67-b914a8ea1b51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ieaa6e26e2efe4d9ea09bc81d737de0e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEyLTE1LTEtMS0w_642edbd5-c534-4e1b-b695-72e0315df619"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="id5b1148bd1f04038a1852875553f8c89_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTEtMS0xLTA_bf8c6a9a-f8fb-4aa4-92ea-d41d5829e140"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i8f0a39a74efd4a798069f6dc88d2753f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTMtMS0xLTA_b6ede1f1-9817-46eb-8b8b-53f1c8dd460a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i5e83024d7d194652beabf70b37e52087_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTUtMS0xLTA_7e4fee79-f28c-4fec-a337-ff6231bad611"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ib9efddc2c4eb4b51ac27ed6cd9f54f5d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTctMS0xLTA_d7101f8a-3dfc-4d84-9bd4-a5a07ce76dfb"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i8c24038538054e02b5a035f3e61a08dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTktMS0xLTA_db51c916-5405-49cb-a59d-694e0103819c"
      unitRef="usd">-17000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i4a0ff66d0a1341e8afc7ed8586d8a024_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTExLTEtMS0w_7bb549a9-0993-4b61-a1fa-88fabe542586"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i7e6daeaa1d88470ca8bab0e45dcff6cc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTEzLTEtMS0w_85b6b758-2bb0-4e7f-9aa4-1220235c66a8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ieaa6e26e2efe4d9ea09bc81d737de0e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzEzLTE1LTEtMS0w_4ed01e88-8c28-4a6d-8f99-ab1f2e5a5d3e"
      unitRef="usd">-17000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="id5b1148bd1f04038a1852875553f8c89_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTEtMS0xLTA_b197d623-a38e-42e3-91cb-af1605e21fa0"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i8f0a39a74efd4a798069f6dc88d2753f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTMtMS0xLTA_7dc2cb31-3744-4111-b1f1-ebe322c35b5a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i5e83024d7d194652beabf70b37e52087_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTUtMS0xLTA_4bc5894d-821c-45da-80c6-c5485aac8b46"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="ib9efddc2c4eb4b51ac27ed6cd9f54f5d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTctMS0xLTA_784eeb49-f674-4348-b29f-7a512f7d2dea"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i8c24038538054e02b5a035f3e61a08dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTktMS0xLTA_431b6690-deda-422d-bd6f-d51bee47671a"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i4a0ff66d0a1341e8afc7ed8586d8a024_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTExLTEtMS0w_842b580c-ba6b-4fbc-a38d-d6a4fb1a5465"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i7e6daeaa1d88470ca8bab0e45dcff6cc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTEzLTEtMS0w_eb823942-4fda-465b-9152-d1b586d55b4a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="ieaa6e26e2efe4d9ea09bc81d737de0e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE0LTE1LTEtMS0w_5a91e160-3bff-4c9e-bf97-8a203770f981"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iffd5948864f247fb8240d73efa22974a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTEtMS0xLTA_c6e9e1c0-2052-47d7-b655-e188a56f2a68"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1d6be1fc79ba48d990cd4dda9a8296c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTMtMS0xLTA_d2cdf3b6-78f1-4770-af4c-3b6f3bd6cdc6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i062dd5eba1074bd9b7e1f64bbe49f973_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTUtMS0xLTA_fef4d9a9-64e8-4943-bfa8-a39301f7b8f7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibf01a553998e486db4187f11f6c70b9a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTctMS0xLTA_bd30199b-e873-4e6a-82d5-7cb04c289345"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib7032f825e9148319be784239d5dc247_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTktMS0xLTA_b30f9a39-3aad-4609-be25-89ea28de8725"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i88665ad826e641d683cd947d6542e94a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTExLTEtMS0w_d1de8b12-ac8b-41e0-8285-2c9430e3d517"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if87e1269e4974cacb4df9177b0d52da2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTEzLTEtMS0w_c2cde8c4-8100-4328-9c6e-3fac18cb7efc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02f3afa788a448f7a63c0f0ccc99339e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo2NmFmMzhmZDE1ODI0ZTQyYjJjYjU5MjE0YWRmOTFlNS90YWJsZXJhbmdlOjY2YWYzOGZkMTU4MjRlNDJiMmNiNTkyMTRhZGY5MWU1XzE1LTE1LTEtMS0w_6e2e2a1b-07d1-4201-af38-4954f856cea2"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id06d07a27e9045a094b87e5c189c3954_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMS0xLTEtMA_4cce8af1-f85d-431f-8090-ec5abeacfbd2"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib6a22f408073435e909cf7aa033ebc6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMy0xLTEtMA_bd32ca86-e286-4b44-a712-d9fa06e1fb5c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ice177b53b8bf471bbf10d5357f0e823f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtNS0xLTEtMA_cb8e4c79-bb83-4167-b566-78acb655682d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i51e1329bd56243e18e983e2de609a849_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtNy0xLTEtMA_eaae17fb-10ac-44ff-a602-99b5212b0d18"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia0a5086b5128478aa64899a4b8b33cf8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtOS0xLTEtMA_13bb0cad-4144-4933-a5aa-e40acc6e7f29"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2b13ef32d5364a38917129aff9fec7b1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTEtMS0xLTA_299feaca-3827-4d4f-8902-ef119a2fc926"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica90cf7838a7461289b9ba848c17f909_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTMtMS0xLTA_6313ffde-2add-487a-822a-afd3d6cb78ca"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id626f58b4ed04285b83a1f5f564106f0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTUtMS0xLTA_606e4c4e-2f72-46f5-910c-7498796938e8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i85b5f8a81b5d42fbb063b001b277bd2a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTctMS0xLTA_93c3e4d6-481e-4a5c-b35e-7a804f7d9f34"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i121d0ae7b5584cf08889319e21df6f00_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzMtMTktMS0xLTA_96f1e1c5-3cf5-465f-9137-cbc830c155dc"
      unitRef="usd">59000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9ab8af9defb944fcb4a112b4a4fd3754_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMS0xLTEtMA_cd9fe6a1-b2f1-47dc-a1e0-26270c026bb1"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica3c0900036b4c57b95574ad6d4370aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMy0xLTEtMA_eb528a93-6158-4469-a046-e9d0664549e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia23692c19eb34a1f8e06494fa27cd511_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtNS0xLTEtMA_c622caf4-0699-4af0-bcce-56629a1d10d2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia8677bf18cb544efa1b2a3272f0a47a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtNy0xLTEtMA_2711dc4a-34ab-44c0-af6a-4839ed81b320"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5d6b068cf6ab41fb9bfee3a5fd9d9251_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtOS0xLTEtMA_9048ab47-3fe1-4a70-9aa2-d6d0af5b50d0"
      unitRef="usd">402000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i12f2b2c632f44cd1a8f7e0b0d9bb1c56_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTEtMS0xLTA_f17595bc-f72f-4f28-93d6-d994a80cd494"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if643fb5543124a6894df897dc47be455_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTMtMS0xLTA_d9c9b8a4-c366-491a-bde7-7a0518acccf1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic4df17beca4f4aae9917df8f72802d26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTUtMS0xLTA_34496b19-5219-436f-b08b-b4045f122fe1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i96b69b9758d9428fa6eee4787db14eb3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTctMS0xLTA_54dd43b0-bc8a-4b4e-87fd-5874782d30f1"
      unitRef="usd">355000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0f07f5009ef24afdb2515077be35b2c3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzUtMTktMS0xLTA_da529ca8-34aa-4cc5-9ce4-e38856ca870a"
      unitRef="usd">374000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if47b6f8be3a54363980225411f0cde09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMS0xLTEtMA_d32aa748-bb49-4c6f-9aef-39674441b726"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd4eb7c2144745c5a54d9ff57aeffc3a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMy0xLTEtMA_e1cd5d37-1a2f-43ee-aa55-8b49146f4e79"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i03afe5c2d65644bf8233215d9ed8ce21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtNS0xLTEtMA_18fbfede-5684-4d5b-a358-a3f5d8219396"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i667292d025a9462f937f9e358ff4597b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtNy0xLTEtMA_b70b9703-5b75-4b22-9aab-bdb69e23aa6d"
      unitRef="usd">92000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e7a58a77c914de6a53aea5b50437da4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtOS0xLTEtMA_e86f474f-0143-4da1-a510-f717bf49d913"
      unitRef="usd">92000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8888c94d17e84a6c8685bb3aa616ceab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTEtMS0xLTA_5b83aeb1-d809-42c0-a520-b413c0e16832"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iabf411e7ed154695860581e937aea220_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTMtMS0xLTA_3a28b67b-c50c-442b-af0f-14c9a2942c9f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib427fd64730a44df9cddac5399f38153_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTUtMS0xLTA_0313733b-6c90-4be0-ab8a-e1d10ace2ffd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i26c47a65b46544c38b3b012501b67980_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTctMS0xLTA_5daef46d-89a8-48fc-8577-98859751be2d"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1da62d5a32854107a7b16eacacfd2bc5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzYtMTktMS0xLTA_2f7407c3-e868-467a-b628-2fb5aa60fc38"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd7f6d0dd3ee4a929304b9754f6827b9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMS0xLTEtMA_0d89e192-6a9d-4c0e-872e-393881b60317"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7a86ee5eed134b6c89a7d0fa2be8b6b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMy0xLTEtMA_3d6498e5-3801-4600-8843-c1cc1332e448"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i88d73446659a4e33b8b0a661934a44b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctNS0xLTEtMA_4fcea71d-8db1-4290-b235-3e9f2c7fb1fd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf7ccf80013542b487ab201e6f185f08_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctNy0xLTEtMA_2b118e86-0081-436c-8187-3698a9e5ead3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7a9e21c8c54c43daa17d22d749c695e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctOS0xLTEtMA_25375caa-1b39-4f15-82f0-2686d89d15db"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if5e32729f23f4e5dbbc51b849d911757_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTEtMS0xLTA_e28f2e37-ac76-4c29-9989-836952658f76"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i07b0f77300a243acb6a9ebbfcb1aaa2a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTMtMS0xLTA_fda277b4-3421-4465-9590-c351425f4810"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6b86fee24be648ad94520f4a1978a1cb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTUtMS0xLTA_3e7fa6df-e1bc-4cad-85eb-a7dc141cb8a9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5c501dddf974f5abc029b567480dbee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTctMS0xLTA_6d34b84d-6891-4323-a0bb-f3b5fb53aaae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i091b7006b6ea46b3b61e3eecc932c387_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzctMTktMS0xLTA_887c8a3e-2f77-4360-9e86-29eb7e303556"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b5b17f159a845539e0a01013b211052_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMS0xLTEtMA_cf8e3877-31b0-4901-85a2-13828969fc8b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7bdda57c7bdb4c5bb74a961da2c1d8aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMy0xLTEtMA_f0a1314b-9b29-467a-87b1-4643bd9a9df2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica17e9ff742a40d783b5644277161e30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtNS0xLTEtMA_89c85ef6-422e-42a5-810f-9e5ede7bcb36"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if0ef3d891cbc4cd69295e9cecc6d5a62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtNy0xLTEtMA_f22810bd-373a-47c9-9be4-dd7d63960e16"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4e02936176ce456aaf00f889622803e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtOS0xLTEtMA_2632dd74-344f-425b-bc73-7a7bc4e03fc7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i483bd58d24394b3b80eb5b353b8efbdb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTEtMS0xLTA_e6fa0ad8-5d30-41f7-b23c-0c16cb2e086f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i793918a7fdaf491fb0c1dbcd66331c49_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTMtMS0xLTA_eebe644f-4ad0-40d7-b079-69ff95a5600c"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4bc268366729489591fd438b0fe8fe17_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTUtMS0xLTA_18b00590-f55f-4efe-a980-70607b22aa85"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idd69e0aa38ac4ec7b4f7d1c9516ad2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTctMS0xLTA_72b8c481-3a32-4802-940e-dbc3296705a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icebfe327fd3d4adab637ef455f461fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzgtMTktMS0xLTA_8bdb73b2-7be6-4f00-ba9c-e05cc95f1a02"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b3c817820c64372aa410440be5205a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTEtMS0xLTA_1aa2b022-5b19-42bd-a036-c1f5bfecc7f3"
      unitRef="usd">290000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic83f94a689444e288ae0dbed266bd406_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTMtMS0xLTA_ee7ff612-3506-4b14-b4ee-592da0bccca8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b704682926148cc84a8db8efc5c796a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTUtMS0xLTA_fcc0404c-1fde-4a9c-b41d-074e7e1a4414"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e4628916abc4126927023ae15fd0a85_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTctMS0xLTA_7a2c226e-08a1-4eb9-ad4c-1455ac8c18fe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie15d37d6fcf94f1d962a65444ddad466_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTktMS0xLTA_60525f58-63a2-4963-8055-ea6b1965b2e6"
      unitRef="usd">290000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia130b62a5f43450aa1a3339b37134132_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTExLTEtMS0w_b410fc7b-b199-435e-a43d-d3b3f185d26c"
      unitRef="usd">258000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if3df7f246cf14229afdd2685344a7de4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTEzLTEtMS0w_bb4e2593-b7af-4586-b789-39296a7ed0d1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2807f56dcaab490eac85b298b86298c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTE1LTEtMS0w_afb0db8b-c22c-493d-a743-a8a1e729af14"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib26b7b22b4244d81b6f3cc21118aec61_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTE3LTEtMS0w_b7799811-fc51-43d3-a7ab-c4f8e8cbce5a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8bf9ac56392a463fac3b411b9205a0a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEwLTE5LTEtMS0w_3afa97de-e735-45be-88fe-d2ccb9624539"
      unitRef="usd">258000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic6a02cc27c7c4c2f8ba5429f74eab5dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTEtMS0xLTA_458cbc8c-6e60-435a-a572-b14df56613a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee3239325c8c46efac7fc183d07c9374_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTMtMS0xLTA_79dafb73-b726-495f-99df-8e288b750009"
      unitRef="usd">275000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia63554eec91f4d6ab395b9acc70717d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTUtMS0xLTA_492302d7-62d3-437a-9717-a5e11c0fa6d9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i287ca8ea377b4ed080264796be545504_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTctMS0xLTA_88a8b4a6-81f3-43d6-836c-e3fb502b3fe3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8db09a55de19497b9b70d729546fbb1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTktMS0xLTA_cab0aa69-c31f-45f0-8470-3f8c0fc59d16"
      unitRef="usd">275000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i14d98b7a9bf04af8884803848570265d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTExLTEtMS0w_47961ad9-8025-4c94-b5f3-edf37142ab20"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia7e091f2feda475987d31a21e338c4f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTEzLTEtMS0w_9050e4aa-1f5e-4f33-a37a-1982ef42d574"
      unitRef="usd">221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3bf7c43c5492487a99e3564c60260e5d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTE1LTEtMS0w_89962c00-dfce-4cf5-b263-b00789375822"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i39f74f7cbb854caba1a1c57ac918a3ad_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTE3LTEtMS0w_8ee0c6af-994c-473a-9320-da78297c0376"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc35b4c7594d4187a5cb7cc2d7f4d264_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEyLTE5LTEtMS0w_69aa3f62-2bda-4f63-94f1-ca86ea270274"
      unitRef="usd">221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i90407e0949ed436885a9125ae3ff3616_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTEtMS0xLTA_d4006f9a-5d6d-4dd7-8f91-8cf2386dd1a8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i728b0c1d082a441b95dd386a599c8098_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTMtMS0xLTA_be74bfb5-2b54-42dc-b847-be4adb474ec0"
      unitRef="usd">191000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3fc07cc2ffcc4a07b93ab604fa085182_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTUtMS0xLTA_df6d4166-0445-4c66-bd5e-bd0afa03b4e3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic3750cadf46e42dfb107576386473746_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTctMS0xLTA_0fd901f4-cc41-475e-bc52-971c831c380d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb00f009ed984b3e9d7ce65a1632e458_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTktMS0xLTA_7d4a7c7e-0ffe-4109-8b52-ebc25c3b414f"
      unitRef="usd">191000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if6dd6a6d63e54e938c5a72c294269cc1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTExLTEtMS0w_97e16909-5e6b-4d1e-b190-8efe65c40616"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i08fc130457454a08b3f267225ed6ed27_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTEzLTEtMS0w_25f7bbad-aad4-46f2-bf56-cb6b13891ec8"
      unitRef="usd">196000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6467d1906b2f4d7e8bf6f78423b52659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTE1LTEtMS0w_08654296-b761-4d8f-998a-6a3592a7187d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7de3243e532c4de2852c89993a892b41_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTE3LTEtMS0w_27c24dfb-97dd-445c-bd7d-5a0c5bd48a0d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i76e47c270d1243bab3c87f29d058155f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzEzLTE5LTEtMS0w_9c2ef73f-6971-43b5-97e7-35d8d8e810e8"
      unitRef="usd">196000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iecf563768fe14889b1e01fe62524d07f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTEtMS0xLTA_21a87c74-13af-445e-861a-e9579b4543e7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a491066de6b4e4792fdd0a3377e0b54_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTMtMS0xLTA_faa843ac-fbf4-4378-b41e-fac4431d95a7"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icdb93f5076a643298235176fc92ef07c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTUtMS0xLTA_6466148f-c305-47b6-84e5-498698b070f3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7e1bd81b4d648f3b5b45923274ecfc0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTctMS0xLTA_7273bdbf-d188-47bf-a503-ebd361d3091a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2e40afe1730c4117941b66edb4d40d3e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTktMS0xLTA_a5d68df2-8fa8-4006-b59a-743d25023a88"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1910fb48ae8b47d59024291ba45240d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTExLTEtMS0w_54125a9d-9b53-46cc-be05-eaeef423b8e0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i149179b3d497412eaee0ad158abcd1d5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTEzLTEtMS0w_14235f25-d24e-414f-b2f5-44cb6d40ef09"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id1e84e538d73498da4853df1d5a84ecf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTE1LTEtMS0w_b453f056-6279-4e7b-a4ee-185a9b4f7c6e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i495b7eb9aafb434b88ff4e62c501d012_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTE3LTEtMS0w_2f036a2e-d36e-4ce2-9cca-8ee784532538"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2370d975c61e4aaa91def0aa9732dfc1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE0LTE5LTEtMS0w_7980d468-2783-45a7-9b1d-1979959425cb"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibfbfb9218ab84c998baded784956a8d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTEtMS0xLTA_e93322af-c2ed-4edd-aa2a-deb9779c8275"
      unitRef="usd">326000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia3eb3c9e8db1400ab82cf431989eeb20_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTMtMS0xLTA_7cd7f83d-74f3-405c-b7fa-7483034f162a"
      unitRef="usd">468000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie0f174f676614246ac5cc662923bd7de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTUtMS0xLTA_91076104-e972-4504-a9e6-9c26dc958926"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1deac4fc07e246e48d31f4bb339ce199_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTctMS0xLTA_8cdff4b5-10d4-4db2-b339-07ed5c847c8f"
      unitRef="usd">498000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTktMS0xLTA_497cb109-15a0-4a82-a4b6-efa18b327ef4"
      unitRef="usd">1292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied9cc57e45454c60a2afcf99a471a7a6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTExLTEtMS0w_910692de-7d9f-413a-8458-2c96852fc831"
      unitRef="usd">325000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iea250ccc936041e7a2dfb8b6d72e949b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTEzLTEtMS0w_8bf12d06-773c-4185-a838-ee381202d4b8"
      unitRef="usd">428000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc0707765e4e4b9ea9465ed6da91604f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTE1LTEtMS0w_f7c68944-f118-4a09-87ee-a991fca3b9ef"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib36b1192c28e46a9bc24708ace77b04c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTE3LTEtMS0w_d40d7040-9989-428e-aece-ac5843cb5e34"
      unitRef="usd">468000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo1M2NiNmYyYTc1MGI0ZTM3ODNiMTZjYTcwODRhYWJjZC90YWJsZXJhbmdlOjUzY2I2ZjJhNzUwYjRlMzc4M2IxNmNhNzA4NGFhYmNkXzE1LTE5LTEtMS0w_dcbe4e70-1913-4691-80c2-a98efa025c19"
      unitRef="usd">1221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ifa625a65fc9249b88c46cf2eac079bb8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzUzODg_f1bc9e8f-5f69-42af-925b-ce4325d5205e"
      unitRef="number">0.30</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iec626e4bae224a9f838923e9721430eb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzUzOTQ_8204c630-a1a8-4d7b-884d-60657dc5b772"
      unitRef="number">0.45</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ibf509bb5a7f240e8bfdf5c3c69c7f006_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0MTU_b204ad0b-c198-4350-b2e1-135b0804d960"
      unitRef="number">0.15</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iad12fdc5a7d14e5ea50cf778b94402fd_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0MjE_044c1473-f4d7-41cb-a33b-708d294c0446"
      unitRef="number">0.30</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i9213c4b474fe4561ae99450da35e89eb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0NTE_49643d79-ad35-4d44-bd8c-3f2c98e1fd70"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i755061a1bfda44be8dce382e25583fc2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0NTc_c653d5ce-9091-4dee-950c-09a3b80d860e"
      unitRef="number">0.45</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i95e72546c73c4aa4ae96105aad140dd7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU0OTk_6d5e0357-7730-490a-90c1-cf61a73b6cf0"
      unitRef="number">0.05</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests
      contextRef="idb0d794972b549a0b3f947ab5849bf7e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzU3MzU_3f0bc700-4dbc-4eb7-bc28-6f643200dee9"
      unitRef="number">0.11</mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzYyOTU_66cda4a0-bd94-43bc-afab-9155e19de814"
      unitRef="usd">280000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzYzMzY_f5ccfd6c-2f1a-4884-b56e-74bcd76b6116"
      unitRef="usd">150000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzYzODk_a2e4af71-483b-4d94-82fe-21b9495e274c"
      unitRef="usd">50000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwNjQ_48072714-78b3-4c15-bf65-52cbc60f7867">&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&#160;&#x2014;&#160;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzEtMS0xLTEtMA_8e653741-02f8-4b92-bcbe-4f2b123c4a00"
      unitRef="usd">724000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzEtMy0xLTEtMA_4929bebd-716b-42f4-981b-2c3212cc39a5"
      unitRef="usd">289000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzEtNS0xLTEtMA_9a3b2ea7-832e-4b97-87f4-e49f3bd98238"
      unitRef="usd">84000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzItMS0xLTEtMA_0d702a72-289c-449b-8d77-2781c0f926bc"
      unitRef="usd">745000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzItMy0xLTEtMA_ca510bf5-0c62-4bdf-929e-66e636b67f5f"
      unitRef="usd">275000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzItNS0xLTEtMA_17367d02-42ca-41fe-9d79-1ca39de0b080"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzMtMS0xLTEtMA_65d80ed8-c7d3-42ba-b125-8956d4868101"
      unitRef="usd">731000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzMtMy0xLTEtMA_c6d09875-2412-4191-8a13-03ae9d23c1fd"
      unitRef="usd">278000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzMtNS0xLTEtMA_da9f1998-72fb-4ca8-98b4-467f55534dae"
      unitRef="usd">87000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzQtMS0xLTEtMA_fc56812f-06b2-4dbd-a7cc-6bbfe6602e38"
      unitRef="usd">748000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzQtMy0xLTEtMA_f183101e-28c2-4288-8867-18b3c7195244"
      unitRef="usd">280000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzQtNS0xLTEtMA_004df056-3754-42c8-9d34-ef5691366c11"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzUtMS0xLTEtMA_c80e5c51-ef37-4f3c-a84b-b5e3e7ceae9a"
      unitRef="usd">770000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzUtMy0xLTEtMA_5dfe3e78-3c9c-459b-a633-051735d9b08d"
      unitRef="usd">308000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzUtNS0xLTEtMA_8cd6e6ec-3315-4af8-9ab0-37d1ec7ec703"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i382c108bc8474154b35a6d4fdd79419a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzYtMS0xLTEtMA_02aa8f76-8ede-4176-b270-8b5c3d59ec96"
      unitRef="usd">4230000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzYtMy0xLTEtMA_c7dc0592-760a-4151-a981-59a552dba551"
      unitRef="usd">1715000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTpmOGNlNWRhZjlkMTA0ZTljOWY2N2M2ZDQ4ZDUwNzU0Yy90YWJsZXJhbmdlOmY4Y2U1ZGFmOWQxMDRlOWM5ZjY3YzZkNDhkNTA3NTRjXzYtNS0xLTEtMA_1f359259-7c21-4312-9639-8f7338c72f86"
      unitRef="usd">469000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwNjU_50aae49d-3fb2-4753-800c-92f729308d22">The following amounts were reflected as components of &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Postretirement&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gain (loss) arising during the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,048&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (cost) credit arising during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,045&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;786&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization included in benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service credit amortization included in benefit cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMS0xLTEtMA_fcf550af-14da-4901-b75c-d6c8f242e6ab"
      unitRef="usd">1048000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMy0xLTEtMA_7c43dfc3-f455-4609-b144-698854893944"
      unitRef="usd">-448000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtNS0xLTEtMA_76c865be-8a30-477d-a163-c2a33be9ed36"
      unitRef="usd">-816000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtNy0xLTEtMA_4d5c17b4-b3e0-46ea-a696-8b806e364d08"
      unitRef="usd">815000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtOS0xLTEtMA_072133d0-5e3e-425d-9649-7578230e0560"
      unitRef="usd">-407000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMTEtMS0xLTA_b267cffd-3239-4f28-b352-80e92ef5638b"
      unitRef="usd">-227000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMTMtMS0xLTA_ceda3fa3-c109-489f-9d82-44d0fb3d729c"
      unitRef="usd">144000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMTUtMS0xLTA_043c4ccb-d01b-4038-b3af-18bdf799b118"
      unitRef="usd">198000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzMtMTctMS0xLTA_dec6da0d-2ad4-4680-9c39-ab7d2fa04bf3"
      unitRef="usd">112000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMS0xLTEtMA_24fe3018-4b24-4a9c-87a3-8fe58eec9ab7"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMy0xLTEtMA_9c2d0a7d-501c-41d6-a59d-87ad191ee54a"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtNS0xLTEtMA_ed10b125-20db-498a-9df7-1a532c1f01a6"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtNy0xLTEtMA_72ab7df2-99c6-4ed5-8c41-ecae5410c848"
      unitRef="usd">29000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtOS0xLTEtMA_969d9453-957b-4974-a3bc-0d98a9c1b34b"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMTEtMS0xLTA_9ffa5d9d-d156-4149-bc8f-197e15c1881c"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMTMtMS0xLTA_a52c0e38-74ce-40ee-b367-2d1b5cabc216"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMTUtMS0xLTA_235922c0-7e83-4c18-b9d5-c9a6cc0215fc"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzQtMTctMS0xLTA_510c0479-1c3a-4531-b4c7-0ae59142a856"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMS0xLTEtMA_300a542c-dd17-4cde-9f75-f57d86f40318"
      unitRef="usd">-1045000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMy0xLTEtMA_27a9149e-1351-4d24-944d-4e3478af733d"
      unitRef="usd">449000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtNS0xLTEtMA_ce1cde50-6522-412a-bfd2-f5c3155acc98"
      unitRef="usd">820000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtNy0xLTEtMA_4ae00600-0ea9-4eab-b435-ed00e8809f20"
      unitRef="usd">-786000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtOS0xLTEtMA_5b75b8fe-962a-4606-a2ee-48225f2116eb"
      unitRef="usd">345000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMTEtMS0xLTA_e86dedc6-1805-408f-96c4-435af8b1cadf"
      unitRef="usd">228000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMTMtMS0xLTA_4bd13f70-1fc2-4062-9212-f08f4f3a9594"
      unitRef="usd">-127000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMTUtMS0xLTA_83fbd908-4505-4c4e-b358-74b235e510a1"
      unitRef="usd">-195000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzUtMTctMS0xLTA_0eddb297-392c-437e-91f2-dc70eed1ec5c"
      unitRef="usd">-101000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMS0xLTEtMA_72512422-0c96-4293-979a-528a4bc25d6b"
      unitRef="usd">-298000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMy0xLTEtMA_75cfb44c-9081-4eaa-a259-41fb32690f06"
      unitRef="usd">-303000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtNS0xLTEtMA_2665e8b0-1d0a-4a03-86e0-536ca94f23a1"
      unitRef="usd">-151000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtNy0xLTEtMA_80a27209-6aaa-4535-ba4e-021cdb0de0da"
      unitRef="usd">-142000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtOS0xLTEtMA_ec1aa848-750d-4b77-8030-11966059747b"
      unitRef="usd">-127000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMTEtMS0xLTA_f99c04c7-b71a-491f-bec8-51aefbd8c5ae"
      unitRef="usd">-64000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMTMtMS0xLTA_b78fd730-f142-487d-b940-68172d72590a"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMTUtMS0xLTA_730c0c83-a89a-42ce-a851-52ef3b20edb1"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzYtMTctMS0xLTA_603aecf0-b68a-4498-a1a4-7624ce46baaf"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMS0xLTEtMA_d5306579-5bfe-4550-a9fd-18ecedb366b9"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMy0xLTEtMA_3a1586dd-d73b-40d2-bd86-d855985dd13e"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctNS0xLTEtMA_8cdc72d7-6b3f-44ee-a9db-0d5914b448e9"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctNy0xLTEtMA_f266a82f-d716-4d4d-b899-fd044627b31b"
      unitRef="usd">-16000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctOS0xLTEtMA_95e979a9-868c-4a74-9b6a-12e71aaa70cc"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMTEtMS0xLTA_60b56030-bd0e-43e4-8f13-39381a31af82"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMTMtMS0xLTA_8fd4221e-18b5-462c-8194-cc915116c200"
      unitRef="usd">-63000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMTUtMS0xLTA_6742c041-3e8a-4042-9cf3-edd76aaeb472"
      unitRef="usd">-73000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzctMTctMS0xLTA_0ceaed96-20fc-4136-8acf-d2cce7fd1e8e"
      unitRef="usd">-78000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="if7408e11850240218278c7eae714eb3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMS0xLTEtMA_9fa809e7-cd63-47a5-905f-9b6575d1c87d"
      unitRef="usd">260000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="ib4228e236b524592b6881eb16a38c13a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMy0xLTEtMA_e89f4b07-e556-4512-b000-43eeabe7ee16"
      unitRef="usd">254000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="id38c22c81cc941e48bf78381097f50dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtNS0xLTEtMA_91b56272-200b-471c-aef1-63b840191798"
      unitRef="usd">102000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtNy0xLTEtMA_e01220e0-f138-442c-b2fa-d80584e23418"
      unitRef="usd">126000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtOS0xLTEtMA_cd0bc8d4-8c34-4b9b-b68b-b569201cb028"
      unitRef="usd">109000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMTEtMS0xLTA_d812c036-a51e-4600-9896-7fafc1b20940"
      unitRef="usd">52000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="iba967fbd75634791abd5af201082537c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMTMtMS0xLTA_e8a7cdff-8a7a-4cb6-a2fd-276ab38a4561"
      unitRef="usd">-105000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i2b93b781ac1d4389b09d1da2e546277a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMTUtMS0xLTA_78d2bbdc-5e49-4e95-82a7-8f998b47231d"
      unitRef="usd">-91000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i0910e322eea541708e50f3e95e1d06c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToxZTU2MmNmMTljZTU0MGEyYTEzZmJiOGMzZjk5NDlmNS90YWJsZXJhbmdlOjFlNTYyY2YxOWNlNTQwYTJhMTNmYmI4YzNmOTk0OWY1XzgtMTctMS0xLTA_65bc9f02-9c48-4b0e-825b-bf4148485ecb"
      unitRef="usd">-88000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxMTI_ea568f24-8fc7-45b4-9a22-7b2d5642231e">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Pension&#160;and&#160;Other&lt;br/&gt;Postretirement&#160;Benefit&#160;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtMS0xLTEtMA_3c612590-25ed-45a6-ab71-7649f60085ea"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtMy0xLTEtMA_61e598c8-1e1d-4e76-b003-d7d5f7838260"
      unitRef="number">0.0340</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtNS0xLTEtMA_0df4f768-92b5-4175-948e-2342f418a7b8"
      unitRef="number">0.0440</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtNy0xLTEtMA_1e6a5f42-4bbd-4ec9-b77b-f876d0566d41"
      unitRef="number">0.0110</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtOS0xLTEtMA_1edec8cd-341a-463a-a294-7f56bbcc296d"
      unitRef="number">0.0150</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzMtMTEtMS0xLTA_749c90e4-404b-4762-961e-0d62bfddc33a"
      unitRef="number">0.0220</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtMS0xLTEtMA_a7d1ce19-c984-4c7b-83d1-9df990f11a7a"
      unitRef="number">0.0670</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtMy0xLTEtMA_0a26da8d-997a-4fb7-b81e-39b36faf0c90"
      unitRef="number">0.0730</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtNS0xLTEtMA_d178bd72-086b-4a93-847e-04146c6cc60c"
      unitRef="number">0.0810</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtNy0xLTEtMA_a7b1cca1-207e-4414-bed4-e6bee9299a29"
      unitRef="number">0.0380</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtOS0xLTEtMA_77be7618-d10d-474b-8f79-19bbfb1b545a"
      unitRef="number">0.0440</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzQtMTEtMS0xLTA_f826eb98-ef3a-444d-9287-b7d7a2c22881"
      unitRef="number">0.0490</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtMS0xLTEtMA_89979e61-e9c7-4649-a8aa-4f6b29f21050"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtMy0xLTEtMA_d87233bb-27e8-4167-9185-4d83e78b98f8"
      unitRef="number">0.0420</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtNS0xLTEtMA_e62d46cb-aa1a-4a04-a0ca-8f4b5d717173"
      unitRef="number">0.0430</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtNy0xLTEtMA_782d5412-0a8c-4d21-b70c-592942d89b0e"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtOS0xLTEtMA_e231b6e4-6e6a-4bb6-9319-71f662f5b945"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzUtMTEtMS0xLTA_b55d14d5-9b65-46bf-9d76-971834ad4d1d"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtMS0xLTEtMA_986775dc-e1df-472c-af24-cd3902889756"
      unitRef="number">0.0470</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i1311a8ef04b2469ca47343b0ef5b85da_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtMy0xLTEtMA_0cd7bddc-2016-4db4-b8c7-55c8ea4573bb"
      unitRef="number">0.0490</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="id17002770ffc4c23bb1ec5b4a3cbfe35_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtNS0xLTEtMA_34ebc2ac-d91d-41ef-a5f7-9d3d6816bb7f"
      unitRef="number">0.0340</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i4adf86e01a244bb0ba9ba735be640a29_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtNy0xLTEtMA_86af32b0-0bd5-4991-b2e8-c81d7f1f3a08"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i3ac33d933b984eb0800eaf2a51c6bd98_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtOS0xLTEtMA_df2f1aac-d471-4233-9c56-32a2eb573120"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="ib689195e89b14202b20e0494390f4ae6_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzYtMTEtMS0xLTA_91e0c4d0-9fe8-40d8-a942-7810a1a78378"
      unitRef="number">0.0290</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="idb0d794972b549a0b3f947ab5849bf7e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtMS0xLTEtMA_31f15799-5e64-4d06-92f4-fcee9853f17e"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i74135854883f44a0bb9ee84c11306656_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtMy0xLTEtMA_e9ff18cb-5a0e-4833-a826-a738d637757b"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i818016db2b54406e88278d77b05a6d54_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtNS0xLTEtMA_5a78f3c9-90e8-449a-a4c3-2f6737a87a62"
      unitRef="number">0.0340</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtNy0xLTEtMA_60f3d9ae-8e9b-4e48-a44c-a8d8eeec05a0"
      unitRef="number">0.0150</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtOS0xLTEtMA_4c416f3a-ea92-4488-9b00-a3b076b5f751"
      unitRef="number">0.0110</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzgtMTEtMS0xLTA_714beec0-37fd-4a2f-af79-28ec3085f25d"
      unitRef="number">0.0150</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="idb0d794972b549a0b3f947ab5849bf7e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktMS0xLTEtMA_49a4b230-f4ce-446c-9b84-cc0611fcde4c"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i74135854883f44a0bb9ee84c11306656_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktMy0xLTEtMA_40f603b5-d053-4185-9214-ee1f952b04da"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i818016db2b54406e88278d77b05a6d54_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktNS0xLTEtMA_f653d379-3bdf-4185-985a-7044d090b729"
      unitRef="number">0.0420</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktNy0xLTEtMA_041419da-b071-4635-aa03-fbc101a6cd7d"
      unitRef="number">0.0290</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktOS0xLTEtMA_4058bfff-c76e-41dd-bf56-2f5836d4cb4d"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzktMTEtMS0xLTA_0bf63e25-60eb-4f52-8464-8940f50f508a"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="idb0d794972b549a0b3f947ab5849bf7e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTEtMS0xLTA_82abe72a-b434-4ddd-9612-121a411608bc"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i74135854883f44a0bb9ee84c11306656_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTMtMS0xLTA_b70422dd-8411-41fc-8ccc-5dcb1d49b8a1"
      unitRef="number">0.0470</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i818016db2b54406e88278d77b05a6d54_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTUtMS0xLTA_d80fc752-37e6-4409-918a-54e82d38b8b9"
      unitRef="number">0.0490</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i67b6db65c6024850a158f13f22048bf4_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTctMS0xLTA_a8f2bc0f-ad0c-452b-92a3-7df0c420b50f"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i20446a0c4abb418588d30ab024ada07f_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTktMS0xLTA_e5f4db83-e562-438c-b075-2e54c4131160"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i502ad3ca61b044c6bf16cde2a7bfc679_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZToyYjUxMzE5ZGEyZWM0NDlmOTMzZWVmYWYzY2JkNjhhZi90YWJsZXJhbmdlOjJiNTEzMTlkYTJlYzQ0OWY5MzNlZWZhZjNjYmQ2OGFmXzEwLTExLTEtMS0w_e5b0c45c-2525-4849-ac06-eb8fdf20bbdf"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i42dbde811d0f43b89555c0b2477f1fac_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4Xzg1NjA_80a20631-048f-4eeb-9681-3c882213f0b5"
      unitRef="number">0.0670</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i58dc9cde42be4f269b8259f1f6a7f155_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4Xzg1OTY_de8473e5-0bc8-4b41-9024-a0325c5a591d"
      unitRef="number">0.0650</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ifaf22a93cc2d4d0a814975c167a0a1fe_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4Xzg2MDI_b3ae4b6f-3e7f-4544-a888-45953586dcc0"
      unitRef="number">0.0670</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkxNDE_98312fba-56d4-49fa-b3da-bdb919e759a6">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The health care cost trend rate assumptions for other postretirement benefit plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year that the trend rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4OGJhNTY2MDRlMWY0N2U5YWY5Zjk3OTEyNjMxYmU4YS90YWJsZXJhbmdlOjg4YmE1NjYwNGUxZjQ3ZTlhZjlmOTc5MTI2MzFiZThhXzEtMS0xLTEtMA_b2246b7d-e51b-4033-9d78-9ec0f20808f0"
      unitRef="number">0.064</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4OGJhNTY2MDRlMWY0N2U5YWY5Zjk3OTEyNjMxYmU4YS90YWJsZXJhbmdlOjg4YmE1NjYwNGUxZjQ3ZTlhZjlmOTc5MTI2MzFiZThhXzEtMy0xLTEtMA_c8c6a9ca-2781-498b-8b84-90418a03789d"
      unitRef="number">0.066</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i2cfd3d09310f4317b6f6249083ad8378_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4OGJhNTY2MDRlMWY0N2U5YWY5Zjk3OTEyNjMxYmU4YS90YWJsZXJhbmdlOjg4YmE1NjYwNGUxZjQ3ZTlhZjlmOTc5MTI2MzFiZThhXzItMS0xLTEtMA_a2c333f6-b580-4117-b904-b95f050bb18c"
      unitRef="number">0.045</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i023d84f2ec3e4b1fbefe060484ea5a92_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90YWJsZTo4OGJhNTY2MDRlMWY0N2U5YWY5Zjk3OTEyNjMxYmU4YS90YWJsZXJhbmdlOjg4YmE1NjYwNGUxZjQ3ZTlhZjlmOTc5MTI2MzFiZThhXzItMy0xLTEtMA_71788c2f-c859-477a-ace7-d02dff2947f9"
      unitRef="number">0.045</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwMjU_8e55b87e-787d-4c04-bc87-04e5ca029a00"
      unitRef="usd">158000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwMjk_3d7a8f16-45a6-43ba-945e-cf2df9df73bc"
      unitRef="usd">158000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODQvZnJhZzpkNjAxMGQ2NGNjNDA0ZWNiYmQ5ZDMzMWY5MWJiZTRkOC90ZXh0cmVnaW9uOmQ2MDEwZDY0Y2M0MDRlY2JiZDlkMzMxZjkxYmJlNGQ4XzkwMzY_44ba681d-57b5-4496-a270-c05af2a237ce"
      unitRef="usd">143000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzE0MjY_0186a6ee-2ae2-4728-996e-0c57db38c56c">Other (Income) Expense, Net&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from investments in equity securities, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates losses of approximately $500&#160;million will be recorded in the first quarter of 2022 from ownership interests in investment funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other, net (as presented in the table above) in 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment, which were fully divested by the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest paid was $779 million in 2021, $822 million in 2020 and $841 million in 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzE0MTc_3209cfa6-6124-44dd-8bf8-de9680f20a26">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from investments in equity securities, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates losses of approximately $500&#160;million will be recorded in the first quarter of 2022 from ownership interests in investment funds.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzEtMS0xLTEtMA_6a36f0dc-2e28-4fcc-9113-96d1bbe4b7e0"
      unitRef="usd">36000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzEtMy0xLTEtMA_d21ae584-44c5-4084-884b-de95cbe5d569"
      unitRef="usd">59000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzEtNS0xLTEtMA_2ab3bd0f-f4d5-4f8e-8fd4-2f6eee197687"
      unitRef="usd">274000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzItMS0xLTEtMA_8f7c2f1a-b204-4e73-8460-6ff3d6001161"
      unitRef="usd">806000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzItMy0xLTEtMA_9b734659-4d9c-4bc2-bf3f-320d59e3f698"
      unitRef="usd">831000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzItNS0xLTEtMA_c4fcd1d7-ec0e-45bd-82ce-8af53c1ab35a"
      unitRef="usd">893000000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzMtMS0xLTEtMA_c62ac268-b230-4db3-9ecc-2696ad2c1a24"
      unitRef="usd">-297000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzMtMy0xLTEtMA_cb9ab8b5-92e6-4c62-82ab-8d64f34e4d11"
      unitRef="usd">-145000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzMtNS0xLTEtMA_30179f26-404c-428e-998b-b6f595ff499f"
      unitRef="usd">-187000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzQtMS0xLTEtMA_2d9066c2-9a8d-44f1-8ab1-f0b739e8b158"
      unitRef="usd">1940000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzQtMy0xLTEtMA_955609ea-6089-4b81-8192-b644c085f230"
      unitRef="usd">1338000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzQtNS0xLTEtMA_a49b8ad9-b942-4160-95df-2840406c2f97"
      unitRef="usd">170000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzUtMS0xLTEtMA_ea051a09-869c-4e12-bccf-4604ff87a672"
      unitRef="usd">-212000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzUtMy0xLTEtMA_b50dd7c0-47e5-4973-a07d-8450f6634e83"
      unitRef="usd">-339000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzUtNS0xLTEtMA_7b6ce491-d69d-494d-8857-f591b47837f1"
      unitRef="usd">-545000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzYtMS0xLTEtMA_de9d06ee-5003-4677-8323-da7cf6704b02"
      unitRef="usd">256000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzYtMy0xLTEtMA_e6a0c884-9a53-4a5b-8037-fff54b0fde29"
      unitRef="usd">130000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzYtNS0xLTEtMA_de61dba5-c27c-4ef2-b2e4-8c880c06b465"
      unitRef="usd">-38000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzctMS0xLTEtMA_f52e060d-1093-4808-9ff2-521c9254e0a2"
      unitRef="usd">1341000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzctMy0xLTEtMA_7416a50c-00fe-445a-822b-b1bdeb5b0188"
      unitRef="usd">890000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90YWJsZTo0NGRiMjdiODVjMTE0Yjc1YTVlYjViZWNhNDM5YWRhOC90YWJsZXJhbmdlOjQ0ZGIyN2I4NWMxMTRiNzVhNWViNWJlY2E0MzlhZGE4XzctNS0xLTEtMA_16f4fa32-195d-46a6-93b7-d3326a30bd64"
      unitRef="usd">-129000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if9977d228ad648dea6127cc9cf399ac2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzEwOTk1MTE2MzA0ODQ_cb788af3-d98f-4759-ad32-f9bc7f14ea72"
      unitRef="usd">-500000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3cb2ff06220a49eb8adeb3181d31932d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzUyNg_1e505b75-4f13-46a0-a441-27a0edd4b08f"
      unitRef="usd">162000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:InterestPaid
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzEzODM_9c3b4405-612d-4b07-a601-a06fb8de60ee"
      unitRef="usd">779000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzEzOTM_a1beeeef-0df0-4cb4-bd27-adb808a8f224"
      unitRef="usd">822000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xODcvZnJhZzpmNjg1Yjk2MjYwYjY0ZDYxYWYzNzM4MTYyNmVmNjllYy90ZXh0cmVnaW9uOmY2ODViOTYyNjBiNjRkNjFhZjM3MzgxNjI2ZWY2OWVjXzE0MDY_988f8267-e047-47d4-bac9-9fc94f41a040"
      unitRef="usd">841000000</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUwOTc_cd1fb2df-14a2-44a4-be1a-acf5b15e9142">Taxes on Income&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate applied to income from continuing operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Differential arising from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;GILTI and the foreign-derived intangible income deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of VelosBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Pandion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related costs, including amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of OncoImmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Peloton&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Cuts and Jobs Act of 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act (TCJA) was enacted in December 2017 and the Company reflected the impact of the TCJA in its 2017 financial statements. However, since application of certain provisions of the TCJA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;remained subject to further interpretation, in certain instances the Company made reasonable estimates of the effects of the TCJA, which were since finalized and resulted in additional income tax expense in 2018 and 2019. The Company&#x2019;s remaining transition tax liability under the TCJA, which has been reduced by payments and the utilization of foreign tax credits, was $2.6 billion at December&#160;31, 2021, of which $390 million is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the remainder of $2.2 billion is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the U.S., particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2022), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. Beginning in 2021, the Company has an additional tax incentive in the form of a tax holiday in Switzerland for a newly active legal entity which is effective through 2030. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from continuing operations before taxes consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,854&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taxes on income from continuing operations consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,334&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product intangibles and licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;370&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pensions and other postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses and other tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,749&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;692&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,441&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December&#160;31, 2021, $181 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $164 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $686 million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards. Valuation allowances of $123&#160;million have been established on these U.S. tax credit carryforwards and NOL carryforwards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes paid in 2021, 2020 and 2019 (including amounts attributable to discontinued operations) were $2.4 billion, $2.7 billion and $4.5 billion, respectively. Tax benefits relating to stock option exercises were $21 million in 2021, $12 million in 2020 and $65 million in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,537&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amounts in 2021 and 2019 reflect settlements with the IRS discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Amount in 2019 includes $78 million related to the divestiture of Merck&#x2019;s Consumer Care business in 2014.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company were to recognize the unrecognized tax benefits of $1.5 billion at December&#160;31, 2021, the income tax provision would reflect a favorable net impact of $1.5 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December&#160;31, 2021 could decrease by up to approximately $11 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties associated with uncertain tax positions amounted to a (benefit) expense of $(37) million in 2021, $16 million in 2020 and $(53) million in 2019. These amounts reflect the beneficial impacts of various tax settlements, including the settlements discussed below. Liabilities for accrued interest and penalties were $192 million and $205 million as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#x2019;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190&#160;million (of which $172&#160;million related to continuing operations and $18&#160;million related to discontinued operations). The Company&#x2019;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236&#160;million net tax benefit in 2021 (of which $207&#160;million related to continuing operations and $29&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the IRS concluded its examinations of Merck&#x2019;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million (of which $142&#160;million related to discontinued operations with an offsetting credit of $35&#160;million related to continuing operations). The Company&#x2019;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $364 million net tax benefit in 2019 (of which $106&#160;million related to continuing operations and $258&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IRS is currently conducting examinations of the Company&#x2019;s tax returns for the years 2017 and 2018. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company&#x2019;s income tax returns are open for examination for the period 2003 through 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxMDQ_f4934914-00a5-49fb-b9fb-00cb03650824">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate applied to income from continuing operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Differential arising from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;GILTI and the foreign-derived intangible income deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of VelosBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Pandion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related costs, including amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of OncoImmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Peloton&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Cuts and Jobs Act of 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItMS0xLTEtMA_7cf99248-2363-4108-a81c-2cf11ca3f81f"
      unitRef="usd">2915000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItMy0xLTEtMA_a1e5d601-42a2-420b-9932-5727e1e2db64"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItNS0xLTEtMA_dea2e9cb-c13a-4c5e-9476-5dc311a3ea65"
      unitRef="usd">1231000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItNy0xLTEtMA_136981a5-148a-4bcf-8201-073bee8c5e2b"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItOS0xLTEtMA_106cd3ee-befd-4e38-88d5-4ed78a803515"
      unitRef="usd">1506000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzItMTEtMS0xLTA_23fe2671-7686-4260-a75b-4270ab36de7a"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtMS0xLTEtMA_db182184-6c90-4167-b1f8-5f040f9ba3a5"
      unitRef="usd">-1446000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtMy0xLTEtMA_d45f1854-722c-4ce5-a3d6-04b0c66c0ef0"
      unitRef="number">-0.104</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtNS0xLTEtMA_c6bf6545-9270-4f4c-8649-ea22a7d94816"
      unitRef="usd">-965000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtNy0xLTEtMA_c1746737-8141-42f8-8e62-6f0b14f412be"
      unitRef="number">-0.165</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtOS0xLTEtMA_5d8f53aa-91a6-41d8-b577-f5170eec0091"
      unitRef="usd">-461000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzQtMTEtMS0xLTA_1b89ed96-8509-441d-82ee-b491b955614f"
      unitRef="number">-0.064</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtMS0xLTEtMA_e6b40bbb-3500-4ef7-b4be-2a8d6e6e8d92"
      unitRef="usd">-75000000</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtMy0xLTEtMA_6f9765db-ddb6-4a51-a4f7-6ab2ea81bcae"
      unitRef="number">-0.005</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtNS0xLTEtMA_bbb402e4-880b-4303-9f7a-737e5c155323"
      unitRef="usd">349000000</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtNy0xLTEtMA_62e17814-7ca2-493e-8cd8-8d170d0baec2"
      unitRef="number">0.060</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtOS0xLTEtMA_1d269307-3806-4b31-8e4c-3fbf83e4487e"
      unitRef="usd">323000000</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzUtMTEtMS0xLTA_6110a3b6-b45f-48fb-b9df-b6508b6917ee"
      unitRef="number">0.045</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMS0xLTEtNDkyNjE_e66bb819-9201-4e3c-b617-1f4006d52cab"
      unitRef="usd">-275000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMy0xLTEtNDkyNjE_dcb82e1c-2bdc-4be5-90ab-59af8dd9f16e"
      unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtNS0xLTEtNDkyNjE_9333e974-1843-455d-a29f-83e16ea789ce"
      unitRef="usd">-13000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtNy0xLTEtNDkyNjE_c03414a3-5761-4cb9-b8de-e4c63d707751"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtOS0xLTEtNDkyNjE_409f0613-de33-4d0e-bd86-189d409efdcf"
      unitRef="usd">-139000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMTEtMS0xLTQ5MjYx_1fc1b0a3-8e20-4931-a3e2-351f62a9272f"
      unitRef="number">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMS0xLTEtMA_b56c01c5-05ac-49b5-bb8d-3cd4f67321af"
      unitRef="usd">81000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMy0xLTEtMA_fb99ae27-3acc-446e-9b20-2e6a025d0d41"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtNS0xLTEtMA_e40f2e50-8a15-4c0d-a569-f7a372c34d81"
      unitRef="usd">108000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtNy0xLTEtMA_bf07db90-ff2e-4416-9641-2c06f6ac1d78"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtOS0xLTEtMA_374c873a-f5f7-4315-beb4-d44d84bcb23d"
      unitRef="usd">116000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzYtMTEtMS0xLTA_ed6c0c55-db03-4ffd-9968-f8fb53da3e18"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMS0xLTEtNDkyNzM_6dcb171d-1818-4979-854a-206a07b4dddf"
      unitRef="usd">-9000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMy0xLTEtNDkyNzM_e3ba1c40-7540-4b72-8a97-a711df55efab"
      unitRef="number">-0.001</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtNS0xLTEtNDkyNzM_006bc606-0147-4f59-bd77-2d16fbf1d0e0"
      unitRef="usd">559000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtNy0xLTEtNDkyNzM_d3f1b4ad-9a65-4af5-837b-d0b92f375f55"
      unitRef="number">0.095</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtOS0xLTEtNDkyNzM_84c3090c-6838-4ae4-92af-e219cc090e8e"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThree>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMTEtMS0xLTQ5Mjcz_381388ac-560c-4ce2-9240-e4d5138cd84d"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMS0xLTEtMTY2OQ_d9a58920-482c-468f-b2b8-e49a5730b22e"
      unitRef="usd">356000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMy0xLTEtMTY2OQ_95eafa10-4f78-400e-a9fd-1e2374cdce4a"
      unitRef="number">0.026</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtNS0xLTEtMTY2OQ_46da2efb-d693-4ca4-9186-80c999ddd9db"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtNy0xLTEtMTY2OQ_a26e5f94-4613-40dd-9cb9-1aa65c449305"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtOS0xLTEtMTY2OQ_ed6bfd1a-8100-48b9-9706-98875786ac75"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzgtMTEtMS0xLTE2Njk_2fda4481-c1c1-4cab-ae34-434976016f20"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTEtMS0xLTQ5Mjg1_6961600e-8606-4659-a971-41e6527352a4"
      unitRef="usd">102000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTMtMS0xLTQ5Mjg1_680944d1-0084-4a5a-b2d7-52db7c72465b"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTUtMS0xLTQ5Mjg1_130de4ca-0c5a-4ee0-af0e-733b39536efb"
      unitRef="usd">37000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTctMS0xLTQ5Mjg1_65c9fec3-9f96-4405-8c0d-5a9c85d1239b"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTktMS0xLTQ5Mjg1_1709c10c-741f-4715-8a1f-e2039a043ee0"
      unitRef="usd">115000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEwLTExLTEtMS00OTI4NQ_2f13f3d1-aebc-481a-ac08-bb2a3d3724b3"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktMS0xLTEtMA_9016c46e-1bff-4614-ad42-44487d18ac7e"
      unitRef="usd">61000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktMy0xLTEtMA_e68610f0-7bc7-4fe2-b537-25b429a06434"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktNS0xLTEtMA_dac40042-7137-4e6e-a12a-a689d61e07bb"
      unitRef="usd">105000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktNy0xLTEtMA_f4b92ce7-cae7-4a11-a274-e9d73e06a7cc"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktOS0xLTEtMA_e0a3bf1f-60db-46a2-ac3d-689b9dd45e62"
      unitRef="usd">39000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzktMTEtMS0xLTA_5f1d85e4-1722-4782-b7c9-b44a47895c11"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTEtMS0xLTQ5MzEw_a332ee3f-ef4c-4101-b619-6b76831d0459"
      unitRef="usd">8000000</mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTMtMS0xLTQ5MzEw_fbae032b-499d-4324-9a73-78e8be361c63"
      unitRef="number">0.001</mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTUtMS0xLTQ5MzEw_4dfac976-848d-47f2-a787-0b0e3b645d7d"
      unitRef="usd">38000000</mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTctMS0xLTQ5MzEw_59d03240-33df-4391-b04f-12fdf19d29c5"
      unitRef="number">0.006</mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTktMS0xLTQ5MzEw_b99d0123-4c55-430f-af1c-2d1759cb41aa"
      unitRef="usd">70000000</mrk:IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzEyLTExLTEtMS00OTMxMA_5b759042-a199-4948-8834-d29d3d0d130c"
      unitRef="number">0.010</mrk:EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTEtMS0xLTA_653e95a7-bff9-41fa-9a7a-9627427e777b"
      unitRef="usd">2000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTMtMS0xLTA_38f6b054-b700-4751-b37f-febb44446798"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTUtMS0xLTA_33679186-f08a-4023-adf7-8279988770ee"
      unitRef="usd">57000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTctMS0xLTA_ea0cd153-80fb-434c-a8be-3923701c6ce5"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTktMS0xLTA_c200221b-22ff-4029-8053-0f62201718c6"
      unitRef="usd">-12000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzExLTExLTEtMS0w_b6c26d2d-bed0-456a-9002-8581fe546989"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTEtMS0xLTQ5Mjk4_d1d6bb8c-fe64-4a1c-9693-777453ed0edf"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTMtMS0xLTQ5Mjk4_637d6d27-86c1-4aad-b2bb-2811c5b0a278"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTUtMS0xLTQ5Mjk4_95e144c1-b4d0-4ba0-ab39-51e1d89c4c73"
      unitRef="usd">97000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTctMS0xLTQ5Mjk4_c1747532-1e0f-427e-bf25-d77db471be9d"
      unitRef="number">0.017</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTktMS0xLTQ5Mjk4_b6fc7425-702a-4474-b818-5ac409e3e5ab"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTExLTEtMS00OTI5OA_e1abb610-3c48-4265-a699-741eb32c39d6"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTEtMS0xLTA_7af0b16f-659e-4742-9951-e91cb4b6b83b"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTMtMS0xLTA_3f262efa-629e-4f00-bef5-7e16c5ca5cd0"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTUtMS0xLTA_15b27ccb-b797-4328-b3ca-84c4f087e617"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTctMS0xLTA_8112e593-9f15-4b8b-8a27-47805867cd93"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTktMS0xLTA_9d2e8bdf-db9d-4a00-828d-925ccfbd0592"
      unitRef="usd">209000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombination>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE0LTExLTEtMS0w_e70c4052-b378-46ad-8fdc-151f52f1a1a9"
      unitRef="number">0.029</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTEtMS0xLTA_1484a5a5-7044-4163-9f06-ea5962ff8998"
      unitRef="usd">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTMtMS0xLTA_8fd6db13-a259-4554-941d-762368ade830"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTUtMS0xLTA_afd587bd-0faa-43bd-94c2-6826f3c12016"
      unitRef="usd">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTctMS0xLTA_88febb05-6a3e-4c84-993e-17714781b5e6"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTktMS0xLTA_268197f7-ce74-4968-bb05-9fa82be42533"
      unitRef="usd">117000000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE1LTExLTEtMS0w_72aed657-54fe-4d7a-934d-bb5d059e004a"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTEtMS0xLTA_05358249-9bea-4967-8d04-4ccf714fc3a7"
      unitRef="usd">-37000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTMtMS0xLTA_0b6b7080-8ab8-4ae5-8ab5-bf285e23353f"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTUtMS0xLTA_13405e45-b55d-4bac-aae9-3d8e7f240c45"
      unitRef="usd">-47000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTctMS0xLTA_78d8a911-fca4-4a7c-b6fb-41c31a4d2c3b"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTktMS0xLTA_fb315186-c2da-4cc4-8946-3054d5b92a14"
      unitRef="usd">-86000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE2LTExLTEtMS0w_e6386dbb-440b-4841-993c-8a909d2ed164"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTEtMS0xLTA_07635374-7af8-4772-91cb-b14d5bec7001"
      unitRef="usd">1521000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTMtMS0xLTA_5eeddc65-38af-4f52-b040-a6f412c00c86"
      unitRef="number">0.110</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTUtMS0xLTA_994421e3-9ae9-4316-9c03-7aa0a63dc90d"
      unitRef="usd">1340000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTctMS0xLTA_e0a125a8-1e71-402b-a25c-5eda61ecb67a"
      unitRef="number">0.229</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTktMS0xLTA_a99298e1-8d38-46eb-9da5-6366cefb747c"
      unitRef="usd">1565000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo3ZThjNTM3YWY1NmE0NjgzYTI1MGNiYjAxMzNhMzU1Mi90YWJsZXJhbmdlOjdlOGM1MzdhZjU2YTQ2ODNhMjUwY2JiMDEzM2EzNTUyXzE3LTExLTEtMS0w_bd0d3c16-5d0d-4890-9981-54467d42d224"
      unitRef="number">0.218</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzY5Nw_28e028af-0a69-4517-a4e0-ffefd8ce0975"
      unitRef="usd">2600000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent
      contextRef="i4d3b1868b07e42d9beeb1de061d22b1f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzcxNg_c4ee8365-a545-45f9-8b48-2dc38430257e"
      unitRef="usd">390000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent
      contextRef="idb2506788d4645da9386ce90a8f1d696_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzc3Ng_80abff14-1c2b-4115-bed4-526d8fc317e0"
      unitRef="usd">2200000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxMDc_663ca790-2e9b-4b61-ac3d-b1fb7b250409">&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from continuing operations before taxes consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,854&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzEtMS0xLTEtMA_52c2324f-f604-472c-9e37-a878f09ee391"
      unitRef="usd">1854000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzEtMy0xLTEtMA_4ed720da-27d9-47ac-9e29-f46ef3f9cad4"
      unitRef="usd">-3814000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzEtNS0xLTEtMA_2f7c4cb0-2346-4755-bf19-367c180b8cba"
      unitRef="usd">-66000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzItMS0xLTEtMA_58402377-a96a-4f83-a67d-f02166e8e698"
      unitRef="usd">12025000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzItMy0xLTEtMA_cea4b89d-f7a8-445b-bbea-795698dd1a4a"
      unitRef="usd">9677000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzItNS0xLTEtMA_db985a99-91cd-420e-ad37-3f55b898d61e"
      unitRef="usd">7237000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzMtMS0xLTEtMA_5175eb97-c23c-4287-90e4-199b33490ed7"
      unitRef="usd">13879000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzMtMy0xLTEtMA_610645cc-1c14-4963-9e78-438471e13908"
      unitRef="usd">5863000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTplNjgxYWRiNmM0OGU0NmZkOGNhMWZkMTJlOTVmNDdjMy90YWJsZXJhbmdlOmU2ODFhZGI2YzQ4ZTQ2ZmQ4Y2ExZmQxMmU5NWY0N2MzXzMtNS0xLTEtMA_5282d04b-1146-4299-aca5-dcc6573e0d6b"
      unitRef="usd">7171000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxNDc_3de82cb6-585b-47a0-961f-0c5c8963d43b">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taxes on income from continuing operations consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,334&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzItMS0xLTEtMA_1b051f2d-d271-4316-bd98-c3c4031d23b8"
      unitRef="usd">74000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzItMy0xLTEtMA_1d01cd02-19dd-46e6-b725-374e4778574a"
      unitRef="usd">893000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzItNS0xLTEtMA_0bf7f371-65d1-42de-9ddf-63372bea7df3"
      unitRef="usd">642000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzMtMS0xLTEtMA_0c1a5f72-22da-4b4c-b03f-60956f2dc2ba"
      unitRef="usd">1273000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzMtMy0xLTEtMA_1dc2ba80-0aba-44e7-bca1-7c9de505ed16"
      unitRef="usd">969000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzMtNS0xLTEtMA_a1de0f03-2c29-49ae-bae6-ae3d755ddf56"
      unitRef="usd">1523000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzQtMS0xLTEtMA_4ae85d5b-2583-455c-b59f-d2b4167c3134"
      unitRef="usd">-13000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzQtMy0xLTEtMA_fcb3d9c0-57ad-4356-9bbf-0918bb3e86e6"
      unitRef="usd">44000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzQtNS0xLTEtMA_8bd9ca5a-0c69-4ac6-985c-17ac93538992"
      unitRef="usd">-40000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzUtMS0xLTEtMA_f52a1df3-6d36-4aed-bdb3-de993a392cea"
      unitRef="usd">1334000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzUtMy0xLTEtMA_10c4fe34-0358-4477-b3e0-7111d801dd3f"
      unitRef="usd">1906000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzUtNS0xLTEtMA_1a699664-a424-4f61-b4fa-4b8707682955"
      unitRef="usd">2125000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzctMS0xLTEtMA_cee73f1c-3a94-48d3-9fc0-a5316c976b93"
      unitRef="usd">240000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzctMy0xLTEtMA_27fcf8fa-9951-47ce-ac7b-d42a6f34748c"
      unitRef="usd">-605000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzctNS0xLTEtMA_280015ca-aaaf-4cdc-b018-661f33427d0d"
      unitRef="usd">-328000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzgtMS0xLTEtMA_b6310a05-93a3-4ed7-8a5f-3a27dab5e060"
      unitRef="usd">-77000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzgtMy0xLTEtMA_20d65dac-5091-4bea-b5b7-ed5487b27775"
      unitRef="usd">64000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzgtNS0xLTEtMA_c73df0e2-1c7b-44be-ad19-add4315ad3b3"
      unitRef="usd">-228000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzktMS0xLTEtMA_0a0585e4-598c-4a3f-888e-4f46fbcb2c29"
      unitRef="usd">24000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzktMy0xLTEtMA_a83dabae-21de-4e44-aba8-9c8a3692dd67"
      unitRef="usd">-25000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzktNS0xLTEtMA_c07df3e9-3036-4e4b-945e-9d4103db8b01"
      unitRef="usd">-4000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzEwLTEtMS0xLTA_d0d4f814-b15d-4a32-8655-55cda0b5a2cf"
      unitRef="usd">187000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzEwLTMtMS0xLTA_0e6aa497-0a17-46f2-b8cb-8a0e011e6cd4"
      unitRef="usd">-566000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzEwLTUtMS0xLTA_344e6833-50c0-402f-b0a5-17c8ee5b1bde"
      unitRef="usd">-560000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzExLTEtMS0xLTA_faa7d47b-3f0a-4a09-80bb-3346473c843e"
      unitRef="usd">1521000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzExLTMtMS0xLTA_6b135077-9a0c-48ca-8d21-be4907e9e745"
      unitRef="usd">1340000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZTo1NmU5NDNhYTNlMmM0NjA2ODRhMTI0MWE3ZDk1MDc3Yy90YWJsZXJhbmdlOjU2ZTk0M2FhM2UyYzQ2MDY4NGExMjQxYTdkOTUwNzdjXzExLTUtMS0xLTA_c6367602-fd6c-443e-bdb0-162f69118f4f"
      unitRef="usd">1565000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxMzE_ba5847b4-3b8c-4036-8ac7-85ab30bdf231">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product intangibles and licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;370&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;589&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pensions and other postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses and other tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,749&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;692&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,441&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzItMS0xLTEtMA_a647f506-0332-43b5-a0f3-41d57a092233"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzItMy0xLTEtMA_1aa0e1ef-5c2c-4f5e-b86b-5fa338c6e011"
      unitRef="usd">2933000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzItNS0xLTEtMA_c00b095f-ba9e-44a3-8501-7677479490cb"
      unitRef="usd">109000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzItNy0xLTEtMA_a906a278-48cb-47ab-bb14-2d8839c6a769"
      unitRef="usd">1250000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzMtMS0xLTEtMA_214e484b-d31f-4142-8b1d-c4baee6654f1"
      unitRef="usd">119000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzMtMy0xLTEtMA_e21469a9-90a2-4854-8a72-6c20272504da"
      unitRef="usd">370000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzMtNS0xLTEtMA_16c73da1-98e5-4e6d-9803-58e8aa87e8ac"
      unitRef="usd">43000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzMtNy0xLTEtMA_9bea1d16-e0f2-44e6-9b27-a8ebd83260d9"
      unitRef="usd">315000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzQtMS0xLTEtMA_22193a81-3e3a-447c-a7f1-81c23edea0bb"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzQtMy0xLTEtMA_2e8c3037-4d65-488a-b18a-a1f533254b44"
      unitRef="usd">589000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzQtNS0xLTEtMA_73ce7d3b-f556-4b67-80de-961616128366"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzQtNy0xLTEtMA_0747aabd-039c-486e-84e6-b9d8c8f9c769"
      unitRef="usd">587000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzUtMS0xLTEtMA_08f9760c-42c1-40d7-9d00-9b8c45af24c0"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <mrk:DeferredTaxLiabilitiesEquityMethodInvestment
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzUtMy0xLTEtMA_6247c2fc-f7de-4744-b620-2df33753cdfb"
      unitRef="usd">335000000</mrk:DeferredTaxLiabilitiesEquityMethodInvestment>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzUtNS0xLTEtMA_b395ba29-ba0d-49f4-a594-9f1a7523d725"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <mrk:DeferredTaxLiabilitiesEquityMethodInvestment
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzUtNy0xLTEtMA_2731bc52-308c-4bd3-8493-46076a4a51d2"
      unitRef="usd">175000000</mrk:DeferredTaxLiabilitiesEquityMethodInvestment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzYtMS0xLTEtMA_91af133c-df5c-4a01-8dc9-06fada664f05"
      unitRef="usd">487000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzYtMy0xLTEtMA_958cf0a0-4e21-4ded-ba6a-119b13abfe53"
      unitRef="usd">338000000</mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzYtNS0xLTEtMA_43b01109-c264-4d96-843f-753f3bda5433"
      unitRef="usd">826000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzYtNy0xLTEtMA_1689fb8f-7a0e-4d9a-87c4-17c27553492e"
      unitRef="usd">248000000</mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzctMS0xLTEtMA_19108cfa-b5de-4ba8-8b81-c4dedb4aa6b5"
      unitRef="usd">301000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzctNS0xLTEtMA_b101b9e4-98e0-4f3e-8423-3ac9961a024b"
      unitRef="usd">235000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <mrk:DeferredTaxAssetsUnrecognizedTaxBenefits
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzgtMS0xLTEtMA_bcd2bd4f-961a-423f-9383-295c662dea82"
      unitRef="usd">75000000</mrk:DeferredTaxAssetsUnrecognizedTaxBenefits>
    <mrk:DeferredTaxAssetsUnrecognizedTaxBenefits
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzgtNS0xLTEtMA_3989c752-2b08-468f-9fac-c01b83e02d8d"
      unitRef="usd">117000000</mrk:DeferredTaxAssetsUnrecognizedTaxBenefits>
    <mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzktMS0xLTEtMA_5edb47a1-a6e8-4c3e-a47d-b815eab46eb1"
      unitRef="usd">867000000</mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards>
    <mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzktNS0xLTEtMA_56880cfd-f51b-4805-8e2b-c334e22f8f51"
      unitRef="usd">764000000</mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEwLTEtMS0xLTA_31a126a3-f101-4c8f-b1b8-b6888f4be73b"
      unitRef="usd">434000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEwLTMtMS0xLTA_e63e2475-c9f0-46f9-9411-a4028a326872"
      unitRef="usd">180000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEwLTUtMS0xLTA_404c0930-b3bf-4f8e-a7f2-2208e70f862c"
      unitRef="usd">743000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEwLTctMS0xLTA_4b4735f6-82e6-4ba6-b0fb-d91d55035873"
      unitRef="usd">81000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzExLTEtMS0xLTA_bc2ccfa5-b7b3-485a-ad37-20bc66251714"
      unitRef="usd">2283000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzExLTMtMS0xLTA_8e86f4ad-2ea2-47bd-a353-89fa833b1f65"
      unitRef="usd">4745000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzExLTUtMS0xLTA_3e3ae5a1-a4f1-4258-b9a1-2e9d1d30fee1"
      unitRef="usd">2837000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzExLTctMS0xLTA_9b737c8d-2958-4863-aecd-655f6586d662"
      unitRef="usd">2656000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEyLTEtMS0xLTA_128e820c-ce5b-48f7-953c-eb6afe4d47ab"
      unitRef="usd">287000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEyLTUtMS0xLTA_9eecf7c0-24dd-4c97-a2b4-bf17ebbc3700"
      unitRef="usd">404000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEzLTEtMS0xLTA_2f9fb38e-02ad-45a5-b699-917d3dcaee6f"
      unitRef="usd">1996000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEzLTMtMS0xLTA_521af7eb-7d19-42c7-8531-fbc4383e3d6b"
      unitRef="usd">4745000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEzLTUtMS0xLTA_b219dd43-a071-43d3-a65b-79e54e338c18"
      unitRef="usd">2433000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzEzLTctMS0xLTA_45a2ca69-08b0-44b7-842f-88b44c8b40fa"
      unitRef="usd">2656000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE0LTMtMS0xLTA_b5bf8743-9c5f-4c5d-84f6-c811729f5e52"
      unitRef="usd">2749000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE0LTctMS0xLTA_62c63990-7f2b-4598-9712-b0b39313fdb6"
      unitRef="usd">223000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ie7418d8deee94241a890cc5e06e3fb35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE2LTEtMS0xLTA_6caf8411-55df-4c85-acae-766ab3e8ee2c"
      unitRef="usd">692000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i412ceb3578cd4323882f96bffbb8f4c0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE2LTUtMS0xLTA_5ced279d-4c95-445f-bd99-f4c4cfc55d95"
      unitRef="usd">782000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE3LTMtMS0xLTA_19d464b8-a68c-4c21-aeb5-a367ef612cf1"
      unitRef="usd">3441000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToxZGQzZGMyMTI1ODk0MzE5OGZjYjI4ODkyNTliMmNkNS90YWJsZXJhbmdlOjFkZDNkYzIxMjU4OTQzMTk4ZmNiMjg4OTI1OWIyY2Q1XzE3LTctMS0xLTA_088e2894-e3aa-4af6-a20e-1a49f87e3ccc"
      unitRef="usd">1005000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzIxMjM_5684a7d1-d5b0-410c-b2b6-8bcb7ffd6577"
      unitRef="usd">181000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="iee0d42255922420582e8788d38817637_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzIyMjI_0b8c9171-b212-451c-b2e1-4cc2a1271ccf"
      unitRef="usd">164000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzIzNTA_3c090196-51c6-4f70-b671-dc97271d78d4"
      unitRef="usd">686000000</mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="id6a9a13cd0a149fd8df342c997fb0ade_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQzOTgwNDY1MjUwNDQ_02d26574-b748-4372-a1a4-5136913f3c66"
      unitRef="usd">123000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:IncomeTaxesPaid
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI1NTM_f66cc417-45fc-4519-ba71-260f76ff7fdc"
      unitRef="usd">2400000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI1NTc_656bd658-26dd-465d-b998-d7762b3b71ba"
      unitRef="usd">2700000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI1NjQ_fef4642d-6b8b-4963-b5a0-87dcbaea9c32"
      unitRef="usd">4500000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI2MzU_dc1fe04e-7fb5-415a-bfaa-b9e0a1ad539c"
      unitRef="usd">21000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI2NDU_7bff5d9b-3a39-4554-9096-43343bc4bd5e"
      unitRef="usd">12000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI2NTg_2406a41f-90f7-4225-968e-9454fff63b28"
      unitRef="usd">65000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzUxMTc_1927e46e-3972-402a-9290-b28ac8b6948d">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,537&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amounts in 2021 and 2019 reflect settlements with the IRS discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Amount in 2019 includes $78 million related to the divestiture of Merck&#x2019;s Consumer Care business in 2014.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzEtMS0xLTEtMA_2d5543f8-da22-4048-bcb4-e70b6992fd27"
      unitRef="usd">1537000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzEtMy0xLTEtMA_644c64a9-6fef-4daf-956e-ff27f3ac7191"
      unitRef="usd">1225000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8b25cba6160a4486b14740ddd2b481ef_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzEtNS0xLTEtMA_f10e7044-ef34-4199-a1f8-cd73435eb89e"
      unitRef="usd">1893000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzItMS0xLTEtMA_1af0b8c6-bcb8-4f9a-b0f0-d5fbf7e4313c"
      unitRef="usd">306000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzItMy0xLTEtMA_ce174669-620b-4787-ad73-eee68de2d560"
      unitRef="usd">298000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzItNS0xLTEtMA_c55203bb-aa30-455a-8996-e2f5e703149f"
      unitRef="usd">199000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzMtMS0xLTEtMA_e3b302bc-00ad-44d0-b204-b7838ac4978d"
      unitRef="usd">63000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzMtMy0xLTEtMA_20300c47-62b3-48db-aae2-27cb2d06c6bb"
      unitRef="usd">110000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzMtNS0xLTEtMA_88f5b517-a5ef-408b-8df8-92bc304b42ee"
      unitRef="usd">46000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzQtMS0xLTEtMA_de98c83e-24c6-4ce3-bd95-65dd724c11f3"
      unitRef="usd">230000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzQtMy0xLTEtMA_befada82-180a-471e-9f00-0b08a91b3d29"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzQtNS0xLTEtMA_88745945-43fc-4391-a352-32d024b1a0fb"
      unitRef="usd">454000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzUtMS0xLTEtMA_514f4c95-3492-4d10-9251-d84d069bfd98"
      unitRef="usd">46000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzUtMy0xLTEtMA_9ace67b6-3896-4891-9f03-82983135ff0c"
      unitRef="usd">70000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzUtNS0xLTEtMA_3a38aef6-bf27-45ad-93dd-4924c9647230"
      unitRef="usd">356000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzYtMS0xLTEtMA_52bff443-c097-4e86-93eb-2aa86fed6aa8"
      unitRef="usd">58000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzYtMy0xLTEtMA_a0dde91e-cd66-4543-ac2d-7e23209c2160"
      unitRef="usd">22000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzYtNS0xLTEtMA_e4f25c27-d971-42c3-a6a7-ed6f6646c300"
      unitRef="usd">103000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctMS0xLTEtMTYzNw_dfbdfaaa-1a08-45c4-a807-1f2d1a2d81a9"
      unitRef="usd">43000000</mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction>
    <mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctMy0xLTEtMTYzNw_9b760063-c7e7-4810-aadb-356bb338f9c9"
      unitRef="usd">0</mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction>
    <mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctNS0xLTEtMTYzNw_3038acb8-c1b0-4be8-8c6b-4399b19df6c7"
      unitRef="usd">0</mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctMS0xLTEtMA_207f5f4b-67cd-4a20-8ac4-8f18f69261de"
      unitRef="usd">1529000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctMy0xLTEtMA_4de47856-1774-4720-9adc-7517cb0e0bf2"
      unitRef="usd">1537000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90YWJsZToyNWQyNmViNzIxYWM0NmM4OTRmODAzOTgzMDMwMTYyNy90YWJsZXJhbmdlOjI1ZDI2ZWI3MjFhYzQ2Yzg5NGY4MDM5ODMwMzAxNjI3XzctNS0xLTEtMA_b90be423-cc1b-4def-b608-a422335f09e6"
      unitRef="usd">1225000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i622d15e154f84cc28b01ef17d5fe85b8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzI4NzE_305ce2f1-f729-4aa2-b104-0e28bf84e926"
      unitRef="usd">78000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzMwMTA_6cb22867-bdfe-4bfe-9915-de6ca6c439b7"
      unitRef="usd">1500000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzMwODU_695cabf8-5883-4797-a023-d1caabd10d10"
      unitRef="usd">1500000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzMzMzY_0b2a1b6c-c818-4f7d-8154-4e4d4c082693"
      unitRef="usd">11000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzM5MjM_f03710cc-8a9a-493a-b255-675aad0afd9e"
      unitRef="usd">-37000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzM5MzM_dbb64edc-b82c-4924-9e4f-cd940fc05995"
      unitRef="usd">16000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzM5NDY_948d91d7-1e9f-47b5-9e47-92b1b28475fc"
      unitRef="usd">-53000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQxMjM_247743f6-861d-4664-8dc0-99998a438488"
      unitRef="usd">192000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQxMzA_5e5c1114-519b-47ed-b6f2-09683c6908f5"
      unitRef="usd">205000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib84dc814a0974bf0836891662899fabc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2Mzc0MjE_0f73e45a-b55b-4fae-8a39-01fd27db0dd9"
      unitRef="usd">190000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9efea9cf6b604686982b9cdfac42f3df_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcwOTQ_6f9de2f1-4374-4bca-ae2f-7a16d9051d75"
      unitRef="usd">172000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i76e98608767a40d2a24b489eafd3e853_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxMDg_7a4467f1-8a13-422f-8ff8-358edaf105fe"
      unitRef="usd">18000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ib84dc814a0974bf0836891662899fabc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2Mzc0NDM_8a1c34d5-4353-429e-9fd7-6b12f4b2cbc4"
      unitRef="usd">236000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i9efea9cf6b604686982b9cdfac42f3df_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxMzU_402b2749-285a-4bf9-b481-9a3b4e4aa8bf"
      unitRef="usd">207000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i76e98608767a40d2a24b489eafd3e853_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxNDk_84aff1a6-f7a1-490f-92eb-aa69539f1ac6"
      unitRef="usd">29000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9158afc2f18a4d47b2a3ce049a91f164_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQzNDg_6ebe03b2-8a52-4d5c-a5c9-2fbec2437670"
      unitRef="usd">107000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i85b88606a448480e91ccbb985a641950_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxNzY_1e782943-3443-44e9-aba1-52a3a5ae6d56"
      unitRef="usd">142000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i836d57ab500a430aa624c66b51480417_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2NDAxNjE_f42f4952-4eb7-4019-9049-f278c638dae9"
      unitRef="usd">35000000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i9158afc2f18a4d47b2a3ce049a91f164_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzQ1MzU_b6eeef64-ecc7-40f1-9774-11bad80b59aa"
      unitRef="usd">364000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i836d57ab500a430aa624c66b51480417_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcxODk_63b1c048-427e-41ca-9d3c-3641facb83f7"
      unitRef="usd">106000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i85b88606a448480e91ccbb985a641950_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTAvZnJhZzoxYmY2YmVjMDgxNjI0MjM5YWNmM2E3YWE0OWRmM2NlZi90ZXh0cmVnaW9uOjFiZjZiZWMwODE2MjQyMzlhY2YzYTdhYTQ5ZGYzY2VmXzEwOTk1MTE2MzcyMDM_d0d4f1da-ec42-4fa7-a488-f688f33e3ea2"
      unitRef="usd">258000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzQxMg_1b4f4639-b681-4402-a892-b5957ef4e9c2">Earnings per Share&lt;div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share (shares in millions) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income from Continuing Operations Attributable to Merck &amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,345&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic Earnings per Common Share Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per Common Share Assuming Dilution Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;In 2021, 2020 and 2019, 9 million, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzQxMA_b4d494b6-184a-4817-9dff-ca037ea76457">&lt;div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share (shares in millions) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income from Continuing Operations Attributable to Merck &amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,345&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic Earnings per Common Share Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per Common Share Assuming Dilution Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMS0xLTEtMjYxNw_bc76a1c0-708e-4cc0-9b1d-69938feddf50"
      unitRef="usd">12345000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMy0xLTEtMjYxNw_4fb43007-43f2-467d-9dee-dddc2362836c"
      unitRef="usd">4519000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtNS0xLTEtMjYxNw_96d51feb-1bdb-4388-a7a1-7e06d32ea4bc"
      unitRef="usd">5690000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItMS0xLTEtMjYxNw_13d726d8-5f13-4dee-b91c-d73a00cdda15"
      unitRef="usd">704000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItMy0xLTEtMjYxNw_6b187f57-ff85-4766-ba5c-1019ebb5ecf7"
      unitRef="usd">2548000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItNS0xLTEtMjYxNw_071bc1b1-1b5d-42c7-9c0f-42466110c482"
      unitRef="usd">4153000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMS0xLTEtMA_71002ff4-7b68-45fd-be28-ca3b6c916890"
      unitRef="usd">13049000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMS0xLTEtMA_abd68b94-daa2-49e7-898c-886b5ef8dcc0"
      unitRef="usd">13049000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMy0xLTEtMA_809c44a2-7ea3-4885-8947-30bdc5405eb3"
      unitRef="usd">7067000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtMy0xLTEtMA_d2211447-67d8-450f-b05d-c81467147f44"
      unitRef="usd">7067000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtNS0xLTEtMA_361c2733-ddb9-4f70-b923-cdba8a3ac951"
      unitRef="usd">9843000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEtNS0xLTEtMA_a8e5780d-c56d-48ed-a73f-3faf0cb266e9"
      unitRef="usd">9843000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItMS0xLTEtMA_1fb0fd7c-3437-4a7f-9c13-04ef5f334d84"
      unitRef="shares">2530000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItMy0xLTEtMA_f7a53062-9d6b-4597-b4d9-34e96132c1c4"
      unitRef="shares">2530000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzItNS0xLTEtMA_70da1ad6-5cf5-4bf5-a8c6-bff4dbd4ca86"
      unitRef="shares">2565000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzMtMS0xLTEtMA_275273fd-f976-49ca-8456-e839edfcd92e"
      unitRef="shares">8000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzMtMy0xLTEtMA_73ab96fd-9494-4d95-a611-a59595e71d2f"
      unitRef="shares">11000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzMtNS0xLTEtMA_45f2dded-25f2-4421-ac8b-c226e9cf5801"
      unitRef="shares">15000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzQtMS0xLTEtMA_0c1b21e7-7622-47c1-9e45-d733c5300b77"
      unitRef="shares">2538000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzQtMy0xLTEtMA_d5568e4e-3fa0-4b5b-bfbf-017f01894eaf"
      unitRef="shares">2541000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzQtNS0xLTEtMA_d675bb72-ff86-4ca7-8d52-8b632e111e88"
      unitRef="shares">2580000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzgtMS0xLTEtMjY2OQ_f4c8db26-408b-4c06-b3ab-aafcc8ac1ff1"
      unitRef="usdPerShare">4.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzgtMy0xLTEtMjY2OQ_9196e04c-874d-494d-b17f-369595bb3fdf"
      unitRef="usdPerShare">1.79</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzgtNS0xLTEtMjY2OQ_22f572fe-5b91-4bd4-8433-cc26345d8f39"
      unitRef="usdPerShare">2.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzktMS0xLTEtMjY2OQ_a84d6cc8-524d-437f-adad-ad4496372541"
      unitRef="usdPerShare">0.28</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzktMy0xLTEtMjY2OQ_8238c10c-911d-4647-b22b-272545b5165e"
      unitRef="usdPerShare">1.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzktNS0xLTEtMjY2OQ_d4322ec3-cebb-45a4-89d3-bb6e843f9bb2"
      unitRef="usdPerShare">1.62</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzUtMS0xLTEtMA_bffea7c9-ca5d-4482-b02d-63af78b5d808"
      unitRef="usdPerShare">5.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzUtMy0xLTEtMA_8368a061-8edc-4015-8125-1b2812c068b9"
      unitRef="usdPerShare">2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzUtNS0xLTEtMA_5944e4db-065d-4fc1-9caf-9d82cdd71277"
      unitRef="usdPerShare">3.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEyLTEtMS0xLTI2ODA_f27c45d5-52c0-4d3d-a404-af66459e6c46"
      unitRef="usdPerShare">4.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEyLTMtMS0xLTI2ODA_4461c86c-dca2-49b1-8da5-4c10e826cd52"
      unitRef="usdPerShare">1.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEyLTUtMS0xLTI2ODA_4d964f51-ef75-4d92-a115-d9306ba0bbff"
      unitRef="usdPerShare">2.21</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEzLTEtMS0xLTI2ODA_33fd902d-0b7f-4f71-bc89-27ecd2b3050d"
      unitRef="usdPerShare">0.28</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEzLTMtMS0xLTI2ODA_3b99722e-fd66-4dbe-99f0-09b154114720"
      unitRef="usdPerShare">1.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzEzLTUtMS0xLTI2ODA_711a9753-2743-4f62-8d22-f3428854befa"
      unitRef="usdPerShare">1.61</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzYtMS0xLTEtMA_e18faf45-64f4-44ff-9097-a070227e7d71"
      unitRef="usdPerShare">5.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzYtMy0xLTEtMA_7a0f6a1f-7961-4aa7-878f-6c3320c47b2b"
      unitRef="usdPerShare">2.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90YWJsZTpmZDhlZTliYjM5MWQ0NzdmOTViYWJjYjc5OGM2ZDVjNy90YWJsZXJhbmdlOmZkOGVlOWJiMzkxZDQ3N2Y5NWJhYmNiNzk4YzZkNWM3XzYtNS0xLTEtMA_096a1e54-829f-4bcb-883b-99bb4b90f4b9"
      unitRef="usdPerShare">3.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzE4OQ_cae79c11-d9ac-419f-bdba-284d08de7554"
      unitRef="shares">9000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzE5Mw_fc9fbf45-623a-49dd-8bc3-0cbcd9f6b594"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTMvZnJhZzo2ZDBmZDlkYzljZGY0NjhhODMwMjI4NzAxNjgyNjRkMC90ZXh0cmVnaW9uOjZkMGZkOWRjOWNkZjQ2OGE4MzAyMjg3MDE2ODI2NGQwXzIwMA_835f7517-c434-42ea-8316-163dec4878bf"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzg4Nw_08e78c9b-3385-431a-8991-969620edc339">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in each component of other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.903%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2019, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,922&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,383&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;410&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,769&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,756&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Spin-off of Organon (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;449&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Primarily relates to foreign currency cash flow hedges that were reclassified from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 14).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes pension plan net loss of $3.6 billion and $5.4 billion at December 31, 2021 and 2020, respectively, and other postretirement benefit plan net gain of $473 million and $391 million at December 31, 2021 and 2020, respectively, as well as pension plan prior service credit of $190 million and $255 million at December 31, 2021 and 2020, respectively, and other postretirement benefit plan prior service credit of $181 million and $244 million at December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzg4Mw_f0237706-6413-444f-97d9-f9680f39f53b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in each component of other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.903%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2019, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,922&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,383&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;410&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,769&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,756&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Spin-off of Organon (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;449&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Primarily relates to foreign currency cash flow hedges that were reclassified from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 14).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes pension plan net loss of $3.6 billion and $5.4 billion at December 31, 2021 and 2020, respectively, and other postretirement benefit plan net gain of $473 million and $391 million at December 31, 2021 and 2020, respectively, as well as pension plan prior service credit of $190 million and $255 million at December 31, 2021 and 2020, respectively, and other postretirement benefit plan prior service credit of $181 million and $244 million at December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67716ab8d95d41c1918c1fd2f92b31b0_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtMS0xLTEtMA_78f8df45-6bf7-4b5c-ad06-4d332756f6cc"
      unitRef="usd">166000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53553e2c388c408a80697cd5600f2014_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtMy0xLTEtMA_3e2235a6-417c-463c-ad64-70fd2dd11e60"
      unitRef="usd">-78000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a24da076c044d1fa1d2d467928316c3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtNS0xLTEtMA_2b93ea78-f594-4fa5-bd4c-1a9b7750b22d"
      unitRef="usd">-3556000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2d1a929ea734ccb8df8f7b64219510e_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtNy0xLTEtMA_5394e905-e029-4a74-b5bc-26567195f784"
      unitRef="usd">-2077000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd9336867cce49919c9a776ee62bc1b2_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEtOS0xLTEtMA_bc043dc3-150a-4f40-ac4c-e8401413fae9"
      unitRef="usd">-5545000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItMS0xLTEtMA_72cf5024-760a-484d-9567-ca69e017c223"
      unitRef="usd">86000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItMy0xLTEtMA_c5f2eecb-a494-4459-a002-67a0df8e5e76"
      unitRef="usd">140000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItNS0xLTEtMA_a60d98eb-1ebc-4ea2-a774-21611d636e9b"
      unitRef="usd">-948000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItNy0xLTEtMA_3d9324b4-6fae-45d3-87ae-dc1bfc44b21d"
      unitRef="usd">112000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzItOS0xLTEtMA_edf9b032-ffc7-4286-a37a-797b1da0af19"
      unitRef="usd">-610000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtMS0xLTEtMA_000f91df-355f-4fc8-bf55-b05e31454f11"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtMy0xLTEtMA_e853b3e4-8a2a-4f80-99b7-e9387c7160c1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtNS0xLTEtMA_bb6708c3-2f3f-430f-8eac-4801e1c2b7c6"
      unitRef="usd">-192000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtNy0xLTEtMA_e871b54d-8998-485c-838a-8c9f4d50bebb"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzMtOS0xLTEtMA_a8d48722-aebc-4c3f-a3d4-c6ea56aafb6d"
      unitRef="usd">-161000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtMS0xLTEtMA_cf1822bf-9051-4629-a7f0-f428153588c9"
      unitRef="usd">71000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtMy0xLTEtMA_0635beec-22de-41ed-852b-2aa208d26237"
      unitRef="usd">140000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtNS0xLTEtMA_da5ddfb3-026c-4708-9d4e-d3009bdb5fc2"
      unitRef="usd">-756000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtNy0xLTEtMA_5a479b89-1320-4faf-9189-7e630b7a8bfb"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzQtOS0xLTEtMA_18dcfb75-393f-4d98-b2e7-808a92cd8bad"
      unitRef="usd">-449000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtMS0xLTEtMA_6c5002bc-50d1-4872-bbbb-ad1a769d01f1"
      unitRef="usd">261000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtMy0xLTEtMA_a2fe5085-f6a5-4694-85f5-2e278806e5c0"
      unitRef="usd">44000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtNS0xLTEtMA_7800263b-33fc-4685-bf21-905b2f99dc38"
      unitRef="usd">-66000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtNy0xLTEtMA_21affa4c-203b-4b4f-b8c2-5796999961ba"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzUtOS0xLTEtMA_63b5f7e6-3a76-46d3-b815-1e1839da4a84"
      unitRef="usd">239000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtMS0xLTEtMA_f1578265-1e5f-4580-8faa-f1bebba37bf2"
      unitRef="usd">55000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtMy0xLTEtMA_b09f705f-6ae0-47a5-8902-06b141fc77c7"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtNS0xLTEtMA_285ef4fc-4c82-43d6-9bd5-18dcef39be0f"
      unitRef="usd">-15000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtNy0xLTEtMA_81453916-fff5-4471-9683-05bce24f88b6"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzYtOS0xLTEtMA_2c04ceff-9e2d-4a58-88d7-c3bd7d2da359"
      unitRef="usd">40000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctMS0xLTEtMA_e442fc1d-6532-4d7d-a0d9-7ba359fa51fb"
      unitRef="usd">206000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctMy0xLTEtMA_e12569ee-c68a-457f-9a73-e14ec6b291eb"
      unitRef="usd">44000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctNS0xLTEtMA_96a7679a-e4f0-4ebf-a7b0-aa641ec1ba54"
      unitRef="usd">-51000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctNy0xLTEtMA_3210f7fb-bd2c-48be-aa39-4b8d1d6f6cc8"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzctOS0xLTEtMA_bb54e9ec-d263-4e8d-9549-2f8352628c86"
      unitRef="usd">199000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9173ec988cdc4f45a02518f13ed9382f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtMS0xLTEtMA_c4d807d2-5947-44e6-a788-fe86c267e7fa"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifae88c9d3d7f45e783bc0099e84b590f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtMy0xLTEtMA_a8242371-fefd-4538-84a7-667e3f234df9"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2c5ae9f573574b7f958f12a3ffa519ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtNS0xLTEtMA_678fc666-0e2d-4f6b-9b2b-03012154f659"
      unitRef="usd">-705000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if85f1bf2149b48e282027711d3cac1e3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtNy0xLTEtMA_ba51b495-7578-4fff-a534-9901326474a2"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzgtOS0xLTEtMA_b964b7a4-1c49-4fbb-a07d-7ddfb07a3c29"
      unitRef="usd">-648000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e3b8b15d7e64a8f9877988ce4a10017_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTEtMS0xLTA_c3104c33-d764-467d-a18d-7822129f29dc"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i125b2cdaed7c4239afe4d7fce006c0b6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTMtMS0xLTA_657e7102-d90a-4c0d-a6a0-5e9dd4fe2df1"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c54f5a5a29a410190d2348b3cb74190_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTUtMS0xLTA_fcb78633-2dd7-435f-a82e-7fc143a965ff"
      unitRef="usd">-4261000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice3199f2dd06439293c869fd20ba1ae5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTctMS0xLTA_974d9670-3dee-496b-9fea-3d5ad892b1cd"
      unitRef="usd">-1981000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a458b3d31d042a4bb104dc181064e79_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzEzLTktMS0xLTA_6f2e51b4-52a2-4195-ad71-84d606a01685"
      unitRef="usd">-6193000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTEtMS0xLTA_3643a781-96b9-4a46-a982-f42fb9012d19"
      unitRef="usd">-383000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTMtMS0xLTA_1c22251f-804f-47db-8bc9-389a96fa84bf"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTUtMS0xLTA_db35597c-9bc4-4aba-bb33-b15ad48e9375"
      unitRef="usd">-599000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTctMS0xLTA_23e86e10-171d-40d6-af8f-cd7477bc7a22"
      unitRef="usd">64000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE0LTktMS0xLTA_c62f67bb-79c0-43de-8ed5-c8e597238cf0"
      unitRef="usd">-915000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTEtMS0xLTA_154539e0-47db-406a-bc45-09052720bb6f"
      unitRef="usd">-84000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTMtMS0xLTA_e12785a9-84d5-4e26-b098-f8148ac7aa0e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTUtMS0xLTA_86e8be02-cbb4-42f1-90ae-5b214b4727a5"
      unitRef="usd">-111000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTctMS0xLTA_b6289a5a-4829-4fc3-96b8-460adb7b6196"
      unitRef="usd">-89000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE1LTktMS0xLTA_28aab6c3-0b30-4d4b-a3a4-ee6cd033bc75"
      unitRef="usd">-284000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTEtMS0xLTA_29faf566-eb0b-4ca2-8ce9-a9e5fc6c4b6b"
      unitRef="usd">-299000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTMtMS0xLTA_92d3f5f7-d610-4288-897d-2ed5f43a9158"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTUtMS0xLTA_f9aa1777-9136-416f-80b6-809ee0aa465a"
      unitRef="usd">-488000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTctMS0xLTA_ea772fc7-baa5-4061-9a74-102f1cbcf423"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE2LTktMS0xLTA_f560f966-d0d5-4ef2-8f24-e314a7d123ee"
      unitRef="usd">-631000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTEtMS0xLTA_fd1636f6-720a-4898-b81b-b0eb7a4624da"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTMtMS0xLTA_a9710a99-70a5-4b98-857f-622e0e8cdabd"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTUtMS0xLTA_e89e1d0c-f94d-4764-9f67-160b264bcca2"
      unitRef="usd">-272000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTctMS0xLTA_f18a7278-d0c1-4bfe-8eb2-3553e9b57d5b"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE3LTktMS0xLTA_b5cfdbca-9c57-4774-903a-0925c399b001"
      unitRef="usd">-253000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTEtMS0xLTA_563cb772-14a6-4009-9a19-a4f30750125a"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTMtMS0xLTA_24edc921-6f51-47c6-98fc-d568f3d139b4"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTUtMS0xLTA_3dba9e0d-52a6-4149-aa72-af41222f09d6"
      unitRef="usd">-63000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTctMS0xLTA_6aead144-35b2-4228-8e17-3a6dc895a728"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE4LTktMS0xLTA_7423628d-7ad5-46b4-930f-6ffc182bd13a"
      unitRef="usd">-63000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTEtMS0xLTA_2f1fd112-d46f-4829-ab09-c7cd5add1fea"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTMtMS0xLTA_44fa7876-ca6a-452c-a180-b869b74730a2"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTUtMS0xLTA_f33cea2e-c1c8-4559-b24b-4b4eac1474c3"
      unitRef="usd">-209000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTctMS0xLTA_94c7dcc8-07be-4eef-948b-5c03767aa2ad"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzE5LTktMS0xLTA_cc1622bd-79a4-4eb9-908b-57d6a71dae85"
      unitRef="usd">-190000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib83101efb98444978fff619393569f09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTEtMS0xLTA_1427a760-8854-4865-a5f6-c64ac06e4458"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3e64bdf883624544a35fdd92827fb92f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTMtMS0xLTA_c386931d-93fb-4173-85d5-ba7c3d489f0d"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i144b086740d64654bd9a30061c1a7812_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTUtMS0xLTA_e7afe2fc-1474-4e62-8c8c-5727cda5a3ce"
      unitRef="usd">-279000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i51564faf2000464284c4a9cae610de81_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTctMS0xLTA_0c091807-5ee4-40f8-a85f-a26aeee5f1b7"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIwLTktMS0xLTA_66c16e03-dc53-40c6-8599-9851a09acf27"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id16d9426fdca4a16a4bd46315c4d4084_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTEtMS0xLTA_869c15c1-f68d-4ea3-96ff-0db7e43d40bd"
      unitRef="usd">-266000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4063360a866a4d7484c9f7904b09eb53_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTMtMS0xLTA_dd05d0b3-25a9-4731-a7f6-ca2db73ea229"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6168466248344c884d7d9bc139939b7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTUtMS0xLTA_20fda646-b0f6-496c-ae4b-8a95be8f1202"
      unitRef="usd">-4540000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i615fa016c2ed4e2383a651cb2aab2822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTctMS0xLTA_9c21e43e-06d0-4f2e-b43d-560f19f1096c"
      unitRef="usd">-1828000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d1f8e2c09b84254b99b8e105564e52b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIxLTktMS0xLTA_654baa7a-9d6c-4aa5-816f-180c594fd015"
      unitRef="usd">-6634000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTEtMS0xLTA_56126825-6d76-4adb-9996-49c1cf9b4a69"
      unitRef="usd">333000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTMtMS0xLTA_deb5f48a-77bb-4123-a6eb-506b3bc94fa0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTUtMS0xLTA_9db1b2cd-5bcf-451f-b8a1-849883d9e18d"
      unitRef="usd">1922000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTctMS0xLTA_d807e7a8-f51e-4006-b32c-0512074da53b"
      unitRef="usd">-304000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIyLTktMS0xLTA_feb80543-c985-4032-9203-5db8ea3cebf4"
      unitRef="usd">1951000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTEtMS0xLTA_044e26b4-03f9-4d12-9ee8-cb94af3941ca"
      unitRef="usd">75000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTMtMS0xLTA_dda6de81-3a39-4ddf-afcd-f161856214f9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTUtMS0xLTA_83cfc017-daff-466e-a7c5-5e183f3df7db"
      unitRef="usd">374000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTctMS0xLTA_3729d69e-4980-4e91-9728-ff1fc1aafaaa"
      unitRef="usd">119000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzIzLTktMS0xLTA_6527a93f-2047-49bf-a4f2-54a626fb8147"
      unitRef="usd">568000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTEtMS0xLTA_54e2e12f-6b5c-4efe-a65f-195d061f525e"
      unitRef="usd">258000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTMtMS0xLTA_705cdf35-da43-4697-9624-0ca8229f7490"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTUtMS0xLTA_e46f1050-c5ed-4b24-8746-426ba8c5f370"
      unitRef="usd">1548000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTctMS0xLTA_c10aab31-f8ab-4ead-8b3a-1067072d0a49"
      unitRef="usd">-423000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI0LTktMS0xLTA_8575c02c-1f22-4346-afbc-4740e215880c"
      unitRef="usd">1383000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTEtMS0xLTA_3cce5baf-e290-4ed5-9f39-7e82251271ff"
      unitRef="usd">-192000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTMtMS0xLTA_870432c4-6fee-4d9c-bc53-459d07d9321a"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTUtMS0xLTA_ff02d74b-458b-490d-8b91-e43532e2841d"
      unitRef="usd">-281000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTctMS0xLTA_9bd1fac1-64e9-47df-91fe-8a1a9c2418e3"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI1LTktMS0xLTA_07454ec0-0b71-437e-8b1e-5345b6501022"
      unitRef="usd">-473000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTEtMS0xLTA_dec82d33-a460-48a7-9cd2-49c7e0a61720"
      unitRef="usd">-40000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTMtMS0xLTA_4d83fa8a-9a5e-4ee6-b82c-3e4e7fd6a720"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTUtMS0xLTA_f3864d89-0b08-44ef-bed9-75b3923ef592"
      unitRef="usd">-60000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTctMS0xLTA_5dc209bd-5174-46f2-b96a-a680aa593543"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI2LTktMS0xLTA_772a7db9-772c-4ca0-9689-2acf2bea59de"
      unitRef="usd">-100000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTEtMS0xLTA_978cc457-84ef-45b3-a181-7d7db4e231b0"
      unitRef="usd">-152000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTMtMS0xLTA_54d6b99a-830f-4312-a81b-f17cfb22fff6"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTUtMS0xLTA_4e37128b-0e60-40a3-ab86-ca2e83c56486"
      unitRef="usd">-221000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTctMS0xLTA_b0112a67-821d-4ef2-b954-c625baef60b9"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTktMS0xLTA_cf203b4a-7f50-4db7-badd-3f15e54eaa03"
      unitRef="usd">-373000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTEtMS0xLTA_199cf0a4-da60-46f1-b23a-e37aafb72e43"
      unitRef="usd">410000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTMtMS0xLTA_2547ed7c-2d15-4e12-95f3-af190b97850d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTUtMS0xLTA_7b9fd023-09cf-4ad6-9839-ea9b16b727c4"
      unitRef="usd">1769000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTctMS0xLTA_13ea3c1d-1945-47fd-9308-29ce3a1a8275"
      unitRef="usd">-423000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI4LTktMS0xLTA_a588a368-a852-4f67-907c-5694225f0601"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i7fb921df5a3344479ba1d43d9830762c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTEtMS0xLTIzNjc_ceb4c190-225b-484c-a17d-77cddbebaf91"
      unitRef="usd">0</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i42284bdc14ed44d2aadb1f4b24061db8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTMtMS0xLTIzNjc_8b825570-96b8-47ad-9f50-ffb37a8976e9"
      unitRef="usd">0</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i468f8965c2154e51b7ca705eb4ab6f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTUtMS0xLTIzNjc_9c2bc582-6fb5-4398-bf3c-6fc02a7710c2"
      unitRef="usd">28000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="id3d68cbedc5b49459dc41e3627a11e87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTctMS0xLTIzNjc_eb12cea5-07af-45c1-bdaa-c9700f24feb8"
      unitRef="usd">421000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i52711b1bf6764fd78c0ef6f9e7df950f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI3LTktMS0xLTI0MTM_abc4959d-2ccb-4ec0-bbbe-a1a0aabfcf79"
      unitRef="usd">449000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id92ec4a36cf94e91ae66e6a887ecd413_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTEtMS0xLTA_112db5e6-85aa-4786-8570-2e0321c4a334"
      unitRef="usd">144000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i192fe0af931a48ed803ea8f1c256afe9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTMtMS0xLTA_8effd6fc-387b-4fc6-bde4-f624af069335"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf472479cca849d1b21d8c0dc0ed9d69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTUtMS0xLTA_052602ca-04fc-4e5f-b900-72bbc8387cef"
      unitRef="usd">-2743000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb6c7a465398473797dd31962d89b8c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTctMS0xLTA_512c3d43-76e8-4cfc-85cf-d46622e8fc27"
      unitRef="usd">-1830000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i333ee6c0baa94ce7a67cc850a8d3a772_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90YWJsZTpjZWQ4NWMwMTM0Y2Y0OGZkYTkxYjg2YmU0OThhOWZiMS90YWJsZXJhbmdlOmNlZDg1YzAxMzRjZjQ4ZmRhOTFiODZiZTQ5OGE5ZmIxXzI5LTktMS0xLTA_3af9b8b4-42ec-4643-aedd-5370b8607724"
      unitRef="usd">-4429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="id9f5696787284d468844d796e307282b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzUxNQ_6f8c008f-9025-483a-8111-31de57de552b"
      unitRef="usd">3600000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i306e82501fa8410bb91080177d50d682_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzUyMg_02d88d9b-c021-4dbc-b5b5-2b288176794d"
      unitRef="usd">5400000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="ib425c1e1a40c4df8944d884d3d307ad0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzYxNg_3a35ecd1-13ab-47ee-af11-7c6b8b5909de"
      unitRef="usd">-473000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i924ea9183ae449d796b1a0a7b05f0e67_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzYyMw_35188569-0527-42c6-9955-00abe0f283df"
      unitRef="usd">-391000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="if225d2f0b77c4d51944e158ac6b67edc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzcxNQ_d1fde680-352e-467f-adbf-22548a0464cf"
      unitRef="usd">-190000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i4a311768e0b74998947f7049aaba9c79_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzcyMg_7262ae94-f656-4cfb-910b-4b1256fcf855"
      unitRef="usd">-255000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i8de7afcf6cd04006ba705dd72d2915dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzgyOA_5738e142-8e94-4798-9af9-862c852ea20f"
      unitRef="usd">-181000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="ia855c9dc8c7e44ce9dc6bc2b51ed6d1c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTYvZnJhZzoyOTE3ZDRjZjQzMWQ0MjI4YmI3NjliMzhjNzRhZWZlYS90ZXh0cmVnaW9uOjI5MTdkNGNmNDMxZDQyMjhiYjc2OWIzOGM3NGFlZmVhXzgzNQ_f9fb6998-bc9d-4f45-8ca2-d08b7eedd8cb"
      unitRef="usd">-244000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NjI_f3800733-aa45-4e42-bcfd-4d4879b18796">Segment Reporting&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operations are principally managed on a products basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S.&#160;government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2021, the amortization of intangible assets previously included as part of the calculation of segment profits is now included in unallocated non-segment corporate expenses. Prior period Pharmaceutical and Animal Health segment profits have been recast to reflect this change on a comparable basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,765&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;417&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,792&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R II/Varivax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;506&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;334&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;807&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;179&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;770&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;370&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;825&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;825&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Molnupiravir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress HD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;474&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;769&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,324&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;367&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,964&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;42,754&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;36,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;17,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;34,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;667&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,628&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,758&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,568&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other segment sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;26,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;48,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;19,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;21,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;38,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;382&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;26,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;48,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;19,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;21,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;39,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales (including sales to Organon). Other for 2021 also includes $185&#160;million related to the achievement of milestones for an out-licensed product that triggered contingent payments to Merck.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;48,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Continuing Operations Before Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30,977&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,950&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,927&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#x2019;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity loss from affiliates and depreciation included in segment profits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, by geographic area where located is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,759&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;857&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzExMg_7275f4f7-3683-45e4-961b-f351e907f254"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NDY_f8f7e7db-ff52-4df2-922b-5feab041fbd6">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,765&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;417&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,792&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R II/Varivax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;506&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;334&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;807&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;179&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;770&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;370&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;825&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;825&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Molnupiravir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;632&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress HD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;474&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;769&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;312&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,324&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;367&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,964&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;42,754&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;36,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;17,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;34,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;667&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,628&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,758&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,568&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other segment sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;26,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;48,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;19,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;21,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;38,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;382&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;26,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;48,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;19,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;21,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;39,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.71pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.53pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales (including sales to Organon). Other for 2021 also includes $185&#160;million related to the achievement of milestones for an out-licensed product that triggered contingent payments to Merck.&lt;/span&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="ief0fabdbe30d4ec8b1cd71e2cd64c3ea_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMS0xLTEtMA_2023e1e5-c3f3-4f3a-9549-eb987d8c2f66"
      unitRef="usd">9765000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03c80f2ba2ae4750bb0b2f180be80c68_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMy0xLTEtMA_49cbb339-6d2b-405a-85bb-9268f5043dac"
      unitRef="usd">7421000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a1ce584193c48a6b0103a7644f7ef6f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtNS0xLTEtMA_8b6c5fd1-8653-48c3-a5e9-5de96838cc65"
      unitRef="usd">17186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic54db7d5cebb4ef48b74f960b41c1c27_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtNy0xLTEtMA_4e2ddb3f-8b24-445d-be80-087b3b52d4b5"
      unitRef="usd">8352000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5639e6827db9445ca99ec3429d38514b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtOS0xLTEtMA_a203dcca-9b25-4826-87b7-144849ad7409"
      unitRef="usd">6028000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i585f62c2af3048dab19b2ccec8904d68_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMTEtMS0xLTA_bb61f92d-d098-4379-ad0b-01d702eb0b8c"
      unitRef="usd">14380000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i118a055047184fcfaf92090074d7ad4b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMTMtMS0xLTA_bbbaeaed-20da-48b0-95b0-c62da0636e08"
      unitRef="usd">6305000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ed4f4d9b9f84b11afd909432b51fa6b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMTUtMS0xLTA_c8757595-a51c-4167-ab88-f90c1ebc70a1"
      unitRef="usd">4779000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7ee5ac9fe1248559264115ca0ce8e31_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQtMTctMS0xLTA_9a527e6d-5dfa-466a-86a4-2e4bfe3bd359"
      unitRef="usd">11084000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38ca7fbd199642df8e35c5b087f2f181_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMS0xLTEtMA_feaa0080-34fd-4f86-b389-1b858a4d4fb3"
      unitRef="usd">515000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i412a988a09de489e882e0bf3f1cdad5d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMy0xLTEtMA_0eeaa648-38c0-42a6-971d-d10916fff983"
      unitRef="usd">473000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9b7bca2629345b48bdf4ab1a9cc002a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtNS0xLTEtMA_75f4feb1-23ea-481f-ba4b-2a1eea5599ae"
      unitRef="usd">989000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58b89ac54cd84d5f97104114e72eb401_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtNy0xLTEtMA_3653dc79-35c0-4a26-8138-1001f02b6be8"
      unitRef="usd">417000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iacf7482af6de46c1b860e27aaab98d93_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtOS0xLTEtMA_d3a220be-b10a-4d80-ab1d-f3af87ba5444"
      unitRef="usd">308000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6dcf9b8bc9de4148a0ee6c3a5a6f2815_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMTEtMS0xLTA_a9a1b3cb-7568-4060-b924-371d77ce7595"
      unitRef="usd">725000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2464e70d7ef4f7bb40db6173462adaf_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMTMtMS0xLTA_8aecd1ae-ec8f-4917-968b-743f837277c2"
      unitRef="usd">269000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d5e11e3ccd6431c909fb49ed639bb98_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMTUtMS0xLTA_5b0ddba3-22a9-4041-b34e-17d4bb5e1164"
      unitRef="usd">176000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3890b29d4919406994442f1b5b0164b3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUtMTctMS0xLTA_62ff1306-018f-439d-8195-4d7f2c7dc758"
      unitRef="usd">444000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i126a4a0ccf3f40efaba2835b745502dc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMS0xLTEtMA_035f1ac8-d5a8-4675-88de-4b90cac26f19"
      unitRef="usd">417000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifec348f46f8349989fde334c3a0e6693_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMy0xLTEtMA_4d22b1ab-fb14-4909-ba8e-a120fee622a1"
      unitRef="usd">287000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie62a9ffa2b864eba96a15816fc03a298_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtNS0xLTEtMA_604f3cb7-6a6b-48e3-a1ca-0554763b8394"
      unitRef="usd">704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96bd5d4591c74fc59a16a07549d1b809_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtNy0xLTEtMA_02c158e5-0e09-4809-a83e-5feacef2ff1e"
      unitRef="usd">359000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iedd13c82855e45e18ee1bcb4674461b2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtOS0xLTEtMA_11c9c59c-a7ca-4719-aaa6-834945a8b0a6"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48dea599db224c139d74cfb868f7ca31_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMTEtMS0xLTA_f777ea12-f713-4c35-85ca-dcba2aeac99a"
      unitRef="usd">580000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if671aaa852bb4d1cafc2487adea83e34_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMTMtMS0xLTA_b0f52d91-ae87-4b63-a71c-22b0741d0df5"
      unitRef="usd">239000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06e29a49f9e146509c3cb1014ab81958_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMTUtMS0xLTA_0faf800e-689a-4dd1-96d8-b23106f7b4cc"
      unitRef="usd">165000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idbecde3516774ea4a214f44d642a3ea4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzYtMTctMS0xLTA_4e0187fa-baca-43f3-b193-29bfb52717e1"
      unitRef="usd">404000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30ab7314f4724a408939aecfacc08cdb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMS0xLTEtMA_a0c02f82-0988-41da-b15a-4fb9400af231"
      unitRef="usd">1881000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67504f9dc2414b458ecaaf3418bf800b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMy0xLTEtMA_6a617470-6f6e-4142-a89a-3aa1850716f6"
      unitRef="usd">3792000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7410d9a99f3144d289bb5915b56f611f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktNS0xLTEtMA_4a4fed8d-78d0-4930-8f7a-64304d35cc1c"
      unitRef="usd">5673000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30070b5abd3a408f95c70d3b9328afa1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktNy0xLTEtMA_c529768f-a6af-40d9-a068-e96cfad68825"
      unitRef="usd">1755000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c07bfb932384999b083744d5271f56b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktOS0xLTEtMA_71c5f6a8-9400-43c8-b799-9095c808dad0"
      unitRef="usd">2184000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d896fcb2b074166b1af7ecd1df7ecc5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMTEtMS0xLTA_7ffd458e-ca35-4d00-8bba-d124edf1bb5b"
      unitRef="usd">3938000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4449be5f9f4d4dd7bb5f71f197d1195e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMTMtMS0xLTA_92fd14c3-2f26-4274-910a-88bc17f0f0a4"
      unitRef="usd">1831000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia24b2aefb0cd4d1b92b0312679c47a00_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMTUtMS0xLTA_8f2e292b-c18c-4230-9cd0-e32f705f8d0c"
      unitRef="usd">1905000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18ad66ab734b47e3b0b68f6d3ecd75cf_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzktMTctMS0xLTA_66dc82b9-f77b-4b4f-9a41-e9db0dc23d97"
      unitRef="usd">3737000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i092a9a3dd77c432aa3fd0dfe58c9fc24_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTEtMS0xLTA_cec6b7a4-4422-4bf1-8102-bc41f9c08168"
      unitRef="usd">1629000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifee03932a98f4e90a47a62b45b98473d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTMtMS0xLTA_f4d11897-3ef7-4909-b307-6bca7846fe31"
      unitRef="usd">506000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f84682c651e42369b0be205d5dc544b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTUtMS0xLTA_64ac0ef2-af1a-4d9d-9132-90a492023298"
      unitRef="usd">2135000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d55e46f9c6a4d77998096a6a91e85c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTctMS0xLTA_5307674d-139e-4d11-b8a3-8bb843ea0c5a"
      unitRef="usd">1378000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69815c97a5284f8892611939d8f5ebb7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTktMS0xLTA_70b152b7-9839-4772-894a-3161fcd5b3da"
      unitRef="usd">500000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8887b54a6020401cafc8b73bf4852968_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTExLTEtMS0w_fdd886ad-8186-41d8-82f5-e783fa3dc039"
      unitRef="usd">1878000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc8d5492cb544bc9894b3d738712a155_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTEzLTEtMS0w_71955305-116f-4c64-99f0-ae07eec6b7ec"
      unitRef="usd">1683000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8f17a778d3d46d6a0f56138bb37401e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTE1LTEtMS0w_f253c968-8ef7-4b34-b862-a7e40b18b226"
      unitRef="usd">592000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f8600b39d154c5299e9b719a4e65eff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEwLTE3LTEtMS0w_8fa5ea7c-baa1-49f7-bf67-d2d2b39eebfd"
      unitRef="usd">2275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f6ea600d207424d9ebdc43381b8d663_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTEtMS0xLTA_1feaea23-2a14-464a-9a49-33713223adbf"
      unitRef="usd">547000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb046a0ba0c04045b30d5722effaafb2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTMtMS0xLTA_faabc7fa-6621-4352-a32c-5a3e06ba32f1"
      unitRef="usd">346000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae5bfe0049f14a07b613d265fd540357_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTUtMS0xLTA_ab0e57e4-4886-4331-9e02-2afcf97b3460"
      unitRef="usd">893000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i350b1e0896d840898c101f9718c2c2f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTctMS0xLTA_4ecd1211-8bb7-4488-9a9d-954be8e5bcf4"
      unitRef="usd">727000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdcd82740163451e95d5ef31c1a6f103_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTktMS0xLTA_e65fdb24-ad6d-43c1-8222-281e1c9cb87b"
      unitRef="usd">359000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie59e38a3f1f14f8c99ea483759e328a1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTExLTEtMS0w_4cf408e0-621b-4715-b108-d4094bc967fe"
      unitRef="usd">1087000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iafb83f4e70884ababc7ef0c9ff8f1f20_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTEzLTEtMS0w_3f600018-984f-4963-b976-acb614cd75ef"
      unitRef="usd">679000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3921cbd5aeac4547b3df48439ab8f6d2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTE1LTEtMS0w_2a9ae10d-2b14-4d70-861a-173fd8f00bad"
      unitRef="usd">247000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9ce69f481d241f28a3dee75585ddbbc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzExLTE3LTEtMS0w_ffe37423-1874-4589-8075-875f113b1eca"
      unitRef="usd">926000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbceb0e389804da8ae6d0759d4119f73_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTEtMS0xLTA_1be814dc-c6d8-4aa3-99c6-fd4a9b629565"
      unitRef="usd">473000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14e8ffa354eb405b9df85f225faa97a4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTMtMS0xLTA_421821e7-48b7-41f1-b03f-58b4d596c635"
      unitRef="usd">334000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6825addbac14de89b7448f21f1dbe0d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTUtMS0xLTA_40ff43f1-b338-4bc1-9b0d-27d841db38e4"
      unitRef="usd">807000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7528d7d63d24a0ebc48ba15ef1742c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTctMS0xLTA_3b6fe149-744e-4daf-b997-a89ab64f5fc7"
      unitRef="usd">486000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3e69f638636462c981930e509c9d3c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTktMS0xLTA_1c98dc41-1290-4821-a462-8f0dd7c14eb7"
      unitRef="usd">311000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17a52444ed7149d9a832be8c913ccfb2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTExLTEtMS0w_c9f212ec-82cb-49ce-b351-66e5211a726c"
      unitRef="usd">797000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2262179634dd4d6eb718ea17322c0302_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTEzLTEtMS0w_a828c0a4-9fb7-401b-9aa4-f2daada67f52"
      unitRef="usd">506000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i290541092ab24a35bbac3de5b7d6757f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTE1LTEtMS0w_7c34079b-846c-4992-af0e-96c229106364"
      unitRef="usd">284000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9cb120af06d848bd9bd55575768c0454_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEyLTE3LTEtMS0w_66a956b7-19d4-4e82-a344-c340553e487c"
      unitRef="usd">791000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie68cf814d8754d468098e25c4faec59e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTEtMS0xLTA_e20be0b0-873f-4491-bb72-7bf32988a163"
      unitRef="usd">100000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec491afd16ff4fe9ac6ba8cce69bdefc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTMtMS0xLTA_afc0b605-19ca-4f13-ab42-bb0cb3d16dde"
      unitRef="usd">79000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3727a4b434224ffab2d1dd6ab2a31446_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTUtMS0xLTA_9a2efce4-4110-465b-aedd-1fec628a9e82"
      unitRef="usd">179000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie09b13d69e694ea999debfb5ba7aa578_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTctMS0xLTA_f92c10ea-bddd-43d5-9ab2-c31d59fb4d55"
      unitRef="usd">103000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic347c94c641d49f6b9ce87d0eac2090f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTktMS0xLTA_45d3d6f3-7bc3-4c3a-81fc-1935bccfc4b4"
      unitRef="usd">67000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6d75f1dea9e4e668d532d7b2c10b2e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTExLTEtMS0w_3970e9ec-c0ad-4b9a-b88e-ad202c1f3167"
      unitRef="usd">170000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ec4b2a3d76b4364b2d56779a19fa6ca_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTEzLTEtMS0w_7500b37f-54d8-49b1-8d62-ff73d693543e"
      unitRef="usd">130000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i43bc6db40c0145fa82725faf6c749c89_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTE1LTEtMS0w_fa184d36-7e64-4ecd-ae9f-038bef31b124"
      unitRef="usd">108000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if76ee5e9706c4379b1703add36dffafe_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzEzLTE3LTEtMS0w_c0686b37-3e37-4449-9045-7bd2f764c30e"
      unitRef="usd">238000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ddb209f66734519ba2f0f9440875f4c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTEtMS0xLTA_3e051995-2b2d-4c83-a4a4-62524b69dee8"
      unitRef="usd">762000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i287f086f0a1348718abecee8bf3fbdbf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTMtMS0xLTA_c468dbab-8735-489b-8cf4-141cdf8cdf1d"
      unitRef="usd">770000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d92ef43e74548739e46fef213a2b691_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTUtMS0xLTA_1d00473f-4efe-4c04-ac7a-f756e6d347f7"
      unitRef="usd">1532000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96a4d1d25cbb48a890bf52a4c3b2ce24_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTctMS0xLTA_fd2a1a1e-aeb2-43e8-8427-40208fb7fa82"
      unitRef="usd">583000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c9956b24fe747cead1ba231ba98dfdc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTktMS0xLTA_59eb50e1-c1ed-4f0f-a37d-2581357381fa"
      unitRef="usd">615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i621acda9e95e42d49d9d543db91d4937_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTExLTEtMS0w_758fcbf0-33e1-477f-a03e-21bad4230b24"
      unitRef="usd">1198000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4146bb447d743da9ee890800435e8b8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTEzLTEtMS0w_f0667ab5-f47b-4971-8717-77690caa5e33"
      unitRef="usd">533000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e080a31cc484b33b1889bec0d989641_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTE1LTEtMS0w_a8cf54b9-8f12-4bf2-8607-63557407376f"
      unitRef="usd">598000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f25ff9318914fa99b0b7fc3b0911f02_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE1LTE3LTEtMS0w_a501c29f-eaa7-4b52-b7a2-d688b7d01794"
      unitRef="usd">1131000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc9f572a206f4619a83415208462c648_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTEtMS0xLTI4NjM5_b7b3d68d-0f0c-4f56-aace-846ce289577b"
      unitRef="usd">153000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib14128500dc8496a9a941b07e7570826_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTMtMS0xLTI4NjM5_25d5792c-0717-4ab4-8a31-bd5c7879b9f2"
      unitRef="usd">218000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i24b4e19b01d14af2b9e7a5be87b0ba14_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTUtMS0xLTI4NjM5_05b40543-a66c-4985-a260-e4751e1492b0"
      unitRef="usd">370000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i680941386a504ccaa708270ef21bba50_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTctMS0xLTI4NjM5_9fcc539e-5274-4856-8088-846d3f0e74d8"
      unitRef="usd">119000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3351be1b9677432389243aef036d0f4e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTktMS0xLTI4NjM5_1fd003cc-8212-4a56-ad84-0274542452b7"
      unitRef="usd">162000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7339a2912de4accacec0a80f0cbde96_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTExLTEtMS0yODYzOQ_aac62bf5-2d23-406b-b5d7-eb4f82651c2b"
      unitRef="usd">281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2c9827e87644e79a48ea79d80420a22_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTEzLTEtMS0yODYzOQ_233ca8b6-3d8a-4c4c-9eb2-276571c51c23"
      unitRef="usd">84000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99ea00653e9e4cee964d9489c3bd0732_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTE1LTEtMS0yODYzOQ_a1f7b768-2f50-4514-9156-73d1c831b335"
      unitRef="usd">81000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26d42dde9fe44012ad67da4ad05352c6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTE3LTEtMS0yODYzOQ_72ef2105-1801-46d1-b215-727935f97b06"
      unitRef="usd">165000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5022ef10f96e4b7aa61a055fd68efe83_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTEtMS0xLTM2OTE4_cd7fd218-9fdf-44e2-9337-ed9bb952a3e3"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icef9b40b31044eefab0cf6ddf301bf11_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTMtMS0xLTM2OTE4_a03a92cc-1c6b-4ebb-9972-65570a826a71"
      unitRef="usd">258000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6cc9260dfb142b3ae1b4e51b2636178_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTUtMS0xLTM2OTE4_6d0f47c3-9deb-4040-b3f6-e1e85b742e45"
      unitRef="usd">259000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2985d0dd5ea145ce8d2f0ef7df6b36cc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTctMS0xLTM2OTE4_91a35130-2db2-4251-aaf1-eeed300c4dd5"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c0ac23a8c384de6a68683e097588935_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTktMS0xLTM2OTE4_0411bfa8-5d51-44b1-98be-ae69b56eb842"
      unitRef="usd">248000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica9555c3b16d4029b0bdd2a58b8ca117_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTExLTEtMS0zNjkxOA_b9f47a10-e85c-4aed-888c-cfdbab0c670f"
      unitRef="usd">251000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0e00b0f2a574b709afc847e290d1f4d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTEzLTEtMS0zNjkxOA_a12d3bd5-da5f-4f8c-91e6-c1d136504906"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifcc00e8952a6492f83da929648c7859c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTE1LTEtMS0zNjkxOA_da44efaa-a0c2-4563-a70f-cca371705217"
      unitRef="usd">271000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bb2f997ceca4c2db0eb415936f392d9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE3LTE3LTEtMS0zNjkxOA_af7d48d4-3eed-4f78-9858-6300d972b8f5"
      unitRef="usd">273000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i588ccd376cce4c459b89838c0dc320a9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTEtMS0xLTA_36efd89b-2fd3-4fea-b175-7d4b1d6d1016"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c2ca26bde454c769f7a36998e53e53c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTMtMS0xLTA_c213e0d0-d24d-49a6-833e-b6d01134fb73"
      unitRef="usd">199000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe6c4413e27f4dbdaed582d92345ee15_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTUtMS0xLTA_356b89ad-ff35-4bae-9f14-fdf5725d0890"
      unitRef="usd">259000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fe52f351a8d4153a56a10fd4e76f488_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTctMS0xLTA_18724378-16c5-4d8b-9fd9-40fbb5ebfbb7"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82d4d56c6b614201adb1944e0e9e1c92_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTktMS0xLTA_5ba280ab-2c64-441c-a68a-044f1a16c831"
      unitRef="usd">287000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i044a677ce7ed4b15a2562a43b2b9abd8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTExLTEtMS0w_d869e81e-d116-4a7d-bf15-c610543134d8"
      unitRef="usd">329000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idbe73e300fe4433fa589eb9c59eef229_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTEzLTEtMS0w_523b1494-524e-4eae-b48d-602f35b3f4d4"
      unitRef="usd">282000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b81951a30894213954768ae743f31a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTE1LTEtMS0w_7adae931-8233-4537-9c15-6ab726321d16"
      unitRef="usd">380000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cd822d77da04087961e1a434edc2bdb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE2LTE3LTEtMS0w_e4fd14f6-d5a7-41b6-87b0-8e6310a6c96a"
      unitRef="usd">662000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i919922d6658d4bf094bffc6057c2d318_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTEtMS0xLTA_c8404977-b8d0-4a3e-9c16-a5dba4182608"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2a5bec58714422fbaf00a68687b7d72_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTMtMS0xLTA_9dd8f5b8-9cc0-40fc-9de3-c58279a5cfb0"
      unitRef="usd">208000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f251d58dc4741a5b4bc331916be0226_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTUtMS0xLTA_842d43eb-b815-40f9-9558-98671ee562b8"
      unitRef="usd">212000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i238867c42030496c888ff5fec0f238f4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTctMS0xLTA_e80a6bd8-09a3-4e15-8e78-d5f06930663e"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic05c8e25b2f143a6a83cd529f6a9edb3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTktMS0xLTA_48d41027-b900-4508-bcf7-485647aba8be"
      unitRef="usd">207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3caea6cd27384755bedf9d283e539fe4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTExLTEtMS0w_db2e91de-600b-4085-8012-06ddd16e4dd7"
      unitRef="usd">213000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie49045b590b94189b3ba82d3341d8dc1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTEzLTEtMS0w_23e88e86-be26-40cf-8772-861714d72d89"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib08607411f484218996fb2684f207c26_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTE1LTEtMS0w_751f6ee0-7fd6-40bd-8c95-a1bbfa00dd37"
      unitRef="usd">242000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57867663740a4d66a1abfa217c854234_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzE5LTE3LTEtMS0w_3907f276-0f5b-4898-9ee8-dde55d056385"
      unitRef="usd">249000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17685f23777c4777b25d05b30847170a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTEtMS0xLTA_d4dd9f29-ef4e-4a2e-b7ee-303939f63471"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if341417b19c14b84884a2711d11c29c4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTMtMS0xLTA_4ec77fd9-4ce2-4816-bf31-8cb39021513d"
      unitRef="usd">207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id336dc1a92684f6d959130b607011823_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTUtMS0xLTA_21008e36-d9d8-4c6a-9071-cc8d5560b819"
      unitRef="usd">202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic49ea5e6124f4cb291979ada6f6e1d4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTctMS0xLTA_93f82a2b-f442-4f06-b418-9a818e4398dd"
      unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i360f6b57fbae4cd3a936581cb768c93c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTktMS0xLTA_174a38d9-8f65-4f6a-804a-2de34f99f1ec"
      unitRef="usd">202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i790f602712d84379bed540b6f76fc57b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTExLTEtMS0w_106b1cb2-f683-4d14-a853-21aed6a22283"
      unitRef="usd">211000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id141d171a5bb4e19948360b7c1265792_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTEzLTEtMS0w_bba1f401-c458-4062-9a65-1da702f52c8d"
      unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41a6fdd6f73f41219529c1d7d8607b4d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTE1LTEtMS0w_e1ee34c9-2575-477b-acec-6ad664dee833"
      unitRef="usd">233000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide35d7caf43044a8842880c9892d8610_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIwLTE3LTEtMS0w_a6541dc7-7e0c-4ae3-96e4-6247c15bf865"
      unitRef="usd">263000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b2ade8ccf2247a083b1043ad7d0e5a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTEtMS0xLTA_da83b48b-c4e7-4429-bcb5-72cfa9670387"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf3d0c3a557a4c4a845f4c3c31bf35fe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTMtMS0xLTA_55a96727-b483-44b0-a86a-b088f4fb05d4"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0948681bcbfe41be84f9be49d7bee81b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTUtMS0xLTA_677c43f0-4d64-4676-b48f-ef52533db629"
      unitRef="usd">-1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id628e1c6911e4ad79edefc7fbd510f4c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTctMS0xLTA_97660f35-243c-4a68-83da-c789f4d1523a"
      unitRef="usd">74000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ceda0300e794bddb9081944d2f35ec9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTktMS0xLTA_3927a446-4d96-486a-b9d5-0456324a091d"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9682639f648451a9580e7c6106d6bea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTExLTEtMS0w_daaf493b-bdae-4bf8-b249-f249073f2339"
      unitRef="usd">130000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcfe45979c5843819de5fd1faa5f6164_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTEzLTEtMS0w_5d07d413-9379-4b5d-b0dd-e090ce2c00d6"
      unitRef="usd">63000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5014f16e8514b5fa48152d56fdf4acb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTE1LTEtMS0w_d2708fb4-6401-49e6-b179-2b44f3569f8a"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab537984b5264cc6ab6b179f58898f76_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzIyLTE3LTEtMS0w_0e4a21e9-2beb-4cd2-8d63-8873a1628f90"
      unitRef="usd">121000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i653304b28e3a4aba996ff5ad6455596d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTEtMS0xLTA_f869c707-028c-41a1-a413-fec28a85f536"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbc699a519cd4da6b9151325ddcc9476_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTMtMS0xLTA_7650f744-8d6b-4d63-b229-45e308e5c8cc"
      unitRef="usd">825000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6522f24b64a418290e82b61d41d2138_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTUtMS0xLTA_3f6a89ed-b600-4cbd-9638-1aea42c048c7"
      unitRef="usd">825000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id497588ccac6414284ef2d78c4360759_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTctMS0xLTA_98498d80-ac0c-4295-a33e-9688d5518eea"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id57de4669b2c404ba2df9d8c63350b95_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTktMS0xLTA_d8050b5a-c1ef-436b-b633-577665347ae5"
      unitRef="usd">838000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05c9b8eb51bf4bfdb4aa84f8464b6ad4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTExLTEtMS0w_1c4726cf-e675-4844-aee2-3a24734c2d11"
      unitRef="usd">838000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4c5d62997704e51815fd6ff6a3f63f8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTEzLTEtMS0w_1e19afb3-a48b-4206-9d7d-b3a4e162812e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e966b911fc84965a21f483f48ad5f9b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTE1LTEtMS0w_710c5d29-aaa4-465a-a97b-c1649d425c56"
      unitRef="usd">830000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i670abf0ceee14b2bb45e1d0361ced108_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI0LTE3LTEtMS0w_09e80501-c5f8-4e63-8def-13b402c46963"
      unitRef="usd">830000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide0875049533455190662cb3270eca92_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTEtMS0xLTA_1abb06c9-468c-4628-9f9e-30bc5dfaec3d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1e34030eb894f44a8c12d5525d6bd13_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTMtMS0xLTA_d1d7e404-ea46-4c7a-b87b-784466e27090"
      unitRef="usd">299000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d3bc8edf0b84232bcf558d786724b9e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTUtMS0xLTA_3dfbcb91-ac8f-43d7-856d-f8301f9887eb"
      unitRef="usd">299000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08867c31927d455abd0c72bb2f6dd29f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTctMS0xLTA_01cc1659-bad0-4d9c-8971-1b24d4f4bd28"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibca75dc6c120487cab23cf75b4de21d6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTktMS0xLTA_77732773-73c8-461c-a700-44d67ee16184"
      unitRef="usd">330000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i573ac9203d854868906b1f2a5afd90e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTExLTEtMS0w_87df5e7f-0690-4af7-9931-ee55958aca35"
      unitRef="usd">330000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0d492c360fb47b893486098bafc98b4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTEzLTEtMS0w_2d92e002-8031-473e-a67c-963bf017901a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75797ab2cf2f4e1ca746e1ac560446c3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTE1LTEtMS0w_de11efd3-14f9-41bd-92dc-e7635ad36e40"
      unitRef="usd">411000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5527cbc51fe7422dbd7d4c2cf6cfcd9f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI1LTE3LTEtMS0w_61d4c0f1-5aa1-4c06-a07d-a1ff3cd33ad8"
      unitRef="usd">411000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53d4058d922d48bfa4f4476cc78aa40d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTEtMS0xLTA_5a42430d-581a-4f69-9640-092f983d5d50"
      unitRef="usd">78000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibff774d7ca444bf697bf7b5e3ab1a652_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTMtMS0xLTA_249c6b1e-f600-400b-bc52-beb7f1761e96"
      unitRef="usd">241000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib54e43721fb14ed08c10d118aa1018f9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTUtMS0xLTA_bfd6a5a4-1d12-4bfa-9b67-11f7d5de3f71"
      unitRef="usd">318000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7e35d6b25834f2f8c64c46be0b8e79b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTctMS0xLTA_c32ce3ac-0a8d-4d38-8fee-50688918a549"
      unitRef="usd">81000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1399a756a222419cb0f46fbcf7b54698_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTktMS0xLTA_2ce76526-94a4-4082-9b06-9178b5edd297"
      unitRef="usd">247000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id72757c16e414c11b68254cb75195b3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTExLTEtMS0w_b1514489-82c3-40eb-9116-cdda9c655e02"
      unitRef="usd">327000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia75b7a5a1281432abceddda5981a31d6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTEzLTEtMS0w_0543222d-e801-4326-bc3e-ebf7a90267e1"
      unitRef="usd">92000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8971c73b69b24487819c96119033483f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTE1LTEtMS0w_b52b2e7b-4d95-4c7b-9601-bf9a74b348a0"
      unitRef="usd">214000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fe780ac69be4298a4650d36dd0c8e48_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI3LTE3LTEtMS0w_10abc3fa-8ee4-44d7-afe9-e32c4f8f2d2c"
      unitRef="usd">306000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9af6d5d2383c47e9b7f3aae3de39cd9c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTEtMS0xLTM2MjE1_c8590424-28b0-45d0-8bc7-5d764b296595"
      unitRef="usd">632000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic36b66816cc44e4b89e9cca0a8e2fc39_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTMtMS0xLTM2MjE1_6b8698c9-b3ad-4a5c-868a-07b46c4aef96"
      unitRef="usd">320000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2128d2249b5433c8c29182a6113f86a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTUtMS0xLTM2MjE1_48863648-a766-4905-8c7d-73b41be32397"
      unitRef="usd">952000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6802fc4302e74a7fb1b161db797c4710_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTctMS0xLTM2MjE1_a499956f-6acb-40cb-84f9-f6636ecba804"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i335b959ce3ae469ea04ba9f29a1064b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTktMS0xLTM2MjE1_6ee7d1e9-f74e-4b8f-a680-2e170bf94780"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4eca5885fc0477bb9a10919f5131fce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTExLTEtMS0zNjIxNQ_31e2ae06-7e4f-4b64-8c3a-ac90d1e83400"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58ef4256ffaa4cf08d46414850e9f302_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTEzLTEtMS0zNjIxNQ_301a2dcc-1a6b-4ab2-93fb-59a47914bb9a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0fc97751676240338ec6973bc3f4329b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTE1LTEtMS0zNjIxNQ_e3ab4da3-e3fe-41c1-ac92-93e16d938c86"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f098b0847574bfaa047e6960ba579da_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTE3LTEtMS0zNjIxNQ_3eda8864-aa96-46c7-9231-3a9dbc7951c3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic789d859ce7147209a488fcef20e508a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTEtMS0xLTA_4f4c3d7d-45a8-4c54-bfda-c281e7b8dd02"
      unitRef="usd">294000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icad804308bbf473898a71229679ec50c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTMtMS0xLTA_0370d051-2b41-4b47-b751-0546dc36598f"
      unitRef="usd">474000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8fd691878ec45c88dccd5fc5b741c66_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTUtMS0xLTA_c9dc3e04-9d92-483a-9250-193eb7f5f1d1"
      unitRef="usd">769000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d83bf3c10424ac1b31714923c7c7222_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTctMS0xLTA_1fbb1221-5a25-4562-8b14-644bc64ef2e8"
      unitRef="usd">326000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idbd7b557051941028e48d4c7979df2d5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTktMS0xLTA_32c2e8d4-78fd-4882-b722-ccc19bc89631"
      unitRef="usd">531000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if1f22b920f0142a7a77c93888483253f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTExLTEtMS0w_f81b9191-0df5-41b3-b1d4-ae3af2778633"
      unitRef="usd">857000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a08aa9a691f42a684ca26528ec547e8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTEzLTEtMS0w_ed479747-bc0a-4b61-b51e-88bf3c0a4f7b"
      unitRef="usd">398000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89c5034ed9c54f56861f85fb06ac04b8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTE1LTEtMS0w_8ee0c9da-0acf-4904-9fac-75ce1bb6424d"
      unitRef="usd">576000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20da1a75201d44228058bec6bb25681c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzI5LTE3LTEtMS0w_84a3eb09-b8d9-45a2-af25-aca61583ba13"
      unitRef="usd">975000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc21603e76ba43718a1da2416c551b71_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTEtMS0xLTA_7f2b0a8d-f390-450d-ab83-43ea63b396cd"
      unitRef="usd">312000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i860379b9e6694ee69337ca4a63a63ee9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTMtMS0xLTA_f5b4f9c9-4a78-4fd7-b293-92f92f1658c6"
      unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i79ad805324a7466aaa2adf87437b786d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTUtMS0xLTA_4946176f-3a2a-4142-8a86-d8dc5bf25111"
      unitRef="usd">342000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49c259f812e0493c9a80f73147db4d87_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTctMS0xLTA_4b748adc-c39f-460e-8d3c-abee7363e2c3"
      unitRef="usd">259000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie334b2fb8b4f428eae8891ba5428e8ff_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTktMS0xLTA_f31a0189-9447-42e0-b6b2-5852299b53b7"
      unitRef="usd">22000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b03e2bf2dfd474289cfb9e6b903b9e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTExLTEtMS0w_8bd6f825-dad5-4ae4-aff8-1248081beb16"
      unitRef="usd">281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib19f798e233b445dad2d45692dd72895_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTEzLTEtMS0w_e244e3a6-f8b3-4f67-8db6-d8bb7bd2cb0e"
      unitRef="usd">194000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2747d6aa809047c68d271b385afc8f32_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTE1LTEtMS0w_34c48e74-cfe2-4081-83ce-e5f0a3722a6d"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i362f6d1d48a4452382e6007cfe8aba1e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM1LTE3LTEtMS0w_3ac4d93c-b0ef-49d5-8758-8761dd87a2a3"
      unitRef="usd">204000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e40e495bd0b4d74a40b380b6538afee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTEtMS0xLTA_a7734f53-aab9-436c-8381-a4e73be12cdd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bfcb3bbc22441859e766a0bf136e8f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTMtMS0xLTA_427500e7-450f-44be-9327-7fec54f7180a"
      unitRef="usd">252000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7844fb1fab6b467795efe381ddc3d257_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTUtMS0xLTA_20e2bbff-d9ce-4522-8e68-db946c025570"
      unitRef="usd">252000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i077c0c6c35484b8d80c194006e499277_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTctMS0xLTA_38e8e4dc-5a19-4fb8-bd4e-1a01f76021b6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaad4da76bf1442ad9c12d29fa802065d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTktMS0xLTA_64b028d5-ec32-4fe2-a819-bc8abdcfd860"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6abee35368bc428188fc163b9c321692_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTExLTEtMS0w_0543aa8a-2e0e-462d-abce-1fc0f3866c71"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia410bb854da34475906908a70e1b9ddd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTEzLTEtMS0w_246effe1-b9c7-48ad-9a16-1fdf154c757b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d519f01b8384c2bbf73455aae73e495_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTE1LTEtMS0w_55967405-fb22-4a2b-bb33-89621a6366d0"
      unitRef="usd">215000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb7e2aa6c1ea4be2baa790c8abd97c73_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM2LTE3LTEtMS0w_648704fd-3e2b-474f-a326-40359e15e5b3"
      unitRef="usd">215000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida5e0a42af0a415dbc7ac173403c6c0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTEtMS0xLTA_5c603c35-c696-463d-be54-a7e0642f89c1"
      unitRef="usd">1404000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1120f19a2bf44abbb0c3dc54b2a33858_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTMtMS0xLTA_0cfcad49-8b08-464b-9b99-0ea2ae80aa2d"
      unitRef="usd">1920000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe420bf94cdc4e508956f70224f4c347_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTUtMS0xLTA_08e59176-344b-4995-8523-5b2d99017463"
      unitRef="usd">3324000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i875bb4453f9346a9889252db74a91e92_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTctMS0xLTA_82ed5d8d-40cf-4878-a967-4cc314d43a5d"
      unitRef="usd">1470000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id52da847ebfb42a892f32e61b9768325_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTktMS0xLTA_ed54bc9c-202d-4869-a34d-2611f1e5f316"
      unitRef="usd">1836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31403cbad4be41ff806afb334c3cc801_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTExLTEtMS0w_90abb185-321d-480e-bad6-e35ffd9ec875"
      unitRef="usd">3306000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5e7beb95553472b82caa89c381f3e73_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTEzLTEtMS0w_5cdd7740-ee97-4d57-8341-3dad25623c67"
      unitRef="usd">1724000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id707418566a14de9abb8afa077ffcce7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTE1LTEtMS0w_80240667-3aff-4e7a-a313-5d4d398277c0"
      unitRef="usd">1758000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3dbba2c093f84e089af32d87b1ea49e7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM4LTE3LTEtMS0w_dc3a7770-8fa9-4886-91a6-74f2f871c240"
      unitRef="usd">3482000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4359fa8ee9ae4e1ca5acfc1ef3d4769a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTEtMS0xLTA_84ad6b44-3f16-4f9d-b7b7-141eb0fa1e97"
      unitRef="usd">367000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i855aacd97879416694b822d5b5a4e61f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTMtMS0xLTA_b29f0d22-0717-487e-976b-25315a0e006f"
      unitRef="usd">1597000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i053d6ba1ed2841b3916017660c6df7d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTUtMS0xLTA_4df7b66e-cad0-4cf2-9e04-7d9dd42c20cb"
      unitRef="usd">1964000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib04c71c3f757454aa800a15a8010af43_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTctMS0xLTA_e3fbbe05-99a5-49b1-a9d0-71bef0cf3196"
      unitRef="usd">477000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8c1036618754c889e448fee724b87f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTktMS0xLTA_d05aade9-0e02-4397-a6f6-2939df241b82"
      unitRef="usd">1494000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if22268e596b0476aa1a363dc33a72e0c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTExLTEtMS0w_b450d0db-8908-4987-81f6-26fca3ef40de"
      unitRef="usd">1971000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic5fc3ab73c2d4c188100a9ccbc477ac4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTEzLTEtMS0w_19ff3ae1-73c4-4104-8513-9c59108ca0d7"
      unitRef="usd">589000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0eddcbbe421b4d6fb2d8b67f56b5b5f7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTE1LTEtMS0w_78ce2360-36f8-483c-80a2-76b987612cdb"
      unitRef="usd">1452000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ade6018d32b4458a32138623c4dd828_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzM5LTE3LTEtMS0w_c04b1dfb-5472-4055-bca1-a8df8c1d7cb8"
      unitRef="usd">2041000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05f4bd9b10014321983b0401d103bbd4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTEtMS0xLTA_a21332f2-0f68-4b2b-83a8-a7257daa51bd"
      unitRef="usd">1007000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f952e92f0ca4e6483f30550b71d62ae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTMtMS0xLTA_b404b05d-115a-4f41-ae48-e9343e475c94"
      unitRef="usd">1302000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9a7a6ab9b3e4c83ba2682007c4d5f5a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTUtMS0xLTA_cae38ea0-422e-4368-bc91-63ef07641d0b"
      unitRef="usd">2310000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i409834fa971041c59a9219af6cc8a8fe_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTctMS0xLTA_e9f3e259-1218-418f-97ec-b5a9c76f2940"
      unitRef="usd">984000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab2f301fabb64c4b9a1224b62e33cf45_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTktMS0xLTA_88ec3d07-6369-43a2-8d38-3a2483efefce"
      unitRef="usd">1328000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i84e8d6fd87284f119ad6bbeb297f087b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTExLTEtMS0w_c0cbc172-4ef1-497a-b769-7b3ffea1a169"
      unitRef="usd">2312000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f80c96aec434110897f030eab369d00_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTEzLTEtMS0w_d1b23f06-67d1-4508-b1fd-4991f6fb722b"
      unitRef="usd">1215000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia05ecde19c334fc3869d0a13c50b3d91_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTE1LTEtMS0w_4d0e7f40-9dff-4bd6-a454-89d5ce71f89c"
      unitRef="usd">1661000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8b51fa1e63844c0a772c0468f3aecc2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzQ5LTE3LTEtMS0w_67f0c80e-4055-4ef4-8587-b17e338515de"
      unitRef="usd">2873000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31f4c85d94b444cc93caffa1905c6ad7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTEtMS0xLTA_97e26595-60d8-4510-a866-3a5129b088c5"
      unitRef="usd">20401000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec26147c7b0f4628a255c9ed76696470_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTMtMS0xLTA_43691ea2-28f8-45be-ae69-d94dfe3ab84e"
      unitRef="usd">22353000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTUtMS0xLTA_16aaae66-ee3e-4ff9-b0e2-a6c47df6b25b"
      unitRef="usd">42754000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82c0463faf174f59a03cfbd4c245e30b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTctMS0xLTA_52a3564f-7c10-488a-89a9-07f573b24eb2"
      unitRef="usd">18010000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac282dd562d44386a140bff679bd6312_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTktMS0xLTA_3017802e-1d81-4eb4-aa5e-5e3e6d8c18f8"
      unitRef="usd">18600000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTExLTEtMS0w_e0c2a829-77ec-4b9a-b3c6-e93b2952430f"
      unitRef="usd">36610000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8227972e5ae047dcb65cacbe11fda43e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTEzLTEtMS0w_00b52398-1bd1-4005-9b67-62862fbac441"
      unitRef="usd">16854000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief9e718c9899485dac81e79d2b65a8c1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTE1LTEtMS0w_a32f9311-2247-49d6-8d04-222099fa1750"
      unitRef="usd">17246000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUwLTE3LTEtMS0w_88a58884-164b-43b0-889a-f58283c986ef"
      unitRef="usd">34100000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i902f509e24c5427593e3c70a397619cb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTEtMS0xLTA_916150d1-ec32-413c-a3e9-c30bc514387b"
      unitRef="usd">667000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c92b7d768b04f0496a1e4096d91ca45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTMtMS0xLTA_9710d9e3-a326-4667-8773-b4b8f68367ab"
      unitRef="usd">2628000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1b64b45d21a43908135485c4336af56_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTUtMS0xLTA_f14a2d3a-5686-446f-a880-0192c7cc3b38"
      unitRef="usd">3295000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b007460a32c4c97a79e96fba3124285_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTctMS0xLTA_40160fbe-80ac-4fac-a025-6e07f3b5fdb5"
      unitRef="usd">612000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaa79b78c2ca447ee97688bc48b4bb2a4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTktMS0xLTA_dd0f474d-5617-411b-adbb-cada1a71462d"
      unitRef="usd">2327000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a7e4a72b7eb4ea4aa580f1844e390d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTExLTEtMS0w_5766fda6-ba66-44c4-8a79-9773f78e56db"
      unitRef="usd">2939000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67bce372466c44158bf7d70262025e3c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTEzLTEtMS0w_0dd7cd1d-b6eb-4ad9-9373-dff0d912209a"
      unitRef="usd">582000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53fdee9f2db04a4ab37654bf8ad3ce55_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTE1LTEtMS0w_ab3793f3-0e23-4a28-90f1-e9f6d0cfb6ba"
      unitRef="usd">2201000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcecb7d348a3418fb83648e67423787b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUyLTE3LTEtMS0w_024b3a90-af1f-4764-9dea-827af7f6c7e7"
      unitRef="usd">2784000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d3835e3db0c4b86b4b85421ffd621a8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTEtMS0xLTA_bba315c5-9213-4ce8-8971-cacb4eb9f9a6"
      unitRef="usd">1091000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i391af24746af409e98e68c04fd6b1a6a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTMtMS0xLTA_7fcd887e-3ec9-4645-8e4d-9aa7eff85238"
      unitRef="usd">1182000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6f76e1d339d419f8e388024ded2d57c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTUtMS0xLTA_d7b78680-60dd-4cdf-ba42-8b87b228f688"
      unitRef="usd">2273000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bd674a922374a05b288a846e7656f8f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTctMS0xLTA_23a51879-7d46-4a9e-9191-1ad12b25e90f"
      unitRef="usd">872000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice28c52b471c4e2990f1d5fda9a6605a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTktMS0xLTA_3856a97d-9b57-4108-a732-d74b7060a2ef"
      unitRef="usd">892000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8dd74afd8fe9493dbddd22f40067b822_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTExLTEtMS0w_67c5677c-790e-4087-b39d-3a6602284fbb"
      unitRef="usd">1764000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if84e446473224b92a8e962c9c6661bef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTEzLTEtMS0w_a30cfe52-2f14-418c-aaf1-ce265216044c"
      unitRef="usd">724000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie92e22bab44c4a8585d741cb84b22e0b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTE1LTEtMS0w_ed94018c-7bea-46e7-bf5c-2106bceca153"
      unitRef="usd">885000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17d4f819332f4489a002b37af48a6b7b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzUzLTE3LTEtMS0w_dff38ac3-1cfc-4752-ae29-c66b631600b0"
      unitRef="usd">1609000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f07294b8d184726bdd9f9431afa7552_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTEtMS0xLTA_93b8eff1-a4fe-4587-9f7b-4d7483f9a50b"
      unitRef="usd">1758000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic659ca2172564f53a729023707985665_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTMtMS0xLTA_f7971ad4-9480-4caa-a620-2952eae9e8df"
      unitRef="usd">3810000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTUtMS0xLTA_56e5620f-0f87-4817-84d8-82ddd3fb17b4"
      unitRef="usd">5568000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8410cf640294595a9c6c3993a24c454_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTctMS0xLTA_0ba44a65-c248-4b78-b951-df328e3e53a0"
      unitRef="usd">1484000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice06d069455f4c78a72b7a22c07b369f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTktMS0xLTA_d6ebf943-b750-4fa0-8dc0-26a5a05c3174"
      unitRef="usd">3219000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTExLTEtMS0w_ab415cbc-0a4e-4cad-ad29-8d8cf7917a75"
      unitRef="usd">4703000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9405751ff5f547cb86645a579c2708c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTEzLTEtMS0w_428f0eae-0965-4117-8718-b3c36c2349ad"
      unitRef="usd">1306000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i84c516c5302941878e7cd4bc6ff5a4be_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTE1LTEtMS0w_3da442e2-8ab5-478e-ba65-1fa351ed09fe"
      unitRef="usd">3086000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU0LTE3LTEtMS0w_fb11b955-6998-4ad8-bf93-89ba46e82389"
      unitRef="usd">4393000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i980d80d9d41b4b498a1d29eae232be01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTEtMS0xLTA_49b0ac78-49c8-45a3-8010-441fb2eed11a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d40fffde89545dba8648608f3dae7f5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTMtMS0xLTA_55ebd349-eed1-4925-b11b-644d82e02889"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTUtMS0xLTA_26153f6a-32b0-488c-b39a-9b6a7ad89ab2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2fa1c27df5144fb9b2e20a19423662bc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTctMS0xLTA_9ceea117-f487-4c6c-8e60-2db11116d061"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14452d35763c4c49b6af96a9eedff2c6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTktMS0xLTA_d1a55ff5-5b01-48fb-940d-6e61dc365dcd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTExLTEtMS0w_80e1f954-a0aa-43cc-9f66-cb5871c62770"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c19fc0232664dbb82ab1947769dbc56_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTEzLTEtMS0w_764d453e-7f09-46f1-ba68-41b9ccd42005"
      unitRef="usd">174000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3c67e1533834abb9370666fb82dabbe_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTE1LTEtMS0w_0d5384e7-27bb-4aa8-97a3-643801f76b42"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU1LTE3LTEtMS0w_8629e0a4-137d-4e3a-b1f9-119aab87fdd3"
      unitRef="usd">175000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie42b1731f9424c6490b9e6d7083ba158_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTEtMS0xLTA_60ce99d4-c9a4-43dd-8032-15ac4bd112bb"
      unitRef="usd">22159000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i700c5af718dc4cc7a9afb37161495201_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTMtMS0xLTA_99b3340d-eb33-49fa-8f19-06219215f81a"
      unitRef="usd">26163000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTUtMS0xLTA_67d43e31-bdaf-41ff-b7ad-b844ac1dad93"
      unitRef="usd">48322000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i244f5c86b05d45859ccbbae1bc5a1e4f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTctMS0xLTA_42d4de7f-cbf4-494f-a05b-148a6a6e252c"
      unitRef="usd">19517000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia07ef034ee544842829927be984fee2c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTktMS0xLTA_a850567f-dd3b-4eb7-98c8-52f584e6916a"
      unitRef="usd">21819000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTExLTEtMS0w_ad893593-1895-45f3-b41e-7f618a477ea3"
      unitRef="usd">41336000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieaa0b2b1f7064efc9056cdd5245618a1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTEzLTEtMS0w_ef2bc4e5-fbf0-48d9-8832-9808ac169865"
      unitRef="usd">18334000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9887835dab646e18759f89f0b92d691_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTE1LTEtMS0w_da4edfd8-a8b4-4180-b940-d5feaf49ee8b"
      unitRef="usd">20333000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU2LTE3LTEtMS0w_e3942785-1bd6-4cd0-a89d-5617c1d0aadd"
      unitRef="usd">38668000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f650db9484346c99e5ce03c627df6a8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTEtMS0xLTA_5914affe-8332-468e-a451-dd499c358b37"
      unitRef="usd">266000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie2dd5fc45690468599bc819ec36baa72_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTMtMS0xLTA_eab65b72-1bd0-4863-8761-fea64cde3e7d"
      unitRef="usd">116000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb0c9180eaed41789a00b00eaa6420dd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTUtMS0xLTA_48f664cc-893d-4aaf-bb8f-8f9712efc582"
      unitRef="usd">382000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee23680a9ed04180b885349d2534edf5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTctMS0xLTA_e66a08ef-810e-4b3a-bfbb-a4fa013180e6"
      unitRef="usd">71000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib47cf1b70e6843698113f3bbfd683a3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTktMS0xLTA_269832a6-fa35-4293-8662-8557e87c2b81"
      unitRef="usd">111000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i485ba6b68e3543b6a383a01f55dc222e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTExLTEtMS0w_b7a9574e-8c86-462a-a468-7307b367a849"
      unitRef="usd">182000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91f4520623a2490cb524e95878a17cbb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTEzLTEtMS0w_cedea8e6-d512-42fa-bb38-f2cc5e6d6091"
      unitRef="usd">86000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97c7636f13a047af99200a56c856358a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTE1LTEtMS0w_bb373037-8b92-4f35-b8c3-6caddbe7c1c8"
      unitRef="usd">368000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdb5826a89fe434cacb3a48a5d577261_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU3LTE3LTEtMS0w_d0852f16-6c47-4a2b-b443-918e59856f1d"
      unitRef="usd">453000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51b6e713277c47e29642541d538d06f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTEtMS0xLTA_fbee6936-b05e-4853-a4c1-f1ed3c8d156c"
      unitRef="usd">22425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c78a1f59ce94b479267d48bca0bdcf7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTMtMS0xLTA_c6a6a0fc-9562-4648-a86a-aa85db7a3520"
      unitRef="usd">26279000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTUtMS0xLTA_7170a2b8-94e2-42ff-9ffa-29ca58540dc1"
      unitRef="usd">48704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5553318c17394c7c86186b52781cbbf1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTctMS0xLTA_6376409d-d91c-4058-af6e-dfc75a0ecf11"
      unitRef="usd">19588000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3887d92fb9d4538b9b8882d8131625e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTktMS0xLTA_2f8c275c-fb2c-4c21-a278-70d3db2f2961"
      unitRef="usd">21930000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTExLTEtMS0w_42b6d99b-d9cc-47d8-bfa5-42484a9e91b6"
      unitRef="usd">41518000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1126352971dd46669a405313ec339037_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTEzLTEtMS0w_d77110bf-4f0b-4695-abc4-b0241557c49c"
      unitRef="usd">18420000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idefdfd681b4e4b51923fd6feb08020aa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTE1LTEtMS0w_5f1ad70a-71b4-43b8-987b-13426385a775"
      unitRef="usd">20701000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmNjE2N2NlNzViZjA0NTRhYWQwN2RmNjNjMGRiYzZlZS90YWJsZXJhbmdlOmY2MTY3Y2U3NWJmMDQ1NGFhZDA3ZGY2M2MwZGJjNmVlXzU4LTE3LTEtMS0w_8f51c7ad-a456-4ee2-957c-49b6152d2216"
      unitRef="usd">39121000000</us-gaap:Revenues>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzM4NDgyOTA3MDY1MDM_aa700d37-430f-41df-9569-d3f760233eeb"
      unitRef="usd">185000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0ODI_4ab054ff-a9ee-4280-9f37-3b4608b86318">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;48,704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="i51b6e713277c47e29642541d538d06f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzEtMS0xLTEtMA_8c6f3621-7afe-4ada-98bd-931e88a0bc97"
      unitRef="usd">22425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5553318c17394c7c86186b52781cbbf1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzEtMy0xLTEtMA_932fd403-f1cd-4ef9-9853-f25038bc1ad5"
      unitRef="usd">19588000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1126352971dd46669a405313ec339037_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzEtNS0xLTEtMA_acacc8be-c925-4c9c-b244-01621db18e3a"
      unitRef="usd">18420000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd29895771bf4e55817628fdfec5709d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzItMS0xLTEtMA_922f79f7-85b3-479a-869f-7b73910cffb1"
      unitRef="usd">13341000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0dbed4d7248d48c98107ad18eed29ce9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzItMy0xLTEtMA_b0bc1c81-29d9-41fb-9702-c1c92de43449"
      unitRef="usd">11547000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifba4578f496546feae50404f7c94acf7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzItNS0xLTEtMA_2caf855c-4c7d-44ce-9f2e-4242e5534422"
      unitRef="usd">10496000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb727fa4e7aa4178a7b1e42c772bdcb7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzMtMS0xLTEtMA_e51c0122-a0e5-48b9-adbf-c608dfbd2703"
      unitRef="usd">4378000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8fcd9e2f534e45aeaf0506c607d7115c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzMtMy0xLTEtMA_5de745a4-b0a2-4e97-aa55-ffc3473f2333"
      unitRef="usd">2751000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f39fabecb0945059db383224430a917_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzMtNS0xLTEtMA_98d71152-535f-429c-a8e5-bfb582c71bee"
      unitRef="usd">2180000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d71201413c34bac8b783c4fe7712fce_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzQtMS0xLTEtMA_4e5b0b98-cac1-4885-b2a9-84f8192e8bd8"
      unitRef="usd">2726000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id86c1551379c460aa0a9da151aab63c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzQtMy0xLTEtMA_a8ce5a4d-a545-4e29-9cbe-e3b07ff1110f"
      unitRef="usd">2602000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf5faa00c2fd48289d394fa06ad542e8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzQtNS0xLTEtMA_c0ec445b-600a-4641-b487-e2152e0bb67e"
      unitRef="usd">2609000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i702054b971f24d8d84a6e2447ac82145_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzUtMS0xLTEtMA_3a712697-517e-4c7c-9a11-6560d53d8d87"
      unitRef="usd">2407000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80d78a41cef745c09b4167941714950f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzUtMy0xLTEtMA_65966d84-b81d-4b75-99fa-313aeffb2bd5"
      unitRef="usd">2113000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia83ef2bbdf9d4c628f48c7199364718a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzUtNS0xLTEtMA_17c32b14-8861-4afa-bcfd-0eeabe54fd66"
      unitRef="usd">2126000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie65d141d77524275b769848de141bc4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzYtMS0xLTEtMA_29644a51-ece0-4a70-ab04-dfe4dab8bbae"
      unitRef="usd">2206000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18e4eed626644fac94b8f8c13407308e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzYtMy0xLTEtMA_53254457-120f-4148-bbbc-90b5d2a51b71"
      unitRef="usd">1890000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0317b49ef7a406ab77915a805d48780_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzYtNS0xLTEtMA_aa9a3e30-b260-4c66-b4e5-4d590b6f68b1"
      unitRef="usd">2015000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iadfd209928014784a6e2ed68f848e3da_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzctMS0xLTEtMA_05ab2a54-ce73-4f4b-9c47-09bfe4a46630"
      unitRef="usd">1221000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f86df598e9d4df4b133bb5dfcb2e6c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzctMy0xLTEtMA_02963f38-2ed9-4440-b54b-486802d8dd3b"
      unitRef="usd">1027000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b351db0a29943e88f99348848e492c8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzctNS0xLTEtMA_093dca04-5497-4989-a1a8-6f2a090116c8"
      unitRef="usd">1275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzgtMS0xLTEtMA_92635d90-ca26-49aa-a273-5c610a06a311"
      unitRef="usd">48704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzgtMy0xLTEtMA_04e9daf3-3da6-4ec3-a934-9add3abb4f62"
      unitRef="usd">41518000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTpmOGQ2Y2E3MmRjMTM0ZDU2OTEyMzg4OWJiOTUxMTZmOC90YWJsZXJhbmdlOmY4ZDZjYTcyZGMxMzRkNTY5MTIzODg5YmI5NTExNmY4XzgtNS0xLTEtMA_76cfee26-1ddd-48ea-9ee5-71886a8b3f0e"
      unitRef="usd">39121000000</us-gaap:Revenues>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NTc_ffb6ccde-d4b0-4642-be1d-4208f5a69c82">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Continuing Operations Before Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30,977&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,950&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,927&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzItMS0xLTEtMA_5330200a-5706-48f2-9279-12867e443cc4"
      unitRef="usd">30977000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzItMy0xLTEtMA_9e9367f3-2032-4fce-8017-7a93b7423d84"
      unitRef="usd">26106000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzItNS0xLTEtMA_efa142d5-60c0-4713-92ee-8fef7e56d58a"
      unitRef="usd">23448000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzMtMS0xLTEtMA_00d63fc9-3ad7-4a69-b296-84d8265b1835"
      unitRef="usd">1950000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzMtMy0xLTEtMA_c5b50ae2-e36d-44a2-b37f-8f52fae43245"
      unitRef="usd">1669000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzMtNS0xLTEtMA_7f5b096c-b4cb-46b2-bc2f-c376f8b2ee32"
      unitRef="usd">1612000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzQtMS0xLTEtMA_8ed51149-8c30-4c0a-ad2f-7a87920e1d98"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzQtMy0xLTEtMA_83daf04e-c234-4b24-a488-d5cc73ec5593"
      unitRef="usd">1000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzQtNS0xLTEtMA_202ac495-2d04-41c2-87bd-f5ca1e4ae6b6"
      unitRef="usd">-7000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzUtMS0xLTEtMA_0c64681c-37e6-4855-9657-957643dd8287"
      unitRef="usd">32927000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzUtMy0xLTEtMA_367bc1e2-914c-4538-a69b-32e553385327"
      unitRef="usd">27776000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzUtNS0xLTEtMA_e6d54afd-151e-44a2-b9cf-eb34b0e80146"
      unitRef="usd">25053000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifb0c9180eaed41789a00b00eaa6420dd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzYtMS0xLTEtMA_e0dc359c-1136-456e-bec6-daf7388c96f2"
      unitRef="usd">156000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i485ba6b68e3543b6a383a01f55dc222e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzYtMy0xLTEtMA_ffe2a33c-3ca1-4337-81a0-812247dea3c7"
      unitRef="usd">75000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icdb5826a89fe434cacb3a48a5d577261_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzYtNS0xLTEtMA_f723da4e-4ab5-43e7-87f7-5d6d84172c3d"
      unitRef="usd">295000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzgtMS0xLTEtMA_a9398c08-0937-4f85-81e3-fa8cd0dcc21e"
      unitRef="usd">36000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzgtMy0xLTEtMA_f429e4ae-dfc9-4302-b0fe-a5c05723bbec"
      unitRef="usd">59000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzgtNS0xLTEtMA_ea7cdd20-5f30-4231-9caa-71d3d191bf4a"
      unitRef="usd">274000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzktMS0xLTEtMA_d8027688-d555-463c-b016-98233e6103a6"
      unitRef="usd">806000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzktMy0xLTEtMA_8ed187cc-fd7a-4f25-bf61-27e02f2297c7"
      unitRef="usd">831000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzktNS0xLTEtMA_3db3c6c1-bf3f-4229-add6-5791936130e9"
      unitRef="usd">893000000</us-gaap:InterestExpense>
    <us-gaap:AdjustmentForAmortization
      contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTEtMS0xLTM4NzE_6dead26b-058b-4734-ba82-8389189822b2"
      unitRef="usd">1636000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTMtMS0xLTM4NzE_69ea5383-cc5a-4ae9-a211-90c4c475614a"
      unitRef="usd">1817000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTUtMS0xLTM4NzE_388b398d-115d-4bf5-b31e-4ea4ea859877"
      unitRef="usd">1695000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:Depreciation
      contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTEtMS0xLTA_bd8e251e-db8f-4aa8-a70b-96b10c9e8f78"
      unitRef="usd">1414000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTMtMS0xLTA_318a8035-ba6a-400a-ad02-de98d7d89dc1"
      unitRef="usd">1519000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEwLTUtMS0xLTA_2f57e64b-f6db-45f2-9f40-6a57baad44eb"
      unitRef="usd">1491000000</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzExLTEtMS0xLTA_bcd41291-84af-4343-b1a5-6e8dd77d8c87"
      unitRef="usd">11692000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzExLTMtMS0xLTA_5b8a7ddd-a969-4efb-80a3-c873a0ecf071"
      unitRef="usd">12911000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzExLTUtMS0xLTA_662575fb-e021-4ba4-b869-f583f9d76999"
      unitRef="usd">9351000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEzLTEtMS0xLTA_a371195b-9cf4-44d6-a8c3-82391b483653"
      unitRef="usd">661000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEzLTMtMS0xLTA_2439418e-3d05-4284-8384-99777bbecd34"
      unitRef="usd">575000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzEzLTUtMS0xLTA_37006e78-aa82-403c-a198-8f49791ca533"
      unitRef="usd">626000000</us-gaap:RestructuringCharges>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i6d04744f38bc4f50aeb0b9035131e4f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE1LTEtMS0xLTA_8a9c7198-7531-4060-b63b-1132eb36d011"
      unitRef="usd">3031000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i952bc606582d42a3b2562ab4180826e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE1LTMtMS0xLTA_2efcfd0e-4633-41b1-9894-cdf92ab29c12"
      unitRef="usd">4394000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i3eeefe13657143c78acb020d8b85b471_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE1LTUtMS0xLTA_78b61106-def9-47ec-a6ba-da2bf3314cfd"
      unitRef="usd">4395000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE2LTEtMS0xLTA_e894887f-69a0-4bfc-b28a-f917716e5f6b"
      unitRef="usd">13879000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i596b49be9c954f9aa33ceace77c8bcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE2LTMtMS0xLTA_5c9bdda3-c6bc-4614-acff-14191901c70c"
      unitRef="usd">5863000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if5c650b7720147ddb81cef733e05ea81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo3Zjk0OTNkY2I5MzM0MzA1YmM4MTJkZDU4MGYxMGEwYy90YWJsZXJhbmdlOjdmOTQ5M2RjYjkzMzQzMDViYzgxMmRkNTgwZjEwYTBjXzE2LTUtMS0xLTA_9c12c885-26a8-40ef-bf9b-1722ed9a7e7e"
      unitRef="usd">7171000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NjU_bb99fe38-4e1b-4ddf-b099-5049db0f3e2b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity loss from affiliates and depreciation included in segment profits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzMtMS0xLTEtMA_024c8590-1346-4b68-870e-6076985bdd8f"
      unitRef="usd">-11000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzMtMy0xLTEtMA_ddc810c5-a5c0-4cb5-9bee-f0ba6c823caf"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzMtNS0xLTEtMA_b0704adc-bfd4-4540-b2c4-81dd7c3306ca"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzMtNy0xLTEtMA_e4187bae-331e-44ca-bafc-6fda1be21ec0"
      unitRef="usd">-11000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie68d1d3451ea4325a959e9d275516f7d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzQtMS0xLTEtMA_93647a16-79ab-4e4c-8dbf-476f15200aea"
      unitRef="usd">6000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icb10083896b84725a4e266c77a0b5a1d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzQtMy0xLTEtMA_5673668d-c3f1-4032-8711-1892763361de"
      unitRef="usd">158000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia0a49fca60ff477190674fc5dbb820fc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzQtNS0xLTEtMA_7608968a-8016-4ec4-b657-748433283eeb"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzQtNy0xLTEtMA_7e967aad-3618-45c9-9265-1635d440719d"
      unitRef="usd">164000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzctMS0xLTEtMA_0ae181f2-a351-438d-b6f0-ea7c8b1d0de3"
      unitRef="usd">-6000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzctMy0xLTEtMA_c6abc55f-c636-4a1f-ad91-99ccda610281"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzctNS0xLTEtMA_78139a7d-deea-4730-ad21-76324523ee9a"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzctNy0xLTEtMA_cdf66ce9-16c4-4aea-85d5-b68fe49e5000"
      unitRef="usd">-6000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4ea012dd67154e6ea8a76c78ee17dd66_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzgtMS0xLTEtMA_7656ef3a-5f11-4f50-aeef-8e65aff0b3e8"
      unitRef="usd">6000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i40fdc8a3931f4c2996cafcf2334b37fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzgtMy0xLTEtMA_cf93580e-85b4-44c0-86ce-efd33dca0970"
      unitRef="usd">143000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ief40865ff7124df7bc27ad5e5da4a7d1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzgtNS0xLTEtMA_22f240d6-f433-481f-b1e7-0969fc998e26"
      unitRef="usd">1000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i634cfa5a79a1479aac68bae07f16d8a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzgtNy0xLTEtMA_9ac71646-75f4-4510-86a2-0df3d648a06c"
      unitRef="usd">150000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzExLTEtMS0xLTA_6739157a-a9ee-4c1e-91b2-6f2ff553fb7d"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzExLTMtMS0xLTA_8fb8c594-cc00-42e3-8134-413095ff3634"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzExLTUtMS0xLTA_398f0be6-d7ce-4e2d-aa5d-724c7467b06a"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzExLTctMS0xLTA_fb044066-85d5-4dd0-8ee4-7a24407b083d"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i92efaeebebc944ac97aa25152ee95d59_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzEyLTEtMS0xLTA_785691ca-c087-4164-ab6e-047d339b7df3"
      unitRef="usd">9000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i538c2113c35e4b21b766ecce772a1785_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzEyLTMtMS0xLTA_c871af83-7d1f-49e5-81d2-d5e9dad82935"
      unitRef="usd">105000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i72e6266905c0417596e1d828f3b4c4ce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzEyLTUtMS0xLTA_b3c09eb4-3d93-44c2-8bbb-981be97d1d8b"
      unitRef="usd">10000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icd79b8a8afe14b6ca1b435e156cf1e8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZToyOTBlYjljMTMzNTI0ODlkOGVjZDQ4ZDkzMGZlMzQ2OS90YWJsZXJhbmdlOjI5MGViOWMxMzM1MjQ4OWQ4ZWNkNDhkOTMwZmUzNDY5XzEyLTctMS0xLTA_87e475a5-da90-41ee-a53f-808133f1cacd"
      unitRef="usd">124000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90ZXh0cmVnaW9uOjY3ZWQyNWU4MDQyZDRhZTA4ZTA3YTgxY2IwZGU2M2M4XzU0NDI_5c0cc8ba-eb60-45a5-b364-12a26e89f3c9">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, by geographic area where located is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,759&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;857&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i74f96c6b07354101b83e5657c2f98734_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzEtMS0xLTEtMA_77d62b12-123f-4164-97e0-6f75aabaabd1"
      unitRef="usd">11759000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic77becba44594afaa9cd2ceb1fd401d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzEtMy0xLTEtMA_bb03349d-0761-43cf-a830-3e4f5be4a0d8"
      unitRef="usd">10394000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0089f10a0e6b4fc399437bdbe0f24541_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzEtNS0xLTEtMA_8f3c6d46-3dbc-43dd-b5dc-6c93e090abef"
      unitRef="usd">8963000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idbc8434b69594d2faec9792cab27130a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzItMS0xLTEtMA_3df553cf-8627-42e6-a83c-a02e76399ce3"
      unitRef="usd">6081000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i89793641482a462a8870d840e39282bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzItMy0xLTEtMA_a213ff84-bdc2-4369-acff-2297b96ae74a"
      unitRef="usd">5314000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i59e29b586bba44708bb5e13fc1cccac7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzItNS0xLTEtMA_0c8d6686-69fc-49b1-988b-c341555c940d"
      unitRef="usd">4129000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i52450a8e8d2546b5bd337d8497a5289c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzMtMS0xLTEtMA_f2f865e9-2b9a-4e03-915e-28253a9e67dc"
      unitRef="usd">857000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i69892ca182474febb07a4d42f2311e31_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzMtMy0xLTEtMA_d96a21e0-175c-4902-a961-8865611e4ea8"
      unitRef="usd">737000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6db0658921f94c4da60d8ab9e661845b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzMtNS0xLTEtMA_81240c8f-2e60-46bc-b349-4ff635d0e58a"
      unitRef="usd">692000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i960c222e9b7d4a59927d7e6165657a27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtMS0xLTEtNTAwODc_b2653619-7324-41f6-9c24-27f35457bef2"
      unitRef="usd">220000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ff168ce1b424a539e923a9b1865cba9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtMy0xLTEtNTAwODc_3c539596-cd99-4f87-b039-23b705326651"
      unitRef="usd">216000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i61c65b2ff6c94bb8bcc3df47b62d5705_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtNS0xLTEtNTAwODc_7974031a-8a4a-4bfb-807e-8d49b95f423e"
      unitRef="usd">174000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibb7975455e654a058dcc8d1764cb18b9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtMS0xLTEtMA_e2a531b5-cad1-4a54-8c1b-02c9c65f71e7"
      unitRef="usd">199000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibc2004b75c2c4673a8d52b5496f1f227_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtMy0xLTEtMA_e299f246-4971-4b58-abd5-bf6243c00255"
      unitRef="usd">169000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic467a8caacc54f36b9cd0bbb7b623a98_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzQtNS0xLTEtMA_710ae2d8-1c18-40c5-a762-30c419fa2577"
      unitRef="usd">180000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i81c87fa80f5a449daba8c6132b457304_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzYtMS0xLTEtMA_a0aab881-132f-45b9-aef6-ff8a2ec4fd09"
      unitRef="usd">159000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4457dd521ae041f5801d7bde8d26fffe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzYtMy0xLTEtMA_dc49342c-cbd3-4fc1-9778-4ebc84f2733b"
      unitRef="usd">166000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib520017c77134d6d8203bb67065a1066_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzYtNS0xLTEtMA_7484249d-3c20-4903-99bf-9d0d197b5a84"
      unitRef="usd">152000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iba482b7988f246148ad09c509cd17ccd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzctMS0xLTEtMA_48fc91e6-58f5-4fd1-9b92-e7fe90739756"
      unitRef="usd">4000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8dd9499f0549458ca5c8d1f40663fd48_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzctMy0xLTEtMA_47bcf06c-55ff-478d-9f52-4363fb27b7c2"
      unitRef="usd">4000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i77ace3e3f4dc49a9b53a1d8959fe23aa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzctNS0xLTEtMA_f40cb2f9-20c7-4828-9053-519595a77d92"
      unitRef="usd">7000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib8b85b81b3df4143813c92eac8590ae3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzgtMS0xLTEtMA_bb4f850d-bcc7-4da4-9fe7-d079bf902279"
      unitRef="usd">19279000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib57ea5f7a6144ca49a5572c7efe125b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzgtMy0xLTEtMA_966d0a8d-c985-4cc8-abff-3039ab752802"
      unitRef="usd">17000000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7071cda02b544795b02b9668d83532cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8xOTkvZnJhZzo2N2VkMjVlODA0MmQ0YWUwOGUwN2E4MWNiMGRlNjNjOC90YWJsZTo1ZWQ3MDQ2MWEzMjI0ZTc5OWQzZGEwNjc0MWMwNTg4OC90YWJsZXJhbmdlOjVlZDcwNDYxYTMyMjRlNzk5ZDNkYTA2NzQxYzA1ODg4XzgtNS0xLTEtMA_cd53beeb-313b-4e97-9a24-5bf631d842b6"
      unitRef="usd">14297000000</us-gaap:PropertyPlantAndEquipmentNet>
    <dei:AuditorName
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMDIvZnJhZzo4NWVkZDNhN2NmOGQ0YjI4ODUwZTBlZDRjY2QwYmE3Yy90ZXh0cmVnaW9uOjg1ZWRkM2E3Y2Y4ZDRiMjg4NTBlMGVkNGNjZDBiYTdjXzM4NDgyOTA3MDY3MDg_167833f7-b997-42f3-b7ea-e626a0d5f81c">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yMDIvZnJhZzo4NWVkZDNhN2NmOGQ0YjI4ODUwZTBlZDRjY2QwYmE3Yy90ZXh0cmVnaW9uOjg1ZWRkM2E3Y2Y4ZDRiMjg4NTBlMGVkNGNjZDBiYTdjXzM4NDgyOTA3MDY3MDk_74342bb9-6181-4356-bac1-8792e3239b77">Florham Park, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i090a240c01204951a8d43aeb0084e26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFlMWU5MzRiZmZmZDQ1Nzg5MWZiNmUzM2RhZTUwZDY0L3NlYzoxZTFlOTM0YmZmZmQ0NTc4OTFmYjZlMzNkYWU1MGQ2NF8yNDEvZnJhZzo3ZTliYjkyMjkwMzI0Nzk1YmVjNGUwNzE1NmYyY2IwNy90ZXh0cmVnaW9uOjdlOWJiOTIyOTAzMjQ3OTViZWM0ZTA3MTU2ZjJjYjA3XzEwOTk1MTE2MjgyOTY_1c554e82-561f-4a7e-b099-6e83fd9270e8">238</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>137
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0W[/!!G#$),V^38Y)6_^>'O8D8"L[G>"-<I)B>+L0+$=<L%3.<_(61JR\&>
M#E"J>#D;7B<.BGC*@GWBVGO$L1R[AM 0-_]$T\K<J3$_-9CGRMRJ>_M/7^-6
M7G8+/'?7U_ @A\DBR7E:3E45\G]_@:?(N61)]@_R#J]ZAU>\PS.]XWJU8'5#
MB)O;5OLSPL*O6/C-6 S2-*<QN6(++F0='1Q'BIPA=+H5G6Y#IP@*6E7X?3<E
M'&M&XPSCU*LX]5"<LU1&<D5&4<S(99Y,F:CC@F/8[:[?PR*S7Y'I-R%SQ6ZC
M3(*/)+FD26WXX#@73 1WKW^WN];[US19O"=#OK\'X1[L(R0/*I('*/A041Q
M6@/4L)8<;G]@]1$6MJ6UTD)QOO  0GH\YRDV<@:0GF>U/<NR,$9;ZFTW&3[P
M,Q<0U86P[)&)I)(1+L!=>2K%:J?;#.B7GS"2CB;I-"%Y31_(>0B3,9I%02F!
MB!-Q2,=IVP=VW[>P.6!K>;;=)@P'82A8ENUM#DBAT%_3>M_AD%!X6>0#C6.^
MB-);\C&*00PYQ7*CK:7>QL7Z,=]B@L!X7_-E6LL5A_O,TBB&^DS.,78Z!=BX
M=C]F5X7C6/#[* WJW8ECXJ&HTX&-:_AC:F.>29C2?T6+W7,$1[1ZENMBW'1:
ML'%-OXXD9 0^([;S9OJ63%B0"R!;RPE'&O(D@=DUD3RX@X+.VO>M4IH75)![
M&N?L+<98YPX;%WU(JJ$*[LDJF?*XEJ@A:UQA-8>M\X.-"_S&5^3L(9C3%(K9
M75G, '1Y,SG#JE>=*AQ<Y=>!MCT2,!'F%,*.?,TE1%VJ7%=;V9;(?H&L^K;[
M8\=W>CW7[5K=P\Y]'2^=,)Q&"6.<3^,H(*.8T[I*Z'2-TMWB8!]T^SVK_-G!
M0F<$IU%&^ 'M7OLN!=&":*<9I-60G&=97I\2#)@W+,-&3N<"IU$N^,YCR)W0
M"A>%FLAJ&>%(EQPCI,7>:23VPUP(5<F6Y6LQ[4!7\WIB.*+!55KHG49"?YY*
M)LH&GJ@F=$.UEAF.:&"F==YII//%T)$AI)];+FJ5U(#SA0H0DT$0,  "F+"$
MQ#AJO7<:]0&3!(H$<I)G<#NK'TT<Q]27.%K/G4;-P%G"Q*T*L ^ (.=*Q!8T
MK7<?#FBDIA7>P87Y?#BZ(H,\C"34$0,I&2AH44*.8EJGHB<&/$-_Z6JA=QL)
M_60.6H9YR@!C\I2K%=[%%7X _6Y8]+R[7&, ,%+1,N_BDEQUWV,F(AZJQ2$E
M$+6)V02U7@_Z[=4KTYK,UJ(,KL\5O5&4J<;NAD%Y-(*+M;/0 &9BI>7>;;B.
MLV:U]MUN7CC<Z 9CI:7>;23U0R F@-1Y&K('\IG5ASH.I0H(U[9L'VO*72WU
M+B[1F[RX/8AHH.%P[;;MM%UT*+7"N[@R;X8RVVK0(85,U7K+C 'K^E;(@ I=
MU,.J;*J*.)F!(LHYVZRX73!65 ?02!3UYIS'(=0O1'(R901D*B07=$4<KUP<
MW5O?F$%>"\DR KU78.N*.H)R%2I575>K@C;*BE5_]6R40K=BD9"NX+D9E &%
M<1#SK.ADU,FL')>5&I= K3:7'@#;C(B:I;B??:USEXNG&M7D6'^22PZI@80Y
M4Q_G8<@Z];@'+[=XJ_.(AR> )W1_!J2G>L+3J<7#,X.YWS, 0+]'<"XZMWAX
M0FC>\AF #"V?I].)AV< >[_?\Q_YO8LA;ZWL>R\7@5KB/5R7GQ*!.-*3/:'%
MWL/5N4$$X@ 0@1V<BU9W#]?A)T0@#F2*0*V!'JZ!SO]GOHO.-JV!WLMIH*\U
MT'\V#30@/=43OM9 _U<UT "@(A#GHC70?RX--  9(M#7&NB;--!]//-=;+;Y
M6@/]E]- ?^N_E\^F@0:D)WM":Z#_JQIH %!9V.T.,#):!/WG$D$#T*X0[&SM
M;5#K$L4>D0PJR3R5Y3:'ZFJU#V50[+[HZ,?+32P75"UK9"1F,S"U]GLP@J+<
M%U*>2+XH=DI,N90\*0[GC$+UK!Z ^S,.H[D^42^H=N<<_P=02P,$%     @
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M"5F.D^5"BYT;L%9"FW'-O6[-" [2 LS_:R'TR\(&J(?ZV?]02P,$%     @
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MZGDZHH;Z47/#UQP"6: AL7[HQ++J-%E"PW!>$UNL<! X@$@GS_K\/5-?:$R
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M6:D-X/>U$.KEBWX'?OB;A\O_ U!+ P04    " "(A5E4=QZ,_^\"   F"
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MSNI/\JU9B), :/<$H"8 _=\ NPFPE0"$>@*<)L!19_![ G 3@)4 V^L)<)L
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M]%"_Z>G,\G@_KGD&,\"Z8&O;!T31T$I< #;>9)GRTS:(^FV0<S%  1.3F$X
M &%BM=P&T<C5<.UTJ-_I'%8"/YIN._$EAGA@#%F?D!&+-&1_<&*N?R 8"8C#
MN%)M@&CRK(7 YZ+*JOQ/.$;5IH3Y38G><U/]WFQJT<Y:+K;HIA:R,OE$^!@5
M<!\TB4V_!<#D/&XN"\#*(NP8[TQ[$.;W(%?98W]*)&>U%;\!SX088"H(Q>;
MAF X"<SU(@!SL=#&@OF-Q=0D%TVSERG2+76<G&SICQ+K=!5 ,6823R%4$C@V
MJ9EV$NS(V4'1M**XV7?BT]\@$+=9)=_\)=ON_BH3'CP.8;;B)]9B; F@3(GQ
M0J:<1E<2_-9ALEYK!<^:O7AT+SX9(.NQM5,&H;!<LYA\ !B+8A<G[1&8WR.D
MA=J9J59JSZ]8J?L%'9]-7:ZX@&<&0+S#$%N\(!C!IMY L,!YOL^T%6!^*S =
M5/R!B[SH]P\Z?JC>N6^0V.)-K(-R !1;0\O&T! [F&D3P/Y/$\"@LPQ[Q@90
MS)P[4@#E"HDV >Q$$S#>#GP].((W+Y'&@3]TP2$Q-]D!E.PE:FX10+ X=D9/
M&P+F-P1R7ASNY$C:)TE]H*4^.$'J3[D9!/5>8&MT8IWA B!B7>M) 10;7TR8
MTM-J'_C5_D!O/YC(XF BCU"#M)V:VPH0B@2FKH!U+1S3<* ]0'#DR,+DMCZ,
MAB/<@,V"8&%Q.WZ%P N9LM(F(/";@,.([QWP>-R?- X&BK:44]-B+@$0H>;D
MEP(HQIR9J8U!X#<&G]9KGG?+S$\/@]?^GK4<+8>S;NEZ5#>\[3OCDUR$WF5E
M9US5]N=WKJQ2KJZ]JN_!+H!,@G5*#:!(8*YT -#H5&3: :-+C7X7H0+]I<J5
M)>+H=<K[5V]4(K^0.'!;P4IN:#<ALF[B054EH8NZ-AK!L8.64_FAK$4?^6U1
M5=UUS#7Z-\\$>EU4>;E?R2QYA1=4?2QTL7PH]O>LVF?2:PZWB]%0IILI^DV/
MR_XNQ0PUG*-OM4R^Z W8H8!OP6:2+ %4DI@S9@J@(G>/:H,3^ W./WC3O!]Z
MK!KZ@(^Z5O"RNR,NO>IJ/(OX[P4'QX^" (AU=."M9DI8&Z/ ;XR>ET*?U(F)
MG3P1=N2.'(U\>R-3A/X)V=,3"2?9$UHN 4+9$Y&-FN18WYGST0\*MES<=C_,
M:%!WE:2_FW_X]/#CC\ON)P_&YQ_Q^[3_"8>NIO]%R==,R$'9H)*O996+=Y$,
MKNA_I-&_:>M=][.%F[IMZVWW<L,SN3Y2 /G]NI8]-KQ1#SC\5.;B?U!+ P04
M    " "(A5E4#FP\)04"  !W!   &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6R-5$UOVS ,_2N$T4,+;)$_VF8H' .M@V([% @2M#L,.R@V'0N5+4]2
MXN[?CY(=(\.:H1=+I/@>R2?*::_TJZD1+;PULC6+H+:VNV/,%#4VW,Q4ARV=
M5$HWW)*I=\QT&GGI08UD<1C>LH:+-LA2[UOI+%5[*T6+*PUFWS1<_WY J?I%
M$ 5'QUKL:NL<+$L[OL,-VN=NI<EB$TLI&FR-4"UHK!;!?727)R[>![P([,W)
M'EPG6Z5>G?&M7 2A*P@E%M8Q<%H.F*.4CHC*^#5R!E-*!SS=']D??>_4RY8;
MS)7\+DI;+X(O 918\;VT:]5_Q;&?&\=7*&G\%_HA=CX/H-@;JYH13!4THAU6
M_C;J< *(KL\ XA$0?Q20C "O'!LJ\VTMN>59JE4/VD43F]MX;3R:NA&MN\6-
MU70J"&>S7+5&25%RBR5L+"UT1194!3DW-3S2+1NX7'%-WAJM*+B\@L_PO%G"
MY<457(!HX4E(25=B4F:I(L?+BC'[PY ]/I-]B<4,DN@3Q&$<O0///PX/_X8S
MTF$2(Y[$B#U?<H;O7/\_[K?&:IJXG_])DDQ)$I_D^DR2-1*7*)S>+L5[H@T$
MMY[ /<-#-B=U#J?"_!L2A<D4,Q3&3L;"/<DGKG>B-2"Q(E0XF]\$H(<Q'PRK
M.C\I6V5I[ORVIC\#:A= YY52]FBXX9O^-=D?4$L#!!0    ( (B%653U='>Q
MRP8  $<0   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*5886_;-A#]
M*X0'%"V@VHG3KD6;!$C:%>V -D&S;A^&?:"ED\2%(E62LN/]^KTC*=E)TZ##
MOC26=#R^>_?NCNSQQKIKWQ(%<=-IXT]F;0C]J\7"ERUUTL]M3P9?:NLZ&?#H
MFH7O'<DJ+NKT8GEP\/.BD\K,3H_CNTMW>FR'H)6A2R?\T'72;<])V\W)[' V
MOOBLFC;PB\7I<2\;NJ+PI;]T>%I,7BK5D?'*&N&H/IF=';XZ?\;VT>!W11N_
M]UMP)"MKK_GA0W4R.V! I*D,[$'BSYK>D-;L"#"^9I^S:4M>N/][]/XNQHY8
M5M+3&ZO_4%5H3V8O9Z*B6@XZ?+:;]Y3C><[^2JM]_%=LLNW!3)2##[;+BX&@
M4R;]E3>9AQ]9L,P+EA%WVBBB?"N#/#UV=B,<6\,;_XBAQM4 IPPGY2HX?%58
M%TX_R3 X$K86%STYR4SYXT6 9_Z^*+.7\^1E^1TOATOQT9K0>O&+J:BZ[6 !
M2!.NY8CK?/F@Q[=4SL7182&6!\O#!_P=37$>17]'W_%WX1IIU#\QP$*\0916
MJTHF99A*7#KR9$)Z 3;>*2--J:065WA)D&'PXL^SE0\.0OKK 43/)D3/(J)G
M_Y/Y_^Y%?"177HM'LNM?(]1Y(3X8L/DXO;9.A);PONNEV3X1R@LI&FU7B+4E
MJ4,K2@F793* L0S0N4;Q."^4,78MN9)&8Q YI&U#Z^S0M$*!*G0(7SK51SX[
MJE0)X+X0:UGF7RMEM6U4R6B<[!7YF ADJ=LAZ9VMAA)M1_RVP_SHIY?+PQ>O
MO;"[D!EQ[Q12UDNMMR@1@YY2"4[OY(7K5Z5M8*F'BD38V-&-:82G)F:Z$)M6
ME6WTRF1=MA(=H"0$6@(<.SA+.-]G$J:%*XM'I&/GP%%O79 K39-9"N>.U_QQ
MA.9%.R"*B8EO(60N]TAZ_\"*B802?"D?&&2B/EI$C\C:&A XNV OQH,_L&%*
MD>A*K+:W4EN(.NLI8"2$B!]^$_)*>>LJJ.96]A"GUBP6%-R#(4Z D5<,# 4(
MP8K*#0W(M9J\U*Q(QNTH2,5/A6BM[U60FJ%;2-9$3!Q-.4ILU,:^VK'96C%6
MC"?.FQ^_\F +Q,T 5;;71. _X]V*%3BJ5<B.,R;+Y"*9/JB0"N1.?NZF;S\Q
M>XGH43PR.%460E8<=AD#XE*I,'JFBOI!DD?SVZSV[=:C1*6)TI_(+78?.)M
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M#*[9%V_:VI7.^F\>#[ '/OFXE/6>\WK7*^L]N2Y^:IOAX(N7366K?('' %R
M\%HA?'Y][XHO;'E9/'VR*:ZOKI_<L][3<.*GM-[3E?46CEG\U[.M'WJ@D/^^
M9X//P@:?T0:?_68H_5?6*][TKBE=5\./\,1-VWCXI#)$\W_XMR^OGUQ_7?QR
ML$49/K%5L7.-@;=,7?@!_@!<-O@"UJG'RA8#/&UX)UH3?[]ICYUI3H5IJL+4
M-?[9P:=^W'I7.=,C)*XI[@ZN/!0&-QOZMJX14M<,MK=^*)PO4$P,\'];71:O
M\.^EK+LU-0 $B^ &<!6--\2V\(?>%K9V0/L(^26><''IRL+/1URZV)Y@HU_;
MW@V M;O&]O[@NO@P;8%GW'H+>^)9\!R#:5!"P$>NKRXZT\/;^%] <V<(YSVR
M.*"DW^!9<8D2! *^?PL8,-O:QDT HVX K&PR:.R'KO4CG&AH\6<030!NW7J/
M#\)[KAKA3GH[C'V#&Q7;=CA<%B" 8+O63VXQP_[= 38N?@*4OD\/[0N@# ]O
MFZ9X<G7U^PW!#>(9WK2%/P!Z#VU=P>-$+%]\'8[ J/<'6*PPOOBY;99NE:[=
M_GV$T^&5WL*?E)H*L]NYV@&H<)1;VPMUI.1T@(6]VS=NYTI /[RTJT>ZE.TX
M%$T[K-#2!LZ.A.8G< C2"0$5@@6T>L(;F-$P7W/!UPS8&>BT(PBMGK%2Z<8;
M^J0T/:"Y*EJ^>#XQ*@3G+X$OX5?OF&"5Z5X! N 8'D@2+@ (?8LD#(]LA,/"
M.\71PNU62$@F<GB/>\#1&#IZ!>@$KZ6D#RHZ".!W"TBF4\/GXQ'IW\++9=M7
M^$Q@8:09_3G=G!=W/=(?4B3RP,[ [[<&[@((RPV' AD02<Y^*&U'YX13/Q <
MMX8(Q;L#PM[U[9$P#D<' J#W >WPL^WI$O%$0"C_P(V&!$"@NEWR*UQ4@W0#
M.(@281/1ATRE0)Z0/9)UW:[H^G9+C(R' 2O'MPW\"HSK!W?$#[[&IV UY$5@
M:0M\3X#BGG"-&_CAHQL!0T=X273M2&X9S[3UH01NW5L QI66D737CK5>K(4;
M A$.ZYLF[M495Z%8(>&Y RHVR?9G\*3]X 9>\ES%5\>Z T0.+'!L4396M\"'
M8(ZU(TKK_CTLOB/ILXR_!F% 2NL!28G<!E"'.VL;72,(4M(IO/L1T NR$,4%
M$><EZ;>^ @JH3YN,98_FQ(<74H-S,O:4)5**T(6%<ZJ6+@>L/30%TV5%XK$0
M07.E&+VP",I:7AN@:DY$]SZP4C?V<$5>;^@,I3*(TUZH6FX  #UGP4>W2A1$
MRC=A+EBP ?1,.5O(13EXW[;5G:OKR^*7!,5E2T*ZJ>0G0 I*PGXL!U(QRN<L
MRT3VH38%Q=-X7AGN?T1 +\E& %N_%U5G/=BU/I,7N$Y@8UQ(4,HLOH37C]L<
M9C<(?E;$$[%W2@J!J_VB3)3;/J)#0\LB;[&@0_$:#\"B_B&2F$DQ)6Z\"Z1'
M>4:YT1-#)JOA,@P?H/5 VYE580@723L!5MO>DB#1>P\;*E%<DG91[D^VW"0T
MU%R -".RA=NTID>%"<12V5OPQ3IBN[-7;][^P1R[KU^<LYQ'Z54#@A$FU ,C
MD1*R!9 DT'R_9^X3&A+J$ZD]%#DCP"O,>:GDGF*<.1\L''"@FN(&J;$I3TSH
M]=R,3;@%;=!&8 4Q72_90[A;W9;P8<DKXT<' T?;HG1*C$8XU):?WXU-*2LF
M+R'!#P(481=>^,OENTN@N+HV/1"41\;A-X8HQ'NT?YB]DL<+N]L!Z_B9"M0M
M<*UA=EY6/-DYX77:B;B6;"UF39$>PID[P6^I^!T2_ H9;\1 <\$5H-=!*(_'
MD4_=$A6C, &S$5WS6TOF:W%6/'M]\V-Q+GI3Y0*R1.$M2'_D;GRO;1 [<!2U
M&:-MFQV+\,+R"*WJX@"V=WTB Y&O&SPB.&/3'IUX#;OEA2(=I.A'P_-3*."$
M_-A<' '\ ;>>X5/ET-0&RJF&:>3@P*\'S8&F/MX8(1YLCK#ZPQ;#FQ=JTV60
MA:='54H#G/,M$%WF=_R:[O4,_M0>P3P0[MX0]8'+9?RA> GW!4J+I+8R)'U@
MDP_(4D;J<*A?8,?2]NCOZ?75#A[&':.?0# #-H"  1^@(<=>;/A=XKH,A]X2
M@H:#9S^C013:U-R.?T,P2,$&B5.W=W! ! BM'* 4/!G8=[7[!YE[8DJRH^P'
MUA7!*R3 U*'<,78[$(9'4]IQH(O$N[H%1@)*HN,I*+EGRO=/ !D_7#B0USO7
MPT_@D!5G/[[Z_O6YJJ"=>'^)WNQMU_8D&<B%-1_0$ &'4N5+@!P==+K1AT#"
M $Q ^3X!)<<WB7C>1ZBO/HF5!\N"QJG _@!:! :[LP (_*M$D$+##S+U@3 A
M"8&R"(\MBP".@ \/-@A)&_0+<RO)<4.T)88[6Z5(Z7:/(JM%9NK@,[A?TID6
M+SI*5Q238* E+_ZS,.;VJL+)-DKMWMO:'4"9\TEZT, -V*FJU=LMQT1$ QR"
MWO7 5FH3]585#P,((KS=6[KEP/9H6(W12A40\6-1 PMH*<1(R+WWE*L2CY[O
MF3BFLML!1'NI[%H"17OPXT7JWQI7XW,7@*P+.@>K):3@N0OW?6X2+]OH#X4$
M-YI1^M_'%O=5=P3M=HY1L,/+?_=TM7!QC3"U*-X^$\/PJZPFR^!+'AQDE+:K
MKRA#=N.0$'2[];:_I6/ ,^"[(CV Z@9J;GNZ[^TI?4C@!Z/)\+911-4G(1T@
M*CQ\,*:7( *A'M1 ZCH%P-!P<W #KB=#4:DONT24H;B)^<#KL!:YR:R#5Z12
MBK/7-Z_."Q93<R8)U +\B=@O2>4GO-H!NED.1YB\!B$?3!D;T7G*_?8#KHJ2
MA V?7>:51^6#<A5U-',;FMTUZ!.,5](=E"".P+4F.X@<-S; ,Q$(?C4<% ,K
M)7"?$$!)3KTA_4P \=YR;Q%N=$'3RT#CI2W9<9-P1'2/6LM6-X<7V2DLHQ<*
M6(0K-$=4)/^P[#IR&$OW7<'?:>Z)Z5;L/N-6'H^+SS"TZ(^E2VQ(<;E!/0.
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M:E9C(Y(I.07:L]Z/XED'N2+ D_*^:'<4A$3JZPDDT[!\/:*L[D]P_!:6A4?
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M'65\@0DPX( L.,E; 9Y,7* &6D^JR)8N3EEV\=*PAA?-J]&#4YKA>HI6E?(
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M=\"&X&/30A.D:@DU.YA1_:7^Y>47R^[E['%T+Y]AC<G@O,K@-P!R2UO=4'^
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M:$<7N7=CD!!FT"8JW#NNC=N&9JGD]M@SGK5/+44>S]A86P9'USZ77E\DZU?
M?"!'MG72A/ L-E_%#[6O/M88-*%07GK*-UPX5S3F*.GHS@Q<,@0. "O1X*'G
M$E*CHVEQ4X88Y9O,"0HVT<ZR,HJB,EI(%&3)K3*I%!6.AEU6S*Q,Q%XC8J\_
M4\&7:FD6R6+N*@O[P"\:B]A1H0R&.M)<HC*GC>2;7UTH$39+]X*NIJ0W0Q]
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MLM2T?X-3+*C]#HW+9VF!MS(6&_E(EQ2-M3*=I<S>S$K#"0C)7F5\33B^-6Q
MRKP_\JWI)"J5.*0:^A,EK)/WXW/-7 H!5B\U5 +T-R1_AMI-NY/0R^'T<XI=
M<2UU9)V;#AQ(>C?H[4T8!B&UE@V7K=$X(W%@V+VKP+[!0B"&,:9L9DU-X#EC
MR0L.QXO6-045.\E1KA\YK_64=/1-!J%@A>V)A35^2TQA'TVW?)PX7XW:+>\Y
M$?(5L'$3"[N+,SD9=YA@L'#Z1#K82TI>YQ?E-&"+JC9T!E*U]T$FK$A1BB;
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M]<]@8U/E&\7EAJCG!$)[!I_+BQZ+J3Z'-6P11@=1H&CG,E%P7\)5&@Y,-8>
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MVIS_Q4B(J- "O-]:6S9?Z(#V=_K7_P-02P,$%     @ B(595#RK3//B'P
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MI1)M_;XPOGE(UCMP;G7SDP\H; UO@%F_Z5_3I$LU!_<N<U>VJI,<0DB-??P
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M+< \?<'H7NB _J/KW?\ 4$L#!!0    ( (B%652H;+=O/A\  .5J   9
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MM\0F<#&#M03_A6Z ,-^1' (IF/Q&[CWN-?*3E@03O!_ @J=3[57 2 @HA?7
M\7-5G9T9*%(!2@6(CJP&^(,6WEC%U=87PU-T:$Z:9^;Q!\N"9[W(:JT5R)Z/
M*#H-*K_T+C4)BQJ-IZ0=3^ GS^_I8OJ["C[( X%IW2 *;Q"%4'\D"MY&NDFT
M.;P^/G&W2/(B9OZ%R!E4<)TQTX+\H_/8HY ZT33>$<FV$UH15TPTUD)EO08E
MFT) CO-"XI(-.,##.]2A9 S(;Z 5LPH6N/*@ #R^V.V]AZC&6:G02X?'SGAU
MQ@-J86$T*Z"!\VH.[\F;L_8PI]AI6J7U08Q7W<R=SUSG&QUFV'>(B1I4\#S(
M#L=K!.&7%EDT)3A5X.QWX&7\'EB%&D'\R>M..M\2US$DNA1D]4XMA#6&S:DG
M(-H9, >R.$0-0"L]K?0IOMI0O"I@ 8"7C_ VZ,$;6"0@6&X<1USPNX>T1$F#
M6;+.<,@X!,@#ZL# Q6,D4 VWL,/W\P2G92B_EE:D$\'I('L K)=8#07+CY*I
M0.M[?DOHJ@ ILL<R;;@J'$(?8E"B59U8Q\D,RC,*XP^^[[LM3;_$Z.W0-^G6
M=MV6XE^IT-Z=EOJG21][N&UA(RN\ X67^XJ))P&!/](P0056'E6EXQMT"CBN
M84/9T"[DOY+_U6 *+W+RH%E:P>7WA.\ F%0=Y 6YQ'D):XC*1_M=+1[LMHS:
MXE$ 7R!_%+]SN$#?*IO).#WB]0:-'ZQ=]C@,@M"&A]5":B^S8ZA+&Z]8?XPC
M4D?I[B6.*PZ2(&Z7/=D,NZ)A-#K$W_)8N3"CTBR&OW =+@WZ20IKA3"T)4%'
MQ%VRA/;3-4DM#>!R#\MX"<KBP-&#G9WG5[,OXT*R?8R."H138(E@9> M,UU4
M5/)HHAQP.TIF8Q %BMOZ3-UIQ=X3R#8R&AY1;1JLM+D,EW%+NQ,.W2S:R9Z:
M0NWQXS8&#/S;O-86KY [S>&9B)//M<8 I1?%$?S[H?9RL=Q@'5_,AV4F,J#%
M!\\04<&H/I,5?4=U4J';2TMM[V3I'S5J/"_+YQ1/N*Q 73!6,+6-+"J.DPI>
M#,-:3/PP0Z07M3O?Z)P+%Q6[Z(*5%2I#9+B!'C\AY('SX/V+(+P*1]5VI?F*
M707V\X4F;#A5>Y_9R@19E!X&RX9YU;/CD,G$S#G612XQ@XVV-#4)BSW2?FLA
M=-)GB(QL;49M$QNH-2\K=:FU9WP$EQ$\VK]F$9G5O\4BOFDEWM"CA9F2(F#/
MMC-;W9&G6E?!2EC/M)1Y"EQ<@SG8D&I&=^W2M[6@##'A@CIL+64>BOC0VA[+
M5'2U(R;["A40&J1.:=9A=%,[:$UM#2\L6+VI:JW<M"%O31')$X@/3HA]R+^L
M49C<GE_0E4OO2#*SBD,(QEWK9Y9;LN>$+=BEAYQSY2_%]0%]8GSB0P$^U1<Q
M^!GH="'>8I;E8RBC) >(5R'W6!.E(@^!'4077P^IV\?  )1!E>(G(],D13\%
MNNB3EIC_HIPEE?S$:[F1AS6 GD94L\/_QO!?=-7\^2N,=.NH:6I3'TUF;I\>
MR[90.0E^+@:SJPOXF"SP>S2^H(\I?]"=P12(\E.WB PF5XL+,5W-Q6 YOQ"T
MR)._M3Z1K+\J$6MR/$C6FRZ]0G0A T3Q"!.T695A4[0-PDV,#W6)Y2/R_JD*
MR2%^)&T1%F7*A_CH$008T=@D3YL!6ZY54:@'4IM.&$MV/'$XZV_8V)HFX@]E
M?#OB<EN0P/=0CX,QM6&*':PGZ8'3R"2[5PE-H=3I-= /P%< ;.B>-D\*A*&-
MJ">"GJ[V"AR82;41-EB"8UK!9\PY!@K+_Q[G-884R)*@L]C>-$E;<L 0PX3Q
M?4"'PY382MGS:!3-!3C$&6H6\A5E8MQ4!F$5+;D;@'G!U8>V=@F #<5TM%K.
MOP/<OLCDDG!BOD6=29($R\#%H$P'C&PVKBM?!H=ZBD$('6/VA4L? "1'FWR,
M'R_!6E),B+GTC024+VGPTTP7NI">[^&E]YI32'/C=.]EDZPEDE'?<H3V<I8M
M:#$B 5R?L6*C]"P11:M7(M9KM!FN'"X^Q(7XA_%=Z.:O-9&,]+0OEG>TC+](
MX*M/Q =X 52"QEJKW,EH-OXN7*$)**!H.!Z/Q<Q^FXRF\]9CJ&*BX60^%G/]
MB5<^Z<Q1FRLUG^%DW\AU81AYP@)W<K4:3G]H[OMC24WH_GB/ FXPM7OTQ<3;
MVU?O/_+0B$2S./&7H#=@MJ((.VUMR<#K4J#P;,CO%8WZ,0FI-1)W4N)*PSJ1
M38Q-G=L+$TRA >\HK,C7-HI@E+W*0B%UW*IKZA*[J?Z_$CB?0CD!A0DCYA6[
M]Y@4-M,P<FFIK<Y5>WSKMZD/)GG-?K_SOSC3W589<<E":9782T"\*!ZI<\6J
MA%]8';SU$A(W;BSWW!N$SZ)NVU^<"WC+M5)PGV \^G:!UZPK21-M#.[[,>9;
M./^WJ%)O@>Y.U6ET^6+IQGBKL(\%U"\M!54G=5'+RP<@*W,6@WQ?<'F&D\64
MM$H$Z@(^\8=Q6=[BTY_P:5)LYO)D.!U']M=\BCXBKGBGVJ3&@Q-U.AW8[0KT
M+'EA2[DKY([6?2VK!TFEIF;AJ*<:UE%SU0XU K O=:?46B^V^<<ME,<.\!#U
M/[SF-';_G7!Q;V). 5U30>6M[<9H_G[M3?MU@+3A0[\]Z_:4VGX?5#MU.@Y6
M?>:M.C$%,T-PE5GD">"O&6R?(SR?>9R$ YUPS3OQG2P=]RV&R^5*1!-[83J,
M5M/S(#6.LZE],1K.YY&8S3WDQM.3R$&X6M2Z J@"1/WDI@4W@R$6$S<@.&MB
M/AS/KLYC^ZO*#>BW':"C8!YBC@[#=++"E9SCP@&99_0EPCN3:$6"/ES"LON\
M!0;J"?SUM:L% TX:C#0>CI>H9Y;CX/H2=-&_D.!7"QQI,1L[WA@O@0;#532V
M6%UAR#<9 RTL0O@4('D%2.+/.2P0TC BH@ZOYD2]%5)R3N2%B\O5##B*_ _
M;JV:?49L\<I&YJY#]3VA_\&/A;#?[8#U[@*C+K;BH#MU!I=<EI+BGLQV-06-
MC&E5DP:B6IHLT+V@MHQ2$@X;B92W.<D;\!73BL-+TNT7)B6<93HJ)+U_+-1]
MFI ;P5W>9'SRSEC%R].YBC*$MI^IL4QI]Z4YQZ) SK!*.B4/ZI%CZJ,U1D1=
MC$:)MD-PY#2:5!?'R@2F$G%FNLR'_6^.$MS.1?X4]<A41$?#E@DV">CL(2'G
M$9YSRNRY;)AH97U$,PRW<OF%:P ]=N6<-?B9V,7WI5PN1A<D'.^$M:N0F1T/
MAR ]ZFNZI/G)%4!CZIX\@\,@POR*^7^^,/_?-.@,W  OO] !9 )/+6;MY,I@
M"J]B_L<@#\*\9%5G\CG3Z;3#1>W@4/0Y"EL\MHXK)3JM$WC4Z3!*0%[8XD3H
MT7B>12.-7C2:6FS?K<E3O=1M**>R:AC4:54;Y.]TQHB:JB[^8BZM\=,UACOW
MW_JD7OS]D\MW^MY/X0(%]ELY_OAH H#G8K8:+L?H?<S _I)AFEX-F3\'T7 Z
M@ZD.5E? *]&$.'>XG%.2;H9WX',Q6UV8Y"0UDZF\&0BT:'S:A]'^=4H3[$WF
MS0 EL"Q7\]Y'7G<S1(^KV0<E$H,ERLCB1&;QUG;8GV&ND[;5LCCU[&DF:A=V
M5!ZP>A].?9\HC8/I:GHA5DL_5$I-^&0;L2BW!*M49X05)49=OG2CS=(@NIHA
M>2[ U>E?"WA(+,0 'KEH+'XO 8HG)[F?2)'!!/"<\;^^9QP.Q,O_<NI;'$CM
M>K0PN0X,JUW1#1$Y,?.NT/^L7M5*JK3JQ"N5^%-[4H3FESR\W2IG:Q:ZTO%$
M%?GU/K*&[W2F"?5."*#3ZMUL!IJ1?-1!-$'-%RUG)Z'!0RQ'5QC31[UL/YB>
M'M9ZT_;;FT8'@)^DN9/Q3J(_>3C ;,M*;7X'TI= 9^SRS!/3P,4KS^-X<8R3
M8)>X[&SI=:UFM@VEKP7%:S\YV<=_IOOP&YI41H9+X5%B+5UB1%FS-JN_LX-Z
MU$S[;8K$S3_K5B>7E2R/:7X)3AB);+&+<ZRG(A,TB5@^M8'6K_",B$V^ I1I
M)RE2+K(7M 2/EAYG2PM8=#I0!]7S",*P@ZZ,. \,>;/=+A*J1^ZYT<E;DR.6
M7RK,%QQX>R%EA+@]XOQV%--J@ UC\4&:-G+J)%SW5O-LTS3K2^U+@EFC"6:/
MX7OV::S4<8,2U4.Z-^.8!M&/(1V(=UV7LS=6(C'[!QX<[?:)L4:>-8'"]'2W
M$I4638V,6)T2@0C^IS]JC$;NL'V !>0VC/;2\,7$O"CYQ=*]&,9"9(-*'526
M061TP$0FSI(#EM_<\I/3>>[^ST2;MTR7X ?EZ':XNKG="(:*;!/@^5RLPH2%
M^T8W5K.^NTY5>X.L59Z48M(RTA/1=F3F(!@%!)!>L8K*L0AAUGJZ?:7YR04H
M6A-O@JM%ZT&XM+IJ7[T2'^IUEFXR:HF@?16M9>5JU&*V1*\=O#UO3-Z!<@X
MN?M3SDZOE@L"Z*TI:@#-Y'[]YHRKUAX&- WM LN2!B>R7N*LPO/)=&*U4,):
M!>^.FABQ /X?(C36"$6+:0="XV[E2A3'VZ&6I8:B?0R!V/QJ8:'AL\_G*WL!
MR[BX=X"+ST/J@&:D?1E'':MJ] ;B)/4T#=E+?T.1WV 3)&/;/6.8,^M2\IP5
MZD#"=E=OXWN0%AQ:K=%*Z<14NG&. I?'_#X&@*2R>Z1DF<+<XR* ;=KY4//S
M=2G-)IDFIIHO+3IU?AZAH;<9IDVCOB;>UXX7NW*. *)-0.PWB,;!>K=QIZ?L
M,WXA3K>&V(UA'>MP1J9\M,=?@_9B\@2LIT_"^NGH@DQY!<$67EQJZ[K?Y()^
M5E1%TUY^BX0]5:/-0I%?=@O\7]0HT6AI&UH(_&H\[M,H;76I50(2IJT@:69V
M+_]#+@M,;]C*?2E2W_W C0$)NK _!SF[IZIHSJ"@$ZM:G,.@-3T'T0A":]MV
M\WPPQS1'0.$H<KQIDM"\3U<V@U#C%)/&9UI'5\V%\7)M[SC(T34:EP&CW2A;
M<OCB,MP<PCSHM3NQ#\OY5FI3R/5F+_A^C%-N0D.%24ZIC8X>Q2!&SY0VW )(
MNXW3M4X!@ .V=<7)?9Q7X%KAH0JZW=80P@[EX&*CJ-Y$EH4-H*8PK&%0Y0*'
MTIW"E)=W%*%=&Z%YT5O'_%QA*@N,4Q^U'C[$7\ *_"E+O\76$^$T/]8Z3@0A
M;#]:Y^V':8\0(Q8VD!!R!7>C &=+;FW+2*'I=VM]UH.>EX\ZA8%O\06(]/?Q
MO4FV[-/='F-^6 B%[CPAR\]-_>? TX;'7EH0QL_[SYHJ6K2JX-#5.?=<R(26
MF$_ T4N@E5B"N]QQPY..HL,-OR,]@G-ZW[=(Y.WJ,>CP^$-1UF@>2_%'@!:.
M:^QUYZA#_,U@]1BV#\!;(<K-(V/1KFZU)F>;HB3O(<UNP$XQCQOL J ^AQI4
M+W58:'_A)"%<V?:W#FZQ:.KJ$:,#$"K&-[<;?G3OSJ.#VSFL9B]LA7B@_[7!
MX#X*&QER9SR2%S\/*@%&'')C4DV5-9=G/D@ EZA,[0RAS5)4<K//TS\0/!<B
MO8TU':(1'!O2C3P2W+7[6>MG#PMP\E"@S< ]>?Z@G^MDQ_U+A4DO4-?Y[58G
M)CNEC-;45D%Z<D-;[%O5209W"@/NYB$IQD3FIDC787%X _RU ['\DV?@GVG@
M9%(#(.28'])P5N9X!S=Y7^\I,S>WR\^5=*[=9/RN@G?>OCB_F(/5U(]HA$EU
MO:)Z]9MSE/$WV?F%L)R2^P:8;N@*\P#,^'BV%SE3N@FSS^3]1CQ[^J[1)T8)
M&5GAR/3TW4:!M@P2([W1?=!5<^+7O/'K?'0]7:S:Q16XMER-6]?Q&M[SNF26
M8[HZ]YZ9:S?(G-V T?:3\B(=(\*E53L+ 9?^M6F,\V2*AI-E.W_!5[&3=MEQ
M#Z]&P^EBVG$/K\(35U'7>U>17X4P=)Q<V)1Y1W;7KL@\ZOQ^-?:_?G#'=M@M
MKGQPA\/#([S_?;KTO[9+H!Z$6==7K[SF?YU==7['Y@+_.PN1:S@;+J=8X\66
MJT;GV6JB$S[<H[!LW!_/5X&V8I[U5<X-=<_ND%_--FK6L-W)N>5R:?_O3MY%
M^G]O;8-#3)ZVP-%DW/E]/IX'W_\)G%O)_,0"=WSSX 7#1)W?L>?#_\Z+X\\I
M:->B:CP3:'6U"C45=4 QB5 X%KJLZ(>R+I.A?/W"C<AX/-)&5](JVN7J[^(W
MH<$Q?C3F3.^7QVP+'BTA#\=,/4HI[)$_64SU"BY]^#:GY3#XI0);DB%S:0OJ
M9*>Y@X<VX=$!0T&OE+:_/BRW@2OL=<*=6AZP87,'.?LV%$PV=B*/L+LL;$5M
M1>'4:6$[EE 3PK3])6C?H(S*:&7#]('&P 2#1GQD8HUB^]0=&S;AYE$G>C>!
MZ-TY.^Z7AL$;JJNN#>1AMW#3"=ST23BPEMJDY+>3S[E&3Q8WF$%<O]8K7_87
M&+RPV>SKB2Q[+Q=+<9TD:2B,5TM_QZRI6OGG$9)$S)=B-14?F(W1MHZOL (_
M7MCB*U9U;875O>P[1,#3 ]J4IF41T$+8'[U$QHW>.Z5/OSE;>N5]G*<SC+=&
M-+PD5_<^2"UWIF&Q,_=D!>UY-/?3B^X(J;C5U?G(V0C=XN4?C[:6G)CH+?!Q
MY?), NOY8C)NI,*BZ$3VF]QSCR<YS6A404/+X*6[.%?;%-8?8N>Z$._N7HO/
M*H49WL,T:\KW8GYG07)N-GDT8)D37QRI&O3QI$(?O%>HQSB#NT?#=P UBD;S
M[]#_QL755<TMMD;: V544F],\&DZ*N_Q%$SPLTJ540R*N(4S,.FX)IUGK4T[
M-#6002_-4P;1)QUC8U(33J1TX92T*\28>*815H/59^8&;^,+QZ\Q:=E+D[*P
M\2N[//#NZCL^S9'Z135R5;"%1E=LK=1C'KE/]W!Q?]Q@AG@#^I;[6G%( '=(
M=8,M[0>:Z1Y:?XE.#4&G3W'*,!RH@\7"4U2""'2D9;XO7KK#]I6>S<L]9Z&:
MY,RFSPZ9W8 8]+.1U)M54 N1,[#->"G3KH-7\%0<LW^&ULK62W"[_A?=+>#;
M>WMZ!UQJG=^A]VEW*6QJOVINIFGLG!DX)Z6QS>:B4^\-:;/D\^G<RXK3(9&%
ML55Q8WI<RIB.HB"+WE6>,+ 7H_%7P8Z<Z1_Y-N>!3U'5A&%APJ5#!ZR5"M-)
M.,3M+_H-HS.MYN\Y"9SOE$T5A#4'T/1II0JT\DTXON_6= XV-A1%Y+TH-RW+
M&H]>0COJ=2G@*<-=W?,ZO\7,F)+,L@8UWL?(3,?NBLY ?VD7V#^N%KB5[E /
MGC<5O8@P55P+3)D1AH*J1A:/D7,!_:H1#@).\<;L;G1=:J3A#RA;F"<VM/JC
MCDDI8UXS@9B&,W-H <TI@)U:P2N*'!4$Y8]B5P,/X#D=6HT>XL^<A.[1*_HH
MXM)3$X!\6DJNU&K#I&V6Q@(3%$/:F'^4]BC8V!Y.X=K$4!D0F*2H=YC\!"
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M,3DN>&ULW5K;<MO($?V5*45)254018!WRW:59&^\SE[L6%ZG:E-Y& )#<M8
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M5[,[Z'6/H<\!MRX4?95.PAXNMX>A"$RG>SH%F&PL/ZB0A@X<<H&^4'B1*LD
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MT@MXOC)@<=4%;=#\I/+Y?P%02P,$%     @ B(595+Y7R!Y%#0  6R0  !D
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M""Y$+]5A1$ XA[&*CK*[2/;"<XL+_/6H.8)H&B$;5#JC4:>$WPY93MV(:6R
MW3W[6N[(L]3>C\7//GK;563,D+S0N9M9O/ =GT%0&^6SV"HD#"K<UMC:UX+
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M3E\3Y_!YN0%5IF2(OF);%P__QE6;."&_=1!\IH*C<E*F:<<U#9FW9T)."RH
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M:SXPN6/I>P 6BX?!] YVRJA2(\TPDR="?#.]N]@8EH*%[0,\#X@>_;7D<D@
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MQ(>Z4,50P V4ZS3,@H;OLA<E?J7R6(S22&1)EKX@;]19/&)YHQ<M7K+%=_(
M![/BUAA9KQ5?_^MVV5@#;_GW"XN-N\7&O-CX#X/W]\@3_]@H?BSK@]C(1C0]
M6_/^\!T/;[%%1NPW9;X1MC=U#31L@Y@#$&5N,1E^F'_&^!*/+S_=?]]<"5D7
M8J<,\T*=*[=6&'+'0ZP6N3(6U "7K:4'N%(/JA)JNZOT0:DF%E\C.(NB),6B
MXW->H-;U=7@BBM(@EK5I(.T@ELKI">WTCN8VM-ZN-3DL]^HT0J\ZJP# %J8[
M4Z1EBU>R-)!F/H/^'F35JO#"@GEH,B\1$["0Z5#;*]@I=SNC'[#V\M"'[B]_
MFF?I[$N/_$97 !@6WEH!-U;;)> .KAR)Q0@1756T'UY;1#/3%0 Z^'5:N]&F
M_ 4K 6FQ:FUK5-@@MW]GES^[\<$>N9>F -"0V"AK*PS>EQ:^ 'IO6G/P:L7B
M0]@"!U[ 6YKC'KR,_>\ W2NY5K4RL@(N#W!+H6MU;3>E*822\-Z#DD9@/XR0
MD&24NN8G\,]2%Y&S2@*)FB.[E96PRFQIK=EUFO!TF$F.[=!PZKJ5[0;J/3%U
MZ*7PZA+HL0UNSVG,$86AYS4\S@LG8]A2AXJ# U-H2!]L7@?ZA7EE@]Q#-H @
M"GZY*A\I%&J>RJJ*0EHEG!/XY\_\A)?8(<I5+.Y.FK_?D!_29"2Z<DLBZY8]
M&6IZ&\NF:=EYJHKBDG NP:>U/;=NGSCD&@2!+9700UW#$85>_N2B0,#E^<'J
M^*PY!1<[ ?1_@HM?G7$(?O4; $'>]SX!? F="!ST4!:J+FB9O(+QA2A: V-9
M&NTF73N_8RQW\B"7Y!N:1QP=1]?PY78'/?RL6'SWX,.9+.E#%/R8WCT#GZY8
MZ\Y1U>-.Y=Y3L1U/=D<6/Z&N(.KJ P$Z6\IE697V0!*!9PF>9L*FVX$Z5IHU
M=L5Y78U@&E ,K5XC<,-Z(&V]KIG"!BO^-W>*G;\[Z $\):-EZY@GR"[K\V2S
MLAY-;%<(J;!!VIS$MVG9R\)FD1\U1/55F8=-;%IXF@L-CI@S_!16!Q7UV.4/
M(#-XO[: '+%BY>-YHL\U!!/T!F48X>1R#GX3QC1+TH78@XQ>C1?SD(<BW,TF
M75:B<:_&Z>SX&DCO0H**(#6OVH+PQ+1%7\@X'0H9S>?GA!A52>^KCC=:WB!8
MRX9P?0#+R.L>L>6U6E&%0<GPK.W! WN>=PX XK97T[[NTR?V3\Z8'P^JK;91
MCM??53+_?'V?(P^05SKR)CXAJ[:Z0.E#N@>2"LPQI#,_S:5Y5R#!"0]N,"B.
MY42#FHT56&KD.0Q D02/K8CX)%N1M\90*/NLR\\IC34^!)^K0"#[/.\L'1KF
M+#'JY[:DZ&O %7!H)#=T=[XZ.'I'QT>!/<6A5!7BS93-Y^L5Q4B)S$KUIL"N
MJT@\:#@%DU'$^H=L37H.M#HCFO) 1S8]0';20E3-=-'-V+DNP$L\H]- (JG!
M#T&XO50+H;\HHZ]SS;S^?7P/D:&6^E9;U81*A.T!>%2(^,30<?8S4U%_A9='
M7$B?L'T%=I]PE@(DY<BN9S/A5R+ME(/YSMC>,(H@$!%L.8/=EOHZ4!8G1X%*
M#QG>8_9</ G12RK]J7(U>CMPO3/)%\59<2SGGVQP5:XHHL%[#6V6*Z*VNG4)
MBDM'3H"A. W5VHF$J%O;6, "S**3IG)FTZ /R8E2/2J3ER"4I=K(AU(;I]J>
M6WY:@IQ_K8[C'$1=(!^5>8F'9Y-XL0 !S6;Q=.:X9Y[$R82(WPLZQ4#/M#A%
M);].@T4\3R+ZA\Z$UT^3>#HZN[X+3:;07LWE7)$)!=V,WK-C'FGA"_%/2H?N
M>*#?%;%:3BO6Z,.9R![%J?AS]YOA]].9B$WC!&^3>(S?C']/Q5&6Q L:D+'$
M=![/^@/9ZRXY@U\);!#^YOS_GD^Q?&YQAV/NG(H$/[A2H5^_4^/ESJ!HT4O=
MD22@TFT#)+$ @D8V'C<@]:TKC'X,.]Q=W*[71JW)QN^.KBS^+NM6@FE\@RDN
MTRN1+J+Q>"I>B>DHGH[%7[T7T*MQ-)NG@KT.]CK/=6\N1]$LF\/><9R.J0I>
MJ3+,NIQFTRLQ&\6+F;CU#1*$-BMEC NP[\Q:HF]WIJ&9V)7UM5ZM,#M:C&>8
M"Z0GXI:K4*XO,><;+-]U'+V*8"  WAQD7V978@J[F#JR+P<P/.NTL:G19)81
M"),XFXEI/,)UEH[$#XKCFWNX'D5P479"S"R:9PL2,XX7"<1D+"8+Z'&)>&):
M%J4CW@*X8@KG27"=HN@B.&^#1X RM DF!S,[T^DPI];H792J^5R& (H9AJ^I
MUJMK?\KI^O?3J"%>437WR,_#/FSJ+]'P08!A%(@9C6AK=WWE@AW+@6H<F4#A
MKI\8;"(5.:'J\'2ZA5 WIM<%F<[8WL3PJ'=(=,]U=UC*C^5D8.@8ADV66Z8
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M(]/,<*7SR1156WEII-SA"7OY\2((4">5\F$A=T8!&OI!5^T)6>+MU 8XS1=
MW^2+#:-GR^.7 9>5><R5G9-WM)XUV(Z6.@>?-'V?G%VPDC9SBWP@L--;"2.
MS2>FDEC5U59\;QODSYU!=E@?@2X_9P_:0;K6E+ENE21DY$=AII^JDJ4#]IJF
M,J:-%V@A=$0/B N9$<$:45;L*]S"A[R<B<^WV&@*%Y[]XYZWW]<V:_>-^,I1
M(1NKO%3!)N_K6T22/!,T0[E6"LFVE 3)B%W5SZ!<RI6:HE%3:)^P$XB.G5D[
M\!M ]JS1WLJ4@Z(D<\)-L5V*\:>/&;S1NZS82R*6O89_R\H](F+!AL5WYC'Y
M%)[G!'/]Q'53^N Z'CL>GN/[W.)XKB^N(1*8?-J10-<(UM-)W40D*>RSX_JP
MCAZ,8AQUOFVG"Y@Y@0M[F:;"2U(1)($(8-KAL:Q6T'6\Y['-F!FB)C?7,.;0
ML%[,8QCF. Q&+1TE=UF^A"'WE".#WA=^0"Z'SUY.0AY)&@R-^T4:4K^0W![V
MD3SRC@YG^#HAEB/\:/@QKT#Q^/"I!S;"VH. R0EVVK($)@6..X\'G/4=+XT&
MG'7\U.\8^WXDSD,)"9VY%VC([*8"#CF:+"&1^N#,W5B]Q\'0MR7/EOQ:\F?)
MFX4C Q]VVGTUKJMR6UG0ZARRQEX@7'QR"<'Y"^)($,#=\YPH)4\M=.FS&_CD
M^Q%'4[B!+V7[[Y$X3!,GB<;HDD->['>$9TIZ#D< UWDXEH*A XK=X&EWN7./
MO9,.+7FS[,O^29+KD5?]0M%-11@KR9V0KY'(IFDZ$#4P-HX&HN9$H==)VL>!
MHAU" R]]]HFAA8@"\*9]EWWD4/G*OGX/B/-?^J E@_)5B[E6&^M<$%)F131W
MP/LH94SZY^;3]6)1DQ'LG4/8VIHL:Y%G[/'E)+USECKBJL^L#32C@96:GNRA
M'OAW>V 24V#F.4FD)#G@;P$_]9G9ZC,^'=T[B,S([A6/E.*D7*5MZ#BVAJUB
ML2??;V"H5 I,N\.^JTQ>MECLMWMEH\=V4=S#LIW[X2P56$9A/.=S?SX+S!.'
M/ V*3O,[63PZ71ICX(<Z))_*,SKW@EDR!.>%L_ 8.,N!&+FIG!;JC?^!KS&T
MYIA?)7<IO!VF5DZ:\V?:[9L!2/8P,PJ5_J%FG" MA0SP/YOFT![<G!JEU+C:
M9&:W^4[$VCMQ$FRZXX:&[$?L&\/B.3%6&SLA]-\4]N53LG%T =>GQ[%62+VY
M6DN8I+R$<,Z9$<</PF<L 6HDB6@)L#@ AFW-JEMO_!_@SO*64U[X;WM$=RP6
M>SC7F5CUX#<Y_-UZL7G4PKG-'O(MM(G*U5%W(%#=4@S"WFY>[O;:BX0R'W?=
ME^/.]QM9ZFP?N<?][!P? 4/"LMW4B%$*Q (%TU./!5A&7"<+;=292W^G 3#S
MFXRC!\)DDZ\W9)DYAT-!*B&K^@5V/X@WNKWI0!@M^.][=L,Q?$%*:U]FRW_L
M*2]W21Q7QR*@4_U-ZB IIVPI9UXUD_#,4I@S/8/?6YP1B:R0SZ"CYG<0JZK@
MX+<!6C1O _(763T]JT/?%5@]!Z"KJ-'B$(7O&9EC^#%U7=U6M1+:1[N36BOE
M:#,U[_X6.@5+5GEEUC30=Q2MF=3E24+T#NXO$]+2H=GL=SI["G0 H57XEI5!
M2*<*'E68;6";.(=EJH)4WO,KRXQZO)0JL 3D?4/20#2E]VVUA/0YG1E!AT76
M;,0*H@()!+AE551K0UU#_U8N-F7^&X%GF6QR&.05! *&:&(_.,3->UF0N. 1
M!:G*X2':JEU()#18=@E*2_3UEFX&4_UCOUR;H!B"G2NC\*01/$\1<6QM:Y2&
MOGEP:(S(M.V@U1\(.IZ(\)5AN8Z-F+7Q7_KT?5[> 1LK9[/ R'55:Y?E@&\P
M-0K<D?W/T@:BE(N\WV\K,K=$>NS/;<6],HKLM#X!*9L%PC436RO#WZ&AE7G#
MIY6<2>JU@P; R"C)S(=$-Z:VYXU]K%&9M1@F*U'M>S=/46\0N@_M-'8%-YB5
M/+)PVZ:;S<BOC-6//5:-^(6E_G2K44-&=QDV_73]J_+FJQ8,>%ZOWDM@9\(8
M6W6^]H%V&,D=;S42;%"&$3D7P:2;"FNI;";'@-&1/H$ZD7#IJ,%((+M$Y&\#
MRVH'9ALU3M.RP?01O1V& H$3P[L/$9Y%6,54>Y*$U)ZZXH>MK->L2PXA'PL_
M4D0:]._-TW&;'U-8F,[%C]"$ZPP!'5&*V?[Z-EM\(_=.PM<^/<6Q]V0\(Q[]
M0!@_VG#']"+_)3H*5[7Z3N*-)^C[4.O'_($36)R-LV;\*QVCELPR7O!:EHM'
M.U]EPXG=*>C64]^98JMZ^J&J=VSUCD!WW?$ZAT\1IB&&'\6/_/1%;//'F1_K
M43!NQ://VL+W.K9W,_HE)Z.AL?7I9JAC+%V&_>-XT9S]TB2E,);/;[#\V,[4
MH!.'OZ$3\/%>S)T\+^RS.,, XOD:(.$TCSL,8SF>YH?Z=:@<^!$4Y$OV?42'
MCYQ5ZG-7]"0-L;,15* MZ>E)^4!0)$Z?(:A^Z))N\"V!B0ER2$><3H0P !3R
M0JO5)T*Z_@E=X@7QF*,^5@XU$HUE$:ORPV.BGEK209AY"(<06?@#A"BUJ41M
M9>]8&PYV? \(0<D<D+W>JPZ!@O@BP7Q) :GLP?>?Z,QWZGE$3<]12\&$#NU0
M0ELTL9G-.[7]?G44B"CUK.5':8S7,+&?A4G\E+JQ]CMXYM,YK!>'UC,OCE^F
M5-*Q<K0>3:A./!HKE4\E_ ,X75*EOC-*,U[X?4X-NR2%3'HB37K!@1N9!K2$
M-$XT3&_B8!F+$F.9C4ZJ)<\)$M(RJ:.*#6ARZ)PXL=/%OA/'I)9B9Y[.N1,]
MC52F3J62R4?YH,^][/6RJ\?>JG;G^-"#CM*4RZ7PN(";<TFG>:+9<&!5JQ*;
M3H-1N"GI6 <1%F+@18'1\!S5B=B!W]A%XLI') _*'+SLX(1+#D=X&%Q0=?2D
MC@!;6>K3Z!T%#"V?T\ _1N1E0H=C4TVXKP?YANQ4\#!C&2!L.6^BG=?.";0)
MRO0=RQ"M )L)Z% HR1B8H"P3ZCR4#P5IPZC L(\^&A,'JI.<1M=4T9PT'26_
MZN*1AEO;0@6#>J 5$P[B- +TYP6)BK^*@[=4Y=E7<&6FV-,PS<IM]CQR1%]O
M!#J6S4K6W 5X7U'4OV\YW4A1T2A6LN798KM:XQ.1J[C0K%6%&,^,6]Y8_G^O
M1]@4**6@@H0331-1P_NLX+[V0<]4%!#K_ZFVE/]/'0>^ 2Y%QB*(G:(IB- :
MA-W(8G00.CXQN^3_8\^G@%=%5T)@JN4FG+>Q^8](8^ZQJ;-&GU8W4$&-.O\?
M(1"HXY[1<T[J7W;4'1Y,3-%PKO^/T_Z4YS?%1:6E)_G%+4ET#!=J^0.Y>1%,
MG'3Q0\_MS31]/DIW+ND:@5!U7A-G6?SP9WM'7V O7])>-CHUGG#EDX$IMGDY
MS4=E+*<I'#_)@6<F,)XL+OH_E-4X%<!XQZ25RR,#TD%'-Q=WB=*7)3#&KE0
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M02OUI:UV_"-2L&IMM>6/V#W0W=0![:NJ:LT7FJ#[5;%W_P-02P,$%     @
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M K%V$S"^4\H>&R[!Z:-J\S=02P,$%     @ B(595!/T\J-2#@  AR@  !D
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M8!@-[T?UT^6:0IMK3MG!C4/VG7<U[QR1G I*6]D.R][Y;#[[G.ZL)F/!0CP
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M7.BYRCZ*IOB]ZP_N?)X6XB>F=\(I3M_*;<EPU %4/LWT1ML:#XUH$C.E&4S
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M/+/HQ@V>E3WD>0=)'X D%-ZKQJX,O&XJ7NT#S)#?EB3=D#RG!Q%?\7(*$9D
M#2DY@!=M@XX\7O0 WNM/:V'OX:^SN;$:=?'W <QXBQE[S/@Y$_D?(>%BQ9HE
M-R :X*Q< ?YK5<,;"VH!RIN7>^:B-Y?>G&D.S,!"29R;YB6\XEK<,#=-##K"
MI\7I9[&.=2O5/>> $P%EWL#%6FO>E/=P5I;K>BV9Y15T=,^99$W)X1?6K'&6
M@Z\:*2;0<,_*LCM$/P*2IO@,LGSL7M$D25+?HI,PRWPKF21Q,NYA#X4QY[@X
M<5PB2LF,$0M1LF[&5_^L^Q F@-;H&O(42!Q"4,3HF*!4@Y2$8_@-?P4$O?WX
M0TX)_0E(@;\(4B(I>2X*>QG(2$<D<W$7*01Q7(SAZC$Q!#0E8V0W=D;XH&/
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MB/'_G*'^+DT%RZY/IPN!05Z>!R+RLB(4B9>"F\#+$O  F4'2*Z*<QF [ J^
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M""_@B-"+ ,46U#-P!>H0OFXP8.&,=;.S8EBLIQ<*=!"C'W730RA@CVQ6G^T
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M(HIPW"3_R.NP'K].[+,WI-2SD[?7;TXSEI*'/.JI!<0#8K\@HRL2%2V@F]5
M@,EII.C>E+$0JT.%C_F(JZ(@8]-SG7@I0?6B6$<KB9D=/@!D-W<85*([*$ :
MVIXM4?)[V#],)'!>@I1#*QOHK>F$ ,#NK4H,98"%1 #QWG)O 6YP/>OX,M!\
M; H2_J6X9QZI90-W@9?',2 \G,A8/C)@$:XPWZ$>^R=%(D"54*Q!]SV"OSTY
MGI-;H1]4DT)P>%Q\AJ&%]9,E%J0W+075R($$.Y:%\YXQ3:OU7BXK*I.EDQ7A
M*32&8UVR5[J8.J1XQCOT./3 "9D'YQ@(,.]JH!6*GP6'9LY:1;*1R & 3#H
M8:"H0]_9U2#?1"3#/-$9C%\RJ?,+4\ Q#\+[+$R4F$9>/8!X_09X[1U95_#)
M!I86>Y[B@42U4U+SWD;Y6"^TPZJR146.7<GA,;R<T?+3TO^+R^K[".<O+HV/
M"=2'H?7WNCM^:6B;Q++.@UT"CQ1H!7)L<J3_Q !'#O66C)JQX.%:M"]_FMSL
M,,!-IPLPH*M:.O7<<5]QY@V;SR"GA!+$IH[ 7Z0D@2P"_V/@]G+X )15OCD@
MLT.R0M,*[67,#UK @)Z;KB>.ZB5A"9*]*-/;:B!R@#<&3CG %A0B")=,=!3Y
MK1FNT57[-)>0$F-$<\F1>9](AYUG[RG:7/XQZ#D5THB=9VEFGLVG.?%+>-^7
M%R'C=S%K6+X3<_L=G^I8C.[AJW@S-?Z,G ]^U(>4O5E!;B5%W^'B%B'\6325
MIFTQ9Y-7['T4QI2,4O3I*^,?2,PN=/> DRAC39N ,-SD$C7FM$F.,9#<B5M
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M2+6GIO;%R-J=5);2T+G'/:[IH(G*&M!Z(:79O=@ ^Z/K[#]02P,$%     @
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M^[RU_L)C)RPI,_A<B3]Y;LOSP7P .1:L$?96K5]BAV?B[&5*&/\7UNW>V7@
M66.LJKK#%$'%9?N?W7<\[!R8AP\<B+L#L8^[=>2CO&*679QIM0;M=I,U]^"A
M^M,4')<N*6^LIE5.Y^S%,GO?<,,=0R: 6S3(=%8"@10L59KY!6 RAU]X1KE
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MP!9X#$DP3T*XP@*U8X'+3%4(EMWODA& I HYBFAO? R_V9( ;_G;IZW=.5_
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M6>84,J?O^=919"HTJ)C$!627/%/LCN>5:!QLR8C*<_K8: \L^'Z=)6OB"IK
M8 "":RW!8F-?\<8C\(D(IH?4.#)1\BPWOH%=2P3PVD/)<M^*1>D@'KOABOU&
M? )U>OFI(I$=*.,6YJO!P/.4?9$E\(D-8%66:^NUP=G$^\DRE )5&#0 &_;'
MGN>Q27,7G(7103>T4G\<1!Z+[!5; -*TZ)$]"0@0F2;[7BQ4A3:$A(9L<MK8
MY'38)B'P22MC[^]1F49(M7\[:\:XQ4?2<KN6W@A% 5.1" )6YXW4&<JMSZH'
M^<+P[(7>\D2\.@'TU$+=B1-"?4?5C-X@.V@#N4P(BLASK6F!74N%0">+0[A_
MPW-B^9;B00<#DFI3Y6;-A! H XM+OU4&^#3![:'5<VWLJO'#%^R2*[6C];6Q
MZ@_&HJ\SOLARL^)>MF.U_7H4<=&P@$L(1*1@*R,8C^Y.L<T OW6(_<%=-*_O
MNO._1E2X OVVWFK9-8VZ'>-:\D(C@I J4.-)I12RMI6J5D$NB]5SL.4-."MX
M&P#_.)B&Y!@^6#Q<\:$&[FOL_05[DV_6S<$X]/SF*0K9@,7'C<7'@Q;O")=4
MUD O&@EGORA<?M^0WF_%2HF5,191W@N!PI6Z ]C0PDL*$]YVD+''@VS4@02:
MCP!7'O^PSWT&)]GO/C?&77IA$Q6,38YI@W32?>FL2#K&*W0KG45'.FF?=+KK
MQMI.,AN6#@#G4SX\=+[6RKOJ_GIV>\;>RCR'Y>#XFZYG7/(M&?6%UN0GQGEW
M!\^N43QN"U=#BZR)]VJOXC@0AE#^Q'$9\BCC29U6XU]/(']AR!Z+I:*)XX8X
MT$!TU\MO$+>N.QW'\8Q!NE0WA&-_%CY.TO(X"9L/_7$4^6P2.<QYX2!S%TFB
M*E0$V)?L,)H[0-R0F\ 0TZ =$+()%HV]R?QQ;C_)HB9]W4/:[\R#11@PA,$,
M-1FAXD#,$[KQ\4W@SP@EQS&HW;6M)T'&#VL+!@SV#,D;>S&"=.QUVF, \K]1
MX/,ICC2=>*UM>#'(8#SSO8:K.68-@0>R:!C"7L#D')C$QP@4A#+T2:CC>432
MFZ$D(Q(O-,:SR= *,FM6D-G@"G)5F/H0K72%HYLFWH&EHUI\PY07PHF/7)=H
M'**D_.M"*917 UT91;L[DZRT$$UPBUD7+45]*\ @D\<#J"5@G+Q'3@S\;Y6\
MRU**TCO3ZLNI6V2'I;Z>JFZG6E(,NS$3+NR$^="$M]T)8T)+J\N8\9I-C+B0
M&84E)X1JN5PB\BYV8',5XIQ);2@0X7H-K3G&<@H"T-HZ4[85AHIECL/:)=IU
MIX[^()Y*LQ*FM,50!EX5X@'#N_+8\O+8HF#""3<>;;-Z9"=Q(]*%77=,A;)K
MTZTI=TDZTK=R <I#&L UM>WY" \C'S/U^G\TK?]?[LD9K $^/K=Y9 J]II/#
M-'T4PJ=HTS7SX-.Q0;RZ,A"&@T'>O''1^:"+7M?) "K7EE>PNL+ EJB^4E=,
MT+@>2;^'1SK,27K<">,DE9+/N9D*,M?FO%M;!5H!G_H4>H$IZ?THS(F&8#9N
MM*:,\2^1B3I*4FYYY@6[Y;G0@\4D3$3M\M I6]E"R0B9.OV+):2]QS9+;.MN
M31+BU S>M64^-V)3Q@;?XW0_V"0,\.1SG?$]8Y/9./8P8II S$"+:3@?&V<:
M^>-P E,=S>9@V'Y ;C:.(ZI-3? -7*>3V6E=D\-Y(T+M97X',AZ.NVQ"E=$$
MC]:P)L 2K(;SZ&B7M_T&<20\/D;%9Z,8'7HZ4%"[ OPWA=M'C&LP'FA,'$V[
M-J(N%F)1%N3KFOHQGHY=$3I&X2P\9;/8S8VS.E^&88P'4#T,M%3EQ!75 ]LR
MH7%.C67)"8KG%,*SX[J 3FS*1M#E=$_Y1P6@GES;?:)$1@'P.3%_Q_JT/) M
M_^W2;WB@-<*1A9T0)IB<4$46ML0^,/.ATI;OM;L]WB.!&J%6BR\.EOQP1-V[
M.S0\_E]8&RS0ZH9E9Y?#5<^3,F-WM\*-4A_;;K!R>R+,_WAN<J"7.L4> )%V
M9>IW%4!WR@U&?H#H[<>306K0R6#!' M1_E'7'87#PS993','H]Z#0AL:;F7Q
M5O"5*- +-C!;7<KD.XA>@YQAH<-H(!5W8"E;HWDSCI,_MBC4%HR=D+SE>JNR
M#5=9OF,;"-)7-"42@:YCOJ;$HT #7%-]>6GE9;*U9,?<?1A@&*Q&[>I\$;EU
MTSE>EBI;5,;<L8C:CG= MU$("EN?U58*7<FT,E-H1+QHUETKU!Y5"M)<6F_H
MX)MO56%VP>^STNPLZ&U6/(>HEV!'K7@ABS,R@GTA8ED+4B6T7' )G'[B[FS
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M6NUAQ>YN#)Y*=(B90U].O<#43REHP'(!9N54WBJ&RROMT5(_?,)Y-EI,W12
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MME*6*M<O2VJ5J)T!W:^5LH>-<] VW_D_4$L#!!0    ( (B%653DHW5-\P,
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M<8Z?=/H<V&O.B7..*<C\HLA<8FAJQZ/V&Z $EV)G^Z8KF[["X,N^[1MF7RE
MMG7:SNW#5?V-[X"MF 84QY*N!^_ZX@PIDY&4R5D:?7?S7V+B61.V>USJ';)I
M[F%[T%P]<.]@E]E4*UZ!.'E:F#G-&Y18!J$-'I*;RR&)KHP?E-0:BW5(#N[_
MBJWJY=65DE5?8IKLC=X- BC[+FN;\LA/,V++DOA9EN(D\_/"\I:&?D%SNY/Z
M)+*3V,^*$&Y6MV]9NWMW#85/<S*6;Y"PJ/2)58-TKUC%H6,MMYRR-(N+"&=1
M7ASD""\']9,HA%]$B<V-#VBE2U3JIZ&C*Y(O\B,D+0(JK&H:VY4DB2PXRTX'
MM_"3T 5 _2*R6Y'5S88M$J7#Y20A@9<X$IRTC9:KK6N.2$/9=V;H(./JV'^7
M0]MY.CXT[T],;07>HX9O4#6\R) K:FB(@V#DSC6AM338TMRTQG\(KNP!W-](
M:8Z"=3#^E2S^!5!+ P04    " "(A5E4G)\4K!4%  "\#   &0   'AL+W=O
M<FMS:&5E=',O<VAE970S."YX;6R55VUOVS80_BL'KQU:P)$EZL52EAA(F@T+
MD*Q!DZT?AGV@)=H6*HDN237-O]]#RE8<V7&W#Z0E\>ZYNX?'X_GL4:HO>B6$
MH>]UU>CST<J8]>EDHO.5J+GVY%HT6%E(57.#5[6<Z+42O'!*=35AOI],:EXV
MH]F9^W:G9F>R-579B#M%NJUKKIXN124?ST?!:/OA4[E<&?MA,CM;\Z6X%^;/
M]9W"VZ1'*<I:-+J4#2FQ.!]=!*>7B95W G^5XE'O/).-9"[E%_MR79R/?.N0
MJ$1N+ +'SS?Q0525!8(;7S>8H]ZD5=Q]WJ+_YF)'+'.NQ0=9?2X+LSH?I2,J
MQ(*WE?DD'W\7FWABBY?+2KN9'CO9.!I1WFHCZXTR/*C+IOOEWS<\["BD_BL*
M;*/ G-^=(>?E%3=\=J;D(RDK#33[X$)UVG"N;.RFW!N%U1)Z9G8C>:/ICC_Q
M>27&=".;Y<F#4#5=B;DAWA1T(Q"TIG</5D*_/YL8F+7*DWQCXK(SP5XQ$3"Z
ME8U9:?JU*43Q$F "?WNGV=;I2W84\4KD'H7!F)C/@B-X84]"Z/#"5_$0ZU6I
M\TKJ5@GZ^V*NC4+"_',$/.K!(P<>O0)^CW-4M)4@N>CH-3V]UPW,M$AQHP_1
M>A37GM93O>:Y.!_A.&JAOHG1[-E X?8/88E<U'.AP!?E$H=)&U' EU-'GIU\
M8MXT?DN---CGHA7V8TQOB(VC;/L;0B@8" $Q&&=I0C__E+* _7( )W8BTZP7
M";VI_U(DBIW(U,T),-*!  NQ-(TR-Z= B(8";BE,W!Q1L&>"67 ;P[.CV4 D
ML8Y&:=2+1)X_=-2:B::^G9,, D,^(NLH"S,WI_ C&A+FNZ78S9;1H4#L!'!@
M[ R/O-02*EHE3PK12)Q_;G?O16PV[,!QQ )K=!@92RG+GN/R]_<Z@4"($8#;
MH3:BR<!*EEIWPV' OEO(4G: 41:1W:YIE%#BQ4/8D*9!C)'!(;MX/,:(XB2D
MQ%$2_I 29$(<9Y3X-IM^"(Z,B>,4TC'"3X9[SB@"+W8@B.%V3BGRD0AP*]YC
M%4Z$2 ([8B_#(@XD#CK*R\[&A'#1CMA+A^H9L6G@1N(2_I Z0[[8D7CA00FD
MADTVC/V]8ZQ/"60.\IGMGZM=$3]D]-&L4$@8-HXAH][ ]7&2^;9"Q.,P\>E(
MM8S[:AD?KY;M>ET)6Q)Y19>\XDTNZ-ZU)]=-UX/@,C]4+?\'[GR#V[4]Y3,N
MVHS*)8B1A+Y'X6.SI*J[ 4M-7--"5FAD].F+POI<2B^T%D9OF-J\O O>@Z-@
M'*-4VM\D3>FFY/.R*DT)X(L\5RV,VMM6.L6\50JN4K4C%?H1: \VT'_(9BNT
M"X6M9+:\A&'<F41M=":1"Y]=AR**$_X-D2T%@K5=6Q\AN7OCW9/@2K^GJ>=3
MBK&G5>">E"WL@AUDB9?06UNT,=LXKYN\:@MX@CMIS<MB2YY9X2Y: 0,9UK/<
MF=T&^>0=R9^DSY_D/]^VMQRGH>,%;Q_[_70=S2YMA]+IJ)G#E^]+>WOYL[N9
M'%W&;C*YPX8#A:KA+CR6L:[NL8AUUW$P33='&@7U 2D@^ (;1C&JSX.T6=VQ
MN>9/KJ&PER%*VHW0@+^NUZTEO&R@(K0!6M+GQR'6)SL=92W4TO7-FMS&=\UE
M_[5OS2^ZCO19O.OK;[E:EN@Q*[& JKU^1J2Z7KE[,7+M^M.Y-.AVW>,*?R^$
ML@)87TC4I,V+-=#_89G]"U!+ P04    " "(A5E4DA:_,;<"   @!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R%5=MNVS ,_17" X86Z.)+[ET2
M(&DWK ,*!$VW/0Q[4&PE%BI+KB@O[=^/DA/'&YKLQ:$H\?!0(D\F.VV>,.?<
MPDLA%4Z#W-KR.@PQS7G!L*-+KFAGHTW!+"W--L32<);YH$*&210-PH()%<PF
MWK<TLXFNK!2*+PU@513,O"ZXU+MI$ <'QX/8YM8YPMFD9%N^XO9;N32T"AN4
M3!1<H= *#-],@WE\O>BY\_[ =\%WV++!5;+6^LDM[K)I$#E"7/+4.@1&/[_Y
M#9?2 1&-YSUFT*1T@6W[@/[9UTZUK!GR&RU_B,SFTV 40,8WK)+V0>^^\'T]
M?8>7:HG^"[OZ;'\00%JAU<4^F!@40M6_[&5_#ZV 470B(-D'))YWG<BSO&66
MS29&[\"XTX3F#%^JCR9R0KE'65E#NX+B[.S3<R7L*UP\LK7D>#D)+8&ZK3#=
M RQJ@.0$0)S O58V1_BD,I[]#1 2FX92<J"T2,XBWO*T ]WX"I(HB<_@=9L2
MNQZO>[[$G_,U6D-=\.L,9J_!['G,W@G,5=W#H#=PHXN"VFME=?H$3&7P2,.!
M%6W6KD?#%#+?@_C6]9Y/-#^,BTN5UJFP264/J6J7;:6""\R9X0A"4=](Z7R7
M(! 8PD9+&D:\]C?L/A%]XO&AE*: _ZT73#*5<OC*5.4HQM"]Z@^'$%]%O>'1
M[H[V]GC4AV5ETIS&"%U!__!__VZ4Q,E'B..C.6C,P0#N$"N7D:J++YN-BW'+
M'K;LN'O9<*2NXL6:&^JL%LOQ2<8NP3%=:00]@I"O3HB<HM1RXOJJHK8GE7.7
M_<'I0^:>B303F9>=DM)CYZV6"UM36W"S]=J$%%TI6P]PXVWD;UY/_?%XK9WW
MS&P%O;GD&PJ-.L-^ *;6HWIA=>DU8*TM*8HW<Y)P;MP!VM]H;0\+EZ#Y4YC]
M 5!+ P04    " "(A5E41,8>VV,&  !Y$0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6SM6%EOXS80_BL#-RUB0)%U64>:!'#V:+? [@;)'BB*/M#6
MV&8CB2I)V^O^^@ZI(_;&<5-@'_K0%XF2.-\W]TBZV AYKY:(&KZ41:4N!TNM
MZ_/12,V66#+EBAHK>C(7LF2:+N5BI&J)++="93$*/"\>E8Q7@ZL+>^]&7EV(
ME2YXA3<2U*HLF=Q>8R$VEP-_T-VXY8NE-C=&5Q<U6^ =ZH_UC:2K48^2\Q(K
MQ44%$N>7@XE_?IV8_7;#)XX;M;,&8\E4B'MS\2:_''A&(2QPI@T"H],:7V!1
M&"!2X\\6<]!3&L'==8?^VMI.MDR9PA>B^,QSO;P<I /(<<Y6A;X5FY^QM6=L
M\&:B4/8(FV9OD@Q@ME):E*TP:5#RJCFS+ZT?=@12[PF!H!4(K-X-D=7R)=/L
MZD**#4BSF]#,PIIJI4DY7IF@W&E)3SG)Z:N[)9-X=DUVY?!"E!1KQ:R[;@I6
M*3C]P*8%JN'%2!.9$1G-6N#K!CAX M@/X*VH]%+!JRK'?!]@1%KVJ@:=JM?!
M4<27.',A]!T(O, _@A?VIH<6+SQJ^M2:?L.VE&D:)E*R:H%V_=MDJK2DM/G]
M"%G4DT66+'J";*(H[6OC604?#:,6\!(U2HHIPF>;/)B?3=8HJ1;@->,2/K%B
MA2#F\+X5_(F4TU_[LG'=<?8/2X1-RP&LY9@;CG7'(5J.1<,!O+)^MM[V@%4Y
M+?P,-DS!2>:FGF-.66B?G/B>&X=0HVQA'*I75:.MN&+KV$T;E$CUTIJ<PTKQ
M:@&:-)N+@GJ#N6(/7CJ'7Y')-GO(53,LIX0?^E:M1BNKT:LOAHCVY'S-<R2F
M+<<BA]#UX?O^&-#QEJO[L[E$).-(#50:)-,(ONO14\^-Z!C88X^Y%@650\'U
MELC<S&P(+**?NLGNQH+/$4ZW1N4AC&GGV$W-^4CJC/O4&1\-WIWME_PO8GE3
M-6W8%.@M&M76:#+I3HO9?9LFMG)A8GQ/:A_*E6?3\1TZN4.G+%T3:J@-'6OI
MX+3+(\H?O10K1:$GCW!%L6T#3:%]M[+![-+^83%9+"0N3%#>K[32)&S2XA=6
MK6AB0%O[<.H/P<^<*(KA!.+0C:.N-.RCR$E2'Q+ROLD.E#.NVB>GH9,$*04H
M<OT(J*W/D7=2IW$0#R$)W2R!R8;)7 %5?Z7F*&53K^_E@E5DL34-0=6\.A/S
M.4D[6920+*7&&";Y']2V;0<AF;=$?P^LP;,^;+#V $R)M]BGP1!BLNN'[]+
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M(:\VNN0AH-D-Y*,XUA8!0 B!["1'A$'U\H;8?5GKL<2X]"K=YI"=)(98#0*
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MU\6>/\'+M2YI /HW15&?_J %VI^-O?E?4$L#!!0    ( (B%651%_5F5E ,
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M<_CP0%_;X +^H/TP^\J. LU\%UIB<NO#?$2]'E"39U#C!#XI:6L#'V2!Q<\
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M'T7=>_<5Y%:B+6',,. L6&8LRC"D+(1=P26[E0A8**W79*\TQ&&,NW28LZC
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MTP6<;[K.C@LB,/TG._\?4$L#!!0    ( (B%652#<895@ ,  *0(   9
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+56VV[C-A#]E8&P*#: JKML);4-
MV,D6FX=L@TW:HBCZ0$NT1807E:36V;_OD)(=I]EXTX>^4*0T<\Z<X9"CV4[I
M!]-2:N%1<&GF06MM=Q''IFZI("92'97X9:.T(!:7>AN;3E/2>"?!XRQ))K$@
M3 :+F7]WJQ<SU5O.)+W58'HAB/ZZHESMYD$:[%]\9MO6NA?Q8M:1+;VC]M?N
M5N,J/J T3%!IF)*@Z68>+-.+5>'LO<%OC.[,T1R<DK52#VYQW<R#Q 5$.:VM
M0R#X^$(O*><.",/X>\0,#I3.\7B^1__9:T<M:V+HI>*_L\:V\Z *H*$;TG/[
M6>T^TE%/Z?!JQ8T?83?8YF4 =6^L$J,S1B"8')[D<<S#D4.5O.*0C0Z9CWL@
M\E%>$4L6,ZUVH)TUHKF)E^J],3@FW:;<68U?&?K9Q0>B)9-; QW5<-<23>']
M/5ES:LYFL44"9Q;7(]AJ ,M> 4LSN%'2M@8^R(8VSP%BC.P07K8/;Y6=1+RB
M=01Y&D*69.D)O/P@-_=X^??DWA[D_KE<&ZNQ.OXZ@5\<\ N/7[R"?TEXW7/B
M"LZ VL!+OF]E]33F?4NA_A<N/=XV,VR;?QA@$NN$<V=Y!NX#,;!1'$^?N8 _
MT''<'<#<4K%&_SSUZ75#@D-Z#I_P-KB6M1(4-EH)N,1=9;)'1O@%&<<XEM9J
MMNZM*Q>P"FZHKA_@!R*ZG] C"AU$!.\@S<*\*'%2A"6"OX,RG)PGSPBNF*D'
M#@SLB2+TD:#>>_*(THAL8"E4+^U+\D]*.@2-2EV8U])2S 8:3I,"LK L*J1/
MR]PCLH&:O%5 'B:%"WP:)I,I/L_#JLAA^07CW.+F*"'P@AGSCS>?L1BIBP)Y
M\^1IG)0(>VS+C.D]^?OT#"I(4TC+-\ 2=!-NTC#>^\O-451>9NK&*H$5,:R&
M9\=[Y![*_FV;=^S2*MY0C47T_<K K8ZJRF4NFKJ\95&6O66_(8DR3$.48"*B
M279<AU@U43KQ6!XRCZKBE+Q]BJ[V*?K_!4\&P=4@./U/@A,G.'TAN!@$5X/@
MU-?)];YH.LVPD3+^%7H\T.,]\*/K48TK'NS;QK- QXDTT;>NM_BH<PBJM[X_
M&O3&,S8TD</;0PM>#IWGR7SHWS=$;QDJXG2#KDDTQ8ZGAYXX+*SJ?!]:*XM=
MS4];_(V@VAG@]XU2=K]P!(<?D\4_4$L#!!0    ( (B%653KGG\*G@4  +P/
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;+57;6_;-A#^*P<O&&3
MM46*>NN2 $FZ81W:-4BZ[<.P#[1$VUPET27I..ZOWY&2;;E-C*3(/EBF*/*Y
MY^X>DL?3M=*?S$(("_=UU9BSP<+:Y>O)Q!0+47,S5DO1X)>9TC6W^*KG$[/4
M@I=^4EU-:!@FDYK+9G!^ZONN]?FI6ME*-N):@UG5-=>;2U&I]=F #+8=-W*^
ML*YC<GZZY'-Q*^P?RVN-;Y,=2BEKT1BI&M!B=C:X(*\OF1OO!_PIQ=KTVN \
MF2KUR;V\+<\&H2,D*E%8A\#Q[TY<B:IR0$CC<X<YV)ET$_OM+?HOWG?T9<J-
MN%+57[*TB[-!-H!2S/BJLC=J_:OH_(D=7J$JXY^P;L>R: #%REA5=Y.102V;
M]I_?=W'H3<C"1R;0;@+UO%M#GN4;;OGYJ59KT&XTHKF&=]7/1G*R<4FYM1J_
M2IQGSS_8A=!PI6I,Z<+%^D[ VZ90M8#@G3)F",%'/JV$&9Y.+-ISLR9%AWW9
M8M-'L F%]ZJQ"P,_-Z4H#P$F2'3'EF[97M*CB&]$,8:(C("&E!S!BW;>1QXO
M>@3OY\\K:3?P]\746(T"^><()MMA,H_)'L&\6O!F+@S(!BX^7+V%Z<:'5S6B
ML0_%\,EH@A<+*+90H&:@?/**@^3)+GF53Q[7 KB!F:IP]9G7\$9H><?=0C"8
M9GQ:7& 6$U0O*[41 E#J*.0&KE9:BZ;8P$51K.I5Q:THH17+):]X4PCXC3<K
M7,?@TT'R$33"L[+\'M%/@"0)/H,T&[J_:!3'B6_149BFOA6/8A8/.]AC;DP%
M;C\"-X&BXL;(F2QXNZ;+?U>="R/ V6@:L@0("R'(&1HFJ,$@(>$0/N*G@*"U
M'W_(**$_ <GQ$T%*)"$O1>$@ BEIB:3.[SR!@+%\"#=/\2&@"<&5YWZ,X8,.
M 8,91'OV 8WRUJDXWG?V_4/3QVT=D UHF'368M(#S/,GY.=K+!+%K<=IV#42
MEXRM<+A%'1:BGB)J]+!Z(HQ=AG1&72!&>>;^DQ')HY<63!!EB!FA')VS"4/I
MN#BZV&9L+Q="(,N!8M?_(9: .N-(@F5.MC&VDH@\42ZTE0HEK51H2@^T0A'-
M>;-]WV4WZ0O*O3Q#,+2U1\.\MZ+"YVN%YJE+<.:HIWGG.F/DF%QH^ U*DO1<
M8;BOA$[-7CH9S;QTDHB]M'2B*-I[/\JIBWN(5K"-J\AO.6EO2091ZBD1]#.(
MD^S%Z!QF)LYZI&+FUA&-'"D4^M,$U>Z-/05EY$!1+&T5%;@P[Q74?R%A^"P]
MD9CNS=']%A2AJ>>*BI&P%X$TR7<1P+T8;I>R>:5F,S?^@Y[S!GD%!L^^WY45
MT/-R[STP9(3;]S%-DF\/0,;PN47Q)U_*HE:7)UZ94>A;;,1HWN[WUUIB<2RK
M#6;<';H&K()9=R@7VT.YX&8!,SS282%*5Q[8!3):BP.AX($]TZIV5<@[AW++
ML8R#L=\B;@2&TOBCWY'&<KZ27W#"',MX Q@0C#@8/P$=XG=<5JX*?(5,7KEN
M+'RG%HQ 1M+*)Q)HTQBTF1N"N,>;A1%MV,9>7UAY5JM2M*1XK;257UKA((NE
ME@JO$T+?2<Q H0P.:4I7UV,9(GG5D7=]3A2^:/)PI:N>'.(2JQ]5R@(752-F
MTK8@^]P3-AS[[.QX++OKQQ+3[B$<LB-S$HT3F,JJ\JI&DR?QF.T['I"'']7N
M71CZI?#7D6HS\OUM);=$.K@ I19NA>Q8[HP[![UQM_[JOO$H)_N.9QDWF+6J
M<O\'OGX5;"U*Z;5]XC;Y ],4"Y#O,_TDOQ\GDI&OB.!R^PXBXX=J_DGO1E4+
M/??W1H-Z636VO5SM>G=7TXOV1K8?WMYKWW,]=[JLQ RGAN,T'H!N[XKMBU5+
M?S^;*HNW/=]<X/5::#< O\\4:K-[<09V%_;S_P!02P,$%     @ B(595'L3
MK#O "P  (1P  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULM5EK<]NX
M%?TK&#?3VC.,10!\>I/,*$ZZ<1LGKIU-I^WT TQ"$B9\* !I6_OK>RY(R98C
M:Y/=Z0>^@8O[ON>"+VY;^\4MM.[875TU[N7!HNN6)Y.)*Q:Z5NZX7>H&7V:M
MK56'1SN?N*75JO23ZFHBPC"9U,HT!Z]>^'<7]M6+MN\JT^@+RUQ?U\JN7NNJ
MO7UYP _6+R[-?-'1B\FK%TLUUU>Z^V5Y8?$TV5 I3:T;9]J&63U[>3#E)Z\S
M&N\'?#;ZUCVX9R3)==M^H8>S\N5!2 SI2A<=45"XW.A3755$"&Q\'6D>;):D
MB0_OU]3_ZF6'+-?*Z=.V^J<IN\7+@^R E7JF^JJ[;&_?Z5&>F.@5;>7\F=T.
M8U-YP(K>=6T]3@8'M6F&J[H;]?!@0A8^,4&,$X3G>UC(<_E&=>K5"]O>,DNC
M08UNO*A^-I@S#1GEJK/X:C"O>W6EYU!QQR[ULK6=:>;L\).ZKK0[>C'I0)]&
M38J1UNN!EGB"%A?LO&VZA6-OFU*7VP0F8&S#G5AS]UKLI?A&%\=,\H")4/ ]
M].1&6NGIR>^6]C_3:]=9^,9_]Y"/-N0C3SYZBKR"XE@[8Z=MO53-ZB^.7=BV
M[(O.[=+F=Q+K%GI-\,]_R@1/?W)L.9)EM]IJIAR;M17BRYVP?VEE1P,PJ$_7
MU]I"A5Z#= IQXCG[Y?CJF)TUW4BQ8I_:3E4_^/IBH1 8A>X[4ZCJA'ULX([M
M?,7^KE>=[4O%GK$\2),8US2(P, SQM. 9PENLD#& M<D"$5&'Z) 9J%_(4.:
M$05IFM,''H19Q*959513:*2"&]WTFCUG[U?-4ME?%3OD1RSF,8M2R?(L9Q%/
MF0PSEHJ8B23'H@F+HMTT='-CZH$$31-9RM(P8C+.F8"V8O D)$A B@CO/ZNB
M@*4<^UG94CE33=8W#(."+.-,!FDN6!PDX(8':0P>(#-(!KG,: S,P8,<0F*D
M3,E'_M&K<G+^_/SY)3L[FWQ6UMRH.PQ*1,[B,"$",L:S3#,\AT0D)5)))EF,
MQ40@TIA=-+JO6YHI\#J"#J*$9;F$'E(O$&DR90G4*O U%PF[A"$_Z:]><U)&
M+ M3%L$^DG.6YNFP.'A/<P[1OW:*<2R?DDIQA!+$< N&) YH7$#"=ZU;&O*/
M:=%W\%T%%WUM34E9.$T$2VE\$$OH".PGG 3C.023) R)Q:&A"]AH51O'>"R9
MX!F3-(V3)2 OU RN<":[7%A8\,XT#!]B\$"F@X1TQ^DNQ1GR?6COU QV2D G
MS_VP2'B#2ZA99(*1 R8@?PHG,3 JBQ M((/,!L^ :@0'PR!-Y'-$Q(UJ?F6'
M\='P,13P 3H+:$^2WX#S1+)_:WNM[A2HT5#RM#1B<>*5AL]@F2,VSNJZ;X;X
MN3+ULFT,\_$F?F(9_)B.S3.T3,?]<^B/2UTC$DN]^2!(3ASK9XE!=*R?(S!*
MQP?=V]851E-PH%2[MK:*P<5$!$F@?&B:7$8*<AO(!V^&9WPV=F#XO*V:?FFL
MNC$6(D&3")T<\;U>Z'NO9P[YV6KG)IL[]NX-9(C@HG!#!+.$V\9PD"P&/^0V
M".X<W@\_@XO=*%?TE;*[8GU::J11-_FL[=?^IF6'X@C""3*5))/ZD/>^Q;$>
MIU09K2?=JS06_M@\4TH5]RH5\&<ZWAAUK3LDBK^IIK\Q")R \@<"'X-E( 7=
M1SX4,IG0&R@4Z<*_3^$3,HC@DC2[!CB3%&A!G-,Y3T@;=!?EGB(</,XHO"-B
M+@AAM(\H&Y8MMS(T.Y1'E -"FBK)3P,)*?.,B$AD87H6N!<^)I,$1D>BD3O3
M/7-C,76^4(D0XF$\2"!>(P$10#4+0BR 2X*L(9,@H:<DR.A;&@BD)QD%E%&F
M#4*X8N^TJKK%"7L/J ;L4WQ!."*PD =)'R*/D2X\VX+>YLC+<>:S'RT=I!!D
MJ)24:@:2C@3.*>'R823$R5*!M$B"IM D:3S+O,!A/HJZQ<XC2=?6R2!+',0)
M):S(IW>![(2J%4JO7K)IB%2*NH84/-ACF])A=/1D(""#/[CE\'W( "\?^'ND
M>Y0'\MTDX$@G$2HKW)CG04SU#.Y%;($C>!DL05D>QI+(31)V ?L#:SZ+)1C"
MP3A4!9_BR RD-:H'&!?!L,]HL4A0?<9RPA=H+$@5\YE?,J-:CD5S2;4<R\;<
M5_<,L^@-EDY# @(R#RCK>6BQK'K'3--IVR@"ZY"P5BO6M!W37WL\=5[J$E'<
MM<RV?5,"O!W[5/I-G%N-]H22AV/GVA9?-J#)+:@2 5$!/<U,YP)VNS#%@M';
M$5"-"FT0<!A7M,Y?AY>J*?&FKD'3J,K\ZCGU8V!)IS7J"ZI=?'3L\\KO9XO-
M;%N/:Z*FO58K;3>#T3E]T1ZY0EG6=*TU^O\H"/+%SD2RI(IK3;6BQHPZ+#?2
MQB*MG[#H:]6PQ1! W\P>T&L ^8JJ)UL^0+2F6T!L0KTS"PTNC"-!X J5<1U0
MK=, ?:K3U>K81]#EO6(''M"J^NE#]!:DE2MM;TR!;V/@')-]_*#KWA&<<X.R
M?V/: +=G?07!2Y^BP,_U:F#66"@9WFIA&=(#@>UC'U:#"HU[H#;H'P\.TS$2
M**= 7ZH:W2(.BM:B.X& :]?9TM/:G1:ZG-.S;VM-Y[U 43\ N7"%#FWY'(KJ
M5O"9II]A7&]IPIAZ[BD.+Q!7'^U<-6T#NP\,DQY]VX LVHXL8.0SCF19&_BW
M[\LK14K =%*"@KG H->5%ZRB--Z,1H%#M'WWO()*&Q)][:O=0N%DS7P.]9)O
M-N3A1&.I5K6W+.C[J#G>TZ;%FS8MWMM9G;:-:RO@.V+\<M0QF?%GW<ZM6B*6
MV-1JM:MGVTN9=E!.W!*._O+ ^Z2]T0?;RPW*QEKS^[7@:0H13*Y5:B!_#%._
MLZMK#"URU2D"'@]R]28SCWGX+>#>4@?LW)1EI=E;!=>EM#"=640H@&D@(\K_
M 741'*4]3]@IPE)1-2-8B!K(?5L3 J&@X-(;07U*XF$%5=*I ^BY4(690<;#
M(2O TLU(B);S4U%V !VHGG.@:YQ!YSUR$BHX4A2Q0_6=L%&6AX1N $X&!P50
M$5390T& ACJ@!\5H4WK&0K/'<9*-XR1['>=2PS4+@\3N,R8<?+VA<#&F;KCI
M&9K@FD T/%ZS3^I.[VS^]ZZTVY&FB+;'#*P3T_(;!GP5.?6AU%.8?UQJZZ>Y
M+=XH+?T.3[O:7O?D*7 (]8? I^F %WA(G;\ LD5SMAMC 3G$H0>?A&<)[6TA
MIWL<SMEA>O0(#JVU(($-"2&F08KF0,1!&*\1V'H(1_\%AR%(^0OP1M46%)\G
MM,N!0$0XF$&- $T$K8"_-E_TW9+R%SO,P@3M'-IY.N>HE=.:MI7&@GH(]B4-
M( 26^FN2HQJ\H7I5F,V@B$?^8\QS?XUR3D7-P1!4TQ$F)7)4U2Z]B(><R @:
M"2$Y+9T#<@]3.MNOT_Q8SH'A,2).J>],1+*N1?V]R($'"8? JEX.0JO1>,6D
M9Y0+,@_SXB!+I-_)X>G><$HWX93N#:>W7WN#\O2^=2/FF<YFWK='C+*EJ+.A
M_)14I1]%W:[PVKOR[O :V:DV[*AM=LJ'[)@'[#SVOD<1]2@RMMV>8,A@DL&3
M*?R^C;YA W1+!^YQ .YCGS;1<%J'SL,[?-C2,_)L?+^QP-$?[6$I_",L)4]P
ME'S#4"2I^4%:>)H5GO\15G:Q\>W=%ENT^Q73'@%'^[@G&+)-,&1[@^&""C+0
M6L N  2':DQ,^Z@/V ?$Z/<AE+W+[/;\^[67F[7U_=K(#\'3D&5,(X^]_@=0
M"J>.VN_TAI1\_-YPCE3S&R E07?-D94DCX!*N/@1Q$%[1[3UBDPZ?O3;.&A]
MJ=/>1A^T5\BI&FVP#C7;G%KE>%V=P %+!YPU],0\#<(P'+:U19[N])#)@]\V
M6&ON?TX1_N^;;OB#LWF[^?\U'7[[W \??IZ=*XMNP+%*SS U/$Z!4^WP0VIX
MZ-JE_PETW79=6_M;]&: FS0 WV<M>K[Q@1;8_!5\]3]02P,$%     @ B(59
M5)/L6(\C @  @@0  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL?51-
MC],P$/TK5DX@K>HD[0):I9'ZP0H.RU9; 0?$P4TFB;6.'6RG6?;7,[;34"3:
M2S(SGGGSQGYV-BC];!H 2UY:(<TR:JSM[B@U10,M,S/5@<252NF6671U34VG
M@96^J!4TC>-WM&5<1GGF8SN=9ZJW@DO8:6+ZMF7Z]QJ$&I91$IT"3[QNK O0
M/.M8#7NP7[N=1H].*"5O01JN)-%0+:-5<K=>N'R?\(W#8,YLXB8Y*/7LG,_E
M,HH=(1!06(? \'>$#0CA@)#&KQ$SFEJZPG/[A'[O9\=9#LS 1HGOO+3-,OH0
MD1(JU@O[I(9/,,YSZ_ *)8S_DF',C2-2],:J=BQ&!BV7X<]>QGTX*TB3"P7I
M6)!ZWJ&19[EEEN695@/1+AO1G.%']=5(CDMW*'NK<95CG<V_,-MK(*HBCQUH
MYG;*D#=;L(P+\S:C%GNX3%J,>.N EU[ 2U+RH*1M#/DH2RC_!:!(;F*8GABN
MTZN(6RAF9)[<D#1.$P,U*L)>@9U/@\\][/P"[*.NF>2O?N(;LL&QE> E"U*1
M)=EI,-@I!'![[KEDLN!,D#T&P;$PY,?J8*Q&9?V\PF@Q,5IX1HM+1]&W!]"N
MEPI'(6LRSFO^=Q ![=:CN;MWS-.,'L\)T#-=M*!KKWY#"M5+&R0R1:<+M@JZ
M^IL>;N<#TS5':0BHL#2>O<>^.B@^.%9U7F4'95&SWFSPD0#M$G"]4LJ>'-=@
M>G;R/U!+ P04    " "(A5E455^KO:L%  !A'@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6R]F5MOVS84@/\*8?2A!;I8)&79#I( 2=RA!1;4J)'M
M8=@#(]$V44ET22I.AO[X'4J.Z,0RZ2Z!7Q)=>.[DQV/Q;"W5=[WDW*"'(B_U
M>6]IS.JTW]?IDA=,G\@5+^'-7*J"&;A5B[Y>*<ZR6JC(^R2*DG[!1-F[.*N?
M3=7%F:Q,+DH^54A71<'4XQ7/Y?J\AWM/#[Z)Q=+8!_V+LQ5;\!DWMZNI@KM^
MJR43!2^UD"52?'[>N\2GDT%D!>H1?PJ^UEO7R(9R)^5W>_,E.^]%UB.>\]18
M%0S^W?-KGN=6$_CQ8Z.TU]JT@MO73]I_KX.'8.Z8YM<R_TMD9GG>&_50QN>L
MRLTWN?[,-P$-K+Y4YKK^B];-V.&PA])*&UELA,&#0I3-?_:P2<26 $[V")"-
M 'DI$.\1H!L!>JA O!&(Z\PTH=1YF###+LZ47"-E1X,V>U$GLY:&\$5IZSXS
M"MX*D#,7LZ;>2,[199K*JC2B7*"IS$4JN$;O)]PPD>L/Z#=T.YN@]^\^H'=(
ME.A&Y#G439_U#7AA=?73C<6KQB+98Q$3="-+L]3H4YGQ[+F"/KC?QD">8K@B
M7HT3GIX@BC\B$A'<X=#UX>)1A_CD8'$\]D1#VXK06A\-5.3K',W$HA1SD;+2
M=%;G[S] %GTQO-#_>"S'K>6XMASOL7Q=3S>N4"9T;:RSNHV.I-9AJ7(/%:41
M).Y^.^4=HW#\<M1D=]1XO#7H612#-HJ!-PI(E*I8CH")*%TRM>!W+/VN+:0L
M;'B&F(8(%5S#LZQJ^&,D(*@)&IZF7-RSNYQWQ=]8'VSY3*+AB^B[QHRZPTK:
ML)*#PU(0DH'ZBS+-*UA#=D$R^]X&5V9(FB54,:V4XC!S<L'N1"X,S)BN>)*=
M&I!DIYS);D#)OD(-VXB&WHBF2MKL0S2F4B5:<25DXS]_6 G%;%VZ'/9K!;P4
M-5X\"V+4>CCRZIIPV$M3L=>3T>XD'PQ'+U(WVDD=3I+QBX70-0@/NO,[;KT?
M^V=,=L^5$=HBPV9UI60AZ\F>2MV]ML>[<R':F0N[@_!H9V5W#-J[LG'D-JO(
M&]*-*$51%9[2XJV-#Q^9LY@XV^37IW[G5NK70\-S';M]!U.OLD_:"&BD@"&5
MYO,J!W#,N6T,1&E8N1# 0T"GYMU3)Z"<H$?.E-=1MTUA_SZUF07H)[IF*V%8
M+OX%IV=R;M9,<9\)MX?@P;$GAP,]]I/^E77P*Z?A.CA^8S]J71VN*I%GD!6O
M7D==/#IV\ATSL1^:>Y,/](1E:AX_HE5NO:GWJ1^56,&/(--9"+\A,@A6@C@N
MDH.X")6X8>D27BKPL_6NZ0GFD$:.YL ;H9>!6A%'47)LBA)'4>*GW]O5*F H
MO&B(HRSQ@]"5ZK84UO>9J7NYGV@*S6K!4EX9R&&.-%_LNOO<J",FB8]=)8=2
MXN_'I^RQGH2&JZ*36 %YFJ",/7J3[]!*_/3;G_Q+> %)_\Q9;I8^6XZ.9'CL
MG#N"$G_C&LZY7YY&P9P[HA(_Z%S.OU9&BZQ>H? #Y7D)?#^<'09I=.244P="
MBE^7\H!\..74@9'Z>77#'@)M,MWZ&G'LSQ'488OZ&[V#V^2 GB3<)E/',^KG
MT>O:LX!R$@>W&NIH1P.T:Z;!K_?)U$&.'AMRU$&.^B'URD+XE>,H7 B'0!I
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MM;"!87@ 0Z_&T'-BJ,NP-&6X0$*OJ$3T"4A6T;9TE.9Z.U!ZO?X+).6B[#5
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M\'#G\)_37!?GIC__7U&)[2;+#[MQL4'$<5'9J!!'W2/LG4TY!1,;,RU**&I
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MT6/_;+6XR9^T4[HCX.V,%XHZ J3.'D+1B2-AI;TUE?[27,1#=]&KJF#-01M
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M*,*[9\<O=$%35PP Y%Y?2.X!RCTWRQ^5%X$]04EG7@"2/3>3'Y47-HMQIR+
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M,ZDLW+'*')5=(\X[1C0#M# _6@Y0^<28S8 93/9%:. (\R]HSB2TNSX1SAH
M,>J8)#- #O,CYP"9/Z7CB7Y4R1=RF[9.J;E>U&E2D8\/QTH/@&%Q3Z3G0!?N
M7V"<1_K5CVS-P2)N28\8=<1Q#B#B?A M&^K7(G^;6)PO=G. "6=]T75C%\Z_
MS$!U];46*BOW#-:5J*Z)[%KV<B /]Y/G'T6MLN6VUUEF6QR0P8.^: G(X/YE
MQDUFAE^>:%+J9YTO-/F)S,OB*:U)-55EFD]0[=R=+SJT-_WN$*N06P-WA!@)
MT;'OQ $ZW ^=HS1N+-W6^/B:SU7YI_*U-M"$1WWI 4 .OF-I<E0/<+>DXBBV
M.X!K%-JSLQ%BU-D!!*!'^-%SQ@[PMZ+2V6)2^+(%P!31EPTO 8@1.]8KQW0
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MBJDRSCI0=Z#[!%M'069'N5A0D&H2RH#^%!(:(?V66J-!9J/Y2^P),^W+6B=
MLX_4#=3*.KI(UL_2#:3J,1Q^U&HP:.3[#[62C<R2;5(.I'[D.VAH-QH00D.[
MT8 @'%LCK2,@\W[A?TF'9DL E0VC#H5\.$*T=11D=I3S!$3UA2F$PWV7!N6,
MZ4=K'\AL'Y?K1Z!L56>*YJF8X=(.-1AE:5N=<Z:,L%UY7L=!1(^YJ,YIFJ?-
MF>!=>1(V>'X/;\/J9*]-4QTT/F(FWU4.4K*5*>T;7PXSJ\[NJAM!#^5IUH8*
M0;/R<D]P3%@!D+]O*17O-T6!Y@1U]1]02P,$%     @ B(595%NQ>4(5"
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M?8M=*>,#)H=%NFQ97O:RO!4&%6H#BKH?Z!6;O\!KYGN;WNV]L'Q^Y[O@OZJ
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MMADR$3#/U\)T?+Y('!3G@K/_ %!+ P04    " "(A5E4!(/CC0(+   I50
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M_BVRJXRT+)P;5B$3:2R+U ,:>S=M]]2.]W\9-.U0[I[\QEV*W (:7&9K(K2
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M-FF:7!G60 ?!C2]UD5&_V9>@\"7H]&5-7M*"T@04U%;[B+WQ#5*CT+ 9:E1
MC3JA_C0'JIJ(1@V+^3= =1FOF69<T(S?>&JHB'YR9,8UF""X#6I=IGJLKI"Q
M5S8-[XW0U22%\@02C<7>JU'A01M5I97A3JHG(N2.H371AB:JHZ)AOS3I_SJ%
M&)?M _?_SU*<6[]*+-P6GK(]X+?VAY]G.JY7_J%_6XL;A-JQR_Z NQM$.W:<
M)8&M<%")(<P]%#$=R@3&(-/L2+88]JL5Y [C00MFV35P=]M856 >,YCE!68#
M,.@?]/KS4=9W'/Q"YZ/L +B[!?S',<T6&UV%U!O=1-2M?*3'5.W3NXM&J>GL
ML[68+>Y'#^FMX&9^;N]-Z<=_:2:[=*V(@M.M$:<[,.G=!9!L*KO'9 ,CC^E5
M8"L-7"S2QP/<_:BR O!^)Z6Y#.P"Q6UR]B]02P,$%     @ B(595!DI3:H)
M P  - D  !D   !X;"]W;W)K<VAE971S+W-H965T-S N>&ULC99=;]HP%(;_
MBA7UHI76)@[Y@ J06E UI%6M8-TNIEV88,"J8V>V*>U^_6PGI"DQ66\2VSGO
M.<\Y_LIPS\6SW&*LP&M.F1QY6Z6*:]^7V1;G2%[Q C/]9<U%CI3NBHTO"X'1
MRHIRZH=!D/@Y(LP;#^W8HQ@/^4Y1PO"C '*7YTB\W6+*]R,/>H>!.=ELE1GP
MQ\,";? "JZ?B4>B>7WM9D1PS23@# J]'W@V\GD KL!8_"-[+1AN85):</YO.
M;#7R D.$*<Z4<8'TZP5/,*7&D^;X4SGUZIA&V&P?O-_9Y'4R2R3QA-.?9*6V
M(Z_O@15>HQU5<[[_BJN$8N,OXU3:)]B7MDG@@6PG%<\KL2;("2O?Z+4J1$,
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MC7.A6,8XND$: [Q?"J&W&S,<ZC\#P3]02P,$%     @ B(595'-[HH)1!
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M+W=O<FMS:&5E=',O<VAE970W,RYX;6R]FVUOVS@2@/\*82P.NT 32Z1>>TF
MQ$YW [37(-WM 7>X#[3%V$3UXE)TG!3]\4?)BD:VI(D->-4/C6R3PYDA]7!F
M*%UL,O4M7PJAR7,2I_GE:*GUZOUXG,^7(N'Y>;82J?GE,5,)U^:C6HSSE1(\
M*CLE\9A:EC=.N$Q'5Q?E=_?JZB);ZUBFXEZ1?)TD7+W<B#C;7([LT>L7#W*Q
MU,47XZN+%5^(+T+_M;I7YM.XEA+)1*2YS%*BQ./EZ-I^?QOZ18>RQ5<I-GGC
MFA2FS++L6_'A+KH<685&(A9S78C@YL^3F(@X+B09/;Y70D?UF$7'YO6K] ^E
M\<:8&<_%)(O_+2.]O!P%(Q*)1[Z.]4.V^4-4!KF%O'D6Y^7_9%.UM49DOLYU
MEE2=C0:)3+=_^7/EB$8':O=TH%4'>F@'5G5@AW9PJ@[.7@?;Z>G@5AU*T\=;
MVTO'3;GF5Q<JVQ!5M#;2BHO2^V5OXR^9%@OEBU;F5VGZZ:O?LRS:R#@F/(W(
M9[T4BMREFJ<+.8M%3L[(O[A2O)A,\NM4:"[C_#?R"Y$I^61ZF:G.+\;:Z%%(
M&\^K,6^V8]*>,6U*/F6I7N;D-HU$M"M@; RHK:"O5MQ05.)4S,\)L]\1:E'[
MKR]3\NLOOW7H-3E<BM4O97JP%#OLEW*+2[E>J7-B55(0#[%ZGEDIC_7(@TDE
MUWDNM/']\SQ>1S)=D'H-_/>CZ47NM$CR_R%C.O683CFFTS/F=CE)6$[O2"IT
MUWK9RO%*.07:GJXH#1F[&#\U9Z_=RG9LRZY;[2CIUDJZJ)(-Q_#",40F*RZ5
M8:$F\R57"V%X&',M(J(S<^>I;Z*X7JDL6L^[C)FZ+35]R^U6TJN5]' E[Q_^
MP9/5/Z=M[;KNO^E6FMOTE$^[5?!K%7Q4A8FY8\UB*0<V=[V,1($%@_I8\IF,
MI7YY5VAD6N0%'42N95)Z[='H2YYXO!9=,^^W-'7]O6EO-PE8MRU!;4N VG*=
M9$K+'UO]Q;/9='-!S*;;6*O;Q= )MZ#M7,^R]I3N:!3L-YIV-/(;C79L"VO;
M0M2VV]KQ?+%08F$N">^PMZ0<[;(O/$(KVX)]QCJ=7JQS4[%PQ^\JUM@ [=,I
MYG0J9A^C& 7%Z.D4<SL5HVW%G%[%8"NQV>D4\SH58\<H!ON-C6\X-2:1S<N&
MC<%V!]LR;2"]C:/^\$W3;E,^I(&]!Z*.5HS2H,?5L!O8^';P'Z%F_)EC)@.-
M[6 X1P,G;1R4)]_X)W8'.7LY0(&<%"?G7?ID=,K4"]DHJ<59E&W2SN"V@X^T
M;W3 (\7Q^,6$_L]:95B4#DBC=+"9IL KBO/J]"$>;?/+LWL"+ KXHCB^KE.#
MU9C\(7BLEYCE@# Z',(H((R>"F&T#2?7ZKUC $X4A]-U),P,Y^0G^2CGQ4Z4
ME^EM5NB%60C$HL,1BP*QZ''$ZHQ.:1M"@>5U>Y0!@QC.H*]"?5\_9<=ZE %F
MF#V81QGPB.$AUD$>9>THRNO9/UDC'<>9-/G\]6YZAJ?V  [F#.<\@ M[(W,^
M+BF=5.)VXI6>6YT!:QC.FK\G+9VP-IC.G)XDG@&7&,ZEN\^)V7WNC8L23CYJ
MK/+%@$5L.!8Q8!%[@T5'5B181VSD]CC4 2PY.);^GMF?5J,V2SAG=D^=R0'$
M.7@DE6?:C*WF8J4-1P_)51P F3-<8.4 Q!P<8D<4^#H"IMZ$SVD4&/&(*16)
MYC.U-HM SC"3 &K.<!&3 Q1S3EK?NW':>*)^W]T$>')P/.UX\] E"IQRAN.4
M YQR<$X=L43#=A&Z-Q9U 5$NCJA]IWX2/%\K4<[P7;I:ZW=D*O-YMC:?'XI*
MRD_RU7!IB[$_Q7R9RN]K 8T,O"8\7Y(/L='D)_E0@*SH8)HT1!LS'\1\K93Q
M+N)'%^#E#A>?N8 U%X_/:L\8K'>6CZO^-FW,FG5N!446 ?_ZC@@ ="X.NH5X
MY"OYS--#R>T"PMSA8C>W<>B!QVZ'WQ9N^S@C8#VIK@O <W'@W6]SZVT6427:
M1!6'NCEF'Z#,]8?S*B#.Q<\5CO!JN_3O!Z&[5[OK:.7X?3&S"TQT<28BSC?+
M^T',XNS'2XQXQ /Z>=9@\^ !K#P\TCI\'KQVZ9X%?=#W@%L>SBW<PV_73CT@
MDS?<N:X'T/).=;);"=I=PCW9LP?X\G!\X?[]G:N(YS(>OUX0+,WV&H>PWG"^
M!I1Y>%1VA*_;)Z5VV+/W>0 U#X<:[NL;)2,3J6"6 I>\<##_^H H'P_0#O>O
MWU%@[RL*^  K'X<5[M^I?)1SB54*?*"2/UR2Z .A_%,EB7[7J6"??X%5/LXJ
MW+\''&_X@"5_N.31!RSYIRJW^QW/A; >&/N-!T-P0+WEX&25I1*S%%#D#Y="
M^H E_U0II-]1Y.I+/@( 5( #ZD_%(T%2GNS7 G;E 7""X5*Y . 3X"'1X5X,
MVO5VRH)P_P&;CE8NZXG< J!5@-.J.M[ 3 ;R!,.E=@% *#A5:A>T"_*,-8XV
M*D>W$T#FNGU/8 &U IQ:E:.+$Z67=,75#RP>#@!&P7")7]!XGNQ4B5_0\<R7
MW9=P!,"H &=4PYLB?9()YLP0R!,.E[V%P*?P5-E;V/'@56_)+@14A3BJKE,M
MXEA^/Z!:AQD,S F'R^%"H%.(QT5OU=9NJ_Y[M37;[HG(0B!4B!.JX=_#]K80
MJ!(.EZ*% )WP5"E:)6BGR,Q:*W;<>)X_$6I1ODB1DW*ZM@_%U]_6+VM<EZ\H
M['U_8[^?;E^Y #';-T ^<;60:4YB\6A$6N=%9*NV+U5L/^AL5;XU,,NTSI+R
M<BG,9*FB@?G],<OTZX=B@/K5EJO_ U!+ P04    " "(A5E4<6G  K<#  #.
M#P  &0   'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6R]5]MNVS@0_15"*(H6
MV(U$4M?6-I#:N]T O1A)TSXL]H&1:)NH)'I)*D[[]25E1;)U:Q(8>;%)\<SP
MS'!TQ)GLN/@N-Y0J<)>EN9Q:&Z6V;VQ;QAN:$7G&MS37*RLN,J+T5*QMN164
M)*51EMK(<7P[(RRW9I/RV5+,)KQ0*<OI4@!99!D1/][1E.^F%K3N'URR]4:9
M!_9LLB5K>D75]78I],RNO20LH[ED/ >"KJ;6.7PS1ZXQ*!%?&=W)@S$PH=QP
M_MU,+I*IY1A&-*6Q,BZ(_KNE<YJFQI/F\7_EU*KW-(:'XWOO?Y?!ZV!NB*1S
MGGYCB=I,K= ""5V1(E67?/</K0+RC+^8I[+\!;L*ZU@@+J3B666L&60LW_^3
MNRH1!P;0'3! E0%ZJ &N#' 9Z)Y9&=:"*#*;"+X#PJ"U-S,H<U-:ZVA8;H[Q
M2@F]RK2=FKWG/-FQ- 4D3\!GM:$"7.2*Y&MVDU()_NQY]FI!%6&I?*U7KZ\6
MX-6+U^ %8#GXJ/WHHY$36VEFQK\=5RS>[5F@ 18+&I\!#/\ R$&PQWS^<'/G
MV-S6^:B3@NJDH-(?'O#71 O.I:1*@K_NXK1(6+X&=<+^_:"MP(6BF?QO9$]<
M[XG+/=VA@Q!<2C G0OPPVYQGO,A57R;W;OS2C7E);V<N<G$XL6\/$]9%88QP
M4*...+HU1W>4XWD<%UF1$D430U H]I.8E[&/YMZ3=T  1I[CM6CVH2#V^VEZ
M-4UOE.8GVILXK[,70A'&+49=%'2A _L9^34C?Y31Q?+R)<FV;Q<CA1+4OH)G
M*\ZPWC,\37&&G>Q%*(2M%'=!&*&P/\-1S3!ZRIE'#^'3!0WS@4XCK,XHHZ7@
M21'KXS'*NMU/@#!?%3ER(O! N.&SU0%LE!&BTU1"Y>?H=<-^T,Y]'\R)!K/?
MJ"D<E]/'2%7EZNB=]X+ ;U/M@?D0#U%M1!6.J^I Z<*N-@9AU!;0'I0;1,X
MIT9!X;B$?A$DH2 G&1TMUD;_H/]\Q=HH)0Q.5*Q!MPK#$+5S_1O4,<M&6^&X
MN#ZJ5+O:Z4;M3U@/"'M#-!N!A4]26-A53X3#J$VI!^7A@3)%C<:B<8W]P&+=
M4="Q*U^CI^CY]!0=W#1/I*>H*Y2^[[BM//>A8!0-Y+E14W0Z-45=F=0WS[:8
M]J"0[PY<_%"CI>A)6EI9'5^'_?:=N0_E>;C%R3YHMDRG^Y&(-<LE2.E*FSEG
M@8Y)[)O'_43Q;=E_W7"EN[ERN-$--Q4&H-=7G*O[B6GIZA9^]@M02P,$%
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MIB]_ZLHA6=@+TS@O_R<OB[8!;Y%PGIMT6G4&!-,H6?Q5OZI K'6@_HX.K.K
M]NW JPY\NX/8T4%4'409F84K91SZRJBKBRQ](5G1&JP5'\I@EKW!_2@I\OYD
M,O@U@G[FZBY524X>U*L:Q/J,W*7)^/RKSJ:DKP>&J&1([C2$-2?GY(O*,E5D
MB;SM:Z.B.'\'3[\]]<G;/]Y== R@*6QVPFKDF\7(;,?(E)'/:6(F.?F0#/5P
MTT 'W%CYPI:^W##48E^';<+I&6$>HPY M_MW]QS=^WMWISW$&[[*#"_M\9WV
M( &?DMQD<YAGAOQU!PW()Z.G^=^(>;$R+TKS8F?B(=.FR/00!CJ#6LNR8AB8
M2O,L,I'.72E=V/1+FP6E/%\Q[E7_+CK/Z\'>J^D&=+F"+AN@%S4[6]1L6:-+
M\+,T*]DD'9%XPS^7+XM!Y#I 09G3EWI37W"*^>*O?/$/2(,+IE\;FWM^SQUS
MOQYSR7TTZ,$*:( "_:A"B/4TG4.8(;R[T 8UM%T/SWIW!:![4,':0CT# 8)J
M*&9)7F";95$21C,5DR@I)C-S >W6L]]0GKT5T-Z)@'(7T%X-* UPH-2SY.^=
M"*IP$KY7Q]H05+HF5/1$6*43*ZT7@&S RBQ6=B*LOA,K.[A8J949R@_"&B7P
M1>>&K& BLZBRO8ZL1W%@5J#H80JU"YASUE2V-X@HD"@P*S^T27_V ^:>(W4M
MZ?(N"LQJ"3U$3'8#<T^(NM $ :IQU&H'Q<5C7V#NZJ]K2B X"LQJ"L5%Y?H9
MUK'E,F*09M [2L8D5#,51N:5S&%=FI$PT\/(D!$\B^&I$V&WIKM+T=T)T:H)
MQ>7D?J:+93< BXN5^!EY*?<R>DC4,_PRUL HQ09OU8(4@7;"Q <*R*M6F6O9
M=]O0L^OJN;F$MY+$<$FJN1NFN7.E4=E9#SJOE46U[G<U=:Z@^JZF'"TV9A6,
MX0I6<VU9_4[WZOJT _.MJ^FR[;9[#M7#:9%9T6.XZ)5G!N?IZ'P.-:CR7,-"
M<0#[Q 1*%::W_A5.5 +E.DHSDFZ&@L21&NR<7JPN?W2Y!MH.!:NE3P3.HN@[
MFE*&A\)J*FO05 WN0X+3[8POO$U2 S/&0&E/(?^A'IY5*VNG][R&L^NC,*W"
M,EQA[\T$".Z[RJ*2 A^5T>6^'YO(5B69/,7^E5FU8[C:?1B-='EJ9.4$@JV=
M,<0M>6W/>^,\,&CJ)^0;S!<KD P72+_-O3>%.$*DYN *&<ZU0Q WK5N58]V3
MI,)J%#MDR^/,0*\^V_CV;*N"OD_3S2,5JRX<5Y<GHTQ)1PT%TV"F3!=VQF,U
M@>.:0-L!)!X(P>8\P Q;-N;L%#GG:\=3A^P;G$&L,Q<5/;=$\_I&8E>R+;UQ
MG-[V3C9NIDP1%C)+B1S?..QYAE)9V8A;P]:46];D.&?1=F^[X+J8<Y;">'"2
M@K,LQ@\Y '(&KKX.[_6<"Z%;7C__V15:RX(<9\&]ZPTW4V8(.^&U;"=PFMJS
MWD1]S;O<P^^J-V$)3N $Q]I4;M8;IYASEN#$20A.6((3OTMPPD%PO=KBK#H.
MWYO@Q-H1_G$(KL%,F2(L9);@Q%$(3M0)CC45G"4X@1,<:P=;!2?1@K,$)TY"
M<,(2G/A=@A-U@J.]H.<NN+T93EB&$\=AN 8S98J0D$G+</(H#"?K#-=4<-(R
MG&QBN&U%];&"DY;AY$D83EJ&D[_+<-*UA.NZ)57NS7#2,IP\#L,UF&$-DBK7
M7CT>A>'DX4LX:1E.X@QW6QP;9&&D8O*@9CK#'+/L)D_";M*RFVQBMV.\M;V5
M=0H435/9\IO$B>E'=;1ZOCQ:W2B\ F!H8S^KQ[Y*/CZ(U_:ZSM.&QGY!#RMB
MW[*FC[/FEY*KGN:#?W1HR->4/"[?29%K0^YG93;N1^3/-!ZBY>5;DO3I*<K+
MMV3I-[UR.\JE -]Q*BC< NMH6CMJW'3&$K./$_/-/(J'43+&CM1]2Z*^.$GL
M+2GZ."D>[Q5%PT#.5Q2;H-<N7C2\+-MU1@M%HU]@?N_$B-L5S1@M*?OXL>!W
M/8G">/LJSJ8Q2\#^24X!?<N>_O_UIJIA("3$G;6K<$#4X_)*80ZT#8*]N$FV
M>KJZMGA=7M;;>GY#W_<7EP^MF<5=R,\J&T? -;$>@4E@9:C9;'&]</'%I+/R
MPMT@-2:=EA\G6@&3%@W@]U$*_%M]*0987?*\^@]02P,$%     @ B(595,3G
MW)V\"   C4$  !D   !X;"]W;W)K<VAE971S+W-H965T-S8N>&ULM9S;;N,V
M$(9?13!:H 6Z-L\4BR1 NT'1!;;HHMO#1=$+)682H[:42LJF??M*LN)A2&GH
MA:2;Q([)R7 F_/7Q,+EX+LJ_JP=KZ^3?PSZO+E</=?WX[693W3[80U:MBT>;
M-Y_<%>4AJYNWY?VF>BQMMNTZ'?8;1HC:'+)=OKJZZ'[VH;RZ*)[J_2ZW'\JD
M>CH<LO*_[^V^>+Y<T=7+#W[9W3_4[0\V5Q>/V;W]:.O?'C^4S;O-R<IV=[!Y
MM2ORI+1WEZOOZ+=O*2=MCZ[)[SO[7#FODW8L-T7Q=_OFW?9R15J7[-[>UJV-
MK/GVR;ZU^WUKJG'DG][JZO1+VX[NZQ?K/W2C;T9SDU7V;;'_8[>M'RY7Z2K9
MVKOL:5__4CS_:/L1R=;>;;&ONJ_)<]^6K)+;IZHN#GWGQH/#+C]^S_[M(^%T
MH&*D ^L[L',[\+X#[P9Z]*P;UG569U<79?&<E&WKQEK[HHM-U[L9S2YO\_BQ
M+IM/=TV_^NI]D>55\B'[+[O9VV^2]T5^_^976QZ2:WM3)UF^3=[;)DI5\L;_
M[*MK6V>[??5U\]%O'Z^3K[[X.ODBV>7)3[O]OLE0=;&I&P?;7[.Y[9WY_N@,
M&W'FVMZN$TZ_21AA=*#[V_.[D]?=-TU83K%AI]BPSAX?M=<,\UU>U>53\Y=;
M)W^^;QHD[VI[J/Y"S/.3>=Z9%Z.A=^,Y%*UC?]7U;R?DIRM.E&F&]LD-2MB*
M2:Z@U2OGQ,DY@3K'UEI^F>1%W:1^^V3;D$IDS/)D5BX14G4RKU"O/]99;;?-
M'V%M2UO52=F\'0HL;J4;.^*-/GFC)R98AZD31GKY/3:2KQOQX?2F)]?2R!"I
MEUY.D1&;DUFS1'HI ;4BLR0X8J8;/N:0(Y]T8HY[ VZ2J4F5E^2^E9OED1E,
M0;XH^\PY++$D4Q NRA=),X@/Q=7G[#2?(6*80R!;5$Y-LQQ(LS9^FN79:0;-
MH[A<\;4FK],L,*FF(%]4+Y)F$"&*J]#9:<;-= ' ' +YHF9JFLU0FK6?9A.D
MN6FEAC/-0/U83+92+].,8YP#*L;H$IEF#DGA4G1NIB-FN@!@#H&$L:GPQ4*N
MHEKX$[IO)5^W2D<R#0+(<.7B:^%GVF#C!B%CBP 8 S5B\R!8Q$P7 ,PA4#$V
ME<)8B&%4<_\)S4(.:UJ)D4R#!C)<O&B@WDQCXP8M8XNP& <UXO.P6,0,C:@W
M!Q7C4UF,#["8R]+]@NIL%N,@@#RF7,9+L\)8C#N+R$58C(,4\7E8+&*F"P#F
M$$@8G\IB?(#%1"K\-)_-8AS4C^.R)=;$9S%,MSFH&%^$Q3CH$)^'Q2)FN@!@
M#H%^\:DLQ@=83.A@>V2 Q80R(]LCH'X"ERT1K* %QF("5$PLPF("I$C,PV(1
M,R*RAA8@86(JBXD!%F/<9S$QP&*,C["8<';"<.6B:^'OE6"[BP*$3"S"8@+4
M2,S#8A$S70 PAT#%Q%06$P,LQKB_)28&6(SQD3TQ 1HH8KMB?J8EFFG0,K$(
MBTE0(SD/BT7,L$BF):B8G,IB<H#%&&5>IF7(8DTK.IQI"1HH<?&BZ[3=&[-/
M9?%F:_/BL,N[ +[B<(5% M1-+@)H$O1)S@-H$3/'D& >.9O\4PE-#A :93Z(
MRY#0FN2/"+H$690Q/?-9G*78N$'>Y"*0)D&@Y#R0%C%#(RPN0=CD5$B3(:09
MXZ.X#!EM!,452*+"M8R$)UC8A%8@;6H10%,@3FH>0(N8(9'=;P42IJ8"F@H!
MS03K:A7RF3$C4JY _E1LJ\R?S1Q;<BE0,;7,6:5S6#G3:65LJPR?S0KT2TW%
M,Q7BF0D6UBJD,Y..P)D"[5,Q../^@@N#,P4:IA:!,PU*I.>!LXB9+@"80Z!@
M>BJ<Z1#.W!3V!],AFYF4#>=9@_KIS]TI8P(;-:B87@3$-"B1G@?$(F9B.V4:
M%$Q/Y3 =<IA[>M'G.<0P+48.LS2HG\9E2ZVEK]O8!HIV;ETL0F$:E$C/0V$1
M,UT ,(= P?14"M,AA6D:7#0)*4S3D8VR%-0OC7%8FV=\I85-\!1D+5T$S%*0
MIG0>,(N8(9'$IR!IZ50P2T,PD\H7\C0$,S6VQDY!#M/8@I)'U]@<0_(4A"Y=
M!-52$*MT'E2+F#F&!/,(5"Z=RFIIR&I2^GNF:<AJBHQH>^K<+HNQ6G3.<W3.
M@_2EB\"; ?DR\\!;Q R+S'D#*F>FPIL)X4U*_Z%N0GA31 XGWH!"&ES:^%KY
MYU\,&S4HG5D$W@RHE9D'WB)FN@!@#H&FF:GP9D)X$\YZNL]S"&]B;-%M0 ]-
M%-[\,Q'LUH(!63.+P)L!:3+SP%O$3!< S"'GRNQ4>#,AO GB"[D)X4V,/<,I
M<2_<XL(E@VTT])E-B7-UEBS":Y0X-V#)/,06LR-C-TF)<WF63(6V%PNO;OYS
M7\%?6LF15IZ#SN5;@FN87)LFY5M[TR3EJ3QODYP2YRXM6836*'&NQ))Y>"UF
MIPL%ZI-SFY9,);87"U[%1Y#WD-GX&+-1XMS&);BFR77J3W5L)Y42YUXM6:8P
MP*T,F*LT(&*GBP+JDUL<,+TZ((0UIOV'.!TH#W!;>0XZ^A@I$5#=/=//G.IN
MH<!"E0)NJ<!<M0(1.RIRXY2ZU0+3RP4&Z@68].\NT8%Z ;>5YZ"CCY&: ;7F
M@WE''^UNY<!"I0-N[<!<Q0,1.UTH4)\<F9M>/S!40!#<;Z%#!01\9'5&G0("
M&JT@\ ]1&+8^HTX) 5VFAH Z101TIBJ"F)W820IUZ@CHY$(".E!)$$STH3H"
M-G9+D3J%!#122<#"2@(\XX[*+5-+0)UB CI3-4',#HN)NU-/0"<7%-"!BH(P
MXP-WV @?.3ZC3D$!C504_%P_V!(=JR-HRQ014*>*@$;N_Y\1SM["JV=E<'HQ
MV,JY:7)T<..4RK?_J."GK+S?Y56RMW=-K_;*Q"HICZ7_QS=U\=A5S]\4=5T<
MNI</-MO:LFW0?'Y7-%.K?],6Y)_^ \/5_U!+ P04    " "(A5E4C7N"OV@#
M  #Q"P  &0   'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6RM5FUOVCH4_BM6
MM"NU$C1O)80)D%K8="NQ#8WU[L.T#R8Y@#7'YMI.*?]^MI.FT+KIB_H%XN0\
M3Y[SG./X#'=<_)$; (5N"\KDR-LHM?WH^S+;0('E&=\"TT]67!18Z:58^W(K
M .<65% _"H+$+S!AWGAH[\W%>,A+10F#N4"R+ HL]I= ^6[DA=[=C>]DO5'F
MAC\>;O$:%J"NMW.A5W[#DI,"F"2<(0&KD7<1?IR$%F C_B.PDP?7R*2RY/R/
M65SE(R\PBH!"I@P%UG\W, %*#9/6\7]-ZC7O-,##ZSOVSS9YG<P22YAP^I/D
M:C/R4@_EL,(E5=_Y[E^H$^H9OHQ3:7_1KHX-/)254O&B!FL%!6'5/[ZMC3@
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MG [\-P>JTZ(ZYU"Q"U6KDCU4U(_<J*1%)>=0'1<J.41UCJ#2%I6>0R4N5'J
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M66Q[/RSQ8@+M$G!]HY0]!*[WAZLN^PM02P,$%     @ B(595"*#&0=W P
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M/8:B^\14 L3[!2%\.Y !RGYV_!M02P,$%     @ B(595-K(_%V)!   U \
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MI/DZ4Z\?2(Q5QH"@8"'H\@7<;4L[,%/9C,0[.)T3@:.8?Y&>'A=S<'KR!9P
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M5 .#%\>ZQ8UDZ_PH=<:D9&E^N:(DHEP74.\7C,GG&]U =;@^_A]02P,$%
M  @ B(595)MI^54U!P  ^2D  !D   !X;"]W;W)K<VAE971S+W-H965T.#<N
M>&ULQ5I;;]LV%/XKA-=M+;#9(BDQ=I<$:"[%"C1;T"S;P[ '1J9CHI+HDG0N
MPW[\2$D1946FI*Y37VQ=> [/]3M') _OA?RHUHQI\) FF3J:K+7>O)[-5+QF
M*553L6&9>;,2,J7:W,K;F=I(1I<Y49K,4!"064IY-CD^S)]=RN-#L=4)S]BE
M!&J;IE0^GK!$W!]-X.3IP0=^N];VP>SX<$-OV173UYM+:>YF%9<E3UFFN,B
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M&!6\,30+3*08?ER2OA_%G. BF5D +'A(%.D%$I*9#<$<G,W:$ 2*1\'8L5D
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MA:]PE" M-$DT-9]I 526YBI4K K?F*6%T#T#NB'@QR#;(5/T"2^2IH4 25#
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MP:B$*P)(.+'*4BE@B#>QT$$IDA"YH5T8<SI.R$2QD(GR$W)A69DA\,24I13
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MAS'&.$%AA035[W"/AUP4UWE</02A6&BB%$F,[=@MX0IBC'&"P KIJ43W=TA
M<9/'R4/\B86F2G%D-(Y#[4TR@AACG""L0F;*3<:EA6/(0G&3Q]!#_HF%CDJ1
MW)SQJ#^(,<8)2BN$IMS<1!:-(?O$31X?#X$G%KHI15+A<.@6%2&,,4[05B$E
M%5@"!V<"5+')X]<AX,1"XZ2XR3]>S%V^/4Y^$/-MG->[AV$8;Q;CXLVKSY/$
M_+C8ET%VQ6JXGUY3?K</MFR7'Q]>OADWGU]?3=KW83..F\?#EP_#XF[8[@'3
M[^\WF_'YF^OI^E\WVT^'O_'F_P%02P,$%     @ B(595!<_=7A$"   03T
M !D   !X;"]W;W)K<VAE971S+W-H965T.3(N>&ULQ9M;;^,V%L>_"N$MNC/
MS%BB)$J:)@$FF18[Q0XV2':Z#T4?.#8="Y4E5Z23#K ?OI0L^^A"'OD"U2^)
M+1T>_7GQ[XCDX=5+7OPNET(H\N<JS>3U9*G4^OUT*F=+L>+R7;X6F;ZSR(L5
M5_IK\325ZT+P>55HE4ZIX[#IBB?9Y.:JNG9?W%SE&Y4FF;@OB-RL5KSX=BO2
M_.5ZXDYV%QZ2IZ4J+TQOKM;\23P*]65]7^AOT[V7>;(2F4SRC!1B<3WYX+Z_
M<YVJ1&7R2R)>9.,S*>OR-<]_+[]\FE]/G%*22,5,E3ZX_O<L[D2:EJZTD#]J
MKY/]0\N"S<\[[S]5M=>U^<JEN,O3_R5SM;R>1!,R%PN^2=5#_O(O4=<H*/W-
M\E16?\E+;>M,R&PC5;ZJ"VL%JR3;_N=_UBW1*. R2P%:%Z#= KZE@%<7\*J*
M;I55U?K(%;^Y*O(74I36VEOYH6J;JK2N39*5_?BH"GTWT>74S7W=)3R;D_^H
MI2C(?2Y5(512"-U=BMR*3"P21>Y3GDGRECQN.YSD"W*WY-F3D"3)R$\\*<@O
M/-V(ZD:^6O/LVS\E^;=X%BGQR.XQI1?R04JA)'GU42B>I/*U]KJ[7S^M?-"7
MQX_DU7>OR7>E_\])FNK[\FJJ=*5+Z=-97<';;06II8(N)9_S3"TE^3&;BWG;
MP52WUK[)Z*[);BGJ\:.8O2.>^X90A[H&07>'%W<0.=Z^![W*GV_Q5S<QXLG?
M>_(K3YY5V4)?F;>Z_$W=R_U.;G;EKP]YFA+]NWKAQ?PW1$JPEQ*@E:H>];Q[
MU+I\%-\^ZF>>;?3X^_X?+G-^,#7_[=8SJSR7&'N^B7UZ-7TVR&%[.0QMF0\S
MM>&IYI;:%!G1X[2AZ#U2W7#O/SRQNGJTB-5746SKZQDKO/4=M"KL[2N\'9/A
MX8T2[45'J.@O6:+T:'E47 F)-$*\]Q=?>OBY#F#1&6T UJZ;'>)2%M).EYC,
M7(^YYEYQ&T1W1QFL+H4GT!&':^V\56_/86&W>0QFK59LBP=<NC@O6\.6_'\;
M];!F 7RZ%^>G"P!UQR-H[;K9]*&EV8&@[C@(=8&A[I@0=?L4C;HCLF]B:Q9@
MJ'L$1/5H'([F+O#4O3A0*0"5C@=4VB=EEQ8&D]C<-Q1 2L<!*0604ARD#R+E
M*LF>B,IWK2&5?M4E2Y'."5?[D4O,@Y;V&?DVZ+8,:M,6#A"E.$1-PG,M>;XI
MJJM+0;X)7A@U>\.=V3>Q*08X4Q]5?+\I9DL]WY/55$?R5,@W)!/**-'O-UGW
MA<ID8XE-%*!-3X7V(0BC?6RSKNJ#R4Z![)2=@C#]Z5,F-P7/9D+/"#-5Z"D[
M]IY(@?0TO#C8@. 4)_A98(MZW>%T>PPS:4N&P$#QP' JV#R@O8?3_ERP>7V<
M=QL&-6G+!N)[[EA8JSVCBC&3MF*((!X>08[!FM>/!#V)F$E;8F-] H\5YT'-
MZ\>"GFC,I"T:PH6'APL[U!Z$_NG\*,L;V$\%F.\%EX:9!RSW<):? [/:-=I3
MF$E;,@0##P\&)\,,"._AA#\;9L.41TW:LH'R7CP:S.)AQ9A)>_D1HH:/1XUC
M8.8/1PC4I"T1(H2/1XCS8.8/!PG4I"T:@H2/!PD[S(86/WR@O.]=&F-^8R$;
MI_<Y&//[+_;=^8G!Q#+9]"$,^'@8.!5C/K#=Q]E^+L;\/KQ[DTW<IBT<"._C
M"SMG@,S'EFQJR7T3FV*(&#X>,8X"61_]O<FFR<8RV?0A/OAX?#@397W^=R>;
M!A/+9#. $!'@(>)3ID21\7(+F*?81A,0/<!7>?Z.72\@=7#JROH!^UZF!7/'
MB3N]8C)S7,\RY@,(  $> $X%6 !4#TZE^B$#-NA#VZ5NW"68T:S9BFWQC0U-
M?&FG-7"/7AL)@/(!OL[^=PQG('=PZI+\ </9L*T91I9N #('T3BC%+ :C(G5
MH,_,..KN')J,;$W# *WL"+0>/-%E %IV<= R "T;#[3,0%!F:7W )QL'GPSP
MR<;$)S-PL?LJ9;*Q-0R DQT'SJ$I"VLD=5P<E0Q0R<9#)3OX%98!*-DXH&0
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M$R!]#8Q!G9$21H[4@>R7X"Q)!E+% =R))@.IYP!N492/G;6K<?5%Z(GR!PH
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M ANGP>/_H4#2^ HY[2L^!5:P=A.)S[%)8S $_Y,"*]@16^I1(&F=2WK=Q:E
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MDY$5LP,3]L2<-#$G[U-Z27<](V1Q=&"@77HN3.CF.&DX3KZA](XU][U$)]T
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M7DEQN.(\O"B^J2[]7KE2O*P>UP3G1!B _K[D7!U?S 3-1?/L?U!+ P04
M" "(A5E4F(I GQP$   J%0  &0   'AL+W=O<FMS:&5E=',O<VAE970Y-BYX
M;6RUF%V/XC84AO^*%:G25FJ3V&& &0'2,-FJ<[$M6C2[UX$8L#:Q4]LLLU)_
M?&TG)+#$]GS0FQGR\;SQ>WR.?>3)@?%O8H>Q!,]E0<4TV$E9W4616.]PF8F0
M59BJ)QO&RTRJ2[Z-1,5QEANH+"(4Q\.HS @-9A-S;\%G$[:7!:%XP8'8EV7&
M?\QQP0[3  ;'&Y_)=B?UC6@VJ;(M7F+Y5"VXNHI:E9R4F K"*.!X,PWNX5V*
MD ;,&U\(/HB3WT!;63'V35\\YM,@UB/"!5Y++9&I?]_Q RX*K:3&\4\C&K3?
MU.#I[Z/Z'\:\,K/*!'Y@Q5>2R]TT& <@QYML7\C/[/ G;@S=:+TU*X3Y"P[-
MNW$ UGLA6=G :@0EH?7_[+D)Q D AQ8 -0#Z&1A8@*0!DI<"@P88F,C45DP<
MTDQFLPEG!\#UVTI-_S#!-+2R3ZB>]Z7DZBE1G)PMFBG,: [^ECO,P8()R;$D
M'*OIE6".*=X0"19%1@7X'2SK! %L [Z:H.(<W'_'7"4)N!<J?2H]GP(\"?6
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M.,LQUR^HYQO&Y/%"?Z ]'IW]!U!+ P04    " "(A5E4C^S<6E\"   :!@
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M>+DFDX;:.R!A-0D4)LC1+95&PJ%=P]<YSXIVY2_ZF(&K#9=\1,\]4Y(9*O&
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M,U=-PVXF1E:NA<VEP8;HAFM\XT#9 -Q?2FFV$YN@>S4G_P!02P,$%     @
MB(595.-V.F-$ P  U@L  !H   !X;"]W;W)K<VAE971S+W-H965T,3 S+GAM
M;)U6T6[:,!3]%2O:0RN-)G%" A4@%;)J?:A4E79[=LD%HB8QLTWI_GZV$P(X
M)D-]@=@^Y_C<ZUSGCG:4O?,U@$"?15[RL;,68G/KNGRQAH+P&[J!4JXL*2N(
MD$.V<OF& 4DUJ<A=['F16Y"L="8C/??$)B.Z%7E6PA-#?%L4A/V=0DYW8\=W
M]A//V6HMU(0[&6W("N8@7C=/3([<1B7-"BAY1DO$8#EV[OS;Q \402-^9;#C
M1\](A?)&Z;L:/*1CQU..((>%4!)$_GW #/)<*4D??VI1I]E3$8^?]^KW.G@9
MS!OA,*/Y[RP5Z[$S<% *2[+-Q3/=_80ZH+[26]"<ZU^TJ["1!"^V7-"B)DL'
M1596_^2S3L01P8_.$'!-P"8A/$,(:D)P*2&L":'.3!6*SD-"!)F,&-TAIM!2
M33WH9&JV##\KU;G/!9.KF>2)R0OY!([D 3R4"UH ZB%SYBH!0;*<7\NUUWF"
MKKY=HV\H*]%CEN?RZ/C(%=*(DG,7]:;3:E-\9E,?HT=:BC5'/\H4TE,!5T;0
MA('W84QQIV("BQL4^-\1]K!O,32[G.Y9Z,G%='_8$4W0'$J@]8(S>K,M8U *
MM&'T(U,5UJ$9-IJAU@S/:-Y#"HSDML.JB)$FJGOB8Q*'(_?C.'UMR& 8G&*2
M-B8*<8,Y,=UO3/>[35,F"[>TF:Z(_:/=?!P;EF9MT# :&K8M0GT<V'U'C>^H
MT_=<$ $VUU%KLYYOFFYC0N,X$HM,Z-DMQXWEN-/R"Q4DES=.YYM7!1&W,Q8$
MYAMC 0V]R(BC#<(^[ML#&32!##J+)X$ER"#2BZIGV(@.OUH]PW8,1V=1):.-
MZ45>WTB&!13@@3T9OG>XW[VOEE#-/-DQC@WK%E!DOHXV(7S6^M&GR?]:%=6\
MTYR;OMN8'C93;@.%9VSC@VU\026E_WD-ZTAPNTP&K2-H@WK]R*PE.^K,K> ?
M/D5^T!W-OAW(=#M@#2)HW?SR"O7-*"RHP*R4Q*H5F5>">]3P%,!6NG'D:$&W
MI:B:AF:V:4[O=$MFS$]5TZH;J8-,U?$^$K;*2HYR6$I)[R:6B655$UD-!-WH
MMNJ-"MFDZ<>U;+R!*8!<7U(J]@.U0=/*3_X!4$L#!!0    ( (B%652P[2)4
MK00  &<3   :    >&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6RMF-MNVS@0
MAE^%,'K1 FTD4D<7CH$TV<4&:':#IFDOBKV@)=HF2HDN1=O)/OV2DB+)(D5G
M@;VQ=9@9?3,\_",MCES\K+:$2/!4L+*ZG&VEW'WTO"K;D@)7%WQ'2G5GS46!
MI3H5&Z_:"8+SVJE@'O+]V"LP+6?+17WM7BP7?"\9+<F] -6^*+!X_D08/U[.
MX.SEPA>ZV4I]P5LN=GA#'HA\W-T+=>9U47):D+*BO 2"K"]G5_#C-8JU0VWQ
MC9)C-3@&.I45YS_UR6U^.?,U$6$DDSH$5G\'<DT8TY$4QZ\VZ*Q[IG8<'K]$
M_[U.7B6SPA6YYNP[S>7V<I;.0$[6>,_D%W[\@[0)13I>QEE5_X)C8YN$,Y#M
M*\F+UED1%+1L_O%36XB! YQR0*T#>JU#T#H$=:(-69W6#99XN1#\"(2V5M'T
M05V;VEME0TL]C ]2J+M4^<GE5_Q$*J#J>5MFO"#@ [@A:R($R5^N-!9O;XC$
ME%7OE,7CPPUX^^8=> -H">XH8VH\JH4G%8X.ZF7MHS\UCT83C[XAV04(X'N
M? 0M[M>O=_=/W3U5A*X2J*L$JN,%$_'Z=,&/S^H>N)6DJ/YV1 ZZR$$=.9R(
M?"]XOL^DJI;$Y8:NF*HG+G/ :*;6 ZG>@ZNJ(M):PB9R7$?62_*P5+D>AE4R
M+: _[VQ.@,,..'0"WY8'4DHNGM5"95B2W$78A(J&SX?S$:-I$P9VQ*A#C)R(
M5UFFM@*AX=2J53M81K'>%URDD4$QKJ7+X@0S[C!C)^9OO_94/H,[(K=<KZ@#
MJ:3:!*5SS..SG"Z+$\ZDXTS<4[39F)MYR>66"+#CE11$4D$T,%B1DJRI&SPQ
MASE-1NBF38IB.WS:P:=.^&M>*%6KZO%_S8Q-#83 AR-,TP8%D1USWF'.G9B/
MI9JE?%/2?]2<E6J;>4U)YP9'$HU031,($SLJ]'M9\)VP?ZH.0O4*:H'1<@,8
M5X##R:'Q,R425((,"_&L^HDC%KDSE?:))T,?CZ>'Q2B)PXEL!B('G=G\I:&=
M;-"R0X5C-M,HF=K'8"\[$#G9'O8KR25F3CQD3D>4!F,^BU4:3$V%7KV@6[Z^
M8;9OUA9FJNO#94:<K(%!\0$9VX#-*O2G!KH7+NA6KJ^ZDKJ-:UH8J7L7*Z1%
MM>;S> QI6J$PF!KQ7KJ@6[O.]P.?*5Y11B6=H#=U"LT#8SJ85A!%$T(!>T6#
M;DFS- ?G<$VY"I*QI-F,X,2."WM9@VY=FVX3SC&;.A6EX[;&:C2UWGHU@VXY
M:WN&HND9Z+!G. =M4;9@+!<6(YA,%;K7-N@6M__20)S+PA2T($C'69A&*$SM
M6:!>]9!;]5J=. .(3(V"Z7@^6XQ2.,'7ZQARZUBO%><0+7J6A..I8+%"<331
MC:'!BY1;T;HW2-J\4M6[\'EDBWHEX7C)V:S0Q(Z,>HE#;HFS$ELA3=D*PG#<
M/%JLH.]/K#'4BQMRBUL].ZW*>QJP%R(4_<^OO*B7">26B=<J<1MF^/X:S]&X
MH*91DJ)1/;W!5Q#]">H.BPU5.Q(C:^7E7R2J&*+YJM.<2+ZK/XRLN)2\J ^W
M!.=$: -U?\VY?#G1WUJZ;VO+?P%02P,$%     @ B(595-C&/502!   P X
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M=@3!5=6X5#T8N2\'B(TT,(Z4RQV,F%19 'S/I#2O#]9 ,[3.OP)02P,$%
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MAA)(,PV ]RO.U6&@%VANF:;_ 5!+ P04    " "(A5E41I7ZR4("  "N!0
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MH<WK<V9E!BI(&V#.MT+HP\9>,(SH]!]02P,$%     @ B(595%9BX"X."0
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MY=\SW9:/WX6.2V*G9)C*K3 >?/=4VP#*&C)F#Z R9P\@LLV>0$$[>-D\VYO
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M'80 .SC.MC"3!P0'A#)%;$(H0"AC8Y,R/'OD ,W,K[&.FU3V $\X,C )8WI
M$$&H4B0F! R$*C8QJ7C*P5P+:V9^C77<I+8'$,.1C]QA<@\(-0A5BKB$L()0
MQ<8E%8\X[/!X*HD8K"*)&M<PDG"'$  /QQEW(,\'%5W7,T5@0@A"J&(#DTI8
M_H(M&22I^$7GTUA'3DI\@$8<.9@\%O0#@AQ"E2(Z(6@AU+'122U,<&G8.$50
M*611LZ1J'*MS 2$5(8 JGOQE^N$$(! N$>H4J0IA#J&.355J82%/MH**I&)+
MX<PD%32N1(P@C!!@&$>Z&D0#@5")4*?(5@B,"'5LME+S1(2-9,*:F5]C'3==
MZ/E[YBIA6A (J AUBEB%\(E0Q\8JM;#^9\'63)9E;)%#45:C<[%K<AL(((_C
MW?-CA$ (1M I A8"+H*.#5BTD(M4[$VYH"IJ%HP)JE*[WI03#A("(.0XZXZ$
M"X% CJ!3)"X$9P0=F[AH89I)SA:"E62-9JF+M#,G7@V$CX0 ('F0DX="AT#@
M1M I0A9-%]>/#5FTR-:P1S])5@A6"3+GXBU P$D(D)/'6W4@C0B$@(0F1<I"
M^$=H8E.6AJ<C%2^4DHH1O)*J=+[Y(3@E!'C**,^.812!\)'0I,A:"!4)36S6
MTDB33AHV05.0Z9J;)P0WS@$*H2PA@%D>9-[!Z"(01A*:%,$*@26AB0U6FF!D
M,I4T#&"41% [72)U/4!>,I="3&-#>Z D:8)"NZ!$MT$1HI'*;CLDJ=@"$Y)(
M.^Y/2'A,#/"8;U;]/_Z#1JC_V3>:0\)(8IZBJPD!*#&/[6N22TN#(ELW7M0-
M=9GWHI%6^:ASQZ1R)$PF!IA,8L.Q-",2;!+S!"$%$GP2\]CN);F$S4!E3[D2
M=<.#H9TQB;I<N:;,(2$R,4!DAKR)81F1T)28IVAC0N!)S&,;F>0"'8.*S9.3
M=,,SC3V-=2;JAE& JZX1'A,#/&:T:8>1C BTUU2"F ().HF!CG]N_T!H3E*@
M/8*39%6.K&F0("MJUYQ^)"@F!E#,,>;%<8Q(.$N$!'$%$G 2 XT!/7X*$T1X
MXRY!I7+NII!6U,XKD=P" A3FJ<T,4HQ(($N$!($&$FP2 ^T"/5X*"XK8_9^F
MHHHMZR>IG,TYD#"8&& PQWAY;!<]4NLQ0;R!M'M@H'V@VT24^JLT]FLS239X
M9J=2D@P:%RJ.>XT'_7>(,3[&-->C30HQ0=Z!M+-@H+6@QTP>493V\HQ36<6N
M2$GEFEZ"M!EA@+\<Y>2!#?=HLT),D($@[3 8:#'H<4]HP%)P]P05>X$MJ;!P
M-;6D#0H#Z.48]\+H(M+>A9@B-"&L) 9Z#GJZD4K+HK+FL9**]0:15.AB<9"
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M_K;N^_7R_LOKKKWJ-CO!\/N/ZW7_],WN#WQ9;S[?'_;%_P-02P,$%     @
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MD28FJG-WU5!\:TZB+UQI'<QE1G!*1!F@[Z\Y5V^-\@'-UX_I_U!+ P04
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MD+6K 3!D:*M,M"43MR4_56E1\"R5[J97NR*)WT$$;8W$O54^H54D]J;6ZE8
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MY^;=C>3K]B3YF4O)R_9RQ=(YJQN ^GW!N=S?- /T_WLQ_0]02P,$%     @
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M2>7.YZYFGEK1_&F?%<7C9LGW?%,43:7]N;PT<O:TQ]/3_E0?_@502P,$%
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MJ]/MO:V&I0-Y">27#Q0D4%@^4)1 <?E 20*EY0-E"927#U0D4%D^4)5 =?E
M30*UY0.94QD=(%*'-4!K4ZX-X+4IV 80VY1L YAMBK8!U#9EVP!NF\)M +E-
MZ3: W:9X&T!OKWI[@-Y>]?8 O7WW8QN@MU>]/4!OKWI[@-Y>]?8 O;WJ[0%Z
M>]7; _3VJK<'Z.U5;P_0.ZC> :!W4+T#0.^@>@> WJ';+ 'H'53O - [J-X!
MH'=0O0- [Z!Z!X#>0?4. +V#ZAT >D?5.P+TCJIW!.@=5>\(T#NJWA&@=^PV
MNP%Z1]4[ O2.JG<$Z!U5[PC0.ZK>$:!W5+TC0.^D>B> WDGU3@"]D^J= 'HG
MU3L!]$ZJ=P+HG;H_*P%Z)]4[ ?1.JG<"Z)U4[P30.ZG>":!W5KTS0.^L>F>
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MCQ321P;I(X?TH2%]&$@?!:2/$M*'%)1&**)*"JF28JJDH"HIJDH*JY+BJJ3
M*BFR*HJLBB*KHLBJ*+(JBJR*(JNBR*HHLBJ*K(HB:TJ1-:7(FE)D32FRIA19
M4XJL*476E")K2I$UI<B:463-*+)F%%DSBJP91=:,(FM&D36CR)I19,THLN84
M67.*K#E%UIPB:TZ1-:?(FE-DS2FRYA19<XJLFB*KILBJ*;)JBJR:(JNFR*HI
MLFJ*K)HBJZ;(:BBR&HJLAB*KH<AJ*+(:BJR&(JNAR&HHLAJ*K 5%UH(B:T&1
MM:#(6E!D+2BR%A19"XJL!476@B)K29&UI,A:4F0M*;*6%%E+BJPE1=:2(FM)
MD;6DR"H%A58I*+9*0<%5"HJN4E!XE8+BJQ048*6@""L%A5@I,,:"KF-AC.5<
MR.+<R/JO5[*^C^/^'\<OS[BOVN$U/UG^1^#F)U!+ 0(4 Q0    ( (B%650'
M04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @ B(595-O_F*_N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ B(595)E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " "(A5E4G?,Q8E@'  "I(P  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ B(595+ >0L0C @  >04
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M965T-BYX;6Q02P$"% ,4    " "(A5E4C851JD(&    '@  &
M    @(%!)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
MB(595/Q##Z%H @  UP4  !@              ("!N2T  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( (B%650HH+_Q?@H  #8S   8
M          " @5<P  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " "(A5E4#FP\)04"  !W!   &0              @($+.P  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( (B%653U='>QRP8  $<0
M   9              " @4<]  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ B(595 /[F5J;)@  QWX  !D              ("!240
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "(A5E4AJ^_
MPFP+  "S'P  &0              @($;:P  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( (B%650\JTSSXA\  &%H   9
M  " @;YV  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
MB(595.Z8:@K[$0  Y#P  !D              ("!UY8  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " "(A5E42VITIBP(  " %0  &0
M            @($)J0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( (B%652H;+=O/A\  .5J   9              " @6RQ  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ B(595";)/")I P
MNP<  !D              ("!X=   'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " "(A5E4Q.L+O*(.  !>*0  &0              @(&!
MU   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (B%652^
M5\@>10T  %LD   9              " @5KC  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ B(595*FC=8RV*0  \(4  !D
M     ("!UO   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (B%6503]/*C4@X  (<H   9              "
M@8]$ 0!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ B(59
M5#E9@^-T P  G@@  !D              ("!&%,! 'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " "(A5E4WR"PA8H%  #:#P  &0
M        @('#5@$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( (B%652LG AGC!   *4I   9              " @81< 0!X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ B(595/G";7AP)@  F8,
M !D              ("!1VT! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " "(A5E4:.DP)*\$  #&"@  &0              @('NDP$
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (B%65196354
M@ 4  .,/   9              " @=28 0!X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ B(595!<@.5PC!0  7 \  !D
M ("!BYX! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "(
MA5E4PRJ<60P$  #7"@  &0              @('EHP$ >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( (B%651M(&F^FP\  $<S   9
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M970S.2YX;6Q02P$"% ,4    " "(A5E41,8>VV,&  !Y$0  &0
M    @(%'QP$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M (B%651^?;GU\P\  $(V   9              " @>'- 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ B(595$7]6964 P  $@@  !D
M             ("!"]X! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " "(A5E4;2>.=KP'   S$P  &0              @('6X0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( (B%652#<895@ ,
M *0(   9              " @<GI 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ B(595.N>?PJ>!0  O \  !D              ("!
M@.T! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "(A5E4
M>Q.L.\ +   A'   &0              @(%5\P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( (B%6523[%B/(P(  (($   9
M      " @4S_ 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ B(595%5?J[VK!0  81X  !D              ("!I@$" 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "(A5E4E+8#$ <&  !M'P
M&0              @(&(!P( >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( (B%650LOG#%<@0  ,L/   9              " @<8- @!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ B(595,%GODPT
M!   2@\  !D              ("!;Q(" 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " "(A5E4*H:U8<D1  #Q=@  &0
M@(':%@( >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( (B%
M650?;'"1N08  $,B   9              " @=HH @!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ B(595.6T9).F!P  42\  !D
M         ("!RB\" 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
M    " "(A5E44+_7&,L(  "G/P  &0              @(&G-P( >&PO=V]R
M:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( (B%653C;XFF(0,   H*
M   9              " @:E  @!X;"]W;W)K<VAE971S+W-H965T-38N>&UL
M4$L! A0#%     @ B(595%MY!6[#!0  +"4  !D              ("! 40"
M 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " "(A5E49&"^
MYX4$  !-%0  &0              @('[20( >&PO=V]R:W-H965T<R]S:&5E
M=#4X+GAM;%!+ 0(4 Q0    ( (B%651;L7E"%0@  '4H   9
M  " @;=. @!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @
MB(595+@NG7&& P  I P  !D              ("! U<" 'AL+W=O<FMS:&5E
M=',O<VAE970V,"YX;6Q02P$"% ,4    " "(A5E4VLP@;4P#  "M#0  &0
M            @(' 6@( >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4
M Q0    ( (B%651\L"%+R0(  #,(   9              " @4-> @!X;"]W
M;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ B(595$=/^3Y9!0
MMA\  !D              ("!0V$" 'AL+W=O<FMS:&5E=',O<VAE970V,RYX
M;6Q02P$"% ,4    " "(A5E4TY>7<4L#  "2"@  &0              @('3
M9@( >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( (B%651R
M,[TWFP0  )$1   9              " @55J @!X;"]W;W)K<VAE971S+W-H
M965T-C4N>&UL4$L! A0#%     @ B(595!P'$,-E P  J@L  !D
M     ("!)V\" 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (B%6516%%=6K0(  !@(   9              "
M@>") @!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ B(59
M5'-[HH)1!   !Q,  !D              ("!Q(P" 'AL+W=O<FMS:&5E=',O
M<VAE970W,BYX;6Q02P$"% ,4    " "(A5E4XB)S\T((  #F,@  &0
M        @(%,D0( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0
M   ( (B%651Q:< "MP,  ,X/   9              " @<69 @!X;"]W;W)K
M<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ B(595.Z49 9\!P  \"D
M !D              ("!LYT" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q0
M2P$"% ,4    " "(A5E4Q.?<G;P(  "-00  &0              @(%FI0(
M>&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( (B%652->X*_
M: ,  /$+   9              " @5FN @!X;"]W;W)K<VAE971S+W-H965T
M-S<N>&UL4$L! A0#%     @ B(595(*>@P/( @  '0@  !D
M ("!^+$" 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " "(
MA5E4\C_K=IX$  !#$P  &0              @('WM ( >&PO=V]R:W-H965T
M<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( (B%650T*1"1"@(  /8$   9
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M970X-"YX;6Q02P$"% ,4    " "(A5E4 S53:-L"  "S!P  &0
M    @(%RS0( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    (
M (B%652_P%%BD@4  &@?   9              " @830 @!X;"]W;W)K<VAE
M971S+W-H965T.#8N>&UL4$L! A0#%     @ B(595)MI^54U!P  ^2D  !D
M             ("!3=8" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"
M% ,4    " "(A5E4T^CFF:T%  !A'   &0              @(&YW0( >&PO
M=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( (B%6516VQ*IE D
M #H^   9              " @9WC @!X;"]W;W)K<VAE971S+W-H965T.#DN
M>&UL4$L! A0#%     @ B(595+T4,W5+ P  =PT  !D              ("!
M:.T" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    " "(A5E4
M6L@3-=P3  !>Q0  &0              @('J\ ( >&PO=V]R:W-H965T<R]S
M:&5E=#DQ+GAM;%!+ 0(4 Q0    ( (B%6507/W5X1 @  $$]   9
M      " @?T$ P!X;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%
M  @ B(595#_F9. 9"0  W4X  !D              ("!> T# 'AL+W=O<FMS
M:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4    " "(A5E4C?4Y!7$#  "9#0
M&0              @('(%@, >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+
M 0(4 Q0    ( (B%650WR_?FQ00  '06   9              " @7 : P!X
M;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%     @ B(595)B*0)\<
M!   *A4  !D              ("!;!\# 'AL+W=O<FMS:&5E=',O<VAE970Y
M-BYX;6Q02P$"% ,4    " "(A5E4C^S<6E\"   :!@  &0
M@(&_(P, >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( (B%
M650O./)2\ ,  'X-   9              " @54F P!X;"]W;W)K<VAE971S
M+W-H965T.3@N>&UL4$L! A0#%     @ B(595(3DVC.K @  )0<  !D
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M:&5E=#$P,RYX;6Q02P$"% ,4    " "(A5E4L.TB5*T$  !G$P  &@
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M:&5E=#$P."YX;6Q02P$"% ,4    " "(A5E4W]K"U00"  !8!   &@
M        @($76P, >&PO=V]R:W-H965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4
M    " "(A5E44JPDA/83  ! K   &@              @(%370, >&PO=V]R
M:W-H965T<R]S:&5E=#$Q,"YX;6Q02P$"% ,4    " "(A5E4;2F6I ($   )
M$0  &@              @(&!<0, >&PO=V]R:W-H965T<R]S:&5E=#$Q,2YX
M;6Q02P$"% ,4    " "(A5E40'5!%CD%  #)&   &@              @(&[
M=0, >&PO=V]R:W-H965T<R]S:&5E=#$Q,BYX;6Q02P$"% ,4    " "(A5E4
MG)A0:&L#  "&#0  &@              @($L>P, >&PO=V]R:W-H965T<R]S
M:&5E=#$Q,RYX;6Q02P$"% ,4    " "(A5E4[J.RP=<#   [$0  &@
M        @('/?@, >&PO=V]R:W-H965T<R]S:&5E=#$Q-"YX;6Q02P$"% ,4
M    " "(A5E4UAA$G4,#  #J$P  #0              @ '>@@, >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( (B%6527BKL<P    !,"   +
M  "  4R& P!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (B%653W/L"CJ@<  "-+
M   /              "  36' P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "(A5E4GO@ H2X#  #M0@  &@              @ $,CP, >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "(A5E4YML2@88"  !/0
M$P              @ %RD@, 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..>@!Z )PA   IE0,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1377</ContextCount>
  <ElementCount>800</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>249</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100010003 - Statement - Consolidated Statement of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofIncome</Role>
      <ShortName>Consolidated Statement of Income</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100020004 - Statement - Consolidated Statement of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome</Role>
      <ShortName>Consolidated Statement of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100030005 - Statement - Consolidated Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100040006 - Statement - Consolidated Balance Sheet (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>Consolidated Balance Sheet (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100050007 - Statement - Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofEquity</Role>
      <ShortName>Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100060008 - Statement - Consolidated Statement of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical</Role>
      <ShortName>Consolidated Statement of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100070009 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100080010 - Statement - Consolidated Statement of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statement of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210031002 - Disclosure - Summary of Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SummaryofAccountingPolicies</Role>
      <ShortName>Summary of Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210061003 - Disclosure - Spin-Off of Organon &amp; Co.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCo</Role>
      <ShortName>Spin-Off of Organon &amp; Co.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210111004 - Disclosure - Acquisitions, Research Collaborations and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210151005 - Disclosure - Collaborative Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangements</Role>
      <ShortName>Collaborative Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210191006 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210241007 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210371008 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210411009 - Disclosure - Goodwill and Other Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangibles</Role>
      <ShortName>Goodwill and Other Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210461010 - Disclosure - Loans Payable, Long-Term Debt and Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeases</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210521011 - Disclosure - Contingencies and Environmental Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities</Role>
      <ShortName>Contingencies and Environmental Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210541012 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210581013 - Disclosure - Share-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlans</Role>
      <ShortName>Share-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210651014 - Disclosure - Pension and Other Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>210781015 - Disclosure - Other (Income) Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNet</Role>
      <ShortName>Other (Income) Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>210821016 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>210901017 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>210941018 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>210971019 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>220042001 - Disclosure - Summary of Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SummaryofAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.merck.com/role/SummaryofAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>230073001 - Disclosure - Spin-Off of Organon &amp; Co. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoTables</Role>
      <ShortName>Spin-Off of Organon &amp; Co. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/SpinOffofOrganonCo</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>230123002 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230163003 - Disclosure - Collaborative Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsTables</Role>
      <ShortName>Collaborative Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/CollaborativeArrangements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230203004 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Restructuring</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230253005 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/FinancialInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230383006 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Inventories</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230423007 - Disclosure - Goodwill and Other Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesTables</Role>
      <ShortName>Goodwill and Other Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/GoodwillandOtherIntangibles</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230473008 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/LoansPayableLongTermDebtandLeases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230553009 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Equity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230593010 - Disclosure - Share-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansTables</Role>
      <ShortName>Share-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/ShareBasedCompensationPlans</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230663011 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230793012 - Disclosure - Other (Income) Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetTables</Role>
      <ShortName>Other (Income) Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNet</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230833013 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/TaxesonIncome</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230913014 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/EarningsperShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230953015 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>230983016 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/SegmentReporting</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>240024001 - Disclosure - Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/NatureofOperationsDetails</Role>
      <ShortName>Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/NatureofOperations</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>240054002 - Disclosure - Summary of Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SummaryofAccountingPoliciesDetails</Role>
      <ShortName>Summary of Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/SummaryofAccountingPoliciesPolicies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>240084003 - Disclosure - Spin-Off of Organon &amp; Co. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails</Role>
      <ShortName>Spin-Off of Organon &amp; Co. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240094004 - Disclosure - Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails</Role>
      <ShortName>Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240104005 - Disclosure - Spin-Off of Organon &amp; Co. - Assets and Liabilities of Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails</Role>
      <ShortName>Spin-Off of Organon &amp; Co. - Assets and Liabilities of Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240134006 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240144007 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240174008 - Disclosure - Collaborative Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails</Role>
      <ShortName>Collaborative Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240184009 - Disclosure - Collaborative Arrangements - Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails</Role>
      <ShortName>Collaborative Arrangements - Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240214010 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240224011 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails</Role>
      <ShortName>Restructuring - Charges Activities by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240234012 - Disclosure - Restructuring - Activities by Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringActivitiesbyProgramDetails</Role>
      <ShortName>Restructuring - Activities by Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240264013 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240274014 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Financial Instruments - Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240284015 - Disclosure - Financial Instruments - Information About Interest Rate Swaps (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails</Role>
      <ShortName>Financial Instruments - Information About Interest Rate Swaps (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240294016 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240304017 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240314018 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails</Role>
      <ShortName>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240324019 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails</Role>
      <ShortName>Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240334020 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240344021 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Information on Debt and Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240354022 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240364023 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails</Role>
      <ShortName>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240394024 - Disclosure - Inventories - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesInventoriesDetails</Role>
      <ShortName>Inventories - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240404025 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240434026 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240444027 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240454028 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Other Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240484029 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240494030 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240504031 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240514032 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240534033 - Disclosure - Contingencies and Environmental Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails</Role>
      <ShortName>Contingencies and Environmental Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240564034 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240574035 - Disclosure - Equity - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityShareholdersEquityDetails</Role>
      <ShortName>Equity - Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240604036 - Disclosure - Share-Based Compensation Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails</Role>
      <ShortName>Share-Based Compensation Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240614037 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240624038 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails</Role>
      <ShortName>Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240634039 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails</Role>
      <ShortName>Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240644040 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails</Role>
      <ShortName>Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240674041 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240684042 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240694043 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240704044 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240714045 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240724046 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240734047 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240744048 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240754049 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240764050 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240774051 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240804052 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails</Role>
      <ShortName>Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240814053 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails</Role>
      <ShortName>Other (Income) Expense, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240844054 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails</Role>
      <ShortName>Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240854055 - Disclosure - Taxes on Income - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeNarrativeDetails</Role>
      <ShortName>Taxes on Income - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240864056 - Disclosure - Taxes on Income - Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails</Role>
      <ShortName>Taxes on Income - Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240874057 - Disclosure - Taxes on Income - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income - Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240884058 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails</Role>
      <ShortName>Taxes on Income - Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240894059 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Taxes on Income - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240924060 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Calculations of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240934061 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240964062 - Disclosure - Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240994063 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>241004064 - Disclosure - Segment Reporting - Sales of Company's Products (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails</Role>
      <ShortName>Segment Reporting - Sales of Company's Products (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>241014065 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Consolidated Revenues by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>241024066 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>241034067 - Disclosure - Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails</Role>
      <ShortName>Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="mrk-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>241044068 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mrk-20211231.htm">mrk-20211231.htm</File>
    <File>ex23-consentofindependentr.htm</File>
    <File>ex241-powerofattorney1.htm</File>
    <File>ex242-certificationofboard.htm</File>
    <File>ex311-rule13ax14a15dx14ace.htm</File>
    <File>ex312-rule13ax14a15dx14ace.htm</File>
    <File>ex321-section1350certifica.htm</File>
    <File>ex322-section1350certifica.htm</File>
    <File>exhibit1017-planfordeferre.htm</File>
    <File>exhibit1024-2022annualnqso.htm</File>
    <File>exhibit1025-2022annualrsut.htm</File>
    <File>exhibit21-subsidiarylistas.htm</File>
    <File>mrk-20211231.xsd</File>
    <File>mrk-20211231_cal.xml</File>
    <File>mrk-20211231_def.xml</File>
    <File>mrk-20211231_lab.xml</File>
    <File>mrk-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrk-20211231_g1.jpg</File>
    <File>mrk-20211231_g2.gif</File>
    <File>mrk-20211231_g3.jpg</File>
    <File>mrk-20211231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3155">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="49">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>143
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrk-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 48,
   "contextCount": 1377,
   "dts": {
    "calculationLink": {
     "local": [
      "mrk-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrk-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mrk-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrk-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrk-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mrk-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 1181,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://www.merck.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 13
   },
   "keyCustom": 100,
   "keyStandard": 700,
   "memberCustom": 154,
   "memberStandard": 88,
   "nsprefix": "mrk",
   "nsuri": "http://www.merck.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover Page",
     "role": "http://www.merck.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080010 - Statement - Consolidated Statement of Cash Flows (Parenthetical)",
     "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical",
     "shortName": "Consolidated Statement of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844054 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails",
     "shortName": "Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854055 - Disclosure - Taxes on Income - Narrative (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
     "shortName": "Taxes on Income - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864056 - Disclosure - Taxes on Income - Income Before Taxes (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails",
     "shortName": "Taxes on Income - Income Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874057 - Disclosure - Taxes on Income - Taxes on Income (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails",
     "shortName": "Taxes on Income - Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240884058 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
     "shortName": "Taxes on Income - Deferred Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib57ea5f7a6144ca49a5572c7efe125b4_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240894059 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails",
     "shortName": "Taxes on Income - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240924060 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
     "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240934061 - Disclosure - Earnings Per Share - Narrative (Details)",
     "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib57ea5f7a6144ca49a5572c7efe125b4_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240964062 - Disclosure - Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240994063 - Disclosure - Segment Reporting - Narrative (Details)",
     "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails",
     "shortName": "Segment Reporting - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Nature of Operations",
     "role": "http://www.merck.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241004064 - Disclosure - Segment Reporting - Sales of Company's Products (Details)",
     "role": "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
     "shortName": "Segment Reporting - Sales of Company's Products (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241014065 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)",
     "role": "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
     "shortName": "Segment Reporting - Consolidated Revenues by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "icd29895771bf4e55817628fdfec5709d_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241024066 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)",
     "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
     "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241034067 - Disclosure - Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)",
     "role": "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
     "shortName": "Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ibb7a7a7ca6304ae3b9439603b5c4b897_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241044068 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)",
     "role": "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
     "shortName": "Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i7071cda02b544795b02b9668d83532cf_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210031002 - Disclosure - Summary of Accounting Policies",
     "role": "http://www.merck.com/role/SummaryofAccountingPolicies",
     "shortName": "Summary of Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210061003 - Disclosure - Spin-Off of Organon & Co.",
     "role": "http://www.merck.com/role/SpinOffofOrganonCo",
     "shortName": "Spin-Off of Organon & Co.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210111004 - Disclosure - Acquisitions, Research Collaborations and License Agreements",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements",
     "shortName": "Acquisitions, Research Collaborations and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210151005 - Disclosure - Collaborative Arrangements",
     "role": "http://www.merck.com/role/CollaborativeArrangements",
     "shortName": "Collaborative Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210191006 - Disclosure - Restructuring",
     "role": "http://www.merck.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210241007 - Disclosure - Financial Instruments",
     "role": "http://www.merck.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210371008 - Disclosure - Inventories",
     "role": "http://www.merck.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210411009 - Disclosure - Goodwill and Other Intangibles",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangibles",
     "shortName": "Goodwill and Other Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "000020002 - Document - Audit Information",
     "role": "http://www.merck.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210461010 - Disclosure - Loans Payable, Long-Term Debt and Leases",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeases",
     "shortName": "Loans Payable, Long-Term Debt and Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210521011 - Disclosure - Contingencies and Environmental Liabilities",
     "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities",
     "shortName": "Contingencies and Environmental Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210541012 - Disclosure - Equity",
     "role": "http://www.merck.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210581013 - Disclosure - Share-Based Compensation Plans",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlans",
     "shortName": "Share-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210651014 - Disclosure - Pension and Other Postretirement Benefit Plans",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans",
     "shortName": "Pension and Other Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210781015 - Disclosure - Other (Income) Expense, Net",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNet",
     "shortName": "Other (Income) Expense, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210821016 - Disclosure - Taxes on Income",
     "role": "http://www.merck.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210901017 - Disclosure - Earnings per Share",
     "role": "http://www.merck.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210941018 - Disclosure - Other Comprehensive Income (Loss)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210971019 - Disclosure - Segment Reporting",
     "role": "http://www.merck.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010003 - Statement - Consolidated Statement of Income",
     "role": "http://www.merck.com/role/ConsolidatedStatementofIncome",
     "shortName": "Consolidated Statement of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrk:CostsExpensesAndOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220042001 - Disclosure - Summary of Accounting Policies (Policies)",
     "role": "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies",
     "shortName": "Summary of Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230073001 - Disclosure - Spin-Off of Organon & Co. (Tables)",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoTables",
     "shortName": "Spin-Off of Organon & Co. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230123002 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables)",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables",
     "shortName": "Acquisitions, Research Collaborations and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230163003 - Disclosure - Collaborative Arrangements (Tables)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsTables",
     "shortName": "Collaborative Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230203004 - Disclosure - Restructuring (Tables)",
     "role": "http://www.merck.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230253005 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.merck.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230383006 - Disclosure - Inventories (Tables)",
     "role": "http://www.merck.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230423007 - Disclosure - Goodwill and Other Intangibles (Tables)",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesTables",
     "shortName": "Goodwill and Other Intangibles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230473008 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables",
     "shortName": "Loans Payable, Long-Term Debt and Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230553009 - Disclosure - Equity (Tables)",
     "role": "http://www.merck.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020004 - Statement - Consolidated Statement of Comprehensive Income",
     "role": "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome",
     "shortName": "Consolidated Statement of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230593010 - Disclosure - Share-Based Compensation Plans (Tables)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansTables",
     "shortName": "Share-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230663011 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables",
     "shortName": "Pension and Other Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230793012 - Disclosure - Other (Income) Expense, Net (Tables)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables",
     "shortName": "Other (Income) Expense, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230833013 - Disclosure - Taxes on Income (Tables)",
     "role": "http://www.merck.com/role/TaxesonIncomeTables",
     "shortName": "Taxes on Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230913014 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.merck.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230953015 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230983016 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.merck.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240024001 - Disclosure - Nature of Operations (Details)",
     "role": "http://www.merck.com/role/NatureofOperationsDetails",
     "shortName": "Nature of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "mrk:SalesDiscounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240054002 - Disclosure - Summary of Accounting Policies (Details)",
     "role": "http://www.merck.com/role/SummaryofAccountingPoliciesDetails",
     "shortName": "Summary of Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "mrk:SalesDiscounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240084003 - Disclosure - Spin-Off of Organon & Co. - Narrative (Details)",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
     "shortName": "Spin-Off of Organon & Co. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i0f0a6dd04b8e4082a9f04724e68b1605_I20210602",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030005 - Statement - Consolidated Balance Sheet",
     "role": "http://www.merck.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheet",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094004 - Disclosure - Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails",
     "shortName": "Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240104005 - Disclosure - Spin-Off of Organon & Co. - Assets and Liabilities of Discontinued Operations (Details)",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails",
     "shortName": "Spin-Off of Organon & Co. - Assets and Liabilities of Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib57ea5f7a6144ca49a5572c7efe125b4_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134006 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Narrative (Details)",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
     "shortName": "Acquisitions, Research Collaborations and License Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib5e47ab987cd4d3abdc343a64acdfcdc_D20210401-20210430",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240144007 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions, Research Collaborations and License Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i66e156b81e874c37998b4260b293e32d_I20211119",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240174008 - Disclosure - Collaborative Arrangements - Narrative (Details)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
     "shortName": "Collaborative Arrangements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-1",
      "lang": "en-US",
      "name": "mrk:SupplyCommitmentMinimumNumberOfMarkets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "market",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240184009 - Disclosure - Collaborative Arrangements - Financial Information (Details)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
     "shortName": "Collaborative Arrangements - Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i6154dfd2961f4f43916c01e33c8d1386_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240214010 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.merck.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240224011 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)",
     "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
     "shortName": "Restructuring - Charges Activities by Type of Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ia73cb7250e044a5f85e091f1f1ddae2d_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib57ea5f7a6144ca49a5572c7efe125b4_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234012 - Disclosure - Restructuring - Activities by Program (Details)",
     "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
     "shortName": "Restructuring - Activities by Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240264013 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040006 - Statement - Consolidated Balance Sheet (Parenthetical)",
     "role": "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
     "shortName": "Consolidated Balance Sheet (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240274014 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
     "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ic416afb01c184a70b9da5769b815c0fb_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240284015 - Disclosure - Financial Instruments - Information About Interest Rate Swaps (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
     "shortName": "Financial Instruments - Information About Interest Rate Swaps (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i9de5cdef0a234eefaec97bc914e30cc3_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "interest_rate_swap",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i752aeb3870ee4f6bbfd196995b6998d0_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294016 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
     "shortName": "Financial Instruments - Fair Value of Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i752aeb3870ee4f6bbfd196995b6998d0_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304017 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i0bfc38d37e5a42ac8fc03da3a897894d_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314018 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
     "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240324019 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
     "shortName": "Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i5e1d3b1cd3244e0aad923e07c063a9cc_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ia3e1bd075f93491e9df5f7f32bd7ad1f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240334020 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ia3e1bd075f93491e9df5f7f32bd7ad1f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344021 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails",
     "shortName": "Financial Instruments - Information on Debt and Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354022 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i07d21932e36b4b41b6e9bc6bbba3fad1_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib57ea5f7a6144ca49a5572c7efe125b4_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364023 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
     "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i8b25cba6160a4486b14740ddd2b481ef_I20181231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050007 - Statement - Consolidated Statement of Equity",
     "role": "http://www.merck.com/role/ConsolidatedStatementofEquity",
     "shortName": "Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i296a96e660db43169f0376b184f4d3fc_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240394024 - Disclosure - Inventories - Inventories (Details)",
     "role": "http://www.merck.com/role/InventoriesInventoriesDetails",
     "shortName": "Inventories - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LIFOInventoryAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240404025 - Disclosure - Inventories - Narrative (Details)",
     "role": "http://www.merck.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LIFOInventoryAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib57ea5f7a6144ca49a5572c7efe125b4_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240434026 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
     "shortName": "Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240444027 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
     "shortName": "Goodwill and Other Intangibles - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "if5c650b7720147ddb81cef733e05ea81_D20190101-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454028 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
     "shortName": "Goodwill and Other Intangibles - Other Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240484029 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494030 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i17dae8a27f274a1f9b71d7a871389f36_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:AssetsandLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240504031 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:AssetsandLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240514032 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccrualForEnvironmentalLossContingencies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240534033 - Disclosure - Contingencies and Environmental Liabilities (Details)",
     "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
     "shortName": "Contingencies and Environmental Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccrualForEnvironmentalLossContingencies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060008 - Statement - Consolidated Statement of Equity (Parenthetical)",
     "role": "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical",
     "shortName": "Consolidated Statement of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240564034 - Disclosure - Equity - Narrative (Details)",
     "role": "http://www.merck.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib57ea5f7a6144ca49a5572c7efe125b4_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240574035 - Disclosure - Equity - Shareholders' Equity (Details)",
     "role": "http://www.merck.com/role/EquityShareholdersEquityDetails",
     "shortName": "Equity - Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i296a96e660db43169f0376b184f4d3fc_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604036 - Disclosure - Share-Based Compensation Plans - Narrative (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
     "shortName": "Share-Based Compensation Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614037 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails",
     "shortName": "Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib57ea5f7a6144ca49a5572c7efe125b4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240624038 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails",
     "shortName": "Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240634039 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails",
     "shortName": "Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i00edd76d055e4b64afd262bffa0b265e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644040 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails",
     "shortName": "Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i00edd76d055e4b64afd262bffa0b265e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240674041 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ib8b85b81b3df4143813c92eac8590ae3_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "iba967fbd75634791abd5af201082537c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684042 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "iba967fbd75634791abd5af201082537c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i023d84f2ec3e4b1fbefe060484ea5a92_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240694043 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "iba967fbd75634791abd5af201082537c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070009 - Statement - Consolidated Statement of Cash Flows",
     "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
     "shortName": "Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i382c108bc8474154b35a6d4fdd79419a_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240704044 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i382c108bc8474154b35a6d4fdd79419a_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ibe10670a16e24ae9ace40787b5ce2a22_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240714045 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ie2f1c43c814b41b488e8134de602f0f3_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "id0aeb1e3ef794674a96fff2b9d26c8e9_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724046 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "icdeac8350d854b17860499847d42ea25_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i2cfd3d09310f4317b6f6249083ad8378_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734047 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "ia0a5086b5128478aa64899a4b8b33cf8_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i2cfd3d09310f4317b6f6249083ad8378_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744048 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i2cfd3d09310f4317b6f6249083ad8378_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "iba967fbd75634791abd5af201082537c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754049 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "iba967fbd75634791abd5af201082537c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764050 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i9bdcce48a1354a11a9a216c4ef6a8754_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i2cfd3d09310f4317b6f6249083ad8378_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240774051 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i2cfd3d09310f4317b6f6249083ad8378_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240804052 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
     "shortName": "Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814053 - Disclosure - Other (Income) Expense, Net - Narrative (Details)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
     "shortName": "Other (Income) Expense, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20211231.htm",
      "contextRef": "i090a240c01204951a8d43aeb0084e26c_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 249,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r997",
      "r998",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r997",
      "r998",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r997",
      "r998",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r997",
      "r998",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r1000"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r994"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r994"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r994"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r994"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r994"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r994"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r994"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r1009"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r997",
      "r998",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r993"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r996"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrk_A0.500Notesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2024 [Member]",
        "label": "0.500% Notes due 2024 [Member]",
        "terseLabel": "0.500% Notes due 2024"
       }
      }
     },
     "localname": "A0.500Notesdue2024Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A0.50eurodenominatednotesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.50% euro-denominated notes due 2024 [Member]",
        "label": "0.50% euro-denominated notes due 2024 [Member]",
        "terseLabel": "0.50% euro-denominated notes due 2024"
       }
      }
     },
     "localname": "A0.50eurodenominatednotesdue2024Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A075NotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Notes due 2026",
        "label": "0.75% Notes due 2026 [Member]",
        "terseLabel": "0.75% notes due 2026"
       }
      }
     },
     "localname": "A075NotesDue2026Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.375Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2036 [Member]",
        "label": "1.375% Notes due 2036 [Member]",
        "terseLabel": "1.375% Notes due 2036"
       }
      }
     },
     "localname": "A1.375Notesdue2036Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.375eurodenominatednotesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% euro-denominated notes due 2036 [Member]",
        "label": "1.375% euro-denominated notes due 2036 [Member]",
        "terseLabel": "1.375% euro-denominated notes due 2036"
       }
      }
     },
     "localname": "A1.375eurodenominatednotesdue2036Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.875EuroNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.875% Euro Notes Due 2026 [Member]",
        "label": "1.875% Euro Notes Due 2026 [Member]",
        "terseLabel": "1.875% euro-denominated notes due 2026"
       }
      }
     },
     "localname": "A1.875EuroNotesDue2026Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.875Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.875% Notes due 2026 [Member]",
        "label": "1.875% Notes due 2026 [Member]",
        "terseLabel": "1.875% Notes due 2026"
       }
      }
     },
     "localname": "A1.875Notesdue2026Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A145NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.45% Notes Due 2030",
        "label": "1.45% Notes Due 2030 [Member]",
        "terseLabel": "1.45% notes due 2030"
       }
      }
     },
     "localname": "A145NotesDue2030Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A170NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.70% notes due 2027",
        "label": "1.70% notes due 2027 [Member]",
        "terseLabel": "1.70% notes due 2027"
       }
      }
     },
     "localname": "A170NotesDue2027Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A190NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.90% notes due 2028",
        "label": "1.90% notes due 2028 [Member]",
        "terseLabel": "1.90% notes due 2028"
       }
      }
     },
     "localname": "A190NotesDue2028Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.35NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2022 [Member]",
        "label": "2.35% Notes Due 2022 [Member]",
        "terseLabel": "2.35% notes due 2022",
        "verboseLabel": "2.35% notes due 2022"
       }
      }
     },
     "localname": "A2.35NotesDue2022Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.40NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.40% Notes Due 2022 [Member]",
        "label": "2.40% Notes Due 2022 [Member]",
        "terseLabel": "2.40% notes due 2022",
        "verboseLabel": "2.40% notes due 2022"
       }
      }
     },
     "localname": "A2.40NotesDue2022Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.500Notesdue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.500% Notes due 2034 [Member]",
        "label": "2.500% Notes due 2034 [Member]",
        "terseLabel": "2.500% Notes due 2034"
       }
      }
     },
     "localname": "A2.500Notesdue2034Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.5EuroNotesDue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.5% Euro Notes Due 2034 [Member]",
        "label": "2.5% Euro Notes Due 2034 [Member]",
        "terseLabel": "2.50% euro-denominated notes due 2034"
       }
      }
     },
     "localname": "A2.5EuroNotesDue2034Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.75NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.75% Notes Due 2025 [Member]",
        "label": "2.75% Notes Due 2025 [Member]",
        "terseLabel": "2.75% notes due 2025"
       }
      }
     },
     "localname": "A2.75NotesDue2025Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.90NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.90% Notes Due 2024",
        "label": "2.90% Notes Due 2024 [Member]",
        "terseLabel": "2.90% notes due 2024"
       }
      }
     },
     "localname": "A2.90NotesDue2024Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A215NotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.15% notes due 2031",
        "label": "2.15% notes due 2031 [Member]",
        "terseLabel": "2.15% notes due 2031"
       }
      }
     },
     "localname": "A215NotesDue2031Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A235NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2040",
        "label": "2.35% Notes Due 2040 [Member]",
        "terseLabel": "2.35% notes due 2040"
       }
      }
     },
     "localname": "A235NotesDue2040Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A245NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes Due 2050",
        "label": "2.45% Notes Due 2050 [Member]",
        "terseLabel": "2.45% notes due 2050"
       }
      }
     },
     "localname": "A245NotesDue2050Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A275NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.75% notes due 2051",
        "label": "2.75% notes due 2051 [Member]",
        "terseLabel": "2.75% notes due 2051"
       }
      }
     },
     "localname": "A275NotesDue2051Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A280NotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Notes Due 2023 [Member]",
        "label": "2.80% Notes Due 2023 [Member]",
        "terseLabel": "2.80% notes due 2023"
       }
      }
     },
     "localname": "A280NotesDue2023Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A290NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.90% notes due 2061",
        "label": "2.90% notes due 2061 [Member]",
        "terseLabel": "2.90% notes due 2061"
       }
      }
     },
     "localname": "A290NotesDue2061Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.40NotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.40% Notes Due 2029",
        "label": "3.40% Notes Due 2029 [Member]",
        "terseLabel": "3.40% notes due 2029"
       }
      }
     },
     "localname": "A3.40NotesDue2029Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.70NotesDue2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes Due 2045 [Member]",
        "label": "3.70% Notes Due 2045 [Member]",
        "terseLabel": "3.70% notes due 2045"
       }
      }
     },
     "localname": "A3.70NotesDue2045Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.875NotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.875% Notes Due 2021",
        "label": "3.875% Notes Due 2021 [Member]",
        "terseLabel": "3.875% Notes Due 2021"
       }
      }
     },
     "localname": "A3.875NotesDue2021Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.90NotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.90% Notes Due 2039",
        "label": "3.90% Notes Due 2039 [Member]",
        "terseLabel": "3.90% notes due 2039"
       }
      }
     },
     "localname": "A3.90NotesDue2039Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A4.00NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.00% Notes Due 2049",
        "label": "4.00% Notes Due 2049 [Member]",
        "terseLabel": "4.00% notes due 2049"
       }
      }
     },
     "localname": "A4.00NotesDue2049Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A415NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Notes Due 2043 [Member]",
        "label": "4.15% Notes Due 2043 [Member]",
        "terseLabel": "4.15% notes due 2043"
       }
      }
     },
     "localname": "A415NotesDue2043Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A63DebenturesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point three percentage debentures due on two thousand and twenty six.",
        "label": "6.3% Debentures Due 2026 [Member]",
        "terseLabel": "6.30% debentures due 2026"
       }
      }
     },
     "localname": "A63DebenturesDue2026Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleratedDepreciationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Depreciation [Member]",
        "label": "Accelerated Depreciation [Member]",
        "terseLabel": "Accelerated Depreciation"
       }
      }
     },
     "localname": "AcceleratedDepreciationMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleronPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acceleron Pharma Inc.",
        "label": "Acceleron Pharma Inc. [Member]",
        "terseLabel": "Acceleron Pharma Inc."
       }
      }
     },
     "localname": "AcceleronPharmaIncMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AccrualForChargebacks": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual for chargebacks reflected as a direction reduction to accounts receivable.",
        "label": "Accrual For Chargebacks",
        "terseLabel": "Accrual for chargebacks reflected as direct reduction to accounts receivable"
       }
      }
     },
     "localname": "AccrualForChargebacks",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AccrualForRebates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual for rebates recorded as current liability.",
        "label": "Accrual For Rebates",
        "terseLabel": "Accrual for rebates included in accrued and other current liabilities"
       }
      }
     },
     "localname": "AccrualForRebates",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to acquisitions, research collaborations and license agreements.",
        "label": "Acquisitions Research Collaborations And License Agreements [Text Block]",
        "terseLabel": "Acquisitions, Research Collaborations and License Agreements"
       }
      }
     },
     "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_AdempasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adempas",
        "label": "Adempas [Member]",
        "terseLabel": "Adempas"
       }
      }
     },
     "localname": "AdempasMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueAdempasVerquvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Adempas/Verquvo",
        "label": "Alliance revenue - Adempas/Verquvo [Member]",
        "terseLabel": "Alliance revenue - Adempas/Verquvo"
       }
      }
     },
     "localname": "AllianceRevenueAdempasVerquvoMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueKoselugoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Koselugo",
        "label": "Alliance revenue - Koselugo [Member]",
        "terseLabel": "Alliance revenue - Koselugo"
       }
      }
     },
     "localname": "AllianceRevenueKoselugoMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AlliancerevenueLynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Lynparza [Member]",
        "label": "Alliance revenue - Lynparza [Member]",
        "terseLabel": "Alliance revenue - Lynparza"
       }
      }
     },
     "localname": "AlliancerevenueLynparzaMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corporation",
        "label": "AmerisourceBergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AnimalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Animal Health [Member]",
        "label": "Animal Health [Member]",
        "terseLabel": "Animal Health"
       }
      }
     },
     "localname": "AnimalHealthMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AnimalHealthsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Animal Health segment [Member]",
        "label": "Animal Health segment [Member]",
        "terseLabel": "Animal Health"
       }
      }
     },
     "localname": "AnimalHealthsegmentMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AntelliqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antelliq [Member]",
        "label": "Antelliq [Member]",
        "terseLabel": "Antelliq"
       }
      }
     },
     "localname": "AntelliqMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ArQuleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ArQule [Member]",
        "label": "ArQule [Member]",
        "terseLabel": "ArQule"
       }
      }
     },
     "localname": "ArQuleMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ArtivaBiotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Artiva Biotherapeutics, Inc.",
        "label": "Artiva Biotherapeutics, Inc. [Member]",
        "terseLabel": "Artiva Biotherapeutics, Inc."
       }
      }
     },
     "localname": "ArtivaBiotherapeuticsIncMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Other Assets and Liabilities Recognized, Net",
        "label": "Asset Acquisition, Other Assets and Liabilities Recognized, Net",
        "terseLabel": "Other net assets (liabilities)"
       }
      }
     },
     "localname": "AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Recognized Identifiable Assets and Liabilities, Cash and Cash Equivalents",
        "label": "Asset Acquisition, Recognized Identifiable Assets and Liabilities, Cash and Cash Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesCashAndCashEquivalents",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "noDecimalsMonetaryItemType"
    },
    "mrk_AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Recognized Identifiable Assets and Liabilities, Deferred Tax Liabilities",
        "label": "Asset Acquisition, Recognized Identifiable Assets and Liabilities, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAndLiabilitiesDeferredTaxLiabilities",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "noDecimalsMonetaryItemType"
    },
    "mrk_AssetsandLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee [Table Text Block]",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsandLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.merck.com/20211231",
     "xbrltype": "stringItemType"
    },
    "mrk_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG [Member]",
        "label": "Bayer AG [Member]",
        "terseLabel": "Bayer AG"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BelsomraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Belsomra [Member]",
        "label": "Belsomra [Member]",
        "terseLabel": "Belsomra"
       }
      }
     },
     "localname": "BelsomraMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BridionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridion [Member].",
        "label": "Bridion [Member]",
        "terseLabel": "Bridion"
       }
      }
     },
     "localname": "BridionMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb",
        "label": "Bristol Myers Squibb [Member]",
        "terseLabel": "Bristol Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net",
        "terseLabel": "Other assets and liabilities, net",
        "verboseLabel": "Other assets and (liabilities), net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CancidasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancidas [Member].",
        "label": "Cancidas [Member]",
        "terseLabel": "Cancidas"
       }
      }
     },
     "localname": "CancidasMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health, Inc.",
        "label": "Cardinal Health, Inc. [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cases Company Agreed To Toll Statute Of Limitations[Member]",
        "label": "Cases Company Agreed ToToll Statute Of Limitations [Member]",
        "terseLabel": "Cases Company Agreed To Toll Statute Of Limitations"
       }
      }
     },
     "localname": "CasesCompanyAgreedToTollStatuteOfLimitationsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ChargesRelatedToProgramDiscontinuation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges related to program discontinuation",
        "label": "Charges related to program discontinuation",
        "terseLabel": "Charges related to program discontinuation"
       }
      }
     },
     "localname": "ChargesRelatedToProgramDiscontinuation",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementProfitSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Profit Sharing",
        "label": "Collaborative Arrangement, Profit Sharing",
        "terseLabel": "Alliance revenue - profit sharing"
       }
      }
     },
     "localname": "CollaborativeArrangementProfitSharing",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementSalesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Sales, Net",
        "label": "Collaborative Arrangement, Sales, Net",
        "terseLabel": "Net sales by Merck"
       }
      }
     },
     "localname": "CollaborativeArrangementSalesNet",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Abstract]",
        "label": "Collaborative Arrangements [Abstract]",
        "terseLabel": "Collaborative Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAbstract",
     "nsuri": "http://www.merck.com/20211231",
     "xbrltype": "stringItemType"
    },
    "mrk_CommercialandOtherLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial and Other Litigation [Member]",
        "label": "Commercial and Other Litigation [Member]",
        "terseLabel": "Commercial Litigation"
       }
      }
     },
     "localname": "CommercialandOtherLitigationMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CommercialmilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "commercial milestone [Member]",
        "label": "commercial milestone [Member]",
        "terseLabel": "Commercial Milestone"
       }
      }
     },
     "localname": "CommercialmilestoneMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CompanionAnimalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Companion Animals [Member]",
        "label": "Companion Animals [Member]",
        "terseLabel": "Companion Animals"
       }
      }
     },
     "localname": "CompanionAnimalsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company pension investments which are categorized as level three assets percentage.",
        "label": "Company Pension Investments Which Are Categorized As Level Three Assets Percentage",
        "terseLabel": "Percentage of Company's pension investments categorized as level 3 assets"
       }
      }
     },
     "localname": "CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Line Items]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Table]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ConsumercarebusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "consumer care business [Member]",
        "label": "consumer care business [Member]",
        "terseLabel": "consumer care business"
       }
      }
     },
     "localname": "ConsumercarebusinessMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discussion of the accounting policy for contingent consideration.",
        "label": "Contingent Consideration [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_ContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.",
        "label": "Contingent Payments Collaborative Arrangement",
        "terseLabel": "Contingent payments collaborative arrangement"
       }
      }
     },
     "localname": "ContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CorporateObligationsFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate obligations fixed income securities.",
        "label": "Corporate Obligations Fixed Income Securities [Member]",
        "terseLabel": "Corporate obligations"
       }
      }
     },
     "localname": "CorporateObligationsFixedIncomeSecuritiesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CorporateObligationsInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate obligations investment funds.",
        "label": "Corporate Obligations Investment Funds [Member]",
        "terseLabel": "Corporate obligations"
       }
      }
     },
     "localname": "CorporateObligationsInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CostsExpensesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.",
        "label": "Costs Expenses And Other",
        "totalLabel": "Total costs, expenses and other"
       }
      }
     },
     "localname": "CostsExpensesAndOther",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DebtSecuritiesandEquitySecuritiesFVNI": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities and Equity Securities, FV-NI",
        "label": "Debt Securities and Equity Securities, FV-NI",
        "totalLabel": "Total debt and publicly traded equity securities, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesandEquitySecuritiesFVNI",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Taxes Assets And Liabilities Net [Table]",
        "label": "Deferred Income Taxes Assets And Liabilities Net [Table]",
        "terseLabel": "Deferred Income Taxes Assets And Liabilities Net [Table]"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAssetsAndLiabilitiesNetTable",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating loss carryforwards and other tax credit carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards",
        "terseLabel": "Net operating losses and other tax credit carryforwards, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredTaxAssetsUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets unrecognized tax benefits.",
        "label": "Deferred Tax Assets Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrecognizedTaxBenefits",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredTaxLiabilitiesEquityMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Equity Method Investment",
        "label": "Deferred Tax Liabilities, Equity Method Investment",
        "terseLabel": "Equity method investments, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesEquityMethodInvestment",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.",
        "label": "Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans",
        "terseLabel": "Pensions and other postretirement benefits, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic",
        "label": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic",
        "terseLabel": "Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards"
       }
      }
     },
     "localname": "DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DefinedBenefitPlanCashandOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Cash and Other Investments [Member]",
        "label": "Defined Benefit Plan, Cash and Other Investments [Member]",
        "terseLabel": "Cash And Other Investments"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashandOtherInvestmentsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DefinedBenefitPlanOtherChangesPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in plan assets, not otherwise separately disclosed in the financial statements.",
        "label": "Defined Benefit Plan Other Changes Plan Assets",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefinedBenefitPlanOtherChangesPlanAssets",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DevelopedMarketsEquitiesInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed markets equities investment funds.",
        "label": "Developed Markets Equities Investment Funds [Member]",
        "terseLabel": "Developed markets equities"
       }
      }
     },
     "localname": "DevelopedMarketsEquitiesInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DevelopedMarketsEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed markets equity securities.",
        "label": "Developed Markets Equity Securities [Member]",
        "terseLabel": "Developed markets"
       }
      }
     },
     "localname": "DevelopedMarketsEquitySecuritiesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestones [Member]",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DificidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dificid [Member]",
        "label": "Dificid [Member]",
        "terseLabel": "Dificid"
       }
      }
     },
     "localname": "DificidMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Accrual (Reversal), Income Taxes Payable, Current",
        "label": "Disposal Group, Including Discontinued Operation, Accrual (Reversal), Income Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net",
        "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationsDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Debt",
        "label": "Disposal Group, Including Discontinued Operations, Debt",
        "terseLabel": "Disposal group, including discontinued operations, debt"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsDebt",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Including Discontinued Operations Distribution Received",
        "label": "Disposal Group Including Discontinued Operations Distribution Received",
        "terseLabel": "Distribution from Organon &amp; Co."
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsDistributionReceived",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Research and Development Expenses",
        "label": "Disposal Group, Including Discontinued Operations, Research and Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Restructuring Costs",
        "label": "Disposal Group, Including Discontinued Operations, Restructuring Costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DunboyneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dunboyne",
        "label": "Dunboyne [Member]",
        "terseLabel": "Dunboyne"
       }
      }
     },
     "localname": "DunboyneMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to the amortization of purchase accounting adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Amortization Of Purchase Accounting Adjustments",
        "terseLabel": "Acquisition-related costs, including amortization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAmortizationOfPurchaseAccountingAdjustments",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombination": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination",
        "terseLabel": "Acquisition of Peloton"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombination",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Four",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Four",
        "terseLabel": "Acquisition of Pandion"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationFour",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Four, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Four, Percent",
        "terseLabel": "Acquisition of Pandion"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination, Percent",
        "terseLabel": "Acquisition of Peloton"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationPercent",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Three",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Three",
        "terseLabel": "Acquisition of VelosBio"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationThree",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Three, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Three, Percent",
        "terseLabel": "Acquisition of VelosBio"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationThreePercent",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Two",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Two",
        "terseLabel": "Acquisition of OncoImmune"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Two, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Two, Percent",
        "terseLabel": "Acquisition of OncoImmune"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]",
        "terseLabel": "Differential arising from:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]",
        "terseLabel": "Differential arising from:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount",
        "terseLabel": "GILTI and the foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent",
        "terseLabel": "GILTI and the foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EmergingMarketsEquitiesInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging markets equities investment funds.",
        "label": "Emerging Markets Equities Investment Funds [Member]",
        "terseLabel": "Emerging markets equities"
       }
      }
     },
     "localname": "EmergingMarketsEquitiesInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will be noncash.",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash",
        "terseLabel": "Estimate of cumulative pre tax costs that will be noncash"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays",
        "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EurodominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro-dominated Notes [Member]",
        "label": "Euro-dominated Notes [Member]",
        "terseLabel": "Euro-denominated notes"
       }
      }
     },
     "localname": "EurodominatedNotesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.",
        "label": "Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests",
        "terseLabel": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests"
       }
      }
     },
     "localname": "ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_FederalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal.",
        "label": "Federal [Member]",
        "terseLabel": "Federal Court"
       }
      }
     },
     "localname": "FederalMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point eight five percentage notes due on two thousand and thirty nine.",
        "label": "Five Point Eight Five Percentage Notes Due On Two Thousand And Thirty Nine [Member]",
        "terseLabel": "5.85% notes due 2039"
       }
      }
     },
     "localname": "FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point nine five percentage debentures due on two thousand and twenty eight.",
        "label": "Five Point Nine Five Percentage Debentures Due On Two Thousand And Twenty Eight [Member]",
        "terseLabel": "5.95% debentures due 2028"
       }
      }
     },
     "localname": "FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point seven five percentage notes due on two thousand and thirty six.",
        "label": "Five Point Seven Five Percentage Notes Due On Two Thousand And Thirty Six [Member]",
        "terseLabel": "5.75% notes due 2036"
       }
      }
     },
     "localname": "FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FixedIncomeObligationsInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed income obligations investment funds.",
        "label": "Fixed Income Obligations Investment Funds [Member]",
        "terseLabel": "Other fixed income obligations"
       }
      }
     },
     "localname": "FixedIncomeObligationsInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FosamaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fosamax [Member].",
        "label": "Fosamax [Member]",
        "terseLabel": "Fosamax"
       }
      }
     },
     "localname": "FosamaxMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GardasilGardasil9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gardasil/Gardasil 9 [Member].",
        "label": "Gardasil/Gardasil 9 [Member]",
        "terseLabel": "Gardasil/Gardasil 9"
       }
      }
     },
     "localname": "GardasilGardasil9Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GefapixantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "gefapixant",
        "label": "gefapixant [Member]",
        "terseLabel": "gefapixant"
       }
      }
     },
     "localname": "GefapixantMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GileadSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Sciences",
        "label": "Gilead Sciences [Member]",
        "terseLabel": "Gilead Sciences"
       }
      }
     },
     "localname": "GileadSciencesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and agency obligations fixed income securities.",
        "label": "Government And Agency Obligations Fixed Income Securities [Member]",
        "terseLabel": "Government and agency obligations"
       }
      }
     },
     "localname": "GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GovernmentAndAgencyObligationsInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and agency obligations investment funds.",
        "label": "Government And Agency Obligations Investment Funds [Member]",
        "terseLabel": "Government and agency obligations"
       }
      }
     },
     "localname": "GovernmentAndAgencyObligationsInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_HealthcareServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Services segment [Member]",
        "label": "Healthcare Services Segment [Member]",
        "terseLabel": "Healthcare Services"
       }
      }
     },
     "localname": "HealthcareServicesSegmentMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IAVI [Member]",
        "label": "IAVI [Member]",
        "terseLabel": "IAVI"
       }
      }
     },
     "localname": "IAVIMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IOmetPharmaLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IOmet Pharma Ltd [Member]",
        "label": "IOmet Pharma Ltd [Member]",
        "terseLabel": "IOmet Pharma Ltd"
       }
      }
     },
     "localname": "IOmetPharmaLtdMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ImmuneDesignMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immune Design [Member]",
        "label": "Immune Design [Member]",
        "terseLabel": "Immune Design"
       }
      }
     },
     "localname": "ImmuneDesignMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to amortization of purchase accounting adjustments.",
        "label": "Income Tax Reconciliation Amortization Of Purchase Accounting Adjustments",
        "terseLabel": "Acquisition-related costs, including amortization"
       }
      }
     },
     "localname": "IncomeTaxReconciliationAmortizationOfPurchaseAccountingAdjustments",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IncomeTaxesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes Payable [Member]",
        "label": "Income Taxes Payable [Member]",
        "terseLabel": "Income Taxes Payable"
       }
      }
     },
     "localname": "IncomeTaxesPayableMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InjectableFormulationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "injectable formulation",
        "label": "injectable formulation [Member]",
        "terseLabel": "Injectable Formulation"
       }
      }
     },
     "localname": "InjectableFormulationMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InsuranceContractsOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance contracts other investments.",
        "label": "Insurance Contracts Other Investments [Member]",
        "terseLabel": "Insurance contracts",
        "verboseLabel": "Insurance Contracts"
       }
      }
     },
     "localname": "InsuranceContractsOtherInvestmentsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IntangibleAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset, Measurement Input",
        "label": "Intangible Asset, Measurement Input",
        "terseLabel": "Present value discount rate",
        "verboseLabel": "Discount rate"
       }
      }
     },
     "localname": "IntangibleAssetMeasurementInput",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "mrk_IntangibleAssetProductsAndProductRightsMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset, Products and Product rights, Measurement Input",
        "label": "Intangible Asset, Products and Product rights, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "IntangibleAssetProductsAndProductRightsMeasurementInput",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "mrk_IntangibleAssetsExcludingGoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets Excluding Goodwill [Line Items]",
        "label": "Intangible Assets Excluding Goodwill [Line Items]",
        "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillLineItems",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_InternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International [Member]",
        "label": "International [Member]",
        "terseLabel": "Int\u2019l"
       }
      }
     },
     "localname": "InternationalMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InvanzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invanz [Member].",
        "label": "Invanz [Member]",
        "terseLabel": "Invanz"
       }
      }
     },
     "localname": "InvanzMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoriesProducedinPreparationforProductLaunchesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories Produced in Preparation for Product Launches [Member]",
        "label": "Inventories Produced in Preparation for Product Launches [Member]",
        "terseLabel": "Inventories Produced in Preparation for Product Launches"
       }
      }
     },
     "localname": "InventoriesProducedinPreparationforProductLaunchesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/InventoriesInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of current and noncurrent inventories.",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total current and noncurrent inventories"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Not Expected to be Sold Within One Year [Member]",
        "label": "Inventory Not Expected to be Sold Within One Year [Member]",
        "terseLabel": "Inventory Not Expected to be Sold Within One Year"
       }
      }
     },
     "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory [Table]",
        "label": "Inventory [Table]",
        "terseLabel": "Inventory [Table]"
       }
      }
     },
     "localname": "InventoryTable",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IsentressIsentressHDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Isentress/Isentress HD [Member].",
        "label": "Isentress/Isentress HD [Member]",
        "terseLabel": "Isentress/Isentress HD"
       }
      }
     },
     "localname": "IsentressIsentressHDMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanumetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janumet [Member].",
        "label": "Janumet [Member]",
        "terseLabel": "Janumet"
       }
      }
     },
     "localname": "JanumetMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanuviaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Januvia [Member] .",
        "label": "Januvia [Member]",
        "terseLabel": "Januvia"
       }
      }
     },
     "localname": "JanuviaMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_KeytrudaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Keytruda [Member]",
        "label": "Keytruda [Member]",
        "terseLabel": "Keytruda"
       }
      }
     },
     "localname": "KeytrudaMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LegalDefenseCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Defense Costs [Member]",
        "label": "Legal Defense Costs [Member]",
        "terseLabel": "Legal Defense Costs"
       }
      }
     },
     "localname": "LegalDefenseCostsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LenvimaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lenvima [Member]",
        "label": "Lenvima [Member]",
        "terseLabel": "Alliance revenue - Lenvima",
        "verboseLabel": "Lenvima"
       }
      }
     },
     "localname": "LenvimaMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Amount",
        "terseLabel": "Lessee, operating lease, lease not yet commenced, amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotyetCommencedAmount",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License option payment related to collaborative arrangement",
        "label": "License option payment related to collaborative arrangement",
        "terseLabel": "License option payment related to collaborative arrangement"
       }
      }
     },
     "localname": "LicenseOptionPaymentRelatedToCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LivestockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Livestock [Member]",
        "label": "Livestock [Member]",
        "terseLabel": "Livestock"
       }
      }
     },
     "localname": "LivestockMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LongTermDebtCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Current Maturities [Member]",
        "label": "Long Term Debt, Current Maturities [Member]",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LongTermDebtExcludingCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt Excluding Current Maturities [Member]",
        "label": "Long Term Debt Excluding Current Maturities [Member]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtExcludingCurrentMaturitiesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LongTermDebtInterestPayableYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year Five",
        "label": "Long-term Debt, Interest Payable, Year Five",
        "terseLabel": "Long-term debt, interest payments in 2026"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearFive",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LongTermDebtInterestPayableYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year Four",
        "label": "Long-term Debt, Interest Payable, Year Four",
        "terseLabel": "Long-term debt, interest payments in 2025"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearFour",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LongTermDebtInterestPayableYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year One",
        "label": "Long-term Debt, Interest Payable, Year One",
        "terseLabel": "Long-term debt, interest payments in 2022"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearOne",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LongTermDebtInterestPayableYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year Three",
        "label": "Long-term Debt, Interest Payable, Year Three",
        "terseLabel": "Long-term debt, interest payments in 2024"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearThree",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LongTermDebtInterestPayableYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year Two",
        "label": "Long-term Debt, Interest Payable, Year Two",
        "terseLabel": "Long-term debt, interest payments in 2023"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearTwo",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LossContingencyClaimsonAppealNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims on Appeal, Number",
        "label": "Loss Contingency, Claims on Appeal, Number",
        "terseLabel": "Loss contingency, claims on appeal (in cases)"
       }
      }
     },
     "localname": "LossContingencyClaimsonAppealNumber",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_LynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lynparza [Member]",
        "label": "Lynparza [Member]",
        "terseLabel": "Lynparza"
       }
      }
     },
     "localname": "LynparzaMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ManufacturingAndSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and supply agreements",
        "label": "Manufacturing and supply agreements [Member]",
        "terseLabel": "Manufacturing and supply agreements"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MilestonePaymentsAccruedRegulatory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Accrued Regulatory",
        "label": "Milestone Payments Accrued Regulatory",
        "terseLabel": "Accrued regulatory approval milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentsAccruedRegulatory",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MilestonePaymentsAccruedSalesBased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Accrued Sales Based",
        "label": "Milestone Payments Accrued Sales Based",
        "terseLabel": "Milestone payments accrued"
       }
      }
     },
     "localname": "MilestonePaymentsAccruedSalesBased",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MilestonePaymentsMadetoCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Made to Collaborative Partner",
        "label": "Milestone Payments Made to Collaborative Partner",
        "terseLabel": "Milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "MilestonePaymentsMadetoCollaborativePartner",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MolnupiravirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molnupiravir",
        "label": "Molnupiravir [Member]",
        "terseLabel": "Molnupiravir"
       }
      }
     },
     "localname": "MolnupiravirMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and asset backed securities fixed income securities.",
        "label": "Mortgage And Asset Backed Securities Fixed Income Securities [Member]",
        "verboseLabel": "Mortgage and asset-backed securities"
       }
      }
     },
     "localname": "MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MortgageAndAssetBackedSecuritiesInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and Asset-Backed Securities Investment Funds",
        "label": "Mortgage and Asset-Backed Securities Investment Funds [Member]",
        "terseLabel": "Mortgage and asset-backed securities"
       }
      }
     },
     "localname": "MortgageAndAssetBackedSecuritiesInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MovementinCommonStockandTreasuryStockRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Movement in Common Stock and Treasury Stock [Roll Forward]",
        "label": "Movement in Common Stock and Treasury Stock [Roll Forward]",
        "terseLabel": "Movement in Common Stock and Treasury Stock [Roll Forward]"
       }
      }
     },
     "localname": "MovementinCommonStockandTreasuryStockRollForward",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_NemtabrutinibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "nemtabrutinib",
        "label": "nemtabrutinib [Member]",
        "terseLabel": "nemtabrutinib"
       }
      }
     },
     "localname": "NemtabrutinibMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NotesSubjectToRepaymentAtOptionOfHolderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Subject To Repayment At Option Of Holder [Member]",
        "label": "Notes Subject To Repayment At Option Of Holder [Member]",
        "terseLabel": "Notes Subject To Repayment At Option Of Holder"
       }
      }
     },
     "localname": "NotesSubjectToRepaymentAtOptionOfHolderMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NoxafilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noxafil [Member].",
        "label": "Noxafil [Member]",
        "terseLabel": "Noxafil"
       }
      }
     },
     "localname": "NoxafilMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Low and Middle Income Countries Reached Through Supply And Access Approach",
        "label": "Number of Low and Middle Income Countries Reached Through Supply And Access Approach",
        "terseLabel": "Number of low and middle income countries (more than)"
       }
      }
     },
     "localname": "NumberOfLowAndMiddleIncomeCountriesReachedThroughSupplyAndAccessApproach",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.",
        "label": "Offsetting Assets And Liabilities [Table Text Block]",
        "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis"
       }
      }
     },
     "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_OncoImmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OncoImmune",
        "label": "OncoImmune [Member]",
        "terseLabel": "OncoImmune"
       }
      }
     },
     "localname": "OncoImmuneMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OralAndInjectableFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "oral and injectable formulations",
        "label": "oral and injectable formulations [Member]",
        "terseLabel": "Oral and Injectable Formulations"
       }
      }
     },
     "localname": "OralAndInjectableFormulationsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OralFormulationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "oral formulation",
        "label": "oral formulation [Member]",
        "terseLabel": "Oral Formulation"
       }
      }
     },
     "localname": "OralFormulationMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OrganonCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organon &amp; Co.",
        "label": "Organon &amp; Co. [Member]",
        "terseLabel": "Organon &amp; Co."
       }
      }
     },
     "localname": "OrganonCoMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other long term debt.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherNonoperatingIncomeExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income and expense items not separately disclosed.",
        "label": "Other Nonoperating Income Expense, Other",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseOther",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_OtherPharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other pharmaceutical.",
        "label": "Other Pharmaceutical [Member]",
        "terseLabel": "Other pharmaceutical"
       }
      }
     },
     "localname": "OtherPharmaceuticalMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherPostretirementBenefitPlanNetLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Postretirement Benefit Plan Net Loss [Member]",
        "label": "Other Postretirement Benefit Plan Net Loss [Member]",
        "terseLabel": "Other Postretirement Benefit Plan Net Gain"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlanNetLossMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherPostretirementBenefitPlanPriorServiceCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Postretirement Benefit Plan Prior Service Cost [Member]",
        "label": "Other Postretirement Benefit Plan Prior Service Cost [Member]",
        "terseLabel": "Other Postretirement Benefit Plan Prior Service Credit"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlanPriorServiceCostMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherStateCourtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other state court.",
        "label": "Other State Court [Member]",
        "terseLabel": "Other State Court"
       }
      }
     },
     "localname": "OtherStateCourtMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherVariableRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Variable Rate Debt [Member]",
        "label": "Other Variable Rate Debt [Member]",
        "terseLabel": "Other Variable Rate Debt"
       }
      }
     },
     "localname": "OtherVariableRateDebtMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PandionTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pandion Therapeutics",
        "label": "Pandion Therapeutics [Member]",
        "terseLabel": "Pandion Therapeutics"
       }
      }
     },
     "localname": "PandionTherapeuticsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PatentlitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent litigation [Member]",
        "label": "Patent litigation [Member]",
        "terseLabel": "Patent litigation"
       }
      }
     },
     "localname": "PatentlitigationMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Business Five, Net of Cash Acquired",
        "label": "Payments to Acquire Business Five, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of ArQule, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessFiveNetOfCashAcquired",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Business Four, Net of Cash Acquired",
        "label": "Payments to Acquire Business Four, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of VelosBio Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessFourNetOfCashAcquired",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PaymentsToAcquireBusinessSevenNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Business Seven, Net of Cash Acquired",
        "label": "Payments to Acquire Business Seven, Net of Cash Acquired",
        "negatedLabel": "Acquisition of Peloton Therapeutics, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessSevenNetOfCashAcquired",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PaymentsToAcquireBusinessSixNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Business Six, Net of Cash Acquired",
        "label": "Payments to Acquire Business Six, Net of Cash Acquired",
        "negatedLabel": "Acquisition of Antelliq Corporation, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessSixNetOfCashAcquired",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PelotonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Peloton [Member]",
        "label": "Peloton [Member]",
        "terseLabel": "Peloton"
       }
      }
     },
     "localname": "PelotonMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PensionPlanNetLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension Plan Net Loss [Member]",
        "label": "Pension Plan Net Loss [Member]",
        "terseLabel": "Pension Plan Net Loss"
       }
      }
     },
     "localname": "PensionPlanNetLossMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PensionPlanPriorServiceCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension Plan Prior Service Cost [Member]",
        "label": "Pension Plan Prior Service Cost [Member]",
        "terseLabel": "Pension Plan Prior Service Credit"
       }
      }
     },
     "localname": "PensionPlanPriorServiceCostMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PharmaceuticalsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical segment.",
        "label": "Pharmaceutical segment [Member]",
        "terseLabel": "Pharmaceutical segment",
        "verboseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalsegmentMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_Pneumovax23Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pneumovax 23[Member].",
        "label": "Pneumovax 23 [Member]",
        "terseLabel": "Pneumovax 23"
       }
      }
     },
     "localname": "Pneumovax23Member",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PotentialFutureMilestonePaymentsRegulatory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments Regulatory",
        "label": "Potential Future Milestone Payments Regulatory",
        "terseLabel": "Potential Future Milestone Payments Regulatory"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsRegulatory",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PotentialFutureMilestonePaymentsSalesBased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments Sales-Based",
        "label": "Potential Future Milestone Payments Sales-Based",
        "terseLabel": "Potential Future Milestone Payments Sales-Based"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsSalesBased",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PremiumOnSharesAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on shares acquired",
        "label": "Premium on shares acquired",
        "terseLabel": "Premium on shares acquired"
       }
      }
     },
     "localname": "PremiumOnSharesAcquired",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PrevymisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevymis",
        "label": "Prevymis [Member]",
        "terseLabel": "Prevymis"
       }
      }
     },
     "localname": "PrevymisMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PrimaxinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primaxin [Member].",
        "label": "Primaxin [Member]",
        "terseLabel": "Primaxin"
       }
      }
     },
     "localname": "PrimaxinMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProQuadMMRIIVarivaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQuad/M-M-R II/Varivax [Member].",
        "label": "ProQuad MMR II Varivax [Member]",
        "terseLabel": "ProQuad/M-M-R II/Varivax"
       }
      }
     },
     "localname": "ProQuadMMRIIVarivaxMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProfitShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Share",
        "label": "Profit Share",
        "terseLabel": "Profit share"
       }
      }
     },
     "localname": "ProfitShare",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_ProfitShareCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Share Counterparty",
        "label": "Profit Share Counterparty",
        "terseLabel": "Profit share by counterparty"
       }
      }
     },
     "localname": "ProfitShareCounterparty",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_RealEstateInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate investment funds.",
        "label": "Real Estate Investment Funds [Member]",
        "terseLabel": "Real estate, Investment funds",
        "verboseLabel": "Real Estate"
       }
      }
     },
     "localname": "RealEstateInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ReblozylMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reblozyl",
        "label": "Reblozyl [Member]",
        "terseLabel": "Reblozyl"
       }
      }
     },
     "localname": "ReblozylMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RecognizedAsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized as.",
        "label": "Recognized As [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "RecognizedAsAbstract",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member].",
        "label": "Remicade [Member]",
        "terseLabel": "Remicade"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Three",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Three",
        "terseLabel": "Charge for the acquisition of Peloton Therapeutics, Inc."
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two",
        "terseLabel": "Charge for the acquisition of VelosBio Inc."
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RestructuringReserveIncreaseDecreaseNoncashActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.",
        "label": "Restructuring Reserve, Increase (Decrease) Noncash Activity",
        "terseLabel": "Non-cash activity"
       }
      }
     },
     "localname": "RestructuringReserveIncreaseDecreaseNoncashActivity",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RevenuePerformanceObligationPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Terms",
        "label": "Revenue, Performance Obligation, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTerms",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date",
        "label": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date",
        "terseLabel": "Product return period and expiration"
       }
      }
     },
     "localname": "RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date",
        "label": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date",
        "terseLabel": "Product return period"
       }
      }
     },
     "localname": "RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_RidgebackBiotherapeuticsLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ridgeback Biotherapeutics LP",
        "label": "Ridgeback Biotherapeutics LP [Member]",
        "terseLabel": "Ridgeback Biotherapeutics LP"
       }
      }
     },
     "localname": "RidgebackBiotherapeuticsLPMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RotateqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RotaTeq [Member]",
        "label": "Rotateq [Member]",
        "terseLabel": "RotaTeq"
       }
      }
     },
     "localname": "RotateqMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RoyaltyRateDeductionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Deduction, Percentage",
        "label": "Royalty Rate, Deduction, Percentage",
        "terseLabel": "Royalty rate, deduction, percentage"
       }
      }
     },
     "localname": "RoyaltyRateDeductionPercentage",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_RoyaltyRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Percentage",
        "label": "Royalty Rate, Percentage",
        "terseLabel": "Royalty rate, percentage"
       }
      }
     },
     "localname": "RoyaltyRatePercentage",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_SalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestones [Member]",
        "label": "Sales-Based Milestones [Member]",
        "terseLabel": "Sales-Based Milestones"
       }
      }
     },
     "localname": "SalesBasedMilestonesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SalesDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Discounts",
        "label": "Sales Discounts",
        "terseLabel": "Customer discounts"
       }
      }
     },
     "localname": "SalesDiscounts",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales threshold",
        "label": "Sales threshold",
        "terseLabel": "Sales threshold"
       }
      }
     },
     "localname": "SalesThreshold",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SanofiPasteurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Pasteur [Member]",
        "label": "Sanofi Pasteur [Member]",
        "terseLabel": "Sanofi Pasteur"
       }
      }
     },
     "localname": "SanofiPasteurMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ScheduleOfOtherIntangiblesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Intangibles [Table]",
        "label": "Schedule Of Other Intangibles [Table]",
        "terseLabel": "Schedule Of Other Intangibles [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherIntangiblesTable",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.",
        "label": "Schedule of Accumulated and Projected Benefit Obligation in Excess of Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_SeagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seagen",
        "label": "Seagen [Member]",
        "terseLabel": "Seagen"
       }
      }
     },
     "localname": "SeagenMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SegmentReportingUnallocatedOtherExpensesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other net expenses not allocated to segments.",
        "label": "Segment Reporting Unallocated Other Expenses Net",
        "negatedLabel": "Other unallocated, net"
       }
      }
     },
     "localname": "SegmentReportingUnallocatedOtherExpensesNet",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SentinelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sentinel [Member]",
        "label": "Sentinel [Member]",
        "terseLabel": "Sentinel"
       }
      }
     },
     "localname": "SentinelMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number",
        "terseLabel": "Number of Shares, Expected to Vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment",
        "negatedTerseLabel": "Number of Shares, Adjustment to Merck awards related to the spin-off of Organon (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustment",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Adjustment to Merck awards related to the spin-off of Organon (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred due to Spinoff Transaction",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred due to Spinoff Transaction",
        "negatedTerseLabel": "Number of Shares, Awards transferred to Organon in the spin-off"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredDueToSpinoffTransaction",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Awards transferred to Organon in the spin-off of Organon (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional information pertaining to stock option plans.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block]",
        "terseLabel": "Additional Information Pertaining to Stock Option Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment",
        "terseLabel": "Number of Options, Adjustment to Merck awards related to the spin-off of Organon (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustment",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment, Weighted Average Exercise",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Spin-Off Adjustment, Weighted Average Exercise",
        "terseLabel": "Weighted Average Exercise Price, Adjustment to Merck awards related to the spin-off of Organon (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentWeightedAverageExercise",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction",
        "negatedTerseLabel": "Number of Options, Awards transferred to Organon in spin-off (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransaction",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Transferred in Spinoff Transaction, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Exercise Price, Awards transferred to Organon in the spin-off (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTransferredInSpinoffTransactionWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrk_SimponiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi [Member].",
        "label": "Simponi [Member]",
        "terseLabel": "Simponi"
       }
      }
     },
     "localname": "SimponiMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SivextroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sivextro [Member]",
        "label": "Sivextro [Member]",
        "terseLabel": "Sivextro"
       }
      }
     },
     "localname": "SivextroMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point five five percentage notes due on two thousand and thirty seven.",
        "label": "Six Point Five Five Percentage Notes Due On Two Thousand And Thirty Seven [Member]",
        "terseLabel": "6.55% notes due 2037"
       }
      }
     },
     "localname": "SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point five zero percentage notes due on two thousand and thirty three.",
        "label": "Six Point Five Zero Percentage Notes Due On Two Thousand And Thirty Three [Member]",
        "terseLabel": "6.50% notes due 2033"
       }
      }
     },
     "localname": "SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point four percentage debentures due on two thousand and twenty eight.",
        "label": "Six Point Four Percentage Debentures Due On Two Thousand And Twenty Eight [Member]",
        "terseLabel": "6.40% debentures due 2028"
       }
      }
     },
     "localname": "SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SotaterceptMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "sotatercept",
        "label": "sotatercept [Member]",
        "terseLabel": "sotatercept"
       }
      }
     },
     "localname": "SotaterceptMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_SupplyCommitmentMinimumNumberOfMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment, Minimum, Number of Markets",
        "label": "Supply Commitment, Minimum, Number of Markets",
        "terseLabel": "Number of markets (more than)"
       }
      }
     },
     "localname": "SupplyCommitmentMinimumNumberOfMarkets",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_SupplyCommitmentQuantityCommitted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment, Quantity Committed",
        "label": "Supply Commitment, Quantity Committed",
        "terseLabel": "Quantity committed (in courses)"
       }
      }
     },
     "localname": "SupplyCommitmentQuantityCommitted",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_SupplyCommitmentQuantityDelivered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment, Quantity Delivered",
        "label": "Supply Commitment, Quantity Delivered",
        "terseLabel": "Quantity delivered (in courses)"
       }
      }
     },
     "localname": "SupplyCommitmentQuantityDelivered",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_SupplyCommitmentToJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment to Japan",
        "label": "Supply Commitment to Japan [Member]",
        "terseLabel": "Supply Commitment to Japan"
       }
      }
     },
     "localname": "SupplyCommitmentToJapanMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SupplyCommitmentToUnitedKingdomMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment to United Kingdom",
        "label": "Supply Commitment to United Kingdom [Member]",
        "terseLabel": "Supply Commitment to United Kingdom"
       }
      }
     },
     "localname": "SupplyCommitmentToUnitedKingdomMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SupplyCommitmentToUnitedNationsChildrensFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment to United Nations Children's Fund",
        "label": "Supply Commitment to United Nations Children's Fund [Member]",
        "terseLabel": "Supply Commitment to United Nations Children's Fund"
       }
      }
     },
     "localname": "SupplyCommitmentToUnitedNationsChildrensFundMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SupplyCommitmentToUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment to United States",
        "label": "Supply Commitment to United States [Member]",
        "terseLabel": "Supply Commitment to United States"
       }
      }
     },
     "localname": "SupplyCommitmentToUnitedStatesMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_TermForPayingOffEnvironmentalLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term for paying off environmental liabilities.",
        "label": "Term For Paying Off Environmental Liabilities",
        "terseLabel": "Term for paying off environmental liabilities"
       }
      }
     },
     "localname": "TermForPayingOffEnvironmentalLiabilities",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_ThemisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Themis [Member]",
        "label": "Themis [Member]",
        "terseLabel": "Themis"
       }
      }
     },
     "localname": "ThemisMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]",
        "label": "Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]",
        "terseLabel": "3.60% notes due 2042"
       }
      }
     },
     "localname": "ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_TransitionServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition services agreement",
        "label": "Transition services agreement [Member]",
        "terseLabel": "Transition services agreement"
       }
      }
     },
     "localname": "TransitionServicesAgreementMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_TukysaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tukysa",
        "label": "Tukysa [Member]",
        "terseLabel": "Tukysa"
       }
      }
     },
     "localname": "TukysaMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction",
        "negatedTerseLabel": "Spin-off of Organon"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and Milestone Payments to be Made to Collaborative Partner",
        "label": "Upfront and Milestone Payments to be Made to Collaborative Partner",
        "terseLabel": "Upfront and milestone payments to be made"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments made to partner as part of a licensing or collaborative arrangement.",
        "label": "Upfront Payments Made To License or Collaborative Partner",
        "terseLabel": "Upfront and milestone payments",
        "verboseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPaymentsMadeToLicenseOrCollaborativePartner",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_VaqtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaqta [Member]",
        "label": "Vaqta [Member]",
        "terseLabel": "Vaqta"
       }
      }
     },
     "localname": "VaqtaMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VelosBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VelosBio",
        "label": "VelosBio [Member]",
        "terseLabel": "VelosBio"
       }
      }
     },
     "localname": "VelosBioMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VerquvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verquvo",
        "label": "Verquvo [Member]",
        "terseLabel": "Verquvo"
       }
      }
     },
     "localname": "VerquvoMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZerbaxaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zerbaxa [Member]",
        "label": "Zerbaxa [Member]",
        "terseLabel": "Zerbaxa"
       }
      }
     },
     "localname": "ZerbaxaMember",
     "nsuri": "http://www.merck.com/20211231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific (other than China and Japan)"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r209",
      "r271",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r291",
      "r295",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r443",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r209",
      "r271",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r291",
      "r295",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r443",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r116",
      "r119",
      "r207",
      "r208",
      "r452",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]",
        "terseLabel": "Latin America"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r302",
      "r521",
      "r524",
      "r962"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r451",
      "r486",
      "r617",
      "r623",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r894",
      "r959",
      "r963",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r451",
      "r486",
      "r617",
      "r623",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r894",
      "r959",
      "r963",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r302",
      "r521",
      "r524",
      "r962"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r298",
      "r521",
      "r522",
      "r900",
      "r958",
      "r960"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r298",
      "r521",
      "r522",
      "r900",
      "r958",
      "r960"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r451",
      "r486",
      "r556",
      "r617",
      "r623",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r894",
      "r959",
      "r963",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r451",
      "r486",
      "r556",
      "r617",
      "r623",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r894",
      "r959",
      "r963",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r207",
      "r208",
      "r452",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r224",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r224",
      "r229",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r299",
      "r300",
      "r521",
      "r523",
      "r961",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r299",
      "r300",
      "r521",
      "r523",
      "r961",
      "r977",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r224",
      "r229",
      "r418",
      "r618",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r84",
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r35",
      "r66",
      "r304",
      "r305"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $62 in 2021 and $67 in 2020)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableSale": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease from sale of accounts receivable.",
        "label": "Accounts Receivable, Sale",
        "terseLabel": "Factored accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForEnvironmentalLossContingencies": {
     "auth_ref": [
      "r392",
      "r416",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies.",
        "label": "Accrual for Environmental Loss Contingencies",
        "terseLabel": "Accrued liabilities for environmental matters"
       }
      }
     },
     "localname": "AccrualForEnvironmentalLossContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r56",
      "r909",
      "r937"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r127",
      "r134",
      "r144",
      "r145",
      "r146",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r81",
      "r384"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r134",
      "r144",
      "r145",
      "r146",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r134",
      "r144",
      "r145",
      "r146",
      "r147",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r134",
      "r144",
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": {
     "auth_ref": [
      "r128",
      "r134",
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax",
        "terseLabel": "Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r69",
      "r131",
      "r133",
      "r134",
      "r940",
      "r968",
      "r969"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r144",
      "r145",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r130",
      "r134",
      "r144",
      "r145",
      "r146",
      "r216",
      "r217",
      "r218",
      "r761",
      "r964",
      "r965",
      "r1010"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r121",
      "r134",
      "r144",
      "r145",
      "r146",
      "r761",
      "r832",
      "r833",
      "r834",
      "r835",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of intangible assets, acquired"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Other paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r658",
      "r659",
      "r660",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Other Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r184",
      "r372"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedTerseLabel": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Promotion Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising and promotion costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r266",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other segments",
        "verboseLabel": "All Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r626",
      "r654",
      "r663"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Pretax share-based compensation cost recorded"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r73",
      "r306",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r184",
      "r362",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense for intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Consideration paid"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "auth_ref": [
      "r742",
      "r743",
      "r744"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r200",
      "r279",
      "r286",
      "r293",
      "r331",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r756",
      "r762",
      "r825",
      "r860",
      "r862",
      "r907",
      "r936"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r37",
      "r38",
      "r109",
      "r200",
      "r331",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r756",
      "r762",
      "r825",
      "r860",
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r27",
      "r31",
      "r381",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets of discontinued operations",
        "totalLabel": "Current assets of discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r310",
      "r340"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r308",
      "r311",
      "r340",
      "r915"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Foreign government bonds",
        "verboseLabel": "Debt securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r627",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r773",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r40",
      "r383"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r613",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r613",
      "r619",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r729",
      "r731",
      "r732",
      "r736"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r183",
      "r740"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedTerseLabel": "Business combination, contingent consideration arrangements, change in amount of contingent consideration liability",
        "terseLabel": "Contingent consideration liability, changes in estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r738"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Potential future milestone payments, maximum"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r730",
      "r733",
      "r737"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Contingent consideration, ending balance",
        "periodStartLabel": "Contingent consideration, beginning balance",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r730",
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration, liability, current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r724"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "verboseLabel": "Other net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r724"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt",
        "terseLabel": "Debt assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r724"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "verboseLabel": "In-process research and development (IPR&amp;D)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r723",
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Products and product rights - Reblozyl (12 year useful life)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r723",
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r723",
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r723",
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed": {
     "auth_ref": [
      "r720"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed",
        "terseLabel": "Share-based compensation payments to settle equity awards attributable to precombination service"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r33",
      "r78",
      "r186"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r180",
      "r186",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Year (includes $71 of restricted cash at December 31, 2021 included in Other Assets - see Note 7)",
        "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $103 of restricted cash at January 1, 2021 included in Other Assets - see Note 7)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r180",
      "r830"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r24",
      "r180"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r24",
      "r180"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r801"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r801"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Hedged items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.",
        "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]",
        "terseLabel": "Obligation and Funded Status"
       }
      }
     },
     "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r746",
      "r747",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r426",
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Environmental Liabilities"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r429",
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies and Legal Defense Costs"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r216",
      "r217",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance December\u00a031 (in shares)",
        "periodStartLabel": "Balance January\u00a01 (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r64",
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2021 and 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r139",
      "r141",
      "r142",
      "r156",
      "r923",
      "r952"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income Attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r155",
      "r166",
      "r922",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r260",
      "r261",
      "r302",
      "r823",
      "r824",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r302",
      "r823",
      "r824",
      "r971",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r302",
      "r823",
      "r824",
      "r971",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r260",
      "r261",
      "r302",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of accounts receivable represented by customers with largest balances (as percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r260",
      "r261",
      "r302",
      "r823",
      "r824",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r191",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r557",
      "r606",
      "r970"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r295",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other profits"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r162",
      "r900"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, Expenses and Other"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r402",
      "r403",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r201",
      "r699",
      "r707"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r201",
      "r699"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r201",
      "r699",
      "r707",
      "r709"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r201",
      "r699",
      "r707"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r259",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r196",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r465",
      "r472",
      "r473",
      "r475",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Loans Payable, Long-Term Debt and Leases"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r199",
      "r209",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r843",
      "r908",
      "r911",
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r448",
      "r476",
      "r477",
      "r841",
      "r843",
      "r844"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount of debt",
        "verboseLabel": "Par Value of Debt"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r463",
      "r476",
      "r477",
      "r822"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of loans payable and long-term debt, including current portion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r92",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r93",
      "r199",
      "r209",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r93",
      "r199",
      "r209",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r501",
      "r504",
      "r505",
      "r506",
      "r840",
      "r841",
      "r843",
      "r844",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "terseLabel": "Debt, carrying amount"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r201",
      "r700",
      "r707"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r201",
      "r700",
      "r707"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r184",
      "r201",
      "r700",
      "r707",
      "r708",
      "r709"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Total deferred provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r61",
      "r62",
      "r691",
      "r910",
      "r932"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Subtotal, Liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r673",
      "r674"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes",
        "verboseLabel": "Deferred Income Taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Noncurrent",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r201",
      "r700",
      "r707"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Equity Method Investments, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Product intangibles and licenses, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r692"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory related, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Deferred tax assets on NOL carryforwards relating to foreign jurisdictions"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Accelerated depreciation, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Pensions and other postretirement benefits, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Compensation related, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r693"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance, Assets",
        "terseLabel": "Tax credit and operating loss carryforward, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r674",
      "r694"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Deferred income taxes, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.",
        "label": "Deferred Tax Liabilities, Inventory",
        "terseLabel": "Inventory related, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Product intangibles and licenses, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "terseLabel": "Accelerated depreciation, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r546",
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]",
        "terseLabel": "Actual return on plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod": {
     "auth_ref": [
      "r561",
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold",
        "terseLabel": "Relating to assets sold during the year"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": {
     "auth_ref": [
      "r561",
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held",
        "terseLabel": "Relating to assets still held at December 31"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedLabel": "Actuarial (gains) losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r531",
      "r572",
      "r600",
      "r606",
      "r607"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Net loss (gain) amortization"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r531",
      "r573",
      "r601",
      "r606",
      "r607"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of unrecognized prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r53",
      "r529",
      "r530",
      "r554",
      "r606",
      "r906",
      "r935"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Salary growth rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r581",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Expected rate of return on plan assets",
        "verboseLabel": "Expected rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Salary growth rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation December\u00a031",
        "periodStartLabel": "Benefit obligation January\u00a01"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r540",
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r584",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r548",
      "r557",
      "r559",
      "r604",
      "r606",
      "r607"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "terseLabel": "Termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCurtailments": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDivestituresBenefitObligation": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in benefit obligation of defined benefit plan from disposal or classification as held-for-sale.",
        "label": "Defined Benefit Plan, Benefit Obligation, Divestiture",
        "negatedTerseLabel": "Spin-off of Organon"
       }
      }
     },
     "localname": "DefinedBenefitPlanDivestituresBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDivestituresPlanAssets": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in plan assets of defined benefit plan from disposal or classification as held-for-sale.",
        "label": "Defined Benefit Plan, Plan Assets, Divestiture",
        "negatedTerseLabel": "Spin-off of Organon"
       }
      }
     },
     "localname": "DefinedBenefitPlanDivestituresPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": {
     "auth_ref": [
      "r557",
      "r559",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]",
        "terseLabel": "International equities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": {
     "auth_ref": [
      "r557",
      "r559",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, US [Member]",
        "terseLabel": "U.S.\u00a0equities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2027\u00a0\u2014\u00a02031"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r567",
      "r607"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r531",
      "r571",
      "r599",
      "r606",
      "r607"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r545",
      "r557",
      "r559",
      "r560",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Fair value of plan assets December\u00a031",
        "periodStartLabel": "Fair value of plan assets January\u00a01",
        "terseLabel": "Fair value of plan assets",
        "verboseLabel": "Plan assets at fair value"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effects of exchange rate changes"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r529",
      "r554",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "totalLabel": "Funded status December\u00a031"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.",
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Health care cost trend rate assumed for next year"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r531",
      "r536",
      "r570",
      "r598",
      "r606",
      "r607"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r568",
      "r596",
      "r606",
      "r607"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanOtherChanges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefinedBenefitPlanOtherChanges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": {
     "auth_ref": [
      "r592",
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r592",
      "r593",
      "r606"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r592",
      "r593",
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Plan amendments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r550",
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effects of exchange rate changes"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r556",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Target allocation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": {
     "auth_ref": [
      "r562",
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement",
        "terseLabel": "Purchases and sales, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r532",
      "r575",
      "r603"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r532",
      "r575",
      "r603"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r534",
      "r569",
      "r597",
      "r606",
      "r607"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": {
     "auth_ref": [
      "r563",
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3",
        "terseLabel": "Transfers in (out) of Level 3"
       }
      }
     },
     "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r590",
      "r591",
      "r594",
      "r595",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer contributions to defined contribution savings plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r184",
      "r382"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "negatedLabel": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r184",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.",
        "label": "Depreciation, Depletion, and Amortization [Policy Text Block]",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r113",
      "r115"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, asset"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r111",
      "r115"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.",
        "label": "Derivative Asset, Not Offset, Policy Election Deduction",
        "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r110",
      "r114",
      "r119",
      "r822"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "netLabel": "Derivative assets",
        "terseLabel": "Gross amounts recognized in the consolidated balance sheet, asset",
        "verboseLabel": "Fair Value of Derivative, Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAverageRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Average Remaining Maturity",
        "terseLabel": "Maximum planning cycle of hedges (less than)"
       }
      }
     },
     "localname": "DerivativeAverageRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r112",
      "r115",
      "r117",
      "r797"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative, Collateral, Obligation to Return Cash",
        "negatedTerseLabel": "Cash collateral received, asset",
        "terseLabel": "Cash collateral received from counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r112",
      "r115",
      "r117",
      "r797"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative, Collateral, Right to Reclaim Cash",
        "negatedLabel": "Cash collateral received, liability",
        "terseLabel": "Cash collateral advanced to counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r775"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r119",
      "r774",
      "r777",
      "r783",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r771",
      "r774",
      "r783",
      "r792",
      "r793",
      "r799",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r803"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r782",
      "r784"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r110",
      "r114",
      "r119",
      "r822"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "netLabel": "Derivative liabilities",
        "terseLabel": "Gross amounts recognized in the consolidated balance sheet, liability",
        "verboseLabel": "Fair Value of Derivative, Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r113",
      "r115"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r111",
      "r115"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.",
        "label": "Derivative Liability, Not Offset, Policy Election Deduction",
        "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r768",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount of derivative",
        "verboseLabel": "Total Swap Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r767",
      "r769",
      "r770",
      "r771",
      "r772",
      "r779",
      "r783",
      "r796",
      "r798",
      "r802",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Designated as Hedging Instruments"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Products and product rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r22"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax",
        "totalLabel": "Income from discontinued operations before taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "terseLabel": "Income from Discontinued Operations (in dollars per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Discontinued Operation, Period of Continuing Involvement after Disposal",
        "terseLabel": "Period of continuing involvement after disposal"
       }
      }
     },
     "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod": {
     "auth_ref": [
      "r10",
      "r28",
      "r714"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.",
        "label": "Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period",
        "terseLabel": "Tax provision"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable, less allowance for doubtful accounts"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r27",
      "r31",
      "r380",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Noncurrent Assets of Discontinued Operations",
        "totalLabel": "Noncurrent Assets of Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand, demand deposits with banks or financial institutions, and  other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.",
        "label": "Disposal Group, Including Discontinued Operation, Cash",
        "terseLabel": "Disposal group, including discontinued operation, cash"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Less: Cash and cash equivalents related to discontinued operations",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration received"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r23",
      "r31"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "terseLabel": "Disposal group, including discontinued operations, goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "terseLabel": "Disposal group, including discontinued operations, other intangible assets",
        "verboseLabel": "Other intangibles, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Disposal group, including discontinued operations, inventory",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r381",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Disposal group, other expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "terseLabel": "Disposal group, including discontinued operation, other liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r380",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Disposal group, including discontinued operations, property, plant and equipment",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r23",
      "r31"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Costs, Expenses and Other"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r32",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Spin-Off of Organon &amp; Co."
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCo"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r613",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Cash dividends declared on common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r43",
      "r90"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r36",
      "r49",
      "r65",
      "r205",
      "r436",
      "r438",
      "r439",
      "r445",
      "r446",
      "r447",
      "r858"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Due from related parties, current"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r84",
      "r205",
      "r436",
      "r438",
      "r439",
      "r445",
      "r446",
      "r447",
      "r858"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties, current"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "Europe, Middle East and Africa"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r157",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r230",
      "r233",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248",
      "r807",
      "r808",
      "r924",
      "r953"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net Income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic Earnings per Common Share Attributable to Merck\u00a0&amp; Co., Inc. Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r157",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r233",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248",
      "r807",
      "r808",
      "r924",
      "r953"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net Income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r830"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total, Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Tax\u00a0Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r203",
      "r676",
      "r711"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory rate applied to income from continuing operations before taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r676",
      "r711"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowances"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r676",
      "r711"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges": {
     "auth_ref": [
      "r676",
      "r711"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r676",
      "r711"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r676",
      "r711"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r676",
      "r711"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "R&amp;D tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount",
        "terseLabel": "Tax Cuts and Jobs Act of 2017"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent",
        "terseLabel": "Tax Cuts and Jobs Act of 2017"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r676",
      "r711"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Tax settlements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r654"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Income tax benefits related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r657"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Tax benefits relating to stock option exercises"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss": {
     "auth_ref": [
      "r419",
      "r421",
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of reasonably possible loss exposure in excess of amount accrued for remediation, site restoration, postclosure, monitoring commitments, or other exit costs associated with the sale, disposal or abandonment of a particular property resulting from unanticipated contamination of the assets.",
        "label": "Environmental Exit Costs, Reasonably Possible Additional Loss",
        "terseLabel": "Aggregate possible expenditure on environmental matters in excess of amounts accrued"
       }
      }
     },
     "localname": "EnvironmentalExitCostsReasonablyPossibleAdditionalLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r144",
      "r145",
      "r146",
      "r216",
      "r217",
      "r218",
      "r220",
      "r226",
      "r228",
      "r251",
      "r332",
      "r500",
      "r507",
      "r658",
      "r659",
      "r660",
      "r703",
      "r704",
      "r806",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r837",
      "r964",
      "r965",
      "r966",
      "r1010"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r821"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities held through ownership interests in investment funds"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r821"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Publicly traded equity securities",
        "verboseLabel": "Publicly traded equity securities, fair value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedTerseLabel": "Income from investments in equity securities, net"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r327",
      "r955"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "(Gains) losses for equity securities held through ownership interests in investment funds"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r327",
      "r955"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "verboseLabel": "Unrealized (loss) gains"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r50",
      "r55",
      "r322",
      "r934",
      "r974",
      "r975",
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative downward price adjustment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative upward price adjustment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r810",
      "r811",
      "r812",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r463",
      "r476",
      "r477",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r606",
      "r811",
      "r867",
      "r868",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r810",
      "r811",
      "r814",
      "r815",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r463",
      "r557",
      "r559",
      "r564",
      "r606",
      "r811",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r463",
      "r476",
      "r477",
      "r557",
      "r559",
      "r564",
      "r606",
      "r811",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r463",
      "r476",
      "r477",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r606",
      "r811",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r816",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summarized Information about the Changes in Liabilities for Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r559",
      "r809",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "NAV"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r817"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r463",
      "r476",
      "r477",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r606",
      "r867",
      "r868",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r818",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r773",
      "r779",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r316",
      "r317",
      "r324",
      "r325",
      "r326",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r474",
      "r498",
      "r805",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated aggregate amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Estimated aggregate amortization expense, 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated aggregate amortization expense, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated aggregate amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated aggregate amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r363",
      "r368",
      "r371",
      "r375",
      "r901",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r363",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r371",
      "r901"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixedIncomeInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments that regularly generate a fixed amount of interest income. Examples include, but are not limited to, bonds, certificates of deposit, notes and debt securities.",
        "label": "Fixed Income Investments [Member]",
        "terseLabel": "Fixed Income Investments"
       }
      }
     },
     "localname": "FixedIncomeInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Jurisdiction"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r826",
      "r827",
      "r828",
      "r829"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Exchange losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r119",
      "r557",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).",
        "label": "Foreign Exchange Option [Member]",
        "terseLabel": "Currency Options"
       }
      }
     },
     "localname": "ForeignExchangeOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r557",
      "r970"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Foreign government bonds"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r612",
      "r616",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of issuer's shares to which the forward contract is indexed.",
        "label": "Forward Contract Indexed to Issuer's Equity, Indexed Shares",
        "terseLabel": "Forward contract indexed to issuer's equity, indexed shares (in shares)"
       }
      }
     },
     "localname": "ForwardContractIndexedToIssuersEquityIndexedShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward Contracts"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r349",
      "r351",
      "r862",
      "r905"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Intangible asset impairment charges"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangibles"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r352",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r184",
      "r350",
      "r355",
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Divestitures"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r794"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Hedged Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r795"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r771",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r184",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Intangible asset impairment charge related to marketed product"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r184",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "verboseLabel": "IPR&amp;D impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r82",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r160",
      "r185",
      "r221",
      "r222",
      "r223",
      "r224",
      "r239",
      "r243",
      "r753"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0&amp; Co., Inc.",
        "totalLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r751",
      "r754"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net Income (Loss) Attributable to Noncontrolling Interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r202",
      "r710"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r151",
      "r279",
      "r285",
      "r289",
      "r292",
      "r295",
      "r903",
      "r919",
      "r926",
      "r956"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before taxes",
        "totalLabel": "Income from Continuing Operations Before Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r202",
      "r710"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r200",
      "r219",
      "r279",
      "r285",
      "r289",
      "r292",
      "r295",
      "r331",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r754",
      "r808",
      "r825"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income from continuing operations",
        "totalLabel": "Net Income from Continuing Operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r148",
      "r157",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r233",
      "r241",
      "r242",
      "r808",
      "r917",
      "r920",
      "r924",
      "r948"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from Continuing Operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r148",
      "r157",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r233",
      "r241",
      "r242",
      "r243",
      "r808",
      "r924",
      "r948",
      "r951",
      "r953"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from Continuing Operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r28",
      "r31",
      "r715",
      "r949"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Income from discontinued operations, net of taxes"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r22",
      "r28",
      "r751",
      "r754"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Income of discontinued operations attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r22",
      "r28",
      "r754"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      },
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests",
        "totalLabel": "Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r234",
      "r241",
      "r242",
      "r766"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Income from Discontinued Operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r152",
      "r184",
      "r276",
      "r328",
      "r918",
      "r947"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity loss from affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r613",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r4",
      "r15",
      "r16",
      "r17",
      "r18",
      "r20",
      "r21",
      "r26",
      "r29",
      "r30",
      "r31",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r386",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r681",
      "r688",
      "r690",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r203",
      "r677",
      "r689",
      "r696",
      "r705",
      "r712",
      "r716",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r204",
      "r227",
      "r228",
      "r277",
      "r675",
      "r706",
      "r713",
      "r957"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on Income from Continuing Operations",
        "totalLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails",
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r143",
      "r671",
      "r672",
      "r689",
      "r690",
      "r695",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowances"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign earnings"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. statutory rate applied to income from continuing operations before taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedTerseLabel": "R&amp;D tax credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlements": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount",
        "terseLabel": "Tax settlements"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r181",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r366",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r366",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r193",
      "r370",
      "r897",
      "r898",
      "r899",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Acquired Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r361",
      "r369"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other Intangibles, Net",
        "totalLabel": "Net",
        "verboseLabel": "Other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r149",
      "r273",
      "r839",
      "r842",
      "r925"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r119",
      "r557",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap",
        "verboseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Software Capitalization"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total (approximates current cost)"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserve": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.",
        "label": "Inventory, LIFO Reserve",
        "negatedLabel": "Decrease to LIFO cost"
       }
      }
     },
     "localname": "InventoryLIFOReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r34",
      "r104",
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.merck.com/role/InventoriesInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories (excludes inventories of $2,194 in 2021 and $2,070 in 2020 classified in Other assets - see Note\u00a08)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory classified in Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
      "http://www.merck.com/role/InventoriesInventoriesDetails",
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r105",
      "r194",
      "r250",
      "r345",
      "r347",
      "r348",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product.  Includes supplies used directly or indirectly in the manufacturing or production process.  This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory, Work in Process and Raw Materials",
        "terseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r164",
      "r272"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r330",
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r946"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LIFOInventoryAmount": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.",
        "label": "LIFO Inventory Amount",
        "terseLabel": "LIFO inventory amount"
       }
      }
     },
     "localname": "LIFOInventoryAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r39",
      "r80"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]",
        "terseLabel": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r855"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r855"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r855"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r855"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r855"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r855"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r855"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r855"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r89",
      "r200",
      "r287",
      "r331",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r757",
      "r762",
      "r763",
      "r825",
      "r860",
      "r861"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r72",
      "r200",
      "r331",
      "r825",
      "r862",
      "r914",
      "r943"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r91",
      "r200",
      "r331",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r757",
      "r762",
      "r763",
      "r825",
      "r860",
      "r861",
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Payables included in Accrued and other liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r57",
      "r58",
      "r200",
      "r331",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r757",
      "r762",
      "r763",
      "r825",
      "r860",
      "r861"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Payables included in Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r27",
      "r31",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "terseLabel": "Disposal group, including discontinued operations, liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r27",
      "r31",
      "r381",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities of discontinued operations",
        "totalLabel": "Total current liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r27",
      "r31",
      "r380",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Noncurrent Liabilities of Discontinued Operations",
        "totalLabel": "Noncurrent Liabilities of Discontinued Operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/SpinOffofOrganonCoAssetsandLiabilitiesofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Available borrowing capacity under credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r95",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Legal defense costs reserve"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Long-term debt, current maturities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r209",
      "r431",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r209",
      "r431",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r209",
      "r431",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r209",
      "r431",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r209",
      "r431",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-Term Debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r93",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Loss contingency, claims dismissed (in cases)"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss contingency, claims settled (in cases)"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss contingency, number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss contingency, pending claims (in cases)"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r40",
      "r383"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Machinery, equipment and office furnishings"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery, equipment and office furnishings"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "verboseLabel": "Unallocated"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r100",
      "r200",
      "r331",
      "r433",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r825",
      "r913",
      "r942"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r254",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations.",
        "label": "Net Cash Provided by (Used in) Discontinued Operations",
        "totalLabel": "Net Cash Flows Provided by Discontinued Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net Cash Provided by (Used in) Financing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net Cash Used in Investing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r180",
      "r182",
      "r185"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net Cash Provided by Operating Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r137",
      "r140",
      "r146",
      "r154",
      "r185",
      "r200",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r239",
      "r279",
      "r285",
      "r289",
      "r292",
      "r295",
      "r331",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r808",
      "r825",
      "r921",
      "r950"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income Attributable to Merck &amp; Co., Inc.",
        "totalLabel": "Net Income Attributable to Merck &amp; Co., Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r137",
      "r140",
      "r146",
      "r227",
      "r228",
      "r759",
      "r765"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net income (loss) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r230",
      "r231",
      "r240",
      "r243",
      "r279",
      "r285",
      "r289",
      "r292",
      "r295"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Merck &amp; Co., Inc., basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r243"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Merck &amp; Co., Inc., diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside of the United States"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r507",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r768",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of Interest Rate Swaps Held",
        "verboseLabel": "Number of interest rate swaps held"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutInterestRateSwapsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/NatureofOperationsDetails",
      "http://www.merck.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "auth_ref": [
      "r395",
      "r396",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.",
        "label": "One-time Termination Benefits [Member]",
        "terseLabel": "Separation Costs"
       }
      }
     },
     "localname": "OneTimeTerminationBenefitsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r850",
      "r856"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease, cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r846"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liability",
        "verboseLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r846"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r846"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r848",
      "r851"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r845"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Other Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r854",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r853",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term",
        "verboseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r693"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Valuation allowance on foreign NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "verboseLabel": "Total segment profits"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r108",
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r773",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r129",
      "r131",
      "r576"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedTerseLabel": "Prior service (cost) credit arising during the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r136",
      "r576"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Prior service credit amortization included in benefit cost"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r123",
      "r124",
      "r131"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized (loss) gain on investments, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": {
     "auth_ref": [
      "r134",
      "r144",
      "r145",
      "r831",
      "r833",
      "r837"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r134",
      "r144",
      "r145",
      "r147",
      "r831",
      "r833",
      "r837"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "auth_ref": [
      "r132",
      "r144"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedTerseLabel": "Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r122",
      "r131"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net unrealized gain (loss) on derivatives, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r122",
      "r131",
      "r776",
      "r781",
      "r800"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of gain (loss) recognized in OCI on derivatives"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r131",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "terseLabel": "(Decrease) increase in Sales as a result of AOCL reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r785"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r786"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r138",
      "r141",
      "r144",
      "r145",
      "r147",
      "r155",
      "r500",
      "r831",
      "r836",
      "r837",
      "r922",
      "r951"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other Comprehensive Income (Loss) Net of Taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r138",
      "r141",
      "r754",
      "r755",
      "r760"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax": {
     "auth_ref": [
      "r128",
      "r131"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r128",
      "r131"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Benefit plan net gain (loss) and prior service credit (cost), net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r126",
      "r131",
      "r576"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Net loss (gain) amortization included in benefit cost"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r136",
      "r576"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r136",
      "r576"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "negatedTerseLabel": "Net loss (gain) amortization included in benefit cost"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r773",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "verboseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r526",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Licenses and other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Supplies, Gross",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other investments.",
        "label": "Other Investments [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r42",
      "r90",
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities",
        "verboseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 5.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "negatedTotalLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r528",
      "r529",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r581",
      "r582",
      "r584",
      "r587",
      "r591",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other Postretirement Benefits"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r395",
      "r396",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r168",
      "r171"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r178",
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "(Payments) receipts, net"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid to stockholders"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Three, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Pandion Therapeutics, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessThreeNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Acceleron Pharma Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r169",
      "r735"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid for acquisition of business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Other acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r179",
      "r323"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedTerseLabel": "Purchase of Seagen Inc. common stock"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Payments to acquire investment"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of securities and other investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r170",
      "r742",
      "r743",
      "r744"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r556",
      "r558",
      "r564",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r606",
      "r608",
      "r609",
      "r611",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r56",
      "r529",
      "r530",
      "r554",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r59",
      "r529",
      "r530",
      "r554",
      "r606"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r527",
      "r529",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r581",
      "r582",
      "r584",
      "r587",
      "r591",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r611",
      "r612",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefits"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r584",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r182",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Proceeds from income tax refunds"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r174",
      "r177"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sales of securities and other investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Revenue related to the sale of the marketing rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r172",
      "r657"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Cash received from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductionRelatedImpairmentsOrCharges": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.",
        "label": "Production Related Impairments or Charges",
        "verboseLabel": "Inventory and fixed assets write-offs"
       }
      }
     },
     "localname": "ProductionRelatedImpairmentsOrCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r81",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r80",
      "r383"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment (at cost)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross [Abstract]",
        "terseLabel": "Property, Plant and Equipment (at cost)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r51",
      "r52",
      "r385",
      "r862",
      "r930",
      "r945"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r51",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r66",
      "r74",
      "r862",
      "r944",
      "r972"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "verboseLabel": "Receivables included in Other current assets"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r134",
      "r144",
      "r145",
      "r831",
      "r835",
      "r837"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "negatedTerseLabel": "Reclassification adjustments, pretax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r134",
      "r144",
      "r145",
      "r147",
      "r831",
      "r835",
      "r837"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTotalLabel": "Reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r132",
      "r136",
      "r144"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "terseLabel": "Tax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r285",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Segment Profits to Income Before Taxes"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartiesAmountInCostOfSales": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.",
        "label": "Related Parties Amount in Cost of Sales",
        "terseLabel": "Related party amount in cost of sales"
       }
      }
     },
     "localname": "RelatedPartiesAmountInCostOfSales",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r584",
      "r857",
      "r858",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Payments on debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Charge for the acquisition of Pandion Therapeutics, Inc."
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r668",
      "r896",
      "r992"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 3.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r189",
      "r904",
      "r939"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r33",
      "r48",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Funds collected from factoring of receivable, held in restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r394",
      "r396",
      "r399",
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r395",
      "r398",
      "r406",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Cumulative costs since program inception"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r395",
      "r398",
      "r406",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected restructuring and related cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r395",
      "r398",
      "r406",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Expenses",
        "verboseLabel": "Total pretax restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r184",
      "r393",
      "r402",
      "r406"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 4.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Restructuring costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r402",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r395",
      "r396",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r396",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending balance",
        "periodStartLabel": "Restructuring reserve, beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r68",
      "r507",
      "r661",
      "r862",
      "r941",
      "r967",
      "r969"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r216",
      "r217",
      "r218",
      "r220",
      "r226",
      "r228",
      "r332",
      "r658",
      "r659",
      "r660",
      "r703",
      "r704",
      "r806",
      "r964",
      "r966"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r587",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r612",
      "r616",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r587",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r612",
      "r616",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r581",
      "r582",
      "r584",
      "r587",
      "r591",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r581",
      "r582",
      "r584",
      "r587",
      "r591",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r195",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r158",
      "r436",
      "r438",
      "r439",
      "r445",
      "r446",
      "r447",
      "r973"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r150",
      "r200",
      "r270",
      "r271",
      "r284",
      "r290",
      "r291",
      "r298",
      "r299",
      "r302",
      "r331",
      "r433",
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r825",
      "r926"
     ],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Sales",
        "totalLabel": "Sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r852",
      "r856"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales",
        "verboseLabel": "Total sales"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r134",
      "r836",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Changes in AOCI by Component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Information on Investments in Debt and Equity Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r928",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r93",
      "r209",
      "r476",
      "r478",
      "r501",
      "r504",
      "r505",
      "r506",
      "r840",
      "r841",
      "r844",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.",
        "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r590",
      "r591",
      "r594",
      "r595",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r774",
      "r783",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Location and Pretax Gain or Loss Amounts for Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r4",
      "r15",
      "r16",
      "r17",
      "r18",
      "r20",
      "r21",
      "r26",
      "r29",
      "r30",
      "r31",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Calculations of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.",
        "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Between Effective Tax Rate and U.S. Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.",
        "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment, Net by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Sales of Company's Products"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Summary of Expected Benefit Payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r363",
      "r370",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Goodwill Activity by Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.",
        "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]",
        "terseLabel": "Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Income Before Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Other Intangibles"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Summary of Interest Rate Derivatives"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r44",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Effect of Net Investment Hedges"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r782",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r406",
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r400",
      "r401",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r396",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r159",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Consolidated Revenues by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r150",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r279",
      "r282",
      "r288",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r279",
      "r282",
      "r288",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Equity Loss from Affiliates and Depreciation Included in Segment Profits"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r639",
      "r644",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Nonvested RSU and PSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r627",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r632",
      "r644",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summarized Information Relative to Stock Option Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Determine Weighted-Average Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r96",
      "r197",
      "r252",
      "r253",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r493",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Summary of Common Stock and Treasury Stock Transactions"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r688",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]",
        "terseLabel": "Continuing Operations"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r266",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r302",
      "r398",
      "r409",
      "r958"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r266",
      "r268",
      "r269",
      "r279",
      "r283",
      "r289",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Pretax share-based compensation cost recorded, related to continuing operations",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Period over which share-based payment awards vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Contractual term of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Nonvested December 31 (in shares)",
        "periodStartLabel": "Number of Shares, Nonvested January 1 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share)",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares collectively authorized for future grants under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r646"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Number of Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r656"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r634",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding, December 31 (in shares)",
        "periodStartLabel": "Number of Options, Outstanding, January 1 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of\u00a0Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r647"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r625",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price of options granted (in dollars per share)",
        "verboseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r627",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Quantity of stock options that vest per year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r650",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r656"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.",
        "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted-average interest rate of commercial paper"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r190",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Capitalized Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r14",
      "r266",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r302",
      "r358",
      "r388",
      "r398",
      "r409",
      "r958"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r98",
      "r144",
      "r145",
      "r146",
      "r216",
      "r217",
      "r218",
      "r220",
      "r226",
      "r228",
      "r251",
      "r332",
      "r500",
      "r507",
      "r658",
      "r659",
      "r660",
      "r703",
      "r704",
      "r806",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r837",
      "r964",
      "r965",
      "r966",
      "r1010"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r251",
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r63",
      "r64",
      "r500",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "negatedTerseLabel": "Issuances (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r63",
      "r64",
      "r500",
      "r507",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r64",
      "r70",
      "r71",
      "r200",
      "r307",
      "r331",
      "r825",
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Merck\u00a0&amp; Co., Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Merck\u00a0&amp; Co., Inc. Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityBeforeTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.",
        "label": "Stockholders' Equity before Treasury Stock",
        "totalLabel": "Stockholders' equity before deduction for treasury stock"
       }
      }
     },
     "localname": "StockholdersEquityBeforeTreasuryStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r145",
      "r200",
      "r216",
      "r217",
      "r218",
      "r220",
      "r226",
      "r331",
      "r332",
      "r507",
      "r658",
      "r659",
      "r660",
      "r703",
      "r704",
      "r751",
      "r752",
      "r764",
      "r806",
      "r825",
      "r831",
      "r832",
      "r837",
      "r965",
      "r966",
      "r1010"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r198",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r507",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteSpinoffTransaction": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.",
        "label": "Stockholders' Equity Note, Spinoff Transaction",
        "terseLabel": "Spin-off of Organon &amp; Co.",
        "verboseLabel": "Spinoff transaction"
       }
      }
     },
     "localname": "StockholdersEquityNoteSpinoffTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Share-based compensation plans and other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r60",
      "r912",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement [Domain]"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r60",
      "r912",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment [Axis]"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r718"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Transition tax for accumulated foreign earnings, liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent": {
     "auth_ref": [
      "r718"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current",
        "terseLabel": "Transition tax liability, current"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent": {
     "auth_ref": [
      "r718"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as noncurrent.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent",
        "terseLabel": "Transition tax liability, noncurrent"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade names"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r916"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "totalLabel": "Investments"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r316",
      "r317",
      "r324",
      "r325",
      "r326",
      "r474",
      "r498",
      "r805",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r97",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r97",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r64",
      "r500",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchases of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r97",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "terseLabel": "Less treasury stock, at cost: 1,049,499,023 shares in 2021 and 1,046,877,695 shares in 2020"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r500",
      "r507",
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Treasury stock shares purchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r395",
      "r396",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r206",
      "r557",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r670",
      "r682"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance December\u00a031",
        "periodStartLabel": "Balance January\u00a01",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r683"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Settlements",
        "terseLabel": "Unrecognized tax benefits from adjustments related to examination"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r678"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Liabilities for accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties associated with uncertain tax positions, expense (benefit)"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r684"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions related to current year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r683"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions related to prior year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r686"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapse of statute of limitations",
        "negatedTerseLabel": "Unrecognized tax benefits, reduction resulting from divestiture of Merck's consumer care business"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r687"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Favorable net impact to income tax provision if unrecognized tax benefits were recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r262",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Valuation Technique, Discounted Cash Flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Common shares issuable (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r232",
      "r243"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Average common shares outstanding assuming dilution (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r230",
      "r243"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1000": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1001": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r1002": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r1003": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r1004": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r1005": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r1006": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r1007": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r1008": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r1009": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3),(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6395460&loc=d3e13647-108346"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB TOPIC 5.Y.Q4)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "60",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6406278&loc=d3e26268-112671"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(b)(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=122636397&loc=SL7495116-110257"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r993": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r994": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r995": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r996": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r997": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r998": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r999": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>144
<FILENAME>0000310158-22-000003-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000310158-22-000003-xbrl.zip
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MJD2YU4]5OG+K'];N =(^A<9_ E!+ P04    " ")A5E4B8 =L<T&   >.0
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M6H,XBV."V.[6U'YAHZ)5S.4N)0L02"$()^)U/G3(=>2L!HN/3N'RJ'O:OKB
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MIX<\\[C>^#5_<M ^P[CW+U!+ P04    " ")A5E4DWP0ZP('   F&P  '@
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M#<>Z:S(-VAB4P9+2\S76< -2H<'/&%9@.C1A7)/Y5*138BKW6,V?<\UK(<Z
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MA<LYVY9U"/?A]Y$-X+PW=*UD\31Z6QM45KH$LHS/D6FJ-/,*^.)EP@ND/@F
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M"=XO6$9+N*!KN.89R=]W2BQ#MZ2"Q;5BR?ZFB GAZ:_K&K*/?E*6TVT*MJ-
MS^X2MF027,=P'B-^F#@1*\Q=\B*P5=8/L(=(-A5O!/X3#57W';3MOC6TW9ZU
M-X,?!?&$"LEB%A*%&W@,DX31&,Y83O*0D10N8Y12\9I2#!Y7XL^J1->;^B>6
M1YAFX'BZ3;][LM[.9*\J458$XTH.]C%\-CX9$P.>%:T#,J%0(6)18B+X\O.:
M!,7/1RK"+[7N0=L]'N(,,#IPGH<&'"JS@_:QXUC#"<\*DF_T-WMXU(&$"KK<
M0%CSC3G)A$@=Z(&J[0]+.,WS"HF_I@47$K J9UQD8%O=7R'F0IO$K Q194.)
M (HX(YC2D&9+*FIDKMU1$\E^!*EVN$4$<96FB >#IPK.FLE$^Q;TKXH)JH96
MJ1)^0L\A.0)$8?<.HR,E5B:H4@F<N^AF=A<F)%]1. VE$ML#UP.21_?ILARS
MR.I^"[%DA"F&6:Z%3=(Q80+!%8*6"D9'B4F: IIAY3%S%!2(J^PT=&R[%1U&
M>@'HF*A5I746O*!"QRRWH!O:C>_2V3L&[NZ7_V57DBQ3NK5:<H$=V<67)25%
M28/MAV'$RB(EFX#ENN6UT;!!O^12\BQ00_)6M1ZV31-91ZS%S=88# S?\M7B
MD A>1MO S4XQ]$XQ9?1<YGI&W_?WBBW#WBM[R:UM&P-O\)^[[5F&Y7NO<FMJ
M)FHVD.\2.^:DY;:V!@6)(CP6!$YQ!_;C'DEI_)QR7OS_DT\?!:;J#'/0[N&\
M@C.Z%!41&W!Z>DK<K]F&C1<2M52:K5>I_O"<'+0]'+?Z"1,BN-* .9-A@O,Y
MC1ZQ\LH^^!?TO$*U>>'U*:= >A!A!%M>GM ,ZK_7W\'WP\G2]78,@GH&O%$1
M+DA&F[X$F)Q>7\[/+V8P/U],/IR=S^;3MZ_"+J)=_UM$N_T=$_?-6GVA[AY?
M:0;<TKBQ);NE\!N>:^ *%R53N#O?//Y]+8.IU\R.Y?;D0E+P^D86")H2%?+9
M%>6^W?6JLNY-R!)[OI+[3?:=HO?>=YIG??O2]\#Q/U!+ P04    " ")A5E4
MFBXCA=\;  "UV@  '@   &5X:&EB:70Q,#$W+7!L86YF;W)D969E<G)E+FAT
M;>U=6W/;.+)^/[\"ZSD[8U?1LN7+)'&RJ5(L>49[?"M;239/IR 2DC"A2"TO
M5K2_?KL;  E*I"PGCB79FIJ:L4CBWNC+UXW&N[\UKTX[7ZY;;) ,?7;]\<-Y
M^Y1M[>[M?3X\W=MK=IKLS\[%.3NJ[==9)^)!+!,9!MS?VVM=;K&M09*,3O;V
MQN-Q;7Q8"Z/^7N=F#ZLZVO/#,!8U+_&VWK_#)_!?P;WW__/N;[N[K!FZZ5 $
M"7,CP1/AL32609]]]D3\E>WNZJ].P]$DDOU!P@[V#P[8YS#Z*N^X>I_(Q!?O
M33WO]M3O=WO4R+MNZ$W>O_/D'9/>/[;D?GU?O.[NUWO\C7MT(.K=P][KUUZO
M+GK[!\+M]OZ_#IW<@\]5F3B9^.(?6T,9[ X$MG]R]*IV?#!*WHZEEPQ.ZOO[
M?]^B3]^_ZX5! NU%4%[]J:K)*GO_+N%=7Y@ZNV'DB6C7#7V?CV)Q8OYXZ\EX
MY//)B0Q\&8A=*O1VR*,^=*(;)DDX/#F&#MR)*)$N]W>Y+_O!22*^)?IUWK?:
MONI? IU*/-.R?EVC5WN)-_ONS>O:F_WJU_NU>O9NC^I6]<,0XA$/_K%UN&4*
MC+CGP7J>'(R^L3KTFKJI>NR+WNPHPM%68>9U^5W\^.2@]@I';IX109B'5L7T
M?$LMB*D'NA9&)[_LTS]O\<UNCP^E/SGYK1%)[O_FQ$#2N[&(9$^]CN5_!,PA
M5$T_QVKY7T%I6A9-#HH 6M\&LBL35H>9>55<_A\<BPLD+:*M2NK:5/]LJ[>W
MEVG'4-WK$1)X^9;3C 6V$C0*;3(O3)'O&.(W6W(?-V1A&^\1KRD9WO=-RJ;4
M2R[U-)SWHG5S^G_LUU\.7[]EIU<UA[4O3VO/:H37YXU+=G9UPYJML];-3:O)
MKAM?+EJ7'79U]JP&VFS?M$X[5S>WO\%*7ERW+F\;G?;5Y>J,L2.'(F:78LQN
MPB$/[ATMU7@B$VC-+8S_J'3\VZ;/3]V="IVFUQ-N(N\$XS%K@&KM@7+. X_=
MB#@A3?V?/$AY-&%UA[3R976_?#9W5IHY;DIM2FU*V:7TYCU^4]L_0N4Y5/C"
M221\CEQHQN#.U5TRB??S(KP;AWZ:5!=YB!)N_7>0J>$CWA>[W4CPK[N\!^5/
MN#_FD[C8RJ. !JLAFCN-#^<MT#= ,%]V0/6XG5G&>4N\G'>/)X+J4W-4+G!^
M_:7^^_[;V?]> ZVL0?<;B,. E=AFE0-)(]ABHNHU8_5U&F;U.%L^ZCUAP,(>
M:XJ>B"+N@UT1W('>0TAEPX?]%Q!7BDDC:LHXB60WI5*W[D!XJ?]LYJEZHCYQ
M/^7%F0*ML#$,TR")JX=_N$[#_U0Y^AOAB1CXL9J!SS(9R(#QC&)8PW5Q(JKG
MX7B-YJ%Z&J[YA#;%@TC@]W4:>O4&:%H$ ./_( +1DZX$F^BY#'V.-/!YH,Q"
MM?P1ZX@(5!Z:C>KASZ+C*SW\=M5(;K6,.-I_TV"GX7#D2QZX<YC^.@V\_:]*
MV9B! DV>//)H-^\V[Q9[M_J6Y@-[;WLL[S%"O84]V4>9)_O[#==7ZVRU/HYO
M8 U1_I7'Z_]*XT3V)@^%DXK%GF:4[5JE!O3QYOKJMO78XRVXD@]_+_J,'SP#
MCZH?= :"78C(_6HV58B;*G!KC+3!'BB!F0U@VP4R J4AC, @>'U0?_66]"41
MQ$IQWL:G!TJAI#_K;W?8* KOI$?F-4N#7JJ<#V!7!7U!U6);GJD7&RGMEX/?
M#47D3]C7(!P'Z,I ^SS"";[VP[0_@(^C41@5^T*5Z<Z@:IO P/4K[#L/)E9/
M)7X0TC>N'U+TD@?*45;9J7ZH-"9=#'J,!1K]2*@!(8Y LZC&TA<1U>)AE_$1
MC]P!>XV>EOTW#C[DRB7CL.Z$"O-A"(U43,.<0</+:]/B;=J-I8<&#+L*A%Y;
MK+STD\XXU)]L6Q-$L6&<M./8#-=A(7R!\P@#S)<-?L+ (YBW%&@&)D& 'AU.
MA(C-_.C9QC602<QBT[@4L8.3?L?]%/K)E:U-5('=3?U$#F'V8-T]@\T(G"$T
M2YEG:'1;[K [$.!! C7"MV# NSP6V#@/@A2,^$@D'+9!I'">#R&/E _,#8=#
MF21"L*$0":YN3V"7)):<./3-MH3J8<_!,H99]2+""O5T8&,QKB50N@N=A"[!
M8R&#&F/7-EW9).30DQ'T7[@BCLU',E;DHW>.!TH"S"B&5K$NV:4P</BP9,_<
M#G@TTB33# =#0=0!BYKMG2)1Z34?575P)]]&MTU# =5R]P'\[L<9IWHD YR;
MDUW\Z&F%2;4T:9V#, 7QB2B[T@$:YZBQ?&K==D@/:)QW6C>7(&+A"6M<-EFS
M?=NY:7_X2*5N3_]L-3^>_UQI1-K@XT[JX]JOE;/[<WS3B_1*30[L5<UN3U"6
M1?C5UGL;:?ZD^=#$0A")7_V<I7E&JUZOUM ,BVH"JQQV@>,>UG&N!0=9.A$\
M<M2?ABD"MP8N#:+A+G1Y%QB?P 5BV\!6-4=K!V#XP=*8E<OD.;)67#<'U)5$
M^BS)P3!L$89V)UT*I>!Y<_ OF)Q8Z'C_[_@+!Y1U4(O 7NC[X1B9ZW82]@4*
M#L=62"H))^O;6"8#D&3Q" >C&7;]@(&^D QBD Y]&018?P-8NL_JIN$ UA=$
ME ]J!H]HNAC9C""%H7>S,W$,TF'IQ%H_.*@=K3:];O,=K4D8[6+!:5N'L75W
MV+G@7J;S/\<QNCNHEVK][W3 930"#1$V^C,<J[?#&JDG$VO$0\5*S6"5LOM\
M1BQV%M;S:\OG=ZLNG _N%\XXQR)PA8$+O#21RBPJBLJQ<K&23)11G+##?3"1
M)[$E(:>KTF(7%LRJ*A!C(]K!3$*+<30*98 _M'!4Z^^E:#%#R:(,1!UAR+\*
MA":FA2 9H&2>A9$1_?BS4D9CV[YTZ5P0-$Z2U73TMUB/DYJUE(AM:&3$HP2K
MCD38V]G0X;UT>%A)AYVYZQ,/N(\6-!Y/ S:H\!A%<+%2>=AV?7&.X>281X9"
M$ !BU:YIQN>P]%T\#0=6/A)ZIAAF]/CO%*A 1-"/-V_9]L$.-I+3;\Z@RR6R
M<Y\4@^'\^LO1J[=0YAX94!@0;K91%.Z"O<-Q_B)AAI0-.2LGXQ\;>HTQ7#]$
MRF)=P7@@X<.YN\YA>@?%9@LYQ570?,#:B?EJ::@)OU=@C5**(_,!E.5Q5?N(
MC\0+8B$KM%N?$2,XJF0$5X%;SM2!2(?<$["' ]=/<:A@-^:.<&U;:G [1H3V
MM:/D"V*@5!9!VB+T=MLL(F@V; HM&<[CPH!DD))T0%E!*"*("83^L'64#5"A
M$HLQ'PJR/&/-B@)/JCYHH]2B:9)A*&)!',X,&;;5AI#N(:3C2D(ZU2!OON V
M/FZ@^*);1!GJ@Y"-122*I#+/8:$7WH9?#1.U"2HC(R]3(NYSC]/T+R4*^R><
M'9F/'RT>>_ XT> _Z%1?9)<L:4_DFO@T50)':0035.#[3"OQY*XPCC.H.D))
M&80)ZOEQ @R,&"V^G=TR:ILH]5C P*56H!5@-RMX8V3 4R@@UDRJ-:EDBK>+
MN*SG'?6!XI&&L9,A -W5;!DJ\J5Q<64GHV9!/(6C 7>>YN^#B';W% @7"^3B
MJM2\V=VPZWM(\\.:^08NM.-PXP]X/'] ([,PSB*)9L74CLI=^Z3(-90/^$+;
M<2B*T9H9A+XGIH1ZR6K9[OYI/\-83AF5!-$#XU N:B;^G<H[-'4RO%[[HUT>
M#W+KR: -!LQG8,')T+,@?:T?&*8R@O:%9\9;')^R(HW[V&&#<"SNE*\!N%^N
M[^:-[E8TJEM3IT*)UY&51;+141B'&KCF@3*($[108=30G?^%^72 0NZ;WZ*3
M0QN"E=]E4SX4/$[13@.!D&3Q+&C9XMF-)(0?VL1;/S-M=<"]QL/A-F5&)^6+
M2(IMQ:Y!FF4$-DRA;M7$\$BH&[O%DC/-SV)&LWA"!B-D+$FUJL&.Z2[I3OP8
M23X_ JQ&]<YPM=2!M?A>>JC4,K.53'1R*E@NV5N<I/,X)EM9>^)0F%5?Q-,U
MT\P:*5BZ\-3-R0A6N?5-N"D)R!PE/1,B7E4ALBPU7"1C(<!"2@.!2-FQ<A\J
ME0%^OW)F<3*$19 !JOTG),7.V8@UHEG*L@LM #S3XTJ6!K$\!O9:JF+])DJQ
M&NF8551QB -KMNLH<[-*6\M"[D"E&"O^G:EHU+7<#U!0:DH(J52IJ?R.D,F-
M/O-HQ-E<,TYDQX]5G$]>U35?T@JW>$GH4F:&$ *$&SO#>'AL)+K,YY?;Y[]Q
MSV<>)PI')I8R'6H\8W[@86'8EY&'QP851['.7#OP+5BFP #:%>WR.RY]TF")
M(*P(X%QI,2X![8^J&D)>52\*ARR10U*+Z?^F\JK _XPC74=A/^+# H/+&>_T
M9X;#S3<Z\5\82D(40&IW/CA>QNGPH  BC;2:Y8.U M'+6"4T87ORE(</)U /
MZ8J*5VRVFA[6XX4H'W[/EENDXH/:FZ6QV5:M\E3Q:O+9&89!AUI*<CYLN&TQ
M'KO$F5K-:VU(7L?>Y)RU,-V$!FS3N8D>-.HI9KFCZPY=-[4A=H7/H_\4?E3&
M!,1.M7VHW*F5:I@5PZ#[G7%>A8UI/6YV# 5673\&&:#M?_RMT+7M,*+@$84(
M8'QRK+P.A0 ))X_8M1_3.2,^$S4QA7L:>S=3F!<-7J8^!:G1O)4O.L?ZL, X
M3'U<'YP)4KT]?70KGXHXLZ1S85,M.7[0U?'\E-:S-5-:P7 +^H+TJE(>NK*N
MK"6M;[NG('2EAD*OR"N ZA&BD=*5(XXL2#M5JS<.Z3;Y+H3Z*(HQ$KN>^3*/
M69E1!)V2UHS"N0DER #Q32C!8Y$]>M>5-]\<K4'ZEM&L%*5CH7]99UM(\D8"
M/]/D;.']B\B8^59)$)9N&HH'&/ [)<R5OXS$K^O")\@'*9C8EGQY!%@N5^\3
MPB@\!4\&&S3G/@KZH_8T K#\J.=Z">6/ 6AE(A:"]DAKB&>] W?R0DZ3KLL*
MJ@P,N7]!F0_V"7=;2A>BEK6A(LN4B4(IQ2N5?H;1 I0 NLBU/!V.&K *LF&6
M:0::0@?D65QC-Z)?8[?"K;%Z#=-F[1[B^7ME1IB3[&@[)"%".(4^C64\4.QS
MP",/_AX5>S0$TC'\VH1RZ#G2F0,\X,%]Y40&HRI.>YBHC5(.8!F$X&!$6 /&
MHIEL7NKC>=TW/N#"%&8L' _@@])E?+U=[E.M*"BZPEHW6A!,AQ'W)LJHJII8
M[%"8)K R?70P0K'Q@(Z$8L2PC#7JA7CC $R\B8ES!PM<10[/0EX+)<1Y[#V^
M%HE?VNV'"I 'M?JP++(_LR?EX__4./_8*&8D:#59X^+J8UG^W^<I&)Y'FH'9
M3;_1';\[AO G+S'5N/@M!P9>/24 $J9WF<J)ACEUJ&)U]%6&>J:Q$GV>4,:.
MDMTYH-A+$;X%?47+,'6:S$I=4_#=D'%&TE/[Y17V.$HC=X!9?7A2R-$$MI>;
M'98H5*2#)G%6OH315_VT]<TEY"K+;G/YY;:5YW,*YH6NK4C<UA+3ALV-87@2
M.B#3W!"#]W!J@-5^Z<N(F./"!YM]/W2YUFU+5FE=F  LN_G;0I$JCG:NBG-B
M:11B(&'<U#IMGSXEK8 S@I0I%@*#KN:N9-?>K6#'"!X->?15.Y"4.VS:O U,
M;#W63DE58^4!B_/ ?;!ZP?":28ICT4S\H\<?GY\^5!WIO5KZ4%.2.>_%3X3]
ME?>"L18OQF\;"* \A)V8B^?I"W5_C/=9PJZ+@99Z#Q'7RAKSS#0QY9''.D>1
MN)-A&ON3F;CU+%C]!Y@GI<34IV!4XVS,H54NO57AFBNSVZK#VE=MMUE>_"7O
MN$)?M/]R;CALMA<I:*]:(2RIP2;O/,9_QC&U<='<MVS5R1BFSV_<V7?-S"X)
MA<B4K!0%RS _##!U;1)QC-*V5L]AL%SXT2CM LECF%#V#:6=)6A5:,O/4:&!
MB!83/$[KK_38H>"!4B&*13" L[ICR4R[R.MU$I<_PCL,+$3 V$*S[00O=FIE
M*UMKENEX"@@/LLP!=N4[N>)M$O*:(%631:E\!^#\Y.8N+%>%3HRO9B.?E)C"
M*7!AOR8R0?=%CTO,2P%*7F(R^\(8@JF!:*^'<!'LMZ4+3MY0)(-PRIXHJ58%
MEF4V2!:,:T+[07O$,YAJ#O#X%1T*@%?*?5RX_8-R#D]*O1B;R(A,I#W#R(B7
MP*'7[=C\W/CL1UP2_.@GK;95]?)5O-5;_34&YY>L(A,X7X+.D54V;^/<!];-
MF*GW518976-QI"X0>%@Z-B+<:$*+M#2#S5<K*UHSP&@O5-%RQ,\DFIN.TKK?
ML)]CS2_2^=B:;.]E ]"-$@AQD2E<)I+XHAWE&]3P!U##!["8Q;##A9GR' C1
M>42VG",G)=B@5-"@X=T+U.>4P9OEX[$JSN=K/@RJ-K5>B>TL$62>_*, J2+3
M*$*VBUZ \H)-C0WJ^7".,7=?% ]93<&=724-@\??S<\ !UW/JC>)6^Y)W.+A
M#!*BMUG;[[3[VXIA@(&DL&$.FF\8]7D@_Z-ODP/MA8^(F9HGL0KX %,J,3^,
MM'0PVKIK'W/1LIPBGB.'T.'0EYZIW&CB/96J26.O^CHU%9^E3\*Y&=@-["AU
MDS0B*#KWH%HI_U0]<_F<8ZL+J%9]A56R] :H(0WHCKHL0P&1FTX9'N'2^Y,?
MR_WT&(2WHA>C?:KD)3>M9NNV_<>EBD7^W.[\V;YDC>R.--8X/<60Y-6X7VX3
MD;P0)_Y#!"+B_FHD0EO6FA6O'</['&/H%3*L03AF&$H%KY A&;/#/M^A;ON\
M3SF+V38WF4MNL@:L>\OHI$WA#>-T<A'-&%]EE*JH6AV2E GS0J%3$J@SCU@F
MD4.=,M4K]\MCE%@-8VK%B)(@YM=6!IEW[8\:5I!GQ7'8TU!S.8N:2>F3QB:!
M0HF#5/LAZ6+6@+)#8VI44),3-1O%W)-9EFJ34[HK;(+PBE<%J$R1/ A@&:(8
M,4PMS::.C"9E@*7)),F>:#*K0X*UN#9V29YAMC020]D7>&),(0:8=DF[AJ,"
M_:+C%N@5=XL^OT:@<IQRE4V7>S!'2)3*?.FG0'8^>;^A%"R+C =Y-K4_4Q@J
M;) X3"/T^I])=)JC67^KKQ;"8_4\)U_5GY(>3%\3G!E7)D@J2_ !W]'5L5E&
MCSQ;1^%.%!TG4-9:-C54.5ZR@BTN'&CU3*7DNODR/^,J%IGS!:S[%>:W60W1
MN3+FRKJX!)LJ/U!#,3K-0Y9[9J=#>=5TH!2([606&E4)V'A18;FQ%!;\W#H9
M +H+71R%BLG,Q4F%%"3 ]ZUZ@$$1!$ZLT/"U/$@GNYA5A?JXP)FGRJ/V@"=?
M*=$)QKOPOC+-5.HBX*-X^<)P:=DP7US8S]%+"OO9N-<J+!U*!M;$K"5+/IYX
M5LA[1GE4%(AE.)M">3!5@ \,:(1'\(&)$+,&+M(%LQ7S!FB5NY"D?88GEB:E
M27T%E:/CF;L:I<^RC6=1AL#&,K/GDY,91!]J]:=.'KY:&MRZ(<Z?[*AEDRQP
M5NQ5J^7/#_;H#&9N1RTY)U,R1[/A^HBV4MYNZ[H42OM(-XQ,O<B\YV$ 5K/2
M%=#^GD)O%_!XQ<1(BN'IU&1!58\5*YGNAJ[_P>ZU0J;(.>XZZLC<"N<8TC?+
M-Z2SR^LH!'T"/!K]Z#@(9UV,[+7S+:V]]Z#:>7#=^'+1NNP\*(7)4WEB5EV]
M7#>GPK6ZO6'I>V35U[7RSB80,/H&#%)2"O=P5":T!U659-R\^(_ITWF9,,NB
MI[J3BH3M<\IB%!?' %F5I[\HCOP)ZX$(H7LA\YNEGD%HR@8TG<\%0#/K"8G>
M_DV0QW=S@O*;S_71@2D/5D7:&Y,&!/3QS/E%!^/L"])Z:K'0F3:"YY;/,Q+#
M$)3:V9SC]"'/8N*5JJJ5S+(CDW33#\5E("SHR=B-!)7!T%#'KGS 8\I5L72R
M>?-F@:H/7BV-;,!VJ**<OT)*^FB?4748-,C[F$<W'&$>7/PKRY:H05L.'\&"
MHCV -RC)P&$$6\);,1SYH;J7"0-\'81VZ:PK77 >ISXEUMVV(X%VC)>3@!8'
MR8:>CV6L0X"A9*!RSDL5K9LU#YW%>YOTU8*NB@]RLF@BBD*BKH&Q$0-U]60T
M=!1P+E2L-13'#)7.U ^ZJLI19 AR#XH+%*Z8R[(0Q929'Y@],IE8IS_FD7DE
ME8?*Z!V.X#?9:5F4=-90,1;*4?6DW5AZDD=26<?XC/=ZTI>4<9G""@Z/WI[J
MBM'!##_5?2X_A\J?U0:JWD&*':G4G=!5\XN[=!S9HQLSX,\$-PEND)@PA6-5
M6'L]L&R?;BR,U.:REPFC-L(%_8<O>XWF+5*LC/TB[Z!#_'AE-VR^..,Z^7O@
M.CT,>Z1S 1)3O XU1\D/%+@P#^$02OF@J\883NFKU.%:U%H1B_I)Q3[&U]1^
M;%=OT\*C'TY:<L;63^U*7=4.(;PZ8Q]:EZVS]FF[<?/EIT*OJX6>3\?N5OA
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MH#P7V"%7^SWF#S,["BX:>$R4X&;V>!4<RX?CT(>G6!&NL9LXAFT"7LB/PWN
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M:R&P/1)&"(&P1UDZ$06<"7$(^._Z8EK\AKID=]Q^'?+[[?8?'>!&((CGY'1
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M!TC]KX0]W2>\Z[U%\1#-NUN$W<+C:9U-2^QHN4CY0M%X6A,HWI'TS$PF45&
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MAU^H @[E_F.$+7??D2TRKQF0'&^W<U_5EINE91R*L;Q1;9J0=Z,1\& Y?QX
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M;IFR#2^\W9?RRW[_"76+EYUCN(<:OYA@B8,"&,R]JQA-#A"A 9N7$X0[ 2/
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M?(@PUHD91R,=9L2WZ8*N-)-<J0_5-"Q .4X1U81R3A,P0J&:*R0*:5]B3<-
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M95+5G-++Z*FH:LO<KF#V%FJ%/K7ZY8B]$E"#ZJL+G)/QIL!=NVH4D:__V&B
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MS>#GUG]V1(M7RK[JC4XL:( ,:( S#0S;V0*VL_1D@X;L;UD G./2:VHR++H
MS:TF:')"^R[K4\0_IP+D%_AW0C9JHR8O.30K6!42]#3@<#/<)WRQ$-=9E:!(
M<J5@5I7RO%,9L9J5:Q,>#H@WB08D.#5?^A"3*L>M:^%CN2Q3\RIG5B/@T 'P
M!V,97&8K]-"$+(4%NNC4JD;MGT;M.>H-;=X;L$_@O#8$GH'H4<T1-0??* QI
MM4-JN**-9.2:+.U*?<D:\#=4>2GARZLX,Q(J&SKF;+5(XG#1I:X[%@"D/%N/
MGQ;B%)]&VS&2KU/C<&*G='U89GR5%AK1X>>:VXEW]4IP'/SU'&"3"#V\?<:J
MEAGI.=#@-(Q!$CXC]0V-.TVMS?B_1T1[-3L"0I)&1FPD\P\2/?C_^K<U["[!
MW5Z$YI /^_YB<YHX-]P9/-K'@\ 8Z^.3$<96BS?/Q='KTU=OWK\^.KGX(BKW
MU>[NGHCCL?:E.N)+$S6!Q0=HFXWB"8D_)>N90!J*.(I!B@LH"B")21C*Q7^R
M&$9!VH"N*F/H_><[:^>U')^'!X& .1KI7? *KP7=>4ZDB191\MI:7%CQ244N
MLVQ[W)9I<J#1!KQ]3L)H>;T,&8P43X7&"J)ACBS++FH3W^(XH SAX4@GM+M4
M)9P86]LQM(GBG%#EA@-,BLQ?W-80S\E(2B-[CB?2>++)Z.\>:AVC$XA3T'K%
M\2?XMW\*4:!_SNL7*E4Y,IXJ4??)_P>B@Q)\ HI-M!Z J@+J2V2Y!WD7T2(#
M6;<1JZ<<D=W"?!%H]X>V"RYW=ZP9W<;(S5WB=FW?<5PBCDNLN5N[U6*%PVC:
MAVB!-?;B^@PY0Q,74!@U->J/3UOIHZ%N)'B0?A'*<:("'I=#KU*T;<+#I#[2
MUMB[TR1)WD(:"C8K@[R6%8G#X^%/0ASZYXT^3J^RI$I+M)1<U*:">Z<3+@!;
MUJC5VPZTB>TV8@R\6)&BL-6%C(V._E_'ERS:T25!%_NF\!>-]RF &@DN0"9P
M<:[AVZ%(RRB#M4H[O@V)%@"1RU*Z](I&L(2L7A'2A>6F <\44$[SK+J<:GM9
MCE-FC,/>JJW;!HTQ)(]D)7S1<. LC>M9NYXJHM5PUFC;X!6#6#0#/2@F.P>2
MK+481I<V.B; \8%OE1E-P>(;!B1U^Y#(3*?P),A<@R$(=,=%AXUCU> &2\8[
M*7A0.Y54FM&7C:5N/PIP5[ MXZO6E+EQ<O7%&*[4Z0@:#2CT*E<S4(2)JS$P
M!!S5 #)RRW&QC(<57\"W1JF1EV.'=CCP:RQ\[*-1A0?;69OK?2*[8H.:XP65
M;#VKPI)OFO2#,4:NF5D#,:Y*#.SB]:19N@&@@.8YTN3-FJ*J-%8!G@'EC$(D
M,5T*A4PXDH0XL/CSTLH/!0O3?>/N-42T.;P'!-^6SSOF@A^(J?<OYN$<*/[]
M>F.^3-(W&+A, &@Y-I@86"L9&>"3&K$[[0@<5%;$+ 3\\UTG9T<O4IQ6-OS5
M>@HL(^_T<*^!9G"#C[O%X?TAN[231C3Z5V?R!>?X 2?I)/LM4<GAF$A;QPJV
MJI8(4>2NR29TP*D?%MP*LF](4SR8'\*++I&5U[FR2+?\K.E(KV4[%MHLLJ 0
M90VUN#'O8 -ST92_$K3W>,.E?#K']^-$:)IF.AK>U&5&%!PK(["I_'.E@9,&
M4_ F" P6S^*R5(I,VA:7 U+H87%S4-Z+M@8.)Z7EQJ;A$%VA@);E0@?A%!36
M- 8^/75)0-/L7\QCO%Z PP+88^G^6<T1:II>8<[PP>L%8D6B06?T""Q!+\?W
MKS;$GGH7+#GB8<SD!T#4"#D:_E#4%PO@!NN*E)H1.\^S><Y$JQV^BA<-LA;,
MC8**:UWE;$*I\UQTZ&A7N L1U-9VK3?S0\S@3>E**,4WP[T\V;\1\?Y+$OH5
M;O,SVWSZ%[=SIDJ 5'((]TU(=#@Y!<.8A=XH+WY5F\P/9HCQ;=J?:8G1-HO[
MM<:X$DF_#3)W8X=Y[OK]KJ>9[]?4G!OC>P-CKZG1R9AH,!+X1E%%2]*R+/46
M2>Z0.8!*0<:7-0F@<JG$[JZ6S4J1*%E@<32Q@ =)L+,A9>-UYI7X!IZ)^8$C
MKCG,R<C9H*65G,6AU3?,XN<M8 ASA/%T@H)J<31X;"WDI3S:M5DU((>24)RU
MUH+IP#;]PQSC#2>%=05J#ZTO>?3-VO/+E_-SQGP=*EE.^\S2(S:DL+$5%WNS
M&0@-"S:1<'G\*]IH\"?9::5]%HB#0!P&X@4BS\M.6<'-7.Q,9;XY,TZSB\+A
MJ90^/'%W^DG2  D#G%$(JS+T!=Y7MPA">&1,LF^X!I,9=YN!NW%T32/WYQUE
MZ7+,@&SQ->];?L:?*4R9Z.G(0XU?4:M<=J,W%&Q_L$44['5<H"FM"ONGF;3X
MN9N(I_$\ ?:>DY4&<6%2)8)DM P8\,SNK&6((.'PAB"3#AG1Q3)*'N (,Q6J
M>$X+ DH4LV>K:2O_N<L!O.@-R!ME_# N),NZ/0?Y;^FQ@6^UO(\*%KMF:;P9
M"L,8-:U]LP;7\BQ1;"'@6##T L^GBX*4 D Z7+_$/ \L'>59BC\B(^(TP03U
M%(HJ,TI+$7]DC;40+'74)7YJ5EX;IK4:;8-*C7]@PL9DLZ>Q2M4D!D2FO9(>
M:$5V]SE0@(#SSK2?Y!.\49^>9=G)EKO\3M_0G/%=V8:_E>[T,Q#=E[TCNJUT
M[![$NS7+,LFBJ&:8<@Y8C]#(A3/JU"X6HCGDVX!<AW^J*_=<H\WG$GMC73F0
M5:%<UZ]UA+:\K6&2%4YQ@]:2>D7SVK:[KTSWVO=M/;9\J]ZE^IF'W;<9V[H
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M%D&&46/_?$?U/U+6!YPT-3^('3TTUL.AG1"%H2@P!E%<G4??-9KQ5>A0$T"
MNN2-F6,J/2\%TV4V3<(6G.34,;8*HFH[,.PU3%9,XWE=@VRMS"Y)PV$3GU]B
M6[P )C=W<^1,11HD?;K2<K<SZ>: GX$XIS"4^OD9H!;EP&( S%5;JM=%6\OX
MLLJJ@H^P'5A<GYC[+NV"F85R'6?PTM)"=CDPG2MR VK@80<@I^>AY,&5W%P;
MZDC40<)48%)36U>L65(MTF'\TL[8=,^UTIV=(.0[-G?V/V.X/Z1QN#G8(4WD
MXFQT<O[\Z&ST[/C5\<7[;Y],^2L,J<>ITJ>&VG@!>F[T@4W^I;*8W5$&EHY3
MX&W<J! #UX92=('\ -5+0UER_#"G0N<-31,6@R0; W8QC3A6K"-B[<<TI,@)
M?%7%Q)_</"QXPDO,"MRD3<S)1C%=FV82>5VPIZ8(B;*1GN#6'VGKMK5-[B>O
MA?"N/X1M:[!)A>0O1O\6?QU?O'SYYM7A\<F+G[H"PAF%H7!YPXD.!-)]ESQA
MQL37NJ9*46*,<)=#&N5#JF449E@51'X, +>IQ$B<%E6.0D%@"LWRS[:T*M=)
M0<76RI7PP$:N:^7%)84=ZSIW*-08N_O22G>$KPGL,TD\\S9:PI6:H5&@_E(W
M9#'U!EIE^HQPR<J\#&T'!A9IR6Z3E#$Z!P2(QTZH$!Y(:SBRIJ61M9AI9QD:
M9PH39V0BLK'ZMV)?AE;]X:HJVI6I/M@AA79=G(GE'E";"EVZJ7LSMX$ AOM1
MJ'B*9HPY+!W=&[H*3LZ.>P 3K!FL0YZ,M:C$UJ"F!@U.T7$X'39#7 O#6LO8
M8^;CXL'=-8>=^HP<DH"L!]/QV/'"?(NBE(*Z[&G>7?*\K@2B@S=-9L^2<L<R
MU$7 R"_*G&7NVD.6.Z\<_RGYL.JRT/6]=)FN=#WV-.+(R2C3&A&F/3!3SG7%
M9;S NKXPE:K4B8ML0&5-0B^4P[ATT8-EUT&&+8QE)':L4QYUX*"/&NV;QZ'#
M::S0Y$:%EQ&WJT02,="NKX%XSI [RW)%((THJ<N8$>%QPTWA-0"G&=N#)>7Z
MB/]40$>B6(>,+$7H6W$ OD"WH,T':7EQUDW))+<4J*GLS)MEFM=]&C<NO">Z
MU'V+I;X2+#\:$H\7[];0IK)=+2<;WCV+HL"(R$M+Z2]YCB:]&9<QILJM0'*S
M?&$FO)5!^H6]'3ZSK*QWEIM&#9JOFBC13O8Q$,?:\<@/:B"NRFF6PR&NQ@OX
MBSAWDL$P6)5R?A@#8O(9AQAZ2K%5]:YPI#:\CA<$I61)!D0<.R:7TDTGY,0^
M9"'N<=3%:Z]A&44M!Y!Y/'3KGAD[-N[:9WV!?Q'.YG7?LN[J3?]\US".,0'%
M$-ZX:YG4$TA%EC"NR@'0K7\;[==:BS'22%&GM/,T[F^ 2)$DT*3?-.2V!((U
M$Y S5@#MDT8"'@HC&G;H?-?=W3>VS[I;UR:Y(++;,.2VK=Y2R7IB'>FRKOW\
M")/DXI#-3NX6F9O1[7_4A:=''-KDVTY9Q;L9D-<<I9#J43]7$14L.C9B+-OZ
MC2(X"HGVN$#;'I2-HYI% ;DA>H N'8H$]\UZ](TUJ"Z#JGR%_BP%:[6K7* +
M%'SQNO^,+MY*0FY1AW"YH\X4P \Y_> Z86/8'"W4=^**V=SBP,E?!"4;OYE2
M>4&.K$%Q/4(/DC+\$6= <R[)6Z%. ^2S >*@TV4=*::;G6I>S%>O$TOD4HJE
MR[RNV7.XBP+8/>:X%PX*X4FN+L:,%]863Y;C&AQ -(QGU4Q@7<J*J)@+4Z:.
MNL6I)7PTYU2;N@#[3'ZD89WGZ1D;-.7*46O%NF:G3FU/S.'8<.9@!LL=UMAG
MB[&6$^R!HD7S^@W4Q[2B9KJLK!%3!TE;>W]-46*:TTKM[$*L$7*=>'0\T5YX
MG$U%]4H*I3[4R[ YQMS-!1%-TW1$L_8."36[M]B05U$R<IIGMN\W@B?#,K'2
M40/?S3(6HJ9OMP@GMM[2K3@=%SX^KT3I.,\;UV9</[Z/7IL'8*UU<61-:$F.
MJ9*DL[^$1TT;Q8?J7#SJ2]-,4<=V#\Z8)%/PN+!#5O$E#IHEZ (RX?)Z^?@&
MW)+1L#MNJ%+-^&!?@[O9DO)SJQKO/1VA <!-R5_6G2+@6-LWT5(NFP-\@L+8
M%?&]W!I&,X<R-39W%VOP(4Z\F^?J*LZJ(EET1#G:4D)-7H TJ" C&J$)F]@2
MC )Q(;F)(0:(;Y:EM1@XD3%%NU >Y\(QMC>:(W6UTFCK3_VP_?;&6M\C8_VN
M"4(?78S$Z=GQN]'!';@@>TQ^7%P#'$3V7K(F.82)Q0L@3-D<2?]+Y%YGF001
MX5D5,PO\U\:6^)=*X^0: Q #6M,_4;(&!1@5F]% ;#[>W-XFFR W #:VK+J1
MI1O;\&E:M!;,YQC25J4FF-Z2*.42*!M&I]_]>T'<SK% V*0S;B&0Q!_4C>/A
MHR3F$)\5IE CMMG$]Y'2J6O?,H'A^1EU=D:'Q!C]#)Y10-=MB2C?'NE600KN
MG/+20UVI+5)A@KJ9[B:>%EZ=^Z_E#OSE-?^N8N#NJ@ASU^Q=$>=\, "J&8<Y
M/F$7"KP)M!?!^P!P0C-2!.JW!=SO_<:DNY0PY-6!+*W14.->52CM39L#WI/"
M@LCJN7]2.5-H;)IAH:,(9 P8!?UPB?G([A>5J/D4K0,LE@<V<W,<$RUM>C:M
M^&[45?3*E!3?QDU4]# @WQ#I# '__JM2C',+J#PDJ88!D]BE$A,K6QF%QVG-
M(&[&!A(-*F%#[-S%YBK4&BU ^2^$?46!UD=(PVR$Z]/I3>05%L!O!_1I_;>H
MFX:91GXMY<V*N%A!GV[ED]A!M^%.7WS'';=B^9 SXMG#MGR[&4:G8S405,,)
M(F2$EHBBU 8*<KRF\M(H5*0#N>!G&0&YET$U*^(ZA]GA"U8J]];)[&O<8!"K
MR2;[FS])S/!=U:5>A5[N#V^FEPQ6I&6--"3IV/%S74WDE&W<>=$?"FJ"K(H:
M [&H$0(H9@AD^:5$A)%IHHBF" 0*ZK6$*]?[TK;['%' *?'BMWE@(H+A7459
M-#!::V@6'75Q7.D?H\5(S[K-:*D-6Y,*7=:!-SQ;R8A<R+J11WOQ5/=E:D4V
M1E*..M >*'-FE#@*K[,M$2.8X9XD:NV@=>;=-*(U'<>8P5%2-H>CT,/L')IA
MVT@7']@$("^QQ S9^"DOP?CEB=0O%4;M\3:7$-0%B-#NG;)QSQ;"<#-?NZGS
MK^JZWPEI.L; 2W9J /LAP<ZD&?2(%A%'+MNHPNW/E],6JQ%2UI)N-*.I0X,(
M.8H?(+6RVB B-^!?SJD**I7DG]0X%5_)<,%QH&RBQ80B2T>LR;VQIE4%!3>
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MA(DFX\Q*Z:P0?G,-@*I-:+4$Y=T\IB)S24L@]X,+FJ+.S4K$#PF)V[V!Q-2
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M\R<DO%$+KA;AL"%JW#3",<M9'0%S#BGU&4=H>,E)(=''PH^RQ9HIC7VL3O!
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MJ.M_]"X^B'LF7OYTT0*WW))X.CQ4+_KZ]=J;YVNO1%<:6<HD1(9' KDJ<S4
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M>$'Z(@MYD+[(#(L]468V0RDK!AIM6F^P#L(#B[H:21='6-L?/VX!#7*=+O4
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MP4,2H$"/ H)E+JH@3* EX?OE;  .S"3]!&V^@".U.XQA.0@"8U@B".XJXP$
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M-49G9@- \-)JH0:%"\7J)!&K"OH8$P_9F5V=W*[$E>6<G(%B<HT SG)A#$6
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M4[RF(0;H8^O['#9G79%,48@"@C0F-P"O>?T[):\VQ3H H[6>6O&2,;H"%1M
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MC%3W_X6O<#H2I?]XMF"(A#F;JF07C(NY9$,%D2#Z0&%(2PB;)\]U9-.Y2S)
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M:@0($"J*>&.;<U)\CCBD9OR;+-NU="?(0)1(28$P0BN]WY11M@TNNB0Q#*F
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M3N:R5)E?'W9QXHNC+A[W,_]VHKY) 3()?:L0DD/PGJPUCC2L$8#-!\&#V?1
M;\/17:'C_=-7'Y:^^*]R"DM3<O=$^O?87-%_.IFOUR+%W'-1CJ%0S2[J=Q$U
M\LAQ\ZM>-E(S5U7P4EA"Y;YRZ3R(-)3:1[06"^)-K?Z&BF<5&NN^ O.!PKJ!
M("*H6J90Q23#@-@TO$0F 1-*LO6\V'VC$?%9F?CP)V2RM1'+P0O!H9#/R8A
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M- @2*-4DUG(.[&O ,21 KP&Y-P0L#-E;-$PQ!  ?2]^?((E:RL96/X 91IL
MEBVUO/Z@J(7*P!Q;<0T: 0IAJC79+(84:%OD;JGE9B*W9,K6(:=6*A0;*;%U
M+3"W&%AP ",Y!XW<&T<M5VAS(45QIE;""H:QE  N^B;%U0I;Y&[!\N$>D6Q:
MJK8DXQ/49#"I6X[,AM7> 9L!Q"%;AK?60#97+@FP<'5 /N:6'!-9$ZV!QG0S
M '3CB-;J -2@:"!KB4RQX J6X!JR$PUL6TOIA@#HQO&=U0'()':V^#Z.E8#
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M_N;VU0^.X_MW35WUR=^^\7'O=G^C_N7-<_M_KNZ_OKK^_-K_7Y>C%"P8* =
M$;= +:KDK#A:8ND1XP!' 4>QV0EO$4UKC2P*W&"FWTD<LGNNF#M6J.6<>#8?
M_>+VQEX.G_'ZBUO_1EXG"'%S^_K]]Y_)RYG6_.S(X[T0KJ72*]M(F0T5A,%;
MD3ZP#,KS*YT3X79BO-,QKT;V6JALEY8QH7"OM8Q.*;")E@?F9=ZS\;Z\G\%]
M^Y@/7]Y=7?O=W9>O/\5;N?$77\OM"QG^\OYJR//OOL3[-%#FT[G&+,.@,&(F
MS"R$W7E :P%A_'I.S>$-],'UU8LWTN58Y@%H)<JDD.EDC"-/;XB\30 0FAK[
M^.;Y7E,_?_[Y_==^^^;1@]C'!G)6IJ 9D"AT$@B\<#)*BHW3:^7SIOZQZRBU
M'T?W$V'VSH6 TPFSU%ON#QL-4L=$0UN>(DUA!(-Z.C.S/HI[W(%1*XB1Y-)R
MPJQ9LC.ACZFWQ;9Q5F=CU,=SJD]O55-H/B"JR:2J%!W3#<_W52!IK@>8<K(?
MQ_M>) "TM U]E2FV!Z(,R33JR)5'[M2HGH6!'CG#/.6@2H&>>Q%.7'#Z0;8*
MR:< E=R1R@&6[NW&&;X7^XA;2J-%9X:M05%&ZJ%YF"?S\".U0NS'T3W]45,B
M&@/J5-R9,>,@+YF:54??U%TY+[,^?H;Y)$9%4RVM^Q3LC"U,O)HW*H)5+9F<
MCU&?*,-\&JMVR]I*L9EBHDB(9=;)UY2WFC0<X/1@/X[W_70+>FXS&K:MBQAS
M XEN,,U%.=AG-G,6!GKL#/-TYADT<_V8EL&4,:;RYH@D60<+N0TYO'F>),,\
MY8DVF+2(UFN@EZ:%Z[2&&N:@EHZP;NOJ^NK>/[OZUNW3Z_DR/+O2Y_[!W9W?
MWWWXZG5'TW.Y^XFU/MZNN]Q\X_:5CZ^O;Y[?/'OUIZMG7Q_&;%6GFYNVBEP%
M72M3Q=(9M0[-9$=8$W0<LYUP+PYFTCY3BHS35C@SB=:3<?<8D"8-]\^V3Z^G
M\/PUIOOT^HO;FS'=YY_\SK=+:1_,I.RU.0\4SABHFVV=@FU@$N?<6X%DT;87
M6W3_O#ND 4\XC[5UAK9IM)@><Z;PGOM(VB<!,\$XP&J67^4XO[H5\S_*B^,T
M_H!2[U-%1VW86U9'3#ZUEP,KC ,4CO=LIQ,6^)6(V8Q'JZBA,G#+(<NP;@7:
M$98._QH[?78UYN<YRHVZX? PO)*&$)HC$74O,VHY6*WE"(/4]VJD$UZB+2"&
M*49J@,TW6F'/ HF"(&K=+Y.VJR/?=2A^/O7O[;?S=?^A=O$GU^<W_]^KYZ>Z
M)G,@X7 Z!D,=45,63Z6CD"E.*2'0O(YM'/>.+PO\:W#\;[]5^9LL;/R6*7%0
MZOQ\;:)!,%FC@814AHP\_3[M>$/0O\;&?\BMR=W5\S=_\T+);ZD8]6QE&F^4
M,N,**@G#,$A>N$>&ME^4/(G9?B-V/[R]LO=RZ_?]1!<T(@R>7J-BLZ%B1E":
M^L1&$=@O-OZU%3Z>GW5<V?(;OV6'(O0IN:NGG"IFZ[*-6ZK4D'J:JMR.BHTO
MIQG_=G][L\#Q6Z9[4@;N#%D+86/0XMJR!GH,@GS8U./+JQ??W%Q?+6S\%CV+
MUB0-K @#<X30U+8]<>LE*^UY\<"_QL;;9_$',47.1*4TY*D1)C4S>4O#W%O7
M-+3OF*:/4TQ]YV_C30O !^,O+Z_NKK;;F6\#X]Z?/[_ZRT% T9UJ@SJ1@ 4;
MXDSZ:G,":&T Y!UW9OR,[[[9&C9NAW_S<V=2[VSV0YZ9G3#*]^P"H26AXHA$
M3MM:3D\PU61".BI2_N@O[D5O7]Y/T^K"RFG*##Y]2FJ:(@@S@,S KX1I%/'N
M];!1_S\\Y)NKO\G/&F(!Y5UGAF95SR9.";%T81I)0]JHSI3@ !?R3E':_A7F
M>/IK=S-GZ"7Y&)85,6CFE5ZD*!4=)M$WVV7^SG;[O*%^DN+ ;S1>YG<VWD]O
MK?\&XQ6+C#1],F7#4HDGV[3.-V<>R%8.<&*_C2U_F(SRH(RO_O+R)S/R_O[Q
M-U-PW3Z2NZ]___SFK^^W_/M>,HO'VZ'PSM_21<PCMN \Y7-!R-L";^01981-
M)S@$1AV']W:??O["[U_? ?GL_N>JY8?T>8)1<^W#YO^H-;276KBZ3W/E9@?H
M<O_RZYO;^Z_\]L7'KO<_GC3^,+/\RY?Z?WW<?W7S)_]&7FV?_(/[UPNL/X__
MO'EN?I@1>S@25 ^V6K$C*IA+P+9Z!_I,-/;?J_1/3/7#F-<7+_QV7,GS+^2;
M]VR6$T[1$^?@)(22L/9$1MQ-K,%,V>.[&L 1S;(7!IWPTCA5]6$\%?@,5GD0
M@J%'PMPB3X5U6&?W% PZ81&^;UI7H =TE!RL?3M.I9X+<90#-&!LUOAA@=A;
MA6_X7:\/'/KXI<\?HA[$(J&I!346WPJ:4Q.52*1U +1*T\OMWZ?MPR(G=%U1
MBI%.-T49,W6.' -&4$\\VA%N9_QSB^2W#%)^;BGN7BCB[H59JRH[1B\TPSVK
M3_'S,)KP )WCNS#("=<*MB8V8WK/LMWXG"$E-$KGA_JZ[+GCXN<-\K;+JD=A
M2"K1>B^IC8I8>7HNM9&KM=IH3%,=F2&/:)!3WO!+TQI]E-X;^G9A,YMVZT6U
M"1Z:(>5W/?U@$3Q*GD7;\/7HW>KT658:44JU$N$H!HD.,*5O'Q8YH9J'&IQK
M=M,RI:%SJTR%!E/-6OT 0U/^N=.BMPP"/[?V>B\4*9&9'+0- H0"+&!M#.^(
MV*<@.3!%'M,@)\RS7'N27O)T5CA?,$D*DQ@\'=C8_CLP0\KO\&V+_-RUFKU0
M9-LH.@;[X))QL$Y3C&T4>MCD#N<C4^11+7+*&ZMID);>(A%N2WNSYS13+I.>
MLZ8C9UKY[; ._2 4D6PX<&:[%02[9P;6K,:: +)'.3!%'M,@)UPK[\".94SQ
MD="P4RW;_#/J4[FG @=85/[/PSJ_99!V%+4>PVNB$-V*\-9#D(2-/8!;SN/(
M#'E,@YQ0B7"9>2]XWS8$%>I<4QUY9EP .H8=68G@[]+;VO H>5;CP4D:E1Z(
MV5&A%2/4J-BAI0.,N-J'14X81:H 0Q%J[MNIR/18VP3:R"6!BAV@8^^?6^3M
M(CP>1:V;-1L5DYLZ"B%OPUK2T&TF>RYVY(/#QS3(Z1B2.TU'-5*=^@.]-\4I
M%56Q&><>?&@E@F\?4Z6#,*1 E4Z0$C5$3DS!4;T/!!@FZ0"+4G=AD%-J]4*5
MK)I9G08I*JT/=E'),)/A S0%_?/$]VV#U*,PA*MJ[IF2,://H*YENS$E?1"V
MGM*!&?*8!CD=0P84;Q"44NZ8M&NAE',=J +;)=D#,R3_CGK]Y.7MS5LEE'80
MGHQN7<6Y.<UX'DYE.,R<2T<9,^5J!^;)XYOEA*?LR("E]V154(K(S'T%@E53
M-]OSG>"?-\O;A12@@_ D4XLV:C*QCC[%H@NWC2^8NB8[\O'(8QKDA+V,:>/$
MY$)8P]$38>$I2ZI+A5;2CD<V_JQ!TH^:2X\22?HH\V6O)8D@3DQ-W3Y3,/7N
M>9J*CJQ)'M,@)ZQKM48XVC1 9\QA-%T85W:UX/G(D;M]R^_>]EGE*+5?:TE*
M3>&6!+F:Y$:<O&2."2OU U/D42UR0MV><RMM!"93#*K*N:76H5&J/.C(403*
MVZ7&P^AVA^F:4I%1&EIQLDZA(87ST'1HBCRF04['$.U8:F\T6G+$F@6R3<W>
M\C:@8O+DR SYD<\"/ A%W'N:83UDN*(:28FRB46+-$CJD4\0']4B)XPBLI48
M"T;?[NK:3'ZWS5-MF(PT(!WX[N&75W_[XN;J^O[W5]_Z__;;FR^VR6_7]_+,
MWYCI\^NO_GKSU=<W+^_DVCZXMJ^^OKJ]?_75U[=^E $471(ZC+ B#7.OY B:
M&W."*3"/L OG>-8[X=ED266K'V,V0@@3;B)9J,\7NM=ZY$[B]+N:_.7MS?P:
M-R^NKN7>[7JSFQTJ7&&FK#FF22H@=1,D,BI]T'P=IQ@]+KV>U$ G/)G)T+IC
MEEP,A8 +M\(/4P85^Z%OJ^3?31_P3RU4CE):BTR<9]*W+9!%E] 6?5)&>$@3
MQR-G?$]JH=-QB%"\YU:H\%1))9.!3WOPS #1<SYP!CAS\I\<HI6C1!X; U,3
MUH# LA''*@6 #"JYP:%[ ![9*"<\V9Q)MEE,IL 43.;$"."Z-<_,//S('<D/
M6?-#OCWS[G=+MW]_LV7;?WT/@S#?3QRJDTEY6TBI@4V&5E"G;$QLF?0 4ZJ.
M9KL3UO%2:M6'V-"!8UK/+7QF>2!>@6+'^P]_B<K=?K^KROW2O_6CK)!J'2-%
MBU*'8\(AV8$4Q9R+2!SXCO]^K7="A44X_:0X>V.LZ-I@6,%BXCH:';CW[<%B
M#VYS,\<OLM_5WP["/9/$*6%KF.>?.<04%.I,[46!X,#<VZ_U3ME)5VRPUR@C
MXX IH!M,\=R\\%"P Y]??6^]/UY=_\1US@^9;[R\_<<6_.M\[-4GV[*K@S#0
M2\9H1;GTNHW9W.[Y6K5MM&-IPP]<H=^[#4^XR=X->) 5SH#L7;-HJS75',9-
MRAGP\,$<O\2+;D8_" 4CM\'4M[MX\P]IRH;F(*5FZO.A,Z#@_LQWPGD[A7*C
M(K5WQ:)%,"!Y]6E!!($#L^][_7#S\G9GSO.$1]1]DJW;*(&"A7V;J%!I"G<Q
MWFZ-'Y=].S;?"=D')6TW:["03P,JB6%*[K6Q2O4CGPZT\B-;':A?W>H8;,*9
MHF)LM;"69;,3IY%[.W*GX6,;Y71,L2AAO;-H*E@G56HCB&W"OLT,Y BK5/_%
MD<W;_9\ !Z$)EX(&H"6-^88VJE)IU)%G#!IXY.ZHQ[7(*6=4YXT9I9(B3ELH
M1]F: 3CW0ET./?7JQY/ZCL(1*A%H-=(6V"4J46M DE55H.JAQ[@_ID5.QQ&/
MVJHK)]>&@RO/=!FPUAHS>38\<,;U^?W7?OO9S?6S-PM<CL*1/FHWFKXK9<Q(
MLAU',B7";%N%]K@<>5R+G##7DEZ\8.>1 QW;C!W):(P>,=\G?'"._+?<7HD^
M]VT5XH%X4J69.U0?-;!'4K::IO<:,Z0H'+G6_?A6.>%=6K4D+*5[FF$D@C4X
MF@S>3)1YQWNWWUCEB]N;^?/>O_KB^7P)/KBV3_[R\NIAH?6'K_Y^!=B'+Z_F
M9_W91:9[X<R@O)$F60O$*,[09YAA$4B--!_ D_TBZ_RW?WTUGOO=0:R3J#0K
MFK=!?@@=U&H/H!:C%6;8L:;_UWM=?W]S)R]DQUT,+Z^O7IM@R)U__]J^>+TR
M^.%'V!YX\\%OWO_FW]M'_T-[HH&3CI9D9G($3(8<?;K%R<+H+3TL[,547B_L
MG6_LT["?7=U?/7O88_W1?!7>,JN;W\KSGS'K7K%S]_8R8/RW5-YQ&?##4T^R
M##BP,7!&MS232]5)^MXI&TWOK!YP5+K_3[E^^>V5[)?N/R9I@Y0\M;'=;NRU
M"5*O[&Z8!CONN$CTK[CYD$)^>3^1^='-R]N?2QXORN TC8LM):FI8FG(#I:E
MPW;*-.J>=W"?P@KOG&A]=G-W]]%\W69RZ]?CRN\^?/5'V0Y*/H\?WOWJAR^_
MX6]^P(MOY/K5!\]N)X&^NOGJYOGS#80O[^='?7;UXNK^ :H[SL=^R 2>R]6+
M?YP*;(_\XER@#P=N7E./@CR:VG3YB: @I:B<MUP )E(><H%]PN]7(^/[-<ER
M;:]K0-][K?<;UR<64GZWN/Y3V/RRN/X];+Z9X-A>X/B'T/GBS:._&#Y<7:!V
MXX';:I50M3;3!>8LDJ?BWJ_3.@9JWH_:%JPC_&&#%WHF'C'YKMMB \UNY8PY
M_\7DSO7]\W/C^8\;-<<V "M%*0T0F&D*/.@8GC38\@$N*_RW/'_Y8)X/GC^_
M^:M<#[_[X-K^Y'<SM_"['^HIFT4_\V?R_&./^3EF3GEWO^,@_N-TCZ %^ RU
MDE$AL:)FD@J<H@L?8"_N?JUTPJ-ZY5%:ADBU8<JA,Q]_&+10/+8Y)0=RE0^J
M:_N8K31Y_VI+B6^NYS_O?ER;W.+;S?67]S?CS^?H'%5'&U@@5S!LO"UKYRJ9
MT^1=B]H>#)K>&'37_-N=0=.[&S2=S*#FK55I8M0[.K5IS5ZI.VJ".O0AF9GF
M?6W0S,N@OZ#\R.]LT/G44QDT)3?KS5*MTX@-)0P::,2V8K;5 [1U?O!7N;6_
M/_69D?'^]FK<NSW8[K^FIKK[TY?_=9!(R&VZ2-N:0!)BJ]O>1K:9MS0KK7@Y
MKEF^\-NXN7VQY2]??BVW[_E4[H3WL3JK=55-F-&],0V$+C-UU-Z"XT"IR5,3
MYNG3$B!KVU2 +9!A2TR941@RAF+OT(]OS$>@V=.;48NX><:>;>LCG?;$827&
MM&D1C@.4PYZ:BN]%:TMKWM)(M?ATEMV9 Z;C!'='&T>H4NXB=IWP,FK'1)XS
MU00X/S%!I]%]&\&&/DET('?W)[^_NGW(VK?6GR]GQGYW<_O9S7A=&7FPUKAY
M>7U_^^K?_^O+WW[\]>,O]X\0\? !VX-W'WM<7;M]Z-?SC??0J+<#?XL Y%":
M5L#*H(THN^8FA4;^#D?'4/,+1T]91)AP 1B4Q^!MIS-I="J4$_>HR>Q 182%
MHR>L7:!84/.4!1"G,E-AE5ZJ>L,DP.<5U]X\]?<WMW[U[,'&I^KRV"NLGB;,
M;<M4BG$I6R^>:Z*47 *DYJUA@^F\PMPEPNI)HM[,ECAS=6+-.#^S0IKZB+%P
M"A1OYQ7U+A!63Q,$9]!K/=1Z;=OEM"QJ=7JKB2."6OHX;!#\>\,^]/]\<7-W
M?_O]$[\S[(5$)E NVBG+R(9E.I+$EDW ZS:EKQ]7@.W;UD\2+A+GY 7 72KF
MGLAKVNYJ5<^6VL##AHM=V_II?+AC8Y^JI>LP="[<2R9/TJ.T*6QB_Z=]%ZR#
MW\^:ID[>$Q(T(2P6D@OAS!;#F"<Z'@8R'(GT%XJ(G_J(WW( O34"2!HHJIBI
M$EE)H@E03%(_#Q]Q(:KAO;B,;3>!E2$MZX3*:+K-(-UFCG:-T3J?A<NX.("<
MT(,D*$88X*,X:MYNEWIJ,\C@3#&%X6@>9'>)Y/M91!+6\Y"9&&[W@\O@$M12
MG__(6N8C1Z/UCJUV0JX5@I$3Z2#LF.LV?DZ:89AUQLP'Z(%8^=NI5])H,VUU
MM)FR44TR[16Y!,S$CC0.<$]HA>?W"I"'E<J6>!HNL.0)EVB G*C(MO_U )LW
M#N/H3V@U]9Q:GVQN/I68LVP+ISIUK6.FWK#C\1W?<U6N;K?+9?[AJ^_?_,_Y
M&>5V?/WJ,__6G_^$VV^>].GU-R_O[QZ>41;+W[7W)8EK]N(Q$X'64;A%!"@;
MM$%^@+F."R^/.G4R]]&"MXDTCIQ5";7;!)#4'KD>8)7!V9M(>L_4:K:N ]-V
M4S4W3=9JZ[:M;]U_"-BIB4ZX$0NZE3*:6\&'N2M1R_ J(\*MV@'VN9R+''O4
M,)-/]<W\^$?<?NH/'V9/?G!WY_<?R;T_N[F]\I_<'/W[#_I([K[^X-JVO[9+
MI]_*\_D"'^46@:)N8H1[CHH5LEC&P=&V4;LYC\/ID_?.H5,@^.<&R!^(T(M#
M6ZK09@0B+MM4=^Z#2J&!G;8105V3+@Y=I-A8'/HE=3)(9;OAR903IEZH $UU
ME((:58L=C^H\&H?^\'HNG7UP_T>_?X#8P[N_\-N'ZX^+5N=$*X?( \N@C(I9
MD<@I%S1O"2+%DD@+MGN$;>F>&[34<T9,#.JBTE0TS*"'':T^=@&P7<I^9P7,
M;>K)9$X&R@T=16U;(=DK1-,RX#Q:"W>142UE?ZX<RC-':EK3E/<987(H=R':
M+NJ(^N #[#0\((>6LC\K#M5$K%@I$FV-+Y4'U=P)<6B,T@^PR^TH'%K*_H)H
M14.Z(KBGXL@M"37,C!:-IW9"6;1:L-TC;$.GF)?";63,FJ:J;Z5FAT""OLX;
M?QMHMC'Q'V\1XN8;MS_([9_]_NYA$/)\QJ?7W_K=_?9]__[EM?T<7@Y$J\>H
M/.RE,!;BL"V1[*" /1551B)C:ZGIT'5,LFM1?[%<W@M]% !BH&JSAF6X,FM*
M4]=7&5;2 7;D'I ^)]/SBSY/?2S#=0:<6EN=F@.2T]0<G'/!VI.VNI*WHTGY
MQ:BGWE K>=26&)L)YIQY1'&;U#*6(K#RN878G2%V!!637J+FZ?P+"+1J0[AB
M2K4#KKK30NS9"?@3K@ "+#U5;[K-#V@B1:U) )1&I?DZ45P"?H]<W@M]6C&K
M8[N:G096#G',6TM+X30E?5J'B4O +_K\B_)QZQVWX;*]&9J 5IFY(4-NTO+4
M\XL^2\ O1OVB@.3*'4D%*"-CI@P$(V*JHBGL5SZW$+LWQ(H@6#,K,1';TS;>
M 'DX<X.!Q<8J.?U6Q'[RPF^?75T_.SA@STB_GZ[\-3V]NQ+6"H2I%A+*#6KJ
M,ZLJ0K'8<U;Z_4RHO!?VY"RIL\6H(-L0'>XS&-5)J(RI.*V;\N<EWQ=[3CML
M5"7Y5!A2,%!$I7,%[D"-F*/98L^YJ_=%J-.&(]@6B].8 <@1>FA3JRT5+&W
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MX7?6*%Y%@IW5W4IG3U7;1BLT0[*9=EEJJ7E.E YPEVD5"7;$[T6I_W$EHR8
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M?M'HJ6C42V^#NH9X8&U(C%ZG&$F=-(#/F487(>T7LYZ,6:E#JU$Z >#8YEJ
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M^E^*^A2I1TV)/6;N$J93Z-74IZLO=:;M!T#]0M7^4!4S\VU!NI4/L+3",TN
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MEUP-%#J,@(99@AE:<JDMB%>8OATT_L6)]#O7G\>3I]N/NUQA;RU-R.49D 5
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ML#5&9>R2)(]8^-BS1G$ ?##W[J60;).&/ 1SZ39=RJC,8N5OPEFJQ\/'B:-
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M3<I*&I0,SW F>L&D^ Y0OACL_WQDS8O)L0<GX2D9DB5;-(+,U8 $=9*A2D>
MT6/@&<:!7C!#%F*_CEAKX-J]6:A"#*"9"@[&I-MH(RO]!/>R%V(O6.CLTZR
ME0.I=%<&:";,814*>Z6601<IEM Y3-C8AR'4!A8K,FH"<M',6LQFILP)_&4J
ML!ARF6'CE(C-F22UEJ!G@F%#!I?$*77P+O["IQ]\',I"[.4*G7VFQ^1P&."L
M/ @T9QG.B:%N)>HQT]=%BB5TCA(V]F&(](@FQB-R =H6L2'D/%."9$%1\V+(
M!8>-4R*VDDD?ZID9H?B8*&W6-%$?6[$^GZ0&N8NW_7::O/GPX=6V@>WFQ;3W
MWWYQ_9G<?/F367/G=<].W5ZY"--,"-ACVV-$5"+IJ".;BS=?'#D01Y8,VI\P
M@[6K2<'"%9H"J0\0S<)F*96SW(>X&X19 /XZ@!LIL5@#<P)O@WM.4\A#]!(*
MZ0SSAQ: [XXJVJ5$*C8Z4)&!4Q6A925,4;J(*)-S71PY$$>6*MJ?,.@VA1&I
M;6E$AIE/1*!5:8*C4&Z+, <BS +PUP%L!7!*H.0]!HRN4PFY8NX5L(C+&3:
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ME*>168H. %'59-6M@1:IE=I93JR6 #D!!T])D&T9:M+!8&ZPS=WEAJ.G4F"
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MF4HVF*^R4HTV[6ME,/4*__W.D?WM:[^+>'4]S3(?^W5/^=5'?H0-K/?M:%<
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M6WW^WU\_MS>WB]3W?G]]]?^S]R5,;2/;PG]%Q7OW%=1G.9:\)_>FBD 6YL;
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MKC$T.D[/L/NV#JAIZZU&S]69 QJ##<JO8=H,?G9$5*+9V7^Q*L,#<=5*97A
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M*OV=MTH4$)='QRB(B+C(][6+");)A->T)I/*A'%<2.JO;-^M84/]E\.&JI[
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M+K/).I?(A9,U4"B ,0/<"QLLX8E><E#EO  [QZU RC7$P"LXPQ(F9IF6N=#
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M-$(< TVU!)E\V0CH<1K;/L+GDL7(:RT?=!4>R<?6'Z=%S'8S!0](WH]#C4V
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M]#C%QA,^%C'/)((M3GS@_)MWB-X8X+1F@O+&W@0@.!9BT?-%=D$@3M0K4%A
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MI;=F6SN&Y0Y]K'0.]C;0$$$8C7FR,3!Z!8L!BAT#(7XZ\/<6\R4,UV@FD*]
MUE7);%U<>&&C_(TBK%O;#)3VD'49 *O0#C&25@,>?LG]$+.F\C83JK^$M L9
M\%0'A  +AM36Y!*#1!Z)EW*;@;B0<2>E KX5'@SJ!KV8"C+0:43?QU1-A\8I
MR+HK#.U@V4V@ ?A04%UR+4ZQDI>"ST,D#6J3$03 KH%M>PA@SY4QPAK&A6PN
M*W[%!H#O@W:$@B=ODW *?]O>I-@4@=H$>/%L$X;MZP:0=>S&5$#:VV:B[5TC
M.ZD+KUXOJ_L +W(YZ!&AOU=T;@NJ*.K?+$E\H5_$5VCG;)C@> <6@.^M-6JS
M87G.7[UXS=DY*@G*)]8IG7BDDY*R*W.4,^3:.)0"!@^"?\U.T0]^&GCHBQKS
MH9_B>O8T"Y ]*!"CB ,6/:2;!LOW<1*EL+0U ],&G0#K.\'>\D%J@\$U7J+3
MN=B0BT1NUO)G<S%U@,GE:\[V!9TH K .05+O%:!7T)(0SALI.\YXO'Y)[.:2
M6).](6;I?K.@5ENKQ[X<"+:BD#EZ/ 'A FRFJ,AD+4= N0\]1SIO2[RR*MG.
MH-HL@Z(JV=[\BN&J9+LJV;XSG6<^=JE)1CS&H%<QMKYI0OI[BIF%X7J%](7G
M.QY "AB[3#S=(@!Z_GC=)6&_/'_"4!)CY,:)0GL$;_8<OHFNZ#-^R=:N%:).
M;<';T,83:: $*5"R(^9XZ+1)0LT;4WL?Y?E#A8B[HO.?[0D+V^+<W5#CY9RY
M7/^8LFC-%;Z@?%L\<$2.L^9P_2J,QEP$H3<3<H/_=\KL]9>Q[PZF=CCQ63QF
MVJ=I*"H* X]Q[9U(?P%6*=P4V5?*-;1I$#T-(WO=;D1M]S.[B@E*%!Q6C52\
M6+.8!.?F<<L#+[+3,6;^KQ=V=(* :KB><*9>$[M6"'(Q:]J_/=_G#J)HJFI^
MOG+L\[BWNM]R([T9QZ&U;A3>,$_X41"LO4Y[EXJ%!RSB^42%0UE,)O%NLX!6
MV[#0P21,_63S'-NGF.,9KA>W-E :A'!\<(9K!0LV-<!"X!@DIPK@;QKZO+\&
M=7.M(A/SX^(IEJ%Z]DS*O20Y3"C3QJ+WN,MCT<-[XR!Y#I>M.;KT?LS&J":@
MN17\"JEF;P+\ ;W -N::4 2$,PV72OH#PX3&38/D_M\I6S?M[NZC2D9-L$AP
M'@ FIA'?M%YBQV&T;L4B3TV2K47*!7$B+[I0MNYZ\6C3,(Y*=NQ$.UUO8KI2
M.HA,-Y8TUQ^J7)8TA'!S6336(T8#GP2J;9YVLN_[KL^OM3RO["B@\1K#8E75
M6F";9Q)2:WR1YCB;$5A( *1RV4*"X(;GGLZ.57]>"7WO,),?3+EUJW/X*>:P
MR%HE[+<^$?.RE#)"W?;1"Z^218O#5# 7!K!K2(-=-HMR-P'"F*J1 F19P*.]
M/-L6Z=4)A[)K%X-/DA%+-&Q3HJ43=-,;IG;%^<^-TYP54-=;@5D ZF:!1SN!
M3P9PV6C==*TJS]6T385RM0V4L1E2G?KIFMWI.6:]&H?7($S11!,5YE>A*.<O
M@12)=]-H]!PU@(#[Z_7*S8B67)S,<\%<G&PF(+5SF2RV7MR$AUI\/+5QTN,U
M/+JF^2FHUFDD^LW@.!+VRP.M'Q7438S[9/#\X+-+./P+9JV9W&\ Z<;UD#V9
M)!YV;>'KE;WVU/;#>((FA6SO%4Y&H+[XZ!,,O8!<@IM6V8YQKG6[J>;#%&A8
M>IB1!UQ0J8+R,K+>-@X#L9YXS:&QC]@\=XP5VEJ<^BY+@&:_G)^^T=YQ^)P#
M(L:8 (/M=6D2-'V'L#WPPP1[$V+*!GZ:X>JF^0D'.'.#;2J@:YI8'T'Y S!*
M!#)HO"'F:*F4HR*LY5TG*/K/TW@BZN\W#>BG-#5US2 _B2S/]<-K!D!?"<ZG
MA5:+M2)T<>Q>AN#2/T1]>T6;:-$-(*3&Q9O&9 Y8X 6 <>MM(;IAZ/F5)VL'
M"7;V%/DR\GRT7Z"X W/(L4Y5M>.@8M]+YGJ=E7P>FX9XIRP &EEW94\QL7##
MD!"3+X>;EGLY7\TSXJ"*!BAN=K/$S+UB>?(8.[X)=_G&(>$90'C]I8^KU>>-
MPBC>O"R)TXAZ<*T7@D5=?X-A=6[#A=:Z0X2'W!>J.Z:K;A: 7KV_!E-WO6FJ
ME%TC1H*(?OXR=.^AH'6C<(QV)(MK&K"\G]C$)(S_3KTDE!U(X-V.ZWN;V4OT
M'/M0G?+$+HR36 N02TY).XL\+@RJ$ARQ5XMN<3B1V7 8V$Q8K.)-A$^.)S3F
M^))'4YD[M6%G\ GL#&T?L6J=)_ ;_<8VI=G0![2R-#>-J-L@-AC"%K*BMWTV
MPKK0=3;+[<T#JS'GVA&@B,@\[]8UO,9LO!EDDK>8$*R>CWBV'S!_&HOY%!]P
M^)^-63T'82#F;HM19CRF_G!PR<F$BTK&F-Y@O-$L[H=7"T[!<_ZU<WMMHVGN
M+#\Z6>2,I_?$F07=A0=E-DQ#91-H^S3O'%1! <8T 5$M._,MSS0H;ZRYT6AY
MSDE=2T;BB&G0.UAMXS%VKT+4A#43;\,)7Q(HK 045@(*-;KU+D6;VF(395"M
M$;*W4K*$FE&&6E;+GE"1LKS%HG8:.L#*9Y.8OU:_O 'RFOAL^MH+:,=TTYOR
M"P#D;RY1>04M1[Z$WB>^SHO,ZPU1:)Y$\+^CWBR_KM-7KQ)GP7>M>K?37OIU
MHVXLO_6FQW9A0;T'?VRG5>^;W94>^XH@(: ! ,?3_-=.<V?F3'SN)GB(F(?D
M.9I"9/DM4OC\EQ/FH)Q\;4ZNM9GSQ\?-'M?8<QR?K[O]P6(F(OG'3!6W!&T%
MM250.RS8M@\#LD@\_5$A*CC&9D)4R:\%4)5T/-.AI-DC430#\BB\$K^W9\&?
ML^L"$-\L/YOED-\R1+ZC'CT[S/TWT/M^(!3P6 K$)]8]&JI%*ZH9J!=D<+D!
M(LS^.8S"-'!TN4*7_EL!VQ:Q@8?#1'C"+9UH'@N,!BH88B8%O!=4K;$GE/[=
M]P=[4D_C&V36TWIG26$=,,-&JN,PH-;O;#+-.K>Y7A0G.CGF2DW<Q(@^V6I;
M]M >G!_IG[ ;MS,8G&D'9P?UE;EL:R&7?3F4/V"1/:KH_OXX;"+='VPBA9L;
M0.'F#12^@*R%)\[QL/>AG1,Y&P)@F]J4LRC.A_,*VL?6;1.L3(&G1IS:XF/#
M'OO39^UJ%&HCA@,*F8=] < ^ABT/L>)_T8A.;7?__.!B3Z,A%=D8@$1#KVU"
M,UPGD2?6#ON@>2\C'FAX$QKKL,'2@*-PLJ __PV<J&-6G*CB1+]):U_JYW7M
M0Q@Z1":'V!)LWQE[..1(^!&UW0^'^QNID&P,NUHTF6:"_2&#=*RK/IXA:'K3
MR .*P0=8##F0/>+CF[E<66WQ0YOZQ#/G$H="$0NC7**$IH'P.)R,@/71A"+M
MX_L_M-TD'8>1O)M//$'%FH&5*&T-_P) )-C6EEG8/ K?#_?MX304VPL -J*
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MG:H;U0:LI>I&M4VKOWLWJ@<0*HL*IO!%GO.OG=M7;;9W;E[=(TBON3/I+N1
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MIZ&6J[S 3CK.K<#+D-(ULU$V#$OF 37(*Z/<.<)RIVQK>(*D1A9KB%UFXXV
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M2W'L"@4Z0#.5H!82'\ /\EWH =022LPQR9LUJ32OHT!-*9<'2 L8X0I+[$G
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M+!@0TD5,R?OD[REV2!(A+_*0":K.C;O"T'-R!&>APKQR,._Y5^0#TNJH:_L
M;W*G!2$EU,LAX8ZJ;Q)Y287Y?)EP4;-?I>6[O,%'$>DDPR!\Q9;W<:$, HA4
M.-K0$^:P2:)\]PJ-2B/39$??0I D'[5&OK $RY'&' 4+Y7]PG&G.'3D!82:H
MOF06-<X=#X.\. _]Q[,^#3XS!S7W!=N_A;"/CI_=FWKI/8OR\XN;@^FD)!0B
MZ@6BL8B$R(]44[4]M<($,I&BF \5),<NX0A(0=\I.L-4'N/L3&X*<LC .#E9
M,%J!+3CD;..9:JC2$.-26B+U^2"GTDI)]%MS>B>E7K>%,*TG:J8^'.Z71P;)
MA"!9Z(""O]B#3W1>5R7>("83$HG*HU^3L*_- C[O:$+7@T:/->##6H'8J0IK
MIDOKC&3/2W@SMZ3806F)_Y^]=W%J&\GZAO\5U>S.%M3:#C;7)+M310B99#>9
M4)!DWN?YZJNWVE+;UB!+'ET@GK_^/;=NM609# G!-MYZG@E@N=67T^=^?H<I
MQ+ QD@IN:$8CAGHA57.F]SF\E/0%1+)!TJ).-8G1_6>[PO?-'I 34[B5LX_>
M,7-^ZF^";RGGRO[A,79),35H&+RU*-)N#)JG1G%%VAH;"%3V#"2_D9P>)JK#
MV<%3D^S("/82YC21G,R)7P;UFC)Y9R4B9+4RP2*@*+H=F%5*L[ZR6HE;LCC^
M.=XY$T1R!*^SD22]-<(QA0PWQ)VK$$F"XCC<^PAH"@99@SOZB9/J:.-0(=0&
MW#Z\TBYNF(O.0_UGTMA"CV.5O@7Q+2^D!//D?E4N'AJP>9C1+[7K"69#I WR
M$;>7%LT(FX>))4[D74PF6#4[ I7(=K\!RV0(-GLL4,G"C<&<P0[N<LN%FNHU
MWB-"Y"HRVQ_(V#F<>H2D64H"H7:3$(E)P*7)VY?)F0!HDE;BH1RP+-/'W9:N
MDC\P6SWY+G9X*57$V2O#-6X2FB_7Y,A%-V4"^]2TJ[V92G'4\4ZYYHX+ QA%
MNODKR$1,9&D&Z&?F-%J2V\"Y\ZCUF@Y2><H-N$@],S 8)@G&H)ZB*,_$M3 9
M33-LFT7(U.8!C+?.N+HC(N:2B(0[$X_O,\A'F</:\7Y+XC9E7X1$/V(PW[!;
M\ZB.;TP"*QG*L:)2CK66CI)"Y;.^H6T7O.1*I:%<)3!I)XB_RS#<.*,@5=?*
MM-MVI%=ECES%P-/0,2FRIMIDYNTSV"G<"LP$KQL:F%0L^+* PF3#6"6):QLY
MO,C%^;Z)R>>>Q4"D4+Y)WF(3I61 +^DKG F/9=>LYXON']@TYVF91LOQ<7)J
M<3*M-8!NMG+6A)7/RSF>[;2.N0:UDI9J:K)+%Y$J8G^$/Z$V8B%W6!([).68
M4AUOZT);%>$<SE6E/OOW7I=:AE$38+Y8X4--XJ1]O064JU:<U].;MI?10+MC
MH<VQ]:5\,)K.ZB<T4&J\.#RJ*01$HJV9AI#A&#5?X-ML("1<B7\E"(=&'9[K
MK"MSGRL.1NY&(*7M?!]:'+>/0"&1( >SHTM-(OY28\8R>>M#SD94/"MT=4:*
M\E%'.IJ8)A"QTT8#Y2XJCK[M<)!5?6+&Z5'I LB^-*HP(\^<[:!>74M85][Q
MS=S3.M78OPEKY0D#4K9=5"3,9H W_2F94?/*,<1[*QO-[D8VLJHYF.S]MZ=
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M=9?XL>^]2WN=_7O8/KWY1D2OL[=W<\#X86R?^QUW]22..KTN;O$GN)"GG[T
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MH!I&1U(.F/'1!B4YIQHO%3F:K*E*#N98%H93L.72 ALW;;'30C%G0T+)K.?
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MC[_ &KRDR.D2-HV$(#\S%<"YNT^X-7;BF+M S=]4 +(!&%FKM+%($%L@ +A
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M1W,_WNETYWYVT["[O<YA=^_[#[O7V3M<;+;/:"=X-V##\43__=/N3[4SB?0
MZ @$+^-(&^8LG^(1SWXX0<$8#U_T)E^];I4 F._7#XS/ZGM+@\/.?NU^'-;O
M!Y&$1&$L4<O&;?8$E-LM\P-Z(Z:D%&]_KXU*^7UKO8^?"3#HG "#*OLFMZ^F
M@^WVNJ2UU78U3:[YYUY]AX4)SMW$'WL"^+899IQ,;M&$[G<"^[>?0!=/@)&Q
MYRJ_LAK>J.??WQJ>G>:,D.Y*<&%G[ZCW(+F_NYW]P[NG),.T&LP!I(EVM_.\
M-RMVT77"2N96;WNQ#>\>/=Z._Y;$;;)EVR>89_&^B(>K0"7=G=Z!MQ7K,2A#
M:4%82BNPV6_U6.4F>\#[0 0#%S/4V4KL^>[.D;?E5 5M/[%[^MSP>7$N/.)Q
MK.JUI8(SEX;^6<G>7H$[?&P\E1>D#WQB\(+EG_>)[?:U_'-]6VE*NP*;^T%P
M[Y9_IB73:"\[T]@Y9*;1Z^[M>%M_A1&F:.0*BSRN=)" T%\!=O&*RHJ6?Y[?
MJIIL=-@["T.L!'Z8VDMG$G?2H&9AA9;WT!OE\"H<.]8U>UM._?+ZJ=&/LK4K
MH"9LF.RCW+;CRG5;.8OC7&-L'7=]^>>ZBA1RM+NS=AQX>2GDWGQD<P77]@KN
M'SW?7,'-%5P;LMXWZ#KHN(A4@#4I!<-3U#T7RT#N^_<G]^[VUNX*4/RJ>&%.
M;?.-Y9_KK]P59/DG^A;K0C%3]3?M7R[_=%?'E[R2<N1,NM L_TQ74N(=]9;)
MI;G_P'AR/U[@KH2TY793RS_1U8V)+O]\SVP#L.6?ZSG6G@A8X&*S[1W6<D':
MCVA!?TEB[VTXF>BH_1ZFHPKO-9<'MH^S+/$)QL4D*FR=?EX\V^4170((#2EP
MA\O$N;_!,]!= <[]#4&UC<!99*(1S&31/-Q'E8PZO4(R7H&9KI ,/RU;;B[_
M9%?&OE_1R.3A[NYSVUMY;63<2A@H*YL[@I#)WI8+C;Q4CN0?DX/]6/O/U?3S
M_FO<=@NFH3P^'1U7"6GETB)61^E;D>##ZNA\*Z5'K5),9\5"):N<3[=R_KP[
MQ4T>6;P]W^F91GQKHA^!9KT*J24K(Y1_C<*D'X%<7HE(ZRHYTS<!U@?S\S_?
M/5S^75T9===VY;LP;:E7(\%SQ92TU<EGN=$;]&C '2[NY]*S*"S7W#G869K=
M&X67P-F+>*J\+X1#_H5!%Y=^([]TC_:691>Y$<P[ Z6^]'LG/5!>>5ME3XI_
M2O^5=?&7[BV_OU2.X77E&)PV( ]_% ^P\0^3W?8H]F0#"3T2@_D-T6/]9 3R
MUT>L;94G(W2/P,HR;^NWXXNW*T'MNP?[^ZLPSX.=WM+(EH] HL,TN<Y'WL4T
M#A $?A6V\'#G<-_;&H<IC(-WK"%@\D@;>A9K4&#]Q$>7J&@[WC$BT"_]OG[I
M=@^69AMM;Z)CTYOHK=.;:.GW$JOJ]@YGV=$C;>>%/PK_2B:C5,?A@I;@(VLN
MW:/GR[)YGVPGD7.=A=C4*O=>:^H[=Q,I+@E4&<)^/=_K5:?9A)KZ4/B>2PW@
M>; @#1S'H-Q15T'32N:QSGUVQO-+Z[$<9&N<1'&!?;E0Y_>V/J@I=8UY&/5_
MK]/K?5=-NM>A7.\;->G]AUG+HCOM;7WN7#RX K(HI=X"-;L\U'E_,$)W#0_A
ML%QT$24L@;=5=GE;;-Z/N_</AWWE3.).]W\6^^IQ[O+2$YV$>+TMMPE8]_F"
M%OH/*9Q9="ES0D!PF8IAD>6\KIM+9I;E5"1;VXC7[OZ*S+L&]6FF?W#+])>7
MIC[H#!LG12'F@IKE'*WB2CY>*;![8V_+:<1YTTJ6A:1, H+=_1MXT[+,N9:*
M8*=^N#+"?*NB.WE9T?<-=]U>?J'64$/B2(&;=*J']EG<Q=Q:7JR[A26RK>;R
MMGY+KLH>HZMP#QX._>#^2NU#HA_\>%O[AN*B9>$DKDUF&G-2!^M5H."'KKI^
M#._,TE,,)\QY6Q_]/+G=FEHB8GGP L9'<>:M (]QI62II"S(899.S?I/$>M5
M5=,=TVA%./S]*_^6Y1":=?65<G\^>('*HW#.&PI4EH5V*ISSCB3SF/,NBPB1
M7T;3%9FV]4K>@T\^KE?22;&_EQ[_F+.WI>A;'U3JCU9$MC:R]9L6\$CQS=NR
MH1]I6C>C$SQJ3$L2@4'M"!+* H G_EGF!&_/NV K+A$?/K_V;B1[ENHKN.2/
MF#)T1X)Q$\=K1+(VV2/+0R3+FO%X)[7ZH.=M90E&?U)?3W*@FO^H>)9H'GNO
MSW6&"5%Y A.[F,;^-,?MI@JEI=[GGF3.'.SO>5M^I+,TN2(4HIN]]<O6(WT9
M$_QPG ])I*G.SSN-L?A!9\\D@_O!ZQ&?6A[BFHB/!Y*#BV<>-B5I/%;B85(,
M1RM C8>] ^">0SU0D_"KBE%(?>Y<=-:%) \V)%GJ5'<OQED2.OW2[0*1_N?L
MMWE[^<N_^NFS7Y9EHT^P,W 8>Q?%9!)IK)6 #7\3PH/#I1&=*Y,8O0K)N7?-
MHWM,S]8__G;4ZQV\].!_Q\$?Q176[Y0U/<G \RYR-=3>NW>OO"2%?TZ\NX%F
M['9I)I4%[^&?'FO%6_\]_9_?/GXZ;1_>+9.S:2&]WF.NI'YV7(5E4SSX3B^(
M^;F\Q[1_L+<]A]NOUOWZ</&N_18O4?#AP[GGX$2NRTEU]X_J^N+MV7Q+DU(L
M)_6("N++RN8<= YW<3>J9',1?F44(.^5RB[U@H73>">6A#R WRY(Z$M[D=_"
MG]OG87;IG:HTFK990GY*0U#OVK_I(5DDGJ1.R=TNV5FO)[NP#CR-2?%#D2LT
MQX"5O2I2F& ;M\BKG?P:+-? $,^<ZE'OX#N?ZAP;Q@PT5NDPC,F]"%SBY1)O
MW]IFXZTX+2^9$?7J_.3X49TS;>)B.O#>GI[W2C9NK:(:/_\83<>3\-@H/'<P
M)#9:SP):SYLPS7)L&:;!WLP5%DV%OF?+IV[Q5]R\WX^K+9^=?YSHZ)L(QEW
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MS =JT.GW)H7NSD(;V*NCXCO_'5FGXT0-=;N?:G795@.8[ L57:MI]M.SZ@4
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M E<0 M$Y!>DPXK_M,[#7/+FCY;?-3M$_ZQX</,X5SLEVL,Z0FBH>#Y5@,&G
MFE)B)<S9(_(&:?.KV+)P^'-/EA=-6>&\,UXL)JLS&! ND%&= -5MJ!#E\*G9
M3NL 0B?9/$.3'$;T(UE9X,"2])#6OG)%CN<GDC5HLUZ;%=SV^MG[Y+9Q9TXF
MYJ*C"C'OFN_L'QKZ!GQ'U69,&"0S$WOMMK$?Z]P2\+.>#ZS([J(8>\I_G+UO
M@M8(H#(( &\9.K;Q&]==N 99J+1=E7J7?@LJ,C5[8:?E:%74BB:E.6B6UV&-
MW'[Q?S=%D(@KMC$-SG )F8M[[,]"98R5FBY)["/4?"IB5HEY]A$"1ZM%(H.A
M^/P#;/H$@0ESU,"'DV[#*W<=D;\]9XUE3>%+HRDAV$9W9W\LB#MYPW>1-U*4
MI:CS)LL#50HO)4_: JV+KF8Z9<5A"$O#QW0:,)$]'/[J0MT"U-1/T/ICBM :
MV:MMJIS!W'V;R>R%0;70Y9)3$&2LDL6IU]9MJI+2<X@?NZHMS/G@DQ1W*5HK
M6AQ:WG\[EYQ.[6*/?R)!03;%I(E4O<+TB-O)FZVL^_X]B-T>2^LDSH*:6-OJ
M+L/1[Q7+KG?4G5V@(176GFMNB!Y,$Z[CH]N>S' <'8&6@?NQ!02K0,/9Y*BD
M;>DGSD1VEJWMM<D#.WQIG/LX^KU*)BE&*=OG%STG]]7 W?V UTYROV__#O'-
M?0DBUM(2SEA7S"DG3G"F=KZ9WM2S;-5I[CK%_ $;SYCNDIN6<0/7Z!>=W/[=
MP\?E%7Y/LUQH:T,0L O[R<I*#HEZFZA_,23JMV L0Z)^ET:_4XGZ_GW?>Y:9
M/+,Q,6%;,U<PN,')S.EW"^@'DZH]$X\@]?V!=Z'3'1K42.)6V:AMNK[(F@@/
MCS$V5GN])F"#&OR;56RZQ+?71&I-NKNOMU1(>_6E.P/R'3=O"?U34K3G67+G
M33"W;U;F:7.GL\(5I6O,U""I1W]CO AV'SXZ/!HD;)"PVY.P-W_@K]-T0>XE
M&O61A!V:-/*K&6D[%K\V9]D[[&2/+ BF=C&H[5N&03BW43@M:LIFZB&M-DCI
M&L9P  P=[7T#P)/DC;SN[0YF#$W,KE-WN5-1E#ZR1;O"_JJY)BH.4FDB,#FB
MM;1>'(EAP[ITS7LD'R W7R,='SWYBJ47>5)OF4ZB/=!4[22)HQ^2:I+46?Z=
M^>,.FVW_Y1\OXNB79;%(JG_3T+9KRKZO:#>.F_(NIR?>KBFY4U'9OH/^^RJ;
MD$J]ZV;O 8HFD[XI<:^F*@N,ZXS455DUTS+/RIC+.D?++9M9JZ[NU(BJ4JT&
MX,I8O\L>YD]1/_TG,AD$+5 2Y44SVX^.PS1PWT\,IEA(],(CQ9H8_19&':+\
MK4VA.#W?]NB_,# ^ JMHI9W.]6P-^#.U)8F3QPBDS=F:*RF)V)1 <^:Y9G@_
M\VUC&3@ETBDG-N$S9#)HO'OT=GMCF',HCY2HV:7GMT,?T>O;%E'G=H)D+TVR
MFO&92PFYI>=9V=:P&@JI+6'DGAAJ(9W[ GWB+ E. \.N#M^QTY1*:CD%(6RD
MK$@O8L$SR",89H4N%PZXQP-DPR4Q3=FK=,X/M;=53]6V89<7-Y*! 6'53F'"
M!(NVF6%JO52%NLZNE[O;;B]BZ$;[1;O1;K_;\0Y;"B77/!T@(?.513"#,0.#
M=+ZE4J #8K4H,MK5])H!]YW@;H+&K_O1&T-[JSX\+ZA=#2<Q*[Y\3W **/R5
MRK<NQ>*ZWK6<<,X6*0<25OK3.L"R_[DM?A"4J%#Y-K.J;,^ _LM)0Y?^6?*O
MDO1?! 7$G38T!1#>"M4"*IR"I+<W5-@BZW,'#Z+#"+N%&8^ ,D11?"CVV$)X
M._^@EXT<TZ3 4W3(61H6:&P%&[E.#<0&^2?CR@023%<8P*6[B^QTN0X,6W2V
M="=&8<P>(IW/5T#<8%Z@50'S5C-#AG8UR I<P)A@*7U;I[!H>GFU<11@Y9!Y
M"BD^ RN&)RY\,NI0>6UDJH0J8 7RC('80=!#SZIDKL$I:!SKNSMKHDI)" I3
MMLB/8:\\3Z5*:+XHD6ZT#YI*PPT6[LQ3T3/&XN4ETZ(8,O=HO!PSPJZ,1I7B
MA%<W*A[@SE!G""P89^20Y)!N]'T%1THZ3B8.A,@&DJX)4FGE>-Q60+MQR2E+
MNZZ0+H2_DU!D5W6^UXWN&VLR[WQ2@UC3KL ]4+UOV3230LV%;WA?)<\Q\/Z;
M@;L^^+?R6 U-T0)#Q4@/HPI*%AYC2 7J1H*FK4(4H0N/ 4-J74F52HO;-]VV
MW:O%R+POZ'Q68Q:S!\50XG?C7*#5=N_0,[(4:#9$.4LR,E4] &.\>KXG(QI?
M683 >*TS,T5JNH/]<4J<M#;((J7Y4RU&EB,RU69MN$;4CMZ!Q:]40L9%"-A)
M_@ZC>\]"^LS,P]IDC64W*MYNF:6,**_)[L;N\KHGOS2GMA]^Y<UMCFN_#$50
MGXFV\M1]/LVJNGGIX(5BT[NA<-K>,Z*<K?1RS17.J.=&4TO9QM!$,+!\UV+=
M'<3!<&K0(L5=T%EJ],"O6J<OS6FL/R<GI<["X]349VBQAGDH .]+-S735E0@
MJT3Q.;+YJ*U$U'TKX"67I%D7P?_*X):#!;L'>BM@LA*>6ZY:UP;B6C&_1'$D
M^VOT7Y9!==,#;!\YF1'C:H(MP[O?7WY4&REN^Z6]7^9=J(NL-XE]:XDWP$6&
M GSG5?"F0G6#Q4=;J*U',O>R.WQG$J(G@QU3; >RQF$)<Z!L&QN^7_;.V4R&
M$A16A, 1"4Q.KOX)O]-*%[:F(-3I)T4JVQ_5+6#C&6963#<CV%V[<*T.TXA%
M,5GUFB1X4RDZ/C%I)5Z1JY"U;,Q6O$/XEKS/>Q29Q'R 0H(Z]II;3<H(S!7J
MJ,_(J!W0FG:?'CT:T)I;,)8!K;E+H[\':$W:Q',^,>$5\C\N/B,/OWDSSTV0
MCO<S8KHNJM2ALO!/5*DN]J@[PHB3^"P)1ZPLR777M;H/Q2,G002,#+XT8?MK
MGM7"]1K,&BQJ1!RTPUWHP("Y1+\SD6D._+1DD<&VDD3 "G&2\\4VG<V!:?7S
MF5:G,%N+,V5\L)ZB:)JZY5*?JJ\;&IBP5BS$&)?T.9:<$3 >+5OVJ][V1I5M
MP[K?TKH[X[U*QZDA5BA2*$G E7MZ; 1;UK4J9?(DDX'L:% MG@^\H]CDCGTB
MMCP9(>A_%J\2OB$XUDKHBJ-"5<KNX\2+)O0-UN:WM-OF=QP%@^*>)!7"[>"A
M$5?'_[GA%6"-AU-;6'2,]PD(6)4(C8T\9Q#;.Q!;J!,M\S4(!%\:-$BD/O.<
M_@ON>A,:X0063C-1>@4MHS61K%)2J8D<2$-C7R;@-"S[UUOV'#SQ@ Z3/4LF
MR3B:@L1>@1>35M,D0<=DCI28L),A:WR)-1X6[NLM'.T>CC(9](G?DEPVG=M5
M"[3^X:-'"I#AWV#Q[H-YK45UDOUFH@JCOFRVV^8K$TGCC4&EPB'7#LT;#LKT
MW(3\Z)NL\N;5(W)UV3HZ+<$'^-F<$U)LJ'7S,MI;Y]GP&!S"'/4]$ ,O9!J0
MV!G4@O-&0RLJB*P.<86OQ<8J%+X^8#\;B[M#$X9U['*P!"2"NR^NUYJ+L[P<
M2<5/08K&H89SAF605.(BRWND;&H%V=O2>8(D^BPI]%2@"WP:2I__+U0\ZYI(
MK:U%]LB^(EF'VI8\"RNBP%=-EOA!]E"2^XL*+4#'J<*>O(&?566[,"W>:?V:
M5FG*\(E[#:CFMAHC3P_6Z >9N3,7BD[3"?-I];6W$^(N<7C>,[Q'01_RCVS2
M#:78BTXJ#]7P&DG==W-.Y=G8U_N2GFNF/3H>,WSS\-&C(^L^';\Z%J>,1IP]
MU!0CYN)<B$$3DCC6^5X;52X]CQIRE$AL*UJ]91>\)>_)1.KXM<^4$_GTCPZ]
M:L;SHW#HOL+[>620AAXG>C5+?,Y!OU=LO:QQ_[1(&.R&)!DHA4#8ZUW%H(:Y
M7\8;L*0Y;*TN)[\P5]S#0BT:KW\="68)'C6&78_269)/<9%9G]A;09'+[)QI
MZ5 94JD+0OJV8BB?R+IC8IL*K=S*3EQAQ?)?A,N1Z(0E15/.D6CG4T-# !/&
MF3  ;20YV$*Q6IZ_I5 4'\H,O-E9677)V27!JN3ON%J;[T::9!2"F#F41-:S
MKP*% (RBL20YP6_AQ5 DB;V1D F@ DY"&\*#W-9T6\?4M>8A]T!C^S!2R_7C
M=>YQH915G+J1(M5SH;&8%$4K3-+B6 E4\R(=D=FFM*WXX$3O\KNW]:,/*2H:
M++4OZ[O?&47"G^LX^TFA2#HKK)T\7WH@B7:1R)+YE]F5](MQ5=;]-Q..+U.=
M$DVD9F_$3<A*-"][I%W,UI6XG/&M^39RFK#A:Z2,7)G'1_M/_M8EYM/=% NX
MKS60>H,]W'VI^VV%6M@&^P6?;(_]\)QZ\T<<_91@P)@/*5EG?43FYWG"M%2>
M&:#TR_HW(Q)Q(U]UL^F1%88R\"RI)K!:/ZF+*;(I<^^'B(!Q#H&9'C;5@TF_
M,ICV)E_J<QR@HK-APKZHWFL8^D_ZV4<SG%$[.1/?5_J,K[+[A?34[PJ9-WED
M9^RN(_J:(>S-$0,5%&$A5)W80BS&C:&(6<>+[!.,.O2N4IS.+1K0>V&&I+)2
MJM(]LPA,)D8O!WRIY^< EF3CKN84;04.Z==\*'CQ$V>7S'":&4W8K,PG2/^1
MK\+-OKF-F5".(Z7O#:%JF4%R *I8H,K! %39@K$,0)5=&OUM E6VY3SW;?CT
MDP035[P,@2]J85'FQS=WRJ+ICP+]44R3<Y(,WER5RT>Z#(2-@.'<+\\D.RC(
M6Y1DVL/4A$5!OLQV#_BR&5^I=_0HT^-KQ3,<ZX1&[G9JWC=GW["M/R[EG\Y+
M8[=)(*I_I9S]N6)@%5,)M\0,9:_0BK02LUW:'M<2&JV2"QMB-7U-QA^Y*>U^
M]$?A8-=8VLY(>'1IN2C1+V'LAU%76=;KO+R8>&WE@GLM_>C7)2)BIXZ3W"21
MECFYXE"6XP&\(+LIA4]36><DR7*.5)&-R]'[2X)RQJ7V;7%UZRJW;KJ98+I9
M%OKEVHXO/NJX.WSP(Q>3*W\:M@" CB*'R]]=6GI^>;0PX+Z_2WK"W=_>QS7[
MP&U=^T&_ZP?[;-,8LRNT(KHIT<0O$$/N1Z^]!Q4/X(IATT]IU;@0=EE8_\)W
M%C4CDPBXT+8CW^^&&CDNT!-OO#3.N!VQ1?:Z';GG1.)'X8G/;F>=GG.<FG6D
M;<AA/> ^)]-.I3J7&G&4F(DJ(J]]@6L5A7ID1!\[\<S+.#%H/W&PJ^"0$$=R
MH@N$F;LGJAP:INE&_X%MCVJ_JXFKT@W[-Z&TFA>J*WSU>N(]UUZ[3LWT*.^7
M:SAJIBT+4\CL /NRO&HT]$S*/= A[Z;1&.V!)'_1<\ICA]:I"HHH6RZ3]$]A
MZ=TZ-B> P[$9X3"H(F=0<,S[LWG4[L,"K&S&W_[Y[O7>P0O:"S0X3#$J/,=)
M"T7&C/&D]*MV837[>0E3*_>H+%<"K:+7:[0+X[YS&<[MAE;VXVK#>]@707<.
M\S!>UH"D10JJ#'*QGF4+V=67&W:=+CF2C..#Q5J-^]&QH27QGA^;AY656I"A
MF=?WZF0&.+JY>9HVFUH[]S+YSF6E=;K*8R/*EA?!MG*[/YEWVF/:X"*,*IM)
ML9G6_GG9ZY\7/HCZ6R."224L">7LV!1\$4MIB$P*\ZR9U:;TW'9P[.0:I;\:
MTAQB6O2VX@S)P[F)%-.8%P%[<FF)"=[\$63IK0I !L&Y4]:0LZD_Q)@E3<"V
MG9<-E[PF=R(2<\=OJ^4.>6<,8**XWISS47BXQJ5]PV64E75&\I!4WJP?DSV@
M'!UX]]X]3.\P7@KECA[BP:*$+8#-$S?HL&=9N)!DJ;CZ5G@A *5>4:4KG?E,
M$;??$,]T7PM>/I##;CO-W=^/E[<X<=EHU\@DJ[6B18@^YPL(^FAI)XR+B( 5
M21EZY3FW_9ZH8>W7)Y%4=<C'>FZ\]L@0X6>FABZA;-9<QOEJW=C.O@=\LZQQ
M<(IT]+3/[/8Z-K:W*@H>J[\'Z7<&X1!NNY0Q1:ZWCU][8"9!_89CCRJ,QZ<$
M/[7%@-#Y DZD"[7MQ'04<A>_S,L8UU<8>39HX/7KXU1A<Q>Q@'MSUIL/:'%L
M7\3[HUOZ8IZ..R1A3_8&$R.41OY/L-]-A(&Q5S[$E!./7AF?>/M,-UP(79]8
M(I<\T@3Z4"U6678B6U.F%(,DT70W9D&@K4=G:&R RHTP$:%4 Z<+<R,DTFPZ
MS-=S\88$!M/.0_*E:_#&) UE/A'#XE+3&6>TQ#-P"XN9,DU0>DZY+I;!6@$=
MM=PS7Z,J8:84%Z:D&RS-[*5_"M &LR@NKJ5O"6G*.,*$U\/?'=9UKP/,1F_O
MDV]UX.8HN:FEP$*9,K+&DZMSIG>QWF"V.:GC[2O%V^T&.0 #+##@<  &;,%8
M!F# +HW^'C!8?(%^N)IQN^-^N+MO/2M,E<\M^N-1;*.P>R9 Z<=!9PG,H1[*
M[<NSEFM9N/V40I#>R-#ZV=" +1"GU_PJ"IU(9AJU^R0QVQ\]5L)HI8HU'\=1
M2MZ>N<!&6=I1CH"S)%V  $P4'.@\6WW;T-[HMRR\]UIKAWQ;O4\LA"!\;3,W
M;%.M[&_)KETJD5E'@$6,7'V1B3"*%8^LHT^ROB(S+'<*OH@E,"")@^+,I'&M
MEO)$4YXZ2<^J-'5B>?G UV,&S*3(NQV:MD@(07*Q@PBT1Z1"TC1*E^6:(!RH
MW_-T(AX0)V?+W',[Z+=MP]&YG#:#)&V53=[,G:%BMUN(F>9T,F.?%X>+*C33
M*'E/A7=Q)^TJ" ">9U4K9'"\VYC]D2=%]L:LO(CHG!A_U"@-3RN"I[+Y"^RO
M#BC&:Z#CTG@(66)&Y_<B:QF4%:R*K]DVEZ)XD 0SP'J8UNRXI<K='?,)N":I
M-&OGZ+$I6M(I0:5D%7<.T>&)[5?$$/!E#8A L9=,0(-1"]&J<UM-@KF38?=U
M /=6R+&!&F@.6F$;46>%DL)/Y=3:.2P+.Z:^A+T!Y+/$F&8C$G++_#XELJE!
M*C/GW6N#=^;8FUZ^P[G,KAI_7$$7F' JGV5+,"19@ $'(3_Q VG(?SW8/XI&
MP#G!$4T:@5688Q&W. GA]75ZQD5LNR_H/'.=&G7-YJKX"2K&I%B;C!,-'"XP
MLI=,DH6"4#!7)D?OK1M0:1?08R2$2*W0CYX]^9O@7_R5ZY]FNZ"!Y%\M\0&<
M;"T2T=>X4M%06QHDB2_O1Z]38.K2WKWJP$R*J^M.0J\*B94) %8XI- $6L06
M0@V>=Q )&\9GG#V]Q\RJ6O/2YD$AK*2=LFJRAUV[W/CDJ>D?B03V;'\2\W0Y
ME1BO10?(&:: DU"!@1A 1G11.F&CSS,]13:4-,9>*FS5:W)T0V)@?6( ^5F?
MAEXUB3\ELB?I%(2'E[%QYZ&G>.9=+T4;A3P7*.#0%_$ZOH%:<&LZ'7G34'8*
M CLI__WH V\(OX$$Y@H /&Z3H,OL&3Y<C3\P WY%ZIZQ@EM!WL!(TKR3A6',
MP@HM@V)-QUJ70):/PR]^3$UV9F!-^YI+.8=1L,@]WOZE8=&;N]ZREE^ UZR_
M&MM#IKE.!NJBTSD? (B&!;^S!6\J](?Q4"J!TT6F).KNF:.>_Q*6?MFQ3BJZ
MYAY^)L%?/@'X$31P4S+L#*-@VZM!;/!<@OKP -6#7'Q-^L225/A9@<)IUNYD
M;-)6E99^PTI\S9689.Q?SL2[--N4^2@;$+]A5;CJGHPJ@4F'N,J!R? K+YCM
M86.*7@QG$KN4GX2_\![1R 00?V;N8G3*."QYNC1;X %SS<$AV!+I406R+#4H
M8K]"H$03&CI!M!Q'JB%]'S"%J;D@MP_V# ]1J#YRC6-SY4%0ZXG>Q>3=526Y
M@W.Z/"L;\K:S\RP7O%%E]E]E I9M@5/LI;#,@+M,>*MI9O?F./C03 C1H>"4
MQ%H4]&1RX4LF'D&A3II4S>S/-OE(?]=-*=Q]]'.@L/H:++]-1U4+*A"D$,AS
MK>9<;%!,<UAE:4WSR1'+4=I<@-OQ0TN"F?! __A8)30 NBMC'!FXZ[5>\M-Q
MHZI,)HR_M&TZ-;;$,3%Y6K=^4BC1[)E/[S8?D4B7 F$]$X\[6-:@VK6>95,M
MJ0E];.83FH.XI[=HUQ;KV&.KDO*IP-E6.W/][MM\N_WC?X^J[_XQX'\L_N=H
MP/]LP5@&_,\NC?X:^)]M, 3Z8[&O<DDFJ-X5B#Z*DKQ(@N7W\HIE. :+:AP0
MJOMWX(*2C>@M-B>FK6\0 M_$_GJTOQ50C$XRK3.AB)!SQLG4&_37 OO@%X_5
M8/-)[:)\). NA>*<-3/!]NB!H,9Q28-0 LJ[M-;#YO9+SHEP75F:*)[[8:PW
M0 X;_(%\K3)%H+GNQ=XXJ49E84DP[).\@#_+IT#&>V-=<>0%-LGOFA6<1XZ-
M#'.7")F@1=LD7AKAH0+*V=I@H ,GU8T)8P>S*!?*W HS#[PD+C> ="1>QTM'
M(4&VQ]PP](":;P_S3JAD@K7F-:A-[U/ (P 7SWANDS$9$C0&,$3O@3[M(2?N
M9A7-X#AZ *YH^?C>[(X0RR:&?[@UC,'J6!6FE=BZRQ54D;'QK5VO?ETHP9PV
MJB.STC,R3.&3,%EF617)I*RY,G\"TY]$(OV4C--JE&AF>,*YZN:A>@BVW8EY
M#$E% Z+3\*$RU&1/6E9P#1_GNCK;;HU'-DW&L,4Y3N^RL8*'U"Z@7&6=@6@_
M.L6;F5THLX=6[U)S"C-\TB6WM*.8)'/.59?>(V-M% ^NOS++N9ACRKU_"VS,
M6,D/;98'/IIZ@5H^/M("KNNLSW[T&__+J40[2",LVC-BC< 8<@IE_,!^)>';
M0V$&Q.7"M,PV%$[B^[B.,[E6"XXR6F1(*?M"@2\E2!239U8TK(<,Z^QU_I'Z
MR%<EWSC$:Y95B^?-T\/R<[<QA*CB/J@&W.:J,\"6VF@1H/C&4N-DP /<I8B!
M*!X,);<=7IF#V,(+C1R9J??<6JY8]&BJS;HZ>F]_;8!19&W.1+/_:FGY)YGQ
MMKL$T$U@(_!AZN@^4=PE$7XI-M*CTZ3F@&1*/J42OK!"@#?4VJM: %Y>))]^
M#9AD,2M1^'R& WZ>U;4AUK)=[YFJX<*=K5GG*3(0\ #1/C'IHY KO%V<<7J!
M9MG37X8/ 7<?M:1E!3 X,1Q=PO=!_T2(FW[:*L>$ HY6HAE2"'<YM9I.1)@)
MX>IZ$/(@3HL)568)E("=+2.CN+P[!^:3UZ_0H[>0)@YY]A%6VRAH."@$,74R
M3SW#R"I^-B+\'R\2V'C<'H*-M7"7=PZ*'=OT_6Z*1PT%Y\2ST233Q#+]X,WI
M#P\!\V@,*=DE4-Z.K6Q,P1V;K7X5^4, Q6K)%JCTM$9]10#4ZC1EL+3Q9L.7
M^!.PD KR6 ._!0)>>SZ30BF7:2IL$HZV N6-*<OQ.9_#M#+P#N@\+;CMH)A7
M]NS4W@K*_QYWCNU8#V0.^E;I>#EV]9<55Y&@CM159/JT+G!Q<C(HR$:^@%VA
M5;/3<MRRPO,'QB)CF.6A@RY)H?<?L"OVO1[X/):P?Y4 UFL!CJYC!@B)/2Y)
MUAOZ?24,!!IPE :@17>4Z1+C1)P"G3.V-'B^$V76Z*SBGIT^1XT4Y/H[DI9[
MBE*A2>ZW;K?KP/:AVJ ^_[P0_WF="EG[\Y/M* 7]G%BO4L:Q'_WW+,L#W0X"
MD^Q<3I%,FF#P48T5#JH^_-^(@K7X87KF^*/(-[<][=8!<TTV<, ,-,MJV!VT
M1\_E=3SSV]G*[)=7 D_S%<U*&>ZD3"6BGS"S%]G3!0+[R[BG0Q1),+V2MG2
ML-+/1L(P)J@<\V.#T< D))!4_VVPWH)9=G8P(X&8F=MC2*]C:\$:$YE]%FX:
M&J_?QH&,T.2F(.\#)Q-W'K4] X39$QVNVD+UU+BL%B4W]//T^ZH9H4QJB$,Q
M4SS[ZUKE:T&P:Q#SSJ#>C]ZM60J61Z:AH?D+)5$\*T])NHX;COS"UY>AX,E&
M]4KLC$OB[3,?;!-;G\-3T>Y!'01\?57EU_H(T4XE-_N-!:\)%Y#YV$^6\=2V
M-V%!GJ(_*+UZC3K(_&JZ54_CKFWOY7? NV9%XK9,Z^;%8UY#;H/M#QIS"Y.
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MJ$F.[([?_L/#@1C\QG43*+MEA)AXH;J%Y(!PL$+WK,:,N8%$TPEU22P<?9)
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M QVQO+5KF39(V)<\E$*74[L;K'B>(FCP2L3E,9_'4;K(]"\H3V->2AY3!4"
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M4E =S,IBM*OTHU+&-%LC)^178]+1(*UCKK,_VTRPY<S[Q*D6[@!ESN%T<N5
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M9H.](B9K0E*/$)#R[C=<>CN7WG'*\?E&X;P'?Y4C+RODOW-IFEP_O$ZJ<2N
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M#%"&#QB),;AX)8W %30CUI&\Z!8QBPSD(K\!7 $&R&XIRX"& &"-YS5C!AR
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MK^#?;9'UE0>X%%?90*,4]W+SZT)WXIT*#UFFIB9=><XNI =\7WY!><3_YDV
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M9LWP#@OI7\BNHEM4@B[> 5;PQ."NY0'V@KR$P]N)C[X ?6A>6N(E$[XC$K3
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MMD-A"EO<!!HCS,1 ?X&(:O_$2K,68P*B]N=G/]P]L*[_[)<OQ"W>3R]89;>
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MYTD==,/XO/XI3+3XP;Q\H)RDS+R(;>"1>0%7*+,R_6 2\MWH1K&AUEE1.7W
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MBI;W.@TZ=@;A(6UPI^720:>^Y]R4\63[W)3#X>R#TG P>FX8/ULW>/((IE>
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M\D9]A IMQ/5B15/8)T0$RVD"XD<-(LI5((%!'!HCQSC:JQ<G3EZ9CL)@E#W
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MS3^];-C+OQO?<-1+)SOH],;]_9GLH#_::M@?B!B8((#FD'S_\63PQ*3XA*B
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MSJK8J[&&RR'HZI6QE-,KX'"F%**V+;7R6)^*^N"ZHJZ)J8#++*8T96[?V3#
MU06O=MDFZ[U8:VF.7J5%^Z>G>435YLVX?'9Z,I#+TT&G[S:9ZG?&GNY,[M9U
MGC2O"R0\K^MZJTAQFM=;!4]XZDYXT.EMFG!-6JT=-AUN(V2? \Q7J*I&1F%N
MV(+B+)Z7FL*H8@%&P/ES26E0Y>>ZG,T%A]],?A<1Z0!K8()!MIAAQKG('#55
MHM9*:F%YWC=OX=7K[VP+K^?( Q#^Z\1T&7HIN)!;M>S:[<38)AEWM:[B4X^&
M:.F+ 0Z_0$T#F2,I3O\\.7G/2<N^710A<E)G8:N\5@W3IY'5#/:?GM6,E#2U
M\T1_GZOP5- ^7YHO<JHH"1G,S>H-10J6O-'6 &'R:<2%&31Y/P !+LB(-AZ=
M*E:RKKBZ+KZN8=N :'!D@/5>O_] S>!?M*2*&GN&IZ=4L6S]FG6]4U0TG+KS
M9TYO*JO'NC4MJQ(<A5>H>LCC&43K&T6@?+P0:JE:@4R,X:@I@9A::A>T/-Q
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M6&& M$I#&WEW'9\7G5/G?L+.J?\P_CIF=@OYD]FE#6(=O8S9!LVY::[;<-.
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MG0OBL&$CZGR#6Y KNX7>K*9A8Q@<PKXZ[#LZA'UW8"Z'L.\^S?YF8=]F@?9
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M$3=ZEX>V]RG5):5AD]5OO#)ZDQJ(R?=*%%VEQ<2,82]UJ^S_Y; @BSM^M08
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M@X6IEM4R3E7O$>LX?$NAS[!18<XQL76GZ6F>70 1J ["+0=U6;S-JD,W)3J
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MKAM#+\QK\>Q.4C]94;KPW#-O?JZJ NB9#R;+Z)W),I)7W_Z1_OSW6?[#SX>
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M<&:-)(E=HHTMB<HUS=)4\L79R5FW2D9KC0;I@[J5-]0R7\[YFE["S )%C^,
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M%UAGSH246(.XSSIT>3GHCTQWT1DZ3>UO54<F56!K\7[>M2$51B&'!4.@!-7
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MX9=/'3\ZO@*0J7==2AE-WF)L6L#9Z.ZW+'W'JWY-W]]>]76QRM2?>;D5UN"
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MC+$ATASM/#3PL=-SW;.\=7_T!WD5]\L/+%6/B\*ZEY]^G[H\HQS+_'^ (A7
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MW:[T.*I '-)6,<*9U>D? 2/.!0N<V+N!Y-X1F((HCX\HD]F%*@BOJ>$@O _
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M#VW^L=-SW;.\97_T!WD5]\OM+ZU!%F:VR*7)JIPA8J)PU@:(2 I@7#BPPB'
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M%R>3GZ=S,W<WM>-VM7N7(O+X@/MYP+>>$(E^#7=LYD<!G1KE\6*Y(JNP/)G
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MT>N* C_5I!FG>WU]<M3!84ZITZ;("04]D(C<6&(XSNS@*J<NQE XO_<4*/6
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M>/Q6.',K/%4%3._3MG@@SVQQ"C_!\]81L!!4J.9T+?_"3"<S^0 ':K),PQ^
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M[Y'[W=!P4 $=#CU?!7<\AXT[2DT7(Z#<-(T^.ZOGY)UTHP%=+Y:?'!++T Q
M;Z8+)KNB&HL9"/H9_ 74PT9C:YMB<E5V1@/0Z,&M/+*KZ6Q2OV;:)[BQA0<N
MJI&)7<_3]-9/)N^PO2F8'7B&T+_1OQ2@$=YSTI&LOFQ_DGI25L[;$_,7-J5O
M$+<2;Z8=( C_FY.>.^8R/-_OA3G[Z%W-0:Q;9\/!J" ^90VM+=I(Z!^"1?RY
M6,*^MR&/3F VL<;>2/GJ22N44D@*&XZP4W>O!<RFK=B9A]U.G(MD],(8&,/
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M(E.BDUP2(1VV>I-PZ#K-8M#SI*+8O6.YO>:_T.->&C0>\K_"]?QXGN8UO2]
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MBC/I6>(,QFF<YRP&#?$53PP'=^WMUQPZ6WW3T5+@<4:&H ,BD<.FLS$AHZ)
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MW^<AZ"1]IO9SV7M5&44%I-F"2RLH=](:634"7,][#>W,,-8YFW>YYD R1XY
ML:G]BL*M<YSCXUS3ZL7B6JVT*V!L*)?48KAJ@\!3%NR0(NDE6!T[X6/=_NA\
M\ \0A<.<K8^ROE6I)AQ#*-D?5)6RQ^&.C\F>J@4?I\8[8%HOU$"G0)Y.XC$L
M6&]8^ X+"AC!5(*KF-UV6&OP[-8+'%CK-_A2]V3"]C''@_CBM[W_^6G*19S
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MR/B)%/77X5D/FJ>OFG/L<4'=@;ESL;3A''=[@[(Q2X(ZE[4FX$-CDK<4QX5
MF'Z=0YK^L)1*JT &O/6CZC!];2LG+>;K\$V7+V8-T898I]VKLN:QG-7?N-!!
M>X_MU1_\80S#3GR3EC5:9S3XW=+NMO#R%#1$OS1[_,/;L;_O*\<9=@I\,AD-
MXEB P^XR$VTDL 1:!<8O=#C#SD_2<5 !D7)"I%%):6JIS8>K*>?S[=@+C&;=
MV)7MYI,QHQ^&QQF5*^^UU#X!XYE]R_9)94,J)V*J+-/NSQ6,V[FJ#!:GDW?5
M+U=Y%?4$D?*V%;+.N">N@,^5FY_VXR^C/WX-[?YIQY[]TCXI8R\_^G7V=@O
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MFZ9NKP71<.M;M]<)W]HAPG4T=6:A/  ^\MUC6&K?SMMYO,'_C"=?P0=IO>C
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M$U8%(W0I]<D@.!,93<HX2J.GUXZ'%"G:RV]ZO3AXV8U_IO[7=DB#/WN=V-C
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MTGDYJZZ>#G7XMU'GM%@'NEEK6Q7;F3[U9@M:H=-#*3QM':9.;'F<A10.NSC
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MOC7.(:&SKX ?]#JCX<5?.7?:^($B;XS2,],S]_.P/\ML.4C$]Q-\037'T;Z
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M8]G[JSS%O;<JJ?*0V1?G%%6.L7,X%2!.<'+L?ZA9>D!82+R2",:?_IUY!$B
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MAOY\#U:>L "Y*$4O!-9F-[ L-](H[KQ,.I%S270Z24D(0D8OI'KZ@%F!M;G
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MVTQ3#0J=%SI?$SI_4@E>[*=%BOFA9$+.F9 ..V0D#;FY!$'IY@R*D.OPF./
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MH['+N%N:I?'+.A/@ IK_%2HH5%"H8 VIH BC0H %A@H5%"HH5/#D5#![*H
M$I@C/C#*.6!K@Z$,L/)8,FN\GSX5H/0N?,)0QK=;A98A!!.45DB:W.,I"(RT
M(1H)+*,00?M@[6QY P5"UA5"9H]P"F9< *%!,N 0N?8D1);^[[$*AMC2V'AM
M(6105&FQ#-3$@)3@%/$($CDN(HHR@I+<@35TMFAH@9"7"R&8ND 9E]@HSQUS
M)H(&A@-(#-1'ML1ZS0(A\X600<UFA-R]C.%TA4X@[B$BBR-/J@@8GQ040>B,
MK>R6""%U#/"GGG5-N [+#(7AAM8Z.>_V&O%RWCPH-NGDH2V*_^_GLW:WD8_U
M=7_:^C_P<Z]]]AK1S<S5=Q_9=B$OD)B9_+A8W]9$#[&Q5=U4F%X5_%2-W+,X
M<?99NP6M);0M?G1[CQ0E;=Z)Y?6)?>_\-'V1OVY?<?7/.R!IL*4<^Z1!86X$
ML3IP9L%AK#E0.=I4NXV&?_IC".=-V(_U#@?98MV]=F\;,H;:'H0WW0R)B45V
M6MU>)^VEU>O^V4NOU#_MQ_>-EFWYAFW^#IV$ENFT/"2$'/SZBL9^:_?1\R"S
MR4%ZD%^:;?]E3;'S\W^/L3_]JV7_-N?[)U_8'GU'][=WQ.>3_QSOUSBXF]Y_
M=+%W\('O'30;>TE]^KR]\RWAH-@]^20.,:4AZ<H614(4XDHRY/(_A14\2F\Y
M(WJC@B1BSC*$=,[A=FS_U';2G:#,KO*V[+_"F%NQ?KZ 2#_!8U'_P3%4-3)6
M#I)XK<XZ[7\:(:W?:-744FL#'3BRG0S#5:+$JL\I::-71%9!C.![W<S'0W'P
MJM7NI7]?TVEN5'[<I]2TP@VIOK[-8O>/\$HR9 WJ]J&F ^MO_%K$]"5).KBF
M/>O"Z^L??@Z-[EG37KYNM.K'KS_T\^W5Q7T\K>^G__+/%XW0.WYMS*9F)O>M
MN<HGN?KB_JMDLVYI<T?N]5_C9),S^>#+>),\^-ICRU*RF:!CJF4??TUB.O?-
MIL,CO.QU(7LU8ZWZG52H"0JWY_E6(NZ]=X3%Y"'K$*MD,@TRI :2N?J] SW[
MM?HA&R@_5ME$J?ZXE3K5-VAN*<EC7LNDB69/K?K5A_0);*=;O4M2+J1C\G#J
MDJK%R!B]119#C5<R(DL0,DE*WU.2W^BX0=8:QVG1,LX#/].#&TV2V:U9#FZJ
M@R-F$N!Z,*UWVB-9?;@;LM&J9*15V[>TWRL[K1HRU*9JLO2]8USO,^Q+R.K&
MA*W>VK-LA"SDJ"9EYO(%S^D+YM3I;?;<?S'4)N[)IZZ];W?2/UL5?/7'MG4T
MHB7<HIRCCVQK2E?H8OR*4_ESIW^((7_N S4%4W8G%)M/UIQP/%(<HU_4/%N4
M37*&(^-Z3W=^HXV$_YUEE.4$498G>+0) I:6 7$!*Q$-XX: "5%$%1EU0=E
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M=/J<VW5:?JX,KML-V@W:#=H-V@VN=(/K=GE=(PNU? ),9[->SBH#7<MPG9F
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MTVS@N?I8T^^S^N%9'X)I&3'F5U]&;#G%_/=AV.W'27G[VGGA7#^E,S4%SYV
MNMK,+<3AAQQ6AY*]E]*B-QF\PQ ,H(60HG5DG9?>:US4FZ0ATY60Z9?/_YKS
MV!(J7;3-3.@,A$PZLB"\9>AY!$T_2K ;SY1Q#SB*OAB:;I63+9NF_+WC@DU@
M@K(6@3PJH=$7PH=H#)$8$0JXF^%"<Z96A!<S9TI*I0/W@H&RD@'4U .M@>F<
M'*^]-;7*CR'AH&'&VF)&Y@09G"==HH8 P=O:Z)Y(A<W!:MTP8STP8^;]1 %2
M1II)YVOK5QN1.9=KIA(W!/I.&0D-,QIFW*;_$9*$2&36YP(ZZV"CS4(DIY.*
M&I=.ZVG^QTJP(<Z"L\FXJ$-@P=?&J0(+"[8HYI77F1;,%@?-_VBX<$M1U 1.
M">0I&"*QH(PWVIEL0[&.BZCPVEWB&RY<!Q<^SC@#T;NL"S#"[<S H68N"<<*
M9$(,;Y1,:>,9K=)-8Z9-.==6.8N."5(RQ<L")0#F@#9&*USF@?.E4S\:T;_=
M8.*7:4#Q\[9-,40(F5EG"H,L O,<.'-<YF(,>6K6K&RKM6GNVFJN=\$)B<D6
M'\$+$VP2LNB4BM$IHVR:NQZ:^_5$<XM4 8@!L22"(,T-AH4H W- SKM*$:2X
MQ$=OFOM8-+> -5GR&.GQ@2?T7H,TJF0O8X2;:F[3T*MJJ#C14)Y$IL5Q3!5'
MC#C5TRX2D.4H@BJI^&+"NC'B[Z0DYO7ZI:QP&M8-AFX<KU..%QN%MUQ9B):C
M)<)?L_42,0E(?-EXW9L1UDEJ:4S7Q: O\\D"Y'P;+6)B2<<:R ^)>5$LTPF5
MY=DD)\U##]9= X'N(KOSA@68&]9<LC?@8O(6T*<H(9#T%BM3"((;P:&DT+#F
M[K!FEFB (@:EBF(Z",T@F,R<2,ATUL5J7E\MC^)P;T.:[P9I"OA0K @U@0:D
M1Z]EP22SB*H4:V^"-"TFLB($FJ4M%%2AA! 9HC6$0#FR$!*P0&Y7*@@)43V&
MM(6&0]\;#G&;I/!*9F4"!!!D7'V()H2 B@!)-,9S=W@S2X50P8FH16(A!?*N
MDE ,P0++EH.31'ZTR^1=V?,!GH8U#6O6-:!LH/A8R)NRB=/%+$KTSF>$G*).
M?NG*(@UK;HXUL_2*(IP7*DA69!0,7!85=10S ;/@,LH88"7!Y*;PWYO"^\2]
ME85SG1"")%WGH(1WV@H9(XJF\'<8NIVE9I!"QYA\8<E(Q8 #LN 4B6W1/!,<
M)U^+I:WJ"&K3]^]&WU6)TG#P@2L%/FE48*/RD0<19=)+[QBWH,8MXL LT2."
M\%84S3Q'LOQ>$PY$*(P[H8.+42MW2?> A@8-#2ZG^U%#CDGDG!)$7WS11J5D
MB0Z8H-32.9O-^J] ZV?)(R%;Y#$@2RG;6AM0L0#.,.&"=4'&DGVI?/_!V/_K
MUJ=8?69)5_#A=I2RN^#R_>Q>'^SD40^[3JR]6XD)P:;6UQK<3_O#<;_*T]-1
MWL6#_J?\4UT")C<!]L\O-8YSO<+&LQ_$C]^HK+&J-;]))[%V@W:#=H-V@W:#
M^^^IN/ZUI/[<_&-SOO\B#E(/W^=!7%$]J67K^CWD'4RT.@F3G0-C(4%P7N3(
M2Y$J:>ZGYS:7V,'L*-.D=_VKX8 F?T0KTER-J[D:7^=S1*4+($0P#! X@Y "
MP^(2"RH:&;(JKE;;7+"Q\. V,=>HQF?#A>,,JV22!RM\R@#&&&>"4QQY4D5I
M3/&&N- "DBO"BUF>I]<F28V9):$)+TR1K*X8\TI)HQ-R;2_I6M! HX'&C4'#
MV(Q1IV *UY"5<#RH4*0 9W54?NF"4@TT;A<T9JF9SKI$I,*PI"TP<,$Q],JR
M[%2T)FCK+ROIW4"C@<:-04,4Z:4L(@>E0"3M2XG*!$$ 894M2^=0-@]D-> 0
MY\K-F11\+;%M4#,HUC,45C(MC0U%%'2E- ^DX<(M;8!:*S%X2$D'X**0!Q(5
M2ENDY3;:LNP&:,.%U>#"+.=1I9RC$9J) +&&)Z!6N>9, B2#,OF,@7 !UJ@*
M?U/.%3?-*,)'7;2A9X7D%$9.!-]$Z54P%I;NY].8_BV'$V=YB[H4M,2DR(:C
M8J!=I?HI,FUU5EQE99UXQ-U[FNH>VU6=DN3)28D<H!!R&P"544D?/4)JJKLF
MJCM+-4PJ)RZL834)C)&1U?4W5?LS.V+EY*5;V53W\:MN,8G<+B]%/1&0DB->
MK!P*'2'1+^:F5K>IZ%55=)87" :$54K6D\VN1M^!N2(" XD1E14V1+MFG/A.
M.U/=@V+]/!SM#T=XD'N#X0%=M:8'A.$@C:]526H-:]:YE1]GSC(*"($(/(?L
MHC?)$<V/B9@]H8YLH;@[Q!<^2P;8 OK.T;8#37!O)2N@."/J1@R>6\V"=4F+
M!*B!;SP[#S&W$HX[*WRMP/OCQ@83;=%<6B&]);K!/4&$3 J<#8@!H>WMK0=F
M;,TPX^OS+]NHC!80.3,E$&98KAC&')G(/')G58CRDD+2#3D:<MP\Q5!GS;7F
M1:  $#E8&\B%C=)R7TU70X[U0(X_3R.']-%$'B*C?X!!1LF\=.3@Y,3)IPDN
MJ="0HR'';:8&< ^ KF#R"#H%3-)K861-?A7!+UV\MODCJT&(.(<0OQQM%^E0
M(R$$*%_#DCDS3$$R1$@Q.IZXOCM_I#6<>E#8<.-8*,=:M-U%"]:!E]I[] 8+
MHLT@?0AM&V,],./C/*N ;<6U5Z 22QD4 Y>(50@AF"X%E :!!E:W"]G4=VW5
M-VE1LLHE!K+QP>@0,6L$\A6"%UPO7=RHJ>\MAR"/$PB^OGX1/[]^OHW L_(B
M,!-R85"@MI\5CF7)<]0:,*%M"OSX%9C;E(HG6XO@R Z3/U@R&,EYA"# \*;
M:Z+ 7\\H<- EA8*!%9\\ ^\5"R@SBUF!M:B#@TO\^J; CT6!D[,E*6.T(L7-
M7#KE( =(1?N@;#)-@==$@<6< G_9>K_MLG&> [!01"VG[@3S5D4FC4A9A6QM
M6LL.<ZUZP2E5_?=AV.W'W:/>P0A33KW<-7IKE0N6[C93LO=26G+[,W@B(,$
M6@@I6E<*^A5N*PP.]U@:'K#I91J(73N3X?DV61H=N$2F/"8&4#1S1AH6E*B[
MRRZG*#>>B2?2^@<<.&Q)E&N+&V0=#1$<2WZ+!Z'1%\*/:$S)7(0"[9#RFD#&
MK+*!TLD&@84IX0@RB*HR#)83Z\G6<W)"8WQ,_6,::*P?:&1.F,%YTB5J"!"\
M=0J16(?-P6K=0&--0&-6V2#%&).RQ#,,1P;:9E:7C)683<R1.^/O.O&I@<;W
M!1KDBTB(L02?"^BL@XTV"Y&<3BIJM,U#62/DF"M[8)0$48]'6G)3P/#,/ ^!
MW)08I2XR$+(T#Z7AQNU%9L$I@3P%HS6 (D.EG<DV%.NXB-.:C*N)S#;<6%5^
MP_-M+0*Q"I&8RT+5TO"9!9,Y<SP0DIB<5>(5-SBW:W0*K"GOBL]HZI@@)5.\
M+% "8*;5C[%&MGC@?.F^#<U3N*/$AL_;4AEEE4P,!#<,P%N&7!JFT/M:^A*)
MH[7CU8]?=;T+3DA,MO@(7IA@DY!%IU2,3AF7;L#45/>.4AH^;VL3T8HLF>2U
M1)D3F@6= XM<@5 Z% BEJ>[C5]U2Z9;D,=+C T\$W!JD425[&2.L5'4;95Y9
M1L/G[> A:\LE,67+&6A1RQ,IPYSWQ2(D9U5>/\Y\JSV3;I*P]&#;I=TXUJ8<
M+S8*;[FR$"U'2V3;I,03&7%(-STJU !@90 @YK,!A ,H7CM&_V<&07B&,@.+
M (I');P/MNH_,?0''&N[JG;>48ID@Z/;"_V[F+R%6F!/0E#&%2M3".1?"@XE
MA;9?N!Y(-$LR<-P5I)5AHJB:9&!#/<<8&$?I)1&3$O!15$)O6/2]85$!'XH5
M(7 O0'KT6A9,,HNH2K&V8=&:8-$L=P&CUM;50D]6UF)RO"8\D5<4HE9@I50.
M><.BAD4/#XNX35)X);,R 0*(8+(/T8004!$HW;390W/35@E(LY0(XD59:M1,
M:Q,8V.28,T4S'[C+/KO$434WK<'10PL;&R@^%G++;.)T,8L2O?,9(:>HD]<M
M;+Q&<#3+M'!)H,Q%,(>!?#4M-0M<&Y9 : =1:@$='!'A7='YMX8)WPTF^,2]
ME87S6F0[2((##DIXIZV0,6*K3+$F<#"7P)$EMQ8@L2 @,RB:F(FSCFE(6CD?
M/(C5[0(W1/C>$$&5* T'(KM*@4\:R0F/RD<>1)1)M[R0=4&$65Z(2CE$GC23
M1=:4+B%84 X8L;RHT-J(8>5%+AHB?#>(8**&')/(.26(OM2^+"HE2Z3!!*56
MF>39_(8;P\(LW40CF&2\9\9)6]---',Y.)95X8Y+SU4P#\QQN&Y5C:L,[%LE
M-TY&U%6JN!W5[2[XM'] =XQ+*/,+NLXG/.A_RCWL]*MW*W$HV-3Z6B/\:7\X
M[E>Y>CK*N]TX?ZI+P>0FP/[Y"<9QKE?8>/:#_/$;=4%6M?876H9V@W:#=H-V
M@W:#Z][@L7?>^G4X^HRCU,M?X@X.WN>./%<>]6A:;ZU\8]19L";QX)PPM:N?
M%RF"L(CH+?=YZ=9;,]XS<2M:>&$U?H2:SUKUW&'V"5APA3, X P)#)@MVM<B
M0L8'?$3Y&:UZY_KA!6(0PGF2-%/[<-6Z:<)DE=%8*?SRK3'.XT7#A2OBPBR'
MM,CLN0++(M? 0*-GZ%)B!K(QZ%3-<=EXIO3YX$+#A(8)-V^7HVQQ(HJDM8/:
MFL_XJ(,B-/#"RN5;]#4.<6M8,<OQ%#';[,"QD.D'9"^9=R8SS-+9C"(XJ1N'
M:'AQBWCAC5$@N2DA0:V Z2/($J+QVIH,)C8.<6>X$.?JXQ("V" 9)$0&G+P,
M9TID'D5T*F9,$!N':)AP2SN;.<64E2PJ*R*RR6"2)GFI<JGUIZ1;=F>S<8A;
MPXI9'F0@H A$(UAT03$ Z5G XEEQRCA4TAF\A$,TI7TL2LNE,E)BTLX[X#ZC
MR1;0.J,#8/)P?:5MRGG5(.%<62D3@K*QYB8KLN0^('.V $O)6##2*"=(.SUO
MBOEX%9,'B")JGY(&;:P/(27G#;>RG@)OUG0-%':6-&A%TA;!,Y.B9R =,"S.
M,A<MU]9J5*'UIOP.M#8EX8Q4,92205@5=.062HX8>?*E-'-Z=]HIYLVI#LX*
MIK,1-:47F?<8652QV,B--6K=S.F==KRZ!YWZ]^$H[N XT]-UJ:OQJ#?<KW-^
MO7W^!U"H[N;[_+[89+DI/ : #$$)K:P760!!BUFZ&$-C!+=>G>K/S_1YL1U$
MSN \9[F@8: @$NX$PZ37M6BLEQG=8PC4M^J6:PL:RH+5Y#MP84KM3%#_R]81
M;*0$&-IF_]T7C)J"@T(G:U4=YI+/Y.,+S;R6D@GZ.R4/-OI:\]U! X8&#*L'
MAF!<R<6:K*T&6VQ(4<80+ _&INR6[C#3V,2M5W6: D86VB(7CL7JP( (F:'!
MS$)1 5/4RO!+FO<VT&B@<7,V43P )!V$,5"T0RZM=*FD% HW*C<V<><5EH[!
MH43%:P#2:10,L&MTB99<#:#72P1K&IMHP'!KNQ7 2]$9E:G)@Y#1:$'L0MF2
M2K%BZ;Y3C4W<>@VD*6!H"^#)U6"F:Z;-+4&'+)YY6B9K A9M5I< T#1W;36W
M>!($DZ3*L8!2SI,D),%11_0\1]MV+.Z^+)'8JO?Z;1L+\NA+8=%R6[M+&1:2
MY"Q&XEU@+(I".JK6J;]%4\_5JB<4&1# :4@%.!344H".0F3C8_*^&=;[5]NO
M9]36:&XR]X+Q0C_ !E[KP6=2X!"24 % MJ9PWX'N)F/0B(11)?+,4B2'C-N,
MI7B=(*>E2_TTT[JZ0C['.@H1LI)6,K*O@8%*EE5KRZ3.UBNTV8JX9J;UL1_]
M?TFJ,\KC@]X(#W)O_!GWVYG_BZ#%HL% G* +Q#G.@^:IA$380F1>QM*B]_<+
M.3!_YC]G&QR/D0E1L0:D8,XZQ;Q0*<L &*5_#('[EI>XMGCAE HJH%?)"%#6
M(F%$34J$J)TQV;? _9WAPNS,/_>!%Z@U!'U1#%PNS*NB&10/06N; R<_03SD
MD'V#A+6%!)Y"A.316N.!_!'G) JR4(;G"-(U"G'_4#$[\I]!^Q()( 3WD2A$
MX@RS3<PC#QR2<N3%- K1\.(V*42NA\B%ARPL0$X!)3I4.J6D4(H;X$7#A2OB
MPNS(OS809%2)Y:+(M:A.AI,Q=6G&41>>="T;U"A$@X1;V9S0-919.$\H('*/
M1;@H+7 1-&"^08"S48@50<7LQ#\XE7SFFB7?E0C)ACG!"]-2^.*3R,I>TAFR
M*>UC45JA9/;6:Q$000@58J1?L^)DU(,5-]A1;,IYU1#A[,2_H/7PJ"2SU@*#
MZ 4+5BM63!+61>^]]AO/M&Z*^6@5,P>G,&'RTI"[I\!)Z4RRM0Z$U4&99DWO
M7V%G)_[);-J@LV<ER;JUS\DC+R&R*(@ 9>Z"3)<T?6]:^UBTUJMD/;?"^1!
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M@*$!P^J!02A;G(@B:>T@*7#&1QT408(75B(T-K$>@#%+296 )L@BF2S>$IL
MS9RQP+0"([,"$5)H;**!QBV"AC=&@>2FA 00#4$&R!*B\=J:#"8V-G&WX#!+
MU03#"T@K64+A&!@OF.NJ1O&@DLXYD?/8V$0#AEO:!,LIIJQD45DIL,E@DB9Y
MJ7*QH5CIKMZSN+&)VP",N?3%E)3A)C$)&AD4ZQC*Z)B+'JVWY">62T[Z-<U]
M+)K+I3)28M+..^ ^H\D6T#JC V#R<$/-;1IZU>CA+'4O..N3\$3SI=,,T %#
ME3U+(8"/MLBDW,8SS753S\>KGCQ %%'[E#1H8WT@X'9=]?=ZOKX9UG51VUF*
MFW2%()6X-X^:_'29R:CRF)A13J)2'DN^I,A(4]W'HKHI"6>DBJ&4#,*JH".W
M4'+$R),OI5G6.U;16>J7+2@B:L,4$.4%823#S)$EF;DND=P7']?-LCZ"LI.7
M:M9?H_[!01[TXN%HE ?QJ#?<KS-^O7R !<^^;OAR\WP 7VRRW!0> T"&H(16
MUHLL@.#%+%U:HE&#6\0=-9\/@-RC=$XQBXZ8 ;>>!6\UX]85S\'YZ,1CB. O
M1IZ[:)IQ(U+R/8"&LF U.1%<F +"=?]E2XZF2 DPM'R .P:'63Y \=KYY IS
M17)R&V1F/B;+BJQQ?>ZD+[7A5X.%!@NKAX5@7,G%FJRM!EML2%'&$"P/QJ;L
M;.,2ZP$7LVP PQUDGP+SO @&+BD6HE8UD4AJ#CE:81N7:*!QFURB> !(.@AC
MH&B'G R52R6E4+A1N7&)NP6'639 $C8H+9&A$H&XA)#,"QM9\44@(A?"V,8E
M&BS<SI8%\%)T1F5J6B%D-%H0MU"VI%*LP+9EL1YP,<L%T"IR 1"9$;77L*K)
M0\8&EG@AFA&<$9!7W6ZS:>[Z:6[Q%L DJ7(LH)3SO&Y <]01/2=&V78L[CAR
M.%?&1_.LA>3,N1H=P,*9UT*P$(0R,:O"0]EXMB"]KVGG8]%.*#(@@-.0"GEY
M!;44H*,0V?B8O&]V=4VT=I8*8%S";+6HY?21>#B2U@IRUR,1=(=6^*PN<=*;
MZCX6U4W&H!$)HTH(/D4,R&W&4KQ.D-/2-6*:85V1BLY2 :3425M=&$8K&-#O
M+-3, +*S64'TW)5U,ZPK:*)\NKOS2G)YOGWU=53MM6D1UJSR+:J\GM^%#XE+
MG^J96V$2 Z<R<]QR%JT)FBPS%,T?0^3\2GIY1TF##8+6N E78Q>K@9K9GC[W
M2KE04X%E5.2UJ\B0>\VLL&0@<HH!ZIZ^?,B1^ 8SWPG,K*J556,ZMPL_LQR!
M&(++47MF9?%$=X1GM>X+L\Y8K9.R*&1C.@V"'@P$K:J15&,ZJX&:6<8!HC22
M%H0%6@\&L7#F3%),\IBR) \9(#2FTV#F081K5]6JJ3&=VX6?609#S#8'+0EY
MC".F8X4A( J9:8%22? Y^)5W.6DX\-AQ8%7-D!K=6%$,=[XV EA=VQHE7;=M
M@E',!:M8R8*4O<2<L&P\TW)5)SB;LC]V95]52Z%F]&\9!&;I%5J('&013'O'
MR>H'P= &RPP24+N:&8/-ZC<@N*>&/LWJKTCA9\D:WEGC;;$L%T=<O_:B=D+5
M+$@NI7'$_34^'*M_W8H.TU%-+D8CF!]8'=N%HUXP\+4M!_%F>("[\ZU^KIII
ML[)96K->;(N#J,OW8EOY]*P)[J]-)L\<VO^*_=%_X^YA?M$?Q]WA^'"4&Q-<
MB6'8^GRJT8;)"903C'-?J]\*QX+BB7'MBP&#-N=+#K \G CT+1B N\@/7LEX
MEVZGV?"_X?]]IE%]"_\;SE\1YV?Y5"YCR+6LN9$U?S,69(Y>8(ZGX" #&.L?
M^BYCP_B&\0WCUSR'K6'\BC%^EK3F@N16>\$TNLP@!V#!9\YL%AJD++R+\5AK
M&\8WC&\8WS#^MI($&\:O&.-GV8)<6N#>1F:,ADFZCC?*LB)D#$*AL#QO/'/>
M-8QO&/^ ,7ZQ(#6,7YL,S1:KOR/LGZ5JDD ;*:1CPBKB]R8C"])$IB1DCB[J
MZ%?7>*J!< /A!L)KGA[;B/:J-T9G>;*$J5K*D)C@2&@;B62'8 U#+6CM=-&Y
M%CM80<9,0]J&M UIUSPWN2'MJI%VEHQL@S$B9LNL=LC UX:JX"PCKZ3(+"!$
M56,:<'YOLB%M0]J&M.N!M*M*_KY*8&%PN,?2\(!-K]=@^.HP/$L1=R$5+JUE
M,B7) ')A+DAD1C@M@JIMCM+&,_%$&?-8@+C+(__; 8;=3/^F_J=G?Z<?Q^.>
MWH%5L'KJ3P/8A\/Q0;\<35[J#U(>'#QEOD/8E:JI.U;3[H)/^P=T^WBYXLJJ
MN+U;"??K37FM\?RT/QSWJZ \'>7=[F#'3W51F=RLSW=VB7"<ZP4VGOT@?KR5
MQ[CNI$ZD_/S/WLO!ISP^V",A&/?Z@[A[F'*B7WK#@YT\ZN%XG.D-'.7>B#XV
MZL<#>AO'O8-A[W"<GTR_0J)6P:U'W^GMXU&]6F]8>B$/<NG3]TE_Z&)Y;W]W
M>)3S\>N]_5UZQ,T3U3LKQ'LX>M\?=#JDZ+'70:;O6HKDCQ<NW%J)UQM:^$(F
MK_>IVCPRD@=YM-<?8&=Y21+2R;&H$RD;=]+2W]LG'*X?J7_%44XD%Z/^^&-]
M*1+PTH7V<51-:I6Y^J'Y:^$@=:_]/*3K#(ZZ ++]:=P;?A[,7^Q)]Z%<2HXD
MC73ESSO]N-/[G$FN!T."9YKV?J$E&!R<$<>IM7AUN$=WC1>)I_ZV-()>O30*
M_BTFU"W.\^Z17^28]T(>3<1'B2>]NB/>S6!E-T]N1Z!F0[RB1/V,XYUN<+'^
MDO_WD-9\MZ+4+0_S<M,TE=US@ZH3_'^NPC@+AJA=X+H4HBO)UWB=X39ZE.!"
MO(!QNK.,L\[2+[-A/#_X&4>C(T+)CGLNQSC] V6<[_YGA\>]_Q[@7_[P]8>/
MZI7\1;Y^\5*_^_#/G==OZIBVZ//O/[]Z\QL0<^R_(L;X[L7+K__S]9>OK^C?
M;26<+-$%9DS6# PZYDNT3.AL>-)2YZ"OY$=8"[&&:630 NC*SD1O0"C#H]0H
M+FJHUU9UE:NJ@_(F!<X<]^0+:%EK>W///(]1DTH5#7;CF=E<E&9RYH4>>7.[
M=<U_F-J+X>%N(O925WW<)SM$7.A?^5/>[<E*F0Y.&\&=?A[A*.X<_;C9.V]4
MJN#T!X<XN?.<69D"CJU$XSQK^-Q/!SO''N[<MZ:.")]]!0,Y'8<'%W]ESF#%
M7.WL/9DGP=V9Z9G[N3.:N33O,PNCC!\9%AKM4]S]C$?CC;^=-LIDD>=G\.S#
M7_B(I=S:(TYX "GH<-0M]]..#D\8WM]Q;<;2VQE5%/N/OL@B>P6!_-P$VCHO
M2C!9J819\V1@F_3G374\>\.__PT?[".4WD,>_<_5\'1T")\M4I\S$#,Q!D$6
M+GAM'6,]1'#>6I><*#I T@KXQ)[1=W)Z7NU+X-E;GSCJ$H%(2L <A0&M#$14
MVF]<1(@7NV>W!S!7)9?=4[ZO;NK/4RCO9NGT1)ZB_F?233TGHL8CV1,.7@MT
M"13FP&N#5FGB]HMJZ6FN!9N9_--&_B1".!<UW,I8(X7I]>#W' ]'(QKC/W#<
M'_\Y& 9Z^$]5Z5X.]@]I%#2<2-_JAOV&QO6/W6'\^/W9?+WUX9<OVR$D92TJ
MEIT3#*1+9"-0,O3:N91D=DIM]#)1H_UJ^$:'^4+)56OMROUQN$=CI2_4&,V$
M!E;EQC \/)AXT#M(<CU>0$?(0YDKK-"%:^),#>*\&M2PSS"2;-%M/O</=GKA
M<$Q#&8_I8WMAZM;3/<8U$E2&N[O#S^.GWPKC3!F*N @9NE#FC,YTX5.:UEW<
M'^>GQ[_\E/KC_5T\>MH?=)/3?>FGTW?0YR,JW0TG;\\8P2:?L()I,8[IG:=O
M;W9OG8D&3]YS?--Z<>';?//B]RZ[K-U47EWKJI>_9_AMC-4*O=15OU'NY)L5
MB\Y_=,&6W(2^WLWFTSE%77QTH:+^V3V%Q_G\BW??:OCBU/.OO'_1@HV4^]FF
M77)&?IU!\3^16-GHJ'=.0E8V&?>\<[VDDBR_=7WEY[^GK>DE'_P*,:6@;2;Z
M;='49KT('K6V,MI<LI#$VY?=F_['U(3_/+/@,Q9\B@0?\]&C1[,G3>/A6W_]
M]O7=B]V/;[_2=[[2=_=>?MZ2OWQ^^^95GZY)_[_E[\[M2?_WQ[H/_>[%JX^O
M__K] W'1#Z\^_+/_]L/SKV_?_&-G2[XDKDK_?_A]E[CH--N=_GV^'4J46F-@
MB%UL43CFG.5,1"E#S"[H7!8G!MU3?/LV:J.O:J_[-DS&TDE%#QUZ;YHU]&"A
M]\9I099;$1-R&32 ]3K0;]X8EYS22L92H5?X!KUK ;U')] +IE@="6NY2(F!
MA\)\"98IB0XS03$$L?',FO.U!-84_JY;,O(AL>/G--0NJG"AT_3 V@FOG@E>
M*^9X=5R:H=&;$3U8R:-13G,QRI>#&IG,Z=&?D[P;Z'HYSQHE!B55!I8DX1<H
M$"QX;1@MM2LZ)!G]79<TO!WFN!BA6MOR=: ]VIL /F0?O8;B$96*&6.V-KH0
M,70XPX]QYMJNY_(XT_#D:G@RHT(F.8[&!2:2 ?)"DV&.B _!2^3%.@X@8>.9
MOS$36J$Z7S=.>%VR<UE.P*UJY,^SG9H\/B#EJ;LM<_LUMX+F9E-??<N47YR_
MJC87[+8LS(*>[DU?HR/!6J/M0V%UB[S-YZ-1%<$N]WLBC2\'S_=JSNWK\BT'
M5318OA(L;\W3O*2U!^\<TSR0AYJR8+7) 4M)1X204!NY\4S?4;&[6XT-WD/X
M;Q5=4-8:<QX*PVN8<^^8,Z."*G"CDK ,M20J"$&Q4*1F$"*(E&F=B]IXYM2*
M@F(M[K6<UOY[<EKJ>PM[_7"?#.DD\VZ:;E<7X*_^P<ZY++OQZ32[TSEY)[#T
M1SXXV)T@6@.H*P'4;_.DJ"@R/5@$*]UIC&@$0X^*@5?&>0-&U&ZN@OMS"/5C
M"SO=OYXOAK>KZ/G*64G3\_71\QD1$4%PYW5DV43.0/O$',=Z/H=K*W0RPMBJ
MY^=/ZM^+GM]U/.H^M/1U/>M]+0;R$-RE-6(@>Z./JT:E;NT:'ET)C_Z<\8ZO
M[^EY?ML&1?R"%UWC,(6\(^D86J^8L\Y(GE1,JNLQ<P-,:@&1[R @<GL*WC;;
M5Z/X1Z<5G];="B,3*SQ[\C528<%JR40J0,H@4O"XZF[2#[*-[,/;8)M+N#^N
M?=%3XC%LJ_5^D#_^H"[86KL;"5BW+-?[;JRRGBFP-S]]X(+3P8F@" ]%[;:J
MHI=D&ITF3IS5LFU56@KL'7+:Y]NI>&^2!N8]5PQX4 R3!1:Q&$YDUG)5[K"=
MUJWFD*W,HJUU/=2[+X:ZUG!_WZ50UQ/N;^P'M<-F#PCN9R'5:+@$;A/C(64&
M+@%S3I.PD^&6:()VSJY%%>H[J'QZ^U5'[KZ2Z'K5>NS5L,5H6B;T=D?VC2(N
MXZYPY)A@8_QDO:;H'J?E]SS.M>Q85SPQU>IDP_T:@EJO"<I?]O-@3.O6#?,>
MIZL+K_5^Z _B<"__>#RN)[U!7J\9V[S'.5HO_'EY7#\V'NX=3H"T=U"/$.Q.
MB]>D"OS=/FVK+7QI;>&U6M;>/W 7!S'W\."B6K4GE8.O4FKU'D,8/]<#+(.#
MQUWX_R8%.U^_B%^VN4*!0'0U>,499 4,@^8,?79&%^."-1O/A#[/7GM[T_J<
MHV-&@N,>]N)DVD_*71UUQ:ZPRS(==PC?53$_&-92GOO8GQ2YFE;,&I#@](3L
M[=':[C0 N0Q U)H!R/,+@6-6Y/HJR&%Y$#9F+SGWX+1#[[T0(3B3!5BQ=$_I
M:WG##3(N@(PW[[]N6S E.!Z82EX09-0C_E!S!4MVA!].QWJ PM025!=!1A6)
MJPA#4=:@,U%)4\#JY)5107$=O/-%XT45NYLPW*XP?/R\K80.1DG.8G"10<+(
M0I:*H? VN203.$(KTM<+A>%);6Y1K0)!W^[1D^-N!//E$CMDS,<M",YT-Z@O
M_8&#8>GW_HWC@WPXZFW]\:+W8=@G*_2)UO5PE*NS3/)A-GO/Q[W:T>#XBW/7
M>M+;RJ/X<<Z<G;%A<P4;RV%WU='P"'?IW6G7C:X0_8523:(3:B[!"E!.K4"N
MY_(CNGR($U%F\ON3Y=HH26_;DFS6W#*G.3 (/#%?E&:AI 2(";RHR9%B\WSK
MSO_LT5*3USJ)AU0YP-W=J4#MCX;IL+:^.-@A=MVUO=@?Y4_]X>%X]ZC&YU(O
M''72>%IF#W9&P\/W._/[YYU%A<W>FW/518E"C>?DE?XX;@-"DGQX0*]^K7UB
MNDX<)P=>)ZQLTL>COU??IRO1<#],.%K79Z'4^J*]*E_O22-J/P\V\?'H ZD_
M[KJ$]$95/:\L_$I&4R*ZXH2!!,;%4J25.0?">@5EL?#+)OPK%OY7+]Y^V59)
MBUBX8^BXKS73//.)' $?G:Q:(8,@1^!\W?[_K+!,\CRNN#@1QZX4[HGL7*NG
MBUGK0L!5_?"X9DY]_@MK^79V1_(S%@SC_Q[V)ZR_:@U=;H\4]H=QSKU70_H8
M_#A1\7F[<MDMPO!@IW>4<7365"ZPB_-VE;SY..J'B@1A^"F?[91PDCST[.]A
M]+=G%[QY_P7%)U'$+N.H2_WKS:GW^$(?<GW%ZX_A7CXF*&=[*Q5"N$'LXRZM
M^_A@=-@]XY/>^+#&G,<3M5O4N*>RK)C[7?[CI',3"5?WQY-I@[&R.T']J2L>
MI@&A\4XFLT:&*T[;H$R4_,FTBQ/ND[WXTMF3\:DF5(?'0D@OC7>&HP-6S1%!
M=[5M2WGVZ]W7Z<TI2WJFU/>0+GP\P=UD[PX'[R<3D'(XZ"+>T\YMQ_&2?9HB
M4N<?+X[ T93CG43?SK7$>4%C?GDB;B<IMJT7S@4659!%Y=LF$F\,@KRB& H#
MY)EY4S*3N61%=-+X4C:>*;UY/A'HI/=-K.H_.JX$CV>4\*J-KU8I#_\BB:X"
M_7R0_JCJ77^?,+"<)F?*FWA<*!YOGG_9]B4+KS(R;40@PL4-><Y>,>.2MHY<
MYZPBB8?:7. ZA[DXRD5XP:^!%]?+0&EX<7.!^$5O2XM.84Q,(R@&2I7:SMPP
MJP*0U7#)QT "8387!-9N"2]6* \-+VXB'G_*;6T+)A$BBR8AV12;&4KIF <9
MN$Y2A1IV56)!;[5C\=CLS:7E5W"8$9B)@U\Y8NT>>W)4ID=\["/QOWWRU::\
M\9I]V,Y3OOOQ+2Y*SCYN350G8#3ML4+J\O.DC^GO_?''A\]97U>+T2-%'-;%
M#O6DTY-Y+Z/NN_4/AJ/::N;L1,QWASW;H28.1_O#+@94!>0]N9*C0=>&N#\>
M'^91]_UQ/6 U<3OKAT[[,?V#P\F-NLM-/(M^Y^A.(F?'+7 VC]<C?]GOVKJ3
M.[O7G_9()F$FD>V3P])M+W;O5 B<?Y0I+M*C5GDG^9Z,L#<<S8^#;G/L1_7G
M.C37F^SO8IPX27/^UR2RMU<=I1V:[N.Y^M]#[()Q-*Y!PE&JKM:X5V/=_=*?
M>5IG7;S9+<DI( _XJ/?^D/2L+N=X@8O^X*2P>DY[^&$XJG-S@9N+,4XVC&=>
M*TU_?TS8,AKN'8=4I]'6Z3S^N?G'YI/>+X>CX?Y$$'_>(2&;<*0NYMJOW9MV
MCSK?M+M,&AV^)VD;TD7H0J.)9([R ?;K7T]Z.\/Q?HU"T*]S0HWO,TEN=9QI
M*NB/U-O)N%O58'*;X:>*BE,G>P?)I-$2'G?=GGQE--Z<<+4WBY2O@] 3_=C/
MH\XN=MD9U;/OA.LSF="=25LHFL*J I%6>;A7;SP>3@2R:A M[WZ=D!$]=^TG
M/CY^R/'^<-#IR>FF503<4^FEKQ6:ATDDZGB,-!?'T:[#25/HZ:A[[W>'@49;
M#U4.]R8=VZ8!LOD^Y?71/@WK/G>G&6>!I%];Z4Q"N'2M<9USDIS!\56/,];F
MOC9I83VNX??3TS8Q7).G[<]#R)FLVTO4:/V#D&?59B8#W71V^VCT/ 0G"S5J
M&N/ID.UI;RO^_S0_-)$_3^&\VQ1[7N.TX^'A*.9_9+K4J;<G:D;0UJ_K]?]U
M:O"D]W(0-X_C0Z,\C0W7(.,L5D32>+6]@KKMZXD@8[ :N!8NI.P]U@8!:$#(
M;U0!.+=I<,K25^O^[SRJ+Y!RBN]Y-V +7KV@>[QYKK8^_*)?OWF_78*/,9;$
MO'>< 4^">94*4TE#B49+ETQM.75^9^#)%=<X(' C!193% 0>O<X><K)6\*@]
M0%OCU:_QR\];+[:V=980"RUO,<$RD)E6VQ;+4!BTB1OOK*M98 MV?[H,XBON
M>6,1.M2>'@J<"K53MU$\I@1"*)7:,M_.,K_?IEDNJ=;8L*I6N.=HF->I5B6T
M229:^^"[ZC^+5/E\DL:0F-%BHG91!/LTESC%=[[-:HAKG#@&[T=8[SEE*C64
M<,("!Y4K[9+$'8[&7<!CYCO\ U,7?A_W=O 36;],QFRO/ZAR=7ID:4@V<3 \
MF%Z,C-6H;J6,JL^[6_?71G0'XCS#;N-IZMD<U1&.#_=K(/]X9!T_76JSX\%P
M#9J[Q?2\D*P,1UV:P/M1GFR^36C(!;X>+5C,(R+;-6Q%5QOU)XQRG'<7RM7I
M-9K<+E\MCRP;<!)08A )K.(U>TP4LC!1."W$I-2($/RB6D+G(EO/I\/\_624
M?]"2MTC6!9$L]>K%;U^WBQ$..4?FN38,2M#$*'AFR019$K?(C29&<4D@Z\H)
MA%"R1XZUEY0"*SFQBR)0&^.<CD+AI,;,\<(O$=)L"W_5A?_S\S8JFU*(R RG
M'V3M#7,2:>%S2"6HB-G)NO"7['C4S*I%)J<S&-],0#YMQ+KF[]5HC$^AUUR1
MY)D7DPYKV&=X>- %<[K/7810W=;[Y,6Z,UP##:==T],H6"]0;48^R82O[CH>
M3.Y!8YT$S4Z"18/N1&?G_/YQ0/]T,8D:J:RW_;7+N"$/[ 1:)P&62YZPIC9F
MG-A*3-4>C@^.G;_YV.!G6H'._M$$GICE68K*)/$D'6>>G,#S7-K!DYD!IX_4
M@P-=[.[X&POG9W.IQ/*#4_8I'0_SBM9A58=5?B=_>]2OMZ]KTLZA? ,:R,F$
M[< =)Q@@2V!\33^+EA$9C002SIK(%3D@N2:5KRZG?%7'[=MJ7W&U/XIM<OP4
MDEO/,N?$ &14S!FC&:*"6J7+I9H:(?CYY9Y P$GJ^/G<PFEP$B<%5>;(]I30
MVGI,Y_R9FY/&]/^Y<>I;TV/V?/85# 3 AP<7?^5<;_![(NU=M>93TS/W<V<T
M:VW^/K,PROB18:'1/L7=SW@TWOC;:5>%_)3Y&3S[\!<^8BFW]H@3[RC5?/UN
MN9]V!GUR/NKON#9CZ>V,*N#\1U]DD;V"4$I)H*WSH@23E4J8-4\&MLGY?M/1
MF>'?_X8/]A%*[R&/OJ:.3_)&\=DB];F*^SXI_S*/2!.\#SQ[ZQ,G\Q,A>1TP
M1V% *T.&2&F_<;+%DIY7$P)&%L=IG#PE(";B798JAIS F12UNB> .1,2&O1"
MWL'=<KRGMYC0G9# \5S.*=8_CLWHA$#?5GF+&V89'Z=KUKVT67+Q?<S^Y-C&
M3CYAWL- LC>1,J+4';F>I>)/78OUFE)RHD>'=?GI28:GIG<N2_T^Y_ATR*F;
MTL['.9[52UV7*L+_1%+\T5%U4^2QOR).^Z&3>]2S0W/G;2:\I&Z8#J?NV]2E
MZ2X\2=B>.HUXDA1^ X>Q\UNG)5UFCN(DJWR!NUUSA]9+E%*>A'+[]RLO)Q;C
M'!-=3;[&0G/R3?-PQIPXS;F24(1TY/ID"-*(E)0@]TL+;>T]F9,7]+5/DXHB
M"T\Y3))\ON1XV"6L=<&;EZ<2!O[XC/N3'?_9M<:]Y]-L@3I?>_4DS&@N0CT1
M_7,O3P+7X_QI$NI?YBS&5.TGL>P\JJ=,NV2GFC$QK9UQLBTPW27 P8">9S*&
M<3[^LUNM&KKI4DG&DS-&-9]CP2;$I(Q"_C))XJC;&_MY$IZ:)D3,'1#,].[)
M#$_LU^1LP@QKGRQ\SN/4KPZ1GIS8G5,O']]B[NF/IFE4<\,]B8I-#SR>!/-K
MD.P3CNJ9R+,3>$>''L[Y]3,1^OGD 5Z?F-@WP]_SP>%H4)^P.?L7./ORU8N/
M1Z\^1/[JPR]RZT7<=K8X03C#;+*: 8%4+?(?F2E9:FY4*$!DEJCP)6&>RS<7
MSY*@ND83.S8GAAWWO.4R:G=#BL[;F?M [L5FZ=MFYCQ 8/I4,Y+. 41WQO)F
ML+"B<-\B6/B]SD5%A+B+_;T&"4M" M_Z^GX[F.)K8(!9CXD!CYF%DB-SRML
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M&\YY;:361Y\TR@C:10@,>:W(GCC% WAKE D--M1F;0NC7_,[4P@J2GDC8-$
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MR;!)C>BF_V# 4\,9I,Y.D'$AOQKSA-O"YYMB>U81XD#-_HG  9@!6XW&U,-
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M":QGU#TQ>]TM,3UQ+*>X-(62H%8I&)H5N<YX$+B?,_W,1D09DW<UVZ[E-=O
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M8F)]+27+IZ4UPC'=;W:*-]/F^S5'8O,013$Q \8<-;-9"J8EI_6R&D4K>@F
M(WIJ0(RI9;?H%L&K[H1;K+WUL3,NQFYG[2:3Q;0]+B6[;!.LD0^H71T<]&7W
M9[=_I3Z;.B;?-<'K8X(S,,DZ^MB;]HW-/2S<D+D8F[4)S\9#LVXCG>UM735S
M-P(T3.$K9</!G>J)U<]:(+_E=ZO/[%:$V+T,>WVV![.^;O,9&Y2PGZ/#3@4
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M)UMF9W72RDKEJQ=41R07&R:;#^D7-08(6;;[<:$[6YB9&IV>J7/*M+L ^T&
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MN'3;,P?[^.(T5)1NP_Q,#O-!471GS@^PB<089_S54T]+J9>J-X%=HA?-\,Y
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M5)+$91[C::*4E\)%O"3WZ&IF42)II!(:^X1P2C(:14G $Y#J?A Q<EM7\Y8
MOG+*\\71\9E_</PZ.(0_#_=/3Q+E2>'YS*6A)"[QB'*SU,_<E'!/AH+'24:
M%L)K:&%Z4T2J[ZYN&O-W9!8*)  5.-=UAMTR=FK54L<_.]9N1X]HM5'W@"J;
M@)OVUC)4 ;D."CKX>=LEHAE64X(XQ6RT6E5IGT';R5;;V=WIK]W8L.FW#W89
MZ) <0__U\\= \75!]B%.6]39EQU&\$#>!<3C0.L>R2*?IH*$5#+/2XD,8KZT
M -OPP*@\^_D8+%$@_G<4E?614GTN: ]T<<BYF)67DI8_',4? ,6_#T^ RCV1
M9L*-*14NH4'@8M#+]:E*!.!+E$A@UC4A%WMY=N@VGES7<]4Z )K$E8X#P+0K
M,%69T\MY?X !5%8=[SB6\IJ01>.0Z-#G3D?_MYVOK0??:O05^31(M8@A9V7M
MQ;/=TKN!'?D%$X)K_-CC2ZOXK?\ /VC&O]PQNGPG\K].(?08X/67?/H*S^]#
M<Q+O[$&T!5BH*[;J806S?#GX?."?2!D(EJK$C0(2N212L4NC-'$IH=3SXC #
ME' ]/EA(A'(.6@K6J9'+R=@P1X]H+>EU?%4WV4]?E^75VE/*YJDA]]^JGEI3
MRXV&L)_@K+?KS!$_0C\:U;UVW:%48 BDM85BS1$7?_) \34_L"-Z%O_[C51?
MS>T?IP4_P_(TN/77<$W3RT. !?NF23E0RS&\[-<A?.;!.?=/R[E%>#@Z\ _V
MS\C!,??^.3[S_OF,7'QZ^>GS&7 ><.[5A\$!<MX\YW[FP:>K/T%]G<+S/L"[
M/XR0BX_VX7_'>U^ <Z\.?WL-W/WZ"P"[+P=79R>2^Y'D,75YF'D YL+(95&6
MN(#J8E_1@',OF:^XA9,721"IR.,A":6?A;&?@#7@P[<E$.XSL @YG:#S%53!
MLY?FW.?U9)\]ECIR;GS1*G:(-MHZ1R^+&>K..^5)NHEE/65<H^098(<2GENM
M;MA3#0!H5O=B.[\]?#///*]T>%:ST$?]HKUZ2>)V^O#A._A\;Z[B%R=!P!)/
M),KU91JZA 2QF[(D<&,5AE*DJ> \??8RWHD\;\<S_UM0BT8VFMNUN8DC+$S$
MJS!=9QZ&(MZ5$MO+2;$EBG5$[<7!WHGG)ZE' NIZ7/DN 64&$ ES]N*(1%*
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M>FGCV@9W.RGSVE/8D;Q937K62?^L27VITX[KU)I)8O,D#VQ!JDW_;#0<P;+
MFKU8.-4Z9Z8/)-K6*3CQ2QSX#M!J%X_MYTY_<"MXC<]H&>#(1L%9\X:\:EF?
M/\3IU)M=O\2FZ?H^]+3D]SBH[?1RW0QZ[_2)X4WY$P?-1.N['\,WO29SXI_Q
M KUJUN?U>'E^SZMS21'P=T<1]B[V/[YZSW*>-8L")48)XHS:["(;E +X&5I$
MX'1 $938-O,.QRV.Q@W2\DB'HTC+VJ3E[?NH210V'[00YQ$7BB*3KPD(Y;'#
M/LJ0'$B+VI8+..6M+L<- O-(UZ,(S+H$YNOK]\%;#EJMD.0F@0<2$S(T$N12
MTA34/PO.UH[&VWB!KWJ:<U=/1_-^R)/G[_GC&,ZZ<7RO<$X.ZE(C8V'X&]AW
M(T!3'EVGWWS/5\_W#V'K#6RPS?UEI-.(.VN0\3(@+&P*A K8_[F;W"'&: Q@
M2S2*PP.TM"DY%;A,)$COKE\]7\A_%OEESX?[/ :;ZA=WP?OX-RQ1%MSO&J#@
MV6_>J^!R WF"/,L6+8"\&J/@'T*<!D8"<D>W=LRVQIM*?XK +%%@CMYK"BR'
M)HV 'O-<*DWFE *%@B,TAV635[G7Y?:B>],;PX"*S"Q-9@YV]]X# <HMLPU2
M%A@SSR?1FH+T1$]%H!%S&U.^0[<M%PC-32RHB;+59X(S%[.:J%(=&^QWN_WS
M.L8T928OOUV.Y<:H2%/I;F'6ZJTV>^=?=3VM:S6^<M$ >SJ,+R<__!PZP].N
MO7C9Z=6!COI#/U\=QH+>\G4DIGEYFDZ^C9N4\G%CFO$WCU_>KE^Z5GFL>4UJ
MT%MZX\MXF]SXVK<>J[>9$ ]ZZK=?D_AAGWQ.8Y5W>NHM;8KNV6GHJ6LLWKWR
M62WF1_EF5/6ZEP.Q=VY!=*?)-S=/6M66([/H>TSJQB*=[9__XLW.I/#[GC\Q
M5^9_6P>RF[J?/8_68Z\7'Z;=I?/8HQ>F=45I[]G(I[D>O5R'GBV-:U_2YYG
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MN[5#U M-GT,-I'9XP7<>S)WI].-A;8/I]/TFOZ%8WOJ(Y>UX7@*9RP3RBZM
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M%:@I'*YPN%LYW,.PM7"XYP"L!U,.YQ+526,#<NDHXBX8I)V6* :LHN%"6BV
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M)/6^6+O63FK+;Z/6ZAYJBQ%M>3W4VME ;6G<_F%@7AJH/0<DG[FNFZ1/5/.
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M.Z/CFZK+O*ALMUOUST:PT[V\<>/R-'_\^=>P@K]4O^<??C@_CMG85>,+(R!
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MQ(6V+G*3++=;.QROZ-;^W;!HR97)%L#P6JM,?LOB/E>H7;S1SQ]J%\_[/A<
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MGL*G;?=@\"N,(X_PS'9GMFS\P3\N"P?MG@W@4[_#0O1#0:E[H=2'V0P=CQE
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MG';>)P&<3]8E58I"MU6A6]%KK"CR>A3Y8N8.A:,V@67&,G?Q30HC:RA%GIO
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MEVRSB F48'+ E$$67 G;E ;1I +1,=6H<XKA,VPS(#\1R$\B.'#E9-P;@7^
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MDB$C)TF=YLC&^UZN\.3T>3W^N@H5IA7*F"_ ^:C[03_KH9_?E^L53'&R@-X
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M@">C/7FM:MPHEH=!OBJ@%P4'.6 MU;6S?B6H!-7)Q@JVL0E,*HKX[JZ]&''
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M6][4P/)DL>QK]2:B2=DQLO?,7N>J3<C9Q&KJP/)4L;S(@?2ZEF:#@N:C A0
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M-X<Z*K+*%S+<<V2J)QQ@GBR8%QF*J<02HXZ@*%>Q'EB4@$L!8@FVN1:"3VZ
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MY ,TR^:;3\T!SD-)8"F]YC2R0/1EC,/'^9H ]]YYAG:P8O"SK/ZEHT(HLOA
M/E4 1A'+M@:W-,]IQ!%Q-9'9:XYL#C=R*]W^$X<C&D<8ND/IZF(8-<*((=8T
MBW1'>@!GR1=)]H\DU.9Q@C8G+X*6,H_.'H/@J'W0'71A7?NJ6X+(YG1>T]F
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MZZ#M>WC6U+]5-6^.M,306R)21SYD!QF*8T%Q!3L8E9OW R[6+;$L/3]8/?<
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M(4$VWL1FS& T9-@#Z^?!RS@]!,%A+A12'V64!^%-7!C96XQ$:FGP*)XE0"C
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M]E8=G.ZMD&^2J@W/B;B"C@Y<";T->^D-L<=J6GX+'6]!OFLY:TNRWMBI"X9
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M0"ERSCG25918@K#%2 &J^A8)E(7,RN6D20;7LXU]!;+LHXDJH*\%*T15$T^
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MW7!9.RX6?HZ^ /KL2<A:28"2483$N*"4M9VEG(':#9>.BOLZSW&E.'3%&;)
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M K)L$<I<O0\I DC^I _U_0WUKX]?28"LP!O1RCL+4#D)-"8)+T/1$3)_[JZ
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M@/=%H')&9(W&)(I4C-O9#<IUG&XU3OL.Q"UW( !+#8ZD0@V0DDP8$WK#(N5
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M4*"V48"JR6@7995N9]?(BTD>.ED[63M95Q8YTLFZ#61="B71SED*20I5) I
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M'ORX\5<VL=9[:^)\"C'6CB:SX7[(\Y8F[5O\3CB8=QGM31JT_]=8D:)H(+%
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MKJ4\-:+X8F=I$[63.[OF 5QDYM?&K<LEJ7-KN-PJBM<:[;VL-4/6)B5%V29
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M=%[=_2,9Y8_)?=FSRJJ<E<9/MM<XA6>/%5:'BS88.F9=YVO\>3"<G9@\)67
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MQ!F(8!<=1X&#W.7..\H"P)84I7DM8%N;J2-%^L[2D0Y:=) >>R%0<)@AGE)
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M:&)*@)@&]7OZ.O<"[+H NP9M;AZ6TZ-S\E+S6PSH,G8[17Y/"/.]._);<\_
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MU(:L%<KGW'&KB.XEH/K+;50[L $R$R.>IQ)SAA.RB?@\1TP)XQTGUFYL*5Q
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M9T,\-V'7B"VAPFI$HB)Y%KG+U=8>B1BL)-$[J>S&%IU!5YH:\,XR8%04T**
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M1E*2Q!BG*N"PL<6HK@=XUS 3;ZWGE]4C%^^:1@9+76AD%C3R>=2"<)(1;+%
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M7O4,]\#G#D\-Y!\0+1/!.>8\Y8PI1ZCD1%MAB1>6Q8$0A[^)83N+5,^C!!%
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M?R;YE.8QSS10H&L50,LB]1'M!G^84E+_Y[]_6[.+]];SS^G$?L^H6&#P:?G
M&2B?4V8VU>ULW8^M@09:MV:>J[%V(TK[+.AIQ=?H?F25\_7TM7OH?*WI@)A'
MKLI?W4XX\WVPH?JV_;D)A@N84.W0:#5]]J:/G;69K4K=0CZS3<-:H9#.U&E6
M3CLMG":.A<0)9YHP;VBT7@N#;62';R<KI;GVY+SI=,)YL]7:;H>WU\=S\-+M
M\$YJ?HL!7<9N9UTB.]\^O7EW^>G-SL7._ENR]^H+WKE\+?;>?#H^.'[+X=\7
MN_NMYL[)[I?=]W<C.W]\^?0*[N7R[;>=XP]P?^\N=_:_\$\GN\V=X\_P;[C>
MQ[<7!_0=^>_EV]&J?BNY2@)+A!FCB#,GD,6)(4Z"4!8;2AG+RIVFA/ZZ/NE6
M=0OASR5$7_BX\/$4?#RB.WV'E+]/TFL:@U\<4X_,"[(61Q(3$IYZQ).(R&GI
MD$B6,>UEKFS*DT ,&Q\C7'BZ\'1]4Z56B*>G3H5R0D4KDK*2<.XM-U8(1;T"
MVB54.%[Q] 3]*Q^G-Q?6G8AU;S6\P X;D9"S)B+.+4-:8(*45(HKPPWV;F.+
M8+,JTY<*[Q7>6P_>*_II#9ARI+F7P=)2I7.FOD-<68><(QS1H#4S7EHE34X1
MI6+&Z?HUJNA-U7^KXPA^V_X:V_U.]Z)1Y93&\*2^I?<\=>WZ"-31P+XBJ.$>
M%/*9B'QV1MV8E/#(-7<H,)(0[ ]%VA$XH=S9&*44/(%Q3,BXFK9"IO'][#)7
M+?#.1SZIMV&AAZG];U>_'9:[_&Y/J[&CE[GWR) ]?N_TBJ4W.87<Z"\1.$0:
M:U!.5 8E1G"DK:)(>M@Y!5H+#W9CBZF5'BQ8*.19F4A%PYB.'D8'<<L\6L$2
M9'04B$<9X"?,D-!16ZL5?/4;6WS<]UX06A!:A/Q247PCY(V+E@0B4<0)A#S
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MR.%7:0PR1 46O(U1IHTM\L*8<7=!"6XLQ8U9N+=P;PDPKSP'WP28!24V@>&
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M[G[]^ 7?2^SQMW+O[_\Y?'NTU]W[^A'>?GWW<>_O7?&?KR\GO44^O/VR]_G
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M6KW(18 ]9T);Q^3U\3_'(;@9,.]<UH2O %X(P+O3SB;7DFN1(\E6*P(V.&)
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M(L)IA39-%"CB3!*6F!$V.G!-J6=QEZAZ^]*9UR%POFPQ@K6MBM*ZL'@_=*\
MIZ)F4=2\G8YX9R:UX:JPI50?D(82DYTC:%0F[YW0:%MN;,O9Z@.UFM%3D=N'
M"?S.E=OJ':Q&GB?>@:<V:XJBK%RB!+23Q%C*"56> <M!ZZ!7YAU4H6ZO=_#
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M$(M86$F!C]D8H3A( (=.?XR6&ZYQ,8T2][_#AXJ%1\3")/[+ N=<LDP,A4Q
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M%5WY7_F_(OXSRW.B+EO!')@4#17)F<P"E\KE9!^:_W6+945Z8:K)*YKR4>5
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M4WQ?_NC0G78^(SOP8Q>U&5/LY$'_Z'&"I;R0N+.S_\O_MFC(\8EP-!]Q0/Y
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ME. BE<VC-(&.D7F#'QX'K8<3B)U<KJ/-*:"5OQV?Y"I/%,<+L(N6$-[HR'W
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ME3VA<-*PU82*,P;5,"4I9SCA%:7ALEDP5V<(:I+*F/+[G+.2)7$T%R6>8SL
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MM$P:DE7)8V_.C)F;S:D+9WQ*:,?!\UWQO)ATRN3U&8%5ZBK-1,8EA0DG;\%
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M&!F>Z5!ZOO[-Z.FWX\T71Z/?3:/AL5N/++(W6>IL;?U0?:GS>C>)"&;@&!W
M]^&O(N"//^H3Z>\AQ->XSO#^BL:C1:^I4U[?@S[4*M4>KDS*6>=J5H;,Y_+K
M'2UZ@A9=K'JUCNB%+&W968*$->T",C%15QP9=9>+1XN.%GV,6N39R69S7HI$
M(JM79:'9EBJ%8I[/%?UUM.@)6G3QZ2%#+9,]K:)U54.J;8<0>+)@E]7(F@<>
M+3I:]'%NIN%T:"A]5B":8:O2Q^Q@A(49HYW(HNMISL6,9VT,WT=ID[8WN'%+
M.C@G_/_9^];F)I)D[;_2X3UQ8B9"Y:G[!38<P0SLO)Q8P\S"["Q\F:BK+9 E
MKUH"S*]_L[HE2[9ED"W9M$S%#&"KU=UUR7PRGZRLR@!N$"$YDXKL'="-8V5%
MX[\_C0<]%S0PH23SW/-LQI*1UH"KG1+U<DMY-\7[V  )EI+PB!4B)8&$@PGA
M.CED. Y(1DF"9U($'Z[W/@H<%#CX6JI^XEA+$#%%* ]).? &;!!1!,NM"J0X
M /<8C%UDVFD<23*"(R"+%G'F/3))2N2=T(IX297"Q0,H*G^K!71/3/*8,BHE
M;X(.UH''KY0TP7DARXE-]ZCRBTPZ!9/!!8M()9S+$B22TV8TXL09[P,'%!9[
M!T1MZSBUHO/?D<Y'YJ6*1#"F&;?.&::PE#*!\@?X=9,\NJ+S-]5YLE2[5##-
MHT)4N5R[U&IDE&5(<J8Q24HZ3D'GB\87C;^IQBL:)1AX@X7'G"AA<K41375B
M#FB_+QI_GQJ_R(33DIJ(+4>$J8!X9!8Y\/01(<9:IU4*@64KOZUS&;N7!W?;
M!+T=.?NMG/:VC>I(G#JB&"@&I]Q+;K S40:%-7.6B%*-L1/(1I?SQR3VT9C
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M'T.T.DH4!*%@YQ-X]HYIE*CW(LH@L0$[OWFUPJ+RWZ'**Z\DDXF <>?*)F/
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MV[7)G6$<OQSWA[<C%BMZVCF@V9Q8.$55LCPJ:SE1VBI'(J=>*>H"7"S$H@-
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M*DBCV1XMG=,,OL!GW&9@,?L!L3/P=5%E]($T<GX$5X!T4HJ%K!^$''4YD7K
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M=3*AQ_Z(G3L^V KV#,Y(XO*1"B :A1_0#'P_AENN4U*-*ND<0ZD7!4+;3 D
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M+4"['JR4'Z!KB]USYU@(.MT 2$EP\3(7)T:R_&!VNM1HDX_J.J-Z#NB#G7B
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ME0$YKY C>N\6:8FP3;,[I+"YPJ?DS!W8W8[+/&=DAMNUD,4-'#'Y.8&P5Z"
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M\]J7XYZ5<8Q&-B0]>BYG_+_"7>$7GG_Q5O#KF'@-(*\^EM6S:A+@U05)\2)
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MJZH=Y Y:9H3*_$']F(9#PHU977O*TU@T,#$?7/A,=?"9V)@4@2(X.=XV9,_
M4=<4.BIT5.BH)<D8ALX9STJ2,2Q=*_,L#"?-0160F<M)30JY)^%__B!#H'P?
MKW+ATV>M^/'SGTE=^+&SYXX; :/QDG=C%>^(F92Y$R!XPMHAAWF,1>3E$_<-
M!%72QB: X.LC77W3D6[N %>.=/ISD$ZO@&[YWT14FW1B)LMIZI5&??SCFNAJ
M952JP(0CETQK 9!<($9'@>3S05*EI2B05""I&\\!26T2\@Q+],6LF.,X:=86
M $-C.\!P9IOB5ZOV.+7DVN:4@&R,42[W4Q5S7"O.J&*.JICCI&C.*VJH:A:J
MFH6J9J&J6:AJ%JJ:A<L4J]APG\#_ZIHJ=[,13@%U?+3VXR/=U!IZO<EK>>FF
M?N#UPI]8 NL?AW5TBPHGP?1C\^-'9L>\:!?\"3*.OUUY5-3OH3UABJ./($QJ
M'^;+?/E,)CI65US*,.FT072K)>U^6<O(S%7W6G'VXA9 GO*#*LA3D)=SD0K&
MJQZP1UTS' 28D'K],+@+ ;SF =^1O!<[GN/-^*D,)A_P9,2(D1OJH:,QNY4#
M8RN'BM>3J)B%]7"D:KXKZDA%\7X%1ZK>G'"DUJ2#=:].E1!.5?4?!:<*3I^G
M0?+(Q4QY%-%&\U7(M2N.>P5RJN:/ CD%<CA<D82HZYI5URS]8-C4JH;)'N]U
M[<&0R3<RCS#B*!:((W60Z)[HXPL HI-_TXH["&I4:&%^X)?A@N=V>+M#\<4[
M/'^/"!\Y5\X61-!EX],7TB1EDN)"E80255*7$(L5CYKRD_T#6%512 &L E@M
M5U1-:UBFWCQPC#H@;=7AQKE6%&&-+4'8XG'R:1[XLB:[/F:RY^L-R4IN>X6X
MJMR00ER%N#G$!?/=JNF- \<R&\VZ0%R]611QS>U 7+WY&NY18Q[6KKJ(T19@
MK:IAI+!686UVY"0Z9LDC)[W!455@(\=4 )K"O@1K2W"W\9*X.U*5V)H.OO5]
M]=VJ@DD*?!7XYL"WAK_73''>KR$H^/]&@0!'_I9>4?"M;@?X+N!F>"[X5J>#
MKRC 4ML_\%7%FQ3X*O#-@6\CK_D:_P J-%+TY=@:%P7?QBN";])_=E84UF!<
MW7V5**SZ1!264'(;^X>SJ@Z4 EH%M'F@K>/ONB: MHG:U[):;FT-0+N)7MW:
M/*_NGM5AYIBKDJ<4YBK,G:7<UKERBP&KH6L#@'& '<7<[**$W]@'0"NBY;ZT
M0CL)L?77U&BQTFFJU#;V5JE5J5H*8!7 C@.LKB?5K& X44P?:.@(UP&\1P L
MQXLK%@+RP&0 S&ZZ-&3D"\)K"^\GMQQD"^&G0,VQW-8%\7/I6L^+-NA,D+21
M"ZM=%$!5D:LGBEPUQRBGBEQM"ORH(E>JR-6D:/(?6U/*JE$QJ]M2'FK+2EF!
M#J%*6:E25JJ4E2IEM7O> E6)0'D+E+> .P@LS:SI>E/3:G5#.^B%/\NB",$_
M6M5H)$D-,TW^YG27Z1,U6%K]/MCA[B,Y?$:)@88LK[)_ODY58D"AET(O+9<!
M:S7 MM(/',NJ5C5-Y&/-0Z[#+O7O&'%]@O9P&'C8+9B*<9&/S&<==Q#)LBI9
MK:D9!59*8RWTA%?17+C42OX(*<5%^9"%/*%/=8AO[FLBJZYJ!ZP1.9^P[15X
MKN>@J,D/BBP9_<0[GL11E,)AF_GSD)0W 9T-GE,+4DV#RX4*][U.$%-C1LSH
M/JJ<J@2 4CGW&#5K5K.>+VI5;M;*FF:9=:LR>(3%OF8#-^3]XP7N)2!S!)_:
M@R#D@#<=0*=#)*_9QYOJ-9NU44VR*$@*V_KF: (1BQZ2XQADQI(F!I+8W_$=
M]GO&&G_\4PF'IJE5]P0.59:^@L-=A,,T6$BOE_L 9!T\^\5RS'.+.Z>0)THW
M T)<T2$'0T"]% (E#F&?Y#[S(Z$N/E7>>4)5W(P#^940T] ,8_?QDE<T4'"I
MX'('X7+9FJ@:O*Y:T^L'PV;-,AJB)FHL5,DC;"3JMF,.C_0N9$*M;+/! V,^
M/PX)8?7+5UX0WW4Y;A["#0&,4L!QB3@<1,4IB=#1&LO[(M_&[_"#L?>F2F6"
MW]S23M3(V4:U9N:"+7F-:,T:,:?QP8;U82]@466\*UA4L)B#Q;JFUYIU@$6K
MJC>J A;E.0['&8Z$K103 9:$D9U#S-8$8HZCXV'K E#IGGE!'^\KD;.S0]&E
M?AQ;WYYBP+;OO.,Z*_6'SSW1F06B,P+:&^7D["9%44.@:'U?,=-0R>L*,Q5F
M3CF^H7AB@4D\H(G]_">U/8WZHP#0&X"\D"?X9!")H/>)^2SDQR,>PRY,"6Q.
M-_7Q&RV']LCG"D<SNPL(D6B<8[V8&HNT8GJ5G$EUHI/BJ$I(5SBJ<+0 C@*$
M-AZ##L"6P-%+_)6<,2S!5  L_V"^[^(WOE.["Y"38*7(0-1KBR/EBY8'54@Y
MV014I99O E2^/A[6-QT/YP[PN:T^=<Y=(BS(,,N&9NBBH ;61N(YY 6+(AGZ
MBLH@38\UWY #H8U8"]A&%#DR<A3:4A7!,H)A:4!%C80:%46,C!B&J:B1 ]J7
M5\$-;4(%KY;$=KI_*KC*UU0J^'ZKX&7#>LS@*(SB*2KXTS7R,EU<J=VKH_\>
MJMWSR*'4[@4)MG]J]SQJ[)W:/8\8AJ6HH=3N=:G=JM" 4KNW5NW.0B L-.2-
MS) OZK@V7MYQO?,0HC+N%83L (14<Q"".LG"AK>Q4L-[EV%#A29M!&2HT*15
MAR;)\1AZ.8K;D>NX8%UX;C2@TKJY23YUV>Q\\=T7?^7K5^*_F^)OF&4[\"/,
M1^FX<!F+(,(?,K#P4%Q"R3_-+I)K=@<8P7A6==SV7)NT;#N(02WP[\B)&_9V
M'Q&LBE()%";L*"98>KD?/+ PZ-#!( A]-I09;U?X*:)!2WZ^#X*N8FV5H.^J
MH!ME&^G= 8KC34&G'=#0D9N_N,)X$11L^(,>1I#]CWC+2!D5U8UH^6Y$56V,
M<JH;T:9(D>I&I+H138JFZD:DNA&]4C>B35.&35U9O4H9WE%EV-3U<AA[3#?I
MHVY1O>K@_VQ9&.^:M_LP:5FWWM)W!W!5_$8.\_HS:L6'79=UR/$CLV-^3';9
M@:O8X6K'+64 !V4I*W#857 P5@@.)ZY/?=NEWOZ @Z$T!P4.NPH.>'R.Q8$#
M7S>K6NI12XH<\2L$+REM(0<(2EM0@+"K@& \$Q 6U!#&?.IZE7/+RGAJLVY5
MW9TW:YSK[>[\,K>JILD;KT%@.\73BQNE1+S.]&>P__H(\)^/UV?DU(\&O(#H
M46#'O'YHF=QVL8NF_-Q)/G<">+4?# CM]S'3SO5YI+N+3$U%8P_,!.29=J3-
M;!I'<'40$?Z> ;V+" T9P;P\!W/T'MQ!5S[CE!_OB!N3]U5V6.IN#C\KJ=MG
MJ;NECX$?](9@MPZ8'Z'FBH5W>S05PUUF_\/6F6)_Q?XC['](/3OVA!%WYOH_
MVUBV>A^$X>CX1 F#$H8183AB'==W]T\6SEH?E2PH61B1A3/:9MY^B<'5];$2
M R4&(V)P%3),)-L[!4E5J]E723@,8"CDBMZA?RCS,1VAC^D$?4QOL:$#'6"!
M!AJ-^)"P1X,-+Z#PB8..JJS5@OYNBJQ,I%B\NC/ZB5#^I$?92_V<>4 R&FLM
M^&MK0K>-BJXM%PX][ZG-:J76+/;8U1ZTO8 H-A*^Y ]\[P[@378!V?S?!6!I
M^V9W3GU '>[T1A1!Y"%!"+_+'M=!."38^QD_I&%(?7'SJC;AUZ;.D]N082VR
M#2UZ;+P12XY1!+!;$*PK"-C+2W7@R80,C2!=>H^'&@S6O.?R+:<?AU%,1<-*
M2D+V;\PB49(0>*;C8IH_1A\,0D8'G#OXL0H6'>N+C'_7%_L7*G1=V,#XTT69
MPHCU*59:]8;\E(2/Y(;9<>@.L(P(;F_'CW87&0^[6/;<B.N(^2%AK*7 =L-J
MEXU<::+<@]*'M&Q>HD!OFE8)-U,J&@ OQ=%;=$A<3 3. O^NC'6?B,/: WXR
M%G*M.RGX]-!U;;%(@P 8#JB'I1QX&;K<HL6#;A#"6YWL)(T]VHRW6?[OF:5A
MTB*8XM%8:B+P7-%NBD81&XA3-7R:X!U8/<FTD>BEZD; G<C7E1E5J1Y<SR.=
M./3=J NL; ?]H61_L##29M51TIFU "/"?U(@BBM;O__6#@]^GU1$7.?_WCR=
M=F94M3=KUM_>_'XZ8#VBURJSM*RLCNF-2!F=F.U\4HQ*3QE1];TE(I5>64'G
MT[T09\& 9;B@E87'^\0T7RV]>7,RF?518HPE3186!3,5A57G/V]NBO/:Q_+\
M;.;MFL)XXO)VC;Y CO(&Q0AR>+@Y_731NOUR?7SSE+4.QL+[VG2UBG_D\B)4
MZ]PZKG*:*NH4J"VXH=0S0/>0$;YBV]1--+3TZEOG7:*6/ZG#BH=BD2VLS,GU
M:R<&=9I')3EYK0B'T&8D BIA&6"?ARRU69=Z'>QS@ _B/"9NX$\.&:AW@7A@
MIM;-W@!'EV5-)#]"E?']3-5$%D:7)H.HCF[,T$]6-O1FH9$OZJ*:<.J^NL^J
MJE4:(F5^\6H#S::U<I>5;E3JC=F7EWULW:HTC=KRGK#F9OD."OJESX^O#_^4
MLB,LJ4NTI"X.IUK+8]JL^9R\@MIKAO6OS_'_<?A^IKMID@3;P#+7EQ^/KV_)
M>84<M;Z>WJS4J[*=%'D[(VV/NQ3PK),[T-Z]M$2]>D[-2^6A;9J<;IA;N.",
M#J(#\L?QQ<7IR?$U^=XZ_-RZ_O;"+M "MTIU!=5'N)=P_Q])B+%-Y/V#^;[;
M 2'_3D%GS[F_UD;:;:+>VZ1D*-AOY1-J3T/'F;4"<R:(];1E6+4VUC(L:/UE
MYEUZM"(MO#;S@H?$LNN YA\\8-'E/EAX_-S'3XP_^;+KS(K$O4EFK-BT3^W,
M"1Z(3]$M'\$M#J:C%K (UWBLWFQ6&F9SJ5-UL%'T8EK_HE7&C)6;*%:]8NC+
M&52O/U@=*%M[ACWUC!"OUSE?FYZD>P,#H(,8E+Y7"W;:/"+<N@./[?'\T3U5
M0-N?FYA?2%%:@VZV[E?NBF-@GAF]MO(?:PJ.+&(^S_:9CAS)ZF9E+2<!?")7
MH>O;;I]ZDY/YD-;'?LGR!UL0!3W>M=38KD"SHBS=NKX\.[TX)F>GMX>?3TZ/
MSXXV0,+708E,$KZ"'&3RS*5[1GF;#R23I"FU;W90KU#"D]\:3V];I%4A?[:N
M6X>?OURL57+R%8'60XX;YKM!."X^0BY8^9,7M$$X, 8@!+L:&':K-LI<JZAQ
M^5[G_JBD_,5G^>?QQ<7Q[6=R6"$GUZWOI\?7FR'GZ]TD#[O4#>%Y?'N<4!F5
M,.RH,)RWKK^1X[.SXPMR>/EZ";.;103%[OO"[E>M\^.S%OFC0@ZO6Z>?%+\K
M?M]I?K_]?'G>NB&?*^33V>7AFC4=Q?"*X5_>A+_A\'[6^GKZ_?ME^?SRR_7Q
M-\7VBNUWFNUO;H^O/H,.?U8AYZUOEXK?%;_O-+]?M;Z<D8\5<GUY^_F\M5Y'
MK>)WQ>\OS^^WUZ>'IRUR CS_Y>9&(;SB^-WF^,//H,K?XDGV<87<')\>*9A7
M3+_K3']Z\>F8?*J0V\]?SDX5NRMVWVUV_[-U^_D;>FO^;ET?'2M^5_R^V_Q^
M=7Q[?(UQ!W\?7QP=G[U>_X;-(H-B^$(,OZ(TM#46*!E/52QAQAAFD&'451<^
M]VF/X2]L$)1$03?\0]XD$M#2SDGYNGS]X(&%/).-RG0^44>$\7 6S$\3F6E)
M/AJ^QRG)VFZ+% /$*GY^6K\PJ027C*DTFN@6Q78W>66)4,][.L\-5@1SW$HC
MWX6OV5Z,S$PHZ=$? 0PR*29''"D\:1X?C!:6=CB9)J?*C!3*X3.-BEE?JLR(
M;E7JUK*I;[.O&16COOJ"NPVM4FT4R^';E>UVL=3Z'8OL.[A16?@O2%Z5A;^V
M+/P]+&DY5D-LY&<[<(;PO^Z@Y_W^_P%02P,$%     @ B8595+PP*)'Y*
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MM:\/23C'^/F"W[&&*[L8?U ZO6F>=*(5+W_=9.=>!W_]OGMQ#/MN(_8>+A+
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MNE^*"Q!%+;WW+<(]-/ID8S06L/4)E+Z[R20.J"8.K !G ?&_4?%'_*I96DM
M%I#] L?<6R0T="]#64#X_!&O^54!G^S*%SJ[80"$+F9&_*Y@L(./;@6?)+?E
M;C+4RHBK#?;PSM4>0-V'0QO].66W*<-0\69([(CAZ7;F68=*4]5Y 2KA+1#Y
M[G&.-%W"906T!0.1)BNT7SW"&96W7VTFIGV#'5@P7>M>^#7!AULS-&C[?6>S
MPS.?$3^2[TXNY*/:>5$.O=VX3.S&X,Y#?1[I#!!+0!;(]6] 47C%M#I3'LH"
MPK>\,-XA@/E_5YAR+Z#QA+^2-UW>=PF@#>(53Z?^#)U^3-[1_A'#/+-H=D-]
M.,KJS!8&+=\[B2D3:I31'E4XU@.-QMQ;7$Y-XI4,D%AZTU_C?M&=\'BK%YCE
M#M[Y_C(?P#WH<P@>5HVY#/*=B:\R*8<Z_ADT?/>A*6<&7:0'K^+\;(S&ADUZ
MJ<SRUX#X<"?%/ AI8DLJ'*"KLGJ[;H+#4GO[\I'SP (VB2<J9_9IF*2K&9]8
M5<W?^]CJMEN9VW1'&TQ8#FV!W)H<"B5!5_6!7>LAM52RBPDKNA(N5? 6L#VI
MYMC#A\GPP8"Y_?_W,7/'77SB$U8"%UBOJAO>8W2>Y(XR]1E<CS?700-U;5L7
M:A-Y_N+S 68UI26Y[_EWY'UR9MUR 9>EX :H?L7/4JCTW6]\B@>0).->:V%M
MEA ;[!E)#2L\![-/2A@5OJIJ9,$:A,FG0NU\Q-?M)26@%@QA.>)6JBEE[H#G
M>?6[.@5H571V)IDLUFAN?<)="K2[/^7O3\->+-PQ"2F(*UZQT)LR#\2J5I,V
M@=K28[9[ULG9Y T\&S4M+%@C4HA['"BG$1/*[+9PP_> $I'DA6-*@T')D\:X
M+)B$:Q <YND>ZEB&LH#PEW@R ;E]&K[ J<F&S(5=9+&@9*D"V(^T=HC&:-[[
M/8#64>?\M#*AOZ.O[FK6W (.W^$S0;!SA/-?_G:C.8UK6E@PH+_3&?3M:2)H
MEZ$L(#Q;2-^H.'A- QN&TS[*N=Q/M4&TY> 6#&5Q3U#:V.>WI-(#UESZ#O09
M&&+-,;SSWO>,+V_1/^JYM01D!8]>X4\N9B!#:"G$:HT1'] 7[GN_LVC,@J>
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M#+SU$=L:#%,5WR$U%,V.;];6 KGX@>96&R,(5R'2BK<6E@7L'S$0"F-5G\
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MFX_Z7S@[HTE2!57P[?P]I!8P93\3C8;J526'%)3NX]/=1C(F;WYXIMR]DGR
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MLQB,#C6U@_M,[#!@@:!, $H>+0F512<MU5<K/S3<H)/)SA.P"%I"EY<\\"H
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M\*BC)&N@2LMXVN: PEAP+K,&*"8+HXY#H"M,(]U7N]%E/V'T(\?#H1I,0>:
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M)JLQ+#^7 [^GX@3TP.*LJ6# :W80_O??-9,$DQ^_IS6(?#$>S_WH/5PVD]F
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M"-H)DGG9(@+0)%C%"8N&&718)%-M[B@\\(HG*&M_N.&;^E:KG=X_'E[XT7^
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M@V:;I<2WAE1[O/+X<]^3J6L]-.N+E,J[)/=@OHAQ,H?TP>/?O_132 ,J Y/
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MYM=A2B-XC>:Y@%?E"&^"?OE[\"5#Y>/YI)F?G5^/"7^VI/=-IR\N+R<-_OM
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MVC0JF%-'4N(&%T1MA.ZGKNU74)"M2]!;A; >YIV'*@>U0/:M(-O>'.Y1=NL
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M6TA K-KXALA+#30:9Q,=\"E"P$Q(R<[CB4[H(AK3Z"&HX6V@ANK<1IP#=='
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MSJ];'K^9K_P_9XP.B9:EF<KDJD>R<W+)D#@&IS!K+W4'E6UZ]G/7W,'RVJ#
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M<N&V=BJE+\GK!'3PFUR,2L+D-K[E0S##[VE]:/Z!)WF@E!O$'^]!*86^LY3
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M6'S.7MHVQU%WC.=!HD8Z:= $]C[2WT+"%U]J>Y\+QYC6OMK0V4HRL4P"1^@
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M)EDMFVP()U1KJ2SB@6D+(M2@.*3&(OJ\)_[6CI>'^@Y^[OW"^':!<R0$116
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MRPD<MP','2NV]=T0^W8_-QQ@URQ I"9+[JJ!:(7DR$QF7:Q/U@Y:8#=^^DN
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MKV=#,VC4"$[_NK&_,.F5"1!":[U9VQ&EMP[(ER!K+#'E(82:P)070*BY =E
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M0I/)/#_A17E[(?>0OF]Q]?%&;^2AJ2D%+83+388;K\[HHPF&^:RDLY2J#VG
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M5Q=&C/'X/BZXLE71:I^@W=* B2@@.F$AJQ 5"L^;9Y]*FB.ZX!J%X=@+KC$
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MY)WOC>79D31GM[/0W_&"3EQPJ(4OD&0L8&Q5@-9+\+K$(H5R&.82'M]E'(=
MXCU1[%GJS\:/6<2EQX[F1E+Q[XOS#W_PALUQ_.7R_+>K_A^K$UW)6R4)5"3.
MTQ(G:\$30F@724ZB5WXN$>II1_8Z(PZ20[-(88\=7YOIO]56@\:!ZSH<_>4\
M+PE7=$+&M0?)%H01"@RYUCXQV:8O:H)P7GBL!SH_'A_5Z]PX..[,HM<]=FSW
M,/KEG#,^NBDWYG^UWB$M26>E;])CV)[&8*N[4P%2#C8;[4ATNK>;9WRO<^6
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M;.%>][F<6Y[B!Y/)4_"Z0V778Y;'&N/6@,"2M%?@@W(R<99!U]5CNC"?/7V
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MR+L_\B0MRM&A62OU3@/Y3,<E^74'>B<K#7^#$ 6GWK%]C^1!SQ&1#ZJ=1-I
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M/3N))^8OL7MQ%6L4+GS?/,G**&G2NAGP!7,,RMF'LO(<_:X1*'7X7?J+4QS
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MS3^5//:];><QZ571$D'E;X.&,.IPI('JJP.Q)*=-'\Y5GC*W]Z 7BIHCK&0
MWJ4LB8[%^ DAUGW0%P[I]9'3YL>YZ:*U>6(7M3R:"RH:D!+OP5I*ZEG_KT.E
M>^./'UN#:5V($TJ4N0.)"K])M?Z&[>;.>NL7UFQ!!N,*#E+N9,HHT!_U^W,
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MM9RWUYO^Z%T-$WM\4-L$^_IFNG@DZ86VYM;6(,U7.#>@[4CJD0_2%^/Q^]0
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MT\9[^RF-&>5[F%WC!EVOEEY=Z.D*0^06_(D>?Z'XI:4!1%4JFSVKM^NACLK
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MP._[R672N5/C,;XTNRY^NJ:"S[K2_8U(?Z16<.LV,ZNI6OEKS4:[)?)NS-*
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M4%OW."S]KQGLW^,2E!@>KH@I3TJJXFTY<LW!^O[#@LA#AM)DB,3*(CX23[;
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MR[&DG<]CXUW,JI89+K^OY2YS$D,.QP:OY>9VU^M5+.Y,[P/3FRFZVT&!V3G
M%)=K@T*[3K(@KSS.=1'3K19\IL**R&TGYIY_B?V R&5!6H[3 X%U9C+M'GH
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MM;SG'*&::A]RI2%V^3MU7%E)V=$CNT3[I8'YSV.7V*?Q1S >T EA\S_U-5U
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M-Y%4O/X6AGO^!F0WWP/Q;>2P12B^ZTTN6:S_\!/ZYFJWQ (:)W0"^IHYA/?
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MU.LE\!RV)!7TKLBR75)%B+<AWORZ4?+F0DXVN8["X8S!Z<8#?*L=\8"P;]O
M=6'X#9)0:KL*/SX\EOUT,3!R*%:BJ.LP:]P :6Z*VD9]G'OJ<&&DO;>Z@\.
M<6*:/TYXQL):M% @+0YTNCZ+A]]@K2TY[![-U2B C<*@,*RDB.>BT);@[;$"
M^35EK3.(L-(:^NNZDIUL*89]55"+8*&P\T:*[YR^E_<FC[OS@_1<UW>C$-7F
MKR%//+Z'&)/S*8)2R._P<X"/=#3PB>_;ETLS8N*75^-OJ]-QKL8."I^>.*37
MT!]]AC&8\,BJK8MPT-H1H(U0UN$]JPM-P>#TAV9F"?I =2:(G'\"6LA',/&A
M@2[\Z+H[G'N=(H%S*%3B6W3UWYNTO!(>Y.5*3I$\(Z#TB\G>5WQPI%&FR_ X
MZ>\&V[TT5+A.F#+X_@/3P7W$0522%&:\<4YOV/\9PY>BDOT2R@59JHB>DB/A
MU^ #4#:T"VI&?=\<#539+9;9=UV"/4[MK/ML _A@)T7<R_@J8O27K2QFWF@F
MGH6F,7M=24Y774%7:VP+$"T8 <&A+7FB*.P)WJ$FGZ1*SFNR601?A.E/CBYO
MU]S+4E"3R;U8K-KE*T5_\<7G:^A .3FA5XP3)5:SBFO?:LT]'Q9OQ8QHLI^C
M.>NWPWC&>#F=G45IK_B/MGL^W5IRIS>T3N-10] 9O=4VJD(, :+0+90;40Z0
MU,0A@E7D6VH6)"-4+N-6/O*D('VEFYN8UX[:YUD?=7V[W?0VK7;7B7^OM[W\
M=W[H$)QZFB/1']Z!OBQ18^/LX8YV<BJ](<'5*1O[YTA0L.,9B^K\.7YZ=C*V
MF_MG<(_4J6.PFM_0=A7Q$DR4C%8!.T//4" ;EDTM9^HFDXRG2-(Y&U[?:QOP
M?'1^0O7!#Y(E1C7VH]1-,S6S%"<,DRG"@#QU>=_^A<* J/][24JCD"?@U^:\
M7!ZA8/I#1@X 2_#@=%4HUO$MTIQQB'7J#?)74/?I*K'^"9JN>W.P<>HX\.^]
M@S#H*5S?M^W-5PNBLVZ/VILM_=0@LJ9]"%I8R*Q)Q8/OXS6B5,"NF9PX_6BK
MNY/>/-=7IK2G<FHM,G2_) IJ[IC)_++N[I0S;A.E$B%1Q$(1&J>%GMXD" />
MN"-"Y>]#!2?*55SJ-K,C/J0CW3&,I N.EJ:;4^U.M0PE/9^SW)#PDD*Z,G4_
MS33J>!=VUY/CZ2?&R>G5X$F:^H8TOC@I"?[$FQ>*SVGQ'_R1(O+X2Z1CL.E+
M[XMQL6];#ZX>L?X^'UK:!5PPP V-#@0@I!^SM33>P@70+'0==3&R^3ELGTFQ
MI.0?]1<\4O-G?NH8]?W+%\WO+/M/-*Z^'RZ+_UZ'Y4=7#9&NZ%/M.K-CNZ>&
M,^Z8N+B2A%=LA7/5WDUIX4ZTL*\8WRXS\&1AME;R_8.UG3]>Q)37[A-C\\/A
MTG[W,>&$\<KN1^ZBM&=>K]V^<\A;/=O8J$/GV-Q2'\?^V&BT7RS4Y'01/^XL
M/ "FC%-/78  \DN=DPTW2LKT&:J(;((H+P84EJ[_,&H#>H5?\F=TVA.BTE.)
M;%Z30'LN/\,D#=(5-BP9M=5#M(6=(>>B7<'A;' Q<FIU21!4!_]55WSCB@H;
MGG[,JOQCV<85NT?Z3*+]%]U-FU)2U.^M2+DL@+-2CB[9M*::5>4F?,W*290Y
M^XCWS>5QX\TE)"" "7>OB8]&<".<D"&6,$O9+2*>\=&(.YS>2>9S=*!5D<36
MO+*Y=76-M419S<'*]1 7CI9O4V=I,CDHW7_GL%!L\ 3DO#M]/$;X!#A2_2&T
M$WYKHAIY<6/F#13W?G;-=V]ZSF7F<4G5^J8776GMNE2P0'+.M72PS$WS;S\^
M\1S&Y11L>%;/N)%D:1.EW'':W&)%;4;W%D+&??(:FJLJU!().\*F/Q^-Y+T5
M=K1_E:.LI4P30&H912\@3T!TD(6/")P59'I3BZI^[FN^F72XJ<YX&K]:_3@5
MT)BW54:LJ(VD7O6K1QM&JE+Q/[]ZN&>%6E^B [%Q9""@1$[4:_1" 01G )F9
MZD968UZ_1'+ZZ2]*QF0!-KC-]GF!SW%['1HZC_(HD_5QY^_=\_)^;OZ2"&OC
M]NSF<FH#D=GR<X=[^3JX^X9X90O_U/[YY(D/*@R]$([F)KGB4PG^0#-1@F2)
M=R\I<X& *') SB*,DSQ9(#N[>Y A$CS=+]#W.77P4>[-7UEOD&L;R]&)/9G4
M:3#[.0RU(5C0;A#:]8:X F_7?,JDPD!S;D,WRA/QXKJ5V,VH([8;>_TUS[,^
MIGT^I_6)<5BL^7Y[J[K'KEW(P#L-MH]7;78"A(>,@D1=2*OD"'$5)D2;^@GH
M&>/L'2UR)9S+R59JO.DL_B' UC'/B==#\ORP!(<NU="=MNP2AC@0G_1[/=_7
MJ/GY5#_CLCI;&75$IV ^0"Q>EO 82,:I8LUC=DFZLJV(>%M!P#4;R#"M=]ZI
MD1#33V2K\L]S?Y)P_8/:ESTS?OY$K:M@[Y&_@SSZHZ,#-7DW=EY&"8]7)VJV
MF9IX\V>"LF=6YO?F;FS?8'J4:S#2SQ5F9CP<+'>]28=01PY18:#,*>3'+N[.
M!"L.789!1B26W\.4=;57)CM,QC^F/IW;3;@N_358^CK[^U\N8WU;I>W7D3R(
M-EDXZSH5]>E)SGH1N@%YG(;9)./6(FZI(T HHGJ7SG;#:&X6\+!&ZJ<<$[K[
MM-+>GW9G,K^O92C=@M6C \'?*V]_\-6R%_BAHQ1E*??PE:)PMR:/)@?'\5CY
M#8GMJX$E]:/".4:C6GQG30W'$_W^0 M04=O0FU'X=R3N/H:;*@&*>!<S#(XG
MA&)1$9R03K^W"!<_EQ.0?GVS&R=&CXI+JFMJXP;GKM!.&Y0F_<&8(;B;33E+
M$O^]J<[6D\-:SL&'(;4\'XYW0[T1H-D-2TQ'B0XQ6N*.,9[N;%1@?UY=PD5\
M.^[;U=?Q*?G^'"&5W0:GMV==,P+[7S96?]%ZG*"J(>[.8:%_GW8ARG5^NN=E
MRFV;SJJO>3EOOIZNC'GR>OQU K(,3NWL?V^E/"&5J^W.D&?ZP#6/.,A"#N+*
MX\@6B!_Q/MZ\DQZ,5=*$U"A)(PI^S-?&>A38@.=G+&<U'-VCSSPK---Z33.0
M])QFTX:5BIMQNOHS(>;D:L2?'F_0-6P1V]AH,WQJ\#.4=W6=;D4T+M-F1(W"
M<B<W5.//NZCG_[Z-RFH9?TF^+9!AU!(VQZL6R^M__YR/W(7S&UIKBN,3>U/;
M]ZB^-XS\%N$^%!%P HH_ ;EASL^3'A!U&Q[Y*6HW34FZN2F)/998LK@R*N:?
M<+:SZM>8<J_Q-7IN_VFFX%.'$FJLVQ^.F&;N^3+WG_K#+_&NI5),;$?AUY\.
M:*X6=LIW:'4!B7F60M\,=.##()$SJ(@=&-_27& [%-1D5]:_.O?#2:)4(\_Y
MB(A1<7PWX"UE5=EX+?*N,(MY(54:ZA0N0)5RGI7(#&,C5[><<S([UHB!L_IA
M.GPPETAJ9_Z$ E/::#NWTGO%^D>[Z5@+M=[$QUM)W94B%X5/'U"(AF,'7U/<
MM(^Y7OI?D?)?IN7XOB L5"3T:=?8O!]:0T-BXB+<(S>J7-ND0,AU,*% //.V
MS+K=PK;HOG5S336N+*(N]HF59MG* S:FH=6'1P(/WTAYKC[19J2:JK86,RA;
M*60!63=/#Z3AZ1[AH>$O&:-4A(8IK'X9%@W.-P[!YZ<QTC7ONJ%-?99B\1)5
MK]EC!"])@(+Z!$/S7;W3'D9DI=_L>&ZD>29>->076-L;[H]H$X=QY9.H+"ZX
MC=K%71ACMDMZUT1H6!EN;IO+9JK\4&1LFY-^8CQZ=:Z7O[3EV=XENDM9GV^"
M6(^Y_JM22/Q'DEC N*C[ETH<@[_!.Q&@EAMU6[>6(+/,VH _%0N<DHR'F9XQ
M9V-3X?R<H'&L_+DVRJ;APQJF0?R/677=CN4WEX:.DEE._4+C$29D*FE=J(#@
M-(=B$9]W24P8PVASW&IH$Y=]+N"PT:/YY?/H8(G+.L(YKT-@1GU/DSX/G7'M
M[-W&V.@J-KHVRCR460H#B"!(EW<7D5O,.%7SL"4LLILKGG:-5PCWXJ9":LC@
M1U]GK](?+F:83?&ERL3>I80\4ZX9*9N!Z^?(UH57QZ1F7:=KQ-Q4:'=NW"=G
MOXQ4[:^V\[W)\8PA;?TNF,J9VWIXKP.^N'X*;2H^L+4!&54]=T,'<_&1\SS/
MYY9QOCC7R7B#RC^$32.<']TX?^'\Z:0N'T@=IBT#"0BGDBZ[]H!I$ YHEO7,
M:VB\1X>8#ZZK.ZE(38HS= Z5X,U3V1=C?%OY2SC_ MNOSZ=0%532W8N9[>A"
M4D% #@9W'WH.WH\YO5S9#+1A(TC7L@#SUNMWTX?"E=3L Y_R?DJ]<@+:?-;2
M==&\!59>7-%9ZA6NBRFQ5,L;1.;.?+?%-(\/6^5ZV6C>'+MI0)?P/?$.,'HO
MQ_E*0\QQ5WFR&\_<:/&/.8T_(@4NW,QZ?[%6T3'/XN]^1&7\)CG#1Z&+I%J7
M*. (GV, T.%+"$.X222NI_7XIR[JD43L(198-:[S3KZ*<3N34)M\IKCT!"3C
M(1ASXVRUVV]%Q!EBV %7P@Q 0Y2A+K YY.FVD!6>,9AR@13P&6^S=0+Z7M7E
M501HW8C-+"B<G6F([!-*$318*QWNW'.C"T;H4)=I"#(3KHWK(;&84R[4$47K
MMHZPVY)=F70 B_<0#^D!WCS<8ZEI;"O_2UUMM$8EVZ64B!\#HDKS>MO8,_NW
MJHOD?[\,E(PY ='".(A/X)V6DM%4OA*HTS2&=GHO><AEHVH1S"$A0?\&3Q=I
M^IT=*WG]!J%]^=4 /&K]V"$C=S9#5TP_>.;ZUHJ87S*;%W=%*WNO$/]1T=H?
M8HJSRNJ#$AKZC5&!_EB+JYD<I_DC.D3[.H)IKP;+2>]A2$S+D$6W=30KPIVX
M.P_IQD2:I]IR?FR(IUN'XH5'6GG^T&$MG<KA.3RGO+D19NHMO$'+=^9R&RM#
M6MYZNN#'<PDYSL.6EE8/*F8M9]HK>IA.O2HN!AG0@!B$_P@0SGYUX=\IU$E'
MH5GAW#!ZP*,,!@6:EQ09&0#[C@98ZLQ\3;$>7_#HW#F+Z?B?H-['=T&)9^$.
M@ Z%CNHVS_@!*+SE+ $%G("(?ZZG#"V:-L0OFG<<XN9+O#USQ0N'^XL&$RPK
M>XM^=#]T*GYD9?5U1 0CW08I-C&@62WHAC#J$A41;<_@+%1Q:Y(""_07T2#8
M(X#.BXILCU,:>B_:<DRJ_0PH>^>[MW-K-N,5\JFZN,$ K>YT@JP3I0O*< /B
M! ;$5WN& !'&T#PK=/@DF/%E?)CM:;Q HT<-GB6AR;SA Z&203"8+F*I;C]5
M>$\\Z]$O-VB@K87%ADSB(Y<K"?IGOAH]<HBYK9#Y*:2-M_OCF4NS]U,FATL]
MN[/L8UG.FIX&@10N@$@+8W!Y$FL&A2%V7.IKRPV_I^6,6ZZ,X6_XK.M^>'MB
M5]ZMMWJLK*FWD>(/,_1\L,W,!/SDEK<^(+S:IA\*K?E@"8-6E9<M#/C89%XS
MH;1/PESX7XMO>:M*[CR2R+#1<6/!B"<%]W%JYDP3ME4+G6?@94\%/Q9_[_#R
MN+V=0A<1DA-_OR!8I?K4+S)UV4/)F660I^!9&D(8 ":* C.K5N2TQVY@4YPN
MBA#9/$:2QRHBJVN+<M>/N-[K<(K.]EX/\Q >8+JUK]2.^73(\S$Y\Z,S3QC2
MF>72_=?7PMC;LX770-P@Y;-:_[YY]YO:GB;Z4081.#WT*W-,M>2VR)+FR^8;
M'"ECVA4,:)>)W0_,K'D-3+**?R;JL5ZV^%$L=I-@*7QZ/XD@3G4*7ZA2OJ5R
ME?2RK@%W MK6*2#IDC_!;[FD<*HZPYEP*_GX=8+3SO"ZSPOKV0<5S@3#7D]/
M\5$69^0V\[N+^-8D2A>3'YAROH 81)F",B*<H5SK*O2XJ2Y&SAX\M)57$,^;
MQ?,QI<+-GSG63#COW9L[EM;%)5T?B8*1A.WGK@=&GUK&I.8>/I"64*%[?;%?
M_+I?,JF>1L,ZCMV'+QT$^%)HH3C);O YM*-'-**&ICOHRE*'.9JW1=XO!_MB
M?69+?3)(4K/Y ]>]%XE_MG>S#[31!Y?(760I.AU+G1L;S![068+.R!*F1I3
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MCC6%)[ ]39]6X"+OGO);UXF T#B_"_9BOJ//:K?QCM^3K=8D]V?7%I<G90Q
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M1^BR4+WP.&>=1I6(O+OP! &6'6-KJZ/<W<4ML#J ?"UP31F5.)-(J[' 2P3
M!4>R9><]R]VEEVL;!I]NU]^'FC)9#D R$P(U.$KY>1/SP]58"$&)F!"CA\8E
M_5P8K\YZ/<P,,MUHU>+"<Q,T5L#3XNP4IX#!34U6$<#@%>5QJL< E?B-)D*P
M]Y1C<@>CK*"1?8JD.U^XP>K)" TM<4]J?!9^\QZ&]SVA(2"0K\"N_M'MRZ56
M\=E5U]FCD%U?9*Z_=WRWDQ45$XG&SVBD5&VL*B_QQ TK=^<X&F1@E<MR"(L&
MZ5VA :8<;LN;#R:T#Q_36!#7$)9_%.F(Z^MJO+VT]')B?"DC2&3#@68T[[ N
MK^]+[N%T5-0S<)V)7<B^*XD'-RU("56TA_3&RT%7Q.!=2-3(F&3B>8M(K8*]
M2?=W+MW:N?YLM0O5PZA,L%A^_72L1[O;@MO1L#6I'QUL>#S"WBT]RM!L]&NK
M8(P9-@0;8H]_B84,';YJ3*_&?U4D-"40^[)$?7#GNIEY[\;ZZR/)^!G&^<K3
M@^\Q#-6A%CB/4TF,PP+GGG?29:REJ@_ 6LJ+\<;"SS9EAZC.,PV%"@!/BI R
M2Y9+UT8=V\HF^5^$Q-3P]_'K;UH8'IU?0M?>'7V*6H"J?@ZM%K:/<ANPR,Q9
MOVB<3SW#GK%C==J*L.FIB1ZSSF1 +W"A)5?DDCLKD/*G!#-6NX\%5)U\<%69
MNK#944"4TBC:R=-E;"$0?\\L%[7 H2'6@$,\./OR!/.F0U/E;:7+RBSFV_&V
M9U!O).P7P,]1</T2CG.+\C^2.'E@$,N>R21Q:P@V1?.X6KC1+VMSEB)- \=)
MCJDF!//V:F0:---/WA\*%8_:[WCL_ASK*W;O]GL=FX,S9>_X:X/G/I>J;J*O
MQPS?PE4<K7M=CWR^%8N)3FG2H^]/:;,.=7UQD=NCCQ>T7AQA9K4[(\ZX_D9)
M?C;SI+=!<?61[!=N-MS/98+<B<"558)>A#2NS86_ QR 7=PJ8TM"B99#4=X<
M2]3/>?QFM2(T*-13F;:ENY2^X.=1*54OIM(7'.W(Q[;@ID,EYLWW/2)YCAXQ
MX)Z=1R&9-/Q@TA'@"N$Z;Z\A,8MIL?&0C'2DW;\Q*\[N%<G9?2=7Y02,:;O/
M_#Y:V'J;YT8!(4@;$R2E.WU#M:-4L>CQ^ =D<+T-<Z'QY:?,M*)ZZ[/O;Z@K
M[U?72 07NP7;:PT%G>CNT.%UV&8SXOFM5;WF)*\:E7P3ZK"=\=A\%V^-3;OX
M M0"7PP1P)TIT9R[??&((W(4GC_5K7RJE()"RU"Z+0//\6XN$=4+?<)6O6!]
MGNM"W8X'1?,EO:X7M^Y;B461#YZ]F]Z'Q&U%W<2HH^7HGUH-5N4H  TT%^YX
MJ6'CP<YC&Z/ -&4%B'>]'J)P6A*)%4EOY$9-9G_X.2$F'\,TS??4>4UCTP@.
MPY)S7L*/[O<OH$R^CBA_HC__Y(RE1;]6?\=:C'DSN/.)OGFPY>^.B+XY"+F.
MORYM#4K&==&'GQ#'A&,F>0?]G)>FGJ4S2BX'/KUY9DWR81$1N#8ZE]S.*-XW
MS]M3+>6H6Q^NB+PSD5]_M1W<"[TONM5&Z%([@UO :0?ATN<J8M6GS;<NK%RY
M/?\Z!W/FO?BS*_45@^%%U5*\[6\.8,@Q/@3KMDSW'8$/$U')%H%?L,_%:FZ]
M'CRKR,=\B?:(O+HH+_X2MF*SCPO4"-SN4?6\_^7RK*DCCI4*@HI,YO9SC?>O
M=[(EKQ0':[9&2/?9K^>A,"SV0]J8VN::IB&)["PR'\&0H]ZTTB\VD6O!O:Y$
M0$DS),Q,T;[!I-[CI?4T(J7UWL7$F67>%T2 $SN$J^.)WQ.S<%,X*Z;H[H>K
M-UZ6>*K=LXC$6^AI<:T:00\LG([)PRDOH.5PY;-=&0XA3\+@T'BK^S?8FAI%
MO AW$ZV)@#E+KC%AZ:NZQ)?7J2T%Q3CM+AL5JLQ]CJ>4AGF.%SHC(\\(8@97
MC,49_-_$!%:;85YGUH_GYCXZ8EQ?^[#E4+64Y-NKPMD7WW:VEP]8-L%&6?!/
M\5?QC["SE2^;3O8O>1=R6-:C]-Z+?.S1,T02 0[!+%I-<&$.QN?WU^/\++OZ
MG>O7:*JD K*KA$YJ((UY]M40?-POU/7QYKE@DU46KE6/][0:(TLP.Q65TX*H
M]3SYV<!.[6"8(9?BR[3J57Z7U;B^<BRZ$S2!/.93M'[B?7,K\IRV\8OMLS#'
M+LW/]34OZ5*.,,9_"5+UV\SM[XV?-\-U\'8F"6CE6M>/G!RN8D+ZE3K<VYA+
MV[0X'[>"RC>D9M"8Q*+.J;Z>.\'1/5U0D%OGS56XOMX^>7CH?@;3$]>#IX7N
MZB7$&G*X!\PO'(F;.I4Q19$@=YE5_^!1":];"6RZ !!._NY%"$^\*A$ QSLW
MV(5;4_[G<46=(T5X,QJR3SV1U:]3[R1$R=X2O%:*OV)V#B?310CRQ&SWMAIC
MJBK\YD_!3[[.O.7CPQZ:<IUFF,=RL>[FAD@%N*(\_-K*LW\<['/O;4\^[#1^
M]G;B@G1W!:.RRQ),J'[/WFFDEA#BO@S+LR\E\91\_.VM:1B7VN6\8)$1.2OK
MF4N #C? 3?WN0JL[9CYS7HT!JSO,OW&W&NY5XCQ3Y*FE621M[8N=SD O,%2N
MHX^,>W,TUT[C@D=WS-W74F13-N$AFWLK^A^L?46GJ0E3MBBL21S7J]$Z+::7
M^$+KS%& A_. 3;]<GO/XTE;>=<64O7B66^T/$[@OJ>GIMI3BH+B@.<>FA_WU
M=F[-T<G.1IU+=[VMC3-FQ/$/WJ-Z#BG.->'?TVTUYER G_W$;2K2<]P@[316
M6&II8<@H>;[/]83/6$".AG35:GUBUOPYBWM93X2BR!SX.?=%L\&U9)/!P<;I
M4A3ETYU!.3C<-)1AHUD7E,%W<_#9=?L/'W_./]KCTZI)8)?H"CU'Y4]9R)RE
MRPC?RQGV7EZTO<]1E-4A],V9=?@_WT;XXSK--^>WYQ[0@)\U1*%$W5(X*1N'
M5DI.1I1O!;]X'@O#] : W6U<;&\RCX(NU:(>-2K<<W0L _<$$^TKXI;/Y5N,
MP<DF-FO]N=#6$Z_[%+-=7_!GJH'24K2ZQL>0\^"2%!6^8(YOJA^^F7"82VC)
M.$SVE=&UB62M2ZCTVUXZB80BPLNH 2PV\W@S/N<<9MZ.NYM#C @4<UET;>B@
M;)348#?QLOLZ)PB=8D$$,R-4KT"4&/8HOB7-YI&9T6RW)>U]-_XKDG!GF;3I
MV?<8:;RM8-1DB$=W-)R-E5EKK:SBN"6*I?7K[HS]?$H^3&2YQRY(;%U,_WXO
M="$9]X*W*QGFW$ H6(Z*7K+L?.>K%7MB^?47.B6]82(0LX4DZ&G=!#7#-YCZ
MU5 Q]_:I?<->%AT6_NIDEK*5L3L2JU,&&,7,F,Q"QP\Y]-7#*ZX$C%Z1L?A@
ME% @M6) )IYQM(/]%X7WNN)>XT1+"/ /2^4=B*JQ561L6[I7Z1?3<-4]?5+3
M!!U"7)3_)T<3]9%/CE[7!V;-'NQT"23<([_AAUZ1+DVKQCW+W5._JA*5TTL0
M]=N@X4LX?*'#6:)6\0XGN9YW<KSO1NO/3X#"54R?",%[VEL= <I?C2G-7"EB
M/GPNI#1MSTEJ-L20O[O0U]6-Z!B@2=H$;I94-WQZ'ZIOM>WO[BE]\Y[SQ*,;
M]?%K[RLY>N,<'F(^U5_=Y @5NG7(75^/X>H5S2)Q1KJD.'.",>X49F!J2PUF
M'R 5MH>U[U0@Q]#Z[-SB2[+3Y=2R79>^HGWP5Q-SH4\+9'$AIECAS 9Z:@NM
M38<KC &*W%E4!U12Z;D/S&KC1Y^H/@3-[\3<."^T\E--95?YAWOW(D/[@3/%
M15:" _$!Y^JB#0]HX&WS+]75-=6?%7>TRZ#U8G([2S,D&-3&.5-^Z:98^1UK
M:X@U"DXQ_Z]:9QGZ@;%/]<G=+HU4C051W]MZD?4]P0J>C%:7MC9@^?KOW.Z6
MC..4/4O3SP!5;U>O?L_X7+K:3^)N58!4L5UEI5M4E:#_Y8/>]EGXZ[:J>3C*
M@%,+J[AVR1#LGC'4'3NUGN?,1F+/3XB/.XP_V-9XV.@Q2P1DEO/OWUGKZ8C1
MFPQ^('VI2Y"A5![L2)Z\$*O(]>6<(@7OLV(,HW7,0)D<>=5?G$_]A_?ZVFX'
M%N ZJP4FO%OM!UN&2YGE&25[N4^_>=3PC-\0C:-C0P]MP$[A-!9HP4]2A=ZE
MD85EF./(5+A@R,XXFS.\\9FP_/[O!3Y!+4B@9"5;T.\;,24WSJWW9;&<3ZC4
MN]@N+Y@2CW<RKYRM'G-QV=D<!;^.;OCB6S([T!DCMS=9V.ON\E9/%_EV'K3@
M;-=P+SY$*[H-4\T&M^0@HXH&3%(#UD#/:SKDORY.+U24,$;KZ75E"'*EUVO_
MB$5<VQ<3KK;/L8V1"GD+?;AV:?EC-4@5=%88>S47$N-T@7<Y^J M@9;AHX8
M:D$@[*5G_L"6X'Q4QQT7"<]L-N$KJ=%)SBX^\=L24#/<<\:>Q9,,&&2-<LKU
MIU],S8RVT!3'E)I&MYU+L=('W5'81)?\C$'Y%^7C;2K!-&LN%&X0_Z3/UPY,
M5(\1 4=Z6TPF(7BJES-_W&+(ON16![,//)62E;*KNTQS6W7_6F,'.!-?OCDE
M4<E3';;AK_-RA7Y+1F!FI^Q\;FS!6)OP@C1^SCD1^<RBOQIQ_(GNY*=DL?P&
MVDZ1&6V7ND&.1$(((U;8]+IF953XLV4 @X!.C&N01>];%<:S:;QYUYL-%OY
M_KBWNJ7^^VG6QM<3D85RVS"M"%Q[MG #J.Y7^%:OZU->S?46T!)^1WM; DT?
M+UZ?<07<3(L3 >'BBZ*''[;4PRQSC#WEX64E3B^YP\&OV%R&^@)<>W+'([/,
MHGD?K[UA6P/&/@X-ZNSW#8;CDWGKTNAE>^..#PNZ#X9-JF_I'LSVJRI,/UWB
M;<V94O/LV@<O3:J'R4&9H E[7QGF%F_UOC):KAIBY=%C;O0:M#\RQF/#N[93
M\*<KHW_S>,.UV3FV->!C?"?#Q^>\UUS2T+[VIQ<,-%0QM],#T==0V<W%7-<M
MT.GRYDNCJF'1CUONG.82-\C#Q0U(8Q?*0Q_IM5D,KH31BMKX&+<7Y4]9G7Q2
ME!(ESB!8-8L+_'[E#-PK8!DRYR:IB(#3L-!ZZ(XZ1_Z,2<4+RL@[<N\_QM$,
M;DXG>%[%7R[RF<Z?OF&)RW1(:'4>]#"4YG=3:O.]D#/2@<H=$M,!5]W])0&7
M,]5N5VCJLG)?$,6T]V6A)54OS_N9]EF^KC_BIT5XDK[RR</LZB5#NZGST35D
M4=&PK6N8N<\Q]H(7IT3,^1.@!\U/"^A"K/6-1( @<C90 ?!7*RZ^ ;P0LX\O
MNY@-+BH>;W]ZY:XRF=K.O33+_Z=Y<_]G>H_C^.ITDM/MD0B).;8N+K63-(3F
MI.,R%D,X=%*2DEIL+FVQ;T?B($;*7*?:J;FV[!@2OA43FW@4*I=,;&0NF7'X
M:INS'H_SPSF_G,[Y[?P%[\?G_7B\/Y_7\_UYO6;A-[A6[10:?6ZBQV[5[P_;
M#EV.YV.7896MO 7YB%#T;G95/K_ZE[M5Z-$P4NWTR4O]TF>N*CKBP=OR61L-
M\DGG8,II4T$\6H6!G<:M'16JB_6D*%2KW^4UUU4W(-?=KRE"PW?R2KP5X\HR
MC)>KVX,94[^XRGT)]2(4L7%ZJ(ZSZ_:F1_.>H1OD3I_*U,$/'LLPM 5$'L]K
MS,'I6+39=6MH83A6SRC#'*4CT($+$$AX;'<+:;$S*]6W;ET*YK1KSC*LDPY9
M;;5QAP0?4:V9R*7ZR1[;/C_VR(I8M\$&T_=7Z#)W)?$W'/!]2XF1?44S[IY]
M#][+)X+0CL,,"Q?-M%7X8&T#?3I]_F,,\^DEK83C%:^+PF]&:9UP,[>_4Q_]
M5 ITG*0&/R>  ;,-6;C:Z,./D^.J0X#%;&.5C+&.@V[XWF3X<6J96<[,NO02
M7!G?!><D6_=Y<.^,(?RAH/:/]M8#%]R9U3LMY:-%!1HG6()H6\=F2M8W;YIB
M#W4I25X=+K878FZ'=O' THR&YB-"'<,R&ZSVT**ET[ 0WJMX;:"" >N61._-
MD$7Y]J3B\>*D$S:WO,[7-QZCK^Y5J3K"!PUWHT'(7[(V2BEQ)IPJ?!LCNIYQ
M;1F6F59 ;P=E64!>7G9#L7#<O[GN>&%D>W4=$:FQQE"142ZMG+=*$P?2Z)B'
MN1.H5K#=4C8F?I=8&2E8\ED=9N=G>%<18F+@K:E<0J?'-6K-[[LS^IDK>_ZE
M_9OF(.PWQ!0$9C\DR_@59\M/]9CIO!L_XK*&L.E<)M:$F^(? :3>!$))G9@;
M\$)_FGBPAB0";)[OOL_8([[>\J'\_![DN;P(A$)?F!N>,BY%OI0>H;+99M-3
MA*F[C[BW=E;G'GV?9Z2KJQ=U&E%\?I.J9H].(:]YRXR+[:S9=\WEL]A)K:/>
MQ) 0FUT>)BZ=>M1H:N@Y,)\:]G 6GGEKNBJRP&R%@W%#G7W8OLVO^G2:S(D*
M!JE-.3&GV ]Y01?N*X]#V/[O.0?+>^:Y>GR/SO G:J2ANS\C GO3,/D[R'\_
MK?<#/+X[I<A@L;.,APWW/#"M%@AGF+NNW>EI,(AF$]8F*U.ZUIN&JB,B_+HN
MUIYR3/X5U5M9H_]T+@M\^<L .4 0LU][ZT^_<C5MWSL68_8F]-6(G<0M%83L
M!>6QRNQ=K7/C*[_5%);"B!B4? 00=7.028*,.X?T4FQ+[R=6F>BL_.[K,?GP
M&]$4K^O8@QLS1,\T39+KLP3/TGK:EAG3 J #E"7VB2A5#FT+;>C\72N68<X-
MR&1%'Y*I4J1>]*7>#VP^*$A#S2[#^-%]&PI>F*[>)QP 35Z0C(S:C*XJ^O":
M)AO%BXT'CW29_>4SZ\N.6X/<-M &0$S&+@3O_\G,Z>28GL7(&2I5\Y8V@*5\
MA5=^RDJU "1GU.25<K&,)G:\%R?&H/U<(UB]+CZOTK8$ /A&= UI1B>-C'0;
MS%J&V9(EJN<'DO$9X5U!W?5@B0-Y[957AQ^L>JEA^6,09AO!)@DN$:4P]QI&
M62?KF^\>H[73=I!W-$TP3G4SN1ONW:YF&X^R\)J(82HH&<N20Q 72H+>L'\0
M \9^ _UG.<ZEV7@BRI"RLPQ !I<^XXJ??TI0@%Y39U2-0H!&546"RVJ/"KL\
M9-N'5DYXJ/,0Z44#3^##WNQ^X-KHQ6KPM%?9%]QV;_YU@**57H0QE>>.I>Z]
M,+K>%F>"0&I+-^NW?\O;J$X?'@'?$B(LI^Z3F2\"9<GP'&I@-^@"Z7EOC;>/
M"PA"HGVEF;7?#,V$^,?NX3@*14-V*!E<2:P1;,BF^\0L)7@4N3G$!>T):R+Q
M+W6[S8][87A7?95$E)*(EEXK9-&#TD>/NR7:H2<;M-F;D.GY0 G=CBT7UQ0E
M>+@M4'"%.O+MD;4+(U4,NBX#%%-RHL07H:8T[!(9%;O ;CV3<Q5YX#*%4T,K
MB0IG04Z]U\#7G8?)3JV#/K.)!74 W>)MY.)!^%$F7H*U9QD'8[;1E(^#KWXA
MK?$?TC8Y<RU23:-"BCA<_PDRAB5YOK[ZGAK7_!_@]<^]V?\_@-/[!U!+ P04
M    " ")A5E47._9_E5   "U10  $P   &UR:RTR,#(Q,3(S,5]G-"YJ<&?E
MO =44]_;+ABD*F($*0)"D"K2+!0%)-+;#RE*#1 5J1$B*@("B2@= 0$! 0$1
M$ 0A]- DTJ5+ETX"@I1  A@B:1/]_^]WO[EK9M9W9^Z:-6O-7MGA+')V>?=^
MW_=YGG-RPOC.6 *<-#,R-0*PL !8%%D4 0 &%O#2,,C; P"PL "<!P  7 !V
M%CX *_.(>0KS303 _O<8 #!C$?V/8QN6<_\^YP@ $.T-8/OW_YT ?\N?GO^V
M_M=?UG<L_[W'=T?^V]E'--ZQ_D?+=W_:,?" *U9>\,?P1U[P!Q*7E2\ KNB9
M6K"Q_:O7O\<R?P]/CHN]G$X"5+.M/SOZ9HNLAV!\ ?!R,?O68&61!!SA96'E
M96%T D#,OME9_A; OPO+$58V=@Y.KJ/'N)DGU)T$'&%A93W"QLK._F<8EC#F
MYP V7G:^LQ=U.4Y9W^&4].>_%)Z<SR6E5]4F8#-"D+Y\]^'SH\<$A4X+B\C(
MRIV3/Z^JIJYQY:JFOH&AD;&)J=G-6[9V]@Z.3F[WW#T\O;Q]'CT.>!(8%/ST
M141D5'1,;%Q*ZNNT](PWF5GO"PJ+/A27?"RMKJFMJT<W-#:U=W1V=?=\[>T;
M'1N?F)SZ/CV#Q2VO_%A=^[F^0=S=V_]%.B#_/OQC%W,]6?Y;^3^TBY=IUQ$V
M-E8VSC]VL1P)_',"+QO[V8L<?+K6G'?\3TE>"N?BUTO.KVH[*G79AB!P]^'(
M,4%I5:P,\8]I?RW[KQGV_/^69?]AV'^W:Q:@#SCRM[ R7VRLK$R+V)B%G9/]
M3^'DXOQ;N/Y=COTMW'\*SW^4/YVP_.F!E96#^>(YRGF4YW^Z,.:9;BG-F $<
M9V4Z."\K+P ,H%'?QYT#_'^HLC*^_;\TI];KM(]@7P8@?+$:3+J6UQG[B\?<
M:7)/J34VWY!GZ'TZK$&T-R48OQPW][75Z;*)B/&<E#UOGQN) 7C.  BUB!(W
ML<AHNG(H. 5GP=UIMZ/6T!S1YG^J0Z%-^U*^]-&SN1JQ<9>[!PJ[MR-=GEW3
MBSOW[LA_H0(9(_^#_37[@Q"SR?+</>,6- :=B%L=^5&?YF'84).)WY94C B7
M/M5--,$$2QL9L;P.S[_.SF_]OZX*D%\P .P7F"8_"W4@<Q(M+<CZ!!6[L?W-
M!JJ.BEHS/KWI-6DJ8\JZ%RXTO1IG6-\0-3G^UORS.WI<(]BLGZUC'T,R(B^6
MTD<6:U O="YM-KFW)G^$D0[,@[V]MD@X7/MVB/R]>.10U0!IU3 A<T;M0>2*
MPN=G.DGOXWZ_((V1,QB 8_&D6^2\Y9*U<25E/!7\J/B[BS?\QX+3AF:CBTX?
M[BI;LBK"8F+@H6K,[,BM:H[;_,^0ZN!:8'RH.W/J0C1TMA[9V7?;]Y?""^PP
M5W8C>UW+4]G7-3<.4IIG.ZXD7E>&SUR52L&IO?KRW,CD&[V8 6B3T ZI^.DD
MU+DX;=^#)UGRA5XALDWQ.CK[>#]2M/X'#T/"8'Y%$[Y;J/*7*?VL+19*/\'R
MMT>I>0P FR496A04C5M+TE'8X%B )7%XD9[Z)K1,EBGT^*-,+\(:/#T&^ S9
M7U:*E369;#O[V1Y'Y6$'D73A63KW\1GM++\\[&<A:R*;N'"2,<$ =&<,=(/(
MD7-<1,_"MXEK2#JW;X,,L'*13NFLL+MP'5RT<>[]LV/_9W6->A,W?(PLJM=$
MM$P(R %W'"IE9)!RC&\UQ?4- =4FSU%[5^\E:'S=B&^,<GQVYI7".]2:,9W[
MQ;++>0:@9Y%;YTR'P)?QVFL@V\EM&7=KO\G# <+LEZK*AZN&8>IN$N=*!5)A
M%Q7Y60^5W[=*,%T$'E3L0HS>,B>@[8AB4S/;^'W*O/)5[=HDW]SD$A<'QYZ8
MB5N_[>J)Q@T)@^A'Z7<=:)B_7@9BC/[+Y5$@\CIQ#-NSM4Y8MB;G$_6M*2?2
MW&+RHR3$]ZQ:'G0K:%V)5\GV5QZK>UA:6B[],EFJB8JE^-/G$#RT5RTB]?5E
M\(I0PRFEZ7TQ]N^O$X[*DRBTERBQMWZ%YY]7.W_]<*4O,LL+? 'LOO-="[>&
MSR]=Q]0>X)-Q"7<W]<:5^=9NC*HX6:(WGT)4IR2,L,LB=AG2NZM<^&4.$R?]
M([,%NEK/'HLK,0TM0HPR +6!,9;MB]\QV*[NS(_.SB:G;J:H3M;INI.:@_#;
MN4(QWH?W/!\DXK<3QGECHV1?ODNKV4(N92+K4?C+P4)Q&!@X+N_[+*961>F3
MBO(]HMAJ3G# @_<F[ZNCO%3[M8)'+TH(!LI8VYVC%K7Q(M9"5<CRA*2EBM>/
MD9'B)T>H2G"9S^5U'>OUR1W^0>EFO2S-#:S#3<FLF!VY8&G%K:[XRZ<V^%FH
MWZ@>S.DZ4/UI&2T*@<2II:0N(#X$P^E]</BA0.WMHR WAYJ:* FYE&Z'B@I!
M9Z>ZCAOEVCP_\DTZ!R7,:"!F6RAB*E>+5H(X$U1L0BY_1"O&,8/*1Y".^"CV
M5M#?U7NF) T?6-[H,-AI YF3VGK.OQL!1NA+V<\S **H4-'B4"$B*9\HTKY\
MBY"#BOR56;<I:J3@'U#4XZG@TG'JZ!U)4XD3I095KSI#-P^BEX!47M _Q-<8
M$9VS,$&5!]IR,&R0;YT!Y%7]VJW&EMC]99E6PKU7NCP'&1)&O/(!BJU>)UAH
M<M:&_(#_5%G6&  ^G?/4*V1P/H2<AXN.V6< CJ_;/XW\D,&S4' A2J[EL_\9
MZ^=(H2>4*H,4\[,.!8$N0$ 0,_ Q_%310JHN.:P,LIDK/J74-9CPJTI&1L^L
M\GR;ZU6I@'LI&K8I\@+)$RZ.QGO+S)5H(4Z1HKO 47D\.AT_&(#;9,2!"P6>
MG:=%\?L)"=:Q:ZOII??/8T+@>_YU3]Q;%YDKJDDU9P B.DBWLK^@'ZWC=KZX
M2K2.8>O0R/VNL;HC31'V0M:9PM'9 ?Z!9VS8#=PC2M@+GDB RO:MH6]!A)M
M,BR)?/,IG'J).7 J[1T8*\OL#8X'$5X'BQ90Y+[K#%-V:G[/MDZM( O=^AF
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MNS[ZS5=UO&+_;C3UY&:7)GXQ$J%$/H_;1,07^8B(?_3T_?%N=T?M"NIL4^K
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M[)-#;_IB?_M250I=9SESMR'1P)  ]X=K]^T%ZRMK??F ZI"0S#>\9VYZXAD
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M,V:D.P-]<FCWVN?5W(-X30B>8O!!ZXUO83JK:O'AB?=Q@#7J32SX&'E-KXF
M3GCL"^X44=K)(.5HW:J+(PTAY2<=J%]E[1-()G&;C3>$=<\\@R41[-M SQD
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M DHDJB!.EJVDU5. 1Y[7 9V:\9QSF!Z-PY77%G%._'UYW.<VLK,#BWJK&F!
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MG/DJ%O3'Y]TE-_A9_>KJ=YRSVI[L),54'K3;>[S^7)=%_915O,;9ITW=NCK
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MCMR+QP@IQ,?'>X6TWU[%CZ?J]M]R(7F\)*XJ*_AJS3[*:5QMK^'%DK/(C^(
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M]6,MV,_>8WXH\3G'J_=97E6=D(9%\U)'R&4L1AA&#@HA2CB&22C_$SH1"TA
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M=XAS$ SN#''RP9-UA3BG6K<CQ-EK!^[3=EW$5'$JO@PX"WF 0AB%+):?=A1
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M&18R=O,,>A-M;DO.-[G43[Z_ ?>5W.7! #V2W-&GZ&\6+7V0KS(W8_LL:Z5
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M'7M2*]81D)<&K>OM0]L,Z"UYTX#4=%PIP^>26&$J$8=42@01S33WZU] 17F
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MQ<?V3/-J;%.NG9L)O?-TIW!7%K(?I=>H#5J]P5[Q70JS4AZTVM>[H;7^H 4
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ML+??_F/2C0J4_3:=_?1_F\9^Z^*'J_0:=R@/)>4X&&6Z5!YWD!PD #E\[,@
MQ&+]6*[)\M>JW#Y^K/=;=7VD8YTZZQ LFA(21DBY%#)+($H2# D+ \AQ+CC%
M&4YBJU6VY?ASF^PZ\<&=EO^JW;'6Q61XOT-MV>EP!=A0#)<3$YGYV!Z!]SS=
M[3#_M<%\)SPXWA7XRG7<W#CDW ;06<HP;23=.(!>A-2-?,S$'83K/_XFUKHP
MCV+OHN3A(DTC&DO$8<YTE%T6)OH(,8$AHPQG/,GCW"K*SJ5P<Z/0KD"?[MND
MQGO0H79E4R=IHA;!QRQH1J*O91?/#'MQV^"KMGMPJR%H5)Q!_^ !W.?12?B8
M@'^-GL(#T#KK+CPTAOUFD,4$L_ZJ!JVVBJ4J=8D^UEHOJ"0Y%HC!-(T%1(&(
M(2:1A#$7/$Y9BDF8F.X#72;*W"C]0,)ZW]FB7/Z%5CF_^3,=UC-SA-<ZYJ%O
MF;>36L9\FV<Z"TVTP^/94E:[.V[ '=C8N7" R?9TW #1W\YQ],1Q"YC?5Y5@
MY=VJ^)?@M^1'&YBQWH5KWH@56>KDR.L5[RJ*OO^A9U^Q"".<$APG$"&A_B 1
MAB1.0IB3'"4YD0$E5F'H%\@RM[EL5R=8;[4^=G+K;O4E*^K:;77W\ZUZW:H-
M*59@0WX ]184[7<L&K7 3VT X\]VBYI+K&JVAIG(5I[GPKX6=9QZI\=5/WC]
M9F\_9<V=:5MUW*U/'&#J=#ERB3R3KCX< /=\L>'BD9<D!>D .QU*]_Z?VV+S
M])O8W)>\%[*U")-(5P)$,!)(-YUA*22",)BE"0TSR9(TS.S2RHW&-?IV)\TJ
M;P0%2R5W$W]+I*QS#VSS^<UP-V-'=UA.%>]6D]U/6N*?&QA;7!NI@4FTX,B,
M'4.4/.3GG!OY%;)Q#,$XGGMC>K/]GL<W=B_X=BE*><W4TF=;ESM5D^%-5?ZW
M8)M=Q?I],?IB]?X'$\K=D;O^*Z5L"]J+S;KNG[*/'$VQC*),2(@Y8A %80()
MY0@BQC#",A<8&6^*>)9U;IYFIZ[> .\I7+LJ.Y5W"0Y[I>OHO$9O?>N^69/^
MFU8>--J;+_1]OR3G]VAF9'K?>^TCK6YH]+;=EE&P\^3O@?F.T(S>AXFVC)2
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MTU))^',3Y'!9-,()U,?%%UR.Y-01 U?@P]_@YX]7H >NEAO\I"4_O7%_<0#
M,%1>C_1/#/VJA_3#<)P[=C]S]]A(<.7J;]4R4JVX)8V30'=8QQ!1'D%*TQB&
MVIO.(LX11C:.<_?@N;FUW\C2=N&]PRA13^<IHE 0&4#$8UU^)M)M+UF.4Q2F
M$4ELC@%'833!@=\E&)EQZAC-/;-F)Y++4/9#)1V'KK</GSA4_5"EEZ'ISWX_
MEI4.\U\^*$&N&=L^;)<Z$>14SDWKR=V(JBCY9['1C79_+&0B:<Y%!@5-*40Q
M4<P6(@8#(G'(91)3&8Q(X'0IH]%G,'U:YHLL/++/0ZJK3=5]Q,D/>[)P:%Y3
MPIG86E.1UC,+Z4\6]!0#QS(Q&]WV:_E&O;H*EK:HT^1*'\ [)E*' DY,QNZA
M?4GH'L88T9TH1,GG<B/6[[8B"N*@C4$,1$Z9Q Q*EBEJQSR$-!$!Y $7(J$R
M#QDQ[DAT=(BYN:_A+RCY-[#2<@*^%4!+:M$ZYSB,YZ,7+@?',Q$VN-0B@G<M
M+F-Z"QT'R**?T,5 310*< PP1ZV#!B$8:A=T_,;I6@0-"G[0%FCXRG%.[^[4
M[4.Q*M;W:HE?EGR]D%@MQG7#M2R.!41)*"&1F81JV#C*6,:SQ"K[\O@P<^.Y
M3CAPIZ6S<R]/ &GF*%X.CV>FZQV1[T"J971^4#X,A5,G[,10D[I3P^H^=XS.
M7#V. CZ4E2CN5N]_L'L=WJ[[/>K,S7862DB4<98Q&*(H5=Y.%$!,4PQYC'&0
MTD!@8M7V97"TV1%"(RP0K;2 M>):DL,PQ&8<X0PXSU318=8)"CI)/>2T&&'B
ME#.&1YR4.HR4?\X@9C?9KY5^*Y9BO2E7HBMHHM9KU5;PK^).+]H492T8R\,@
M(@@F2:Z8),LYQ"),%,A9$&"!11H8,8G9<'.CDE9 4.TD!.3QL2J_DR5XZ+0!
M;8T-\[6# >[G%UINT?3,+SMAP:YV3H?M7EZG )HOQ-P".=&B[#) K59IYO@,
MK-@,'C+9ZLU<H?Y*SN*N<2Y='8!RT$&KW[E;M\Z2HJH$7\B42D21A!'#NH.5
M[A^2B0RF,<MIA,,HY%:AT*8#SXV=#_O0/Y+",OK0&' S7\\'C)YIN1;YL$O?
M(:@]L=TY@+9 .?4%C0>?U"VTA>2YAVA]_SB*JJL$O2%KP?5.OEBMFYJ#^Q3K
M-T_[2UJ>O-;U';X\UEV7OFPWZXU.NEO=_5UYM/<;P:^_*RGOQ/L?HF+%6M2%
M(!8H92'%0D*.)8$HX +F+$QA$F1!$D9)FE.Z>*R/#+YM2+4QX[F)I+?YOI_K
MX.]3[R0&K<B@D[DI^G(%6B5!3\LK\)]DM27*ZPW!3\4*<)U87ZV!DAJL-5*6
MF=R3O3YYS&A.$90R"=2B17>]3:)$44&D)DI,TB2.V]?G_<JP.N5L7YY.@[F]
M.N\$J]>G(/YKO3QFD_T,7P?/OD*M#J1:']#7^: ""GT"_>M:Q4&M^>X]N3I\
M4<Z\7N[\CHEMYM1MF4KV2;V>B0WRW&F:>OB1^;"/M1NWNOLDE!Q=[L'39P5Q
M$SJAO(=-+>X7^:%8D14KR/*F;/S ]S\V.MB"+M6-Z\TBY(*25$V,/-8K1T24
M7Y6JEXUG) ]B'C*96YT+.)1M;HO+G6J@UNUJE\;T= 7V^EV!G88Z'FJG(^B4
M!'_LU03O5]N'UB>WK KK\B4PF^!>R;2>)[%7LZI][K%[_-TF+#N4;]HL9_?
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M+]^)%2M$4XAPD3)*&8DSJ/Y@$,59!O,TI!#EF."4!#SD1I/$\#!SFP^TE.!
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MFC\5MY;;>H?MIBI7ZD?6K*=NRF7!GIH_][EH#&,F$"$08R0@X@&&.,02!DF
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M'M*!>>R&:%ID73E'=:R<JO[HVJ5*60%U*1'*[$'CI3E9*;:7Q&1W9]_2H$W
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MP($A/\H7''J\CAOVC%4/%/RXP$2Y&[;)-(SB&!$:0 _'&40Q"B"-1 @3$N-
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MDJH,M<UR?28L>Y?B 1J5P ^-4C_6U+#+>GI/5BN=FE0]U(Z?NYK8C)M',-S
MO%QI +8JS X-IKSEG5U/V,L=*?=$TRDA=Y5E5#+N"=@A$?=]7#<2UA[U?L3-
M+L[F<4669>U\JW\2UDP#\S!A::!8-Q-^ !'#&)( 2Z<VCK$7$I81SZH.9$<Y
MID;"+?&JU&T[ONQJ#3.^' 'C@?E2:W 4&-B*!FQI,0-M8RA%W'%E3R2=<F57
M64;ERIZ '7)EW\=UC;#.%\HYKH\M$A2RP$,93(@?JVK6DOVX+TW$8X90Q&D@
M8KO@Z?;CI\9LC726C': F1E1=4=B8/YI!!O@4.>TSHZ#B?>&&#E.^)1ZQR'
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MI:*%Z?1\>4 ;*FP/.QPC_KXD"TTLIGWB#)$UFYC<H37TQ"&>]"30$K1J5#Y
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M[CCS82 2%&$F ASYS8;WH_DVA-'@'?:P'T?@Q@?YH&?58TBG]\M9:JF<OY^
MG(U>BF55'=ENA\+,%&:[$NZ0'8=/&WG5=D,M,:A$;OG2,_#SW^'G3^[V'JQ0
M<KK?8#;RJ'L,5F <[BO8W=R-JE02:U4R>+$H_E0A7RJ-]8M09T6B?)0/O?N>
ME_.8):$?>@0*S#/IIR493%67NX0GF733:!:RT&:OU&S8J;EN7S^^!TT9BAGP
M ^CA&=BJ G:ZZ!53HPU0ZH _E$*6\0Z&QC%C+_>0#TQ? Z)M36IVX#EE-<.A
M1Z4U.S@.><WR[HX5>?/RM2C)XI=5L7G]I(L1JNI:JH&\BBG;"%YOV!9+?53U
M\;NJGB[F<M69)4+$,(U\3WIE40)5?T\8T43^.^:^EUDQ74<YID9]C1K@2>DQ
M X4^DQ:5L);U>3M:QHSF1L![8-[;0OU+!?56"=#6 FS5F($J0.#C%6/8%^CM
M!Z7;"KT=91FW1&\_P(YJ]/9\G//N#0_%(F=ONP)'7A 'OA>ED,1!(+U"YD$2
MA@AZ4<32( OC$+MJW7 P]-3H<;]U@&[?)5?-"]W<2YH$O"]*VV1T"SN8,>,P
MZ Y,AA=[-,Q )3CXH_[_,.6?K'$;JTW#X?!3Z=%P!A:+!@WGGG#[QL*?Q7J>
M>BG.0B$@#5($4<2X]!$C#@,2QT&49&D61_-UL28+,]YS+)\5.6ZE'.X;?E1C
M2*/L]- QI_I$\8;MA94ES9CSAO89F%X':BDLE9QF,^$6^I-M(ZQDO'5:O@N
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M>9VAT_X#*,DWN>0I=>*6I2=L9A3#/5/74 ^]0UICV1:X3GEZ?ZG%4-<696;
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MXXB*##OH3)X89FH/MC8T^#<@M:U0R+QXFN?5%D!7+C%&3EJ I_"]O&;W@]K
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MOUV+N;[/)ST;LX0RD854KZ)C3B#"20AQH@(8LTS03")"F%52W=Y]I\8[C6G
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MW**0\PX?U'A<N+P?-Y@F+76)K^2/^?R?:UFU+HLC'6)E6,%,Q)H:F(:0!41
M&20!EZ$.N4+N0@W'AYD:,VRL!+?/S\N"-DNVC<V]6L2=0-B.&J[';6!FN!8R
M9YHXCXA7EC@QU*@D<=[=?8ZX<'7/KG"5R/.#YAK]4SD73<7AFY=O^GY-_\A4
M8HH13#*3\(:$A(QD&&8929&2-$F%4Y/PBR-.C3BV!H,=BTW+#&-S+^*XC+L=
MAWA%<V ZN19(]W9PMN#X;05W<=1QV\#9@G#0 L[Z@^[Y#=OMJOK,PHB4/.3S
M?TEQ)_2 <S4W!U;'3K+T8DOJV$A\HS^[6L5AR&1,60@3BC%$*M L%9(,QE%$
M4(0#IJ15,M80QDV-T%HKC52)^[)HD.F[G/#PFI,R,"]V3@IJWV[ UCO0=:]-
MFJ"[21,W8#.E1N?)1L-Z^"FUSZ]XS:D=*0?C-:;8*<=BJ#DXDX?A?<C1<C6&
M JN;SS'8&-YJD$W+%],$QF0.O7EY__2\*%[D<J9BFDH4!GJ]$!"(L%*02+U>
M8$D6)XH%F*?1=2<Z)T:>VFOV;?'T3/,7P+OF7EV>? +UOH<S'K!\_7.8'2?,
M:J)U8] :Y?/(#5VN?&+TUZY</@^*11'SA1OX8J];KM_[ZX4I!#ZH,33Y:)E,
MDP@*$ID#%$(A"3F'*0E3Q>,4Q<2ILL-M^*GQ6,=6P)J'L-A8>RVAG9V(OJSF
M"]Y7H;8NWH=%SD-2F@UL _/:61->F=QLX+G,<%9WZ5/1S%;;0A2]>CA6FS(3
M*E $4Y-I&PN(@@!#&F,%:8(1DSI$T]&93<-IZQ&=R&R$)M.UJ)30IE<KK.>U
MQIXO7L!J24T79+E?U78#%)TOP7>Z6#MHC-M-QN5-#^\0#TYH&M>M=17$I\K8
M?*/I4K3L&=712I4]H.M8G>R U-F:9)O[C%B)[.#6;OVQRP?=25PO&9_DTD@X
MMC7-'_5MZW=#4YO/LC@(=00*(Q9PB 3/(%4)A32D48QY))E*;3>Z+P\WM5AT
M:S'8FFK/)!;X7B9EOZ@-?N:V 6PK9["UMX>8A 6&]E3L%\N1>/AJ3)TXV!ZB
M,P1L<9/1V-?>H2[U.GRJWQY!]^R"(LIC%6*H,-4D&^, DMB(/" 9XC#!<4B<
M%,PG?!CH?%AT#"^[=?HT3]\&Z?@Z=&/75^O?:M&FU=^APX=Y/E_)C_/O4MQI
M5L\?YMLCCZ=BN9K_B]8RUU4IW"?Y<_7MAUQ\E[\7^>JQU*$2#L) ZM4M-OU'
MXHQ!D@0(XB0. V*R(+E3GN-UYDSMP7]?KN9/U283?7A85IJ(1LEZXT9;87@#
M]'<P<N.&*R?.CD[&FXZ!&:AV!%:>@*TK]?'&#3 .<#-/7:]NP'])N@3W9SJ?
M.9.6'T"]\MR5)HU*C7[@VV=33W?M7>F_6J[Y2J]N\X>ZXKS5B,L486E&4TAC
M@B%*F?[)_!$C&04"*88%<2SD/C'4U(ASQU+ B])5=/H,JG;,YP>K@5EM%Z;&
M2H]K(WLP?!<IGQIN['+C"VX?*1R^](E^+/%5WTN^H:44)N5!TU#%2%T]I3<O
MVVL^TY>J8/D'78K[Y^J<]S=]Y:J\RS_+Y;P0?Y?SAT?]OKO]+I?T0;[_:99]
MI?R\G'.I5V9*AF$J(252TPYA$<0!55!E0O$08QPA)]H9T?:I\5AK*Z"UL3K@
MJZT%S\9<4W1<U#Z"!^.DOO*7>0Z$Z8F\+,&S7(+2('.ZO/7UORTQHCA5& 8H
M5?HE%2>09H)"S!D1E"59E HW89F)?E_&T9S9?&,:<T%K+Z@,O@&__0_]GMB]
M=B<Z]P._QRN/(#,N@:[?NX)Y[ 5T+VR<!Y7W-Z#QO_F"5$J@-08WX,)WRE^<
M\ JSYS7P&-/^42.95YB8_=#H-4P8*-:Z8.C]>E6NC#A8_G!G,NWR<LY-8:&<
MA8GB/)(2Q@F*355P AE3 NKW)$&97M"ER$KB?G!+IQ9'W6ZVSS9V@LI0S7M;
M'SR__'I/LZ=7W1B3-X$7F^U[K>/OS?[78,17V+6S,NX+J[>UTWH]70NZ\\OH
MZ@%[U&O&?R'!IV(ERW=K&04Q:;-19"83&@H8Q"PT99<I))&*]3N$(DGUFR,2
MUMDH)\:8&MT;*_\-Y,9.(-82&$L=RNQ. 'DY[<0#/ ,3:HU,92)XUR#3(\'D
M%$0.!8770S52*LDQR#P5])W'X%Q=WHE/CE=>=][TG2JY"Y>Z,5VY7)FJ][)8
MS$4U\7<K^516:@P1"P*!&=,Q<2 @P@F'1(42$BQCGJ8DC)&53N'I(:;&<SM6
M@LI,)Z6+,V">)SL_$ W,=3W0L7Y\+P-P+D[3G^[$:/IO^_'9F=N/\HA?=J]]
MPBVN= ]E/A;YPS>Y?#*YO(W,UN]TU>3O-J^: (>2J Q!B>,4HD2&$ >*0Z2_
M%Y2IB">)5>:(Y7A3>_0_%C0WC2M?JH)TD^/8BN@]FQ/G6F)\H?V"VIJGJIK"
M_O5N@__E:,@SJ@.SA;$6&'.!L7>CKP>V)O>(DVR M(^9/ ,Z4OSD UBGL,H!
MIC,AELU=1@NW'%SJAEXN'W-GZ9W#:B-YO?PNVY[4;4=JTVF)EH^W?#7_/E^]
MS$(EHPCA&":9T*P=8<W:%!$8R##A(28L#*T7HSW&GQJ+:_,@K_H8-@;:4TL?
M]"]S]L"8CIK/TIA?]=2HVZ/_TKKP*VB< +>C &_/\0-/P$B<WZ+;?JT!K532
MS:R83BC+G7E:MO,TS_EB+:I61IS+A1$SDZ:CQO-2\GEEL:=N15> ?.:-T>>N
MH[U!KG"Y^T:YYC;]3M-^U[=<+ZM-U;O\>;W:B"^J1(J4H  &*I,0!9@8!0@!
M R98P$*9!)F3Z.6I@:;VSNC8"2I#^RM<GL36[@3*!V(#OQ'Z@>5\ZG,)":^'
M-B<'&_7,Y9++^T<F%Z_O<>(1=C<6(]PLJ&0<QQFA# JN"$1)%$ <&X']E!"F
M$%)19+4/>'J(J5%">'#>$6&'S?SC,%H<=UP-SL!/_S%<^IQV' ?(X;#C:J!&
MBMN<ODAN9QUG(3AWU''\@^.==)PU?.>@X_R5?<6_GYZ*_.NJX/^H3I3+N[)<
M2S'CC&,:L0PF,C7EKQF!5*8AC+"**6=2*N74.^3$.%-CNMI,4!H[;^J<U1+,
M*U.KC-;Z-XYIK*<P1C$E::C?P1E/C4QB+""1F%6*#B*4.*%9.GNNTLF^KNAR
M-1K2^V,.A_<;4\O-)?B_-%_3Y<N__Z\P#?XS] ^UC!(D(QW'DUA%$$4B@"PF
M"/*49DBP,):"-E"_S\7(0+<C#@^S7D)5I%'C' \ M%UD[P&ZP0_W*B+X6A-!
M;>0-J,WTJ4Y_%@?/FO3'QQI9B?ZLPX?Z\^<O[UE33N?+*ANJLV;X^WSU^$=>
M,+/C8(Z\JC5$:11W<SY?U+M#7XS&C]F8J/J^MS7N+U_E:K6H4X1G+(E#I6(,
M282P7AL("DF ]%R0@!$91BA.T"RO4D7%-X>R\\$LMGKD2/W('=@]W./7Y+0Y
M5E4..+%VO/;*\S12K;I1PVNRF[O['S^THZ#K:;TC4H)=7RO9\]I;4+E[LY$R
M?]%,NW798U7[X-/BM^)].'/'K88?'/:#2OGA1W3?1OHZ__FYF.>K#_/OTOSW
M6>H'42^U'V2[FKO/O_THOCT6:Z,G=YN+;X_SI1G]NVSEM%+".1620Z$7!A 1
M*B$6!,,@D%)F)(ZDL*K,\&3/U)9MZ5^29"\A-[/??_$Q09=WLT:&?>"7@/8&
M5.X XTO]Q]:C3CKK?0ZT5Z!U"]R:[G&58Z#RK,=^F8_YLM]<&WG>1MJ),_/W
M7,V?,E-7_?&\G;_MHZ0702L]?ZMV_LQ_JWK^2N.AIR-3CRB?V>SS,<IH.X,>
M(>EN(_J\;4\I_GGY7)1T\=NR6#_?M8?R^K>\:C>F%WCWSTVGL4KEKTDMJA5O
M9C((DC@-,<Q(1"'",H8T34*(@C@02$@B$Z=SV:NLF=J+\'ZGWS&M;'24Y[]J
M<NR62:-!/O!+L/4#5(Y4B4!-@DG7%[!QYJ81"MTT+?'=8]D+L'[E_:^R:%RU
M?Q_@'8C_>[EI/YY]LR[GN2S+M\43F^?M0N=T"RG3:6HIQ6XK*?UO.AX1=[DP
M;0Q.Z9#-TC F& FFN3C,((I8 BEG"H9*QC0,&<?*469E1.M=*&4<F96['#XO
M"Z[=K]+7]-37?9>%?@DOBN=JO^67N\]?_IT^/?_G.\>]^S&_%W8OA(G.]<"O
MC]9KT''[8E/ UO?][H"@<=^\A5H 3NA)>MQ9>X6)\_IZ&M/^45]FKS Q^Z^^
MUS"AIZ(*?Y1BO9#WJAJNKJ'_HS3]$_40W^3/U1N-[3]FB7Z/)9%2D 61@HCP
M$.)0)#!,]>^YE (AY:2/8C?NU!897]=/3W3Y8BK #J2;.HX XXG1>7HG38V8
MGCT=&'^6>6FJQZKF?8;"_OC+U[]L?KO5TO]<E*NE7,V;LX5N>RS-9ZI8/O5H
M/68[SW8OK0%F;^CURO%F8YTI^[.R'1CC066]QR161[S\"I%8CCVNK(@;( <B
M(8X?=^-&(>>S]YJB5R^W0BP-C>L?[Y??BA_Y3*01$<H$^SB-(<(LA$P$$8RS
M6$224::4M.'!,V-,C?-J,T%CIUZZF[\52V!LM2.A<X">)QQ/, U,+KT0LB81
M"PR.$$8I^5\>BN]_U9^NN.*?R/P(ZQ\K@CAWWU'(P,*Q]L&WN;3WCNSA?L0W
M^O-]559UK^YR7CS)CT59?M"&'[WZ756R\_F1EO)^O:I%\&8HYI0Q&L,0F[U:
MPDQBC(B@BC-$DS@5.IARW*L=PLZID8UI[ZZ7_]_GI7.(,]1,6F_LOO;\#+_E
M>W1CUTQ9[:4)BVL_P2_&TU^!>=A/[ B#VEU0^0N+]:H11?6Z)3SDE/C>+![$
MUK&WD8<$_,@&\Z##7;NB;EN7M.UOF\2^O157(%'&XYA"C&0 4:(D9'',(,X$
MCU&0A2QS*C=P'']J+X#."GO3^F6S:.N5&NDZ(:Y+8.\P#YV_TEA^%N*1EL-.
MV VT++:SX966QTX G5XFN]VF1[UHU"W02L,FU0A%(98H"&"$A31*4@RR+&4P
M$RD/"*51%E'K>M&C0TR-OJ*#,K\T="B'/ [C>4;R \[ I',,ES[UHL<!<J@7
MO1JHD;+4G+Y(;O6B9R$X5R]Z_(/CU8N>-7RG7O3\E5<?E7#]%5@O3$5(G;E0
M/#TOY:/9R:\T.YJH<R^NR$(=X$4)A411"E&0"LA"$<,T8!FF*DADXM:\YSI[
MIL:<;Q^-PG/5'>/V_NV=T1XW?A3YN32A02;*^0QD:/A'# @[OC3'43O>["WO
M1SHSN0;?H<Y2>MGT6F<LUP!XYNSEJMOV[<G8'HR:$[R-JDX0B2S!-((R-HMH
M:G*P]*\@(PJG6&9)%#GV8SPVS-0H<VME?3K<6ZWH!*IV1'@]5@/S6Q^8>C1B
M/(>"YR:,1X<:N0'C.7</FR^>O?K:>.R/?+G)KOE&?S:+W/)+L5A\*):F.<3>
M&SZDH6)A0"$E6$ 4IK%1-L\@)E$8A9(EFC'ZA6*NIDR-4KKV5SO[K0=]0S#G
MN7&-OH9$?,3 ZR3PP'@"&E=&BKCZ8CI0L.5LSBO%67UA.QUB];YC3THMU$K?
M5-[FHOWQW3;M^JUI]MSLN(0A2Q * Q@DJ5[,IHC6_=*2-,8Q540A*IP8U';D
MJ1'F6_H\7]%%]=BVECMRI37HEM0X!)1#,V%C:)4&N?E+QVQ0V3U  VUGM/QR
MG/7HXU*:*R@'#.9\ _<SAR9SUD24G^3*K#3;_A5Q*&(L" R0!AUI1H(L%<HD
M+&.$48P$LCI1/3?(U&AH)[E86PJ,J?;[ZB>QO'STX .A@=GE*#@]3A].HF1_
M_N #K9%.('JBYG06<0F.,Z<1)S\ZVGG$)>.[)Q(7K^U9YUBKVWU]E.:FO.Z5
M6$EX2RQ8F! 8L0Q!1".]UHU8#*FD5(=N,I3<:85[:J"I\6 K]U<9"EI+>VV*
MG<36+@SS@=C O-@/+/=*N0M(^"UK.S78N#5H%UP^*!B[='UOB=O]'7ES+-K9
M"..$ZW4;@X21&**,1A"C3/\UPJF,(Z(D<6I[?6G J='%Q2,N9VG0\WC;48=/
M% >FD'.G@\9F\.<@6U6V"/F6$3T_Z-AZHE80'!$6M?N</X71#TOYS[7,^<N[
MXHG.\QE5(A549C 4(H!(,@QU4$(@1R&B,2:*8:LV @YC3HUXNNJ1&U/!G[6Q
MCH&*#>1VQ.,9R(&YIR>&7C0T3Z RN!CF_KBOKFIY @@;><I3'^U'/'>Y?FYE
MN3*IKGDI9UG TH@E(619K$.;@,>0B22":4+C($"$(^Y$,GOWGQJAM.8!6=OG
M1B'[X*E8$,%HJLDYC2 B&8>,:@13E3+%::3"E+=BSL/!MRN^_#\*0#N^O>([
M-3"W;M!X?P$-9S8]X;-7YMP?8U26/.'@/B.>NJSGR=UCL5RU#4E;:8I&F:(=
MZ8M^BF8$!S+((@*)#(4I-](K/M/L)&:A#+B(XR!U*S>R''AJ?-F:"FDCWS%O
MO_&F-Z(YD=>1\9-<\CE=@&?Z+)>.IWJV$V)YJ#< S$.?Z1F3ZQ[9=7OB \64
M#<D8RV\ 736ZNO,<?)L_>>0<5_3\GO'9#C[N$9\C) <G?*Z?[\=K'^?<K%3S
MA]N'I:SUR)LSER3), T(A3$/*40<Q9K(=*07!DQR2O7?J942Q\61IL9<&T/!
MUE(W;CH-JAT9>8%J8/8YAM( Z0,7H?!*):='&Y4[+CJ]3Q:7/]!3O$,JN5P:
M432SC65*O^M@JLF3>EO7>^MQ-P7?Y2TK5TO*5[.,X3"I3LAD6&4P99!*'L(D
MP2K0H$C.G$[(KK!E:@S3NM);B>.*:;%CH)' 'IBC-C@W^^:5DD;M"/BE<>77
M&[#U9JN>H;FL=<@CFWF U:\JQA7VC*M\<3UP!^H6'F[9FU6-5EY;*ZZ_LGLJ
M:V_I@INZ'SWX)]FH9LSYQK!Z36O*S3\6^8.)$;_(U7J9W^>-,BY-XP"I $$<
M!A*BB'-(]=H3(I4I+)E@4>*HF#RTR2ZD,8Y,\D:YH5VN+BN#3=.*YTI@LH\
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M. =1DA%M':<AH*&F/LEEA*.4L2BVJE=_:8"Y<5DC8V79-&(ZI>Q?!+*?MGS
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MS\P&X;Q&>.,?8;OEQR-N(Z\M9U[*X+!)58_GY/:>O>=Q&;=/[]&8+]N;]SP
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M%"6*,AYERBFKR6;0N1E:79E=F<P"8EOZ\@O<Z)RU%_<NV E<[>6[(OLD*7N
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M]=F^RLUF6;?5:7Z[S[5;9&DD14HCH$BL22>#(2!$&P\BY$+%*(LBZICSYB:
MU1LZ:1)<1]I;"Z_U(F^WJ1D!S9<LM];^:R_R7?!3F[/UYZ#-VJH.Q_:*CEDZ
MS0;.D:NF]8KPP@73;."Y7BO-ZBF#4WI-GK!>MJKGOZX;@WTU?<%,0Q$A*C<U
M79H^X,O"U,<L7S_K?SP6)5W^LBZVC^6N)?SY7N$?M3(?]-/+!2*4I\9"(]S4
ML<2)!"2-0I"J#,$0A2E,K0Z^7T#VN5F!;>6#5G=-#4U+MTK]NH7/#H"@@X#)
M7VDQ"&H0JA*--0Q!%X>#*#D#15!AX>BGFO(-LUL49OK>C+RBS/.5&9+3/?7D
M^<X0GTS^J?/-IYZ8,]GKDXO@[K3X*NF];(_B]$JH5,(3@&AF.I^J&!!(.( <
MLHS3A%-NW5RK^^"Y+5BU;/9[]P.0KCLNAJH^,N?68@UP71RH;^^[& K#1,Z+
M*R^!D]/BG*H]7HN#RR=S6YP3LNNW./OW(0W[]"=<AYK09?/2,,HBCG@$:$(E
M0(1I8YNEH<ED%"QA(HGMB>7,\^?&+UK$?_T7','L/Y8NW>I.<;O.-3>B,;J9
MUY%N /.<P\2EC=]-V$S6R\\)(\=^?A<1Z&WJ=WK7A)W]+HI\V-[O\F4#CFZ4
M,JV2VVJ5W^@/4R'CL'? F5 Z$S>+(TQYRB"0(5, Q2@!1)K\/PPC4[\84AY:
MG_0,%F-N#/CJ,!#^D];GP\/#=N50".>&.;$X6YH$Z;&/HEHEVMJ3IA^HT>.D
MZ\6Y"&2W$/0;9L/AM&N269GJ<&R\V7$[4+L9U+[SM^$/G^ZX[F8 #D[W;G_:
M,.>X:7O:MCG5HS:^][(]9BF_R'*[-&V(WFOM/Z_S8OU9ZO\UUWXN:BHN%R+&
MD* D URDL>G>! %CC -M@H<RD8K3*'4[(O0AUOP.#K^TQ;'*.K=+?[J/K;1F
M07LTB@3/DJX=#Q:]S**=9WFRF9EFM>NJ4W%IJ]#=_JAQIU)@*""HE IJK:I;
M=GKY<P'[1-FK;]>+8),Z;7U">>R-]?KL&:;RZE='+K!0&519 A1/3#]Q*0%!
MPORD6 @SAL+(>B\RB<1SV[;TI_-^UBALC&FFU::/<KO)>7WV-*?<WNI%N+X!
MFMWTCKQZ3)Z^:?2?VVLQHQQ?U]?C?VN6;^]K,J\\W^Z4O62F;R7'_YY<WRZL
MDV;['@SL*T"U+H3R>5T\Y>;@^NNC-&79/JU-!263++.ERV]R_=!(U]SX96>:
MO:VR;6K3:R%)+)*4AP"&F (411@0BA!@$*(HQBJ)L)4Y,XFT<S-E.G('K+%V
M;XV!]3FY=GO8V4S9R.;)^0C;ML[33MN@4;=:GCH:!]W9?GUMMCU$VHXP"R,'
MYOJ4^(7C>$< _WK8[QB##EMT3*?%NB#?O5SQ7'9"+K.0TI0+T_!-Z15#\@2P
M4"@0"?UOAG#(N%-%^<M#S8WNC:3!@:@W1,GV(&Q'VWYP&YESAT+F3)_7T?#*
M?3W#34I<U]4^9AV+.P;:J>?B)VLR^J3VQ3T_K)Z*Y5,5KOE*Z:^VC<9<4,P$
ME1@"S!4"B'(.2)ABD&EVH6&&:4*<>.5&>>9&/HV'75LJ?%_5-M\+'U C?2 :
M\1W-T!OGSM+0G&Y&QC8EST; WP7[2>J4'OYP,DEOKTV2N_7H!UJ_]N&-,DUK
M ?H!\,3&\_38891<^2X^YI3ERZJ:QJ\:B^W:]'U>T#26*@E#(*,T PAC":A2
M$BBE?R813*1=3=+K0\V-2&NWXEZ^H".U&VOVP&M'B'Y &YGK:KPZ4MYUP//'
M8->Q\$I./<--RCO7U3ZF%(L[!O9A:--H&J):W>_K\#0UVE_]R,N%X!#KK1X&
M4<9C@+19!B@UE71B2;6I1I(LM>K=Z#CN['BDE?:P])26U'$G:(N[':>,@.;8
M!#, 2/<6#6ZP^&W48#GVM.T:W  Y:=K@>+NOLX_3NA I3",%50H8,_O&3"B
M(\1!C)!)M(N9OF#Q6)E<6NCU9N@YQDW%(X[''^]K:KW;^P;NP?^AJRU=/__K
MO\ T_ ]XZP'%Z0S$)&19R"*09#$#B,<04 0CLR (FD&8"B2:&7BW&EP5Q0/^
M[>B3HO]6\BIUHH8_'@'_H<<\_QO*H8QY /-2]4UF5]3DADHFOLJ7F-/ZOQ;U
M%CE?O2D>'HK5UTW!_YNNQ#<37KA=/U?__E(LE^^+]1]T+18QES%A"09I$IK#
M;1'JI8%R$"G*,<TBO318IT2Z#CXW<[65/\A70:U!4(E<'7.V2C2_^MWH$32*
M.*02.D]0/W.-#?O(%#9+Q.W#T\9$?J)(LQ%FP"E<;"B$/9%?SH^<+(AKJ++=
M>*S!SQBVO?B\+K1AN'DV"Y4I&/+N']N\B@#[95V4^W+:(@TY5HP#E, $( $A
MP,;_P1.BJ)!AR,/4Q>%A-^S<%I!6ZKO*%JO+!^TD#WZBFX 7Y>;/;N:MY0S8
M6;C^<1UYA>B%]"ZHQ!ZEFKD;4E[-7<NA)[5XW> X-GH=[W:W>S]_I^L'_0:9
M9 BZ+&OO2E.I(10A%OH] ^:_ .&8 A9S#" E6<(IA"JQ.C6_,L[LR.A U*"1
MU=YNZH-4A6E&E52 R528O!X$J$A3@+&(9"82A42\>))K5DP(:G>\J6#U ^=U
M&]\31&.3]=E7;D#!E3ZP[,US3Z!-9(F?!\]3\QX+*'HLZKZ[)S.>+53HVLDV
MEP\SB0\L[:]Z&%FVF1"+D&<$29P"26 *$*($4)92D*HX$TJ(!$HK=XK%6+-;
M;_2#OIL<5A/;LVEWCF6U<_Q)[R[+2GI'X[</:SN+UQ."(S/GX4[[+J@%O=ME
M>OFS:RWP\&K,]HTWJ05KH?BQV6ISR\!  OY=BNU2?E)O)=M\6)D>/U4MZV_R
MQ^:U%ON_%YAQ'HHX 31%L;&Q4D TO8 X8PBAC&>2,:<8@JM#SHU16HD-H7PL
M5O= #_H0&.F#COB.D037@;?C%;]PCDPO=D@&OW^C3%]D- @J%7Q&%UCCY3>P
MX/JPT\846,-P$DY@?^?02(+N8S_N<BUD"(E@F &800I0EDG 0@X!(3'!'$%-
M34YQD!?&F1O[''T=-^2Q7 +6]E#Z9KA&/X@>@-2 P^=>'#P?.)\?:^)#YEZ%
M3P^6^R]W;POX;4VK'+OG!U8L%QF" A-% 0REWMJ8WCZ:%A(@9:AW/$PQ!HEM
M.\"#)\_MPV^$"VKI[)O_'<+5_W'?!,+H>Q$K_9U:_)W5=7!KO\.G3=;2[ZP2
MW59^YR\8NAJO\R=J*OQ5%1/*!44T(AGG(,HR E"2(8"Q8B#5'U^FS+(<1W8^
MUTM#S,_9^I[FZ^!O=+FM+->]O$T-$]=E^ C1$">(AIB#--+6#<J$091((%F2
M2)51E@BW=+H;\)R"V.K#,OI0;(VQWRECEZ^J.E/Z$RB+92ZJ9L&L:812FDX1
M=P'U@#>A"<1$O[P\BS3>YGR8QDD"$JA8*+#D(4.+E;0./QV ]JYZX]@QIGOI
M:NB<BUX<86=K*PY_ T<W$G> ]'^[ PS#\TI[M@B/!IG8%#ROXJD->.&ZH8W0
MGK0I6:R?*^98<!DJC)(4P A!@"*I $WTYXS3-&:0<4QAO-@4&[JT^X(/'^_$
MEKM!1C2#S!C!3_3Q<5W\R!\T*99!FP\W((SC"$N[[WDX0B-_S3O!FA ,G[VL
MSJGLN=W4P1 3=X0ZI]YITZ:S5PW[BIN.\9_I>O.L+=152:N2PF^+!YJO%DC$
M82QD FAFNKPC'@*22 1XRJC2ZW(JE%6+:*O1YF81-<(&E;1!1]S@]UI@1T]/
M/]1VW[PW $>F@!NP<R8%*TR\<D3_B)-2AI7RQPQB=]/@E#.IUT%3E+B39%LE
MW2XHI @)*$#"$U/_2') .,<@3,(L%MK(3QAW+)9W::RYD4DEU-WP7/D^6&W-
M?R]@C;X3J*6L2J$?),U7DGI-5[H&A^\TI8OC39V>=$WQ,VE)5V]Q#\M\Q?EZ
M2TTH^A?)C 6]B$.8AI1AD& 3.8@DT89'G(*0PT@QGN)46M<&/WGZW!BA$; J
MY+VN10SRJIEF[72AYN_Z1Q/47%0U)-H-QM*51,ZCW4\;-V,X,E&T\&GA@D:Z
M6\"P#QR\"92)P@7/O5O&I;<V[Q8M3]ZD9T^1A!>QZ8D?/+UGLJC!B^)V8P4O
M7S3,0-+/VSYL*P/L%VUN5?7D:/G]_;+XXR]2W,M=0UU3F,04KBR6RZK$D28E
M6>X"73.ADI@F@,19") B%% %&4C"B$<18BI*K [<O$HU0XIME0J,5L%/1J\_
MWP5&M<#H%E3*=9MS'^H7M JZ66M^YMC.KIM\YL8G=E^3YK%3Y2AH>S4P_4@V
MJ2GJ%<QCH]7OPP=&<IJPT->TE.)-\? H]4;;K/NOUGK/?5]W7'_>7_*9/E=E
M7TQBYJ?'JIO/W[0@4IB<J!^/DNL?OQ7F5Y^VFW*C[4(C_+9)8V)(&^FA?B\4
M-Z=GIGDQXR"AB&"8L)3%3COKJ02?VXI12U6U ZT5N0MJ52HS7#;*!)LB>#+\
M,CAT?;(7PVX-F>-TC[S,5/H 9A0*NDH'':T#]AQTKVLT#RK5[\Z^(N\ZKXCY
MM;YJ#\)=4,/@,7!VXHGS&WX[E?#3!O%./"4GH<!3CW]#;=4W]3ZTXU1J3-\L
M2BB5(@8X3$S':I$!G)(00$10I@3D&4S<XIEZQYM?<-,K?]X?.\3M%@IO*([,
M[G71U3>G%6I'V!)88>*_^.K%$:>OOWI-^;,E6*_>-,"C?-0^:M_:XX,P55%4
M;E)8ZN@737"=H<W.0/_&_,>4'WBB2Y,\L6 P@BHD,8@$QP!QC %+PP0@ BE.
M>1)Q@JT=TIZ%FYOI;,1S\,#ZGBH+;_8+3L#8/I/CIGUWP5Z[H*M>'5]75NO*
MP?%:Y5VI6C:9'SIJON"<.CCE7W!NI_+IO\0<NWG_1YJ$OL,#WT-.=_8P$E@'
M1Q=CC3%@:0ZSY-=B(\NW6ZEG,6VL3DZU/1^'$D0$48"4_A^<*@PHIA&GH22)
MLJXP>7Z(N2V3X<]9\J=@9>0,Q%8&1E('BCT/H\7B=S,X(R]A-2Z_'N RH#C,
M!8 <5I*;@9IH/3@'F"<>[X6@CXW/WS@=I_8*?L",_5?>XM(H'A[7\KM<E?F3
M.6,H'J0Y>M#4NZ1EJ2F7U_X8\5_;<F->D_=:A5>?WGSX;&[1?UC5+7,_%^5F
M+3?YNO;9["L"E^^+]:]RTYYIO):J6,MO],>"8)9&1$&@]RP2($020+@4($DX
MHQ3'B>1XL9+WYD3DFV-GFA?3RNK#VR7N'.DVXCF!-L66)F'JIWLM\9]-WM1Z
MD_^S]B!WHWB:MK954L 0=\V+O4TN_J!9OQR3.IRZ2 0U%+OSZ_,EV0^.N(\A
M"_:8!8;J H/:G7ZI#  F1-*W%^NE9W($-]F+J?0"?KB7GK[SCKX7E\I7\Y2_
MR_S^NSD<>9)K>F\V3MN'^M#DMU+OJ59OZ)*;B(-\=7]2MW]?#9E1E4#*@)0B
M!(AS"3 VX?!)PC(A,IRE-W:,]R'FW+9-IXU!;NT#XF4R[5;)EY^BD5>_\TM;
MJV30:!ETU R,GE5=^;VFN]OWNHY2O7G<Z1BYN8D745^X'XI/N*^W4/$ZV@#/
M5QJ_E7H;L-FNC[T2H?Z1H)0!&)LJ?BE+ 4ZY E1D84P8#1FTZ@38/\S<J#S]
M.0[_%(B=L$/<8)<QM7"%>4%J9$;5(/TIV(L9O+W!)789+ >WF!?0)G*-?<U_
M!(]%KC=-&\W&,GB4^L%Z5+T$';UV>H79_%'HRXIM:0Y&S/]O_M!7/ =E_L-7
M5L15[/I\:I=OGLZO=E6! ]_:]:N'&>2F..4WN7XPQ<PZO8)5"A$)%0:(4J(-
M:H$ 930%%,LDE%QJ99TJ]9P?9FXL6E7J_-96ZG0SAB\ 250(<9*D(,Q0JO<C
M% )LZGC E(>82\DA3]V"KFZ'<IIHJWW94^$+3+N=P>T C;P.'1:$O0O>_6AS
M+MK@JK]2_:'WAZ,Y6^C]L'BUL"\,-:F%W*_NL85[Y>H!%NHJ?Z#+OTBZW'QO
MXR\AHB(E!,0Q#P%"B&I.31B(TQBR#'(:0:O"'^<?/S<NK24,:A$=#*M3W"RL
MSYO0&/EK/P!BB*EYBHB#B7D3,E-%X;@AY&8G7@2@SSX\O6DZN_"BP ?VX.6K
M;JV/_TM1B#_RY;(J3;Z(](XYUEMG@!6+ ((9!#2**(A#*%(:)FFLY+"B^ ?C
MS(V]NO7;6T&;:NV.%8HN 6MGRWB :V1Z&X34#<7LS^(P4@7[P[%>J&S]684O
MUZH_?_G S>$^>,T4AJWJPK[-2[XL2KT/W3GL0VW&)$AD@*90[Q@3$]$="0%B
MR007"5:*.>7-VPT[-\H87(;($F7+S8]W[,;>#'6#:3OEA_="CW)>X8:3W]V1
MW=#3[I:<X#C9/;G=/;#&Q[*:52G.)^.9S+I5*1>2BE!F<0:45! @B3"@"D.0
M9C0D^F],(B?/E=VP<R.CSVNYH3_J/.HFT99W$W)-Z-2N>HUC'0Z[>;"C*__H
MCFWNG$M=WN>!W@6-R!ZK8SA!Y+?\A=W0T]:W<(+CI("%V]W#F.KUMLQ7LBSU
MDUF^JA[\IEB5N7Y"]8^J/&1=_:W#G!]JKY-84!1SCA $@A/-8)!PP#@, 8>1
MY"2,:"B<^I#=)L[<F.V5$%7>A:.1=>.<V+'9=$B/S'*M(D%'D[O@0)>@H\Q!
M#<Z@U<<?!?K!U2LUWBC2I)3I![YC*O7TU!N* +'K!1G8A8(,[W[(-<]+LT<^
M"F7Y(DW!WGQU_\;4+])FZY8NS<D 7 B%H" XU#O<2&C+DJ8 "XB S#+!TC3!
M2>I>#VA:'>9&YB?1;#O)@X[H@9'=6%8[?0<4!IKX9;%T[\W[%9C0EKZU7% '
MB3-!DI=?*\]E@UYF+OU7$)I8C^F+";W,1)VM*_1"HO@*X/\J-YME)6QI_MFT
M3^(1B5/%&(A4% ,4ZO>,)8H!01.J!%8X%;!-G+-;+BU'MN*WP^2VL<^2]F+>
M&E]_'FN[M<8G?B\9 6_^MZG&<+=;#DQ1YKTZ8X:U]X(V<ISZ^;%?./"\%Y#K
MD>3]MP_<'9CV\=^+I;ZC-*46-L\F+_GK8[XJE.HTYUA0@1F!# *(3$/"),.
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MN@LH9R/3G1YP:S_I YXL^XFRK%WDN]*1KZE^&[G\^EW*S:N5>"5$;BZCR[W
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M_V9NBT_.;3##NFX*;\::<96JG"H*\T2EMCAD"O,8YV9*)"$4J013,ENJ>UL
M[8N/ \EM?*</+J\^N!,4 WY\C_,E++0N0VZJ%<?7D>3(OZM'*2"=8[F62LA-
M%$<9G7!3Q2A46&_ @0PAG4Q^5 7V-CD./K+;R8^24_^3Y_U]RB&>+X)55G_Y
MH#:S)#,F*C>65VP(,'M&PF!.: JQ-!O%E*0ZS9R+V'8--C6#RZ9>547=^!/X
M5:W$=Y\R?!W$=N\H0](UN)_I0MW"FZIF4YG&%I \G\J%X4@<K9;X-61Z%@UT
M8Z>U5&#'(T8L$.@FS'%90,=[+JG6PWEX;_[VC[\UOS$_.%NK?_SM7U!+ P04
M    " ")A5E4Y.I>L.IX 0#TOA$ %    &UR:RTR,#(Q,3(S,5]P<F4N>&UL
M[+U9=QM)DB[X?G]%3LWK6*7O2Y_NOH>24M4Z-RNE(ZENWYD7'%_,272"@!H
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M*FJ5E&<R9K<-%)YX_E90$,<#A3[$.#04Q%TXRRLX!S22<RV)Z%!C/,; %<]
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MA,*4RM'RK,+^QF(+0K:"C3L:V/0M^E$@Z7/X]BZ3I*9ENJD NEP2)H3,N%!
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MN_WR$H \0<)V8#FV1&P?\AX%</[W8G9!^EAV)1#+U21G;I/#>J&)%]I6'8/
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M:>3$([J0POZ9SWLO':9;54L4["3.<2#A[71Y_BY/DK6,U2Y^AA4+JO@(SI<
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MFG#U:3'+$\^*+@(M%)O(@Q+24K M-5A!H@DA%RN>2XWOAZ+':1K6]O2C\T>
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M5#$"T[25BW')X\;V.J>]X+&V!,B9N"0QNF0,6!0A&&49EC;UR"\F=5QNX5Y
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M1RVTNMA3Q". Q:L+DEJ]'D4B>7?^9;GXVN7]5YU4)LHG5#8S**;V9*\[?<1
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ME#;P?(ZJ,23GVZ8K7BKZ$5C$.FOUC^EL-B%IY&BX!X&Q-N>PM$D$D6J*V83
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MXI84CJ854YM[-$T4-0(S=(NO^S5''EF.&0-XG2EZ,=[25ZY X28@+46,KLT
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M#5O#V@AO?2IC!-AZ-Z=GS</L;RO\M"CK/TBTE^D>KTS"( I(\DR)$9,@I*A
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M3#B144I(FKPSE72](\4S%"MMW:4"TVW&E>Q-^N 5*<T0N><]SSVUW&/Q^$&
M?9)25[U<Z^:K GY=A'KZE9"XIWVJ'B.P(JP3-M8>T)QV)HW@BT1 $:.RJ#P%
MT$.#_,=L#%Z',D; ]ZS]$;CA+V#^UEU7::QD+FGBBL(,%54&5XJ%@O2IBTXW
M+(5O=.UY-$GQ T%Y1VT>F[W>#+_<](.\O*;*<G3.4]!@L(XR<I%6*),9>+!*
M.BT+BL&=D(=D'U?R^D @WE.[(["_&ZI?U.CNNO=N3NA<U!"")3>+Y0Q>6P$N
M9&8"0Y)$FUL+N]-\7.GK?4!\(+V.()G] @Z?;H7DB2?&E(,032V',+0%\6Q
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M<LZ7 FS?F1_,!"F+ MHY*556O&X[E>KNC+;G*)O<%, ],; 84"$C'_E_7/S
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MIQ(&T,O(2+LD_=WBGRS(WV>EG-);EN89;68S+#GH^4C8,HV?ORX7YU^^7HB
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M-E'X;1=J%+9=&G8@J]HT\#00>3D!B\P:%E%P=WN:_+MVY-U)Y]T[\NZB@ E
M:=,,]LWYLHGR5B=8D;745A;(F-@3%;I"R(;-LG4^JF**2</LE(]1-#T8[:/Q
MAWKQ'BK^"<#H5<ZMMF7U!_YH5OJBEJ5="[IQBV/+6:)2L[<$I&("(T,SX#5
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ME&<\%G*.2AX&4#N1.>Z&.!S8AM/5!(#X\:G&;%N6/ 8J+"BHL6HV]:(R2[(
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MQG*PK">(E^TJDLIAU$FVVTX*3&87+%K-WWI=O'32*C7,G=&'Z1DWW#U<S\\
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MNU_3&HY<#:?..56.W*EH!),I **QH(N0*K=(WH=GHHZGGC^5N^P]X:(W44[
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M!96<*QHE_6GC8;?CJ1<_JRVV'_6%ZP,C'3ASSR;%HD\R>.\@R5(O%9(&9ZP
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M+S>OMXD*9,GO"(-^X@E+WFS(\PFT-!__/):<.FA9&87RUJ$'GRVOY=^>HJ/
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MO\N!V\U1MF2[-'<@56#$@6000B&'0!N5@V.&L3((!/N>/FTWC 8@.%F$4X-
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MS@"UJI$J]Q!+JK=2CD?EB_)FR#G"$X\?!H67<R8_AA2[:[+SYK:G'L5^28@
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MQ3= G!F&M1N(0XJI@+(^D<#1 )88O) 1=:M.\],R.NN>@2&V,-J3Q D U4&
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M'L1$[P C<_IB*BYF8:0M83CSG>C/O,H_/WQ"D:B\UN3#!&90@5N(4C%@0KN
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M2I%!$9<:G4O6J3O1Z[C#-T?@8:;3;T]G@5,K:!#(9KX=^5EQW5^@BYHA0Z[
MY-HG)A))QV,!IC7/-@>IHI_4!%_*1N678G''06AZ SO]#19Z3H$X1>G"UQD7
M22EPVI"00LXFF<"\;%-(UM>U:7_#<%]2&'H,Z"8>A=O67WT3S/?=_5=BRAR]
ME+( 9W4YJ:3D.18*W8W(QL1@I;5JTN/O2?)G>CEZW*O@7.#RHN\^OXGIV:T3
MMUVG-B%F+1%8J/,R0MVS)BA'YB9&5TQ!\E-S/0F'"&*F-ZFS><UO!LK_V/1E
MKW5Q0?JH.:2B H7\+H"GN A"9$PP=)RSV8:TXRP\FG.10#OSZ= 5#,+R7Z[
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MO[JXOD[?KU;QW&'/*4H_G/>@ZP 295D$.G($B"!\<!1M!=5H*^,P0J<M:)@
MO:-KKRMP_DA,+6^XJ\;W>75!#+[#M")[_7>M@=K=1571K_%3O:#Z0D:;5I_Q
ME]7FKB!$T"4QRT G(X"2Z 2^* ',N<*%J-T1K2.,D5F:]O7^]("?$A%=F0:=
M0A>?+Q\A?]]@OL,6BYRQX&JM;UU4'V( ;QA9?/0Z%B^C]8U:U?<C<"_8NI<#
MV_&TU14(_X[A?/OI-0F]7F)^(-GG=Y3RWC.R'(IR*0"%6AE4R9072$_\:>8H
M.1"&Q=@8C?M1NA<L_<N!90/]S?LQ[M>P7M-'?<'#E]L>_EDG?*![FL\IGNH<
M,]YJ!_5EE_(G9<#K@N"M=$88&;ALXR(F>:J['\7<>@2_M+XS*5C D,G*E ^@
M(IF?0XK<L]!:N\RD=VT>+P>1.:-GNP$(&Q)_'J>Y#H[S&ZE5=M[_03'*:OW+
MU97?;JUD9*+P)"78L!,=_<[7/[J(V<8Z@8*UZ81\EK1>]LN.#HM[6PW'U%'O
MH+M>P2>Y-DY[B#[7R9P8P7,5P:CL0];*JF!.#[L>MKZ.#(<A8#M -Q/"+=6[
M@?77L]_?GQ6RM20HR=+1&**84Y*%GL+90+0FCU*(I]"TP?3_?5Q]^7]7/_$2
M3%=_V.%HAZ";S^L8((>H<'64/#MP.#^OUKCXN+O O]K&60Q3RA/MEG,/R@D!
M09!33M(8I70N))PF[N4>*=,6@[3"RCB2[P ZWPOHV[)MY3@W464HS*DZ3=-!
M1&'!"DK.#1=>8)O+Y(?IZ65?Z6E#H8.TT26FKBS-,2R*10-2%PLJY_J0+@/(
M9&NI1["6M5HR_C!%/1UDAVG[60 =(/H.('1UV7-I8=\9W96;E3IZXTP!82.O
MA?L)@DL%G%:HT9L899OX^3G*>H/4(?I_N-%A'&5T *YG[@\?9+$(CD+F.H R
MD%$J'B%J5[O;,'LALLM1-,'; <3V%'*-!,'6*NL E=]J)'_X^NVW?U_@FHCZ
M]/47_(+GEZ<#L2"#K'VB"8FK73%:8I"<08HMB\BBS=7I?O1-/&+O9)%: VWU
MA,%_8*B"VA7<W.?ORJ"Y$T[X%"%X1@;-A81@O0'#DPS):!%-F_FR@\B<]D!N
M@9/'H#BZTGI"Y&6QXDYB\LK!IU*D+#J#MD&3T H24Z( ]R9KQI%IWZ;MZPFB
M.D';^%!X#'1'ZJ4#B-T_*G[X^JT6]G78XL?5>H&;G9VZF$26-H+U7I#(C #/
MG 4=I0QH0O:Z308[@,B)1V&<[ ANI;<.(/D &U<VRW+QQI1$/$2R66$M'11,
M@K2NCKYV*:DV%W./DC2MQVL&@KLY\"@:Z0!:]P5V.0CF/::+]6)+?/V^N?+C
M(0@MO2+'C4;5TFH& :T!9QW+2@5K6)O"^/UIG!9\(X'B6;\VBH9F@;U?5\MO
MS,E"/T'K A[KLF;/)?@:(G,E KH2F+F[ .YD\+M%YK27+5,A\% ]=0#"GQ=_
MUCKZ6C/_9C?@:A<D7_'BHK/::@5,8#TBD$+BD@M8II&30 ,VNE9^BJII[U3:
M0&PT+4S<_7[?5%Z'S:?K(M7[K,7H)&,FU?&+X?(2U"NGR'8$-QICL>Y.+>B#
MW>P#/W;:E&!<!+66^H2 VJRW9^]J-^8N7.66<Q;I2/<N&?*KC,+5$CP8A4E3
M!(O1[=5V2S_UEA^B/]WU0=]][,0CTIMGCX?+N =@7.%9VV)<+50)J#RHA :"
MY\2XXY$CIA##7F-C]H?&E.'V$2J[J_0#Y#>QVO^Q6"X^7WR^?M/*-F<6ZT@8
M7V,MJ2%&G2&EF",7*4HF1U/\=Q\]L>H/4=QJ#"E.K?[PYRW"M>*%2?)P5F5B
M7PH-3G *D:Q@-K&2=1GO2/CNHZ=)<T93_\%2G%C]=434[A;_?<)E6"]6.Q=H
M<V!6$V"M4!R4"0FBK(.\G4U">YMQOX$<>\'@01(F7JYPDBCA>-E/#9XKNG]?
M;O[ M"@+S%=QMW&V2!L9I56FQMTR@V<%P;B".?#"B]GK9F\_ #U&QG1'R@BJ
M78TMYT[ 4BN:4]A<%]'0*5E0B0Q2U7+F; 0XEWE=(1"2B1DCW^M"9!!2OJ=A
M0IB,H]@'H'*$E#NX0KOO=6^<[B_?)MH;0QQ1* 4Y8CVL3:!CN][B4,;-.!>%
M '"B^]L'R)MX-<B$KZ3'ZJI+ -Z:27AO#N&9U:IP4>W)D1 5BPJ\-A0[6@H;
M8R()YC8#S(;1V=M+ZM% >1:*HVFM2TP^./WUC!LOL]81T(9,OM[3T:&S!2O1
M>F]M$(T&=^])X+0/6E.@\'@]3?P(44<%A.77JSK]6]??__UID3Z]6N/UQ?N_
M,;^ZK-7Z0-#"2T[?XCI5%7_$,PHW=%:[EC6N07&KP$6O0-B2F [>&-QG >A8
M]$S[\-4.BI/IK$LW>7ONY/HC;F]FLM[BTB8IA$ 2,]:.7&\B!.T$!<PY2^>9
M5K)-K?%A]$[[X#:%$QU=BQ/[U.OIDZ^6RXMP_GX;ECFL\X_X9;%CZLWR'6XO
MULO-;^62W[>K];:LSA>KG?V^PW)._WSSPVK[Z;)VXD8>KY;YQ\47(G(WDK5^
MY7I9S*O/J^7'RY?2\T#_V[Q9[G[:MY]]Z28V9XXLW"1O09*20"%20A"S@A2D
M#YY+LOQ]9J+WS..T[Y!M?7_/<A^$K2[/DVOI_GQ1E\?_]/F/\]77.C)SN5TO
MXL7E:CO\<_LS*32<_P^&]5FL6Y<89B@AYUH(GR%Z'\$)EGF.J;;<GJK2;"CQ
MT][$3W'2M-5OEY"^,V+S=3A/-6M>+#_^2MYAM[!TD6ZMW+D6T2]D\Q]P_?G2
MG_QVG=IXIY+C00 3MLY,=A:"T@FT43R@$SGI-EMG6G,V[:7>)#<HTR'C8$NA
M\RFNQK65V]:_*P<C5F^F)I\9.L#0% DF"PE*J0@Q<0E"Q)3KPW%V3;.'I\F;
M=F#PR5 [HH[F/8BUIOZK9<WU5^5A*SW!A-;]B3CAZ-8#)3/!3-=HI/=2(FA)
M0%5>*W",.TC<HK/"E(AM'K>ZG>GJT<FBL@5CM":)E$)'AV&4V[N,W EA^5ZE
M:8,E\D)GN@Y!V'$S78=HKH/P^/D!D<9RX8L4P&TJH+2T$*61%/0'M,(%B;(-
M%%_43-=!L!@\TW6(CGH'W7512.:&!8$@9*0(I@0&/I@"SC@M**J)(;>9$?0"
M9KH.@L,!,UV'Z*:/F:[,\[J^2 -S=04H!=D4<7,%R8D2.?,YVJ=&#;R\F:Z#
M5'A_INL0>7;@<.Y/%A4L%^N<IX" (?'OR428]H#&JD)96!"FS2WE#&>Z'H*5
M<23? 70>F2OIE-*A9 F<52Z<%^ S9?16,YVTULS+-NW\\Y_I.EXH=) VNL34
M=0LG"N&5#4#.E=(425)Q 0M$K8.3S!O%V]PESVJFZR!M[SO3=8CH.X#0\V-$
MA6(B)@G:6PO*H(&H'!F=L$(%R7*VC6;;S'.FZR#]#Y[I.D 9'8#KD &AFF3G
M8O# B[;UI3M!X/0[%HWA3#AN<QN\O9R9KL= L+7*.D#E?F\K1=08HBY4-L)1
M>*DRA*P36$RR1"$Q9ML$A^,U2G0RT?68.&U\774)P/>X_K)(NYV(9XFKH'D.
M$&TAZT4G():4@0L>;"P<1:,!KD^2-8<VB$$P>!9HA^JD2X"]6=)/Q\WNM>Z,
M6QV$- ID])2'RXAT/K@ P6ON*8XPNM%VM:?IFD./P[@0.U@K76+LNHKENGKE
M5MN&](Y,A!Q_XG47@2_$F\( &ATW-KM@\=2U?/>IG$-CP[CX&TECP]'H+]&X
MQ(^URZQ5?=[GU7J[^/=.@[^5M^O%:GW+I[\F(A?;,^=UB*4$J)>&0%Z>!)J*
MAZ14B=YS%^.I?.$^],ZAA6%<C(ZNQ2Y]Y_=<_HVRN,TOJUH0?F9#*5Q2CE_K
M"T"Q0(9HC026N5 F<MYJ)^4 (N?0%M 2E8?JJU/'60VKFMKJRR(OEA_?US$+
MX?RWRVKND+87X;Q6J2Z6MWL9;HH&?[Q8T[^Z+!,[*\FRDA*%,<HS4,YJB$E;
MD#ISI:5B9+DG@N^(;,VAOG]<P$^%B2Z]]0U?O^*V&G^U_1\O\,/J]<6ZED+N
M>D;/) DZ!%G'AB#QF7(!%U.$Z(J01:,NC5YA#J5X#I7ZX\*Z@28[=>J/<_H>
MM]OSRZTD_,P([33)DN)^+J^6UD>LTW3JAD.DL%^VN7X_E.(YU.F?"K,':[)3
MS#Y<;7Z6=>!H**8JB'6530P08Q:@.<]2%$W?/-5MPL,4[H5)_Y(P.8*F#C_I
M5]MP/G7[R,V('/J[/U_4QH<ZS^YB<X*ND6<_^X3-(L/D,$&/2/'&U:8YP*AT
M=88:O$(/%(]JFP(FF]KDT]WVB%CA=$$Z'HS2!925#F*U62S!VI*<R;[-D?]"
M>T2&(.RX'I$AFNL@D7J^X+R6F(N(INZG\Z!T2+7351!PM,G1*"_Q%-60,^\1
M&02+P3TB0W34.^BN=R[:8(QF#*1PQ%)()##A$9B5'$L6(C:J.7H!/2*#X'!
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M@PN&:*Z#V.&1WB"+O"ZCK1V*)=<Q8@)\?4 ,-NHHA7)*M['((_KR.AE1, @
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MN10B,PU;4"?C>PZ5V*U,L#-4S>/T>W49)(\CL(?CB1OQI4S_.26!*<5!96;
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M=LNBN*;@,00H0E X5X2%0!$>R!P=^I@SBVTBGZ?I&B49^?;3=W^Z^H@;Z_I
M$OZ!_M$_SY)4*A@>08:ZU\[I6BW()'"R+O0A98IX3R"$9\B<]DP=$4</IB%-
ME#4?W[2+G@]Y1GGJIS7R4P_1>AIO)0Q36G$#D=%9J#P!S%NK0.AH-,;H<CF%
MH8[MK6Y2K-WG_+I:KO[ ]>XQ\SO9[P1_8PG..,,X]R!U293ZDR7X8BUPRUS.
MV?/2:,_R8?1V[;^&(.OQUX9FZIN/([L6QJH\^.W#WXN/^;1&CO 07D_C*'-,
MR43*$HJJ^^@*4H)I$P+:J!5RF6*C)OTVCI+ L'L[7"U)=0])>U5N6]WE592+
MZ*2R&EQ@D9(8E2"Z$D"G'(1F.JMBGL'<(9_;M9L;@HMK-]=<^!/><&S6V[/W
MI)W=W??[A,NP7JPNI\UX##YP6SN($)2INZX1R5G;4#QSZ'3:*]2@3[AE/?2G
MNY;S* G3 *F]ME=CBGYJ[%S1_?MR\P>F15E@OGJ7$9Y9RX2''(E^I4TFX;@(
M0F$.!;V(=J^'T_WP\Q@9TV!H)-6NQI9S)V"IP_%2V%R_J!5>.)>,3 8-JW7Q
M'"AA%F #DU9+;KC:ZZIT$%*^IV%"F(RCV >@<H24)\3)0/=[<T-<<HB1^0*I
M[K]3EA*8Z!4'#,9(%);GN\G@L='.Q.^3)SNH3J*2#EYYWBR_X.4"CDONKNND
MSZ**2<F 4'PBH043*5&M4\W(OE ''K'1T-3'*)I%9'0@#E8-E'+LLJ^1X'5)
M^96PSF+A*?!2(,BZTM;4=C#Z%8S4VCJI0S%MZA7O$#(+[S46F Y700<.ZFJH
M\.L+^NQE^OIA'98;2FI)4_=WX6E9@TGEH.C:+%4KHGS6@?X8#9ILN&XT2&0
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MB_6[Y=75G[:E[S//-1U1&5E4:=-L:1C$()ER$8PQ'MSC%]21<-F:LQZN\5%
MN.P8$1V<D'UM1EF8.G!JLX!"DHR=8MZ@8]GJY%4)X% W ?8I35[-\-@7:I;C
MJ_!H))(S,U_6(=.KZY9X)(.P0ECC^AVN;ZZJ2=BL%MVN4WF[H8'^]MOE>N/?
MKV<<R2)X$J7,U?D).;!8UZD ?:/CVO(LVM34CT/_M([%):*])4#Z-=//<_V6
MN%T]PS,(4$DE2<Z@K!$!>83>!+I&@Y1)!Q>\://X- ;UTXZS_G&.Q!C@Z/=
M_(R'\,R-R)*N0KHA=:V/,A0QB>)(! E+*2J2&3CG@3B(^FF7"5SB@6@'CBZ:
MP0[B^CU>7U]M<J3K?\RO/]+?KTJZN?ZX7&T++Z2R,29CF=+@Z8*TR(*-BC21
M;:D9I()MFB9&96.:>3H_WB$9%2X]GY9WF&_2Q@ \X/\W^+S&W\NKSY^OYJGF
MV.H3P\TU_=%O\T_S+:+(9*BHR*TLS"==6]K=1C&&)>E]R%)(4&U*!AHP,\W
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MQ]=0!Y[4HXV(7$@?N&*V0)VWY6IW)M0.K&B$DG5%HFP#KTM9-7R0>E]>-7R
MK*>>'/W"HMR8E.9)DX&M*XHT9N) .\X*!N.<\4Z;(1L>+F75\"%*&[AJ^! )
M3CW)9N^R7/+6M$)+I%MGB0FO6. @6:XMPAJ%C6E(/_QEK!H^$@3C2*^#2V//
M\MO"M>$H"W-U>I]6PK.@E& BZ@PZ4"RHVL1.%[!J^ C(C"CM#C SJ-6R\&1B
M,HKQ6$UA2,# E\#H!+B@9996-GJJ&*N7OAV>SNWECJVO#C#XZZ).)*EL;9\G
M?UW09].?S#)DCC%)IBR/9'\-L C!U#Y?J8N6SH0VQ2O[*.K"YQE1]\L&BN@"
M4%NZ?_GC,R[6.#,F>BUY8F!Y8=ISDDFJB5"21T992X=;X>@!(5UX2RWA<[S8
M#T=-V*)F@1]JE_<X#E3^GYLM_O^T7+WZ5,7T[XU\9C;'2"YQ9")I30? *N:3
MI]A @D4K8G%"M/&A]I'4A1O5#DOCJ.)45/UM-)/T,Q(!:5N6,PL4/6AC-:,X
M$FIVE3S.H#C]QT>G$U<YMK%']ZF8I@OD;  Z6N!=6*)WI TBX>.K1?X9O^#5
M\G.5UJUAI4C"8Y&!6:%4+5ZFN-1"+3.UT7#K2?EM\H$ODC7Q4*O6@!I/);T@
M['IUDZYO5G5>RD=8?<#U+(:"(=(]K:%N2 Q>L\@UQ;(15;"^]L^UN>:>HV::
M[I-SXNDT!4P*H\W^ET<B^OL"KC;_ O,F,[([&^LW>$VW=D$,Q3*/@F[MD@7S
M*F M3<B*+O&LU9!-# =\Y30M+,WATU+P71BF;>CYVW*]J8Q_O5P0AS?$Y*[*
M9;E8;\N7MW]O4\3\RQ_7*R"-SA>P^KH1[9LE_71Q3<1=;82_BV.%RD%%9\D"
MQ=KU@Y&%B!2@I"@R@"#OL54@V(RI:98RGS&H[ ,.%]$$\<L_;^;77ZNPJJ9>
ME;+I!, U5)_EFS],LKJZR4@">M@?,%Y+Q$B$C-\@T4)"K=LEH*3(G:8X5Y:Z
MM[J.(M0JL:@Q"@J&;>*-AJ1UU"YA0=L,"IC 3&ZUSZDV<@>F@HXE*:&>-+O^
M[W:)$W T1KO$(2KKKM!]4U:"PADE3**;RM7!V-RQ&&QF5GO4QF%4?E"+XG]4
MN\1!:O]^N\0A.N@.1;MW9CIF@?X_DH\!4,N3Z.2)D%A"0__C04DWWH2/BVF7
M.$BS0]HE#A%S!\]4^^KVN8PJ(_":2\J5E\R\R<"**2[(Z **05,_?N!VB8,T
M/;!=XA"Q=X">EPLB'?"H>"HL&$4AEW5DA!V/#"(/*6HE7*/F^A^L(OF8RVQ\
M#?4 MP>%4RDEB(5+)B4$IE%;!G4007*V@-9%2FM:AB3]5R0?I-X7*Y(/D77'
M%<E0[_/B,BL8/:OW.YEL49@C7E1,*0@<4HIZ(17)!REM8$7R(1*<M&GFY:I:
M[[3@6GJ612T+B;EFW71FJ'(N,:@8'J^]N-R:Y&-A,([T.K@V]E3)"N\M(%>U
MYK%6R=K P,; @HA>EKIM([69 -)_3?(QD!E1VGUTVPUY53!.E&R]9ES)^N0N
M>#6'C@FIK8; ;2I-NZ)^L*KDDSS=L?75@>5Z^/"T?3?X*UY_7.9O9;+K&7EY
M,MKBF-=U\+A!"AH+Q:5U@%;=T(=2N28@'$1>%Q[1B*AX\6UP#!5U\0)^_R&*
M?GV%&X4M\H,R2 XA1(F&J0R"D:0<@P2*B>2-C#QBUFTBL"'4=>&"M</=Z JZ
MB,?EMZOE9UQ=?WU[!7596J[G;5,#]P:OVRT2.^9;QW\V/IGWUF_$T:J"V@'C
M#D6-#37S$#4+6:%Q#HIJE#/N=+&8EU:9B)$I5U?:1IY8=+Y6>HC$C0418- J
MIQ.>BW^@Q6*'H&ODQ6*'*'+J]4][EQQ!%B[Z8.H5DYG.6;)H?&*!.QNYH0AL
M6+C['[Q8[" <#%HL=HA2ID;6WJ'HX#7*D PK*5'4QJ5DWB=D,O :V^>,;M T
MHQ]OL=A!ZAVT6.P067>P6.;O[V<R>I'K!DC%R?/47EOF*9!G#CF%]!XD.<$O
MH.-'6"QVD-*>+A8[1((=)"WNK;X"F04DARSHDK?OY!Y%9$%XNK Q:31M5LWV
MO5CL&#R<*-WN%@YYHAT3UE+L.O*=(F 62R;O+B0E/%J>S7C;*(];.'3FE6/'
MH.)TV79P2;Q^,W-8!/#LZPYU\JS 10:E>%:*%IX,7A!NO$MBX,:Y,V\?.^62
M.%""_2V9 E&<AY29<S'5#B%+<9T'E@,OPB(0F,=S(8]<,G7F_6/'FH,3I=N!
M/?C+VYF5UGHL1*+G=+7%*!EXFQB$@BID _;%J2M-MA&>><G8*?;@0 GVN%BL
M6*V*EIDAKWODXV9 D5,L&R\"3UX#/"H>O.C%8L=H>Q39=1 P'+V%*%-\+6+D
M+&D+-27H60#M6!(D2>E"U%8/N36.:!7_#UPL=DSVZZPJ[@#*#]YH7CU\HYFI
M%!*OSKA/=18^UKP0<<=0DZDVJ12GVQ0<O435A2X@.P@7RT9*&K%.:>^CZ>X'
M]3\1UOA__Q__/U!+ 0(4 Q0    ( (F%653_6X>B+@,  &4)   >
M      "  0    !E>#(S+6-O;G-E;G1O9FEN9&5P96YD96YT<BYH=&U02P$"
M% ,4    " ")A5E4B8 =L<T&   >.0  &@              @ %J P  97@R
M-#$M<&]W97)O9F%T=&]R;F5Y,2YH=&U02P$"% ,4    " ")A5E4DWP0ZP('
M   F&P  '@              @ %O"@  97@R-#(M8V5R=&EF:6-A=&EO;F]F
M8F]A<F0N:'1M4$L! A0#%     @ B8595'I9V73#!P  YA\  !X
M     ( !K1$  &5X,S$Q+7)U;&4Q,V%X,31A,35D>#$T86-E+FAT;5!+ 0(4
M Q0    ( (F%6515KPLOR <  !,@   >              "  :P9  !E>#,Q
M,BUR=6QE,3-A>#$T83$U9'@Q-&%C92YH=&U02P$"% ,4    " ")A5E4HFD;
M?DL$   !$   '@              @ &P(0  97@S,C$M<V5C=&EO;C$S-3!C
M97)T:69I8V$N:'1M4$L! A0#%     @ B8595)*]-89C!   8@X  !X
M         ( !-R8  &5X,S(R+7-E8W1I;VXQ,S4P8V5R=&EF:6-A+FAT;5!+
M 0(4 Q0    ( (F%652:+B.%WQL  +7:   >              "  =8J  !E
M>&AI8FET,3 Q-RUP;&%N9F]R9&5F97)R92YH=&U02P$"% ,4    " ")A5E4
M?CU3<: Q  !.& $ '@              @ 'Q1@  97AH:6)I=#$P,C0M,C R
M,F%N;G5A;&YQ<V\N:'1M4$L! A0#%     @ B8595.&=XK#0,P  LR0! !X
M             ( !S7@  &5X:&EB:70Q,#(U+3(P,C)A;FYU86QR<W5T+FAT
M;5!+ 0(4 Q0    ( (F%651 %GX@A2<   "+!0 >              "  =FL
M  !E>&AI8FET,C$M<W5B<VED:6%R>6QI<W1A<RYH=&U02P$"% ,4    " ")
MA5E4QE3+L0%#" "/KV8 $               @ &:U   ;7)K+3(P,C$Q,C,Q
M+FAT;5!+ 0(4 Q0    ( (F%652\,"B1^2@  )OE 0 0              "
M <D7"0!M<FLM,C R,3$R,S$N>'-D4$L! A0#%     @ B8595+!/RN3_1P
M)R # !0              ( !\$ ) &UR:RTR,#(Q,3(S,5]C86PN>&UL4$L!
M A0#%     @ B8595/7=J*4_&@$ ?)P, !0              ( !(8D) &UR
M:RTR,#(Q,3(S,5]D968N>&UL4$L! A0#%     @ B8595)E<RKYGR@  6S !
M !,              ( !DJ,* &UR:RTR,#(Q,3(S,5]G,2YJ<&=02P$"% ,4
M    " ")A5E4 :K$!I45  #E%0  $P              @ $J;@L ;7)K+3(P
M,C$Q,C,Q7V<R+F=I9E!+ 0(4 Q0    ( (F%652';.01\$H  /UZ   3
M          "  ?"#"P!M<FLM,C R,3$R,S%?9S,N:G!G4$L! A0#%     @
MB8595%SOV?Y50   M44  !,              ( !$<\+ &UR:RTR,#(Q,3(S
M,5]G-"YJ<&=02P$"% ,4    " ")A5E4"N,#93Y. @!35A@ %
M    @ &7#PP ;7)K+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " ")A5E4
MY.I>L.IX 0#TOA$ %               @ $'7@X ;7)K+3(P,C$Q,C,Q7W!R
;92YX;6Q02P4&     !4 %0#(!0  (]</

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
